0001628280-23-005061.txt : 20230224 0001628280-23-005061.hdr.sgml : 20230224 20230224162230 ACCESSION NUMBER: 0001628280-23-005061 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 165 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230224 DATE AS OF CHANGE: 20230224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 23667723 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-K 1 mrk-20221231.htm 10-K mrk-20221231
FALSE2022FY0000310158P3M0.1http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#RestructuringChargeshttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpensehttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent33.3300003101582022-01-012022-12-310000310158mrk:A0.500Notesdue2024Member2022-01-012022-12-310000310158mrk:A1.875Notesdue2026Member2022-01-012022-12-310000310158mrk:A2.500Notesdue2034Member2022-01-012022-12-310000310158mrk:A1.375Notesdue2036Member2022-01-012022-12-3100003101582023-01-31xbrli:shares00003101582022-06-30iso4217:USD00003101582021-01-012021-12-3100003101582020-01-012020-12-31iso4217:USDxbrli:shares00003101582022-12-3100003101582021-12-310000310158us-gaap:CommonStockMember2019-12-310000310158us-gaap:AdditionalPaidInCapitalMember2019-12-310000310158us-gaap:RetainedEarningsMember2019-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000310158us-gaap:TreasuryStockCommonMember2019-12-310000310158us-gaap:NoncontrollingInterestMember2019-12-3100003101582019-12-310000310158us-gaap:RetainedEarningsMember2020-01-012020-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-310000310158us-gaap:TreasuryStockCommonMember2020-01-012020-12-310000310158us-gaap:NoncontrollingInterestMember2020-01-012020-12-310000310158us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310000310158us-gaap:CommonStockMember2020-12-310000310158us-gaap:AdditionalPaidInCapitalMember2020-12-310000310158us-gaap:RetainedEarningsMember2020-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000310158us-gaap:TreasuryStockCommonMember2020-12-310000310158us-gaap:NoncontrollingInterestMember2020-12-3100003101582020-12-310000310158us-gaap:RetainedEarningsMember2021-01-012021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310000310158us-gaap:TreasuryStockCommonMember2021-01-012021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310000310158us-gaap:NoncontrollingInterestMember2021-01-012021-12-310000310158us-gaap:CommonStockMember2021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-12-310000310158us-gaap:RetainedEarningsMember2021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000310158us-gaap:TreasuryStockCommonMember2021-12-310000310158us-gaap:NoncontrollingInterestMember2021-12-310000310158us-gaap:RetainedEarningsMember2022-01-012022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310000310158us-gaap:NoncontrollingInterestMember2022-01-012022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310000310158us-gaap:TreasuryStockCommonMember2022-01-012022-12-310000310158us-gaap:CommonStockMember2022-12-310000310158us-gaap:AdditionalPaidInCapitalMember2022-12-310000310158us-gaap:RetainedEarningsMember2022-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000310158us-gaap:TreasuryStockCommonMember2022-12-310000310158us-gaap:NoncontrollingInterestMember2022-12-31mrk:segment0000310158srt:MinimumMember2022-01-012022-12-310000310158srt:MaximumMember2022-01-012022-12-310000310158country:USmrk:PharmaceuticalsegmentMembersrt:MinimumMember2022-01-012022-12-310000310158country:USmrk:AnimalHealthsegmentMembersrt:MinimumMember2022-01-012022-12-310000310158country:USsrt:MaximumMember2022-01-012022-12-310000310158us-gaap:NonUsMembersrt:MinimumMember2022-01-012022-12-310000310158us-gaap:NonUsMembersrt:MaximumMember2022-01-012022-12-310000310158us-gaap:BuildingMembersrt:MinimumMember2022-01-012022-12-310000310158us-gaap:BuildingMembersrt:MaximumMember2022-01-012022-12-310000310158us-gaap:MachineryAndEquipmentMembersrt:MinimumMember2022-01-012022-12-310000310158srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2022-01-012022-12-310000310158us-gaap:SoftwareAndSoftwareDevelopmentCostsMembersrt:MinimumMember2022-01-012022-12-310000310158srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2022-01-012022-12-310000310158mrk:OrganonCoMember2021-06-0200003101582021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MaximumMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:ManufacturingAndSupplyAgreementsMembersrt:MaximumMember2021-06-022021-06-020000310158mrk:OrganonCoMember2022-01-012022-12-310000310158mrk:OrganonCoMember2021-01-012021-12-310000310158mrk:OrganonCoMember2022-12-310000310158mrk:OrganonCoMember2021-12-310000310158mrk:OrganonCoMember2021-06-022021-06-02xbrli:pure0000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:SubsequentEventMember2023-02-012023-02-240000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:SubsequentEventMember2023-02-240000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMemberus-gaap:SubsequentEventMember2023-01-310000310158mrk:ImagoBioSciencesIncMemberus-gaap:SubsequentEventMember2023-01-012023-01-310000310158mrk:ImagoBioSciencesIncMemberus-gaap:SubsequentEventMember2023-01-310000310158mrk:RoyaltyPharmaMember2022-10-012022-10-310000310158us-gaap:LicensingAgreementsMembermrk:ModernaMember2022-09-012022-09-300000310158mrk:OrnaTherapeuticsMemberus-gaap:LicensingAgreementsMember2022-08-012022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:LicensingAgreementsMembermrk:DevelopmentMilestonesMember2022-08-012022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMember2022-08-012022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMember2022-08-012022-08-310000310158mrk:OrnaTherapeuticsMemberus-gaap:LicensingAgreementsMember2022-10-012022-12-310000310158mrk:OrionCorporationMemberus-gaap:LicensingAgreementsMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:DevelopmentMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-12-310000310158us-gaap:LicensingAgreementsMembermrk:DevelopmentMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158us-gaap:LicensingAgreementsMembermrk:FirstCommercialSaleMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:AcceleronPharmaIncMember2021-11-012021-11-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2021-11-012021-11-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembersrt:MinimumMember2021-11-012021-11-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembersrt:MaximumMember2021-11-012021-11-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembermrk:RegulatoryMilestonesMember2022-01-012022-12-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:BristolMyersSquibbMember2022-01-012022-12-310000310158mrk:AcceleronPharmaIncMember2021-11-300000310158mrk:AcceleronPharmaIncMember2021-11-190000310158mrk:AcceleronPharmaIncMemberus-gaap:MeasurementInputDiscountRateMember2021-11-190000310158mrk:PandionTherapeuticsMember2021-04-012021-04-300000310158mrk:PandionTherapeuticsMember2021-04-300000310158mrk:PandionTherapeuticsMember2021-01-012021-12-310000310158mrk:OralAndInjectableFormulationsMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:GileadSciencesMember2021-03-012021-03-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:GileadSciencesMembermrk:OralFormulationMember2021-03-012021-03-310000310158mrk:InjectableFormulationMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:GileadSciencesMember2021-03-012021-03-310000310158us-gaap:LicensingAgreementsMembermrk:ArtivaBiotherapeuticsIncMember2021-01-012021-01-31mrk:research_programmrk:collaboration_target0000310158us-gaap:LicensingAgreementsMembermrk:DevelopmentMilestonesMembermrk:ArtivaBiotherapeuticsIncMember2021-01-012021-01-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:ArtivaBiotherapeuticsIncMember2021-01-012021-01-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:ArtivaBiotherapeuticsIncMember2021-01-012021-01-310000310158us-gaap:LicensingAgreementsMembermrk:ArtivaBiotherapeuticsIncMembersrt:MinimumMember2021-01-012021-01-310000310158us-gaap:LicensingAgreementsMembersrt:MaximumMembermrk:ArtivaBiotherapeuticsIncMember2021-01-012021-01-310000310158mrk:OncoImmuneMember2020-12-012020-12-310000310158mrk:OncoImmuneMember2020-12-310000310158mrk:OncoImmuneMember2020-12-310000310158mrk:OncoImmuneMember2020-01-012020-12-310000310158mrk:COVID19Member2021-01-012021-12-310000310158mrk:VelosBioMember2020-12-012020-12-310000310158mrk:VelosBioMember2020-12-310000310158mrk:VelosBioMember2020-01-012020-12-310000310158mrk:VelosBioMember2021-01-012021-12-310000310158mrk:VelosBioMember2021-12-012021-12-310000310158mrk:VelosBioMember2021-12-310000310158mrk:SeagenMember2020-09-012020-09-300000310158mrk:SeagenMember2020-09-300000310158mrk:SeagenMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000310158mrk:SeagenMembermrk:DevelopmentMilestonesMember2020-09-012020-09-300000310158mrk:SeagenMembermrk:SalesBasedMilestonesMember2020-09-012020-09-300000310158mrk:SeagenMembermrk:TukysaMember2020-09-012020-09-300000310158mrk:SeagenMembermrk:RegulatoryMilestonesMembermrk:TukysaMember2020-09-012020-09-300000310158mrk:SeagenMembermrk:TukysaMembersrt:MinimumMember2020-09-012020-09-300000310158mrk:SeagenMembersrt:MaximumMembermrk:TukysaMember2020-09-012020-09-300000310158mrk:DunboyneMember2020-09-012020-09-30iso4217:EUR0000310158mrk:DunboyneMember2020-09-300000310158mrk:SentinelMember2020-07-012020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-012020-07-310000310158mrk:SentinelMember2020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-012020-07-310000310158mrk:ThemisMember2020-06-012020-06-300000310158mrk:ThemisMember2020-06-300000310158mrk:COVID19Membermrk:ThemisMember2020-01-012020-12-310000310158mrk:IAVIMember2020-05-012020-05-310000310158mrk:COVID19Member2020-01-012020-12-310000310158mrk:ArQuleMember2020-01-012020-01-310000310158mrk:ArQuleMember2020-01-310000310158mrk:ArQuleMember2020-01-160000310158mrk:ArQuleMemberus-gaap:MeasurementInputDiscountRateMember2020-01-160000310158mrk:LynparzaMembermrk:SalesBasedMilestonesMembermrk:AstraZenecaMember2022-01-012022-12-310000310158mrk:LynparzaMembermrk:SalesBasedMilestonesMembermrk:AstraZenecaMember2022-12-310000310158mrk:LynparzaMember2022-01-012022-12-310000310158mrk:LynparzaMembermrk:SalesBasedMilestonesMembermrk:AstraZenecaMember2020-01-012020-12-310000310158mrk:LynparzaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:AstraZenecaMember2022-12-310000310158mrk:RegulatoryMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-01-012022-12-310000310158mrk:RegulatoryMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2020-01-012020-12-310000310158mrk:LynparzaMemberus-gaap:LicenseMember2022-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:AlliancerevenueLynparzaMember2022-01-012022-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:AlliancerevenueLynparzaMember2021-01-012021-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:AlliancerevenueLynparzaMember2020-01-012020-12-310000310158mrk:AllianceRevenueKoselugoMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:AllianceRevenueKoselugoMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:AllianceRevenueKoselugoMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158us-gaap:OtherCurrentAssetsMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:OtherCurrentAssetsMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:LynparzaMember2020-01-012020-12-310000310158mrk:EisaiMember2021-03-012021-03-310000310158mrk:SalesBasedMilestonesMembermrk:EisaiMembermrk:LenvimaMember2022-01-012022-12-310000310158mrk:SalesBasedMilestonesMembermrk:EisaiMembermrk:LenvimaMember2021-01-012021-12-310000310158mrk:SalesBasedMilestonesMembermrk:EisaiMembermrk:LenvimaMember2020-01-012020-12-310000310158us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMembermrk:EisaiMembermrk:LenvimaMember2022-12-310000310158mrk:RegulatoryMilestonesMembermrk:EisaiMembermrk:LenvimaMember2022-01-012022-12-310000310158mrk:RegulatoryMilestonesMembermrk:EisaiMembermrk:LenvimaMember2021-01-012021-12-310000310158mrk:RegulatoryMilestonesMembermrk:EisaiMembermrk:LenvimaMember2020-01-012020-12-310000310158us-gaap:LicenseMembermrk:LenvimaMember2022-12-310000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:EisaiMember2022-01-012022-12-310000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:EisaiMember2021-01-012021-12-310000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:EisaiMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2020-01-012020-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2022-01-012022-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2021-01-012021-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2020-01-012020-12-310000310158us-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2022-12-310000310158us-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2021-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2022-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMembermrk:EisaiMember2021-12-310000310158mrk:AdempasMembermrk:BayerAGMembermrk:SalesBasedMilestonesMember2022-01-012022-12-310000310158mrk:AdempasMembermrk:BayerAGMembermrk:SalesBasedMilestonesMember2020-01-012020-12-310000310158mrk:AdempasMemberus-gaap:OtherIntangibleAssetsMember2022-12-310000310158mrk:VerquvoMemberus-gaap:OtherIntangibleAssetsMember2022-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-12-310000310158mrk:AdempasMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:AdempasMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:AdempasMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:VerquvoMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:VerquvoMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:VerquvoMemberus-gaap:SalesMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158mrk:BayerAGMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158mrk:BayerAGMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158mrk:BayerAGMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158mrk:BayerAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158mrk:BayerAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158mrk:BayerAGMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2022-01-012022-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2021-01-012021-12-310000310158mrk:RidgebackBiotherapeuticsLPMembermrk:LagevrioMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2020-01-012020-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-12-310000310158us-gaap:AccountsPayableAndAccruedLiabilitiesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembersrt:MinimumMember2022-01-012022-12-310000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembersrt:MaximumMember2022-01-012022-12-310000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ReblozylMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ReblozylMember2021-01-012021-12-310000310158srt:ScenarioForecastMember2023-12-310000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2022-01-012022-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2022-01-012022-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-310000310158us-gaap:RestructuringChargesMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-01-012022-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-01-012022-12-310000310158mrk:AcceleratedDepreciationMember2022-01-012022-12-310000310158us-gaap:OtherRestructuringMember2022-01-012022-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2021-01-012021-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2021-01-012021-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-01-012021-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-01-012021-12-310000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-01-012021-12-310000310158us-gaap:RestructuringChargesMember2021-01-012021-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2021-01-012021-12-310000310158mrk:AcceleratedDepreciationMember2021-01-012021-12-310000310158us-gaap:OtherRestructuringMember2021-01-012021-12-310000310158us-gaap:CostOfSalesMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OtherRestructuringMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-12-310000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2020-01-012020-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2020-01-012020-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2020-01-012020-12-310000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2020-01-012020-12-310000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2020-01-012020-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2020-01-012020-12-310000310158us-gaap:RestructuringChargesMember2020-01-012020-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2020-01-012020-12-310000310158mrk:AcceleratedDepreciationMember2020-01-012020-12-310000310158us-gaap:OtherRestructuringMember2020-01-012020-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2020-12-310000310158mrk:AcceleratedDepreciationMember2020-12-310000310158us-gaap:OtherRestructuringMember2020-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2021-12-310000310158mrk:AcceleratedDepreciationMember2021-12-310000310158us-gaap:OtherRestructuringMember2021-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-12-310000310158mrk:AcceleratedDepreciationMember2022-12-310000310158us-gaap:OtherRestructuringMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2022-01-012022-12-310000310158srt:MaximumMemberus-gaap:NondesignatedMember2022-01-012022-12-310000310158us-gaap:ForeignExchangeContractMember2022-01-012022-12-310000310158us-gaap:ForeignExchangeContractMember2021-01-012021-12-310000310158us-gaap:ForeignExchangeContractMember2020-01-012020-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310000310158mrk:EurodominatedNotesMember2022-01-012022-12-310000310158mrk:EurodominatedNotesMember2021-01-012021-12-310000310158mrk:EurodominatedNotesMember2020-01-012020-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2021-01-012021-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMembermrk:EurodominatedNotesMember2020-01-012020-12-310000310158us-gaap:InterestRateSwapMember2022-01-012022-12-31mrk:interest_rate_swap0000310158mrk:A2.40NotesDue2022Member2022-12-310000310158mrk:A2.35NotesDue2022Member2022-12-310000310158mrk:LongTermDebtCurrentMaturitiesMember2022-12-310000310158mrk:LongTermDebtCurrentMaturitiesMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310000310158us-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:NondesignatedMember2022-12-310000310158us-gaap:NondesignatedMember2021-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-12-310000310158us-gaap:InterestRateSwapMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-12-310000310158us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMember2022-01-012022-12-310000310158us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMember2021-01-012021-12-310000310158us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:ForeignExchangeContractMember2020-01-012020-12-310000310158us-gaap:InterestRateSwapMember2021-01-012021-12-310000310158us-gaap:InterestRateSwapMember2020-01-012020-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2022-01-012022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2021-01-012021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:SalesMember2020-01-012020-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2022-01-012022-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2021-01-012021-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateContractMember2020-01-012020-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:ForwardContractsMember2022-01-012022-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:ForwardContractsMember2021-01-012021-12-310000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:ForwardContractsMember2020-01-012020-12-310000310158us-gaap:CommercialPaperMember2022-12-310000310158us-gaap:CommercialPaperMember2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMember2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2022-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:SanofiPasteurMember2022-12-310000310158mrk:SanofiPasteurMember2021-12-310000310158us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrk:McKessonCorporationMember2022-01-012022-12-310000310158us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrk:AmerisourceBergenCorporationMember2022-01-012022-12-310000310158us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMembermrk:CardinalHealthIncMember2022-01-012022-12-3100003101582022-10-012022-12-3100003101582021-10-012021-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2022-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2021-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2022-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2021-12-310000310158mrk:PharmaceuticalsegmentMember2020-12-310000310158mrk:AnimalHealthsegmentMember2020-12-310000310158mrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158mrk:AnimalHealthsegmentMember2021-01-012021-12-310000310158mrk:PharmaceuticalsegmentMember2021-12-310000310158mrk:AnimalHealthsegmentMember2021-12-310000310158mrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158mrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158mrk:PharmaceuticalsegmentMember2022-12-310000310158mrk:AnimalHealthsegmentMember2022-12-310000310158us-gaap:DevelopedTechnologyRightsMember2022-12-310000310158us-gaap:DevelopedTechnologyRightsMember2021-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2021-12-310000310158us-gaap:TradeNamesMember2022-12-310000310158us-gaap:TradeNamesMember2021-12-310000310158us-gaap:LicenseMember2022-12-310000310158us-gaap:LicenseMember2021-12-310000310158mrk:ReblozylMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:ZerbaxaMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:SivextroMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:GardasilGardasil9Memberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:BridionMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:AnimalHealthMember2022-12-310000310158mrk:AnimalHealthMemberus-gaap:DevelopedTechnologyRightsMember2022-12-310000310158mrk:AnimalHealthMemberus-gaap:TradeNamesMember2022-12-310000310158mrk:SotaterceptMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-310000310158mrk:GefapixantMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-310000310158mrk:ZerbaxaMember2020-01-012020-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-01-012022-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-012022-12-310000310158mrk:DerazantinibMemberus-gaap:LicenseMember2022-01-012022-12-310000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2021-01-012021-12-310000310158mrk:NemtabrutinibMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2021-12-310000310158mrk:NotesSubjectToRepaymentAtOptionOfHolderMember2022-12-310000310158mrk:NotesSubjectToRepaymentAtOptionOfHolderMember2021-12-310000310158us-gaap:CommercialPaperMember2022-12-310000310158us-gaap:CommercialPaperMember2021-12-310000310158mrk:A2.75NotesDue2025Member2022-12-310000310158mrk:A2.75NotesDue2025Member2021-12-310000310158mrk:A215NotesDue2031Member2022-12-310000310158mrk:A215NotesDue2031Member2021-12-310000310158mrk:A275NotesDue2051Member2022-12-310000310158mrk:A275NotesDue2051Member2021-12-310000310158mrk:A3.70NotesDue2045Member2022-12-310000310158mrk:A3.70NotesDue2045Member2021-12-310000310158mrk:A3.40NotesDue2029Member2022-12-310000310158mrk:A3.40NotesDue2029Member2021-12-310000310158mrk:A170NotesDue2027Member2022-12-310000310158mrk:A170NotesDue2027Member2021-12-310000310158mrk:A290NotesDue2061Member2022-12-310000310158mrk:A290NotesDue2061Member2021-12-310000310158mrk:A4.00NotesDue2049Member2022-12-310000310158mrk:A4.00NotesDue2049Member2021-12-310000310158mrk:A415NotesDue2043Member2022-12-310000310158mrk:A415NotesDue2043Member2021-12-310000310158mrk:A145NotesDue2030Member2022-12-310000310158mrk:A145NotesDue2030Member2021-12-310000310158mrk:A245NotesDue2050Member2022-12-310000310158mrk:A245NotesDue2050Member2021-12-310000310158mrk:A1.875EuroNotesDue2026Member2022-12-310000310158mrk:A1.875EuroNotesDue2026Member2021-12-310000310158mrk:A075NotesDue2026Member2022-12-310000310158mrk:A075NotesDue2026Member2021-12-310000310158mrk:A190NotesDue2028Member2022-12-310000310158mrk:A190NotesDue2028Member2021-12-310000310158mrk:A3.90NotesDue2039Member2022-12-310000310158mrk:A3.90NotesDue2039Member2021-12-310000310158mrk:A235NotesDue2040Member2022-12-310000310158mrk:A235NotesDue2040Member2021-12-310000310158mrk:A2.90NotesDue2024Member2022-12-310000310158mrk:A2.90NotesDue2024Member2021-12-310000310158mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember2022-12-310000310158mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember2021-12-310000310158mrk:A0.50eurodenominatednotesdue2024Member2022-12-310000310158mrk:A0.50eurodenominatednotesdue2024Member2021-12-310000310158mrk:A1.375eurodenominatednotesdue2036Member2022-12-310000310158mrk:A1.375eurodenominatednotesdue2036Member2021-12-310000310158mrk:A2.5EuroNotesDue2034Member2022-12-310000310158mrk:A2.5EuroNotesDue2034Member2021-12-310000310158mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember2022-12-310000310158mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember2021-12-310000310158mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember2022-12-310000310158mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember2021-12-310000310158mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember2022-12-310000310158mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember2021-12-310000310158mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember2022-12-310000310158mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember2021-12-310000310158mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember2022-12-310000310158mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember2021-12-310000310158mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember2022-12-310000310158mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember2021-12-310000310158mrk:A63DebenturesDue2026Member2022-12-310000310158mrk:A63DebenturesDue2026Member2021-12-310000310158mrk:A280NotesDue2023Member2022-12-310000310158mrk:A280NotesDue2023Member2021-12-310000310158mrk:OtherLongTermDebtMember2022-12-310000310158mrk:OtherLongTermDebtMember2021-12-310000310158mrk:OtherVariableRateDebtMember2022-12-310000310158mrk:OtherVariableRateDebtMember2021-12-310000310158us-gaap:BuildingMember2022-12-310000310158us-gaap:VehiclesMember2022-12-310000310158country:USmrk:GardasilGardasil9Member2022-12-31mrk:case0000310158mrk:GardasilGardasil9Memberus-gaap:NonUsMember2022-12-310000310158mrk:GardasilGardasil9Membercountry:CO2022-12-310000310158mrk:ZetiaantitrustlitigationMember2020-08-31mrk:claim0000310158mrk:ZetiaantitrustlitigationMemberus-gaap:PendingLitigationMember2022-06-302022-06-300000310158mrk:ZetiaantitrustlitigationMember2022-01-012022-12-310000310158mrk:CommercialandOtherLitigationMember2022-01-012022-12-31mrk:Plaintiff0000310158mrk:CommercialandOtherLitigationMember2022-12-310000310158mrk:BridionMemberus-gaap:PendingLitigationMemberus-gaap:PatentsMember2022-12-192022-12-190000310158mrk:BridionMemberus-gaap:PatentsMember2022-01-012022-12-310000310158mrk:BridionMemberus-gaap:PendingLitigationMemberus-gaap:PatentsMember2022-12-310000310158mrk:PatentlitigationMember2022-01-012022-12-310000310158mrk:LegalDefenseCostsMember2021-12-310000310158mrk:LegalDefenseCostsMember2022-12-310000310158us-gaap:CommonStockMember2022-01-012022-12-310000310158us-gaap:CommonStockMember2021-01-012021-12-310000310158us-gaap:CommonStockMember2020-01-012020-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2021-12-310000310158us-gaap:PerformanceSharesMember2021-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310000310158us-gaap:PerformanceSharesMember2022-01-012022-12-310000310158us-gaap:RestrictedStockUnitsRSUMember2022-12-310000310158us-gaap:PerformanceSharesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-01-012020-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2020-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2020-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USmrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherInvestmentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:CorporateObligationsInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:CorporateObligationsInvestmentFundsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:CorporateObligationsInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:CorporateObligationsInvestmentFundsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:FixedIncomeObligationsInvestmentFundsMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:InsuranceContractsOtherInvestmentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:InsuranceContractsOtherInvestmentsMember2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Member2021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:InsuranceContractsOtherInvestmentsMember2020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2020-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:InsuranceContractsOtherInvestmentsMember2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:InsuranceContractsOtherInvestmentsMember2021-01-012021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherInvestmentsMember2021-01-012021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Membermrk:InsuranceContractsOtherInvestmentsMember2022-12-310000310158country:USus-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Member2022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2020-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2020-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2020-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2020-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2022-01-012022-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-01-012022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2022-01-012022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-01-012022-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMembermrk:InsuranceContractsOtherInvestmentsMember2021-01-012021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-01-012021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMemberus-gaap:OtherInvestmentsMember2021-01-012021-12-310000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2021-01-012021-12-310000310158us-gaap:PensionPlansDefinedBenefitMembermrk:RealEstateInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignPlanMember2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158us-gaap:CashAndCashEquivalentsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:DevelopedMarketsEquitiesInvestmentFundsMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:EmergingMarketsEquitiesInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanRealEstateMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsInvestmentFundsMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Membermrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:DevelopedMarketsEquitySecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Membermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:CorporateObligationsFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembermrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Memberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Memberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanDerivativeMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel1Member2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2021-12-310000310158country:USus-gaap:DefinedBenefitPlanEquitySecuritiesUsMembersrt:MinimumMember2022-12-310000310158country:USus-gaap:DefinedBenefitPlanEquitySecuritiesUsMembersrt:MaximumMember2022-12-310000310158country:USus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMembersrt:MinimumMember2022-12-310000310158country:USsrt:MaximumMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2022-12-310000310158country:USus-gaap:FixedIncomeInvestmentsMembersrt:MinimumMember2022-12-310000310158country:USsrt:MaximumMemberus-gaap:FixedIncomeInvestmentsMember2022-12-310000310158country:USmrk:DefinedBenefitPlanCashandOtherInvestmentsMembersrt:MaximumMember2022-12-310000310158country:US2022-12-310000310158country:US2022-01-012022-12-310000310158country:US2021-01-012021-12-310000310158country:US2020-01-012020-12-310000310158country:US2021-12-310000310158country:US2020-12-310000310158country:USsrt:ScenarioForecastMember2023-01-012023-12-310000310158srt:ScenarioForecastMemberus-gaap:SubsequentEventMember2023-01-012023-03-310000310158mrk:IncomeTaxesPayableMember2022-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000310158us-gaap:OtherAssetsMember2022-12-310000310158us-gaap:OtherAssetsMember2021-12-310000310158us-gaap:ForeignCountryMember2022-12-310000310158us-gaap:DomesticCountryMember2022-12-310000310158us-gaap:DomesticCountryMember2022-01-012022-12-310000310158us-gaap:DomesticCountryMember2021-01-012021-12-310000310158us-gaap:DomesticCountryMember2020-01-012020-12-310000310158us-gaap:ForeignCountryMember2022-01-012022-12-310000310158us-gaap:ForeignCountryMember2021-01-012021-12-310000310158us-gaap:ForeignCountryMember2020-01-012020-12-310000310158us-gaap:InternalRevenueServiceIRSMemberus-gaap:DomesticCountryMember2022-01-012022-12-310000310158us-gaap:InternalRevenueServiceIRSMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:DomesticCountryMember2022-01-012022-12-310000310158us-gaap:SegmentDiscontinuedOperationsMemberus-gaap:InternalRevenueServiceIRSMemberus-gaap:DomesticCountryMember2022-01-012022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000310158mrk:PensionPlanNetLossMember2022-12-310000310158mrk:PensionPlanNetLossMember2021-12-310000310158mrk:OtherPostretirementBenefitPlanNetLossMember2022-12-310000310158mrk:OtherPostretirementBenefitPlanNetLossMember2021-12-310000310158mrk:PensionPlanPriorServiceCostMember2022-12-310000310158mrk:PensionPlanPriorServiceCostMember2021-12-310000310158mrk:OtherPostretirementBenefitPlanPriorServiceCostMember2022-12-310000310158mrk:OtherPostretirementBenefitPlanPriorServiceCostMember2021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:LenvimaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:LenvimaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:LenvimaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ReblozylMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ReblozylMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ReblozylMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ReblozylMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ReblozylMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ReblozylMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ReblozylMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ProQuadMMRIIVarivaxMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ProQuadMMRIIVarivaxMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:ProQuadMMRIIVarivaxMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ProQuadMMRIIVarivaxMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:RotateqMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:RotateqMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:RotateqMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:RotateqMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:Pneumovax23Membermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:VaqtaMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BridionMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BridionMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BridionMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BridionMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrevymisMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrevymisMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrevymisMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrevymisMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:DificidMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:DificidMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:DificidMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:DificidMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:InvanzMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:InvanzMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CancidasMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CancidasMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CancidasMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AdempasMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AdempasMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AdempasMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AdempasMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LagevrioMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LagevrioMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LagevrioMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LagevrioMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:BelsomraMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:BelsomraMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:BelsomraMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:JanuviaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:JanuviaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:JanuviaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:JanuviaMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:JanumetMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:JanumetMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:JanumetMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:OtherPharmaceuticalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:OtherPharmaceuticalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:OtherPharmaceuticalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:LivestockMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:LivestockMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:LivestockMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:LivestockMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembercountry:USmrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembercountry:USmrk:AnimalHealthsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembercountry:USmrk:AnimalHealthsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:CompanionAnimalsMembermrk:AnimalHealthsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMemberus-gaap:AllOtherSegmentsMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembercountry:US2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMember2022-01-012022-12-310000310158us-gaap:OperatingSegmentsMembercountry:US2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMember2021-01-012021-12-310000310158us-gaap:OperatingSegmentsMembercountry:US2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:OperatingSegmentsMember2020-01-012020-12-310000310158country:USus-gaap:CorporateNonSegmentMember2022-01-012022-12-310000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2022-01-012022-12-310000310158us-gaap:CorporateNonSegmentMember2022-01-012022-12-310000310158country:USus-gaap:CorporateNonSegmentMember2021-01-012021-12-310000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2021-01-012021-12-310000310158us-gaap:CorporateNonSegmentMember2021-01-012021-12-310000310158country:USus-gaap:CorporateNonSegmentMember2020-01-012020-12-310000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2020-01-012020-12-310000310158us-gaap:CorporateNonSegmentMember2020-01-012020-12-310000310158country:US2022-01-012022-12-310000310158mrk:InternationalMember2022-01-012022-12-310000310158country:US2021-01-012021-12-310000310158mrk:InternationalMember2021-01-012021-12-310000310158country:US2020-01-012020-12-310000310158mrk:InternationalMember2020-01-012020-12-310000310158us-gaap:EMEAMember2022-01-012022-12-310000310158us-gaap:EMEAMember2021-01-012021-12-310000310158us-gaap:EMEAMember2020-01-012020-12-310000310158country:CN2022-01-012022-12-310000310158country:CN2021-01-012021-12-310000310158country:CN2020-01-012020-12-310000310158country:JP2022-01-012022-12-310000310158country:JP2021-01-012021-12-310000310158country:JP2020-01-012020-12-310000310158srt:AsiaPacificMember2022-01-012022-12-310000310158srt:AsiaPacificMember2021-01-012021-12-310000310158srt:AsiaPacificMember2020-01-012020-12-310000310158srt:LatinAmericaMember2022-01-012022-12-310000310158srt:LatinAmericaMember2021-01-012021-12-310000310158srt:LatinAmericaMember2020-01-012020-12-310000310158mrk:OtherCountriesMember2022-01-012022-12-310000310158mrk:OtherCountriesMember2021-01-012021-12-310000310158mrk:OtherCountriesMember2020-01-012020-12-310000310158us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310000310158us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310000310158us-gaap:MaterialReconcilingItemsMember2020-01-012020-12-310000310158country:US2022-12-310000310158country:US2021-12-310000310158country:US2020-12-310000310158us-gaap:EMEAMember2022-12-310000310158us-gaap:EMEAMember2021-12-310000310158us-gaap:EMEAMember2020-12-310000310158srt:AsiaPacificMember2022-12-310000310158srt:AsiaPacificMember2021-12-310000310158srt:AsiaPacificMember2020-12-310000310158srt:LatinAmericaMember2022-12-310000310158srt:LatinAmericaMember2021-12-310000310158srt:LatinAmericaMember2020-12-310000310158country:CN2022-12-310000310158country:CN2021-12-310000310158country:CN2020-12-310000310158country:JP2022-12-310000310158country:JP2021-12-310000310158country:JP2020-12-310000310158mrk:OtherCountriesMember2022-12-310000310158mrk:OtherCountriesMember2021-12-310000310158mrk:OtherCountriesMember2020-12-31

As filed with the Securities and Exchange Commission on February 24, 2023

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
_________________________________
FORM 10-K
(MARK ONE)
 
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Fiscal Year Ended December 31, 2022

OR
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the transition period from                  to                 

Commission File No. 1-6571
mrk-20221231_g1.jpg
Merck & Co., Inc.
126 East Lincoln Avenue
RahwayNew Jersey07065
(908740-4000
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S Employer Identification No.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of Each Exchange on which Registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.     Yes ☒    No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes ☐    No 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes   No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check One):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes    No  
Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2023: 2,538,592,467.
Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2022 based on the closing price on June 30, 2022: $230,820,000,000.
Documents Incorporated by Reference:
Document Part of Form 10-K
Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023, to be filed with the
Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report
 Part III


Table of Contents
   Page
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
   42
Item 7.
Item 7A.
Item 8.
(a)
Item 9.
Item 9A.
Item 9B.
Item 9C.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Item 15.
Item 16.


PART I
 
Item 1.Business.
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
On June 2, 2021, Merck completed the spin-off (the Spin-Off) of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned.
All product or service marks appearing in type form different from that of the surrounding text are trademarks or service marks owned, licensed to, promoted or distributed by Merck, its subsidiaries or affiliates, except as noted. All other trademarks or services marks are those of their respective owners.
Product Sales
Total Company sales, including sales of the Company’s top pharmaceutical products, as well as sales of animal health products, were as follows:
($ in millions)202220212020
Total Sales$59,283 $48,704 $41,518 
Pharmaceutical52,005 42,754 36,610 
Keytruda20,937 17,186 14,380 
Gardasil/Gardasil 9
6,897 5,673 3,938 
Lagevrio5,684 952 — 
Januvia/Janumet4,513 5,288 5,276 
ProQuad/M-M-R II/Varivax
2,241 2,135 1,878 
Bridion1,685 1,532 1,198 
Alliance revenue - Lynparza(1)
1,116 989 725 
Alliance revenue - Lenvima(1)
876 704 580 
RotaTeq783 807 797 
Simponi706 825 838 
Animal Health5,550 5,568 4,703 
Livestock3,300 3,295 2,939 
Companion Animals2,250 2,273 1,764 
Other Revenues(2)
1,728 382 205 
(1)Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(2)Other revenues are primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements.
1

Pharmaceutical
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. Certain of the products within the Company’s franchises are as follows:
Oncology
Keytruda (pembrolizumab), the Company’s anti-PD-1 (programmed death receptor-1) therapy, as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors), including MSI-H/dMMR colorectal cancer (CRC), MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. Keytruda is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and non-squamous NSCLC, in combination with chemotherapy for HNSCC, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with platinum-and fluoropyrimidine-based chemotherapy for esophageal or GEJ carcinoma, in combination with chemotherapy, with or without bevacizumab, for advanced cervical cancer, in combination with chemotherapy for locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), and in combination with axitinib for advanced renal cell carcinoma (RCC). Keytruda is also approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Keytruda is also approved as a monotherapy for the adjuvant treatment of certain patients with RCC, for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC. In addition, the Company recognizes alliance revenue related to sales of Lynparza (olaparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, for certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic, and metastatic castration-resistant prostate cancers; alliance revenue related to sales of Lenvima (lenvatinib), an oral receptor tyrosine kinase inhibitor, for certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC; and alliance revenue related to Reblozyl (luspatercept-aamt) for the treatment of certain types of anemia.
Vaccines
Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to help prevent certain diseases caused by certain types of human papillomavirus (HPV); ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella; M−M−R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help prevent measles, mumps and rubella; Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella); RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children; Pneumovax 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease; and Vaqta (hepatitis A vaccine, inactivated) indicated for the prevention of disease caused by hepatitis A virus in persons 12 months of age and older.
Hospital Acute Care
Bridion (sugammadex) Injection, a medication for the reversal of two types of neuromuscular blocking agents used during surgery; Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant; Dificid (fidaxomicin) for the treatment of C. difficile-associated diarrhea; Primaxin (imipenem and cilastatin) for injection, an antibiotic for the treatment of certain bacterial infections; Noxafil (posaconazole), an antifungal agent for the prevention of certain invasive fungal infections; Invanz (ertapenem) for injection, an antibiotic for the treatment of certain bacterial infections; Cancidas (caspofungin acetate) for injection, an anti-fungal agent for the treatment of certain fungal infections; and Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections.
Cardiovascular
Adempas (riociguat), a cardiovascular drug for the treatment of chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension in certain patients; Verquvo (vericiguat), a medicine to reduce the
2

risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in certain adults with symptomatic chronic heart failure and reduced ejection fraction.
Virology
Lagevrio, an investigational oral antiviral COVID-19 medicine available in the U.S. under Emergency Use Authorization (EUA); Isentress/Isentress HD (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Neuroscience
Belsomra (suvorexant), an orexin receptor antagonist, indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
Immunology
Simponi (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases; and Remicade (infliximab), a treatment for inflammatory diseases, both of which the Company markets in Europe, Russia and Türkiye.
Diabetes
Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) for the treatment of type 2 diabetes.
Animal Health
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as an extensive suite of digitally connected identification, traceability and monitoring products. Principal products in this segment include:
Livestock Products
Nuflor (Florfenicol) antibiotic range for use in cattle and swine; Bovilis/Vista vaccine lines for infectious diseases in cattle; Banamine (Flunixin meglumine) bovine and swine anti-inflammatory; Estrumate (cloprostenol sodium) for the treatment of fertility disorders in cattle; Matrix (altrenogest) fertility management for swine; Resflor (florfenicol and flunixin meglumine), a combination broad-spectrum antibiotic and non-steroidal anti-inflammatory drug for bovine respiratory disease; Zuprevo (Tildipirosin) for bovine respiratory disease; Zilmax (zilpaterol hydrochloride) and Revalor (trenbolone acetate and estradiol) to improve production efficiencies in beef cattle; Safe-Guard (fenbendazole) de-wormer for cattle; M+Pac (Mycoplasma Hyopneumoniae Bacterin) swine pneumonia vaccine; Porcilis (Lawsonia intracellularis baterin) and Circumvent (Porcine Circovirus Vaccine, Type 2, Killed Baculovirus Vector) vaccine lines for infectious diseases in swine; Nobilis/Innovax (Live Marek’s Disease Vector), vaccine lines for poultry; Paracox and Coccivac coccidiosis vaccines; Exzolt, a systemic treatment for poultry red mite infestations; Slice (Emamectin benzoate) parasiticide for sea lice in salmon; Aquavac (Avirulent Live Culture)/Norvax vaccines against bacterial and viral disease in fish; Compact PD vaccine for salmon; Aquaflor (Florfenicol) antibiotic for farm-raised fish; and Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability.
Companion Animal Products
Bravecto, a line of oral and topical parasitic control products, including the original Bravecto (fluralaner) products for dogs and cats that last up to 12 weeks; Bravecto (fluralaner) One-Month, a monthly product for dogs, and Bravecto Plus (fluralaner/moxidectin), a two-month product for cats; Sentinel, a line of oral parasitic products for dogs including Sentinel Spectrum (milbemycin oxime, lufenuron, and praziquantel) and Sentinel Flavor Tabs (milbemycin oxime, lufenuron); Optimmune (cyclosporine), an ophthalmic ointment; Nobivac vaccine lines for flexible dog and cat vaccination; Otomax (Gentamicin sulfate, USP; Betamethasone valerate USP; and Clotrimazole USP ointment)/Mometamax (Gentamicin sulfate, USP, Mometasone Furoate Monohydrate and Clotrimazole, USP, Otic Suspension)/Posatex (Orbifloxacin, Mometasone Furoate Monohydrate and Posaconazole, Suspension) ear ointments for acute and chronic otitis; Caninsulin/Vetsulin (porcine insulin zinc suspension) diabetes mellitus treatment for dogs and cats; Panacur (fenbendazole)/Safeguard (fenbendazole) broad-spectrum anthelmintic (de-wormer) for use in many animals; Regumate (altrenogest) fertility management for horses; Prestige vaccine line for horses; Scalibor (Deltamethrin)/Exspot for protecting against bites from fleas, ticks, mosquitoes and sandflies; and Sure Petcare products for companion animal identification and well-being, including the microchip and pet recovery system Home Again.
For a further discussion of sales of the Company’s products, see Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” below.

3

2022 Product Approvals
Set forth below is a summary of significant product approvals received by the Company in 2022.
ProductDateApproval
KeytrudaJanuary 2022
European Commission (EC) approved Keytruda as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
February 2022
Japan’s Ministry of Health, Labor and Welfare (MHLW) approved Keytruda plus Lenvima for radically unresectable or metastatic RCC.
February 2022
MHLW approved Keytruda for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care).
March 2022
U.S. Food and Drug Administration (FDA) approved Keytruda as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
April 2022
EC approved Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1.
April 2022
EC approved Keytruda as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial carcinoma.
May 2022
EC approved Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence.
KeytrudaJune 2022
EC approved Keytruda as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection. Additionally, EC approved expanded indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
August 2022
MHLW approved Keytruda as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
September 2022
MHLW approved Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence.
September 2022
MHLW approved Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment.
September 2022
MHLW approved Keytruda as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection.
October 2022
China’s National Medical Products Administration (NMPA) approved Keytruda as monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-based chemotherapy.
November 2022
NMPA approved Keytruda for the treatment of patients with high-risk early-stage TNBC whose tumors express PD-L1, in combination with chemotherapy as neoadjuvant treatment, and then continued as a monotherapy as adjuvant treatment after surgery.
4

Lagevrio(1)
December 2022
NMPA granted emergency conditional approval for Lagevrio for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19.
Lynparza(2)
March 2022
FDA approved Lynparza for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.
August 2022
MHLW approved Lynparza for the adjuvant treatment for patients with BRCA-mutated, HER2-negative high recurrent risk breast cancer.
August 2022EC approved Lynparza as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.
September 2022NMPA approved Lynparza as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.
December 2022EC approved Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
Vaxneuvance
June 2022
FDA approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through 17 years of age. Vaxneuvance is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
September 2022
MHLW approved Vaxneuvance for prevention of infections caused by Streptococcus pneumoniae in the elderly or adults who are considered at increased risk for disease caused by Streptococcus pneumoniae.
October 2022
EC approved an expanded indication for Vaxneuvance to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
(1)    Being jointly developed in collaboration with Ridgeback Biotherapeutics LP.
(2)    Being jointly developed and commercialized in a worldwide collaboration with AstraZeneca.
Competition and the Health Care Environment
Competition
The markets in which the Company conducts its business and the pharmaceutical industry in general are highly competitive and highly regulated. The Company’s competitors include other worldwide research-based pharmaceutical companies, smaller research companies with more limited therapeutic focus, generic drug manufacturers, and animal health care companies. The Company’s operations may be adversely affected by generic and biosimilar competition as the Company’s products mature, as well as technological advances of competitors, industry consolidation, patents granted to competitors, competitive combination products, new products of competitors, the generic availability of competitors’ branded products, and new information from clinical trials of marketed products or post-marketing surveillance. In addition, patent rights are increasingly being challenged by competitors, and the outcome can be highly uncertain. An adverse result in a patent dispute can preclude commercialization of products or negatively affect sales of existing products and could result in the payment of royalties or in the recognition of an impairment charge with respect to intangible assets associated with certain products.
Pharmaceutical competition involves a rigorous search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well-positioned to compete in the search for technological innovations. The Company is active in acquiring and
5

marketing products through external alliances, such as licensing arrangements and collaborations and has been refining its sales and marketing efforts to address changing industry conditions. However, the introduction of new products and processes by competitors may result in price reductions and product displacements, even for products protected by patents. For example, the number of compounds available to treat a particular disease typically increases over time and can result in slowed sales growth or reduced sales for the Company’s products in that therapeutic category.
The highly competitive animal health business is affected by several factors including regulatory and legislative issues, scientific and technological advances, product innovation, the quality and price of the Company’s products as well as competitors’ products, effective promotional efforts and the frequent introduction of generic products by competitors.
Health Care Environment and Government Regulation
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access. Changes to the U.S. health care system as part of health care reform enacted in prior years, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales and profits.
United States
The Company faces increasing pricing pressure from managed care organizations, government agencies and programs that could negatively affect the Company’s sales and profit margins, including, through (i) practices of managed care organizations, federal and state exchanges, and institutional and governmental purchasers, and (ii) federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Patient Protection and Affordable Care Act of 2010 (ACA), the American Rescue Plan Act of 2021 (American Rescue Plan Act), and the Inflation Reduction Act of 2022 (Inflation Reduction Act).
In the U.S., federal and state governments for many years have pursued methods to reduce the cost of drugs and vaccines for which they pay. For example, federal and state laws require the Company to pay specified rebates for medicines reimbursed by Medicaid and to provide discounts for medicines purchased by certain state and federal entities such as the Department of Defense, Veterans Affairs, Public Health Service entities and hospitals serving a disproportionate share of low income or uninsured patients.
Additionally in the U.S., consolidation and integration among health care providers is a major factor in the competitive marketplace for pharmaceutical products. Health plans and pharmacy benefit managers (PBMs) have been consolidating into fewer, larger entities, thus enhancing their purchasing strength and importance. Private third-party insurers, as well as governments, employ formularies to control costs by negotiating discounted prices in exchange for formulary inclusion. Failure to obtain timely or adequate pricing or formulary placement for Merck’s products or obtaining such placement at unfavorable pricing could adversely affect revenue. In addition to formulary tier co-pay differentials, private health insurance companies and self-insured employers have been increasing the cost-sharing required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private health insurance companies also are increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. These same management tools are also used in treatment areas in which the payor has taken the position that multiple branded products are therapeutically comparable. As the U.S. payor market concentrates further, the Company may face greater pricing pressure from private third-party payors.
In order to provide information about the Company’s pricing practices, the Company annually posts on its website its Pricing Transparency Report for the U.S. The report provides the Company’s average annual list price, net price increases, and average discounts across the Company’s U.S. portfolio dating back to 2010. In 2022, the Company’s gross U.S. sales were reduced by 39.7% as a result of rebates, discounts and returns.
Legislative Changes
In 2022, Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of
6

the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028.
The long-term implications of the Inflation Reduction Act remain uncertain and subject to various factors, including the manner in which U.S. Department of Health and Human Services decides to implement the statute. Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time. Merck is working to mitigate the potentially harmful effects that the law could have on innovation.
In addition, in 2021, Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.
The Company also faces increasing pricing pressure in the states, which are looking to exert greater influence over the price of prescription drugs. A number of states have passed pharmaceutical price and cost transparency laws. These laws typically require manufacturers to report certain product price information or other financial data to the state. Some laws also require manufacturers to provide advance notification of price increases. The Company expects that states will continue their focus on pharmaceutical pricing and will increasingly shift to more aggressive price control tools such as Prescription Drug Affordability Boards that have the authority to conduct affordability reviews and establish upper payment limits.
Regulatory Changes
In November 2020, the Department of Health and Human Services Office of Inspector General issued a Final Rule that would have, effective January 1, 2023, eliminated the Anti-Kickback Statute safe harbor for rebates paid to Medicare Part D plans or to PBMs on behalf of such plans. Congress has delayed implementation of this Final Rule until January 1, 2026 and pending federal legislation would repeal it entirely. While the Company cannot anticipate the effects of this change to the way it currently contracts, this new framework could significantly alter the way it does business with Part D Plan Sponsors and PBMs on behalf of such plans. This rulemaking also established, effective January 1, 2021, a new safe harbor for point of sale discounts at the pharmacy counter and a new safe harbor for certain service arrangements between pharmaceutical manufacturers and PBMs.
The pharmaceutical industry also could be considered a potential source of savings via other legislative and administrative proposals that have been debated but not enacted. These types of revenue generating or cost saving proposals include additional direct price controls.
European Union
Efforts toward health care cost containment remain intense in the European Union (EU). The Company faces competitive pricing pressure resulting from generic and biosimilar drugs. In addition, a majority of countries in the EU attempt to contain drug costs by engaging in reference pricing in which authorities examine pre-determined markets for published prices of drugs. Reference pricing may either compare a product’s prices in other markets (external reference pricing), or compare a product’s price with those of other products in a national class (internal reference pricing). The authorities then use the price data to set new local prices for brand-name drugs, including the Company’s drugs. Guidelines for examining reference pricing are usually set in local markets and can be changed pursuant to local regulations. Some EU Member States have established free-pricing systems, but regulate the pricing for drugs through profit control plans. Others seek to negotiate or set prices based on the cost-effectiveness of a product or an assessment of whether it offers a therapeutic benefit over other products in the relevant class. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In some EU Member States, cross-border imports from low-priced markets also exert competitive pressure that may reduce pricing within an EU Member State.
Additionally, EU Member States have the power to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement. In the EU, pricing and reimbursement plans vary widely from Member State to Member State. Some EU Member States provide that drug products may be marketed only after a reimbursement price has been agreed. Some EU Member States may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to already available therapies or so-called health technology assessments (HTA), in order to obtain reimbursement or pricing approval. The HTA of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in
7

most EU Member States. The HTA process, which is governed by the national laws of these countries, involves the assessment of the cost-effectiveness, public health impact, therapeutic impact and/or the economic and social impact of use of a given pharmaceutical product in the national health care system of the individual country in which it is conducted. Ultimately, HTA measures the added value of a new health technology compared to existing ones. The outcome of HTAs regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to these pharmaceutical products by the regulatory authorities of individual EU Member States. A negative HTA of one of the Company’s products may mean that the product is not reimbursable or may force the Company to reduce its reimbursement price or offer discounts or rebates.
A negative HTA by a leading and recognized HTA body could also undermine the Company’s ability to obtain reimbursement for the relevant product outside a jurisdiction. For example, EU Member States that have not yet developed HTA mechanisms may rely to some extent on the HTA performed in other countries with a developed HTA framework, to inform their pricing and reimbursement decisions. HTA procedures require additional data, reviews and administrative processes, all of which increase the complexity, timing and costs of obtaining product reimbursement and exert downward pressure on available reimbursement.
To obtain reimbursement or pricing approval in some EU Member States, the Company may be required to conduct studies that compare the cost-effectiveness of the Company’s product candidates to other therapies that are considered the local standard of care. There can be no assurance that any EU Member State will allow favorable pricing, reimbursement and market access conditions for any of the Company’s products, or that it will be feasible to conduct additional cost-effectiveness studies, if required.
Japan
In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricings for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules. In addition, if a Merck product has the same medical action or composition of another product that is subject to market expansion re-pricing, the Merck product could also be subject to re-pricing unless it meets exception criteria. The next government-mandated price reduction will occur in April 2023.
China
The Company’s business in China has grown rapidly in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business has increased accordingly. Continued growth of the Company’s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company’s current in-line products, and the absence of trade impediments or adverse pricing controls. In recent years, the Chinese government has introduced and implemented a number of structural reforms to accelerate the shift to innovative products and reduce costs. Since 2017, there have been multiple new policies introduced by the government to improve access to new innovation, reduce the complexity of regulatory filings, and accelerate the review and approval process. This has led to a significant increase in the number of new products being approved each year. While the mechanism for drugs being added to the government’s National Reimbursement Drug List (NRDL) evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. A new NRDL was recently completed in which new entries averaged 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through volume based procurement (VBP). In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.
Emerging Markets
The Company’s focus on emerging markets, in addition to China, has continued. Governments in many emerging markets are also focused on constraining health care costs and have enacted price controls and measures impacting intellectual property, including in exceptional cases, threats of compulsory licenses, that aim to put pressure on the price of innovative pharmaceuticals or result in constrained market access to innovative medicine. The Company anticipates that pricing pressures and market access challenges will continue in the future to varying degrees in the emerging markets.
Beyond pricing and market access challenges, other conditions in emerging market countries can affect the Company’s efforts to continue to grow in these markets, including potential political instability, changes in trade sanctions and embargoes, significant currency fluctuation and controls, financial crises, limited or changing availability of funding for health care, credit worthiness of health care partners, such as hospitals, and other
8

developments that may adversely impact the business environment for the Company. Further, the Company may engage third-party agents to assist in operating in emerging market countries, which may affect its ability to realize continued growth and may also increase the Company’s risk exposure.
In addressing global cost containment pressures, the Company engages in public policy advocacy with policymakers and continues to work to demonstrate that its medicines provide value to patients and to those who pay for health care. The Company advocates with government policymakers to encourage a long-term approach to sustainable health care financing that ensures access to innovative medicines and does not disproportionately target pharmaceuticals as a source of budget savings. In markets with historically low rates of health care spending, the Company encourages those governments to increase their investments and adopt market reforms in order to improve their citizens’ access to appropriate health care, including medicines.
Operating conditions have become more challenging under the global pressures of competition, industry regulation and cost containment efforts. Although no one can predict the effect of these and other factors on the Company’s business, the Company continually takes measures to evaluate, adapt and improve the organization and its business practices to better meet customer needs and believes that it is well-positioned to respond to the evolving health care environment and market forces.
Regulation
The pharmaceutical industry is also subject to regulation by regional, country, state and local agencies around the world focused on standards and processes for determining drug safety and effectiveness, as well as conditions for sale or reimbursement.
Of particular importance is the FDA in the U.S., which administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling, and marketing of prescription pharmaceuticals. In some cases, the FDA requirements and practices have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. At the same time, the FDA has committed to expediting the development and review of products bearing the “breakthrough therapy” designation, which has accelerated the regulatory review process for medicines with this designation. The FDA has also undertaken efforts to bring generic competition to market more efficiently and in a more timely manner.
The EU has adopted directives and other legislation concerning the classification, approval for marketing, labeling, advertising, manufacturing, wholesale distribution, integrity of the supply chain, pharmacovigilance and safety monitoring of medicinal products for human use. These provide mandatory standards throughout the EU, which may be supplemented or implemented with additional regulations by the EU Member States. In particular, EU regulators may approve products subject to a number of post-authorization conditions. Examples of typical post-authorization commitments include additional pharmacovigilance, the conduct of clinical trials, the establishment of patient registries, physician or patient education and controlled distribution and prescribing arrangements. Non-compliance with post-authorization conditions, pharmacovigilance and other obligations can lead to regulatory action, including the variation, suspension or withdrawal of the marketing authorizations, or other enforcement or regulatory actions, including the imposition of financial penalties. The Company’s policies and procedures are already consistent with the substance of these directives; consequently, it is believed that they will not have any material effect on the Company’s business.
The Company believes that it will continue to be able to conduct its operations, including launching new drugs, in this regulatory environment. (See “Research and Development” below for a discussion of the regulatory approval process.)
Access to Medicines
As a global health care company, Merck’s primary role is to discover and develop innovative medicines and vaccines. The Company also recognizes that, in collaboration with key stakeholders, it has a role to play in helping to ensure that its science advances health care, and its products are accessible and affordable. The Company is committed to ensuring a reliable, safe global supply of its quality medicines and vaccines, and to developing, testing and implementing innovative solutions that address barriers to access and affordability of its medicines and vaccines. The Company’s approach is designed to enable it to serve the greatest number of patients today, while meeting the needs of patients in the future. The Company’s efforts in this regard are wide-ranging and include a set of principles that the Company strives to embed into its operations and business strategies to guide the Company’s worldwide approach to expanding access to health care. The Company systematically evaluates its pipeline candidates to identify potential to address significant public health burden and unmet medical needs in underserved health care settings. Products continue to be evaluated for their potential throughout their life cycle to account for changes in the external environment. The Company also collaborates with different stakeholders,
9

including private, governmental, multilateral and non-profit organizations, to design and deliver sustainable solutions to help address access challenges at the payer, provider and patient levels.
In addition, through innovative social investments, including philanthropic programs and impact investing, Merck is helping to strengthen health systems and build capacity, particularly in under-resourced communities. The Merck Patient Assistance Program provides certain medicines and adult vaccines for free to people in the U.S. who do not have prescription drug or health insurance coverage and who, without the Company’s assistance, cannot afford their Merck medicines and vaccines. Globally, Merck has made substantial contributions to access to health through key initiatives, including product donations for humanitarian assistance in low-income countries through the Medical Outreach Program. The Mectizan Donation Program, the longest running disease-specific drug donation program of its kind, supports the elimination of two neglected tropical diseases – onchocerciasis and lymphatic filariasis. Additionally, through Merck for Mothers the Company provides funding, and scientific and business acumen to help global health partners end preventable deaths from complications of pregnancy and childbirth. Merck has also provided funds to the Merck Foundation, an independent grantmaking organization, which supports a variety of organizations dedicated to addressing systemic barriers to health equity.
Privacy and Data Protection
The Company is subject to a significant number of privacy and data protection laws and regulations globally, many of which place restrictions on the Company’s ability to transfer, access and use personal data across its business. The legislative and regulatory landscape for privacy and data protection continues to evolve. There has been increased attention to privacy and data protection issues in both developed and emerging markets with the potential to affect directly the Company’s business, including the EU General Data Protection Regulation (GDPR), which imposes penalties of up to 4% of global revenue.
The GDPR and related implementing laws in individual EU Member States govern the collection and use of personal health data and other personal data in the EU. The GDPR increased responsibility and liability in relation to personal data that the Company processes. It also imposes a number of strict obligations and restrictions on the ability to process (which includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities, and the security and confidentiality of the personal data. Further, the GDPR prohibits the transfer of personal data to countries outside of the EU that are not considered by the EC to provide an adequate level of data protection, including to the U.S., except if the data controller meets very specific requirements. Following the Schrems II decision of the Court of Justice of the EU in 2020, there is considerable uncertainty as to the permissibility of international data transfers under the GDPR. In light of the implications of this decision, the Company may face difficulties regarding the transfer of personal data from the EU to third countries. Since then, the Company diligently entered into the EU-approved Standard Contractual Clauses with its vendors, suppliers, collaboration partners and clinical trial sites in order to facilitate the lawful transfer of personal data from the EU to the U.S. In addition, President Biden issued an Executive Order on October 7, 2022 to address the data privacy concerns raised in the Schrems II decision through introducing, among other measures, further safeguards and oversight of personal data collection by U.S. signals intelligence activities and providing individuals with a redress mechanism in the U.S. for their data protection concerns. Further certainty for the international transfer of personal data from the EU via the EU-U.S. Data Privacy Framework (successor to the invalidated EU-U.S. Privacy Shield) may come by way of a new EU Adequacy Decision, issued in draft form by the EU Commission on December 13, 2022 and expected to come into force in mid-2023. However, it remains likely that such a new Adequacy Decision will be contested by privacy advocates and be subject to legal review.
Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant monetary fines and other administrative penalties as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning implementation and compliance practices is often updated or otherwise revised.
There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against the Company, harm to its reputation, and adversely impact its business and operating results. The uncertainty regarding the interplay between
10

different regulatory frameworks further adds to the complexity that the Company faces with regard to data protection regulation.
In August 2021, China passed the Personal Information Protection Law (PIPL) that aims to standardize the handling of personal information in China which became effective in November 2021. The PIPL currently applies to the processing of personal information of natural persons in China, the processing of personal information outside China where the purpose is to provide products and services in China, and to analyze the activities of individuals in China. While similar to the GDPR, the PIPL contains unique requirements not found in the GDPR.
The Company has developed and implemented comprehensive plans to ensure compliance with the PIPL, with those relating to data localization and cross-border transfers yet to be completed pending forthcoming guidance from the Cyberspace Administration of China.
Additional laws and regulations enacted in the U.S. (such as comprehensive data protection acts in California, Virginia, Colorado, Utah and Connecticut), Canada, Europe, Asia, and Latin America, have increased enforcement and litigation activity in the U.S. and other developed markets, as well as increased regulatory cooperation among privacy authorities globally. The Company has adopted a comprehensive global privacy program to manage these evolving requirements and risks and to facilitate the transfer of personal information across international borders.
Distribution
The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, PBMs and other institutions. Human health vaccines are sold primarily to physicians, wholesalers, physician distributors and government entities. The Company’s professional representatives communicate the effectiveness, safety and value of the Company’s pharmaceutical and vaccine products to health care professionals in private practice, group practices, hospitals and managed care organizations. The Company sells its animal health products to veterinarians, distributors, animal producers, farmers and pet owners.
Patents, Trademarks and Licenses
Patent protection is considered, in the aggregate, to be of material importance to the Company’s marketing of its products in the U.S. and in most major foreign markets. Patents may cover products per se, pharmaceutical formulations, processes for, or intermediates useful in, the manufacture of products, or the uses of products. Protection for individual products extends for varying periods in accordance with the legal life of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent and its scope of coverage.
The Food and Drug Administration Modernization Act includes a Pediatric Exclusivity Provision that may provide an additional six months of market exclusivity in the U.S. for indications of new or currently marketed drugs if certain agreed upon pediatric studies are completed by the applicant. Current U.S. patent law provides additional patent term for periods when the patented product was under regulatory review by the FDA. The EU also provides an additional six months of pediatric market exclusivity attached to a product’s Supplementary Protection Certificate (SPC). Japan provides the additional term for pediatric studies attached to market exclusivity unrelated to patent term.

11

Patent portfolios developed for products introduced by the Company normally provide market exclusivity. The Company has the following key patent protection in the U.S., the EU, Japan and China (including the potential for patent term extensions (PTE) and SPCs where indicated) for the following marketed products:
ProductYear of Expiration (U.S.)
Year of Expiration (EU)(1)
Year of Expiration (Japan)(2)
Year of Expiration (China)
Januvia
Expired(3)
Expired2025-2026Expired
Janumet
Expired(3)
ExpiredN/AExpired
Janumet XR
Expired(3)
N/AN/AExpired
Isentress20242023
2023-2026(4)
Expired
Simponi
N/A(5)
2024(6)
N/A(5)
N/A(5)
Lenvima(7)
2025(8)
2026(8) (SPCs)
2026Expired
Bridion
2026(8)
20232024Expired
Bravecto2026 (with pending PTE)2025 (patents), 2029 (SPCs)20292025
Gardasil2028ExpiredExpiredN/A
Gardasil 9
2028
2025 (patents), 2030(8) (SPCs)
N/A2025
Keytruda202820312032-20332028
Lynparza(9)
2028(8) (with pending PTE)
2024 (patents), 2029(8) (SPCs)
2028-20292024
Zerbaxa
2028(8)
2023 (patents), 2028(8) (SPCs)
2028 N/A
Adempas(10)
N/A(11)
2028(8)
2027-20282023
Belsomra2029N/A2031N/A
Prevymis
2029(8) (with pending PTE)
2024 (patents), 2029(8) (SPCs)
20292024
Verquvo(10)
2035 (with pending PTE)
N/A(12)
N/A(12)
N/A(12)
Vaxneuvance
2031 (with pending PTE)No PatentNo PatentN/A
Delstrigo2032 (with pending PTE)2031 (patents), 2033 (SPCs)N/A2031
Pifeltro2032 (with pending PTE)2031 (patents), 2033 (SPCs)20362031
Recarbrio
2033(8) (with pending PTE)
2029 (patents), 2034 (SPCs)2034 (with pending PTE)N/A
Welireg2035 (with pending PTE)N/AN/AN/A
Note:    Compound patent unless otherwise noted. Certain of the products listed may be the subject of patent litigation. See Item 8. “Financial Statements and Supplementary Data,” Note 11. “Contingencies and Environmental Liabilities” below.
N/A:    Currently no marketing approval.
(1)The EU date represents the expiration date for the following four countries: France, Germany, Italy, and Spain (Major EU Markets). If SPC applications have been filed but have not been granted in all Major EU Markets, both the patent expiry date and the SPC expiry date are listed.
(2)The PTE system in Japan allows for a patent to be extended more than once provided the later approval is directed to a different indication from that of the previous approval. This may result in multiple PTE approvals for a given patent, each with its own expiration date.
(3)As a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. before the end of 2023, and it is likely that exclusivity will extend through May 2026.
(4)Expiry date reflects the approved product and includes granted PTE for the 600 mg tablet in Japan.
(5)The Company has no marketing rights in the U.S., Japan or China.
(6)The distribution agreement with Janssen Pharmaceuticals, Inc. expires on October 1, 2024.
(7)Part of a global strategic oncology collaboration with Eisai Co., Ltd.
(8)Eligible for 6 months Pediatric Exclusivity.
(9)Part of a global strategic oncology collaboration with AstraZeneca.
(10)Being commercialized in a worldwide collaboration with Bayer AG.
(11)The Company has no marketing rights in the U.S.
(12)The Company has no marketing rights in the EU, Japan or China.

12

The Company has the following key U.S. patent protection for drug candidates under review in the U.S. by the FDA. Additional patent term may be provided for these pipeline candidates based on Patent Term Restoration and Pediatric Exclusivity.
Under Review in the U.S. Currently Anticipated
Year of Expiration (in the U.S.)
MK-7264 (gefapixant)
2027
The Company also has the following key U.S. patent protection for drug candidates in Phase 3 development: 
Phase 3 Drug CandidateCurrently Anticipated
Year of Expiration (in the U.S.)
MK-7962 (sotatercept)(1)
2027
MK-8591A (doravirine + islatravir)
2032 (pending PTE for doravirine)
MK-1308A (quavonlimab + pembrolizumab)
2035
MK-7684A (vibostolimab + pembrolizumab)
2035
MK-4280A (favezelimab + pembrolizumab)
2035
MK-1654 (clesrovimab)
2036
MK-4482 Lagevrio(2)
2038
V-116 (pneumococcal vaccine)2038
MK-3475A (pembrolizumab + hyaluronidase subcutaneous)2039
(1)As a biologic product, sotatercept will be eligible for 12 years of data exclusivity upon approval in the U.S.
(2)Received Emergency Use Authorization from the FDA for the treatment of high-risk adults with mild to moderate COVID-19.
Unless otherwise noted, the patents in the above charts are compound patents. Each patent may be subject to a future patent term restoration of up to five years and six month pediatric market exclusivity, either or both of which may be available. In addition, depending on the circumstances surrounding any final regulatory approval of the compound, there may be other listed patents or patent applications pending that could have relevance to the product as finally approved; the relevance of any such application would depend upon the claims that ultimately may be granted and the nature of the final regulatory approval of the product. Also, regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a compound’s patent estate. In the U.S., the data protection generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication and 12 years from first marketing approval of a biological product.
While the expiration of a compound patent normally results in a loss of market exclusivity for the covered pharmaceutical product, commercial benefits may continue to be derived from: (i) later-expiring patents on processes and intermediates related to the most economical method of manufacture of the active ingredient of such product; (ii) patents relating to the use of such product; (iii) patents relating to novel compositions and formulations; and (iv) in the U.S. and certain other countries, market exclusivity that may be available under relevant law. The effect of product patent expiration on pharmaceutical products also depends upon many other factors such as the nature of the market and the position of the product in it, the growth of the market, the complexities and economics of the process for manufacture of the active ingredient of the product and the requirements of new drug provisions of the Federal Food, Drug and Cosmetic Act or similar laws and regulations in other countries.
Additions to market exclusivity are sought in the U.S. and other countries through all relevant laws, including laws increasing patent life. Some of the benefits of increases in patent life have been partially offset by an increase in the number of incentives for and use of generic products. Additionally, improvements in intellectual property laws are sought in the U.S. and other countries through reform of patent and other relevant laws and implementation of international treaties.
For further information with respect to the Company’s patents, see Item 1A. “Risk Factors” and Item 8. “Financial Statements and Supplementary Data,” Note 11. “Contingencies and Environmental Liabilities” below.
Worldwide, all of the Company’s important products are sold under trademarks that are considered in the aggregate to be of material importance. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and can be renewed indefinitely.
Royalty income in 2022 on patent and know-how licenses and other rights amounted to $537 million. Merck also incurred royalty expenses amounting to $3.0 billion in 2022 under patent and know-how licenses it holds.
13

Research and Development
The Company’s business is characterized by the introduction of new products or new uses for existing products through a strong research and development program. At December 31, 2022, approximately 19,200 people were employed in the Company’s research activities. The Company prioritizes its research and development efforts and focuses on candidates that it believes represent breakthrough science for unmet medical needs that will make a difference for patients and payers.
The Company maintains a number of long-term exploratory and fundamental research programs in biology and chemistry as well as research programs directed toward product development. The Company’s research and development model is designed to increase productivity and improve the probability of success by prioritizing the Company’s research and development resources on candidates the Company believes are capable of providing unambiguous, promotable advantages to patients and payers and delivering the maximum value of its approved medicines and vaccines through new indications and new formulations. Merck is pursuing emerging product opportunities independent of therapeutic area or modality (small molecule, biologics and vaccines) and is building its biologics capabilities. The Company is committed to ensuring that externally sourced programs remain an important component of its pipeline strategy, with a focus on supplementing its internal research through acquisitions as well as a licensing and external alliance strategy focused on the entire spectrum of collaborations from early research to late-stage compounds, as well as access to new technologies.
The Company’s clinical pipeline includes candidates in multiple disease areas, including cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, respiratory diseases, and vaccines.
In the development of human health products, industry practice and government regulations in the U.S. and most foreign countries provide for the determination of effectiveness and safety of new chemical compounds through preclinical tests and controlled clinical evaluation. Before a new drug or vaccine may be marketed in the U.S., recorded data on preclinical and clinical experience are included in the New Drug Application (NDA) for a drug or the Biologics License Application (BLA) for a vaccine or biologic submitted to the FDA for the required approval.
Once the Company’s scientists discover a new small molecule compound or biologic that they believe has promise to treat a medical condition, the Company commences preclinical testing with that compound. Preclinical testing includes laboratory testing and animal safety studies to gather data on chemistry, pharmacology, immunogenicity and toxicology. Pending acceptable preclinical data, the Company will initiate clinical testing in accordance with established regulatory requirements. The clinical testing begins with Phase 1 studies, which are designed to assess safety, tolerability, pharmacokinetics, and preliminary pharmacodynamic activity of the compound in humans. If favorable, additional, larger Phase 2 studies are initiated to determine the efficacy of the compound in the affected population, define appropriate dosing for the compound, as well as identify any adverse effects that could limit the compound’s usefulness. In some situations, the clinical program incorporates adaptive design methodology to use accumulating data to decide how to modify aspects of the ongoing clinical study as it continues, without undermining the validity and integrity of the trial. One type of adaptive clinical trial is an adaptive Phase 2a/2b trial design, a two-stage trial design consisting of a Phase 2a proof-of-concept stage and a Phase 2b dose-optimization finding stage. If data from the Phase 2 trials are satisfactory, the Company commences large-scale Phase 3 trials to confirm the compound’s efficacy and safety. Another type of adaptive clinical trial is an adaptive Phase 2/3 trial design, a study that includes an interim analysis and an adaptation that changes the trial from having features common in a Phase 2 study (e.g., multiple dose groups) to a design similar to a Phase 3 trial. An adaptive Phase 2/3 trial design reduces timelines by eliminating activities which would be required to start a separate study. Upon completion of Phase 3 trials, if satisfactory, the Company submits regulatory filings with the appropriate regulatory agencies around the world to have the product candidate approved for marketing. There can be no assurance that a compound that is the result of any particular program will obtain the regulatory approvals necessary for it to be marketed.
Vaccine development follows the same general pathway as for drugs. Preclinical testing focuses on the vaccine’s safety and ability to elicit a protective immune response (immunogenicity). Pre-marketing vaccine clinical trials are typically done in three phases. Initial Phase 1 clinical studies are conducted in normal subjects to evaluate the safety, tolerability and immunogenicity of the vaccine candidate. Phase 2 studies are dose-ranging studies and provide additional data on safety, immunogenicity and/or effectiveness. Finally, Phase 3 trials are conducted in the intended population for licensure and provide data on immunogenicity and/or effectiveness, as well as safety, to support applications for regulatory approvals. If successful, the Company submits regulatory filings with the appropriate regulatory agencies.
In the U.S., the FDA review process begins once a complete NDA or BLA is submitted, received and accepted for review by the agency. Within 60 days after receipt, the FDA determines if the application is sufficiently complete to permit a substantive review. The FDA also assesses, at that time, whether the application will be granted
14

a priority review or standard review. Pursuant to the Prescription Drug User Fee Act V (PDUFA), the FDA review period target for NDAs or original BLAs is either six months, for priority review, or ten months, for a standard review, from the time the application is deemed sufficiently complete. Once the review timelines are determined, the FDA will generally act upon the application within those timelines, unless a major amendment has been submitted (either at the Company’s own initiative or the FDA’s request) to the pending application. If this occurs, the FDA may extend the review period to allow for review of the new information, but by no more than three months. Extensions to the review period are communicated to the Company. The FDA can act on an application either by issuing an approval letter or by issuing a Complete Response Letter (CRL) stating that the application will not be approved in its present form and describing all deficiencies that the FDA has identified. Should the Company wish to pursue an application after receiving a CRL, it can resubmit the application with information that addresses the questions or issues identified by the FDA in order to support approval. Resubmissions are subject to review period targets, which vary depending on the underlying submission type and the content of the resubmission.
The FDA has four program designations — Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review — to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product’s development and the ability for the manufacturer to do a rolling submission of the NDA/BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The Breakthrough Therapy designation provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product’s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA’s goal is to take action on the NDA/BLA within six months, compared to ten months under standard review. More than one of these special designations can be granted for a given application (i.e., a product designated as a Breakthrough Therapy may also be eligible for Priority Review).
Due to the COVID-19 public health crisis, the U.S. Secretary of Health and Human Services has exercised statutory authority to determine that a public health emergency exists, and declared these circumstances justify the emergency use of drugs and biological products as authorized by the FDA. While in effect, this declaration enables the FDA to issue Emergency Use Authorizations (EUAs) permitting distribution and use of specific medical products absent NDA/BLA submission or approval, including products to treat or prevent diseases or conditions caused by the SARS-CoV-2 virus, subject to the terms of any such EUAs. The FDA must make certain findings to grant an EUA, including that it is reasonable to believe based on the totality of evidence that the drug or biologic may be effective, and that known or potential benefits when used under the terms of the EUA outweigh known or potential risks. Additionally, the FDA must find that there is no adequate, approved and available alternative to the emergency use of the authorized drug or biologic. The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect the public health or safety.
The primary method the Company uses to obtain marketing authorization of pharmaceutical products in the EU is through the “centralized procedure.” This procedure is compulsory for certain pharmaceutical products, in particular those using biotechnological processes, and is also available for certain new chemical compounds and products. A company seeking to market an innovative pharmaceutical product through the centralized procedure must file a complete set of safety data and efficacy data as part of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA). After the EMA evaluates the MAA, it provides a recommendation to the EC and the EC then approves or denies the MAA. It is also possible for new chemical products to obtain marketing authorization in the EU through a “mutual recognition procedure” in which an application is made to a single member state and, if the member state approves the pharmaceutical product under a national procedure, the applicant may submit that approval to the mutual recognition procedure of some or all other EU Member States.
Outside of the U.S. and the EU, the Company submits marketing applications to national regulatory authorities. Examples of such are the Ministry of Health, Labour and Welfare in Japan, the National Medical Products Administration in China, Health Canada, Agência Nacional de Vigilância Sanatária in Brazil, Korea Food and Drug Administration in South Korea, and the Therapeutic Goods Administration in Australia. Each country has a separate and independent review process and timeline. In many markets, approval times can be longer as the regulatory authority requires approval in a major market, such as the U.S. or the EU, and issuance of a Certificate of Pharmaceutical Product from that market before initiating their local review process.
15

Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally or in late-stage clinical development.
MK-4482, Lagevrio, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing Lagevrio in collaboration with Ridgeback Biotherapeutics LP (Ridgeback). The FDA granted Emergency Use Authorization (EUA) for Lagevrio in December 2021; last issued in February 2023, to authorize Lagevrio for the treatment of adults with a current diagnosis of mild-to-moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. Lagevrio is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the EMA issued a positive scientific opinion for Lagevrio, which is intended to support national decision-making on the possible use of Lagevrio prior to marketing authorization. In October 2021, the EMA initiated a rolling review for Lagevrio for the treatment of COVID-19 in adults. On February 24, 2023, Merck and Ridgeback announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended the refusal of the marketing authorization for Lagevrio. Merck and Ridgeback will appeal the decision and request a re-examination of the CHMP’s opinion. Applications to other regulatory bodies worldwide are underway.
In October 2022, Merck provided an update on new clinical and non-clinical studies of Lagevrio. A preliminary analysis of the University of Oxford’s PANORAMIC study, conducted in the UK in highly-vaccinated adults mostly over 65 years of age, showed no evidence of a difference between Lagevrio added to usual care compared to usual care alone for the reduction of hospitalizations and deaths through Day 28 (primary endpoint was not met); the incidence of hospitalizations and death through Day 28 was very low overall. The main secondary endpoint (time to first self-reported recovery) in the PANORAMIC study was 6 days shorter with the Lagevrio group compared to the usual care group; in addition, the use of Lagevrio also was associated with earlier recovery across a wide range of other symptom measures, as compared to the usual care group. Additionally, an analysis of real-world data from a separate study conducted by investigators in Israel (known as the Clalit study) showed that in a cohort of non-hospitalized, high-risk patients, Lagevrio reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above; no evidence of benefit was found in younger adults ages 40 to 64 years. Also, Merck reported results from a separate, non-clinical 6-month carcinogenicity study in transgenic mice, which demonstrated that Lagevrio was not carcinogenic at any dose tested.
MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and the EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck’s NDA for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has been extended pending the receipt of additional information from the Company. Merck plans to submit the information to the EMA in the first half of 2023.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,650 clinical trials, including more than 1,200 trials that combine Keytruda with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Keytruda is under priority review by the FDA for use in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of certain patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy. The FDA set a PDUFA date of April 21, 2023 for the supplemental BLAs
16

for Keytruda and Pedcev. The combination regimen was granted Breakthrough Therapy designation by the FDA in February 2020. The applications are supported by efficacy and safety data from the Phase 1b/2 EV-103 trial (also known as KEYNOTE-869) Dose Escalation/Cohort A and Cohort K. Results from Dose Escalation/Cohort A were published in the Journal of Clinical Oncology. Results from Cohort K were presented in a late-breaking session at the 2022 European Society for Medical Oncology Congress.
Keytruda is also under review by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. This submission is based on data from the Phase 3 KEYNOTE-913 trial. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Additionally, Keytruda is under review by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This submission is based on data from the Phase 2 KEYNOTE-158 trial along with supportive data from the KEYNOTE-164 and KEYNOTE-051 trials. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Keytruda is under review in the EU for the adjuvant treatment of patients with stage IB (≥4 cm), II or IIIA NSCLC following complete surgical resection. The submission is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS.
Keytruda is under review in Japan for the treatment of patients with relapsed or refractory PMBLC. This submission is based on data from the Phase 2 KEYNOTE-170 study and the Phase 1 KEYNOTE-A33 study.
In January 2023, Merck announced that it will stop the Phase 3 KEYNOTE-991 trial investigating Keytruda in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer. Merck is discontinuing the study based on the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from a planned interim analysis. At the interim analysis, Keytruda in combination with enzalutamide and ADT did not demonstrate an improvement in overall survival or radiographic progression-free survival, the trial’s dual primary endpoints, compared to placebo plus enzalutamide and ADT. Data from this study will be presented at an upcoming medical meeting.
MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca PLC.
In August 2022, the FDA granted priority review for a supplemental NDA for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC. The supplemental NDA was based on results from the Phase 3 PROpel trial, which were presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium and later published in NEJM Evidence. The FDA initially set a PDUFA date in the fourth quarter of 2022, but in December 2022 the FDA extended the PDUFA date by three months to provide further time for the full review of the submission. Lynparza is also under review in Japan for the treatment of certain patients with mCRPC based on the PROpel trial.
MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai). Merck and Eisai are studying the Keytruda plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program that includes studies across 13 different tumor types (biliary cancer, CRC, endometrial carcinoma, esophageal cancer, gastric cancer, HCC, HNSCC, melanoma, pancreatic cancer, prostate cancer, NSCLC, small-cell-lung cancer (SCLC) and RCC).
The Company also has several other programs in Phase 3 clinical development.
MK-1308A is the coformulation of quavonlimab, Merck’s novel investigational anti-CTLA-4 antibody, with pembrolizumab being evaluated for the treatment of RCC.
Subcutaneous MK-3475, pembrolizumab, is being evaluated for comparability with the intravenous formulation of pembrolizumab in NSCLC.
Subcutaneous MK-3475A, the coformulation of pembrolizumab with hyaluronidase, is being evaluated for comparability with the intravenous formulation of pembrolizumab in NSCLC.
MK-4280A is the coformulation of favezelimab, Merck’s novel investigational anti-LAG3 therapy, with pembrolizumab, being evaluated for the treatment of CRC and hematological malignancies.
17

MK-6482, Welireg (belzutifan), is a hypoxia-inducible factor-2α (HIF-2α) inhibitor being evaluated for a supplemental indication for the treatment of patients with RCC.
MK-7119, Tukysa (tucatinib), is a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers in development for the treatment of breast cancer and colorectal cancer. In September 2020, Seagen granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa.
MK-7684A is the coformulation of vibostolimab, an anti-TIGIT therapy, with pembrolizumab being evaluated for the treatment of melanoma, NSCLC and SCLC.
In December 2021, Merck announced that the FDA had placed clinical holds on the investigational new drug applications for islatravir (MK-8591) programs that were in development for the treatment and prevention of HIV-1 infection. The FDA’s clinical hold was based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced it will initiate a new doravirine/islatravir (MK-8591A) Phase 3 clinical program for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in previously untreated adults and as a switch in antiretroviral therapy in virologically suppressed adults with HIV-1 infection. The Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational NDA for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for PrEP. The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. A Phase 1b study in adults with HIV-1 infection assessing MK-8527, a novel NRTTI candidate, will commence shortly.
V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) for treatment of pneumococcal infection in adults. In June 2022, Merck announced the presentation of positive results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of V116 in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to Pneumovax 23 across age groups. In April 2022, Merck announced that V116 received Breakthrough Therapy designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 trials evaluating V116 are ongoing.
MK-7962, sotatercept, is an investigational activin receptor type IIA-Fc fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH). Sotatercept was obtained in connection with Merck’s acquisition of Acceleron Pharma Inc. in 2021. In October 2022, Merck announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept for the treatment of PAH (World Health Organization [WHO] Group 1). The trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in 6-minute walk distance (6MWD, which measures how far patients can walk in 6 minutes). Eight of nine secondary efficacy outcome measures achieved statistical significance, including the outcome measure of proportion of participants achieving multicomponent improvement (defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement in WHO Functional Class [FC] or maintenance of WHO FC II), and the outcome measure of time to death or the first occurrence of a clinical worsening event. The Cognitive/Emotional Impacts domain score of PAH-SYMPACT, which was assessed as the ninth and final secondary outcome measure, did not achieve statistical significance. Results will be presented at the upcoming American College of Cardiology Annual Scientific Session. The Company anticipates filing sotatercept with regulatory authorities in 2023.
MK-1654, clesrovimab, is a respiratory syncytial virus (RSV) monoclonal antibody that is being evaluated for the prevention of RSV medically attended lower respiratory tract infection in infants and certain children over 1 year of age. Two Phase 3 trials are currently enrolling.
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million for the Phase 3 trial. If
18

such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties.
The charts below reflect the Company’s research pipeline as of February 17, 2023. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2
Cancer
MK-0482(2)
     Non-Small-Cell Lung
MK-1026 (nemtabrutinib)
     Hematological Malignancies
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
Hepatocellular
Melanoma
Small-Cell Lung
MK-2140 (zilovertamab vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
Non-Small-Cell Lung
Ovarian
Pancreatic
MK-2870(1)(3)
Neoplasm Malignant
MK-3475 Keytruda
Advanced Solid Tumors
MK-3543 (bomedemstat)
Myeloproliferative Disorders
MK-4280 (favezelimab)(2)
    Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
     Esophageal
     Melanoma
Renal Cell
     Small-Cell Lung
MK-4830(2)
        Colorectal
     Esophageal
     Melanoma
Non-Small-Cell Lung
Ovarian
Renal Cell
     Small-Cell Lung
MK-5684(1)
Prostate
MK-5890 (boserolimab)(2)
     Non-Small-Cell Lung
     Small-Cell Lung



Cancer
MK-6440 (ladiratuzumab vedotin)(1)(3)
Breast
Esophageal
Gastric
Head and Neck
Melanoma
Non-Small-Cell Lung
Prostate
Small-Cell Lung
MK-6482 Welireg(3)
Biliary
Colorectal
Endometrial
Esophageal
Hepatocellular
Pancreatic
Rare cancers
Von Hippel-Lindau Disease-Associated Tumors (EU)
MK-7119 Tukysa(1)
Advanced Solid Tumors
Biliary
Bladder
Cervical
Endometrial
Gastric
Non-Small-Cell Lung
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684A (vibostolimab+pembrolizumab)
Biliary
Bladder
Breast
Cervical
Colorectal
Endometrial
Esophageal
Gastric
Head and Neck
Hematological Malignancies
Hepatocellular
Ovarian
Prostate

Cancer
MK-7902 Lenvima(1)(2)
Biliary
Pancreatic
Prostate
Small-Cell Lung
V940(1)(2)
Melanoma
Dengue Fever Virus Vaccine
V181
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
MK-8591D (islatravir+lenacapavir)(1)(5)
Hypercholesterolemia
MK-0616
Nonalcoholic Steatohepatitis (NASH)
MK-6024 (efinopegdutide)
Overgrowth Syndrome
MK-7075 (miransertib)
Pulmonary Arterial Hypertension
MK-5475
Pulmonary Hypertension Due To Left Heart Disease
MK-7962 (sotatercept)
Schizophrenia
MK-8189(6)
Thrombosis
MK-2060
Treatment Resistant Depression
MK-1942


19

Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
     MK-4482 Lagevrio (U.S.) (May 2021)(1)(7)
Cancer
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-3475 Keytruda
Biliary (September 2019)
Cutaneous Squamous Cell (August 2019) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017)
MK-3475 (pembrolizumab subcutaneous)
Non-Small-Cell Lung (August 2021)
MK-3475A (pembrolizumab+hyaluronidase subcutaneous)
Non-Small-Cell Lung (February 2023)
MK-4280A (favezelimab+pembrolizumab)
Colorectal (November 2021)
Hematological Malignancies (October 2022)
MK-6482 Welireg(3)
Renal Cell (February 2020)
MK-7119 Tukysa(1)
Breast (October 2019)
Colorectal (August 2022)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Melanoma (January 2023)
Non-Small-Cell Lung (April 2021)
Small-Cell Lung (March 2022)
MK-7902 Lenvima(1)(2)
Colorectal (April 2021)
Esophageal (July 2021)
Gastric (December 2020)
Head and Neck (February 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
HIV-1 Infection
     MK-8591A (doravirine+islatravir) (February 2020)(5)
Pneumococcal Vaccine Adult
V116 (July 2022)
Pulmonary Arterial Hypertension
MK-7962 (sotatercept) (January 2021)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (November 2021)
New Molecular Entities
Antiviral COVID-19
MK-4482 Lagevrio (EU)(1)
Cough
MK-7264 (gefapixant) (U.S.)(8) (EU)






Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• Second-Line Hepatocellular Cancer
(KEYNOTE-394) (U.S.)
• First-Line Locally Advanced Or Metastatic Urothelial Carcinoma
(KEYNOTE-869) (U.S.)
• Locally Advanced Or Metastatic Merkel Cell Carcinoma
(KEYNOTE-913) (U.S.)
• Adjuvant Non-Small-Cell Lung Cancer
(KEYNOTE-091) (EU)
• Relapsed Or Refractory Primary Mediastinal B-Cell Lymphoma
(KEYNOTE-170/KEYNOTE-A33) (JPN)

MK-7339 Lynparza(1)
• First-Line Metastatic Prostate Cancer
(PROpel) (U.S.) (JPN)



Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) On FDA clinical hold.
(5) On FDA partial clinical hold for higher doses than those used in current clinical trials.
(6) Phase 2b development costs are being co-funded.
(7) Available in the U.S. under Emergency Use Authorization.
(8) In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.



Human Capital
As of December 31, 2022, the Company had approximately 69,000 employees worldwide, with approximately 28,000 employed in the U.S., including Puerto Rico, and, additionally, approximately 15,000 third-party contractors globally.(1) Approximately 67,000 of the Company’s employees are full-time employees. Globally, women comprise 50% of employees, and in the U.S. individuals from underrepresented ethnic groups comprise 34% of its workforce (the Company defines workforce as its employees). Women comprise 46% of the members of the Board of Directors. Additionally, the Company’s senior management team is made up of 34% women. Approximately 22% of the Company’s employees are represented by various collective bargaining groups. The Company’s voluntary turnover rate was approximately 8.5% and 8.8%, respectively, in 2022 and 2021.
The Company recognizes that its employees are critical to meet the needs of its patients and customers and that its ability to excel depends on the integrity, skill, and diversity of its employees.
(1) Third party contractors include the Company’s temporary workers, independent contractors, and freelancers who are viewed as full-time equivalent employees. They exclude outsourced service providers.
Talent Acquisition
The Company uses a comprehensive approach to ensure recruiting, retention and leadership development goals are systematically executed throughout the Company and that it hires talented leaders to achieve improved gender parity and representation across all dimensions of diversity. The Company provides training to its
20

managers and external recruiting organizations on strategies to mitigate unconscious bias in the candidate selection and hiring process. In addition, the Company utilizes a comprehensive communications strategy, employee branding and marketing outreach, social media and strategic alliance partnerships to reach a broad pool of talent in its critical business areas. In 2022, the Company hired approximately 8,900 employees across the globe through various channels including the Company’s external career site, direct passive candidate sourcing, diversity partnerships, employee referrals, universities and other external sources.
Global Diversity and Inclusion
Diversity and inclusion are fundamental to the Company’s success and core to future innovation. The Company fosters a globally diverse and inclusive workforce for its employees by creating an environment of belonging, engagement, equity, and empowerment. The Company is proactive and intentional about diversity hiring and development programs to advance talent. The Company creates competitive advantages by leveraging diversity and inclusion to accelerate business performance. This includes fostering global supplier diversity, integrating diversity and inclusion into the Company’s commercialization strategies and leveraging employee insights to improve performance. In addition to these efforts, the Company has ten Employee Business Resource Groups that provide opportunities for employees to take an active part in contributing to the Company’s inclusive culture through their work in talent acquisition and development, business and customer insights and social and community outreach.
The Company’s diversity goals include increasing representation in senior management roles (defined as an individual holding either a Vice President or Senior Vice President title) by 2024 of (i) women globally to 40%, up from 31% in 2020, (ii) Black/African Americans in the U.S. to 10%, up from 3% in 2020, and (iii) Hispanics/Latinos in the U.S. to 10%, up from 5% in 2020. As of December 31, 2022, representation in senior management roles at the Company for (i) women globally was 34%, (ii) Black/African Americans in the U.S. was 6%, and (iii) Hispanics/Latinos in the U.S. was 8%. In addition, by 2025, the Company seeks to maintain or exceed both its current inclusion index score and its current employee engagement index score based on employee surveys.
Gender and Ethnicity Data(1)(2)
202220212020
Women on the Board of Directors46%46%46%
Women in senior management roles(3)
34%36%31%
Women in management roles(4)
45%44%42%
Women in the workforce50%50%50%
New hires that were women52%53%50%
Members of underrepresented ethnic groups on the Board of Directors15%23%23%
Members of underrepresented ethnic groups in senior management roles (U.S.)(3)
28%25%20%
Members of underrepresented ethnic groups in management roles (U.S.)(4)
27%26%25%
Members of underrepresented ethnic groups in the workforce (U.S.)34%32%30%
New hires that were members of underrepresented ethnic groups (U.S.)47%46%40%
(1)    As of 12/31. As self-identified to the Company.
(2)    2020 data has not been restated to adjust for the Organon Spin-Off in 2021.
(3)    “Senior management role” is defined as an individual holding either a Vice President or Senior Vice President title.
(4)    “Management role” is defined as all managers with direct reports other than individuals holding an Executive Vice President title.
Compensation and Benefits
The Company provides a valuable suite of compensation and benefits programs that reflect its commitment to attract, retain and motivate its talent, and support its employees and their families in every stage of life. The Company continuously monitors and adjusts its compensation and benefit programs to ensure they are competitive, contemporary, helpful and engaging, and that they support strategic imperatives such as diversity and inclusion, equity, flexibility, quality, security and affordability. For example, the Company regularly monitors and evaluates its pay practices and policies to ensure that it is paying employees equitably across all genders, races and ethnicities. The Company offers a personal health care concierge service to assist U.S. employees participating in the Company medical plan with their health care needs. Aligned with its business and in support of its cancer care strategy, the Company provides enhanced cancer screening benefits with cash incentives, immediate access to a leading cancer center of excellence for U.S. employees and high value cancer support resources (e.g., caregiving and mental health) for employees and their families. Globally, the Company implemented a minimum standard of 12 weeks of paid parental leave, which inclusively applies to all parents. In the U.S., the Company’s benefits rank in the top quartile of Fortune 100 companies under the Aon 2022 Benefits Index. The Company has been included in the
21

Seramount (previously the Working Mother) 100 Best Companies ranking for 36 consecutive years and was named a top ten Best Company for Moms in 2022.
Employee Well-being
The Company is committed to helping its employees and their families improve their own health and well-being, whether physical, mental, financial, or social. The Company’s programs ensure quality, competitive value, protection from significant financial hardship and access to tools and resources to support employees and their families in all stages of their career and their lives, winning the Company awards such as the Best Employers Excellence in Health & Well-being from the Business Group on Health 2022. The Company fosters an array of flexible work arrangements that includes flextime, summer hours, remote work, telework, job sharing and part-time work to help employees succeed personally as well as professionally. As part of the Company’s overall culture of well-being, it also offers onsite services so employees can thrive. For example, in the U.S., these include onsite health care professionals at many major sites, cafeterias committed to healthy menu offerings, onsite childcare, onsite gyms, and the convenient option to bank through its two employee credit unions.
COVID-19 Response
The Company recognizes that it has a unique responsibility to help in response to the COVID-19 pandemic and is committed to supporting and protecting its employees and their families, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral approaches and supporting its health care providers and the communities in which they serve. The Company continues to provide employees with easy and regular access to information, including guidance around hygiene measures and travel and how to best collaborate via the Company’s hybrid work model. Examples of pandemic support resources and programs available to the Company’s employees include pay continuation for workers who have been sick or exposed, an updated policy that enables employees with medical backgrounds to volunteer in SARS-CoV-2-related activities, resources to prioritize physical and mental wellness, adjustments to medical plans to cover 100% of a COVID-19-related diagnosis, testing and treatment, childcare resources and more.
Engaging Employees
The Company strives to foster employee engagement by promoting a safe, positive, diverse, and inclusive work environment that provides numerous opportunities for two-way communication with employees. Some of the Company’s key programs and initiatives include promoting global employee engagement surveys, ongoing pulse checks to the organization for interim feedback on specific topics, fostering professional networking and collaboration, identifying and providing opportunities for volunteering and establishing positive, cooperative business relations with designated employee representatives.
Talent Management and Development
As the Company pursues its goal of becoming the world’s premier research-based biopharmaceutical company, there is a consistent focus on the importance of continuously developing its diverse and talented people. The Company is committed to talent growth for all, allowing its employees to move more fluidly across the organization, unlocking an environment that allows them to shape their career pathways via non-linear and inclusive opportunities and experience. Merck’s current talent management system supports company-wide performance management, leadership development, talent reviews and succession planning. Annual performance reviews help further the professional development of the Company’s employees and ensure that the Company’s workforce is aligned with the Company’s objectives. The Company seeks to continuously build the skills and capabilities of its workforce to accelerate talent, improve performance and mitigate risk through relevant continuous learning experiences. This includes, but is not limited to, building leadership and management skills, as well as providing technical and functional training to all employees.
Environmental Matters
Environmental Sustainability
The Company strives to be a strong environmental steward, and realizes that its strategy and efforts need to continuously evolve in the face of a changing climate. The Company’s environmental sustainability strategy has three focus areas:
Driving operational efficiency;
Designing new products to minimize environmental impact; and
Reducing any impacts in the Company’s upstream and downstream value chain.
A primary focus of the Company in each of these areas is on climate action. Merck believes that climate change could present risks to its business, as discussed in further detail in Item 1A. “Risk Factors” under the
22

headings “Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects” and “Environmental, social and governance (ESG) matters may impact the Company’s business and reputation.” Some of the potential impacts of climate change to the Company’s business include increased operating costs due to additional regulatory requirements, physical risks to the Company’s facilities, water limitations and disruptions to its supply chain. These potential risks are integrated into the Company’s business planning, including investment in reducing energy usage, water use and greenhouse gas emissions.
In 2021, the Company’s Scope 1, 2 and 3, reduction targets were verified by the Science-Based Targets initiative (SBTi). The Company has made progress toward its climate goals and aspires to meet and exceed the evolving expectations of its stakeholders and employees. These goals include achieving carbon neutrality for greenhouse gas emissions across operations (Scopes 1 and 2) by 2025, reducing Scope 1 and 2 operational greenhouse gas emissions 46% by 2030 (from a 2019 baseline), reducing Scope 3 greenhouse gas emissions by 30% by 2030 (from a 2019 baseline), and sourcing 100% of its purchased electricity from renewables by 2025. Other environmental sustainability initiatives of the Company include:
Low Carbon Transition Playbook. In 2021, the Company launched its Low Carbon Transition Playbook, a tool intended to help create a site strategy by identifying gaps, uncovering opportunities and creating a common platform for assessment of levers and resource deployment across a range of sustainability initiatives. It also details how employees and stakeholders can accelerate the Company’s environmental work, along with explanations of the collective benefits of these actions for the business and for stakeholders. Functions across the Company are expected to take advantage of this document to strategize and develop new ways to meet many of the Company’s broader sustainability goals and streamline the Company’s tracking and reporting of specific metrics and categories.
Waste Diversion Playbook. In 2022, the Company created its Waste Diversion Playbook, which is a tool, similar to the Low Carbon Transition Playbook, to help sites self-assess and develop their waste diversion strategies to achieve the Company’s corporate waste goals. The objectives are to identify and prioritize the most effective and least resource intensive actions, improve tracking and reporting and generate knowledge sharing between sites.
Partnering for progress across the Company’s value chain. The Company is a signatory to Schneider Electric’s Energize program, a pioneering collaboration to help pharmaceutical and health care suppliers address their own operational Scope 2 greenhouse gas emissions through green power procurement, which in turn is intended to help the signatories reduce their Scope 3 emissions.
Product stewardship and green and sustainable science. The Company’s product stewardship program focuses on identifying and either preventing or minimizing potential safety and environmental hazards throughout a product’s life cycle. The Company is also committed to understanding, managing and reducing the environmental impacts of its products and the materials associated with discovering and producing them. The Company’s green and sustainable science program uses a “green-by-design” approach. By using more efficient and innovative processing methods and technologies, the Company is reducing the amount of energy, water and raw materials the Company uses to make the Company’s products, thereby reducing the amount of waste the Company generates and lowering the Company’s production costs.
Management does not believe that expenditures related to these initiatives should have a material adverse effect on the Company’s financial condition, results of operations, liquidity or capital resources for any year.
Environmental Regulation and Remediation
The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites. Expenditures for remediation and environmental liabilities were $4 million in 2022 and are estimated to be $23 million in the aggregate for the years 2023 through 2027. These amounts do not consider potential recoveries from other parties. The Company has taken an active role in identifying and accruing for these costs and, in management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December 31, 2022 and 2021, respectively. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should have a material adverse effect on the Company’s financial condition, results of operations, liquidity or capital resources for any year.
23

Geographic Area Information
The Company’s operations outside the U.S. are conducted primarily through subsidiaries. Sales worldwide by subsidiaries outside the U.S. as a percentage of total Company sales was 54% in both 2022 and 2021 and 53% in 2020.
The Company’s worldwide business is subject to risks of currency fluctuations, governmental actions and other governmental proceedings abroad. The Company does not regard these risks as a deterrent to further expansion of its operations abroad. However, the Company closely reviews its methods of operations and adopts strategies responsive to changing economic and political conditions.
Merck has operations in countries located in Latin America, the Middle East, Africa, Eastern Europe and Asia Pacific. Business in these developing areas, while sometimes less stable, offers important opportunities for growth over time.
Available Information
The Company’s Internet website address is merck.com. The Company will make available, free of charge at the “Investors” portion of its website, its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). The address of that website is sec.gov. In addition, the Company will provide without charge a copy of its Annual Report on Form 10-K, including financial statements and schedules, upon the written request of any shareholder to the Office of the Secretary, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065 U.S.A.
The Company’s corporate governance guidelines and the charters of the Board of Directors’ four standing committees are available on the Company’s website at https://www.merck.com/company-overview/leadership/board-of-directors/ and all such information is available in print to any shareholder who requests it from the Company.
The Company’s 2021/2022 Environmental, Social & Governance (ESG) Progress Report, which provides enhanced ESG disclosures, is available on the Company’s website at https://www.merck.com/company-overview/esg/esg-resources/. Information in the Company’s ESG Progress Report is not incorporated by reference into this Form 10-K.
Item 1A.Risk Factors.
Summary Risk Factors
The Company is subject to a number of risks that if realized could materially adversely affect its business, results of operations, cash flow, financial condition or prospects. The following is a summary of the principal risk factors facing the Company:
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition. The Company expects that sales of Lagevrio, which were $5.7 billion in 2022, will decline significantly to approximately $1.0 billion in 2023.
The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.
The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
The Company faces continued pricing pressure with respect to its products.
Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company’s operating results.
24

The Company faces intense competition from lower cost generic products.
The Company faces intense competition from competitors’ products.
COVID-19-related disruptions have had an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.
The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects.
Environmental, social and governance (ESG) matters may impact the Company’s business and reputation.
Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
The Company may not be able to realize the expected benefits of its investments in emerging markets.
The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company’s business, results of operations and financial condition.
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.
Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
Developments following regulatory approval may adversely affect sales of the Company’s products.
The Company is subject to a variety of U.S. and international laws and regulations.
The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
Product liability insurance for products may be limited, cost prohibitive or unavailable.
The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company could be a target of future cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
Social media and mobile messaging platforms present risks and challenges.
25

The above list is not exhaustive, and the Company faces additional challenges and risks. Investors should carefully consider all of the information set forth in this Form 10-K, including the following risk factors, before deciding to invest in any of the Company’s securities.
Risk Factors
The risks below are not the only ones the Company faces. Additional risks not currently known to the Company or that the Company presently deems immaterial may also impair its business operations. The Company’s business, financial condition, results of operations, cash flow or prospects could be materially adversely affected by any of these risks. This Form 10-K also contains forward-looking statements that involve risks and uncertainties. The Company’s results could materially differ from those anticipated in these forward-looking statements as a result of certain factors, including the risks it faces described below and elsewhere. See “Cautionary Factors that May Affect Future Results” below.
Risks Related to the Company’s Business
The Company is dependent on its patent rights, and if its patent rights are invalidated or circumvented, its business could be materially adversely affected.
Patent protection is considered, in the aggregate, to be of material importance to the Company’s marketing of human health and animal health products in the U.S. and in most major foreign markets. Patents covering products that it has introduced normally provide market exclusivity, which is important for the successful marketing and sale of its products. The Company seeks patents covering each of its products in each of the markets where it intends to sell the products and where meaningful patent protection is available.
Even if the Company succeeds in obtaining patents covering its products, third parties or government authorities may challenge or seek to invalidate or circumvent its patents and patent applications. It is important for the Company’s business to successfully assert and defend the patent rights that provide market exclusivity for its products. The Company is often involved in patent disputes relating to challenges to its patents or claims by third parties of infringement against the Company. The Company asserts and defends its patents both within and outside the U.S., including by filing claims of infringement against other parties. See Item 8. “Financial Statements and Supplementary Data,” Note 11. “Contingencies and Environmental Liabilities” below. In particular, manufacturers of generic or biosimilar pharmaceutical products from time to time file abbreviated NDAs or BLAs with the FDA seeking to market generic/biosimilar forms of the Company’s products prior to the expiration of relevant patents owned or licensed by the Company. The Company normally responds by asserting one or more of its patents with a lawsuit alleging patent infringement. Patent litigation and other challenges to the Company’s patents are costly and unpredictable and may deprive the Company of market exclusivity for a patented product or, in some cases, third-party patents may prevent the Company from marketing and selling a product in a particular geographic area.
Additionally, certain foreign governments have indicated that compulsory licenses to patents may be granted in the case of national emergencies or in other circumstances, which could diminish or eliminate sales and profits from those regions and negatively affect the Company’s results of operations. Further, court decisions relating to other companies’ patents, potential legislation in both the U.S. and certain foreign markets relating to patents, as well as regulatory initiatives may result in a more general weakening of intellectual property protection.
If one or more important products lose patent protection in profitable markets, sales of those products are likely to decline significantly as a result of generic versions of those products becoming available. The Company’s results of operations may be adversely affected by the lost sales unless and until the Company has launched commercially successful products that replace the lost sales. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively affect product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.
A chart listing the patent protection for certain of the Company’s marketed products, and U.S. patent protection for candidates in Phase 3 clinical development is set forth above in Item 1. “Business — Patents, Trademarks and Licenses.”
As the Company’s products lose market exclusivity, the Company generally experiences a significant and rapid loss of sales from those products.
The Company depends upon patents to provide it with exclusive marketing rights for its products for some period of time. Loss of patent protection for one of the Company’s products typically leads to a significant and rapid loss of sales for that product as lower priced generic versions of that drug become available. In the case of products that contribute significantly to the Company’s sales, the loss of market exclusivity can have a material adverse effect on the Company’s business, cash flow, results of operations, financial condition and prospects. While the key U.S.
26

patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity in the U.S. toward the end of 2023. The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Merck expects that exclusivity for Janumet will be lost in other European countries in April 2023. While the Company lost market exclusivity for Januvia in China in 2022 with the approval of a generic equivalent product, the impact on sales in 2023 is expected to be modest. It is anticipated that a generic equivalent of Janumet will be approved in China in the first quarter of 2023, but the impact to sales in 2023 is also expected to be modest. As these products lose exclusivity, the Company anticipates that sales of Januvia and Janumet will decline substantially.
Key products generate a significant amount of the Company’s profits and cash flows, and any events that adversely affect the markets for its leading products could have a material adverse effect on the Company’s results of operations and financial condition. The Company expects that sales of Lagevrio, which were $5.7 billion in 2022, will decline significantly to approximately $1.0 billion in 2023.
The Company’s ability to generate profits and operating cash flow depends largely upon the continued profitability of the Company’s key products, such as Keytruda, Gardasil/Gardasil 9, Lynparza, Bravecto, and Bridion. As a result of the Company’s dependence on key products, any event that adversely affects any of these products or the markets for any of these products could have a significant adverse impact on results of operations and financial condition. These events could include loss of patent protection, increased costs associated with manufacturing, generic or over-the-counter availability of the Company’s product or a competitive product, the discovery of previously unknown side effects, results of post-approval trials, increased competition from the introduction of new, more effective treatments and discontinuation or removal from the market of the product for any reason. Such events could have a material adverse effect on the sales of any such products.
In particular, in 2022, sales of Lagevrio, which were $5.7 billion, represented a substantial portion of the Company’s revenue and profit growth. The Company expects that sales of Lagevrio will decline significantly to approximately $1.0 billion in 2023.
The Company’s research and development efforts may not succeed in developing commercially successful products and the Company may not be able to acquire commercially successful products in other ways; in consequence, the Company may not be able to replace sales of successful products that lose patent protection.
In order to remain competitive, the Company, like other major pharmaceutical companies, must continue to launch new products. Expected declines in sales of products after the loss of market exclusivity mean that the Company’s future success is dependent on its pipeline of new products, including new products that it may develop through collaborations and joint ventures and products that it is able to obtain through license or acquisition. To accomplish this, the Company commits substantial effort, funds and other resources to research and development, both through its own dedicated resources and through various collaborations with third parties. There is a high rate of failure inherent in the research and development process for new drugs and vaccines. As a result, there is a high risk that funds invested by the Company in research programs will not generate financial returns. This risk profile is compounded by the fact that this research has a long investment cycle. To bring a pharmaceutical compound from the discovery phase to market may take a decade or more and failure can occur at any point in the process, including later in the process after significant funds have been invested.
For a description of the research and development process, see Item 1. “Business — Research and Development” above. Each phase of testing is highly regulated and during each phase there is a substantial risk that the Company will encounter serious obstacles or will not achieve its goals. Therefore, the Company may abandon a product in which it has invested substantial amounts of time and resources. Some of the risks encountered in the research and development process include the following: preclinical testing of a new compound may yield disappointing results; competing products from other manufacturers may reach the market first; clinical trials of a new drug may not be successful; a new drug may not be effective or may have harmful side effects; a new drug may not be approved by the regulators for its intended use; it may not be possible to obtain a patent for a new drug; payers may refuse to cover or reimburse the new product; or sales of a new product may be disappointing.
The Company cannot state with certainty when or whether any of its products now under development will be approved or launched; whether it will be able to develop, license or otherwise acquire compounds, product candidates or products; or whether any products, once launched, will be commercially successful. The Company must maintain a continuous flow of successful new products and successful new indications for existing products
27

sufficient both to cover its substantial research and development costs and to replace sales that are lost as profitable products lose market exclusivity or are displaced by competing products or therapies. Failure to do so in the short term or long term would have a material adverse effect on the Company’s business, results of operations, cash flow, financial condition and prospects.
The Company’s success is dependent on the successful development and marketing of new products, which are subject to substantial risks.
Products that appear promising in development may fail to reach the market or fail to succeed for numerous reasons, including the following:
findings of ineffectiveness, superior safety or efficacy of competing products, or harmful side effects in clinical or preclinical testing;
failure to receive the necessary regulatory approvals, including delays in the approval of new products and new indications, or the anticipated labeling, and uncertainties about the time required to obtain regulatory approvals and the benefit/risk standards applied by regulatory agencies in determining whether to grant approvals;
failure in certain markets to obtain reimbursement commensurate with the level of innovation and clinical benefit presented by the product;
lack of economic feasibility due to manufacturing costs or other factors; and
preclusion from commercialization by the proprietary rights of others.
In the future, if certain pipeline programs are cancelled or if the Company believes that their commercial prospects have been reduced, the Company may recognize material non-cash impairment charges for those programs that were measured at fair value and capitalized in connection with acquisitions or certain collaborations.
Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company’s business, results of operations, cash flow, financial condition and prospects.
The Company faces continued pricing pressure with respect to its products.
The Company faces continued pricing pressure globally and, particularly in mature markets, from managed care organizations, government agencies and programs that could negatively affect the Company’s sales and profit margins. In the U.S., these include (i) practices of managed care groups and institutional and governmental purchasers, (ii) U.S. federal laws and regulations related to Medicare and Medicaid, including the Medicare Prescription Drug Improvement and Modernization Act of 2003, the ACA, the Inflation Reduction Act, and (iii) state activities aimed at increasing price transparency, including new laws as noted above in Item 1. “Competition and the Health Care Environment.” Changes to the health care system enacted as part of health care reform in the U.S., as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, could result in further pricing pressures. In addition, in the U.S., larger customers have received higher rebates on drugs in certain highly competitive categories. The Company must also compete to be placed on formularies of managed care organizations. Exclusion of a product from a formulary can lead to reduced usage in the managed care organization.
In order to provide information about the Company’s pricing practices, the Company annually posts on its website its Pricing Transparency Report for the U.S. The report provides the Company’s average annual list price and net price increases across the Company’s U.S. portfolio dating back to 2010. In 2022, the Company’s gross U.S. sales were reduced by 39.7% as a result of rebates, discounts and returns.
Outside the U.S., numerous major markets, including the EU, Japan and China have pervasive government involvement in funding health care and, in that regard, fix the pricing and reimbursement of pharmaceutical and vaccine products. Consequently, in those markets, the Company is subject to government decision making and budgetary actions with respect to its products. In Japan, the pharmaceutical industry is subject to government-mandated annual price reductions of pharmaceutical products and certain vaccines. Furthermore, the government can order re-pricing for specific products if it determines that use of such product will exceed certain thresholds defined under applicable re-pricing rules.
The Company expects pricing pressures to continue in the future.
28

Unfavorable or uncertain economic conditions, together with cost-reduction measures being taken by certain governments, could negatively affect the Company’s operating results.
The Company’s business may be adversely affected by local and global economic conditions, including with respect to inflation, interest rates, and costs of raw materials and packaging. Uncertainty in global economic and geopolitical conditions may result in a slowdown to the global economy that could affect the Company’s business by reducing the prices that drug wholesalers and retailers, hospitals, government agencies and managed health care providers may be able or willing to pay for the Company’s products or by reducing the demand for the Company’s products, which could in turn negatively impact the Company’s sales and result in a material adverse effect on the Company’s business, cash flow, results of operations, financial condition and prospects.
As discussed above in “Competition and the Health Care Environment,” global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. The Company anticipates all of these actions, and additional actions in the future, will negatively affect sales and profits.
If credit and economic conditions worsen, the resulting economic and currency impacts in the affected markets and globally could have a material adverse effect on the Company’s results.
As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation. Any such disruptions, delays or costs may result in the Company’s inability to meet demand for the Company’s products.
The Company faces intense competition from lower cost generic products.
In general, the Company faces increasing competition from lower-cost generic products. The patent rights that protect its products are of varying strengths and durations. In addition, in some countries, patent protection is significantly weaker than in the U.S. or in the EU. In the U.S. and the EU, political pressure to reduce spending on prescription drugs has led to legislation and other measures that encourage the use of generic and biosimilar products. Although it is the Company’s policy to actively protect its patent rights, generic challenges to the Company’s products can arise at any time, and the Company’s patents may not prevent the emergence of generic competition for its products.
Loss of patent protection for a product typically is followed promptly by generic substitutes, reducing the Company’s sales of that product. Availability of generic substitutes for the Company’s drugs may adversely affect its results of operations and cash flow. In addition, proposals emerge from time to time in the U.S. and other countries for legislation to further encourage the early and rapid approval of generic drugs. Any such proposal that is enacted into law could worsen this substantial negative effect on the Company’s sales, business, cash flow, results of operations, financial condition and prospects.
The Company faces intense competition from competitors’ products.
The Company’s products face intense competition from competitors’ products. This competition may increase as new products enter the market. In such an event, the competitors’ products may be safer or more effective, more convenient to use, have better insurance coverage or reimbursement levels or be more effectively marketed and sold than the Company’s products. Alternatively, in the case of generic competition, including the generic availability of competitors’ branded products, they may be equally safe and effective products that are sold at a substantially lower price than the Company’s products. As a result, if the Company fails to maintain its competitive position, this could have a material adverse effect on its business, cash flow, results of operations, financial condition and prospects. In addition, if products that were measured at fair value and capitalized in connection with acquisitions experience difficulties in the market that negatively impact product cash flows, the Company may recognize material non-cash impairment charges with respect to the value of those products.

29

COVID-19-related disruptions have had an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the full extent to which the COVID-19 pandemic or any future pandemic, epidemic or similar public health threat will adversely impact its business, operations, financial performance, results of operations, and financial condition.
The Company’s business and financial results have been negatively impacted by COVID-19-related disruptions since the start of the pandemic. Merck believes that global health systems and patients have largely adapted to the impacts of COVID-19, however, a substantial portion of Merck’s Pharmaceutical segment revenue is comprised of physician-administered products which could be adversely affected by the pandemic if it continues. The continued duration and severity of the COVID-19 pandemic is uncertain and difficult to predict. The degree to which COVID-19-related disruptions impact the Company’s results in 2023 will depend on future developments, beyond the Company’s knowledge or control, including governmental and third-party actions taken to contain or prevent the spread and treatment of the virus and mitigate its public health and economic effects. In addition, any future pandemic, epidemic or similar public health threat could present similar risks to the Company’s business, cash flow, results of operations, financial condition and prospects.
The Company has significant global operations, which expose it to additional risks, and any adverse event could have a material adverse effect on the Company’s results of operations and financial condition.
The extent of the Company’s operations outside the U.S. is significant. Risks inherent in conducting a global business include:
changes in medical reimbursement policies and programs and pricing restrictions in key markets;
multiple regulatory requirements that could restrict the Company’s ability to manufacture and sell its products in key markets;
trade protection measures and import or export licensing requirements, including the imposition of trade sanctions or similar restrictions by the U.S. or other governments;
foreign exchange fluctuations;
diminished protection of intellectual property in some countries; and
possible nationalization and expropriation.
In addition, there may be changes to the Company’s business and political position if there is instability, disruption or destruction in a significant geographic region, regardless of cause, including war, terrorism, riot, civil insurrection or social unrest; and natural or man-made disasters, including famine, flood, fire, earthquake, storm or disease. Events like these could result in material adverse effects on macroeconomic conditions, currency exchange rates and financial markets.
Climate change or legal, regulatory or market measures to address climate change may negatively affect the Company’s business, results of operations, cash flows and prospects.
The Company believes that climate change has the potential to negatively affect its business and results of operations, cash flows and prospects. The Company is exposed to physical risks (such as extreme weather conditions or rising sea levels), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term).
The adverse impacts of climate change include increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat. Extreme weather and sea-level rise pose physical risks to the Company’s facilities as well as those of its suppliers. Such risks include losses incurred as a result of physical damage to facilities, loss or spoilage of inventory, and business interruption caused by such natural disasters and extreme weather events. Other potential physical impacts due to climate change include reduced access to high-quality water in certain regions and the loss of biodiversity, which could impact future product development. These risks could disrupt the Company’s operations and its supply chain, which may result in increased costs.
New legal or regulatory requirements may be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in the Company being subject to new or expanded carbon pricing or taxes, increased compliance costs,
30

restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, investments in data gathering and reporting systems, upgrades of facilities to meet new building codes, and the redesign of utility systems, which could increase the Company’s operating costs, including the cost of electricity and energy used by the Company. The Company’s supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to the Company, all of which may affect the Company’s ability to procure raw materials or other supplies required for the operation of the Company’s business at the quantities and levels we require.
Environmental, social and governance (ESG) matters may impact the Company’s business and reputation.
Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are increasingly sensitive to ESG concerns, such as diversity and inclusion, climate change, water use, recyclability or recoverability of packaging, and plastic waste. This focus on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing the Company’s products. The Company’s ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. While the Company strives to improve its ESG performance and has set certain ESG goals and initiatives, the Company risks negative stockholder reaction, including from proxy advisory services, as well as damage to its brand and reputation, if the Company fails to meet its goals and initiatives or otherwise does not act responsibly, or if the Company is perceived to not be acting responsibly, in key ESG areas, including equitable access to medicines and vaccines, product quality and safety, diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency, and addressing human capital factors in the Company’s operations. Responding to these ESG considerations and implementation of the Company’s ESG goals and initiatives involves risks and uncertainties, requires investments, and depends in part on third-party performance or data that is outside of the Company’s control. In addition, some stakeholders may disagree with the Company’s ESG goals and initiatives. If the Company does not meet the evolving and varied ESG expectations of its investors, customers and other stakeholders, the Company could experience reduced demand for its products, loss of customers, and other negative impacts on the Company’s business and results of operations.
Failure to attract and retain highly qualified personnel could affect the Company’s ability to successfully develop and commercialize products.
The Company’s success is largely dependent on its continued ability to attract and retain highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical research and development, governmental regulation and commercialization. Competition for qualified personnel in the pharmaceutical industry, both in the U.S. and internationally, is intense. The Company cannot be sure that it will be able to attract and retain quality personnel or that the costs of doing so will not materially increase.
The Company may experience difficulties and delays in manufacturing certain of its products, including vaccines.
Merck has, in the past, experienced difficulties in manufacturing certain of its products, including vaccines. For example, in 2020 the Company issued a product recall for Zerbaxa following the identification of product sterility issues. The Company may, in the future, experience other difficulties and delays in manufacturing its products, such as (i) failure of the Company or any of its vendors or suppliers to comply with Current Good Manufacturing Practices and other applicable regulations and quality assurance guidelines that could lead to manufacturing shutdowns, product shortages and delays in product manufacturing; (ii) delays related to the construction of new facilities or the expansion of existing facilities, including those intended to support future demand for the Company’s products; and (iii) other manufacturing or distribution problems including supply chain delays, shortages in raw materials, changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in types of products produced, or physical limitations that could impact continuous supply. As previously disclosed, the Company is working to reduce the level of nitrosamines in its sitagliptin-containing medicines such as Januvia. Difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages. In addition, the Company could experience difficulties or delays in manufacturing its products caused by natural disasters, such as hurricanes. Manufacturing difficulties can result in product shortages, leading to lost sales and reputational harm to the Company.
31

The Company may not be able to realize the expected benefits of its investments in emerging markets.
The Company has been taking steps to increase its sales in emerging markets. However, there is no guarantee that the Company’s efforts to expand sales in these markets will succeed. Some countries within emerging markets may be especially vulnerable to periods of global financial instability or may have very limited resources to spend on health care. In order for the Company to successfully implement its emerging markets strategy, it must attract and retain qualified personnel. The Company may also be required to increase its reliance on third-party agents within less developed markets, which may affect its ability to realize continued growth and may also increase the Company’s risk exposure. In addition, many of these countries have currencies that fluctuate substantially and, if such currencies devalue and the Company cannot offset the devaluations, the Company’s financial performance within such countries could be adversely affected.
The Company’s business in China has grown rapidly in the past few years, and the importance of China to the Company’s overall pharmaceutical and vaccines business outside the U.S. has increased accordingly. In addition to its commercial operations, the Company has significant research and manufacturing operations in China. If geopolitical tensions were to increase and disrupt the Company’s operations in China, such disruption could result in a material adverse effect on the Company’s product development, sales, business, cash flow, results of operations, financial condition and prospects.
Also, continued growth of the Company’s business in China is dependent upon ongoing development of a favorable environment for innovative pharmaceutical products and vaccines, sustained access for the Company’s currently marketed products, and the absence of trade impediments or adverse pricing controls. As noted above in “Competition and the Health Care Environment,” pricing pressure in China has increased as the Chinese government has been taking steps to reduce costs, including implementing health care reform that has led to the acceleration of generic substitution, where available. While the mechanism for drugs being added to the NRDL evolves, inclusion may require a price negotiation which could impact the outlook in the market for selected brands. In 2021, drugs were added to the NRDL with an average of more than 60% price reductions. A new NRDL was recently completed in which new entries averaged 60% price reductions. While pricing pressure has always existed in China, health care reform has increased this pressure in part due to the acceleration of generic substitution through the government’s VBP program. In 2019, the government implemented the VBP program through a tendering process for mature products which have generic substitutes with a Generic Quality Consistency Evaluation approval. Mature products that have entered into the last five rounds of VBP had, on average, a price reduction of more than 50%. The Company expects VBP to be a semi-annual process that will have a significant impact on mature products moving forward.
For all these reasons, sales within emerging markets carry significant risks. However, at the same time, macro economic growth of selected emerging markets is expected to outpace Europe and even the U.S., leading to significant increased health care spending in those countries and access to innovative medicines for patients. A failure to maintain the Company’s presence in emerging markets could therefore have a material adverse effect on the Company’s business, cash flow, results of operations, financial condition and prospects.
The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company’s business, results of operations and financial condition.
The ongoing war between Russia and Ukraine, and the financial and economic sanctions imposed by the U.S., the EU and other countries in response, are having pervasive direct and indirect effects on the global economy, and may adversely affect the Company’s business, results of operations and financial condition. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials.
For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies.
The financial impacts of the war between Russia and Ukraine were immaterial to the Company’s consolidated financial statements in 2022. However, the degree to which the war and related disruptions will impact the Company’s results in the future is difficult to predict and will depend on developments outside of the Company’s control, including, but not limited to, the duration and severity of the war, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical
32

shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets. Such developments may negatively impact the Company directly or indirectly as well as the parties with which the Company conducts business. In addition, the effects of the war between Russia and Ukraine could heighten other risks disclosed herein, which could materially adversely affect the Company’s business, results of operations and financial condition.
The Company is exposed to market risk from fluctuations in currency exchange rates and interest rates.
The Company operates in multiple jurisdictions and virtually all sales are denominated in currencies of the local jurisdiction. Additionally, the Company has entered and will enter into business development transactions, borrowings or other financial transactions that may give rise to currency and interest rate exposure.
Since the Company cannot, with certainty, foresee and mitigate against such adverse fluctuations, fluctuations in currency exchange rates, interest rates and inflation could negatively affect the Company’s business, cash flow, results of operations, financial condition and prospects.
In order to mitigate against the adverse impact of these market fluctuations, the Company will from time to time enter into hedging agreements. While hedging agreements, such as currency options and forwards and interest rate swaps, may limit some of the exposure to exchange rate and interest rate fluctuations, such attempts to mitigate these risks may be costly and not always successful.
A portion of Merck’s indebtedness bears interest at variable interest rates, primarily based on the London Interbank Offered Rate (LIBOR). LIBOR is the subject of national, international and other regulatory guidance and proposals for reform, which will cause LIBOR to cease to exist entirely in the future. While the Company has begun to implement alternative reference rates as alternatives to LIBOR, the Company cannot predict the consequences and timing of any additional or unexpected developments, which could include an increase in interest expense.
Pharmaceutical products can develop unexpected safety or efficacy concerns.
Unexpected safety or efficacy concerns can arise with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals, or declining sales, as well as product liability, consumer fraud and/or other claims, including potential civil or criminal governmental actions.
Reliance on third-party relationships and outsourcing arrangements could materially adversely affect the Company’s business.
The Company depends on third parties, including suppliers, alliances with other pharmaceutical and biotechnology companies, and third-party service providers, for key aspects of its business including development, manufacture and commercialization of its products and support for its information technology (IT) systems. Failure of these third parties to meet their contractual, regulatory and other obligations to the Company or the development of factors that materially disrupt the relationships between the Company and these third parties could have a material adverse effect on the Company’s business.
Negative events in the animal health industry could have a material adverse effect on future results of operations and financial condition.
Future sales of key animal health products could be adversely affected by a number of risk factors including certain risks that are specific to the animal health business. For example, the outbreak of disease carried by animals, such as African Swine Fever, could lead to their widespread death and precautionary destruction as well as the reduced consumption and demand for animals, which could adversely affect the Company’s results of operations. Also, the outbreak of any highly contagious diseases near the Company’s main production sites could require the Company to immediately halt the manufacture of its animal health products at such sites or force the Company to incur substantial expenses in procuring raw materials or products elsewhere. Other risks specific to animal health include epidemics and pandemics, government procurement and pricing practices, weather and global agribusiness economic events. In addition, in 2022, sales of Bravecto were $1.0 billion, which represented approximately 19% of the Company’s Animal Health segment sales. Any negative event with respect to Bravecto could have a material adverse effect on the Company’s Animal Health sales. If the Animal Health segment of the Company’s business becomes more significant, the impact of any such events on future results of operations could also become more significant.
33

Biologics and vaccines carry unique risks and uncertainties, which could have a material adverse effect on the Company’s future results of operations and financial condition.
The successful development, testing, manufacturing and commercialization of biologics and vaccines, particularly human and animal health vaccines, is a long, complex, expensive and uncertain process. There are unique risks and uncertainties related to biologics and vaccines, including:
There may be limited access to, and supply of, normal and diseased tissue samples, cell lines, pathogens, bacteria, viral strains and other biological materials. In addition, government regulations in multiple jurisdictions, such as the U.S. and the EU, could result in restricted access to, or transport or use of, such materials. If the Company loses access to sufficient sources of such materials, or if tighter restrictions are imposed on the use of such materials, the Company may not be able to conduct research activities as planned and may incur additional development costs.
The development, manufacturing and marketing of biologics and vaccines are subject to regulation by the FDA, the EMA and other regulatory bodies. These regulations are often more complex and extensive than the regulations applicable to other pharmaceutical products. For example, in the U.S., a BLA, including both preclinical and clinical trial data and extensive data regarding the manufacturing procedures, is required for human vaccine candidates, and FDA approval is generally required for the release of each manufactured commercial human vaccine lot.
Manufacturing biologics and vaccines, especially in large quantities, is often complex and may require the use of innovative technologies to handle living micro-organisms. Each lot of an approved biologic and vaccine must undergo thorough testing for identity, strength, quality, purity and potency. Manufacturing biologics requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, the Company may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes.
Biologics and vaccines are frequently costly to manufacture because production ingredients are derived from living animal or plant material, and most biologics and vaccines cannot be made synthetically. In particular, keeping up with the demand for vaccines may be difficult due to the complexity of producing vaccines.
The use of biologically derived ingredients can lead to variability in the manufacturing process and could lead to allegations of harm, including infections or allergic reactions, which allegations would be reviewed through a standard investigation process that could lead to closure of product facilities due to possible contamination. Any of these events could result in substantial costs.
Risks Relating to Government Regulation and Legal Proceedings
The health care industry in the U.S. has been, and will continue to be, subject to increasing regulation and political action.
As discussed above in “Competition and the Health Care Environment,” the Company believes that the health care industry will continue to be subject to increasing regulation as well as political and legal action, as future proposals to reform the health care system are considered by the Executive branch, Congress and state legislatures.
In 2022, Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028.
In addition, in 2021, Congress passed the American Rescue Plan Act, which included a provision that eliminates the statutory cap on rebates drug manufacturers pay to Medicaid beginning in January 2024. These rebates act as a discount off the list price and eliminating the cap means that manufacturer discounts paid to Medicaid can increase. Prior to this change, manufacturers have not been required to pay more than 100% of the Average Manufacturer Price (AMP) in rebates to state Medicaid programs for Medicaid-covered drugs. As a result of this provision, beginning in 2024, it is possible that manufacturers may have to pay state Medicaid programs more in rebates than they received on sales of particular products. This change could present a risk to Merck in the future for drugs that have high Medicaid utilization and rebate exposure that is more than 100% of the AMP.
34

In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company cannot predict what additional future changes in the health care industry in general, or the pharmaceutical industry in particular, will occur; however, any changes could have a material adverse effect on the Company’s business, cash flow, results of operations, financial condition and prospects.
The Company’s products, including products in development, cannot be marketed unless the Company obtains and maintains regulatory approval.
The Company’s activities, including research, preclinical testing, clinical trials and the manufacturing and marketing of its products, are subject to extensive regulation by numerous federal, state and local governmental authorities in the U.S., including the FDA, and by foreign regulatory authorities, including in the EU, Japan and China. In the U.S., the FDA administers requirements covering the testing, approval, safety, effectiveness, manufacturing, labeling and marketing of prescription pharmaceuticals and vaccines. In some cases, the FDA requirements have increased the amount of time and resources necessary to develop new products and bring them to market in the U.S. Regulation outside the U.S. also is primarily focused on drug safety and effectiveness and, in many cases, reduction in the cost of drugs. The FDA and foreign regulatory authorities, including in the EU, Japan and China, have substantial discretion to require additional testing, to delay or withhold registration and marketing approval and to otherwise preclude distribution and sale of a product.
Even if the Company is successful in developing new products, it will not be able to market any of those products unless and until it has obtained all required regulatory approvals in each jurisdiction where it proposes to market the new products. Once obtained, the Company must maintain approval as long as it plans to market its new products in each jurisdiction where approval is required. The Company’s failure to obtain approval, significant delays in the approval process, or its failure to maintain approval in any jurisdiction will prevent it from selling the products in that jurisdiction. The Company would not be able to realize revenues for those new products in any jurisdiction where it does not have approval.
Developments following regulatory approval may adversely affect sales of the Company’s products.
Even after a product reaches the market, certain developments following regulatory approval may decrease demand for the Company’s products, including the following:
results in post-approval Phase 4 trials or other studies;
the re-review of products that are already marketed;
the recall or loss of marketing approval of products that are already marketed;
changing government standards or public expectations regarding safety, efficacy, quality or labeling changes;
scrutiny of advertising and promotion; and
the withdrawal of indications granted pursuant to accelerated approvals.
In the past, clinical trials and post-marketing surveillance of certain marketed drugs of the Company and of competitors within the industry have raised concerns that have led to recalls, withdrawals or adverse labeling of marketed products. Clinical trials and post-marketing surveillance of certain marketed drugs also have raised concerns among some prescribers and patients relating to the safety or efficacy of pharmaceutical products in general that have negatively affected the sales of such products. In addition, increased scrutiny of the outcomes of clinical trials has led to increased volatility in market reaction. Further, these matters often attract litigation and, even where the basis for the litigation is groundless, considerable resources may be needed to respond.
In addition, following in the wake of product withdrawals and other significant safety issues, health authorities such as the FDA, the EMA, Japan’s PMDA and China’s NMPA have increased their focus on safety when assessing the benefit/risk balance of drugs. Some health authorities appear to have become more cautious when making decisions about approvability of new products or indications.
If previously unknown side effects are discovered or if there is an increase in negative publicity regarding known side effects of any of the Company’s products, it could significantly reduce demand for the product or require the Company to take actions that could negatively affect sales, including removing the product from the market, restricting its distribution or applying for labeling changes. Further, in the current environment in which all pharmaceutical companies operate, the Company is at risk for product liability and consumer protection claims and
35

civil and criminal governmental actions related to its products, research and/or marketing activities. In addition, dissemination of promotional materials through evolving digital channels serves to increase visibility and scrutiny in the marketplace.
The Company is subject to a variety of U.S. and international laws and regulations.
The Company is currently subject to a number of government laws and regulations and, in the future, could become subject to new government laws and regulations. The costs of compliance with such laws and regulations, or the negative results of non-compliance, could adversely affect the business, cash flow, results of operations, financial condition and prospects of the Company; these laws and regulations include (i) additional health care reform initiatives in the U.S. or in other countries, including additional mandatory discounts or fees; (ii) the U.S. Foreign Corrupt Practices Act (FCPA) or other anti-bribery and corruption laws; (iii) new laws, regulations and judicial or other governmental decisions affecting pricing, drug reimbursement, and access or marketing within or across jurisdictions; (iv) changes in intellectual property laws; (v) changes in accounting standards; (vi) new and increasing data privacy regulations and enforcement, particularly in the EU, the U.S., and China; (vii) legislative mandates or preferences for local manufacturing of pharmaceutical or vaccine products; (viii) emerging and new global regulatory requirements for reporting payments and other value transfers to health care professionals; (ix) environmental regulations; and (x) the potential impact of importation restrictions, embargoes, trade sanctions and legislative and/or other regulatory changes.
The Company is subject to evolving and complex tax laws, which may result in additional liabilities that may affect results of operations and financial condition.
The Company is subject to evolving and complex tax laws in the jurisdictions in which it operates. Significant judgment is required for determining the Company’s tax liabilities, and the Company’s tax returns are routinely examined by various tax authorities. In connection with the Organization for Economic Cooperation and Development (OECD) Base Erosion and Profit Shifting project, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company believes that its accrual for tax contingencies is adequate for all open years based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities; however, due to the complexity of tax contingencies, the ultimate resolution of any tax matters may result in payments greater or less than amounts accrued. In addition, the Company may be negatively affected by changes in tax laws, or new tax laws, affecting, for example, tax rates, and/or revised tax law interpretations in domestic or foreign jurisdictions, including, among others, any potential changes to the existing U.S. tax law by the current U.S. Presidential administration and Congress, as well as any changes in tax law resulting from the implementation of the OECD’s two-pillar solution to reform the international tax landscape.
The Company has taken the position, based on the opinions of tax counsel, that its distribution of Organon common stock in connection with the 2021 Spin-Off qualifies as a transaction that is tax-free for U.S. federal income tax purposes. If any facts, assumptions, representations, and undertakings from the Company and Organon regarding the past and future conduct of their respective businesses and other matters are incorrect or not otherwise satisfied, the Spin-Off may not qualify for tax-free treatment, which could result in significant U.S. federal income tax liabilities for the Company and its shareholders.
Adverse outcomes in current or future legal matters could negatively affect Merck’s business.
Current or future litigation, claims, proceedings and government investigations could preclude or delay the commercialization of Merck’s products or could adversely affect Merck’s business, results of operations, cash flow, prospects and financial condition. Such legal matters may include, but are not limited to: (i) intellectual property disputes; (ii) adverse decisions in litigation, including product safety and liability, consumer protection and commercial cases; (iii) anti-bribery regulations, such as the FCPA, including compliance with ongoing reporting obligations to the government resulting from any settlements; (iv) recalls or withdrawals of pharmaceutical products or forced closings of manufacturing plants; (v) product pricing and promotional matters; (vi) lawsuits, claims and administrative proceedings asserting, or investigations into, violations of securities, antitrust, Federal and state pricing, consumer protection, data privacy and other laws and regulations; (vii) environmental, health, safety and sustainability matters, including regulatory actions in response to climate change; and (viii) tax liabilities resulting from assessments from tax authorities.
As previously disclosed, Merck, along with certain subsidiaries, are defendants in a number of lawsuits filed starting in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The lawsuits filed on behalf of
36

twenty-five direct purchasers, eight retailers, and a class of indirect purchasers are scheduled to proceed to trial on April 17, 2023. In these cases, plaintiffs seek up to a maximum of $12.7 billion in damages after trebling.
See Item 8. “Financial Statements and Supplementary Data,” Note 11, “Contingencies and Environmental Liabilities” for more information on the Company’s legal matters.
Product liability insurance for products may be limited, cost prohibitive or unavailable.
As a result of a number of factors, product liability insurance has become less available while the cost of such insurance has increased significantly. The Company is subject to a substantial number of product liability claims. See Item 8. “Financial Statements and Supplementary Data,” Note 11. “Contingencies and Environmental Liabilities” below for more information on the Company’s current product liability litigation. With respect to product liability, the Company self-insures substantially all of its risk, as the availability of commercial insurance has become more restrictive. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities. The Company will continually assess the most efficient means to address its risk; however, there can be no guarantee that insurance coverage will be obtained or, if obtained, will be sufficient to fully cover product liabilities that may arise.
Risks Related to Technology
The Company is increasingly dependent on sophisticated software applications and computing infrastructure. The Company could be a target of future cyber-attacks that could lead to a disruption of its worldwide operations, including manufacturing, research and sales operations.
The Company is increasingly dependent on sophisticated software applications, complex information technology systems, computing infrastructure, and cloud service providers (collectively, IT systems) to conduct critical operations. Certain of these systems are managed, hosted, provided or used by third parties to assist in conducting the Company’s business. Disruption, degradation, or manipulation of these IT systems through intentional or accidental means by the Company’s employees, third parties with authorized access or unauthorized third parties could adversely affect key business processes. Cyber-attacks against the Company’s IT systems or third-party providers’ IT systems, such as cloud-based systems, could result in exposure of confidential information, the modification of critical data, and/or the failure of critical operations. Misuse of any of these IT systems could result in the disclosure of sensitive personal information or the theft of trade secrets, intellectual property, or other confidential business information. The Company continues to leverage new and innovative technologies across the enterprise to replace outmoded technology and improve the efficacy and efficiency of its business processes, including data acquisition; the use of which can create new risks.
Although the aggregate impact of cyber-attacks and network disruptions on the Company’s operations and financial condition has not been material to date, the Company continues to be a target of events of this nature and expects them to continue. The Company monitors its data, information technology and personnel usage of Company IT systems to reduce these risks and continues to do so on an ongoing basis for any current or potential threats. There can be no assurance that the Company’s efforts to protect its data and IT systems or the efforts of third-party providers to protect their IT systems will be successful in preventing disruptions to the Company’s operations, including its manufacturing, research and sales operations. Such disruptions have in the past and could in the future result in loss of revenue, or the loss of critical or sensitive information from the Company’s or the Company’s third-party providers’ databases or IT systems and have in the past and could in the future also result in financial, legal, business or reputational harm to the Company and substantial remediation costs.
Social media and mobile messaging platforms present risks and challenges.
The inappropriate and/or unauthorized use of certain social media and mobile messaging channels could cause brand damage or information leakage or could lead to legal implications, including from the improper collection and/or dissemination of personally identifiable information. In addition, negative or inaccurate posts or comments about the Company or its products on any social networking platforms could damage the Company’s reputation, brand image and goodwill. Further, the disclosure of non-public Company-sensitive information by the Company’s workforce or others through external media channels could lead to information loss. Although there are internal Company Social Media and Mobile Messaging Policies that guide employees on appropriate personal and professional use of these platforms for communication about the Company, the processes in place may not completely secure and protect information. Identifying new points of entry as new communication tools expand also presents new challenges.
37

Cautionary Factors that May Affect Future Results
(Cautionary Statements Under the Private Securities Litigation Reform Act of 1995)
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. The Company does not assume the obligation to update any forward-looking statement. The Company cautions you not to place undue reliance on these forward-looking statements. Although it is not possible to predict or identify all such factors, they may include the following:
Competition from generic and/or biosimilar products as the Company’s products lose patent protection.
Increased “brand” competition in therapeutic areas important to the Company’s long-term business performance.
The difficulties and uncertainties inherent in new product development. The outcome of the lengthy and complex process of new product development is inherently uncertain. A drug candidate can fail at any stage of the process and one or more late-stage product candidates could fail to receive regulatory approval. New product candidates may appear promising in development but fail to reach the market because of efficacy or safety concerns, the inability to obtain necessary regulatory approvals, the difficulty or excessive cost to manufacture and/or the infringement of patents or intellectual property rights of others. Furthermore, the sales of new products may prove to be disappointing and fail to reach anticipated levels.
Pricing pressures, both in the U.S. and abroad, including rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and health care reform, pharmaceutical reimbursement and pricing in general.
The impact of the global COVID-19 pandemic and any future pandemic, epidemic, or similar public health threat, on the Company’s business, operations, financial performance and prospects.
Changes in government laws and regulations, including laws governing intellectual property, and the enforcement thereof affecting the Company’s business.
Efficacy or safety concerns with respect to marketed products, whether or not scientifically justified, leading to product recalls, withdrawals or declining sales.
Significant changes in customer relationships or changes in the behavior and spending patterns of purchasers of health care products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing health care insurance coverage.
Legal factors, including product liability claims, antitrust litigation and governmental investigations, including tax disputes, environmental concerns and patent disputes with branded and generic competitors, any of which could preclude commercialization of products or negatively affect the profitability of existing products.
Cyber-attacks on the Company’s or third-party providers’ information technology systems, which could disrupt the Company’s operations.
Lost market opportunity resulting from delays and uncertainties in the approval process of the FDA and foreign regulatory authorities.
Increased focus on privacy issues in countries around the world, including the U.S., the EU, and China. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amount of focus on privacy and data protection issues with the potential to affect directly the Company’s business, including laws in a majority of states in the U.S. requiring security breach notification.
38

Changes in tax laws including changes related to the taxation of foreign earnings.
Changes in accounting pronouncements promulgated by standard-setting or regulatory bodies, including the Financial Accounting Standards Board and the SEC, that are adverse to the Company.
Economic factors over which the Company has no control, including changes in inflation, interest rates and foreign currency exchange rates.
This list should not be considered an exhaustive statement of all potential risks and uncertainties. See “Risk Factors” above.
Item 1B.Unresolved Staff Comments.
None.
Item 2.Properties.
The Company’s corporate headquarters is currently located in Kenilworth, New Jersey. The Company has previously announced that it intends to consolidate its New Jersey campuses into a single corporate headquarters location in Rahway, New Jersey by the end of 2023. The Company also maintains operational or divisional headquarters in Kenilworth, New Jersey; Madison, New Jersey and Upper Gwynedd, Pennsylvania. Principal U.S. research facilities are located in Rahway and Kenilworth, New Jersey; West Point, Pennsylvania; Boston and Cambridge, Massachusetts; South San Francisco, California; and Elkhorn, Nebraska (Animal Health). Principal research facilities outside the U.S. are located in the United Kingdom, Switzerland and China. Merck’s manufacturing operations are currently headquartered in Rahway, New Jersey. The Company also has production facilities for human health products at seven locations in the U.S. and Puerto Rico. Outside the U.S., through subsidiaries, the Company owns or has an interest in manufacturing plants or other properties in Japan, Singapore, South Africa, and other countries in Western Europe, Central and South America, and Asia.
The Company and its subsidiaries own their principal facilities and manufacturing plants under titles that they consider to be satisfactory. The Company believes that its properties are in good operating condition and that its machinery and equipment have been well maintained. The Company believes that its plants for the manufacture of products are suitable for their intended purposes and have capacities and projected capacities, including previously disclosed capital expansion projects, that will be adequate for current and projected needs for existing Company products. Some capacity of the plants is being converted, with any needed modification, to the requirements of newly introduced and future products.
Item 3.Legal Proceedings.
The information called for by this Item is incorporated herein by reference to Item 8. “Financial Statements and Supplementary Data,” Note 11. “Contingencies and Environmental Liabilities”.
Item 4.Mine Safety Disclosures.
Not Applicable.
39


Executive Officers of the Registrant (ages as of February 1, 2023)
All officers listed below serve at the pleasure of the Board of Directors. None of these officers was elected pursuant to any arrangement or understanding between the officer and any other person(s).
NameAgeOffices and Business Experience
Robert M. Davis56
Chairman, President and Chief Executive Officer (since December 2022); Chief Executive Officer and President (July 2021-December 2022); Executive Vice President, Global Services, and Chief Financial Officer (April 2016-July 2021)
Sanat Chattopadhyay63
Executive Vice President and President, Merck Manufacturing Division (since March 2016)
Richard R. DeLuca, Jr.60
Executive Vice President and President, Merck Animal Health (since September 2011)
Cristal Downing 54Executive Vice President and Chief Communications & Public Affairs Officer (since August 2021); Vice President Medical Devices, Global Communications and Public Affairs Johnson & Johnson (December 2020-August 2021); Vice President Financial Communication, Johnson & Johnson (January 2018-December 2020); Prior to that, Senior Director Communications at Johnson & Johnson
Chirfi Guindo57Senior Vice President, Chief Marketing Officer, Human Health (since July 2022); Prior to that, Executive Vice President, Head of Global Product Strategy and Commercialization, Biogen Inc. (July 2018-July 2022); Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation, Biogen Inc. (November 2017-June 2018)
Rita A. Karachun59
Senior Vice President Finance - Global Controller (since March 2014)
Michael A. Klobuchar47
Executive Vice President, Chief Strategy Officer (since July 2021); Senior Vice President, CFO of Merck R&D and Head of Global Portfolio and Alliance Management (January 2019-June 2021); Senior Vice President of Corporate Strategy and Planning and President of Emerging Businesses (December 2017-January 2019)
Lisa LeCointe-Cephas41
Senior Vice President, Chief Ethics and Compliance Officer (since April 2021); Executive Director, Head of Global Investigations (February 2018-April 2021); Prior to that, Senior Counsel, Litigation and Government Investigations, Bristol-Myers Squibb Company
Dean Li60Executive Vice President, President, Merck Research Laboratories (since January 2021); Senior Vice President, Discovery Sciences and Translational Medicine, Merck Research Laboratories (November 2017-January 2021); Vice President, Translational Medicine (March 2017-November 2017)
Caroline Litchfield54
Executive Vice President and Chief Financial Officer (since April 2021); Senior Vice President, Corporate Treasurer (January 2018-March 2021)
Steven C. Mizell
62
Executive Vice President, Chief Human Resources Officer (since October 2018); Prior to that, Executive Vice President, Human Resources, Monsanto Company
Johannes J. Oosthuizen
55
Senior Vice President and President Merck U.S. Human Health (since January 2022); Senior Vice President and Head of Global Oncology Commercial (January 2021-December 2021); Senior Vice President and President of MSD K.K. (July 2016-December 2020)
Joseph Romanelli49Senior Vice President and President MSD International Human Health (since July 2022); Chief Executive Officer JiXing Pharmaceuticals (July 2021-July 2022); President MSD China (December 2016-July 2021)
David M. Williams54
Executive Vice President, Chief Information and Digital Officer (since August 2020); Acting Chief Information and Digital Officer (December 2019-August 2020); Vice President and Chief Information Officer, Merck Animal Health (May 2017-December 2019)
Jennifer Zachary45Executive Vice President, General Counsel and Corporate Secretary (since January 2020); Executive Vice President and General Counsel (April 2018-January 2020); Prior to that, Partner, Covington & Burling LLP
40



PART II
 
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
The principal market for trading of the Company’s Common Stock is the New York Stock Exchange (NYSE) under the symbol MRK.
As of January 31, 2023, there were approximately 95,850 shareholders of record of the Company’s Common Stock.
Issuer purchases of equity securities for the three months ended December 31, 2022 were as follows:
Issuer Purchases of Equity Securities
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs($ in millions)
Period
Total Number
of Shares
Purchased(1)
Average Price
Paid Per
Share
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs(1)
October 1 — October 31$5,047
November 1 — November 30$5,047
December 1 — December 31$5,047
Total
(1)    The Company did not purchase any shares during the three months ended December 31, 2022 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion in Merck shares for its treasury.


41

Performance Graph
The following graph assumes a $100 investment on December 31, 2017, and reinvestment of all dividends, in each of the Company’s Common Stock, the S&P 500 Index, and a composite peer group of major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Johnson & Johnson, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Roche Holding AG, and Sanofi SA.
Comparison of Five-Year Cumulative Total Return
Merck & Co., Inc., Composite Peer Group and S&P 500 Index
End of
Period Value
2022/2017
CAGR*
MERCK$24219%
PEER GROUP**17512%
S&P 5001579%
mrk-20221231_g2.jpg
201720182019202020212022
MERCK100.0140.0171.2158.8161.7241.5
PEER GROUP100.0106.1125.7134.2164.8174.8
S&P 500100.095.6125.7148.8191.5156.8
*    Compound Annual Growth Rate
**    Peer group average was calculated on a market cap weighted basis as of December 31, 2017.

This Performance Graph will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference. In addition, the Performance Graph will not be deemed to be “soliciting material” or to be “filed” with the SEC or subject to Regulation 14A or 14C, other than as provided in Regulation S-K, or to the liabilities of section 18 of the Securities Exchange Act of 1934, except to the extent that the Company specifically requests that such information be treated as soliciting material or specifically incorporates it by reference into a filing under the Securities Act or the Exchange Act.
Item 6.     [Reserved]
42

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following section of this Form 10-K generally discusses 2022 and 2021 results and year-to-year comparisons between 2022 and 2021. Discussion of 2020 results and year-to-year comparisons between 2021 and 2020 that are not included in this Form 10-K can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed on February 25, 2022.
Description of Merck’s Business
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 3 to the consolidated financial statements).


43

Overview
Financial Highlights
($ in millions except per share amounts)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Sales$59,283 22 %26 %$48,704 17 %16 %$41,518 
Net Income from Continuing Operations Attributable to Merck & Co., Inc.:
GAAP$14,519 18 %21 %$12,345 **$4,519 
Non-GAAP (1)
$19,005 40 %43 %$13,623 81 %98 %$7,545 
Earnings per Common Share Assuming Dilution from Continuing Operations Attributable to Merck & Co., Inc. Common Shareholders:
GAAP$5.71 17 %21 %$4.86 **$1.78 
Non-GAAP (1)
$7.48 39 %43 %$5.37 81 %98 %$2.97 
* > 100%
(1) Non-GAAP net income and non-GAAP earnings per share (EPS) exclude acquisition and divestiture-related costs, restructuring costs, gains and losses from investments in equity securities, and certain other items from Merck’s results prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Prior periods have been recast to conform to the current presentation. For further discussion and a reconciliation of GAAP to non-GAAP net income and EPS, see “Non-GAAP Income and Non-GAAP EPS from Continuing Operations” below.
Executive Summary
Merck’s 2022 results reflect sustained strong demand for the Company’s innovative product portfolio benefiting patients globally, enabled by strong operational and commercial execution, the completion of business development transactions to support its science-led strategy, as well as progress in its pipeline across therapeutic areas, modalities and stage of development.
mrk-20221231_g3.jpg
Worldwide sales were $59.3 billion in 2022, an increase of 22% compared with 2021, or 26% excluding the unfavorable effect of foreign exchange. The sales increase was primarily due to growth in virology (driven by the benefit of Lagevrio sales), oncology, vaccines and hospital acute care. Sales within the Animal Health business were consistent with prior year. As discussed below, COVID-19-related disruptions negatively affected sales in 2022, but to a lesser extent than in 2021, which benefited year-over-year sales growth.
Merck continues to execute strategic business development opportunities to augment its robust internal pipeline with compelling external science. Highlights of 2022 activity include the following:
Exercised an option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 under an existing collaboration and license agreement with Moderna, Inc. (Moderna).
Entered into a collaboration with Orna Therapeutics (Orna), a company pioneering a new investigational class of engineered circular RNA therapies, to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.
Entered into a global co-development and co-commercialization agreement for Orion Corporation’s (Orion) investigational candidate ODM-208 (MK-5684) currently being evaluated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
44

Entered into a license and collaboration agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors.
Exercised an option to obtain an exclusive license (outside of Chinese mainland, Hong Kong, Macau and Taiwan) for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound SKB-264 (MK-2870).
Entered into a license and collaboration agreement expanding the Company’s relationship with Kelun-Biotech pursuant to which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer (Kelun-Biotech retained rights for certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau); the transaction closed in February 2023.
Entered into agreement to acquire Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases; the acquisition closed in January 2023.
During 2022, the Company received numerous regulatory approvals within oncology. Keytruda received approval for additional indications in the U.S. and/or internationally as monotherapy in the therapeutic areas of biliary, colorectal, endometrial, gastric, melanoma, small intestine and renal cell cancers, as well as in combination with chemotherapy in the therapeutic areas of breast and cervical cancers. Keytruda was also approved in combination with Lenvima in Japan for the treatment of certain adult patients with radically unresectable or metastatic renal cell carcinoma (RCC). Lenvima is being developed in collaboration with Eisai Co., Ltd. (Eisai). Lynparza, which is being developed in collaboration with AstraZeneca PLC (AstraZeneca), received approval in the U.S., the European Union (EU) and Japan for the adjuvant treatment of certain adult patients with high-risk early breast cancer and in the EU for the treatment of certain patients with mCRPC.
Also in 2022, Vaxneuvance, a vaccine to help prevent pneumococcal disease, was approved for expanded indications in the U.S. and the EU to include use in infants, adolescents and children. Additionally in 2022, Lyfnua (gefapixant) was approved in Japan for adults with refractory or unexplained chronic cough. In addition, in 2022, Lagevrio, which is being developed in a collaboration with Ridgeback Biotherapeutics LP (Ridgeback), received emergency conditional approval in China for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19.
In addition to the recent regulatory approvals discussed above, the Company advanced its late-stage pipeline with several regulatory submissions.
Keytruda is under review in the U.S. and/or internationally for supplemental indications for the treatment of certain patients with hepatocellular, Merkel cell, non-small-cell lung and urothelial cancers, as well as primary mediastinal B-cell lymphoma (PMBCL). Lynparza is under review for supplemental indications in the U.S. and Japan for the treatment of certain patients with mCRPC. MK-4482, Lagevrio, an investigational oral antiviral COVID-19 medicine, is under a rolling review by the European Medicines Agency (EMA); the Committee for Medicinal Products for Human Use of the EMA has recommended the refusal of the marketing authorization, which Merck and Ridgeback intend to appeal. MK-7264, gefapixant, a selective, non-narcotic, orally-administered, investigational P2X3-receptor antagonist being developed for the treatment of refractory, chronic cough is under review in the U.S. and the EU.
The Company’s Phase 3 oncology programs include:
Keytruda in the therapeutic areas of biliary, cutaneous squamous cell, gastric, hepatocellular, mesothelioma, ovarian, prostate and small-cell lung cancers;
Lynparza in combination with Keytruda for non-small-cell lung and small-cell lung cancers;
Lenvima in combination with Keytruda for colorectal, esophageal, gastric, head and neck, melanoma and non-small-cell lung cancers;
MK-1308A, the coformulation of quavonlimab, Merck’s novel investigational anti-CTLA-4 antibody, and pembrolizumab for RCC;
MK-3475, subcutaneous pembrolizumab for non-small-cell lung cancer (NSCLC);
MK-3475A, the subcutaneous coformulation of pembrolizumab with hyaluronidase, for NSCLC;
MK-4280A, the coformulation of favezelimab, Merck’s novel investigational anti-LAG3 therapy, and pembrolizumab for colorectal cancer and hematological malignancies;
Welireg for RCC;
45

MK-7119, Tukysa (tucatinib), which is being developed in collaboration with Seagen Inc. (Seagen), for breast and colorectal cancers; and
MK-7684A, the coformulation of vibostolimab, an anti-TIGIT therapy, and pembrolizumab for melanoma, non-small-cell and small-cell lung cancers.
Additionally, the Company currently has candidates in Phase 3 clinical development in several other therapeutic areas including:
V116, an investigational 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults;
MK-7962, sotatercept, for the treatment of pulmonary arterial hypertension (PAH);
MK-1654, clesrovimab, for the prevention of respiratory syncytial virus;
MK-8591A, islatravir in combination with doravirine for the treatment of HIV-1 infection (which is on partial clinical hold for higher doses than those used in current clinical trials); and
MK-4482, Lagevrio, which is reflected in Phase 3 development in the U.S. as it remains investigational following Emergency Use Authorization in 2021.
Merck’s capital allocation priorities are to make investments in its business to drive near- and long-term growth, including investing in opportunities to address important unmet medical needs and supporting the Company’s commercial opportunities. In addition, Merck remains committed to its dividend and will continue to pursue the most compelling external science through value-enhancing business development transactions. Research and development expenses in 2022 reflect higher clinical development spending particularly in the therapeutic areas of oncology, cardiovascular, infectious diseases and vaccines.
mrk-20221231_g4.jpg
In November 2022, Merck’s Board of Directors approved an increase to the Company’s quarterly dividend, raising it to $0.73 per share from $0.69 per share on the Company’s outstanding common stock. During 2022, the Company returned $7.0 billion to shareholders through dividends.
mrk-20221231_g5.jpgmrk-20221231_g6.jpg
GAAP and Non-GAAP EPS were negatively affected in 2022, 2021 and 2020 by $0.22, $0.65, and $1.56, respectively, of charges for certain upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions.
War in Ukraine
In February 2022, Russia invaded Ukraine. The Company’s primary concerns are the safety and well-being of its employees and ensuring patients and customers have continued access to medicines and vaccines needed for patient and public health. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials. For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with international sanctions. Merck is donating profits
46

resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. The financial impacts of the war were immaterial to the Company’s consolidated financial statements for 2022. Sales to Russia were approximately 1% of total Merck consolidated sales for 2022 and are expected to decline in future periods. The Company is unable to determine at this time the future direct or indirect impacts of this war on the Company’s business.
COVID-19
Although COVID-19-related disruptions had some negative effect on sales in 2022, Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic. Merck’s revenue in 2022 benefited from sales of Lagevrio, which were $5.7 billion. Merck expects sales of Lagevrio will decline significantly in 2023 to approximately $1.0 billion.
In 2021, COVID-19-related disruptions resulted in an estimated negative impact to Pharmaceutical segment sales of approximately $1.3 billion because a substantial portion of Pharmaceutical segment revenue is comprised of physician-administered products, which were unfavorably affected by social distancing measures and fewer well visits. Sales in 2021 benefited from $952 million of Lagevrio sales.
In April 2021, Merck announced it was discontinuing the development of MK-7110 for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck’s acquisition of OncoImmune (see Note 4 to the consolidated financial statements). This decision resulted in charges of $207 million to Cost of sales in 2021.
Operating expenses in 2021 reflect a minor positive effect as investments in COVID-19-related research largely offset the favorable impact of lower spending in other areas due to the COVID-19 pandemic.
In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided Merck with $102 million of funding in the first quarter of 2022 to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. The funding was recognized as a reduction to Cost of sales over the expected production period, offsetting the depreciation expense related to the amounts that were capitalized in connection with the modification of the manufacturing facilities. Merck and Johnson & Johnson have commenced an arbitration regarding a dispute concerning two agreements pursuant to which Merck was supporting the manufacturing and supply of Johnson & Johnson’s SARS-CoV-2/COVID-19 vaccine and vaccine drug product. The amounts included in the consolidated financial statements for these agreements were immaterial in 2022. Merck does not believe the outcome of the arbitration will have a material impact on the Company’s financial statements.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In 2022, the U.S. Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.
Supply Chain
As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation.
47

Operating Results
Sales
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
United States$27,206 21 %21 %$22,425 14 %14 %$19,588 
International32,077 22 %29 %26,279 20 %17 %21,930 
Total$59,283 22 %26 %$48,704 17 %16 %$41,518 
Worldwide sales grew 22% in 2022 attributable in part to higher sales in the virology franchise driven by Lagevrio. Also contributing to revenue growth were higher sales in the oncology franchise largely due to strong growth of Keytruda and increased alliance revenue from Lenvima and Lynparza, as well as higher sales in the vaccines franchise, primarily attributable to growth in Gardasil/Gardasil 9 and the launch of Vaxneuvance for pediatric use. Higher sales of hospital acute care products, including Bridion, Zerbaxa, Dificid and Prevymis, as well as higher revenue related to third-party manufacturing arrangements also drove revenue growth in 2022. As discussed above, COVID-19-related disruptions had some negative effects on sales in 2022, but to a lesser extent than in 2021, which benefited year-over-year sales growth. Sales growth in 2022 was partially offset by lower sales of diabetes products Januvia and Janumet, the Pneumovax 23 vaccine, and virology products Isentress/Isentress HD.
Sales in the U.S. grew 21% in 2022 primarily driven by higher sales of Keytruda, Lagevrio, Gardasil 9, as well as increased alliance revenue from Lenvima and Reblozyl (obtained as part of the Acceleron Pharma Inc. (Acceleron) acquisition in November 2021), and the launch of Vaxneuvance for pediatric use. Higher sales of Bridion, Welireg, Zerbaxa and Dificid, as well as increased revenue from third-party manufacturing arrangements also contributed to U.S. sales growth in 2022. Lower sales of Pneumovax 23 and Januvia partially offset revenue growth in the U.S. in 2022.
International sales grew 22% in 2022 primarily due to higher sales of Lagevrio, Gardasil/Gardasil 9, Keytruda, and Zerbaxa, as well as increased revenue from third-party manufacturing arrangements, partially offset by lower sales of Januvia/Janumet, Simponi, Isentress/Isentress HD, Remicade, and Pneumovax 23. International sales represented 54% of total sales in both 2022 and 2021.
See Note 19 to the consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.
Pharmaceutical Segment
Oncology
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Keytruda$20,937 22 %27 %$17,186 20 %18 %$14,380 
Alliance Revenue - Lynparza (1)
1,116 13 %18 %989 36 %35 %725 
Alliance Revenue - Lenvima (1)
876 24 %28 %704 21 %20 %580 
Alliance Revenue - Reblozyl (2)
166 **17 — 
* > 100%
(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5 to the consolidated financial statements).
(2) Alliance revenue represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5 to the consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), NSCLC, melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, PMBCL, tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma, including non-muscle invasive bladder cancer. Additionally, Keytruda is approved as monotherapy for the adjuvant treatment of certain patients with RCC at intermediate-high or high risk of recurrence and for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Keytruda
48

is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, Keytruda is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC, in combination with axitinib for advanced RCC, and in combination with Lenvima for certain patients with advanced endometrial carcinoma or advanced RCC. The Keytruda clinical development program includes studies across a broad range of cancer types.
Global sales of Keytruda grew 22% in 2022 primarily driven by higher demand as the Company continues to launch Keytruda with multiple new indications globally. Sales in the U.S. continue to build across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, HNSCC, and MSI-H cancers. Keytruda sales growth in the U.S. also benefited from increased uptake across recent launches in earlier-stage indications including in high-risk early stage TNBC, as well as certain types of RCC and melanoma. Keytruda sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe.
Keytruda recently received numerous regulatory approvals summarized below.
DateApproval
January 2022
EC approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.
February 2022
Japan’s Ministry of Health, Labor and Welfare (MHLW) approval of the combination of Keytruda plus Lenvima for radically unresectable or metastatic RCC, based on the CLEAR (Study 307)/KEYNOTE-581 trial.
February 2022
MHLW approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care), based on the KEYNOTE-158 trial.
March 2022
U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-158 trial (Cohorts D & K).
April 2022
EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1, based on the KEYNOTE-826 trial.
April 2022
EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial carcinoma, based on the KEYNOTE-164 and KEYNOTE-158 trials.
May 2022
EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence, based on the KEYNOTE-522 trial.
June 2022
EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection, based on the KEYNOTE-716 trial. EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
August 2022MHLW approval as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.
September 2022MHLW approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence, based on the KEYNOTE-522 trial.
49

September 2022MHLW approval in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on the KEYNOTE-826 trial.
September 2022MHLW approval as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection, based on the KEYNOTE-716 trial.
October 2022
China’s National Medical Products Administration (NMPA) approval as monotherapy for the treatment of patients with HCC who have been previously treated with sorafenib or oxaliplatin-based chemotherapy, based on the KEYNOTE-394 trial.
November 2022NMPA approval for the treatment of patients with high-risk early-stage TNBC whose tumors express PD-L1, in combination with chemotherapy as neoadjuvant treatment, and then continued as a monotherapy as adjuvant treatment after surgery, based on the KEYNOTE-522 trial.
January 2023FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of Keytruda. Under the terms of the more significant of these agreements, Merck pays a royalty of 6.5% on worldwide sales of Keytruda through December 2023 to one third party; this royalty will decline to 2.5% for 2024 through 2026 and will terminate thereafter. The Company pays an additional 2% royalty on worldwide sales of Keytruda to another third party, the termination date of which varies by country; this royalty will expire in the U.S. in September 2024 and on varying dates in major European markets in the second half of 2025. The royalties are included in Cost of sales.
Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca (see Note 5 to the consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza grew 13% in 2022 largely due to higher demand globally across the multiple approved indications, particularly in the U.S. largely attributable to uptake in the earlier-stage breast cancer indication following approval by the FDA in March 2022.
Lynparza received several regulatory approvals in 2022 summarized below.
DateApproval
March 2022
FDA approval for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial.
August 2022
MHLW approval for the adjuvant treatment of patients with BRCA-mutated, HER2-negative high recurrent risk breast cancer, based on the OlympiA trial.
August 2022
EC approval as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy, based on the OlympiA trial.
September2022NMPA approval as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status, based on the PAOLA-1 trial.
December 2022EC approval in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated, based on the PROpel trial.
Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai (see Note 5 to the consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with Keytruda for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 24% in 2022 reflecting uptake in the advanced RCC and advanced endometrial carcinoma indications, particularly in the U.S.
Reblozyl is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (see Note 5 to the consolidated financial statements). Reblozyl is approved for the treatment of certain types of anemia. Merck recorded alliance revenue of $166 million in 2022, which includes
50

royalties of $146 million, as well as the receipt of a regulatory approval milestone payment of $20 million, compared with alliance revenue of $17 million in 2021.
Vaccines
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Gardasil/Gardasil 9
$6,897 22 %27 %$5,673 44 %39 %$3,938 
ProQuad839 9 %11 %773 14 %13 %678 
M-M-R II
411 5 %7 %391 %%378 
Varivax991 2 %4 %971 18 %18 %823 
Pneumovax 23
602 (33)%(30)%893 (18)%(19)%1,087 
Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 22% in 2022 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Sales of Gardasil 9 in the U.S. increased due to public sector buying patterns and higher pricing, partially offset by lower demand.
In 2022, China’s NMPA expanded the use of Gardasil 9 for use in girls and women ages 9 to 45. The vaccine was previously approved for use in girls and women ages 16 to 26.
The Company is a party to certain third-party license agreements pursuant to which the Company pays royalties on sales of Gardasil/Gardasil 9. Under the terms of the more significant of these agreements, Merck pays a 7% royalty on worldwide sales of Gardasil/Gardasil 9 to one third party (which expires in December 2023) and an additional 7% royalty on sales of Gardasil/Gardasil 9 in the U.S. to another third party (which expires in December 2028). The royalties are included in Cost of sales.
Global sales of ProQuad, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, grew 9% in 2022 primarily due to higher pricing in the U.S. and higher demand in Europe.
Worldwide sales of M-M-R II, a vaccine to help protect against measles, mumps and rubella, grew 5% in 2022 primarily due to higher pricing in the U.S.
Global sales of Varivax, a vaccine to help prevent chickenpox (varicella), grew 2% in 2022 primarily reflecting higher pricing in the U.S., partially offset by lower tenders in Latin America.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, declined 33% in 2022 primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) in 2021. The Company expects the decline in U.S. sales of Pneumovax 23 to continue. Lower demand in Europe also contributed to the Pneumovax 23 sales decline in 2022.
In June 2022, the FDA approved an expanded indication for Vaxneuvance to include use in individuals 6 weeks of age and older. The FDA’s approval was based on data from seven randomized, double-blind clinical studies assessing safety, tolerability and immunogenicity of Vaxneuvance in infants and children. Also in June 2022, the CDC’s ACIP unanimously voted to include Vaxneuvance as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age. These recommendations subsequently were adopted by the director of the CDC and the U.S. Department of Health and Human Services, and published in the CDC’s Morbidity and Mortality Weekly Report (MMWR). The ACIP also unanimously voted to include Vaxneuvance in the Vaccines for Children program. In October 2022, the EC approved an expanded indication for Vaxneuvance to include use in infants, children and adolescents from 6 weeks to less than 18 years of age. Vaxneuvance was previously approved for use in the U.S. and the EU in 2021 for individuals 18 years of age and older. In September 2022, Vaxneuvance was approved in Japan for use in adult patients. Vaxneuvance remains under review in Japan for use in pediatric patients. Sales of Vaxneuvance were $170 million in 2022, largely due to inventory stocking in the U.S. Merck is party to a third-party licensing agreement pursuant to which the Company pays a royalty of 7.25% on net sales of Vaxneuvance through 2026; this royalty will decline to 2.5% on net sales from 2027 through 2035. The royalties are included in Cost of sales.

51

Hospital Acute Care
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Bridion$1,685 10 %16 %$1,532 28 %27 %$1,198 
Prevymis428 16 %24 %370 32 %30 %281 
Dificid263 50 %50 %175 60 %60 %110 
Zerbaxa169 **(1)**130 
Welireg123 ****13 — — — 
* Calculation not meaningful.
** >100%
Global sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 10% in 2022 due to higher demand globally, particularly in the U.S., largely attributable to Bridion’s growing share among neuromuscular blockade reversal agents and an increase in surgical procedures. Bridion will lose market exclusivity in the EU in July 2023 and the Company anticipates sales of Bridion in these markets will decline thereafter.
Worldwide sales of Prevymis, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 16% in 2022 due to higher demand globally, particularly in the U.S. and Europe. In February 2023, the FDA granted priority review for a supplemental New Drug Application for Prevymis for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (D+/R-); the Prescription Drug User Fee Act (PDUFA), or target action, date is June 5, 2023.
Worldwide sales of Dificid, for the treatment of C. difficile-associated diarrhea, grew 50% in 2022 due to higher demand in the U.S.
In December 2020, the Company temporarily suspended sales of Zerbaxa, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. As a result, the Company recorded an intangible asset impairment charge in 2020 related to Zerbaxa (see Note 9 to the consolidated financial statements). The phased resupply of Zerbaxa that was initiated in the fourth quarter of 2021 was completed in 2022.
Sales of Welireg, for the treatment of certain adult patients with von Hippel-Lindau disease-associated RCC, increased to $123 million in 2022 due to continued uptake in the U.S. following launch in 2021.
Cardiovascular
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Alliance Revenue - Adempas/Verquvo (1)
$341  % %$342 22 %22 %$281 
Adempas238 (6)%7 %252 14 %11 %220 
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5 to the consolidated financial statements).
Adempas and Verquvo are part of a worldwide collaboration with Bayer to market and develop soluble guanylate cyclase (sGC) modulators (see Note 5 to the consolidated financial statements). Adempas is approved for the treatment of certain types of PAH and chronic thromboembolic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration was essentially flat in 2022 compared with 2021 reflecting higher profit share related to Adempas that was partially offset by lower profit share for Verquvo reflecting higher launch costs. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories declined 6% in 2022; excluding the unfavorable effect of foreign exchange, sales grew 7% primarily reflecting higher demand in Japan.

52

Virology
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Lagevrio$5,684 **$952 $— 
Isentress/Isentress HD633 (18)%(13)%769 (10)%(11)%857 
* > 100%
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note 5 to the consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide. The increase in sales of Lagevrio in 2022 primarily reflects higher sales in the UK, Japan and the U.S., as well as the launch in Australia. In December 2022, China’s NMPA granted emergency conditional approval for Lagevrio for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe COVID-19. Merck expects sales of Lagevrio will decline significantly in 2023 to approximately $1.0 billion reflecting in part the waning impact of the COVID-19 pandemic.
Worldwide sales of Isentress/Isentress HD, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 18% in 2022 due to lower global demand, reflecting in part competitive pressure particularly in Europe, Latin America and the U.S. The Company expects competitive pressure for Isentress/Isentress HD to continue. Isentress/Isentress HD will lose market exclusivity in the EU in July 2023 and the Company anticipates sales declines of Isentress/Isentress HD in these markets will accelerate thereafter.
Diabetes
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Januvia/Janumet$4,513 (15)%(9)%$5,288 — %(2)%$5,276 
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 15% in 2022 primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as lower demand in the U.S. The sales decline was partially offset by increased demand in Latin America reflecting in part higher government tenders.
While the key U.S. patent for Januvia and Janumet claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note 11 to the consolidated financial statements), the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity in the U.S. toward the end of 2023. As a result of competitive pressures, the Company anticipates pricing and volume declines for Januvia and Janumet in the U.S. in 2023 and thereafter.
The Company lost market exclusivity for Januvia in all of the EU and for Janumet in some European countries in September 2022. Merck expects that exclusivity for Janumet will be lost in other European countries in April 2023. While the Company lost market exclusivity for Januvia in China in 2022 with the approval of a generic equivalent product, the impact on sales in 2023 is expected to be modest. It is anticipated that a generic equivalent of Janumet will be approved in China in the first quarter of 2023, but the impact to sales in 2023 is also expected to be modest.
Combined sales of Januvia and Janumet in Europe, China and the U.S. represented 19%, 11% and 36%, respectively, of total combined Januvia and Janumet sales in 2022.
In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug’s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities’ interim acceptable NTTP limits for continuing distribution of product to the market. The Company is making progress in its efforts to reduce the level
53

of nitrosamines in its sitagliptin-containing medicines. However, difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages.
Animal Health Segment
($ in millions)2022% Change% Change
Excluding Foreign
Exchange
2021% Change% Change
Excluding Foreign
Exchange
2020
Livestock$3,300  %7 %$3,295 12 %10 %$2,939 
Companion Animal2,250 (1)%4 %2,273 29 %26 %1,764 
Sales of livestock products were essentially flat in 2022 primarily due to the unfavorable effect of foreign exchange, offset by higher pricing, as well as increased demand for ruminant and poultry products. Sales of companion animal products declined 1% in 2022 reflecting the unfavorable effect of foreign exchange and supply constraints for certain vaccines, largely offset by higher pricing in the portfolio, as well as higher demand for the Bravecto line of products, which had sales of $1.0 billion in 2022.
Costs, Expenses and Other
($ in millions)2022% Change2021% Change2020
Cost of sales$17,411 28 %$13,626 — %$13,618 
Selling, general and administrative10,042 4 %9,634 %8,955 
Research and development13,548 11 %12,245 (9)%13,397 
Restructuring costs337 (49)%661 15 %575 
Other (income) expense, net1,501 *(1,341)51 %(890)
 $42,839 21 %$34,825 (2)%$35,655 
* Calculation not meaningful.
Cost of Sales
Cost of sales was $17.4 billion in 2022 and $13.6 billion in 2021. Cost of sales includes $3.0 billion and $502 million in 2022 and 2021, respectively, related to the collaboration with Ridgeback for Lagevrio (see Note 5 to the consolidated financial statements). Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $2.0 billion in 2022 and $1.6 billion in 2021. Amortization expense in 2022 and 2021 includes $250 million and $153 million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with AstraZeneca and Bayer, respectively (see Note 5 to the consolidated financial statements). Additionally, costs in 2021 include charges of $225 million related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $205 million in 2022 and $160 million in 2021, primarily reflecting accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 70.6% in 2022 compared with 72.0% in 2021. The gross margin decline primarily reflects the unfavorable impacts of higher amortization of intangible assets (noted above), as well as higher sales of Lagevrio and revenue from third-party manufacturing arrangements, both of which have lower gross margins. The gross margin decline was partially offset by the favorable effects of product mix, foreign exchange and charges in 2021 related to the discontinuation of COVID-19 development programs (noted above).
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses were $10.0 billion in 2022, an increase of 4% compared with 2021. The increase was primarily due to higher administrative costs, as well as higher promotional spending and selling costs, partially offset by the favorable effects of foreign exchange and lower acquisition-related costs.
Research and Development
Research and development (R&D) expenses were $13.5 billion in 2022, an increase of 11% compared with 2021 primarily due to higher intangible asset impairment charges (largely related to nemtabrutinib), higher charges for upfront and option payments related to collaborations and licensing arrangements, higher compensation
54

and benefit costs reflecting in part increased headcount to support expanded clinical development activity, and increased clinical development spending. The increase in R&D expenses was partially offset by a charge in 2021 for the acquisition of Pandion Therapeutics, Inc. (Pandion).
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $7.7 billion in 2022 and $7.1 billion in 2021. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were $4.1 billion in 2022 and $4.7 billion in 2021. The decrease in these expenses in 2022 largely reflects a $1.7 billion charge in 2021 for the acquisition of Pandion, partially offset by $690 million of upfront and option payments in the aggregate for collaboration and licensing agreements with Moderna, Orna and Orion. See Note 4 to the consolidated financial statements for additional information related to these business development transactions. R&D expenses also include impairment charges of $1.7 billion and $275 million in 2022 and 2021, respectively, largely related to nemtabrutinib (see Note 9 to the consolidated financial statements). The Company may recognize additional impairment charges in the future related to the cancellation or delay of other pipeline programs that were measured at fair value and capitalized in connection with business combinations and such charges could be material. R&D expenses also include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business combinations. The Company recorded a net reduction in expenses of $75 million in 2022 compared with $35 million of expenses in 2021 related to changes in these estimates.
Restructuring Costs
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. Merck expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately $900 million by the end of 2023.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $337 million in 2022 and $661 million in 2021. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $666 million in 2022 and $868 million in 2021 related to restructuring program activities (see Note 6 to the consolidated financial statements).
Other (Income) Expense, Net
Other (income) expense, net, was $1.5 billion of expense in 2022 compared with $1.3 billion of income in 2021 primarily due to net unrealized losses from investments in equity securities in 2022 compared with net realized and unrealized gains from investments in equity securities recorded in 2021.
For details on the components of Other (income) expense, net, see Note 15 to the consolidated financial statements.
55

Segment Profits
($ in millions)202220212020
Pharmaceutical segment profits$36,852 $30,977 $26,106 
Animal Health segment profits1,963 1,950 1,669 
Other non-reportable segment profits — 
Other(22,371)(19,048)(21,913)
Income from Continuing Operations Before Taxes$16,444 $13,879 $5,863 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Pharmaceutical segment profits grew 19% in 2022 primarily due to higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits grew 1% in 2022 reflecting lower manufacturing costs, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rates from continuing operations were 11.7% in 2022 and 11.0% in 2021. The tax rate from continuing operations in 2022 and 2021 reflect a favorable mix of income and expense. The tax rate from continuing operations in 2022 also reflects the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. These items reduced domestic pretax income by approximately $2.9 billion in 2022. The tax rate from continuing operations in 2021 also reflects higher foreign tax credits from ordinary business operations that the Company was able to credit, the beneficial impact of the settlement of a foreign tax matter, as well as a net tax benefit of $207 million related to the settlement of certain federal income tax matters (see Note 16 to the consolidated financial statements). Additionally, the tax rate from continuing operations in 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized.
Non-GAAP Income and Non-GAAP EPS from Continuing Operations
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items. These excluded items are significant components in understanding and assessing financial performance.
Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be
56

comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with GAAP.
In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and pre-approval milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Merck’s non-GAAP results no longer exclude charges related to these items. Prior periods have been recast to conform to the current presentation.
A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:
($ in millions except per share amounts)202220212020
Income from continuing operations before taxes as reported under GAAP$16,444 $13,879 $5,863 
Increase (decrease) for excluded items:
Acquisition and divestiture-related costs (1)
3,704 2,484 3,642 
Restructuring costs666 868 880 
Loss (income) from investments in equity securities, net1,348 (1,884)(1,292)
Other items:
Charges for the discontinuation of COVID-19 development programs 225 305 
Other (4)(20)
Non-GAAP income from continuing operations before taxes22,162 15,568 9,378 
Taxes on income from continuing operations as reported under GAAP1,918 1,521 1,340 
Estimated tax benefit on excluded items (2)
1,232 204 556 
Net tax benefit from the settlement of certain federal income tax matters 207 — 
Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition — (67)
Non-GAAP taxes on income from continuing operations3,150 1,932 1,829 
Non-GAAP net income from continuing operations19,012 13,636 7,549 
Less: Net income attributable to noncontrolling interests as reported under GAAP7 13 
Non-GAAP net income from continuing operations attributable to Merck & Co., Inc.$19,005 $13,623 $7,545 
EPS assuming dilution from continuing operations as reported under GAAP$5.71 $4.86 $1.78 
EPS difference1.77 0.51 1.19 
Non-GAAP EPS assuming dilution from continuing operations$7.48 $5.37 $2.97 
(1)Amounts in 2022, 2021 and 2020 include $1.7 billion, $302 million and $1.7 billion, respectively, of intangible asset impairment charges.
(2) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 6 to the consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down
57

and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS are charges related to the discontinuation of COVID-19 development programs (see Note 4 to the consolidated financial statements), as well as a net tax benefit related to the settlement of certain federal income tax matters (see Note 16 to the consolidated financial statements), and an adjustment to tax benefits recorded in conjunction with the 2015 acquisition of Cubist Pharmaceuticals, Inc.
Research and Development
Research Pipeline
The Company currently has several candidates under regulatory review in the U.S. and internationally, as well as in late-stage clinical development. A chart reflecting the Company’s current research pipeline as of February 17, 2023 and related discussion is set forth in Item 1. “Business — Research and Development” above.
Acquisitions, Research Collaborations and Licensing Agreements
Merck continues to remain focused on pursuing opportunities that have the potential to drive both near- and long-term growth. Certain recent transactions are summarized below; additional details are included in Note 4 to the consolidated financial statements. Merck actively monitors the landscape for growth opportunities that meet the Company’s strategic criteria.
In February 2023, Merck and Kelun-Biotech closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical ADCs for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175 million, which will be recorded in Research and development expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago, a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and Research and development expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, which resulted in a $250 million charge to Research and development expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. In February 2023, Merck and Moderna announced that mRNA-4157/V940 was granted Breakthrough Therapy Designation by the FDA for the adjuvant treatment of patients with high-risk melanoma following complete resection.
In August 2022, Merck and Orna entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in 2022. In addition, Orna is eligible to receive future contingent
58

development-related payments, as well as royalties on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.
In July 2022, Merck and Orion announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with mCRPC. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in 2022.
Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments, as well as tiered royalties on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s TROP2-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in 2022, and agreed to make additional payments upon completion of specified project activities, technology transfer, as well as payments to fund Kelun-Biotech’s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent developmental and sales-based milestone payments and royalties on future net sales.
Acquired In-Process Research and Development
In connection with business combinations, the Company has recorded the fair value of in-process research projects which, at the time of acquisition, had not yet reached technological feasibility. At December 31, 2022, the balance of IPR&D was $7.7 billion, primarily consisting of MK-7962 (sotatercept), $6.4 billion; MK-7264 (gefapixant), $832 million; and MK-1026 (nemtabrutinib), $418 million. Sotatercept is in Phase 3 clinical development and the Company anticipates filing sotatercept with regulatory authorities in 2023. Gefapixant is under review in the U.S. and the EU. Nemtabrutinib is in Phase 2 clinical development.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates. The time periods to receive approvals from the FDA and other regulatory agencies are subject to uncertainty. Significant delays in the approval process, or the Company’s failure to obtain approval at all, would delay or prevent the Company from realizing revenues from these products. Additionally, if the IPR&D programs require additional clinical trial data than previously anticipated, or if the programs fail or are abandoned during development, then the Company will not recover the fair value of the IPR&D recorded as an asset as of the acquisition date. If such circumstances were to occur, the Company’s future operating results could be adversely affected and the Company may recognize impairment charges, which could be material.
In 2022, 2021, and 2020 the Company recorded IPR&D impairment charges within Research and development expenses of $1.6 billion, $275 million and $90 million, respectively (see Note 9 to the consolidated financial statements).
Additional research and development will be required before any of the remaining programs reach technological feasibility. The costs to complete the research projects will depend on whether the projects are brought to their final stages of development and are ultimately submitted to the FDA or other regulatory agencies for approval.
Capital Expenditures
Capital expenditures were $4.4 billion in 2022, $4.4 billion in 2021 and $4.4 billion in 2020. Expenditures in the U.S. were $2.7 billion in 2022, $2.8 billion in 2021 and $2.6 billion in 2020. The Company plans to invest approximately $20 billion in capital projects from 2021-2025, approximately half of which relates to investments in the U.S., including expanding manufacturing capacity for oncology, vaccine and animal health products.
Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020, of which $1.3 billion in 2022, $1.1 billion in 2021 and $1.2 billion in 2020, related to locations in the U.S. Total depreciation expense in 2022, 2021 and 2020 included accelerated depreciation of $120 million, $91 million and $268 million, respectively, associated with restructuring activities (see Note 6 to the consolidated financial statements).
59

Analysis of Liquidity and Capital Resources
Merck’s strong financial profile enables it to fund research and development, focus on external alliances, support in-line products and maximize upcoming launches while providing significant cash returns to shareholders.
Selected Data
($ in millions)202220212020
Working capital$11,483 $6,394 $437 
Total debt to total liabilities and equity28.1 %31.3 %34.7 %
Cash provided by operating activities of continuing operations to total debt0.6:10.4:10.2:1
The increase in working capital in 2022 compared with 2021 is primarily due to increased cash and investments reflecting strong operating performance. The increase in working capital in 2021 compared with 2020 is primarily related to decreased short-term debt.
Cash provided by operating activities of continuing operations was $19.1 billion in 2022 compared with $13.1 billion in 2021. The increase in cash provided by operating activities of continuing operations reflects stronger operating performance. Cash provided by operating activities of continuing operations was reduced by milestone and option payments related to certain collaborations of $2.0 billion in 2022 and $435 million in 2021. Cash provided by operating activities of continuing operations continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases. The mandatory change in R&D capitalization rules that became effective for tax years beginning after December 31, 2021 (related to the Tax Cuts and Jobs Act of 2017 (TCJA)), increased the amount of taxes the Company pays in the U.S. beginning in 2022.
Cash used in investing activities of continuing operations was $5.0 billion in 2022 compared with $16.4 billion in 2021. The lower use of cash in investing activities of continuing operations was primarily due to lower cash used for acquisitions, partially offset by higher purchases of securities and other investments coupled with lower proceeds from sales of securities and other investments.
Cash used in financing activities of continuing operations was $9.1 billion in 2022 compared with cash provided by financing activities of continuing operations of $3.1 billion in 2021. The change was primarily driven by the cash distribution received in 2021 from Organon in connection with the spin-off (see Note 3 to the consolidated financial statements), proceeds from the issuance of debt in 2021 compared with no such proceeds in 2022, and higher dividends paid to stockholders in 2022, partially offset by net repayments of short-term borrowings and treasury stock purchases in 2021 that did not occur in 2022.
In December 2021, the Company issued $8.0 billion principal amount of senior unsecured notes consisting of $1.5 billion of 1.70% notes due 2027, $1.0 billion of 1.90% notes due 2028, $2.0 billion of 2.15% notes due 2031, $2.0 billion of 2.75% notes due 2051 and $1.5 billion of 2.90% notes due 2061. Merck used the net proceeds from the offering of the 2027 notes, the 2031 notes, the 2051 notes and the 2061 notes for general corporate purposes, including the repayment of outstanding commercial paper borrowings (including commercial paper borrowings in connection with Merck’s acquisition of Acceleron), and other indebtedness. Merck has committed to allocate an amount equal to the net proceeds of the offering of the notes due in 2028 to finance or refinance, in whole or in part, projects and partnerships in the Company’s priority environmental, social and governance (ESG) areas.
In June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including the repayment of outstanding commercial paper borrowings and other indebtedness.
In 2022, the Company’s $1.25 billion, 2.35% notes and the Company’s $1.0 billion, 2.40% notes matured in accordance with their terms and were repaid. In 2021, the Company’s $1.15 billion, 3.875% notes and the Company’s €1.0 billion, 1.125% notes matured in accordance with their terms and were repaid. In 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.
The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
60

The Company expects foreseeable liquidity and capital resource requirements to be met through existing cash and cash equivalents and anticipated cash flows from operations, as well as commercial paper borrowings and long-term borrowings if needed. Merck believes that its sources of financing will be adequate to meet its future requirements. The Company’s material cash requirements arising in the normal course of business primarily include:
Debt Obligations and Interest Payments — See Note 10 to the consolidated financial statements for further detail of the Company’s debt obligations and the timing of expected future principal and interest payments.
Tax Liabilities — In connection with the enactment of the TCJA, the Company is required to pay a one-time transition tax, which the Company has elected to pay over a period of eight years through 2025 as permitted under the TCJA. Additionally, the Company has liabilities for unrecognized tax benefits, including interest and penalties. See Note 16 to the consolidated financial statements for further information pertaining to the transition tax and liabilities for unrecognized tax benefits.
Operating Leases — See Note 10 to consolidated financial statements for further details of the Company’s lease obligations and the timing of expected future lease payments.
Contingent Milestone Payments — The Company has an accrued liability for a contingent sales-based milestone payment related to a collaboration with AstraZeneca where payment has been deemed probable by the Company but remains subject to the achievement of the related sales-based milestone. See Note 5 to the consolidated financial statements for additional information related to this sales-based milestone.
Purchase Obligations — Purchase obligations are enforceable and legally binding obligations for purchases of goods and services including minimum inventory contracts, research and development and advertising. Purchase obligations also include future inventory purchases the Company has committed to in connection with certain divestitures. As of December 31, 2022, the Company had total purchase obligations of $6.0 billion, of which $1.7 billion is estimated to be payable in 2023.
In March 2021, the Company filed a securities registration statement with the U.S. Securities and Exchange Commission (SEC) under the automatic shelf registration process available to “well-known seasoned issuers” which is effective for three years.
Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
The Company believes it maintains a conservative financial profile. The Company places its cash and investments in instruments that meet high credit quality standards, as specified in its investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issuer. The Company does not participate in any off-balance sheet arrangements involving unconsolidated subsidiaries that provide financing or potentially expose the Company to unrecorded financial obligations.
In November 2022, Merck’s Board of Directors increased the quarterly dividend, declaring a quarterly dividend of $0.73 per share on the Company’s outstanding common stock for the first quarter of 2023 that was paid in January 2023. In January 2023, the Board of Directors declared a quarterly dividend of $0.73 per share on the Company’s outstanding common stock for the second quarter of 2023 payable in April 2023.
In October 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions, on or off an exchange, or in privately negotiated transactions. The Company did not purchase any shares of its common stock for its treasury during 2022 under this program. As of December 31, 2022, the Company’s remaining share repurchase authorization was $5.0 billion. The Company anticipates making modest share repurchases under this program in 2023. The Company purchased $840 million and $1.3 billion of its common stock during 2021 and 2020, respectively, under authorized share repurchase programs.
Financial Instruments Market Risk Disclosures
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
61

Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management, and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other Comprehensive Income (Loss) (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
Because Merck principally sells foreign currency in its revenue hedging program, a uniform weakening of the U.S. dollar would yield the largest overall potential loss in the market value of these hedge instruments. The market value of Merck’s hedges would have declined by an estimated $647 million and $648 million at December 31, 2022 and 2021, respectively, from a uniform 10% weakening of the U.S. dollar. The market value was determined using a foreign exchange option pricing model and holding all factors except exchange rates constant. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck’s major foreign currency exposures relative to the U.S. dollar.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
A sensitivity analysis to changes in the value of the U.S. dollar on foreign currency denominated derivatives, investments and monetary assets and liabilities indicated that if the U.S. dollar uniformly weakened by 10% against all currency exposures of the Company at December 31, 2022 and 2021, Income from Continuing Operations Before Taxes would have declined by approximately $190 million and $125 million in 2022 and 2021, respectively. Because the Company was in a net short (payable) position relative to its major foreign currencies after consideration of forward contracts, a uniform weakening of the U.S. dollar will yield the largest overall potential net loss in earnings due to exchange. This measurement assumes that a change in one foreign currency relative to the U.S. dollar would not affect other foreign currencies relative to the U.S. dollar. Although not predictive in nature, the Company believes that a 10% threshold reflects reasonably possible near-term changes in Merck’s major foreign
62

currency exposures relative to the U.S. dollar. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The economy of Türkiye was determined to be hyperinflationary in 2022. Consequently, in accordance with U.S. GAAP, the Company began remeasuring the monetary assets and liabilities of those operations in earnings beginning in the second quarter of 2022. The impact to the Company’s results is immaterial.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI, and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. The Company is not currently a party to any interest rate swaps.
The Company’s investment portfolio includes cash equivalents and short-term investments, the market values of which are not significantly affected by changes in interest rates. The market value of the Company’s medium- to long-term fixed-rate investments is modestly affected by changes in U.S. interest rates. Changes in medium- to long-term U.S. interest rates have a more significant impact on the market value of the Company’s fixed-rate borrowings, which generally have longer maturities. A sensitivity analysis to measure potential changes in the market value of Merck’s investments and debt from a change in interest rates indicated that a one percentage point increase in interest rates at December 31, 2022 and 2021 would have positively affected the net aggregate market value of these instruments by $2.0 billion and $3.2 billion, respectively. A one percentage point decrease at December 31, 2022 and 2021 would have negatively affected the net aggregate market value by $2.4 billion and $3.9 billion, respectively. The fair value of Merck’s debt was determined using pricing models reflecting one percentage point shifts in the appropriate yield curves. The fair values of Merck’s investments were determined using a combination of pricing and duration models.
Critical Accounting Estimates
The Company’s consolidated financial statements are prepared in conformity with GAAP and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates. Application of the following accounting policies result in accounting estimates having the potential for the most significant impact on the financial statements.
Acquisitions and Dispositions
To determine whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses, the Company makes certain judgments, which include assessment of the inputs, processes, and outputs associated with the acquired set of activities. If the Company determines that substantially all of the fair value of gross
63

assets included in a transaction is concentrated in a single asset (or a group of similar assets), the assets would not represent a business. To be considered a business, the assets in a transaction need to include an input and a substantive process that together significantly contribute to the ability to create outputs.
In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. The fair values of intangible assets are determined utilizing information available near the acquisition date based on expectations and assumptions that are deemed reasonable by management. Given the considerable judgment involved in determining fair values, the Company typically obtains assistance from third-party valuation specialists for significant items. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition.
The judgments made in determining estimated fair values assigned to assets acquired and liabilities assumed in a business combination, as well as asset lives, can materially affect the Company’s results of operations.
The fair values of identifiable intangible assets related to currently marketed products and product rights are primarily determined by using an income approach through which fair value is estimated based on each asset’s discounted projected net cash flows. The Company’s estimates of market participant net cash flows consider historical and projected pricing, margins and expense levels; the performance of competing products where applicable; relevant industry and therapeutic area growth drivers and factors; current and expected trends in technology and product life cycles; the time and investment that will be required to develop products and technologies; the ability to obtain additional marketing and regulatory approvals; the ability to manufacture and commercialize the products; the extent and timing of potential new product introductions by the Company’s competitors; and the life of each asset’s underlying patent and related patent term extension, if any. The net cash flows are then probability-adjusted where appropriate to consider the uncertainties associated with the underlying assumptions, as well as the risk profile of the net cash flows utilized in the valuation. The probability-adjusted future net cash flows of each product are then discounted to present value utilizing an appropriate discount rate.
The fair values of identifiable intangible assets related to IPR&D are also determined using an income approach, through which fair value is estimated based on each asset’s probability-adjusted future net cash flows, which reflect the different stages of development of each product and the associated probability of successful completion. The net cash flows are then discounted to present value using an appropriate discount rate. Amounts allocated to acquired IPR&D are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization.
Certain of the Company’s business combinations involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. The fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Changes in any of the inputs may result in a significantly different fair value adjustment.
If the Company determines the transaction will not be accounted for as an acquisition of a business, the transaction will be accounted for as an asset acquisition rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired IPR&D with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.

64

Contingent Sales-Based Milestones
The terms of certain collaborative arrangements require the Company to make payments contingent upon the achievement of sales-based milestones. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company based on future sales forecasts. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized over its remaining useful life, subject to impairment testing.
Revenue Recognition
Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covers chargebacks and rebates. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. See Note 11 to the consolidated financial statements for information regarding 340B legal proceedings.
The Company continually monitors its provision for aggregate customer discounts. There were no material adjustments to estimates associated with the aggregate customer discount provision in 2022, 2021 or 2020.

65

Summarized information about changes in the aggregate customer discount accrual related to U.S. sales is as follows:
($ in millions)20222021
Balance January 1$2,844 $2,776 
Current provision12,408 12,412 
Adjustments to prior years(155)(110)
Payments(12,179)(12,234)
Balance December 31$2,918 $2,844 
Accruals for chargebacks are reflected as a direct reduction to accounts receivable and accruals for rebates as current liabilities. The accrued balances relative to these provisions included in Accounts receivable and Accrued and other current liabilities were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. The product returns provision for U.S. pharmaceutical sales as a percentage of U.S. net pharmaceutical sales was 1.1% in 2022, 0.9% in 2021 and 0.5% in 2020. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including Keytruda, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
Through its distribution programs with U.S. wholesalers, the Company encourages wholesalers to align purchases with underlying demand and maintain inventories below specified levels. The terms of the programs allow the wholesalers to earn fees upon providing visibility into their inventory levels, as well as by achieving certain performance parameters such as inventory management, customer service levels, reducing shortage claims and reducing product returns. Information provided through the wholesaler distribution programs includes items such as sales trends, inventory on-hand, on-order quantity and product returns.
Inventories Produced in Preparation for Product Launches
The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory does not begin until the related product candidates are in Phase 3 clinical trials and regulatory approval is considered by the Company to be probable. The Company monitors the status of each respective product within the regulatory approval process; however, the Company generally does not disclose specific timing for regulatory approval. If the Company is aware of any specific risks or contingencies other than the normal regulatory approval process or if there are any specific issues identified during the research process relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. Expiry dates of the inventory are affected by the stage of completion. The Company manages the levels of inventory at each stage to optimize the shelf life of the inventory in relation to anticipated market demand in order to avoid product expiry issues. For inventories that are capitalized, anticipated future sales and shelf lives support the realization of the inventory value as the inventory shelf life is sufficient to meet initial product launch requirements. Inventories produced in preparation for product launches capitalized at December 31, 2022 and 2021 were $516 million and $256 million, respectively.

66

Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property and commercial litigation, as well as certain additional matters including governmental and environmental matters (see Note 11 to the consolidated financial statements). The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable.
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2022 and 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. When a legitimate claim for contribution is asserted, a liability is initially accrued based upon the estimated transaction costs to manage the site. Accruals are adjusted as site investigations, feasibility studies and related cost assessments of remedial techniques are completed, and as the extent to which other potentially responsible parties who may be jointly and severally liable can be expected to contribute is determined.
The Company is also remediating environmental contamination resulting from past industrial activity at certain of its sites and takes an active role in identifying and accruing for these costs. In the past, Merck performed a worldwide survey to assess all sites for potential contamination resulting from past industrial activities. Where assessment indicated that physical investigation was warranted, such investigation was performed, providing a better evaluation of the need for remedial action. Where such need was identified, remedial action was then initiated. As definitive information became available during the course of investigations and/or remedial efforts at each site, estimates were refined and accruals were established or adjusted accordingly. These estimates and related accruals continue to be refined annually.
The Company believes that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on the Company. Expenditures for remediation and environmental liabilities were $4 million in 2022 and are estimated to be $23 million in the aggregate for the years 2023 through 2027. In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December 31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
Share-Based Compensation
The Company expenses all share-based payment awards to employees, including grants of stock options, over the requisite service period based on the grant date fair value of the awards. The Company determines the fair value of certain share-based awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. Total pretax share-based compensation expense from continuing operations was $541 million in 2022, $479 million in 2021 and $441 million in 2020. At December 31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock option, restricted stock unit and performance share unit awards which will be recognized over a
67

weighted-average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
Pensions and Other Postretirement Benefit Plans
Net periodic benefit cost for pension plans totaled $554 million in 2022, $748 million in 2021 and $450 million in 2020. Net periodic benefit credit for other postretirement benefit plans was $93 million in 2022, $83 million in 2021 and $59 million in 2020. Pension and other postretirement benefit plan information for financial reporting purposes is calculated using actuarial assumptions including a discount rate for plan benefit obligations and an expected rate of return on plan assets. The changes in net periodic benefit cost year over year for pension plans are primarily attributable to changes in the discount rates. Additionally, net periodic benefit costs in 2022 and 2021 reflect higher settlement charges incurred by certain plans compared with 2020.
The Company reassesses its benefit plan assumptions on a regular basis. For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The discount rates for the Company’s U.S. pension and other postretirement benefit plans ranged from 5.50% to 5.90% at December 31, 2022, compared with a range of 2.60% to 3.10% at December 31, 2021.
The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid. In developing the expected rate of return, the Company considers long-term compound annualized returns of historical market data, current market conditions and actual returns on the Company’s plan assets. Using this reference information, the Company develops forward-looking return expectations for each asset category and a weighted-average expected long-term rate of return for a target portfolio allocated across these investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.00% compared to 6.70% in 2022.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Actuarial assumptions are based upon management’s best estimates and judgment. A reasonably possible change of plus (minus) 25 basis points in the discount rate assumption, with other assumptions held constant, would have had an estimated $81 million favorable (unfavorable) impact on the Company’s net periodic benefit cost in 2022. A reasonably possible change of plus (minus) 25 basis points in the expected rate of return assumption, with other assumptions held constant, would have had an estimated $59 million favorable (unfavorable) impact on Merck’s net periodic benefit cost in 2022. Required funding obligations for 2023 relating to the Company’s pension and other postretirement benefit plans are not expected to be material. The preceding hypothetical changes in the discount rate and expected rate of return assumptions would not impact the Company’s funding requirements.
Net gain/loss amounts, which primarily reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions, are recorded as a component of AOCL. Expected returns for pension plans are based on a calculated market-related value of assets. Net gain/loss amounts in AOCL in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees.
Restructuring Costs
Restructuring costs have been recorded in connection with restructuring programs designed to streamline the Company’s cost structure. As a result, the Company has made estimates and judgments regarding its future plans, including future termination benefits to be incurred in conjunction with involuntary separations when such separations are probable and estimable. When accruing termination costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better
68

estimate than any other amount, the Company recognizes the minimum amount within the range. In connection with these actions, management also assesses the recoverability of long-lived assets employed in the business. In certain instances, asset lives have been shortened based on changes in the expected useful lives of the affected assets. Severance and other related costs are reflected within Restructuring costs. Asset-related charges are reflected within Cost of sales, Selling, general and administrative expenses and Research and development expenses depending upon the nature of the asset.
Impairments of Long-Lived Assets
The Company assesses changes in economic, regulatory and legal conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company’s property, plant and equipment, goodwill and other intangible assets.
The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its long-lived assets to be held and used may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the asset’s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows approach.
Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the factors considered in the assessment include general macroeconomic conditions, conditions specific to the industry and market, cost factors which could have a significant effect on earnings or cash flows, the overall financial performance of the reporting unit, and whether there have been sustained declines in the Company’s share price. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Other acquired intangible assets (excluding IPR&D) are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives. When events or circumstances warrant a review, the Company will assess recoverability from future operations using pretax undiscounted cash flows derived from the lowest appropriate asset groupings. Impairments are recognized in operating results to the extent that the carrying value of the intangible asset exceeds its fair value, which is determined based on the net present value of estimated future cash flows.
IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist (such as unfavorable clinical trial data, changes in the commercial landscape or delays in the clinical development program and related regulatory filing and approval timelines), by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. For impairment testing purposes, the Company may combine separately recorded IPR&D intangible assets into one unit of account based on the relevant facts and circumstances. Generally, the Company will combine IPR&D intangible assets for testing purposes if they operate as a single asset and are essentially inseparable. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
The judgments made in evaluating impairment of long-lived intangibles can materially affect the Company’s results of operations.
Taxes on Income
The Company’s effective tax rate is based on pretax income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. An estimated effective tax rate for a year is applied to the Company’s quarterly operating results. In the event that there is a significant unusual or one-time item recognized, or expected to be recognized, in the Company’s quarterly operating results, the tax attributable to that item would be separately calculated and recorded at the same time as the unusual or one-time item. The Company considers the resolution of prior year tax matters to be such items. Significant judgment is required in determining the Company’s tax provision and in evaluating its tax positions. The recognition and measurement of a tax position is based on management’s best judgment given the facts, circumstances and information available at the reporting date. The Company evaluates tax positions to determine whether the benefits of tax positions are more
69

likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. If the more likely than not threshold is not met in the period for which a tax position is taken, the Company may subsequently recognize the benefit of that tax position if the tax matter is effectively settled, the statute of limitations expires, or if the more likely than not threshold is met in a subsequent period (see Note 16 to the consolidated financial statements).
Tax regulations require items to be included in the tax return at different times than the items are reflected in the financial statements. Timing differences create deferred tax assets and liabilities. Deferred tax assets generally represent items that can be used as a tax deduction or credit in the tax return in future years for which the Company has already recorded the tax benefit in the financial statements. The Company establishes valuation allowances for its deferred tax assets when the amount of expected future taxable income is not likely to support the use of the deduction or credit. Deferred tax liabilities generally represent tax expense recognized in the financial statements for which payment has been deferred or expense for which the Company has already taken a deduction on the tax return, but has not yet recognized as expense in the financial statements.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 2 to the consolidated financial statements.
Cautionary Factors That May Affect Future Results
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on this Form 10-K and Forms 10-Q and 8-K. In Item 1A. “Risk Factors” of this annual report on Form 10-K the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties. 
Item 7A.Quantitative and Qualitative Disclosures about Market Risk.
The information required by this Item is incorporated by reference to the discussion under “Financial Instruments Market Risk Disclosures” in Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

70

Item 8.Financial Statements and Supplementary Data.                
(a)Financial Statements
The consolidated balance sheet of Merck & Co., Inc. and subsidiaries as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2022, the notes to consolidated financial statements, and the report dated February 24, 2023 of PricewaterhouseCoopers LLP, independent registered public accounting firm, are as follows:
Consolidated Statement of Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
202220212020
Sales$59,283 $48,704 $41,518 
Costs, Expenses and Other
Cost of sales17,411 13,626 13,618 
Selling, general and administrative10,042 9,634 8,955 
Research and development13,548 12,245 13,397 
Restructuring costs337 661 575 
Other (income) expense, net1,501 (1,341)(890)
 42,839 34,825 35,655 
Income from Continuing Operations Before Taxes16,444 13,879 5,863 
Taxes on Income from Continuing Operations1,918 1,521 1,340 
Net Income from Continuing Operations14,526 12,358 4,523 
Less: Net Income Attributable to Noncontrolling Interests7 13 4 
Net Income from Continuing Operations Attributable to Merck & Co., Inc.14,519 12,345 4,519 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 704 2,548 
Net Income Attributable to Merck & Co., Inc.$14,519 $13,049 $7,067 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations$5.73 $4.88 $1.79 
Income from Discontinued Operations 0.28 1.01 
Net Income$5.73 $5.16 $2.79 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
Income from Continuing Operations$5.71 $4.86 $1.78 
Income from Discontinued Operations 0.28 1.00 
Net Income$5.71 $5.14 $2.78 
Consolidated Statement of Comprehensive Income
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
202220212020
Net Income Attributable to Merck & Co., Inc.$14,519 $13,049 $7,067 
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized (loss) gain on derivatives, net of reclassifications(71)410 (297)
Net unrealized loss on investments, net of reclassifications  (18)
Benefit plan net gain (loss) and prior service credit (cost), net of amortization335 1,769 (279)
Cumulative translation adjustment(603)(423)153 
 (339)1,756 (441)
Comprehensive Income Attributable to Merck & Co., Inc.$14,180 $14,805 $6,626 
The accompanying notes are an integral part of these consolidated financial statements.
71

Consolidated Balance Sheet
Merck & Co., Inc. and Subsidiaries
December 31
($ in millions except per share amounts)
20222021
Assets
Current Assets
Cash and cash equivalents$12,694 $8,096 
Short-term investments498  
Accounts receivable (net of allowance for doubtful accounts of $72 in 2022
and $62 in 2021)
9,450 9,230 
Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021
classified in Other assets - see Note 8)
5,911 5,953 
Other current assets7,169 6,987 
Total current assets35,722 30,266 
Investments1,015 370 
Property, Plant and Equipment (at cost)
Land295 326 
Buildings13,166 12,529 
Machinery, equipment and office furnishings16,760 16,303 
Construction in progress9,186 8,313 
39,407 37,471 
Less: accumulated depreciation17,985 18,192 
 21,422 19,279 
Goodwill21,204 21,264 
Other Intangibles, Net20,269 22,933 
Other Assets9,528 11,582 
 $109,160 $105,694 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt$1,946 $2,412 
Trade accounts payable4,264 4,609 
Accrued and other current liabilities14,159 13,859 
Income taxes payable1,986 1,224 
Dividends payable1,884 1,768 
Total current liabilities24,239 23,872 
Long-Term Debt28,745 30,690 
Deferred Income Taxes1,795 3,441 
Other Noncurrent Liabilities8,323 9,434 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2022 and 2021
1,788 1,788 
Other paid-in capital44,379 44,238 
Retained earnings61,081 53,696 
Accumulated other comprehensive loss(4,768)(4,429)
102,480 95,293 
Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021
56,489 57,109 
Total Merck & Co., Inc. stockholders’ equity45,991 38,184 
Noncontrolling Interests67 73 
Total equity46,058 38,257 
 $109,160 $105,694 
The accompanying notes are an integral part of this consolidated financial statement.
72

Consolidated Statement of Equity
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions except per share amounts)
Common
Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury
Stock
Non-
controlling
Interests
Total
Balance January 1, 2020
$1,788 $39,660 $46,602 $(6,193)$(55,950)$94 $26,001 
Net income attributable to Merck & Co., Inc.— — 7,067 — — — 7,067 
Other comprehensive loss, net of taxes— — — (441)— — (441)
Cash dividends declared on common stock ($2.48 per share)
— — (6,307)— — — (6,307)
Treasury stock shares purchased— — — — (1,281)— (1,281)
Net income attributable to noncontrolling interests— — — — — 15 15 
Distributions attributable to noncontrolling interests— — — — — (22)(22)
Share-based compensation plans and other— (72)— — 444 — 372 
Balance December 31, 20201,788 39,588 47,362 (6,634)(56,787)87 25,404 
Net income attributable to Merck & Co., Inc.— — 13,049 — — — 13,049 
Other comprehensive income, net of taxes— — — 1,756 — — 1,756 
Cash dividends declared on common stock ($2.64 per share)
— — (6,715)— — — (6,715)
Treasury stock shares purchased— — — — (840)— (840)
Spin-off of Organon & Co.— 4,643 — 449 — (1)5,091 
Net income attributable to noncontrolling interests— — — — — 16 16 
Distributions attributable to noncontrolling interests— — — — — (29)(29)
Share-based compensation plans and other— 7 — — 518 — 525 
Balance December 31, 20211,788 44,238 53,696 (4,429)(57,109)73 38,257 
Net income attributable to Merck & Co., Inc.  14,519    14,519 
Other comprehensive loss, net of taxes   (339)  (339)
Cash dividends declared on common stock ($2.80 per share)
  (7,134)   (7,134)
Net income attributable to noncontrolling interests     7 7 
Distributions attributable to noncontrolling interests     (13)(13)
Share-based compensation plans and other 141   620  761 
Balance December 31, 2022$1,788 $44,379 $61,081 $(4,768)$(56,489)$67 $46,058 
The accompanying notes are an integral part of this consolidated financial statement.

73

Consolidated Statement of Cash Flows
Merck & Co., Inc. and Subsidiaries
Years Ended December 31
($ in millions)
202220212020
Cash Flows from Operating Activities of Continuing Operations
Net income from continuing operations$14,526 $12,358 $4,523 
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:
Amortization2,085 1,636 1,817 
Depreciation1,824 1,578 1,669 
Intangible asset impairment charges1,749 302 1,718 
Loss (income) from investments in equity securities, net1,419 (1,940)(1,338)
Charge for the acquisition of Pandion Therapeutics, Inc. 1,556  
Charge for the acquisition of VelosBio Inc.  2,660 
Deferred income taxes(1,568)187 (566)
Share-based compensation541 479 441 
Other1,301 805 1,294 
Net changes in assets and liabilities:
Accounts receivable(644)(2,033)(1,002)
Inventories(161)(674)(895)
Trade accounts payable(289)405 684 
Accrued and other current liabilities(50)277 (1,152)
Income taxes payable380 (540)814 
Noncurrent liabilities(545)484 (617)
Other(1,473)(1,758)(2,433)
Net Cash Provided by Operating Activities of Continuing Operations19,095 13,122 7,617 
Cash Flows from Investing Activities of Continuing Operations
Capital expenditures(4,388)(4,448)(4,429)
Purchase of Seagen Inc. common stock  (1,000)
Purchases of securities and other investments(1,204)(1)(95)
Proceeds from sales of securities and other investments721 1,026 2,812 
Acquisition of Acceleron Pharma Inc., net of cash acquired (11,174) 
Acquisition of Pandion Therapeutics, Inc., net of cash acquired (1,554) 
Acquisition of VelosBio Inc., net of cash acquired  (2,696)
Acquisition of ArQule, Inc., net of cash acquired  (2,545)
Other acquisitions, net of cash acquired(121)(179)(1,365)
Other32 (91)125 
Net Cash Used in Investing Activities of Continuing Operations(4,960)(16,421)(9,193)
Cash Flows from Financing Activities of Continuing Operations
Net change in short-term borrowings (3,986)2,549 
Payments on debt(2,251)(2,319)(1,957)
Proceeds from issuance of debt 7,936 4,419 
Distribution from Organon & Co. 9,000  
Purchases of treasury stock (840)(1,281)
Dividends paid to stockholders(7,012)(6,610)(6,215)
Proceeds from exercise of stock options384 202 89 
Other(240)(286)(436)
Net Cash (Used in) Provided by Financing Activities of Continuing Operations(9,119)3,097 (2,832)
Cash Flows from Discontinued Operations
Net cash provided by operating activities 987 2,636 
Net cash used in investing activities (134)(250)
Net cash used in financing activities (504) 
Net Cash Flows Provided by Discontinued Operations 349 2,386 
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(410)(133)253 
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash4,606 14 (1,769)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets)
8,167 8,153 9,934 
Less: Cash and cash equivalents related to discontinued operations  12 
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets)
$12,773 $8,167 $8,153 
The accompanying notes are an integral part of this consolidated financial statement.
74

Notes to Consolidated Financial Statements
Merck & Co., Inc. and Subsidiaries
($ in millions except per share amounts)
1.   Nature of Operations
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 3).
2.    Summary of Accounting Policies
Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.
Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no
75

goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines
76

and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company’s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including Keytruda, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 19 for disaggregated revenue disclosures.
77

Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings. Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020.
Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.2 billion in 2022, $2.0 billion in 2021 and $1.8 billion in 2020.
Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 3 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles — Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are
78

expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income from Continuing Operations. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
79

Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards — In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted — In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.

80

3.    Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the consolidated statement of income for the above MSAs include sales of $383 million and $219 million in 2022 and 2021, respectively, and related cost of sales of $404 million and $195 million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $511 million and $964 million at December 31, 2022 and 2021, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $345 million and $400 million at December 31, 2022 and 2021, respectively, and are included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s consolidated statement of income as Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million in 2021 and $743 million in 2020 related to the spin-off of Organon, which are also included in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees.

81

Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
Years Ended December 31
2021(1)
2020
Sales$2,512 $6,476 
Costs, Expenses and Other
Cost of sales789 1,867 
Selling, general and administrative877 1,513 
Research and development103 161 
Restructuring costs1 3 
Other (income) expense, net(15)4 
1,755 3,548 
Income from discontinued operations before taxes757 2,928 
Tax provision50 369 
Income from discontinued operations, net of taxes707 2,559 
Less: Income of discontinued operations attributable to noncontrolling interests3 11 
$704 $2,548 
(1) Reflects amounts through the June 2, 2021 spin-off date.
4.    Acquisitions, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
Recently Completed Transactions
In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175 million, which will be recorded in Research and development expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and Research and development expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.

82

2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to Research and development expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within Other (income) expense, net upon receipt of the related approvals.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge to Research and development expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved.
Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option
83

exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $111 million to fund Kelun-Biotech’s ongoing research and development activities, of which $51 million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
2021 Transactions
In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron’s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron’s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS.
In addition to sotatercept, Acceleron’s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $20 million in 2022 and remains eligible to receive up to $80 million in sales-based milestones.
The transaction was accounted for as a business combination. The Company incurred $280 million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in Selling, general and administrative expenses and Research and development costs in 2021.
The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:
November 19, 2021
Cash and cash equivalents$340 
Investments285 
Identifiable intangible assets: (1)
IPR&D - sotatercept 6,380 
Products and product rights - Reblozyl (12 year useful life)
3,830 
Deferred income tax liabilities, net(1,814)
Other assets and liabilities, net82 
Total identifiable net assets9,103 
Goodwill (2)
2,411 
Consideration transferred$11,514 
(1)    The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s development work focused on advancing a pipeline of precision immune modulators targeting
84

critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and Research and development expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.
In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead’s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.
Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0 billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5 billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.
Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck’s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead’s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.
In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in Research and development expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.

85

2020 Transactions
In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. OncoImmune’s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50 million for a 20% ownership interest in the new entity, which was valued at $33 million resulting in a $17 million premium. Merck also recognized other net liabilities of $22 million. The Company recorded Research and development expenses of $462 million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in 2021, which are reflected in Cost of sales and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.
Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio’s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180 million (primarily cash) and Research and development expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of Research and development expenses of $43 million, an increase to total consideration paid of $47 million, and an increase to net assets recorded of $90 million.
In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $616 million in Research and development expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16 million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales-based milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as Research and development expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and is receiving tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.
Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.
86

Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note 5 for additional information related to this collaboration.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&D of $113 million, cash of $59 million, deferred tax assets of $72 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $239 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&D impairment charge of $90 million within Research and development expenses. The Company also recorded a reduction in Research and development expenses resulting from a decrease in the related liability for contingent consideration of $45 million. In 2022, the Company wrote off the remaining IPR&D intangible asset and related contingent consideration liability; the net impact to Research and development expenses was immaterial.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5 million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.
In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305 million in 2020, of which $260 million was reflected in Cost of sales and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments. The remaining $45 million of costs were reflected in Research and development expenses and represent amounts related to the Themis acquisition noted above (an IPR&D impairment charge, partially offset by a reduction in the related liability for contingent consideration).
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in 2020. ArQule’s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.

87

The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
January 16, 2020
Cash and cash equivalents$145 
IPR&D - nemtabrutinib (1)
2,280
Licensing arrangement for derazantinib80
Deferred income tax liabilities(361)
Other assets and liabilities, net34
Total identifiable net assets2,178 
Goodwill (2)
512 
Consideration transferred$2,690 
(1)    The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note 9).
5.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $400 million and $550 million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million and $160 million, respectively, from Merck to AstraZeneca. A regulatory milestone of $105 million that was accrued at December 31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.6 billion at December 31, 2022 and is included in Other Intangibles, Net. The amount is
88

being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lynparza$1,116 $989 $725 
Alliance revenue - Koselugo54 29 8 
Total alliance revenue$1,170 $1,018 $733 
Cost of sales (1)
492 167 247 
Selling, general and administrative185 178 160 
Research and development106 120 133 
December 3120222021
Receivables from AstraZeneca included in Other current assets
$303 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
123 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600  
(1)    Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.
(2)    Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Merck made sales-based milestone payments to Eisai aggregating $600 million, $200 million and $500 million in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million, $75 million and $10 million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $814 million at December 31, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

89

Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lenvima$876 $704 $580 
Cost of sales (1)
212 195 271 
Selling, general and administrative158 127 73 
Research and development136 173 185 
December 3120222021
Receivables from Eisai included in Other current assets
$214 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
 625 
(1)     Represents amortization of capitalized milestone payments.
(2)     Represents accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $400 million and $375 million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $633 million and $57 million, respectively, at December 31, 2022 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Adempas/Verquvo$341 $342 $281 
Net sales of Adempas recorded by Merck238 252 220 
Net sales of Verquvo recorded by Merck22 7  
Total sales$601 $601 $501 
Cost of sales (1)
210 424 196 
Selling, general and administrative153 126 47 
Research and development75 53 63 
December 3120222021
Receivables from Bayer included in Other current assets
$143 $114 
Payables to Bayer included in Accrued and other current Liabilities (2)
80 472 
(1)    Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense.
(2)    Amount as of December 31, 2021 includes accrued milestone payment.
90

Ridgeback Biotherapeutics LP
In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Net sales of Lagevrio
$5,684 $952 $ 
Cost of sales (1)(2)
3,038 502 17 
Selling, general and administrative (2)
147 37 6 
Research and development (2)(3)
88 137 349 
December 3120222021
Payables to Ridgeback included in Accrued and other current liabilities (4)
$348 $283 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses in all periods now include an allocation for overhead charges.
(3)    Amount in 2020 includes upfront payment.
(4)    Includes accrued royalty and milestone payments.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $166 million in 2022, which includes royalties of $146 million and the receipt of a regulatory approval milestone payment of $20 million, compared with alliance revenue of $17 million in 2021.
6.    Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
91

The Company recorded total pretax costs of $666 million in 2022, $868 million in 2021 and $880 million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December 31, 2022, Merck has recorded total pretax accumulated costs of approximately $3.3 billion. The Company expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following table summarizes the charges related to restructuring program activities by type of cost:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Year Ended December 31, 2022
Cost of sales$ $72 $133 $205 
Selling, general and administrative 19 75 94 
Research and development 29 1 30 
Restructuring costs212  125 337 
 $212 $120 $334 $666 
Year Ended December 31, 2021    
Cost of sales$ $52 $108 $160 
Selling, general and administrative 12 7 19 
Research and development 27 1 28 
Restructuring costs451  210 661 
 $451 $91 $326 $868 
Year Ended December 31, 2020    
Cost of sales$ $143 $32 $175 
Selling, general and administrative 44 3 47 
Research and development 81 2 83 
Restructuring costs385  190 575 
 $385 $268 $227 $880 
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 14) and share-based compensation.

92

The following table summarizes the charges and spending relating to restructuring program activities:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Restructuring reserves January 1, 2021
$567 $ $19 $586 
Expenses451 91 326 868 
(Payments) receipts, net(422) (186)(608)
Non-cash activity (91)(118)(209)
Restructuring reserves December 31, 2021
596  41 637 
Expenses212 120 334 666 
(Payments) receipts, net(329) (120)(449)
Non-cash activity (120)(221)(341)
Restructuring reserves December 31, 2022 (1)
$479 $ $34 $513 
(1)    The remaining cash outlays are expected to be largely completed by the end of 2025.
7.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.

Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or OCI depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in AOCL and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi,
93

the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI, and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202220212020202220212020
Net Investment Hedging Relationships
Foreign exchange contracts$(48)$(49)$26 $(1)$(13)$(19)
Euro-denominated notes(162)(296)385    
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.

Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
In 2022, nine interest rate swap contracts with a total notional amount of $2.25 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.4% fixed-rate notes and $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt.
The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.

94

The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2022202120222021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$ $2,263 $ $13 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20222021
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contractsOther current assets$ $ $ $14 $— $2,250 
Foreign exchange contractsOther current assets220  4,824 271 — 6,778 
Foreign exchange contractsOther Assets27  1,609 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities 101 2,691 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities 1 91 — 1 43 
  $247 $102 $9,215 $328 $25 $12,245 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$186 $ $8,540 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities 307 10,926 — 96 10,640 
  $186 $307 $19,466 $221 $96 $20,713 
  $433 $409 $28,681 $549 $121 $32,958 
As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:
20222021
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$433 $409 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(220)(220)(110)(110)
Cash collateral received/posted(66)(19)(164) 
Net amounts$147 $170 $275 $11 

95

The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202220212020202220212020202220212020
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$59,283 $48,704 $41,518 $1,501 (1,341)(890)$(339)$1,756 $(441)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (13)(40)40  — — 
Derivatives designated as hedging instruments — — 4 1 (76) — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
 — —  — — 684 333 (383)
Increase (decrease) in Sales as a result of AOCL reclassifications
773 (194)(6) — — (773)194 6 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (2)(2)(4) — — 
Amount of loss recognized in OCI on derivatives
 — —  — — (2)(2)(4)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Years Ended December 31202220212020
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(49)$313 $(12)
Foreign exchange contracts (2)
Sales(37)9 13 
Interest rate contracts (3)
Other (income) expense, net  9 
Forward contract related to Seagen common stockResearch and development  15 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
(3)     These derivative contracts serve as economic hedges against rising treasury rates.
At December 31, 2022, the Company estimates $104 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.

96

Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20222021
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
  GainsLossesGainsLosses
Commercial paper$498 $ $ $498 $ $ $ $ 
U.S. government and agency securities68   68 80  80 
Corporate notes and bonds3   3 4   4 
Foreign government bonds    2   2 
Total debt securities569   569 86   86 
Publicly traded equity securities (1)
1,284 1,647 
Total debt and publicly traded equity securities$1,853 $1,733 
(1)    Unrealized net losses of $462 million were recorded in Other (income) expense, net in 2022 on equity securities still held at December 31, 2022. Unrealized net losses of $232 million were recorded in Other (income) expense, net in 2021 on equity securities still held at December 31, 2021.
At December 31, 2022 and 2021, the Company also had $832 million and $596 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During 2022, the Company recorded unrealized gains of $56 million and unrealized losses of $12 million related to certain of these equity investments still held at December 31, 2022. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these investments still held at December 31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2022 were $289 million and $19 million, respectively.
At December 31, 2022, 2021 and 2020, the Company also had $598 million, $1.7 billion and $800 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $1.0 billion, $(1.4) billion and $(583) million for the years ended December 31, 2022, 2021 and 2020, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.


97

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20222021
Assets
Investments
Commercial paper$ $498 $ $498 $ $ $ $ 
Foreign government bonds     2  2 
Publicly traded equity securities1,015   1,015 368   368 
 1,015 498  1,513 368 2  370 
Other assets (1)
U.S. government and agency securities68   68 80   80 
Corporate notes and bonds3   3 4   4 
Publicly traded equity securities269   269 1,279   1,279 
340   340 1,363   1,363 
Derivative assets (2)
Forward exchange contracts 218  218  351  351 
Purchased currency options 215  215  184  184 
Interest rate swaps     14  14 
  433  433  549  549 
Total assets$1,355 $931 $ $2,286 $1,731 $551 $ $2,282 
Liabilities
Other liabilities
Contingent consideration$ $ $456 $456 $ $ $777 $777 
Derivative liabilities (2)
Forward exchange contracts 402  402  120  120 
Written currency options 7  7  1  1 
 409  409  121  121 
Total liabilities$ $409 $456 $865 $ $121 $777 $898 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of December 31, 2022 and 2021, Cash and cash equivalents included $11.3 billion and $6.8 billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(146)57 
Payments(119)(109)
Other(56)(12)
Fair value December 31 (2)
$456 $777 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At December 31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December 31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above.
98

Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. 
The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December 31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.5 billion and $2.8 billion of accounts receivable as of December 31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December 31, 2022 and 2021, the Company had collected $67 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022. Cash collateral received by the Company from various counterparties was $66 million and $164 million at December 31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.

99

8.    Inventories
Inventories at December 31 consisted of:
20222021
Finished goods$1,841 $1,747 
Raw materials and work in process7,063 6,220 
Supplies238 196 
Total (approximates current cost)9,142 8,163 
Decrease to LIFO cost(293)(16)
 $8,849 $8,147 
Recognized as:
Inventories$5,911 $5,953 
Other Assets2,938 2,194 
Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.3 billion at December 31, 2022 and 2021, respectively. Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At December 31, 2022 and 2021, these amounts included $2.4 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $516 million and $256 million at December 31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.
9.    Goodwill and Other Intangibles
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2021
$15,614 $3,268 $18,882 
Acquisitions2,431 5 2,436 
Other (1)
(48)(6)(54)
Balance December 31, 2021 (2)
17,997 3,267 21,264 
Other (1)
(61)1 (60)
Balance December 31, 2022 (2)
$17,936 $3,268 $21,204 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2022 and 2021.
The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note 4).
Other acquired intangibles at December 31 consisted of:
 20222021
  Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Products and product rights$23,555 $16,745 $6,810 $23,671 $15,776 $7,895 
IPR&D7,661  7,661 9,281 — 9,281 
Trade names2,879 635 2,244 2,882 493 2,389 
Licenses and other7,651 4,097 3,554 6,604 3,236 3,368 
 $41,746 $21,477 $20,269 $42,438 $19,505 $22,933 
Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December 31, 2022 were Reblozyl, $3.5 billion; Zerbaxa, $406 million; Sivextro, $122 million; Gardasil/Gardasil 9, $120 million; and Bridion, $97 million. Additionally, the Company had $4.6 billion of net acquired intangibles related to animal health at December 31, 2022, of which $2.3 billion related to products and product rights and $2.2 billion was attributable to trade names, primarily related to Allflex. At December 31, 2022, IPR&D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-7264 (gefapixant), $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $418 million, obtained through the acquisition of ArQule in
100

2020 (see below and Note 4). Some of the more significant net intangible assets included in licenses and other above at December 31, 2022 include Lynparza, $1.6 billion, related to a collaboration with AstraZeneca; Lenvima, $814 million, related to a collaboration with Eisai; and Adempas, $633 million, related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations.
In 2020, the Company recorded an impairment charge of $1.6 billion within Cost of sales related to Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of Zerbaxa, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the Zerbaxa intangible asset for impairment. The Company revised its cash flow forecasts for Zerbaxa utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the Zerbaxa intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to Zerbaxa that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120 million to Cost of sales in 2020 related to the Zerbaxa recall. A phased resupply of Zerbaxa was initiated in the fourth quarter of 2021 and completed during 2022.
IPR&D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization.
In 2022, the Company recorded $1.7 billion of intangible impairment charges within Research and development expenses, of which $1.6 billion represents IPR&D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note 4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.
In 2021, the Company recorded a $275 million IPR&D impairment charge related to nemtabrutinib. As part of Merck’s annual impairment assessment of IPR&D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&D impairment charge noted above.

101

In 2020, the Company recorded a $90 million IPR&D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck’s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45 million.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates.
The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.
Aggregate amortization expense primarily recorded within Cost of sales was $2.1 billion in 2022, $1.6 billion in 2021 and $1.8 billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $1.8 billion; 2024, $1.7 billion; 2025, $1.6 billion; 2026, $1.5 billion; 2027, $1.3 billion.
10.    Loans Payable, Long-Term Debt and Leases
Loans Payable
Loans payable at December 31, 2022 included $1.7 billion of notes due in 2023 and $197 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.65% and 0.08% for the years ended December 31, 2022 and 2021, respectively.


102

Long-Term Debt
Long-term debt at December 31 consisted of:
20222021
2.75% notes due 2025
$2,496 $2,495 
2.15% notes due 2031
1,986 1,986 
2.75% notes due 2051
1,979 1,979 
3.70% notes due 2045
1,978 1,977 
3.40% notes due 2029
1,738 1,736 
1.70% notes due 2027
1,494 1,493 
2.90% notes due 2061
1,483 1,484 
4.00% notes due 2049
1,471 1,470 
4.15% notes due 2043
1,239 1,239 
1.45% notes due 2030
1,237 1,235 
2.45% notes due 2050
1,213 1,212 
1.875% euro-denominated notes due 2026
1,060 1,123 
0.75% notes due 2026
995 993 
1.90% notes due 2028
994 994 
3.90% notes due 2039
985 984 
2.35% notes due 2040
984 983 
2.90% notes due 2024
749 748 
6.50% notes due 2033
711 715 
0.50% euro-denominated notes due 2024
531 563 
1.375% euro-denominated notes due 2036
527 559 
2.50% euro-denominated notes due 2034
526 558 
3.60% notes due 2042
492 491 
6.55% notes due 2037
408 409 
5.75% notes due 2036
339 338 
5.95% debentures due 2028
307 306 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
250 250 
6.30% debentures due 2026
135 135 
2.80% notes due 2023
 1,749 
Other167 215 
 $28,745 $30,690 
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 1.40% and zero for 2022 and 2021, respectively.
With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2022, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.2 billion; 2027, $1.5 billion. Interest payments related to these debt obligations are as follows: 2023, $882 million; 2024, $845 million; 2025, $778 million; 2026, $751 million; 2027, $720 million.
The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
103

Leases
The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.
Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Operating lease cost was $334 million in 2022, $343 million in 2021 and $340 million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $335 million in 2022, $340 million in 2021 and $334 million in 2020. Operating lease assets obtained in exchange for lease obligations were $57 million in 2022, $117 million in 2021 and $473 million in 2020.
Supplemental balance sheet information related to operating leases is as follows:
December 3120222021
Assets
Other Assets (1)
$1,346 $1,586 
Liabilities
Accrued and other current liabilities281 304 
Other Noncurrent Liabilities1,013 1,225 
$1,294 $1,529 
Weighted-average remaining lease term (years)7.07.0
Weighted-average discount rate3.1 %2.6 %
(1)    Includes prepaid leases that have no related lease liability.

104

Maturities of operating leases liabilities are as follows:
2023$323 
2024258 
2025224 
2026157 
2027126 
Thereafter404 
Total lease payments1,492 
Less: Imputed interest198 
$1,294 
At December 31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $232 million.
11.    Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2022, approximately 70 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney’s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena
105

sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government’s information request by seeking information relating to Merck’s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company’s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government’s investigation.
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
106

In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark defendants’ motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $12.7 billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.
340B Program Litigation
Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M‑M‑R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck’s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.
Merck KGaA Litigation
As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement
107

and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCl), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District
108

Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.
In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia, Janumet and Janumet XR.
As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.
Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for Janumet in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the Janumet SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the Janumet SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An ex-parte preliminary injunction was granted in Finland, which has been subsequently maintained in inter-partes proceedings, Czech Republic and Switzerland, and an inter-partes preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be prima facie valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.
Lynparza In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company;
109

the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2022 and 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Environmental Matters
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is de minimis and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.
In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December 31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
12.    Equity
The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.

Capital Stock
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202220212020
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,049 3,577 1,047 3,577 1,038 
Purchases of treasury stock   11  16 
Issuances (1)
 (10) (9) (7)
Balance December 313,577 1,039 3,577 1,049 3,577 1,047 
(1)     Issuances primarily reflect activity under share-based compensation plans.
13.    Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees
110

and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.
At December 31, 2022, 87 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.
Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.
Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $541 million, $498 million and $475 million, respectively. The amounts in 2021 and 2020 include $479 million and $441 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $78 million, $69 million and $65 million, respectively.
The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.
The weighted average exercise price of options granted in 2022, 2021 and 2020 was $87.10, $75.99 and $77.67 per option, respectively. The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202220212020
Expected dividend yield3.1 %3.1 %3.1 %
Risk-free interest rate3.0 %1.0 %0.4 %
Expected volatility22.5 %20.9 %22.1 %
Expected life (years)5.95.95.8
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2022
18,572 $65.27 
Granted2,326 87.10 
Exercised(6,317)60.77 
Forfeited(862)73.11   
Outstanding December 31, 202213,719 $70.55 6.5$554 
Vested and expected to vest December 31, 202213,199 $70.09 6.4$539 
Exercisable December 31, 20228,730 $65.24 5.4$399 
111

Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202220212020
Total intrinsic value of stock options exercised$225 $106 $51 
Fair value of stock options vested30 27 25 
Cash received from the exercise of stock options384 202 89 
A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2022
11,790 $74.88 1,966 $77.13 
Granted7,170 87.12 951 88.52 
Vested(5,150)75.40 (725)87.87 
Forfeited(1,110)78.65 (171)77.58 
Nonvested December 31, 202212,700 $81.25 2,021 $78.60 
Expected to vest December 31, 202211,254 $80.96 1,895 $78.26 
At December 31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
14.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.
Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202220212020202220212020202220212020
Service cost$372 $403 $360 $283 $328 $297 $48 $48 $52 
Interest cost457 404 431 145 123 136 46 45 57 
Expected return on plan assets(753)(755)(774)(383)(416)(414)(86)(79)(75)
Amortization of unrecognized prior service cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Net loss (gain) amortization128 298 303 96 142 127 (43)(42)(18)
Termination benefits2 56 10 1 5 3  37 2 
Curtailments12 16 10  (26) (1)(29)(4)
Settlements239 216 13 1 8 15    
Net periodic benefit cost (credit)$425 $600 $304 $129 $148 $146 $(93)$(83)$(59)
Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.
In connection with restructuring actions (see Note 6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.
112

The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests if related to the spin-off of Organon (each as noted above).
Obligations and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:
Pension BenefitsOther
Postretirement
Benefits
U.S.International
  202220212022202120222021
Fair value of plan assets January 1$13,067 $12,672 $12,195 $12,009 $1,292 $1,221 
Actual return on plan assets(3,129)1,250 (2,793)891 (306)118 
Company contributions293 305 155 189 46 33 
Effects of exchange rate changes  (848)(671)  
Benefits paid(219)(219)(250)(233)(90)(86)
Settlements(918)(941)(16)(55)  
Spin-off of Organon   (55)  
Other  30 120 5 6 
Fair value of plan assets December 31$9,094 $13,067 $8,473 $12,195 $947 $1,292 
Benefit obligation January 1$13,999 $14,613 $11,575 $12,458 $1,541 $1,607 
Service cost372 403 283 328 48 48 
Interest cost457 404 145 123 46 45 
Actuarial (gains) losses (1)
(3,851)(332)(3,283)(240)(392)(103)
Benefits paid(219)(219)(250)(233)(90)(86)
Effects of exchange rate changes  (732)(678)(1)(1)
Plan amendments  4 4   
Curtailments12 15  (38) (12)
Termination benefits2 56 1 5  37 
Settlements(918)(941)(16)(55)  
Spin-off of Organon   (118)  
Other  28 19 5 6 
Benefit obligation December 31$9,854 $13,999 $7,755 $11,575 $1,157 $1,541 
Funded status December 31$(760)$(932)$718 $620 $(210)$(249)
Recognized as:
Other Assets$5 $9 $1,052 $1,395 $ $ 
Accrued and other current liabilities(59)(64)(19)(22)(8)(8)
Other Noncurrent Liabilities(706)(877)(315)(753)(202)(241)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
At December 31, 2022 and 2021, the accumulated benefit obligation was $17.2 billion and $24.9 billion, respectively, for all pension plans, of which $9.7 billion and $13.8 billion, respectively, related to U.S. pension plans.

113

Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2022202120222021
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation$9,186 $13,013 $2,779 $2,507 
Fair value of plan assets8,421 12,072 2,445 1,731 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$9,081 $12,916 $1,226 $2,462 
Fair value of plan assets8,421 12,072 948 1,723 
Plan Assets
Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2022 and 2021, $765 million and $943 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.
If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

114

The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20222021
U.S. Pension Plans
Cash and cash equivalents$49 $ $ $98 $147 $3 $ $ $289 $292 
Investment funds
Developed markets equities211   2,443 2,654 236   3,799 4,035 
Emerging markets equities   707 707    919 919 
Real estate   131 131      
Equity securities
Developed markets1,956    1,956 2,915    2,915 
Fixed income securities
Government and agency obligations 1,934   1,934  2,870   2,870 
Corporate obligations 1,438   1,438  2,005   2,005 
Mortgage and asset-backed securities 22   22  23   23 
Other investments
Derivatives 101   101      
Other  4  4 2  6  8 
Plan assets at fair value$2,216 $3,495 $4 $3,379 $9,094 $3,156 $4,898 $6 $5,007 $13,067 
International Pension Plans
Cash and cash equivalents$57 $8 $ $13 $78 $82 $10 $ $18 $110 
Investment funds
Developed markets equities375 2,957  90 3,422 531 4,292  121 4,944 
Government and agency obligations177 2,656  130 2,963 240 4,025  171 4,436 
Emerging markets equities52   59 111 137   72 209 
Corporate obligations8 9  129 146 9 8  171 188 
Other fixed income obligations10 7  4 21 15 8  3 26 
Real estate 1  10 11  1  16 17 
Equity securities
Developed markets263    263 369    369 
Fixed income securities
Government and agency obligations 448   448 3 591  3 597 
Corporate obligations 157   157  223  2 225 
Mortgage and asset-backed securities 69   69  90   90 
Other investments
Insurance contracts (2)
 18 761 1 780  44 937 1 982 
Other1 3   4 1 1   2 
Plan assets at fair value$943 $6,333 $761 $436 $8,473 $1,387 $9,293 $937 $578 $12,195 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
115

The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20222021
  Insurance
Contracts
Real
Estate
OtherTotalInsurance
Contracts
Real
Estate
OtherTotal
U.S. Pension Plans
Balance January 1$ $ $6 $6 $ $ $7 $7 
Actual return on plan assets:
Relating to assets still held at December 31  (3)(3)  (5)(5)
Relating to assets sold during the year  2 2   7 7 
Purchases and sales, net  (1)(1)  (3)(3)
Balance December 31$ $ $4 $4 $ $ $6 $6 
International Pension Plans
Balance January 1$937 $ $ $937 $935 $ $ $935 
Actual return on plan assets:
Relating to assets still held at December 31(147)  (147)(34)  (34)
Purchases and sales, net(39) (39)(42)  (42)
Transfers into Level 310  10 78   78 
Balance December 31$761 $ $ $761 $937 $ $ $937 
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
  2022  2021  
Cash and cash equivalents$2 $ $ $8 $10 $11 $ $ $28 $39 
Investment funds
Developed markets equities22   257 279 24   378 402 
Emerging markets equities   74 74    92 92 
Real estate   14 14      
Government and agency obligations1    1 1    1 
Equity securities— 
Developed markets206    206 290    290 
Fixed income securities
Government and agency obligations 212   212  275   275 
Corporate obligations 137   137  191   191 
Mortgage and asset-backed securities 2   2  2   2 
Other Investments
Derivatives 12   12      
Plan assets at fair value$231 $363 $ $353 $947 $326 $468 $ $498 $1,292 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of
116

returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Expected Contributions
Contributions during 2023 are expected to be approximately $270 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $20 million for other postretirement benefit plans.
Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2023$627 $271 $84 
2024634 257 86 
2025650 262 87 
2026676 283 89 
2027694 297 90 
2028 — 20323,948 1,704 474 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Amounts Recognized in Other Comprehensive Income
Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202220212020202220212020202220212020
Net (loss) gain arising during the period$(42)$813 $(472)$116 $772 $(424)$ $156 $199 
Prior service (cost) credit arising during the period   (4)(4)64    
 $(42)$813 $(472)$112 $768 $(360)$ $156 $199 
Net loss (gain) amortization included in benefit cost$128 $298 $303 $96 $142 $127 $(43)$(42)$(18)
Prior service credit amortization included in benefit cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Settlements and curtailments251 232 23 1 (18)15 (1)(29)(4)
 $347 $492 $277 $83 $108 $124 $(101)$(134)$(95)
117

Actuarial Assumptions
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202220212020202220212020
Net periodic benefit cost      
Discount rate3.00 %2.70 %3.40 %1.50 %1.10 %1.50 %
Expected rate of return on plan assets6.70 %6.70 %7.30 %3.70 %3.80 %4.40 %
Salary growth rate4.60 %4.60 %4.20 %2.90 %2.80 %2.80 %
Interest crediting rate5.00 %4.70 %4.90 %3.00 %3.00 %2.80 %
Benefit obligation      
Discount rate5.50 %3.00 %2.70 %3.90 %1.50 %1.10 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %2.90 %2.80 %
Interest crediting rate5.30 %5.00 %4.70 %3.30 %3.00 %3.00 %
For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.00%, as compared to 6.70% in 2022.
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120222021
Health care cost trend rate assumed for next year7.8 %6.4 %
Rate to which the cost trend rate is assumed to decline4.5 %4.5 %
Year that the trend rate reaches the ultimate trend rate20382032

Savings Plans
The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $175 million, $158 million and $158 million, respectively.

118

15.    Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202220212020
Interest income$(157)$(36)$(59)
Interest expense962 806 831 
Exchange losses237 297 145 
Loss (income) from investments in equity securities, net (1)
1,419 (1,940)(1,338)
Net periodic defined benefit plan (credit) cost other than service cost(279)(212)(339)
Other, net(681)(256)(130)
 $1,501 $(1,341)$(890)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140 million will be recorded in the first quarter of 2023 from ownership interests in investment funds.
Interest paid was $937 million in 2022, $779 million in 2021 and $822 million in 2020.
16.    Taxes on Income
A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:
 202220212020
  AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income from continuing operations before taxes$3,453 21.0 %$2,915 21.0 %$1,231 21.0 %
Differential arising from:
Foreign earnings(1,835)(11.1)(1,446)(10.4)(965)(16.5)
GILTI and the foreign-derived intangible income deduction462 2.8 (75)(0.5)349 6.0 
State taxes(110)(0.7)2  57 1.0 
R&D tax credit(81)(0.5)(81)(0.6)(108)(1.8)
Tax settlements(10)(0.1)(275)(2.0)(13)(0.2)
Valuation allowances108 0.7 102 0.7 37 0.6 
Restructuring11 0.1 61 0.4 105 1.8 
Acquisition of VelosBio  (9)(0.1)559 9.5 
Acquisition of Pandion  356 2.6   
Acquisition of OncoImmune    97 1.7 
Other(80)(0.5)(29)(0.1)(9)(0.2)
 $1,918 11.7 %$1,521 11.0 %$1,340 22.9 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $2.2 billion at December 31, 2022, of which $732 million is included in Income taxes payable and the remainder of $1.5 billion is included in Other Noncurrent Liabilities. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable.
The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding
119

a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032.
Income from continuing operations before taxes consisted of:
Years Ended December 31202220212020
Domestic$1,011 $1,854 $(3,814)
Foreign15,433 12,025 9,677 
 $16,444 $13,879 $5,863 
Taxes on income from continuing operations consisted of:
Years Ended December 31202220212020
Current provision
Federal$2,265 $74 $893 
Foreign1,164 1,273 969 
State57 (13)44 
 3,486 1,334 1,906 
Deferred provision
Federal(1,510)240 (605)
Foreign71 (77)64 
State(129)24 (25)
 (1,568)187 (566)
 $1,918 $1,521 $1,340 
Deferred income taxes at December 31 consisted of:
 20222021
  AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$ $2,575 $ $3,207 
R&D capitalization1,341  274 — 
Inventory related43 423 119 370 
Accelerated depreciation 657  589 
Equity investments 92  335 
Pensions and other postretirement benefits372 284 487 338 
Compensation related335  301 — 
Unrecognized tax benefits91  75 — 
Net operating losses and other tax credit carryforwards912  867 — 
Other511 267 434 180 
Subtotal3,605 4,298 2,557 5,019 
Valuation allowance(599) (287) 
Total deferred taxes$3,006 $4,298 $2,270 $5,019 
Net deferred income taxes $1,292  $2,749 
Recognized as:
Other Assets$503 $692 
Deferred Income Taxes $1,795  $3,441 
The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2022, $349 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $345 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $563 million of deferred tax assets relating to various U.S. tax credit carryforwards and
120

NOL carryforwards. Valuation allowances of $247 million have been established on these U.S. tax credit carryforwards and NOL carryforwards.
Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $3.2 billion, $2.4 billion and $2.7 billion, respectively. Income taxes paid consisted of:
Years Ended December 31202220212020
Domestic (1)
$1,891 $1,211 $977 
Foreign1,348 1,201 1,763 
 $3,239 $2,412 $2,740 
(1)    Includes TCJA transition tax payments.
Tax benefits relating to stock option exercises were $45 million in 2022, $21 million in 2021 and $12 million in 2020.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202220212020
Balance January 1$1,529 $1,537 $1,225 
Additions related to current year positions344 306 298 
Additions related to prior year positions48 63 110 
Reductions for tax positions of prior years (1)
(40)(230)(4)
Settlements (1)
(6)(46)(70)
Lapse of statute of limitations(40)(58)(22)
Spin-off of Organon (43) 
Balance December 31$1,835 $1,529 $1,537 
(1)    Amount in 2021 reflects a settlement with the IRS discussed below.
If the Company were to recognize the unrecognized tax benefits of $1.8 billion at December 31, 2022, the income tax provision would reflect a favorable net impact of $1.8 billion.
The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2022 could decrease by up to approximately $31 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures.
Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $54 million in 2022, $(37) million in 2021 and $16 million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $256 million and $192 million as of December 31, 2022 and 2021, respectively.
In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.
The IRS is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2003 through 2022.

121

17.    Earnings per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202220212020
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$14,519 $12,345 $4,519 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 704 2,548 
Net Income Attributable to Merck & Co., Inc.$14,519 $13,049 $7,067 
Average common shares outstanding2,532 2,530 2,530 
Common shares issuable (1)
10 8 11 
Average common shares outstanding assuming dilution2,542 2,538 2,541 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.73 $4.88 $1.79 
Income from Discontinued Operations 0.28 1.01 
Net Income$5.73 $5.16 $2.79 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.71 $4.86 $1.78 
Income from Discontinued Operations 0.28 1.00 
Net Income$5.71 $5.14 $2.78 
(1)     Issuable primarily under share-based compensation plans.
In 2022, 2021 and 2020, 2 million, 9 million and 5 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.

122

18.   Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesInvestmentsEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance January 1, 2020, net of taxes
$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(383)3 (633)64 (949)
Tax84  120 89 293 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(299)3 (513)153 (656)
Reclassification adjustments, pretax2 
(1)
(21)
(2)
306 
(3)
 287 
Tax  (72) (72)
Reclassification adjustments, net of taxes2 (21)234  215 
Other comprehensive income (loss), net of taxes(297)(18)(279)153 (441)
Balance at December 31, 2020, net of taxes(266) (4,540)(1,828)(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax333  1,737 (304)1,766 
Tax(75) (332)(119)(526)
Other comprehensive income (loss) before reclassification adjustments, net of taxes258  1,405 (423)1,240 
Reclassification adjustments, pretax192 
(1)
 466 
(3)
 658 
Tax(40) (102) (142)
Reclassification adjustments, net of taxes152  364  516 
Other comprehensive income (loss), net of taxes410  1,769 (423)1,756 
Spin-off of Organon (see Note 3)
  28 421 449 
Balance at December 31, 2021, net of taxes144  (2,743)
(4)
(1,830)(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684  70 (584)170 
Tax(143) 12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541  82 (603)20 
Reclassification adjustments, pretax(775)
(1)
 329 
(3)
 (446)
Tax163  (76) 87 
Reclassification adjustments, net of taxes(612) 253  (359)
Other comprehensive income (loss), net of taxes(71) 335 (603)(339)
Balance at December 31, 2022, net of taxes$73 $ $(2,408)
(4)
$(2,433)$(4,768)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from AOCL to Other (income) expense, net.
(3)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 14).
(4)    Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.

123

19.    Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.
124

Sales of the Company’s products were as follows:
Years Ended December 31202220212020
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$12,686 $8,251 $20,937 $9,765 $7,421 $17,186 $8,352 $6,028 $14,380 
Alliance revenue - Lynparza (1)
584 532 1,116 515 473 989 417 308 725 
Alliance revenue - Lenvima (1)
579 297 876 417 287 704 359 220 580 
Alliance revenue - Reblozyl (2)
123 43 166  17 17    
Vaccines
Gardasil/Gardasil 9
2,065 4,832 6,897 1,881 3,792 5,673 1,755 2,184 3,938 
ProQuad/M-M-R II/Varivax1,724 518 2,241 1,629 506 2,135 1,378 500 1,878 
RotaTeq508 275 783 473 334 807 486 311 797 
Pneumovax 23
346 256 602 547 346 893 727 359 1,087 
Vaqta95 78 173 100 79 179 103 67 170 
Hospital Acute Care
Bridion922 762 1,685 762 770 1,532 583 615 1,198 
Prevymis188 240 428 153 218 370 119 162 281 
Dificid241 22 263 166 10 175 102 7 110 
Primaxin1 238 239 2 258 259 2 248 251 
Noxafil51 187 238 60 199 259 42 287 329 
Invanz4 185 189 (5)207 202 9 202 211 
Cancidas6 168 174 4 208 212 7 207 213 
Zerbaxa89 79 169 4 (5)(1)74 56 130 
Cardiovascular
Alliance revenue - Adempas/Verquvo (3)
329 12 341 312 30 342 259 22 281 
Adempas 238 238  252 252  220 220 
Virology
Lagevrio1,523 4,161 5,684 632 320 952    
Isentress/Isentress HD274 359 633 294 474 769 326 531 857 
Neuroscience
Belsomra79 179 258 78 241 318 81 247 327 
Immunology
Simponi 706 706  825 825  838 838 
Remicade 207 207  299 299  330 330 
Diabetes
Januvia1,248 1,565 2,813 1,404 1,920 3,324 1,470 1,836 3,306 
Janumet355 1,344 1,700 367 1,597 1,964 477 1,494 1,971 
Other pharmaceutical (4)
969 1,282 2,249 841 1,275 2,118 882 1,321 2,202 
Total Pharmaceutical segment sales24,989 27,016 52,005 20,401 22,353 42,754 18,010 18,600 36,610 
Animal Health:
Livestock710 2,590 3,300 667 2,628 3,295 612 2,327 2,939 
Companion Animals1,112 1,138 2,250 1,091 1,182 2,273 872 892 1,764 
Total Animal Health segment sales1,822 3,728 5,550 1,758 3,810 5,568 1,484 3,219 4,703 
Other segment sales (5)
      23  23 
Total segment sales26,811 30,744 57,555 22,159 26,163 48,322 19,517 21,819 41,336 
Other (6)
395 1,333 1,728 266 116 382 71 111 182 
 $27,206 $32,077 $59,283 $22,425 $26,279 $48,704 $19,588 $21,930 $41,518 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020.
(6)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
125

Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202220212020
United States$27,206 $22,425 $19,588 
Europe, Middle East and Africa14,493 13,341 11,547 
China5,191 4,378 2,751 
Japan3,629 2,726 2,602 
Asia Pacific (other than China and Japan)3,614 2,407 2,113 
Latin America2,582 2,206 1,890 
Other2,568 1,221 1,027 
 $59,283 $48,704 $41,518 
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
Years Ended December 31202220212020
Segment profits:
Pharmaceutical segment$36,852 $30,977 $26,106 
Animal Health segment1,963 1,950 1,669 
Other segments  1 
Total segment profits38,815 32,927 27,776 
Other profits1,160 156 75 
Unallocated:
Interest income157 36 59 
Interest expense(962)(806)(831)
Amortization(2,085)(1,636)(1,817)
Depreciation(1,642)(1,414)(1,519)
Research and development(13,011)(11,692)(12,911)
Restructuring costs(337)(661)(575)
Other unallocated, net(5,651)(3,031)(4,394)
$16,444 $13,879 $5,863 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.

126

Equity income/loss from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthAll OtherTotal
Year Ended December 31, 2022      
Included in segment profits:
Equity income from affiliates$39 $ $ $39 
Depreciation5 177  182 
Year Ended December 31, 2021      
Included in segment profits:
Equity income from affiliates$11 $ $ $11 
Depreciation6 158  164 
Year Ended December 31, 2020      
Included in segment profits:
Equity loss from affiliates$6 $ $ $6 
Depreciation6 143 1 150 
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202220212020
United States$12,891 $11,759 $10,394 
Europe, Middle East and Africa6,993 6,081 5,314 
Asia Pacific (other than China and Japan)966 857 737 
Latin America225 199 169 
China207 220 216 
Japan135 159 166 
Other5 4 4 
 $21,422 $19,279 $17,000 
The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.
127

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Merck & Co., Inc.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheet of Merck & Co., Inc. and its subsidiaries (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of income, of comprehensive income, of equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). We also have audited the Company’s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Basis for Opinions
The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management’s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

128

Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
U.S. Rebate Accruals - Medicaid, Managed Care and Medicare Part D
As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. Certain of these discounts representing a portion of the accrual take the form of rebates, which are amounts owed based upon definitive contractual agreements or legal requirements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. Management uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. The accrued balance relative to the provision for rebates included in accrued and other current liabilities was $2.7 billion as of December 31, 2022, of which the majority relates to U.S. rebate accruals – Medicaid, Managed Care and Medicare Part D.
The principal considerations for our determination that performing procedures relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing the rebate accruals, as the accruals are based on assumptions developed using pricing information and historical customer segment utilization mix, and a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating evidence related to these assumptions.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. rebate accruals - Medicaid, Managed Care and Medicare Part D, including management’s controls over the assumptions used to estimate the corresponding rebate accruals. These procedures also included, among others (i) developing an independent estimate of the rebate accruals by utilizing third party data on historical customer segment utilization mix in the U.S., pricing information, the terms of the specific rebate programs, and the historical trend of actual rebate claims paid, (ii) comparing the independent estimate to the rebate accruals recorded by management, and (iii) testing rebate claims paid, including evaluating those claims for consistency with the contractual terms of the Company’s rebate agreements.
mrk-20221231_g7.gif
PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 24, 2023
We have served as the Company’s auditor since 2002.
129

Item 9.     Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Not applicable.
Item 9A.      Controls and Procedures.
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form 10-K, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Act)) are effective. For the fourth quarter of 2022, there have been no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) of the Act. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2022. PricewaterhouseCoopers LLP, an independent registered public accounting firm, has performed its own assessment of the effectiveness of the Company’s internal control over financial reporting and its attestation report is included in this Form 10-K filing.
Management’s Report
Management’s Responsibility for Financial Statements
Responsibility for the integrity and objectivity of the Company’s financial statements rests with management. The financial statements report on management’s stewardship of Company assets. These statements are prepared in conformity with generally accepted accounting principles and, accordingly, include amounts that are based on management’s best estimates and judgments. Nonfinancial information included in the Annual Report on Form 10-K has also been prepared by management and is consistent with the financial statements.
To assure that financial information is reliable and assets are safeguarded, management maintains an effective system of internal controls and procedures, important elements of which include: careful selection, training and development of operating and financial managers; an organization that provides appropriate division of responsibility; and communications aimed at assuring that Company policies and procedures are understood throughout the organization. A staff of internal auditors regularly monitors the adequacy and application of internal controls on a worldwide basis.
To ensure that personnel continue to understand the system of internal controls and procedures, and policies concerning good and prudent business practices, annually all employees of the Company are required to complete Code of Conduct training. This training reinforces the importance and understanding of internal controls by reviewing key corporate policies, procedures and systems. In addition, the Company has compliance programs, including an ethical business practices program to reinforce the Company’s long-standing commitment to high ethical standards in the conduct of its business.
The financial statements and other financial information included in the Annual Report on Form 10-K fairly present, in all material respects, the Company’s financial condition, results of operations and cash flows. Our formal certification to the Securities and Exchange Commission is included in this Form 10-K filing.
Management’s Report on Internal Control Over Financial Reporting
Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2022.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls
130

may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
The effectiveness of the Company’s internal control over financial reporting as of December 31, 2022, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
mrk-20221231_g8.jpg
mrk-20221231_g9.jpg
Robert M. DavisCaroline Litchfield
Chairman, President and Chief Executive OfficerExecutive Vice President and Chief Financial Officer

Item 9B.    Other Information.
None.
Item 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
Not Applicable.
131

PART III
 
Item 10.Directors, Executive Officers and Corporate Governance.
The required information on directors and nominees is incorporated by reference from the discussion under Proposal 1. Election of Directors of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023. Information on executive officers is set forth in Part I of this document on page 40.
The required information on compliance with Section 16(a) of the Securities Exchange Act of 1934, if applicable, is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
The Company has a Code of Conduct — Our Values and Standards applicable to all employees, including the principal executive officer, principal financial officer, principal accounting officer and Controller. The Code of Conduct is available on the Company’s website at merck.com/company-overview/culture-and-values/code-of-conduct/values-and-standards. The Company intends to disclose future amendments to certain provisions of the Code of Conduct, and waivers of the Code of Conduct granted to executive officers and directors, if any, on the website within four business days following the date of any amendment or waiver. Every Merck employee is responsible for adhering to business practices that are in accordance with the law and with ethical principles that reflect the highest standards of corporate and individual behavior.
The required information on the identification of the audit committee and the audit committee financial expert is incorporated by reference from the discussion under the heading “Board Meetings and Committees” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
Item 11.Executive Compensation.
The information required on executive compensation is incorporated by reference from the discussion under the headings “Compensation Discussion and Analysis,” “Summary Compensation Table,” “All Other Compensation” table, “CEO Pay Ratio,” “Pay vs. Performance” table, “Grants of Plan-Based Awards” table, “Outstanding Equity Awards” table, “Option Exercises and Stock Vested” table, “Pension Benefits” table, “Nonqualified Deferred Compensation” table, and “Potential Payments Upon Termination or a Change in Control”, including the discussion under the subheadings “Separation” and “Change in Control,” as well as all footnote information to the various tables, of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
The required information on director compensation is incorporated by reference from the discussion under the heading “Director Compensation” and related “2022 Schedule of Director Fees” table and “2022 Director Compensation” table of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
The required information under the headings “Compensation and Management Development Committee Interlocks and Insider Participation” and “Compensation and Management Development Committee Report” is incorporated by reference from the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.

132

Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Information with respect to security ownership of certain beneficial owners and management is incorporated by reference from the discussion under the heading “Stock Ownership Information” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
Equity Compensation Plan Information
The following table summarizes information about the options, warrants and rights and other equity compensation under the Company’s equity compensation plans as of the close of business on December 31, 2022. The table does not include information about tax qualified plans such as the Merck U.S. Savings Plan.
Plan CategoryNumber of
securities to be
issued upon
exercise of
outstanding
options, warrants
and rights
(a)
Weighted-average
exercise price of
outstanding
options, warrants
and rights
(b)
Number of
securities remaining
available for future
issuance under equity
compensation plans
(excluding
securities
reflected in column (a))
(c)
Equity compensation plans approved by security holders(1)
13,719,333(2)
$70.55 86,776,452 
Equity compensation plans not approved by security holders— — — 
Total13,719,333 $70.55 86,776,452 
(1)Includes options to purchase shares of Company Common Stock and other rights under the following shareholder-approved plans: the Merck & Co., Inc. 2010 and 2019 Incentive Stock Plans, and the Merck & Co., Inc. 2010 Non-Employee Directors Stock Option Plan.
(2)Excludes approximately 12,700,042 shares of restricted stock units and 1,980,608 performance share units (assuming maximum payouts) under the Merck Sharp & Dohme 2010 and 2019 Incentive Stock Plans. Also excludes 182,601 shares of phantom stock deferred under the MSD Employee Deferral Program and 487,534 shares of phantom stock deferred under the Merck & Co., Inc. Plan for Deferred Payment of Directors’ Compensation.
Item 13.Certain Relationships and Related Transactions, and Director Independence.
The required information on transactions with related persons is incorporated by reference from the discussion under the heading “Related Person Transactions” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
The required information on director independence is incorporated by reference from the discussion under the heading “Independence of Directors” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
Item 14.Principal Accountant Fees and Services.
The information required for this item is incorporated by reference from the discussion under Proposal 4. Ratification of Appointment of Independent Registered Public Accounting Firm for 2023 beginning with the caption “Pre-Approval Policy for Services of Independent Registered Public Accounting Firm” through “Fees for Services Provided by the Independent Registered Public Accounting Firm” of the Company’s Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023.
133

PART IV
 
Item 15.Exhibits and Financial Statement Schedules.
(a)    The following documents are filed as part of this Form 10-K
1.    Financial Statements
Consolidated statement of income for the years ended December 31, 2022, 2021 and 2020
Consolidated statement of comprehensive income for the years ended December 31, 2022, 2021 and 2020
Consolidated balance sheet as of December 31, 2022 and 2021
Consolidated statement of equity for the years ended December 31, 2022, 2021 and 2020
Consolidated statement of cash flows for the years ended December 31, 2022, 2021 and 2020
Notes to consolidated financial statements
Report of PricewaterhouseCoopers LLP, independent registered public accounting firm (PCAOB ID 238)
2.    Financial Statement Schedules
Schedules are omitted because they are either not required or not applicable.
Financial statements of affiliates carried on the equity basis have been omitted because, considered individually or in the aggregate, such affiliates do not constitute a significant subsidiary.
134

3.    Exhibits
Exhibit
Number
 Description
3.1
3.2
4.1Indenture, dated as of April 1, 1991, between Merck Sharp & Dohme Corp. (f/k/a Schering Corporation) and U.S. Bank Trust National Association (as successor to Morgan Guaranty Trust Company of New York), as Trustee (the 1991 Indenture) — Incorporated by reference to Exhibit 4 to MSD’s Registration Statement on Form S-3 (No. 33-39349)
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
135

*10.1
*10.2
*10.3
*10.4
*10.5
*10.6
*10.7
*10.8
*10.9
*10.10
136

*10.11
*10.12
*10.13
*10.14
*10.15
10.16
10.17
*10.18
*10.19
*10.20
*10.21
*10.22
*10.23
*10.24
*10.25
*10.26
*10.27
*10.28
137

*10.29
*10.30
*10.31
*10.32
*10.33
*10.34
*10.35
*10.36
*10.37
21
23
24.1
24.2
31.1
31.2
32.1
32.2
Exhibit 101:
101.INSXBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
                
*Management contract or compensatory plan or arrangement.
Certain portions of the exhibit have been omitted pursuant to a request for confidential treatment. The non-public information has been filed separately with the Securities and Exchange Commission pursuant to rule 24b-2 under the Securities Exchange Act of 1934, as amended.
Long-term debt instruments under which the total amount of securities authorized does not exceed 10% of Merck & Co., Inc.’s total consolidated assets are not filed as exhibits to this report. Merck & Co., Inc. will furnish a copy of these agreements to the Securities and Exchange Commission on request.

Item 16.    Form 10-K Summary

Not applicable.

138

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated:    February 24, 2023
 
MERCK & CO., INC.
By:ROBERT M. DAVIS
(Chairman, Chief Executive Officer and President)
By:/s/ JENNIFER ZACHARY
Jennifer Zachary
(Attorney-in-Fact)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
SignaturesTitleDate
ROBERT M. DAVIS
Chairman, Chief Executive Officer and President;
Principal Executive Officer
February 24, 2023
CAROLINE LITCHFIELD
Executive Vice President and Chief Financial
Officer; Principal Financial Officer
February 24, 2023
RITA A. KARACHUN
Senior Vice President Finance-Global Controller;
Principal Accounting Officer
February 24, 2023
DOUGLAS M. BAKER, JR.DirectorFebruary 24, 2023
MARY ELLEN COEDirectorFebruary 24, 2023
PAMELA J. CRAIGDirectorFebruary 24, 2023
THOMAS H. GLOCERDirectorFebruary 24, 2023
RISA J. LAVIZZO-MOUREYDirectorFebruary 24, 2023
STEPHEN L. MAYODirectorFebruary 24, 2023
PAUL B. ROTHMANDirectorFebruary 24, 2023
PATRICIA F. RUSSODirectorFebruary 24, 2023
CHRISTINE E. SEIDMANDirectorFebruary 24, 2023
INGE G. THULINDirectorFebruary 24, 2023
KATHY J. WARDENDirectorFebruary 24, 2023
PETER C. WENDELLDirectorFebruary 24, 2023
Jennifer Zachary, by signing her name hereto, does hereby sign this document pursuant to powers of attorney duly executed by the persons named, filed with the Securities and Exchange Commission as an exhibit to this document, on behalf of such persons, all in the capacities and on the date stated, such persons including a majority of the directors of the Company.
 
By:/S/ JENNIFER ZACHARY
Jennifer Zachary
(Attorney-in-Fact)
139
EX-10.7 2 exhibit107-2017annualnqsot.htm EXHIBIT-10.7 2017 ANNUAL NQSO TERMS AND CONDITIONS Document

Exhibit 10.7
TERMS FOR
2017 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS
UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN

This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.

Grant Type:NQSO
Option Price:$63.97
Grant Date:May 5, 2017
Expiration Date:May 4, 2027
Vesting DatePortion that Vests
May 5, 2018First: 33.333%
May 5, 2019Second: 33.333%
May 5, 2020Balance

I. GENERAL INFORMATION

This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment: For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II. TERMINATION OF EMPLOYMENT

A. General Rule. If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the same day of the third month (“Within Three Months”) after the date of the termination (but in no event after the expiration of the Option Period). Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open. Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later day (e.g., November 28, 29 and 30 all correspond to February 28 in non leap years). If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.

B. Retirement. If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately. Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its
original Expiration Date. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

C. Involuntary Termination. If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

D. Sale. If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this option, and/or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

E. Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

F. Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the first anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of



this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).

G. Disability. If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

H. Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B, D, E, F and G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

I. Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.

III. TRANSFERABILITY

This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.

IV. ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute
discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.

V. GRANTS NOT PART OF EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This stock option is subject to the provisions of the 2010 Incentive Stock Plan. For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http://onemerck.com

Unless you notify the Company in writing that you wish to refuse this grant within 60 days of the Grant Date, you will be deemed to acknowledge that you have read, understood and agree to all of the terms, conditions and provisions of this document and the Merck & Co., Inc. 2010 Incentive Stock Plan. If you wish to reject this grant, you must send your written notice of rejection to the Company at:

Attention: Global Executive Compensation and Benefits
Merck & Co., Inc.
2000 Galloping Hill Road, Building K-1
Kenilworth, New Jersey, U.S.A. 07033



Appendix A
Recoupment of Compensation for Compliance Violations
POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1. “Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2. A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3. An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4. “Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1. The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2. The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3. If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking
Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4. In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.
image_0.jpg
EX-10.8 3 exhibit108-2019annualnqsot.htm EXHIBIT-10.8 2019 ANNUAL NQSO TERMS AND CONDITIONS Document

Exhibit 10.8
TERMS FOR
2019 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN

This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.


Grant Type:NQSO – Annual
Option Price:$77.62
Grant Date:May 3, 2019
Expiration Date:May 2, 2029
Vesting DatePortion that Vests
May 3, 2020First: 33.333%
May 3, 2021Second: 33.333%
May 3, 2022Balance

I. GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.

This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment: For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.TERMINATION OF EMPLOYMENT

A.General Rule. If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the same day of the third month (“Within Three Months”) after the date of the termination (but in no event after the expiration of the Option Period). Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open. Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later day (e.g., November 28, 29 and 30 all correspond to February 28 in
non leap years). If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.

B.Retirement. If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately. Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

C.Involuntary Termination. If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

D.Sale. If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this option, and/or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.



E.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

F.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).

G.Disability. If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

H.Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B, D, E, F and G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

I.Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this

stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.

III.TRANSFERABILITY

This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.

IV.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

V.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.

VI. GRANTS NOT PART OF EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This stock option is subject to the provisions of the 2010 Incentive Stock Plan. For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http://one.merck.com





Appendix A
Recoupment of Compensation for Compliance Violations


POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to


refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.




image_1b.jpg

EX-10.13 4 exhibit1013-plansepmrk2019.htm EXHIBIT-10.13 US SEPARATION BENEFITS PLAN AS OF 1/1/19 Document


Exhibit 10.13







MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN


Amended and Restated as of January 1, 2019



MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN


SECTION 1
PREAMBLE
Merck Sharp & Dohme Corp. established the MSD Separation Benefits Plan (the "MSD Plan"), as amended from time to time, to provide benefits to eligible non-union employees whose employment with Merck Sharp & Dohme Corp. or a participating wholly owned subsidiary (collectively, "MSD") was terminated under certain circumstances at the initiative of MSD.

Schering-Plough Corporation established the Schering-Plough Separation Benefits Plan (the "Schering Plan"), as amended from time to time, for the purpose of providing severance benefits to eligible union and non-union employees whose employment with Schering Corporation and certain of its U.S. affiliated companies was terminated under certain circumstances.

Effective January 1, 2012, the Schering Plan merged into the MSD Plan with the MSD Plan being renamed the Merck & Co., Inc. U.S. Separation Benefits Plan (the "Plan"). The Plan was amended and restated in its entirety at that time. Effective January 1, 2013, September 1, 2013, October 1, 2013, November 15, 2014 and January 1, 2017, the Plan was reinstated in its entirety. Effective January 1, 2019, the Plan is again being amended and restated in its entirety as set forth herein.

The purpose of the Plan is to provide benefits to eligible employees whose employment with an Employer is terminated at the initiative of the Employer for reasons described below. This Plan is part of the MSD Separation Allowance Plan (Plan No. 514).
1


SECTION 2
DEFINITIONS

For the purposes of this Plan, the following terms shall have the following meanings:


2.1Annual Base Salarymeans

(a)With respect to a Participant who is exempt as of his or her Separation Date, his or her annual base salary in effect as of his or her Separation Date, according to the Employer’s payroll records, without reduction for any contributions to Employer-sponsored benefit plans. For the avoidance of doubt, (i) with respect to a Participant who is exempt and regularly scheduled to work less than full-time as of his or her Separation Date, Annual Base Salary is the reduced annual base salary in effect on his or her Separation Date applicable to the less than full time position, according to the Employer’s payroll records, without reduction for any contributions to the Employer-sponsored benefit plans and (ii) no adjustment is made to Annual Base Salary if the Participant’s annual base salary in effect during any period prior to his or her Separation Date is higher or lower (for any reason, including promotion/demotion or a move to or from full-time or part-time status) than his or her annual base salary in effect as of his or her Separation Date, according to the Employer’s payroll records.

(b)With respect to a Participant who is non-exempt as of his or her Separation Date, the hourly rate according to the Employer’s payroll records in effect as of his or her Separation Date multiplied by the number of hours the Eligible Employee is regularly scheduled to work as of his or her Separation Date (up to a maximum of 2080 hours).

Annual Base Salary does not include bonuses, commissions, overtime pay, shift pay, premium pay, lump sum merit increases, cost of living allowances, income from stock options or other incentives under an Incentive Stock Plan of the Employer (or the Parent or any of its subsidiaries), stock grants or other incentives, or other pay not specifically included above.

For example, a Participant who is regularly scheduled to work less than full-time on his Separation Date has 10 Complete Years of Continuous Service (9 at full-time and 1 at less than full-time), had an annual base salary of $100,000 as a full-time employee but on his Separation Date has an annual base salary of $50,000 according to the Employer’s payroll records because it was reduced as applicable for the less than full-time position. The Participant’s Separation Pay will be calculated using 10 Complete Years of Continuous Service and an Annual Base Salary of
$50,000. There is no adjustment in Annual Base Salary for prior years of higher annual base salary due to full-time service.

2.2Base Pay Rate” means

(a)With respect to an Eligible Employee who is exempt, his/her annual base pay according to the Employer’s payroll records in effect as of the date the Eligible Employee is offered a Qualified Alternative Position or a Negotiated Job Offer. For an Eligible Employee who is regularly scheduled to work less than full-time, annual base pay is the reduced annual base pay to the less than full-time position.

(b)With respect to an Eligible Employee who is non-exempt, the hourly rate according to the Employer’s payroll records in effect as of the date the Eligible Employee is
2


offered a Qualified Alternative Position or a Negotiated Job Offer multiplied by the number of hours the Eligible Employee is regularly scheduled to work (up to a maximum of 2080 hours).

Base Pay Rate is calculated without reduction for any contributions to Employer-sponsored benefit plans. Base Pay Rate includes applicable shift pay and premium pay but does not include bonuses, commissions, overtime pay, lump sum merit increases, cost of living allowances, income from awards granted under an Incentive Stock Plan of the Employer (or the Parent or its subsidiaries), or other pay not specifically included above.

2.3Basic Life Insurancemeans life insurance provided to an Eligible Employee under a plan sponsored by Parent or a subsidiary of Parent equal to 1x "base pay" as defined under the life insurance plan in which the Eligible Employee participates, as it may be amended from time to time.

2.4Benefits Continuation Periodmeans the period of time, as set forth on Schedule B-2, during which a Participant is eligible to receive Separation Benefits, provided, however that the Participant may elect to end the period earlier than indicated on Schedule B-2 by notifying the Employer's health and insurance plan administrator (i) within the later of thirty (30) days from the Participant's Separation Date or the date by which the Participant is provided to review the Separation Letter so that the Benefit Continuation Period ends on the date it would have otherwise begun, or (ii) during the Employer's annual open enrollment period for health and insurance benefits so that the Benefit Continuation Period ends the following January 1 (provided that date is not beyond the period set forth on Schedule B-2), or (iii) mid-year with a qualified status change that otherwise permits the Participant to make a change to the Participant's healthcare coverage in accordance with the terms of the Employer's healthcare plan so that the Benefits Continuation Period ends on the date the mid-year change would otherwise be effective under the terms of the Employer's healthcare plan (provided that date is not beyond the period set forth on Schedule B- 2).

2.5Change in Controlshall have the meaning set forth in the CIC Plan (and, for avoidance of doubt, a valid amendment of that definition under the CIC Plan shall constitute an amendment of this Plan without further action).

2.6CIC Planmeans the Merck & Co., Inc. Change in Control Separation Benefits Plan, as amended and restated effective January 1, 2013 and as it may be further amended from time to time, and any successor thereto.

2.7Claims Reviewermeans the Merck & Co., Inc. Employee Benefits Committee (or its delegate) whose members are appointed by the Parent's Executive Vice President of Human Resources or his or her delegate; provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate.

2.8Codemeans the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder.

2.9Complete Years of Continuous Servicemeans (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (d) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.

2.10Continuous Servicemeans (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the
3


Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (d) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service".

2.11Eligible Employeemeans (a) any regular full-time or regular part-time employee of an Employer who is on the Employer's normal U.S. payroll and as to whom the terms and conditions of employment are not covered by a collective bargaining agreement unless the collective bargaining agreement specifically provides for coverage under the Plan; or (b) a U.S. Expatriate on an Employer's normal U.S. payroll.
The term “Eligible Employee” shall not include:
(i)an employee (x) who is a party to an employment agreement with the Employer or with the Parent (or any of its subsidiaries) or (y) who is entitled, upon termination of employment with the Employer, to separation, severance, termination or other similar payments (1) under another plan or program sponsored by the Employer or Parent (or any of its subsidiaries); or
(2) pursuant to a separate agreement with the Employer or Parent (or any of its subsidiaries) or
(z) who is a party to an agreement with the Employer or Parent (or any of its subsidiaries) that provides that no payment or benefits are due to the employee in connection with his or her termination of employment; provided, however, in each case under the foregoing clauses (x),
(y) and (z) unless the plan, program or agreement expressly provides for benefits under this Plan;

(ii)a participant in the CIC Plan (but this clause shall only apply during the Protection Period (as defined in Section 8.1));

(iii)temporary employees (including college coops, summer employees, high school coops, flexible workforce employees, post-doctorate research fellows and any other such temporary classifications ) and/or employees called by the Employer at any time for employment in the
U.S. on a non-scheduled and non-recurring basis, and who becomes an employee of the Employer only after reporting to work for the period of time during which the person is working;

(iv)an Excluded Person;

(v)employees of a non-US subsidiary of an Employer (or who are dual employees of a non- US subsidiary of an Employer) who are on assignment in the US;

(vi)employees whose employment ends for any reason while on unapproved leaves of absence;

(vii)employees whose employment ends for any reason while on approved leaves of absence for a period equal to or more than six continuous months regardless of the reason(s) for the leave excluding the following approved leaves of absence: medical disability leaves, military leaves and family medical leaves under federal or state family medical leave laws;

4


(viii)employees whose employment ends for any reason while on approved leaves of absence for medical disability for a period equal to or more than one year;

(ix)employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.
For purposes of the foregoing clauses (vii) and (viii), a series of leaves of absence is considered one continuous leave for purposes of calculating the six-month or one-year requirement if the employee does not return to active employment for any reason, including but not limited to because the employee’s former position is unavailable and the employee is unable to secure a new position.
Whether an individual is an Eligible Employee or not is determined as of the date of his/her Termination due to Workforce Restructuring or for Rebadged Employees as of the date of his/her termination of employment due to an outsource transaction.

2.12     “Employermeans individually and collectively, the entities identified on Schedule A attached hereto.

2.13     “ERISAmeans the Employee Retirement Income Security Act of 1974, as amended, and the regulations promulgated thereunder.

2.14Excluded Personmeans a person who (i) is an independent contractor, or agrees or has agreed that he/she is an independent contractor, or (ii) has any agreement or understanding with the Employer, or any of its affiliates that he/she is not an employee or an Eligible Employee, or (iii) is employed by a temporary or other employment agency, regardless of the amount of control, supervision or training provided by the Employer or its affiliates, or (iv) is a “leased employee” as defined under Section 414(n) of the Internal Revenue Code of 1986, as amended, or (v) is not treated by the Employer as an employee for purposes of withholding federal income taxes, regardless of any contrary Internal Revenue Service, governmental or judicial determination relating to such employment status or tax withholding. An Excluded Person is not eligible to participate in the Plan even if a court, agency or other authority rules that he/she is a common-law employee of the Employer or its affiliates.

2.15 Intentionally Omitted.

2.16 Intentionally Omitted.

2.17IAM Agreementmeans a collective bargaining agreement between Merck Sharp & Dohme Corp. and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.

2.18Legacy Inspire Employeemeans an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent as S6 (Legacy Inspire) under infotype 35, and (iii) not covered by a collective bargaining agreement.

2.19Legacy Merck Employeemeans an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired or transferred to such entity after December 31, 2012, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement, other than one of the IAM Agreements. For the avoidance of doubt, “Legacy Merck Employee” excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.

5


2.20Legacy Merck Entitymeans (a) for the period prior to November 4, 2009, Old Merck and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.

2.21Legacy Schering Employeemeans an Eligible Employee who (a) as of December 31, 2012 is employed by a Merck Entity and either continues to be employed by such entity until his/her Separation Date or is rehired by or transferred to such entity after December 31, 2012, and
(b) as of his/her Separation Date is (i) employed by an Employer, (ii) coded in the employee data base of Parent as S1 (Legacy Organon), S2 (Legacy Intervet) or S5 (Legacy Schering-Plough) under infotype 35, and (iii) not covered by a collective bargaining agreement other than one of the IAM Agreements or an agreement that specifically provides for benefits under this Plan. For the avoidance of doubt, “Legacy Schering Employee” excludes employees who are covered by the IAM Agreement at the Kenilworth, NJ site who elect to retain their recall rights.

2.22Legacy Schering Entitymeans (a) for the period prior to November 4, 2009, Schering- Plough Corporation and its direct or indirect wholly owned subsidiaries and (b) for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.

2.23Merck Entitymeans for the period beginning November 4, 2009, New Merck and its direct or indirect wholly owned subsidiaries.

2.24Merck Retiree Medical Planmeans the retiree medical plan sponsored by Merck Sharp & Dohme which includes the following components: (i) the Merck Group Retiree Medical Plan which provides group retiree medical and prescription drug benefits to eligible retirees and their eligible dependents, in each case who are under age 65 or not Medicare-eligible as more fully described in the Merck Group Retiree Medical Plan SPD, and (ii) the Merck Retiree HRA which provides reimbursement benefits to eligible retirees and their eligible dependents who are eligible for subsidized retiree medical benefits and, in each case ,who are age 65 or older and Medicare- eligible as more fully described in the Merck Retiree Health Reimbursement Account SPD.

2.25Misconductmeans conduct which includes (a) falsification of an Employer's or Parent's records/misrepresentation; (b) theft; (c) acts or threats of violence; (d) refusal to carry out assigned work; (e) unauthorized possession of alcohol or illegal drugs on an Employer's or Parent's premises; (f) being under the influence of alcohol or illegal drugs during work hours; (g) willful intent to damage or destroy an Employer's or Parent's property; (h) violation of the Parent's "Our Values and Standards"; (i) acts of discrimination/harassment; (j) conduct jeopardizing the integrity of the products of an Employer, Parent or one or more of its subsidiaries; (k) violation of rules, policies, and/or practices of an Employer or Parent; or (l) other conduct considered to be detrimental to an Employer, the Parent or one or more of its subsidiaries.

2.26Most Recent Hire Datemeans (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (d) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity
6


as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT. For the avoidance of doubt, the most recent hire date at an acquired entity may occur before the date the entity was acquired by a Legacy Schering Entity, Legacy Merck Entity or Merck Entity, provided such date is reflected on the Employer’s employee data system.

2.27"Negotiated Job Offer" means an offer of employment (or an offer of continued employment) with a successor employer or outsource vendor the terms and conditions of which are negotiated by an Employer, Parent or one of its subsidiaries or affiliates and may include, among other things, a reduction in Base Pay Rate.

2.28New Merckmeans Merck & Co., Inc. (formerly known as Schering-Plough Corporation) on and after November 4, 2009.

2.29Non-Legacy Company Employeemeans an Eligible Employee who (a) is first hired by a Merck Entity on or after January 1, 2013, and (b) as of his/her Separation Date is (i) employed by an Employer, and (ii) coded in the employee data base of Parent with a blank indicator under infotype 35, and (iii) not covered by a collective bargaining agreement. For purposes of determining whether an Eligible Employee is a “Non-Legacy Company Employee” only, an Eligible Employee who was an employee of an entity on the date that it was acquired by a Merck Entity is considered to be first hired by a Merck Entity on the date the entity became a wholly owned subsidiary of New Merck or one of its wholly owned subsidiaries.

2.30"Offer Outside Geographic Parameters" means (A) for an Eligible Employee who is not eligible to participate in the Company’s sales incentive plan and who does not qualify as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee’s residence immediately prior to the extension of the Negotiated Job Offer and his/her new principal business location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her principal business location at the time the Negotiated Job Offer is extended or (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who is eligible to participate in the Company’s sales incentive plan or who qualifies as other field-based personnel, a Negotiated Job Offer that results in the relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee’s residence immediately prior to the extension of the Negotiated Job Offer and his/her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her geographic workload center location at the time the Negotiated Job Offer is extended and (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.
The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.
Whether a position is an Offer Outside Geographic Parameters shall be determined at the time a Negotiated Job Offer is offered or communicated to the Eligible Employee by the Employer.

2.31Old Merckmeans Merck & Co., Inc. prior to November 4, 2009 (subsequently known as Merck Sharp & Dohme Corp).

2.32Outplacement Benefitsmeans benefits for outplacement counseling or other outplacement services made available to a Participant as provided pursuant to Section 4.4 of this Plan.

2.33Parentmeans New Merck.

7


2.34Participantmeans an Eligible Employee who has experienced a Termination due to Workforce Restructuring and who has signed, and, if a revocation period is applicable, not revoked, a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.

The term "Participant" shall also include, where and as applicable a Rebadged Employee who has signed and, if a revocation period is applicable, not revoked a Release of Claims in a form that is satisfactory to the Employer in its sole and absolute discretion.

2.35Planmeans the Merck & Co., Inc., U.S. Separation Benefits Plan as set forth herein, and as may be amended from time to time.

2.36Plan Administratormeans the Parent or its delegate.

2.37Plan Yearmeans the calendar year January 1 through December 31 on which the records of the Plan are kept.

2.38Qualified Alternative Positionmeans a position with an Employer, the Parent or any of its subsidiaries which does not result in either of the following:
(i)a reduction in the Eligible Employee's Base Pay Rate; or

(ii)(A) for an Eligible Employee who is not eligible to participate in the Company’s sales incentive plan, relocation of the Eligible Employee's principal business location to a new principal business location (x) where the distance between the Eligible Employee’s residence immediately prior to the relocation and his/her new principal business location is more than 50 miles greater than the distance between the the Eligible Employee's residence and his/her principal business location immediately prior to the relocation or (y) that is more than 75 miles from the Eligible Employee's residence immediately prior to the relocation and not closer to the Eligible Employee's residence at that time, and (B) for an Eligible Employee who is eligible to participate in the Company’s sales incentive plan or who qualifies as other field- based personnel, relocation of the Eligible Employee's geographic workload center location to a new geographic workload center location (x) where the distance between the Eligible Employee’s residence immediately prior to the relocation and his/her new geographic workload center location is more than 50 miles greater than the distance between the Eligible Employee's residence and his/her geographic workload center location immediately prior to the relocation and (y) more than 75 miles from the Eligible Employee's residence at the time the Negotiated Job Offer is extended and not closer to the Eligible Employee's residence at that time.
The Employer, in its sole and absolute discretion, will determine (i) whether an Eligible Employee qualifies as other field-based personnel, (ii) distance using a nationally recognized mapping service, (iii) principal business location, and (iv) the geographic workload center.

Whether a position is a Qualified Alternative Position shall be determined at the time such position is offered or communicated to the Eligible Employee by his/her manager.

2.39"Rebadged Employeemeans an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by the Employer in a transaction with a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and:

(a)(i) accepts the Negotiated Job Offer; or (ii) declines the Negotiated Job Offer, provided the Negotiated Job Offer is not an Offer Outside Geographic Parameters; and

(b)remains employed with the Employer through the date established by the Employer as the employee's Separation Date unless the Employer expressly waives this provision.

8


Whether an Eligible Employee is a Rebadged Employee shall be determined by the Employer or Parent in its sole discretion. An Eligible Employee shall not be considered to be a Rebadged Employee if his or her employment with the Employer (i) does not end as set forth in this Section 2.38 (ii) ends due to the declination of a Negotiated Job Offer that is an Offer Outside Geographic Parameters, or (iii) ends as a result of any of the events described in Section 3.1(e).

For the avoidance of doubt, a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes of the Plan.

2.40Release of Claimsmeans the agreement that an Eligible Employee must execute in order to become a Participant and to receive Separation Plan Benefits, which shall be prepared by the Employer or the Parent and shall contain such terms and conditions as determined by the Employer or the Parent, including but not limited to a general release of claims, known or unknown, that the Eligible Employee may have against the Employer (and the Parent and any of its subsidiaries and/or affiliates), including claims related to the employment and termination of employment of the Eligible Employee; such Release of Claims may also contain, in the Employer’s or the Parent's discretion, other terms and conditions including, without limitation, cooperation in litigation, non-disclosure, confidentiality, non-disparagement, non-solicitation and/or non-competition provisions.

2.41Section 16 Officermeans an “officer” as such term is defined in Rule 16(a)-1(f) of the Securities Exchange Act of 1934 of the Parent who is also an Eligible Employee of an Employer.

2.42Separation Benefitsmeans the benefits provided pursuant to Sections 4.2 and 4.3 of this Plan.

2.43Separation Datemeans the Eligible Employee’s last day of employment with the Employer due to a Termination due to Workforce Restructuring or, in the case of a Rebadged Employee, due to the outsourcing transaction. The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.

2.44Separation Paymeans the cash benefit payable under this Plan pursuant to Section 4.1 or to a Rebadged Employee pursuant to Section 4.5.

2.45Separation Plan Benefitsmeans, collectively, Separation Pay, Separation Benefits and Outplacement Benefits.

2.46"Termination Due to Non-Performance" means a termination of an Eligible Employee's employment as determined and caused by the Employer due to the Eligible Employee's failure to perform his or her job assignments in a satisfactory manner.

2.47Termination due to Workforce Restructuringmeans the termination of an Eligible Employee's employment as determined and caused by the Employer due to:
(a)the elimination of an Eligible Employee's job;
(b)organizational changes; or
(c)a general reduction of the workforce.
Whether an Eligible Employee's job is eliminated is determined by the Employer but excludes the maintenance of the position with the elimination of a part-time or job share arrangement or other flexible work arrangement.

Organizational changes are determined by the Employer and include the following actions: discontinuance of operations, location closings, corporate restructuring but exclude a reduction in job title, grade or band level, Base Pay Rate, short term incentive opportunity (e.g., cash bonuses under any bonus or incentive plan or program of the Parent), long-term incentive compensation
9


opportunity, equity compensation opportunity and/or other forms of remuneration of an Eligible Employee with or without a change in the Eligible Employee's job duties where such reduction is due to (i) a general change in the Employer’s or the Parent’s compensation framework as it applies to similarly situated Eligible Employees (e.g., a change in the general compensation framework applicable to similar jobs with the Employer, or an identifiable segment of the Employer such as a subsidiary, division or department); (ii) an action to align the Eligible Employee with the Employer's or the Parent's compensation and career framework as it applies to similarly situated Eligible Employees; or (iii) a demotion or other action taken as a result of the Eligible Employee's performance or behaviors.

An Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring if his or her employment with the Employer (i) does not end due to this Section 2.46 (a), (b) or (c) or (ii) ends as a result of any of the events described in Section 3.1(d).

For the avoidance of doubt with respect to outsourcing transactions, (x) an Eligible Employee whose employment with the Employer is terminated by the Employer in connection with the outsourcing of work by the Employer in a transaction with a third-party vendor where the individual is offered a Negotiated Job Offer and declines the Negotiated Job Offer because it is an Offer Outside Geographic Parameters, is considered to have incurred a Termination due to Workforce Restructuring provided his or her employment with the Employer does not end as a result of any of the events described in Section 3.1 (d), and (y) a Rebadged Employee shall not be considered to have experienced a Termination due to Workforce Restructuring for purposes the Plan.

2.48U.S. Expatriatemeans a U.S. citizen or individual with U.S. Permanent Resident status who is employed by the Employer and on assignment outside the U.S. and who is not an Excluded Person.
10


SECTION 3
ELIGIBILITY FOR BENEFITS

3.1Eligibility.
a)
(a)An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013.    Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring only if the Eligible Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.

(b)A Rebadged Employee will be eligible for Separation Pay described in Section 4.5; provided, however, that a Rebadged Employee who is a Legacy Inspire Employee will be eligible for Separation Pay described in Section 4.5 only if his/her employment with an Employer is terminated by the Employer in connection with the outsourcing of work on or after May 17, 2013. Separation Pay shall be provided under this Plan to a Rebadged Employee only if the Rebadged Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. A Rebadged Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant. A Rebadged Employee is not eligible for Separation Benefits or Outplacement Benefits.

(c)An Eligible Employee will also be entitled to receive those pension benefits set forth in Schedule D (Change in Control/Pension) and retiree medical benefits set forth in Schedule E (Change in Control/Retiree Medical) if (i) a Change in Control has occurred and (ii) within two years thereafter, the Eligible Employee’s employment with the Employer (or successor employer) is terminated by the Employer (or successor employer) for any reason other than for Misconduct, death or "Permanent Disability" (as such term is defined in the CIC Plan), and (iii) the Eligible Employee signs and returns the release of claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.

(d)Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to have incurred a Termination due to Workforce Restructuring under the Plan if his or her employment ends as a result of any of the following events:
(i)a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest, in each case where either
(x)the Eligible Employee is offered and accepts, or continues in, a Negotiated Job Offer; or
(y)the Eligible Employee is offered and declines a Negotiated Job Offer, unless the Negotiated Job Offer is an Offer Outside Geographic Parameters with the acquiring entity or vendor;
11


(ii)the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is a Rebadged Employee;
(iii)the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee;
(iv)a termination for Misconduct;
(v)death (unless the Eligible Employee dies after he/she has been notified of his/her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his/her date of death;
(vi)the Eligible Employee terminating employment with the Employer prior to the date identified as the date the employee would experience a Termination due to Workforce Restructuring unless the Employer expressly agreed to waive this provision;
(vii)failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee’s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason; or
(viii)Intentionally Omitted;
(ix)the Eligible Employee's decision to decline a Qualified Alternative Position for any reason (including, but not limited to because the employee is a part-time employee and is offered a full-time position, is a shift-worker and the position offered is on a different shift or has a job share or other flexible work arrangement and the position offered is not a job share or does not include a flexible work arrangement) that is offered to the Eligible Employee prior to the Eligible Employee's Separation Date; or
(x)the Eligible Employee's decision to accept an alternate position with the Employer, Parent or any of its subsidiaries (whether or not the position is a Qualified Alternative Position) and to later decline it; or
(xi)Termination Due to Non-Performance.

(e)Notwithstanding anything herein to the contrary, an Eligible Employee shall not be considered to be a Rebadged Employee under the Plan if his or her employment ends as a result of any of the following events:
(i)a divestiture of a subsidiary, division or other identifiable segment of the Employer or Parent or a transfer of the Eligible Employee to a joint venture or other business entity in which the Employer or the Parent directly or indirectly will own some outstanding voting or other ownership interest;
(ii)the Employer's decision to outsource work to a third-party vendor where the Eligible Employee is offered a Negotiated Job Offer and declines it because it is an Offer Outside Geographic Parameters;
(iii)the Eligible Employee's voluntary resignation for any reason including after reaching early or normal retirement age under the retirement plan applicable to the Eligible Employee;
(iv)a termination for Misconduct;
12


(v)death (unless the Eligible Employee dies after he/she has been notified of his/her scheduled Separation Date but before the Separation Date occurs and a valid Release of Claims is executed by the Eligible Employee's estate) in which case the Eligible Employee's Separation Date shall be deemed to have occurred on the day before his/her date of death;
(vi)the Eligible Employee terminating employment with the Employer prior to the date identified by the Employer as the Separation Date unless the Employer expressly agreed to waive this provision;
(vii)failure by the Eligible Employee to return to work at the Employer (or the Parent or any of its subsidiaries) for any reason, including, but not limited to the Eligible Employee’s failure to secure a position at the Employer (or the Parent or any of its subsidiaries) upon a return from a leave of absence for any reason; or
Intentionally Omitted
(viii)Termination Due to Non-Performance.


3.2Termination of Eligibility for Benefits. A Participant shall cease to participate in the Plan, and all Separation Plan Benefits shall cease upon the occurrence of the earliest of:

(a)Termination of the Plan prior to, or more than two years following, a Change in Control;
(b)Inability of the Employer to pay Separation Plan Benefits when due;
(c)Completion of payment to the Participant of the Separation Plan Benefits for which the Participant is eligible; and
(d)The Claims Reviewer's determination, in its sole discretion, of the occurrence of the Eligible Employee’s Misconduct, regardless of whether such determination occurs before or after the Eligible Employee’s Separation Date, unless the Claims Reviewer determines in its sole discretion that Misconduct shall not cause the cessation of Separation Plan Benefits in a particular case.
13


SECTION 4
BENEFITS

4.1Separation Pay. Separation Pay shall be payable under this Plan to a Participant who is not a Rebadged Employee as set forth on Schedule B-1. The terms of Schedule B-1 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. For Separation Pay payable under this Plan to a Rebadged Employee, see Section 4.5 of this Plan.

4.2


(a)A Participant who is covered under any of the Employer's group employee medical and dental plans as of his or her Separation Date will be provided the opportunity to continue such employee coverage during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2 of this SPD. as such coverage may be amended from time to time, in accordance with the terms and conditions of such plans, provided the Participant timely pays the required contribution to continue coverage. The required contribution is calculated at active employee rates, as the same may be changed from time to time, during his or her Benefits Continuation Period.


(b)A Participant who, prior to his or her Separation Date, had elected no employee medical or dental coverage under the applicable employee medical or dental plan will not be permitted to change from no medical and/or dental coverage to coverage as a result of a Termination due to Workforce Restructuring.

(c)Employee medical and dental continuation coverage, as it may be amended from time to time, at active rates shall continue during the Benefits Continuation Period. The Benefits Continuation Period begins on the first day of the month following the Participant's Separation Date and shall end on the last day of the month in which the Benefits Continuation Period ends as determined in accordance with Schedule B-2 of this SPD, provided the Participant pays the required contributions for coverage in the time and manner required. If the Participant fails to pay the required contributions for coverage in the time and manner required, or the Participant elects to terminate active medical and/or dental coverage, coverage will end as of the last day of the month for which the contribution was paid and it will not be reinstated during the Benefits Continuation Period. If the Participant has medical and/or dental coverage on the last day of the Benefits Continuation Period, the Participant may be eligible to continue coverage in effect at the end of the Benefits Continuation Period in accordance with COBRA by timely electing and paying the full COBRA premium.

(d)If, as of his or her Separation Date, a Participant is eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then he or she (i) shall be eligible to continue employee medical and dental benefits in accordance with this Section 4.2 and, (ii) following the completion of the Benefits Continuation Period, shall be eligible for retiree medical benefits at subsidized rates under the Merck Retiree Medical Plan, as it may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan. If a Participant is not eligible to continue active medical coverage during the Benefits Continuation Period (i.e., because the Participant had no employee coverage on his/her Separation) or the Participant's employee medical coverage ends during the Benefits Continuation Period (for any
14


reason, including non-payment), the Participant cannot enroll for medical coverage as a retiree until the end of the Benefits Continuation Period. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all employee medical and/or dental benefit coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited. A Participant cannot be covered as an employee and as a retiree (even under the retiree no coverage option, if available) in a medical plan of an Employer (or Parent) during the same period; provided, however, that a Participant may be covered through COBRA at full COBRA rates for dental coverage even if during that period the Participant is also covered as a retiree for medical coverage.

(e)Rebadged Employees are not eligible for continuation of employee medical and dental benefits at active contribution rates during the Benefits Continuation Period described in this Section 4.2.

4.3Life Insurance Benefits

(a)A Participant shall be eligible to continue Basic Life Insurance coverage at no cost to the Participant during his or her Benefits Continuation Period, as determined in accordance with Schedule B-2, subject to and in accordance with the terms of the applicable life insurance plan as they may be amended from time to time. The Participant is responsible for paying applicable tax on imputed income, if any, for Basic Life Insurance coverage during his or her Benefits Continuation Period. The terms of such Schedule B-2 are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan.

(b)Basic Life Insurance coverage shall end on the last day of the month in which the Benefits Continuation Period ends. If the Participant elects to end the Benefits Continuation Period earlier than the period set forth on Schedule B-2 as permitted in Section 2.4, all Basic Life Insurance coverage that the Participant would otherwise have been eligible to receive during the maximum Benefits Continuation Period will be permanently and irrevocably forfeited.

(c)Rebadged Employees are not eligible for the life insurance benefits described in this Section 4.3.

4.4Outplacement Benefits. Benefits for outplacement counseling or other outplacement services, as set forth in Schedule C, will be made available to a Participant. The terms of such Schedule C are hereby fully incorporated into and shall be considered as part of Section 4 of this Plan. Outplacement benefits shall be provided in kind; cash shall not be paid in lieu of outplacement benefits nor will Separation Pay be increased if a Participant declines or does not use the outplacement benefits. Rebadged Employees are not eligible for outplacement benefits described in this Section 4.4.

4.5.    Separation Pay for Rebadged Employees. A Rebadged Employee who is a Participant shall be eligible for Separation Pay under this Plan in an amount equal to 50% of the Separation Pay that would be payable had he or she experienced a Termination due to Workforce Restructuring.

For the avoidance of doubt, a Rebadged Employee shall not be eligible for any Separation Plan Benefits other than the Separation Pay described in this Section 4.5.
15


4.6Reduction of Benefits. Notwithstanding anything in this Plan to the contrary, a Participant's Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits, if applicable, shall be reduced by:

(a)any amount the Plan Administrator reasonably concludes the Participant owes the Employer (or the Parent or any subsidiary or affiliate of the Parent) including, without limitation, unpaid bills under the corporate credit card program, and for vacation used, but not earned;
(b)any severance or severance type benefits that the Employer (or the Parent or any subsidiary or affiliate of the Parent) must pay to a Participant under applicable law;
(c)where permitted by law, any payments received by the Participant pursuant to state workers compensation laws;
(d)short-term disability benefits where state law does not permit Separation Pay to be offset from short-term disability benefits (or where the Employer in its sole and absolute discretion determines it is administratively easier for the Employer to reduce Separation Pay by short-term disability benefits in lieu of reducing short-term disability benefits by Separation Pay);
(e)For Participants whose employment ends on or after January 1, 2017 who experienced one or more one-way transfers from a non-U.S. subsidiary to another non-U.S. subsidiary and/or to a U.S. subsidiary, any severance or severance type benefits paid by the Parent or any subsidiary or affiliate of the Parent to the Participant as a result of such transfer(s), provided such amount is determined using the exchange rate on the date(s) of the one-way transfer(s) or the Separation Date, whichever provides the lowest amount.

Notwithstanding anything in the Plan to the contrary, a Participant’s Separation Pay (including Separation Pay described in Section 4.5) and Separation Benefits are not meant to duplicate pay and benefits provided by the Employer (or the Parent or any of its subsidiaries) in connection with any Participant's Termination due to Workforce Restructuring or in connection with a Participant's termination due to the outsourcing of work to a third-party vendor, including pay and benefits under the federal Worker Adjustment Retraining and Notification Act and any state or local equivalent (collectively, the "WARN Act"). If the Plan Administrator determines that a Participant is entitled to WARN Act damages or WARN Act notice, the Plan Administrator in its sole and absolute discretion may reduce the Participant's Separation Pay and Separation Benefits under the Plan by the WARN Act damages or pay and benefits after receiving WARN Act notice, but not below $500, with the remaining Separation Pay and Separation Benefits provided to the Participant in accordance with the terms of the Plan in satisfaction of the Participant's WARN Act notice rights or damages. In all other cases, Separation Pay paid under the Plan in excess of $500 will be treated as having been paid to satisfy any WARN Act damages, if applicable.
16


SECTION 5
FORM AND TIMING OF BENEFITS; FORFEITURE AND REPAYMENT OF BENEFITS


5.1Form and Time of Payment

(a)Except as otherwise provided in subsection (b), Separation Pay, less taxes and applicable deductions shall be paid in a lump sum as soon as practicable after the Participant's Termination due to Workforce Restructuring (or in the case of a Rebadged Employee, after termination of employment due to the outsourcing transaction) and the expiration of any period during which the Participant may consider, sign and, if a revocation period is applicable, revoke the Release of Claims, but in no event later than March 15 of the calendar year following the year of a Participant's Separation Date.

(b)If it is determined by the Employer or Parent in its discretion, that (i) the Participant is, as of his or her Separation Date, a "specified employee" (as such term is defined in Section 409A(2)(B) of the Code); and (ii) the Separation Pay payable pursuant to the terms of the Plan constitutes nonqualified deferred compensation that would subject the Participant to “additional tax” under Section 409A(a)(1)(B) of the Code (the "409A Tax"), then the payment of Separation Pay will be postponed to the first business day of the seventh month following the Separation Date or, if earlier, the date of the Participant's death.

5.2    Taxes. Separation Pay payable under this Plan shall be subject to the withholding of appropriate federal, state and local taxes.

Notwithstanding anything in this Plan to the contrary, the Employer or Parent will take such actions as it deems necessary, in its sole and absolute discretion, to avoid the imposition of a 409A Tax at such time and in such manner as permitted under Section 409A of the Code, including, but not limited to, reducing or eliminating benefits and changing the time or form of payment of benefits.

5.3Forfeiture of Benefits. The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent’s Executive Vice President and General Counsel and the Parent’s Executive Vice President, Human Resources. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to:
(a)breach of any obligations of the Participant's terms and conditions of employment;
(b)making false or misleading statements about the Employer, the Parent or any of its subsidiaries or their products, officers or employees to competitors, customers, potential customers of the Employer, the Parent or any of its subsidiaries or to current or former employees of the Employer, the Parent or any of its subsidiaries; and
(c)breaching any terms of the Release of Claims, including any non-solicitation or non-competition provisions, if applicable.
17


5.4Cessation of Separation Pay and Separation Benefits. Separation Pay, Outplacement Benefits and Separation Benefits shall cease in the event a Participant is rehired by the Employer, the Parent or one of its subsidiaries or affiliates.

5.5Return of Separation Pay. Upon the occurrence of an event described in Section 5.3 or
5.4 of this Plan, the Participant shall repay to the Employer that portion of the lump sum amount that would not have been paid had the Separation Pay been paid in weekly installments from the Participant's Separation Date. If the Participant receives short-term disability benefits from the Employer after his or her Separation Date, the Employer reserves the right to seek repayment by the Participant of that portion of the Separation Pay that would not have been paid in accordance with Section 4.6 had the Separation Pay been paid in installments.

5.6Death of Participant.

For Participants Who Die Before January 1, 2017:

If a Participant dies before January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then

(a)any unpaid Separation Pay will be paid to the Participant's estate; and
(b)if the Participant was eligible to continue medical and/or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were covered under the Participant's medical and dental coverages (other than coverages applicable to retirees and their dependents) on that date, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or
(ii) was eligible to participate in the Merck Retiree Medical Plan at unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium and thereafter may be eligible for retiree medical benefits at unsubsidized rates under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare- eligible will not be eligible to participate in the Merck Retiree Medical Plan or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation Period for the remaining COBRA period, if any, in accordance with COBRA by paying the full COBRA premium, or (iv) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his/her date of death, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he/she had been eligible for long term disability benefits, as may be amended from time to time; and
18


(c)if the if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were not covered under the Participant's medical coverage at the time of the Participant’s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for retiree medical benefits at the subsidized or unsubsidized rates, as applicable, under the terms of the Merck Retiree Medical Plan applicable to such Participant, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan and will only be eligible for such coverage if they are eligible for subsidized coverage (dependents eligible for unsubsidized coverage are not eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan), or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized or unsubsidized rates but had at least 25 years of service as of his/her date of death, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of medical plan that would have been applicable to such Participant if he/she had been eligible for long term disability benefits, as may be amended from time to time.

Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.

The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.

For Participants Who Die On or After January 1, 2017:

If a Participant dies on or after January 1, 2017 following his or her Separation Date and a valid Release of Claims was signed by the Participant or is signed by the Participant's estate then

(a)any unpaid Separation Pay will be paid to the Participant's estate; and
(b)if the Participant was eligible to continue medical and/or dental coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were covered under the Participant's medical and dental coverages at the time of the Participant’s death, they may continue such employee coverage for the balance of the Benefits Continuation Period, provided they continue to remain eligible dependents and they pay the applicable contributions at active employee rates, as they may change from time to time, to continue coverage. Thereafter, if, as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan, or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the completion of the Benefits Continuation Period the surviving dependents may be eligible to continue coverage in effect at the end of the Benefits Continuation
19


Period in accordance with COBRA by timely electing COBRA coverage and paying the full COBRA premium; or (iii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his/her Separation Date, then following the completion of the Benefits Continuation Period, surviving eligible dependents shall be eligible for retiree medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan; and

(c)if the Participant was eligible to continue medical coverage during the Benefits Continuation Period on the Participant's date of death and the Participant’s surviving dependents were not covered under the Participant's medical coverage at the time of the Participant’s death or if the Participant was not eligible to continue medical coverage during the Benefits Continuation Period and, in either case, if as of his or her Separation Date, such Participant (i) was eligible to participate in the Merck Retiree Medical Plan at subsidized rates, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for retiree medical benefits at subsidized rates under the terms of Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan; or (ii) was not eligible to participate in the Merck Retiree Medical Plan at subsidized rates but had at least 25 years of service as of his/her Separation Date, then following the date of death, surviving eligible dependents who were not then enrolled for coverage under the Participant’s medical coverage shall be eligible to enroll for medical benefits at subsidized rates under the terms of the Merck Retiree Medical Plan, as may be amended from time to time, provided that those eligible dependents who are age 65 or older and Medicare-eligible will only be eligible to participate in the Merck HRA component of the Merck Retiree Medical Plan.

Medical and dental coverage under this Section 5.6 shall be subject to and in accordance with the terms of the applicable plans as they may be amended from time to time.

The Separation Date of an Eligible Employee who dies prior to his or her scheduled Separation Date but after he or she was notified of a scheduled Separation Date shall be deemed to have occurred on the day before his/her date of death.
20


SECTION 6

PLAN ADMINISTRATION

6.1Plan Administrator. Parent or its delegate is the Plan Administrator for purposes of ERISA.

6.2Powers and Duties of Plan Administrator. The Plan Administrator or its delegate shall have the full discretionary power and authority to: (i) construe and interpret the Plan (including, without limitation, supplying omissions from, correcting deficiencies in, or resolving inconsistencies or ambiguities in, the language of the Plan); (ii) determine all questions of fact arising under the Plan, including questions as to eligibility for and the amount of benefits; (iii) establish such rules and regulations (consistent with the terms of the Plan) as it deems necessary or appropriate for administration of the Plan; (iv) delegate responsibilities to others to assist in administering the Plan; and (v) perform all other acts it believes reasonable and proper in connection with the administration of the Plan. The Plan Administrator or its delegate shall be entitled to rely on the records of the Employer in determining any Participant's entitlement to and the amount of benefits payable under the Plan. Any determination of the Plan Administrator or its delegate, including interpretations of the Plan and determinations of questions of fact, shall be final and binding on all parties.

With respect to determining claims and appeals for benefits under this Plan, the Claims Reviewer (and its delegate) shall be deemed to be the delegate of the Plan Administrator and shall have all of the powers and duties of the Plan Administrator described above.

6.3Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent’s Executive Vice President, Human Resources (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan:

(a)grant some, all or any portion of the benefits under this Plan to an employee who would not otherwise be eligible for such benefits under Section 3 above;
(b)waive the requirement set forth in Section 3 for any individual Eligible Employee or group of Eligible Employees to execute a Release of Claims; and
(c)grant additional Separation Plan Benefits to a Participant.
21


SECTION 7

CLAIMS AND APPEALS PROCEDURES

7.1Claims.
(a)Any request or claim for benefits under the Plan must be filed by a claimant or the claimant’s authorized representative within 60 days after the date claimant’s employment with an Employer ends; provided, however, for claims under Section 5.3, claims must be filed within 60 days after the date Separation Plan Benefits are cancelled.

(b)Any request or claim for benefits under the Plan shall be deemed to be filed when a written request made by the claimant or the claimant's authorized representative addressed to the Claims Reviewer at the address below is received by the Claims Reviewer.

Claims Reviewer for the Separation Benefits Plan
c/o Secretary of the Merck & Co., Inc. Employee Benefits Committee Merck & Co., Inc.
2000 Galloping Hill Road Mailstop K-1 3029
Kenilworth, NJ 07033
The claim for benefits shall be reviewed by, and a determination shall be made by, the Claims Reviewer, within the timeframe required for notice of adverse benefit determinations described below.

(c)The Claims Reviewer shall provide written or electronic notification to the claimant or the claimant’s authorized representative of any “adverse benefit determination.” Such notice shall be provided within a reasonable time but not later than 90 days after the receipt by the Claims Reviewer of the claimant's claim, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the claim. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 90-day period indicating the special circumstances requiring an extension and the date by which the Claims Reviewer expects to render the benefit determination. No extension can exceed 90 days from the end of the initial 90-day period (i.e., 180 days from the receipt of the claim by the Claims Reviewer) without the consent of the claimant or the claimant’s authorized representative.

(d)An “adverse benefit determination” is a denial, reduction, or termination of, or a failure to provide or make payment (in whole or part) for a benefit, including one that is based on a determination of a claimant’s eligibility to participate in the Plan.

(e)The notice of adverse benefit determination shall be written in a manner calculated to be understood by the claimant and shall:
(i)set forth the specific reasons for the adverse benefit determination;

(ii)contain specific references to Plan provisions on which the determination is based;
(iii)describe any material or information necessary for the claim for benefits to be allowed and an explanation of why such information is necessary; and

(iv)describe the Plan’s appeal procedures and the time limits applicable to such procedures, including a statement of the claimant’s right to bring a civil action under section 502(a) of ERISA following an adverse benefit determination on review.

7.2Appeals of Adverse Benefit Determinations.

(a)Any request to review the Claims Reviewer’s adverse benefit determination under the Plan must be filed by a claimant or the claimant’s authorized representative in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination by the
22


Claims Reviewer. If the claimant or the claimant’s authorized representative fails to file a request for review of the Claims Reviewer’s adverse benefit determination in writing within 60 days after receipt by the claimant of written notification of adverse benefit determination, the Claims Reviewer’s determination shall become final and conclusive.

(b)Any request to review an adverse benefit determination under the Plan shall be deemed to be filed when a written request is made by the claimant or the claimant's authorized representative addressed to the Employee Benefits Committee at the address below is received by the Secretary of the Employee Benefits Committee.
Merck & Co., Inc. Employee Benefits Committee c/o Secretary Employee Benefits Committee Merck & Co., Inc.
2000 Galloping Hill Road Mailstop K-1 3029
Kenilworth, NJ 07033

(c)If the claimant or the claimant’s authorized representative timely files a request for review of the Claims Reviewer’s adverse benefit determination as specified in this Section 7.2, the Employee Benefits Committee shall re-examine all issues relevant to the original adverse benefit determination taking into account all comments, documents, records, and other information submitted by the claimant or the claimant’s authorized representative relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination. Any such claimant or his or her duly authorized representative may:

(i)upon request and free of charge have reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits; whether an item is relevant shall be determined by the Employee Benefits Committee in accordance with 29 CFR 2560.503-1 (m)(8); and
(ii)submit in writing any comments, documents, records, and other information relating to the claim for benefits.
(d)The Claims Reviewer shall provide written or electronic notice to the claimant or the claimant’s authorized representative of its benefit determination on review. Such notice shall be provided within a reasonable time but not later than 60 days after the receipt by the Claims Reviewer of the claimant's request for review, unless the Claims Reviewer determines that special circumstances require an extension of time for processing the request for review. If the Claims Reviewer determines that an extension of time for processing is required, written notice of the extension shall be furnished to the claimant before the expiration of the initial 60-day period indicating the special circumstances requiring an extension and the date by which the Claims Reviewer expects to render the benefit determination. No extension can exceed 60 days from the end of the initial 60-day period (i.e., 120 days from the date the request for review is received by the Claims Reviewer) without the consent of the claimant or the claimant’s authorized representative.

(d)If the claimant’s appeal is denied, the notice of adverse benefit determination on review shall be written in a manner calculated to be understood by the claimant and shall:
(i)     set forth the specific reasons for the adverse benefit determination on
(ii)     contain specific references to Plan provisions on which the benefit determination is based;
(iii)contain a statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to the claimant’s claim for benefits; whether an item is relevant shall be determined by the Claims Reviewer in accordance with 29 CFR 2560.503-1 (m)(8); and
(iv)include a statement of the claimant’s right to bring a civil action under section 502(a) of ERISA.
23


SECTION 8
AMENDMENT AND TERMINATION

8.1Amendment and Termination.

(a)Except as otherwise set forth in subsection (b) below, Parent or its delegate has the right to amend, suspend or terminate the Plan at any time without prior notice to or the consent of any employee; provided, however, that amendments that apply only to Section 16 Officers must also be approved by the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate. No such amendment shall give the Employer or Parent the right to recover any amount paid to a Participant prior to the date of such amendment. Any such amendment, however, may cause the cessation and discontinuance of payments of Separation Plan Benefits to any person or persons under the Plan. Parent may delegate the authority to amend, suspend or terminate the Plan to the person, entity or committee selected by the Chief Executive Officer and as set forth in the applicable written corporate grant signed by the Chief Executive Officer (the “Corporate Grant”). Such Corporate Grant shall allow for the delegation of the authority to an individual, entity or committee; provided the financial impact of such amendment, suspension or termination does not exceed certain predetermined thresholds identified in the applicable Corporate Grant. The person, entity or committee provide with the authority to amend, suspend or terminate the Plan by the Corporate Grant, may further delegate the authority to amend, suspend or terminate the Plan to an individual, entity or committee, in accordance with the appropriate corporate action. Amendments to the Plan must be in writing and approved in accordance with the Corporate Grant.

(b)Except to the extent required by applicable law, for the entirety of the Protection Period, the material terms of the Plan, including this Section 8.1, shall not be modified in any manner that is materially adverse to a Qualifying Participant.

(c)Parent or any such successor to Parent, shall pay all legal fees and related expenses (including the costs of experts, evidence and counsel) reasonably and in good faith incurred by a Qualifying Participant if the Qualifying Participant prevails on at least one material item of his or her claim for relief in an action (x) by the Qualifying Participant claiming that the provisions of this Section 8.1 have been violated (but, for the avoidance of doubt, excluding claims for plan benefits in the ordinary course) and (y) if applicable, by the Employer, Parent or its successor to enforce post-termination covenants against the Qualifying Participant.

(d)Definitions. For purposes of this Section 8.1:

(i)Protection Period” shall mean the period beginning on the date of the Change in Control and ending on the second anniversary of the date of the Change in Control; and

(ii)Qualifying Participant” shall mean an individual who is an Eligible Employee or a Participant as of the date immediately prior to the Change in Control.
24


SECTION 9
GENERAL PROVISIONS

9.1Unfunded Obligation. Separation Plan Benefits provided under this Plan shall constitute an unfunded obligation of the Employer. Payments shall be made, as due, from the general funds of the Employer. This Plan shall constitute solely an unsecured promise by the Employer to pay such benefits to Participants to the extent provided herein.

9.2Applicable Law. It is intended that the Plan be an "employee welfare benefit plan" within the meaning of Section 3(1) of ERISA, and the Plan shall be administered in a manner consistent with such intent. The Plan and all rights thereunder shall be governed and construed in accordance with ERISA and, to the extent not preempted by federal law, with the laws of the state of New Jersey, wherein venue shall lie for any dispute arising hereunder.

9.3Severability. If any provision of this Plan shall be held illegal or invalid for any reason, said illegality or invalidity shall not affect the remaining parts of this Plan, but this Plan shall be construed and enforced as if said illegal or invalid provision had never been included herein.

9.4Employment at Will. Nothing contained in this Plan shall give an employee the right to be retained in the employment of the Employer or shall otherwise modify the employee's at will employment relationship with the Employer. This Plan is not a contract of employment between the Employer and any employee.

9.5Heirs, Assigns, and Personal Representatives. The Plan shall be binding upon the heirs, executors, administrators, successors, and assigns of the parties, including each Participant, present and future.

9.6Payments to Incompetent Persons, Etc. Any benefit payable to or for the benefit of a minor, an incompetent person or other person incapable of receipting therefore shall be deemed paid when paid to such person’s guardian or to the party providing or reasonably appearing to provide for the care of such person, and such payment shall fully discharge the Employer, Parent, the Plan Administrator, the Claims Administrator and all other parties with respect thereto.

9.7Lost Payees. Benefits shall be deemed forfeited if the Plan Administrator is unable to locate a Participant to whom Separation Plan Benefits are due. Such Separation Plan Benefits shall be reinstated if application is made by the Participant for the forfeited Separation Plan Benefits within one year of the Participant’s Separation Date and while the Plan is in operation.
25


SCHEDULE A


List of participating Employers:

All U.S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries, successors and assigns:

Comsort, Inc.

Merck Global Health Innovation Fund, LLC

HMR Weight Management Services Corp.

ILUM Health Solutions, LLC (formerly known as Healthcare Services and Solutions, LLC)
26


SCHEDULE B-1

Separation Pay for Participants with a Separation Date Occurring on or after January 1, 2013

Amount of Separation Pay in weeks (Annual Base Salary divided by 52)
27


Complete Years of Continuous Service at Separation
Date
BAND LEVEL

Band 200

Band 300

Band 400

Band 500

Band 600

Band 700/800
0
10
12
18
24
26
26
1
10
12
18
24
32
40
2
10
12
18
24
32
40
3
10
12
18
24
32
40
4
10
12
18
24
32
40
5
12
14
20
26
34
42
6
14
16
22
28
36
44
7
16
18
24
30
38
46
8
18
20
26
32
40
48
9
20
22
28
34
42
50
10
22
24
30
36
44
52
11
24
26
32
38
46
54
12
26
28
34
40
48
56
13
28
30
36
42
50
58
14
30
32
38
44
52
60
15
32
34
40
46
54
62
16
34
36
42
48
56
64
17
36
38
44
50
58
66
18
38
40
46
52
60
68
19
40
42
48
54
62
70
20
42
44
50
56
64
72
21
44
46
52
58
66
74
22
46
48
54
60
68
76
23
48
50
56
62
70
78
24
50
52
58
64
72
78
25
52
54
60
66
74
78
26
54
56
62
68
76
78
27
56
58
64
70
78
78
28
58
60
66
72
78
78
29
60
62
68
74
78
78
30
62
64
70
76
78
78
31
64
66
72
78
78
78
32
66
68
74
78
78
78
33
68
70
76
78
78
78
34
70
72
78
78
78
78
35
72
74
78
78
78
78
36
74
76
78
78
78
78
37
76
78
78
78
78
78
38+
78
78
78
78
78
78
28


SCHEDULE B-2

MEDICAL / DENTAL AND LIFE INSURANCE CONTINUATION

COMPLETE YEARS OF CONTINUOUS SERVICE AT SEPARATION DATE

BENEFITS CONTINUATION PERIOD
< 5
26 weeks
5 – 9.9
39 weeks*
10 – 19.9
52 weeks*
20+
78 weeks*


*For Participants who are eligible for subsidized retiree medical benefits under the Merck Retiree Medical Plan on their Separation Date, the Benefits Continuation Period shall continue to the last day of the month in which the number of weeks set forth above occurs.
29


SCHEDULE C


OUTPLACEMENT BENEFITS



BAND LEVEL

BENEFIT

DURATION
Band 200
Quick Start Plus3 Months
Band 300
Professional--Career Assistance
3 Months
Band 400
Professional--Career Transition
6 Months
Band 600/500
Executive12 Months
Band 800/700
Executive Premium12 Months

The Outplacement Benefits are provided through a third party vendor. The vendor and/or the programs may change from time to time.
30


SCHEDULE D (Change in Control/Pension)

Description of Change-in-Control Benefits under the Pension Plan

This Schedule describes benefits under the Pension Plan and the Supplemental Plan (as each is defined below) provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.

I.If an Eligible Employee’s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan:

1.For an Eligible Employee who participates in the Retirement Plan for Salaried Employees of MSD or its successor (the “MSD Pension Plan) and on his or her Separation Date is not at least age 55 with at least ten years of Credited Service under the MSD Pension Plan but would attain at least age 50 and have at least ten years of Credited Service under the MSD Pension Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a subsidized early retirement benefit on his “Prior Plan Formula” (as defined in the MSD Pension Plan) under the MSD Pension Plan commencing in accordance with the terms of the MSD Plan.

2.For an Eligible Employee who participates in the MSD Pension Plan or the Legacy Schering Retirement Plan, or their successors (collectively the “Pension Plan”) and on his or her Separation Date is not at least age 65 but would attain at least age 65 within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for a Prior Plan Formula benefit unreduced for early commencement under the Pension Plan commencing in accordance with the terms of the Pension Plan.

3.For an Eligible Employee who participates in the MSD Pension Plan and on his or her Separation Date is not eligible for the “Rule of 85 Transition Benefit” (as such term is defined in the MSD Pension Plan) but would have been eligible for the Rule of 85 Transition Benefit within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be deemed to be eligible for the Rule of 85 Transition Benefit upon commencement of his or her pension benefit under the MSD Pension Plan.
4,    For an Eligible Employee who participates in the Pension Plan on his or her Separation Date who is not vested in his or her accrued benefit under the Pension Plan, he or she shall be vested in his accrued benefit under the Pension Plan on his or her Separation Date.

II.The benefits described in this Schedule D shall be payable from the Pension Plan and, to the extent that such benefits cannot be paid from the Pension Plan the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause such benefits to be paid under a Supplemental Retirement Plan of MSD or the Legacy Schering Benefits Excess Plan, as applicable and any successors thereto (collectively, the “Supplemental Plan”) or under new arrangements or from the Employer's general assets.
31


SCHEDULE E (Change in Control/Retiree Medical)


Description of Change-in-Control Benefits under Health Plan

This Schedule describes benefits under the Health Plan provided to an Eligible Employee under the Plan if such Eligible Employee signs and returns the Release of Claims in use under the CIC Plan and in accordance with the process established under the CIC Plan.

I.If an Eligible Employee’s employment is terminated in circumstances entitling him or her to the benefits provided in Section 3.1 (c) of the Plan:

If the Eligible Employee is eligible to participate in the Health Plan and on his or her Separation Date is not at least age 55 with the requisite amount of service with an Employer to satisfy the requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan but would attain at least age 50 and meet the service requirements to be considered a retiree eligible for subsidized retiree medical benefits under the Health Plan within two years following the date of the Change in Control (assuming continued employment during the entirety of such two-year period), then the Eligible Employee shall be eligible for subsidized retiree medical benefits under the Health Plan on the date his or her Benefits Continuation Period Ends on the same terms and conditions applicable to salaried U.S.- based employees of the Employer whose employment terminated the last day of the month prior to the Eligible Employee’s Separation Date who were treated as retirees eligible for subsidized retiree medical benefits under the Health Plan as of that date.


II.The Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law and to preserve grandfathered status of arrangements subject to Section 409A of the Code), cause the benefits set forth in this Schedule E to be provided from insured arrangements, or pursuant to new arrangements, individual arrangements or otherwise. Further, notwithstanding anything to the contrary, to the extent any benefits to which an Eligible Employee is entitled under this Schedule E would reasonably be likely to constitute a discriminatory benefit under Section 105(h) of the Code or a similar law or regulation at the time the benefit is to be provided to the Eligible Employee, as determined in the sole discretion of the Parent, the Employer may, to the extent it deems necessary or appropriate (including to comply with applicable law), modify the benefit so that the benefit would no longer constitute a discriminatory benefit under Section 105(h) of the Code or such similar law, including, but not limited to, eliminating all subsidy from the Parent or the Employer, requiring that the Eligible Employee pay for participation in the benefit program with after-tax funds or causing the full employer and employee portions of the cost of the benefit to be imputed as gross income to the Eligible Employee.

III.For purposes of this Schedule E, “Health Plan” means one or more plans sponsored by the Parent or one of its subsidiaries that provide medical benefits to Eligible Employees and to former Eligible Employees who are considered retirees thereunder and to the eligible dependents of each of the foregoing.

32


AMENDMENT 2019-1

MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(as Amended and Restated as of January 1, 2019)

WHEREAS, Merck, Sharp & Dohme Corp. (the "Company"), a subsidiary of Merck & Co., Inc. ("Merck"), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the "Plan");

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck's Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the "Executive Committee") in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the "Committee"} the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.Section 2.7 of the Plan is hereby amended in its entirety to read as follows:

"2.7    "Claims Reviewer" means the Merck & Co., Inc. Employee Benefits Committee (or its delegate); provided, however, for Section 16 Officers, Claims Reviewer means the Compensation and Benefits Committee of the Board of Directors of Parent or its delegate."
2.The first paragraph of Section 5.3 is hereby amended and restated to read as follows:
"5.3    Forfeiture of Benefits. The Employer reserves the right, in its sole and absolute discretion, to cancel all Separation Plan Benefits and seek the return of Separation Pay in the event a Participant engages in any activity that the Employer considers detrimental to its interests (or the interests of the Parent or any of its subsidiaries) as determined by the Parent's Executive Vice President and General Counsel and the Parent's Executive Vice President & Chief Human Resources Officer or by such other individual who acts as the successor or equivalent thereto of either of the aforementioned positions. Activities that the Employer considers detrimental to its interest (or the interests of the Parent or any of its subsidiaries) include, but are not limited to:"

3.The first paragraph of Section 6.3 is hereby amended to read as follows:

"6.3    Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent's Executive Vice President & Chief Human Resources Officer, or by such other individual who acts as the successor or equivalent thereto of such position, (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan:"

4.Schedule A of the Plan is hereby updated to read as follows:


"SCHEDULE A




List of Participating Employers:

All U. S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:

Comsort, Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)
HMR Weight Management Services Corp. (and its subsidiaries)
ILUM Health Solutions, LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Tilos Therapeutics (and its subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, 2020
Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in 2020 as of which the Plan Administrator determines Antelliq Corporation shall become an Employer."

IN WITNESS WHEREOF, the Committee has caused this Amendment 2019-1 to the Plan to be executed by the undersigned on this 19th day of December, 2019.





By /s/ Michael Arseneault
Michael Arseneault
Executive Director, Managing Counsel Global Compensation and Benefits












2


AMENDMENT 2020-1

MERCK & CO., INC. U.S. SEPARATION BENEFITS PLAN
(as Amended and Restated as of January 1, 2019)

WHEREAS, Merck, Sharp & Dohme Corp. (the "Company"), a subsidiary of Merck & Co., Inc. ("Merck"), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (as Amended and Restated as of January 1, 2019) (the "Plan");

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck's Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the "Executive Committee") in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the "Committee") the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.    The first paragraph of Section 6.3 is hereby amended to read as follows:

"6.3    Additional Discretionary Authority. The Plan Administrator may, upon written approval of the Parent's Executive Vice President & Chief Human Resources Officer (or his or her delegate), or by such other individual who acts as the successor or equivalent thereto of such position (or his or her delegate), (written approval of the Compensation and Benefits Committee of the Board of Directors of the Parent or its delegate with respect to Section 16 Officers), take the following actions under the Plan:"
IN WITNESS WHEREOF, the Committee has caused this Amendment 2020-1 to the Plan to be executed by the undersigned on this 25th day of February. 2020.



By /s/ Michael Arseneault
Michael Arseneault
Executive Director, Managing Counsel Global Compensation and Benefits









U.S. SEPARATION BENEFITS PLAN CHANGE
RESOLVED, that effective as of January 1, 2020, Amendment 2020-1 to the Merck & Co., Inc. U.S. Separation Benefits Plan as Amended and Restated as of January 1, 2019 (the “Plan”) be and hereby is adopted, in substantially the same form as attached hereto as Appendix A;

    FURTHER RESOLVED, that Michael Arseneault, Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel is provided with the authority to make such changes as necessary and proper to the terms of the Plan the intent of the Resolutions and to ensure that such documents comply with the Resolutions described herein and to prepare such other documents as are necessary to implement the Resolutions described herein, applicable law and the administration of applicable plans.




AMENDMENT 2020-2

MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)

WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.A new definition of Legacy Quantified Ag, Antelliq Corporation, or ArQule, Inc. Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:

Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee” means an Eligible Employee who was formerly an employee of Quantified Ag, Antelliq Corporation, or ArQule, Inc. respectively who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2019 or 2020 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”

2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the



Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (e) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”

3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service".

4.Section 2.24 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:

“2.24 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system,
(c)for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system,
(d)for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the
2


most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”

5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows:
“3.1(a) Eligibility.

(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013 and
(2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annul Base Salary. A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”

6.Schedule A of the Plan is hereby updated to read as follows:

“SCHEDULE A

List of participating Employers:
3


All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:

Comsort, Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)
HMR Weight Management Services Corp. (and its subsidiaries)
ILUM Health Solutions, LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 through October 1, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through July 1, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.”

IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2020-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”); to be executed as of the 10th day of December, 2020.




By /s/ Michael Arseneault

Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel
4


AMENDMENT 2021-1 TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.A new definition of Legacy Pandion Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:

Legacy Pandion Employee” means an Eligible Employee who was formerly an employee of Pandion Therapeutics, Inc. who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2021 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”

2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter



from each anniversary to the next, and (f) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”

3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."

4.Section 2.27 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:

“2.27 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system,
(c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system,
(d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected
2


on the Employer’s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”

5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a)An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, and (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees. A Grandfathered Legacy Schering Employee will be eligible for
3


Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”

6.IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2021-1 of the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”); to be executed as of the 31st day of March, 2021.




By /s/ Michael Arseneault

Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel
4


AMENDMENT 2021-2 TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)
WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.A new definition of Legacy Pandion Employee is hereby added to the Plan’s Article II in the correct alphabetical order to read as follows:

Legacy IdentiGEN Employee” means an Eligible Employee who was formerly an employee of IdentiGEN who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2020 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”

2.Section 2.9 “Complete Years of Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

“2.9 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc., Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (e) for a Legacy Pandion Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter



from each anniversary to the next, (f) for a Legacy IdentiGEN Employee a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, and (g) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”

3.Section 2.10 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

2.10 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Pandion Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (e) for a Legacy IdentiGEN Employee the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (f) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."

4.Section 2.27 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:

“2.27 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c)or a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Pandion Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (e) for a Legacy IdentiGEN Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system and (f) for a Non-Legacy Company Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998,remained continuously employed by Merial through the
2


date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”

5.Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows: “3.1(a) Eligibility.
(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”

6.Schedule A of the Plan is hereby updated to read as follows:

SCHEDULE A

List of participating Employers:
3



All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:

Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an employer under the Plan
Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan”
4


IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2021-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019)(the “Plan”); to be executed as of the 16th day of December, 2021.






By /s/ Michael Arseneault

Michael Arseneault
Exec. Dir., Managing Counsel Global Compensation & Employee Benefits/Merck Office of General Counsel
5


AMENDMENT NUMBER 2022-1 TO

MERCK & CO. INC. U.S. SEPARATION BENEFITS PLAN

As Amended and Restated effective January 1, 2013



The Merck & Co., Inc. U.S. Separation Benefits Plan (the Plan) is hereby amended effective as of May 1, 2022, as follows:

1.The Preamble of the Plan is hereby amended to insert the following new paragraph after the 3rd paragraph to read as follows:

On May 1, 2022, Merck Sharp & Dohme Corp. converted to a limited liability company named Merck Sharp & Dohme LLC.

2.Section 2.16 of the Plan is amended in its entirety to read as follows:

“’IAM Agreement” means a collective bargaining agreement between Merck Sharp & Dohme LLC or Merck Sharp & Dohme Corp., and District 15, Lodge 315 of the International Association of Machinists and Aerospace Workers.”

3.Section 2.26 of the Plan is amended to add LLCafter the words Merck Sharp & Dohme

4.Section 2. 33 of the Plan is amended in its entirety to read as follows:

“Old Merck” means Merck & Co., Inc. prior to November 4, 2009 (subsequently known on and after November 4, 2009 and prior to May 1, 2022 as Merck Sharp & Dohme Corp., and on and after May 1, 2022 as Merck Sharp & Dohme LLC).”

5.Section 3.1 Paragraph #4 of the Plan is amended in its entirety to read as follows:

“#4. notwithstanding the foregoing sub-clause (A), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme LLC, Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under Schedule B-1 of the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees; and”

6.Schedule A of the Plan is amended in its entirety to read as follows:

“All U. S. direct and indirect wholly owned subsidiaries of Merck & Co., Inc. excluding the following and their subsidiaries:

Comsort Inc. (and its subsidiaries)
Merck Global Health Innovation Fund LLC (and its subsidiaries)



Antimicrobrial Stewardship LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
Tilos Therapeutics (and its subsidiaries) for the period of time after the date Tilos Therapeutics became a subsidiary of the Company and before January 1, 2020
Antelliq Corporation (and its subsidiaries) for the period of time after the date Antelliq Corporation became a subsidiary of the Company and before such date in 2020 as of which the Plan Administrator determines Antelliq Corporation shall become an Employer.”


IN WITNESS WHEREOF, the Director, Global Compensation & Employee Benefits, Merck Office of General Counsel on behalf of the Merck & Co, Inc. Oversight Committee has caused this Amendment 2022- 1 of the Plan to be executed as of this 14th day of December, 2022.

By /s/ Michael Arseneault

Michael Arseneault
Dir., Global Compensation & Employee Benefits Merck Office of General Counsel



AMENDMENT 2022-2
TO THE
MERCK & CO., INC., U.S. SEPARATION BENEFITS PLAN
(Amended and Restated as of January 1, 2019)

WHEREAS, Merck & Co, Inc. (the “Company”), a subsidiary of Merck & Co., Inc. (“Merck”), sponsors the Merck & Co., Inc., U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019) (the “Plan”);

WHEREAS, pursuant to Article 8.1 of the Plan, the Company (or its duly authorized representative) has reserved the right to amend or terminate the Plan at any time;

WHEREAS, pursuant to the grant of authority of Merck’s Chief Executive Officer, the Company has delegated the authority to amend the Plan to the Merck & Co., Inc. Executive Oversight Committee (the “Executive Committee”) in accordance with its charter;

WHEREAS, in accordance with its charter the Executive Committee has delegated to the Merck & Co., Inc. Oversight Committee (the “Committee”) the authority to make certain amendments to the Plan in accordance with the charter of the Committee; and

WHEREAS, the Committee desires to ratify and adopt the amendment to the Plan described herein.

NOW, THEREFORE, an amendment to the Plan be and hereby is ratified and adopted and is incorporated as follows:

1.A new definition of Acceleron Pharma Inc. Employee and Vence employee is hereby
added to the Plan’s Article II in the correct alphabetical order to read as follows:

Acceleron Pharma Inc. Employee” means an Eligible Employee who was formerly an employee of Acceleron Pharma Inc. who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2021 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”

Vence Employee” means an Eligible Employee who was formerly an employee of Vence who became an employee of Merck & Co, Inc. or one of its subsidiaries in 2022 and continues to be employed by such entity until his/her Separation Date, and as of his/her Separation Date is employed by an Employer.”

2.Section 2.10 “Complete Years of Continuous Service” of the Plan is hereby amended
In its entirety to read as follows:

“2.10 “Complete Years of Continuous Service” means (a) for a Legacy Schering Employee, a year from the Participant’s Most Recent Hire Date with a Legacy Schering Entity to its anniversary, and thereafter from each anniversary to the next, (b) for a Legacy Merck Employee, a year from the Participant's Most Recent Hire Date with a Legacy Merck Entity to its anniversary, and thereafter from each anniversary to the next, (c) for a Legacy Inspire Employee, a year from the Participant’s Most Recent Hire Date with a Merck Entity to its anniversary, and thereafter from each anniversary to the next, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion Employee, IdentiGEN, Acceleron Pharma Inc. or Vence from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next and (e) for a Non-Legacy Company Employee, from the Participant’s Most Recent Hire Date with a Merck Entity, and thereafter from each anniversary to the next.”

1


3.    Section 2.11 “Continuous Service” of the Plan is hereby amended in its entirety to read as follows:

2.11 “Continuous Service” means (a) for a Legacy Schering Employee, the period of a Participant's continuous employment with a Legacy Schering Entity commencing on the Participant's Most Recent Hire Date with a Legacy Schering Entity and ending on the Separation Date as reflected on the Employer’s employee database, (b) for a Legacy Merck Employee, the period of a Participant's continuous employment with a Legacy Merck Entity commencing on the Participant's Most Recent Hire Date with a Legacy Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (c) for a Legacy Inspire Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, (d) for a Legacy Quantified Ag, Antelliq Corporation, ArQule, Inc., Pandion, IdentiGEN, Acceleron Pharma or Vence Employee, the period of a Participant's continuous employment with a Legacy and Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database, and (e) for a Non-Legacy Company Employee, the period of a Participant's continuous employment with a Merck Entity commencing on the Participant's Most Recent Hire Date with a Merck Entity and ending on the Separation Date as reflected on the Employer’s employee database. For the avoidance of doubt, service prior to November 4, 2009 by a Legacy Schering Employee with a Legacy Merck Entity or a Legacy Merck Employee with a Legacy Schering Entity is excluded from “Continuous Service.” Notwithstanding anything contained in this Plan to the contrary, employment with a Legacy Schering Entity, Legacy Merck Entity or a Merck Entity as an Excluded Person does not count as "Continuous Service."

4.    Section 2.29 “Most Recent Hire Date” of the Plan is hereby amended in its entirety to read as follows:

“2.29 Most Recent Hire Date” means (a) for a Legacy Schering Employee, his or her most recent hire date at a Legacy Schering Entity or an entity acquired by a Legacy Schering Entity as reflected on the Employer’s employee data system, (b) for a Legacy Merck Employee, his or her most recent hire date at a Legacy Merck Entity or an entity acquired by a Legacy Merck Entity as reflected on the Employer’s employee data system, (c) for a Legacy Inspire Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, (d) for a Legacy Pandion, IdentiGEN, Acceleron Pharma, Inc. or Vence Employee his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system, and (e) for a Non-Legacy Company Employee, his or her most recent hire date at a Merck Entity or an entity acquired by a Merck Entity as reflected on the Employer’s employee data system. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 1997, transferred from that entity to Merial as of January 1, 1998, remained continuously employed by Merial through the date he or she transferred employment from Merial to a Legacy Merck Entity and whose transfer to a Legacy Merck Entity occurred between October 1, 2000 and June 1, 2001, is his or her most recent hire date on the Employer's employee data system at a Legacy Merck Entity prior to his or her transfer to Merial. Notwithstanding the foregoing, the most recent hire date for a Legacy Merck Employee who was employed by a Legacy Merck Entity on December 31, 2007, transferred from that entity to PRWT as of January 1, 2008, remained continuously employed by PRWT through September 3, 2010 and who was rehired by a Legacy Merck Entity as of September 3, 2010, is his or her most recent hire date on the Employer’s employee data system at a Legacy Merck Entity prior to his or her transfer to PRWT.”

2


Section 3.1(a) Eligibility of the Plan is hereby amended in its entirety to read as follows:
“3.1(a) Eligibility.

(a) An Eligible Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) when he/she experiences a Termination due to Workforce Restructuring; provided, however, that (1) a Legacy Inspire Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring on or after May 17, 2013, (2) a Legacy Quantified Ag, Antelliq Corporation or ArQule, Inc. Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2020 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in no case shall an eligible Legacy ArQule, Inc. Employee receive benefits under the Plan equal to less than six months of Annual Base Salary, (3) a Legacy Pandion, IdentiGEN, Acceleron or Vence Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan and provided further that in the case of a Termination due to Workforce Restructuring that occurs on or before April 1, 2022 (i) an eligible Legacy Pandion Employee shall receive benefits under the Plan equal to no less than 26 weeks of Annual Base Salary and (ii) notwithstanding the foregoing clause (iii), the two individuals specified in Section 7.1(a) of the Company Disclosure Letter to the Agreement and Plan of Merger, dated as of February 24, 2021 among Merck Sharp & Dohme Corp., Panama Merger Sub, Inc. and Pandion Therapeutics, Inc. shall receive benefits under the Plan equal to no less than 39 weeks of Annual Base Salary if and only if such individuals otherwise qualify as eligible Legacy Pandion Employees, and (4) a Legacy IdentiGEN Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) only if he/she experiences a Termination due to Workforce Restructuring after the date in 2021 as of which he/she first became entitled to benefits under the Plan and which is set forth on Schedule A to the Plan A Grandfathered Legacy Schering Employee will be eligible for Separation Plan Benefits described in Section 4 (excluding Section 4.5) if he or she experiences a Grandfathered Legacy Schering Termination. Separation Plan Benefits shall be provided under this Plan to an Eligible Employee who experiences a Termination due to Workforce Restructuring or to a Grandfathered Legacy Schering Employee who experiences a Grandfathered Legacy Schering Termination, in each case only if the Eligible Employee or Grandfathered Legacy Schering Employee has executed and, if a revocation period is applicable, not revoked a Release of Claims in a form satisfactory to the Employer or Parent in its sole and nonreviewable discretion. An Eligible Employee or a Grandfathered Legacy Schering Employee who has executed and, if a revocation period is applicable, not revoked a Release of Claims is a Participant.”

3.Schedule A of the Plan is hereby updated to read as follows:
“SCHEDULE A
List of participating Employers:
All U. S. direct and indirect wholly owned subsidiaries of Merck & Co. Inc. excluding the following and their subsidiaries:
Antimicrobial Stewardship, LLC
Merck Global Health Innovation Fund LLC (and its subsidiaries)
Peloton Therapeutics, Inc. (and its subsidiaries) for the period of time after the date Peloton Therapeutics, Inc. became a subsidiary of the Company and before January 1, 2020
3


Effective for the period between June 17, 2020 through September 30, 2020, Quantified Ag. Effective as of October 1, 2020, Quantified Ag became an employer under the Plan.
Effective for the period between April 1, 2019, through June 30, 2020 Antelliq Corporation. Effective as of July 1, 2020, Antelliq Corporation became an employer under the Plan.
Effective for the period between January 1, 2020, through January 31, 2020 ArQule, Inc. Effective as of February 1, 2020, ArQule, Inc. became an employer under the Plan.
Effective February 25, 2021, Pandion, Inc. became an employer under the Plan
Effective for the period between August 5, 2020, through December 31, 2021 IdentiGEN Effective as of January 1, 2022, IdentiGEN, Inc. became an employer under the Plan
Effective as of November 19, 2022, Acceleron Pharma Inc. became an employer under the Plan
Effective January 1, 2023, Vence shall become and employer under the Plan”

IN WITNESS WHEREOF, the Merck & Co, Inc. Oversight Committee has caused this Amendment 2022-2 of the Merck & Co., Inc. U.S. Separation Benefits Plan (Amended and Restated as of January 1, 2019)(the “Plan”); to be executed as of the 13th day of December, 2021
By/s/ Michael Arseneault
Michael Arseneault
Counsel, Global Compensation & Employee Benefits/Merck Office of General Counsel


4
EX-10.23 5 exhibit1023-2019annualceon.htm EXHIBIT-10.23 2019 ANNUAL CEO NQSO TERMS AND CONDITIONS Document

Exhibit 10.23

TERMS FOR
2019 STOCK OPTION CEO GRANT
UNDER THE
MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN

This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.

Grant Type:CEO GrantExercisable DatePortion Becoming Exercisable
Option Price:$77.62May 3, 2020First: 33.333%
Grant Date:May 3, 2019May 3, 2021Second: 33.333%
Expiration Date:November 30, 2027May 3, 2022Balance

I.GENERAL INFORMATION
IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing- equity/managing-your-existing-awards/accepting-awards- grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.


This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment, Forfeiture and Clawback: This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.VESTING; EXERCISE; EMPLOYMENT TERMINATION

A.Vesting: This option will vest in its entirety if your employment continues through December 31, 2019, or immediately if you die before then.
B.Exercisability. This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above.
C.Termination. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the fifth anniversary of the date your employment terminates due to your retirement (the “Termination Date”) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.
D.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

E.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the





portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).

F.Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

G.Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.

III. TRANSFERABILITY
This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.
IV.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
V.ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.
VI.GRANTS NOT PART OF EMPLOYMENT CONTRACT
Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.
This stock option is subject to the provisions of the 2010 Incentive Stock Plan, including but not limited to choice of law. For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via http://one.merck.com.







APPENDIX A
RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS

POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.





Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.








APPENDIX B
RESTRICTIVE COVENANTS

You agree that to the extent permitted by law, during your employment with the Company and/or one of its affiliates and until this Award is fully exercisable (the “Restricted Period”) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .  Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.



EX-10.24 6 exhibit1024-2019annualrsut.htm EXHIBIT-10.24 2019 ANNUAL RSU TERMS AND CONDITIONS Document

Exhibit 10.24
TERMS FOR
2019 RESTRICTED STOCK UNIT GRANTS
UNDER THE MERCK & CO., INC. 2010 INCENTIVE STOCK PLAN



This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document. Different terms may apply to any prior or future RSU Awards.


Grant Type:RSU
Grant Date:May 3, 2019
Vesting DatePortion that Vests
May 3, 2020First: 33.333%
May 3, 2021Second: 33.333%
May 3, 2022Balance

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2010 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RS Award.

A.Restricted Period. The Restricted Period is the period during which this RSU Award is restricted and subject to forfeiture. The Restricted Period ends with respect to one-third of this RSU Award on each of the First, Second and Third anniversaries of the Grant Date as shown in the box above, unless ended earlier under Article II below. No voting rights apply to this RSU Award. No fractional shares will be awarded: all calculations are subject to rounding.

B.Dividend Equivalents. During the Restricted Period, dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the time of distribution. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

C.Distribution. Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or
any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.

E.Subject to Recoupment. For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.TERMINATION OF EMPLOYMENT

If your employment with the Company is terminated during the Restricted Period, your right to this RSU Award will be determined according to the terms in this Section II.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

C.Involuntary Termination. If the company determines that your employment is involuntarily terminated during the Restricted Period but on or after the First Anniversary , a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. An “involuntary termination” includes termination of your employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

D.Retirement. If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested)



times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Death. If your employment terminates due to your death during the Restricted Period, all of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. If you die during the Restricted Period but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.

F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this RSU Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award.

H.Change in Control. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered “deferred compensation” under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.

I.Joint Venture. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.

III.TRANSFERABILITY

This RSU Award is not transferable and may not be assigned or otherwise transferred.

IV. ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or
electronic system established and maintained by the Company or a third party designated by the Company.

V.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.

VI. GRANTS NOT PART OF EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This RSU Award is subject to the provisions of the 2010 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via http://one.merck.com






Appendix A
Recoupment of Compensation for Compliance Violations

POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an


individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.



image_1a.jpg

EX-10.25 7 exhibit1025-2020annualnqso.htm EXHIBIT-10.25 2020 ANNUAL NQSO TERMS AND CONDITIONS Document

Exhibit 10.25
TERMS FOR
2020 NON-QUALIFIED STOCK OPTION (NQSO) GRANTS
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN


This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.

Grant Type:NQSO – Annual
Option Price:
$77.67
Grant Date:
May 1, 2020
Expiration Date:
April 31, 2030
Vesting DatesPortion that Vests
May 1, 2021First: 33.333%
May 1, 2022Second: 33.333%
May 1, 2023Third: Balance

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at:

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in Forfeiture of the stock option.

This stock option becomes exercisable in equal installments (subject to a rounding process) on the Vesting Dates indicated in the accompanying box. This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment: For employees in Band 600 and above, this Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).


II.TERMINATION OF EMPLOYMENT

A.General Rule. If your employment is terminated for any reason other than those specified in the following paragraphs, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the same day of the third month (“Within Three Months”) after the date of the termination (but in no event after the expiration of the Option Period). Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open. Where there is no corresponding day of a month, the last day of the month is deemed to be the same day as a later date (e.g., November 28, 29 and 30 all correspond to February 28 in non-leap years). If you are rehired by the Company or JV, this option nevertheless will expire unless exercised Within Three Months, or the original Expiration Date if earlier.
B.Retirement. If you retire from service with the Company the portion of this stock option that would have become exercisable according to its original schedule within one year of the date your employment terminates will vest and become exercisable on its applicable Vesting Date and the remainder will expire immediately. Whether already vested on the date your employment terminates or vested as a result of such retirement, this option will expire on the earlier of (a) the day before the fifth anniversary of the termination date or (b) its original Expiration Date. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.




C.Involuntary Termination. If your employment is terminated by the Company and the Company determines that such termination was involuntary, including the result of a restructuring or job elimination, but excluding non-performance of your duties and the reasons listed under paragraphs B or D through H, the portion of this stock option that is unvested will expire on the date your employment ends; the portion of this stock option that is vested will expire on the day before the one year anniversary of the date your employment ends, but in no event later than the original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

D.Sale. If your employment is terminated and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of this stock option award will vest and become exercisable immediately upon such termination: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. Whether already vested on the date your employment terminates or vested as a result of such sale, this stock option will expire the day before the first anniversary of the date your employment with the Company ends, but in no event later than the original Expiration Date. Notwithstanding the foregoing, the Committee may determine, for purposes of this stock option grant, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this option, and/or in the option price of such option. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

F.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. This stock option will expire on such earlier date than otherwise specified in this paragraph as may be required under applicable non-U.S. law (e.g., in France, six months from the date of death). If you die while any portion of this stock option remains outstanding, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph B, C, D, G or H as applicable (and at least a year from your death in those jurisdictions where such extension is required by law).

G.Disability. If your employment is terminated and the Company determines that such termination resulted from your inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this stock option will continue to become exercisable on applicable Vesting Dates and will expire on the earlier of (a) the day before the fifth anniversary of the day your employment terminates and (b) its original Expiration Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this option nevertheless will expire according to this paragraph notwithstanding such rehire.

H.Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination by reasons of retirement, involuntary termination, sale, misconduct, death or disability, as described in paragraphs B through G above or termination prior to a change in control. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

I.Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through H above apply to this stock option while the option holder is employed by the JV.

III.TRANSFERABILITY

This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.




IV.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

V.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.

VI.GRANTS NOT PART OF EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This stock option is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding Merck’s LTI program and your stock options, visit the Long-Term Incentives page on Sync > HR portal.





Appendix A
Recoupment of Compensation for Compliance Violations


POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.
2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.
3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.
4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.
2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.
3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.

EX-10.26 8 exhibit1026-2020annualceon.htm EXHIBIT-10.26 2020 ANNUAL CEO NQSO TERMS AND CONDITIONS Document

Exhibit 10.26
TERMS FOR
2020 STOCK OPTION CEO GRANT
UNDER THE
MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN

This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.

Grant Type:CEO GrantExercisable DatePortion Becoming Exercisable
Option Price:$75.36May 1, 2021First: 33.333%
Grant Date:May 1, 2020May 1, 2022Second: 33.333%
Expiration Date:November 30, 2027May 1, 2023Balance

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing- equity/managing-your-existing-awards/accepting-awards- grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.


This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment, Forfeiture and Clawback: This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.VESTING; EXERCISE; EMPLOYMENT TERMINATION

A.Vesting: This option will vest in its entirety if your employment continues through December 31, 2020, or immediately if you die before then.
B.Exercisability. This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above.
C.Termination. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the fifth anniversary of the date your employment terminates due to your retirement (the “Termination Date”) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.
D.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

E.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the



portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).

F.Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

G.Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.

III.TRANSFERABILITY
This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.
IV.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
V.ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.
VI.GRANTS NOT PART OF EMPLOYMENT CONTRACT
Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.
This stock option is subject to the provisions of the 2019 Incentive Stock Plan, including but not limited to choice of law. For further information regarding Merck’s LTI program and your stock options, visit the Long-Term Incentives page on Sync > HR portal.





APPENDIX A
RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS

POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.



Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.






APPENDIX B
RESTRICTIVE COVENANTS

You agree that to the extent permitted by law, during your employment with the Company and/or one of its affiliates and until this Award is fully exercisable (the “Restricted Period”) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .  Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.



EX-10.27 9 exhibit1027-2020annualrsut.htm EXHIBIT-10.27 2020 ANNUAL RSU TERMS AND CONDITIONS Document

Exhibit 10.27
TERMS FOR
2020 RESTRICTED STOCK UNIT GRANTS
UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN


This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document.
Different terms may apply to any prior or future RSU Awards.

Grant Type:RSU - Annual
Grant Date:May 1, 2020
Vesting DatesPortion that Vests
May 1, 2021First: 33.333%
May 1, 2022Second: 33.333%
May 1, 2023Third: Balance

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.

A.Restricted Period. The Restricted is the period during which this RSU Award is restricted and subject to forfeiture. The Restricted Period ends with respect to one-third of this RSU Award on each of the First, Second, and Third anniversaries of the Grant Date as shown in the box above, unless ended earlier under Article II below. No voting rights apply to this RSU Award. No fractional shares will be awarded: all calculations are subject to rounding.

B.Dividend Equivalents. During the Restricted Period, dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the time of distribution. If any portion of this RSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

C.Distribution. Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.

E.Subject to Recoupment. For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).


II.TERMINATION OF EMPLOYMENT

If your employment with the Company is terminated during the Restricted Period, your right to the RSU Award will be determined according to the terms in this Section II.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.




C.Involuntary Termination. If the company determines that your employment is involuntarily terminated during the Restricted Period but on or after the First Anniversary, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. An “involuntary termination” includes termination of your employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

D.Retirement. If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of RSUs that have vested pursuant to Paragraph A. The remainder and any accrued dividends will be forfeited on the date your employment ends. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Death. If your employment terminates due to your death during the Restricted Period, all of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.

F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this RSU Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award.

H.Change in Control. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered “deferred compensation” under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.

I.Joint Venture. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.


III.TRANSFERABILITY

This RSU Award is not transferable and may not be assigned or otherwise transferred.

IV.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

V.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.







VI.GRANTS NOT PART OF THE EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via http://one.merck.com




Appendix
Recoupment of Compensation for Compliance Violations


POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.


Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.


Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.

EX-10.28 10 exhibit1028-2020psutermsan.htm EXHIBIT-10.28 2020 ANNUAL PSU TERMS AND CONDITIONS Document

Exhibit 10.28

2020 PERFORMANCE SHARE
UNIT AWARD TERMS
UNDER THE
MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN


I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be-named, independent, publicly traded company (“NewCo”) during the first half of 2021 (“Spin-Date”). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the “Company.”



Grant Type:PSU - Annual
Grant Date:March 31, 2020
Award Period:
Jan. 1, 2020 –
Dec. 31, 2022










IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.

II.DEFINITIONS. For the purpose of these Award Terms:

Award Period” means the three-year period commencing on January 1, 2020 and ending on December 31, 2022.

Code” means the Internal Revenue Code of 1986 or any successor thereto.

Earnings Per Share or EPS” means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.

The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates; (2) the impact of significant unplanned acquisitions and/or divestitures, extraordinary items and other unusual or non-recurring charges and/or events; (3) an event either not directly related to Company operations or not reasonably within the control of Company management; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.

EPS Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s EPS goal as determined under paragraph C of Section III.

Final Award” means the percentage of the Target described in Section III hereof.

Grant Date” means the date as of which a Performance Share Unit is granted.

Peer Healthcare Companies" are the healthcare companies used by the Committee in evaluating the Company’s TSR Performance for the entire Award Period. For 2020 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.



AbbVie
Eli Lilly
Novartis
AmgenGlaxoSmithKlinePfizer
Astra Zeneca
Bristol-Myers Squibb
Roche
Johnson & Johnson
Sanofi-Aventis
The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.

Performance Share” means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.

Performance Unit Grantee” or “Grantee” means an eligible employee who receives a Performance Share Unit.

Performance Share Unit” or “PSU” means an award of Performance Shares as described in these Award Terms.

Target Shares” means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as “target” for the entire Award Period.

Total Shareholder Return” or “TSR” means the change in value of one share of a company’s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.

TSR Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s TSR Performance as determined under paragraph B of Section III.

III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS

The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).

A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.

B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:

1.     If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.

For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].

2.    If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.

C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:

2020 OriginalCo EPS



Earnings Per Share Goals
Payout Percentage
Less than $5.18
0%
$5.18 (Threshold)
25%
$5.69 (Target)
100%
$6.03150%
$6.38 (Stretch)
200%

2020 through 2022 for OriginalCo and RemainCo
Earnings Per Share Goals
Payout Percentage
Less than $17.11
0%
$17.11 (Threshold)
25%
$18.80 (Target)
100%
$19.93150%
$21.05 (Stretch)
200%

Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.

D.The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a “RemainCo Grantee”) or NewCo (a “NewCo Grantee”) on the Spin-Date and is subject to Article IX except as noted below.

1.     If the Spin-Date is after January 1, 2020 and before December 31, 2021,

    a.    For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2020 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33 percent.

    b.    For NewCo Grantees, the Final Award will equal 100 percent Target Shares.

2.    If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) 2020 through 2022 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50 percent.

E.Maximum Award. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.

IV.DIVIDENDS

During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

V.TERMINATION OF EMPLOYMENT

A.General Rule. If a Grantee’s employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.




B.Involuntary Termination. If a Grantee’s employment terminates during the Award Period and the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period, a pro rata portion (based on the number of completed months held during the Award Period prior to the date employment terminated) of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on actual performance during the Award Period as determined in accordance with Section III. The remainder will be forfeited on the date employment ends. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. An “involuntary termination” includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and the reasons listed under paragraphs C through G of this section.

C.Sale. If a Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of his or her subsidiary, division or joint venture, the following portion of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on the Final Award: one third if employment terminates on or after the Grant Date but before the first anniversary of the Award Period thereof; and all if employment terminates on or after the first anniversary of the first day of the Award Period. The remainder will be forfeited on the date a Grantee’s employment ends.

D.Retirement. If a Grantee terminates employment during the Award Period by retirement (including early and disability retirement), then this PSU Award will continue and be distributable on a pro rata basis at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. For Grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other Grantees, “retirement” is determined by the Company.

E.Death. If a Grantee’s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If a Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B, C, D or G of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.

F.Misconduct. If a Grantee’s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee’s receipt of notice of such termination.

G.Disability. If a Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.

H.Joint Venture Service. A transfer of a Grantee’s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-G above apply to this PSU Award while a Grantee is employed by the joint venture or other entity.

VI.DISTRIBUTION OF PERFORMANCE SHARES

A.General Rule. Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the



end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.

B.Death. In the case of distribution on account of a Grantee’s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee’s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.

VII.TRANSFERABILITY

Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following a Grantee’s death.

VIII.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

IX.ADMINISTRATIVE POWERS

In addition to the Committee’s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.

X.CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS

A.PSUs Subject to Clawback. For employees in Band 600 and above, this PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below); and

2.The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.

B.“Executive” means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.

C.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.

D.Exclusions from Clawback. This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2)



are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

E.Compliance Violations. For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

XI.Change-in-Control

Upon the occurrence of a change-in-control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.

If the Company terminates a Grantee’s employment except as described in Section V(F), (1) during the Award Period and (2) within two years following a change-in-control, the Final Award will be 100% and will be distributed when distributed to active Grantees.

XII.SECTION 409A COMPLIANCE.

Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.












Appendix A
Recoupment of Compensation for Compliance Violation

POLICIES AND PROCEDURES

Policy

It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.



4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.



EX-10.29 11 exhibit1029-2020annualceop.htm EXHIBIT-10.29 2020 ANNUAL CEO PSU TERMS AND CONDITIONS Document

Exhibit 10.29

2020 CEO PERFORMANCE SHARE UNIT AWARD TERMS
UNDER THE
MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN


I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, yet-to-be-named, independent, publicly traded company (“NewCo”) during the first half of 2021 (“Spin-Date”). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the “Company.”


Grant Type:
PSU – CEO
Grant Date: Award
March 31, 2020
Period:
Jan. 1, 2020 – Dec. 31, 2022








IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.

II.DEFINITIONS. For the purpose of these Award Terms:

Award Period” means the three-year period commencing on January 1, 2020 and ending on December 31, 2022.

Code” means the Internal Revenue Code of 1986 or any successor thereto.

Earnings Per Share or EPS” means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.

The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates; (2) the impact of significant unplanned acquisitions and/or divestitures, extraordinary items and other unusual or non-recurring charges and/or events; (3) an event either not directly related to Company operations or not reasonably within the control of Company management; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.

EPS Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s EPS goal as determined under paragraph C of Section III.

Final Award” means the percentage of the Target described in Section III hereof.

Grant Date” means the date as of which a Performance Share Unit is granted.

Peer Healthcare Companies" are the healthcare companies used by the Committee in evaluating the Company’s TSR Performance for the entire Award Period. For 2020 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.




AbbVie
Eli Lilly
Novartis
AmgenGlaxoSmithKlinePfizer
Astra Zeneca
Bristol-Myers Squibb
Roche
Johnson & Johnson
Sanofi-Aventis
The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.

Performance Share” means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.

Performance Unit Grantee” or “Grantee” means an eligible employee who receives a Performance Share Unit.

Performance Share Unit” or “PSU” means an award of Performance Shares as described in these Award Terms.

Restricted Period” has the meaning set forth in Appendix B.

Target Shares” means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as “target” for the entire Award Period.

Total Shareholder Return” or “TSR” means the change in value of one share of a company’s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.

TSR Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s TSR Performance as determined under paragraph B of Section III.

III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS

The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).

A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.

B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:

1.     If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.

For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].

2.    If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.

C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:







2020 OriginalCo EPS
Earnings Per Share Goals
Payout Percentage
Less than $5.18
0%
$5.18 (Threshold)
25%
$5.69 (Target)
100%
$6.03150%
$6.38 (Stretch)
200%

2020 through 2022 for OriginalCo and RemainCo
Earnings Per Share Goals
Payout Percentage
Less than $17.11
0%
$17.11 (Threshold)
25%
$18.80 (Target)
100%
$19.93150%
$21.05 (Stretch)
200%

Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.

D.The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a “RemainCo Grantee”) or NewCo (a “NewCo Grantee”) on the Spin-Date and is subject to Article IX except as noted below.

1.     If the Spin-Date is after January 1, 2020 and before December 31, 2021,

    a.    For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2020 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33 percent.

    b.    For NewCo Grantees, the Final Award will equal 100 percent Target Shares.

2.    If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) 2020 through 2022 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50 percent.

E.Maximum Award. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.

IV.DIVIDENDS

During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

V.TERMINATION OF EMPLOYMENT

A.General Rule. If the Grantee’s employment is terminated during the Award Period before January 1, 2021 for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.

B.Retirement or Other Reason. If the Grantee’s employment terminates for retirement or any other reason not specified in this Article V on or after January 1, 2021, then this PSU Award will continue and be distributable in



full at the time active Grantees receive distributions with respect to the Award Period based on the Final Award as if employment had continued.

C.Death. If the Grantee’s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If the Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B or E of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.

D.Misconduct. If the Grantee’s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee’s receipt of notice of such termination.

E.Disability. If the Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.

F.Joint Venture Service. A transfer of the Grantee’s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-E above apply to this PSU Award while the Grantee is employed by the joint venture or other entity.

VI.DISTRIBUTION OF PERFORMANCE SHARES

A.General Rule. Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.

B.Death. In the case of distribution on account of the Grantee’s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee’s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.

C.Violation of Restrictive Covenants. If the Grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.

VII.TRANSFERABILITY

Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following the Grantee’s death.

VIII.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

IX.ADMINISTRATIVE POWERS

In addition to the Committee’s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.




X.CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS

A.PSUs Subject to Clawback. This PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below); and

2.The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.

B.“Executive” means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.

C.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.

D.Exclusions from Clawback. This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

E.Compliance Violations. For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

XI.CHANGE-IN-CONTROL

Upon the occurrence of a Change-in-Control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.

If the Company terminates the Grantee’s employment for any reason other than Misconduct, as provided above (1) during the Award Period and (2) within two years following a Change-in-Control, the Final Award will be 100% and will be distributed when distributed to active Grantees.

XII.SECTION 409A COMPLIANCE.

Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.










Appendix A
Recoupment of Compensation for Compliance Violation

POLICIES AND PROCEDURES

Policy

It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.


4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback
Policy for PSUs Upon Significant Restatement of Financial Results.












APPENDIX B
Restrictive Covenants

Non-Compete. The Grantee agrees that to the extent permitted by law, during his employment with the Company and/or one of its affiliates and until December 31, 2022 (the “Restricted Period”) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.  Nothing herein will prohibit the Grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

Non-Solicit. During the Restricted Period, the Grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that the Grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.


EX-10.30 12 exhibit1030-2021annualceon.htm EXHIBIT-10.30 2021 ANNUAL CEO NQSO TERMS AND CONDITIONS Document

Exhibit 10.30

TERMS FOR
2021 STOCK OPTION CEO GRANT
UNDER THE
MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN

This is a summary of the terms applicable to the stock option specified in this document. Different terms may apply to any prior or future stock option.

Grant Type:CEO GrantExercisable DatePortion Becoming Exercisable
Option Price:$73.73May 4, 2022First: 33.333%
Grant Date:May 4, 2021May 4, 2023Second: 33.333%
Expiration Date:November 30, 2027May 4, 2024Balance

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards- grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your stock option within 90 days. Failure to accept the terms and conditions of your stock option within 90 days may result in forfeiture of the stock option.

This stock option expires on its Expiration Date, which is the day before the tenth anniversary of the Grant Date. If your employment with the Company is terminated, your right to exercise this stock option will be determined according to the terms in Section II. The vesting and exercisability of this option is also subject to the Restrictive Covenants set forth in Appendix B.

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

Subject to Recoupment, Forfeiture and Clawback: This Stock Option Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.VESTING; EXERCISE; EMPLOYMENT TERMINATION

A.Vesting: This option will vest in its entirety if your employment continues through September 30, 2021, or immediately if you die before then.
B.Exercisability. This option will become exercisable in equal installments (subject to a rounding process) on the Exercisable Dates indicated in the accompanying box above.
C.Termination. Any portion of this option that is vested will expire unless exercised before the New York Stock Exchange closes (the “Close of Business”) on the day before the fifth anniversary of the date your employment terminates due to your retirement (the “Termination Date”) but in no event after the Expiration Date. Close of Business for any day on which the New York Stock Exchange is not open means the close of business prior to that date when the Exchange is open.
D.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this stock option (whether vested or unvested) will expire immediately upon your receipt of notice of such termination.

E.Death. If your employment terminates as a result of your death, the portion of this stock option that is unvested will vest immediately upon your death. Whether already vested on the date of your death or vested as a result of your death, this stock option will expire on the day before the second anniversary of your death, even if such date is later than the Original Expiration date. you die while any portion of this stock option remains outstanding, but after your employment terminates, the



portion that remains outstanding after such employment termination will become immediately exercisable and will continue to be exercisable until the expiration date prescribed in paragraph C (and at least a year from your death in those jurisdictions where such extension is required by law).

F.Change in Control. If the Company involuntarily terminates your employment without Cause before the second anniversary after the closing of a change in control, each unvested Stock Option that is outstanding immediately prior to the change in control will immediately become fully vested and exercisable. All options, including options vested prior to such time, will expire on the day before the fifth anniversary of the termination of your employment following a change in control (but not beyond the Expiration Date). This extended exercise period does not apply in the case of termination under Paragraph C. If this stock option does not remain outstanding following the change in control and is not converted into a successor stock option, then you will be entitled to receive cash for this option in an amount at least equal to the difference between the price paid to stockholders in the change in control and the Option Price of this stock option. A "change in control" has the same meaning that it has under the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

G.Joint Venture. Employment with a joint venture or other entity in which the Company has determined that it has a significant business or ownership interest (a “JV”) is not considered termination of employment for purposes of this stock option. If you transfer employment from the Company to a JV or from a JV to the Company, such employment must be approved by, and contiguous with employment by, the Company or the JV. The terms set out in paragraphs A through F above apply to this stock option while the option holder is employed by the JV.

III. TRANSFERABILITY
This stock option is not transferable and may not be assigned or otherwise transferred except, under specific terms, by executives who hold or who retired within the prior 12 months from a Section 16 officer position.
IV.ELECTRONIC ACCEPTANCE
The Company may, in its sole discretion, decide to deliver any documents related to the stock option or future options that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.
V. ADMINISTRATION
The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.
VI.GRANTS NOT PART OF EMPLOYMENT CONTRACT
Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of Incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.
This stock option is subject to the provisions of the 2019 Incentive Stock Plan, including but not limited to choice of law. For further information regarding your stock options, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program.





APPENDIX A
RECOUPMENT OF COMPENSATION FOR COMPLIANCE VIOLATIONS

POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non- cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve- month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.



Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs upon Significant Restatement of Financial Results.






APPENDIX B
RESTRICTIVE COVENANTS

You agree that to the extent permitted by law, during your employment with the Company and/or one of its affiliates and until this Award is fully exercisable (the “Restricted Period”) you will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by you to be in development by the Company or any of its Affiliates .  Nothing herein will prohibit you from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

During the Restricted Period, you will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that you have violated the restrictive covenants set forth in this Appendix B, then you agree and covenant that any Unexercisable portion of this Award will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.



EX-10.31 13 exhibit1031-2021annualpsut.htm EXHIBIT-10.31 2021 ANNUAL PSU TERMS AND CONDITIONS Document

Exhibit 10.31


2021 PERFORMANCE SHARE UNIT AWARD TERMS
UNDER THE
MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN


I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, publicly traded company, Organon & Co. (“NewCo”) during the first half of 2021 (“Spin-Date”). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the “Company.”
Grant Type:PSU – Annual
Grant Date:March 31, 2021
Award Period:Jan. 1, 2021 – Dec. 31, 2023









IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.
II.DEFINITIONS. For the purpose of these Award Terms:

Award Period” means the three-year period commencing on January 1, 2021 and ending on December 31, 2023.

Code” means the Internal Revenue Code of 1986 or any successor thereto.

Earnings Per Share or EPS” means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.

The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates; (2) the impact of significant unplanned acquisitions and/or divestitures, extraordinary items and other unusual or non-recurring charges and/or events; (3) an event either not directly related to Company operations or not reasonably within the control of Company management; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.

EPS Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s EPS goal as determined under paragraph C of Section III.

Final Award” means the percentage of the Target described in Section III hereof.

Grant Date” means the date as of which a Performance Share Unit is granted.

Peer Healthcare Companies" are the healthcare companies used by the Committee in evaluating the Company’s TSR Performance for the entire Award Period. For 2021 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.




AbbVie
Eli Lilly
Novartis
AmgenGlaxoSmithKlinePfizer
Astra Zeneca
Bristol-Myers Squibb
Roche
Johnson & Johnson
Sanofi-Aventis
The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.

Performance Share” means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.

Performance Unit Grantee” or “Grantee” means an eligible employee who receives a Performance Share Unit.

Performance Share Unit” or “PSU” means an award of Performance Shares as described in these Award Terms.

Target Shares” means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as “target” for the entire Award Period.

Total Shareholder Return” or “TSR” means the change in value of one share of a company’s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.

TSR Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s TSR Performance as determined under paragraph B of Section III.

III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS

The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).

A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.

B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:

1.     If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.

For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].

2.    If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.

C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:






2021 OriginalCo EPS
Earnings Per Share Goals
Payout Percentage
Less than $5.98
0%
$5.98 (Threshold)
25%
$6.58 (Target)
100%
$6.97150%
$7.36 (Stretch)
200%

2021 through 2023 for OriginalCo and RemainCo
Earnings Per Share Goals
Payout Percentage
Less than $20.66
0%
$20.66 (Threshold)
25%
$22.70 (Target)
100%
$24.06150%
$25.42 (Stretch)
200%

Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.

D.The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a “RemainCo Grantee”) or NewCo (a “NewCo Grantee”) on the Spin-Date and is subject to Article IX except as noted below.

1.     If the Spin-Date is during 2021,

    a.    For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2021 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33 percent.

    b.    For NewCo Grantees, the Final Award will equal 100 percent Target Shares.

2.    If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) 2021 through 2023 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50 percent.

E.Maximum Award. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.

IV.DIVIDENDS

During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

V.TERMINATION OF EMPLOYMENT

A.General Rule. If a Grantee’s employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.




B.Involuntary Termination. If a Grantee’s employment terminates during the Award Period and the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period, a pro rata portion (based on the number of completed months held during the Award Period prior to the date employment terminated) of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on actual performance during the Award Period as determined in accordance with Section III. The remainder will be forfeited on the date employment ends. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. An “involuntary termination” includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and the reasons listed under paragraphs C through G of this section.

C.Sale. If a Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of his or her subsidiary, division or joint venture, the following portion of this PSU Award will be distributed at such time as it would have been paid if employment had continued, based on the Final Award: one third if employment terminates on or after the Grant Date but before the first anniversary of the Award Period thereof; and all if employment terminates on or after the first anniversary of the first day of the Award Period. The remainder will be forfeited on the date a Grantee’s employment ends.

D.Retirement. If a Grantee terminates employment during the Award Period by retirement (including early and disability retirement), then this PSU Award will continue and be distributable on a pro rata basis at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which the Grantee was employed by the Company or JV, and the denominator of which is 36. For Grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other Grantees, “retirement” is determined by the Company.

E.Death. If a Grantee’s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If a Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B, C, D or G of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.

F.Misconduct. If a Grantee’s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee’s receipt of notice of such termination.

G.Disability. If a Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.

H.Joint Venture Service. A transfer of a Grantee’s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-G above apply to this PSU Award while a Grantee is employed by the joint venture or other entity.


VI.DISTRIBUTION OF PERFORMANCE SHARES

A.General Rule. Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be



issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.

B.Death. In the case of distribution on account of a Grantee’s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee’s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.

VII.TRANSFERABILITY

Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following a Grantee’s death.

VIII.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

IX.ADMINISTRATIVE POWERS

In addition to the Committee’s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.

X.CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS

A.PSUs Subject to Clawback. For employees in Band 600 and above, this PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below); and

2.The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.

B.“Executive” means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.

C.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.

D.Exclusions from Clawback. This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2)



are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

E.Compliance Violations. For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

XI.Change-in-Control

Upon the occurrence of a change-in-control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.

If the Company terminates a Grantee’s employment except as described in Section V(F), (1) during the Award Period and (2) within two years following a change-in-control, the Final Award will be 100% and will be distributed when distributed to active Grantees.

XII.SECTION 409A COMPLIANCE.

Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.



Appendix A
Recoupment of Compensation for Compliance Violation

POLICIES AND PROCEDURES

Policy

It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.


4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.



EX-10.32 14 exhibit1032-2021annualceop.htm EXHIBIT-10.32 2021 ANNUAL CEO PSU TERMS AND CONDITIONS Document
Exhibit 10.32


2021 CEO PERFORMANCE SHARE UNIT AWARD TERMS
UNDER THE
MERCK & CO., INC. 2019 STOCK INCENTIVE PLAN


I.GENERAL. These Performance Share Units (“PSUs”) are granted under and subject to the following Award Terms and the Merck & Co., Inc. 2019 Stock Incentive Plan (the "Merck ISP"). The Company has announced its intention to spin-off (the “Spin-Off”) certain products into a new, independent, publicly traded company, Organon & Co. (“NewCo”) during the first half of 2021 (“Spin-Date”). As appropriate, the Company will be referred to as OriginalCo before the Spin-Date, and on and after the Spin-Date as RemainCo. Collectively, OriginalCo and RemainCo are the “Company.”


Grant Type:
PSU – CEO
Grant Date: Award
March 31, 2021
Period:
Jan. 1, 2021 – Dec. 31, 2023








IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.
II.DEFINITIONS. For the purpose of these Award Terms:

Award Period” means the three-year period commencing on January 1, 2021 and ending on December 31, 2023.

Code” means the Internal Revenue Code of 1986 or any successor thereto.

Earnings Per Share or EPS” means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.

The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) fluctuations in foreign exchange rates versus Plan rates; (2) the impact of significant unplanned acquisitions and/or divestitures, extraordinary items and other unusual or non-recurring charges and/or events; (3) an event either not directly related to Company operations or not reasonably within the control of Company management; (4) the effects of significant accounting changes in accordance with U.S. GAAP, or other significant legislative changes; (5) gains or losses arising from investments in equity securities, whether realized or unrealized and (6) the impact of share repurchases above or below Plan levels.

EPS Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s EPS goal as determined under paragraph C of Section III.

Final Award” means the percentage of the Target described in Section III hereof.

Grant Date” means the date as of which a Performance Share Unit is granted.

Peer Healthcare Companies" are the healthcare companies used by the Committee in evaluating the Company’s TSR Performance for the entire Award Period. For 2021 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.





AbbVie
Eli Lilly
Pfizer
AmgenGlaxoSmithKlineRoche
Astra Zeneca
Bristol-Myers Squibb
Johnson & Johnson
Novartis
Sanofi-Aventis

The Committee intends that the Peer Healthcare Companies be subject to such adjustment as may be necessary to reflect merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.

Performance Share” means a phantom share of Common Stock. Until distributed pursuant to Article VI, Performance Shares shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Merck ISP.

Performance Unit Grantee” or “Grantee” means an eligible employee who receives a Performance Share Unit.

Performance Share Unit” or “PSU” means an award of Performance Shares as described in these Award Terms.

Restricted Period” has the meaning set forth in Appendix B.

Target Shares” means the number of Performance Shares that will be distributable if the Performance Measures are achieved at the level identified as “target” for the entire Award Period.

Total Shareholder Return” or “TSR” means the change in value of one share of a company’s Common Stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.

TSR Performance Payout” means the percentage of Target Shares to be paid out based upon the Company’s TSR Performance as determined under paragraph B of Section III.

III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS

The Performance Unit Grantee shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).

A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.

B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:

1.     If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.

For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].

2.    If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s TSR by more than 10 percentage points, no TSR Performance Payout will be earned with respect to this portion of the PSU.








C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:

2021 OriginalCo EPS
Earnings Per Share Goals
Payout Percentage
Less than $5.98
0%
$5.98 (Threshold)
25%
$6.58 (Target)
100%
$6.97150%
$7.36 (Stretch)
200%

2021 through 2023 for OriginalCo and RemainCo
Earnings Per Share Goals
Payout Percentage
Less than $20.66
0%
$20.66 (Threshold)
25%
$22.70 (Target)
100%
$24.06150%
$25.42 (Stretch)
200%
Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.

D.The Final Award will depend upon whether and when the Spin-Off occurs and whether the grantee is an employee of RemainCo (a “RemainCo Grantee”) or NewCo (a “NewCo Grantee”) on the Spin-Date and is subject to Article IX except as noted below.

1.     If the Spin-Date is during 2021,

    a.    For RemainCo Grantees, the Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 66.67 percent and (y) the 2021 OriginalCo EPS Payout Percentage TIMES Target Shares TIMES 33.33 percent.

    b.    For NewCo Grantees, the Final Award will equal 100 percent Target Shares.

2.    If the Spin-Off does not occur, the Final Award for all grantees will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) 2021 through 2023 EPS Payout Percentage for OriginalCo and RemainCo TIMES Target Shares TIMES 50 percent.

E.Maximum Award. Anything in these Award Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award may not exceed four times the Target Share, valued as of the Grant Date.

IV.DIVIDENDS

During the Award Period, dividend equivalents will be accrued on the Performance Shares if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Award only on the Final Award. Such dividends shall be paid as additional shares in an amount equal to the sum of the dividends paid during the Award Period on the Final Award divided by the price of a share of Merck common stock on the date the Final Award is determined. If any portion of this PSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

V.TERMINATION OF EMPLOYMENT

A.General Rule. If the Grantee’s employment is terminated during the Award Period before September 30, 2021 for any reason other than those specified in the following paragraphs, this PSU award will be forfeited on the date employment ends.




B.Retirement or Other Reason. If the Grantee’s employment terminates for retirement or any other reason not specified in this Article V on or after September 30, 2021, then this PSU Award will continue and be distributable in full at the time active Grantees receive distributions with respect to the Award Period based on the Final Award as if employment had continued.

C.Death. If the Grantee’s employment terminates due to death during the Award Period, all of this PSU Award will continue and be distributed to his or her estate at the time active Grantees receive such distributions with respect to this PSU Award, based on the Final Award. If the Grantee dies while any portion of this PSU Award remains outstanding, but after employment terminates for the reasons listed under paragraphs B or E of this section, the portion that remains outstanding will continue and be distributable at the time active Grantees receive such distributions with respect to that Award Period based on the Final Award.

D.Misconduct. If the Grantee’s employment is terminated as a result of deliberate, willful or gross misconduct, this PSU Award will be forfeited immediately upon the Grantee’s receipt of notice of such termination.

E.Disability. If the Grantee’s employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then this PSU Award will continue and be distributable in accordance with its terms as if employment had continued based on the Final Award and will be distributed at the time active PSU Grantees receive distributions with respect to this PSU Award.

F.Joint Venture Service. A transfer of the Grantee’s employment to a joint venture, including, in the case of grants to Legacy Merck Employees, any other entity in which the Company has determined that it has a significant business or ownership interest, is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-E above apply to this PSU Award while the Grantee is employed by the joint venture or other entity.

VI.DISTRIBUTION OF PERFORMANCE SHARES

A.General Rule. Following the end of the Award Period, each Grantee shall be entitled to receive a number of shares of Common Stock equal to the Final Award plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible, but in no event later than the end of the calendar year in which the Final Award is determined in accordance with Section III. Unless otherwise determined by the Committee, the Company shall withhold any applicable taxes directly from a Performance Share Unit before it is denominated in actual shares of Common Stock.

B.Death. In the case of distribution on account of the Grantee’s death, the portion of the Performance Share Unit distributable shall be distributed to the Grantee’s estate. Unless the Committee determines otherwise, the Company will withhold any applicable taxes directly from a Performance Unit before it is denominated in actual shares of Common Stock.

C.Violation of Restrictive Covenants. If the Grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.

VII.TRANSFERABILITY

Prior to distribution pursuant to Section VI, the PSU Award shall not be transferable, assignable or alienable except by will or the laws of descent or distribution following the Grantee’s death.

VIII.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

IX.ADMINISTRATIVE POWERS

In addition to the Committee’s powers set forth in the Merck ISP, anything in these Award Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of



an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.

X.CLAWBACK POLICY FOR PSUS UPON SIGNIFICANT RESTATEMENT OF FINANCIAL RESULTS AND CERTAIN COMPLIANCE VIOLATIONS

A.PSUs Subject to Clawback. This PSU Award will be subject to recoupment in the event of violations of the Company policy for Recoupment of Compensation for Compliance violations as set forth in Appendix A as amended from time to time. In addition, PSUs, and any proceeds therefrom, are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.The Audit Committee of the Board will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as those terms are defined below); and

2.The Compensation and Benefits Committee of the Board will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Compensation and Benefits Committee will seek reimbursement from the Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.

B.“Executive” means executive officers for the purposes of the Securities Exchange Act of 1934, as amended.

C.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.

D.Exclusions from Clawback. This Section does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

E.Compliance Violations. For employees in Band 600 and above, this PSU will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

XI.CHANGE-IN-CONTROL

Upon the occurrence of a Change-in-Control (as such term is defined in the Merck ISP), the Final Award shall be 100%. The Final Award will be distributed at the same time and in the same manner as described in Section VI.

If the Company terminates the Grantee’s employment for any reason other than Misconduct, as provided above (1) during the Award Period and (2) within two years following a Change-in-Control, the Final Award will be 100% and will be distributed when distributed to active Grantees.

XII.SECTION 409A COMPLIANCE.

Anything in the ISP or these Award Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code, made due to a separation from service (as defined in Section 409A) will not be made before the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.




Appendix A
Recoupment of Compensation for Compliance Violation
POLICIES AND PROCEDURES

Policy

It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.


4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

Delegation to Management for Certain Recoupment Decisions The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback
Policy for PSUs Upon Significant Restatement of Financial Results.












APPENDIX B
Restrictive Covenants

Non-Compete. The Grantee agrees that to the extent permitted by law, during his employment with the Company and/or one of its affiliates and until December 31, 2022 (the “Restricted Period”) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.  Nothing herein will prohibit the Grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

Non-Solicit. During the Restricted Period, the Grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that the Grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.


EX-10.33 15 exhibit1033-2021specialret.htm EXHIBIT-10.33 2021 SPECIAL RETENTION RSU TERMS AND CONDITIONS Document
Exhibit 10.33

TERMS FOR
2021 RETENTION RESTRICTED STOCK UNIT GRANTS
UNDER THE MERCK & CO., 2019 INCENTIVE STOCK PLAN


This is a summary of the terms applicable to the Restricted Stock Unit (RSU) Award specified in this document.
Different terms may apply to any prior or future RSU Awards.
Grant Type:RSU
Grant Date:
May 4, 2021
Vesting DatePortion that Vests
May 4, 2024100%

Eligibility: Eligibility for grants is determined under the Merck & Co., Inc. 2019 Incentive Stock Plan for employees of the Company, its subsidiaries, its affiliates or its joint ventures if designated by the Compensation and Benefits Committee of Merck’s Board of Directors, or its delegate (the “Committee”).

I.GENERAL INFORMATION

IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.

A.Restricted Period. The Restricted is the period during which this RSU Award is restricted and subject to forfeiture. The Restricted Period begins on the Grant Date and ends on the third anniversary of the Grant Date unless ended earlier under Article II below. No voting rights apply to this RSU Award. No fractional shares will be awarded: all calculations are subject to rounding.

B.Dividend Equivalents. During the Restricted Period, dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made, without interest or earnings, at the end of the Restricted Period. If any portion of this RSU award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations.

C.Distribution. Upon the expiration of the Restricted Period if you are then employed, you will be entitled to receive a number of shares of Merck common stock equal to the number of RSUs that have become unrestricted and the dividend equivalents that accrued on that portion. Prior to distribution, you must deliver to the Company an amount the Company determines to be sufficient to satisfy any amount required to be withheld, including applicable taxes. The Company may, in its sole discretion, withhold from the RSU Award distribution a number of shares to pay applicable withholding (including taxes).

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Internal Revenue Code or any successor thereto. Specifically, distributions made due to a separation from service (as defined in Section 409A) to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will not be made until administratively feasible following the first day of the sixth month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.

E.Subject to Recoupment. For employees in Band 600 and above, this RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s policy for Recoupment of Compensation for Compliance Violations, as set forth in Appendix A (as may be amended from time to time).

II.TERMINATION OF EMPLOYMENT

If your employment with the Company is terminated during the Restricted Period, your right to the RSU Award will be determined according to the terms in this Section II.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, division or joint venture, the following portion of your RSU Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date. The remainder will be forfeited on the date your employment ends. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

C.Involuntary Termination. If the company determines that your employment is involuntarily terminated during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date your employment ends. An “involuntary termination” includes termination of your employment by the Company as the result of a restructuring or job



elimination, but excludes non-performance of your duties and the reasons listed under paragraphs B, or D through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

D.Retirement. If your employment terminates by retirement during the Restricted Period, the unvested portion of this RSU Award and any accrued dividend equivalents will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or JV, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Death. If your employment terminates due to your death during the Restricted Period, a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date of your death.. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, G or H of this section, the remaining, non-forfeited portion of this RSU Award and accrued dividend equivalents will be distributed to your estate as soon as possible after your death.

F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then a pro rata portion of your unvested RSU Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of this RSU Award times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36. The remainder and any accrued dividends will be forfeited on the date your employment ends..

H.Change in Control. If the Company involuntarily terminates your employment during the Restricted Period without Cause before the second anniversary after the closing of any change in control, then this RSU Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active RSU Grantees receive distributions with respect to this RSU Award. If this RSU does not remain outstanding following the change in control and is not converted into a successor RSU, then you will be entitled to receive cash for this RSU in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck common stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire. Change in control is defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control), but if RSUs are considered “deferred compensation” under Section 409A of the Internal Revenue Code, the definition of change in control will be modified to the extent necessary to comply with Section 409A.

I.Joint Venture. Employment with a joint venture or other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by, and contiguous with employment by, the Company. The terms set out in paragraphs A-H above apply to this RSU Award while you are employed by the joint venture or other entity.

III.TRANSFERABILITY

This RSU Award is not transferable and may not be assigned or otherwise transferred.

IV.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

V.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this grant. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all eligible employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the eligible employees, the form, amount and timing of incentives, the terms and provisions of incentives and the writings evidencing incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such eligible employees are similarly situated.

VI.GRANTS NOT PART OF THE EMPLOYMENT CONTRACT

Notwithstanding reference to grants of incentives in letters offering employment or in specific employment agreements, incentives do not constitute part of any employment contract between the Company or JV and the grantee, whether the employment contract arises as a matter of agreement or applicable law. The value of any grant or of the proceeds of any exercise of incentives are not included in calculating compensation for purposes of pension payments, separation pay, termination indemnities or other similar payments due upon termination of employment.

This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program.



Appendix
Recoupment of Compensation for Compliance Violations


POLICIES AND PROCEDURES

Policy
It is the policy of the Compensation and Benefits Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee with respect to any performance period beginning after December 31, 2013, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Policy Violation relating to the research, development, manufacturing, sales, or marketing of Company products; and b) the Committee concludes that the Material Policy Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve- month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.

2.A “Material Policy Violation” is defined as a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products.

3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Policy Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Policy Violation.

4.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.


Procedures
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.

2.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.

3.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, and to what extent and in which manner, to seek Recoupment.

4.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.


Delegation to Management for Certain Recoupment Decisions
The Committee hereby delegates to the Chief Executive Officer (who may further delegate as he deems appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Section 16 Officers of the Company. Section 16 Officers are employees of the Company who are subject to Section 16 of the Securities Exchange Act of 1934. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non- cash incentive compensation award to any executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Nothing in this policy shall replace or otherwise limit or affect the Clawback Policy for EIP Awards Upon Significant Restatement of Financial Results and/or the Clawback Policy for PSUs Upon Significant Restatement of Financial Results.

EX-10.34 16 exhibit1034restrictedstock.htm EXHIBIT-10.34 2022 EXECUTIVE CHAIRMAN RSU TERMS AND CONDITIONS Document

Exhibit 10.34

TERMS AND CONDITIONS
2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN

I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Terms and Conditions (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.



Grant Type:RSU - Annual
Grant Date:May 3, 2022
Vesting DatePortion that Vests
May 3, 2023100%



IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.


A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest. The RSU Award will vest on May 3, 2023 as shown in the box above, except as otherwise provided in Article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.

B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.

C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.




E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).

F.Violation of Restrictive Covenants. If the grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.

II.TERMINATION OF EMPLOYMENT

If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Retirement or Other Reason. If your employment terminates by retirement or any other reason not specified in this Article II prior to July 1, 2022, the RSU Award will vest on the Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on January 1, 2022 and ending on the date employment terminates, and the denominator of which is 6. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. If your employment terminates by retirement or any other reason not specified in this Article II on or after July 1, 2022 and prior to the Vesting Date, the RSU Award will vest in full on the Vesting Date following your termination. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.

C.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, or E, the RSU Award will immediately vest and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, or E of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.

D.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

E.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) and dividend equivalents that have accrued through the corresponding Vesting Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.









III.TRANSFERABILITY

Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.

IV.TAX WITHHOLDING

Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.

The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.

You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.

V.DATA PRIVACY

The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.




A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.

B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.

C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.

D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.

E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.

F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.

If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.

VI.GOVERNING LAW

This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.








VII.SEVERABILITY

The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

VIII.WAIVER

You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.

IX.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.


X.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.

This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program


APPENDIX A
Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results
Policy
It is the policy of the Compensation and Management Development Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

In addition, awards under the Executive Incentive Plan (“EIP”) and Performance Share Units (“PSU”) under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company’s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.
2.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
4.“Executive” means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.
5.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.


Procedures
For Compliance Violations
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have
2.full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the
3.Chief Executive Officer.
4.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.
5.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking
Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
6.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

For EIP Awards and PSUs Upon Significant Restatement of Financial Results
EIP Awards and PSUs for Executives are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.    The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above); and
2.    In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.
3.    In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.
4.    The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

Delegation to Management for Certain Recoupment Decisions
Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the



extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

The Committee shall have sole discretion to make all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.

This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the “Applicable Rules”). To the extent the Applicable Rules require recovery of any bonus and/or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.

The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.

The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX B
Restrictive Covenants

Non-Compete. The grantee agrees that to the extent permitted by law, during his employment with the Company and/or one of its affiliates and until May 3, 2023 (the “Restricted Period”) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.  Nothing herein will prohibit the grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

Non-Solicit. During the Restricted Period, the grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that the grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.




TERMS AND CONDITIONS
2022 EXECUTIVE CHAIRMAN RESTRICTED STOCK UNIT GRANT
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN

I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Terms and Conditions (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.



Grant Type:RSU - Annual
Grant Date:August 3, 2022
Vesting DatePortion that Vests
August 3, 2023100%


IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.


A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest. The RSU Award will vest on August 3, 2023 as shown in the box above, except as otherwise provided in Article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.

B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.

C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.




E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).

F.Violation of Restrictive Covenants. If the grantee violates the Restrictive Covenants as set forth in Appendix B during the Restricted Period, this entire Award, and any accumulated dividend equivalents, shall immediately lapse and be forfeited.

II.TERMINATION OF EMPLOYMENT

If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Retirement or Other Reason. If your employment terminates by retirement or any other reason not specified in this Article II prior to January 1, 2023, the RSU Award will vest on the Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award (whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on July 1, 2022 and ending on the date employment terminates, and the denominator of which is 6. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. If your employment terminates by retirement or any other reason not specified in this Article II on or after January 1, 2023 and prior to the Vesting Date, the RSU Award will vest in full on the Vesting Date following your termination. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service.

C.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, or E, the RSU Award will immediately vest and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, or E of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.

D.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

E.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Date set forth in paragraph I(A) and dividend equivalents that have accrued through the corresponding Vesting Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.

III.TRANSFERABILITY

Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.




IV.TAX WITHHOLDING

Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.

The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.

You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.

V.DATA PRIVACY

The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.

F.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which



the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.

A.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.

B.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.

C.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.

D.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.

E.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.

If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.

VI.GOVERNING LAW

This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.

VII.SEVERABILITY

The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.







VIII.WAIVER

You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.

IX.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.


X.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.

This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program



APPENDIX A
Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results
Policy
It is the policy of the Compensation and Management Development Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

In addition, awards under the Executive Incentive Plan (“EIP”) and Performance Share Units (“PSU”) under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company’s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.
2.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
4.“Executive” means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.
5.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.


Procedures
For Compliance Violations
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have
2.full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.
3.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.
4.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its
discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
5.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

For EIP Awards and PSUs Upon Significant Restatement of Financial Results
EIP Awards and PSUs for Executives are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.    The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above); and
2.    In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.
3.    In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.
4.    The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

Delegation to Management for Certain Recoupment Decisions
Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy



is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

The Committee shall have sole discretion to make all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.

This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the “Applicable Rules”). To the extent the Applicable Rules require recovery of any bonus and/or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.

The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.

The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX B
Restrictive Covenants

Non-Compete. The grantee agrees that to the extent permitted by law, during his employment with the Company and/or one of its affiliates and until August 3, 2023 (the “Restricted Period”) he will not, without the prior written consent of the Board, engage, directly or indirectly, whether as officer, director, board member, owner, principal, agent, distributor, representative, consultant, employee, partner, advisor or in any other capacity with any company that is directly or indirectly engaged in the business of researching, developing, producing, marketing or selling any products, technology or services that competes with or upon commercialization will compete with any (a) product, technology  or service developed,  marketed or sold by the Company or any of its Affiliates or (b) product, technology or service known by him to be in development by the Company or any of its Affiliates.  Nothing herein will prohibit the grantee from acquiring or holding not more than 1 percent of any class of publicly traded securities of any business.

Non-Solicit. During the Restricted Period, the grantee will not, directly or indirectly, solicit, or induce any other person to solicit, any employee of the Company or its affiliates to leave his or her employment.

Forfeiture. If the Company determines that the grantee has violated the restrictive covenants set forth in this Appendix B, then he agrees and covenants that this entire Award, including any accumulated dividends, will be immediately forfeited. This remedy is not the Company’s exclusive remedy. The Company reserves all other rights and remedies available to it at law or in equity.




EX-10.35 17 exhibit1035-2022annualrsut.htm EXHIBIT-10.35 2022 ANNUAL RSU TERMS AND CONDITIONS (GUINDO) Document

Exhibit 10.35

GLOBAL TERMS AND CONDITIONS
2022 RESTRICTED STOCK UNIT GRANT FOR CHIRFI GUINDO
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN




I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the Restricted Stock Unit (“RSU”) award specified in this document (“RSU Award”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This RSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.



Grant Type:RSU - Annual
Grant Date:August 3, 2022
Vesting DatesPortion that Vests
August 3, 2023First: 33.333%
August 3, 2024Second: 33.333%
August 3, 2025Third: Balance



IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at (http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your RSU Award within 90 days. Failure to accept the terms and conditions of your RSU Award within 90 days may result in Forfeiture of the RSU Award.

A.Restricted (Vesting) Period. The Restricted Period is the period during which this RSU Award is subject to forfeiture and is eligible to vest. The RSU Award will vest with respect to one-third of this RSUs subject to the RSU Award on each of the First, Second, and Third anniversaries of the Grant Date (each a “Vesting Date”) as shown in the box above, except as otherwise provided in Article II below. No voting rights apply to this RSU Award. No fractional shares will be issued upon settlement of the RSU Award; all calculations are subject to rounding.

B.Dividend Equivalents. During the period commencing on the Grant Date and ending on the date immediately prior to the date the RSU Awards are settled in accordance with paragraph I(C), dividend equivalents will be accrued for the holder (“you”) if and to the extent dividends are paid by the Company on Merck Common Stock. Payment of such dividends will be made in cash via local payroll, without interest or earnings, at or around the time of distribution of the shares of Common Stock in settlement of the underlying RSUs. If any portion of this RSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with paragraph IV.

C.Distribution (Settlement of RSU Award). Upon vesting of the RSU Award (including as a result of the events set forth in Article II), you (or your estate, in the event the RSU Award vests pursuant to paragraph II(E)) will be issued a number of shares of Merck Common Stock equal to the number of RSUs (unless otherwise provided in paragraph II(H)) with respect to which the RSU Award has vested and the dividend equivalents that accrued on that portion; provided, however, that in the event the RSU Awards vests upon a Change in Control (as defined below) pursuant to paragraph II(H) that does not constitute a “change in control event” within the meaning of U.S. Treasury Regulations Section 1.409A-3(i)(5), the RSU Awards will instead be settled on the original Vesting Dates set forth in paragraph I(A). Any amount required to be withheld, including amounts required to satisfy Tax-Related Items, in connection with the distribution of the RSU Award (or otherwise arising from your participation in the Plan) will be recovered from you as described in paragraph IV.

D.409A Compliance. Anything to the contrary notwithstanding, no distribution of RSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. Specifically, distributions made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A)” and any



such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that dividend equivalents that otherwise would have accrued will accrue during the period during which distribution is suspended.

E.Subject to Recoupment. This RSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).

II.TERMINATION OF EMPLOYMENT

If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Restricted Period described in paragraph I(A), your right to the RSU Award will be determined according to the terms in this Article II and for grantees outside the United States, also in paragraph 12 of Section A (“Nature of Grant”) of Appendix B, Part I.

A.General Rule. If your employment is terminated during the Restricted Period for any reason other than those specified in the following paragraphs, the unvested portion of this RSU Award (and any accrued dividend equivalents) will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period, the RSU Award, any any accrued dividends, will continue to vest on the following original Vesting Date(s), as set forth in paragraph I(A), provided you sign and refraining from revoking a severance agreement in a format prescribed by the Company, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as the Company provides. If the Company determines that your employment is involuntarily terminated during the Restricted Period and you do not sign and refrain from revoking a severance agreement as outlined above, and you are involuntarily terminated on or after the first anniversary of the Grant Date, the RSU Award will vest on the next subsequent Vesting Date following your employment termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to the RSU Award (whether or not vested), multiplied by (ii) a fraction, numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion, if any, of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of your employment by the Company or the Employer, as applicable, as the result of a restructuring or job elimination, but excludes non-performance of your duties and the reasons listed under paragraphs C through H of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.


C.Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or JV, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A). Notwithstanding the foregoing, the Committee may determine, for purposes of this RSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this RSU Award. .

D.Retirement. If your employment terminates by retirement during the Restricted Period, the RSU Award will vest on the next subsequent Vesting Date following your termination with respect to a pro rata portion of your unvested RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date equal to (i) the total number of RSUs subject to this RSU Award



(whether or not vested), multiplied by (ii) a fraction, the numerator of which is equal to the number of completed monthly periods during the period commencing on the Grant Date and ending on the date employment terminates, and the denominator of which is 36, (iii) reduced by the number of RSUs that have vested pursuant to paragraph A. The remaining portion of the RSU Award and any accrued dividends will be forfeited on the date your employment terminates. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated under paragraphs B, C, D, G or H, the RSU Award will immediately vest with respect to any portion of this RSU Award that has not vested as of your death and dividend equivalents that have accrued though such date. If you die during the Restricted Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, the RSU Award will immediately vest with respect to the remaining, non-forfeited portion of this RSU Award and dividend equivalents that have accrued through the date of death.

F.Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this RSU Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.

G.Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this RSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.

H.Change in Control. If this RSU Award is assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Restricted Period without Cause before the second anniversary of the closing of the Change in Control, then the RSU Award will continue to vest on the original Vesting Dates set forth in paragraph I(A) with respect to the unvested portion of the RSU Award and dividend equivalents that have accrued through the corresponding Vesting Date. If this RSU Award does not remain outstanding following the Change in Control and is not converted into a successor RSU, then the RSU Award will immediately vest with respect to the portion of the RSU Award that is unvested as of the Change in Control and dividend equivalents that have accrued though such date and, at the election of the Company, you will be entitled to receive cash for such portion of this RSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding an MSD Change in Control).

I.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this RSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this RSU Award following a transfer of employment accordance with this section.

J.Good Reason. If your employment is terminated for Good Reason, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s), as set forth in paragraph I(A), provided you sign and refraining from revoking a severance agreement in a format prescribed by the Company, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as the Company provides. “Good Reason” is defined to include the following: a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction



affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to the Company’s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of this letter, provided that you deliver written notice of a claim of Good Reason to the Company’s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD’s failure to cure.

III.TRANSFERABILITY

Prior to distribution pursuant to Article I(C), the RSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.

IV.TAX WITHHOLDING

Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the RSU, the subsequent sale of shares of Common Stock acquired upon the lapsing of the Restricted Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the RSU Award to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at lapsing of the Restricted Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon lapsing of the Restricted Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the RSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.

The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.

You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or



deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.

V.DATA PRIVACY

The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.

A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.

B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.

C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.

D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.

E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.

F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.

If you agree with the data processing practices described in this Article, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.

VI.GOVERNING LAW

This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard



to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.

VII.SEVERABILITY

The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

VIII.WAIVER

You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.

IX.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the RSU or future RSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

X.COUNTY-SPECIFIC APPENDIX

The RSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the RSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.

XI.ADMINISTRATION

The Committee is responsible for construing and interpreting this grant, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this RSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this RSU Award shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any Eligible Employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among eligible employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.

This RSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your RSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program



APPENDIX A
Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results
Policy
It is the policy of the Compensation and Management Development Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

In addition, awards under the Executive Incentive Plan (“EIP”) and Performance Share Units (“PSU”) under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company’s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.
2.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
4.“Executive” means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.
5.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.


Procedures
For Compliance Violations
1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have
2.full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.
3.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.
4.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its
discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
5.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

For EIP Awards and PSUs Upon Significant Restatement of Financial Results
EIP Awards and PSUs for Executives are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.    The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above); and
2.    In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.
3.    In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.
4.    The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

Delegation to Management for Certain Recoupment Decisions
Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.
Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy



is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

The Committee shall have sole discretion to make all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.

This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the “Applicable Rules”). To the extent the Applicable Rules require recovery of any bonus and/or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.

The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.

The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion



APPENDIX B
ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.
This Appendix, which is part of the Global Terms and Conditions for 2022 Restricted Stock Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan, contains additional “terms and conditions” that will apply to you if you reside outside the United States.
The terms and conditions in Part I of this Appendix apply to all grantees who reside outside the United States. The additional terms and conditions in Part II of this Appendix will also apply to you if you reside in one of the countries referenced in Part II.
The information in this Appendix is based on the laws in effect in the respective countries as of March 1, 2022. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix B as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the Restricted Period lapses and shares of Common Stock are issued to you or you sell shares of Common Stock acquired under the Plan.
In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and/or employment after the Grant Date, the information contained herein may not apply to you in the same manner. The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.





APPENDIX B - PART I: ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES
The following additional terms and conditions will apply to you if you reside in any country outside the United States.
A.Nature of Grant
In accepting the RSU Award, you acknowledge and agree that:
1.the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time;
2.the grant of the RSU Award is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past;
3.all decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company;
4.your participation in the Plan is voluntary;
5.your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time;
6.the RSU Award and any shares of Common Stock acquired under the Plan, and income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate or JV of the Company, and that are outside the scope of your employment or service contract, if any;
7.unless otherwise agreed with the Company in writing, the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate or JV of the Company;
8.the RSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation;
9.the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any subsidiary, affiliate or JV of the Company;
10.the future value of the shares of Common Stock underlying the RSU is unknown, indeterminable and cannot be predicted with certainty;
11.no claim or entitlement to compensation or damages shall arise from termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);
12.for purposes of the RSU Award, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in the Terms, your right to vest in the RSU under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of “garden leave” or similar period mandated under local law; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes of the



grant (including whether you may still be considered to be providing services while on a leave of absence);
13.the RSU Award and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability;
14.the Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares; you should consult with your personal tax, legal and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan; and
15.neither the Employer, nor the Company or any subsidiary, affiliate or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the RSU Award or any amounts due to you pursuant to the vesting of the RSU Award, the subsequent sale of shares acquired under the Plan or the receipt of any dividends and/or dividend equivalents.
B.Insider Trading/Market Abuse Laws
You acknowledge that, depending on your or your broker’s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., RSUs) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have “inside information” regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.
C.Foreign Asset/Account, Exchange Control and Tax Obligations
You acknowledge that, depending on your country, you may be subject to foreign asset/account, exchange control and/or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividend equivalents, dividends, and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and/or from a brokerage/bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult your personal tax, legal and/or financial advisors regarding the same.
D.Language
You acknowledge that you are proficient in the English language or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the RSU Award and/or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control.
E.Imposition of Other Requirements and Issuance of Shares
The Company reserves the right to impose other requirements on this RSU Award and the shares of Common Stock acquired pursuant to the RSU Award, to the extent the Company determines it is necessary or advisable to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.



In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may require the immediate forced sale of the shares of Common Stock issuable upon vesting of the RSUs. Alternatively, unless otherwise set forth in this Appendix, the Committee, in its sole and absolute discretion, may determine to pay out the RSUs in cash equal to the fair market value of the shares of Common Stock underlying the RSUs.



APPENDIX B - PART II: COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS
CountryAdditional Terms and Conditions and Notifications
Algeria
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Argentina
Securities Law Information
Neither the Award nor the underlying shares of Common Stock are publicly offered, listed on any stock exchange in Argentina or registered with the Argentine Securities Commission (Comisión Nacional de Valores).
Labor Law Acknowledgement
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
In accepting the grant of the RSU Award, you acknowledge and agree that the grant of the RSU Award is made by the Company, not the Employer, in its sole discretion and the value of any RSU Award and shares of Common Stock acquired under the Plan shall not constitute salary or wages for any purpose under Argentine labor law, including, but not limited to, the calculation of (i) any labor benefits including, without limitation, vacation pay, thirteenth salary, compensation in lieu of notice, annual bonus, disability, and leave of absence payments, or (ii) any termination or severance indemnities.
If, notwithstanding the foregoing, any benefits under the Plan are considered as salary or wages for any purpose under Argentine labor law, you acknowledge and agree that such benefits shall not accrue more frequently than on an annual basis.
Australia
Australian Offer Document
This offer document sets out information regarding the offer to participate in the Plan for Australian resident grantees of the Company and its subsidiaries, affiliates and JVs. This information is provided by the Company to ensure compliance of the offer with Australian Securities and Investments Commission (“ASIC”) Class Order 14/1000, ASIC Regulatory Guide 49 and relevant provisions of the Corporations Act 2001.
Additional Documents. In addition to the information set out in this Appendix B, you are also being provided with copies of the following documents:
(a)    the Plan;
(b)    the Plan Prospectus (which contains a summary of the Plan);
(c)    the Terms;
(d)    LTI Program Overview; and
(e)    the summary of tax consequences of participation in the Plan for Australia, which is accessible by logging into your account at Morgan Stanley
(collectively, the “Additional Documents”).
The Additional Documents provide further information to help you make an informed investment decision about participating in the Plan. Neither the Plan nor the Plan Prospectus is a prospectus for the purposes of the Corporations Act 2001.
You should not rely upon any oral statements made in relation to this offer. You should rely only upon the statements contained in this Appendix B and the Additional Documents when considering participation in the Plan.
General Information Only. The information herein is general information only. It is not advice or information that takes into account your objectives, financial situation and needs.
You should consider obtaining your own financial product advice from a person who is licensed by ASIC to give such advice.
Risks of Participation in the Plan. Investment in shares of Common Stock involves a degree of risk. If you elect to participate in the Plan, you should monitor your participation and consider all risk factors relevant to the vesting or issuance of shares of Common Stock under the Plan as set forth below and in the Additional Documents
You should have regard to risk factors relevant to investment in securities generally and, in particular, to holding shares of Common Stock of the Company. For example, the value at which an individual share of Common Stock is quoted on the New York Stock Exchange (“NYSE”) may increase or decrease due to a number of factors. There is no guarantee that the value of a share of Common Stock will increase. Factors that may affect the value of an individual share of Common Stock include fluctuations in the domestic and international market for listed stocks, general economic conditions, including interest rates, inflation rates, commodity and oil prices, changes to government fiscal, monetary or regulatory policies, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.
More information about potential factors that could affect the Company’s business and financial results will be included in the Company’s most recent Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q. Copies of these reports are available at http://www.sec.gov/, on the Company’s “Investor Relations” page at https://investors.merck.com/home/default.aspx, and upon request to the Company.
In addition, you should be aware that the Australian dollar (“AUD”) value of any shares of Common Stock acquired under the Plan will be affected by the USD/AUD exchange rate. Participation in the Plan involves certain risks related to fluctuations in this rate of exchange.
Common Stock in a U.S. Corporation. Common stock of a U.S. corporation is analogous to ordinary shares of an Australian corporation. Each holder of a share of Common Stock is entitled to one vote. Further, shares of Common Stock are not liable to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.
Ascertaining the Market Value of Shares of Common Stock. You may ascertain the current market value of an individual share of Common Stock as traded on the NYSE under the symbol “MRK” at: https://www.nyse.com/quote/XNYS:MRK. The AUD equivalent of that value can be obtained at: https://www.rba.gov.au/statistics/frequency/exchange-rates.html.
This will not be a prediction of the market value of an individual share of Common Stock when the RSU Award vests or shares of Common Stock are issued under the Plan or of the applicable exchange rate on the vesting date or the date the shares of Common Stock are issued.
Tax Information
The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Tax Assessment Act”) applies (subject to the conditions in the Tax Assessment Act).
AustriaThere are no country-specific provisions.
BelgiumThere are no country-specific provisions.



Bermuda
Securities Law Information
The Plan and the Terms, including this Appendix B, are not subject to, and have not received approval from either the Bermuda Monetary Authority or the Registrar of Companies in Bermuda and no statement to the contrary, explicit or implicit, is authorized to be made in this regard. If any shares of Common Stock acquired under the Plan are offered or sold in Bermuda, the offer or sale must comply with the provisions of the Investment Business Act 2003 of Bermuda. Alternatively, the shares may be sold on the New York Stock Exchange on which they are listed.
Brazil
Compliance with Law
By accepting the RSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the expiration of the Restricted Period, the sale of shares obtained pursuant to the expiration of the Restricted Period, and the receipt of any dividends or dividend equivalents.
Labor Law Acknowledgment
By accepting the RSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value over the Restricted Period without compensation to you.
Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service; (ii) the Plan is not a part of the terms and conditions of your employment or service; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.
BulgariaThere are no country-specific provisions.



Canada
Termination of Employment
This provision replaces paragraph (9) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, the RSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company;
This provision replaces paragraph (11) of the “Nature of Grant” section in Part I of this Appendix B:
Except to the extent explicitly required under local employment standards legislation, no claim or entitlement to compensation or damages shall arise from termination of the RSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);
This provision replaces paragraph (12) of the “Nature of Grant” section in Part I of this Appendix B:
For purposes of the RSU Award, except to the extent expressly provided in your Terms or expressly required by applicable legislation, your employment relationship will be considered terminated (regardless of the reason for such termination) and your right to vest in the RSU Award under the Plan, if any, will terminate as of the date that is the earliest of (a) the date you are no longer employed or providing services to the Company or any parent, subsidiary, affiliate or JV, (b) the date you receive written notice of termination of employment, or (c) the date written notice of termination is delivered to your last known address (together, the “Termination Date”). Except to the extent explicitly required by applicable legislation, the Termination Date will exclude any notice period or period of pay in lieu of such notice required under statute, contract, common/civil law or otherwise. You will not earn, or be entitled to earn, any pro-rated vesting for that portion of time before the date on which your right to vest terminates, nor will you be entitled to any compensation for lost vesting. In case of any dispute as to whether termination of employment has occurred that cannot be reasonably determined under your Terms and the Plan, the Committee shall have the sole discretion, subject to applicable legislation, to determine whether such termination of employment has occurred and the effective date of such termination.
Notwithstanding the foregoing, if applicable employment standards legislation explicitly requires continued entitlement to vesting during a statutory notice period, your right to vest in the RSU Award under the Plan, if any, will terminate effective as of the last day of your minimum statutory notice period, but you will not earn or be entitled to pro-rated vesting if the vesting date falls after the end of your statutory notice period, nor will you be entitled to any compensation for lost vesting.
Securities Law Information
You are permitted to sell shares of Common Stock acquired through the Plan through the broker designated by the Company under the Plan, if any, provided the resale of shares of Common Stock acquired under the Plan takes place outside of Canada through the facilities of a stock exchange on which the shares of Common Stock are listed. The shares are currently listed on the New York Stock Exchange.
Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only.
The following provisions will apply to you if you are a resident of Quebec:
Language Consent
The parties acknowledge that it is their express wish that the Terms, as well as all documents, notices and legal proceedings entered into, given or instituted pursuant hereto or relating directly or indirectly hereto, be drawn up in English.
Les parties reconnaissent avoir exigé la rédaction en anglais de la convention, ainsi que de tous documents exécutés, avis donnés et procédures judiciaries intentées, directement ou indirectement, relativement à ou suite à la présente convention.
Data Privacy
This provision supplements the “Data Privacy” section in the Terms:
You hereby authorize the Company and the Company’s representatives to discuss with and obtain all relevant information from all personnel, professional or not, involved in the administration and operation of the Plan. You further authorize the Company, and its subsidiaries, affiliates or JVs and Morgan Stanley Smith Barney and any other stock plan service provider that may be selected by the Company to assist with the Plan to disclose and discuss the Plan with their respective advisors. You further authorize the Company and its subsidiaries, affiliates and JVs to record such information and to keep such information in your employee file.
Chile
Securities Law Information
THE OFFER OF THE RSU AWARD CONSTITUTES A PRIVATE OFFERING OF SECURITIES IN CHILE EFFECTIVE AS OF THE GRANT DATE. THE OFFER OF THE RSU AWARD IS MADE SUBJECT TO GENERAL RULING N° 336 OF THE CHILEAN COMMISSION OF THE FINANCIAL MARKET (“CMF”). THE OFFER REFERS TO SECURITIES NOT REGISTERED AT THE SECURITIES REGISTRY OR AT THE FOREIGN SECURITIES REGISTRY OF THE CMF, AND, THEREFORE, SUCH SECURITIES ARE NOT SUBJECT TO OVERSIGHT OF THE CMF. GIVEN THAT THE RSU AWARD IS NOT REGISTERED IN CHILE, THE COMPANY IS NOT REQUIRED TO PROVIDE PUBLIC INFORMATION ABOUT THE RSU AWARD OR SHARES OF COMMON STOCK IN CHILE. UNLESS THE RSU AWARD AND/OR THE SHARES OF COMMON STOCK ARE REGISTERED WITH THE CMF, A PUBLIC OFFERING OF SUCH SECURITIES CANNOT BE MADE IN CHILE.



The People's Republic of China
The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (“SAFE”) as determined by the Company.
The following terms and conditions apply only if you are classified as Band 600 and higher on the Grant Date.
Payment of Award and Termination of Employment
You will be permitted to hold shares of Common Stock issued to you at the end of the Restricted Period. Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment. The Company is under no obligation to arrange for such sale at any particular price. You will receive the sale proceeds, less any broker’s fees or commissions and subject to satisfaction of any Tax-Related Items. If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and be sold on your behalf as described above. Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.
Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan. The sale may occur (i) immediately upon vesting or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.
Broker Account
Any shares of Common Stock issued to you at expiration of the Restricted Period must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.
Exchange Control Compliance
You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends, dividend equivalents and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
The following terms and conditions apply only if you are classified as below Band 600 on the Grant Date.
Payment of Award
To facilitate compliance with exchange control laws in China, any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at expiration of the Restricted Period, less any broker’s fees or commissions and Tax-Related Items, which will be remitted to you in accordance with applicable exchange control laws and regulations. You will not be permitted to hold shares of Common Stock after vesting. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Exchange Control Compliance
You understand and agree that, to comply with exchange control laws in the PRC, the cash payable to you at expiration of the Restricted Period will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
Termination of Employment
Notwithstanding any terms or conditions of the Plan or the “Termination of Employment” section of the Terms to the contrary, the cash equivalent of any shares of Common Stock that vest upon termination of your employment will be distributed to you no later than six months from the date of termination of your employment, as determined by the Company in accordance with the Terms, or within any other such timeframe as may be required by SAFE. If the Terms provide that all or a portion of your outstanding RSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and become distributable immediately upon your termination of employment as described above. Any other portion of your RSU Award that is not vested as described above will expire immediately upon your termination of employment.



Colombia
Securities Law Information.
The shares of Common Stock are not and will not be registered with the Colombian registry of publicly traded securities (Registro Nacional de Valores y Emisores) and therefore the shares of Common Stock may not be offered to the public in Colombia. Nothing in this Appendix B should be construed as the making of a public offer of securities in Colombia.
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Pat I of this Appendix B:
You acknowledge that pursuant to Article 128 of the Colombian Labor Code, the Plan, the RSU Award and any income realized under the Plan do not constitute a component of your “salary”. Therefore, they will not be included and/or considered for purposes of calculating any and all labor benefits, such as legal/fringe benefits, vacations, indemnities, payroll taxes, social insurance contributions and/or any other labor-related amount which may be payable.
Costa RicaThere are no country-specific provisions.
CroatiaThere are no country-specific provisions.
CyprusThere are no country-specific provisions.
Czech RepublicThere are no country-specific provisions.
Denmark
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in this Appendix B:
By accepting the RSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.
Stock Option Act
You acknowledge that you received the Employer Statement (attached as Appendix C below) which summarizes select terms of your RSUs.
As set forth in Section 1 of the Stock Option Act, the Stock Option Act only applies to “employees” as that term is defined in Section 2 of the Stock Option Act and to the extent you are subject to Danish law. If you are a member of the registered management of the Company's subsidiary, affiliate or JV in Denmark or otherwise do not satisfy the definition of employee or are not subject to Danish law, you will not be subject to the Stock Option Act and the Employer Statement will not apply to you.
Please note the Stock Option Act was revised as of January 1, 2019. The standard termination provisions in the Terms will apply for any grants made under the Plan. The relevant termination provisions are detailed in the “Termination of Employment” section in your Terms.



EcuadorThere are no country-specific provisions.
EgyptThere are no country-specific provisions.
Estonia
Language Consent
By accepting the grant of the RSU Award, you confirm having read and understood the documents related to the grant (the Terms and the Plan), which were provided in the English language, and that you do not need the translation thereof into the Estonian language. You accept the terms of those documents accordingly.
Võttes vastu Award-de pakkumise kinnitad, et oled ingliskeelsena esitatud pakkumisega seotud dokumendid (Tingimused ja Plaan) läbi lugenud ja nendest aru saanud ning et ei vaja nende tõlkimist eesti keelde. Sellest tulenevalt nõustud viidatud dokumentide tingimustega
FinlandThere are no country-specific provisions.
France
Tax Notification
Your RSU Award is not intended to be French tax-qualified.
Language Consent
By accepting the RSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant l’attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions générales et dispositions, qui ont été transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.
GermanyThere are no country-specific provisions.
GreeceThere are no country-specific provisions.
Guatemala
Consent to Receive Information in English
By participating in the Plan, you acknowledge that you have reviewed the Terms and are sufficiently proficient in English, or, alternatively, you will seek appropriate assistance, to understand the terms and conditions of this RSU Award.



Hong Kong
Securities Law Information
Warning: The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You should exercise caution in relation to the offer. If you are in any doubt about any of the contents of the Plan and the Terms, including this Appendix B, you should obtain independent professional advice. The RSU Award and any shares of Common Stock issued pursuant to the RSU Award do not constitute a public offering of securities under Hong Kong law and are available only to Eligible Employees of the Company or its subsidiaries, affiliates and JVs. The Terms, including this Appendix B, the Plan and other incidental communication materials distributed in connection with the RSU Award (i) have not been prepared in accordance with and are not intended to constitute a “prospectus” for a public offering of securities under the applicable securities legislation in Hong Kong and (ii) are intended only for the personal use of each Eligible Employee of the Employer, the Company or its subsidiaries, affiliates and JVs and may not be distributed to any other person.
Payment of Award
Notwithstanding any discretion contained in Section 11(d) of the Plan, the grant of the RSU Award does not provide any right for you to receive a cash payment and the RSU Award is payable in shares of Common Stock only.
Sale of Shares
Shares of Common Stock received at vesting are accepted as a personal investment. In the event the Restricted Period on your RSU Award expires within six months of the Grant Date and shares of Common Stock are issued to you, you agree that you will not offer to the public or otherwise dispose of the shares of Common Stock prior to the six-month anniversary of the Grant Date.
Hungary
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
IndiaThere are no country-specific provisions.



Indonesia
Language Acknowledgment
A translation of the documents relating to this grant into Bahasa Indonesia can be provided to you upon request to mellisa.riana.dewi@merck.com. By accepting the RSU Award, you (i) confirm having read and understood the documents relating to this grant (i.e., your Terms, including this Appendix B, and the Plan) which were provided in the English language, (ii) accept the terms of these documents accordingly, and (iii) agree not to challenge the validity of this document based on Law No. 24 of 2009 on National Flag, Language, Coat of Arms and National Anthem or the implementing Presidential Regulation (when issued).
Persetujuan dan Pemberitahuan Bahasa.
Terjemahan dari dokumen-dokumen terkait dengan pemberian ini ke Bahasa Indonesia dapat disediakan untuk anda berdasarkan permintaan kepada mellisa.riana.dewi@merck.com. Dengan menerima Penghargaan ini, anda (i) mengkonfirmasi bahwa telah membaca dan memahami dokumen-dokumen berkaitan dengan pemberian ini (yaitu, Syarat-syarat anda, termasuk suplemen ini dan Program) yang disediakan dalam Bahasa Inggris, (ii) menerima persyaratan di dalam dokumen-dokumen tersebut, dan (iii) setuju untuk tidak mengajukan keberatan atas keberlakuan dari dokumen ini berdasarkan Undang-Undang No. 24 Tahun 2009 tentang Bendera, Bahasa dan Lambang Negara serta Lagu Kebangsaan ataupun Peraturan Presiden sebagai pelaksanaannya (ketika diterbitkan).
IrelandThere are no country-specific provisions.
Israel
Securities Law Information
The grant of the RSU Award under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 2000 Galloping Hill Road, Kennilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company’s filings on the following web site: http://www.sec.gov/edgar/searchedgar/companysearch.html.
Trust Arrangement
You understand and agree that the RSU Award is offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the “Israeli Sub-Plan”), the Trust Agreement (the “Trust Agreement”) between the Company and the Company’s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the “Trustee”), and the Terms. In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and/or the Plan, the Israeli Sub-Plan will govern the RSU Award granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.
Requirement to Return Signed Confirmation Letter
You are required to execute the Confirmation Letter - Trustee 102 Awards (“Confirmation Letter”) provided to you in connection with Awards granted to you under the Israeli Sub-Plan. In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the RSU Award to qualify for preferential tax treatment. By accepting this RSU Award, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the RSU Award may not qualify for favorable tax treatment. For more details, please contact Daphna Ben-Ari at daphna.ben-ari@merck.com or +972 9533306.
Confirmation of Section 102 Capital Gains Award Terms
The RSU Award is intended to be Capital Gain Awards that qualify for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the RSU Award, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the Awards granted to you.
By accepting the RSU Award, you: (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; (b) accept the RSU Award subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; and (c) agree that the shares of Common Stock issued to upon expiration of the Restricted Period of the RSU Award will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement. Furthermore, by accepting the RSU Award, you confirm that you understand the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon expiration of the Restricted Period of the RSU Award to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.



Italy
Plan Document Acknowledgment
By accepting the RSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms: (a) your RSU Award cannot be transferred other than by will or the laws of descent and distribution; (b) in the event of involuntary termination of your employment, your right to receive Awards and to receive distributions from Awards, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (d) you are responsible for all Tax-Related Items; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your RSU Award may be adjusted; (f) if a Change in Control, as described in the Plan, occurs, your RSU Award may immediately vest; (g) all decisions with respect to future grants will be at the sole discretion of the Company; and (h) the “Data Privacy” section of your Terms.
JapanThere are no country-specific provisions.
JordanThere are no country-specific provisions.
KoreaThere are no country-specific provisions.
Lebanon
Securities Law Information
The grant of Awards and distribution of the Plan and the Terms, including this Appendix B, to Eligible Employees does not constitute the marketing or offering of securities to the public in Lebanon pursuant to Law No. 161 (2011), the Capital Markets Law. Offers under the Plan are being made only to Eligible Employees of the Employer or the Company or any other subsidiary, affiliate or JV of the Company.
LithuaniaThere are no country-specific provisions.
Malaysia
Director Notification
If you are a director of the Company’s Malaysian subsidiary, affiliate or JV, you are subject to certain notification requirements under the Malaysian Companies Act. Among these requirements is an obligation to notify the Malaysian subsidiary, affiliate or JV in writing when you receive or dispose of an interest (e.g., RSU Awards or shares of Common Stock) in the Company or any related company. Such notifications must be made within 14 days of receiving or disposing of any interest in the Company or any related company.
Data Privacy
This provision replaces the “Data Privacy” section in your Terms:
You hereby explicitly and unambiguously consent to the collection, use and transfer, in electronic or other form, of your personal data as described in the Terms and any other grant materials by and among, as applicable, the Employer, the Company and its subsidiaries, affiliates and JVs for the exclusive purpose of implementing, administering and managing your participation in the Plan.
You understand that the Company and the Employer may hold certain personal information about you, including, but not limited to, your name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of Common Stock or directorships held in the Company, details of all Awards or any other entitlement to shares of Common Stock awarded, canceled, exercised, vested, unvested or outstanding in your favor, for the exclusive purpose of implementing, administering and managing the Plan (“Data”). The Data is supplied by the Employer and also by you through information collected in connection with the Terms and the Plan.
You understand that Data will be transferred to Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future, which is assisting the Company with the implementation, administration and management of the Plan. You understand that the recipients of the Data may be located in the United States or elsewhere, and that the recipients’ country (e.g., the United States) may have different data privacy laws and protections than your country. You understand that you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative at kon.li.yoong@merck.com. You authorize the Company, Morgan Stanley Smith Barney and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing your participation in the Plan. You understand that Data will be held only as long as is necessary to implement, administer and manage your participation in the Plan. You understand that you may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your local human resources representative. Further, you understand that you are providing the consents herein on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your employment status or service with the Employer will not be adversely affected; the only adverse consequence of refusing or withdrawing your consent is that the Company would not be able to grant RSU Awards to the you or administer or maintain such RSU Awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.
Privasi Data
Peruntukan ini menggantikan bahagian “Privasi Data” dalam Terma-terma anda:
Anda dengan ini secara eksplisit dan tanpa sebarang keraguan mengizinkan pengumpulan, penggunaan dan pemindahan, dalam bentuk elektronik atau lain-lain, data peribadi anda seperti yang diterangkan dalam Terma-terma atau apa-apa bahan geran oleh dan di antara, seperti mana yang terpakai, Majikan, Syarikat dan mana-mana anak syarikat, syarikat sekutu atau usahasamanya untuk tujuan ekslusif bagi melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan.
Anda memahami bahawa Syarikat dan Majikan mungkin memegang maklumat peribadi tertentu tentang anda, termasuk, tetapi tidak terhad kepada, nama anda, alamat rumah dan nombor telefon, tarikh lahir, nombor insurans sosial atau nombor pengenalan lain, gaji, kewarganegaraan, jawatan, apa-apa saham atau jawatan pengarah yang dipegang dalam Syarikat, butir-butir tentang semua Anugerah atau apa-apa hak lain untuk saham biasa yang dianugerahkan, dibatalkan, dilaksanakan, terletak hak, tidak diletak hak ataupun yang belum dijelaskan bagi faedah anda, untuk tujuan eksklusif bagi melaksanakan, mentadbir dan menguruskan Pelan tersebut ("“Data"”). Data tersebut dibekalkan oleh Majikan dan juga oleh anda melalui maklumat yang dikumpul berkenaan dengan Terma-terma dan Pelan.
Anda memahami bahawa Data ini akan dipindahkan kepada Morgan Stanley Smith Barney atau pembekal perkhidmatan pelan saham lain yang mungkin dipilih oleh Syarikat pada masa depan, yang membantu Syarikat dengan pelaksanaan, pentadbiran dan pengurusan Pelan. Anda memahami bahawa penerima-penerima Data mungkin berada di Amerika Syarikat atau di tempat lain, dan bahawa negara penerima (contohnya, Amerika Syarikat) mungkin mempunyai undang-undang privasi data dan perlindungan yang berbeza daripada negara anda. Anda memahami bahawa anda boleh meminta satu senarai yang mengandungi nama dan alamat penerima-penerima Data yang berpotensi dengan menghubungi wakil sumber manusia tempatan di kon.li.yoong@merck.com. Anda memberi kuasa kepada Syarikat, Morgan Stanley Smith Barney dan mana-mana penerima lain yang mungkin membantu Syarikat (pada masa kini atau masa depan) untuk melaksanakan, mentadbir dan menguruskan Pelan untuk menerima, memiliki, menggunakan, mengekalkan dan memindahkan Data, dalam bentuk elektronik atau lain-lain, semata-mata dengan tujuan untuk melaksanakan, mentadbir dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa Data hanya akan disimpan untuk tempoh yang perlu bagi melaksanakan, mentadbir, dan menguruskan penyertaan anda dalam Pelan. Anda memahami bahawa anda boleh, pada bila-bila masa, melihat data, meminta maklumat tambahan mengenai penyimpanan dan pemprosesan Data, meminta bahawa pindaan-pindaan dilaksanakan ke atas Data atau menolak atau menarik balik persetujuan dalam ini, dalam mana-mana kes, tanpa kos, dengan menghubungi secara bertulis wakil sumber manusia tempatan. Selanjutnya, anda memahami bahawa anda memberikan persetujuan di sini secara sukarela. Jika anda tidak bersetuju, atau jika anda kemudian membatalkan persetujuan anda, status pekerjaan atau perkhidmatan anda dengan Majikan tidak akan terjejas; satu-satunya akibat buruk jika anda tidak bersetuju atau menarik balik persetujuan anda adalah bahawa Syarikat tidak akan dapat memberikan Anugerah kepada anda atau mentadbir atau mengekalkan anugerah tersebut. Oleh itu, anda memahami bahawa keengganan atau penarikan balik persetujuan anda boleh menjejaskan keupayaan anda untuk mengambil bahagian dalam Pelan. Untuk maklumat lanjut mengenai akibat keengganan anda untuk memberikan keizinan atau penarikan balik keizinan, anda memahami bahawa anda boleh menghubungi wakil sumber manusia tempatan.



Mexico
Securities Law Information
Any RSU Award offered under the Plan and the shares of Common Stock underlying the RSU Award have not been registered with the National Register of Securities maintained by the Mexican National Banking and Securities Commission and cannot be offered or sold publicly in Mexico. In addition, the Plan and any other document relating to any Award may not be publicly distributed in Mexico. These materials are addressed to you only because of your existing relationship with the Company and its subsidiaries, affiliates and JVs and these materials should not be reproduced or copied in any form. The offer contained in these materials does not constitute a public offering of securities but rather constitutes a private placement of securities addressed specifically to individuals who are present Employees of the Company or one of its subsidiaries, affiliates and JVs, made in accordance with the provisions of the Mexican Securities Market Law, and any rights under such offering shall not be assigned or transferred.
Labor Law Acknowledgement
These provisions supplement the “Nature of Grant” section in your Terms:
By accepting the RSU Award, you understand and agree that: (i) the RSU Award is not related to the salary and other contractual benefits granted to you by the Employer and (ii) any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Policy Statement
The invitation the Company is making under the Plan is unilateral and discretionary and, therefore, the Company reserves the absolute right to amend it and discontinue it at any time without any liability to you.
The Company, with registered offices at 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A., is solely responsible for the administration of the Plan and your participation in the Plan and the acquisition of shares of Common Stock does not, in any way, establish an employment relationship between you and the Company since you are participating in the Plan on a wholly commercial basis. Based on the foregoing, you expressly recognize that the Plan and the benefits that you may derive from participating in the Plan do not establish any rights between you and the Employer and do not form part of the employment conditions and/or benefits provided by the Employer, and any modification of the Plan or its termination shall not constitute a change or impairment of the terms and conditions of your employment.
Finally, you hereby declare that you do not reserve to yourself any action or right to bring any claim against the Company for any compensation or damages regarding any provision of the Plan or the benefits derived under the Plan, and you therefore grant a full and broad release to the Company, its subsidiaries, affiliates, JVs, branches, representation offices, shareholders, officers, agents or legal representatives, with respect to any claim that may arise.
Plan Document Acknowledgment
By accepting the RSU Award, you acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms, including this Appendix B, in their entirety and fully understand and accept all provisions of the Plan and the Terms.
In addition, by accepting the benefits under this grant, you further acknowledge that you have read and specifically and expressly approve the terms and conditions in the “Nature of Grant” section of the Terms, in which the following is clearly described and established: (i) your participation in the Plan does not constitute an acquired right; (ii) the Plan and your participation in the Plan is offered by the Company on a wholly discretionary basis; (iii) your participation in the Plan is voluntary; and (iv) the Company and its subsidiaries, affiliates and JVs are not responsible for any decrease in the value of the shares of Common Stock underlying your RSU Award.



Morocco
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of commons stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
NetherlandsThere are no country-specific provisions.
New Zealand
Securities Law Information
WARNING: This is an offer of rights to receive shares of Common Stock upon vesting of the RSU Award subject to the terms of the Plan and the Terms. The RSU Award gives you a stake in the ownership of the Company. You may receive a return if dividends are paid on the shares of Common Stock.
If the Company runs into financial difficulties and is wound up, you will be paid only after all creditors have been paid. You may lose some or all of your investment.
New Zealand law normally requires people who offer financial products to give information to investors before they invest. This information is designed to help investors to make an informed decision. The usual rules do not apply to this offer because it is made under an employee share purchase scheme. As a result, you may not be given all the information usually required. You will also have fewer other legal protections for this investment.
You should ask questions, read all documents carefully, and seek independent financial advice before committing to participate in the Plan.
In addition, you are hereby notified that the documents listed below are available for review at http://one.merck.com/sites/hr/Lists/ChannelContent/CustDispForm.aspx?ID=63&Channel=Money. Filings made with the U.S. SEC can also be found at www.sec.gov.
(i)    this Appendix B which together with the Terms and the Plan sets forth the terms and conditions of your participation in the Plan;
(ii)    a copy of the Company’s most recent annual report (i.e., Form 10-K);
(iii)     a copy of the Company’s most recent published financial statements;
(iv)    a copy of the Plan; and
(v)    a copy of the Plan Prospectus.
A copy of the above documents will be sent to you free of charge on written request being mailed to Investor Relations at Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000.
As noted above, you are advised to carefully read the materials provided before making a decision whether to participate in the Plan. You are also encouraged to contact your tax advisor for specific information concerning your personal tax situation with regard to Plan participation.
NorwayThere are no country-specific provisions.
Panama
Securities Law Information
Your RSU Award is granted pursuant to the Plan and the shares of Common Stock which may be issued on the expiration of the Restricted Period are offered in a private transaction. This is not an offer to the public and the offer is not subject to the protections established by Panamanian securities laws, nor registration requirements.
Peru
Securities Law Notification
The offering of the RSU Award is considered a private offering in Peru; therefore, neither the grant of the RSU Award, nor the issuance of shares at the expiration of the Restricted Period, is subject to securities registration in Peru. For more information concerning this offer, please refer to the Plan, the Terms, the Plan Prospectus and any other grant documents made available to you by the Company. For more information regarding the Company, please refer to the Company’s most recent annual report on Form 10-K and quarterly report on Form 10-Q available at www.sec.gov, as well as the Company’s “Investor Relations” website at http://investors.merck.com.



Philippines
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
PolandThere are no country-specific provisions.
Portugal
Language Consent
You hereby expressly declare that you have full knowledge of the English language and have read, understood and fully accept and agree with the terms and conditions established in the Plan and the Terms.
Conhecimento da Lingua.
O Contratado, pelo presente instrumento, declara expressamente que tem pleno conhecimento da língua inglesa e que leu, compreendeu e livremente aceitou e concordou com os termos e condições estabelecidas no Plano e no Acordo de Atribuição (Terms em inglês).
Puerto RicoThere are no country-specific provisions.
Romania
Language Consent
By accepting the RSU Award, you acknowledge that you are proficient in reading and understanding English or have consulted with an advisor who is sufficiently proficient in English as to allow you to fully understood the terms of the documents related to the grant (the Terms, including this Appendix B and the Plan), which were provided in the English language. You accept the terms of these documents accordingly.
Consimtamant cu privire la limba
Prin acceptarea de aceasta Acordare, confirmati ca aveti un nivel adecvat de cunoastere in ce priveste cititirea si intelegerea limbii engleze sau ati consultat un consultant care este suficient de competent in limba engleza pentru a va permite sa intelegeti pe deplin termenii documentelor referitoare la acordare (anuntul, Acordul si Planul), care au fost furnizate in limba engleza. Acceptati termenii acestor documente in consecinta.
Russia
Payment of Award
If the Company in its sole discretion determines that the issuance of shares of Common Stock pursuant to this RSU Award would not comply with applicable laws, rules and regulations and/or that the approval of a governmental agency that it deems necessary or appropriate has not been obtained or has lapsed for whatever reason by the relevant Vesting Date, the Company will settle this RSU Award in cash only. Alternatively, the Company may permit this RSU Award to vest on the Vesting Date but delay settlement of this RSU Award until such time as it determines it is permissible to issuance shares of Common Stock as determined in accordance with Section 23 of the Plan. In the event that this RSU Award is settled in cash, upon settlement of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll.
Securities Law Information
The Terms, the Plan and all other materials that may be distributed regarding participation in the Plan do not constitute advertising or an offering of securities in Russia. Any securities issued under the Plan have not and will not be registered in Russia, nor will they be admitted for listing on any Russian exchange for trading within Russia. Thus, the securities described in the Terms, the Plan and all other materials that may be distributed regarding participation in the Plan may not be used for an offering or private or public circulation in Russia.
Under the default rule applicable prior to March 1, 2022 and at least temporarily not applicable for the reasons described below, any shares of Common Stock issued pursuant to the RSU Award shall be delivered into a U.S. brokerage account; in no event will any shares of Common Stock issued to you pursuant to the RSU Award be delivered to you in Russia.
Effective March 1, 2022, a set of temporary counter-measures introduced by the Russian President in Decree 79 dated February 28, 2022, and Decree 81 dated March 1, 2022 impact the ability of Russian residents to transact in securities of a foreign company. Under these rules, Russian residents (i.e., Russian citizens and foreign citizens living in Russia on the basis of a residency permit) may not acquire foreign securities (including the shares of Common Stock) and may not receive any cash amounts in their non-Russian bank accounts and/or broker accounts. Until the restrictions are lifted, the Company is prohibited from issuing shares of Common Stock to you at vesting of this RSU Award and reserves the right to settle the RSU Award in cash or alternatively, to delay the settlement of the RSU Award, as described under “Payment of Award” above.



Saudi Arabia
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Serbia
Securities Law Information
The RSU Award is not subject to the regulations concerning public offers and private placements under the Law on Capital Market. As set forth in the Terms, the RSU Award is subject to the laws of the State of New Jersey, U.S.A. (without regard to its conflict of law provisions).



Singapore
Restriction on Sale and Transferability
You hereby agree that any shares of Common Stock acquired pursuant to the RSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the RSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The RSU Award is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the RSU Award being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (e.g., RSU Awards, shares of Common Stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company’s Common Stock or any related company (including when you sell shares of Common Stock acquired upon the expiration of the Restricted Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of .either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.



Slovak RepublicThere are no country-specific provisions.
Slovenia
Language Consent
By accepting the grant of the RSU Award, you acknowledge that you are proficient in reading and understanding English and fully understand the terms of the documents related to the grant (this Appendix B, the Terms and the Plan), which were provided in the English language. You accept the terms of those documents accordingly.
Soglasje za Uporabo Angleškega Jezika
S sprejetjem dodelitve Nagrade (the RSU Award) potrjujete in priznavate, da ste sposobni brati in razumeti angleški jezik ter da v celoti razumete določila dokumentov, povezanih z dodelitvijo (ta dodatek, Določila (the Terms) in Načrt (the Plan)), ki so bili posredovani v angleškem jeziku. Skladno s tem sprejemate določila teh dokumentov.
South Africa
Tax Notification
By accepting the RSU Award, you agree to notify your Employer of the amount of any gain you realize upon the expiration of the Restricted Period. If you fail to advise your Employer of the gain realized upon expiration of the Restricted Period, you may be liable for a fine. You will be responsible for paying any difference between the actual tax liability and the amount withheld.
Securities Law Information
In compliance with South African Securities Law, you acknowledge that you have been notified that the documents listed below are available for your review on the Company intranet site at the web addresses listed below:
1. the Company’s most recent Annual Report (Form 10-K) – http://investors.merck.com/investors/financial-reports/quarterly-financials/default.aspx
2. the Company’s most recent Plan Prospectus - http://one.merck.com/sites/hr/Lists/ChannelContent/CustDispForm.aspx?ID=63&Channel=Money
You acknowledge that you may have copies of the above documents sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000.



Spain
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section in Part I of this Appendix B:
By accepting this RSU Award, you acknowledge that you understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.
You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute Awards under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs over and above the specific terms of the Plan on an ongoing basis. Consequently, you understand that any RSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary Award since the future value of the RSU Award and shares of Common Stock is unknown and unpredictable. In addition, you understand that the RSU Award would not be made to you but for the assumptions and conditions referred to above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any RSU Award shall be null and void.
You also understand and agree that, as a condition of the grant of the RSU Award, the termination of your employment for any reason (including the reasons listed below), the RSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs (unless otherwise specifically provided in the Terms). In particular, you understand and agree that the RSU Award will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Restricted Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to “despido improcednte”), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985.
Securities Law Information
No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the RSU Award. The Plan and the Terms have not been nor will they be registered with the Comisión Nacional del Mercado de Valores, and do not constitute a public offering prospectus.



Sweden
Authorization to Withhold
The following provision supplements the “Tax Withholding” section of the Terms:
Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the “Tax Withholding” section of the Terms, in accepting the RSU Award, you authorize the Company and/or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon vesting to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.
Switzerland
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
Taiwan
Securities Law Information
The RSU Award and the shares of Common Stock to be issued pursuant to the Plan are available only to Eligible Employees of the Company and its subsidiaries, affiliates and JVs. The grant of the RSU Award and offer of participation in the Plan does not constitute a public offer of securities by a Taiwanese company.
ThailandThere are no country-specific provisions.
Turkey
Securities Law Information
Under Turkish law, you are not permitted to sell shares of the Company’s Common Stock in Turkey; instead, the sale must take place outside Turkey, which will be the case if the shares of Common Stock are sold on the New York Stock Exchange on which the shares are currently listed.
You may be required to engage a Turkish financial intermediary to assist with the sale of shares of Common Stock acquired under the Plan. While you should not need to engage a Turkish financial intermediary with respect to the acquisition of such shares of Common Stock (as no consideration is paid for the RSU Award or underlying shares of Common Stock), this is less certain. In light of this uncertainty, you should consult your personal legal advisor prior to the expiration of the Restricted Period or any sale of shares of Common Stock to ensure compliance with the financial intermediary requirements.



Ukraine
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
United Arab Emirates
Securities Law Information
The Plan is only being offered to Eligible Employees of the Company and its subsidiaries, affiliates and JVs and is in the nature of an “exempt personal offer” of equity incentives to Eligible Employees of the Company’s subsidiary in the United Arab Emirates. The Plan, the Terms and any other grant documents you may receive from the Company are intended for distribution only to such Eligible Employees and must not be delivered to, or relied on by, any other person. Prospective recipients of the securities offered (i.e., shares of the Company’s Common Stock) should conduct their own due diligence on the securities. If you do not understand the contents of the Plan and the Terms, you should consult an authorized financial adviser. The Emirates Securities and Commodities Authority and the Dubai Financial Services Authority have no responsibility for reviewing or verifying any documents in connection with the Plan. The Ministry of Economy, the Dubai Department of Economic Development, Emirates Securities and Commodities Authority, Central Bank and the Dubai Financial Services Authority, as applicable depending on your Employer’s location in the United Arab Emirates, have not approved the Plan or the Terms or taken steps to verify the information set out therein, and have no responsibility for such documents.
United Kingdom
Tax Acknowledgment
You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by Her Majesty’s Revenue and Customs (“HRMC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.
Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the “Tax Withholding” section of the Terms.



UruguayThere are no country-specific provisions.
Vietnam
Payment of Award
Any RSU Award granted to you will be settled in cash only. This means that upon vesting of your RSU Award, you will receive in cash the value of the underlying shares of Common Stock at vesting, less any Tax-Related Items and broker’s fees or commissions, which will be remitted to you via local payroll. The Company reserves the right to settle the RSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.




APPENDIX C
MERCK & CO., INC.
SPECIAL NOTICE FOR EMPLOYEES IN DENMARK
ARBEJDSGIVERERKLÆRING/EMPLOYER STATEMENT
I henhold til § 3, stk. 1, i lov om brug af køberet eller tegningsret til aktier m.v. i ansættelsesforhold som ændret pr. 1 . januar 2019 ("Aktieoptionsloven") er du berettiget til i en særskilt skriftlig erklæring at modtage følgende oplysninger om betingede aktieenheder ("Tildeling") tildelt dig af Merck & Co., Inc. ("Selskabet") i henhold til Selskabets 2019 Incentive Stock Plan (“Planen”).


Denne erklæring indeholder kun de oplysninger, der er nævnt i Aktieoptionsloven.  De fuldstændige vilkår og betingelser, der gælder for din Tildeling, fremgår af Planen, vilkårene for 2019 tildeling af betingede aktieenheder for ikke-amerikanske medarbejdere (Global Terms and Conditions) (“Vilkårene”) og af landetillægget, som alle er udleveret til dig. 

I tilfælde af uoverensstemmelse mellem indholdet af denne erklæring og Planen, Vilkårene, har Planen of Vilkårene forrang.
Pursuant to Section 3(1) of the Danish Act on the Use of Rights to Purchase or Subscribe for Shares etc. in Employment Relationships as amended with effect from 1 January 2019 (the “Stock Option Act”), you are entitled to receive the following information regarding restricted stock units (the “Award”) granted to you by Merck & Co., Inc. (the “Company”) under its 2019 Incentive Stock Plan (the “Plan”) in a separate written statement.

This statement contains only the information mentioned in the Stock Option Act.  The terms and conditions of your Award are set forth in their entirety in the Plan and the Global Terms and Conditions including Appendix B thereto (the “Terms”), which have been made available to you. 



In the event of any inconsistency between the contents of this statement and the Plan and the Terms, the terms and conditions of the Plan and the Terms will prevail.
1. Tidspunkt for tildeling af den vederlagsfri ret til at modtage ordinære aktier mod opfyldelse af visse betingelser
Tildelingstidspunktet er den dato, hvor Vederlagsudvalget under Selskabets Bestyrelse eller et underudvalg under samme, eller et eventuelt andet bestyrelsesudvalg, der måtte efterfølge dette, ("Udvalget") godkendte tildeling til dig og besluttede, at denne skulle træde i kraft som anført i Vilkårene.
1. Date of grant of unfunded right to receive shares of Common Stock upon satisfying certain conditions

The Grant Date of your Award is the date that the Compensation and Benefits Committee of the Board of Directors of the Company or subcommittee thereof, or such other successor committee of the Board of Directors (the “Committee”) approved a grant for you and determined it would be effective, which is set forth in the Terms.
2. Vilkår for tildeling af ret til at modtage ordinære aktier mod opfyldelse af visse betingelser

Tildelinger i henhold til Planen sker alene efter Udvalgets eget frie skøn.  Selskabet har meget vide beføjelser til at bestemme, hvem der kan modtage Tildelinger og hvornår, og til at fastsætte betingelserne for Tildelingerne.  Selskabet kan efter dets eget frie skøn vælge fremover ikke at give Tildelinger.   I henhold til bestemmelserne i Planen og Vilkårene har du ikke nogen ret til eller noget krav på fremtidige tildelinger i henhold til Planen.
2. Terms or conditions for grant of a right to receive shares of Common Stock upon satisfying certain conditions
The grant of Awards under the Plan is made at the sole discretion of the Committee.  The Company has very broad powers to determine who will receive Awards and when, and to set the terms of the Awards.  The Company may decide, in its sole discretion, not to make any grants of Awards in the future.  Under the terms of the Plan and the Terms, you have no entitlement or claim to receive future grants under the Plan.




3. Modningstidspunkt eller -periode
Din Tildeling modnes med 33,333 % på hhv. 1-, 2- og 3-årsdagen for tildelingstidspunktet, medmindre den af de i Vilkårene anførte årsager inden da er modnet eller ophørt.  På modningstidspunktet konverteres din Tildeling til et tilsvarende antal ordinære aktier i Selskabet.

3. Vesting date or period
Your Award shall vest 33.333% on each of the first, second and third anniversary of the Grant Date, unless vested or terminated earlier for the reasons set forth in the Terms.  Your Award shall be converted into an equivalent number of Company shares of Common Stock upon vesting of the Award.
4. Udnyttelseskurs
Der betales ingen udnyttelseskurs i forbindelse med modning af din Tildeling eller Selskabets udstedelse af ordinære aktier til dig i overensstemmelse med den ovenfor beskrevne modningstidsplan.
4. Exercise price
No exercise price is payable upon the vesting of your Award or the issuance of shares of the Company’s Common Stock to you in accordance with the vesting schedule described above.



5. Din retsstilling i forbindelse med fratræden
Ved din fratræden vil din Tildeling blive behandlet i overensstemmelse med bestemmelsen “Ansættelsesforholdets ophør” (defineret som Termination of Employment i Vilkårene), hvilken bestemmelse er opsummeret umiddelbart nedenfor.

A. Generel regel. Hvis dit ansættelsesforhold inden for den Betingede Periode (defineret som Restricted Period i Vilkårene) ophører af nogen anden årsag end de nedenfor anførte, fortabes din Tildeling (og eventuelt optjent udbyttemodværdi) på tidspunktet for ophøret af dit ansættelsesforhold.

B. Ufrivilligt ophør af ansættelsesforholdet. Hvis Selskabet vurderer, at dit ansættelsesforhold er ophørt ufrivilligt inden for den Betingede Periode, men på eller efter 1-årsdagen for Tildelingen, vil en forholdsmæssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodværdi blive udbetalt til dig på det tidspunkt, hvor sådan udbetaling ville være sket, hvis dit ansættelsesforhold ikke var ophørt. Denne forholdsmæssige andel vil være svarende til Tildelingens fulde beløb (uanset om Tildelingen er modnet eller ej) gange antal fuldt forløbne måneder inden for den Betingede Periode og forud for tidspunktet for ansættelsesforholdets ophør, delt med 36; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodværdi, fortabes på tidspunktet for ansættelsesforholdets ophør.

C. Salg. Hvis dit ansættelsesforhold inden for den Betingede Periode (som defineret i Vilkårene) ophører, og Selskabet vurderer, at ophøret skyldes et salg af dit datterselskab, afdeling eller joint venture, vil følgende del af din Tildeling og eventuelt optjent udbyttemodværdi blive udbetalt til dig på det tidspunkt, hvor sådan udbetaling ville være sket, hvis dit ansættelsesforhold ikke var ophørt: En tredjedel, hvis ansættelsesforholdet ophører på eller efter Tildelingstidspunktet, men før 1-årsdagen for tildelingen; og hele Tildelingen, hvis ansættelsesforholdet ophører på eller efter 1-årsdagen for tildelingen.

D. Pensionering. Hvis dit ansættelsesforhold inden for den Betingede Periode ophører som følge af pensionering, vil en forholdsmæssig andel af din umodnede Tildeling og eventuelt optjent udbyttemodværdi blive udbetalt til dig på det tidspunkt, hvor sådan udbetaling ville være sket, hvis dit ansættelsesforhold ikke var ophørt. Denne forholdsmæssige andel vil være svarende til Tildelingens fulde beløb (uanset om Tildelingen er modnet eller ej) gange antal fuldt forløbne måneder inden for den Betingede Periode og forud for tidspunktet for ansættelsesforholdets ophør, delt med 36; reduceret med antal modnede betingede aktieenheder. Resten, inklusive eventuelt optjent udbyttemodværdi, fortabes på tidspunktet for ansættelsesforholdets ophør.

E. Dødsfald. Død. Hvis din ansættelse opsiges på grund af din død i den begrænsede periode, men forud for en ansættelsesopsigelse, som er påtænkt i B, C, D, G eller H, vil hele denne tildeling og optjente udbytteækvivalenter straks optjenes. Hvis du dør i den begrænsede periode, men efter at dit ansættelsesforhold ophører af de årsager, der er anført i B, C, D, G eller H, vil den resterende, ikke-fortabte del af denne Award og optjente udbytteækvivalenter straks optjenes.

F. Uredelighed eller pligtforsømmelse. Hvis dit ansættelsesforhold ophører som følge af bevidst uredelighed eller forsætlig eller grov pligtforsømmelse fra din side, fortabes denne Tildeling og eventuelt optjent udbyttemodværdi samtidig med din modtagelse af meddelelse om ansættelsesforholdets ophør.

G. Uarbejdsdygtighed. Hvis dit ansættelsesforhold inden for den Betingede Periode ophører, og Selskabet vurderer, at ophøret skyldes din manglende evne til at opfylde de forpligtelser, der påhviler dig i kraft af din stilling, som følge af fysisk eller mental svagelighed, der forventes at ville vare ved i mindst 6 måneder eller medføre din død, vil - uanset, om du måtte være berettiget til invaliditetsydelser fra nogen invaliditetsordning - denne Tildeling forblive i kraft og kvalificeret til udbetaling i overensstemmelse med Vilkårene på samme måde, som hvis ansættelsesforholdet ikke var ophørt, idet udbetaling i så fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere.

H. Kontrolskifte. Hvis Selskabet eller noget moderselskabs, datterselskabs, tilknyttet parts eller joint venture af Selskabet inden for den Betingede Periode uden Berettigelse (defineret som without Cause i Planen) bringer dit ansættelsesforhold til ufrivillig opsigelse, vil denne Tildeling forblive i kraft i overensstemmelse med Vilkårene på samme måde, som hvis ansættelsesforholdet ikke var ophørt, idet udbetaling i så fald vil ske samtidig med tilsvarende udbetalinger til aktive medarbejdere. Hvis denne Tildeling efter et kontrolskifte ikke længere er udestående og heller ikke er konverteret til en anden Tildeling, vil du være berettiget til for denne Tildeling at modtage kontant betaling med et beløb svarende fair markedsværdi af det vederlag, kapitalejerne i Selskabet modtog i forbindelse med kontrolskiftet til udbetaling senest 30 dage fra kontrolskiftets gennemførelse. Dette afsnit bortfalder, når der er gået 2 år fra kontrolskiftets gennemførelse.

I. Joint Venture. Ansættelse i et joint venture, herunder enhver anden enhed, som Selskabet har en betydelig forretningsinteresse eller ejerandel i, anses i forhold til denne Tildeling ikke for ophør af ansættelsesforholdet.
5. Your rights upon termination of employment
The treatment of your Award upon termination of employment will be determined in accordance with the “Termination of Employment” section of the Terms summarized immediately below.


A. General Rule. If your employment is terminated during the Restricted Period (as defined in the Terms), for any reason other than those specified in the following paragraphs, your Award (and any accrued dividend equivalents) will be forfeited on the date your employment ends.

B. Involuntary Termination. If the Company determines that your employment is involuntarily terminated during the Restricted Period but on or after the first anniversary, a pro rata portion of your unvested Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.



C. Sale. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from the sale of your subsidiary, affiliate, division or joint venture, the following portion of your Award and accrued dividend equivalents will be distributed to you at such time as it would have been paid if your employment had continued: one-third if employment terminates on or after the Grant Date but before the first anniversary thereof; and all if employment terminates on or after the first anniversary of the Grant Date.


D. Retirement. If your employment terminates by retirement during the Restricted Period, a pro rata portion of your unvested Award and accrued dividend equivalents will be distributed to you at such time as they would have been paid if your employment had continued. The pro rata portion will equal the full amount of the Award (whether or not vested) times the number of completed months during the Restricted Period and prior to the date employment terminates, divided by 36; reduced by the number of restricted stock units that have vested. The remainder and any accrued dividend equivalents will be forfeited on the date your employment ends.




E. Death. If your employment terminates due to your death during the Restricted Period but prior to an employment termination contemplated in B, C, D, G or H, all of this Award and accrued dividend equivalents will immediately vest. If you die during the Restricted Period but after your employment terminates for the reasons contemplated in B, C, D, G or H, the remaining, non-forfeited portion of this Award and accrued dividend equivalents will immediately vest.

F. Misconduct. If your employment is terminated as a result of your deliberate, willful or gross misconduct, this Award and accrued dividend equivalents will be forfeited immediately upon your receipt of notice of such termination.



G. Disability. If your employment is terminated during the Restricted Period and the Company determines that such termination resulted from inability to perform the material duties of your role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in your death, whether or not you are eligible for disability benefits from any applicable disability program, then this Award will continue and be distributable in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award.



H. Change in Control. If the Company or a parent, subsidiary, affiliate or joint venture of the Company involuntarily terminates your employment during the Restricted Period without Cause (as defined by the Plan) before the second anniversary of the closing of any change in control, then this Award will continue in accordance with its terms as if employment had continued and will be distributed at the time active employees receive distributions with respect to this Award. If this Award does not remain outstanding following the change in control and is not converted into a successor Award, then you will be entitled to receive cash for this Award in an amount equal to the fair market value of the consideration paid to Company stockholders for a share of Company Common Stock in the change in control payable within 30 days of the closing of the change in control. On the second anniversary of the closing of the change in control, this paragraph shall expire.


I. Joint Venture. Employment with a joint venture including any other entity in which the Company has a significant business or ownership interest is not considered termination of employment for purposes of this Award.



6. Økonomiske aspekter ved deltagelse i Planen
Tildelingen har ingen umiddelbare økonomiske konsekvenser for dig.  Det er først ved modning af Tildelingen og det efterfølgende salg af de modtagne ordinære aktier ved modning, at du vil kunne realisere nogen indtægt under Planen.

Værdien af Tildelingen indgår ikke i beregningen af feriepenge, pensionsbidrag, fratrædelsesgodtgørelse, godtgørelser eller andre lovpligtige, vederlagsafhængige ydelser.

Investering i aktier er ikke uden økonomisk risiko.  Værdien af aktierne på modningstidspunkterne afhænger ikke kun af Selskabets økonomiske udvikling, men også af den generelle udvikling på aktiemarkedet.  Der kan derfor ikke gives nogen garanti for, at en investering i aktier vil være overskudsgivende.


Denne erklæring berører ikke de skattemæssige konsekvenser af deltagelse i Planen, modtagelse af eventuelt udbytte eller et efterfølgende salg af de i medfør af Planen erhvervede ordinære aktier.  Du anbefales at drøfte dette med din personlige økonomiske rådgiver eller skatterådgiver.
6. Financial aspects of participating in the Plan
The grant of the Award has no immediate financial consequences for you.  It is not until vesting of the Award and the subsequent sale of shares of Common Stock acquired at vesting that you may realize any income under the Plan.

The value of the Award is not taken into account when calculating holiday allowances, pension contributions, severance pay, statutory allowance, compensation or other statutory remuneration calculated on the basis of salary.

Investing in shares of Common Stock involves some financial risk.  The value of the shares at the time of vesting and sale will not only be dependent on the Company's financial development, but also on the general development on the stock market.  Consequently, there is no guarantee that investment in shares of Common Stock will yield a profit.

This statement does not address the tax consequences of participating in the Plan, the receipt of any dividends or the subsequent sale of any shares of Common Stock acquired under the Plan.  You are encouraged to discuss this matter with your personal financial or tax advisor.
MERCK & CO., INC.
2000 Galloping Hill Road
Kenilworth, New Jersey
U.S.A. 07033
MERCK & CO., INC.
2000 Galloping Hill Road
Kenilworth, New Jersey
U.S.A. 07033


EX-10.36 18 exhibit1036-2022annualpsut.htm EXHIBIT-10.36 2022 ANNUAL PSU TERMS AND CONDITIONS (GUINDO) Document

Exhibit 10.36

GLOBAL TERMS AND CONDITIONS
2022 SIGN-ON EQUITY GRANT OF PERFORMANCE SHARE UNITS FOR CHIRFI GUINDO
UNDER THE MERCK & CO., INC. 2019 INCENTIVE STOCK PLAN

I.GENERAL. Merck & Co., Inc. (the “Company”) has granted to you the award of Performance Share Units (“PSUs”) specified in this document (“PSU Award” or “Sign-On Equity”) pursuant to the Merck & Co., Inc. 2019 Incentive Stock Plan, including any sub-plan thereto for your country (the “Plan”). This PSU Award is subject to the terms and conditions of the Plan and these Global Terms and Conditions, including any additional terms and conditions for your country in Appendix B (the “Terms”). Unless otherwise defined in this document, capitalized terms used in these Terms are as defined in the Plan.

Grant Type:PSU - Annual
Grant Date:Jan. 1, 2022
Award Period:
Jan. 1, 2022 –
Dec. 31, 2024











IMPORTANT NOTICE: This grant requires you to affirmatively accept it. You MUST log onto the Morgan Stanley website at

(http://www.morganstanley.com/spc/knowledge/managing-equity/managing-your-existing-awards/accepting-awards-grants/) to accept the grant.

Follow the procedure described on the Morgan Stanley website to accept your PSU Award within 90 days. Failure to accept the terms and conditions of your PSU Award within 90 days may result in forfeiture of the PSU Award.

II.DEFINITIONS. For the purpose of these Terms:

Award Period” means the three-year period commencing on January 1, 2022 and ending on December 31, 2024.

Earnings Per Share or EPS” means the Company’s net income divided by the weighted average of the number of shares of Company common stock on a fully diluted basis during the Award Period.

The above result shall be adjusted to exclude charges or items from the measurement of performance relating to (1) restructurings, discontinued operations, purchase accounting items, merger-related costs, the impact of significant acquisitions and/ or divestitures, extraordinary items and other unusual or non-recurring charges and/ or events; (2) an event either not directly related to Company operations or not reasonably within the control of Company management; (3) fluctuations in foreign exchange versus Plan rates; (4) the impact of Share Repurchases above or below planned levels; and (5) the effects of accounting changes in accordance with U.S. generally accepted accounting principles, or other significant legislative changes.

EPS Performance Payout” means the percentage reflecting the attainment level of the Company’s EPS goal as determined under paragraph C of Section III.

Final Award” means the number of PSUs that become eligible to vest based on the attainment level of the goals for each performance metric, as calculated in accordance with Section III hereof.

Grant Date” means the date as of which a Performance Share Unit is granted.

Peer Healthcare Companies” are the healthcare companies used by the Committee in evaluating the Company’s TSR performance for the entire Award Period. For 2022 and for so long thereafter during the Award Period that such companies are publicly traded on a nationally recognized stock exchange, the following are the Peer Healthcare Companies except as described below.




AbbVie
Eli Lilly
Novartis
Amgen
GlaxoSmithKline
Pfizer
Astra Zeneca
Bristol-Myers Squibb
Roche
Johnson & Johnson
Sanofi-Aventis
Gilead Sciences
The Committee intends that the list of Peer Healthcare Companies may be subject to such adjustment as may be necessary to reflect a merger, reorganization, recapitalization, extraordinary cash dividend, combination of shares, consolidation, rights offering, spin off, split off, split up, bankruptcy, liquidation, acquisition, or other similar change in any Peer Healthcare Company.

Performance Share Unit” or “PSU” means an award representing the right to vest in shares of Common Stock based upon the attainment level of the performance metrics in accordance with Section III and as otherwise described in these Terms. Until distributed pursuant to Section VI, these PSUs shall not entitle the holder to any of the rights of a holder of Common Stock, including voting rights; provided, however, that the Committee retains the right to make adjustments as described in Section 7 of the Plan.

Target Shares” means the number of shares of Common Stock that would become eligible to vest if the performance metrics set forth in Section  III are each achieved at the level identified as “target” for the entire Award Period.

Total Shareholder Return” or “TSR” means the change in value of one share of a company’s common stock over the Award Period, taking into account both stock price appreciation (or depreciation) and the reinvestment of dividends. The beginning and ending stock prices will be based on the average closing stock prices during the months of December as applicable. TSR will be calculated on a compound annualized basis over the Award Period.

TSR Performance Payout” means the percentage reflecting the attainment level of Company’s TSR performance as determined under paragraph B of Section III.

III.CALCULATION OF FINAL AWARD OF PERFORMANCE SHARE UNITS

You shall vest in the number of PSUs to the extent provided for in this Section III unless otherwise provided for in Section V (“Termination of Employment”).

A.Performance Metrics. The Final Award will equal the TSR Performance Payout plus the EPS Performance Payout in the proportions determined in Paragraph D below.

B.TSR Performance Payout. The TSR Performance Payout shall be determined as follows:

1.     If the Company’s annualized TSR is greater than the median of the annualized TSR of the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% plus five times the difference in percentage points up to a maximum of 200%; provided, however, that if the Company’s annualized TSR is negative, then in no event will the TSR Performance Payout be greater than 100%.

For example, if the Company’s annualized TSR is 25% and the median annualized TSR of the Peer Healthcare Companies is 20%, then the TSR Performance Payout would be 125% [100% + ((25% - 20%) x 5%)].

2.    If the Company’s TSR is less than the median of the annualized TSR among the Peer Healthcare Companies, then the TSR Performance Payout will equal 100% minus five times the difference in percentage points; provided, however, that if such median exceeds the Company’s annualized TSR by more than 10 percentage points, then the TSR Performance Payout will be 0%.

C.EPS Performance Payout. The EPS Performance Payout shall be determined in accordance with the following performance schedule:




Earnings Per Share Goals
Payout Percentage
Less than $19.53
0%
$19.53 (Threshold)
25%
$21.46 (Target)
100%
$22.75%150
$24.04 (Stretch)
200%

Payout Percentages corresponding to performance between two discrete values in the table will be interpolated.

D.The Final Award will equal the sum of (x) TSR Payout Percent for the entire Award Period TIMES Target Shares TIMES 50 percent and (y) EPS Payout Percentage TIMES Target Shares TIMES 50 percent.

E.Maximum Award. Anything in these Terms to the contrary notwithstanding, the Final Award shall be reduced to the extent necessary to reflect that the value of the Final Award, valued based on the closing price of the Common Stock as of the date the Final Award is determined, may not exceed four times the value of the Target Shares, valued based on the closing price of the Common Stock as of the Grant Date.

IV.DIVIDEND EQUIVALENTS

During the Award Period, dividend equivalents will be accrued on the PSUs if and to the extent dividends are paid by the Company in the Common Stock. Payment of such dividend equivalents will be made, without interest or earnings, at the same time that the Final Award is paid. Such dividend equivalents shall be paid as additional shares in an amount equal to the sum of the dividends paid during the period between the Grant Date and the date immediately prior to the date the PSU Award is settled in accordance with Section VI divided by the price of a share of Common Stock on the date the Final Award is determined. If any portion of this PSU Award lapses, is forfeited or expires, no dividend equivalents will be credited or paid on such portion. Any payment of dividend equivalents will be reduced to the extent necessary for the Company to satisfy any tax or other withholding obligations in accordance with Section X.

V.TERMINATION OF EMPLOYMENT

If your employment with the Company or, if different, the subsidiary, affiliate or joint venture (“JV”) of the Company by which you are employed (the “Employer”) is terminated during the Award Period, your right to the PSU Award, where references to the Final Award in this section include any accrued dividend equivalents, will be determined according to the terms in this Section V and for grantees outside the United States, also in paragraph 12 of Section A (“Nature of Grant”) of Appendix B, Part I.

A.General Rule. If your employment is terminated during the Award Period for any reason other than those specified in the following paragraphs, this PSU Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

B.Involuntary Termination. If your employment terminates during the Award Period and the Company determines that employment was involuntarily terminated the Final Award will become eligible to vest when the Final Award is determined, provided you sign and refrain from revoking a severance agreement in a format prescribed by Merck Sharp & Dohme LLC (“MSD”), which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. If your employment terminates during the Award Period, the Company determines that employment was involuntarily terminated on or after the first anniversary of the first day of the Award Period and you do not sign and refrain from revoking a severance agreement as outlined above, a pro rata portion of the Final Award will become eligible to vest when the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36. The right to the remaining PSUs will be forfeited on the date your employment terminates. An “involuntary termination” includes termination of employment by the Company as the result of a restructuring or job elimination, but excludes non-performance of duties and



the reasons listed under paragraphs C through G of this section. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will be forfeited according to this paragraph notwithstanding such rehire.

C.Sale. If your employment is terminated during the Award Period and the Company determines that such termination resulted from the sale of the subsidiary, affiliate, division or JV that employed you, the Final Award will become eligible to vest on the date the Final Award is determined, provided you sign and refrain from revoking a severance agreement in a format prescribed by MSD, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. Notwithstanding the foregoing, the Committee may determine, for purposes of this PSU Award, whether employment with an entity that is established from the Company’s spin off, split off, split up or distribution of equity securities in connection with that entity constitutes a termination of employment, and may make adjustments, if any, as it deems appropriate, and to the extent not inconsistent with the Plan, at the time of the distribution of such equity securities, in the kind and/or number of shares subject to this PSU Award.

D.Retirement. If you terminate employment during the Award Period by retirement (including early and disability retirement), a pro rata portion of the Final Award will become eligible to vest on the date the Final Award is determined. The pro rata portion shall be determined by multiplying the Final Award by a fraction, the numerator of which is the number of completed months in the Award Period during which you were employed by the Company or the Employer, as applicable, and the denominator of which is 36. For grantees who are employed in the U.S., “retirement” means a termination of employment after attaining the earliest of (a) age 55 with at least 10 years of service (b) such age and service that provides eligibility for subsidized retiree medical coverage or (c) age 65 without regard to years of service. For other grantees, “retirement” is determined by the Company. The right to the remaining PSUs underlying the Final Award will be forfeited on the date your employment terminates. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this grant nevertheless will expire according to this paragraph notwithstanding such rehire.

E.Death. If your employment terminates due to death during the Award Period but prior to the date of an employment termination contemplated under paragraphs B, C, D, G or H the Final Award will become eligible to vest on the date the Final Award is determined. If you die during the Award Period, but after your employment terminates for the reasons listed under paragraphs B, C, D, G or H of this section, any portion of the Final Award that remains outstanding at your death will become eligible to vest on the date the Final Award is determined.

F.Cause. If your employment is terminated for Cause, this PSU Award will be forfeited immediately upon your receipt of notice of such termination. For purposes of this paragraph, “Cause” is as defined in your offer letter from MSD as an act or omission by you, which constitutes: (i) a deliberate (and not justified and appropriate in the performance of your duties) or reckless disclosure of proprietary or other confidential information relating to the Company, MSD or one of their subsidiaries (each a “Merck Entity”), its personnel, research or business; (ii) embezzlement, theft or other misappropriation of the assets of a Merck Entity; (iii) deliberate or reckless falsification of records or reports; (iv) deliberate bad faith or reckless action that causes actual or potential significant injury or loss to a Merck Entity and/or its and/or their employees; (v) insubordination (meaning the repeated refusal to carry out work assignments and/or direction); (vi) willful or repeated failure to perform assigned job duties; (vii) an illegal act on the property of a Merck Entity or in representing a Merck Entity; (viii) a material violation of a Company policy relating to the research, development, manufacturing, sales or marketing of Company products or the overall goodwill or reputation of the Company; (ix) any action that would trigger the claw back provisions of any Bonus or Long-Term Incentive Plans applicable to you; or a (x) breach by you of your representations as set forth in your offer letter from MSD.

G.Disability. If your employment is terminated during the Award Period and the Company determines that such termination resulted from inability to perform the material duties of his or her role by reason of a physical or mental infirmity that is expected to last for at least six months or to result in death, whether or not he or she is eligible for disability benefits from any applicable disability program, then the Final Award will become eligible to vest on the date the Final Award is determined. If your employment is terminated as described in this paragraph and you are later rehired by the Company or the Employer, as applicable, this PSU Award nevertheless will expire according to this paragraph notwithstanding such rehire.

H.Change in Control. Upon the occurrence of a Change in Control (as such term is defined in the Plan), the Final Award shall mean a number of PSUs equal to the Target Shares. If this PSU Award is



assumed, converted or otherwise remains outstanding in connection with a Change in Control and your employment is terminated during the Award Period without Cause before the second anniversary of the closing of the Change in Control, then this PSU Award and dividend equivalents that have accrued through the end of the Award Period will continue to vest at the end of the original Award Period. If this PSU Award does not remain outstanding following the Change in Control and is not assumed, converted, or otherwise remains outstanding, then the PSU Award and dividend equivalents that have accrued through such date will immediately vest and, at the election of the Company, you will be entitled to receive cash for such portion of this PSU Award in an amount equal to the fair market value of the consideration paid to Merck stockholders for a share of Merck Common Stock in the Change in Control. On the second anniversary of the closing of the Change in Control, this paragraph shall expire. “Cause” and “Change in Control” are defined in the Merck & Co., Inc. Change in Control Separation Benefits Plan (excluding MSD Change in Control).

I.Good Reason. If you terminate employment for Good Reason, the RSU Award, and any accrued dividends, will continue to vest on the following original Vesting Date(s) set forth in paragraph I(A), provided you sign and refrain from revoking a severance agreement in a format prescribed by MSD, which agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. “Good Reason” is as defined in your offer letter from MSD and includes the following: a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a position on the Executive Team reporting to MSD’s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of your offer letter from MSD, provided that you deliver written notice of a claim of Good Reason to MSD’s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD’s failure to cure.

J.Transfer of Employment. Transfer of employment between the Company, a subsidiary, affiliate, JV, JV partner or affiliate of the Company who provides services to the JV with such partner or affiliate or other entity in which the Company has determined that it has a significant business or ownership interest (together, the “Company Group”) is not considered termination of employment for purposes of this PSU Award. Such employment must be approved by the Company and contiguous with employment by the entity in the Company Group you were employed by immediately prior to the relevant transfer. The terms set out in paragraphs A through H above shall continue to apply to this PSU Award following a transfer of employment accordance with this section.


VI.DISTRIBUTION OF SHARES

Following the end of the Award Period, you (or your estate, in the case of PSUs that vest pursuant to Section V(E)) shall be entitled to receive a number of shares of Common Stock equal to the Final Award (as modified to the extent provided under Section V and subject to Section X) plus the shares for accrued dividend equivalents set forth in Section IV, rounded to the nearest whole number (no fractional shares shall be issued). Such distribution shall be made as soon as administratively feasible following the last day of the Award Period, but in no event later than the end of the calendar year immediately following the Award Period.

VII.SECTION 409A COMPLIANCE

Anything in the Plan or these Terms to the contrary notwithstanding, no distribution of PSUs may be made unless in compliance with Section 409A of the Code or any successor thereto. In addition, distributions, if any, made upon or by reference to the date of an employment termination shall not be paid unless such termination constitutes a “separation from service (as defined in Section 409A of the Code)” and any such payment to a “Specified Employee” as defined in Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, to the extent required by Section 409A of the Code will instead be made on the first day the seventh month following the separation from service, in the same form as they would have been made had this restriction not applied; provided further, that no dividend or dividend equivalents will be paid, accrued or accumulated in respect of the period during which distribution was suspended.

VIII.SUBJECT TO RECOUPMENT

This PSU Award will be subject to recoupment in the event of certain violations of Company policy in accordance with the Company’s Policies and Procedures for Recoupment of Compensation for



Compliance Violations and for Significant Restatement of Financial Results, as set forth in Appendix A (as may be amended from time to time).

IX.TRANSFERABILITY

Prior to distribution pursuant to Section VI, the PSU Award and any interest therein shall not be sold, assigned, transferred, pledged or otherwise disposed of, alienated or encumbered, either voluntarily or involuntarily, other than by will or the laws of descent and distribution in connection with your death.

X.TAX WITHHOLDING

Regardless of any action the Company and/or the Employer take with respect to any or all income tax, social insurance, payroll tax, payment on account or other tax-related items arising out of your participation in the Plan and legally applicable or deemed applicable to you (“Tax-Related Items”), you acknowledge that the ultimate liability for all Tax-Related Items is and remains your responsibility and may exceed the amount actually withheld by the Company and/or the Employer, if any. You further acknowledge that the Company and/or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSU Award or underlying shares of Common Stock, including, but not limited to, the grant, vesting or settlement of the PSU, the subsequent sale of shares of Common Stock acquired upon the expiration of the Award Period and the receipt of any dividends and/or dividend equivalents; and (ii) do not commit and are under no obligation to structure the terms of the grant or any aspect of the PSU to reduce or eliminate your liability for Tax-Related Items or achieve any particular tax result. Furthermore, if you have become subject to tax in more than one jurisdiction, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

Prior to the relevant taxable or tax withholding event, as applicable, you shall pay or make arrangements satisfactory to the Company and/or the Employer to satisfy any applicable withholding obligations or rights with regard to all Tax-Related Items. In this regard, you authorize the Company and/or the Employer, or their respective agents, at their discretion, to satisfy the Tax-Related Items by one or a combination of the following: (i) withholding from your wages or other cash compensation paid to you by the Company, the Employer and/or any subsidiary, affiliate or JV of the Company; or (ii) withholding from proceeds of the sale of shares of Common Stock acquired at expiration of the Award Period either through a voluntary sale or through a mandatory sale arranged by the Company (on your behalf pursuant to this authorization); or (iii) withholding in shares of Common Stock to be issued upon expiration of the Award Period; provided, however, that if you are a Section 16 officer of the Company under the Exchange Act, then the Company will satisfy the Tax-Related Items (other than U.S. Federal Insurance Contribution Act taxes or other Tax-Related Items which become payable in a year prior to the year in which shares of Common Stock are issued upon settlement of the PSUs by withholding in shares of Common Stock pursuant to (iii) above, unless the use of such withholding method is problematic under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by a one or a combination of (i) or (ii) above.

The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in your jurisdiction(s). In the event of over-withholding, you may receive a refund of any over-withheld amount in cash (with no entitlement to the equivalent in Common Stock), or if not refunded, you may seek a refund from the local tax authorities. In the event of under-withholding, you may be required to pay additional Tax-Related Items directly to the applicable tax authority or to the Company and/or the Employer. If the obligation for Tax-Related Items is satisfied by withholding in shares of Common Stock, for tax purposes, you will be deemed to have been issued the full number of shares of Common Stock subject to the vested PSUs, notwithstanding that a number of the shares is held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of your participation in the Plan.

You shall pay to the Company or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot be satisfied by the means previously described in this section. The Company may refuse to issue or deliver the shares of Common Stock or the proceeds of the sale of shares if you fail to comply with your obligations in connection with the Tax-Related Items.

XI.DATA PRIVACY




The Company is located at 2000 Galloping Hill Road, Building K-1 Kenilworth, New Jersey, U.S.A. 07033 and grants employees of the Company and any subsidiary, affiliate or JV of the Company, the opportunity to participate in the Plan, at the Company's sole discretion. If you would like to participate in the Plan, you understand that you should review the following information about the Company’s data processing practices and declare your consent.

A.Data Collection and Usage. The Company collects, processes and uses your personal data, including, name, home address, email address and telephone number, date of birth, social insurance number or other identification number, salary, citizenship, job title, any shares of Common Stock or directorships held in the Company, and details of all awards, canceled, vested, or outstanding in your favor, which the Company receives from you or your Employer. If the Company offers you the opportunity to participate in the Plan, then the Company will collect your personal data for purposes of allocating Common Stock and implementing, administering and managing the Plan. The Company’s legal basis for the processing of your personal data would be your consent.

B.Stock Plan Administration Service Providers. The Company transfers participant data to Morgan Stanley, an independent service provider based in the United States, which assists the Company with the implementation, administration and management of the Plan. In the future, the Company may select a different service provider and share your data with another company that serves in a similar manner. The Company’s service provider will open an account for you. You will be asked to agree on separate terms and data processing practices with the service provider, which is a condition to your ability to participate in the Plan.

C.International Data Transfers. The Company and its service providers are based in the United States. If you are outside of the United States, you should note that your country has enacted data privacy laws that are different from the United States. The Company’s legal basis for the transfer of your personal data is your consent.

D.Voluntariness and Consequences of Consent Denial or Withdrawal. Your participation in the Plan and your grant of consent is purely voluntary. You may deny or withdraw your consent at any time. If you do not consent, or if you withdraw your consent, you cannot participate in the Plan. This would not affect your salary as an employee; you would merely forfeit the opportunities associated with the Plan.

E.Data Subject Rights. You have a number of rights under data privacy laws in your country. Depending on where you are based, your rights may include the right to (i) request access or copies of personal data the Company processes, (ii) rectification of incorrect data, (iii) deletion of data, (iv) restrictions on processing, (v) portability of data, (vi) to lodge complaints with competent authorities in your country, and/or (vii) a list with the names and addresses of any potential recipients of the your personal data. To receive clarification regarding your rights or to exercise your rights please contact the Company at Attn: Global Privacy Office, 351 N. Sumneytown Pike, North Wales, Pennsylvania, U.S.A. 19454.

F.The collection, use and transfer of your personal data for the purpose of implementing, administering and managing your participation in the Plan is conducted in accordance with the Company’s Global Privacy and Data Protection Policy. You also understand that the Company may, in the future, request you to provide another data privacy consent.  If applicable and upon request of the Company, you agree to provide an executed acknowledgement or data privacy consent form to the Company or the Employer (or any other acknowledgements, agreements or consents) that the Company and/or the Employer may deem necessary to obtain under the data privacy laws in your country, either now or in the future.  You understand that you will not be able to participate in the Plan if you fail to execute any such acknowledgement, agreement or consent requested by the Company and/or the Employer.

If you agree with the data processing practices described in this Section, you will declare your consent by clicking to "Accept" these Terms on the Morgan Stanley website.

XII.GOVERNING LAW

This document may be amended only by another written agreement between the parties. This document will be interpreted and enforced under the laws of the State of New Jersey, United States (without regard to its choice-of-law provisions). For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this document, the parties hereby submit to and consent to the exclusive jurisdiction of the State of New Jersey and agree that such litigation shall be



conducted only in the courts of Union County, New Jersey, or the federal courts for the United States for the District of New Jersey, and no other courts, where this grant is made and/or to be performed.

XIII.SEVERABILITY

The provisions of this document are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.

XIV.WAIVER

You acknowledge that a waiver by the Company of breach of any provision of these Terms shall not operate or be construed as a waiver of any other provision of these Terms or of any subsequent breach by you or any other grantee.

XV.ELECTRONIC ACCEPTANCE

The Company may, in its sole discretion, decide to deliver any documents related to the PSU or future PSUs that may be granted under the Plan by electronic means or request your consent to participate in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Company or a third party designated by the Company.

XVI.COUNTRY-SPECIFIC APPENDIX

The PSU Award shall be subject to any additional provisions set forth in Appendix B for your country, if any. If you relocate to one of the countries included in Appendix B during the life of the PSU Award, the additional provisions for such country shall apply to you, to the extent the Company determines that the application of such provisions is necessary or advisable in order to comply with local law or facilitate the administration of the Plan.

XVII.ADMINISTRATION

The Committee is responsible for construing and interpreting this PSU Award, including the right to construe disputed or doubtful Plan provisions, and may establish, amend and construe such rules and regulations as it may deem necessary or desirable for the proper administration of this PSU Award. Any decision or action taken or to be taken by the Committee, arising out of or in connection with the construction, administration, interpretation and effect of this grant shall, to the maximum extent permitted by applicable law, be within its absolute discretion (except as otherwise specifically provided herein) and shall be final, binding and conclusive upon the Company, all Eligible Employees and any person claiming under or through any eligible employee. All determinations by the Committee including, without limitation, determinations of the Eligible Employees, the form, amount and timing of Incentives, the terms and provisions of Incentives and the writings evidencing Incentives, need not be uniform and may be made selectively among Eligible Employees who receive, or are eligible to receive, Incentives hereunder, whether or not such Eligible Employees are similarly situated.

In addition to the Committee’s powers set forth in the Plan, anything in these Terms to the contrary notwithstanding, the Committee may revise the terms of any PSU not yet granted or, granted but prior to the end of an Award Period if unforeseen events occur and which, in the judgment of the Committee, make the application of the Terms of this PSU Award unfair and contrary to their intentions unless a revision is made.

This PSU Award is subject to the provisions of the 2019 Incentive Stock Plan. For further information regarding your PSU Award, you may access the Merck Global Long-Term Incentives homepage via Sync > HR > Money > Long-Term Incentive Program












APPENDIX A
Policies and Procedures for Recoupment of Compensation for Compliance Violations and for Significant Restatement of Financial Results
Policy
It is the policy of the Compensation and Management Development Committee of the Board of Directors (the “Committee”) that the Committee will exercise its discretion to determine whether to seek Recoupment of any bonus and/or other incentive compensation paid or awarded to an Affected Employee, where it determines, in consultation with the Audit Committee, that: a) the Affected Employee engaged in misconduct, or failed to reasonably supervise an employee who engaged in misconduct, that resulted in a Material Violation relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company; and b) the Committee concludes that the Material Violation caused Significant Harm to the Company, as those terms are defined in this policy. The Committee’s exercise of its discretion may take into account any considerations determined by the Committee to be relevant.

In addition, awards under the Executive Incentive Plan (“EIP”) and Performance Share Units (“PSU”) under the Merck & Co., Inc. 2019 Stock Incentive Plan, or any successor thereto, are also subject to the Company’s right to reclaim their benefits in the event a significant restatement of financial results for any performance period, pursuant to the process described below.

Definitions
1.“Recoupment” is defined to include any and all of the following actions to the extent permitted by law: (a) reducing the amount of a current or future bonus or other cash or non-cash incentive compensation award, (b) requiring reimbursement of a bonus or other cash-based incentive compensation award paid with respect to the most recently completed performance period, (c) cancelling all or a portion of a future-vesting equity award, (d) cancelling all or a portion of an equity award that vested within the previous twelve-month period, (e) requiring return of shares paid upon vesting and/or reimbursement of any proceeds received from the sale of an equity award, in each case that vested within the previous twelve-month period, and (f) any other method of reducing the total compensation paid to an employee for any prior twelve-month period or any current or future period.
2.A “Material Violation” is defined as (i) a material violation of a written Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or (ii) conduct detrimental to the Company, including the Company’s overall goodwill or reputation.
3.An “Affected Employee” is an employee in Band 600 or higher who (i) engaged in misconduct that results in a Material Violation; or (ii) failed in his or her supervisory responsibilities to reasonably manage or monitor the conduct of an employee who engaged in misconduct that results in a Material Violation.
4.“Executive” means current and former executive officers for the purposes of the Securities Exchange Act of 1934, as amended.
5.“Fault” means fraud or willful misconduct. "Willful misconduct" is generally viewed as dereliction of a duty or unlawful or improper behavior committed voluntarily and intentionally; something more than negligence. If the Audit Committee determines that Fault may have been a factor causing the financial restatement, the Audit Committee will appoint an independent investigator whose determination shall be final and binding.
6.“Significant Harm” means a significant negative impact on the Company’s financial operating results or reputation.

Procedures
For Compliance Violations

1.The Committee, acting in consultation with the Audit Committee, shall administer this policy and have
2.full discretion to interpret and to make any and all determinations under this policy, subject to the approval of the full Board of Directors in the case of a determination to seek or waive Recoupment from the Chief Executive Officer.
3.The General Counsel, in consultation with the Chief Ethics and Compliance Officer and the Executive Vice President, Human Resources, is responsible for determining whether to refer a matter to the Committee for review under this policy and for assisting the Committee with its review. The Committee may consult with other Board Committees and any external or internal advisors as it deems appropriate.
4.If the Committee, acting in consultation with the Audit Committee, determines that there is a basis for seeking Recoupment under this policy, the Committee shall exercise its discretion to determine for each Affected Employee, on an individual basis, whether, and to what extent and in which manner, to seek Recoupment.
5.In exercising its discretion, the Committee may take into consideration, as it deems appropriate, all of the facts and circumstances of the particular matter and the general interests of the Company.

For EIP Awards and PSUs Upon Significant Restatement of Financial Results

EIP Awards and PSUs for Executives are subject to the Company’s right to reclaim their benefits in the event of a significant restatement of financial results for any Award Period, pursuant to the process described below.

1.    The Audit Committee will review the issues and circumstances that resulted in a restatement of financial results to determine if the restatement was significant and make an initial determination of the cause of the restatement—that is whether the restatement was caused, in whole or in part, by Executive Fault (as defined above); and
2.    In the case of PSUs, the Committee will (a) recalculate the Company's results for any Award Period with respect to PSUs that included an Award Period which occurred during the restatement period; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from each Executive of that portion of the payout of the PSU that the Executive received within 18 months of the restatement based on the erroneous financial results.
3.    In the case of EIP Awards, the Committee will (a) review the EIP award received by each Executive with respect to the restatement period and determine whether all or a portion of such Award was determined based on the achievement of erroneous financial results; and (b) if it is determined that such restatement was caused in whole or in part by the Executive's Fault, the Committee will seek reimbursement from the Executive of that portion of any EIP Award that the Executive received within 18 months of the restatement based on the erroneous financial results.




4.    The clawback for EIP Awards and PSUs does not apply to restatements that the Audit Committee determines (1) are required or permitted under generally accepted accounting principles (“GAAP”) in connection with the adoption or implementation of a new accounting standard or (2) are caused due to the Company's decision to change its accounting practice as permitted under GAAP.

Delegation to Management for Certain Recoupment Decisions
Only in the case of Compliance Violations, the Committee hereby delegates to the Chief Executive Officer (who may further delegate as deemed appropriate) the authority to administer this policy and to make any and all decisions under it regarding Affected Employees who are not Executives of the Company. Management shall report to the Committee on any affirmative decisions to seek Recoupment pursuant to this delegation.

Disclosure of Recoupment Decisions
The Company will comply with all applicable securities laws and regulations, including Securities and Exchange Commission disclosure requirements regarding executive compensation and any applicable New York Stock Exchange listing standard or requirements. The Company may also, but is not obligated to, provide additional disclosure beyond that required by law when the Company deems it to be appropriate and determines that such disclosure is in the best interest of the Company and its shareholders.

Miscellaneous
Nothing in this policy shall limit or otherwise affect any of the following: 1) management’s ability to take any disciplinary action with respect to any Affected Employee; 2) the Committee’s ability

to use its negative discretion with respect to any incentive compensation performance target at any time; or 3) the Committee’s or management’s ability to reduce the amount (in whole or in part) of a current or future bonus or other cash or non-cash incentive compensation award to any Executive or other employee for any reason as they may deem appropriate and to the extent permitted by law. Any right of Recoupment under this policy is in addition to, and not in lieu of, any other remedies or rights of Recoupment that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, equity award agreement, or similar agreement and any other legal remedies available to the Company.

The Committee shall have sole discretion to make all determinations under this policy. Any determinations made by the Committee shall be final, binding, and conclusive on all Executives and affected individuals.

This policy shall be interpreted in a manner that is consistent with any applicable rules or regulations adopted by the Securities and Exchange Commission, New York Stock Exchange and any other applicable law (the “Applicable Rules”). To the extent the Applicable Rules require recovery of any bonus and/or other incentive compensation, including EIP Awards and PSUs, in additional circumstances besides those specified above, nothing in this policy shall be deemed to limit or restrict the right or obligation of the Company to recover such compensation to the fullest extent required by the Applicable Rules.

The Company shall not indemnify or agree to indemnify any Executive against the loss of incentive compensation subject to this Policy nor shall the Company pay or agree to pay any insurance premium to cover the loss of such incentive compensation.

The Board or the Committee may amend, modify, or terminate this policy in whole or in part at any time and from time to time in its sole discretion.



APPENDIX B
ADDITIONAL TERMS AND CONDITIONS FOR GRANTEES OUTSIDE THE U.S.
This Appendix, which is part of the Global Terms and Conditions for 2022 Performance Share Unit Grants under the Merck & Co., Inc. 2019 Incentive Stock Plan, contains additional “terms and conditions” that will apply to you if you reside outside the United States.
The terms and conditions in Part I of this Appendix apply to all grantees who reside outside the United States. The additional terms and conditions in Part II of this Appendix will also apply to you if you reside in one of the countries referenced in Part II.
The information in this Appendix is based on the laws in effect in the respective countries as of April 2021. Such laws are often complex and change frequently. As a result, the Company strongly recommends that you not rely on the information in this Appendix as the only source of information relating to the consequences of your participation in the Plan because the information may be out of date at the time that the Award Period expires and shares of Common Stock are issued to you or you sells shares of Common Stock acquired under the Plan.
In addition, the information contained in this Appendix is general in nature and may not apply to your particular situation, and the Company is not in a position to assure you of a particular result. Accordingly, you should seek appropriate professional advice as to how the relevant laws in your country may apply to your situation.
Finally, if you are a citizen or resident of a country, or are considered a resident of a country, other than that in which you are currently working, or transfer residence and/or employment after the Grant Date, the information contained herein may not apply to you in the same manner. The Company shall, in its sole discretion, determine to what extent the terms and conditions included herein will apply under these circumstances.




APPENDIX B - PART I: ADDITIONAL TERMS AND CONDITIONS FOR ALL COUNTRIES OUTSIDE OF THE UNITED STATES
The following additional terms and conditions will apply to you if you reside in any country outside the United States.
A.Nature of Grant
In accepting the PSU Award, you acknowledge and agree that:

1.the Plan is established voluntarily by the Company, is discretionary in nature, and may be amended, suspended, or terminated by the Company at any time;
2.the grant of the PSU Award is exceptional, voluntary, and occasional and does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of PSUs, even if PSUs have been granted in the past;
3.all decisions with respect to future PSU grants, if any, will be at the sole discretion of the Company;
4.your participation in the Plan is voluntary;
5.your participation in the Plan shall not create a right to employment or be interpreted as forming or amending an employment or service contract with the Company and shall not interfere with the ability of the Employer to terminate your employment or service relationship (if any) at any time;
6.the PSU Award and any shares of Common Stock acquired under the Plan, and income from and value of same, are extraordinary items that do not constitute compensation of any kind for services of any kind rendered to the Employer, the Company, or any subsidiary, affiliate, or JV of the Company, and that are outside the scope of your employment or service contract, if any;
7.unless otherwise agreed with the Company in writing, the PSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not granted as consideration for, or in connection with, the service you may provide as a director of a subsidiary, affiliate, or JV of the Company;
8.the PSU Award and any shares of Common Stock acquired under the Plan, and the income from and value of same, are not intended to replace any pension rights or compensation;
9.the PSU Award and any shares of Common Stock acquired under the Plan, and the income and value of same, are not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments, and in no event should be considered as compensation for, or relating in any way to, past services for the Employer, the Company or any parent, subsidiary, affiliate or JV of the Company;
10.the future value of the shares of Common Stock underlying the PSUs is unknown, indeterminable and cannot be predicted with certainty;
11.no claim or entitlement to compensation or damages shall arise from termination of the PSU Award resulting from termination of your employment by the Company or the Employer (for any reason whatsoever and whether or not in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any);
12.for purposes of the PSU Award, your employment relationship will be considered terminated as of the date you are no longer providing services to the Employer or the Company or any subsidiary, affiliate or JV (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), and unless otherwise expressly provided in this document, your right to vest in the PSUs under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period or any period of “garden leave” or similar period mandated under local law; the Committee shall have the exclusive discretion to determine when you are no longer providing services for purposes




of the grant (including whether you may still be considered to be providing services while on a leave of absence);
13.the PSU Award and the benefits under the Plan, if any, will not automatically transfer to another company in the case of a merger, take-over or transfer of liability;
14.the Company is not providing any tax, legal, or financial advice, nor is the Company making any recommendation regarding your participation in the Plan, or the acquisition or sale of underlying shares; you should consult with your personal tax, legal and financial advisors regarding the decision to participate in the Plan and before taking any action related to the Plan; and
15.neither the Employer, nor the Company or any subsidiary, affiliate or JV shall be liable for any foreign exchange rate fluctuation between your local currency and the United States Dollar that may affect the value of the PSU Award or any amounts due to you pursuant to the vesting of the PSU Award, the subsequent sale of shares acquired under the Plan or the receipt of any dividends and/or dividend equivalents.
B.Insider Trading/Market Abuse Laws
You acknowledge that, depending on your or your broker’s country of residence or where shares of Common Stock are listed, you may be subject to insider trading restrictions and/or market abuse laws, which may affect your ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., PSUs) or rights linked to the value of shares of Common Stock under the Plan during such times that you are considered to have “inside information” regarding the Company (as defined by the laws or regulations in the applicable jurisdictions or your country). Local insider trading laws and regulations may prohibit the cancellation or amendment of orders you placed before you possessed inside information. Furthermore, you could be prohibited from (i) disclosing the inside information to any third party and (ii) “tipping” third parties or causing them otherwise to buy or sell securities. You should keep in mind that third parties include fellow employees. Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy. You understand you are responsible for ensuring compliance with any restrictions and should consult with your personal legal advisor on this matter.
C.Foreign Asset/Account, Exchange Control and Tax Obligations
You acknowledge that, depending on your country, you may be subject to foreign asset/account, exchange control and/or tax reporting requirements as the result of the acquisition of shares of Common Stock or cash (including dividend equivalents, dividends, and the proceeds of the sale of shares of Common Stock) derived from your participation in the Plan, in, to and/or from a brokerage/bank account or legal entity located outside your country. The applicable laws of your country may require that you report such accounts, assets, the balances therein, the value thereof and/or the transactions related thereto to the applicable authorities in your country. You may also be required to repatriate cash received from participating in the Plan to your country within a certain time after receipt. You acknowledge that you are responsible for ensuring compliance with any applicable foreign asset/account, exchange control and tax reporting requirements and should consult your personal tax, legal and/or financial advisors regarding the same.
D.Language
You acknowledge that you are proficient in the English language or have consulted with an advisor who is sufficiently proficient, to allow you to understand the terms and conditions of this document. If you have received this document, or any other document related to the PSU Award and/or the Plan translated into a language other than English, and if the translated version is different than the English version, the English version will control.
E.Imposition of Other Requirements and Issuance of Shares
The Company reserves the right to impose other requirements on the PSUs and the shares of Common Stock acquired pursuant to the PSU Award, to the extent the Company determines it is necessary or advisable in order to comply with local laws or facilitate the administration of the Plan, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.
In particular, if advisable due to local law requirements, the Committee, in its sole and absolute discretion, may require the immediate forced sale of the shares of Common Stock issuable upon settlement of the PSUs.




Alternatively, unless otherwise set forth in this Appendix, the Committee, in its sole and absolute discretion, may determine to pay out the PSUs in cash equal to the fair market value of the shares of Common Stock underlying the PSUs.




APPENDIX B - PART II: COUNTRY-SPECIFIC ADDITIONAL TERMS AND CONDITIONS AND NOTIFICATIONS
CountryAdditional Terms and Conditions and Notifications
Australia
Australian Offer Document
This offer document sets out information regarding the offer to participate in the Plan for Australian resident grantees of the Company and its subsidiaries, affiliates and JVs. This information is provided by the Company to ensure compliance of the offer with Australian Securities and Investments Commission (“ASIC”) Class Order 14/1000, ASIC Regulatory Guide 49 and relevant provisions of the Corporations Act 2001.
Additional Documents. In addition to the information set out in this Appendix B, you are also being provided with copies of the following documents:
(a)    the Plan;
(b)    the Plan Prospectus (which contains a summary of the Plan);
(c)    the Terms;
(d)    LTI Program Overview; and
(e)    the summary of tax consequences of participation in the Plan for Australia, which is accessible by logging into your account at Morgan Stanley
(collectively, the “Additional Documents”).
The Additional Documents provide further information to help you make an informed investment decision about participating in the Plan. Neither the Plan nor the Plan Prospectus is a prospectus for the purposes of the Corporations Act 2001.
You should not rely upon any oral statements made in relation to this offer. You should rely only upon the statements contained in this Appendix B and the Additional Documents when considering participation in the Plan.
General Information Only. The information herein is general information only. It is not advice or information that takes into account your objectives, financial situation and needs.
You should consider obtaining your own financial product advice from a person who is licensed by ASIC to give such advice.
Risks of Participation in the Plan. Investment in shares of Common Stock involves a degree of risk. If you elect to participate in the Plan, you should monitor your participation and consider all risk factors relevant to the vesting or issuance of shares of Common Stock under the Plan as set forth below and in the Additional Documents.
You should have regard to risk factors relevant to investment in securities generally and, in particular, to holding shares of Common Stock of the Company. For example, the value at which an individual share of Common Stock is quoted on the New York Stock Exchange (“NYSE”) may increase or decrease due to a number of factors. There is no guarantee that the value of a share of Common Stock will increase. Factors that may affect the value of an individual share of Common Stock include fluctuations in the domestic and international market for listed stocks, general economic conditions, including interest rates, inflation rates, commodity and oil prices, changes to government fiscal, monetary or regulatory policies, legislation or regulation, the nature of the markets in which the Company operates and general operational and business risks.
More information about potential factors that could affect the Company’s business and financial results will be included in the Company’s most recent Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q. Copies of these reports are available at http://www.sec.gov/, on the Company’s “Investor Relations” page at https://investors.merck.com/home/default.aspx, and upon request to the Company.
In addition, you should be aware that the Australian dollar (“AUD”) value of any shares of Common Stock acquired under the Plan will be affected by the USD/AUD exchange rate. Participation in the Plan involves certain risks related to fluctuations in this rate of exchange.
Common Stock in a U.S. Corporation. Common stock of a U.S. corporation is analogous to ordinary shares of an Australian corporation. Each holder of a share of Common Stock is entitled to one vote. Further, shares of Common Stock are not liable to any further calls for payment of capital or for other assessment by the Company and have no sinking fund provisions, pre-emptive rights, conversion rights or redemption provisions.
Ascertaining the Market Value of Shares of Common Stock. You may ascertain the current market value of an individual share of Common Stock as traded on the NYSE under the symbol “MRK” at: https://www.nyse.com/quote/XNYS:MRK. The AUD equivalent of that value can be obtained at: https://www.rba.gov.au/statistics/frequency/exchange-rates.html.
This will not be a prediction of the market value of an individual share of Common Stock when the Award vests or shares of Common Stock are issued under the Plan or of the applicable exchange rate on the vesting date or the date the shares of Common Stock are issued.
Tax Information
The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) (the “Tax Assessment Act”) applies (subject to the conditions in the Tax Assessment Act).




AustriaThere are no country-specific provisions.
BelgiumThere are no country-specific provisions.
Brazil
Compliance with Law
By accepting the PSU Award, you acknowledge that you agree to comply with applicable Brazilian laws and pay any and all applicable taxes associated with the settlement of the PSU Award, the sale of shares obtained pursuant to the PSU Award, and the receipt of any dividends or dividend equivalents.
Labor Law Acknowledgment
By accepting the PSU Award, you agree that you are (i) making an investment decision and (ii) the value of the underlying shares of Common Stock is not fixed and may increase or decrease in value over the Award Period without compensation to you.
Further, you acknowledge and agree that, for all legal purposes, (i) any benefits provided to you under the Plan are unrelated to your employment or service; (ii) the Plan is not a part of the terms and conditions of your employment or service; and (iii) the income from your participation in the Plan, if any, is not part of your remuneration from employment or service.
The People's Republic of China
The following terms and conditions apply only to grantees who are citizens of the PRC or are otherwise determined to be subject to the requirements imposed by the State Administration of Foreign Exchange (“SAFE”) as determined by the Company.
The following terms and conditions apply only if you are classified as Band 600 and higher on the Grant Date.
Payment of Award and Termination of Employment
You will be permitted to hold shares of Common Stock issued to you at the end of the Award Period. Notwithstanding anything to the contrary in the Plan or Terms, due to exchange control laws in China, you agree that any shares of Common Stock acquired under the Plan and held by you at the time of your termination of employment with the Company or the Employer will be sold on your behalf, pursuant to this authorization, as soon as administratively practicable following the termination of your employment, but no later than six-months following termination of employment. The Company is under no obligation to arrange for such sale at any particular price. You will receive the sale proceeds, less any broker’s fees or commissions and subject to satisfaction of any Tax-Related Items. If the Terms provide that all or a portion of your outstanding PSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and be sold on your behalf as described above. Any other portion of your PSU Award that is not vested as described above will expire immediately upon your termination of employment.
Due to local regulatory requirements, you agree that the Company may force the sale of any shares of Common Stock issued under the Plan. The sale may occur (i) immediately upon vesting or (ii) within any other time frame as the Company determines to be necessary or advisable for legal or administrative reasons.
Broker Account
Any shares of Common Stock issued to you at expiration of the Award Period must be maintained in an account with Morgan Stanley Smith Barney or such other stock plan service provider as may be selected by the Company in the future until the shares of Common Stock are sold through that broker.
Exchange Control Notification
You understand and agree that, to comply with exchange control laws in the PRC, any cash dividends, dividend equivalents and the proceeds from the sale of the shares of Common Stock will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
The following terms and conditions apply only if you are classified as below Band 600 on the Grant Date.
Payment of Award
To facilitate compliance with exchange control laws in China, any PSU Award granted to you will be settled in cash only. This means that upon vesting of your PSU Award, you will receive in cash the value of the underlying shares of Common Stock at expiration of the Award Period, less any broker’s fees or commissions and Tax-Related Items, which will be remitted to you in accordance with applicable exchange control laws and regulations. You will not be permitted to hold shares of Common Stock after vesting. The Company reserves the right to settle the PSU Award in shares of Common Stock and to force the immediate sale of such shares of Common Stock depending on the development of applicable exchange control laws and regulations.
Exchange Control Notification
You understand and agree that, to comply with exchange control laws in the PRC, the cash payable to you at expiration of the Award Period will be immediately repatriated to China through a special exchange control account established by the Company (or any subsidiary, affiliate or JV) or the Employer prior to being delivered to you. The funds may be paid to you in U.S. dollars or local currency at the Company’s discretion. To the extent the funds are paid to you in U.S. dollars, you understand that you will be required to set up a U.S. dollar bank account in China and provide the bank account details to the Employer and/or the Company so that the funds may be deposited into this account. In the more likely event that the Company converts cash received under the Plan into local currency, the Company is under no obligation to secure any exchange conversion rate and the Company may face delays in converting the proceeds to local currency due to exchange control restrictions in China. You agree to bear any currency fluctuation risk between that time and the time the funds are distributed through any such special exchange account. You further agree to comply with any other requirements that may be imposed by the Company in the future in order to facilitate compliance with exchange control requirements in China.
Termination of Employment
Notwithstanding any terms or conditions of the Plan or the “Termination of Employment” section of the Terms to the contrary, the cash equivalent of any shares of Common Stock that vest upon termination of your employment will be distributed to you no later than six months from the date of termination of your employment, as determined by the Company in accordance with the Terms, or within any other such timeframe as may be required by SAFE. If the Terms provide that all or a portion of your outstanding PSU Award will become distributable at some time following your termination of employment, that portion will automatically vest and become distributable immediately upon your termination of employment as described above. Any other portion of your PSU Award that is not vested as described above will expire immediately upon your termination of employment.
Denmark
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section of this Appendix B:
By accepting the PSU Award, you understand and agree that this grant relates to future services to be performed and is not a bonus or compensation for past services.




France
Tax Notification
Your PSU Award is not intended to be French tax-qualified.
Language Consent
By accepting the PSU Award, you confirm having read and understood the Plan and your Terms, which were provided in the English language. You accept the terms of those documents accordingly.
En acceptant l’attribution, vous confirmez avoir lu et compris le Plan de travail et vos conditions générales et dispositions, qui ont été transmis en langue anglaise. Vous acceptez les termes de ces documents en connaissance de cause.
GermanyThere are no country-specific provisions.
IrelandThere are no country-specific provisions.
Israel
Securities Law Information
The grant of the PSU Award under the Plan is being made pursuant to an exemption from the requirement to file and publish a prospectus in Israel regarding the Plan obtained from the Israeli Securities Authority. Copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission will be sent to you, at no charge, on written request being mailed to Investor Relations at Merck & Co., Inc., 2000 Galloping Hill Road, Kennilworth, NJ 07033, U.S.A. The telephone number at the executive offices is 1-908-740-4000. Alternatively, copies of the Plan and the Form S-8 registration statement for the Plan filed with the U.S. Securities and Exchange Commission are available by searching the Company’s filings on the following web site: http://www.sec.gov/edgar/searchedgar/companysearch.html.
Trust Arrangement
You understand and agree that the PSU Award are offered subject to and in accordance with the terms of the Plan, the Addendum A - Israel to the Plan (the “Israeli Sub-Plan”), the Trust Agreement (the “Trust Agreement”) between the Company and the Company’s trustee appointed by the Company or its subsidiary or affiliate in Israel, currently ESOP Management and Trust Services Ltd. (the “Trustee”), and the Terms. In the event of any inconsistencies between the Israeli Sub-Plan, the Terms and/or the Plan, the Israeli Sub-Plan will govern the PSU Award granted to you in Israel. Capitalized terms used but not defined in this Appendix B for Israel, the Plan or the Terms have the meanings set forth in the Israeli Sub-Plan.
Requirement to Return Signed Confirmation Letter
You are required to execute the Confirmation Letter - Trustee 102 Awards (“Confirmation Letter”) provided to you in connection with the Awards granted to you under the Israeli Sub-Plan. In particular, you must print, sign and deliver a signed copy of the Confirmation Letter to the Trustee within thirty (30) days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, for the PSU Award to qualify for preferential tax treatment. By accepting this PSU Award, you acknowledge and agree that the terms and conditions of the Confirmation Letter are hereby incorporated by reference into the Terms and shall apply to shares of Common Stock acquired upon expiration of the Award Period of the PSU Award. If the Trustee does not receive the signed Confirmation Letter within 30 days of the Grant Date, or by such other date as may be determined by your Employer or the Trustee not to exceed ninety (90) days from the Grant Date, the PSU Award may not qualify for favorable tax treatment. For more details, please contact Daphna Ben-Ari at daphna.ben-ari@merck.com or +972 9533306.
Confirmation of Section 102 Capital Gains Award Terms
The PSU Award is intended to be Capital Gain Awards that qualify for the tax treatment for Approved 102 Awards that are designated by the Company to qualify under the capital gain tax treatment in accordance with the provisions of Section 102(b)(2) of the Ordinance. Notwithstanding the foregoing, by accepting the PSU Award, you acknowledge that the Company cannot guarantee that the Capital Gain Award tax treatment will apply to the PSU Award granted to you.
By accepting the PSU Award, you: (a) acknowledge receipt of and represent that you have read and understand the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; (b) accept the PSU Award subject to all of the terms and conditions of the Plan, the Israeli Sub-Plan, the Confirmation Letter and the Terms; and (c) agree that the shares of Common Stock issued to upon expiration of the Award Period of the PSU Award will be issued to and deposited with the Trustee and shall be held in trust for your benefit as required by the Ordinance, the Israeli Sub-Plan and any approval by the Israeli Tax Authority pursuant to the terms of the Ordinance, the Israeli Sub-Plan and the Trust Agreement. Furthermore, by accepting the PSU Award, you confirm that you understand the terms and provisions of Section 102 of the Ordinance, particularly the capital gains track described in subsection (b)(2) and (b)(3) thereof, and agree that you will not require the Trustee to release the shares of Common Stock acquired upon expiration of the Award Period of the PSU Award to you or sell the shares of Common Stock to a third party, during the Holding Period, unless permitted to do so by the Ordinance or the Israeli Sub-Plan.
Italy
Plan Document Acknowledgment
By accepting the PSU Award, you further acknowledge that you have received a copy of the Plan, have reviewed the Plan and the Terms in their entirety and fully understand and accept all provisions of the Plan and the Terms; in particular, you acknowledge that you have read and specifically and expressly approve the following provisions in the Plan and the Terms: (a) your PSU Award cannot be transferred other than by will or the laws of descent and distribution; (b) in the event of involuntary termination of your employment, your right to receive Awards and to receive distributions from Awards, if any, will terminate as of the date that you are no longer actively employed by the Employer, unless otherwise expressly provided in the Terms; (c) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (d) you are responsible for all Tax-Related Items; (e) if a reorganization, recapitalization, reclassification or other corporate event that results in an adjustment of the shares of Common Stock described in the Plan occurs, your PSU Award may be adjusted; (f) if a Change in Control, as described in the Plan, occurs, your PSU Award may immediately vest; (g) all decisions with respect to future grants will be at the sole discretion of the Company; and (h) the “Data Privacy” section of your Terms.
JapanThere are no country-specific provisions.
NetherlandsThere are no country-specific provisions.




Singapore
Restriction on Sale and Transferability
You hereby agree that any shares of Common Stock acquired pursuant to the PSU Award will not be offered for sale in Singapore prior to the six-month anniversary of the Grant Date of the PSU Award, unless such sale or offer is made pursuant to one or more exemptions under Part XII Division 1 Subdivision (4) (other than section 280) of the Securities and Futures Act (Chap. 289, 2006 Ed.) (“SFA”) or pursuant to, and in accordance with, the conditions of any other applicable provision(s) of the SFA.
Securities Law Information
The PSU Award is being granted to you pursuant to the “Qualifying Person” exemption under section 273(1)(f) of the SFA, on which basis it is exempt from the prospectus and registration requirements under the SFA, and is not made to you with a view of the PSU Award being subsequently offered for sale to any other party. The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.
Director Notification
If you are a director (including an alternate, substitute, associate or shadow director) of a Singaporean subsidiary, affiliate or JV of the Company, you are subject to certain notification requirements under the Singapore Companies Act. Among these requirements is an obligation to notify the Singapore subsidiary, affiliate or JV in writing when you receive an interest (e.g., PSU Awards, shares of Common Stock) in the Company or any related companies. In addition, you must notify the Singaporean subsidiary, affiliate or JV when you sell shares of the Company’s common stock or any related company (including when you sell shares of Common Stock acquired upon the expiration of the Award Period). These notifications must be made within two business days of acquiring or disposing of any interest in the Company or any related company. In addition, a notification must be made of your interests in the Company or any related company within two days of either after the director becomes aware of the change in respect of the particulars of any of the aforesaid, the date on which the director becomes a holder of, or acquires an interest in, the shares, debentures, rights, contracts, participatory interests, other securities or securities-based derivatives contacts, whichever last occurs. There is no prescribed form for such disclosure, although in practice, the company secretary normally would prepare a formatted disclosure form that requests the following information: equity award granted, number of shares acquired, description of consideration, if applicable, and the date of the transaction.
A director shall be deemed to have an interest in securities or securities-based derivative contracts referred to above if a family member of the director (not being him or herself a director), holds or has an interest in those securities or securities-based derivatives contract and any contract entered into by, or any grant made to, a family member of a director of a corporation (not being himself a director) shall be deemed to have been entered into by, made or exercised by or made to the director. A “family member” means a spouse, or a son, adopted son, step-son, daughter, adopted daughter or step-daughter below the age of 21 years.
Spain
Labor Law Acknowledgment
This provision supplements the “Nature of Grant” section of this Appendix B:
By accepting this PSU Award, you acknowledge that you understand and agree that you consent to participation in the Plan and that you have received a copy of the Plan.
You understand that the Company, in its sole discretion, has unilaterally and gratuitously decided to distribute Awards under the Plan to individuals who may be employees of the Company or its subsidiaries, affiliates or JVs throughout the world. The decision is a limited decision that is entered into upon the express assumption and condition that any grant will not economically or otherwise bind the Company or any of its subsidiaries, affiliates or JVs over and above the specific terms of the Plan on an ongoing basis. Consequently, you understand that any PSU Award is given on the assumption and condition that it shall not become a part of any employment contract (either with the Company or any of its subsidiaries, affiliates or JVs) and shall not be considered a mandatory benefit, salary for any purposes (including severance compensation) or any other right whatsoever. Further, you understand and freely accept that there is no guarantee that any benefit whatsoever shall arise from any gratuitous and discretionary Award since the future value of the PSU Award and shares of Common Stock is unknown and unpredictable. In addition, you understand that the PSU Award would not be made to you but for the assumptions and conditions referred to above; thus, you acknowledge and freely accept that should any or all of the assumptions be mistaken or should any of the conditions not be met for any reason, then any PSU Award shall be null and void.
You also understand and agree that, as a condition of the grant of the PSU Award, the termination of your employment for any reason (including the reasons listed below), the PSU Award will cease vesting immediately effective on the date you are no longer providing services to the Employer or the Company or any of its subsidiaries, affiliates or JVs (unless otherwise specifically provided in the Terms). In particular, you understand and agree that the PSU Award will be forfeited without entitlement to the underlying shares of Common Stock or to any amount as indemnification in the event of a termination of your employment as described in the Terms prior to expiration of the Award Period by reason of, including but not limited to, resignation, retirement, disciplinary dismissal adjudged to be with cause, disciplinary dismissal adjudged or recognized to be without good cause (i.e., subject to “despido improcednte”), individual or collective dismissal on objective grounds, whether adjudged or recognized to be with or without cause, material modification of the terms of employment under Article 41 of the Workers’ Statute, relocation under Article 40 of the Workers’ Statute, Article 50 of the Workers’ Statute, unilateral withdrawal by the Employer and under Article 10.3 of the Royal Decree 1382/1985.
Securities Law Information
No “offer of securities to the public,” as defined under Spanish law, has taken place or will take place in the Spanish territory in connection with the grant of the PSU Award. The Plan and the Terms have not been nor will they be registered with the Comisión Nacional del Mercado de Valores, and do not constitute a public offering prospectus.
Sweden
Authorization to Withhold
The following provision supplements the “Tax Withholding” section of the Terms:
Without limiting the Company’s and the Employer’s authority to satisfy their withholding obligations for Tax-Related Items as set forth in the “Tax Withholding” section of the Terms, in accepting the PSU Award, you authorize the Company and/or the Employer to withhold shares of Common Stock or to sell shares of Common Stock otherwise deliverable to you upon settlement to satisfy Tax-Related Items, regardless of whether the Company and/or the Employer have an obligation to withhold such Tax-Related Items.




Switzerland
Securities Law Information
The offering of participation in the Plan is considered a private offering in Switzerland; therefore, it is not subject to registration in Switzerland. Neither this document nor any other materials relating to the Plan (i) constitute a prospectus according to articles 35 et seq. of the Swiss Federal Act on Financial Services (“FinSA”), (ii) may be publicly distributed nor otherwise made publicly available in Switzerland to any person other than an employee of the Company or Employer or (iii) has been or will be filed with, approved or supervised by any Swiss reviewing body according to article 51 FinSA or any Swiss regulatory authority, including the Swiss Financial Market Supervisory Authority.
United Kingdom
Tax Acknowledgment
You agree that you are liable for all Tax-Related Items and hereby covenant to pay all such Tax-Related Items, as and when requested by the Company or, if different, your Employer or by Her Majesty’s Revenue and Customs (“HRMC”) (or any other tax authority or any other relevant authority). You also agree to indemnify and keep indemnified the Company and, if different, your Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on your behalf.
Notwithstanding the foregoing, if you are a director or executive officer of the Company (within the meaning of Section 13(k) of the U.S. Securities Exchange Act of 1934, as amended), the amount of any income tax not collected from or paid by you within ninety (90) days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Items occurs may constitute a benefit to you on which additional income tax and National Insurance contributions may be payable. You understand that you will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for paying to the Company and/or the Employer (as appropriate) the amount of any employee National Insurance contributions due on this additional benefit, which may also be recovered from you through any means set forth in the “Tax Withholding” section of the Terms.



EX-10.37 19 exhibit1037-mrkchirfiguind.htm EXHIBIT-10.37 OFFER LETTER (GUINDO) Document
Exhibit 10.37



mercklogotoprightcornera.jpg



June 8, 2022

Chirfi Guindo


Dear Chirfi,
 
It is my pleasure to offer you a position with Merck Sharp & Dohme LLC (“MSD” or the “Company”), a wholly-owned subsidiary of Merck & Co., Inc. (“Merck”), as its Chief Marketing Officer (the “Position”) on the terms and conditions set forth in this offer letter (“letter” or “offer letter”). We see ourselves as a company inspired to invent, and determined to discover, develop, and deliver medicines and vaccines that will improve the lives of more people in more places around the world.
Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and teamwork of people like you.  We strive to create an environment of mutual respect, encouragement and teamwork that enables our employees to achieve our mission.  As part of our global team, you'll have the opportunity to collaborate with talented and dedicated colleagues while developing and expanding your career.
 
Your offer of employment in the Position is subject to the approval of your appointment by the Board of Directors of Merck.  If approved, you will be a member of the Executive Team (formerly known as the “Executive Committee”), an Officer of Merck (as defined in Section 16 of the Securities Exchange Act of 1934) and will report to me (or my successor as Chief Executive Officer).  The Position will initially be based at our offices in Kenilworth, NJ. In 2023, with the move of our corporate headquarters, the Position will be based in Rahway, NJ. We have advised you not to alter your current employment status until all the contingencies have been satisfied.

Our offer includes the following:

Total Compensation

Base Salary:  You will be paid a gross annual salary of $700,000. This will be paid (bi-weekly) at a rate of approximately $26,923 per pay period. You will be eligible for consideration for a salary increase on an annual basis. Your base salary will be subject to applicable payroll deductions and withholdings.

Executive Incentive Plan (EIP): You will be eligible to participate in the Executive Incentive Plan (EIP) as it applies to similarly situated employees, subject to the terms of the plan. The target bonus for performance year 2022 for the Position is 80% of your annual base salary. The bonus is discretionary and the amount of the bonus, if any, will be determined based on Merck performance. To be eligible for an EIP award, you must be actively employed on or before October 1 and remain actively employed through December 31 of the plan year. Your EIP award, if any, will be pro-rated based on the time you were in an EIP-eligible position during that plan year. Bonuses, if any, for the current performance year will be paid in or about March of the following year.
Chirfi Guindo
Page 1 of 6


Long-Term Incentive (LTI) Program: You will be eligible for consideration for annual grants of stockbased incentives under the Incentive Stock Plan beginning in the annual cycle following the year you begin employment and, for as long as you remain employed, for each annual cycle thereafter. For Executive Team members, annual grants generally include a mix of non-qualified stock options and performance share units (PSUs), with the number and proportion of shares covered by such incentives determined by the Compensation and Management Development Committee of the Board of Directors of Merck (the "Committee"). The current annual grant value for the Position is $2,500,000, comprised of 70% PSUs and 30% non-qualified stock options. The exact number of shares granted will be determined based on the value of Merck stock on the date of grant. Currently, annual grants of Merck & Co., Inc. stock options vest in equal installments over three years and PSUs are subject to a 3-year performance period.

Distribution of shares in connection with PSUs and stock options is dependent on continued employment with Merck, MSD or one of Merck or MSD's subsidiaries ("Merck Entity"); additionally, the level of PSU payout is contingent on Merck performance. Please note that the value and terms and conditions of any future grants may change from time to time. The specific terms and conditions of your grant(s) will be provided to you shortly after the grant(s) are made.

You will be subject to our stock ownership guidelines. The guidelines are intended to reinforce our philosophy concerning "ownership" and, in a concrete way, quantify our expectations concerning ownership of Merck. The guidelines provide that you should acquire Merck stock, over time, equal in value to three times your annual base salary. Importantly, the LTI program - and retention of shares earned in connection therewith - is intended to facilitate the acquisition of shares. Also, there is no required time frame under which you will be required to achieve your stock ownership requirement, however, you will be subject to a 75% retention requirement until you achieve the required base salary multiple.


Sign-On Incentives

Sign-On Cash: You will receive a cash sign-on bonus in the aggregate amount of $530,000, less applicable payroll deductions and withholdings, payable within thirty days of your start date. Your right to retain the sign-on bonus is conditioned upon your continued employment with a Merck Entity for two years. By your signature below, you agree that, if prior to completing two years of employment, you voluntarily terminate your employment with a Merck Entity without Good Reason, as defined below, or if a Merck Entity terminates your employment for Cause, as defined below, you will reimburse the full amount of the sign-on bonus ("Repayment Obligation").  You further authorize the Company to withhold any and all monies otherwise owed to you, to the extent permitted by law, as payment against such Repayment Obligation.  In such case, such monies will be credited towards the Repayment Obligation, but will not relieve you of your obligation to pay the balance of any Repayment Obligation.

"Cause" as used in this offer letter means an act or omission by you, which constitutes: (i) a deliberate (and not justified and appropriate in the performance of your duties) or reckless disclosure of proprietary or other confidential information relating to a Merck Entity, its personnel, research or business; (ii) embezzlement, theft or other misappropriation of the assets of a Merck Entity; (iii) deliberate or reckless falsification of records or reports; (iv) deliberate bad faith or reckless action that causes actual or potential significant injury or loss to a Merck Entity and/or its and/or their employees; (v) insubordination (meaning the repeated refusal to carry out work assignments and/or direction); (vi) willful or repeated failure to perform assigned job duties; (vii) an illegal act on the property of a Merck Entity or in representing a Merck Entity; (viii) a material violation of a Company policy relating to the research, development, manufacturing, sales, or marketing of Company products or the overall goodwill or reputation of the Company; (ix) any action that would trigger the claw back provisions of any Bonus or Long-Term Incentive Plans applicable to you; or a (x) breach by you of your representations as set forth in this letter.

“Good Reason” is defined to include the following: a) a material reduction in base salary without your consent, unless such reduction is part of an across-the-board reduction affecting other Executive Team members in like proportions, b) your involuntary reassignment to any position other than a
Chirfi Guindo
Page 2 of 6


position on the Executive Team reporting to the Company’s Chief Executive Officer within the period beginning on date of hire and ending when the Sign-on Equity Grant has vested fully, or c) a material breach of this letter, provided that you deliver written notice of a claim of Good Reason to the Company’s Chief Executive Officer within thirty (30) days of the facts giving rise to such Good Reason, MSD fails to cure the circumstances giving rise to Good Reason within thirty (30) days of receiving such notice and you actually terminate employment within thirty (30) days after MSD’s failure to cure.

Sign-On Equity: You will receive sign-on equity incentives valued at $12,200,000, $2,500,000 in the form of Performance Share Units and $9,700,000 in the form of restricted stock units (RSUs). Merck & Co., Inc. RSU grants are currently scheduled to be made shortly after the release of company earnings each quarter. The date of your sign-on PSU and RSU grants will be the quarterly grant immediately following your start date (the next quarterly grant date is scheduled for August 2, 2022). Subject to its terms, this PSU grant is subject to a 3-year performance period and this RSU grant will vest one-third on each anniversary of the grant date. Both grants will be eligible for continued vesting as provided under the Severance section of this letter below. A summary of terms and conditions associated with this PSU and RSU grant will be provided to you shortly after the grants are made. Under current equity terms, should you die while actively employed, the terms of Merck’s PSU grants provide for vesting on the date the final award is determined and RSU grants provide for immediate vesting plus dividend equivalents accrued through your date of death. Should you become disabled and your employment is terminated as a result, the terms of Merck’s PSU grants provide for vesting on the date the final award is determined and RSU grants provide for continued vesting on the original vesting dates and dividend equivalents through such corresponding vesting dates.

Benefits

Health and Insurance Benefits Program: You will be eligible to participate in the Health and Insurance Benefits Program, which automatically provides you with basic life insurance and short-term disability coverage. It also allows you to choose from various options including medical, dental, vision, voluntary and dependent life insurance, long-term disability and flexible spending accounts. For most benefits, participation begins on your date of hire. The Benefits Service Center at Fidelity will mail a Benefits New Hire Package to you within 2 weeks of your hire date. This Package provides important information and instructions for enrolling in your benefits. You will have 30 days from the date Fidelity mails your benefits information to enroll. If you do not enroll by the date indicated in the Package, you automatically will be enrolled in medical coverage for you only in the Horizon BlueCross BlueShield PPO plan option (which includes prescription drug coverage), dental coverage for you only, company-provided basic life insurance and short-term and long-term disability coverage. If you enroll dependents under your medical coverage, you will receive an e-mail and/or letter from HMS Employer Solutions (an independent third-party vendor designated to conduct dependent eligibility verifications) requesting documentation to verify your dependent eligibility. Failure to respond or provide required documentation within the required timeframe will result in the removal of your dependent(s) from benefits coverage. In addition, your eligibility for retiree medical coverage will be determined based on Plan rules in effect, using your age and total years of service, at that time.

Pension Plan: You will be eligible to participate in the tax-qualified and non-qualified U.S. Pension Plan, which is a defined benefit pension plan that uses a cash balance formula to calculate your benefit. Your benefit is expressed as a notional account balance that grows with annual Pay Credits ranging from 4.5% to 10.0% of your total pay (based on age and service) and Interest Credits of 3% plus the annual rate of change in the Consumer Price Index (not less than 3.3%). In addition, your prior pension plan benefit will be restored and the value of your benefit will be determined based on Plan rules in effect, using your age and years of service at that time.


401(k)/Savings Plan: You will be eligible to participate in the U.S. Savings Plan (“Savings Plan”). Within 2 weeks following your date of hire, the Benefits Service Center at Fidelity will mail to you a separate enrollment package for the Savings Plan. You may contribute to the Savings Plan on a before-tax, Roth, and after-tax basis. The Savings Plan provides a 75% match of the first 6% of total pay (4.5%
Chirfi Guindo
Page 3 of 6


of total pay) that you contribute per pay period (subject to plan limits and IRS limits). If you do not make an active election within 60 days of your hire date, you automatically will be enrolled to contribute 6% base pay and 6% EIP on a before-tax basis, with an annual increase of 1% until you reach a contribution rate of 10%. To maximize the company match, you must contribute at least 6% of your base pay and 6% of your EIP.

Deferral Program: Beginning in 2023, you will be eligible to defer (1) a portion of your base salary and/or (2) all or part of your EIP bonus, if any. You will receive detailed information just prior to the annual enrollment period in December 2022. In addition, the company will contribute 4.5% of your eligible pay exceeding the Internal Revenue Code pay limit ($305,000 for 2022) to an account established on your behalf.

Financial Planning:  You will be eligible to participate in the executive financial planning program, which provides an annual cash allowance of $10,000 payable in December of each calendar year.  If your start date is on or before October 1 of this calendar year, you will be eligible to commence this benefit in the same calendar year. If you start after October 1, you will be eligible to commence the benefit in the subsequent calendar year.

Vacation and Paid Holiday Policy: You will be eligible for 30 vacation days per year in accordance with Company policy, as well as 12 company paid holidays and 4 year-end shutdown days between the Christmas and New Year’s Day holidays. The number of vacation days for which you are eligible in your first year of employment is dependent upon your date of hire.

Military Reservists: Merck is a Military Friendly Employer and we proudly offer a generous military leave policy for those that are eligible.

Workplace Accommodations: We support employees of all abilities. The Company’s Workplace EnABLEment program offers employees the resources they need to contribute at the highest level and to advance the business goals of the Company. If you need an accommodation, contact the Workplace Accommodation Team via email at workacc@merck.com or by phone at 1-866-675-4748.

Relocation:  You will be eligible for benefits under our Domestic Relocation Policy. As part of our standard domestic relocation benefits, MSD will pay or reimburse you for certain expenses in accordance with this Policy. A global mobility representative will be assigned to you and will be available to explain your specific benefits as well as address any questions you may have.

Severance: As an employee of MSD, you will be an employee at-will. This means that either you or MSD may terminate the employment relationship at any time for any lawful reason or for no reason. In order to accommodate any concerns you may have in joining MSD, MSD agrees that in the event MSD terminates your employment for a reason other than Cause (as defined above) or you terminate your employment for Good Reason (as defined above) prior to such time when all of your Sign-On Equity is fully vested, then you will be entitled to continue to vest in the Sign-On Equity granted to you (“Severance Benefit”); provided that your right to receive the Severance Benefit would be conditioned upon your signing and refraining from revoking a Severance Agreement in a format prescribed by MSD, which Agreement will contain a full release, non-solicitation, non-disclosure, non-disparagement and cooperation in litigation covenants and such other reasonable and customary terms as MSD provides. This Severance Benefit would be in addition to any other severance or separation pay that you may be entitled to under any applicable plan or policy of MSD or Merck.

Prior Service. For the avoidance of doubt, you will be credited for your prior service with the Company eligible in accordance with the terms and conditions on Company plans and policies as those plans and policies apply generally to other Company employees.


Change in Control

Merck has adopted a “Change in Control” (CIC) Program. The Merck CIC Program specifies the types of compensation and benefits-related protections to be provided to eligible Merck employees in the event of
Chirfi Guindo
Page 4 of 6


a change in control of Merck & Co., Inc. You will participate as an Executive Team member at the band level applicable under the program.

Right to Amend or Terminate Plans, Programs and Policies

The compensation and benefits described in this letter are provided under and subject to the terms and conditions of the applicable plans, programs and policies of MSD, Merck and/or the applicable Merck Entity.  Nothing in this letter in any way limits the right of Merck & Co., Inc. and/or a Merck Entity to amend or terminate those plans, programs or policies.

Section 409A

This offer letter shall be interpreted to comply with section 409A of the Internal Revenue Code of 1986, as amended and the regulations promulgated thereunder (“section 409A”) or an exemption thereto. Notwithstanding anything in this offer letter to the contrary, payments made pursuant to the offer letter may only be made in a manner and upon an event permitted by section 409A, and all payments to be paid to you upon termination of employment may only be made upon a “separation from service” as defined under section 409A. If section 409A applies to payments under this offer letter, this offer letter shall be administered in accordance with section 409A, including the six-month delay for “specified employees,” if applicable. Each payment under this offer letter, that is part of a series of installment payments, shall be treated as a separate payment for purposed of section 409A. In no event may you, directly or indirectly, designate the calendar year of any payment. You are solely responsible for any taxes under this offer letter and in no event will Merck have any liability with respect to any tax, interest or other penalty imposed under section 409A.

Except as otherwise expressly provided herein, to the extent any expense reimbursement or the provision of any in-kind benefit under this offer letter (or otherwise referenced herein) is determined to be subject to (and not exempt from) section 409A, the amount of any such expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year will not affect the expenses eligible for reimbursement or in-kind benefits to be provided in any other calendar year, in no event will any expenses be reimbursed after the last day of the calendar year following the calendar year in which you incurred such expenses, and in no event will any right to reimbursement or the provision of any in-kind benefit be subjected to liquidation or exchange for another benefit.

Representations

This offer is made to you based upon your representations that (i) your employment with Merck will not conflict with, or result in the breach of, or violation of, any other agreement, instrument, order, judgment or decree to which you are a party or by which you are bound, and (ii) you are not a party to or bound by any employment agreement, non-compete agreement or confidentiality agreement with any other person or entity that would restrict your employment with Merck and not provided to Merck for its independent review.

By your signature below, you affirm that these representations are true.

In addition to Board approval, this offer is contingent upon your successful completion of a pre-placement drug screen, satisfactory verification of your employment, education, criminal check, satisfactory references and background check results and, if applicable, proof of your eligibility to work in the United States. (A List of Acceptable Documents that establishes your eligibility to work in the U.S., which you are required to bring with you on your first day of work, will be forwarded to you upon your acceptance of the offer). Your employment with Merck is at-will (meaning that you and the Company remain free to end the employment relationship at any time, for any lawful reason, either with or without prior notice) and additionally will be subject to certain terms and conditions of employment, which have been provided to you with this offer. We advise you not to alter your current employment status until all of the contingencies have been satisfied. Nothing herein shall be construed as creating a contract for a specific duration between you and the Company.

Please call Steve Mizell upon receipt of this letter to acknowledge your acceptance of this offer and to begin your “on boarding” process for employment. Beth Perrone will be your initial point of contact
Chirfi Guindo
Page 5 of 6


throughout the on boarding process and will confirm your start date upon successful completion of the above contingencies.  In addition, please print, sign, scan and return this offer letter via email to Steve.

With your abilities and experience, I know you will be able to contribute to the Company and benefit from its growth. I believe this position offers an outstanding career opportunity and look forward to your acceptance.

Sincerely,

/s/ Robert Davis___________

Robert Davis


I accept the employment offer and its terms contained in this letter.




/s/ Chirfi Guindo             June 9, 2022
Chirfi Guindo                Date
Chirfi Guindo
Page 6 of 6
EX-21 20 exhibit21-clean2x22x23.htm EXHIBIT-21 SUBSIDIARY LIST Document

Exhibit 21 - MERCK & CO., INC. SUBSIDIARIES
changes as of 12/31/2022
    The following is a list of subsidiaries of the Company, doing business under the name stated.
Name
Country or State
of Incorporation
7728026 Canada Inc.
Canada
Abmaxis Inc.
Delaware
Acceleron Pharma Inc.
Delaware
Afferent Pharmaceuticals, Inc.
Delaware
Agrident GmbH
Germany
Agro Verhen B.V.
Netherlands
Aleis Pty Ltd
Australia
Allflex Argentina S.A.
Argentina
Allflex Australia Pty. Ltd.
Australia
Allflex dan-mark ApS
Denmark
Allflex Europe Holdings 1 B.V.
 Netherlands
Allflex Europe Holdings 2 B.V.
 Netherlands
Allflex Europe Holdings 3 B.V.
 Netherlands
1



Allflex Europe S.A.S.
France
Allflex Group Germany GmbH
Germany
Allflex Holdings 1 Inc.
Delaware
Allflex Holdings 2 Inc.
Delaware
Allflex Holdings 3 Inc.
Delaware
Allflex India Private Limited
India
Allflex International do Brasil Ltda.
Brazil
Allflex Maroc S.A.R.L.
Morocco
Allflex New Zealand Limited
New Zealand
Allflex Polska Spolka z ograniczona odpowiedzialnoscia
Poland
Allflex SCR Vostok
Belarus
Allflex Services S.A.R.L.
France
Allflex UK Group Limited
United Kingdom
Allflex USA, LLC
Delaware
Antelliq Finance, Inc.
Delaware
Antelliq Holdings France S.A.S
France
Antimicrobial Stewardship LLC
Delaware
2



ArQule, Inc.
Delaware
Beijing Allflex Plastic Products Co. Ltd
China
Beijing Protection Science & Technology Co., Ltd.
China
Biomark LLC
Idaho
BRC Ltd.
Bermuda
Burgwedel Biotech GmbH
Germany
Calporta Therapeutics, Inc.
Delaware
Cambridge Resonant Technologies Ltd
United Kingdom
Canji, Inc.
Delaware
cCam Biotherapeutics Ltd.
Israel
Cherokee Pharmaceuticals LLC
Delaware
Chevillot S.A.S.
France
Controladora MSD Mexicana Sociedad de Responsabilidad Limitada de Capital Variable
Mexico
Cooper Veterinary Products (Proprietary) Limited
South Africa
Corporation Allflex, Inc.
Canada
Cosmas B.V.
Netherlands
Cubist Pharmaceuticals LLC
Delaware
3



Dialstat Trading 91 Pty Ltd T/A Allflex SA
South Africa
Digital Angel S.A.
Argentina
Diosynth France S.A.S.
France
Diosynth Holding B.V.
Netherlands
Diosynth Produtos Farmo-quimicos Ltda.
Brazil
Drovers ID Pty Ltd
Australia
DSD Holding ApS
Denmark
Elastec S.R.L
Argentina
Essex Pharmaceuticals, Inc.
Philippines
Essexfarm, S.A.
Ecuador
Farmacox - Companhia Farmaceutica, Lda
Portugal
Farmasix-Produtos Farmaceuticos, Lda
Portugal
Financiere MSD
France
Fontelabor-Produtos Farmaceuticos, Lda.
Portugal
Frosst Laboratories, Inc.
Delaware
Frosst Portuguesa - Produtos Farmaceuticos, Lda.
Portugal
Global Farm S.A.
Argentina
4



GlycoFi, Inc.
Delaware
Hangzhou MSD Pharmaceutical Co., Ltd.1
China
Harrisvaccines LLC
Iowa
Hawk and Falcon L.L.C.
Delaware
Healthcare Services and Solutions, LLC
Delaware
Heptafarma Companhia Farmaceutica, Lda
Portugal
Hydrochemie GmbH
Germany
Idenix GmbH
Switzerland
IdentiGEN Canada Ltd.
Canada
IdentiGEN Deutschland GmbH
Germany
IdentiGEN Limited
Ireland
IdentiGEN North America Inc.
Delaware
IdentiGEN Switzerland AG
Switzerland
Immune Design Corp.
Delaware
International Indemnity Ltd.
Bermuda
Intervet (Ireland) Limited
Ireland
Intervet (Israel) Ltd.
Israel
5



Intervet (M) Sdn. Bhd.
Malaysia
Intervet (Proprietary) Limited
South Africa
Intervet (Thailand) Ltd.
Thailand
Intervet AB
Sweden
Intervet Agencies B.V.
Netherlands
Intervet Animal Health Taiwan Limited
China
Intervet Argentina S.A.
Argentina
Intervet Australia Pty Limited
Australia
Intervet Canada Corp.
Canada
Intervet Central America S. de R.L.
Panama
Intervet Deutschland GmbH
Germany
Intervet Ecuador S.A.
Ecuador
Intervet Egypt for Animal Health SAE
Egypt
Intervet GesmbH
Austria
Intervet Hellas A.E.
Greece
Intervet Holding B.V.
Netherlands
Intervet Holdings France SAS
France
6



Intervet Hungaria Értékesítő Kft
Hungary
Intervet Inc.
Delaware
Intervet India Pvt Limited
India
Intervet International B.V.
Netherlands
Intervet International GmbH
Germany
Intervet International Sarl
France
Intervet LLC
Russian Federation
Intervet Maroc S.A.
Morocco
Intervet Mexico S.A. de C.V.
Mexico
Intervet Middle East Limited
Cyprus
Intervet Nederland B.V.
Netherlands
Intervet Philippines, Inc.
Philippines
Intervet Productions S.A.
France
Intervet Productions S.r.l.
Italy
Intervet Romania SRL
Romania
Intervet S.A.
Peru
Intervet SAS
France
7



Intervet Schering-Plough Animal Health Pty. Ltd.
Australia
Intervet South Africa (Proprietary) Limited
South Africa
Intervet Sp. z.o.o.
Poland
Intervet UK Production Limited
United Kingdom
Intervet Venezolana S.A.
Venezuela
Intervet Veterinaria Chile Ltda
Chile
Intervet Veteriner Ilaclari Pazarlama ve Ticaret Ltd. Sirketi
Turkey
Intervet, s.r.o.
Czech Republic
Interveterinaria SA de CV
Mexico
IOmet Pharma Limited
United Kingdom
Laboratoires Merck Sharp & Dohme
France
Laboratorios Abello, S.A.
Spain
Laboratorios Quimico-Farmaceuticos Chibret, Lda
Portugal
Lemifar S. A.
Uruguay
Matsuken Yakuhin Kogyo K.K.1
Japan
Maya Tibbi Ürünler Ticaret Limited Sirketi
Turkey
MCM Vaccine B.V.1
Netherlands
8



Merck and Company LLC
Delaware
Merck Canada Inc.
Canada
Merck Capital Ventures, LLC1
Delaware
Merck Frosst Canada & Co.
Canada
Merck Frosst Company
Canada
Merck Global Health Innovation Fund, LLC
Delaware
Merck Global Health Innovation, Private Equity, LLC
Delaware
Merck HDAC Research, LLC
Delaware
Merck Holdings II Corp.
Delaware
Merck Holdings IV Corp.
Delaware
Merck Holdings LLC
Delaware
Merck International Holdings Corp.
Delaware
Merck Lumira Biosciences Fund L.P.1
Canada
Merck Registry Holdings, Inc.
New Jersey
Merck Research Investments LLC
Delaware
Merck Research Laboratories Massachusetts, LLC
Delaware
Merck Sharp & Dohme (Argentina) LLC
Delaware
9



Merck Sharp & Dohme (Asia) Limited
Hong Kong
Merck Sharp & Dohme (Australia) Pty. Limited
Australia
Merck Sharp & Dohme (Chile) Ltda.
Chile
Merck Sharp & Dohme (China) Limited
Hong Kong
Merck Sharp & Dohme (Enterprises) B.V.
Netherlands
Merck Sharp & Dohme (Europe) Inc.
Delaware
Merck Sharp & Dohme (Holdings) Pty Ltd
Australia
Merck Sharp & Dohme (I.A.) LLC
Delaware
Merck Sharp & Dohme (International) Limited
Bermuda
Merck Sharp & Dohme (Israel - 1996) Company Ltd.
Israel
Merck Sharp & Dohme (Malaysia) SDN. BHD.
Malaysia
Merck Sharp & Dohme (New Zealand) Limited
New Zealand
Merck Sharp & Dohme (Sweden) A.B.
Sweden
Merck Sharp & Dohme (Switzerland) GmbH
Switzerland
Merck Sharp & Dohme (UK) Limited
United Kingdom
Merck Sharp & Dohme Animal Health, S.L.
Spain
Merck Sharp & Dohme Asia Pacific Services Pte. Ltd.
Singapore
10



Merck Sharp & Dohme B.V.
Netherlands
Merck Sharp & Dohme BH d.o.o.
Bosnia
Merck Sharp & Dohme Bulgaria EOOD
Bulgaria
Merck Sharp & Dohme Colombia S.A.S.
Colombia
Merck Sharp & Dohme Comercializadora, S. de R.L. de C.V.
Mexico
Merck Sharp & Dohme Cyprus Limited
Cyprus
Merck Sharp & Dohme d.o.o.
Croatia
Merck Sharp & Dohme d.o.o. Belgrade
Serbia
Merck Sharp & Dohme de Espana SAU
Spain
Merck Sharp & Dohme Farmaceutica Ltda.
Brazil
Merck Sharp & Dohme Finance Europe Limited
United Kingdom
Merck Sharp & Dohme Gesellschaft m.b.H.
Austria
Merck Sharp & Dohme Holdings Corp.
Delaware
Merck Sharp & Dohme IDEA GmbH
Switzerland
Merck Sharp & Dohme inovativna zdravila d.o.o.
Slovenia
Merck Sharp & Dohme International Services B.V.
Netherlands
Merck Sharp & Dohme Ireland (Human Health) Ltd
Ireland
11



Merck Sharp & Dohme Latvija
Latvia
Merck Sharp & Dohme Limitada
Bolivia
Merck Sharp & Dohme LLC
New Jersey
Merck Sharp & Dohme Manufacturing Unlimited Company
Ireland
Merck Sharp & Dohme OU
Estonia
Merck Sharp & Dohme Peru SRL
Peru
Merck Sharp & Dohme Pharmaceutical Industrial and Commercial Societe Anonyme
Greece
Merck Sharp & Dohme Research GmbH
Switzerland
Merck Sharp & Dohme Romania SRL
Romania
Merck Sharp & Dohme S.A.
Morocco
Merck Sharp & Dohme s.r.o.
Czech Republic
Merck Sharp & Dohme Salud Animal Colombia S.A.S.
Colombia
Merck Sharp & Dohme Saude Animal Ltda.
Brazil
Merck Sharp & Dohme Singapore Trading Pte. Ltd.
Singapore
Merck Sharp & Dohme Tunisie SARL
Tunisia
Merck Sharp & Dohme, Limitada
Portugal
Merck Sharp & Dohme, S. de R.L. de C.V.
Mexico
12



Merck Sharp & Dohme, s.r.o.
Slovakia
Merck Sharp Dohme Ilaclari Limited Sirketi
Turkey
Merck Teknika LLC
Delaware
Merko Acquisition S.A.
Belgium
Merko Dalton B.V.
Netherlands
Merko N.V.
Belgium
ML Holdings (Canada) Inc.
Canada
MRL San Francisco, LLC
Delaware
MRL Ventures Fund LLC
Delaware
MSD (I.A.) B.V.
Netherlands
MSD (L-SP) Unterstützungskasse GmbH
Germany
MSD (Ningbo) Animal Health Technology Co., Ltd.
China
MSD (Nippon Holdings) B.V.
Netherlands
MSD (Norge) AS
Norway
MSD (Proprietary) Limited
South Africa
MSD (Shanghai) Pharmaceuticals Consultancy Co., Ltd.
China
MSD (Thailand) Ltd.
Thailand
13



MSD Agencies B.V.
Netherlands
MSD Animal Health UK Limited
United Kingdom
MSD Animal Health (Phils.), Inc
Philippines
MSD Animal Health (Shanghai) Trading Co., Ltd.
China
MSD Animal Health A/S
Denmark
MSD Animal Health B.V.
Belgium
MSD Animal Health Danube Biotech GmbH
Austria
MSD Animal Health FZ-LLC
United Arab Emirates
MSD Animal Health GmbH
Switzerland
MSD Animal Health Holdings BV
Netherlands
MSD Animal Health Innovation AS
Norway
MSD Animal Health Innovation GmbH
Germany
MSD Animal Health Innovation Pte. Ltd.
Singapore
MSD Animal Health Innovation SAS
France
MSD Animal Health K.K.
Japan
MSD Animal Health Korea Ltd.
Korea
MSD Animal Health Norge AS
Norway
14



MSD Animal Health Oy
Finland
MSD Animal Health Pension Trustee Limited
United Kingdom
MSD Animal Health S.r.l.
Italy
MSD Animal Health Vietnam Co. Limited
Vietnam
MSD Animal Health, Lda.
Portugal
MSD Argentina Holdings B.V.
Netherlands
MSD Argentina SRL
Argentina
MSD Asia Holdings Pte. Ltd.
Singapore
MSD Belgium BV – SRL
Belgium
MSD Biotech B.V.
Netherlands
MSD Brazil Investments B.V.
Netherlands
MSD Central America Services S. de R.L.
Panama
MSD China (Investments) B.V.
Netherlands
MSD China B.V.
Netherlands
MSD China Holding Co., Ltd.
China
MSD Cubist Holdings BV
Switzerland
MSD Cubist Holdings Unlimited Company
Ireland
15



MSD Czech Republic s.r.o.
Czech Republic
MSD Danmark ApS
Denmark
MSD Egypt LLC
Egypt
MSD EIC Unlimited Company
Ireland
MSD Eurofinance
Bermuda
MSD Europe Belgium BV
Belgium
MSD Farmaceutica C.A.
Venezuela
MSD FI BV
Netherlands
MSD Finance B.V.
Netherlands
MSD Finance Company
Bermuda
MSD Finland Oy
Finland
MSD France
France
MSD Global Holdings B.V.
Netherlands
MSD HH Vietnam Ltd
Vietnam
MSD Holdings 2 G.K.
Japan
MSD Human Health Holding B.V.
Netherlands
MSD Human Health Holding II B.V.
Netherlands
16



MSD IDEA Algerie SPA
Algeria
MSD IDEA Pharmaceuticals Nigeria Limited
Nigeria
MSD IDEA Tunisie SARL
Tunisia
MSD Innovation & Development GmbH
Switzerland
MSD International B.V.
Netherlands
MSD International Business GmbH
Switzerland
MSD International Finance B.V.
Netherlands
MSD International Finance LLC
Delaware
MSD International GmbH
Switzerland
MSD International Manufacturing GmbH
Switzerland
MSD Italia s.r.l.
Italy
MSD Japan Holdings B.V.
Netherlands
MSD Japan Holdings GK
Japan
MSD K.K.
Japan
MSD KSA GmbH
Switzerland
MSD Korea Co., Ltd.
Korea
MSD Laboratories India LLC
Delaware
17



MSD Latin America Services S. de R.L.
Panama
MSD Latin America Services S. de R.L. de C.V.
Mexico
MSD Limited
United Kingdom
MSD Luxembourg S.a.r.l.
Luxembourg
MSD Merck Sharp & Dohme AG
Switzerland
MSD NL 4 B.V.
Netherlands
MSD Panama International Services S. de R.L.
Panama
MSD Participations B.V.
Netherlands
MSD Pharma (Singapore) Pte. Ltd.
Singapore
MSD Pharma GmbH
Germany
MSD Pharma Hungary Korlatolt Felelossegu Tarsasag
Hungary
MSD Pharmaceuticals Investments 1 Unlimited Company
Ireland
MSD Pharmaceuticals Investments 3 Unlimited Company
Ireland
MSD Pharmaceuticals Ireland Unlimited Company
Ireland
MSD Pharmaceuticals LLC
Russian Federation
MSD Pharmaceuticals Private Limited
India
MSD Polska Dystrybucja Sp. z.o.o.
Poland
18



MSD Polska Sp.z.o.o.
Poland
MSD R&D (China) Co., Ltd.
China
MSD R&D Innovation Centre Limited
United Kingdom
MSD RDC Costa Rica Sociedad de Responsabilidad Limitada
Cost Rica
MSD Registry Holdings, Inc.
New Jersey
MSD Shared Business Services EMEA Limited
Ireland
MSD Sharp & Dohme Gesellschaft mit beschränkter Haftung
Germany
MSD Switzerland Investments 1 Unlimited Company
Ireland
MSD Switzerland Investments 4 Unlimited Company
Ireland
MSD Switzerland Investments 5 Unlimited Company
Ireland
MSD Ukraine Limited Liability Company
Ukraine
MSD Unterstutzungskasse GmbH
Germany
MSD Vaccines Limited
United Kingdom
MSD Vaccins
France
MSD Vaccins Holdings
France
MSD Venezuela Holding GmbH
Switzerland
MSD Verwaltungs GmbH
Germany
19



MSD Vietnam Company Limited
Vietnam
MSD Vietnam Holdings B.V.
Netherlands
MSDIG Holdings Unlimited Company
Ireland
MSDRG LLC
Delaware
MSP Singapore Company, LLC
Delaware
MSP Vaccine Company1
Pennsylvania
Multilan AG
Switzerland
Nanjing Organon Pharmaceutical Co., Ltd.
China
Nihon MSD G.K.
Japan
Nourifarma - Produtos Quimicos e Farmaceuticos, Sociedade Uniperssoal, Lda
Portugal
O.PI.VI S.R.L.
Italy
OBS Holdings B.V.
Netherlands
Oncoethix GmbH
Switzerland
OncoImmune, Inc.
Delaware
Organon China B.V.
Netherlands
Organon Egypt Ltd
Egypt
Organon Latin America S.A.
Uruguay
20



Organon Middle East S.A.L.
Lebanon
OS ID AS
Norway
OS ID Hellas M.I.K.E
Greece
P.T. Merck Sharp & Dohme Indonesia
Indonesia
Pandion Therapeutics, Inc.
Delaware
Pandion Operations, Inc.
Delaware
Peloton Therapeutics, Inc.
Delaware
Polnet ID Spolka z ograniczona odpowiedzialnoscia
Poland
PrognostiX-Poultry Limited
United Kingdom
Prondil Sociedad Anónima
Uruguay
PT Intervet Indonesia
Indonesia
PT Organon Indonesia
Indonesia
Putexin Investments Limited
New Zealand
Rigontec GmbH
Germany
Rosetta Inpharmatics LLC
Delaware
S.C. Allflex Romania S.R.L.
Romania
S.C.R. (Engineers) Limited
Israel
21



Schering-Plough, S.A.S.
France
Schering-Plough (Ireland) Unlimited Company
Ireland
Schering-Plough Animal Health Limited
New Zealand
Schering-Plough Canada Inc.
Canada
Schering-Plough Corporation
Philippines
Schering-Plough Corporation, U.S.A.
Delaware
Schering-Plough del Peru S.A.
Peru
Schering-Plough Holdings Limited
United Kingdom
Schering-Plough S.A.
Panama
Schering-Plough S.A.
Paraguay
Schering-Plough S.A.
Spain
Schering-Plough S.A.
Uruguay
SCR Allflex Management, Ltd
Israel
Sentipharm AG
Switzerland
Servicios Veternarios Servet, Sociedad Anónima
Costa Rica
Shanghai MSD Pharmaceutical Trading Co., Ltd.
China
Siren Merger Sub Inc.
Delaware
22



Sistemas de Identificacao Animal Ltda
Brazil
SmartCells, Inc.
Delaware
SOL Limited
Bermuda
Stallmastaren AB
Sweden
SureFlap (NZ) Limited
New Zealand
SureFlap Limited
United Kingdom
Tag ID Investments, Inc.
Delaware
Themis Bio Holdings LLC
Delaware
Themis Bio Holdings B.V.
Netherlands
Themis BioScience GmbH
Austria
Theriak B.V.
Netherlands
Tilos Therapeutics, Inc.
Delaware
UAB Merck Sharp & Dohme
Lithuania
Vaki Aquaculture Systems ehf.
Iceland
VelosBio Inc.
Delaware
VelosBio Canada Inc.
Canada
Vence Corp
Delaware
23



Vence Corp AU Pty Ltd
Australia
Venco Farmaceutica S.A.
Venezuela
Venco Holding GmbH
Switzerland
Vet Pharma Friesoythe GmbH
Germany
Veterinaria Premium, Sociedad Anonima
Guatemala
VetInvent, LLC
Delaware
Vetrex B.V.
Netherlands
Vetrex Egypt L.L.C.
Egypt
Vilsan Veteriner Ilaclari Ticaret ve Sanayi Anonim Sirketi
Turkey
Viralytics Limited
Australia
Vocaltag Limited
Israel
Vree Health Italia S.r.l.
Italy
Werthenstein Biopharma GmbH
Switzerland
Zoöpharm B.V.
Netherlands

___________
1 own less than 100%
24

EX-23 21 ex23-consentofindependentr.htm EXHIBIT-23 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Document

Exhibit 23


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-254700 and 333-254703) and on Form S-8 (Nos. 333-173025, 333-173024, 333-162883, 333-162884, 333-162885, 333-162886, 333-121089, and 333-233226) of Merck & Co., Inc. of our report dated February 24, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 24, 2023

EX-24.1 22 ex241-powerofattorney11.htm EXHIBIT-24.1 POWER OF ATTORNEY Document

Exhibit 24.1

POWER OF ATTORNEY
Each of the undersigned does hereby appoint JENNIFER ZACHARY as his/her true and lawful attorney to execute on behalf of the undersigned (whether on behalf of the Company, or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) the Annual Report on Form 10-K of Merck & Co., Inc. for the fiscal year ended December 31, 2022 under the Securities Exchange Act of 1934, including amendments thereto and all exhibits and other documents in connection therewith.
IN WITNESS WHEREOF, this instrument has been duly executed as of the 24th day of February 2023.
MERCK & CO., Inc.
/s/ Robert M. DavisChairman, Chief Executive Officer and President
Robert M. Davis(Principal Executive Officer; Director)
/s/ Caroline LitchfieldExecutive Vice President and Chief Financial Officer
Caroline Litchfield (Principal Financial Officer)
/s/ Rita A. Karachun
Senior Vice President Finance—Global Controller
Rita A. Karachun
(Principal Accounting Officer)
DIRECTORS
 
/s/ Douglas M. Baker, Jr./s/ Paul B. Rothman
Douglas M. Baker, Jr.Paul B. Rothman
/s/ Mary Ellen Coe/s/ Patricia F. Russo
Mary Ellen CoePatricia F. Russo
/s/ Pamela J. Craig/s/ Christine E. Seidman
Pamela J. CraigChristine E. Seidman
/s/ Thomas H. Glocer/s/ Inge G. Thulin
Thomas H. GlocerInge G. Thulin
/s/ Risa J. Lavizzo-Mourey/s/ Kathy J. Warden
Risa J. Lavizzo-MoureyKathy J. Warden
/s/ Stephen L. Mayo/s/ Peter C. Wendell
Stephen L. MayoPeter C. Wendell

EX-24.2 23 ex242-certificationofboard.htm EXHIBIT-24.2 CERTIFICATION OF BOARD RESOLUTION Document

Exhibit 24.2

I, Kelly Grez, Corporate Secretary of Merck & Co., Inc. (the “Company”), a corporation duly organized and existing under the laws of the State of New Jersey, do hereby certify that the following is a true copy of a resolution adopted by unanimous written consent of the Board of Directors of the Company on February 24, 2023 in accordance with the provisions of the By-Laws of the Company:

“Special Resolution No. [13] – 2023

RESOLVED, that the proposed form of the Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2022, attached hereto, is hereby approved with such changes as the proper officers of the Company, with the advice of counsel, deem appropriate;

FURTHER RESOLVED, that each officer and director who may be required to execute the aforesaid Annual Report on Form 10-K or any amendments thereto (whether on behalf of the Company or as an officer or director thereof, or by attesting the seal of the Company, or otherwise) is hereby authorized to execute a power of attorney appointing Jennifer Zachary as his/her true and lawful attorney to execute in his/her name, place and stead (in any such capacity) such Annual Report on Form 10‑K and any and all amendments thereto and any and all exhibits and other documents necessary or incidental in connection therewith and to file the same with the Securities and Exchange Commission, the attorney to have power to act and to have full power and authority to do and perform in the name and on behalf of each of said officers and directors, or both, as the case may be, every act whatsoever necessary or advisable to be done in the premises as fully and to all intents and purposes as any such officer or director might or could do in person; and

FURTHER RESOLVED that an executed copy of the Action by Unanimous Written Consent be filed with the minutes of the meetings of the Board of Directors of the Company."

IN WITNESS WHEREOF, I have hereunto subscribed my signature and affixed the seal of the Company this 24th day of February 2023.

[Corporate Seal]/s/ Kelly Grez
Kelly Grez
Corporate Secretary

EX-31.1 24 ex311-rule13ax14a15dx14ace.htm EXHIBIT-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO Document

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this annual report on Form 10-K of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 24, 2023

By:     /s/ Robert M. Davis
ROBERT M. DAVIS
Chairman, President and Chief Executive Officer

EX-31.2 25 ex312-rule13ax14a15dx14ace.htm EXHIBIT-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO Document

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1.    I have reviewed this annual report on Form 10-K of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   February 24, 2023

By:      /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

EX-32.1 26 ex321-section1350certifica.htm EXHIBIT-32.1 SECTION 1350 CERTIFICATION OF CEO Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 24, 2023 /s/ Robert M. Davis
 Name: ROBERT M. DAVIS
 Title: Chairman, President and Chief Executive Officer

EX-32.2 27 ex322-section1350certifica.htm EXHIBIT-32.2 SECTION 1350 CERTIFICATION OF CFO Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 24, 2023/s/ Caroline Litchfield
Name: CAROLINE LITCHFIELD
Title: Executive Vice President, Chief Financial Officer

EX-101.SCH 28 mrk-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Consolidated Statement of Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Consolidated Statement of Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Consolidated Statement of Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Nature of Operations link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Summary of Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Spin-Off of Organon & Co. link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Goodwill and Other Intangibles link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Contingencies and Environmental Liabilities link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Share-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Summary of Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Spin-Off of Organon & Co. (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Goodwill and Other Intangibles (Tables) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Share-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Taxes on Income (Tables) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Nature of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Summary of Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Collaborative Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 0000077 - Disclosure - Contingencies and Environmental Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000078 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000079 - Disclosure - Equity - Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) link:presentationLink link:calculationLink link:definitionLink 0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) link:presentationLink link:calculationLink link:definitionLink 0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) link:presentationLink link:calculationLink link:definitionLink 0000099 - Disclosure - Taxes on Income - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000101 - Disclosure - Taxes on Income - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details) link:presentationLink link:calculationLink link:definitionLink 0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000106 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000107 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000108 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details) link:presentationLink link:calculationLink link:definitionLink 0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) link:presentationLink link:calculationLink link:definitionLink 0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 29 mrk-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 30 mrk-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 31 mrk-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Business Acquisition [Axis] Business Acquisition [Axis] Real estate Defined Benefit Plan, Real Estate [Member] Inventory [Axis] Inventory [Axis] Foreign Current Foreign Tax Expense (Benefit) Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Loss contingency, pending claims Loss Contingency, Pending Claims, Number 1.70% notes due 2027 1.70% notes due 2027 [Member] 1.70% notes due 2027 Compensation earned on arragement Research and Development Arrangement, Contract to Perform for Others, Compensation Earned 2.35% notes due 2040 2.35% Notes Due 2040 [Member] 2.35% Notes Due 2040 Investments Debt Securities, Trading, and Equity Securities, FV-NI Summary of Common Stock and Treasury Stock Transactions Schedule of Stockholders Equity [Table Text Block] Deferred provision Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Valuation Technique, Discounted Cash Flow Valuation Technique, Discounted Cash Flow [Member] Debt Instrument [Axis] Debt Instrument [Axis] Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Property, plant and equipment (at cost) Property, Plant and Equipment, Gross Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Property, plant and equipment Property, Plant and Equipment, Additions Foreign exchange contracts Foreign Exchange Contract [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Sales Disposal Group, Including Discontinued Operation, Revenue Lagevrio Lagevrio [Member] Lagevrio Financial Instruments [Domain] Financial Instruments [Domain] Loss contingency, number of plaintiffs Loss Contingency, Number of Plaintiffs Depreciation Depreciation Depreciation Number of Options, Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Stated interest rate Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Location and Pretax Gain or Loss Amounts for Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Other current assets Other Current Assets [Member] Other paid-in capital Additional Paid in Capital, Common Stock Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Other Other Noncash Income (Expense) Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] State Current State and Local Tax Expense (Benefit) Income taxes paid Income Taxes Paid Measurement Input Type [Domain] Measurement Input Type [Domain] Less: Cash and cash equivalents related to discontinued operations Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Settlements Defined Benefit Plan, Plan Assets, Payment for Settlement Document Information [Line Items] Document Information [Line Items] Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Net cash provided by operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Additions related to current year positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Investment, Name [Domain] Investment, Name [Domain] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Tax Rate Effective Income Tax Rate Reconciliation, Percent [Abstract] Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Debt securities, fair value Foreign government bonds Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Fair value of plan assets Fair value of plan assets January 1 Fair value of plan assets December 31 Plan assets at fair value Defined Benefit Plan, Plan Assets, Amount Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Weighted Average Exercise Price, Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Discount rate Intangible Asset, Products and Product rights, Measurement Input Intangible Asset, Products and Product rights, Measurement Input Emerging markets equities Emerging Markets Equities Investment Funds [Member] Emerging markets equities investment funds. Pension Plan Prior Service Credit Pension Plan Prior Service Cost [Member] Pension Plan Prior Service Cost [Member] Payables included in Other Noncurrent Liabilities Liabilities, Noncurrent Entity Address, State or Province Entity Address, State or Province Weighted-average interest rate of commercial paper Short-Term Debt, Weighted Average Interest Rate, at Point in Time Other Comprehensive (Loss) Income Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Weighted Average Remaining Contractual Term, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Insurance contracts Insurance Contracts Insurance Contracts Other Investments [Member] Insurance contracts other investments. Operating Activities [Domain] Operating Activities [Domain] Acquired In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Award Type [Axis] Award Type [Axis] Actuarial (gains) losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) Unrecognized tax benefits from adjustments related to examination Settlements Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities 2027 Defined Benefit Plan, Expected Future Benefit Payment, Year Five Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration] Accrued and other current liabilities Operating Lease, Liability, Current Collaborative Arrangements Collaborative Arrangement, Accounting Policy [Policy Text Block] Costs, Expenses and Other Costs and Expenses [Abstract] Derazantinib Derazantinib [Member] Derazantinib Animal Health Animal Health segment [Member] Animal Health segment [Member] Other fixed income obligations Fixed Income Obligations Investment Funds [Member] Fixed income obligations investment funds. Long-Term Debt Long-Term Debt, Excluding Current Maturities Research and development payments to be made to a collaborative partners Research and Development Payments To Be Made to a Collaborative Partners Research and Development Payments To Be Made to a Collaborative Partners Liabilities Liabilities Operating lease, weighted average remaining lease term Weighted-average remaining lease term (years) Operating Lease, Weighted Average Remaining Lease Term Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash Flows from Investing Activities of Continuing Operations Net Cash Provided by (Used in) Investing Activities [Abstract] Summary of Expected Benefit Payments Schedule of Expected Benefit Payments [Table Text Block] Prior service (cost) credit arising during the period Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Collaborative Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Current provision Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Estimated useful life of property, plant and equipment Property, Plant and Equipment, Useful Life Acquisition of Acceleron Pharma Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Assets Assets, Fair Value Disclosure [Abstract] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Asset Acquisition [Axis] Asset Acquisition [Axis] Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Deferred income taxes Total deferred provision Deferred Income Tax Expense (Benefit) Other Assets Assets for Plan Benefits, Defined Benefit Plan Products and product rights Developed Technology Rights [Member] Amount of gain (loss) recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Januvia Januvia [Member] Januvia [Member] . Other Other Other Investments [Member] Regulatory milestone payments accrued Collaborative Arrangement, Regulatory Milestone Payments Accrued Collaborative Arrangement, Regulatory Milestone Payments Accrued Differential arising from: Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract] Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Available-for-sale Securities [Table] Debt Securities, Available-for-Sale [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Oral Formulation oral formulation [Member] oral formulation Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Company contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Currency Options Foreign Exchange Option [Member] Eligible future contingent development-related payments (up to) Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments Long-term debt, current maturities Long-Term Debt, Current Maturities Finite-lived intangible assets acquired Finite-Lived Intangible Assets Acquired Accounting Policies [Abstract] Accounting Policies [Abstract] Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets Merck & Co., Inc. Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] RotaTeq Rotateq [Member] RotaTeq [Member] Foreign earnings Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Transition services agreement Transition services agreement [Member] Transition services agreement Customer [Axis] Customer [Axis] Interest cost Defined Benefit Plan, Interest Cost Number of interest rate derivatives matured Number of Interest Rate Derivatives Matured Number of interest rate derivatives that matured during the period. Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Assumptions Used to Determine Weighted-Average Fair Value of Options Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Loss contingency, claims settled (in cases) Loss Contingency, Claims Settled, Number Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Taxes on Income Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Acceleron Pharma Inc. Acceleron Pharma Inc. [Member] Acceleron Pharma Inc. Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Buildings Buildings and Improvements, Gross Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Other pharmaceutical Other Pharmaceutical [Member] Other pharmaceutical. Other comprehensive income (loss) before reclassification adjustments, net of taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Cash paid for acquisition of business Payments to Acquire Businesses, Gross Derivative Contract [Domain] Derivative Contract [Domain] Compensation related, Assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation Entity Registrant Name Entity Registrant Name 2026 Defined Benefit Plan, Expected Future Benefit Payment, Year Four Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Benefits paid Defined Benefit Plan, Benefit Obligation, Benefits Paid Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Europe, Middle East and Africa EMEA [Member] Total equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Principles of Consolidation Consolidation, Policy [Policy Text Block] Minimum Minimum [Member] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Inventory write-down Inventory Write-down Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Investment, Name [Axis] Investment, Name [Axis] Valuation allowance on foreign NOL carryforwards Operating Loss Carryforwards, Valuation Allowance Trading Symbol Trading Symbol Entity File Number Entity File Number R&D tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Operating Activities [Axis] Operating Activities [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Estimated aggregate amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Four Foreign Deferred Foreign Income Tax Expense (Benefit) Probable contingent payments Probable Contingent Payments Collaborative Arrangement Probable Contingent Payments Collaborative Arrangement Number of Shares, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total, Tax Rate Effective Income Tax Rate Reconciliation, Percent Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year Costs, Expenses and Other Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Due from related parties, current Due from Related Parties, Current Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Use of Estimates Use of Estimates, Policy [Policy Text Block] Consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Long-term debt, interest payments in 2025 Long-term Debt, Interest Payable, Year Three Long-term Debt, Interest Payable, Year Three Percentage of accounts receivable represented by customers with largest balances (as percent) Concentration Risk, Percentage Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Settlements Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement GILTI and the foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount Taxes on Income Income Tax Disclosure [Text Block] Revenue from related party Revenue from Related Parties Cash and cash equivalents Defined Benefit Plan, Cash and Cash Equivalents [Member] Gross Carrying Amount Intangible Assets, Gross (Excluding Goodwill) Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans Schedule of Health Care Cost Trend Rates [Table Text Block] Net Income (in dollars per share) Earnings Per Share, Basic Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards Deferred tax assets credit loss carryforwards and NOL carryforwards domestic Deferred tax assets credit loss carryforwards and NOL carryforwards domestic Period over which share-based payment awards vest Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Construction in progress Construction in Progress, Gross Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Reclassification adjustments, pretax Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Other Other profits Corporate, Non-Segment [Member] Acquisition of VelosBio Inc., net of cash acquired Payments to Acquire Business Four, Net of Cash Acquired Payments to Acquire Business Four, Net of Cash Acquired Loss contingency, damages sought Loss Contingency, Damages Sought, Value Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Net loss (gain) amortization included in benefit cost Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current 3.70% notes due 2045 3.70% Notes Due 2045 [Member] 3.70% Notes Due 2045 [Member] Net changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Development Milestones Development Milestones [Member] Development Milestones [Member] Other (income) expense, net Other Nonoperating Income (Expense) [Member] Potential future sales-based milestone payments Potential Future Milestone Payments Sales-Based Potential Future Milestone Payments Sales-Based Deferred Income Taxes Assets And Liabilities Net [Table] Deferred Income Taxes Assets And Liabilities Net [Table] Deferred Income Taxes Assets And Liabilities Net [Table] Litigation Status [Domain] Litigation Status [Domain] Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Purchases of treasury stock Payments for Repurchase of Common Stock Taxes on Income Income Tax, Policy [Policy Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Acquisition of VelosBio Income Tax Rate Reconciliation, Asset Acquisition Income Tax Rate Reconciliation, Asset Acquisition Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Receivables included in Other current assets Receivables, Net, Current Investments Marketable Securities, Noncurrent Relating to assets sold during the year Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold Discontinued Operations and Disposal Groups [Abstract] Current Assets Assets, Current [Abstract] Interest and penalties associated with uncertain tax positions, expense (benefit) Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Asset Acquisition [Domain] Asset Acquisition [Domain] (Gains) losses for equity securities held through ownership interests in investment funds Equity Securities, FV-NI, Realized Gain (Loss) Cardinal Health, Inc. Cardinal Health, Inc. [Member] Cardinal Health, Inc. Retained earnings Retained Earnings (Accumulated Deficit) Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Number of Shares, Expected to Vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number Cash equivalents Cash Equivalents, at Carrying Value Sivextro Sivextro [Member] Sivextro [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Scenario [Domain] Scenario [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Gilead Sciences Gilead Sciences [Member] Gilead Sciences Weighted Average Exercise Price, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Document Fiscal Year Focus Document Fiscal Year Focus International Foreign Plan [Member] Other (income) expense, net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Defined Benefit Plan, Plan Assets, Category [Domain] Defined Benefit Plan, Plan Assets, Category [Domain] 4.00% notes due 2049 4.00% Notes Due 2049 [Member] 4.00% Notes Due 2049 Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Cash Flows from Operating Activities of Continuing Operations Net Cash Provided by (Used in) Operating Activities [Abstract] Simponi Simponi [Member] Simponi [Member]. Consideration received Disposal Group, Including Discontinued Operation, Consideration R&D capitalization, Assets Deferred Tax Assets, in Process Research and Development Contingent consideration, liability, current Business Combination, Contingent Consideration, Liability, Current 4.15% notes due 2043 4.15% Notes Due 2043 [Member] 4.15% Notes Due 2043 [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Loss Contingencies [Table] Loss Contingencies [Table] Total current provision Current Income Tax Expense (Benefit) Cumulative downward price adjustment Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Discontinued Operations Discontinued Operations [Member] Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Capital expenditures Payments to acquire productive assets Payments to Acquire Productive Assets Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Summary of Nonvested RSU and PSU Activity Share-Based Payment Arrangement, Activity [Table Text Block] Inventories Increase (Decrease) in Inventories Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Litigation Status [Axis] Litigation Status [Axis] Keytruda Keytruda [Member] Keytruda [Member] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Document Information [Table] Document Information [Table] Loss contingency, trial period Loss Contingency, Trial Period Loss Contingency, Trial Period Total (approximates current cost) Inventory, Gross Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Accrued and other current liabilities Other Current Liabilities [Member] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Actual return on plan assets Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss) Alliance revenue - Adempas/Verquvo Alliance revenue - Adempas/Verquvo [Member] Alliance revenue - Adempas/Verquvo Taxes on Income from Continuing Operations Taxes on income Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Valuation allowance, Assets Deferred Tax Assets, Valuation Allowance Deferred Income Taxes Deferred Income Taxes Deferred Income Tax Liabilities, Net Entity Public Float Entity Public Float Balance Sheet Location [Domain] Balance Sheet Location [Domain] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Cost of sales Cost of Goods and Services Sold Cash collateral received, liability Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Fair Value of Derivative, Liability Gross amounts recognized in the consolidated balance sheet, liability Derivative liabilities Derivative Liability Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Upfront and milestone payments Upfront Payments Made To License or Collaborative Partner Upfront payments made to partner as part of a licensing or collaborative arrangement. Royalty Pharma Royalty Pharma [Member] Royalty Pharma Loss Contingencies [Line Items] Loss Contingencies [Line Items] Software Capitalization Internal Use Software, Policy [Policy Text Block] 2023 Defined Benefit Plan, Expected Future Benefit Payment, Year One Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Developed markets Developed Markets Equity Securities [Member] Developed markets equity securities. Manufacturing and supply agreements Manufacturing and supply agreements [Member] Manufacturing and supply agreements Accounts Receivable Accounts Receivable [Member] Investments Investments Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 Common Stock, Value, Issued Restructuring costs Restructuring Charges [Member] Related party amount in cost of sales Related Parties Amount in Cost of Sales Income from Discontinued Operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Differential arising from: Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract] Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract] Contingencies and Legal Defense Costs Commitments and Contingencies, Policy [Policy Text Block] Accrued and other current liabilities Liability, Defined Benefit Plan, Current Lessee, operating lease, lease not yet commenced, amount Lessee, Operating Lease, Lease Not yet Commenced, Amount Lessee, Operating Lease, Lease Not yet Commenced, Amount Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. 2.75% notes due 2051 2.75% notes due 2051 [Member] 2.75% notes due 2051 Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets) Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Notes Subject To Repayment At Option Of Holder Notes Subject To Repayment At Option Of Holder [Member] Notes Subject To Repayment At Option Of Holder [Member] Restructuring Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount Current Liabilities Liabilities, Current [Abstract] Proceeds from exercise of stock options Cash received from the exercise of stock options Proceeds from Stock Options Exercised Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Weighted Average Remaining Contractual Term, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 2.80% notes due 2023 2.80% Notes Due 2023 [Member] 2.80% Notes Due 2023 [Member] 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Amendment Flag Amendment Flag Estimated useful life of intangible assets Finite-Lived Intangible Asset, Useful Life Operating lease, cost Operating Lease, Cost Net amounts, asset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Income from discontinued operations before taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Cancidas Cancidas [Member] Cancidas [Member]. Acquisitions Goodwill, Acquired During Period Net Cash Provided by Operating Activities of Continuing Operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Debt securities, gross unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Other assets Other Assets, Noncurrent Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Developed markets equities Developed Markets Equities Investment Funds [Member] Developed markets equities investment funds. Ridgeback Biotherapeutics LP Ridgeback Biotherapeutics LP [Member] Ridgeback Biotherapeutics LP First Commercial Sale Milestones First Commercial Sale Milestones [Member] First Commercial Sale Milestones Number of Options, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Depreciation Depreciation, Depletion and Amortization Total costs, expenses and other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Bristol Myers Squibb Bristol Myers Squibb [Member] Bristol Myers Squibb Royalties Royalty Income, Nonoperating Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Additional Information Pertaining to Stock Option Plans Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block] Additional information pertaining to stock option plans. Royalty rate, percentage Royalty Rate, Percentage Royalty Rate, Percentage Real Estate Real Estate Investment Funds [Member] Real estate investment funds. Counterparty Name [Axis] Counterparty Name [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Dunboyne Dunboyne [Member] Dunboyne Products and product rights - Reblozyl (12 year useful life) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Income Tax [Line Items] Income Tax [Line Items] Income Tax [Line Items] Injectable Formulation injectable formulation [Member] injectable formulation Operating lease, payments Operating Lease, Payments Payments on debt Repayments of Long-Term Debt Benefit obligation Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract] Domestic Plan Domestic Plan [Member] Benefit plan net gain (loss) and prior service credit (cost), net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Net unrealized loss on investments, net of reclassifications OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, authorized (in shares) Common Stock, Shares Authorized 6.50% notes due 2033 Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member] Six point five zero percentage notes due on two thousand and thirty three. Acquired Intangibles Intangible Assets, Finite-Lived, Policy [Policy Text Block] Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Profit share Profit Share Profit Share Maximum Maximum [Member] Inventory [Domain] Inventory [Domain] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net Cash Flows Provided by Discontinued Operations Net Cash Provided by (Used in) Discontinued Operations Loss (income) from investments in equity securities, net Equity Securities, FV-NI, Gain (Loss) Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] McKesson McKesson Corporation [Member] McKesson Corporation Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Goodwill, Other Increase (Decrease) Business Acquisition [Line Items] Business Acquisition [Line Items] Measurement Frequency [Domain] Measurement Frequency [Domain] Equity Stockholders' Equity Note Disclosure [Text Block] Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Accrual for chargebacks reflected as direct reduction to accounts receivable Accrual For Chargebacks Accrual for chargebacks reflected as a direction reduction to accounts receivable. Net Income from Continuing Operations Net income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest In-process research and development (IPR&D) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Prevymis Prevymis [Member] Prevymis Spin-off of Organon Defined Benefit Plan, Benefit Obligation, Divestiture Income tax benefits related to share-based compensation Share-Based Payment Arrangement, Expense, Tax Benefit Accounts receivable Increase (Decrease) in Accounts Receivable Title of 12(b) Security Title of 12(b) Security 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Purchases and sales, net Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement Short-term investments Short-Term Investments Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] 5.75% notes due 2036 Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member] Five point seven five percentage notes due on two thousand and thirty six. Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information Defined Benefit Plan, Assumptions [Table Text Block] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Restructuring costs Disposal Group, Including Discontinued Operations, Restructuring Costs Disposal Group, Including Discontinued Operations, Restructuring Costs Segment Reporting Segment Reporting Disclosure [Text Block] Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block] Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets. Inventory related, Liabilities Deferred Tax Liabilities, Inventory Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Other Intangibles Schedule of Intangible Assets and Goodwill [Table Text Block] Deferred income taxes, Liabilities Deferred Tax Liabilities, Net GILTI and the foreign-derived intangible income deduction Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent Liabilities and Equity Liabilities and Equity [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Regulatory milestones payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note 8) Inventories Inventory, Net Trade accounts payable Accounts Payable, Current Income Tax Authority [Axis] Income Tax Authority [Axis] Product return period and expiration Revenue Recognition, Goods, Goods Return Period After to Expiration Date Revenue Recognition, Goods, Goods Return Period After to Expiration Date Aggregate Intrinsic Value, Vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Spin-off of Organon Defined Benefit Plan, Plan Assets, Divestiture Income from Continuing Operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Payment terms Revenue, Performance Obligation, Payment Terms Revenue, Performance Obligation, Payment Terms Average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Equity method, ownership percentage Equity Method Investment, Ownership Percentage Other net liabilities Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward] Target allocation Defined Benefit Plan, Plan Assets, Target Allocation, Percentage Net amounts, liability Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. Notional amount of derivative Derivative, Notional Amount Health care cost trend rate assumed for next year Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value Funds collected from factoring of receivable, held in restricted cash Restricted Cash, Current Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset AmerisourceBergen Corporation AmerisourceBergen Corporation [Member] AmerisourceBergen Corporation Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Other Postretirement Benefit Plan Net Gain Other Postretirement Benefit Plan Net Loss [Member] Other Postretirement Benefit Plan Net Loss [Member] Income taxes payable Increase (Decrease) in Income Taxes Payable Government and agency obligations Government And Agency Obligations Fixed Income Securities [Member] Government and agency obligations fixed income securities. Number of collaboration targets Collaborative Arrangement, Number Of Collaboration Targets Collaborative Arrangement, Number Of Collaboration Targets Loans payable and current portion of long-term debt Debt, Current Pending Litigation Pending Litigation [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Share-Based Compensation Plans Share-Based Payment Arrangement [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Effects of exchange rate changes Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss) Other Assets Deferred Income Taxes And Other Assets, Noncurrent [Member] Deferred Income Taxes And Other Assets, Noncurrent Acquisition of Pandion Effective Income Tax Rate Reconciliation, Business Combination Four, Percent Effective Income Tax Rate Reconciliation, Business Combination Four, Percent Non- controlling Interests Noncontrolling Interest [Member] Total pretax restructuring costs Expenses Restructuring and Related Cost, Incurred Cost 1.45% notes due 2030 1.45% Notes Due 2030 [Member] 1.45% Notes Due 2030 Deferred Income Taxes Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Goodwill [Roll Forward] Goodwill [Roll Forward] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders Earnings Per Share, Diluted [Abstract] Acquisition of VelosBio Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Other acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Current Fiscal Year End Date Current Fiscal Year End Date Intangible Assets Excluding Goodwill [Line Items] Finite-Lived Intangible Assets [Line Items] Other Intangibles, Net Other intangibles, net Net Intangible Assets, Net (Excluding Goodwill) Inventory [Line Items] Inventory [Line Items] Spin-off of Organon & Co. Stockholders' Equity Note, Spinoff Transaction Stock conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Restructuring Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Total current liabilities Payables included in Accrued and other current liabilities Liabilities, Current Other Other Restructuring [Member] Customer Concentration Risk Customer Concentration Risk [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Spin-Off of Organon & Co. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Favorable net impact to income tax provision if unrecognized tax benefits were recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Janumet Janumet [Member] Janumet [Member]. Unrealized gains Equity Securities, FV-NI, Unrealized Gain (Loss) Foreign government bonds Debt Security, Government, Non-US [Member] Upfront and milestone payments to be made Upfront and Milestone Payments to be Made to Collaborative Partner Upfront and Milestone Payments to be Made to Collaborative Partner Income Tax Authority [Domain] Income Tax Authority [Domain] Other Proceeds from (Payments for) Other Financing Activities IPR&D impairment charges Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Term for paying off environmental liabilities Term For Paying Off Environmental Liabilities Term for paying off environmental liabilities. Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Cash collateral received from counterparties Cash collateral received, asset Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Schedule Of Other Intangibles [Table] Schedule Of Other Intangibles [Table] Schedule Of Other Intangibles [Table] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Equity Method Investments, Assets Deferred Tax Assets, Equity Method Investments Equity [Abstract] Equity [Abstract] Adempas Adempas [Member] Adempas Number of Shares, Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Alliance revenue - Lynparza Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Restructuring Costs Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] nemtabrutinib nemtabrutinib [Member] nemtabrutinib Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Inventory Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Reconciliation Between Effective Tax Rate and U.S. Statutory Rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Contingent consideration, measurement input, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Accelerated depreciation, Assets Deferred Tax Assets, Property, Plant and Equipment Entity Central Index Key Entity Central Index Key Interest income Interest income Investment Income, Interest Latin America Latin America [Member] Orna Therapeutics Orna Therapeutics [Member] Orna Therapeutics Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] 1.375% euro-denominated notes due 2036 1.375% euro-denominated notes due 2036 [Member] 1.375% euro-denominated notes due 2036 [Member] Long-term debt, interest payments in 2027 Long-term Debt, Interest Payable, Year Five Long-term Debt, Interest Payable, Year Five Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Separation Costs One-time Termination Benefits [Member] Pandion Therapeutics Pandion Therapeutics [Member] Pandion Therapeutics Measurement Input Type [Axis] Measurement Input Type [Axis] Entity [Domain] Entity [Domain] Derivatives Defined Benefit Plan, Derivative [Member] City Area Code City Area Code Effective interest rate Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate Assets Assets [Abstract] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net Share-based compensation payments to settle equity awards attributable to precombination service Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed Tax settlements Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Research and development Disposal Group, Including Discontinued Operations, Research and Development Expenses Disposal Group, Including Discontinued Operations, Research and Development Expenses Percentage of Company's pension investments categorized as level 3 assets Company Pension Investments Which Are Categorized As Level Three Assets Percentage Company pension investments which are categorized as level three assets percentage. Spin-off of Organon Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction Long-term debt, maturities, repayments of principal in 2023 Long-Term Debt, Maturity, Year One Share-based compensation Pretax share-based compensation cost recorded, related to continuing operations Share-Based Payment Arrangement, Noncash Expense Invanz Invanz [Member] Invanz [Member]. Weighted average fair value of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Charges related to program discontinuation Charges related to program discontinuation Charges related to program discontinuation Other Noncurrent Liabilities Other Liabilities, Noncurrent Equity income (loss) from affiliates Income (Loss) from Equity Method Investments Interest rate swap contracts Interest Rate Contract [Member] Oral and Injectable Formulations oral and injectable formulations [Member] oral and injectable formulations Continuing Operations Continuing Operations [Member] Noncurrent liabilities Increase (Decrease) in Other Operating Liabilities Machinery, equipment and office furnishings Machinery and Equipment, Gross Estimated aggregate amortization expense, 2023 Finite-Lived Intangible Asset, Expected Amortization, Year One Benefit obligation January 1 Benefit obligation December 31 Defined Benefit Plan, Benefit Obligation Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Unrecognized tax benefits, Assets Deferred Tax Assets Unrecognized Tax Benefits Deferred tax assets unrecognized tax benefits. Amount Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Other Postretirement Benefits Other Postretirement Benefits Plan [Member] Customer [Domain] Customer [Domain] Product return period Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date Acquisition of ArQule, Inc., net of cash acquired Payments to Acquire Business Five, Net of Cash Acquired Payments to Acquire Business Five, Net of Cash Acquired Reclassification adjustments, net of taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Salary growth rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase Total lease payments Lessee, Operating Lease, Liability, to be Paid Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Reconciliation of Unrecognized Tax Benefits [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Long-term debt, maturities, repayments of principal in 2024 Long-Term Debt, Maturity, Year Two Acquisitions Business Combinations Policy [Policy Text Block] Other segments Other Segments [Member] Plan amendments Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment Available borrowing capacity under credit facility Line of Credit Facility, Maximum Borrowing Capacity Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Accelerated depreciation, Liabilities Deferred Tax Liabilities, Property, Plant and Equipment Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve U.S. equities Defined Benefit Plan, Equity Securities, US [Member] Capitalized Software Software and Software Development Costs [Member] Revenue related to the sale of the marketing rights Proceeds from Sale of Intangible Assets Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Long-term debt, interest payments in 2024 Long-term Debt, Interest Payable, Year Two Long-term Debt, Interest Payable, Year Two Other Payments for (Proceeds from) Other Investing Activities Reblozyl Alliance revenue - Reblozyl Reblozyl [Member] Reblozyl Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Lapse of statute of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Net periodic benefit cost (credit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Federal Domestic Tax Authority [Member] Bayer AG Bayer AG [Member] Bayer AG [Member] Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Licenses and other Other Intangible Assets [Member] Amortization of unrecognized prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Long-term debt, interest payments in 2026 Long-term Debt, Interest Payable, Year Four Long-term Debt, Interest Payable, Year Four Salary growth rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase ArQule ArQule [Member] ArQule [Member] Scenario [Axis] Scenario [Axis] Valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Total assets Assets, Fair Value Disclosure Quantity of stock options that vest per year Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021 Treasury Stock, Common, Value Tax settlements Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Income from Continuing Operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Customer discounts Sales Discounts Sales Discounts Goodwill [Line Items] Goodwill [Line Items] AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Audit Information [Abstract] Audit Information [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Fair Value of Derivative, Asset Gross amounts recognized in the consolidated balance sheet, asset Derivative assets Derivative Asset IPR&D In Process Research and Development [Member] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Additional funding by others, development costs subject to funding Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding Related Party Transaction [Domain] Related Party Transaction [Domain] Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Number of Options, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Document Annual Report Document Annual Report Legal Entity [Axis] Legal Entity [Axis] Raw materials and work in process Inventory, Work in Process and Raw Materials Cash Flows from Discontinued Operations Net Cash Provided by (Used in) Discontinued Operations [Abstract] Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo Geographical [Axis] Geographical [Axis] Other Noncurrent Liabilities Liability, Defined Benefit Plan, Noncurrent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Mortgage and asset-backed securities Mortgage And Asset Backed Securities Fixed Income Securities [Member] Mortgage and asset backed securities fixed income securities. Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration] 3.40% notes due 2029 3.40% Notes Due 2029 [Member] 3.40% Notes Due 2029 Cash collateral advanced to counterparties Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Income from Discontinued Operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Factored accounts receivable Accounts Receivable, Sale Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] 2025 Defined Benefit Plan, Expected Future Benefit Payment, Year Three Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] Loans Payable, Long-Term Debt and Leases Debt Disclosure [Text Block] Total notional amount of Interest rate derivatives matured Derivative Notional Amount Matured Derivative Notional Amount Matured Product and Service [Domain] Product and Service [Domain] Distribution from Organon & Co. Disposal Group Including Discontinued Operations Distribution Received Disposal Group Including Discontinued Operations Distribution Received Entity Shell Company Entity Shell Company Accrued and other current liabilities Increase (Decrease) in Accrued Liabilities Reductions for tax positions of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Fixed Income Investments Fixed Income Investments [Member] Schedule of Allocation of Plan Assets Schedule of Allocation of Plan Assets [Table Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Forward contract indexed to issuer's equity, indexed shares (in shares) Forward Contract Indexed to Issuer's Equity, Indexed Shares Aggregate possible expenditure on environmental matters in excess of amounts accrued Environmental Exit Costs, Reasonably Possible Additional Loss 2.15% notes due 2031 2.15% notes due 2031 [Member] 2.15% notes due 2031 Financial Instrument [Axis] Financial Instrument [Axis] Milestone payments made to collaborative partner Milestone Payments Made to Collaborative Partner Milestone Payments Made to Collaborative Partner Long-term debt, maturities, repayments of principal in 2025 Long-Term Debt, Maturity, Year Three Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Vehicles Vehicles [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Financial Instruments Financial Instruments Disclosure [Text Block] Present value discount rate Discount rate Intangible Asset, Measurement Input Intangible Asset, Measurement Input Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Settlements and curtailments Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax Sentinel Sentinel [Member] Sentinel [Member] Alliance revenue - profit sharing Collaborative Arrangement, Profit Sharing Collaborative Arrangement, Profit Sharing Prior service credit amortization included in benefit cost Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Net Cash (Used in) Provided by Financing Activities of Continuing Operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] PSUs Performance Shares [Member] Publicly traded equity securities Equity Securities, FV-NI, Current Interest Rate Swap Interest rate swap contracts Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc. [Member] Artiva Biotherapeutics, Inc. Weighted Average Exercise Price, Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 2027 Lessee, Operating Lease, Liability, to be Paid, Year Five 2.40% Notes Due 2022 2.40% Notes Due 2022 [Member] 2.40% Notes Due 2022 [Member] Income from Continuing Operations Before Taxes Income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Maximum planning cycle of hedges (less than) Derivative, Average Remaining Maturity Segments [Domain] Segments [Domain] Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Other net assets (liabilities) Asset Acquisition, Other Assets and Liabilities Recognized, Net Asset Acquisition, Other Assets and Liabilities Recognized, Net Earnings per Share Earnings Per Share [Text Block] Other, Liabilities Deferred Tax Liabilities, Other Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Forward Contracts Forward Contracts [Member] 2.50% euro-denominated notes due 2034 2.5% Euro Notes Due 2034 [Member] 2.5% Euro Notes Due 2034 [Member] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Award Type [Domain] Award Type [Domain] Fair value of stock options vested Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value Income Tax Contingency [Table] Income Tax Contingency [Table] Net cash used in investing activities Cash Provided by (Used in) Investing Activities, Discontinued Operations Recognized as: Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract] Finished goods Inventory, Finished Goods, Gross Number of research programs Collaborative Arrangement, Number Of Research Programs Collaborative Arrangement, Number Of Research Programs COLOMBIA COLOMBIA China CHINA Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Patents Patents [Member] Entity Address, City or Town Entity Address, City or Town Belsomra Belsomra [Member] Belsomra [Member] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] Effects of exchange rate changes Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) Lenvima Alliance revenue - Lenvima Lenvima [Member] Lenvima [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] 2028 — 2032 Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years Noncontrolling Interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Deferred tax assets on NOL carryforwards relating to foreign jurisdictions Deferred Tax Assets, Operating Loss Carryforwards, Foreign Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Treasury Stock Treasury Stock, Common [Member] Auditor Name Auditor Name Pension Benefits Pension Plan [Member] Share price (in dollars per share) Share Price 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] 5.95% debentures due 2028 Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member] Five point nine five percentage debentures due on two thousand and twenty eight. Transaction costs Business Acquisition, Transaction Costs Treasury stock, shares (in shares) Treasury Stock, Common, Shares Tax Reclassification from AOCI, Current Period, Tax Research and development Research and development Research and Development Expense Additions related to prior year positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Supplies Other Inventory, Supplies, Gross NAV Fair Value Measured at Net Asset Value Per Share [Member] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] RSUs Restricted Stock Units (RSUs) [Member] Relating to assets still held at December 31 Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held R&D tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Number of Options, Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) COVID-19 COVID-19 [Member] COVID-19 Sales Sales Revenues Net unrealized (loss) gain on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Inventory [Table] Inventory [Table] Inventory [Table] Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block] Net Income from Continuing Operations Attributable to Merck & Co., Inc. Net Income from Continuing Operations Attributable to Merck & Co., Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Other Defined Benefit Plan Other Changes Plan Assets Changes in plan assets, not otherwise separately disclosed in the financial statements. State Deferred State and Local Income Tax Expense (Benefit) Inventory write-off related to contract termination Production Related Impairments or Charges Amortization expense for intangible assets Amortization of Intangible Assets Goodwill Activity by Segment Schedule of Goodwill [Table Text Block] International equities Defined Benefit Plan, Equity Securities, Non-US [Member] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Debt, carrying amount Debt, Long-Term and Short-Term, Combined Amount Other Assets Other Assets [Member] Recognized as: Recognized As [Abstract] Recognized as. Milestone payment to be made to collaborative partner Milestone Payment To Be Made to Collaborative Partner Milestone Payment To Be Made to Collaborative Partner Imago BioSciences, Inc. Imago BioSciences, Inc. [Member] Imago BioSciences, Inc. Profit share by counterparty Profit Share Counterparty Profit Share Counterparty Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets Primaxin Primaxin [Member] Primaxin [Member]. Inventories Inventory, Policy [Policy Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Counterparty Name [Domain] Counterparty Name [Domain] Upfront and milestone payments made to collaborative partner Upfront and Milestone Payments Made to Collaborative Partner Upfront and Milestone Payments Made to Collaborative Partner Total Merck & Co., Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Intangible Assets Excluding Goodwill [Line Items] Intangible Assets Excluding Goodwill [Line Items] Intangible Assets Excluding Goodwill [Line Items] Transaction costs Asset Acquisition, Consideration Transferred, Transaction Cost Estimate of cumulative pre tax costs that will result in cash outlays Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense). Other, Assets Deferred Tax Assets, Other Vaqta Vaqta [Member] Vaqta [Member] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Estimated aggregate amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Three Summarized Information about the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Long-term debt, maturities, repayments of principal in 2027 Long-Term Debt, Maturity, Year Five Retained Earnings Retained Earnings [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Cash dividends declared on common stock Dividends, Common Stock, Cash Noxafil Noxafil [Member] Noxafil [Member]. Common Stock Common Stock [Member] Transition tax liability, noncurrent Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent Shares collectively authorized for future grants under share-based compensation plans (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Contingent consideration Contingent consideration, beginning balance Contingent consideration, ending balance Business Combination, Contingent Consideration, Liability Statement [Table] Statement [Table] Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Weighted Average Grant Date Fair Value, Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Other Noncurrent Liabilities Operating Lease, Liability, Noncurrent Employer contributions to defined contribution savings plans Defined Contribution Plan, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Charge for the acquisition of Pandion Therapeutics, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off Purchases of treasury stock (in shares) Treasury Stock, Shares, Acquired Less: Income of discontinued operations attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Acquisition of OncoImmune Effective Income Tax Rate Reconciliation, Business Combination Two, Percent Effective Income Tax Rate Reconciliation, Business Combination Two, Percent Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021) Accounts Receivable, after Allowance for Credit Loss, Current Purchases of securities and other investments Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Litigation Case [Domain] Litigation Case [Domain] Cash And Other Investments Defined Benefit Plan, Cash and Other Investments [Member] Defined Benefit Plan, Cash and Other Investments [Member] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Statement [Line Items] Statement [Line Items] Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Number of Shares, Nonvested January 1 (in shares) Number of Shares, Nonvested December 31 (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Commercial Litigation Commercial and Other Litigation [Member] Commercial and Other Litigation [Member] Selling, general and administrative Selling, General and Administrative Expense Business combination, contingent consideration arrangements, change in amount of contingent consideration liability Changes in estimated fair value Contingent consideration liability, changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other Assets Operating Lease, Right-of-Use Asset Debt securities, gross unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax 3.90% notes due 2039 3.90% Notes Due 2039 [Member] 3.90% Notes Due 2039 Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Loans payable and current portion of long-term debt Long Term Debt, Current Maturities [Member] Long Term Debt, Current Maturities [Member] Non-cash activity Restructuring Reserve, Increase (Decrease) Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. 1.90% notes due 2028 1.90% notes due 2028 [Member] 1.90% notes due 2028 Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Auditor Firm ID Auditor Firm ID 6.55% notes due 2037 Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member] Six point five five percentage notes due on two thousand and thirty seven. Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Foreign Jurisdiction Foreign Tax Authority [Member] 2024 Defined Benefit Plan, Expected Future Benefit Payment, Year Two Local Phone Number Local Phone Number Summarized Information Relative to Stock Option Plan Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Inventory related, Assets Deferred Tax Assets, Inventory Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] 2.90% notes due 2061 2.90% notes due 2061 [Member] 2.90% notes due 2061 Intangible asset impairment charges Goodwill and Intangible Asset Impairment Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Depreciation Depreciation, Depletion, and Amortization [Policy Text Block] Total liabilities Liabilities, Fair Value Disclosure Pension Plan Net Loss Pension Plan Net Loss [Member] Pension Plan Net Loss [Member] Net loss (gain) amortization included in benefit cost Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax Foreign earnings Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill and Other Intangibles Goodwill and Intangible Assets Disclosure [Text Block] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Income Statement [Abstract] Income Statement [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) Other Paid-In Capital Additional Paid-in Capital [Member] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders Earnings Per Share, Basic [Abstract] Total intrinsic value of stock options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value sotatercept sotatercept [Member] sotatercept Average common shares outstanding assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative [Line Items] Derivative [Line Items] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Preferred stock investment in counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty Collaborative Arrangement, Preferred Stock Investment In Counterparty Inventories Schedule of Inventory, Current [Table Text Block] Expected life (years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Patent litigation Patent litigation [Member] Patent litigation [Member] Equity securities held through ownership interests in investment funds Equity Securities, FV-NI, Noncurrent Income Taxes Payable Income Taxes Payable [Member] Income Taxes Payable [Member] Collaborative Arrangement Collaborative Arrangement [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Themis Themis [Member] Themis [Member] Information on Investments in Debt and Equity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Total Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax IAVI IAVI [Member] IAVI [Member] Sales threshold Sales threshold Sales threshold Lynparza Lynparza [Member] Lynparza [Member] Weighted Average Grant Date Fair Value, Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Asia Pacific (other than China and Japan) Asia Pacific [Member] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Segments Total segment profits Operating Segments [Member] Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Intangible asset impairment charge related to marketed product Impairment of Intangible Assets, Finite-Lived Effect of Net Investment Hedges Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to) Decrease in Unrecognized Tax Benefits is Reasonably Possible Zetia antitrust litigation Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Other Variable Rate Debt Other Variable Rate Debt [Member] Other Variable Rate Debt [Member] Acquisitions, Research Collaborations and Licensing Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, research collaborations and license agreements. Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Contingencies and Environmental Liabilities Commitments and Contingencies Disclosure [Text Block] Accumulated goodwill impairment losses Goodwill, Impaired, Accumulated Impairment Loss Additional funding by others, percentage of development costs Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs Net income attributable to Merck & Co., Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from issuance of debt Proceeds from Issuance of Long-Term Debt Common stock, shares issued (in shares) Balance January 1 (in shares) Balance December 31 (in shares) Common Stock, Shares, Issued Exchange losses Foreign Currency Transaction Gain (Loss), before Tax Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Pensions and other postretirement benefits, Assets Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Face amount of debt Debt Instrument, Face Amount Other Assets Deferred Income Taxes and Other Assets, Noncurrent Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Loss contingency, new claims filed Loss Contingency, New Claims Filed, Number Investments Investment, Policy [Policy Text Block] Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Pensions and other postretirement benefits, Liabilities Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits. Net Cash Used in Investing Activities of Continuing Operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Potential future regulatory milestone payments Potential Future Milestone Payments Regulatory Potential Future Milestone Payments Regulatory Equity Loss from Affiliates and Depreciation Included in Segment Profits Schedule of Segment Reporting Information, by Segment [Table Text Block] Entity Current Reporting Status Entity Current Reporting Status Accrued and other current liabilities Other Liabilities, Current gefapixant gefapixant [Member] gefapixant Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests Income from discontinued operations, net of taxes attributable to parent Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent (Payments) receipts, net Payments for Restructuring U.S. statutory rate applied to income from continuing operations before taxes Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Japan JAPAN Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Derivative [Table] Derivative [Table] 2.90% notes due 2024 2.90% Notes Due 2024 [Member] 2.90% Notes Due 2024 Number of Options, Outstanding, January 1 (in shares) Number of Options, Outstanding, December 31 (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Other Postretirement Benefit Plan Prior Service Credit Other Postretirement Benefit Plan Prior Service Cost [Member] Other Postretirement Benefit Plan Prior Service Cost [Member] State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Share-based compensation plans and other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net LIFO inventory amount LIFO Inventory Amount 6.40% debentures due 2028 Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member] Six point four percentage debentures due on two thousand and twenty eight. Other Other Countries [Member] Other Countries [Member] Number of Shares, Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Restructuring Restructuring and Related Activities Disclosure [Text Block] Moderna Moderna [Member] Moderna Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Acquisition of Pandion Effective Income Tax Rate Reconciliation, Business Combination Four Effective Income Tax Rate Reconciliation, Business Combination Four Net operating losses and other tax credit carryforwards, Assets Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards Deferred tax assets operating loss carryforwards and other tax credit carryforwards. Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Sales of Company's Products Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Trade accounts payable Increase (Decrease) in Accounts Payable, Trade Consolidated Revenues by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Curtailments Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment Expected rate of return on plan assets Expected rate of return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets Total current assets Assets, Current VelosBio VelosBio [Member] VelosBio Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag Entity Small Business Entity Small Business Obligation and Funded Status Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block] Common stock, dividends declared (in dollars per share) Common Stock, Dividends, Per Share, Declared Intangible assets Finite-Lived Intangible Assets, Net Restricted cash Restricted Cash Distributions attributable to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Summary of Accounting Policies Significant Accounting Policies [Text Block] Tax benefits relating to stock option exercises Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Verquvo Verquvo [Member] Verquvo Sales milestone payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments Investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Other Other Long Term Debt [Member] Other long term debt. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Components of Other Comprehensive Income Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block] Proceeds from sales of securities and other investments Proceeds from Sale, Maturity and Collection of Investments Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Net cash used in financing activities Cash Provided by (Used in) Financing Activities, Discontinued Operations Transition tax for accumulated foreign earnings, liability Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability Number of Options, Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Debt Instrument [Line Items] Debt Instrument [Line Items] Business Combination and Asset Acquisition [Abstract] Issuances (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Class of Stock [Line Items] Class of Stock [Line Items] Net assets acquired Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Asset Acquisition, Assets Acquired And Liabilities Assumed, Net Total operating lease liability Total operating lease liability Operating Lease, Liability U.S. government and agency securities US Government Agencies Debt Securities [Member] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Land Land Rate to which the cost trend rate is assumed to decline Defined Benefit Plan, Ultimate Health Care Cost Trend Rate Government and agency obligations Government And Agency Obligations Investment Funds [Member] Government and agency obligations investment funds. Research and development payments made to a collaborative partner Research and Development Payments Made To a Collaborative Partner Research and Development Payments Made To a Collaborative Partner Estimated aggregate amortization expense, 2024 Finite-Lived Intangible Asset, Expected Amortization, Year Two Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Weighted average exercise price of options granted (in dollars per share) Weighted Average Exercise Price, Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Benefits paid Defined Benefit Plan, Plan Assets, Benefits Paid Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Cumulative upward price adjustment Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Restructuring costs Restructuring costs Restructuring Charges Corporate obligations Corporate Obligations Fixed Income Securities [Member] Corporate obligations fixed income securities. Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal Royalty rate, deduction, percentage Royalty Rate, Deduction, Percentage Royalty Rate, Deduction, Percentage Accrued liabilities for environmental matters Accrual for Environmental Loss Contingencies Long-term debt, maturities, repayments of principal in 2026 Long-Term Debt, Maturity, Year Four Hedging Designation [Axis] Hedging Designation [Axis] Auditor Location Auditor Location Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Nature of Operations Nature of Operations [Text Block] Charge for the acquisition of VelosBio Inc. Research and development expenses Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two Entity Filer Category Entity Filer Category Bridion Bridion [Member] Bridion [Member]. Federal Current Federal Tax Expense (Benefit) United States UNITED STATES Liabilities Liabilities, Fair Value Disclosure [Abstract] Eisai Eisai [Member] Eisai [Member] Consideration paid Asset Acquisition, Consideration Transferred Pretax share-based compensation cost recorded Share-Based Payment Arrangement, Expense Security Exchange Name Security Exchange Name Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share) Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price License License [Member] Estimated useful life of intangible assets, acquired Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Seagen Seagen [Member] Seagen Int’l International [Member] International [Member] Acquisition of OncoImmune Effective Income Tax Rate Reconciliation, Business Combination Two Effective Income Tax Rate Reconciliation, Business Combination Two Increase (decrease) in Sales as a result of AOCL reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Unallocated Segment Reconciling Items [Member] Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Property, Plant and Equipment, Net by Geographic Area Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Service cost Defined Benefit Plan, Service Cost Cash and cash equivalents Cash and Cash Equivalents [Member] Cover [Abstract] Cover [Abstract] Interest crediting rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate Movement in Common Stock and Treasury Stock [Roll Forward] Movement in Common Stock and Treasury Stock [Roll Forward] Movement in Common Stock and Treasury Stock [Roll Forward] Property, Plant and Equipment (at cost) Property, Plant and Equipment, Gross [Abstract] Entity Voluntary Filers Entity Voluntary Filers Pharmaceutical segment Pharmaceutical Pharmaceutical segment [Member] Pharmaceutical segment. Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Segment Reporting [Abstract] Segment Reporting [Abstract] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Defined Benefit Plan, Change in Benefit Obligation [Roll Forward] Other Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change Forecast Forecast [Member] Defined Benefit Plan, Plan Assets, Category [Axis] Defined Benefit Plan, Plan Assets, Category [Axis] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Accrual for rebates included in accrued and other current liabilities Accrual For Rebates Accrual for rebates recorded as current liability. Income Taxes Paid Schedule of Income Taxes Paid [Table Text Block] Schedule of Income Taxes Paid Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Discount rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Net loss (gain) amortization Defined Benefit Plan, Amortization of Gain (Loss) Total Liabilities and Equity Liabilities and Equity 0.75% notes due 2026 0.75% Notes due 2026 [Member] 0.75% Notes due 2026 Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Product intangibles and licenses, Assets Deferred Tax Assets, Goodwill and Intangible Assets 6.30% debentures due 2026 6.3% Debentures Due 2026 [Member] Six point three percentage debentures due on two thousand and twenty six. Total sales Sales Sales [Member] Outside of the United States Non-US [Member] Subtotal, Assets Deferred Tax Assets, Gross Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Income Before Taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Animal Health Animal Health [Member] Animal Health [Member] Reconciliation of Segment Profits to Income Before Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Total Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax Payments to acquire investment Payments to Acquire Investments Liabilities for accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Net income attributable to Merck & Co., Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Net Income (in dollars per share) Earnings Per Share, Diluted Selling, general and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Accumulated benefit obligation Defined Benefit Plan, Accumulated Benefit Obligation Contractual term of options Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Consolidation Items [Axis] Consolidation Items [Axis] Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Equity method investments, Liabilities Deferred Tax Liabilities, Equity Method Investment Deferred Tax Liabilities, Equity Method Investment 2.75% notes due 2025 2.75% Notes Due 2025 [Member] 2.75% Notes Due 2025 [Member] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Other current assets Other Assets, Current Remicade Remicade [Member] Remicade [Member]. Total deferred taxes Deferred Tax Assets, Net of Valuation Allowance Unrecognized tax benefits Balance January 1 Balance December 31 Unrecognized Tax Benefits Product intangibles and licenses, Liabilities Deferred Tax Liabilities, Intangible Assets OncoImmune OncoImmune [Member] OncoImmune Publicly traded equity securities Equity Securities [Member] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic 5.85% notes due 2039 Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member] Five point eight five percentage notes due on two thousand and thirty nine. Corporate notes and bonds Corporate Debt Securities [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Discount rate Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate Other comprehensive income (loss) before reclassification adjustments, pretax Other Comprehensive Income (Loss), before Reclassifications, before Tax Income from discontinued operations, net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 1.875% euro-denominated notes due 2026 1.875% Euro Notes Due 2026 [Member] 1.875% Euro Notes Due 2026 [Member] Amortization Amortization Amortization Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Product and Service [Axis] Product and Service [Axis] Dificid Dificid [Member] Dificid [Member] Component of Other Income / Expense of Nonoperating [Line Items] Component of Other Income / Expense of Nonoperating [Line Items] [Line Items] for Component of Other Income / Expense of Nonoperating [Table] Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Interest expense Interest expense Interest Expense Trade names Trade Names [Member] Tukysa Tukysa [Member] Tukysa Acquisition of Pandion Therapeutics, Inc., net of cash acquired Payments to Acquire Business Three, Net of Cash Acquired Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventory classified in Other assets Other Assets Inventory, Noncurrent Increase (decrease) in revenue hedging activities Increase (Decrease) In Hedge Revenue Increase (Decrease) In Hedge Revenue Inventories Inventory Disclosure [Text Block] Schedule of Long-term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Machinery, equipment and office furnishings Machinery and Equipment [Member] Buildings Building [Member] 3.60% notes due 2042 Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member] Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Disposal group, other expense Disposal Group, Including Discontinued Operation, Other Expense Funded status December 31 Defined Benefit Plan, Funded (Unfunded) Status of Plan Decrease to LIFO cost Inventory, LIFO Reserve Livestock Livestock [Member] Livestock [Member] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Transition tax liability, current Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current 2.45% notes due 2050 2.45% Notes Due 2050 [Member] 2.45% Notes Due 2050 License option payment related to collaborative arrangement License option payment related to collaborative arrangement License option payment related to collaborative arrangement Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Advertising and promotion costs Advertising Expense Subtotal, Liabilities Deferred Tax Liabilities, Gross Purchase of Seagen Inc. common stock Payments to Acquire Equity Securities, FV-NI Dividends payable Dividends Payable, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Common shares issuable (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Net periodic benefit cost Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract] Commercial paper Commercial Paper [Member] Contingent Consideration Contingent Consideration [Policy Text Block] Discussion of the accounting policy for contingent consideration. Estimated aggregate amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Five Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation Measurement Frequency [Axis] Measurement Frequency [Axis] Research and Development Research and Development Expense, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Supplemental Balance Sheet Information Assets and Liabilities, Lessee [Table Text Block] Assets and Liabilities, Lessee [Table Text Block] Legal defense costs reserve Estimated Litigation Liability Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] 2.35% notes due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 [Member] Intangible asset impairment Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Transfers into Level 3 Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3 Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-term debt, interest payments in 2023 Long-term Debt, Interest Payable, Year One Long-term Debt, Interest Payable, Year One Companion Animals Companion Animals [Member] Companion Animals [Member] U.S. statutory rate applied to income from continuing operations before taxes Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Tax provision Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Advertising and Promotion Costs Advertising Cost [Policy Text Block] Corporate obligations Corporate Obligations Investment Funds [Member] Corporate obligations investment funds. Due to related parties, current Due to Related Parties, Current Cash Flows from Financing Activities of Continuing Operations Net Cash Provided by (Used in) Financing Activities [Abstract] 0.50% euro-denominated notes due 2024 0.50% euro-denominated notes due 2024 [Member] 0.50% euro-denominated notes due 2024 [Member] Contingent payments collaborative arrangement Contingent Payments Collaborative Arrangement Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. Actual return on plan assets: Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract] Orion Corporation Orion Corporation [Member] Orion Corporation Premium on shares acquired Premium on shares acquired Premium on shares acquired Research and development Research and Development Expense [Member] Organon & Co. Organon & Co. [Member] Organon & Co. Cost of sales Cost of sales Cost of Sales [Member] Net sales by Merck Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Less: Net Income Attributable to Noncontrolling Interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest EX-101.PRE 32 mrk-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 33 image_0.jpg begin 644 image_0.jpg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image_1a.jpg begin 644 image_1a.jpg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end GRAPHIC 35 image_1b.jpg begin 644 image_1b.jpg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end GRAPHIC 36 mercklogotoprightcornera.jpg begin 644 mercklogotoprightcornera.jpg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end GRAPHIC 37 mrk-20221231_g1.jpg begin 644 mrk-20221231_g1.jpg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end GRAPHIC 38 mrk-20221231_g2.jpg begin 644 mrk-20221231_g2.jpg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end GRAPHIC 39 mrk-20221231_g3.jpg begin 644 mrk-20221231_g3.jpg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end GRAPHIC 40 mrk-20221231_g4.jpg begin 644 mrk-20221231_g4.jpg M_]C_X 02D9)1@ ! @$ 8 !@ #_[@ .061O8F4 90 !_]L 0P " 0$! M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D* M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\ $0@! M+ 'T P$B (1 0,1 ?_$ !\ $% 0$! 0$! ! @,$!08'" D* M"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V M]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'" D*"__$ +41 (! M @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_: P# M 0 "$0,1 #\ ^/?V'_V'_P!N3_@KK^W)\=_A1\*/V[O$'@C_ (0CQ!J%^[ZM MX@U.6*6)]3FA6*-891MVX^F.*^P/^(3;_@J9_P!)=O\ RH:Y_P#'J/\ @TV_ MY2F?M=_]O'_I\GK]_J /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_T MEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O M_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH M:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N? M_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZ MOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_ MJ* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@ M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ M'_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_X MA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3; M_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X* MF?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ M $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!) M=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ M ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#* MAKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A- MO^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@ MJ9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F? M])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27 M;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\ MJ&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AK MG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\ M>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_ M?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^H MH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* / MX7OB;\>?VL/AE\2?$/PWO_VH_'EU/X>UR[TV:YA\87X25X)GB+J#+D E,@'U MHK#_ &L/^3IOB7_V4#6?_2Z:B@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BO$OB[_P % M&OV*O@/\0]0^%'Q;^/.GZ+XATKRO[0TR?3[MVA\V%)H\M'"RG,E=K0 45Q7B#]HKX+^%?C7HG[.GB#QW;VWC3Q'8/>Z)H+6\IDNH$69F<.$ M* 03'#,#\A]1GM: "BN*^"/[17P7_:.T;4O$'P4\=V^O6>D:F^G:C/;V\L8 MANE56:,B5%)(#*&?B+X.TKQ_P""]62_T?6].AO] M*OHT95N+>5!)'( P# ,K X(!YY% &G117*_&7XV?"W]GOP%<_$_XQ^+H=#T& MSEBBN=1GADD5'D<(@Q&K-RQ Z=Z .JHKY]\-?\%5?^">OBS6H- TC]J7P\MS M] #J*** "BN* M^-G[1/P7_9STK3-;^-7CNWT&UUG5$T[3)KBWED$]TRLRQ@1HQ!(4G)P..M=K M0 4444 %%%% !17%>&_VBO@OXO\ C/KO[/7ASQW;W7C+PU9I=ZYH:6\HDM(7 M$15RS($((FB^ZQ/SCWQ:^-'QP^%7[/'@2?XF_&;QA#H6A6T\<,^HW$,DBJ\C M;47$:LW)XZ4 =717SYX<_P""J_\ P3T\5:U;Z!I/[4GA];BYD$<)O8KBUCW$ MX&9)HD1?J6 KZ"1TD021N&5AE64Y!'K0 M%%% !15'Q+XF\.^#/#]YXL\7:[ M::9I>G6SW%_J%_<+%#;Q*,L[NQ 50.22:\$\+_\ !63_ ()X>,/&47@/0_VG M=(_M":<0Q->:?>6MLSDX %S-"D/)[[\>] 'T317%?$_]HOX+?!GQ;X3\"_$W MQY;Z3JWCG4O[/\*6GQ?#NSN(['7M*AO(4E%GH:B0)*K*& 9@&QD!B.YJ MI^T=\-/ G[''_!7SX%>)OV=?"]EX7M_'RG3?$FAZ';K;VDZ23>0[^2@"*"LB M,0 %WP*^-V2>I^+/[+/_ 44^''_ 4E^('[9W[*/@GP%JMGXIT*TTJU7Q?J M<@40K9Z>DK>5%)&RN);/ )8C:3QR,=-^S_\ L._M:?%']KS2?VV/^"@'BWPP MVJ>%=.:U\'^$/"0=K:T8B0"61FX&TRR.!ND9G*DLHC"D Y?X7_&KXW^)_P!H M/]KOPQ\#?!W@K2?%G@]$G\-:CIW@ZVCO-5GCEF?RKR5 'NVD6,HI M*O\ @K%X[N_^"9/A#X\?#]-/N/BOXK\0P^%X-.6S$B#5(Y?W[^1GD/"JLJYP MK747TKUK]CO]DSXP?!;]MCX\_'3QQ96$>@?$'4X)_#DEM?"25T669CYB 90X M=>M>/_"O_@DK\0?!7_!1YOBSJ5U8M\'=#\4WWBSPKI"WH+1:I"M6U?5/AI)/X@\4OX3MFU* M.\6UU0RBTNBOFVT+/$?W:G&UW!SO.<7X9_M6_P#!0_\ ;8^-GQ%US]D[Q%X& M\-^!?ASKKZ7I^F>)M,>=_$,R,^!)*H+Q!PFXE"FP2(/G(9J]0^,W[)?Q@\;_ M /!5'X4_M:Z%96#>#_"/A&ZT[69I;X+<+/)%J2J$BQEAFZBY]SZ5Y?X _9*_ MX*'?L7_''XB:1^R#IO@77? OQ)UI]4L]2\4WSQ/X*"*-'G" M&) LJL!N*>9NPV,';^"G['G[9^O? M$KP+IOQ*_99^ 7@'PYX4>-O%.O:1X2TN_O/$@CV8,2M"[6\C;"=X,>TR,_.U M4H U_$O[5G[>?Q3_ ."B'Q/_ &*/V>_$7@[2;#P]I%I?66O>(-):5M*@-M9O M(RJG^OE>6Y55#_*JEB0<"H/V7O\ @I9\;='^"'[0MY^U/I^DZSXG^ >HM:37 MFC0_9HM5F:6YMXXF &%'VBV(\Q57Y) =N5.?2_@A^R7\8/ ?_!47XL_M7^(+ M.P7PAXP\+VMCHLT5\&G:9(]/5@\6,H,V\O/L/6N$^$7_ 3:^)=_JG[6WACX MP2V6G:+\U09Q$H94)DD1#LC"X))W>K_%']F+]N#1/V?O@UX'^ M'&@_#_QMH_A#P1IVD^/OA/XTTZTFM-3NH+01&:&ZFB8J020,/& 8T8;@SJ0# MMO\ @G;\@_P!E:5\.?".JO>0Q;G@=YI')* 9@R%4D;I&.$"@-Z_\ \%/_ M -G+XE_M5_L?:Y\%_A':V-%=B9%!<$D M."0V(KB M,,V&=U81;U4'C8%\U%RQ#..K_9:_9A_:IO\ ]I'2OBK\8OV9O@E\+?"V@6! MT3PAX5TVYOM1OL.%N(KI8FDM0"P)Q(" @4*2S...\/?LE?\ !2']B'QU\2?# M'[%.A^#/$_@OXAZM+J.EW>NZC]GN_#T\FX;MI= Y16 R/,#>5&V%.Y" $_&K_%2U37-'LKZ*X@$BPW 66-HI) %=0K; M"Q*$E23C)]Z_;J^,G[7W@?XJV.A_#[X\?"OX1> TT=KB3QAXXU"VEN]0NP1F M"*VE.=H!&-J$G:Y+(_B9;>.O'/AOQW%K?BK M6=3OQ#&(=DH\J%F0-($#HH+ ,Q#,<9VA/VB_V+OVJ;7_ (*):I^UO\._@QX" M^*VAZ]X>M].T_2?'>H+''X;ECBA3S4213T:)Y 8PS$7$HPK'<0# ^ __ 4Z M_:&^('[ _P ;?BIK6K>';_QC\*[Q(-*\2Z9IY%GJD4D@5)C"V <[9"" H*LG MR@@YU/A+^V9^WGX5_9CU#_@H5^TGJG@Z7X=KX"$^A^#M'M6COKK5&G@M;:6: M0Q_NHYY7>0A9'VJZ@)UQC_"K_@G#^UQX2_9G_:4^#_C*P\,W&N?%#4(+WP[> M:3J(CL[F4SR23#:P#0(,J5##H<=N??[3]B76OB%_P3"T[]B/XE:A!I>KGP1: M:=@FB0G&,C.,4 ?)5A_P55_:K^$WA/P=^TM\4OVC? M@SXTT#Q+J%O_ ,)%\*O"][;C6M!M)P7#JJ.90Z*,,LA?8[*C Y++[G\?_P!K M?]K7XP_MV']AK]BCQ)X;\-MX?\,1ZYXK\6:]IWVOY)(X9%2.,AEV;;FV'"[B MTI^90O/F'PT_80_;JBTGP9\"M;_9E_9^\.Z=X;N88->^)Y\+:;JMWK-A$I0+ MY$\#.TK+@EV5&=U4EDR^[U']HC]D7]K/X3_MS+^W1^Q%H?AG7KC7O#D>B>+? M"?B"]^R*T:)#&KQOE5V;+>W. P96AZ.K$ \U_X)UW'Q>N/^"POQP'QYM](3 MQ;#X(@@UA]!#BSG:-M-C2>(2?,JR1JDFT\KO([5ZS_P7<_Y1WZ]_V,&E?^E* MU4_8B_8\_:X^&7[>/Q$_:J_:5N?#=R/&_A9(6G\/73&**Z9[1_LR1O\ .(XD MA,0=CEO+!_BKTG_@J/\ LV_$[]K#]D35?@U\(;6SFUN[U:QN(8[^\$$>R*8. M^7(.#@4 ?G;\=?CG^R1^T7^QWH?[.G[./[!>OS_%.?3M(MK;Q'I_P^M;9TN( MO)^T3+/;,TT_FA9%PR@-YF]B"HKZ1^-_[77QZ_9%\*? ;]@;PQX_\(>%/'>I M> K"3Q=X\\>7L?\ 9^AP10M%C?(WENY>VF0,^0Q1% +2 K]Q?!'PIJ_@3X,> M$? ^OI&M_HWA?3[&]6)]RB:&VCC< ]QN4X/>OE[_ (**_L'_ !0^,?QZ\"_M M=? GPIX0\5:_X0L6TW5_!'CF!'L-9L2TS*/W@*;U-Q-]_&"R,""@# '/_LB? M\%#OBUXI^(7Q/_9G^*_Q*\"^.=>\(>#+CQ#X6^(/@.>*73]5ACB0M&XB)C\Q M&ECR%"XVR @X#-3_ .";?[17_!2G]M2+PS\;_%?B_P #Z7\.M/UB[T_Q+:1: M85U#62B.XEB78RQJK/#%Q(A^61B&X!Z[]EG]E/\ :3M+CXC_ ! ^,GP?^%'@ M1O$/AJYTKPAX-\#>&=/CFL#)$%9IK^"%9&5BH.PR."78X0*BUW?_ 2S_9H^ M)_[)G[)&G_!WXOVEE#K=OK-] VTG@&OSJ\:_%/P M5X&^">B_LQ?\%&_^"86J>#-(T@VEJGQ$\":9%;3>9#M4RI*T1CE>0 ^:4N&W M[V(7)&/TB_;R_9?UK]KO]F[5OA#X5\VL=7\=-J1>YN[> M%T8.X65SN8HI)6!6..-I.: ,3_@IQJ]I;^)_V)-8_9MOXO$T4&MQMX&N-8NW M*ZD4ET46AN) _SD1[VP&&6X!XKU7X9_M0?MQ?!3_@HOX5_8\_:L\9^$?%NE M_$'P_<:EI=_XI:)\#M?@F\3ZAJ%VL$LL*7.FR/-'&<[BWV:=M@/&5&3UKM/CC^R7\ M8/'O_!4+X2_M6^'[.P;PCX/\,75CK4TM\%G69X[]5"18RXS<1\^Y]* /'_VQ MOVKOV[?A1XQ\=^(;S]I[X.?#'2?#OFR>#O!.H7-MJ&K^(8$5F0LGSR1R2 * M-JJ#(!T'F&K\;O\ @JC^T+H?_!.3X/?M=>!]%T:V\1>+_%SZ7X@T[[$9()U@ M>]B<1!B3'YC6JL.6*[\>)OB]X!TKX2?##Q.GQ*O[^2T M^,'BF]$FH:=;7*R*ZI'M:42E7R $64Y+.H&+OB?_@FG^U;X@_X)T?"#]F%/ M#VB)XE\"?$:?5=61M;3R7LWGO)@Z/CYF_P!)5=O7Y30!U/[0/[8?[>_["W[/ MLOB#]I'Q'X UKQWX]\4V]AX%MM.A,.G:! T1>XDN798_,$;,B#^ MSO?EVR6THVL ' 0@E2"4"L &)'GG[,?[+W[5VJ?M'Z)\3/B_^S%\#OA;X5\. MVFZ;2O"7A73;J^U.^ ;9/#OW^H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _A"_:P_Y.F^)?_90-9_] M+IJ*/VL/^3IOB7_V4#6?_2Z:B@#]O_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHKY2_P""SOBKXR>#OV%] M9U?X.W^J69.KV<7B>^T5F6YM])8L)F5EP5!?RE8@CY&;)VDT ?3OA_Q7X6\6 M)=R^%?$NGZFNGZA-8W[:?>),+:ZB;;+!)L)V2(W#(<,IX(%:%?F'_P $@/A' M\#]6^,U_\7/V;?VMM1TU+'Q+K,%[\-=3F66?7M$+XLKF:)I$9'56#-($?YU7 ME>0W<_M0?L!^)_%.I_&#]JS]N;]JG4K'1=.MI[GX;VOA3Q%-!;Z';IYGDQRQ M2Q!6E)%N@2(YD=GR2SJ0 ?H'17S#_P $??B+\9?BE^P?X5\6?&W5+W4-1:YO M(-.U34G9KB\L8YF2*21FY^'/A;4;F/X):OXHD,MP<&:+>1( WEJSV;;"JKN\P M;5)8#R'Q-X+^)/[)/['WP@_X*@>%OCIXSU+Q]XC\5P2^+X-4UQY;34[2X%S* M(70\E=ENJ,&+9,K,-NU< '['T5%8WL&HV,.H6K9BGB62,D=589'Z&I: "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^$+]K# M_DZ;XE_]E UG_P!+IJ*/VL/^3IOB7_V4#6?_ $NFHH _;_\ X--O^4IG[7?_ M &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ KQ M7]O?XK?M(?!/X!S?$C]FGX4Z9XTU'3]1B.O:!J%G/)/VG_P!L-_"_QU^# M7Q,O_@AX'U>:/3O"WA+1)5?7[F%RGVF>1RGR2$,00=R1850K.\E?K+X+^'O@ MSX=PZE!X+T"'3TUC6;G5M36$L?M%[.K31K7Q GANP\$VVC1PWMK''"2DBPJ2JP!4"C'3@5XI^ MW2\_P:_X*4>#/VM/VB/@IK7C7X3CP1_9]@;'11J,6BWS"7)D@;Y ^YPP+8R' MRI9HL#]%** /R[_9>_9M^(W[2WPY_:M\0?"WX5ZEX)\ ?$^TQ\./#>K6@LEN M[V)I)8Y(X<[(D+!%++\@,NT%A$<>;>)O%_Q/_:U_9"^$/_!+WPU\!O&FE^/? M#?BN"+QAFVEN+F(3,Y.0-EPKL65<&)E&XLN?V-HH BL;.#3K*'3[ M5-L4$2QQKGHJC 'Y"I:** "BBB@ HHHH **** "BBB@ JEXE\1Z+X/\ #FH> M+?$E^EKIVEV4MY?W4@.V&&)"[N<1B!&H1FRQ.!UH ^#K#_@NO>S_ !4AUR__ &6? M$,'PEO-.AEM?$2QE]1"/?2VHU!HU)C-N9(FB$0^821M^\8D)7T%^UO\ \%%O M!_[-?C7PO\'_ -\*]?^(_COQA9?;M%\+>&5 =K/YL3NY#$ ^7(1A&XBWOH[N2Z4K%X:GUJX01Q21.1 MYBWC2DO&9%'F%MF 57[O_:1_;&_93^ 7P7\,?MM>,?A]IM[XI\2^'K>3P';? MV; =:O?M-N)5MHYMIDBC"S8D8':H#?VPK[Q-X)G^'>N> M"?&O@VX6+Q)X1\0H!/;ABRAU; WKN4J.OBSM?LZ?\ !4>R^+7QVT?] MGSXQ_LU^+OAAK?BK3&O_ _M[?MU M?#O]@OX0Q?$;Q?I3:SJFI7JVF@>&X+P02W\@P96WE6V1QH=S/M(R47JXKYX; MXK_M?_L2?MO?##X9_M#?M$6WQ2\/?%:"Y@N'D\,6]C-HUXFW<;-YH_%C06FA_!3P))IERRZ9IR7UO M+/>22K&85GEB67.7R,R+R/+P ?M'\&?B(GQ?^#_A3XLQZ2=/7Q1X:L=76P:? MS3;"YMTF\O?A=^W?MW8&<9P.E=+7A/\ P37^-/PY^-?[%_@*\^'&NO?Q^&_# M.F^']89[26'R-0M;"W6>(>8J[PI8?.N5/8FO=J "BBB@ HHHH **** "BBB@ M HHHH **S]>\5^%O"SV$7B?Q+I^G-JFH)8Z8M_>)";RZ=69((MY'F2,J.0BY M8A6('!K0H **** "BBB@ HHHH **** "BBB@ HHHH **** /X0OVL/\ DZ;X ME_\ 90-9_P#2Z:BC]K#_ ).F^)?_ &4#6?\ TNFHH _;_P#X--O^4IG[7?\ MV\?^GR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** /QC_X M*]?\%>O^"E_[.O\ P4O\2?LH?LH?$CP3H?AK0_!.D:LJ^(O"*WTKRW*MYG[S M<#C(&!VKY^_X?8_\%S_^CAOA1_X;@?\ Q='_ 6Q_P"4Y_Q#_P"R4>&_Y25X MA7TN6Y;A,3A%4J*[UZON?SMX@^(7%.0<4U<%@JJC3BH-)PB]XIO5J^Y[?_P^ MQ_X+G_\ 1PWPH_\ #<#_ .+H_P"'V/\ P7/_ .CAOA1_X;@?_%UXA17?_8V M_E_%GQ7_ !%OCG_G_'_P7#_(]O\ ^'V/_!<__HX;X4?^&X'_ ,71_P /L?\ M@N?_ -'#?"C_ ,-P/_BZ\0HH_L; ?R_BP_XBWQS_ ,_X_P#@N'^1[?\ \/L? M^"Y__1PWPH_\-P/_ (NC_A]C_P %S_\ HX;X4?\ AN!_\77B%%']C8#^7\6' M_$6^.?\ G_'_ ,%P_P CV_\ X?8_\%S_ /HX;X4?^&X'_P 77V+_ ,$$O^"H M?[>O[:7[67Q2^ 7[8WC?PIK=KX1\$Z?JVE3>&_#2V&)9[DQMN(8EAM'3UK\R MZ^PO^#9;_E)O\>O^R4:'_P"EC5YN:9?A<+AN>FK.ZZL_0O#3CSB7B3B)X3'U M5*"IRE91BM4XI:I)]6?N51117SI^^!1110 4444 %%%% !5#Q5X7T#QOX7U+ MP7XKTN*^TO5[":RU*RF'R7$$J%)(VQV96(/UKDOVCOVGO@#^R+\,Y?C'^TK\ M4]+\'>%X;R&TEUK6)&6%9I21&A*@G+$''%?/G_#_ (_X(V_])"?A_P#^!_\$E/"/[67Q3T+XDR_'CQ'X3B\+:+:Z;X9TC0;2)8= M+C@8LCPL2&1]Q!W#!&Q!GY14?_#_ (_X(V_])"?A_P#^!BZ#;+\O8>>C&O)?\ A_Q_P1M_Z2$_ M#_\ \"YO_C='_#_C_@C;_P!)"?A__P"!'_ (2^ M$X(OLN@Z/:V+726J0O>/# D)N) @ ,CB,%CW/>NKKY _X?\ '_!&W_I(3\/_ M /P+F_\ C=7/#O\ P79_X)#>+/$%CX5\.?M\> [S4=3O(K2PM(KN7?/-(X1$ M7]WU+$ ?6@#ZSHHHH **** "BBB@ HHHH **** /Q@_;3NO#OQ+_ ."A7BKP M!^V?\2_$GAV6/XD:;:>$[B6[:'3M+\+O!=AKN(GY$?=]A?=P"3-G)W8^Z/'7 M[+G[5/C7]@+PW^SQ^SS^V?9:WJ$MQ&+WXF7EQ+!+J.B_O&$4,ULT[$\Q() _ MS1QE2WS$GYJ_X*+?M'^*=2^.EG\#?VW_ -DI=0\/Z)\3[6]\(ZWX7T&9VU_P M^8+Q9+43/*2T[F2V)2)D >-]P4HI.I\*OB-^U%_P3H_X)0P6^F?#'71XW\9> M+[X^"M"N=.ENI_#=A.BL)9X@IVLOEO($8#Y[A"R_?6@"3PO\+[?]B+_@JE\+ M_P!GK]D_XT>+O$%OK^ER/\3?#NMZU]MBBA\N1O.E"JJQOY:^: 0&4A,';*%/ MZ87=W:V%K+?7US'#!#&TDTTKA4C0#)9B> !DDU^7?\ P2@^.OPK^$OCVP\/ M^(_V;_BQJOQ4^(^IK#XM^)/B311Y*22OO9%D=RZ0!L,S$;I& 9NB*GU!\7O' M'B[_ (* ^ ?CA^QC\--&U_X?ZQH5Q;:2?%VN6K+9ZE"UXPG\@Q_,\XM/A%9_&:PT#P&_F-&-9GM[^T-Y M?[/XD8O&BD\!5VX#"2O7O^"J=_I;_MN_#WPY^UY\3O%'A?X!WGA>=DN?#=S. MD4VL(9BRSB!7?'VR\166G> M,(;/P)+H/@Y$@\*S">UQ=S;(?WB[RDC&7=N,;ELDL3ZI^TCI?C+]F3]OWP-^ MT3^VW\.=5^*/@N#X76FBMXATOPZM[;6FLI"%N)S;$".-GF\Z0*0ORW.4R8R M >K_ /!$W6OB'K/PQ^(9_P"$OUW7?AC:^.9[;X3ZIXEF9[N;3T:16^_AE3:( M#MP%#F7 '('VS7PE_P $<_!GC*3XC?&WXZZ)\,=4\$?#+QOXFAN? OAO4[+[ M+E5>+_ M (+8_P#*<_XA_P#9*/#?\I*\0KV__@MC_P IS_B'_P!DH\-_RDKQ"OM,F_W" M/J_S/Y!\6_\ DN:_^&G_ .D(****]0_-0HHHH **** "OL+_ (-EO^4F_P > MO^R4:'_Z6-7Q[7V%_P &RW_*3?X]?]DHT/\ ]+&KQ\\_W+YK]3];\%_^2PE_ MUZG^<#]RJ***^//ZM"BBB@ HHHH **** /S6_P"#K:..;_@E*8I4#*WQ6\,A ME89!!NCD$5^0O_"O_ ?_ $).D?\ @MB_^)K]>_\ @ZR_Y14C_LJ_AC_TK-?D MW7TN01BX5+KM^I_._CE6K4L5@>237NU-G;K$R/\ A7_@/_H2=(_\%L7_ ,31 M_P *_P# ?_0DZ1_X+8O_ (FM>BOH>2'8_!_K>+_Y^2^]F1_PK_P'_P!"3I'_ M (+8O_B:/^%?^ _^A)TC_P %L7_Q-:]%')#L'UO%_P#/R7WLR/\ A7_@/_H2 M=(_\%L7_ ,31_P *_P# ?_0DZ1_X+8O_ (FM>BCDAV#ZWB_^?DOO9D?\*_\ M ?\ T).D?^"V+_XFN3^)WA/PMH^O_#V]TGPUI]K,/BMX< EMK-$;!U"+(RH! MKT.N,^+_ /R%OA[_ -E7\-_^G"*N3'PBL%4TZ,^HX)Q6)EQ=@4YMKVL.K[H_ MJ_HHHKX0_M@**** "BBB@ HHHH **Y/X]>+]9^'OP,\:>/O#CQKJ.A^$]1U" MP::/>@FAM9)$++W&Y1D=Z_GP^%__ 7M_P""X?Q/\ :5X_L/CO\ "VUAU6U$ M\=O-\.E9HP21@D/@]*VH8>MB9.--79Y&?QAH$-^^@:S%JVCM,6'V6]C1T29<$?,%D<+_A]C_P7/_Z.&^%'_AN!_P#%T?\ #['_ (+G_P#1PWPH_P##<#_X MNC^R\?\ \^_R_P P_P"(E\#?]!L?_ 9__(G]#M%?SQ?\/L?^"Y__ $<-\*/_ M W _P#BZJZY_P %Q?\ @N7H>BWFM2_M _"J1;.UDG9%^'(!8(I8@?/[4GE> M/2OR?E_F5#Q)X(G)1CC(W?\ =G_\B?T3T5\^?\$I?VC?B7^UU_P3K^$G[2OQ MCNK.?Q1XQ\)QZAK4NGV@@A:8R.I*1@D(,*.*^@ZX#[@**** "BBB@ HHHH _ MA"_:P_Y.F^)?_90-9_\ 2Z:BC]K#_DZ;XE_]E UG_P!+IJ* /V__ .#3;_E* M9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HH MHH _GB_X+8_\IS_B'_V2CPW_ "DKQ"O;_P#@MC_RG/\ B'_V2CPW_*2O$*^T MR;_<(^K_ #/Y!\6_^2YK_P"&G_Z0@HHHKU#\U"BBB@ HHHH *^PO^#9;_E)O M\>O^R4:'_P"EC5\>U]A?\&RW_*3?X]?]DHT/_P!+&KQ\\_W+YK]3];\%_P#D ML)?]>I_G __P#9 M5_#?_IPBKDQ_^Y5/1GU/!'_)88#_ *^P_-']7]%%%?!']OA1110 4444 %%% M% 'G_P"UE_R:Q\2_^R?ZS_Z0S5_+=^R3_P FW>#_ /L$+_Z$U?U(_M9?\FL? M$O\ [)_K/_I#-7\MW[)/_)MW@_\ [!"_^A-7NY!_O,O3]4?B?CC_ ,D_AO\ MK[_[9(]%HHHKZL_F,**** "BBB@ K(^('_(AZW_V"+G_ -%-6O61\0/^1#UO M_L$7/_HIJF?P,Z,'_O=/_$OS/WD_X($?\H;?V>_^R?P_^CI:^OZ^0/\ @@1_ MRAM_9[_[)_#_ .CI:^OZ_.3_ $ "BBB@ HHHH **** /X0OVL/\ DZ;XE_\ M90-9_P#2Z:BC]K#_ ).F^)?_ &4#6?\ TNFHH _;_P#X--O^4IG[7?\ V\?^ MGR>OW^K\ ?\ @TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** /YXO^"V/_ M "G/^(?_ &2CPW_*2O$*]O\ ^"V/_*<_XA_]DH\-_P I*\0K[3)O]PCZO\S^ M0?%O_DN:_P#AI_\ I""BBBO4/S4**** "BBB@ K["_X-EO\ E)O\>O\ LE&A M_P#I8U?'M?87_!LM_P I-_CU_P!DHT/_ -+&KQ\\_P!R^:_4_6_!?_DL)?\ M7J?YP/W*HHHKX\_JT**** "BBB@ HHHH _-?_@ZR_P"45(_[*OX8_P#2LU^3 M=?K)_P '67_**D?]E7\,?^E9K\FZ^GX?^"IZK]3^<_'7_>\#_AJ?G ****^A M/P,**** "BBB@ KC/B__ ,A;X>_]E7\-_P#IPBKLZXSXO_\ (6^'O_95_#?_ M *<(JY,?_N53T9]3P1_R6& _Z^P_-']7]%%%?!']OA1110 4444 %%%% 'G_ M .UE_P FL?$O_LG^L_\ I#-7\MW[)/\ R;=X/_[!"_\ H35_4C^UE_R:Q\2_ M^R?ZS_Z0S5_+=^R3_P FW>#_ /L$+_Z$U>[D'^\R]/U1^)^./_)/X;_K[_[9 M(]%HHHKZL_F,**** "BBB@ K(^('_(AZW_V"+G_T4U:]9'Q _P"1#UO_ +!% MS_Z*:IG\#.C!_P"]T_\ $OS/WD_X($?\H;?V>_\ LG\/_HZ6OK^OD#_@@1_R MAM_9[_[)_#_Z.EKZ_K\Y/] HHHH **** "BBB@#^$+]K#_DZ;XE_P#90-9_ M]+IJ*/VL/^3IOB7_ -E UG_TNFHH _;_ /X--O\ E*9^UW_V\?\ I\GK]_J_ M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@#^>+_ (+8_P#*<_XA M_P#9*/#?\I*\0KV__@MC_P IS_B'_P!DH\-_RDKQ"OM,F_W"/J_S/Y!\6_\ MDN:_^&G_ .D(****]0_-0HHHH **** "OL+_ (-EO^4F_P >O^R4:'_Z6-7Q M[7V%_P &RW_*3?X]?]DHT/\ ]+&KQ\\_W+YK]3];\%_^2PE_UZG^<#]RJ*** M^//ZM"BBB@ HHHH **** /S7_P"#K+_E%2/^RK^&/_2LU^3=?K)_P=9?\HJ1 M_P!E7\,?^E9K\FZ^GX?^"IZK]3^<_'7_ 'O _P"&I^< HHHKZ$_ PHHHH ** M** "N,^+_P#R%OA[_P!E7\-_^G"*NSKC/B__ ,A;X>_]E7\-_P#IPBKDQ_\ MN53T9]3P1_R6& _Z^P_-']7]%%%?!']OA1110 4444 %%%% 'G_[67_)K'Q+ M_P"R?ZS_ .D,U?RW?LD_\FW>#_\ L$+_ .A-7]2/[67_ ":Q\2_^R?ZS_P"D M,U?RW?LD_P#)MW@__L$+_P"A-7NY!_O,O3]4?B?CC_R3^&_Z^_\ MDCT6BBB MOJS^8PHHHH **** "LCX@?\ (AZW_P!@BY_]%-6O61\0/^1#UO\ [!%S_P"B MFJ9_ SHP?^]T_P#$OS/WD_X($?\ *&W]GO\ [)_#_P"CI:^OZ^0/^"!'_*&W M]GO_ +)_#_Z.EKZ_K\Y/] HHHH **** "BBB@#^$+]K#_DZ;XE_]E UG_TN MFHH_:P_Y.F^)?_90-9_]+IJ* /V__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3; M_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** /YXO^"V/_*<_P"(?_9*/#?\ MI*\0KV__ (+8_P#*<_XA_P#9*/#?\I*\0K[3)O\ <(^K_,_D'Q;_ .2YK_X: M?_I""BBBO4/S4**** "BBB@ K["_X-EO^4F_QZ_[)1H?_I8U?'M?87_!LM_R MDW^/7_9*-#_]+&KQ\\_W+YK]3];\%_\ DL)?]>I_G __\ 95_#?_IPBKDQ_P#N53T9]3P1_P E MA@/^OL/S1_5_1117P1_;X4444 %%%% !1110!Y_^UE_R:Q\2_P#LG^L_^D,U M?RW?LD_\FW>#_P#L$+_Z$U?U(_M9?\FL?$O_ +)_K/\ Z0S5_+=^R3_R;=X/ M_P"P0O\ Z$U>[D'^\R]/U1^)^./_ "3^&_Z^_P#MDCT6BBBOJS^8PHHHH ** M** "LCX@?\B'K?\ V"+G_P!%-6O61\0/^1#UO_L$7/\ Z*:IG\#.C!_[W3_Q M+\S]Y/\ @@1_RAM_9[_[)_#_ .CI:^OZ^0/^"!'_ "AM_9[_ .R?P_\ HZ6O MK^OSD_T "BBB@ HHHH **** /X0OVL/^3IOB7_V4#6?_ $NFHH_:P_Y.F^)? M_90-9_\ 2Z:B@#]O_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V M\?\ I\GK]_J "BBB@ HHHH **** /YXO^"V/_*<_XA_]DH\-_P I*\0KV_\ MX+8_\IS_ (A_]DH\-_RDKQ"OM,F_W"/J_P S^0?%O_DN:_\ AI_^D(****]0 M_-0HHHH **** "OL+_@V6_Y2;_'K_LE&A_\ I8U?'M?87_!LM_RDW^/7_9*- M#_\ 2QJ\?//]R^:_4_6_!?\ Y+"7_7J?YP/W*HHHKX\_JT**** "BBB@ HHH MH _-?_@ZR_Y14C_LJ_AC_P!*S7Y-U^LG_!UE_P HJ1_V5?PQ_P"E9K\FZ^GX M?^"IZK]3^<_'7_>\#_AJ?G ****^A/P,**** "BBB@ KC/B__P A;X>_]E7\ M-_\ IPBKLZXSXO\ _(6^'O\ V5?PW_Z<(JY,?_N53T9]3P1_R6& _P"OL/S1 M_5_1117P1_;X4444 %%%% !1110!Y_\ M9?\FL?$O_LG^L_^D,U?RW?LD_\ M)MW@_P#[!"_^A-7]2/[67_)K'Q+_ .R?ZS_Z0S5_+=^R3_R;=X/_ .P0O_H3 M5[N0?[S+T_5'XGXX_P#)/X;_ *^_^V2/1:***^K/YC"BBB@ HHHH *R/B!_R M(>M_]@BY_P#135KUD?$#_D0];_[!%S_Z*:IG\#.C!_[W3_Q+\S]Y/^"!'_*& MW]GO_LG\/_HZ6OK^OD#_ (($?\H;?V>_^R?P_P#HZ6OK^OSD_P! HHHH ** M** "BBB@#^$+]K#_ ).F^)?_ &4#6?\ TNFHH_:P_P"3IOB7_P!E UG_ -+I MJ* /V_\ ^#3;_E*9^UW_ -O'_I\GK]_J_ '_ (--O^4IG[7?_;Q_Z?)Z_?Z@ M HHHH **** "BBB@#^>+_@MC_P IS_B'_P!DH\-_RDKQ"O;_ /@MC_RG/^(? M_9*/#?\ *2O$*^TR;_<(^K_,_D'Q;_Y+FO\ X:?_ *0@HHHKU#\U"BBB@ HH MHH *^PO^#9;_ )2;_'K_ +)1H?\ Z6-7Q[7V%_P;+?\ *3?X]?\ 9*-#_P#2 MQJ\?//\ J_4_G/QU_WO _X:GYP"BBBOH3\#"BBB@ HHHH *XSXO_P#(6^'O_95_#?\ MZ<(J[.N,^+__ "%OA[_V5?PW_P"G"*N3'_[E4]&?4\$?\EA@/^OL/S1_5_11 M17P1_;X4444 %%%% !1110!Y_P#M9?\ )K'Q+_[)_K/_ *0S5_+=^R3_ ,FW M>#_^P0O_ *$U?U(_M9?\FL?$O_LG^L_^D,U?RW?LD_\ )MW@_P#[!"_^A-7N MY!_O,O3]4?B?CC_R3^&_Z^_^V2/1:***^K/YC"BBB@ HHHH *R/B!_R(>M_] M@BY_]%-6O61\0/\ D0];_P"P1<_^BFJ9_ SHP?\ O=/_ !+\S]Y/^"!'_*&W M]GO_ +)_#_Z.EKZ_KY _X($?\H;?V>_^R?P_^CI:^OZ_.3_0 **** "BBB@ MHHHH _A"_:P_Y.F^)?\ V4#6?_2Z:BC]K#_DZ;XE_P#90-9_]+IJ* /V_P#^ M#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H *S_ !7X MK\.>!O#EWXM\6ZO#8:;80F6\O)SA(DZ;CCMS6A45]86.J6DFGZG917%O*NV6 M">,.CCT*G@B@#RW_ (;G_9'_ .B]:#_W^?\ ^)H_X;G_ &1_^B]:#_W^?_XF MNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#A?\ AN?]D?\ MZ+UH/_?Y_P#XFC_AN?\ 9'_Z+UH/_?Y__B:[K_A5WPS_ .B=Z%_X*(?_ (FC M_A5WPS_Z)WH7_@HA_P#B: /PO_X*B? OX@_M%_\ !5OQE^TI\&_[!UCP5JWP M^T33=/UK_A+M-M_-NK9/&X2I4E-Q<;3<6K-I](1=].YP MO_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/_P#$UW7_ J[X9_] M$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\37FGZ"<+_P -S_LC_P#1>M!_ M[_/_ /$T?\-S_LC_ /1>M!_[_/\ _$UW7_"KOAG_ -$[T+_P40__ !-'_"KO MAG_T3O0O_!1#_P#$T <+_P -S_LC_P#1>M!_[_/_ /$T?\-S_LC_ /1>M!_[ M_/\ _$UW7_"KOAG_ -$[T+_P40__ !-'_"KOAG_T3O0O_!1#_P#$T <+_P - MS_LC_P#1>M!_[_/_ /$T?\-S_LC_ /1>M!_[_/\ _$UW7_"KOAG_ -$[T+_P M40__ !-'_"KOAG_T3O0O_!1#_P#$T ?G/_P<#>*?!_[;O_!/\?!']F#QOH/B M?Q/_ ,+!T+4_[,_MRVLO]%M[@O-)YEV\4?RKSMW;CV!K\\_^&1/CK_T!M!_\ M+?2?_DJOZ)/^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)KNP>85 ML$FH)._>_P#FCXKBS@3*.,:E*>-G4BZ::7(XKXK7OS1EV\C^=O\ X9$^.O\ MT!M!_P#"WTG_ .2J/^&1/CK_ - ;0?\ PM])_P#DJOZ)/^%7?#/_ *)WH7_@ MHA_^)H_X5=\,_P#HG>A?^"B'_P")KM_M[&?RQ^Y_YGR/_$$.%/\ G]7_ / J M?_RL_G;_ .&1/CK_ - ;0?\ PM])_P#DJC_AD3XZ_P#0&T'_ ,+?2?\ Y*K^ MB3_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\ B:/[>QG\L?N?^8?\ M00X4_P"?U?\ \"I__*S^=O\ X9$^.O\ T!M!_P#"WTG_ .2J/^&1/CK_ - ; M0?\ PM])_P#DJOZ)/^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P") MH_M[&?RQ^Y_YA_Q!#A3_ )_5_P#P*G_\K/YV_P#AD3XZ_P#0&T'_ ,+?2?\ MY*KF?B/^Q'^T;KVH^#I])\-:#*FE?$'1-3OS_P )WHZ^5:V]Y')-)\UV-VU% M)VC+'& ">*_I*_X5=\,_^B=Z%_X*(?\ XFC_ (5=\,_^B=Z%_P""B'_XFLZV MA?^"B'_ .)KR#]4.%_X;G_9'_Z+UH/_ '^?_P")H_X;G_9' M_P"B]:#_ -_G_P#B:[K_ (5=\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(? M_B: .%_X;G_9'_Z+UH/_ '^?_P")H_X;G_9'_P"B]:#_ -_G_P#B:[K_ (5= M\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B: .%_X;G_9'_Z+UH/_ '^? M_P")H_X;G_9'_P"B]:#_ -_G_P#B:[K_ (5=\,_^B=Z%_P""B'_XFC_A5WPS M_P"B=Z%_X*(?_B: /%?VA?VOOV9/'/P"\<>"?"WQKT&ZU/6/!^IV.G6WVO9Y MT\MK)'&FYP%7+,!EB ,\D"OP2_9W_87_ &E? OP2\-^$/%7A;0;74;#3EBN[ M?_A/-&?RWW$XW)=E3U[$U_2O_P *N^&?_1.]"_\ !1#_ /$T?\*N^&?_ $3O M0O\ P40__$UUX/&5<%-S@DVU;7^D?+\5<)9;Q?@X8;&3G&,)A_;V,_EC]S_ ,SX M3_B"'"G_ #^K_P#@5/\ ^5G\[?\ PR)\=?\ H#:#_P"%OI/_ ,E4?\,B?'7_ M * V@_\ A;Z3_P#)5?T2?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1 M#_\ $T?V]C/Y8_<_\P_X@API_P _J_\ X%3_ /E9_.W_ ,,B?'7_ * V@_\ MA;Z3_P#)5'_#(GQU_P"@-H/_ (6^D_\ R57]$G_"KOAG_P!$[T+_ ,%$/_Q- M'_"KOAG_ -$[T+_P40__ !-']O8S^6/W/_,/^((<*?\ /ZO_ .!4_P#Y6?SM M_P##(GQU_P"@-H/_ (6^D_\ R56=XP_8U_: U3PEJFF6&@Z#)/%?!\5CK^D?VI%<_99Q)(Q3S;=I(GX8M!_[_/_ /$UW7_"KOAG_P!$[T+_ ,%$/_Q-'_"KOAG_ -$[ MT+_P40__ !->*?L!PO\ PW/^R/\ ]%ZT'_O\_P#\31_PW/\ LC_]%ZT'_O\ M/_\ $UW7_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_ 40_P#Q- '*^%/V MN_V:?'/B.T\(^$?C'H]_J5_+Y5G9P2L7E?&=HRO7BO1ZQ['X?> =+O(]0TSP M1H]O<1-NBG@TR)'0^H8+D&MB@ HHHH _A"_:P_Y.F^)?_90-9_\ 2Z:BC]K# M_DZ;XE_]E UG_P!+IJ* /V__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4 MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ***\^_:B_:6^&W[(_P6U7XX_% M2>Y_LS3-B):V,8>XNYY&"QPQ*2 68GN0 6) !- 'H-%?'OP<_X*VV'B[XO^ M$?A/\=?V6O&GPQ'Q!*KX'UGQ -]OJ;N5$:G,:%"Y>-1MWX:5-V P:M']IK_@ MJEH?P1^,^M? SX5_L\^*OB7J_A'2/[3\;2^'F"0:-;;%?&7_ (*X:=X0^*_B_P"&/P+_ &6_ M&GQ-C^'K.GCG6]! 2UTQT+"1J!T:VO8PD]I/&Q62&502 RL.Q(((()!!H ] HHHH **** M"BBB@ HHHH **** "BBB@ HKY.^/?_!4VU^'GQRUS]G[X#_LR>,?BKKOA.U$ M_BU_#2[8--!4-LW!)&=QN (V@;OE!)! Z;P?_P %._V;O%O[&&H_MMB?4K7P M_HTC6FJZ1+"AOH=0!C46:J&V.[F6(J0VW;(&8J VT ^BZ*^3?V9O^"JFA_&S MXT:)\#?BK^SQXJ^&FK>+])_M+P1/XA8/!K-OM9P5;8A0LBL5X93M(W E0U3X MV?\ !62Q\%?&'Q5\'O@3^R[XS^*$_@)3_P )OJ?A\;+;3&7.],A)"Y4JZG(7 MYHW W!2: /KVBO*OV>_VR?@?^T5^SK!^TWX>\2)H_AO9+_:LGB":.V.ERQ'$ ML<[%MB[>#NW$%64@\UP_[%__ 4;^'_[;WQ9^(?@+X8^$9XM&\$26PL?$DU[ MD:Q'*\J>:L!C4PKF(D;F8E6!(4Y% 'T;1110 4444 %%%% !1110 4444 %% M%% !17@G[:/[?/@W]D'4O#7@2U^'6N^-_&WC&9T\-^$/#D8,]P%(!=VP=BY. M!A6)(;C"L1G_ +(7_!17PA^TWXU\4_!_QK\+==^''COP?:?;-:\+^)R-R6F5 M!G63"_*OF1EMRKQ*C L#D 'T717PXW_!<3X9#6?^$N'[.7C<_"D>)?[$/Q4\ MD?9/M'][RMN=F/GQOW[?X-WR5ZY^U[_P4/\ !?[,/BCPK\+?"/PTUSXB^./& M=N;KP_X6\+[2\MKSB=GPV$;:^W:K9$;D[0N: /H>BOG;]D?_ (*+_#W]IJ?Q MCX5\7> M9^'?BSP#$9_%?AKQ1@/:6P!W3A\+E%Q\VY5(RIP0P)\GT3_@N!\- M=0UW3O$^M_LY>-M)^%NK^(VT73?BE>QJ+-[@$CWY4X9CAV<*K?*2K* #[ MAHI%964,I!!&01WI: "BBB@ HHHH **** "BBB@#^$+]K#_DZ;XE_P#90-9_ M]+IJ*/VL/^3IOB7_ -E UG_TNFHH _;_ /X--O\ E*9^UW_V\?\ I\GK]_J_ M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ KE/C5IOP7O?AQJ6H M_M Z)X=O?"NEP-?:G_PE%A#<6<"1J2962967(!.#C/.!UKJZ\A_;;_9-M?VT M_@DWP-U;XE:IX9TZYU6"[U&?2H$D>[CBW%8'#\;/,,#OVA--\(3^'O@9\&=8>X\)7E[!Y5QX@U!)(GW(O9/,@A)'(1(]I.]V" MV?\ @G,ULW[>/[99\7;/-_X2)A^_Z_8_M6H^O\/E^5[8Q78_!C_@CG?_ 3\ M4^&=8\._MS?%!]*\-:M:WD'AO[<8[&>.&993;M$LFT1O@JP P0QXKI_VF?\ M@E3X<^-OQFUKXY?"O]H+Q9\--8\6Z7_9OC:/PX0T&M6VU48,N]"C,B*&Y96V M@[=Q8L >)?\ !&B'X-6__!,CQ)XI_:AT3P]>>#]!^(.H:CYGBK38KJUMHTL[ M0>8J2JPW[VE5=H+%G*C);!U?@7;?$K_@J?\ MJ^&OVT=8\'W'AOX._"RXF7P M E_'MNM>O _,^.RB1$9B,JODK$"S>8R^S?%C_@EA\+/'G['OAK]BKP5\1=<\ M+>%?#^HK>W,]I''-<:K,/,8M<%@H;=+(9" RI@ *H'+? ?_@D5JGP'\=^% M_%.C_MP?$Z^TOPOJ-M<0>&+B_9;">*%PPMVB63:(B!M*@8P>E %?]NW]I[PC M\#-:U']D3]BCX/Z3JGQL^)\;1ZA;^'M*AA-DDR/F]O715WRA))'7S#A03+(0 MF!)[9_P3^_917]C']ESP_P#!"[U:._U2 RWNO7L&?*DO9FWR"/(!V)\L:D@% M@@8@$D5\^>*?^"(]GXB^,OB+X[:?^VA\0='\0^)M1N;K4+[1U2WDQ-)YAA#Q MN&\L84!.!7U!^RA^SSJ7[,?PI'PRU7XP>(O'$HU*:[_ +;\47)ENL2! M?W6XLQVKMX&>YH ]+HHHH **** "BBB@ HHHH **** "BBB@#Y&_;F_:U^'G M[(>O3?#3]F'X0Z3K/QZ^)@6.QT_0M&A%R[,7"7E\\:AI I:1D5S\Q#$E4#-7 MR9^V_P#L>>)_V)O^".NA?#37-36\U_6/BK:ZSXTEMGW0I/-97">4K?Q*GE6Z M[NC."PX(%?1_Q:_X(OZ?\5/VAO$?[2L?[7WCO0_$/B#4IKC[1HR1PR6D+_*E MM'(K!_+2()&.>509KTOP?_P3:\&Q_LL>*OV4_C7\9?%_Q"TSQ1JAOCK7B&_+ MWVGN$A$?D2,7V['A$@!RI+L""&((!X-_P47^SG]N/]B__A$-GG?\)&G^HZ_8 M_M6F^G\/E^;[8S7H'[=?[5'@S]G#7K[]FO\ 8W^$&DZK\=/BBNV>U\/:3#%) M!YBR$7U\Z*OF2 22R()#@ M(Y"??VOV9?^"57A[X'_&;1?CC\4/VA/%GQ*U; MPCI1TWP1#XC(6#1;;:R*J+O54;B=N0I7BO'/_ 1.L?&7QR\2?M!6 M?[97C_1?$7B74KFZN[S1E2WDC25]WD*Z,&\M0$0+G&U%'84 =[^S9_P2_P#A M;X*_8=T/]DKX]6P\0QMK*:]XGAL[R2&"YU#<&\M60JYB0*D?!4N(\\;L5Y1_ MP2N\,^'O!G_!0?\ :G\)>$M$M=-TO3=%_V?/V@OB?^T#HWC6_U"\^)^H1W=_I]S;HL5DR22N%C9>6&92.? M04 >U4444 %%%% !1110 4444 %%%% !1110!XM^V9\;/V8/V4?!\7[3OQU\ M*Z-=ZSHP:V\*SMI<$NJS7#J^+:TD==\>X,^X@A54L6XSGY2^!OP%_:#\9_#_ M /:$_P""D_[0/AX^'_&'Q%^%FK67A'PM"K+)IVG"QS$9 1D.PM[95! ;",S M&3 ]R_;R_P""8FA?MX?$#P_XW\5_'7Q#X>B\-::;?3-,TJUB>..9I3))_91_X)WZQ^S3\0[[QOXD_:R\?_$*TO]!GTR70/%]^T]H!+)$Q MEV,[ L!&5Z=)&]: /BB/^P_^(;U_]5]H_P"$A]L^?_PD0_7ROTKZSUS]H+]G M?]CC]BGX4?M+_'CP5I6H>.K;X:Z18>&O^);"VLWET=.C#VT$S*9(H_WC^8V= MJK(V02X5N7/_ 0Z^%@UO_A%$_:)\[YZ[']M;_ ()5>&_VT/BKH?Q-UCX\^(O#"^&M)AL=!TK0[2(16)21 MI/.C)(*.6*\C&!&@_A% 'AG@/]F_]H"#]EO]IC]O7]HO2?['\>?%3X=:I]C\ M-P1E&TG2A:,=DBGE7:-(P$/S*D(W'>S*OFWQ8_L,?\&Z?@01>5G_ (2$>3C& M?/\ [7O=^/?'F?AFOMK]EC_@GC=_L[>(=>U+QK^T_P".?B3IOB#P_+I-WH7C M*^:>U6.1T+N%9V&XJI3_ '7:O,M$_P""'_POT[Q!IWAS6?VB?&^J_"[2/$1U MK3OA9>SJUDER2>&DW?,G+*<('*LPWY9F(!];_ P:H/@GX.&M[_MO_"+:?]L\ MS[WF_9H]^??=FNIH "@*H ' %% !1110 4444 %%%% !1110!_"%^UA_P G M3?$O_LH&L_\ I=-11^UA_P G3?$O_LH&L_\ I=-10!^W_P#P:;?\I3/VN_\ MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% '\(7[6'_ "=-\2_^R@:S_P"ETU%'[6'_ "=-\2_^ MR@:S_P"ETU% '[?_ /!IM_RE,_:[_P"WC_T^3U^_U?PO?'GXF_$GX9?M8_%* M_P#AO\0=<\/3W7CS6([F;0]6FM'E07\Q"L8F4L ><&L/_AK#]J;_ *.5^('_ M (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E? M?_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65 M]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': M /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ M': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O M:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': / M[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A M"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:* M_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X: MP_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_ MX:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F M_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_ M:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"C ME?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z M.5^('_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B! M_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^( M'_A97W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"% ME??_ !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A9 M7W_QVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ M !VC_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_Q MVC_AK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC M_AK#]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_A MK#]J;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK# M]J;_ *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J M;_HY7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ M *.5^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY M7X@?^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5 M^('_ (65]_\ ': /[O:*_A"_X:P_:F_Z.5^('_A97W_QVC_AK#]J;_HY7X@? M^%E??_': /[O:*_A"_X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ M (65]_\ ': #]K#_ ).F^)?_ &4#6?\ TNFHKA+N[NK^ZEOKZYDFGFD:2::9 /RSR.3DLQ/)))R2:* /_9 end GRAPHIC 41 mrk-20221231_g5.jpg begin 644 mrk-20221231_g5.jpg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mrk-20221231_g6.jpg begin 644 mrk-20221231_g6.jpg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mrk-20221231_g7.gif begin 644 mrk-20221231_g7.gif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end GRAPHIC 44 mrk-20221231_g8.jpg begin 644 mrk-20221231_g8.jpg M_]C_X 02D9)1@ ! @$!+ $L #_X19,17AI9@ 34T *@ @ !P$2 , M ! $ $: 4 ! 8@$; 4 ! :@$H , ! ( $Q M ( F <@$R ( 4 F(=I 0 ! K -@ +<; G M$ MQL "<0061O8F4@4&AO=&]S:&]P($5L96UE;G1S(#$P+C @5VEN9&]W M

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end GRAPHIC 45 mrk-20221231_g9.jpg begin 644 mrk-20221231_g9.jpg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htm IDEA: XBRL DOCUMENT v3.22.4
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2022
Jan. 31, 2023
Jun. 30, 2022
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 1-6571    
Entity Registrant Name Merck & Co., Inc.    
Entity Address, Address Line One 126 East Lincoln Avenue    
Entity Address, City or Town Rahway    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 07065    
City Area Code 908    
Local Phone Number 740-4000    
Entity Incorporation, State or Country Code NJ    
Entity Tax Identification Number 22-1918501    
Title of 12(b) Security Common Stock ($0.50 par value)    
Trading Symbol MRK    
Security Exchange Name NYSE    
Entity Common Stock, Shares Outstanding   2,538,592,467  
Entity Public Float     $ 230,820,000,000
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
Entity Central Index Key 0000310158    
Documents Incorporated by Reference
Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023, to be filed with the
Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report
   
0.500% Notes due 2024      
Document Information [Line Items]      
Title of 12(b) Security 0.500% Notes due 2024    
Trading Symbol MRK 24    
Security Exchange Name NYSE    
1.875% Notes due 2026      
Document Information [Line Items]      
Title of 12(b) Security 1.875% Notes due 2026    
Trading Symbol MRK/26    
Security Exchange Name NYSE    
2.500% Notes due 2034      
Document Information [Line Items]      
Title of 12(b) Security 2.500% Notes due 2034    
Trading Symbol MRK/34    
Security Exchange Name NYSE    
1.375% Notes due 2036      
Document Information [Line Items]      
Title of 12(b) Security 1.375% Notes due 2036    
Trading Symbol MRK 36A    
Security Exchange Name NYSE    

XML 47 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Audit Information
12 Months Ended
Dec. 31, 2022
Audit Information [Abstract]  
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Florham Park, New Jersey
Auditor Firm ID 238
XML 48 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]      
Sales $ 59,283 $ 48,704 $ 41,518
Costs, Expenses and Other      
Cost of sales 17,411 13,626 13,618
Selling, general and administrative 10,042 9,634 8,955
Research and development 13,548 12,245 13,397
Restructuring costs 337 661 575
Other (income) expense, net 1,501 (1,341) (890)
Total costs, expenses and other 42,839 34,825 35,655
Income from Continuing Operations Before Taxes 16,444 13,879 5,863
Taxes on Income from Continuing Operations 1,918 1,521 1,340
Net Income from Continuing Operations 14,526 12,358 4,523
Less: Net Income Attributable to Noncontrolling Interests 7 13 4
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 14,519 12,345 4,519
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 704 2,548
Net Income Attributable to Merck & Co., Inc. $ 14,519 $ 13,049 $ 7,067
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) $ 5.73 $ 4.88 $ 1.79
Income from Discontinued Operations (in dollars per share) 0 0.28 1.01
Net Income (in dollars per share) 5.73 5.16 2.79
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) 5.71 4.86 1.78
Income from Discontinued Operations (in dollars per share) 0 0.28 1.00
Net Income (in dollars per share) $ 5.71 $ 5.14 $ 2.78
XML 49 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Comprehensive Income - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Comprehensive Income [Abstract]      
Net Income Attributable to Merck & Co., Inc. $ 14,519 $ 13,049 $ 7,067
Other Comprehensive (Loss) Income Net of Taxes:      
Net unrealized (loss) gain on derivatives, net of reclassifications (71) 410 (297)
Net unrealized loss on investments, net of reclassifications 0 0 (18)
Benefit plan net gain (loss) and prior service credit (cost), net of amortization 335 1,769 (279)
Cumulative translation adjustment (603) (423) 153
Other comprehensive income (loss), net of taxes (339) 1,756 (441)
Comprehensive Income Attributable to Merck & Co., Inc. $ 14,180 $ 14,805 $ 6,626
XML 50 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheet - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Current Assets    
Cash and cash equivalents $ 12,694 $ 8,096
Short-term investments 498 0
Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021) 9,450 9,230
Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note 8) 5,911 5,953
Other current assets 7,169 6,987
Total current assets 35,722 30,266
Investments 1,015 370
Property, Plant and Equipment (at cost)    
Land 295 326
Buildings 13,166 12,529
Machinery, equipment and office furnishings 16,760 16,303
Construction in progress 9,186 8,313
Property, plant and equipment (at cost) 39,407 37,471
Less: accumulated depreciation 17,985 18,192
Property, plant and equipment, net 21,422 19,279
Goodwill 21,204 21,264
Other Intangibles, Net 20,269 22,933
Other Assets 9,528 11,582
Total Assets 109,160 105,694
Current Liabilities    
Loans payable and current portion of long-term debt 1,946 2,412
Trade accounts payable 4,264 4,609
Accrued and other current liabilities 14,159 13,859
Income taxes payable 1,986 1,224
Dividends payable 1,884 1,768
Total current liabilities 24,239 23,872
Long-Term Debt 28,745 30,690
Deferred Income Taxes 1,795 3,441
Other Noncurrent Liabilities 8,323 9,434
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 1,788 1,788
Other paid-in capital 44,379 44,238
Retained earnings 61,081 53,696
Accumulated other comprehensive loss (4,768) (4,429)
Stockholders' equity before deduction for treasury stock 102,480 95,293
Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021 56,489 57,109
Total Merck & Co., Inc. stockholders’ equity 45,991 38,184
Noncontrolling Interests 67 73
Total equity 46,058 38,257
Total Liabilities and Equity $ 109,160 $ 105,694
XML 51 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheet (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 72 $ 62
Inventory classified in Other assets $ 2,938 $ 2,194
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (in shares) 6,500,000,000 6,500,000,000
Common stock, shares issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock, shares (in shares) 1,039,269,638 1,049,499,023
XML 52 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Equity - USD ($)
$ in Millions
Total
Common Stock
Other Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock
Non- controlling Interests
Beginning balance at Dec. 31, 2019 $ 26,001 $ 1,788 $ 39,660 $ 46,602 $ (6,193) $ (55,950) $ 94
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 7,067     7,067      
Other comprehensive income (loss), net of taxes (441)       (441)    
Cash dividends declared on common stock (6,307)     (6,307)      
Treasury stock shares purchased (1,281)         (1,281)  
Net income attributable to noncontrolling interests 15           15
Distributions attributable to noncontrolling interests (22)           (22)
Share-based compensation plans and other 372   (72)     444  
Ending balance at Dec. 31, 2020 25,404 1,788 39,588 47,362 (6,634) (56,787) 87
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 13,049     13,049      
Other comprehensive income (loss), net of taxes 1,756       1,756    
Cash dividends declared on common stock (6,715)     (6,715)      
Treasury stock shares purchased (840)         (840)  
Spin-off of Organon & Co. 5,091   4,643   449   (1)
Net income attributable to noncontrolling interests 16           16
Distributions attributable to noncontrolling interests (29)           (29)
Share-based compensation plans and other 525   7     518  
Ending balance at Dec. 31, 2021 38,257 1,788 44,238 53,696 (4,429) (57,109) 73
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net Income Attributable to Merck & Co., Inc. 14,519     14,519      
Other comprehensive income (loss), net of taxes (339)       (339)    
Cash dividends declared on common stock (7,134)     (7,134)      
Spin-off of Organon & Co.         449    
Net income attributable to noncontrolling interests 7           7
Distributions attributable to noncontrolling interests (13)           (13)
Share-based compensation plans and other 761   141     620  
Ending balance at Dec. 31, 2022 $ 46,058 $ 1,788 $ 44,379 $ 61,081 $ (4,768) $ (56,489) $ 67
XML 53 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Equity (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]      
Common stock, dividends declared (in dollars per share) $ 2.80 $ 2.64 $ 2.48
XML 54 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Cash Flows - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash Flows from Operating Activities of Continuing Operations      
Net income from continuing operations $ 14,526 $ 12,358 $ 4,523
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:      
Amortization 2,085 1,636 1,817
Depreciation 1,824 1,578 1,669
Intangible asset impairment charges 1,749 302 1,718
Loss (income) from investments in equity securities, net 1,419 (1,940) (1,338)
Charge for the acquisition of Pandion Therapeutics, Inc. 0 1,556 0
Charge for the acquisition of VelosBio Inc. 0 0 2,660
Deferred income taxes (1,568) 187 (566)
Share-based compensation 541 479 441
Other 1,301 805 1,294
Net changes in assets and liabilities:      
Accounts receivable (644) (2,033) (1,002)
Inventories (161) (674) (895)
Trade accounts payable (289) 405 684
Accrued and other current liabilities (50) 277 (1,152)
Income taxes payable 380 (540) 814
Noncurrent liabilities (545) 484 (617)
Other (1,473) (1,758) (2,433)
Net Cash Provided by Operating Activities of Continuing Operations 19,095 13,122 7,617
Cash Flows from Investing Activities of Continuing Operations      
Capital expenditures (4,388) (4,448) (4,429)
Purchase of Seagen Inc. common stock 0 0 (1,000)
Purchases of securities and other investments (1,204) (1) (95)
Proceeds from sales of securities and other investments 721 1,026 2,812
Acquisition of Acceleron Pharma Inc., net of cash acquired 0 (11,174) 0
Acquisition of Pandion Therapeutics, Inc., net of cash acquired 0 (1,554) 0
Acquisition of VelosBio Inc., net of cash acquired 0 0 (2,696)
Acquisition of ArQule, Inc., net of cash acquired 0 0 (2,545)
Other acquisitions, net of cash acquired (121) (179) (1,365)
Other 32 (91) 125
Net Cash Used in Investing Activities of Continuing Operations (4,960) (16,421) (9,193)
Cash Flows from Financing Activities of Continuing Operations      
Net change in short-term borrowings 0 (3,986) 2,549
Payments on debt (2,251) (2,319) (1,957)
Proceeds from issuance of debt 0 7,936 4,419
Distribution from Organon & Co. 0 9,000 0
Purchases of treasury stock 0 (840) (1,281)
Dividends paid to stockholders (7,012) (6,610) (6,215)
Proceeds from exercise of stock options 384 202 89
Other (240) (286) (436)
Net Cash (Used in) Provided by Financing Activities of Continuing Operations (9,119) 3,097 (2,832)
Cash Flows from Discontinued Operations      
Net cash provided by operating activities 0 987 2,636
Net cash used in investing activities 0 (134) (250)
Net cash used in financing activities 0 (504) 0
Net Cash Flows Provided by Discontinued Operations 0 349 2,386
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (410) (133) 253
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash 4,606 14 (1,769)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets) 8,167 8,153 9,934
Less: Cash and cash equivalents related to discontinued operations 0 0 12
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets) $ 12,773 $ 8,167 $ 8,153
XML 55 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Cash Flows (Parenthetical) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement of Cash Flows [Abstract]        
Restricted cash $ 79 $ 71 $ 103 $ 258
XML 56 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations
12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Operations Nature of Operations
Merck & Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 3).
XML 57 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Accounting Policies
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Summary of Accounting Policies Summary of Accounting Policies
Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.
Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no
goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines
and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company’s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including Keytruda, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 19 for disaggregated revenue disclosures.
Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings. Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020.
Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.2 billion in 2022, $2.0 billion in 2021 and $1.8 billion in 2020.
Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 3 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles — Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are
expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income from Continuing Operations. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards — In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted — In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 58 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Spin-Off of Organon & Co.
12 Months Ended
Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the consolidated statement of income for the above MSAs include sales of $383 million and $219 million in 2022 and 2021, respectively, and related cost of sales of $404 million and $195 million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $511 million and $964 million at December 31, 2022 and 2021, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $345 million and $400 million at December 31, 2022 and 2021, respectively, and are included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s consolidated statement of income as Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million in 2021 and $743 million in 2020 related to the spin-off of Organon, which are also included in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees.
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
Years Ended December 31
2021(1)
2020
Sales$2,512 $6,476 
Costs, Expenses and Other
Cost of sales789 1,867 
Selling, general and administrative877 1,513 
Research and development103 161 
Restructuring costs1 
Other (income) expense, net(15)
1,755 3,548 
Income from discontinued operations before taxes757 2,928 
Tax provision50 369 
Income from discontinued operations, net of taxes707 2,559 
Less: Income of discontinued operations attributable to noncontrolling interests3 11 
$704 $2,548 
(1) Reflects amounts through the June 2, 2021 spin-off date.
XML 59 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions, Research Collaborations and Licensing Agreements
12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Research Collaborations and Licensing Agreements Acquisitions, Research Collaborations and Licensing Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
Recently Completed Transactions
In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175 million, which will be recorded in Research and development expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.
In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and Research and development expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.
2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to Research and development expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within Other (income) expense, net upon receipt of the related approvals.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge to Research and development expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved.
Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option
exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $111 million to fund Kelun-Biotech’s ongoing research and development activities, of which $51 million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
2021 Transactions
In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron’s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron’s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS.
In addition to sotatercept, Acceleron’s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $20 million in 2022 and remains eligible to receive up to $80 million in sales-based milestones.
The transaction was accounted for as a business combination. The Company incurred $280 million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in Selling, general and administrative expenses and Research and development costs in 2021.
The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:
November 19, 2021
Cash and cash equivalents$340 
Investments285 
Identifiable intangible assets: (1)
IPR&D - sotatercept 6,380 
Products and product rights - Reblozyl (12 year useful life)
3,830 
Deferred income tax liabilities, net(1,814)
Other assets and liabilities, net82 
Total identifiable net assets9,103 
Goodwill (2)
2,411 
Consideration transferred$11,514 
(1)    The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s development work focused on advancing a pipeline of precision immune modulators targeting
critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and Research and development expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.
In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead’s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.
Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0 billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5 billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.
Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck’s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead’s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.
In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in Research and development expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.
2020 Transactions
In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. OncoImmune’s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50 million for a 20% ownership interest in the new entity, which was valued at $33 million resulting in a $17 million premium. Merck also recognized other net liabilities of $22 million. The Company recorded Research and development expenses of $462 million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in 2021, which are reflected in Cost of sales and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.
Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio’s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180 million (primarily cash) and Research and development expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of Research and development expenses of $43 million, an increase to total consideration paid of $47 million, and an increase to net assets recorded of $90 million.
In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $616 million in Research and development expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16 million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales-based milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as Research and development expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and is receiving tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.
Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.
Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note 5 for additional information related to this collaboration.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&D of $113 million, cash of $59 million, deferred tax assets of $72 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $239 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&D impairment charge of $90 million within Research and development expenses. The Company also recorded a reduction in Research and development expenses resulting from a decrease in the related liability for contingent consideration of $45 million. In 2022, the Company wrote off the remaining IPR&D intangible asset and related contingent consideration liability; the net impact to Research and development expenses was immaterial.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5 million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.
In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305 million in 2020, of which $260 million was reflected in Cost of sales and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments. The remaining $45 million of costs were reflected in Research and development expenses and represent amounts related to the Themis acquisition noted above (an IPR&D impairment charge, partially offset by a reduction in the related liability for contingent consideration).
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in 2020. ArQule’s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
January 16, 2020
Cash and cash equivalents$145 
IPR&D - nemtabrutinib (1)
2,280
Licensing arrangement for derazantinib80
Deferred income tax liabilities(361)
Other assets and liabilities, net34
Total identifiable net assets2,178 
Goodwill (2)
512 
Consideration transferred$2,690 
(1)    The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note 9).
XML 60 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Arrangements
12 Months Ended
Dec. 31, 2022
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $400 million and $550 million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million and $160 million, respectively, from Merck to AstraZeneca. A regulatory milestone of $105 million that was accrued at December 31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.6 billion at December 31, 2022 and is included in Other Intangibles, Net. The amount is
being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lynparza$1,116 $989 $725 
Alliance revenue - Koselugo54 29 
Total alliance revenue$1,170 $1,018 $733 
Cost of sales (1)
492 167 247 
Selling, general and administrative185 178 160 
Research and development106 120 133 
December 3120222021
Receivables from AstraZeneca included in Other current assets
$303 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
123 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.
(2)    Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Merck made sales-based milestone payments to Eisai aggregating $600 million, $200 million and $500 million in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million, $75 million and $10 million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $814 million at December 31, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lenvima$876 $704 $580 
Cost of sales (1)
212 195 271 
Selling, general and administrative158 127 73 
Research and development136 173 185 
December 3120222021
Receivables from Eisai included in Other current assets
$214 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
 625 
(1)     Represents amortization of capitalized milestone payments.
(2)     Represents accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $400 million and $375 million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $633 million and $57 million, respectively, at December 31, 2022 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Adempas/Verquvo$341 $342 $281 
Net sales of Adempas recorded by Merck238 252 220 
Net sales of Verquvo recorded by Merck22 — 
Total sales$601 $601 $501 
Cost of sales (1)
210 424 196 
Selling, general and administrative153 126 47 
Research and development75 53 63 
December 3120222021
Receivables from Bayer included in Other current assets
$143 $114 
Payables to Bayer included in Accrued and other current Liabilities (2)
80 472 
(1)    Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense.
(2)    Amount as of December 31, 2021 includes accrued milestone payment.
Ridgeback Biotherapeutics LP
In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, Lagevrio has since received multiple additional authorizations worldwide.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Net sales of Lagevrio
$5,684 $952 $— 
Cost of sales (1)(2)
3,038 502 17 
Selling, general and administrative (2)
147 37 
Research and development (2)(3)
88 137 349 
December 3120222021
Payables to Ridgeback included in Accrued and other current liabilities (4)
$348 $283 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses in all periods now include an allocation for overhead charges.
(3)    Amount in 2020 includes upfront payment.
(4)    Includes accrued royalty and milestone payments.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $166 million in 2022, which includes royalties of $146 million and the receipt of a regulatory approval milestone payment of $20 million, compared with alliance revenue of $17 million in 2021.
XML 61 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring
12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Restructuring RestructuringIn 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $666 million in 2022, $868 million in 2021 and $880 million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December 31, 2022, Merck has recorded total pretax accumulated costs of approximately $3.3 billion. The Company expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following table summarizes the charges related to restructuring program activities by type of cost:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Year Ended December 31, 2022
Cost of sales$ $72 $133 $205 
Selling, general and administrative 19 75 94 
Research and development 29 1 30 
Restructuring costs212  125 337 
 $212 $120 $334 $666 
Year Ended December 31, 2021    
Cost of sales$— $52 $108 $160 
Selling, general and administrative— 12 19 
Research and development— 27 28 
Restructuring costs451 — 210 661 
 $451 $91 $326 $868 
Year Ended December 31, 2020    
Cost of sales$— $143 $32 $175 
Selling, general and administrative— 44 47 
Research and development— 81 83 
Restructuring costs385 — 190 575 
 $385 $268 $227 $880 
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 14) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Restructuring reserves January 1, 2021
$567 $— $19 $586 
Expenses451 91 326 868 
(Payments) receipts, net(422)— (186)(608)
Non-cash activity— (91)(118)(209)
Restructuring reserves December 31, 2021
596 — 41 637 
Expenses212 120 334 666 
(Payments) receipts, net(329) (120)(449)
Non-cash activity (120)(221)(341)
Restructuring reserves December 31, 2022 (1)
$479 $ $34 $513 
(1)    The remaining cash outlays are expected to be largely completed by the end of 2025.
XML 62 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments
12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.

Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or OCI depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in AOCL and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi,
the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI, and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202220212020202220212020
Net Investment Hedging Relationships
Foreign exchange contracts$(48)$(49)$26 $(1)$(13)$(19)
Euro-denominated notes(162)(296)385  — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.

Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
In 2022, nine interest rate swap contracts with a total notional amount of $2.25 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.4% fixed-rate notes and $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt.
The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.
The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2022202120222021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$ $2,263 $ $13 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20222021
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contractsOther current assets$ $ $ $14 $— $2,250 
Foreign exchange contractsOther current assets220  4,824 271 — 6,778 
Foreign exchange contractsOther Assets27  1,609 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities 101 2,691 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities 1 91 — 43 
  $247 $102 $9,215 $328 $25 $12,245 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$186 $ $8,540 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities 307 10,926 — 96 10,640 
  $186 $307 $19,466 $221 $96 $20,713 
  $433 $409 $28,681 $549 $121 $32,958 
As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:
20222021
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$433 $409 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(220)(220)(110)(110)
Cash collateral received/posted(66)(19)(164)— 
Net amounts$147 $170 $275 $11 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202220212020202220212020202220212020
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$59,283 $48,704 $41,518 $1,501 (1,341)(890)$(339)$1,756 $(441)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (13)(40)40  — — 
Derivatives designated as hedging instruments — — 4 (76) — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
 — —  — — 684 333 (383)
Increase (decrease) in Sales as a result of AOCL reclassifications
773 (194)(6) — — (773)194 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (2)(2)(4) — — 
Amount of loss recognized in OCI on derivatives
 — —  — — (2)(2)(4)
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Years Ended December 31202220212020
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(49)$313 $(12)
Foreign exchange contracts (2)
Sales(37)13 
Interest rate contracts (3)
Other (income) expense, net — 
Forward contract related to Seagen common stockResearch and development — 15 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
(3)     These derivative contracts serve as economic hedges against rising treasury rates.
At December 31, 2022, the Company estimates $104 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20222021
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
  GainsLossesGainsLosses
Commercial paper$498 $ $ $498 $— $— $— $— 
U.S. government and agency securities68   68 80— — 80 
Corporate notes and bonds3   3 — — 
Foreign government bonds    — — 
Total debt securities569   569 86 — — 86 
Publicly traded equity securities (1)
1,284 1,647 
Total debt and publicly traded equity securities$1,853 $1,733 
(1)    Unrealized net losses of $462 million were recorded in Other (income) expense, net in 2022 on equity securities still held at December 31, 2022. Unrealized net losses of $232 million were recorded in Other (income) expense, net in 2021 on equity securities still held at December 31, 2021.
At December 31, 2022 and 2021, the Company also had $832 million and $596 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During 2022, the Company recorded unrealized gains of $56 million and unrealized losses of $12 million related to certain of these equity investments still held at December 31, 2022. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these investments still held at December 31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2022 were $289 million and $19 million, respectively.
At December 31, 2022, 2021 and 2020, the Company also had $598 million, $1.7 billion and $800 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $1.0 billion, $(1.4) billion and $(583) million for the years ended December 31, 2022, 2021 and 2020, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20222021
Assets
Investments
Commercial paper$ $498 $ $498 $— $— $— $— 
Foreign government bonds    — — 
Publicly traded equity securities1,015   1,015 368 — — 368 
 1,015 498  1,513 368 — 370 
Other assets (1)
U.S. government and agency securities68   68 80 — — 80 
Corporate notes and bonds3   3 — — 
Publicly traded equity securities269   269 1,279 — — 1,279 
340   340 1,363 — — 1,363 
Derivative assets (2)
Forward exchange contracts 218  218 — 351 — 351 
Purchased currency options 215  215 — 184 — 184 
Interest rate swaps    — 14 — 14 
  433  433 — 549 — 549 
Total assets$1,355 $931 $ $2,286 $1,731 $551 $— $2,282 
Liabilities
Other liabilities
Contingent consideration$ $ $456 $456 $— $— $777 $777 
Derivative liabilities (2)
Forward exchange contracts 402  402 — 120 — 120 
Written currency options 7  7 — — 
 409  409 — 121 — 121 
Total liabilities$ $409 $456 $865 $— $121 $777 $898 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of December 31, 2022 and 2021, Cash and cash equivalents included $11.3 billion and $6.8 billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(146)57 
Payments(119)(109)
Other(56)(12)
Fair value December 31 (2)
$456 $777 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At December 31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December 31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. 
The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December 31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.5 billion and $2.8 billion of accounts receivable as of December 31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December 31, 2022 and 2021, the Company had collected $67 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022. Cash collateral received by the Company from various counterparties was $66 million and $164 million at December 31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
XML 63 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Inventories
12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories at December 31 consisted of:
20222021
Finished goods$1,841 $1,747 
Raw materials and work in process7,063 6,220 
Supplies238 196 
Total (approximates current cost)9,142 8,163 
Decrease to LIFO cost(293)(16)
 $8,849 $8,147 
Recognized as:
Inventories$5,911 $5,953 
Other Assets2,938 2,194 
Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.3 billion at December 31, 2022 and 2021, respectively. Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At December 31, 2022 and 2021, these amounts included $2.4 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $516 million and $256 million at December 31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.
XML 64 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangibles
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangibles Goodwill and Other Intangibles
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2021
$15,614 $3,268 $18,882 
Acquisitions2,431 2,436 
Other (1)
(48)(6)(54)
Balance December 31, 2021 (2)
17,997 3,267 21,264 
Other (1)
(61)1 (60)
Balance December 31, 2022 (2)
$17,936 $3,268 $21,204 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2022 and 2021.
The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note 4).
Other acquired intangibles at December 31 consisted of:
 20222021
  Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Products and product rights$23,555 $16,745 $6,810 $23,671 $15,776 $7,895 
IPR&D7,661  7,661 9,281 — 9,281 
Trade names2,879 635 2,244 2,882 493 2,389 
Licenses and other7,651 4,097 3,554 6,604 3,236 3,368 
 $41,746 $21,477 $20,269 $42,438 $19,505 $22,933 
Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December 31, 2022 were Reblozyl, $3.5 billion; Zerbaxa, $406 million; Sivextro, $122 million; Gardasil/Gardasil 9, $120 million; and Bridion, $97 million. Additionally, the Company had $4.6 billion of net acquired intangibles related to animal health at December 31, 2022, of which $2.3 billion related to products and product rights and $2.2 billion was attributable to trade names, primarily related to Allflex. At December 31, 2022, IPR&D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-7264 (gefapixant), $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $418 million, obtained through the acquisition of ArQule in
2020 (see below and Note 4). Some of the more significant net intangible assets included in licenses and other above at December 31, 2022 include Lynparza, $1.6 billion, related to a collaboration with AstraZeneca; Lenvima, $814 million, related to a collaboration with Eisai; and Adempas, $633 million, related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations.
In 2020, the Company recorded an impairment charge of $1.6 billion within Cost of sales related to Zerbaxa (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of Zerbaxa, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the Zerbaxa intangible asset for impairment. The Company revised its cash flow forecasts for Zerbaxa utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the Zerbaxa intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to Zerbaxa that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120 million to Cost of sales in 2020 related to the Zerbaxa recall. A phased resupply of Zerbaxa was initiated in the fourth quarter of 2021 and completed during 2022.
IPR&D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization.
In 2022, the Company recorded $1.7 billion of intangible impairment charges within Research and development expenses, of which $1.6 billion represents IPR&D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note 4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.
In 2021, the Company recorded a $275 million IPR&D impairment charge related to nemtabrutinib. As part of Merck’s annual impairment assessment of IPR&D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&D impairment charge noted above.
In 2020, the Company recorded a $90 million IPR&D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck’s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45 million.
The IPR&D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&D programs and profitably commercialize the underlying product candidates.
The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.
Aggregate amortization expense primarily recorded within Cost of sales was $2.1 billion in 2022, $1.6 billion in 2021 and $1.8 billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $1.8 billion; 2024, $1.7 billion; 2025, $1.6 billion; 2026, $1.5 billion; 2027, $1.3 billion.
XML 65 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Loans Payable, Long-Term Debt and Leases Loans Payable, Long-Term Debt and Leases
Loans Payable
Loans payable at December 31, 2022 included $1.7 billion of notes due in 2023 and $197 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.65% and 0.08% for the years ended December 31, 2022 and 2021, respectively.
Long-Term Debt
Long-term debt at December 31 consisted of:
20222021
2.75% notes due 2025
$2,496 $2,495 
2.15% notes due 2031
1,986 1,986 
2.75% notes due 2051
1,979 1,979 
3.70% notes due 2045
1,978 1,977 
3.40% notes due 2029
1,738 1,736 
1.70% notes due 2027
1,494 1,493 
2.90% notes due 2061
1,483 1,484 
4.00% notes due 2049
1,471 1,470 
4.15% notes due 2043
1,239 1,239 
1.45% notes due 2030
1,237 1,235 
2.45% notes due 2050
1,213 1,212 
1.875% euro-denominated notes due 2026
1,060 1,123 
0.75% notes due 2026
995 993 
1.90% notes due 2028
994 994 
3.90% notes due 2039
985 984 
2.35% notes due 2040
984 983 
2.90% notes due 2024
749 748 
6.50% notes due 2033
711 715 
0.50% euro-denominated notes due 2024
531 563 
1.375% euro-denominated notes due 2036
527 559 
2.50% euro-denominated notes due 2034
526 558 
3.60% notes due 2042
492 491 
6.55% notes due 2037
408 409 
5.75% notes due 2036
339 338 
5.95% debentures due 2028
307 306 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
250 250 
6.30% debentures due 2026
135 135 
2.80% notes due 2023
 1,749 
Other167 215 
 $28,745 $30,690 
Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 1.40% and zero for 2022 and 2021, respectively.
With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp & Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.
Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2022, the Company was in compliance with these covenants.
The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.2 billion; 2027, $1.5 billion. Interest payments related to these debt obligations are as follows: 2023, $882 million; 2024, $845 million; 2025, $778 million; 2026, $751 million; 2027, $720 million.
The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Leases
The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.
Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.
Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Operating lease cost was $334 million in 2022, $343 million in 2021 and $340 million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $335 million in 2022, $340 million in 2021 and $334 million in 2020. Operating lease assets obtained in exchange for lease obligations were $57 million in 2022, $117 million in 2021 and $473 million in 2020.
Supplemental balance sheet information related to operating leases is as follows:
December 3120222021
Assets
Other Assets (1)
$1,346 $1,586 
Liabilities
Accrued and other current liabilities281 304 
Other Noncurrent Liabilities1,013 1,225 
$1,294 $1,529 
Weighted-average remaining lease term (years)7.07.0
Weighted-average discount rate3.1 %2.6 %
(1)    Includes prepaid leases that have no related lease liability.
Maturities of operating leases liabilities are as follows:
2023$323 
2024258 
2025224 
2026157 
2027126 
Thereafter404 
Total lease payments1,492 
Less: Imputed interest198 
$1,294 
At December 31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $232 million.
XML 66 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Contingencies and Environmental Liabilities
12 Months Ended
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
Contingencies and Environmental Liabilities Contingencies and Environmental Liabilities
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2022, approximately 70 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney’s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena
sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government’s information request by seeking information relating to Merck’s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company’s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government’s investigation.
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark defendants’ motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $12.7 billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.
340B Program Litigation
Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson.
Qui Tam Litigation
As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s M-M-R II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the M‑M‑R II vaccine, which charge that the Company misrepresented the efficacy of the M-M-R II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck’s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.
Merck KGaA Litigation
As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement
and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR As previously disclosed, the FDA granted pediatric exclusivity with respect to Januvia (sitagliptin), Janumet (sitagliptin/metformin HCl), and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District
Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.
In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in Januvia, Janumet and Janumet XR.
As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.
Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for Janumet in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the Janumet SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the Janumet SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An ex-parte preliminary injunction was granted in Finland, which has been subsequently maintained in inter-partes proceedings, Czech Republic and Switzerland, and an inter-partes preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be prima facie valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.
Lynparza In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company;
the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2022 and 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
Environmental Matters
The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is de minimis and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.
In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December 31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.
XML 67 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Equity
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Equity Equity
The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.

Capital Stock
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202220212020
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,049 3,577 1,047 3,577 1,038 
Purchases of treasury stock  — 11 — 16 
Issuances (1)
 (10)— (9)— (7)
Balance December 313,577 1,039 3,577 1,049 3,577 1,047 
(1)     Issuances primarily reflect activity under share-based compensation plans.
XML 68 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Plans Share-Based Compensation PlansThe Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees
and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.
At December 31, 2022, 87 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.
Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.
Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $541 million, $498 million and $475 million, respectively. The amounts in 2021 and 2020 include $479 million and $441 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $78 million, $69 million and $65 million, respectively.
The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.
The weighted average exercise price of options granted in 2022, 2021 and 2020 was $87.10, $75.99 and $77.67 per option, respectively. The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202220212020
Expected dividend yield3.1 %3.1 %3.1 %
Risk-free interest rate3.0 %1.0 %0.4 %
Expected volatility22.5 %20.9 %22.1 %
Expected life (years)5.95.95.8
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2022
18,572 $65.27 
Granted2,326 87.10 
Exercised(6,317)60.77 
Forfeited(862)73.11   
Outstanding December 31, 202213,719 $70.55 6.5$554 
Vested and expected to vest December 31, 202213,199 $70.09 6.4$539 
Exercisable December 31, 20228,730 $65.24 5.4$399 
Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202220212020
Total intrinsic value of stock options exercised$225 $106 $51 
Fair value of stock options vested30 27 25 
Cash received from the exercise of stock options384 202 89 
A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2022
11,790 $74.88 1,966 $77.13 
Granted7,170 87.12 951 88.52 
Vested(5,150)75.40 (725)87.87 
Forfeited(1,110)78.65 (171)77.58 
Nonvested December 31, 202212,700 $81.25 2,021 $78.60 
Expected to vest December 31, 202211,254 $80.96 1,895 $78.26 
At December 31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.
XML 69 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans
12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.
Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202220212020202220212020202220212020
Service cost$372 $403 $360 $283 $328 $297 $48 $48 $52 
Interest cost457 404 431 145 123 136 46 45 57 
Expected return on plan assets(753)(755)(774)(383)(416)(414)(86)(79)(75)
Amortization of unrecognized prior service cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Net loss (gain) amortization128 298 303 96 142 127 (43)(42)(18)
Termination benefits2 56 10 1  37 
Curtailments12 16 10  (26)— (1)(29)(4)
Settlements239 216 13 1 15  — — 
Net periodic benefit cost (credit)$425 $600 $304 $129 $148 $146 $(93)$(83)$(59)
Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.
In connection with restructuring actions (see Note 6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests if related to the spin-off of Organon (each as noted above).
Obligations and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:
Pension BenefitsOther
Postretirement
Benefits
U.S.International
  202220212022202120222021
Fair value of plan assets January 1$13,067 $12,672 $12,195 $12,009 $1,292 $1,221 
Actual return on plan assets(3,129)1,250 (2,793)891 (306)118 
Company contributions293 305 155 189 46 33 
Effects of exchange rate changes — (848)(671) — 
Benefits paid(219)(219)(250)(233)(90)(86)
Settlements(918)(941)(16)(55) — 
Spin-off of Organon —  (55) — 
Other — 30 120 5 
Fair value of plan assets December 31$9,094 $13,067 $8,473 $12,195 $947 $1,292 
Benefit obligation January 1$13,999 $14,613 $11,575 $12,458 $1,541 $1,607 
Service cost372 403 283 328 48 48 
Interest cost457 404 145 123 46 45 
Actuarial (gains) losses (1)
(3,851)(332)(3,283)(240)(392)(103)
Benefits paid(219)(219)(250)(233)(90)(86)
Effects of exchange rate changes — (732)(678)(1)(1)
Plan amendments — 4  — 
Curtailments12 15  (38) (12)
Termination benefits2 56 1  37 
Settlements(918)(941)(16)(55) — 
Spin-off of Organon —  (118) — 
Other — 28 19 5 
Benefit obligation December 31$9,854 $13,999 $7,755 $11,575 $1,157 $1,541 
Funded status December 31$(760)$(932)$718 $620 $(210)$(249)
Recognized as:
Other Assets$5 $$1,052 $1,395 $ $— 
Accrued and other current liabilities(59)(64)(19)(22)(8)(8)
Other Noncurrent Liabilities(706)(877)(315)(753)(202)(241)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
At December 31, 2022 and 2021, the accumulated benefit obligation was $17.2 billion and $24.9 billion, respectively, for all pension plans, of which $9.7 billion and $13.8 billion, respectively, related to U.S. pension plans.
Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2022202120222021
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation$9,186 $13,013 $2,779 $2,507 
Fair value of plan assets8,421 12,072 2,445 1,731 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$9,081 $12,916 $1,226 $2,462 
Fair value of plan assets8,421 12,072 948 1,723 
Plan Assets
Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2022 and 2021, $765 million and $943 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.
If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20222021
U.S. Pension Plans
Cash and cash equivalents$49 $ $ $98 $147 $$— $— $289 $292 
Investment funds
Developed markets equities211   2,443 2,654 236 — — 3,799 4,035 
Emerging markets equities   707 707 — — — 919 919 
Real estate   131 131 — — — — — 
Equity securities
Developed markets1,956    1,956 2,915 — — — 2,915 
Fixed income securities
Government and agency obligations 1,934   1,934 — 2,870 — — 2,870 
Corporate obligations 1,438   1,438 — 2,005 — — 2,005 
Mortgage and asset-backed securities 22   22 — 23 — — 23 
Other investments
Derivatives 101   101 — — — — — 
Other  4  4 — — 
Plan assets at fair value$2,216 $3,495 $4 $3,379 $9,094 $3,156 $4,898 $$5,007 $13,067 
International Pension Plans
Cash and cash equivalents$57 $8 $ $13 $78 $82 $10 $— $18 $110 
Investment funds
Developed markets equities375 2,957  90 3,422 531 4,292 — 121 4,944 
Government and agency obligations177 2,656  130 2,963 240 4,025 — 171 4,436 
Emerging markets equities52   59 111 137 — — 72 209 
Corporate obligations8 9  129 146 — 171 188 
Other fixed income obligations10 7  4 21 15 — 26 
Real estate 1  10 11 — — 16 17 
Equity securities
Developed markets263    263 369 — — — 369 
Fixed income securities
Government and agency obligations 448   448 591 — 597 
Corporate obligations 157   157 — 223 — 225 
Mortgage and asset-backed securities 69   69 — 90 — — 90 
Other investments
Insurance contracts (2)
 18 761 1 780 — 44 937 982 
Other1 3   4 — — 
Plan assets at fair value$943 $6,333 $761 $436 $8,473 $1,387 $9,293 $937 $578 $12,195 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20222021
  Insurance
Contracts
Real
Estate
OtherTotalInsurance
Contracts
Real
Estate
OtherTotal
U.S. Pension Plans
Balance January 1$ $ $6 $6 $— $— $$
Actual return on plan assets:
Relating to assets still held at December 31  (3)(3)— — (5)(5)
Relating to assets sold during the year  2 2 — — 
Purchases and sales, net  (1)(1)— — (3)(3)
Balance December 31$ $ $4 $4 $— $— $$
International Pension Plans
Balance January 1$937 $ $ $937 $935 $— $— $935 
Actual return on plan assets:
Relating to assets still held at December 31(147)  (147)(34)— — (34)
Purchases and sales, net(39) (39)(42)— — (42)
Transfers into Level 310  10 78 — — 78 
Balance December 31$761 $ $ $761 $937 $— $— $937 
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
  2022  2021  
Cash and cash equivalents$2 $ $ $8 $10 $11 $— $— $28 $39 
Investment funds
Developed markets equities22   257 279 24 — — 378 402 
Emerging markets equities   74 74 — — — 92 92 
Real estate   14 14 — — — — — 
Government and agency obligations1    1 — — — 
Equity securities— 
Developed markets206    206 290 — — — 290 
Fixed income securities
Government and agency obligations 212   212 — 275 — — 275 
Corporate obligations 137   137 — 191 — — 191 
Mortgage and asset-backed securities 2   2 — — — 
Other Investments
Derivatives 12   12 — — — — — 
Plan assets at fair value$231 $363 $ $353 $947 $326 $468 $— $498 $1,292 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of
returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.
Expected Contributions
Contributions during 2023 are expected to be approximately $270 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $20 million for other postretirement benefit plans.
Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2023$627 $271 $84 
2024634 257 86 
2025650 262 87 
2026676 283 89 
2027694 297 90 
2028 — 20323,948 1,704 474 
Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.
Amounts Recognized in Other Comprehensive Income
Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202220212020202220212020202220212020
Net (loss) gain arising during the period$(42)$813 $(472)$116 $772 $(424)$ $156 $199 
Prior service (cost) credit arising during the period — — (4)(4)64  — — 
 $(42)$813 $(472)$112 $768 $(360)$ $156 $199 
Net loss (gain) amortization included in benefit cost$128 $298 $303 $96 $142 $127 $(43)$(42)$(18)
Prior service credit amortization included in benefit cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Settlements and curtailments251 232 23 1 (18)15 (1)(29)(4)
 $347 $492 $277 $83 $108 $124 $(101)$(134)$(95)
Actuarial Assumptions
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202220212020202220212020
Net periodic benefit cost      
Discount rate3.00 %2.70 %3.40 %1.50 %1.10 %1.50 %
Expected rate of return on plan assets6.70 %6.70 %7.30 %3.70 %3.80 %4.40 %
Salary growth rate4.60 %4.60 %4.20 %2.90 %2.80 %2.80 %
Interest crediting rate5.00 %4.70 %4.90 %3.00 %3.00 %2.80 %
Benefit obligation      
Discount rate5.50 %3.00 %2.70 %3.90 %1.50 %1.10 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %2.90 %2.80 %
Interest crediting rate5.30 %5.00 %4.70 %3.30 %3.00 %3.00 %
For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.00%, as compared to 6.70% in 2022.
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120222021
Health care cost trend rate assumed for next year7.8 %6.4 %
Rate to which the cost trend rate is assumed to decline4.5 %4.5 %
Year that the trend rate reaches the ultimate trend rate20382032

Savings Plans
The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $175 million, $158 million and $158 million, respectively.
XML 70 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Other (Income) Expense, Net
12 Months Ended
Dec. 31, 2022
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202220212020
Interest income$(157)$(36)$(59)
Interest expense962 806 831 
Exchange losses237 297 145 
Loss (income) from investments in equity securities, net (1)
1,419 (1,940)(1,338)
Net periodic defined benefit plan (credit) cost other than service cost(279)(212)(339)
Other, net(681)(256)(130)
 $1,501 $(1,341)$(890)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140 million will be recorded in the first quarter of 2023 from ownership interests in investment funds.
Interest paid was $937 million in 2022, $779 million in 2021 and $822 million in 2020.
XML 71 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on Income
A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:
 202220212020
  AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income from continuing operations before taxes$3,453 21.0 %$2,915 21.0 %$1,231 21.0 %
Differential arising from:
Foreign earnings(1,835)(11.1)(1,446)(10.4)(965)(16.5)
GILTI and the foreign-derived intangible income deduction462 2.8 (75)(0.5)349 6.0 
State taxes(110)(0.7)— 57 1.0 
R&D tax credit(81)(0.5)(81)(0.6)(108)(1.8)
Tax settlements(10)(0.1)(275)(2.0)(13)(0.2)
Valuation allowances108 0.7 102 0.7 37 0.6 
Restructuring11 0.1 61 0.4 105 1.8 
Acquisition of VelosBio  (9)(0.1)559 9.5 
Acquisition of Pandion  356 2.6 — — 
Acquisition of OncoImmune  — — 97 1.7 
Other(80)(0.5)(29)(0.1)(9)(0.2)
 $1,918 11.7 %$1,521 11.0 %$1,340 22.9 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $2.2 billion at December 31, 2022, of which $732 million is included in Income taxes payable and the remainder of $1.5 billion is included in Other Noncurrent Liabilities. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable.
The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding
a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032.
Income from continuing operations before taxes consisted of:
Years Ended December 31202220212020
Domestic$1,011 $1,854 $(3,814)
Foreign15,433 12,025 9,677 
 $16,444 $13,879 $5,863 
Taxes on income from continuing operations consisted of:
Years Ended December 31202220212020
Current provision
Federal$2,265 $74 $893 
Foreign1,164 1,273 969 
State57 (13)44 
 3,486 1,334 1,906 
Deferred provision
Federal(1,510)240 (605)
Foreign71 (77)64 
State(129)24 (25)
 (1,568)187 (566)
 $1,918 $1,521 $1,340 
Deferred income taxes at December 31 consisted of:
 20222021
  AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$ $2,575 $— $3,207 
R&D capitalization1,341  274 — 
Inventory related43 423 119 370 
Accelerated depreciation 657 — 589 
Equity investments 92 — 335 
Pensions and other postretirement benefits372 284 487 338 
Compensation related335  301 — 
Unrecognized tax benefits91  75 — 
Net operating losses and other tax credit carryforwards912  867 — 
Other511 267 434 180 
Subtotal3,605 4,298 2,557 5,019 
Valuation allowance(599) (287) 
Total deferred taxes$3,006 $4,298 $2,270 $5,019 
Net deferred income taxes $1,292  $2,749 
Recognized as:
Other Assets$503 $692 
Deferred Income Taxes $1,795  $3,441 
The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2022, $349 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $345 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $563 million of deferred tax assets relating to various U.S. tax credit carryforwards and
NOL carryforwards. Valuation allowances of $247 million have been established on these U.S. tax credit carryforwards and NOL carryforwards.
Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $3.2 billion, $2.4 billion and $2.7 billion, respectively. Income taxes paid consisted of:
Years Ended December 31202220212020
Domestic (1)
$1,891 $1,211 $977 
Foreign1,348 1,201 1,763 
 $3,239 $2,412 $2,740 
(1)    Includes TCJA transition tax payments.
Tax benefits relating to stock option exercises were $45 million in 2022, $21 million in 2021 and $12 million in 2020.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202220212020
Balance January 1$1,529 $1,537 $1,225 
Additions related to current year positions344 306 298 
Additions related to prior year positions48 63 110 
Reductions for tax positions of prior years (1)
(40)(230)(4)
Settlements (1)
(6)(46)(70)
Lapse of statute of limitations(40)(58)(22)
Spin-off of Organon (43)— 
Balance December 31$1,835 $1,529 $1,537 
(1)    Amount in 2021 reflects a settlement with the IRS discussed below.
If the Company were to recognize the unrecognized tax benefits of $1.8 billion at December 31, 2022, the income tax provision would reflect a favorable net impact of $1.8 billion.
The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2022 could decrease by up to approximately $31 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures.
Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $54 million in 2022, $(37) million in 2021 and $16 million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $256 million and $192 million as of December 31, 2022 and 2021, respectively.
In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.
The IRS is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2003 through 2022.
XML 72 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings per Share
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202220212020
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$14,519 $12,345 $4,519 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 704 2,548 
Net Income Attributable to Merck & Co., Inc.$14,519 $13,049 $7,067 
Average common shares outstanding2,532 2,530 2,530 
Common shares issuable (1)
10 11 
Average common shares outstanding assuming dilution2,542 2,538 2,541 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.73 $4.88 $1.79 
Income from Discontinued Operations 0.28 1.01 
Net Income$5.73 $5.16 $2.79 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.71 $4.86 $1.78 
Income from Discontinued Operations 0.28 1.00 
Net Income$5.71 $5.14 $2.78 
(1)     Issuable primarily under share-based compensation plans.
In 2022, 2021 and 2020, 2 million, 9 million and 5 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 73 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Other Comprehensive Income (Loss)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesInvestmentsEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance January 1, 2020, net of taxes
$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(383)(633)64 (949)
Tax84 — 120 89 293 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(299)(513)153 (656)
Reclassification adjustments, pretax
(1)
(21)
(2)
306 
(3)
— 287 
Tax— — (72)— (72)
Reclassification adjustments, net of taxes(21)234 — 215 
Other comprehensive income (loss), net of taxes(297)(18)(279)153 (441)
Balance at December 31, 2020, net of taxes(266)— (4,540)(1,828)(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax333 — 1,737 (304)1,766 
Tax(75)— (332)(119)(526)
Other comprehensive income (loss) before reclassification adjustments, net of taxes258 — 1,405 (423)1,240 
Reclassification adjustments, pretax192 
(1)
— 466 
(3)
— 658 
Tax(40)— (102)— (142)
Reclassification adjustments, net of taxes152 — 364 — 516 
Other comprehensive income (loss), net of taxes410 — 1,769 (423)1,756 
Spin-off of Organon (see Note 3)
— — 28 421 449 
Balance at December 31, 2021, net of taxes144 — (2,743)
(4)
(1,830)(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684  70 (584)170 
Tax(143) 12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541  82 (603)20 
Reclassification adjustments, pretax(775)
(1)
 329 
(3)
 (446)
Tax163  (76) 87 
Reclassification adjustments, net of taxes(612) 253  (359)
Other comprehensive income (loss), net of taxes(71) 335 (603)(339)
Balance at December 31, 2022, net of taxes$73 $ $(2,408)
(4)
$(2,433)$(4,768)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from AOCL to Other (income) expense, net.
(3)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 14).
(4)    Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.
XML 74 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.
Sales of the Company’s products were as follows:
Years Ended December 31202220212020
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$12,686 $8,251 $20,937 $9,765 $7,421 $17,186 $8,352 $6,028 $14,380 
Alliance revenue - Lynparza (1)
584 532 1,116 515 473 989 417 308 725 
Alliance revenue - Lenvima (1)
579 297 876 417 287 704 359 220 580 
Alliance revenue - Reblozyl (2)
123 43 166 — 17 17 — — — 
Vaccines
Gardasil/Gardasil 9
2,065 4,832 6,897 1,881 3,792 5,673 1,755 2,184 3,938 
ProQuad/M-M-R II/Varivax1,724 518 2,241 1,629 506 2,135 1,378 500 1,878 
RotaTeq508 275 783 473 334 807 486 311 797 
Pneumovax 23
346 256 602 547 346 893 727 359 1,087 
Vaqta95 78 173 100 79 179 103 67 170 
Hospital Acute Care
Bridion922 762 1,685 762 770 1,532 583 615 1,198 
Prevymis188 240 428 153 218 370 119 162 281 
Dificid241 22 263 166 10 175 102 110 
Primaxin1 238 239 258 259 248 251 
Noxafil51 187 238 60 199 259 42 287 329 
Invanz4 185 189 (5)207 202 202 211 
Cancidas6 168 174 208 212 207 213 
Zerbaxa89 79 169 (5)(1)74 56 130 
Cardiovascular
Alliance revenue - Adempas/Verquvo (3)
329 12 341 312 30 342 259 22 281 
Adempas 238 238 — 252 252 — 220 220 
Virology
Lagevrio1,523 4,161 5,684 632 320 952 — — — 
Isentress/Isentress HD274 359 633 294 474 769 326 531 857 
Neuroscience
Belsomra79 179 258 78 241 318 81 247 327 
Immunology
Simponi 706 706 — 825 825 — 838 838 
Remicade 207 207 — 299 299 — 330 330 
Diabetes
Januvia1,248 1,565 2,813 1,404 1,920 3,324 1,470 1,836 3,306 
Janumet355 1,344 1,700 367 1,597 1,964 477 1,494 1,971 
Other pharmaceutical (4)
969 1,282 2,249 841 1,275 2,118 882 1,321 2,202 
Total Pharmaceutical segment sales24,989 27,016 52,005 20,401 22,353 42,754 18,010 18,600 36,610 
Animal Health:
Livestock710 2,590 3,300 667 2,628 3,295 612 2,327 2,939 
Companion Animals1,112 1,138 2,250 1,091 1,182 2,273 872 892 1,764 
Total Animal Health segment sales1,822 3,728 5,550 1,758 3,810 5,568 1,484 3,219 4,703 
Other segment sales (5)
   — — — 23 — 23 
Total segment sales26,811 30,744 57,555 22,159 26,163 48,322 19,517 21,819 41,336 
Other (6)
395 1,333 1,728 266 116 382 71 111 182 
 $27,206 $32,077 $59,283 $22,425 $26,279 $48,704 $19,588 $21,930 $41,518 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020.
(6)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202220212020
United States$27,206 $22,425 $19,588 
Europe, Middle East and Africa14,493 13,341 11,547 
China5,191 4,378 2,751 
Japan3,629 2,726 2,602 
Asia Pacific (other than China and Japan)3,614 2,407 2,113 
Latin America2,582 2,206 1,890 
Other2,568 1,221 1,027 
 $59,283 $48,704 $41,518 
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
Years Ended December 31202220212020
Segment profits:
Pharmaceutical segment$36,852 $30,977 $26,106 
Animal Health segment1,963 1,950 1,669 
Other segments — 
Total segment profits38,815 32,927 27,776 
Other profits1,160 156 75 
Unallocated:
Interest income157 36 59 
Interest expense(962)(806)(831)
Amortization(2,085)(1,636)(1,817)
Depreciation(1,642)(1,414)(1,519)
Research and development(13,011)(11,692)(12,911)
Restructuring costs(337)(661)(575)
Other unallocated, net(5,651)(3,031)(4,394)
$16,444 $13,879 $5,863 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
Equity income/loss from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthAll OtherTotal
Year Ended December 31, 2022      
Included in segment profits:
Equity income from affiliates$39 $ $ $39 
Depreciation5 177  182 
Year Ended December 31, 2021      
Included in segment profits:
Equity income from affiliates$11 $— $— $11 
Depreciation158 — 164 
Year Ended December 31, 2020      
Included in segment profits:
Equity loss from affiliates$$— $— $
Depreciation143 150 
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202220212020
United States$12,891 $11,759 $10,394 
Europe, Middle East and Africa6,993 6,081 5,314 
Asia Pacific (other than China and Japan)966 857 737 
Latin America225 199 169 
China207 220 216 
Japan135 159 166 
Other5 
 $21,422 $19,279 $17,000 
The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.
XML 75 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Principles of Consolidation Principles of Consolidation — The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as Noncontrolling interests in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.
Acquisitions Acquisitions — In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.
Foreign Currency Translation Foreign Currency Translation — The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in Other Comprehensive Income (OCI) and remain in Accumulated other comprehensive loss (AOCL) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in Other (income) expense, net.
Cash Equivalents Cash Equivalents — Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.
Inventories Inventories — Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.
Investments
Investments — Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in OCI. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in Other (income) expense, net is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in OCI. Realized gains and losses for debt securities are included in Other (income) expense, net.
Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in Other (income) expense, net. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in Other (income) expense, net. Realized gains and losses for equity securities are included in Other (income) expense, net.
Revenue Recognition
Revenue Recognition — Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.
The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation, Commission Guidance Regarding Accounting for Sales of Vaccines
and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company’s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.
The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts.
In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material.
The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in Accounts receivable and Accrued and other current liabilities were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.
Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.
The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, three to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.
Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including Keytruda, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.
See Note 19 for disaggregated revenue disclosures.
Depreciation Depreciation — Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40 years for Buildings, and from 3 to 15 years for Machinery, equipment and office furnishings.
Advertising and Promotion Costs Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred.
Software Capitalization Software Capitalization — The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in Property, plant and equipment. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in Other Assets. Capitalized software costs are being amortized over periods ranging from 3 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.
Goodwill Goodwill — Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).
Acquired Intangibles Acquired Intangibles — Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.
Acquired In-Process Research and Development Acquired In-Process Research and Development — IPR&D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.
Contingent Consideration Contingent Consideration — Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations.
Research and Development Research and Development — Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval.
Collaborative Arrangements
Collaborative Arrangements — Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within Cost of sales. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within Sales). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within Selling, general and administrative expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within Research and development expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to Research and development expenses.
In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in Research and development expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to Cost of sales over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to Cost of sales over its remaining useful life, subject to impairment testing.
Share-Based Compensation Share-Based Compensation — The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.
Restructuring Costs Restructuring Costs — The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.
Contingencies and Legal Defense Costs Contingencies and Legal Defense Costs — The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.
Taxes on Income Taxes on Income — Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of Taxes on Income from Continuing Operations. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from AOCL is to utilize the item-by-item approach.
Reclassifications Reclassifications — Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Use of Estimates Use of Estimates — The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.
Recently Adopted Accounting Standards
Recently Adopted Accounting Standards — In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
Recently Issued Accounting Standard Not Yet Adopted — In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 76 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Spin-Off of Organon & Co. (Tables)
12 Months Ended
Dec. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
Years Ended December 31
2021(1)
2020
Sales$2,512 $6,476 
Costs, Expenses and Other
Cost of sales789 1,867 
Selling, general and administrative877 1,513 
Research and development103 161 
Restructuring costs1 
Other (income) expense, net(15)
1,755 3,548 
Income from discontinued operations before taxes757 2,928 
Tax provision50 369 
Income from discontinued operations, net of taxes707 2,559 
Less: Income of discontinued operations attributable to noncontrolling interests3 11 
$704 $2,548 
(1) Reflects amounts through the June 2, 2021 spin-off date.
XML 77 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions, Research Collaborations and Licensing Agreements (Tables)
12 Months Ended
Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:
November 19, 2021
Cash and cash equivalents$340 
Investments285 
Identifiable intangible assets: (1)
IPR&D - sotatercept 6,380 
Products and product rights - Reblozyl (12 year useful life)
3,830 
Deferred income tax liabilities, net(1,814)
Other assets and liabilities, net82 
Total identifiable net assets9,103 
Goodwill (2)
2,411 
Consideration transferred$11,514 
(1)    The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
January 16, 2020
Cash and cash equivalents$145 
IPR&D - nemtabrutinib (1)
2,280
Licensing arrangement for derazantinib80
Deferred income tax liabilities(361)
Other assets and liabilities, net34
Total identifiable net assets2,178 
Goodwill (2)
512 
Consideration transferred$2,690 
(1)    The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
XML 78 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Arrangements (Tables)
12 Months Ended
Dec. 31, 2022
Collaborative Arrangements [Abstract]  
Collaborative Arrangements
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lynparza$1,116 $989 $725 
Alliance revenue - Koselugo54 29 
Total alliance revenue$1,170 $1,018 $733 
Cost of sales (1)
492 167 247 
Selling, general and administrative185 178 160 
Research and development106 120 133 
December 3120222021
Receivables from AstraZeneca included in Other current assets
$303 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
123 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1)    Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.
(2)    Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Lenvima$876 $704 $580 
Cost of sales (1)
212 195 271 
Selling, general and administrative158 127 73 
Research and development136 173 185 
December 3120222021
Receivables from Eisai included in Other current assets
$214 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
 625 
(1)     Represents amortization of capitalized milestone payments.
(2)     Represents accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Alliance revenue - Adempas/Verquvo$341 $342 $281 
Net sales of Adempas recorded by Merck238 252 220 
Net sales of Verquvo recorded by Merck22 — 
Total sales$601 $601 $501 
Cost of sales (1)
210 424 196 
Selling, general and administrative153 126 47 
Research and development75 53 63 
December 3120222021
Receivables from Bayer included in Other current assets
$143 $114 
Payables to Bayer included in Accrued and other current Liabilities (2)
80 472 
(1)    Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense.
(2)    Amount as of December 31, 2021 includes accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Years Ended December 31202220212020
Net sales of Lagevrio
$5,684 $952 $— 
Cost of sales (1)(2)
3,038 502 17 
Selling, general and administrative (2)
147 37 
Research and development (2)(3)
88 137 349 
December 3120222021
Payables to Ridgeback included in Accrued and other current liabilities (4)
$348 $283 
(1)    Includes royalty expense and amortization of capitalized milestone payments.
(2)    Expenses in all periods now include an allocation for overhead charges.
(3)    Amount in 2020 includes upfront payment.
(4)    Includes accrued royalty and milestone payments.
XML 79 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring (Tables)
12 Months Ended
Dec. 31, 2022
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following table summarizes the charges related to restructuring program activities by type of cost:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Year Ended December 31, 2022
Cost of sales$ $72 $133 $205 
Selling, general and administrative 19 75 94 
Research and development 29 1 30 
Restructuring costs212  125 337 
 $212 $120 $334 $666 
Year Ended December 31, 2021    
Cost of sales$— $52 $108 $160 
Selling, general and administrative— 12 19 
Research and development— 27 28 
Restructuring costs451 — 210 661 
 $451 $91 $326 $868 
Year Ended December 31, 2020    
Cost of sales$— $143 $32 $175 
Selling, general and administrative— 44 47 
Research and development— 81 83 
Restructuring costs385 — 190 575 
 $385 $268 $227 $880 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities:
Separation
Costs
Accelerated
Depreciation
OtherTotal
Restructuring reserves January 1, 2021
$567 $— $19 $586 
Expenses451 91 326 868 
(Payments) receipts, net(422)— (186)(608)
Non-cash activity— (91)(118)(209)
Restructuring reserves December 31, 2021
596 — 41 637 
Expenses212 120 334 666 
(Payments) receipts, net(329) (120)(449)
Non-cash activity (120)(221)(341)
Restructuring reserves December 31, 2022 (1)
$479 $ $34 $513 
(1)    The remaining cash outlays are expected to be largely completed by the end of 2025.
XML 80 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments (Tables)
12 Months Ended
Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Years Ended December 31202220212020202220212020
Net Investment Hedging Relationships
Foreign exchange contracts$(48)$(49)$26 $(1)$(13)$(19)
Euro-denominated notes(162)(296)385  — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position
The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount
2022202120222021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$ $2,263 $ $13 
Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:
  20222021
  Fair Value of
Derivative
U.S. Dollar
Notional
Fair Value of
Derivative
U.S. Dollar
Notional
 AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption      
Interest rate swap contractsOther current assets$ $ $ $14 $— $2,250 
Foreign exchange contractsOther current assets220  4,824 271 — 6,778 
Foreign exchange contractsOther Assets27  1,609 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities 101 2,691 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities 1 91 — 43 
  $247 $102 $9,215 $328 $25 $12,245 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption      
Foreign exchange contractsOther current assets$186 $ $8,540 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities 307 10,926 — 96 10,640 
  $186 $307 $19,466 $221 $96 $20,713 
  $433 $409 $28,681 $549 $121 $32,958 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:
20222021
AssetLiabilityAssetLiability
Gross amounts recognized in the consolidated balance sheet$433 $409 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet(220)(220)(110)(110)
Cash collateral received/posted(66)(19)(164)— 
Net amounts$147 $170 $275 $11 
Location and Pretax Gain or Loss Amounts for Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Years Ended December 31202220212020202220212020202220212020
Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)
$59,283 $48,704 $41,518 $1,501 (1,341)(890)$(339)$1,756 $(441)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items — — (13)(40)40  — — 
Derivatives designated as hedging instruments — — 4 (76) — — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of gain (loss) recognized in OCI on derivatives
 — —  — — 684 333 (383)
Increase (decrease) in Sales as a result of AOCL reclassifications
773 (194)(6) — — (773)194 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
 — — (2)(2)(4) — — 
Amount of loss recognized in OCI on derivatives
 — —  — — (2)(2)(4)
(1)    Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Years Ended December 31202220212020
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(49)$313 $(12)
Foreign exchange contracts (2)
Sales(37)13 
Interest rate contracts (3)
Other (income) expense, net — 
Forward contract related to Seagen common stockResearch and development — 15 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2)     These derivative contracts serve as economic hedges of forecasted transactions.
(3)     These derivative contracts serve as economic hedges against rising treasury rates.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities at December 31 is as follows:
 
 20222021
 Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
  GainsLossesGainsLosses
Commercial paper$498 $ $ $498 $— $— $— $— 
U.S. government and agency securities68   68 80— — 80 
Corporate notes and bonds3   3 — — 
Foreign government bonds    — — 
Total debt securities569   569 86 — — 86 
Publicly traded equity securities (1)
1,284 1,647 
Total debt and publicly traded equity securities$1,853 $1,733 
(1)    Unrealized net losses of $462 million were recorded in Other (income) expense, net in 2022 on equity securities still held at December 31, 2022. Unrealized net losses of $232 million were recorded in Other (income) expense, net in 2021 on equity securities still held at December 31, 2021.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
  20222021
Assets
Investments
Commercial paper$ $498 $ $498 $— $— $— $— 
Foreign government bonds    — — 
Publicly traded equity securities1,015   1,015 368 — — 368 
 1,015 498  1,513 368 — 370 
Other assets (1)
U.S. government and agency securities68   68 80 — — 80 
Corporate notes and bonds3   3 — — 
Publicly traded equity securities269   269 1,279 — — 1,279 
340   340 1,363 — — 1,363 
Derivative assets (2)
Forward exchange contracts 218  218 — 351 — 351 
Purchased currency options 215  215 — 184 — 184 
Interest rate swaps    — 14 — 14 
  433  433 — 549 — 549 
Total assets$1,355 $931 $ $2,286 $1,731 $551 $— $2,282 
Liabilities
Other liabilities
Contingent consideration$ $ $456 $456 $— $— $777 $777 
Derivative liabilities (2)
Forward exchange contracts 402  402 — 120 — 120 
Written currency options 7  7 — — 
 409  409 — 121 — 121 
Total liabilities$ $409 $456 $865 $— $121 $777 $898 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Summarized Information about the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(146)57 
Payments(119)(109)
Other(56)(12)
Fair value December 31 (2)
$456 $777 
(1)    Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2)    At December 31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December 31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.
XML 81 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Inventories (Tables)
12 Months Ended
Dec. 31, 2022
Inventory Disclosure [Abstract]  
Inventories
Inventories at December 31 consisted of:
20222021
Finished goods$1,841 $1,747 
Raw materials and work in process7,063 6,220 
Supplies238 196 
Total (approximates current cost)9,142 8,163 
Decrease to LIFO cost(293)(16)
 $8,849 $8,147 
Recognized as:
Inventories$5,911 $5,953 
Other Assets2,938 2,194 
XML 82 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangibles (Tables)
12 Months Ended
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill Activity by Segment
The following table summarizes goodwill activity by segment:
PharmaceuticalAnimal HealthTotal
Balance January 1, 2021
$15,614 $3,268 $18,882 
Acquisitions2,431 2,436 
Other (1)
(48)(6)(54)
Balance December 31, 2021 (2)
17,997 3,267 21,264 
Other (1)
(61)1 (60)
Balance December 31, 2022 (2)
$17,936 $3,268 $21,204 
(1)    Includes cumulative translation adjustments on goodwill balances.
(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2022 and 2021.
Other Intangibles
Other acquired intangibles at December 31 consisted of:
 20222021
  Gross
Carrying
Amount
Accumulated
Amortization
NetGross
Carrying
Amount
Accumulated
Amortization
Net
Products and product rights$23,555 $16,745 $6,810 $23,671 $15,776 $7,895 
IPR&D7,661  7,661 9,281 — 9,281 
Trade names2,879 635 2,244 2,882 493 2,389 
Licenses and other7,651 4,097 3,554 6,604 3,236 3,368 
 $41,746 $21,477 $20,269 $42,438 $19,505 $22,933 
XML 83 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases (Tables)
12 Months Ended
Dec. 31, 2022
Debt Disclosure [Abstract]  
Schedule of Long-term Debt Instruments
Long-term debt at December 31 consisted of:
20222021
2.75% notes due 2025
$2,496 $2,495 
2.15% notes due 2031
1,986 1,986 
2.75% notes due 2051
1,979 1,979 
3.70% notes due 2045
1,978 1,977 
3.40% notes due 2029
1,738 1,736 
1.70% notes due 2027
1,494 1,493 
2.90% notes due 2061
1,483 1,484 
4.00% notes due 2049
1,471 1,470 
4.15% notes due 2043
1,239 1,239 
1.45% notes due 2030
1,237 1,235 
2.45% notes due 2050
1,213 1,212 
1.875% euro-denominated notes due 2026
1,060 1,123 
0.75% notes due 2026
995 993 
1.90% notes due 2028
994 994 
3.90% notes due 2039
985 984 
2.35% notes due 2040
984 983 
2.90% notes due 2024
749 748 
6.50% notes due 2033
711 715 
0.50% euro-denominated notes due 2024
531 563 
1.375% euro-denominated notes due 2036
527 559 
2.50% euro-denominated notes due 2034
526 558 
3.60% notes due 2042
492 491 
6.55% notes due 2037
408 409 
5.75% notes due 2036
339 338 
5.95% debentures due 2028
307 306 
5.85% notes due 2039
271 271 
6.40% debentures due 2028
250 250 
6.30% debentures due 2026
135 135 
2.80% notes due 2023
 1,749 
Other167 215 
 $28,745 $30,690 
Supplemental Balance Sheet Information
Supplemental balance sheet information related to operating leases is as follows:
December 3120222021
Assets
Other Assets (1)
$1,346 $1,586 
Liabilities
Accrued and other current liabilities281 304 
Other Noncurrent Liabilities1,013 1,225 
$1,294 $1,529 
Weighted-average remaining lease term (years)7.07.0
Weighted-average discount rate3.1 %2.6 %
(1)    Includes prepaid leases that have no related lease liability.
Schedule of Maturities of Operating Lease Liabilities
Maturities of operating leases liabilities are as follows:
2023$323 
2024258 
2025224 
2026157 
2027126 
Thereafter404 
Total lease payments1,492 
Less: Imputed interest198 
$1,294 
XML 84 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Equity (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Summary of Common Stock and Treasury Stock Transactions
A summary of common stock and treasury stock transactions (shares in millions) is as follows:
 202220212020
  Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Common
Stock
Treasury
Stock
Balance January 13,577 1,049 3,577 1,047 3,577 1,038 
Purchases of treasury stock  — 11 — 16 
Issuances (1)
 (10)— (9)— (7)
Balance December 313,577 1,039 3,577 1,049 3,577 1,047 
(1)     Issuances primarily reflect activity under share-based compensation plans.
XML 85 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans (Tables)
12 Months Ended
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Assumptions Used to Determine Weighted-Average Fair Value of Options Granted The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:
Years Ended December 31202220212020
Expected dividend yield3.1 %3.1 %3.1 %
Risk-free interest rate3.0 %1.0 %0.4 %
Expected volatility22.5 %20.9 %22.1 %
Expected life (years)5.95.95.8
Summarized Information Relative to Stock Option Plan Activity
Summarized information relative to stock option plan activity (options in thousands) is as follows:
Number
of Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term (Years)
Aggregate
Intrinsic
Value
Outstanding January 1, 2022
18,572 $65.27 
Granted2,326 87.10 
Exercised(6,317)60.77 
Forfeited(862)73.11   
Outstanding December 31, 202213,719 $70.55 6.5$554 
Vested and expected to vest December 31, 202213,199 $70.09 6.4$539 
Exercisable December 31, 20228,730 $65.24 5.4$399 
Additional Information Pertaining to Stock Option Plans
Additional information pertaining to stock option plans is provided in the table below:
Years Ended December 31202220212020
Total intrinsic value of stock options exercised$225 $106 $51 
Fair value of stock options vested30 27 25 
Cash received from the exercise of stock options384 202 89 
Summary of Nonvested RSU and PSU Activity
A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:
 RSUsPSUs
  Number
of Shares
Weighted
Average
Grant Date
Fair Value
Number
of Shares
Weighted
Average
Grant Date
Fair Value
Nonvested January 1, 2022
11,790 $74.88 1,966 $77.13 
Granted7,170 87.12 951 88.52 
Vested(5,150)75.40 (725)87.87 
Forfeited(1,110)78.65 (171)77.58 
Nonvested December 31, 202212,700 $81.25 2,021 $78.60 
Expected to vest December 31, 202211,254 $80.96 1,895 $78.26 
XML 86 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans (Tables)
12 Months Ended
Dec. 31, 2022
Retirement Benefits [Abstract]  
Components of Net Periodic Benefit Cost
The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:
Pension Benefits
U.S.InternationalOther Postretirement Benefits
Years Ended December 31202220212020202220212020202220212020
Service cost$372 $403 $360 $283 $328 $297 $48 $48 $52 
Interest cost457 404 431 145 123 136 46 45 57 
Expected return on plan assets(753)(755)(774)(383)(416)(414)(86)(79)(75)
Amortization of unrecognized prior service cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Net loss (gain) amortization128 298 303 96 142 127 (43)(42)(18)
Termination benefits2 56 10 1  37 
Curtailments12 16 10  (26)— (1)(29)(4)
Settlements239 216 13 1 15  — — 
Net periodic benefit cost (credit)$425 $600 $304 $129 $148 $146 $(93)$(83)$(59)
Obligation and Funded Status
Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:
Pension BenefitsOther
Postretirement
Benefits
U.S.International
  202220212022202120222021
Fair value of plan assets January 1$13,067 $12,672 $12,195 $12,009 $1,292 $1,221 
Actual return on plan assets(3,129)1,250 (2,793)891 (306)118 
Company contributions293 305 155 189 46 33 
Effects of exchange rate changes — (848)(671) — 
Benefits paid(219)(219)(250)(233)(90)(86)
Settlements(918)(941)(16)(55) — 
Spin-off of Organon —  (55) — 
Other — 30 120 5 
Fair value of plan assets December 31$9,094 $13,067 $8,473 $12,195 $947 $1,292 
Benefit obligation January 1$13,999 $14,613 $11,575 $12,458 $1,541 $1,607 
Service cost372 403 283 328 48 48 
Interest cost457 404 145 123 46 45 
Actuarial (gains) losses (1)
(3,851)(332)(3,283)(240)(392)(103)
Benefits paid(219)(219)(250)(233)(90)(86)
Effects of exchange rate changes — (732)(678)(1)(1)
Plan amendments — 4  — 
Curtailments12 15  (38) (12)
Termination benefits2 56 1  37 
Settlements(918)(941)(16)(55) — 
Spin-off of Organon —  (118) — 
Other — 28 19 5 
Benefit obligation December 31$9,854 $13,999 $7,755 $11,575 $1,157 $1,541 
Funded status December 31$(760)$(932)$718 $620 $(210)$(249)
Recognized as:
Other Assets$5 $$1,052 $1,395 $ $— 
Accrued and other current liabilities(59)(64)(19)(22)(8)(8)
Other Noncurrent Liabilities(706)(877)(315)(753)(202)(241)
(1)    Actuarial (gains) losses primarily reflect changes in discount rates.
Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets
Information related to the funded status of selected pension plans at December 31 is as follows:
U.S.International
2022202120222021
Pension plans with a projected benefit obligation in excess of plan assets
Projected benefit obligation$9,186 $13,013 $2,779 $2,507 
Fair value of plan assets8,421 12,072 2,445 1,731 
Pension plans with an accumulated benefit obligation in excess of plan assets
Accumulated benefit obligation$9,081 $12,916 $1,226 $2,462 
Fair value of plan assets8,421 12,072 948 1,723 
Schedule of Allocation of Plan Assets
The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
20222021
U.S. Pension Plans
Cash and cash equivalents$49 $ $ $98 $147 $$— $— $289 $292 
Investment funds
Developed markets equities211   2,443 2,654 236 — — 3,799 4,035 
Emerging markets equities   707 707 — — — 919 919 
Real estate   131 131 — — — — — 
Equity securities
Developed markets1,956    1,956 2,915 — — — 2,915 
Fixed income securities
Government and agency obligations 1,934   1,934 — 2,870 — — 2,870 
Corporate obligations 1,438   1,438 — 2,005 — — 2,005 
Mortgage and asset-backed securities 22   22 — 23 — — 23 
Other investments
Derivatives 101   101 — — — — — 
Other  4  4 — — 
Plan assets at fair value$2,216 $3,495 $4 $3,379 $9,094 $3,156 $4,898 $$5,007 $13,067 
International Pension Plans
Cash and cash equivalents$57 $8 $ $13 $78 $82 $10 $— $18 $110 
Investment funds
Developed markets equities375 2,957  90 3,422 531 4,292 — 121 4,944 
Government and agency obligations177 2,656  130 2,963 240 4,025 — 171 4,436 
Emerging markets equities52   59 111 137 — — 72 209 
Corporate obligations8 9  129 146 — 171 188 
Other fixed income obligations10 7  4 21 15 — 26 
Real estate 1  10 11 — — 16 17 
Equity securities
Developed markets263    263 369 — — — 369 
Fixed income securities
Government and agency obligations 448   448 591 — 597 
Corporate obligations 157   157 — 223 — 225 
Mortgage and asset-backed securities 69   69 — 90 — — 90 
Other investments
Insurance contracts (2)
 18 761 1 780 — 44 937 982 
Other1 3   4 — — 
Plan assets at fair value$943 $6,333 $761 $436 $8,473 $1,387 $9,293 $937 $578 $12,195 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
(2)    The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.
The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:
 Fair Value Measurements UsingFair Value Measurements Using
  Level 1Level 2Level 3
NAV (1)
TotalLevel 1Level 2Level 3
NAV (1)
Total
  2022  2021  
Cash and cash equivalents$2 $ $ $8 $10 $11 $— $— $28 $39 
Investment funds
Developed markets equities22   257 279 24 — — 378 402 
Emerging markets equities   74 74 — — — 92 92 
Real estate   14 14 — — — — — 
Government and agency obligations1    1 — — — 
Equity securities— 
Developed markets206    206 290 — — — 290 
Fixed income securities
Government and agency obligations 212   212 — 275 — — 275 
Corporate obligations 137   137 — 191 — — 191 
Mortgage and asset-backed securities 2   2 — — — 
Other Investments
Derivatives 12   12 — — — — — 
Plan assets at fair value$231 $363 $ $353 $947 $326 $468 $— $498 $1,292 
(1)    Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.
Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets
The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:
 20222021
  Insurance
Contracts
Real
Estate
OtherTotalInsurance
Contracts
Real
Estate
OtherTotal
U.S. Pension Plans
Balance January 1$ $ $6 $6 $— $— $$
Actual return on plan assets:
Relating to assets still held at December 31  (3)(3)— — (5)(5)
Relating to assets sold during the year  2 2 — — 
Purchases and sales, net  (1)(1)— — (3)(3)
Balance December 31$ $ $4 $4 $— $— $$
International Pension Plans
Balance January 1$937 $ $ $937 $935 $— $— $935 
Actual return on plan assets:
Relating to assets still held at December 31(147)  (147)(34)— — (34)
Purchases and sales, net(39) (39)(42)— — (42)
Transfers into Level 310  10 78 — — 78 
Balance December 31$761 $ $ $761 $937 $— $— $937 
Summary of Expected Benefit Payments
Expected benefit payments are as follows:
U.S. Pension BenefitsInternational Pension
Benefits
Other
Postretirement
Benefits
2023$627 $271 $84 
2024634 257 86 
2025650 262 87 
2026676 283 89 
2027694 297 90 
2028 — 20323,948 1,704 474 
Components of Other Comprehensive Income The following amounts were reflected as components of OCI:
 Pension PlansOther Postretirement
Benefit Plans
U.S.International
Years Ended December 31202220212020202220212020202220212020
Net (loss) gain arising during the period$(42)$813 $(472)$116 $772 $(424)$ $156 $199 
Prior service (cost) credit arising during the period — — (4)(4)64  — — 
 $(42)$813 $(472)$112 $768 $(360)$ $156 $199 
Net loss (gain) amortization included in benefit cost$128 $298 $303 $96 $142 $127 $(43)$(42)$(18)
Prior service credit amortization included in benefit cost(32)(38)(49)(14)(16)(18)(57)(63)(73)
Settlements and curtailments251 232 23 1 (18)15 (1)(29)(4)
 $347 $492 $277 $83 $108 $124 $(101)$(134)$(95)
Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information
The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:
 U.S. Pension and Other
Postretirement Benefit Plans
International Pension Plans
December 31202220212020202220212020
Net periodic benefit cost      
Discount rate3.00 %2.70 %3.40 %1.50 %1.10 %1.50 %
Expected rate of return on plan assets6.70 %6.70 %7.30 %3.70 %3.80 %4.40 %
Salary growth rate4.60 %4.60 %4.20 %2.90 %2.80 %2.80 %
Interest crediting rate5.00 %4.70 %4.90 %3.00 %3.00 %2.80 %
Benefit obligation      
Discount rate5.50 %3.00 %2.70 %3.90 %1.50 %1.10 %
Salary growth rate4.60 %4.60 %4.60 %3.20 %2.90 %2.80 %
Interest crediting rate5.30 %5.00 %4.70 %3.30 %3.00 %3.00 %
Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans
The health care cost trend rate assumptions for other postretirement benefit plans are as follows:
December 3120222021
Health care cost trend rate assumed for next year7.8 %6.4 %
Rate to which the cost trend rate is assumed to decline4.5 %4.5 %
Year that the trend rate reaches the ultimate trend rate20382032
XML 87 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Other (Income) Expense, Net (Tables)
12 Months Ended
Dec. 31, 2022
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of:
Years Ended December 31202220212020
Interest income$(157)$(36)$(59)
Interest expense962 806 831 
Exchange losses237 297 145 
Loss (income) from investments in equity securities, net (1)
1,419 (1,940)(1,338)
Net periodic defined benefit plan (credit) cost other than service cost(279)(212)(339)
Other, net(681)(256)(130)
 $1,501 $(1,341)$(890)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140 million will be recorded in the first quarter of 2023 from ownership interests in investment funds.
XML 88 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income (Tables)
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
Reconciliation Between Effective Tax Rate and U.S. Statutory Rate
A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:
 202220212020
  AmountTax RateAmountTax RateAmountTax Rate
U.S. statutory rate applied to income from continuing operations before taxes$3,453 21.0 %$2,915 21.0 %$1,231 21.0 %
Differential arising from:
Foreign earnings(1,835)(11.1)(1,446)(10.4)(965)(16.5)
GILTI and the foreign-derived intangible income deduction462 2.8 (75)(0.5)349 6.0 
State taxes(110)(0.7)— 57 1.0 
R&D tax credit(81)(0.5)(81)(0.6)(108)(1.8)
Tax settlements(10)(0.1)(275)(2.0)(13)(0.2)
Valuation allowances108 0.7 102 0.7 37 0.6 
Restructuring11 0.1 61 0.4 105 1.8 
Acquisition of VelosBio  (9)(0.1)559 9.5 
Acquisition of Pandion  356 2.6 — — 
Acquisition of OncoImmune  — — 97 1.7 
Other(80)(0.5)(29)(0.1)(9)(0.2)
 $1,918 11.7 %$1,521 11.0 %$1,340 22.9 %
Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above.
Income Before Taxes
Income from continuing operations before taxes consisted of:
Years Ended December 31202220212020
Domestic$1,011 $1,854 $(3,814)
Foreign15,433 12,025 9,677 
 $16,444 $13,879 $5,863 
Taxes on Income
Taxes on income from continuing operations consisted of:
Years Ended December 31202220212020
Current provision
Federal$2,265 $74 $893 
Foreign1,164 1,273 969 
State57 (13)44 
 3,486 1,334 1,906 
Deferred provision
Federal(1,510)240 (605)
Foreign71 (77)64 
State(129)24 (25)
 (1,568)187 (566)
 $1,918 $1,521 $1,340 
Deferred Income Taxes
Deferred income taxes at December 31 consisted of:
 20222021
  AssetsLiabilitiesAssetsLiabilities
Product intangibles and licenses$ $2,575 $— $3,207 
R&D capitalization1,341  274 — 
Inventory related43 423 119 370 
Accelerated depreciation 657 — 589 
Equity investments 92 — 335 
Pensions and other postretirement benefits372 284 487 338 
Compensation related335  301 — 
Unrecognized tax benefits91  75 — 
Net operating losses and other tax credit carryforwards912  867 — 
Other511 267 434 180 
Subtotal3,605 4,298 2,557 5,019 
Valuation allowance(599) (287) 
Total deferred taxes$3,006 $4,298 $2,270 $5,019 
Net deferred income taxes $1,292  $2,749 
Recognized as:
Other Assets$503 $692 
Deferred Income Taxes $1,795  $3,441 
Income Taxes Paid Income taxes paid consisted of:
Years Ended December 31202220212020
Domestic (1)
$1,891 $1,211 $977 
Foreign1,348 1,201 1,763 
 $3,239 $2,412 $2,740 
(1)    Includes TCJA transition tax payments.
Unrecognized Tax Benefits
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
202220212020
Balance January 1$1,529 $1,537 $1,225 
Additions related to current year positions344 306 298 
Additions related to prior year positions48 63 110 
Reductions for tax positions of prior years (1)
(40)(230)(4)
Settlements (1)
(6)(46)(70)
Lapse of statute of limitations(40)(58)(22)
Spin-off of Organon (43)— 
Balance December 31$1,835 $1,529 $1,537 
(1)    Amount in 2021 reflects a settlement with the IRS discussed below.
XML 89 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings per Share (Tables)
12 Months Ended
Dec. 31, 2022
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share (shares in millions) are as follows:
Years Ended December 31202220212020
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$14,519 $12,345 $4,519 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 704 2,548 
Net Income Attributable to Merck & Co., Inc.$14,519 $13,049 $7,067 
Average common shares outstanding2,532 2,530 2,530 
Common shares issuable (1)
10 11 
Average common shares outstanding assuming dilution2,542 2,538 2,541 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.73 $4.88 $1.79 
Income from Discontinued Operations 0.28 1.01 
Net Income$5.73 $5.16 $2.79 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$5.71 $4.86 $1.78 
Income from Discontinued Operations 0.28 1.00 
Net Income$5.71 $5.14 $2.78 
(1)     Issuable primarily under share-based compensation plans.
XML 90 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Other Comprehensive Income (Loss) (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
DerivativesInvestmentsEmployee
Benefit
Plans
 Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive Loss
Balance January 1, 2020, net of taxes
$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(383)(633)64 (949)
Tax84 — 120 89 293 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(299)(513)153 (656)
Reclassification adjustments, pretax
(1)
(21)
(2)
306 
(3)
— 287 
Tax— — (72)— (72)
Reclassification adjustments, net of taxes(21)234 — 215 
Other comprehensive income (loss), net of taxes(297)(18)(279)153 (441)
Balance at December 31, 2020, net of taxes(266)— (4,540)(1,828)(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax333 — 1,737 (304)1,766 
Tax(75)— (332)(119)(526)
Other comprehensive income (loss) before reclassification adjustments, net of taxes258 — 1,405 (423)1,240 
Reclassification adjustments, pretax192 
(1)
— 466 
(3)
— 658 
Tax(40)— (102)— (142)
Reclassification adjustments, net of taxes152 — 364 — 516 
Other comprehensive income (loss), net of taxes410 — 1,769 (423)1,756 
Spin-off of Organon (see Note 3)
— — 28 421 449 
Balance at December 31, 2021, net of taxes144 — (2,743)
(4)
(1,830)(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax684  70 (584)170 
Tax(143) 12 (19)(150)
Other comprehensive income (loss) before reclassification adjustments, net of taxes541  82 (603)20 
Reclassification adjustments, pretax(775)
(1)
 329 
(3)
 (446)
Tax163  (76) 87 
Reclassification adjustments, net of taxes(612) 253  (359)
Other comprehensive income (loss), net of taxes(71) 335 (603)(339)
Balance at December 31, 2022, net of taxes$73 $ $(2,408)
(4)
$(2,433)$(4,768)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from AOCL to Other (income) expense, net.
(3)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 14).
(4)    Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.
XML 91 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Sales of Company's Products
Sales of the Company’s products were as follows:
Years Ended December 31202220212020
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$12,686 $8,251 $20,937 $9,765 $7,421 $17,186 $8,352 $6,028 $14,380 
Alliance revenue - Lynparza (1)
584 532 1,116 515 473 989 417 308 725 
Alliance revenue - Lenvima (1)
579 297 876 417 287 704 359 220 580 
Alliance revenue - Reblozyl (2)
123 43 166 — 17 17 — — — 
Vaccines
Gardasil/Gardasil 9
2,065 4,832 6,897 1,881 3,792 5,673 1,755 2,184 3,938 
ProQuad/M-M-R II/Varivax1,724 518 2,241 1,629 506 2,135 1,378 500 1,878 
RotaTeq508 275 783 473 334 807 486 311 797 
Pneumovax 23
346 256 602 547 346 893 727 359 1,087 
Vaqta95 78 173 100 79 179 103 67 170 
Hospital Acute Care
Bridion922 762 1,685 762 770 1,532 583 615 1,198 
Prevymis188 240 428 153 218 370 119 162 281 
Dificid241 22 263 166 10 175 102 110 
Primaxin1 238 239 258 259 248 251 
Noxafil51 187 238 60 199 259 42 287 329 
Invanz4 185 189 (5)207 202 202 211 
Cancidas6 168 174 208 212 207 213 
Zerbaxa89 79 169 (5)(1)74 56 130 
Cardiovascular
Alliance revenue - Adempas/Verquvo (3)
329 12 341 312 30 342 259 22 281 
Adempas 238 238 — 252 252 — 220 220 
Virology
Lagevrio1,523 4,161 5,684 632 320 952 — — — 
Isentress/Isentress HD274 359 633 294 474 769 326 531 857 
Neuroscience
Belsomra79 179 258 78 241 318 81 247 327 
Immunology
Simponi 706 706 — 825 825 — 838 838 
Remicade 207 207 — 299 299 — 330 330 
Diabetes
Januvia1,248 1,565 2,813 1,404 1,920 3,324 1,470 1,836 3,306 
Janumet355 1,344 1,700 367 1,597 1,964 477 1,494 1,971 
Other pharmaceutical (4)
969 1,282 2,249 841 1,275 2,118 882 1,321 2,202 
Total Pharmaceutical segment sales24,989 27,016 52,005 20,401 22,353 42,754 18,010 18,600 36,610 
Animal Health:
Livestock710 2,590 3,300 667 2,628 3,295 612 2,327 2,939 
Companion Animals1,112 1,138 2,250 1,091 1,182 2,273 872 892 1,764 
Total Animal Health segment sales1,822 3,728 5,550 1,758 3,810 5,568 1,484 3,219 4,703 
Other segment sales (5)
   — — — 23 — 23 
Total segment sales26,811 30,744 57,555 22,159 26,163 48,322 19,517 21,819 41,336 
Other (6)
395 1,333 1,728 266 116 382 71 111 182 
 $27,206 $32,077 $59,283 $22,425 $26,279 $48,704 $19,588 $21,930 $41,518 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020.
(6)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Revenues by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202220212020
United States$27,206 $22,425 $19,588 
Europe, Middle East and Africa14,493 13,341 11,547 
China5,191 4,378 2,751 
Japan3,629 2,726 2,602 
Asia Pacific (other than China and Japan)3,614 2,407 2,113 
Latin America2,582 2,206 1,890 
Other2,568 1,221 1,027 
 $59,283 $48,704 $41,518 
Reconciliation of Segment Profits to Income Before Taxes
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
Years Ended December 31202220212020
Segment profits:
Pharmaceutical segment$36,852 $30,977 $26,106 
Animal Health segment1,963 1,950 1,669 
Other segments — 
Total segment profits38,815 32,927 27,776 
Other profits1,160 156 75 
Unallocated:
Interest income157 36 59 
Interest expense(962)(806)(831)
Amortization(2,085)(1,636)(1,817)
Depreciation(1,642)(1,414)(1,519)
Research and development(13,011)(11,692)(12,911)
Restructuring costs(337)(661)(575)
Other unallocated, net(5,651)(3,031)(4,394)
$16,444 $13,879 $5,863 
Equity Loss from Affiliates and Depreciation Included in Segment Profits
Equity income/loss from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthAll OtherTotal
Year Ended December 31, 2022      
Included in segment profits:
Equity income from affiliates$39 $ $ $39 
Depreciation5 177  182 
Year Ended December 31, 2021      
Included in segment profits:
Equity income from affiliates$11 $— $— $11 
Depreciation158 — 164 
Year Ended December 31, 2020      
Included in segment profits:
Equity loss from affiliates$$— $— $
Depreciation143 150 
Property, Plant and Equipment, Net by Geographic Area
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202220212020
United States$12,891 $11,759 $10,394 
Europe, Middle East and Africa6,993 6,081 5,314 
Asia Pacific (other than China and Japan)966 857 737 
Latin America225 199 169 
China207 220 216 
Japan135 159 166 
Other5 
 $21,422 $19,279 $17,000 
XML 92 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Nature of Operations (Details)
12 Months Ended
Dec. 31, 2022
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 2
XML 93 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Summary of Accounting Policies (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Summary Of Significant Accounting Policies [Line Items]      
Customer discounts $ 12,300 $ 12,300 $ 11,400
Accrual for chargebacks reflected as direct reduction to accounts receivable 178 207  
Accrual for rebates included in accrued and other current liabilities $ 2,700 2,600  
Product return period and expiration 12 months    
Depreciation $ 1,824 1,578 1,669
Advertising and promotion costs $ 2,200 $ 2,000 $ 1,800
Minimum      
Summary Of Significant Accounting Policies [Line Items]      
Product return period 3 months    
Estimated useful life of intangible assets 2 years    
Minimum | Capitalized Software      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of intangible assets 3 years    
Minimum | Buildings      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of property, plant and equipment 25 years    
Minimum | Machinery, equipment and office furnishings      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of property, plant and equipment 3 years    
Minimum | United States | Pharmaceutical segment      
Summary Of Significant Accounting Policies [Line Items]      
Payment terms 36 days    
Minimum | United States | Animal Health      
Summary Of Significant Accounting Policies [Line Items]      
Payment terms 30 days    
Minimum | Outside of the United States      
Summary Of Significant Accounting Policies [Line Items]      
Payment terms 30 days    
Maximum      
Summary Of Significant Accounting Policies [Line Items]      
Product return period 6 months    
Estimated useful life of intangible assets 24 years    
Maximum | Capitalized Software      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of intangible assets 10 years    
Maximum | Buildings      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of property, plant and equipment 40 years    
Maximum | Machinery, equipment and office furnishings      
Summary Of Significant Accounting Policies [Line Items]      
Estimated useful life of property, plant and equipment 15 years    
Maximum | United States      
Summary Of Significant Accounting Policies [Line Items]      
Payment terms 90 days    
Maximum | Outside of the United States      
Summary Of Significant Accounting Policies [Line Items]      
Payment terms 90 days    
XML 94 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Spin-Off of Organon & Co. - Narrative (Details)
$ in Millions
12 Months Ended
Jun. 02, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Consideration received $ 9,000      
Disposal group, other expense     $ 556 $ 743
Organon & Co.        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Stock conversion ratio 0.1      
Revenue from related party   $ 383 219  
Related party amount in cost of sales   404 195  
Due from related parties, current   511 964  
Due to related parties, current   $ 345 $ 400  
Minimum | Transition services agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 25 months      
Minimum | Manufacturing and supply agreements        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 4 years      
Maximum | Transition services agreement        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 35 months      
Maximum | Manufacturing and supply agreements        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Period of continuing involvement after disposal 10 years      
Organon & Co.        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Face amount of debt $ 9,500      
XML 95 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]      
Sales   $ 2,512 $ 6,476
Costs, Expenses and Other      
Cost of sales   789 1,867
Selling, general and administrative   877 1,513
Research and development   103 161
Restructuring costs   1 3
Other (income) expense, net   (15) 4
Operating expenses   1,755 3,548
Income from discontinued operations before taxes   757 2,928
Tax provision   50 369
Income from discontinued operations, net of taxes   707 2,559
Less: Income of discontinued operations attributable to noncontrolling interests   3 11
Income from discontinued operations, net of taxes attributable to parent $ 0 $ 704 $ 2,548
XML 96 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)
$ / shares in Units, € in Millions, shares in Millions, $ in Millions
1 Months Ended 3 Months Ended 8 Months Ended 12 Months Ended
Feb. 24, 2023
USD ($)
Jan. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Aug. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 30, 2021
USD ($)
Apr. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Jan. 31, 2021
USD ($)
research_program
collaboration_target
Dec. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
EUR (€)
Jul. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
May 31, 2020
USD ($)
Jan. 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Nov. 19, 2021
USD ($)
Jan. 16, 2020
USD ($)
Business Acquisition [Line Items]                                                    
Research and development                                           $ 13,548.0 $ 12,245.0 $ 13,397.0    
Payments to acquire productive assets                                           4,388.0 4,448.0 4,429.0    
Research and development expenses                                           0.0 0.0 2,660.0    
Inventories               $ 5,953.0                       $ 5,911.0 $ 5,911.0 5,911.0 5,953.0      
Contingent consideration               777.0         $ 841.0             456.0 456.0 456.0 777.0 841.0    
Goodwill               21,264.0         $ 18,882.0             21,204.0 21,204.0 21,204.0 21,264.0 $ 18,882.0    
IPR&D impairment charges                                           1,700.0        
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability                                           $ 146.0 (57.0)      
OncoImmune                                                    
Business Acquisition [Line Items]                                                    
Equity method, ownership percentage                         20.00%                     20.00%    
COVID-19                                                    
Business Acquisition [Line Items]                                                    
Research and development                                               $ 45.0    
Charges related to program discontinuation                                             207.0 305.0    
IPR&D impairment charges                                               90.0    
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability                                               45.0    
Inventory write-off related to contract termination                                               260.0    
Sentinel                                                    
Business Acquisition [Line Items]                                                    
Consideration paid                               $ 410.0                    
Inventories                               9.0                    
Sentinel | Products and product rights                                                    
Business Acquisition [Line Items]                                                    
Finite-lived intangible assets acquired                               $ 401.0                    
Imago BioSciences, Inc. | Subsequent Event                                                    
Business Acquisition [Line Items]                                                    
Research and development   $ 1,200.0                                                
Payments to acquire productive assets   1,350.0                                                
Transaction costs   60.0                                                
Net assets acquired   200.0                                                
Pandion Therapeutics                                                    
Business Acquisition [Line Items]                                                    
Research and development                                             1,700.0      
Transaction costs                   $ 147.0                                
Consideration paid                   1,900.0                                
Other net assets (liabilities)                   $ 156.0                                
OncoImmune                                                    
Business Acquisition [Line Items]                                                    
Payments to acquire investment                         $ 50.0                          
Consideration paid                         423.0                          
Other net assets (liabilities)                         (22.0)                     (22.0)    
Investments                         33.0                     33.0    
Premium on shares acquired                         17.0                          
Research and development expenses                                               462.0    
VelosBio                                                    
Business Acquisition [Line Items]                                                    
Research and development                                             43.0 2,700.0    
Consideration paid               47.0         2,800.0                          
Other net assets (liabilities)               $ 90.0         $ 180.0                   $ 90.0 180.0    
Dunboyne                                                    
Business Acquisition [Line Items]                                                    
Consideration paid                           $ 302.0 € 256                      
Other net assets (liabilities)                           13.0                        
Property, plant and equipment                           289.0                        
Research and development                                                    
Business Acquisition [Line Items]                                                    
Premium on shares acquired                                               16.0    
Acceleron Pharma Inc.                                                    
Business Acquisition [Line Items]                                                    
Cash paid for acquisition of business                 $ 11,500.0                                  
Transaction costs                 $ 280.0                                  
Estimated useful life of intangible assets, acquired                 12 years                                  
In-process research and development (IPR&D)                                                 $ 6,380.0  
Other net liabilities                                                 (82.0)  
Goodwill                                                 2,411.0  
Cash and cash equivalents                                                 $ 340.0  
Themis                                                    
Business Acquisition [Line Items]                                                    
Cash paid for acquisition of business                                 $ 366.0                  
Contingent consideration                                 85.0                  
In-process research and development (IPR&D)                                 113.0                  
Deferred tax assets                                 72.0                  
Other net liabilities                                 32.0                  
Goodwill                                 239.0                  
Cash and cash equivalents                                 $ 59.0                  
Themis | COVID-19                                                    
Business Acquisition [Line Items]                                                    
IPR&D impairment charges                                               90.0    
Business combination, contingent consideration arrangements, change in amount of contingent consideration liability                                               45.0    
ArQule                                                    
Business Acquisition [Line Items]                                                    
Cash paid for acquisition of business                                     $ 2,700.0              
Transaction costs                                     95.0              
In-process research and development (IPR&D)                                                   $ 2,280.0
Other net liabilities                                                   (34.0)
Goodwill                                                   512.0
Share-based compensation payments to settle equity awards attributable to precombination service                                     $ 138.0              
Cash and cash equivalents                                                   $ 145.0
Moderna | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments made to collaborative partner       $ 250.0                                            
Orna Therapeutics | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments made to collaborative partner         $ 150.0                                          
Payments to acquire investment                                       $ 100.0            
Orna Therapeutics | Licensing Agreements | Development Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement         440.0                                          
Orna Therapeutics | Licensing Agreements | Regulatory Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement         675.0                                          
Orna Therapeutics | Licensing Agreements | Sales-Based Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement         $ 2,400.0                                          
Orion Corporation | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments made to collaborative partner           $ 290.0                                        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Subsequent Event                                                    
Business Acquisition [Line Items]                                                    
Research and development $ 175.0                                                  
Eligible future contingent development-related payments (up to) 1,000.0                                                  
Regulatory milestones payments 2,800.0                                                  
Sales milestone payments $ 5,500.0                                                  
Preferred stock investment in counterparty   $ 100.0                                                
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments made to collaborative partner           35.0 $ 30.0                                      
Upfront and milestone payments to be made             30.0                                      
Milestone payment to be made to collaborative partner             25.0                                      
Research and development payments to be made to a collaborative partners             111.0                                      
Research and development payments made to a collaborative partner                                         $ 51.0          
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement           82.0 90.0                                      
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement           334.0                                        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement           $ 485.0 780.0                                      
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement             $ 290.0                                      
Bristol Myers Squibb | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                 22.00%                                  
Royalty rate, deduction, percentage                 50.00%                         50.00%        
Bristol Myers Squibb | Licensing Agreements | Minimum                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                 20.00%                         20.00%        
Bristol Myers Squibb | Licensing Agreements | Maximum                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                 24.00%                         24.00%        
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                                           $ 20.0        
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                                           $ 80.0        
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral and Injectable Formulations                                                    
Business Acquisition [Line Items]                                                    
Profit share by counterparty                     60.00%                              
Profit share                     40.00%                              
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Oral Formulation                                                    
Business Acquisition [Line Items]                                                    
Profit share by counterparty                     65.00%                              
Profit share                     35.00%                              
Sales threshold                     $ 2,000.0                              
Gilead Sciences | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Injectable Formulation                                                    
Business Acquisition [Line Items]                                                    
Profit share by counterparty                     65.00%                              
Profit share                     35.00%                              
Sales threshold                     $ 3,500.0                              
Artiva Biotherapeutics, Inc. | Licensing Agreements                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments to be made                       $ 15.0                            
Number of research programs | research_program                       3                            
Number of collaboration targets | collaboration_target                       3                            
Upfront and milestone payments                       $ 30.0                            
Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                       7.00%                            
Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                       14.00%                            
Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                       $ 217.5                            
Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                       570.0                            
Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                       $ 1,050.0                            
Seagen                                                    
Business Acquisition [Line Items]                                                    
Research and development                                               $ 616.0    
Contingent payments collaborative arrangement                           2,600.0                        
Payments to acquire investment                           1,000.0                        
Upfront and milestone payments                           $ 600.0                        
Forward contract indexed to issuer's equity, indexed shares (in shares) | shares                           5                        
Share price (in dollars per share) | $ / shares                           $ 200                        
Seagen | Tukysa                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments                           $ 210.0                        
Seagen | Minimum | Tukysa                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                           20.00% 20.00%                      
Seagen | Maximum | Tukysa                                                    
Business Acquisition [Line Items]                                                    
Royalty rate, percentage                           33.00% 33.00%                      
Seagen | Development Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                           $ 850.0                        
Seagen | Regulatory Milestones | Tukysa                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                           65.0                        
Seagen | Sales-Based Milestones                                                    
Business Acquisition [Line Items]                                                    
Contingent payments collaborative arrangement                           $ 1,750.0                        
Sentinel | Products and product rights                                                    
Business Acquisition [Line Items]                                                    
Estimated useful life of intangible assets, acquired                               15 years                    
IAVI                                                    
Business Acquisition [Line Items]                                                    
Upfront and milestone payments                                   $ 6.5                
Royalty Pharma                                                    
Business Acquisition [Line Items]                                                    
Compensation earned on arragement     $ 50.0                                              
Additional funding by others, percentage of development costs     50.00%                                              
Additional funding by others, development costs subject to funding     $ 375.0                                              
XML 97 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)
$ in Millions
1 Months Ended
Nov. 30, 2021
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nov. 19, 2021
USD ($)
Dec. 31, 2020
USD ($)
Jan. 16, 2020
USD ($)
Business Acquisition [Line Items]            
Goodwill   $ 21,204 $ 21,264   $ 18,882  
Acceleron Pharma Inc.            
Business Acquisition [Line Items]            
Cash and cash equivalents       $ 340    
Investments       285    
In-process research and development (IPR&D)       6,380    
Products and product rights - Reblozyl (12 year useful life)       3,830    
Estimated useful life of intangible assets, acquired 12 years          
Deferred income tax liabilities       (1,814)    
Other assets and liabilities, net       82    
Total identifiable net assets       9,103    
Goodwill       2,411    
Consideration transferred       $ 11,514    
Acceleron Pharma Inc. | Measurement Input, Discount Rate            
Business Acquisition [Line Items]            
Present value discount rate       0.075    
Discount rate       0.060    
ArQule            
Business Acquisition [Line Items]            
Cash and cash equivalents           $ 145
In-process research and development (IPR&D)           2,280
Identifiable intangible assets           80
Deferred income tax liabilities           (361)
Other assets and liabilities, net           34
Total identifiable net assets           2,178
Goodwill           512
Consideration transferred           $ 2,690
ArQule | Measurement Input, Discount Rate            
Business Acquisition [Line Items]            
Present value discount rate           0.125
XML 98 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 12 Months Ended
Nov. 30, 2021
Mar. 31, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Amortization     $ 2,085 $ 1,636 $ 1,817
Other intangibles, net     20,269 22,933  
Sales     59,283 48,704 41,518
Operating Segments          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales     57,555 48,322 41,336
Operating Segments | Pharmaceutical segment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales     52,005 42,754 36,610
License          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Other intangibles, net     3,554 3,368  
Lynparza          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Amortization     250   106
Lynparza | License          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Other intangibles, net     1,600    
Lenvima | Operating Segments | Pharmaceutical segment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales     876 704 580
Lenvima | License          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Other intangibles, net     814    
Adempas | Operating Segments | Pharmaceutical segment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales     238 252 220
Adempas | Licenses and other          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Intangible assets     633    
Verquvo | Licenses and other          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Intangible assets     57    
Reblozyl | Operating Segments | Pharmaceutical segment          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales     166 17 0
AstraZeneca | Lynparza | Sales-Based Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Probable contingent payments     600    
Liabilities     600    
Milestone payments made to collaborative partner     400   550
AstraZeneca | Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential future sales-based milestone payments     2,100    
Regulatory milestone payments accrued     105    
Potential future regulatory milestone payments     1,100    
AstraZeneca | Lynparza | Regulatory Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payments made to collaborative partner     250   160
Eisai          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
License option payment related to collaborative arrangement   $ 125      
Eisai | Lenvima | Sales-Based Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payments made to collaborative partner     600 200 500
Eisai | Lenvima | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Potential future sales-based milestone payments     2,600    
Eisai | Lenvima | Regulatory Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payments made to collaborative partner     50 $ 75 10
Bayer AG | Adempas | Sales-Based Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Milestone payments made to collaborative partner     $ 400   $ 375
Bristol Myers Squibb | Licensing Agreements          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty rate, percentage 22.00%        
Royalty rate, deduction, percentage 50.00%   50.00%    
Royalties     $ 146    
Bristol Myers Squibb | Licensing Agreements | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty rate, percentage 20.00%   20.00%    
Bristol Myers Squibb | Licensing Agreements | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Royalty rate, percentage 24.00%   24.00%    
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contingent payments collaborative arrangement     $ 20    
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Contingent payments collaborative arrangement     $ 80    
XML 99 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 59,283 $ 48,704 $ 41,518
Cost of sales 17,411 13,626 13,618
Selling, general and administrative 10,042 9,634 8,955
Research and development 13,548 12,245 13,397
Payables included in Accrued and other current liabilities 24,239 23,872  
Amortization 2,085 1,636 1,817
Amortization expense for intangible assets 2,100 1,600 1,800
Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Amortization 250   106
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 303 271  
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 214 200  
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables included in Other current assets 143 114  
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other current liabilities 123 415  
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other current liabilities 0 625  
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other current liabilities 80 472  
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Accrued and other current liabilities 348 283  
Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables included in Other Noncurrent Liabilities 600 0  
Total sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 1,170 1,018 733
Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 1,116 989 725
Total sales | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 54 29 8
Total sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 876 704 580
Total sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Alliance revenue - profit sharing 341 342 281
Sales 601 601 501
Total sales | Bayer AG | Collaborative Arrangement | Adempas      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 238 252 220
Total sales | Bayer AG | Collaborative Arrangement | Verquvo      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales by Merck 22 7 0
Total sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 5,684 952 0
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 492 167 247
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 212 195 271
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 210 424 196
Amortization expense for intangible assets   153  
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 3,038 502 17
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 185 178 160
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 158 127 73
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 153 126 47
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 147 37 6
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 106 120 133
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 136 173 185
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 75 53 63
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 88 $ 137 $ 349
XML 100 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]        
Expected restructuring and related cost $ 3,700      
Estimate of cumulative pre tax costs that will result in cash outlays 70.00%      
Estimate of cumulative pre tax costs that will be noncash 30.00%      
Total pretax restructuring costs $ 666 $ 868 $ 880  
Cumulative costs since program inception $ 3,300      
Forecast        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring and related cost       $ 400
XML 101 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 666 $ 868 $ 880
Cost of sales      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 205 $ 160 $ 175
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales
Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 94 $ 19 $ 47
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative Selling, general and administrative Selling, general and administrative
Research and development      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 30 $ 28 $ 83
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development Research and development Research and development
Restructuring costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 337 $ 661 $ 575
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs Restructuring costs
Separation Costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 212 $ 451 $ 385
Separation Costs | Cost of sales      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 0 $ 0 $ 0
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales
Separation Costs | Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 0 $ 0 $ 0
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative Selling, general and administrative Selling, general and administrative
Separation Costs | Research and development      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 0 $ 0 $ 0
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development Research and development Research and development
Separation Costs | Restructuring costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 212 $ 451 $ 385
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs Restructuring costs
Accelerated Depreciation      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 120 $ 91 $ 268
Accelerated Depreciation | Cost of sales      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 72 $ 52 $ 143
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales
Accelerated Depreciation | Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 19 $ 12 $ 44
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative Selling, general and administrative Selling, general and administrative
Accelerated Depreciation | Research and development      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 29 $ 27 $ 81
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development Research and development Research and development
Accelerated Depreciation | Restructuring costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 0 $ 0 $ 0
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs Restructuring costs
Other      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 334 $ 326 $ 227
Other | Cost of sales      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 133 $ 108 $ 32
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales
Other | Selling, general and administrative      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 75 $ 7 $ 3
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Selling, general and administrative Selling, general and administrative Selling, general and administrative
Other | Research and development      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 1 $ 1 $ 2
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development Research and development Research and development
Other | Restructuring costs      
Restructuring Cost and Reserve [Line Items]      
Total pretax restructuring costs $ 125 $ 210 $ 190
Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration] Restructuring costs Restructuring costs Restructuring costs
XML 102 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Restructuring Reserve [Roll Forward]      
Restructuring reserve, beginning balance $ 637 $ 586  
Expenses 666 868 $ 880
(Payments) receipts, net (449) (608)  
Non-cash activity (341) (209)  
Restructuring reserve, ending balance 513 637 586
Separation Costs      
Restructuring Reserve [Roll Forward]      
Restructuring reserve, beginning balance 596 567  
Expenses 212 451 385
(Payments) receipts, net (329) (422)  
Non-cash activity 0 0  
Restructuring reserve, ending balance 479 596 567
Accelerated Depreciation      
Restructuring Reserve [Roll Forward]      
Restructuring reserve, beginning balance 0 0  
Expenses 120 91 268
(Payments) receipts, net 0 0  
Non-cash activity (120) (91)  
Restructuring reserve, ending balance 0 0 0
Other      
Restructuring Reserve [Roll Forward]      
Restructuring reserve, beginning balance 41 19  
Expenses 334 326 227
(Payments) receipts, net (120) (186)  
Non-cash activity (221) (118)  
Restructuring reserve, ending balance $ 34 $ 41 $ 19
XML 103 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Narrative (Details)
3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
interest_rate_swap
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Derivative [Line Items]          
Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales     $ 104,000,000    
Equity investments without readily determinable fair values $ 832,000,000 $ 596,000,000 832,000,000 $ 596,000,000  
Unrealized gains recognized on investments in equity securities without readily determinable fair value     56,000,000 110,000,000  
Unrealized losses recognized on investments in equity securities without readily determinable fair values     12,000,000 1,000,000  
Cumulative upward price adjustment 289,000,000   289,000,000    
Cumulative downward price adjustment 19,000,000   19,000,000    
Equity securities held through ownership interests in investment funds 598,000,000 1,700,000,000 598,000,000 1,700,000,000 $ 800,000,000
(Gains) losses for equity securities held through ownership interests in investment funds     1,000,000,000 (1,400,000,000) $ (583,000,000)
Fair value of loans payable and long-term debt, including current portion 26,700,000,000 35,700,000,000 26,700,000,000 35,700,000,000  
Debt, carrying amount 30,700,000,000 33,100,000,000 30,700,000,000 33,100,000,000  
Factored accounts receivable 2,500,000,000 2,800,000,000      
Funds collected from factoring of receivable, held in restricted cash 67,000,000 62,000,000 67,000,000 62,000,000  
Cash collateral advanced to counterparties 19,000,000   19,000,000    
Cash collateral received from counterparties 66,000,000 164,000,000 66,000,000 164,000,000  
2.40% Notes Due 2022          
Derivative [Line Items]          
Face amount of debt $ 1,000,000,000   $ 1,000,000,000    
Stated interest rate 2.40%   2.40%    
2.35% notes due 2022          
Derivative [Line Items]          
Face amount of debt $ 1,250,000,000   $ 1,250,000,000    
Stated interest rate 2.35%   2.35%    
Customer Concentration Risk | Accounts Receivable | McKesson          
Derivative [Line Items]          
Percentage of accounts receivable represented by customers with largest balances (as percent)     21.00%    
Customer Concentration Risk | Accounts Receivable | AmerisourceBergen Corporation          
Derivative [Line Items]          
Percentage of accounts receivable represented by customers with largest balances (as percent)     20.00%    
Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.          
Derivative [Line Items]          
Percentage of accounts receivable represented by customers with largest balances (as percent)     13.00%    
Level 2          
Derivative [Line Items]          
Cash equivalents $ 11,300,000,000 $ 6,800,000,000 $ 11,300,000,000 $ 6,800,000,000  
Interest Rate Swap          
Derivative [Line Items]          
Number of interest rate derivatives matured | interest_rate_swap     9    
Total notional amount of Interest rate derivatives matured     $ 2,250,000,000    
Maximum | Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum planning cycle of hedges (less than)     2 years    
Maximum | Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum planning cycle of hedges (less than)     6 months    
XML 104 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Foreign exchange contracts      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ (48) $ (49) $ 26
Foreign exchange contracts | Other (income) expense, net      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing (1) (13) (19)
Euro-denominated notes      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (162) (296) 385
Euro-denominated notes | Other (income) expense, net      
Derivative Instruments and Hedging Activities Disclosures [Line Items]      
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0 $ 0
XML 105 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Fair Value of Hedges (Details) - Loans payable and current portion of long-term debt - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Derivative [Line Items]    
Carrying Amount of Hedged Liabilities $ 0 $ 2,263
Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount $ 0 $ 13
XML 106 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 433 $ 549
Fair Value of Derivative, Liability 409 121
Notional amount of derivative 28,681 32,958
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 247 328
Fair Value of Derivative, Liability 102 25
Notional amount of derivative 9,215 12,245
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 186 221
Fair Value of Derivative, Liability 307 96
Notional amount of derivative 19,466 20,713
Interest rate swap contracts | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 0 $ 14
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Notional amount of derivative $ 0 $ 2,250
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 220 $ 271
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Notional amount of derivative $ 4,824 $ 6,778
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 27 $ 43
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Notional amount of derivative $ 1,609 $ 1,551
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 101 24
Notional amount of derivative $ 2,691 $ 1,623
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 1 $ 1
Notional amount of derivative $ 91 $ 43
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 186 $ 221
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair Value of Derivative, Liability $ 307 $ 96
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Notional amount of derivative $ 8,540 $ 10,073
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Notional amount of derivative $ 10,926 $ 10,640
XML 107 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 433 $ 549
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset (220) (110)
Cash collateral received, asset (66) (164)
Net amounts, asset 147 275
Gross amounts recognized in the consolidated balance sheet, liability 409 121
Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability (220) (110)
Cash collateral received, liability (19) 0
Net amounts, liability $ 170 $ 11
XML 108 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]      
Sales $ 59,283 $ 48,704 $ 41,518
Other (income) expense, net 1,501 (1,341) (890)
Other comprehensive income (loss) $ (339) $ 1,756 $ (441)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other (income) expense, net Other (income) expense, net Other (income) expense, net
Interest rate swap contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of gain (loss) recognized in OCI on derivatives $ (2) $ (2) $ (4)
Amount of gain recognized in Other (income) expense, net on derivatives (2) (2) (4)
Foreign exchange contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Amount of gain (loss) recognized in OCI on derivatives 684 333 (383)
Increase (decrease) in Sales as a result of AOCL reclassifications (773) 194 6
Other (income) expense, net | Interest rate swap contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Hedged items (13) (40) 40
Derivatives designated as hedging instruments 4 1 (76)
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest | Foreign exchange contracts      
Derivative Instruments, Gain (Loss) [Line Items]      
Sales $ 773 $ (194) $ (6)
XML 109 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Foreign exchange contracts | Other (income) expense, net      
Derivative [Line Items]      
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (49) $ 313 $ (12)
Foreign exchange contracts | Sales      
Derivative [Line Items]      
Amount of Derivative Pretax (Gain) Loss Recognized in Income (37) 9 13
Interest rate swap contracts | Other (income) expense, net      
Derivative [Line Items]      
Amount of Derivative Pretax (Gain) Loss Recognized in Income 0 0 9
Forward Contracts | Research and development      
Derivative [Line Items]      
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ 0 $ 0 $ 15
XML 110 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Information on Debt and Equity Securities (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost $ 569 $ 86
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 569 86
Publicly traded equity securities 1,284 1,647
Total debt and publicly traded equity securities, fair value 1,853 1,733
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 498 0
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 498 0
U.S. government and agency securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 68 80
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 68 80
Corporate notes and bonds    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 3 4
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value 3 4
Foreign government bonds    
Debt Securities, Available-for-sale [Line Items]    
Debt securities, amortized cost 0 2
Debt securities, gross unrealized gains 0 0
Debt securities, gross unrealized losses 0 0
Debt securities, fair value $ 0 $ 2
XML 111 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Assets      
Foreign government bonds $ 569 $ 86  
Publicly traded equity securities 1,284 1,647  
Derivative assets 433 549  
Liabilities      
Contingent consideration 456 777 $ 841
Derivative liabilities 409 121  
Commercial paper      
Assets      
Foreign government bonds 498 0  
Foreign government bonds      
Assets      
Foreign government bonds 0 2  
U.S. government and agency securities      
Assets      
Foreign government bonds 68 80  
Corporate notes and bonds      
Assets      
Foreign government bonds 3 4  
Fair Value, Measurements, Recurring      
Assets      
Investments 1,513 370  
Other assets 340 1,363  
Derivative assets 433 549  
Total assets 2,286 2,282  
Liabilities      
Contingent consideration 456 777  
Derivative liabilities 409 121  
Total liabilities 865 898  
Fair Value, Measurements, Recurring | Foreign exchange contracts      
Assets      
Derivative assets 218 351  
Liabilities      
Derivative liabilities 402 120  
Fair Value, Measurements, Recurring | Currency Options      
Assets      
Derivative assets 215 184  
Liabilities      
Derivative liabilities 7 1  
Fair Value, Measurements, Recurring | Interest rate swap contracts      
Assets      
Derivative assets 0 14  
Fair Value, Measurements, Recurring | Commercial paper      
Assets      
Foreign government bonds 498 0  
Fair Value, Measurements, Recurring | Foreign government bonds      
Assets      
Foreign government bonds 0 2  
Fair Value, Measurements, Recurring | U.S. government and agency securities      
Assets      
Other assets 68 80  
Fair Value, Measurements, Recurring | Corporate notes and bonds      
Assets      
Other assets 3 4  
Fair Value, Measurements, Recurring | Publicly traded equity securities      
Assets      
Publicly traded equity securities 1,015 368  
Other assets 269 1,279  
Fair Value, Measurements, Recurring | Level 1      
Assets      
Investments 1,015 368  
Other assets 340 1,363  
Derivative assets 0 0  
Total assets 1,355 1,731  
Liabilities      
Contingent consideration 0 0  
Derivative liabilities 0 0  
Total liabilities 0 0  
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts      
Assets      
Derivative assets 0 0  
Liabilities      
Derivative liabilities 0 0  
Fair Value, Measurements, Recurring | Level 1 | Currency Options      
Assets      
Derivative assets 0 0  
Liabilities      
Derivative liabilities 0 0  
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts      
Assets      
Derivative assets 0 0  
Fair Value, Measurements, Recurring | Level 1 | Commercial paper      
Assets      
Foreign government bonds 0 0  
Fair Value, Measurements, Recurring | Level 1 | Foreign government bonds      
Assets      
Foreign government bonds 0 0  
Fair Value, Measurements, Recurring | Level 1 | U.S. government and agency securities      
Assets      
Other assets 68 80  
Fair Value, Measurements, Recurring | Level 1 | Corporate notes and bonds      
Assets      
Other assets 3 4  
Fair Value, Measurements, Recurring | Level 1 | Publicly traded equity securities      
Assets      
Publicly traded equity securities 1,015 368  
Other assets 269 1,279  
Fair Value, Measurements, Recurring | Level 2      
Assets      
Investments 498 2  
Other assets 0 0  
Derivative assets 433 549  
Total assets 931 551  
Liabilities      
Contingent consideration 0 0  
Derivative liabilities 409 121  
Total liabilities 409 121  
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts      
Assets      
Derivative assets 218 351  
Liabilities      
Derivative liabilities 402 120  
Fair Value, Measurements, Recurring | Level 2 | Currency Options      
Assets      
Derivative assets 215 184  
Liabilities      
Derivative liabilities 7 1  
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts      
Assets      
Derivative assets 0 14  
Fair Value, Measurements, Recurring | Level 2 | Commercial paper      
Assets      
Foreign government bonds 498 0  
Fair Value, Measurements, Recurring | Level 2 | Foreign government bonds      
Assets      
Foreign government bonds 0 2  
Fair Value, Measurements, Recurring | Level 2 | U.S. government and agency securities      
Assets      
Other assets 0 0  
Fair Value, Measurements, Recurring | Level 2 | Corporate notes and bonds      
Assets      
Other assets 0 0  
Fair Value, Measurements, Recurring | Level 2 | Publicly traded equity securities      
Assets      
Publicly traded equity securities 0 0  
Other assets 0 0  
Fair Value, Measurements, Recurring | Level 3      
Assets      
Investments 0 0  
Other assets 0 0  
Derivative assets 0 0  
Total assets 0 0  
Liabilities      
Contingent consideration 456 777  
Derivative liabilities 0 0  
Total liabilities 456 777  
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts      
Assets      
Derivative assets 0 0  
Liabilities      
Derivative liabilities 0 0  
Fair Value, Measurements, Recurring | Level 3 | Currency Options      
Assets      
Derivative assets 0 0  
Liabilities      
Derivative liabilities 0 0  
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts      
Assets      
Derivative assets 0 0  
Fair Value, Measurements, Recurring | Level 3 | Commercial paper      
Assets      
Foreign government bonds 0 0  
Fair Value, Measurements, Recurring | Level 3 | Foreign government bonds      
Assets      
Foreign government bonds 0 0  
Fair Value, Measurements, Recurring | Level 3 | U.S. government and agency securities      
Assets      
Other assets 0 0  
Fair Value, Measurements, Recurring | Level 3 | Corporate notes and bonds      
Assets      
Other assets 0 0  
Fair Value, Measurements, Recurring | Level 3 | Publicly traded equity securities      
Assets      
Publicly traded equity securities 0 0  
Other assets $ 0 $ 0  
XML 112 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
12 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Contingent consideration, beginning balance $ 777 $ 841
Changes in estimated fair value (146) 57
Payments (119) (109)
Other (56) (12)
Contingent consideration, ending balance 456 777
Contingent consideration, liability, current 122  
Sanofi Pasteur    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Contingent consideration, beginning balance 620  
Contingent consideration, ending balance $ 368 $ 620
Contingent consideration, measurement input, discount rate 0.115  
XML 113 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Inventories - Inventories (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Finished goods $ 1,841 $ 1,747
Raw materials and work in process 7,063 6,220
Supplies 238 196
Total (approximates current cost) 9,142 8,163
Decrease to LIFO cost (293) (16)
Total current and noncurrent inventories 8,849 8,147
Recognized as:    
Inventories 5,911 5,953
Other Assets $ 2,938 $ 2,194
XML 114 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Inventories - Narrative (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Inventory [Line Items]    
LIFO inventory amount $ 3,400 $ 3,300
Inventory classified in Other assets 2,938 2,194
Inventory Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventory classified in Other assets 2,400 1,900
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventory classified in Other assets $ 516 $ 256
XML 115 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Goodwill [Roll Forward]    
Goodwill, beginning balance $ 21,264 $ 18,882
Acquisitions   2,436
Other (60) (54)
Goodwill, ending balance 21,204 21,264
Accumulated goodwill impairment losses 531 531
Pharmaceutical    
Goodwill [Roll Forward]    
Goodwill, beginning balance 17,997 15,614
Acquisitions   2,431
Other (61) (48)
Goodwill, ending balance 17,936 17,997
Animal Health    
Goodwill [Roll Forward]    
Goodwill, beginning balance 3,267 3,268
Acquisitions   5
Other 1 (6)
Goodwill, ending balance $ 3,268 $ 3,267
XML 116 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangibles - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net $ 20,269   $ 20,269 $ 22,933  
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]         Cost of sales
IPR&D impairment charges     $ 1,700    
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]     Research and development    
Contingent consideration liability, changes in estimated fair value     $ (146) 57  
Amortization expense for intangible assets     2,100 1,600 $ 1,800
Estimated aggregate amortization expense, 2023 1,800   1,800    
Estimated aggregate amortization expense, 2024 1,700   1,700    
Estimated aggregate amortization expense, 2025 1,600   1,600    
Estimated aggregate amortization expense, 2026 1,500   1,500    
Estimated aggregate amortization expense, 2027 1,300   1,300    
IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 7,661   7,661 9,281  
Zerbaxa          
Intangible Assets Excluding Goodwill [Line Items]          
Intangible asset impairment charge related to marketed product         1,600
Inventory write-down         120
Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 4,600   4,600    
Adempas | Licenses and other          
Intangible Assets Excluding Goodwill [Line Items]          
Intangible assets 633   633    
COVID-19          
Intangible Assets Excluding Goodwill [Line Items]          
IPR&D impairment charges         90
Contingent consideration liability, changes in estimated fair value         $ (45)
sotatercept | IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 6,400   6,400    
nemtabrutinib | IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 418   418    
IPR&D impairment charges 780 $ 807 1,600 $ 275  
nemtabrutinib | Measurement Input, Discount Rate | Valuation Technique, Discounted Cash Flow | Fair Value, Measurements, Recurring          
Intangible Assets Excluding Goodwill [Line Items]          
Discount rate       0.085  
gefapixant | IPR&D          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 832   832    
Products and product rights          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 6,810   6,810 $ 7,895  
Products and product rights | Reblozyl          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 3,500   3,500    
Products and product rights | Zerbaxa          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 406   406    
Products and product rights | Sivextro          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 122   122    
Products and product rights | Gardasil/Gardasil 9          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 120   120    
Products and product rights | Bridion          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 97   97    
Products and product rights | Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 2,300   2,300    
Trade names          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 2,244   2,244 2,389  
Trade names | Animal Health          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 2,200   2,200    
License          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 3,554   3,554 $ 3,368  
License | Lynparza          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net 1,600   1,600    
License | Lenvima          
Intangible Assets Excluding Goodwill [Line Items]          
Other intangibles, net $ 814   814    
License | Derazantinib          
Intangible Assets Excluding Goodwill [Line Items]          
Intangible asset impairment     $ 80    
XML 117 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Goodwill and Other Intangibles - Other Intangibles (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Intangible Assets Excluding Goodwill [Line Items]    
Gross Carrying Amount $ 41,746 $ 42,438
Accumulated Amortization 21,477 19,505
Net 20,269 22,933
IPR&D    
Intangible Assets Excluding Goodwill [Line Items]    
Gross Carrying Amount 7,661 9,281
Net 7,661 9,281
Products and product rights    
Intangible Assets Excluding Goodwill [Line Items]    
Gross Carrying Amount 23,555 23,671
Accumulated Amortization 16,745 15,776
Net 6,810 7,895
Trade names    
Intangible Assets Excluding Goodwill [Line Items]    
Gross Carrying Amount 2,879 2,882
Accumulated Amortization 635 493
Net 2,244 2,389
License    
Intangible Assets Excluding Goodwill [Line Items]    
Gross Carrying Amount 7,651 6,604
Accumulated Amortization 4,097 3,236
Net $ 3,554 $ 3,368
XML 118 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Debt Instrument [Line Items]      
Long-term debt, current maturities $ 1,700 $ 2,300  
Loans payable and current portion of long-term debt 1,946 $ 2,412  
Long-term debt, maturities, repayments of principal in 2023 1,700    
Long-term debt, maturities, repayments of principal in 2024 1,300    
Long-term debt, maturities, repayments of principal in 2025 2,500    
Long-term debt, maturities, repayments of principal in 2026 2,200    
Long-term debt, maturities, repayments of principal in 2027 1,500    
Long-term debt, interest payments in 2023 882    
Long-term debt, interest payments in 2024 845    
Long-term debt, interest payments in 2025 778    
Long-term debt, interest payments in 2026 751    
Long-term debt, interest payments in 2027 720    
Available borrowing capacity under credit facility $ 6,000    
Operating lease, weighted average remaining lease term 7 years 7 years  
Operating lease, cost $ 334 $ 343 $ 340
Operating lease, payments 335 340 334
Right-of-use asset obtained in exchange for operating lease liability 57 $ 117 $ 473
Lessee, operating lease, lease not yet commenced, amount $ 232    
Other Variable Rate Debt      
Debt Instrument [Line Items]      
Effective interest rate 1.40% 0.00%  
6.30% debentures due 2026      
Debt Instrument [Line Items]      
Stated interest rate 6.30%    
1.70% notes due 2027      
Debt Instrument [Line Items]      
Stated interest rate 1.70%    
1.90% notes due 2028      
Debt Instrument [Line Items]      
Stated interest rate 1.90%    
2.15% notes due 2031      
Debt Instrument [Line Items]      
Stated interest rate 2.15%    
2.75% notes due 2051      
Debt Instrument [Line Items]      
Stated interest rate 2.75%    
2.90% notes due 2061      
Debt Instrument [Line Items]      
Stated interest rate 2.90%    
Commercial paper      
Debt Instrument [Line Items]      
Weighted-average interest rate of commercial paper 0.65% 0.08%  
Notes Subject To Repayment At Option Of Holder      
Debt Instrument [Line Items]      
Loans payable and current portion of long-term debt $ 197 $ 149  
Buildings      
Debt Instrument [Line Items]      
Operating lease, weighted average remaining lease term 7 years    
Lessee, operating lease, renewal term 4 years    
Vehicles      
Debt Instrument [Line Items]      
Operating lease, weighted average remaining lease term 4 years    
XML 119 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Debt Instrument [Line Items]    
Long-Term Debt $ 28,745 $ 30,690
2.75% notes due 2025    
Debt Instrument [Line Items]    
Stated interest rate 2.75%  
Long-Term Debt $ 2,496 2,495
2.15% notes due 2031    
Debt Instrument [Line Items]    
Stated interest rate 2.15%  
Long-Term Debt $ 1,986 1,986
2.75% notes due 2051    
Debt Instrument [Line Items]    
Stated interest rate 2.75%  
Long-Term Debt $ 1,979 1,979
3.70% notes due 2045    
Debt Instrument [Line Items]    
Stated interest rate 3.70%  
Long-Term Debt $ 1,978 1,977
3.40% notes due 2029    
Debt Instrument [Line Items]    
Stated interest rate 3.40%  
Long-Term Debt $ 1,738 1,736
1.70% notes due 2027    
Debt Instrument [Line Items]    
Stated interest rate 1.70%  
Long-Term Debt $ 1,494 1,493
2.90% notes due 2061    
Debt Instrument [Line Items]    
Stated interest rate 2.90%  
Long-Term Debt $ 1,483 1,484
4.00% notes due 2049    
Debt Instrument [Line Items]    
Stated interest rate 4.00%  
Long-Term Debt $ 1,471 1,470
4.15% notes due 2043    
Debt Instrument [Line Items]    
Stated interest rate 4.15%  
Long-Term Debt $ 1,239 1,239
1.45% notes due 2030    
Debt Instrument [Line Items]    
Stated interest rate 1.45%  
Long-Term Debt $ 1,237 1,235
2.45% notes due 2050    
Debt Instrument [Line Items]    
Stated interest rate 2.45%  
Long-Term Debt $ 1,213 1,212
1.875% euro-denominated notes due 2026    
Debt Instrument [Line Items]    
Stated interest rate 1.875%  
Long-Term Debt $ 1,060 1,123
0.75% notes due 2026    
Debt Instrument [Line Items]    
Stated interest rate 0.75%  
Long-Term Debt $ 995 993
1.90% notes due 2028    
Debt Instrument [Line Items]    
Stated interest rate 1.90%  
Long-Term Debt $ 994 994
3.90% notes due 2039    
Debt Instrument [Line Items]    
Stated interest rate 3.90%  
Long-Term Debt $ 985 984
2.35% notes due 2040    
Debt Instrument [Line Items]    
Stated interest rate 2.35%  
Long-Term Debt $ 984 983
2.90% notes due 2024    
Debt Instrument [Line Items]    
Stated interest rate 2.90%  
Long-Term Debt $ 749 748
6.50% notes due 2033    
Debt Instrument [Line Items]    
Stated interest rate 6.50%  
Long-Term Debt $ 711 715
0.50% euro-denominated notes due 2024    
Debt Instrument [Line Items]    
Stated interest rate 0.50%  
Long-Term Debt $ 531 563
1.375% euro-denominated notes due 2036    
Debt Instrument [Line Items]    
Stated interest rate 1.375%  
Long-Term Debt $ 527 559
2.50% euro-denominated notes due 2034    
Debt Instrument [Line Items]    
Stated interest rate 2.50%  
Long-Term Debt $ 526 558
3.60% notes due 2042    
Debt Instrument [Line Items]    
Stated interest rate 3.60%  
Long-Term Debt $ 492 491
6.55% notes due 2037    
Debt Instrument [Line Items]    
Stated interest rate 6.55%  
Long-Term Debt $ 408 409
5.75% notes due 2036    
Debt Instrument [Line Items]    
Stated interest rate 5.75%  
Long-Term Debt $ 339 338
5.95% debentures due 2028    
Debt Instrument [Line Items]    
Stated interest rate 5.95%  
Long-Term Debt $ 307 306
5.85% notes due 2039    
Debt Instrument [Line Items]    
Stated interest rate 5.85%  
Long-Term Debt $ 271 271
6.40% debentures due 2028    
Debt Instrument [Line Items]    
Stated interest rate 6.40%  
Long-Term Debt $ 250 250
6.30% debentures due 2026    
Debt Instrument [Line Items]    
Stated interest rate 6.30%  
Long-Term Debt $ 135 135
2.80% notes due 2023    
Debt Instrument [Line Items]    
Stated interest rate 2.80%  
Long-Term Debt $ 0 1,749
Other    
Debt Instrument [Line Items]    
Long-Term Debt $ 167 $ 215
XML 120 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
Other Assets $ 1,346 $ 1,586
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Accrued and other current liabilities $ 281 $ 304
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Other Noncurrent Liabilities $ 1,013 $ 1,225
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Total operating lease liability $ 1,294 $ 1,529
Weighted-average remaining lease term (years) 7 years 7 years
Weighted-average discount rate 3.10% 2.60%
XML 121 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Debt Disclosure [Abstract]    
2023 $ 323  
2024 258  
2025 224  
2026 157  
2027 126  
Thereafter 404  
Total lease payments 1,492  
Less: Imputed interest 198  
Total operating lease liability $ 1,294 $ 1,529
XML 122 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Contingencies and Environmental Liabilities (Details)
$ in Millions
12 Months Ended
Dec. 19, 2022
Jun. 30, 2022
claim
Dec. 31, 2022
USD ($)
case
Plaintiff
Dec. 31, 2021
USD ($)
Aug. 31, 2020
claim
Loss Contingencies [Line Items]          
Accrued liabilities for environmental matters | $     $ 39 $ 40  
Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag     liabilities    
Term for paying off environmental liabilities     15 years    
Aggregate possible expenditure on environmental matters in excess of amounts accrued | $     $ 35    
Legal Defense Costs          
Loss Contingencies [Line Items]          
Legal defense costs reserve | $     $ 230 $ 230  
Commercial Litigation          
Loss Contingencies [Line Items]          
Loss contingency, pending claims     2    
Loss contingency, number of plaintiffs | Plaintiff     2    
Patent litigation          
Loss Contingencies [Line Items]          
Loss contingency, claims settled (in cases)     22    
Zetia antitrust litigation          
Loss Contingencies [Line Items]          
Loss contingency, pending claims | claim         35
Loss contingency, damages sought | $     $ 12,700    
Zetia antitrust litigation | Pending Litigation          
Loss Contingencies [Line Items]          
Loss contingency, new claims filed | claim   23      
Gardasil/Gardasil 9 | United States          
Loss Contingencies [Line Items]          
Loss contingency, pending claims     70    
Gardasil/Gardasil 9 | Outside of the United States          
Loss Contingencies [Line Items]          
Loss contingency, pending claims     15    
Gardasil/Gardasil 9 | COLOMBIA          
Loss Contingencies [Line Items]          
Loss contingency, pending claims     1    
Bridion | Patents          
Loss Contingencies [Line Items]          
Loss contingency, claims settled (in cases)     5    
Bridion | Patents | Pending Litigation          
Loss Contingencies [Line Items]          
Loss contingency, pending claims     2    
Loss contingency, trial period 1 day        
XML 123 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Equity - Narrative (Details) - shares
Dec. 31, 2022
Dec. 31, 2021
Equity [Abstract]    
Common stock, authorized (in shares) 6,500,000,000 6,500,000,000
Preferred stock, authorized (in shares) 20,000,000  
XML 124 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Equity - Shareholders' Equity (Details) - shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1 (in shares) 3,577,103,522    
Balance December 31 (in shares) 3,577,103,522 3,577,103,522  
Common Stock      
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1 (in shares) 3,577,000,000 3,577,000,000 3,577,000,000
Purchases of treasury stock (in shares) 0 0 0
Issuances (in shares) 0 0 0
Balance December 31 (in shares) 3,577,000,000 3,577,000,000 3,577,000,000
Treasury Stock      
Movement in Common Stock and Treasury Stock [Roll Forward]      
Balance January 1 (in shares) 1,049,000,000 1,047,000,000 1,038,000,000
Purchases of treasury stock (in shares) 0 11,000,000 16,000,000
Issuances (in shares) (10,000,000) (9,000,000) (7,000,000)
Balance December 31 (in shares) 1,039,000,000 1,049,000,000 1,047,000,000
XML 125 R80.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares collectively authorized for future grants under share-based compensation plans (in shares) 87,000,000    
Quantity of stock options that vest per year 33.33%    
Period over which share-based payment awards vest 3 years    
Pretax share-based compensation cost recorded   $ 498 $ 475
Pretax share-based compensation cost recorded, related to continuing operations $ 541 479 441
Income tax benefits related to share-based compensation $ 78 $ 69 $ 65
Weighted average exercise price of options granted (in dollars per share) $ 87.10 $ 75.99 $ 77.67
Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards $ 813    
Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards 1 year 10 months 24 days    
Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Contractual term of options 7 years    
Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Contractual term of options 10 years    
XML 126 R81.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) - $ / shares
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Weighted average fair value of options granted (in dollars per share) $ 15.45 $ 9.80 $ 9.93
Expected dividend yield 3.10% 3.10% 3.10%
Risk-free interest rate 3.00% 1.00% 0.40%
Expected volatility 22.50% 20.90% 22.10%
Expected life (years) 5 years 10 months 24 days 5 years 10 months 24 days 5 years 9 months 18 days
XML 127 R82.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Number of Options      
Number of Options, Outstanding, January 1 (in shares) 18,572    
Number of Options, Granted (in shares) 2,326    
Number of Options, Exercised (in shares) (6,317)    
Number of Options, Forfeited (in shares) (862)    
Number of Options, Outstanding, December 31 (in shares) 13,719 18,572  
Number of Options, Vested and expected to vest (in shares) 13,199    
Number of Options, Exercisable (in shares) 8,730    
Weighted Average Exercise Price      
Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share) $ 65.27    
Weighted Average Exercise Price, Granted (in dollars per share) 87.10 $ 75.99 $ 77.67
Weighted Average Exercise Price, Exercised (in dollars per share) 60.77    
Weighted Average Exercise Price, Forfeited (in dollars per share) 73.11    
Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share) 70.55 $ 65.27  
Weighted Average Exercise Price, Vested and expected to vest (in dollars per share) 70.09    
Weighted Average Exercise Price, Exercisable (in dollars per share) $ 65.24    
Weighted Average Remaining Contractual Term, Outstanding 6 years 6 months    
Weighted Average Remaining Contractual Term, Vested and expected to vest 6 years 4 months 24 days    
Weighted Average Remaining Contractual Term, Exercisable 5 years 4 months 24 days    
Aggregate Intrinsic Value, Outstanding $ 554    
Aggregate Intrinsic Value, Vested and expected to vest 539    
Aggregate Intrinsic Value, Exercisable $ 399    
XML 128 R83.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]      
Total intrinsic value of stock options exercised $ 225 $ 106 $ 51
Fair value of stock options vested 30 27 25
Cash received from the exercise of stock options $ 384 $ 202 $ 89
XML 129 R84.htm IDEA: XBRL DOCUMENT v3.22.4
Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)
shares in Thousands
12 Months Ended
Dec. 31, 2022
$ / shares
shares
RSUs  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of Shares, Nonvested January 1 (in shares) | shares 11,790
Number of Shares, Granted (in shares) | shares 7,170
Number of Shares, Vested (in shares) | shares (5,150)
Number of Shares, Forfeited (in shares) | shares (1,110)
Number of Shares, Nonvested December 31 (in shares) | shares 12,700
Number of Shares, Expected to Vest (in shares) | shares 11,254
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares $ 74.88
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares 87.12
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares 75.40
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares 78.65
Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares 81.25
Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares $ 80.96
PSUs  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Number of Shares, Nonvested January 1 (in shares) | shares 1,966
Number of Shares, Granted (in shares) | shares 951
Number of Shares, Vested (in shares) | shares (725)
Number of Shares, Forfeited (in shares) | shares (171)
Number of Shares, Nonvested December 31 (in shares) | shares 2,021
Number of Shares, Expected to Vest (in shares) | shares 1,895
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share) | $ / shares $ 77.13
Weighted Average Grant Date Fair Value, Granted (in dollars per share) | $ / shares 88.52
Weighted Average Grant Date Fair Value, Vested (in dollars per share) | $ / shares 87.87
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share) | $ / shares 77.58
Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share) | $ / shares 78.60
Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share) | $ / shares $ 78.26
XML 130 R85.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]        
Accumulated benefit obligation   $ 17,200 $ 24,900  
Employer contributions to defined contribution savings plans   $ 175 $ 158 $ 158
Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Percentage of Company's pension investments categorized as level 3 assets   4.00% 4.00%  
Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 765 $ 943  
Other Postretirement Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   947 1,292 $ 1,221
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   20    
Other Postretirement Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 0 $ 0  
United States        
Defined Benefit Plan Disclosure [Line Items]        
Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests   10.00%    
Expected rate of return on plan assets   6.70% 6.70% 7.30%
United States | Forecast        
Defined Benefit Plan Disclosure [Line Items]        
Expected rate of return on plan assets 7.00%      
United States | U.S. equities | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   25.00%    
United States | U.S. equities | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   40.00%    
United States | International equities | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   10.00%    
United States | International equities | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   20.00%    
United States | Fixed Income Investments | Minimum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   35.00%    
United States | Fixed Income Investments | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   45.00%    
United States | Cash And Other Investments | Maximum        
Defined Benefit Plan Disclosure [Line Items]        
Target allocation   8.00%    
United States | Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Accumulated benefit obligation   $ 9,700 $ 13,800  
Fair value of plan assets   9,094 13,067 $ 12,672
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   270    
United States | Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   4 6 7
International | Pension Benefits        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   8,473 $ 12,195 $ 12,009
Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year   $ 150    
Expected rate of return on plan assets   3.70% 3.80% 4.40%
International | Pension Benefits | Level 3        
Defined Benefit Plan Disclosure [Line Items]        
Fair value of plan assets   $ 761 $ 937 $ 935
XML 131 R86.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost $ 48 $ 48 $ 52
Interest cost 46 45 57
Expected return on plan assets (86) (79) (75)
Amortization of unrecognized prior service cost (57) (63) (73)
Net loss (gain) amortization (43) (42) (18)
Termination benefits 0 37 2
Curtailments (1) (29) (4)
Settlements 0 0 0
Net periodic benefit cost (credit) (93) (83) (59)
United States | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 372 403 360
Interest cost 457 404 431
Expected return on plan assets (753) (755) (774)
Amortization of unrecognized prior service cost (32) (38) (49)
Net loss (gain) amortization 128 298 303
Termination benefits 2 56 10
Curtailments 12 16 10
Settlements 239 216 13
Net periodic benefit cost (credit) 425 600 304
International | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Service cost 283 328 297
Interest cost 145 123 136
Expected return on plan assets (383) (416) (414)
Amortization of unrecognized prior service cost (14) (16) (18)
Net loss (gain) amortization 96 142 127
Termination benefits 1 5 3
Curtailments 0 (26) 0
Settlements 1 8 15
Net periodic benefit cost (credit) $ 129 $ 148 $ 146
XML 132 R87.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Postretirement Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 $ 1,292 $ 1,221  
Actual return on plan assets (306) 118  
Company contributions 46 33  
Effects of exchange rate changes 0 0  
Benefits paid (90) (86)  
Settlements 0 0  
Spin-off of Organon 0 0  
Other 5 6  
Fair value of plan assets December 31 947 1,292 $ 1,221
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 1,541 1,607  
Service cost 48 48 52
Interest cost 46 45 57
Actuarial (gains) losses (392) (103)  
Benefits paid (90) (86)  
Effects of exchange rate changes (1) (1)  
Plan amendments 0 0  
Curtailments 0 (12)  
Termination benefits 0 37 2
Settlements 0 0  
Spin-off of Organon 0 0  
Other 5 6  
Benefit obligation December 31 1,157 1,541 1,607
Funded status December 31 (210) (249)  
Recognized as:      
Other Assets 0 0  
Accrued and other current liabilities (8) (8)  
Other Noncurrent Liabilities (202) (241)  
United States | Pension Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 13,067 12,672  
Actual return on plan assets (3,129) 1,250  
Company contributions 293 305  
Effects of exchange rate changes 0 0  
Benefits paid (219) (219)  
Settlements (918) (941)  
Spin-off of Organon 0 0  
Other 0 0  
Fair value of plan assets December 31 9,094 13,067 12,672
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 13,999 14,613  
Service cost 372 403 360
Interest cost 457 404 431
Actuarial (gains) losses (3,851) (332)  
Benefits paid (219) (219)  
Effects of exchange rate changes 0 0  
Plan amendments 0 0  
Curtailments 12 15  
Termination benefits 2 56 10
Settlements (918) (941)  
Spin-off of Organon 0 0  
Other 0 0  
Benefit obligation December 31 9,854 13,999 14,613
Funded status December 31 (760) (932)  
Recognized as:      
Other Assets 5 9  
Accrued and other current liabilities (59) (64)  
Other Noncurrent Liabilities (706) (877)  
International | Pension Benefits      
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]      
Fair value of plan assets January 1 12,195 12,009  
Actual return on plan assets (2,793) 891  
Company contributions 155 189  
Effects of exchange rate changes (848) (671)  
Benefits paid (250) (233)  
Settlements (16) (55)  
Spin-off of Organon 0 (55)  
Other 30 120  
Fair value of plan assets December 31 8,473 12,195 12,009
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]      
Benefit obligation January 1 11,575 12,458  
Service cost 283 328 297
Interest cost 145 123 136
Actuarial (gains) losses (3,283) (240)  
Benefits paid (250) (233)  
Effects of exchange rate changes (732) (678)  
Plan amendments 4 4  
Curtailments 0 (38)  
Termination benefits 1 5 3
Settlements (16) (55)  
Spin-off of Organon 0 (118)  
Other 28 19  
Benefit obligation December 31 7,755 11,575 $ 12,458
Funded status December 31 718 620  
Recognized as:      
Other Assets 1,052 1,395  
Accrued and other current liabilities (19) (22)  
Other Noncurrent Liabilities $ (315) $ (753)  
XML 133 R88.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
United States    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation $ 9,186 $ 13,013
Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets 8,421 12,072
Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation 9,081 12,916
Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets 8,421 12,072
International    
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]    
Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation 2,779 2,507
Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets 2,445 1,731
Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation 1,226 2,462
Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets $ 948 $ 1,723
XML 134 R89.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 765 $ 943  
United States      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9,094 13,067 $ 12,672
United States | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 147 292  
United States | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,654 4,035  
United States | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 707 919  
United States | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 131 0  
United States | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,956 2,915  
United States | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,934 2,870  
United States | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,438 2,005  
United States | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 22 23  
United States | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 101 0  
United States | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 8  
United States | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,216 3,156  
United States | Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 49 3  
United States | Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 211 236  
United States | Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,956 2,915  
United States | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 1 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 2  
United States | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,495 4,898  
United States | Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,934 2,870  
United States | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1,438 2,005  
United States | Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 22 23  
United States | Level 2 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 101 0  
United States | Level 2 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 6 7
United States | Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | Level 3 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 0
United States | Level 3 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 6 7
United States | NAV      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,379 5,007  
United States | NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 98 289  
United States | NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,443 3,799  
United States | NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 707 919  
United States | NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 131 0  
United States | NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
United States | NAV | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8,473 12,195 12,009
International | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 78 110  
International | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3,422 4,944  
International | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 111 209  
International | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 11 17  
International | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,963 4,436  
International | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 146 188  
International | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 21 26  
International | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 263 369  
International | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 448 597  
International | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 157 225  
International | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 69 90  
International | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 780 982  
International | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 2  
International | Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 943 1,387  
International | Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 57 82  
International | Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 375 531  
International | Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 52 137  
International | Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 177 240  
International | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 9  
International | Level 1 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 10 15  
International | Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 263 369  
International | Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 3  
International | Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 1 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1 1  
International | Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 6,333 9,293  
International | Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 8 10  
International | Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,957 4,292  
International | Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1 1  
International | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 2,656 4,025  
International | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 9 8  
International | Level 2 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 7 8  
International | Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 448 591  
International | Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 157 223  
International | Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 69 90  
International | Level 2 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 18 44  
International | Level 2 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 3 1  
International | Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 761 937 935
International | Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | Level 3 | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 761 937 935
International | Level 3 | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0 $ 0
International | NAV      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 436 578  
International | NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 13 18  
International | NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 90 121  
International | NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 59 72  
International | NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 10 16  
International | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 130 171  
International | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 129 171  
International | NAV | Other fixed income obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 4 3  
International | NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 3  
International | NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 2  
International | NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 0 0  
International | NAV | Insurance contracts      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets 1 1  
International | NAV | Other      
Defined Benefit Plan Disclosure [Line Items]      
Fair value of plan assets $ 0 $ 0  
XML 135 R90.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) - Pension Benefits - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 $ 943  
Actual return on plan assets:    
Fair value of plan assets December 31 765 $ 943
United States    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 13,067 12,672
Actual return on plan assets:    
Fair value of plan assets December 31 9,094 13,067
United States | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 8  
Actual return on plan assets:    
Fair value of plan assets December 31 4 8
United States | Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 6 7
Actual return on plan assets:    
Relating to assets still held at December 31 (3) (5)
Relating to assets sold during the year 2 7
Purchases and sales, net (1) (3)
Fair value of plan assets December 31 4 6
United States | Level 3 | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Relating to assets sold during the year 0 0
Purchases and sales, net 0 0
Fair value of plan assets December 31 0 0
United States | Level 3 | Real Estate    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Relating to assets sold during the year 0 0
Purchases and sales, net 0 0
Fair value of plan assets December 31 0 0
United States | Level 3 | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 6 7
Actual return on plan assets:    
Relating to assets still held at December 31 (3) (5)
Relating to assets sold during the year 2 7
Purchases and sales, net (1) (3)
Fair value of plan assets December 31 4 6
International    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 12,195 12,009
Actual return on plan assets:    
Fair value of plan assets December 31 8,473 12,195
International | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 982  
Actual return on plan assets:    
Fair value of plan assets December 31 780 982
International | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 2  
Actual return on plan assets:    
Fair value of plan assets December 31 4 2
International | Level 3    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 937 935
Actual return on plan assets:    
Relating to assets still held at December 31 (147) (34)
Purchases and sales, net (39) (42)
Transfers into Level 3 10 78
Fair value of plan assets December 31 761 937
International | Level 3 | Insurance Contracts    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 937 935
Actual return on plan assets:    
Relating to assets still held at December 31 (147) (34)
Purchases and sales, net (39) (42)
Transfers into Level 3 10 78
Fair value of plan assets December 31 761 937
International | Level 3 | Real Estate    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Purchases and sales, net 0 0
Transfers into Level 3 0 0
Fair value of plan assets December 31 0 0
International | Level 3 | Other    
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]    
Fair value of plan assets January 1 0 0
Actual return on plan assets:    
Relating to assets still held at December 31 0 0
Purchases and sales, net 0
Transfers into Level 3 0
Fair value of plan assets December 31 $ 0 $ 0
XML 136 R91.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) - Other Postretirement Benefits - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value $ 947 $ 1,292 $ 1,221
Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 10 39  
Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 279 402  
Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 74 92  
Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 1 1  
Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 14 0  
Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 206 290  
Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 212 275  
Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 137 191  
Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 2 2  
Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 12 0  
Level 1      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 231 326  
Level 1 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 2 11  
Level 1 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 22 24  
Level 1 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 1 1  
Level 1 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 206 290  
Level 1 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 1 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 363 468  
Level 2 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 2 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 212 275  
Level 2 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 137 191  
Level 2 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 2 2  
Level 2 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 12 0  
Level 3      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
Level 3 | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 353 498  
NAV | Cash and cash equivalents      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 8 28  
NAV | Developed markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 257 378  
NAV | Emerging markets equities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 74 92  
NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Real estate      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 14 0  
NAV | Developed markets      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Government and agency obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Corporate obligations      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Mortgage and asset-backed securities      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value 0 0  
NAV | Derivatives      
Defined Benefit Plan Disclosure [Line Items]      
Plan assets at fair value $ 0 $ 0  
XML 137 R92.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)
$ in Millions
Dec. 31, 2022
USD ($)
Other Postretirement Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2023 $ 84
2024 86
2025 87
2026 89
2027 90
2028 — 2032 474
United States | Pension Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2023 627
2024 634
2025 650
2026 676
2027 694
2028 — 2032 3,948
International | Pension Benefits  
Defined Benefit Plan Disclosure [Line Items]  
2023 271
2024 257
2025 262
2026 283
2027 297
2028 — 2032 $ 1,704
XML 138 R93.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Postretirement Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net loss (gain) amortization included in benefit cost $ 0 $ 156 $ 199
Prior service (cost) credit arising during the period 0 0 0
Total 0 156 199
Net loss (gain) amortization included in benefit cost (43) (42) (18)
Prior service credit amortization included in benefit cost (57) (63) (73)
Settlements and curtailments (1) (29) (4)
Total (101) (134) (95)
United States | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net loss (gain) amortization included in benefit cost (42) 813 (472)
Prior service (cost) credit arising during the period 0 0 0
Total (42) 813 (472)
Net loss (gain) amortization included in benefit cost 128 298 303
Prior service credit amortization included in benefit cost (32) (38) (49)
Settlements and curtailments 251 232 23
Total 347 492 277
International | Pension Benefits      
Defined Benefit Plan Disclosure [Line Items]      
Net loss (gain) amortization included in benefit cost 116 772 (424)
Prior service (cost) credit arising during the period (4) (4) 64
Total 112 768 (360)
Net loss (gain) amortization included in benefit cost 96 142 127
Prior service credit amortization included in benefit cost (14) (16) (18)
Settlements and curtailments 1 (18) 15
Total $ 83 $ 108 $ 124
XML 139 R94.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
United States      
Net periodic benefit cost      
Discount rate 3.00% 2.70% 3.40%
Expected rate of return on plan assets 6.70% 6.70% 7.30%
Salary growth rate 4.60% 4.60% 4.20%
Interest crediting rate 5.00% 4.70% 4.90%
Benefit obligation      
Discount rate 5.50% 3.00% 2.70%
Salary growth rate 4.60% 4.60% 4.60%
Interest crediting rate 5.30% 5.00% 4.70%
International | Pension Benefits      
Net periodic benefit cost      
Discount rate 1.50% 1.10% 1.50%
Expected rate of return on plan assets 3.70% 3.80% 4.40%
Salary growth rate 2.90% 2.80% 2.80%
Interest crediting rate 3.00% 3.00% 2.80%
Benefit obligation      
Discount rate 3.90% 1.50% 1.10%
Salary growth rate 3.20% 2.90% 2.80%
Interest crediting rate 3.30% 3.00% 3.00%
XML 140 R95.htm IDEA: XBRL DOCUMENT v3.22.4
Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) - Other Postretirement Benefits
Dec. 31, 2022
Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]    
Health care cost trend rate assumed for next year 7.80% 6.40%
Rate to which the cost trend rate is assumed to decline 4.50% 4.50%
XML 141 R96.htm IDEA: XBRL DOCUMENT v3.22.4
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Component of Other Income / Expense of Nonoperating [Line Items]        
Interest income   $ (157) $ (36) $ (59)
Interest expense   962 806 831
Exchange losses   237 297 145
Loss (income) from investments in equity securities, net   1,419 (1,940) (1,338)
Net periodic defined benefit plan (credit) cost other than service cost   (279) (212) (339)
Other, net   (681) (256) (130)
Other (income) expense, net   1,501 (1,341) $ (890)
Unrealized gains   $ (462) $ (232)  
Forecast | Subsequent Event        
Component of Other Income / Expense of Nonoperating [Line Items]        
Unrealized gains $ 140      
XML 142 R97.htm IDEA: XBRL DOCUMENT v3.22.4
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Other Income and Expenses [Abstract]      
Interest paid $ 937 $ 779 $ 822
XML 143 R98.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Amount      
U.S. statutory rate applied to income from continuing operations before taxes $ 3,453 $ 2,915 $ 1,231
Differential arising from:      
Foreign earnings (1,835) (1,446) (965)
GILTI and the foreign-derived intangible income deduction 462 (75) 349
State taxes (110) 2 57
R&D tax credit (81) (81) (108)
Tax settlements (10) (275) (13)
Valuation allowances 108 102 37
Restructuring 11 61 105
Acquisition of VelosBio 0 (9) 559
Acquisition of Pandion 0 356 0
Acquisition of OncoImmune 0 0 97
Other (80) (29) (9)
Taxes on income $ 1,918 $ 1,521 $ 1,340
Tax Rate      
U.S. statutory rate applied to income from continuing operations before taxes 21.00% 21.00% 21.00%
Differential arising from:      
Foreign earnings (11.10%) (10.40%) (16.50%)
GILTI and the foreign-derived intangible income deduction 2.80% (0.50%) 6.00%
State taxes (0.70%) 0.00% 1.00%
R&D tax credit (0.50%) (0.60%) (1.80%)
Tax settlements (0.10%) (2.00%) (0.20%)
Valuation allowances 0.70% 0.70% 0.60%
Restructuring 0.10% 0.40% 1.80%
Acquisition of VelosBio 0.00% (0.10%) 9.50%
Acquisition of Pandion 0.00% 2.60% 0.00%
Acquisition of OncoImmune 0.00% 0.00% 1.70%
Other (0.50%) (0.10%) (0.20%)
Total, Tax Rate 11.70% 11.00% 22.90%
XML 144 R99.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Contingency [Line Items]        
Transition tax for accumulated foreign earnings, liability $ 2,200      
Deferred tax assets on NOL carryforwards relating to foreign jurisdictions 349      
Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards 563      
Income taxes paid 3,239 $ 2,412 $ 2,740  
Tax benefits relating to stock option exercises 45 21 12  
Unrecognized tax benefits 1,835 1,529 1,537 $ 1,225
Favorable net impact to income tax provision if unrecognized tax benefits were recognized 1,800      
Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to) 31      
Interest and penalties associated with uncertain tax positions, expense (benefit) 54 (37) 16  
Liabilities for accrued interest and penalties 256 192    
Unrecognized tax benefits from adjustments related to examination 6 46 70  
Income Taxes Payable        
Income Tax Contingency [Line Items]        
Transition tax liability, current 732      
Other Noncurrent Liabilities        
Income Tax Contingency [Line Items]        
Transition tax liability, noncurrent 1,500      
Foreign Jurisdiction        
Income Tax Contingency [Line Items]        
Valuation allowance on foreign NOL carryforwards 345      
Income taxes paid 1,348 1,201 1,763  
Federal        
Income Tax Contingency [Line Items]        
Valuation allowance on foreign NOL carryforwards 247      
Income taxes paid 1,891 $ 1,211 $ 977  
Federal | Internal Revenue Service (IRS)        
Income Tax Contingency [Line Items]        
Income taxes paid 190      
Unrecognized tax benefits from adjustments related to examination 236      
Federal | Internal Revenue Service (IRS) | Continuing Operations        
Income Tax Contingency [Line Items]        
Income taxes paid 172      
Unrecognized tax benefits from adjustments related to examination 207      
Federal | Internal Revenue Service (IRS) | Discontinued Operations        
Income Tax Contingency [Line Items]        
Income taxes paid 18      
Unrecognized tax benefits from adjustments related to examination $ 29      
XML 145 R100.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]      
Domestic $ 1,011 $ 1,854 $ (3,814)
Foreign 15,433 12,025 9,677
Income from Continuing Operations Before Taxes $ 16,444 $ 13,879 $ 5,863
XML 146 R101.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Taxes on Income (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Current provision      
Federal $ 2,265 $ 74 $ 893
Foreign 1,164 1,273 969
State 57 (13) 44
Total current provision 3,486 1,334 1,906
Deferred provision      
Federal (1,510) 240 (605)
Foreign 71 (77) 64
State (129) 24 (25)
Total deferred provision (1,568) 187 (566)
Taxes on income $ 1,918 $ 1,521 $ 1,340
XML 147 R102.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Deferred Income Taxes (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Income Tax [Line Items]    
Product intangibles and licenses, Assets $ 0 $ 0
R&D capitalization, Assets 1,341 274
Inventory related, Assets 43 119
Accelerated depreciation, Assets 0 0
Equity Method Investments, Assets 0 0
Pensions and other postretirement benefits, Assets 372 487
Compensation related, Assets 335 301
Unrecognized tax benefits, Assets 91 75
Net operating losses and other tax credit carryforwards, Assets 912 867
Other, Assets 511 434
Subtotal, Assets 3,605 2,557
Valuation allowance, Assets (599) (287)
Total deferred taxes 3,006 2,270
Product intangibles and licenses, Liabilities 2,575 3,207
Inventory related, Liabilities 423 370
Accelerated depreciation, Liabilities 657 589
Equity method investments, Liabilities 92 335
Pensions and other postretirement benefits, Liabilities 284 338
Other, Liabilities 267 180
Subtotal, Liabilities 4,298 5,019
Deferred income taxes, Liabilities 1,292 2,749
Deferred Income Taxes 1,795 3,441
Other Assets    
Income Tax [Line Items]    
Total deferred taxes $ 503 $ 692
XML 148 R103.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Income Tax Authority (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Tax Contingency [Line Items]      
Income taxes paid $ 3,239 $ 2,412 $ 2,740
Federal      
Income Tax Contingency [Line Items]      
Income taxes paid 1,891 1,211 977
Foreign Jurisdiction      
Income Tax Contingency [Line Items]      
Income taxes paid $ 1,348 $ 1,201 $ 1,763
XML 149 R104.htm IDEA: XBRL DOCUMENT v3.22.4
Taxes on Income - Unrecognized Tax Benefits (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Reconciliation of Unrecognized Tax Benefits [Roll Forward]      
Balance January 1 $ 1,529 $ 1,537 $ 1,225
Additions related to current year positions 344 306 298
Additions related to prior year positions 48 63 110
Reductions for tax positions of prior years (40) (230) (4)
Settlements (6) (46) (70)
Lapse of statute of limitations (40) (58) (22)
Spin-off of Organon 0 (43) 0
Balance December 31 $ 1,835 $ 1,529 $ 1,537
XML 150 R105.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]      
Net Income from Continuing Operations Attributable to Merck & Co., Inc. $ 14,519 $ 12,345 $ 4,519
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 704 2,548
Net income attributable to Merck & Co., Inc., basic 14,519 13,049 7,067
Net income attributable to Merck & Co., Inc., diluted $ 14,519 $ 13,049 $ 7,067
Average common shares outstanding (in shares) 2,532 2,530 2,530
Common shares issuable (in shares) 10 8 11
Average common shares outstanding assuming dilution (in shares) 2,542 2,538 2,541
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) $ 5.73 $ 4.88 $ 1.79
Income from Discontinued Operations (in dollars per share) 0 0.28 1.01
Net Income (in dollars per share) 5.73 5.16 2.79
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) 5.71 4.86 1.78
Income from Discontinued Operations (in dollars per share) 0 0.28 1.00
Net Income (in dollars per share) $ 5.71 $ 5.14 $ 2.78
XML 151 R106.htm IDEA: XBRL DOCUMENT v3.22.4
Earnings Per Share - Narrative (Details) - shares
shares in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]      
Antidilutive shares (in shares) 2 9 5
XML 152 R107.htm IDEA: XBRL DOCUMENT v3.22.4
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance $ 38,257 $ 25,404 $ 26,001
Other comprehensive income (loss) before reclassification adjustments, pretax 170 1,766 (949)
Tax (150) (526) 293
Other comprehensive income (loss) before reclassification adjustments, net of taxes 20 1,240 (656)
Reclassification adjustments, pretax (446) 658 287
Tax 87 (142) (72)
Reclassification adjustments, net of taxes (359) 516 215
Other comprehensive income (loss), net of taxes (339) 1,756 (441)
Spin-off of Organon & Co.   5,091  
Ending balance 46,058 38,257 25,404
Derivatives      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance 144 (266) 31
Other comprehensive income (loss) before reclassification adjustments, pretax 684 333 (383)
Tax (143) (75) 84
Other comprehensive income (loss) before reclassification adjustments, net of taxes 541 258 (299)
Reclassification adjustments, pretax (775) 192 2
Tax 163 (40) 0
Reclassification adjustments, net of taxes (612) 152 2
Other comprehensive income (loss), net of taxes (71) 410 (297)
Spin-off of Organon & Co. 0    
Ending balance 73 144 (266)
Investments      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance 0 0 18
Other comprehensive income (loss) before reclassification adjustments, pretax 0 0 3
Tax 0 0 0
Other comprehensive income (loss) before reclassification adjustments, net of taxes 0 0 3
Reclassification adjustments, pretax 0 0 (21)
Tax 0 0 0
Reclassification adjustments, net of taxes 0 0 (21)
Other comprehensive income (loss), net of taxes 0 0 (18)
Spin-off of Organon & Co. 0    
Ending balance 0 0 0
Employee Benefit Plans      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (2,743) (4,540) (4,261)
Other comprehensive income (loss) before reclassification adjustments, pretax 70 1,737 (633)
Tax 12 (332) 120
Other comprehensive income (loss) before reclassification adjustments, net of taxes 82 1,405 (513)
Reclassification adjustments, pretax 329 466 306
Tax (76) (102) (72)
Reclassification adjustments, net of taxes 253 364 234
Other comprehensive income (loss), net of taxes 335 1,769 (279)
Spin-off of Organon & Co. 28    
Ending balance (2,408) (2,743) (4,540)
Pension Plan Net Loss      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI 3,100 3,600  
Other Postretirement Benefit Plan Net Gain      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI (446) (473)  
Pension Plan Prior Service Credit      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI (152) (190)  
Other Postretirement Benefit Plan Prior Service Credit      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI (135) (181)  
Foreign Currency Translation Adjustment      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (1,830) (1,828) (1,981)
Other comprehensive income (loss) before reclassification adjustments, pretax (584) (304) 64
Tax (19) (119) 89
Other comprehensive income (loss) before reclassification adjustments, net of taxes (603) (423) 153
Reclassification adjustments, pretax 0 0 0
Tax 0 0 0
Reclassification adjustments, net of taxes 0 0 0
Other comprehensive income (loss), net of taxes (603) (423) 153
Spin-off of Organon & Co. 421    
Ending balance (2,433) (1,830) (1,828)
Accumulated Other Comprehensive Loss      
Accumulated Other Comprehensive Income (Loss) [Roll Forward]      
Beginning balance (4,429) (6,634) (6,193)
Spin-off of Organon & Co. 449 449  
Ending balance $ (4,768) $ (4,429) $ (6,634)
XML 153 R108.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Narrative (Details)
12 Months Ended
Dec. 31, 2022
segment
Segment Reporting [Abstract]  
Number of operating segments 2
XML 154 R109.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Sales of Company's Products (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Sales $ 59,283 $ 48,704 $ 41,518
Increase (decrease) in revenue hedging activities 810 (203) (19)
Revenue related to the sale of the marketing rights 165 218 54
Operating Segments      
Segment Reporting Information [Line Items]      
Sales 57,555 48,322 41,336
Operating Segments | Pharmaceutical segment      
Segment Reporting Information [Line Items]      
Sales 52,005 42,754 36,610
Operating Segments | Pharmaceutical segment | Keytruda      
Segment Reporting Information [Line Items]      
Sales 20,937 17,186 14,380
Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 1,116 989 725
Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 876 704 580
Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 166 17 0
Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 6,897 5,673 3,938
Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 2,241 2,135 1,878
Operating Segments | Pharmaceutical segment | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 783 807 797
Operating Segments | Pharmaceutical segment | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 602 893 1,087
Operating Segments | Pharmaceutical segment | Vaqta      
Segment Reporting Information [Line Items]      
Sales 173 179 170
Operating Segments | Pharmaceutical segment | Bridion      
Segment Reporting Information [Line Items]      
Sales 1,685 1,532 1,198
Operating Segments | Pharmaceutical segment | Prevymis      
Segment Reporting Information [Line Items]      
Sales 428 370 281
Operating Segments | Pharmaceutical segment | Dificid      
Segment Reporting Information [Line Items]      
Sales 263 175 110
Operating Segments | Pharmaceutical segment | Primaxin      
Segment Reporting Information [Line Items]      
Sales 239 259 251
Operating Segments | Pharmaceutical segment | Noxafil      
Segment Reporting Information [Line Items]      
Sales 238 259 329
Operating Segments | Pharmaceutical segment | Invanz      
Segment Reporting Information [Line Items]      
Sales 189 202 211
Operating Segments | Pharmaceutical segment | Cancidas      
Segment Reporting Information [Line Items]      
Sales 174 212 213
Operating Segments | Pharmaceutical segment | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 169 (1) 130
Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 341 342 281
Operating Segments | Pharmaceutical segment | Adempas      
Segment Reporting Information [Line Items]      
Sales 238 252 220
Operating Segments | Pharmaceutical segment | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 5,684 952 0
Operating Segments | Pharmaceutical segment | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 633 769 857
Operating Segments | Pharmaceutical segment | Belsomra      
Segment Reporting Information [Line Items]      
Sales 258 318 327
Operating Segments | Pharmaceutical segment | Simponi      
Segment Reporting Information [Line Items]      
Sales 706 825 838
Operating Segments | Pharmaceutical segment | Remicade      
Segment Reporting Information [Line Items]      
Sales 207 299 330
Operating Segments | Pharmaceutical segment | Januvia      
Segment Reporting Information [Line Items]      
Sales 2,813 3,324 3,306
Operating Segments | Pharmaceutical segment | Janumet      
Segment Reporting Information [Line Items]      
Sales 1,700 1,964 1,971
Operating Segments | Pharmaceutical segment | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 2,249 2,118 2,202
Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 5,550 5,568 4,703
Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 3,300 3,295 2,939
Operating Segments | Animal Health | Companion Animals      
Segment Reporting Information [Line Items]      
Sales 2,250 2,273 1,764
Operating Segments | Other segments      
Segment Reporting Information [Line Items]      
Sales 0 0 23
Other      
Segment Reporting Information [Line Items]      
Sales 1,728 382 182
United States      
Segment Reporting Information [Line Items]      
Sales 27,206 22,425 19,588
United States | Operating Segments      
Segment Reporting Information [Line Items]      
Sales 26,811 22,159 19,517
United States | Operating Segments | Pharmaceutical segment      
Segment Reporting Information [Line Items]      
Sales 24,989 20,401 18,010
United States | Operating Segments | Pharmaceutical segment | Keytruda      
Segment Reporting Information [Line Items]      
Sales 12,686 9,765 8,352
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 584 515 417
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 579 417 359
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 123 0 0
United States | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 2,065 1,881 1,755
United States | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 1,724 1,629 1,378
United States | Operating Segments | Pharmaceutical segment | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 508 473 486
United States | Operating Segments | Pharmaceutical segment | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 346 547 727
United States | Operating Segments | Pharmaceutical segment | Vaqta      
Segment Reporting Information [Line Items]      
Sales 95 100 103
United States | Operating Segments | Pharmaceutical segment | Bridion      
Segment Reporting Information [Line Items]      
Sales 922 762 583
United States | Operating Segments | Pharmaceutical segment | Prevymis      
Segment Reporting Information [Line Items]      
Sales 188 153 119
United States | Operating Segments | Pharmaceutical segment | Dificid      
Segment Reporting Information [Line Items]      
Sales 241 166 102
United States | Operating Segments | Pharmaceutical segment | Primaxin      
Segment Reporting Information [Line Items]      
Sales 1 2 2
United States | Operating Segments | Pharmaceutical segment | Noxafil      
Segment Reporting Information [Line Items]      
Sales 51 60 42
United States | Operating Segments | Pharmaceutical segment | Invanz      
Segment Reporting Information [Line Items]      
Sales 4 (5) 9
United States | Operating Segments | Pharmaceutical segment | Cancidas      
Segment Reporting Information [Line Items]      
Sales 6 4 7
United States | Operating Segments | Pharmaceutical segment | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 89 4 74
United States | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 329 312 259
United States | Operating Segments | Pharmaceutical segment | Adempas      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical segment | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 1,523 632 0
United States | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 274 294 326
United States | Operating Segments | Pharmaceutical segment | Belsomra      
Segment Reporting Information [Line Items]      
Sales 79 78 81
United States | Operating Segments | Pharmaceutical segment | Simponi      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical segment | Remicade      
Segment Reporting Information [Line Items]      
Sales 0 0 0
United States | Operating Segments | Pharmaceutical segment | Januvia      
Segment Reporting Information [Line Items]      
Sales 1,248 1,404 1,470
United States | Operating Segments | Pharmaceutical segment | Janumet      
Segment Reporting Information [Line Items]      
Sales 355 367 477
United States | Operating Segments | Pharmaceutical segment | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 969 841 882
United States | Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 1,822 1,758 1,484
United States | Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 710 667 612
United States | Operating Segments | Animal Health | Companion Animals      
Segment Reporting Information [Line Items]      
Sales 1,112 1,091 872
United States | Operating Segments | Other segments      
Segment Reporting Information [Line Items]      
Sales 0 0 23
United States | Other      
Segment Reporting Information [Line Items]      
Sales 395 266 71
Int’l      
Segment Reporting Information [Line Items]      
Sales 32,077 26,279 21,930
Int’l | Operating Segments      
Segment Reporting Information [Line Items]      
Sales 30,744 26,163 21,819
Int’l | Operating Segments | Pharmaceutical segment      
Segment Reporting Information [Line Items]      
Sales 27,016 22,353 18,600
Int’l | Operating Segments | Pharmaceutical segment | Keytruda      
Segment Reporting Information [Line Items]      
Sales 8,251 7,421 6,028
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lynparza      
Segment Reporting Information [Line Items]      
Sales 532 473 308
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Lenvima      
Segment Reporting Information [Line Items]      
Sales 297 287 220
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Reblozyl      
Segment Reporting Information [Line Items]      
Sales 43 17 0
Int’l | Operating Segments | Pharmaceutical segment | Gardasil/Gardasil 9      
Segment Reporting Information [Line Items]      
Sales 4,832 3,792 2,184
Int’l | Operating Segments | Pharmaceutical segment | ProQuad/M-M-R II/Varivax      
Segment Reporting Information [Line Items]      
Sales 518 506 500
Int’l | Operating Segments | Pharmaceutical segment | RotaTeq      
Segment Reporting Information [Line Items]      
Sales 275 334 311
Int’l | Operating Segments | Pharmaceutical segment | Pneumovax 23      
Segment Reporting Information [Line Items]      
Sales 256 346 359
Int’l | Operating Segments | Pharmaceutical segment | Vaqta      
Segment Reporting Information [Line Items]      
Sales 78 79 67
Int’l | Operating Segments | Pharmaceutical segment | Bridion      
Segment Reporting Information [Line Items]      
Sales 762 770 615
Int’l | Operating Segments | Pharmaceutical segment | Prevymis      
Segment Reporting Information [Line Items]      
Sales 240 218 162
Int’l | Operating Segments | Pharmaceutical segment | Dificid      
Segment Reporting Information [Line Items]      
Sales 22 10 7
Int’l | Operating Segments | Pharmaceutical segment | Primaxin      
Segment Reporting Information [Line Items]      
Sales 238 258 248
Int’l | Operating Segments | Pharmaceutical segment | Noxafil      
Segment Reporting Information [Line Items]      
Sales 187 199 287
Int’l | Operating Segments | Pharmaceutical segment | Invanz      
Segment Reporting Information [Line Items]      
Sales 185 207 202
Int’l | Operating Segments | Pharmaceutical segment | Cancidas      
Segment Reporting Information [Line Items]      
Sales 168 208 207
Int’l | Operating Segments | Pharmaceutical segment | Zerbaxa      
Segment Reporting Information [Line Items]      
Sales 79 (5) 56
Int’l | Operating Segments | Pharmaceutical segment | Alliance revenue - Adempas/Verquvo      
Segment Reporting Information [Line Items]      
Sales 12 30 22
Int’l | Operating Segments | Pharmaceutical segment | Adempas      
Segment Reporting Information [Line Items]      
Sales 238 252 220
Int’l | Operating Segments | Pharmaceutical segment | Lagevrio      
Segment Reporting Information [Line Items]      
Sales 4,161 320 0
Int’l | Operating Segments | Pharmaceutical segment | Isentress/Isentress HD      
Segment Reporting Information [Line Items]      
Sales 359 474 531
Int’l | Operating Segments | Pharmaceutical segment | Belsomra      
Segment Reporting Information [Line Items]      
Sales 179 241 247
Int’l | Operating Segments | Pharmaceutical segment | Simponi      
Segment Reporting Information [Line Items]      
Sales 706 825 838
Int’l | Operating Segments | Pharmaceutical segment | Remicade      
Segment Reporting Information [Line Items]      
Sales 207 299 330
Int’l | Operating Segments | Pharmaceutical segment | Januvia      
Segment Reporting Information [Line Items]      
Sales 1,565 1,920 1,836
Int’l | Operating Segments | Pharmaceutical segment | Janumet      
Segment Reporting Information [Line Items]      
Sales 1,344 1,597 1,494
Int’l | Operating Segments | Pharmaceutical segment | Other pharmaceutical      
Segment Reporting Information [Line Items]      
Sales 1,282 1,275 1,321
Int’l | Operating Segments | Animal Health      
Segment Reporting Information [Line Items]      
Sales 3,728 3,810 3,219
Int’l | Operating Segments | Animal Health | Livestock      
Segment Reporting Information [Line Items]      
Sales 2,590 2,628 2,327
Int’l | Operating Segments | Animal Health | Companion Animals      
Segment Reporting Information [Line Items]      
Sales 1,138 1,182 892
Int’l | Operating Segments | Other segments      
Segment Reporting Information [Line Items]      
Sales 0 0 0
Int’l | Other      
Segment Reporting Information [Line Items]      
Sales $ 1,333 $ 116 $ 111
XML 155 R110.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Consolidated Revenues by Geographic Area (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales $ 59,283 $ 48,704 $ 41,518
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 27,206 22,425 19,588
Europe, Middle East and Africa      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 14,493 13,341 11,547
China      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 5,191 4,378 2,751
Japan      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 3,629 2,726 2,602
Asia Pacific (other than China and Japan)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 3,614 2,407 2,113
Latin America      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales 2,582 2,206 1,890
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Sales $ 2,568 $ 1,221 $ 1,027
XML 156 R111.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Interest income $ 157 $ 36 $ 59
Interest expense (962) (806) (831)
Amortization (2,085) (1,636) (1,817)
Depreciation (1,824) (1,578) (1,669)
Research and development (13,548) (12,245) (13,397)
Restructuring costs (337) (661) (575)
Income before taxes 16,444 13,879 5,863
Total segment profits      
Segment Reporting Information [Line Items]      
Income before taxes 38,815 32,927 27,776
Total segment profits | Pharmaceutical segment      
Segment Reporting Information [Line Items]      
Income before taxes 36,852 30,977 26,106
Total segment profits | Animal Health      
Segment Reporting Information [Line Items]      
Income before taxes 1,963 1,950 1,669
Total segment profits | Other segments      
Segment Reporting Information [Line Items]      
Income before taxes 0 0 1
Other profits      
Segment Reporting Information [Line Items]      
Income before taxes 1,160 156 75
Unallocated      
Segment Reporting Information [Line Items]      
Interest income 157 36 59
Interest expense (962) (806) (831)
Amortization (2,085) (1,636) (1,817)
Depreciation (1,642) (1,414) (1,519)
Research and development (13,011) (11,692) (12,911)
Restructuring costs (337) (661) (575)
Other unallocated, net $ (5,651) $ (3,031) $ (4,394)
XML 157 R112.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) - Operating Segments - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Segment Reporting Information [Line Items]      
Equity income (loss) from affiliates $ 39 $ 11 $ (6)
Depreciation 182 164 150
Pharmaceutical      
Segment Reporting Information [Line Items]      
Equity income (loss) from affiliates 39 11 (6)
Depreciation 5 6 6
Animal Health      
Segment Reporting Information [Line Items]      
Equity income (loss) from affiliates 0 0 0
Depreciation 177 158 143
Other segments      
Segment Reporting Information [Line Items]      
Equity income (loss) from affiliates 0 0 0
Depreciation $ 0 $ 0 $ 1
XML 158 R113.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net $ 21,422 $ 19,279 $ 17,000
United States      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 12,891 11,759 10,394
Europe, Middle East and Africa      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 6,993 6,081 5,314
Asia Pacific (other than China and Japan)      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 966 857 737
Latin America      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 225 199 169
China      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 207 220 216
Japan      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net 135 159 166
Other      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Property, plant and equipment, net $ 5 $ 4 $ 4
XML 159 mrk-20221231_htm.xml IDEA: XBRL DOCUMENT 0000310158 2022-01-01 2022-12-31 0000310158 mrk:A0.500Notesdue2024Member 2022-01-01 2022-12-31 0000310158 mrk:A1.875Notesdue2026Member 2022-01-01 2022-12-31 0000310158 mrk:A2.500Notesdue2034Member 2022-01-01 2022-12-31 0000310158 mrk:A1.375Notesdue2036Member 2022-01-01 2022-12-31 0000310158 2023-01-31 0000310158 2022-06-30 0000310158 2021-01-01 2021-12-31 0000310158 2020-01-01 2020-12-31 0000310158 2022-12-31 0000310158 2021-12-31 0000310158 us-gaap:CommonStockMember 2019-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000310158 us-gaap:RetainedEarningsMember 2019-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-12-31 0000310158 2019-12-31 0000310158 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2020-01-01 2020-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000310158 us-gaap:CommonStockMember 2020-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000310158 us-gaap:RetainedEarningsMember 2020-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2020-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-12-31 0000310158 2020-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0000310158 us-gaap:CommonStockMember 2021-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2021-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0000310158 us-gaap:CommonStockMember 2022-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2022-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2022-12-31 0000310158 srt:MinimumMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember 2022-01-01 2022-12-31 0000310158 srt:MinimumMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 srt:MinimumMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember country:US 2022-01-01 2022-12-31 0000310158 srt:MinimumMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember us-gaap:NonUsMember 2022-01-01 2022-12-31 0000310158 srt:MinimumMember us-gaap:BuildingMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember us-gaap:BuildingMember 2022-01-01 2022-12-31 0000310158 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2022-01-01 2022-12-31 0000310158 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2022-01-01 2022-12-31 0000310158 mrk:OrganonCoMember 2021-06-02 0000310158 2021-06-02 0000310158 srt:MinimumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MinimumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 mrk:OrganonCoMember 2022-01-01 2022-12-31 0000310158 mrk:OrganonCoMember 2021-01-01 2021-12-31 0000310158 mrk:OrganonCoMember 2022-12-31 0000310158 mrk:OrganonCoMember 2021-12-31 0000310158 mrk:OrganonCoMember 2021-06-02 2021-06-02 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-01 2023-02-24 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-02-24 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember us-gaap:SubsequentEventMember 2023-01-01 2023-01-31 0000310158 mrk:ImagoBioSciencesIncMember us-gaap:SubsequentEventMember 2023-01-31 0000310158 mrk:RoyaltyPharmaMember 2022-10-01 2022-10-31 0000310158 mrk:ModernaMember us-gaap:LicensingAgreementsMember 2022-09-01 2022-09-30 0000310158 mrk:OrnaTherapeuticsMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember us-gaap:LicensingAgreementsMember 2022-10-01 2022-12-31 0000310158 mrk:OrionCorporationMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-12-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:FirstCommercialSaleMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:AcceleronPharmaIncMember 2021-11-01 2021-11-30 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2021-11-01 2021-11-30 0000310158 mrk:BristolMyersSquibbMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2021-11-01 2021-11-30 0000310158 mrk:BristolMyersSquibbMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2021-11-01 2021-11-30 0000310158 mrk:BristolMyersSquibbMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 mrk:BristolMyersSquibbMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 mrk:AcceleronPharmaIncMember 2021-11-30 0000310158 mrk:AcceleronPharmaIncMember 2021-11-19 0000310158 mrk:AcceleronPharmaIncMember us-gaap:MeasurementInputDiscountRateMember 2021-11-19 0000310158 mrk:PandionTherapeuticsMember 2021-04-01 2021-04-30 0000310158 mrk:PandionTherapeuticsMember 2021-04-30 0000310158 mrk:PandionTherapeuticsMember 2021-01-01 2021-12-31 0000310158 mrk:GileadSciencesMember mrk:OralAndInjectableFormulationsMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-01 2021-03-31 0000310158 mrk:GileadSciencesMember mrk:OralFormulationMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-01 2021-03-31 0000310158 mrk:GileadSciencesMember mrk:InjectableFormulationMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2021-03-01 2021-03-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:OncoImmuneMember 2020-12-01 2020-12-31 0000310158 mrk:OncoImmuneMember 2020-12-31 0000310158 mrk:OncoImmuneMember 2020-12-31 0000310158 mrk:OncoImmuneMember 2020-01-01 2020-12-31 0000310158 mrk:COVID19Member 2021-01-01 2021-12-31 0000310158 mrk:VelosBioMember 2020-12-01 2020-12-31 0000310158 mrk:VelosBioMember 2020-12-31 0000310158 mrk:VelosBioMember 2020-01-01 2020-12-31 0000310158 mrk:VelosBioMember 2021-01-01 2021-12-31 0000310158 mrk:VelosBioMember 2021-12-01 2021-12-31 0000310158 mrk:VelosBioMember 2021-12-31 0000310158 mrk:SeagenMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember 2020-09-30 0000310158 mrk:SeagenMember 2020-01-01 2020-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000310158 mrk:SeagenMember mrk:DevelopmentMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:SalesBasedMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember mrk:RegulatoryMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember srt:MinimumMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember srt:MaximumMember 2020-09-01 2020-09-30 0000310158 mrk:DunboyneMember 2020-09-01 2020-09-30 0000310158 mrk:DunboyneMember 2020-09-30 0000310158 mrk:SentinelMember 2020-07-01 2020-07-31 0000310158 mrk:SentinelMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2020-07-31 0000310158 mrk:SentinelMember 2020-07-31 0000310158 mrk:SentinelMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2020-07-31 0000310158 mrk:ThemisMember 2020-06-01 2020-06-30 0000310158 mrk:ThemisMember 2020-06-30 0000310158 mrk:COVID19Member mrk:ThemisMember 2020-01-01 2020-12-31 0000310158 mrk:IAVIMember 2020-05-01 2020-05-31 0000310158 mrk:COVID19Member 2020-01-01 2020-12-31 0000310158 mrk:ArQuleMember 2020-01-01 2020-01-31 0000310158 mrk:ArQuleMember 2020-01-31 0000310158 mrk:ArQuleMember 2020-01-16 0000310158 mrk:ArQuleMember us-gaap:MeasurementInputDiscountRateMember 2020-01-16 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-12-31 0000310158 mrk:LynparzaMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-12-31 0000310158 mrk:LynparzaMember us-gaap:LicenseMember 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:LynparzaMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember 2021-03-01 2021-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-12-31 0000310158 mrk:LenvimaMember us-gaap:LicenseMember 2022-12-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember mrk:SalesBasedMilestonesMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-12-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000310158 mrk:VerquvoMember us-gaap:OtherIntangibleAssetsMember 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 srt:ScenarioForecastMember 2023-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember 2022-01-01 2022-12-31 0000310158 us-gaap:OtherRestructuringMember 2022-01-01 2022-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-12-31 0000310158 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-12-31 0000310158 us-gaap:RestructuringChargesMember 2021-01-01 2021-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-12-31 0000310158 mrk:AcceleratedDepreciationMember 2021-01-01 2021-12-31 0000310158 us-gaap:OtherRestructuringMember 2021-01-01 2021-12-31 0000310158 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-12-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-12-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-12-31 0000310158 us-gaap:RestructuringChargesMember 2020-01-01 2020-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-12-31 0000310158 mrk:AcceleratedDepreciationMember 2020-01-01 2020-12-31 0000310158 us-gaap:OtherRestructuringMember 2020-01-01 2020-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-12-31 0000310158 mrk:AcceleratedDepreciationMember 2020-12-31 0000310158 us-gaap:OtherRestructuringMember 2020-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2021-12-31 0000310158 mrk:AcceleratedDepreciationMember 2021-12-31 0000310158 us-gaap:OtherRestructuringMember 2021-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-12-31 0000310158 mrk:AcceleratedDepreciationMember 2022-12-31 0000310158 us-gaap:OtherRestructuringMember 2022-12-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-12-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000310158 mrk:EurodominatedNotesMember 2022-01-01 2022-12-31 0000310158 mrk:EurodominatedNotesMember 2021-01-01 2021-12-31 0000310158 mrk:EurodominatedNotesMember 2020-01-01 2020-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000310158 us-gaap:InterestRateSwapMember 2022-01-01 2022-12-31 0000310158 mrk:A2.40NotesDue2022Member 2022-12-31 0000310158 mrk:A2.35NotesDue2022Member 2022-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2022-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2022-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:NondesignatedMember 2022-12-31 0000310158 us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-12-31 0000310158 us-gaap:InterestRateSwapMember 2021-01-01 2021-12-31 0000310158 us-gaap:InterestRateSwapMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2020-01-01 2020-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000310158 us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000310158 mrk:SanofiPasteurMember 2022-12-31 0000310158 mrk:SanofiPasteurMember 2021-12-31 0000310158 mrk:McKessonCorporationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000310158 mrk:AmerisourceBergenCorporationMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000310158 mrk:CardinalHealthIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000310158 2022-10-01 2022-12-31 0000310158 2021-10-01 2021-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2022-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2021-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2022-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2021-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2020-12-31 0000310158 mrk:AnimalHealthsegmentMember 2020-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2021-12-31 0000310158 mrk:AnimalHealthsegmentMember 2021-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 mrk:PharmaceuticalsegmentMember 2022-12-31 0000310158 mrk:AnimalHealthsegmentMember 2022-12-31 0000310158 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000310158 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000310158 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000310158 us-gaap:TradeNamesMember 2022-12-31 0000310158 us-gaap:TradeNamesMember 2021-12-31 0000310158 us-gaap:LicenseMember 2022-12-31 0000310158 us-gaap:LicenseMember 2021-12-31 0000310158 mrk:ReblozylMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:ZerbaxaMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:SivextroMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:GardasilGardasil9Member us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:BridionMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:AnimalHealthMember 2022-12-31 0000310158 mrk:AnimalHealthMember us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000310158 mrk:AnimalHealthMember us-gaap:TradeNamesMember 2022-12-31 0000310158 mrk:SotaterceptMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000310158 mrk:GefapixantMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000310158 mrk:ZerbaxaMember 2020-01-01 2020-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-01 2022-12-31 0000310158 mrk:DerazantinibMember us-gaap:LicenseMember 2022-01-01 2022-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0000310158 mrk:NemtabrutinibMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2021-12-31 0000310158 mrk:NotesSubjectToRepaymentAtOptionOfHolderMember 2022-12-31 0000310158 mrk:NotesSubjectToRepaymentAtOptionOfHolderMember 2021-12-31 0000310158 us-gaap:CommercialPaperMember 2022-12-31 0000310158 us-gaap:CommercialPaperMember 2021-12-31 0000310158 mrk:A2.75NotesDue2025Member 2022-12-31 0000310158 mrk:A2.75NotesDue2025Member 2021-12-31 0000310158 mrk:A215NotesDue2031Member 2022-12-31 0000310158 mrk:A215NotesDue2031Member 2021-12-31 0000310158 mrk:A275NotesDue2051Member 2022-12-31 0000310158 mrk:A275NotesDue2051Member 2021-12-31 0000310158 mrk:A3.70NotesDue2045Member 2022-12-31 0000310158 mrk:A3.70NotesDue2045Member 2021-12-31 0000310158 mrk:A3.40NotesDue2029Member 2022-12-31 0000310158 mrk:A3.40NotesDue2029Member 2021-12-31 0000310158 mrk:A170NotesDue2027Member 2022-12-31 0000310158 mrk:A170NotesDue2027Member 2021-12-31 0000310158 mrk:A290NotesDue2061Member 2022-12-31 0000310158 mrk:A290NotesDue2061Member 2021-12-31 0000310158 mrk:A4.00NotesDue2049Member 2022-12-31 0000310158 mrk:A4.00NotesDue2049Member 2021-12-31 0000310158 mrk:A415NotesDue2043Member 2022-12-31 0000310158 mrk:A415NotesDue2043Member 2021-12-31 0000310158 mrk:A145NotesDue2030Member 2022-12-31 0000310158 mrk:A145NotesDue2030Member 2021-12-31 0000310158 mrk:A245NotesDue2050Member 2022-12-31 0000310158 mrk:A245NotesDue2050Member 2021-12-31 0000310158 mrk:A1.875EuroNotesDue2026Member 2022-12-31 0000310158 mrk:A1.875EuroNotesDue2026Member 2021-12-31 0000310158 mrk:A075NotesDue2026Member 2022-12-31 0000310158 mrk:A075NotesDue2026Member 2021-12-31 0000310158 mrk:A190NotesDue2028Member 2022-12-31 0000310158 mrk:A190NotesDue2028Member 2021-12-31 0000310158 mrk:A3.90NotesDue2039Member 2022-12-31 0000310158 mrk:A3.90NotesDue2039Member 2021-12-31 0000310158 mrk:A235NotesDue2040Member 2022-12-31 0000310158 mrk:A235NotesDue2040Member 2021-12-31 0000310158 mrk:A2.90NotesDue2024Member 2022-12-31 0000310158 mrk:A2.90NotesDue2024Member 2021-12-31 0000310158 mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember 2022-12-31 0000310158 mrk:SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember 2021-12-31 0000310158 mrk:A0.50eurodenominatednotesdue2024Member 2022-12-31 0000310158 mrk:A0.50eurodenominatednotesdue2024Member 2021-12-31 0000310158 mrk:A1.375eurodenominatednotesdue2036Member 2022-12-31 0000310158 mrk:A1.375eurodenominatednotesdue2036Member 2021-12-31 0000310158 mrk:A2.5EuroNotesDue2034Member 2022-12-31 0000310158 mrk:A2.5EuroNotesDue2034Member 2021-12-31 0000310158 mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember 2022-12-31 0000310158 mrk:ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember 2021-12-31 0000310158 mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember 2022-12-31 0000310158 mrk:SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember 2021-12-31 0000310158 mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember 2022-12-31 0000310158 mrk:FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember 2021-12-31 0000310158 mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember 2022-12-31 0000310158 mrk:FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember 2021-12-31 0000310158 mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember 2022-12-31 0000310158 mrk:FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember 2021-12-31 0000310158 mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember 2022-12-31 0000310158 mrk:SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember 2021-12-31 0000310158 mrk:A63DebenturesDue2026Member 2022-12-31 0000310158 mrk:A63DebenturesDue2026Member 2021-12-31 0000310158 mrk:A280NotesDue2023Member 2022-12-31 0000310158 mrk:A280NotesDue2023Member 2021-12-31 0000310158 mrk:OtherLongTermDebtMember 2022-12-31 0000310158 mrk:OtherLongTermDebtMember 2021-12-31 0000310158 mrk:OtherVariableRateDebtMember 2022-12-31 0000310158 mrk:OtherVariableRateDebtMember 2021-12-31 0000310158 us-gaap:BuildingMember 2022-12-31 0000310158 us-gaap:VehiclesMember 2022-12-31 0000310158 mrk:GardasilGardasil9Member country:US 2022-12-31 0000310158 mrk:GardasilGardasil9Member us-gaap:NonUsMember 2022-12-31 0000310158 mrk:GardasilGardasil9Member country:CO 2022-12-31 0000310158 mrk:ZetiaantitrustlitigationMember 2020-08-31 0000310158 mrk:ZetiaantitrustlitigationMember us-gaap:PendingLitigationMember 2022-06-30 2022-06-30 0000310158 mrk:ZetiaantitrustlitigationMember 2022-01-01 2022-12-31 0000310158 mrk:CommercialandOtherLitigationMember 2022-01-01 2022-12-31 0000310158 mrk:CommercialandOtherLitigationMember 2022-12-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-12-19 2022-12-19 0000310158 us-gaap:PatentsMember mrk:BridionMember 2022-01-01 2022-12-31 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-12-31 0000310158 mrk:PatentlitigationMember 2022-01-01 2022-12-31 0000310158 mrk:LegalDefenseCostsMember 2021-12-31 0000310158 mrk:LegalDefenseCostsMember 2022-12-31 0000310158 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000310158 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000310158 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000310158 us-gaap:PerformanceSharesMember 2021-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000310158 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000310158 us-gaap:PerformanceSharesMember 2022-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-12-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:FixedIncomeObligationsInvestmentFundsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member country:US us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-12-31 0000310158 mrk:InsuranceContractsOtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:OtherInvestmentsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-12-31 0000310158 mrk:RealEstateInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:CashAndCashEquivalentsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:EmergingMarketsEquitiesInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanRealEstateMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsInvestmentFundsMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:DevelopedMarketsEquitySecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:CorporateObligationsFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 mrk:MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:DefinedBenefitPlanDerivativeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 us-gaap:FairValueMeasuredAtNetAssetValuePerShareMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-12-31 0000310158 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember country:US 2022-12-31 0000310158 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesUsMember country:US 2022-12-31 0000310158 srt:MinimumMember us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember country:US 2022-12-31 0000310158 srt:MaximumMember us-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember country:US 2022-12-31 0000310158 srt:MinimumMember us-gaap:FixedIncomeInvestmentsMember country:US 2022-12-31 0000310158 srt:MaximumMember us-gaap:FixedIncomeInvestmentsMember country:US 2022-12-31 0000310158 srt:MaximumMember mrk:DefinedBenefitPlanCashandOtherInvestmentsMember country:US 2022-12-31 0000310158 country:US 2022-12-31 0000310158 country:US 2022-01-01 2022-12-31 0000310158 country:US 2021-01-01 2021-12-31 0000310158 country:US 2020-01-01 2020-12-31 0000310158 country:US 2021-12-31 0000310158 country:US 2020-12-31 0000310158 srt:ScenarioForecastMember country:US 2023-01-01 2023-12-31 0000310158 srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2023-01-01 2023-03-31 0000310158 mrk:IncomeTaxesPayableMember 2022-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember 2022-12-31 0000310158 us-gaap:OtherAssetsMember 2022-12-31 0000310158 us-gaap:OtherAssetsMember 2021-12-31 0000310158 us-gaap:ForeignCountryMember 2022-12-31 0000310158 us-gaap:DomesticCountryMember 2022-12-31 0000310158 us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000310158 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0000310158 us-gaap:DomesticCountryMember 2020-01-01 2020-12-31 0000310158 us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0000310158 us-gaap:ForeignCountryMember 2021-01-01 2021-12-31 0000310158 us-gaap:ForeignCountryMember 2020-01-01 2020-12-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-01-01 2022-12-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentContinuingOperationsMember 2022-01-01 2022-12-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentDiscontinuedOperationsMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-01-01 2021-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2021-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000310158 mrk:PensionPlanNetLossMember 2022-12-31 0000310158 mrk:PensionPlanNetLossMember 2021-12-31 0000310158 mrk:OtherPostretirementBenefitPlanNetLossMember 2022-12-31 0000310158 mrk:OtherPostretirementBenefitPlanNetLossMember 2021-12-31 0000310158 mrk:PensionPlanPriorServiceCostMember 2022-12-31 0000310158 mrk:PensionPlanPriorServiceCostMember 2021-12-31 0000310158 mrk:OtherPostretirementBenefitPlanPriorServiceCostMember 2022-12-31 0000310158 mrk:OtherPostretirementBenefitPlanPriorServiceCostMember 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ReblozylMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember 2022-01-01 2022-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember 2021-01-01 2021-12-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2020-01-01 2020-12-31 0000310158 us-gaap:OperatingSegmentsMember 2020-01-01 2020-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2021-01-01 2021-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2021-01-01 2021-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-12-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2020-01-01 2020-12-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2020-01-01 2020-12-31 0000310158 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-12-31 0000310158 country:US 2022-01-01 2022-12-31 0000310158 mrk:InternationalMember 2022-01-01 2022-12-31 0000310158 country:US 2021-01-01 2021-12-31 0000310158 mrk:InternationalMember 2021-01-01 2021-12-31 0000310158 country:US 2020-01-01 2020-12-31 0000310158 mrk:InternationalMember 2020-01-01 2020-12-31 0000310158 us-gaap:EMEAMember 2022-01-01 2022-12-31 0000310158 us-gaap:EMEAMember 2021-01-01 2021-12-31 0000310158 us-gaap:EMEAMember 2020-01-01 2020-12-31 0000310158 country:CN 2022-01-01 2022-12-31 0000310158 country:CN 2021-01-01 2021-12-31 0000310158 country:CN 2020-01-01 2020-12-31 0000310158 country:JP 2022-01-01 2022-12-31 0000310158 country:JP 2021-01-01 2021-12-31 0000310158 country:JP 2020-01-01 2020-12-31 0000310158 srt:AsiaPacificMember 2022-01-01 2022-12-31 0000310158 srt:AsiaPacificMember 2021-01-01 2021-12-31 0000310158 srt:AsiaPacificMember 2020-01-01 2020-12-31 0000310158 srt:LatinAmericaMember 2022-01-01 2022-12-31 0000310158 srt:LatinAmericaMember 2021-01-01 2021-12-31 0000310158 srt:LatinAmericaMember 2020-01-01 2020-12-31 0000310158 mrk:OtherCountriesMember 2022-01-01 2022-12-31 0000310158 mrk:OtherCountriesMember 2021-01-01 2021-12-31 0000310158 mrk:OtherCountriesMember 2020-01-01 2020-12-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-12-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-12-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-12-31 0000310158 country:US 2022-12-31 0000310158 country:US 2021-12-31 0000310158 country:US 2020-12-31 0000310158 us-gaap:EMEAMember 2022-12-31 0000310158 us-gaap:EMEAMember 2021-12-31 0000310158 us-gaap:EMEAMember 2020-12-31 0000310158 srt:AsiaPacificMember 2022-12-31 0000310158 srt:AsiaPacificMember 2021-12-31 0000310158 srt:AsiaPacificMember 2020-12-31 0000310158 srt:LatinAmericaMember 2022-12-31 0000310158 srt:LatinAmericaMember 2021-12-31 0000310158 srt:LatinAmericaMember 2020-12-31 0000310158 country:CN 2022-12-31 0000310158 country:CN 2021-12-31 0000310158 country:CN 2020-12-31 0000310158 country:JP 2022-12-31 0000310158 country:JP 2021-12-31 0000310158 country:JP 2020-12-31 0000310158 mrk:OtherCountriesMember 2022-12-31 0000310158 mrk:OtherCountriesMember 2021-12-31 0000310158 mrk:OtherCountriesMember 2020-12-31 shares iso4217:USD iso4217:USD shares mrk:segment pure mrk:research_program mrk:collaboration_target iso4217:EUR mrk:interest_rate_swap mrk:case mrk:claim mrk:Plaintiff false 2022 FY 0000310158 P3M 0.1 http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#RestructuringCharges http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent 0.3333 10-K true 2022-12-31 --12-31 false 1-6571 Merck & Co., Inc. 126 East Lincoln Avenue Rahway NJ 07065 908 740-4000 NJ 22-1918501 Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE Yes No Yes Yes Large Accelerated Filer false false true false 2538592467 230820000000 <div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Proxy Statement for the Annual Meeting of Shareholders to be held May 23, 2023, to be filed with the </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Securities and Exchange Commission within 120 days after the close of the fiscal year covered by this report</span></div> 59283000000 48704000000 41518000000 17411000000 13626000000 13618000000 10042000000 9634000000 8955000000 13548000000 12245000000 13397000000 337000000 661000000 575000000 -1501000000 1341000000 890000000 42839000000 34825000000 35655000000 16444000000 13879000000 5863000000 1918000000 1521000000 1340000000 14526000000 12358000000 4523000000 7000000 13000000 4000000 14519000000 12345000000 4519000000 0 704000000 2548000000 14519000000 13049000000 7067000000 5.73 4.88 1.79 0 0.28 1.01 5.73 5.16 2.79 5.71 4.86 1.78 0 0.28 1.00 5.71 5.14 2.78 14519000000 13049000000 7067000000 -71000000 410000000 -297000000 0 0 -18000000 -335000000 -1769000000 279000000 -603000000 -423000000 153000000 -339000000 1756000000 -441000000 14180000000 14805000000 6626000000 12694000000 8096000000 498000000 0 72000000 62000000 9450000000 9230000000 2938000000 2194000000 5911000000 5953000000 7169000000 6987000000 35722000000 30266000000 1015000000 370000000 295000000 326000000 13166000000 12529000000 16760000000 16303000000 9186000000 8313000000 39407000000 37471000000 17985000000 18192000000 21422000000 19279000000 21204000000 21264000000 20269000000 22933000000 9528000000 11582000000 109160000000 105694000000 1946000000 2412000000 4264000000 4609000000 14159000000 13859000000 1986000000 1224000000 1884000000 1768000000 24239000000 23872000000 28745000000 30690000000 1795000000 3441000000 8323000000 9434000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 44379000000 44238000000 61081000000 53696000000 -4768000000 -4429000000 102480000000 95293000000 1039269638 1049499023 56489000000 57109000000 45991000000 38184000000 67000000 73000000 46058000000 38257000000 109160000000 105694000000 1788000000 39660000000 46602000000 -6193000000 -55950000000 94000000 26001000000 7067000000 7067000000 -441000000 -441000000 2.48 6307000000 6307000000 1281000000 1281000000 15000000 15000000 22000000 22000000 72000000 -444000000 -372000000 1788000000 39588000000 47362000000 -6634000000 -56787000000 87000000 25404000000 13049000000 13049000000 1756000000 1756000000 2.64 6715000000 6715000000 840000000 840000000 4643000000 449000000 -1000000 5091000000 16000000 16000000 29000000 29000000 -7000000 -518000000 -525000000 1788000000 44238000000 53696000000 -4429000000 -57109000000 73000000 38257000000 14519000000 14519000000 -339000000 -339000000 2.80 7134000000 7134000000 7000000 7000000 13000000 13000000 -141000000 -620000000 -761000000 1788000000 44379000000 61081000000 -4768000000 -56489000000 67000000 46058000000 14526000000 12358000000 4523000000 2085000000 1636000000 1817000000 1824000000 1578000000 1669000000 1749000000 302000000 1718000000 -1419000000 1940000000 1338000000 0 1556000000 0 0 0 2660000000 -1568000000 187000000 -566000000 541000000 479000000 441000000 -1301000000 -805000000 -1294000000 644000000 2033000000 1002000000 161000000 674000000 895000000 -289000000 405000000 684000000 -50000000 277000000 -1152000000 380000000 -540000000 814000000 -545000000 484000000 -617000000 1473000000 1758000000 2433000000 19095000000 13122000000 7617000000 4388000000 4448000000 4429000000 0 0 1000000000 1204000000 1000000 95000000 721000000 1026000000 2812000000 0 11174000000 0 0 1554000000 0 0 0 2696000000 0 0 2545000000 121000000 179000000 1365000000 -32000000 91000000 -125000000 -4960000000 -16421000000 -9193000000 0 -3986000000 2549000000 2251000000 2319000000 1957000000 0 7936000000 4419000000 0 9000000000 0 0 840000000 1281000000 7012000000 6610000000 6215000000 384000000 202000000 89000000 -240000000 -286000000 -436000000 -9119000000 3097000000 -2832000000 0 987000000 2636000000 0 -134000000 -250000000 0 -504000000 0 0 349000000 2386000000 -410000000 -133000000 253000000 4606000000 14000000 -1769000000 71000000 103000000 258000000 8167000000 8153000000 9934000000 0 0 12000000 79000000 71000000 103000000 12773000000 8167000000 8153000000 Nature of Operations<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck &amp; Co., Inc. (Merck or the Company) is a global health care company that delivers innovative health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners. </span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co. </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 3).</span></div> 2 Summary of Accounting Policies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company’s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 19 for disaggregated revenue disclosures.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Depreciation expense was $1.8 billion in 2022, $1.6 billion in 2021 and $1.7 billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Advertising and promotion costs are expensed as incurred. The Company recorded advertising and promotion expenses of $2.2 billion in 2022, $2.0 billion in 2021 and $1.8 billion in 2020.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements. <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Intercompany balances and transactions are eliminated. Controlling interest is determined by majority ownership interest and the absence of substantive third-party participating rights or, in the case of variable interest entities, by majority exposure to expected losses, residual returns or both. For those consolidated subsidiaries where Merck ownership is less than 100%, the outside shareholders’ interests are shown as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in equity. Investments in affiliates over which the Company has significant influence but not a controlling interest, such as interests in entities owned equally by the Company and a third party that are under shared control, are carried on the equity basis.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In a business combination, the acquisition method of accounting requires that the assets acquired and liabilities assumed be recorded as of the date of the acquisition at their respective fair values with limited exceptions. Assets acquired and liabilities assumed in a business combination that arise from contingencies are generally recognized at fair value. If fair value cannot be determined, the asset or liability is recognized if probable and reasonably estimable; if these criteria are not met, no asset or liability is recognized. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Accordingly, the Company may be required to value assets at fair value measures that do not reflect the Company’s intended use of those assets. Any excess of the purchase price (consideration transferred) over the estimated fair values of net assets acquired is recorded as goodwill. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Company’s consolidated financial statements after the date of the acquisition. If the Company determines the assets acquired do not meet the definition of a business under the acquisition method of accounting, the transaction will be accounted for as an acquisition of assets rather than a business combination and, therefore, no </span>goodwill will be recorded. In an asset acquisition, acquired in-process research and development (IPR&amp;D) with no alternative future use is charged to expense and contingent consideration is not recognized at the acquisition date. <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Translation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net assets of international subsidiaries where the local currencies have been determined to be the functional currencies are translated into U.S. dollars using current exchange rates and results of operations are translated at average exchange rates. The U.S. dollar effects that arise from translating the net assets of these subsidiaries at changing rates are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Comprehensive Income (OCI)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">) until either the sale or complete or substantially complete liquidation of the subsidiary. For those subsidiaries that operate in highly inflationary economies and for those subsidiaries where the U.S. dollar has been determined to be the functional currency, non-monetary foreign currency assets and liabilities are translated using historical rates, while monetary assets and liabilities are translated at current rates, with the U.S. dollar effects of rate changes included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash Equivalents —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash equivalents are comprised of certain highly liquid investments with original maturities of less than three months.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Inventories —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value. The cost of a substantial majority of U.S. human health inventories is determined using the last-in, first-out (LIFO) method for both financial reporting and tax purposes. The cost of all other inventories is determined using the first-in, first-out (FIFO) method. Inventories consist of currently marketed products, as well as certain inventories produced in preparation for product launches that are considered by the Company to be probable of obtaining regulatory approval. In evaluating the recoverability of inventories produced in preparation for product launches, the Company considers the likelihood that revenue will be obtained from the future sale of the related inventory together with the status of the product within the regulatory approval process.</span> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Investments —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Investments in marketable debt securities classified as available-for-sale are reported at fair value. Fair values of the Company’s investments in marketable debt securities are determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Changes in fair value that are not impairment related are reported net of taxes in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company considers available evidence in evaluating potential impairments of its investments in marketable debt securities, including the extent to which fair value is less than cost, whether an allowance for credit loss is required, as well as adverse factors that could affect the value of the securities. An impairment has occurred if the Company does not expect to recover the entire amortized cost basis of the marketable debt security. If the Company does not intend to sell the impaired debt security, and it is not more likely than not it will be required to sell the debt security before the recovery of its amortized cost basis, the amount of the impairment recognized in earnings, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is limited to the portion attributed to credit loss. The remaining portion of the impairment related to other factors is recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for debt securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investments in publicly traded equity securities are reported at fair value determined using quoted market prices in active markets for identical assets or quoted prices for similar assets or other inputs that are observable or can be corroborated by observable market data. Changes in fair value are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period. Gains and losses from ownership interests in investment funds, which are accounted for as equity method investments, are reported on a one quarter lag. Investments in equity securities without readily determinable fair values are recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, minus impairments. Such adjustments are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Realized gains and losses for equity securities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recognition of revenue requires evidence of a contract, probable collection of sales proceeds and completion of substantially all performance obligations. Merck acts as the principal in substantially all of its customer arrangements and therefore records revenue on a gross basis. The majority of the Company’s contracts related to the Pharmaceutical and Animal Health segments have a single performance obligation - the promise to transfer goods. Shipping is considered immaterial in the context of the overall customer arrangement and damages or loss of goods in transit are rare. Therefore, shipping is not deemed a separately recognized performance obligation.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The vast majority of revenues from sales of products are recognized at a point in time when control of the goods is transferred to the customer, which the Company has determined is when title and risks and rewards of ownership transfer to the customer and the Company is entitled to payment. The Company recognizes revenue from the sales of vaccines to the Federal government for placement into vaccine stockpiles in accordance with Securities and Exchange Commission (SEC) Interpretation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, Commission Guidance Regarding Accounting for Sales of Vaccines </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">and BioTerror Countermeasures to the Federal Government for Placement into the Pediatric Vaccine Stockpile or the Strategic National Stockpile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. This interpretation allows companies to recognize revenue for sales of vaccines into U.S. government stockpiles even though these sales might not meet the criteria for revenue recognition under other accounting guidance. Some customers have bill-and-hold arrangements with the Company. Revenue for bill-and-hold arrangements is recognized when control transfers to the customer even though the customer does not yet have physical possession of the goods. Control transfers when the bill-and-hold arrangement has been requested by the customer, the product is identified as belonging to the customer and is ready for physical transfer, the product cannot be directed for use by anyone but the customer and, in certain circumstances, the customer has inspected and accepted the product at the Company’s facility. For certain services in the Animal Health segment, revenue is recognized over time, generally ratably over the contract term as services are provided. These service revenues are not material.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The nature of the Company’s business gives rise to several types of variable consideration including discounts and returns, which are estimated at the time of sale generally using the expected value method, although the most likely amount method is used for prompt pay discounts. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the U.S., sales discounts are issued to customers at the point-of-sale, through an intermediary wholesaler (known as chargebacks), or in the form of rebates. Additionally, sales are generally made with a limited right of return under certain conditions. Revenues are recorded net of provisions for sales discounts and returns, which are established at the time of sale. In addition, if collection of accounts receivable is expected to be in excess of one year, sales are recorded net of time value of money discounts, which have not been material. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The U.S. provision for aggregate customer discounts covering chargebacks and rebates was $12.3 billion in 2022, $12.3 billion in 2021 and $11.4 billion in 2020. Chargebacks are discounts that occur when a contracted customer purchases through an intermediary wholesaler. The contracted customer generally purchases product from the wholesaler at its contracted price plus a mark-up. The wholesaler, in turn, charges the Company back for the difference between the price initially paid by the wholesaler and the contract price paid to the wholesaler by the customer. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to contracted customers, as well as estimated wholesaler inventory levels. Rebates are amounts owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers after the final dispensing of the product to a benefit plan participant. The provision for rebates is based on expected patient usage, as well as inventory levels in the distribution channel to determine the contractual obligation to the benefit providers. The Company uses historical customer segment utilization mix, sales forecasts, changes to product mix and price, inventory levels in the distribution channel, government pricing calculations and prior payment history in order to estimate the expected provision. Amounts accrued for aggregate customer discounts are evaluated on a quarterly basis through comparison of information provided by the wholesalers, health maintenance organizations, pharmacy benefit managers, federal and state agencies, and other customers to the amounts accrued. The accrued balances relative to the provisions for chargebacks and rebates included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accounts receivable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> were $178 million and $2.7 billion, respectively, at December 31, 2022 and were $207 million and $2.6 billion, respectively, at December 31, 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outside of the U.S., variable consideration in the form of discounts and rebates are a combination of commercially-driven discounts in highly competitive product classes, discounts required to gain or maintain reimbursement, or legislatively mandated rebates. In certain European countries, legislatively mandated rebates are calculated based on an estimate of the government’s total unbudgeted spending and the Company’s specific payback obligation. Rebates may also be required based on specific product sales thresholds. The Company applies an estimated factor against its actual invoiced sales to represent the expected level of future discount or rebate obligations associated with the sale.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company maintains a returns policy that allows its U.S. pharmaceutical customers to return product within a specified period prior to and subsequent to the expiration date (generally, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNDgvZnJhZzozMDhiNDgxYzc0MGY0YjBlYmMwNDkyMjQzM2FhZjg4OC90ZXh0cmVnaW9uOjMwOGI0ODFjNzQwZjRiMGViYzA0OTIyNDMzYWFmODg4XzEzMjUy_b612c274-be74-4be7-b933-709edf98067b">three</span> to six months before and 12 months after product expiration). The estimate of the provision for returns is based upon historical experience with actual returns. Additionally, the Company considers factors such as levels of inventory in the distribution channel, product dating and expiration period, whether products have been discontinued, entrance in the market of generic or other competition, changes in formularies or launch of over-the-counter products, among others. Outside of the U.S., returns are only allowed in certain countries on a limited basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck’s payment terms for U.S. pharmaceutical customers are typically 36 days from receipt of invoice and for U.S. animal health customers are typically 30 days from receipt of invoice; however, certain products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, have longer payment terms, some of which are up to 90 days. Outside of the U.S., payment terms are typically 30 days to 90 days, although certain markets have longer payment terms.</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note 19 for disaggregated revenue disclosures.</span></div> 12300000000 12300000000 11400000000 178000000 2700000000 207000000 2600000000 P6M P12M P36D P30D P90D P30D P90D <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Depreciation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation is provided over the estimated useful lives of the assets, principally using the straight-line method. For tax purposes, accelerated tax methods are used. The estimated useful lives primarily range from 25 to 40 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Buildings</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and from 3 to 15 years for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Machinery, equipment and office furnishings</span>. P25Y P40Y P3Y P15Y 1800000000 1600000000 1700000000 Advertising and Promotion Costs — Advertising and promotion costs are expensed as incurred. 2200000000 2000000000 1800000000 <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Software Capitalization —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software including external direct costs of material and services, and payroll costs for employees directly involved with the software development. These costs are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Property, plant and equipment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. In addition, the Company capitalizes certain costs incurred to implement a cloud computing arrangement that is considered a service agreement, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Capitalized software costs are being amortized over periods ranging from 3 to 10 years, with the longer lives generally associated with enterprise-wide projects implemented over multiple years. Costs incurred during the preliminary project stage and post-implementation stage, as well as maintenance and training costs, are expensed as incurred.</span> P3Y P10Y <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Goodwill —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired. Goodwill is assigned to reporting units and evaluated for impairment on at least an annual basis, or more frequently if impairment indicators exist, by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company concludes it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. If the carrying value of a reporting unit is greater than its fair value, a goodwill impairment charge will be recorded for the difference (up to the carrying value of goodwill).</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired Intangibles —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Intangibles acquired in a business combination include products and product rights, trade names and patents, licenses and other, which are initially recorded at fair value, assigned an estimated useful life, and amortized primarily on a straight-line basis over their estimated useful lives ranging from 2 to 24 years. The Company periodically evaluates whether current facts or circumstances indicate that the carrying values of its acquired intangibles may not be recoverable. If such circumstances are determined to exist, an estimate of the undiscounted future cash flows of these assets, or appropriate asset groupings, is compared to the carrying value to determine whether an impairment exists. If the asset is determined to be impaired, the loss is measured based on the difference between the carrying value of the intangible asset and its fair value, which is determined based on the net present value of estimated future cash flows.</span> P2Y P24Y <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquired In-Process Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires in conjunction with the acquisition of a business represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. The amounts are capitalized and are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, Merck will make a determination as to the then-useful life of the intangible asset, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. The Company evaluates IPR&amp;D for impairment at least annually, or more frequently if impairment indicators exist, by performing a quantitative test that compares the fair value of the IPR&amp;D intangible asset with its carrying value. If the fair value is less than the carrying amount, an impairment loss is recognized in operating results.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Certain of the Company’s acquisitions involve the potential for future payment of consideration that is contingent upon the achievement of performance milestones, including product development milestones and royalty payments on future product sales. If the transaction is accounted for as a business combination, the fair value of contingent consideration liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows, the probability of success (achievement of the contingent event) and the risk-adjusted discount rate used to present value the probability-weighted cash flows. Subsequent to the acquisition date, at each reporting period until the contingency is resolved, the contingent consideration liability is remeasured at current fair value with changes (either expense or income) recorded in earnings. Significant events that increase or decrease the probability of achieving development and regulatory milestones or that increase or decrease projected cash flows will result in corresponding increases or decreases in the fair values of the related contingent consideration obligations. <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development is expensed as incurred. Nonrefundable advance payments for goods and services that will be used in future research and development activities are </span>expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Research and development expenses include restructuring costs and IPR&amp;D impairment charges. In addition, research and development expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration associated with IPR&amp;D assets. Research and development expenses also include upfront and milestone payments related to asset acquisitions and licensing transactions involving clinical development programs that have not yet received regulatory approval. <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. When Merck is the principal on sales transactions with third parties, the Company recognizes sales, cost of sales and selling, general and administrative expenses on a gross basis. Profit sharing amounts it pays to its collaborative partners are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. When the collaborative partner is the principal on sales transactions with third parties, the Company records profit sharing amounts received from its collaborative partners as alliance revenue (within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">). Alliance revenue is recorded net of cost of sales and includes an adjustment to share commercialization costs between the partners in accordance with the collaboration agreement. The adjustment is determined by comparing the commercialization costs Merck has incurred directly and reported within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses with the costs the collaborative partner has incurred. Research and development costs Merck incurs related to collaborations are recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Cost reimbursements to the collaborative partner or payments received from the collaborative partner to share these costs pursuant to the terms of the collaboration agreements are recorded as increases or decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the terms of the collaboration agreements may require the Company to make payments based upon the achievement of certain developmental, regulatory approval or commercial milestones. Upfront and milestone payments payable by Merck to collaborative partners prior to regulatory approval are expensed as incurred and included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Payments due to collaborative partners upon or subsequent to regulatory approval are capitalized and amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over the estimated useful life of the corresponding intangible asset provided that future cash flows support the amounts capitalized. Sales-based milestones payable by Merck to collaborative partners are accrued and capitalized, subject to cumulative amortization catch-up, when determined to be probable of being achieved by the Company. The amortization catch-up is calculated either from the time of the first regulatory approval for indications that were unapproved at the time the collaboration was formed, or from time of the formation of the collaboration for approved products. The related intangible asset that is recognized is amortized to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> over its remaining useful life, subject to impairment testing.</span></div> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company expenses all share-based payments to employees over the requisite service period based on the grant-date fair value of the awards.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records liabilities for costs associated with exit or disposal activities in the period in which the liability is incurred. In accordance with existing benefit arrangements, future employee termination costs to be incurred in conjunction with involuntary separations are accrued when such separations are probable and estimable. When accruing these costs, the Company will recognize the amount within a range of costs that is the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company recognizes the minimum amount within the range. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Legal Defense Costs —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies and legal defense costs expected to be incurred in connection with a loss contingency when it is probable that a liability has been incurred and the amount can be reasonably estimated.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred taxes are recognized for the future tax effects of temporary differences between financial and income tax reporting based on enacted tax laws and rates. The Company evaluates tax positions to determine whether the benefits of tax positions are more likely than not of being sustained upon audit based on the technical merits of the tax position. For tax positions that are more likely than not of being sustained upon audit, the Company recognizes the amount of the benefit that is greater than 50% likely of being realized upon ultimate settlement in the financial statements. For tax positions that are not more likely than not of being sustained upon audit, the Company does not recognize any portion of the benefit in the financial statements. The Company recognizes interest and penalties associated with uncertain tax positions as a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Taxes on Income from Continuing Operations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company accounts for the tax effects of the tax on global intangible low-taxed income (GILTI) of certain foreign subsidiaries in the income tax provision in the period the tax arises. The Company’s policy for releasing disproportionate income tax effects from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is to utilize the item-by-item approach.</span> <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>Certain reclassifications have been made to prior year amounts to conform to the current year presentation. <span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the U.S. (GAAP) and, accordingly, include certain amounts that are based on management’s best estimates and judgments. Estimates are used when accounting for amounts recorded in connection with acquisitions, including initial fair value determinations of assets and liabilities in a business combination (primarily IPR&amp;D, other intangible assets and contingent consideration), as well as subsequent fair value measurements. Additionally, estimates are used in determining such items as provisions for sales discounts and returns, depreciable and amortizable lives, recoverability of inventories, including those produced in preparation for product launches, amounts recorded for contingencies, environmental liabilities, accruals for contingent sales-based milestone payments and other reserves, pension and other postretirement benefit plan assumptions, share-based compensation assumptions, restructuring costs, impairments of long-lived assets (including intangible assets and goodwill) and investments, and taxes on income. Because of the uncertainty inherent in such estimates, actual results may differ from these estimates.</span> <div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one-tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the consolidated statement of income for the above MSAs include sales of $383 million and $219 million in 2022 and 2021, respectively, and related cost of sales of $404 million and $195 million in 2022 and 2021, respectively. Amounts included in the consolidated statement of income for the TSAs were immaterial in 2022 and 2021. The amounts due from Organon under all of the above agreements were $511 million and $964 million at December 31, 2022 and 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $345 million and $400 million at December 31, 2022 and 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s consolidated statement of income as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million in 2021 and $743 million in 2020 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div> 9500000000 9000000000 P25M P35M P4Y P10Y 383000000 219000000 404000000 195000000 511000000 964000000 345000000 400000000 556000000 743000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,512</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,476 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">789</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">877</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">103</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,548 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">757</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,928 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,559 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">704</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div> 2512000000 6476000000 789000000 1867000000 877000000 1513000000 103000000 161000000 1000000 3000000 15000000 -4000000 1755000000 3548000000 757000000 2928000000 50000000 369000000 707000000 2559000000 3000000 11000000 704000000 2548000000 Acquisitions, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Completed Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck will make an upfront payment of $175 million, which will be recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech’s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60 million of transaction costs. Imago’s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck will record net assets of approximately $200 million and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. As Royalty Pharma is sharing the risk of technical and regulatory success with Merck, the development funding was recognized by Merck as an obligation to perform contractual services. Accordingly, the payment received is being recognized by Merck as a reduction to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses ratably over the estimated Phase 2b research period. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million. Royalty Pharma is eligible to receive royalties on future sales. If Royalty Pharma elects to provide the additional funding noted above, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as a higher royalty rate. Merck will record the milestone payments as an expense within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> upon receipt of the related approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized therapeutic cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with stage III/IV melanoma following complete resection in a Phase 2 clinical trial being conducted by Moderna. Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales-based milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Orion is responsible for the manufacture of clinical and commercial supply of MK-5684. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of MK-5684, as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Kelun-Biotech closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational ADC (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of Chinese mainland, Hong Kong, Macau and Taiwan for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870), which is currently in Phase 2 clinical development. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of MK-2870 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">for advanced solid tumors. Upon option </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">exercise, Merck made a payment of $30 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $111 million to fund Kelun-Biotech’s ongoing research and development activities, of which $51 million was paid in 2022. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2021, Merck acquired Acceleron Pharma Inc. (Acceleron), a publicly traded biopharmaceutical company, for total consideration of $11.5 billion. Acceleron’s development work focused on evaluating the transforming growth factor (TGF)-beta superfamily of proteins that is known to play a central role in the regulation of cell growth, differentiation and repair. Acceleron’s lead therapeutic candidate, sotatercept (MK-7962), has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in patients with pulmonary arterial hypertension (PAH). Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. Under a previous agreement assumed by Merck, Bristol Myers Squibb (BMS) was granted an exclusive license to develop and commercialize sotatercept outside of the pulmonary hypertension (PH) field (for which Merck would be eligible to receive contingent milestones and royalty payments), however, Merck retains the worldwide exclusive rights to develop and commercialize sotatercept in the PH field. The agreement provides for Merck to pay 22% royalties on future sales of sotatercept in the PH field to BMS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition to sotatercept, Acceleron’s portfolio includes Reblozyl (luspatercept), a first-in-class erythroid maturation recombinant fusion protein that is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. Reblozyl is being developed and commercialized through a global collaboration with BMS. In connection with this ongoing collaboration, Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck received a contingent regulatory milestone payment of $20 million in 2022 and remains eligible to receive up to $80 million in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The transaction was accounted for as a business combination. The Company incurred $280 million of costs directly related to the acquisition of Acceleron, consisting primarily of share-based compensation payments to settle non-vested equity awards attributable to postcombination service, severance, as well as investment banking and legal fees. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs in 2021. </span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights - Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,514 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s development work focused on advancing a pipeline of precision immune modulators targeting </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.7 billion in 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, Merck and Gilead Sciences, Inc. (Gilead) entered into an agreement to jointly develop and commercialize long-acting treatments in HIV that combine Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, and Gilead’s investigational capsid inhibitor, lenacapavir. The collaboration will initially focus on long-acting oral formulations and long-acting injectable formulations of these combination products, with other formulations potentially added to the collaboration as mutually agreed. There was no upfront payment made by either party upon entering into the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Merck and Gilead will share operational responsibilities, as well as development, commercialization and marketing costs, and any future revenues. Global development and commercialization costs will be shared 60% Gilead and 40% Merck across the oral and injectable formulation programs. For long-acting oral products, Gilead will lead commercialization in the U.S. and Merck will lead commercialization in the EU and the rest of the world. For long-acting injectable products, Merck will lead commercialization in the U.S. and Gilead will lead commercialization in the EU and the rest of the world. Gilead and Merck will co-promote in the U.S. and certain other major markets. Merck and Gilead will share global product revenues equally until product revenues surpass certain pre-agreed per formulation revenue tiers. Upon passing $2.0 billion a year in net product sales for the oral combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold. Upon passing $3.5 billion a year in net product sales for the injectable combination, the revenue split will adjust to 65% Gilead and 35% Merck for any revenues above the threshold.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beyond the potential combinations of investigational lenacapavir and investigational islatravir, Gilead will have the option to license certain of Merck’s investigational oral integrase inhibitors to develop in combination with lenacapavir. Reciprocally, Merck will have the option to license certain of Gilead’s investigational oral integrase inhibitors to develop in combination with islatravir. Each company may exercise its option for an investigational oral integrase inhibitor of the other company following completion of the first Phase 1 clinical trial of that integrase inhibitor. Upon exercise of an option, the companies will split development costs and revenues, unless the non-exercising company decides to opt-out.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2021, the U.S. Food and Drug Administration (FDA) placed full or partial clinical holds on investigational new drug applications for certain oral, implant and injectable formulations of islatravir based on observations of decreases in total lymphocyte and CD4+ T-cell counts in some participants receiving islatravir in clinical studies. In September 2022, Merck announced the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application for the islatravir + lenacapavir once-weekly treatment regimen remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP). The Company remains committed to developing compounds for long-acting HIV prevention and believes in the potential of the nucleoside reverse transcriptase translocation inhibitor (NRTTI) mechanism. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2020, Merck acquired OncoImmune, a privately held, clinical-stage biopharmaceutical company, for an upfront payment of $423 million. OncoImmune’s lead therapeutic candidate (MK-7110) was being evaluated for the treatment of patients hospitalized with COVID-19. The transaction was accounted for as an acquisition of an asset. Under the agreement, prior to the completion of the acquisition, OncoImmune spun-out certain rights and assets unrelated to the MK-7110 program to a new entity owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck invested $50 million for a 20% ownership interest in the new entity, which was valued at $33 million resulting in a $17 million premium. Merck also recognized other net liabilities of $22 million. The Company recorded </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $462 million in 2020 related to this transaction. In 2021, Merck received feedback from the FDA that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in 2021, which are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in December 2020, Merck acquired VelosBio Inc. (VelosBio), a privately held, clinical-stage biopharmaceutical company, for $2.8 billion. VelosBio’s lead investigational candidate, zilovertamab vedotin (MK-2140), is an ADC targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is currently being evaluated for the treatment of patients with hematologic malignancies and solid tumors. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $180 million (primarily cash) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $2.7 billion in 2020 related to the transaction. During 2021, the Company recorded adjustments to these amounts which resulted in a reduction of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $43 million, an increase to total consideration paid of $47 million, and an increase to net assets recorded of $90 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational ADC targeting LIV-1, which is currently in Phase 2 clinical trials. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $616 million in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020 related to this transaction reflecting the upfront payment as well as a $16 million premium relating to the equity shares based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales-based milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the U.S., Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and is receiving tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products are being amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Also in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, closed a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational oral antiviral COVID-19 medicine. See Note 5 for additional information related to this collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines (including a COVID-19 vaccine candidate, V591) and immune-modulation therapies for infectious diseases and cancer for $366 million. The acquisition originally provided for Merck to make additional contingent payments. The transaction was accounted for as a business combination. The Company determined the fair value of the contingent consideration was $85 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payments. Merck recognized intangible assets for IPR&amp;D of $113 million, cash of $59 million, deferred tax assets of $72 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $239 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. In January 2021, the Company announced it was discontinuing development of V591 as discussed below. As a result, in 2020, the Company recorded an IPR&amp;D impairment charge of $90 million within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. The Company also recorded a reduction in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses resulting from a decrease in the related liability for contingent consideration of $45 million. In 2022, the Company wrote off the remaining IPR&amp;D intangible asset and related contingent consideration liability; the net impact to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. The agreement provided for an upfront payment by Merck of $6.5 million and also provided for future contingent payments based on sales. Merck also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, to provide initial funding support to Merck for this effort. In January 2021, the Company announced it was discontinuing development of V590 as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2021, the Company announced the discontinuation of the development programs for its COVID-19 vaccine candidates, V590 and V591, following Merck’s review of findings from Phase 1 clinical studies for the vaccines. In these studies, both V590 and V591 were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. Due to the discontinuation, the Company recorded a charge of $305 million in 2020, of which $260 million was reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The remaining $45 million of costs were reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and represent amounts related to the Themis acquisition noted above (an IPR&amp;D impairment charge, partially offset by a reduction in the related liability for contingent consideration).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in 2020. ArQule’s lead investigational candidate, nemtabrutinib (MK-1026), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies. The transaction was accounted for as a business combination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing arrangement for derazantinib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck recorded intangible asset impairment charges in 2022 and 2021 related to nemtabrutinib and in 2022 related to derazantinib (see Note 9).</span></div> 175000000 1000000000 2800000000 5500000000 100000000 1350000000 60000000 200000000 1200000000 50000000 0.50 375000000 250000000 150000000 440000000 675000000 2400000000 100000000 290000000 35000000 82000000 334000000 485000000 30000000 30000000 25000000 111000000 51000000 90000000 290000000 780000000 11500000000 0.22 0.20 0.24 0.50 20000000 80000000 280000000 <div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Acceleron (inclusive of measurement period adjustments) is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.752%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 19, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangible assets: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - sotatercept </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,380 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights - Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12 year useful life)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,830 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,814)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,103 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,411 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,514 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible assets related to sotatercept and Reblozyl were determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 7.5% for sotatercept and 6.0% for Reblozyl. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Pharmaceutical segment. The goodwill is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.874%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D - nemtabrutinib </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,280</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing arrangement for derazantinib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,178 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of nemtabrutinib was determined using an income approach. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 12.5%. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div> 340000000 285000000 6380000000 P12Y 3830000000 1814000000 82000000 9103000000 2411000000 11514000000 0.075 0.060 1900000000 147000000 156000000 1700000000 0.60 0.40 2000000000 0.65 0.35 3500000000 0.65 0.35 3 30000000 15000000 3 217500000 570000000 1050000000.00 0.07 0.07 0.14 423000000 50000000 0.20 33000000 17000000 -22000000 462000000 207000000 2800000000 180000000 2700000000 43000000 47000000 90000000 600000000 1000000000 5000000 200 616000000 16000000 2600000000 850000000 1750000000 210000000 65000000 0.20 0.33 256000000 302000000 289000000 13000000 410000000 401000000 9000000 P15Y 366000000 85000000 113000000 59000000 72000000 -32000000 239000000 90000000 -45000000 6500000 305000000 260000000 45000000 2700000000 138000000 95000000 145000000 2280000000 80000000 361000000 34000000 2178000000 512000000 2690000000 0.125 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability (which remained accrued at December 31, 2022) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in 2022. Merck made sales-based milestone payments to AstraZeneca aggregating $400 million and $550 million in 2022 and 2020, respectively. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022 and 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million and $160 million, respectively, from Merck to AstraZeneca. A regulatory milestone of $105 million that was accrued at December 31, 2022 was paid in January 2023. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.6 billion at December 31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck made sales-based milestone payments to Eisai aggregating $600 million, $200 million and $500 million in 2022, 2021 and 2020, respectively. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million, $75 million and $10 million, respectively, from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $814 million at December 31, 2022 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Merck made sales-based milestone payments to Bayer of $400 million and $375 million in 2022 and 2020, respectively. There are no sales-based milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $633 million and $57 million, respectively, at December 31, 2022 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2020, Merck and Ridgeback, a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in all periods now include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalty and milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $166 million in 2022, which includes royalties of $146 million and the receipt of a regulatory approval milestone payment of $20 million, compared with alliance revenue of $17 million in 2021.</span></div> 600000000 600000000 250000000 400000000 550000000 2100000000 250000000 160000000 105000000 1100000000 1600000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,018 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">733 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">106</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">303</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trade </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">a</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ccounts payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">600</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amounts in 2022 and 2020 include $250 million and $106 million, respectively, of cumulative amortization catch-up expense.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">158</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">136</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">214</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payments.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">601</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">210</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">153</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">143</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> Accrued and other current Liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. Amount in 2021 includes $153 million of cumulative amortization catch-up expense. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,038</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses in all periods now include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2020 includes upfront payment.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalty and milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> 1116000000 989000000 725000000 54000000 29000000 8000000 1170000000 1018000000 733000000 492000000 167000000 247000000 185000000 178000000 160000000 106000000 120000000 133000000 303000000 271000000 123000000 415000000 600000000 0 250000000 106000000 125000000 600000000 200000000 500000000 2600000000 50000000 75000000 10000000 814000000 876000000 704000000 580000000 212000000 195000000 271000000 158000000 127000000 73000000 136000000 173000000 185000000 214000000 200000000 0 625000000 400000000 375000000 633000000 57000000 341000000 342000000 281000000 238000000 252000000 220000000 22000000 7000000 0 601000000 601000000 501000000 210000000 424000000 196000000 153000000 126000000 47000000 75000000 53000000 63000000 143000000 114000000 80000000 472000000 153000000 5684000000 952000000 0 3038000000 502000000 17000000 147000000 37000000 6000000 88000000 137000000 349000000 348000000 283000000 0.20 0.24 0.50 80000000 166000000 146000000 20000000 17000000 RestructuringIn 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $666 million in 2022, $868 million in 2021 and $880 million in 2020 related to restructuring program activities. Since inception of the Restructuring Program through December 31, 2022, Merck has recorded total pretax accumulated costs of approximately $3.3 billion. The Company expects to record charges of approximately $400 million in 2023 related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2022, 2021 and 2020 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 14) and share-based compensation. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)    The remaining cash outlays are expected to be largely completed by the end of 2025. 3700000000 0.70 0.30 666000000 868000000 880000000 3300000000 400000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_0401cc12-273a-43ee-9699-19953a3fb67c"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_b5707252-e4e5-480e-8fe9-0a271d5f729e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_d92dfa88-1cd4-4e7e-9f0d-1009b053f9ce"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzItMC0xLTEtNzEzMzA_f9645144-e350-4eee-ad75-be6998514e50">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">133</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_635fa9a5-71de-4587-93db-79291926dfda"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_8537ae39-bca8-409c-8fe7-e9a67058af06"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_dae7c0e2-4f06-4a63-806e-306b1af59aa2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzMtMC0xLTEtNzEzMzA_f6bfb51d-8c03-47c0-81d2-8a62e8babe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">94</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_584c2e9d-7007-40b6-9859-23602c807b7e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_a1c8f40d-fab0-4b55-9a0b-7ba9db8b4c4d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_c0c77770-4e11-4b1e-b7a1-a1cf80ce23ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzQtMC0xLTEtNzEzMzA_fec862c6-5790-4d45-895e-67687ab3fd83">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">29</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_19c9b1bc-b359-4138-98a8-9a3a24f13ca4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_213c4a81-b647-4e31-a79b-337f162ff3a7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_37f66a64-e137-4bca-aa6d-fa70e1ec1d02"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzUtMC0xLTEtNzEzMzA_80f498dd-3328-43aa-b1a3-55ef7f945a00">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">125</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">337</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_0034030b-c1b0-4ec7-9e4f-c1ed8dde701a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_1846b15c-2c7d-485a-a541-f8136e60e8ee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_eac21e57-3636-4681-8ad8-c7080bc4ec98"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzgtMC0xLTEtMTA5MjU4_fe25244c-98bc-43eb-b547-a47d47122875">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_08a30a08-d654-4de6-8803-340691e37d43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_1978256d-b52b-4c12-970c-d7d6955a1e4f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_7839a540-fa1d-4b5b-90fb-e4d1a1394fb4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzktMC0xLTEtMTA5Mjcz_b340eba8-3f62-4ad0-8a08-7ed052f87dd9">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_81f59dc0-4744-4650-84c5-1a27a5ba8bb0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_b6fae5b8-5202-4e9a-aca2-d73177a22302"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_cb00ee0d-0749-4231-a1d1-32e91d684498"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzEwLTAtMS0xLTEwOTI4NA_e889f363-c5c3-4f3c-bc6e-3eb87cfdf6c2">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_38481b85-3340-4ca8-b3a6-6eaae3f33b59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_501b15ec-9676-4d4c-be5f-d8814be474c5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_555cf8fd-f7b9-41eb-a19d-5e27aef0e2f1"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzExLTAtMS0xLTEwOTI5NQ_f145cdb7-e1ea-40e1-8978-73db11a6dd96">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_483e5fd0-1dd7-4a6b-bf01-0d5c9bb015ea"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_5c6c223a-d8ac-41a3-a3c7-d444bda5f66f"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_79ada1a0-6ac8-4ffa-bba3-aab54f7ce859"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE0LTAtMS0xLTEwOTI2Nw_7a6cd15c-1678-49df-ae81-597284ba0948">Cost of sales</span></span></span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_19048545-be46-4f98-a989-b2cb9c0a31ef"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7508f199-23e0-46bd-ad11-c0975ee5e5fc"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_7e9077be-89cd-44f6-bb44-48c9b57246d6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE1LTAtMS0xLTEwOTI4Mg_a69159f3-d7b7-4f1f-9735-a18e2a1abe6e">Selling, general and administrative</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_78c3425f-0960-4211-bac8-b2504ea775db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_887d5046-3fec-4b6e-a3d4-21b3a824ec36"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_bcfaded6-f18f-4199-9e63-6bcfcb1577d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE2LTAtMS0xLTEwOTI5Mw_f7661da7-ee06-47d6-8cc7-9e4f47c611ea">Research and development</span></span></span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_38f27e04-c696-4ac8-b11e-fecd56d8dc83"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_537d0db7-2680-4fde-aaf6-2e54a05a87d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_79cbd764-503c-415d-8047-e06280d44ce8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjMvZnJhZzoxYTNiYmY4ZDQ3N2Y0ZjY5YTIyNTE0NzEwZWNkZGY2Ny90YWJsZTpkNWY1NTgzYWFjY2U0MTMwYTZjNmNlNmNmZWNjZjRlNi90YWJsZXJhbmdlOmQ1ZjU1ODNhYWNjZTQxMzBhNmM2Y2U2Y2ZlY2NmNGU2XzE3LTAtMS0xLTEwOTMwNg_a3294b3f-64f7-4f44-8dee-a0ee3b1b7505">Restructuring costs</span></span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 72000000 133000000 205000000 0 19000000 75000000 94000000 0 29000000 1000000 30000000 212000000 0 125000000 337000000 212000000 120000000 334000000 666000000 0 52000000 108000000 160000000 0 12000000 7000000 19000000 0 27000000 1000000 28000000 451000000 0 210000000 661000000 451000000 91000000 326000000 868000000 0 143000000 32000000 175000000 0 44000000 3000000 47000000 0 81000000 2000000 83000000 385000000 0 190000000 575000000 385000000 268000000 227000000 880000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">586 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(608)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">334</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(329)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restructuring reserves December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">479</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)    The remaining cash outlays are expected to be largely completed by the end of 2025. 567000000 0 19000000 586000000 451000000 91000000 326000000 868000000 422000000 0 186000000 608000000 0 -91000000 -118000000 -209000000 596000000 0 41000000 637000000 212000000 120000000 334000000 666000000 329000000 0 120000000 449000000 0 -120000000 -221000000 -341000000 479000000 0 34000000 513000000 Financial Instruments<div style="margin-top:5pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Consolidated Statement of Cash Flows.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:40.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, nine interest rate swap contracts with a total notional amount of $2.25 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.4% fixed-rate notes and $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:45.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">Other current assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,824</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,926</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">19,466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">28,681</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">32,958 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges against rising treasury rates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, the Company estimates $104 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December 31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $462 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2022 on equity securities still held at December 31, 2022. Unrealized net losses of $232 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2021 on equity securities still held at December 31, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, the Company also had $832 million and $596 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During 2022, the Company recorded unrealized gains of $56 million and unrealized losses of $12 million related to certain of these equity investments still held at December 31, 2022. During 2021, the Company recorded unrealized gains of $110 million and unrealized losses of $1 million related to certain of these investments still held at December 31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at December 31, 2022 were $289 million and $19 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, 2021 and 2020, the Company also had $598 million, $1.7 billion and $800 million, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $1.0 billion, $(1.4) billion and $(583) million for the years ended December 31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of December 31, 2022 and 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $11.3 billion and $6.8 billion of cash equivalents, respectively, (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At December 31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December 31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both years relate to the Sanofi Pasteur MSD liabilities described above. </span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at December 31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards, as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s customers with the largest accounts receivable balances are: McKesson Corporation, AmerisourceBergen Corporation and Cardinal Health, Inc., which represented approximately 21%, 20% and 13%, respectively, of total accounts receivable at December 31, 2022. The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business. Bad debts have been minimal. The Company does not normally require collateral or other security to support credit sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.5 billion and $2.8 billion of accounts receivable as of December 31, 2022 and 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. At December 31, 2022 and 2021, the Company had collected $67 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in January 2023 and 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral advanced by the Company to various counterparties was $19 million at December 31, 2022. Cash collateral received by the Company from various counterparties was $66 million and $164 million at December 31, 2022 and 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. P2Y P6M <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.476%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(162)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(296)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div> 48000000 49000000 -26000000 1000000 13000000 19000000 162000000 296000000 -385000000 0 0 0 9 2250000000 1000000000 0.024 1250000000 0.0235 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges as of December 31:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"/><td style="width:45.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.703%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.708%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 2263000000 0 13000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments as of December 31:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value of<br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_37e563cc-0847-4685-a4aa-b2df78c0634b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzQtMS0xLTEtMTA5MTI1_507328d4-5953-40aa-bb60-d776c41d945a">Other current assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_5d3764ae-7962-4144-8a48-4d2a79397f20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzYtMS0xLTEtNzEzMzA_f34250f0-c25b-4299-b688-4cf5678133e0">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">220</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4,824</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_4aefa086-7c77-4642-bb2d-bb8f2b47d6b5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzctMS0xLTEtMTA5MTI5_9d61a38b-8be5-4a47-9830-accd4fb84597">Other Assets</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">27</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,609</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_620583ee-0047-4329-a460-b87d9d6d6bd7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzgtMS0xLTEtNzEzMzA_70cbda6b-9c5e-4117-8090-8ee9156ce887">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2,691</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_42d2702e-e579-4fb1-837d-94a77142070a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzktMS0xLTEtNzEzMzA_5febaa48-3877-4d31-9963-e79a08511786">Other Noncurrent Liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">247</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">9,215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_84583c93-4049-4f73-b740-e1c42f56dfa4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEyLTEtMS0xLTEwOTEzNQ_fc757052-4838-48fe-9b79-cb9facaa8937">Other current assets</span></span></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">8,540</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_c9384c3f-68af-4075-bf25-e022ab126666"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTo0NTk5M2RjNWExYzU0ZWZhOTg5ZThjZmI1MDgyMTVmNy90YWJsZXJhbmdlOjQ1OTkzZGM1YTFjNTRlZmE5ODllOGNmYjUwODIxNWY3XzEzLTEtMS0xLTEwOTE0Mg_fef7617b-92af-4be5-96c2-67ca4800e63d">Accrued and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">10,926</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">19,466</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">20,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">28,681</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">32,958 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 14000000 2250000000 220000000 4824000000 271000000 6778000000 27000000 1609000000 43000000 1551000000 101000000 2691000000 24000000 1623000000 1000000 91000000 1000000 43000000 247000000 102000000 9215000000 328000000 25000000 12245000000 186000000 8540000000 221000000 10073000000 307000000 10926000000 96000000 10640000000 186000000 307000000 19466000000 221000000 96000000 20713000000 433000000 409000000 28681000000 549000000 121000000 32958000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes at December 31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 433000000 409000000 549000000 121000000 220000000 220000000 110000000 110000000 66000000 19000000 164000000 0 147000000 170000000 275000000 11000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.500%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.600%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain (loss) recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">773</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_084a7420-d142-4ff0-9b91-b5ea3cddd416"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_33f68875-9086-4c76-bc9d-dae803ead7a0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNjYvZnJhZzo2NzU3NDkwYzA5M2U0YmUwYjk1ZmMyNzM2OWIwODlmZi90YWJsZTpiM2EzZmIzY2E5MzE0NDY5OTJmMGZjMDE0NWM4MmU0Yy90YWJsZXJhbmdlOmIzYTNmYjNjYTkzMTQ0Njk5MmYwZmMwMTQ1YzgyZTRjXzEyLTAtMS0xLTcxMzMw_a2c8ebf6-e2b5-4ed5-8e92-05b38b304252"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 59283000000 48704000000 41518000000 -1501000000 1341000000 890000000 -339000000 1756000000 -441000000 13000000 40000000 -40000000 -4000000 -1000000 76000000 684000000 333000000 -383000000 773000000 -194000000 -6000000 -773000000 194000000 6000000 -2000000 -2000000 -4000000 -2000000 -2000000 -4000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">     These derivative contracts serve as economic hedges against rising treasury rates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> 49000000 -313000000 12000000 37000000 -9000000 -13000000 0 0 -9000000 0 0 -15000000 104000000 <div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities at December 31 is as follows:</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:27.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.815%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">569</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,853</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $462 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2022 on equity securities still held at December 31, 2022. Unrealized net losses of $232 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in 2021 on equity securities still held at December 31, 2021.</span></div> 498000000 0 0 498000000 0 0 0 0 68000000 0 0 68000000 80000000 0 0 80000000 3000000 0 0 3000000 4000000 0 0 4000000 0 0 0 0 2000000 0 0 2000000 569000000 0 0 569000000 86000000 0 0 86000000 1284000000 1647000000 1853000000 1733000000 -462000000 -232000000 832000000 596000000 56000000 12000000 110000000 1000000 289000000 19000000 598000000 1700000000 800000000 -1000000000 1400000000 583000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis at December 31 are summarized below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.879%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,015</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">498</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">68</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">340</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">218</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">931</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,286</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">402</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">409</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">865</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 498000000 0 498000000 0 0 0 0 0 0 0 0 0 2000000 0 2000000 1015000000 0 0 1015000000 368000000 0 0 368000000 1015000000 498000000 0 1513000000 368000000 2000000 0 370000000 68000000 0 0 68000000 80000000 0 0 80000000 3000000 0 0 3000000 4000000 0 0 4000000 269000000 0 0 269000000 1279000000 0 0 1279000000 340000000 0 0 340000000 1363000000 0 0 1363000000 0 218000000 0 218000000 0 351000000 0 351000000 0 215000000 0 215000000 0 184000000 0 184000000 0 0 0 0 0 14000000 0 14000000 0 433000000 0 433000000 0 549000000 0 549000000 1355000000 931000000 0 2286000000 1731000000 551000000 0 2282000000 0 0 456000000 456000000 0 0 777000000 777000000 0 402000000 0 402000000 0 120000000 0 120000000 0 7000000 0 7000000 0 1000000 0 1000000 0 409000000 0 409000000 0 121000000 0 121000000 0 409000000 456000000 865000000 0 121000000 777000000 898000000 11300000000 6800000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.393%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">456</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At December 31, 2022 and 2021, $368 million and $620 million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at December 31, 2022 includes $122 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div> 777000000 841000000 -146000000 57000000 119000000 109000000 56000000 12000000 456000000 777000000 368000000 620000000 0.115 122000000 26700000000 30700000000 35700000000 33100000000 0.21 0.20 0.13 2500000000 2800000000 67000000 62000000 19000000 66000000 164000000 Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,841</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories valued under the LIFO method comprised approximately $3.4 billion and $3.3 billion at December 31, 2022 and 2021, respectively. Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At December 31, 2022 and 2021, these amounts included $2.4 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $516 million and $256 million at December 31, 2022 and 2021, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,841</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,063</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,142</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,849</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,911</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,938</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1841000000 1747000000 7063000000 6220000000 238000000 196000000 9142000000 8163000000 293000000 16000000 8849000000 8147000000 5911000000 5953000000 2938000000 2194000000 3400000000 3300000000 2400000000 1900000000 516000000 256000000 Goodwill and Other Intangibles<div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31, 2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Accumulated goodwill impairment losses were $531 million at both December 31, 2022 and 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The additions to goodwill in the Pharmaceutical segment in 2021 were primarily related to the acquisition of Acceleron (see Note 4). </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,810</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,651</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,438 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,505 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,933 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the more significant acquired intangibles included in products and product rights, on a net basis, related to human health marketed products at December 31, 2022 were Reblozyl, $3.5 billion; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $406 million;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Sivextro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $122 million; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, $120 million; and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, $97 million. Additionally, the Company had $4.6 billion of net acquired intangibles related to animal health at December 31, 2022, of which $2.3 billion related to products and product rights and $2.2 billion was attributable to trade names, primarily related to Allflex. At December 31, 2022, IPR&amp;D primarily relates to MK-7962 (sotatercept), $6.4 billion, obtained through the acquisition of Acceleron in 2021 (see Note 4); MK-7264 (gefapixant), $832 million, obtained through the acquisition of Afferent Pharmaceuticals in 2016; and MK-1026 (nemtabrutinib), $418 million, obtained through the acquisition of ArQule in </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2020 (see below and Note 4). Some of the more significant net intangible assets included in licenses and other above at December 31, 2022 include Lynparza, $1.6 billion, related to a collaboration with AstraZeneca; Lenvima, $814 million, related to a collaboration with Eisai; and Adempas, $633 million, related to a collaboration with Bayer. See Note 5 for additional information related to the intangible assets associated with these collaborations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded an impairment charge of $1.6 billion within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjg_e7b500cc-8996-45e1-8231-cde2ddbd2b59">Cost of sales</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (ceftolozane and tazobactam) for injection, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections. In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and subsequently issued a product recall, following the identification of product sterility issues. The recall constituted a triggering event requiring the evaluation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset for impairment. The Company revised its cash flow forecasts for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> utilizing certain assumptions around the return to market timeline and anticipated uptake in sales thereafter. These revised cash flow forecasts indicated that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above. The Company also wrote-off inventory of $120 million to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in 2020 related to the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> recall. A phased resupply of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021 and completed during 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IPR&amp;D that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not reached technological feasibility. Amounts capitalized as IPR&amp;D are accounted for as indefinite-lived intangible assets, subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each IPR&amp;D project, the Company will make a separate determination as to the then-useful life of the asset and begin amortization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, the Company recorded $1.7 billion of intangible impairment charges within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzIvZnJhZzozODNjODE1MTJjMzY0ZGRmYjg3NDQ2YjNlYWFjZTJlZC90ZXh0cmVnaW9uOjM4M2M4MTUxMmMzNjRkZGZiODc0NDZiM2VhYWNlMmVkXzkzNDU4NDg4NDgwMjk_b1192ef4-ec86-4241-a5a3-3f1beac17af0">Research and development</span></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses, of which $1.6 billion represents IPR&amp;D impairment charges related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies that was obtained through the 2020 acquisition of ArQule (see Note 4). Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in a $807 million impairment charge recorded in the third quarter of 2022. In December 2022, regulatory authorities provided additional feedback with respect to clinical study design that led to a further reassessment of the development plan for nemtabrutinib, which is expected to result in changes to the clinical study design, and corresponding delays in the anticipated approval and launch timelines, which constituted a triggering event. Utilizing an income approach, the forecasted cash flows were updated to reflect a decline in forecasted revenue coupled with an increase in development cost forecasts, which reduced projected cash flows lowering the estimated current fair value of nemtabrutinib. The revised estimated fair value of nemtabrutinib when compared with its then-related carrying value resulted in a $780 million impairment charge. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $418 million. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material. The Company also recorded an $80 million intangible asset impairment charge related to derazantinib resulting from the termination of the out-licensing agreement and the decision by Merck not to pursue development of derazantinib.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Company recorded a $275 million IPR&amp;D impairment charge related to nemtabrutinib. As part of Merck’s annual impairment assessment of IPR&amp;D intangible assets, the Company estimated the current fair value of nemtabrutinib utilizing projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect the current competitive landscape for nemtabrutinib, including increased expected development costs for additional clinical trial data needed to develop nemtabrutinib, as well as a delay in the anticipated launch date for nemtabrutinib, which collectively reduced the projected future cash flows and estimated fair value. Additionally, the discount rate utilized to determine the current fair value of the asset was reduced to 8.5% to reflect the current risk profile of the asset. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, the Company recorded a $90 million IPR&amp;D impairment charge related to a decision to discontinue the development program for COVID-19 vaccine candidate V591 following Merck’s review of findings from a Phase 1 clinical study for the vaccine. In the study, V591 was generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines. The discontinuation of this development program also resulted in a reversal of the related liability for contingent consideration of $45 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IPR&amp;D projects that remain in development are subject to the inherent risks and uncertainties in drug development and it is possible that the Company will not be able to successfully develop and complete the IPR&amp;D programs and profitably commercialize the underlying product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may recognize additional non-cash impairment charges in the future related to other marketed products or pipeline programs and such charges could be material.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Aggregate amortization expense primarily recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was $2.1 billion in 2022, $1.6 billion in 2021 and $1.8 billion in 2020. The estimated aggregate amortization expense for each of the next five years is as follows: 2023, $1.8 billion; 2024, $1.7 billion; 2025, $1.6 billion; 2026, $1.5 billion; 2027, $1.3 billion.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes goodwill activity by segment:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,614 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,268 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31, 2021 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,997 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,264 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">17,936</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,268</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,204</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes cumulative translation adjustments on goodwill balances.</span></div>(2)    Accumulated goodwill impairment losses were $531 million at both December 31, 2022 and 2021. 15614000000 3268000000 18882000000 2431000000 5000000 2436000000 -48000000 -6000000 -54000000 17997000000 3267000000 21264000000 -61000000 1000000 -60000000 17936000000 3268000000 21204000000 531000000 531000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other acquired intangibles at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products and product rights</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">23,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,810</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,671 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,661</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,879</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">635</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,882 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,651</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,097</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">41,746</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,477</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">20,269</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,438 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,505 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,933 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 23555000000 16745000000 6810000000 23671000000 15776000000 7895000000 7661000000 7661000000 9281000000 9281000000 2879000000 635000000 2244000000 2882000000 493000000 2389000000 7651000000 4097000000 3554000000 6604000000 3236000000 3368000000 41746000000 21477000000 20269000000 42438000000 19505000000 22933000000 3500000000 406000000 122000000 120000000 97000000 4600000000 2300000000 2200000000 6400000000 832000000 418000000 1600000000 814000000 633000000 1600000000 120000000 1700000000 1600000000 807000000 780000000 418000000 80000000 275000000 0.085 90000000 -45000000 2100000000 1600000000 1800000000 1800000000 1700000000 1600000000 1500000000 1300000000 Loans Payable, Long-Term Debt and Leases<div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Loans Payable</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loans payable at December 31, 2022 included $1.7 billion of notes due in 2023 and $197 million of long-dated notes that are subject to repayment at the option of the holders. Loans payable at December 31, 2021 included $2.3 billion of notes due in 2022 and $149 million of long-dated notes that are subject to repayment at the option of the holders. The weighted-average interest rate of commercial paper borrowings was 0.65% and 0.08% for the years ended December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,496</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,060</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">749</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,690 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (as presented in the table above) includes borrowings at variable rates that resulted in effective interest rates of 1.40% and zero for 2022 and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">With the exception of the 6.30% debentures due 2026, the notes listed in the table above are redeemable in whole or in part, at Merck’s option at any time, at varying redemption prices. Effective as of November 3, 2009, the Company executed a full and unconditional guarantee of the then existing debt of its subsidiary Merck Sharp &amp; Dohme Corp. (MSD) and MSD executed a full and unconditional guarantee of the then existing debt of the Company (excluding commercial paper), including for payments of principal and interest. These guarantees do not extend to debt issued subsequent to that date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s borrowings require that Merck comply with covenants and, at December 31, 2022, the Company was in compliance with these covenants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate maturities of long-term debt for each of the next five years are as follows: 2023, $1.7 billion; 2024, $1.3 billion; 2025, $2.5 billion; 2026, $2.2 billion; 2027, $1.5 billion. Interest payments related to these debt obligations are as follows: 2023, $882 million; 2024, $845 million; 2025, $778 million; 2026, $751 million; 2027, $720 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div style="margin-top:6pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has operating leases primarily for manufacturing facilities, research and development facilities, corporate offices, employee housing, vehicles and certain equipment. The Company determines if an arrangement is a lease at inception. When evaluating contracts for embedded leases, the Company exercises judgment to determine if there is an explicit or implicit identified asset in the contract and if Merck controls the use of that asset. Embedded leases, primarily associated with contract manufacturing organizations, are immaterial. The lease term includes options to extend or terminate the lease when it is reasonably certain that Merck will exercise that option. Real estate leases for facilities have an average remaining lease term of seven years, which include options to extend the leases for up to four years where applicable. Vehicle leases are generally in effect for four years. The Company elected to exclude short-term leases (leases with an initial term of 12 months or less) from the lease assets and liabilities on the balance sheet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Lease expense for operating lease payments is recognized on a straight-line basis over the term of the lease. Operating lease assets and liabilities are recognized based on the present value of lease payments over the lease term. Since the Company’s leases do not have a readily determinable implicit discount rate, the Company uses its incremental borrowing rate to calculate the present value of lease payments by asset class. On a quarterly basis, an updated incremental borrowing rate is determined based on the average remaining lease term of each asset class and the Company’s pretax cost of debt for that same term. The updated rates for each asset class are applied prospectively to new leases. The Company does not separate lease components (e.g. payments for rent, real estate taxes and insurance costs) from non-lease components (e.g. common-area maintenance costs) in the event that the agreement contains both. Merck includes both the lease and non-lease components for purposes of calculating the right-of-use asset and related lease liability (if the non-lease components are fixed). For vehicle leases and employee housing, the Company applies a portfolio approach to account for the operating lease assets and liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Certain of the Company’s lease agreements contain variable lease payments that are adjusted periodically for inflation or for actual operating expense true-ups compared with estimated amounts; however, these amounts are immaterial. Sublease income and activity related to sale and leaseback transactions are immaterial. Merck’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost was $334 million in 2022, $343 million in 2021 and $340 million in 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $335 million in 2022, $340 million in 2021 and $334 million in 2020. Operating lease assets obtained in exchange for lease obligations were $57 million in 2022, $117 million in 2021 and $473 million in 2020. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, the Company had entered into additional real estate operating leases that had not yet commenced; the obligations associated with these leases total $232 million.</span></div> 1700000000 197000000 2300000000 149000000 0.0065 0.0008 <div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Long-term debt at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2025</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,496</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,495 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.15% notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,986 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75% notes due 2051</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,979</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,979 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.70% notes due 2045</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,978</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40% notes due 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,738</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70% notes due 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,494</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,493 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2061</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,483</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.00% notes due 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.15% notes due 2043</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.45% notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.45% notes due 2050</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,213</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.875% euro-denominated notes due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,060</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.75% notes due 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">995</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.90% notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">994</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.90% notes due 2039</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">985</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.35% notes due 2040</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">984</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">983 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90% notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">749</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.50% notes due 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">711</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50% euro-denominated notes due 2024</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">531</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.375% euro-denominated notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">527</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.50% euro-denominated notes due 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">526</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.60% notes due 2042</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.55% notes due 2037</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">408</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">409 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.75% notes due 2036</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">339</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.95% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">307</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.85% notes due 2039</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.40% debentures due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.30% debentures due 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80% notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,749 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">167</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">28,745</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,690 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0.0275 2496000000 2495000000 0.0215 1986000000 1986000000 0.0275 1979000000 1979000000 0.0370 1978000000 1977000000 0.0340 1738000000 1736000000 0.0170 1494000000 1493000000 0.0290 1483000000 1484000000 0.0400 1471000000 1470000000 0.0415 1239000000 1239000000 0.0145 1237000000 1235000000 0.0245 1213000000 1212000000 0.01875 1060000000 1123000000 0.0075 995000000 993000000 0.0190 994000000 994000000 0.0390 985000000 984000000 0.0235 984000000 983000000 0.0290 749000000 748000000 0.0650 711000000 715000000 0.0050 531000000 563000000 0.01375 527000000 559000000 0.0250 526000000 558000000 0.0360 492000000 491000000 0.0655 408000000 409000000 0.0575 339000000 338000000 0.0595 307000000 306000000 0.0585 271000000 271000000 0.0640 250000000 250000000 0.0630 135000000 135000000 0.0280 0 1749000000 167000000 215000000 28745000000 30690000000 0.0140 0 0.0630 1700000000 1300000000 2500000000 2200000000 1500000000 882000000 845000000 778000000 751000000 720000000 6000000000 P7Y P4Y P4Y 334000000 343000000 340000000 335000000 340000000 334000000 57000000 117000000 473000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to operating leases is as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_5329407c-e031-4043-82fd-57f6de64b785"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzItMC0xLTEtNzEzMzA_9b31de82-d8be-4bbe-ad13-6f83a7a76cd3"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></span></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,586 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_4db1fe3f-74f6-4ba3-b08d-26002bb43819"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzQtMC0xLTEtNzEzMzA_58b51e37-e4e6-4832-aba9-41f54249bbea">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">281</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_04bd2693-3897-47be-bef4-ea5356a9b5d0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmEzODQxMThkMTU3MjQwZTA5ZTM5NTQxYjkwZTIwODBmL3NlYzphMzg0MTE4ZDE1NzI0MGUwOWUzOTU0MWI5MGUyMDgwZl8xNzUvZnJhZzplM2I3OTM0ZDE1OWM0MjY4YTU2YTVjZDIyYWY0ODNkNC90YWJsZTo4Y2Q0ODExODMyMTE0ODMzODJlYjgxYTc2NWM1ZWYyNS90YWJsZXJhbmdlOjhjZDQ4MTE4MzIxMTQ4MzM4MmViODFhNzY1YzVlZjI1XzUtMC0xLTEtNzEzMzA_3b0600bf-93ed-47bb-8bee-11cbaa0115bc">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,013</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,294</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes prepaid leases that have no related lease liability.</span></div> 1346000000 1586000000 281000000 304000000 1013000000 1225000000 1294000000 1529000000 P7Y P7Y 0.031 0.026 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Maturities of operating leases liabilities are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.875%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,492 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 323000000 258000000 224000000 157000000 126000000 404000000 1492000000 198000000 1294000000 232000000 Contingencies and Environmental Liabilities <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of December 31, 2022, approximately 70 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in the fall of 2018, the Company received a records subpoena from the U.S. Attorney’s Office for the District of Vermont (VT USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) relating to an investigation of potential health care offenses. The subpoena </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">sought information relating to any actual or potential business relationship or arrangement Merck has had with Practice Fusion, Inc. (PFI), a cloud-based, electronic health records (EHR) company that was acquired by Allscripts in January 2018. The Company cooperated with the government and responded to that subpoena. Subsequently, in May 2019, Merck received a second records subpoena from the VT USAO that broadened the government’s information request by seeking information relating to Merck’s relationship with any EHR company. Shortly thereafter, the VT USAO served a Civil Investigation Demand (CID) upon Merck similarly seeking information on the Company’s relationships with EHR vendors. The CID explains that the government is conducting a False Claims Act investigation concerning whether Merck and/or PFI submitted claims to federal health care programs that violate the Federal Anti-Kickback Statute. Merck is cooperating with the government’s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. Merck is cooperating with the California Attorney General’s investigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2020, Merck received a CID from the U.S. Department of Justice. The CID requests answers to interrogatories, as well as various documents, regarding temperature excursions at a third-party storage facility containing certain Merck products. Merck is cooperating with the government’s investigation and intends to produce information and/or documents as necessary in response to the CID.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other Zetia MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants’ and Glenmark defendants’ motions for summary judgment. In the cases filed by direct purchaser plaintiffs, retailer plaintiffs, and indirect purchaser plaintiffs, plaintiffs seek up to a maximum of $12.7 billion in damages after trebling. The court has scheduled trial for these plaintiffs (all plaintiffs other than the Insurer Plaintiffs) for April 17, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal on February 7, 2022 and took the matter under advisement.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in June 2012, the U.S. District Court for the Eastern District of Pennsylvania unsealed a complaint that had been filed against the Company under the federal False Claims Act by two former employees alleging, among other things, that the Company defrauded the U.S. government by falsifying data in connection with a clinical study conducted on the mumps component of the Company’s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine. The complaint alleges the fraud took place between 1999 and 2001. The U.S. government had the right to participate in and take over the prosecution of this lawsuit but notified the court that it declined to exercise that right. The two former employees are pursuing the lawsuit without the involvement of the U.S. government. In addition, as previously disclosed, two putative class action lawsuits on behalf of direct purchasers of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M‑M‑R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine, which charge that the Company misrepresented the efficacy of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II vaccine in violation of federal antitrust laws and various state consumer protection laws, are pending in the Eastern District of Pennsylvania. In September 2014, the court denied Merck’s motion to dismiss the False Claims Act suit and granted in part and denied in part its motion to dismiss the then-pending antitrust suit. As a result, both the False Claims Act suit and the antitrust suits proceeded into discovery, which is now complete, and the parties have filed and briefed cross-motions for summary judgment, which are currently pending before the court.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Merck KGaA Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2016, to protect its long-established brand rights in the U.S., the Company filed a lawsuit against Merck KGaA, Darmstadt, Germany (KGaA), historically operating as the EMD Group in the U.S., alleging it improperly uses the name “Merck” in the U.S. KGaA has filed suit against the Company in a number of jurisdictions outside of the U.S. alleging, among other things, unfair competition, trademark infringement </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and/or corporate name infringement. In certain of those jurisdictions, KGaA also alleges breach of the parties’ coexistence agreement. The litigation is ongoing in the U.S. with no trial date set, and also ongoing in jurisdictions outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered a post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCl), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that these products will not lose market exclusivity in the U.S. until May 2026. However, certain of the rulings are currently being appealed, and an unfavorable court decision would likely cause the products to lose exclusivity toward the end of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in Europe, for which there will be an oral hearing on March 8, 2023. In first instance decisions, the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPC has been found invalid in Germany and Romania, and has been upheld in Czech Republic and Sweden. Appeals are pending in Germany, Czech Republic and Sweden. The Company has filed for injunctive relief in Belgium, Czech Republic, Finland, France, Greece, Hungary, Ireland, Portugal, Switzerland and Slovakia. An </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction was granted in Finland, which has been subsequently maintained in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> proceedings, Czech Republic and Switzerland, and an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter-partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> preliminary injunction has been granted in Ireland. A preliminary injunction was granted in France and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> valid. Preliminary injunctions have been refused in Portugal, Greece, Belgium and Hungary. In Belgium, the Company has filed a main infringement action against generic companies and a request for preliminary measures in that action has been refused.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> —</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey/Delaware against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of December 31, 2022 and 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Environmental Matters</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company and its subsidiaries are parties to a number of proceedings brought under the Comprehensive Environmental Response, Compensation and Liability Act, commonly known as Superfund, and other federal and state equivalents. These proceedings seek to require the operators of hazardous waste disposal facilities, transporters of waste to the sites and generators of hazardous waste disposed of at the sites to clean up the sites or to reimburse the government for cleanup costs. The Company has been made a party to these proceedings as an alleged generator of waste disposed of at the sites. In each case, the government alleges that the defendants are jointly and severally liable for the cleanup costs. Although joint and several liability is alleged, these proceedings are frequently resolved so that the allocation of cleanup costs among the parties more nearly reflects the relative contributions of the parties to the site situation. The Company’s potential liability varies greatly from site to site. For some sites the potential liability is </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and for others the final costs of cleanup have not yet been determined. While it is not feasible to predict the outcome of many of these proceedings brought by federal or state agencies or private litigants, in the opinion of the Company, such proceedings should not ultimately result in any liability which would have a material adverse effect on the financial condition, results of operations or liquidity of the Company. The Company has taken an active role in identifying and accruing for these costs and such amounts do not include any reduction for anticipated recoveries of cleanup costs from former site owners or operators or other recalcitrant potentially responsible parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In management’s opinion, the liabilities for all environmental matters that are probable and reasonably estimable have been accrued and totaled $39 million and $40 million at December 31, 2022 and 2021, respectively. These liabilities are undiscounted, do not consider potential recoveries from other parties and will be paid out over the periods of remediation for the applicable sites, which are expected to occur primarily over the next 15 years. Although it is not possible to predict with certainty the outcome of these matters, or the ultimate costs of remediation, management does not believe that any reasonably possible expenditures that may be incurred in excess of the liabilities accrued should exceed approximately $35 million in the aggregate. Management also does not believe that these expenditures should result in a material adverse effect on the Company’s financial condition, results of operations or liquidity for any year.</span></div> 70 15 1 35 23 12700000000 2 2 2 P1D 5 2 22 230000000 230000000 liabilities 39000000 40000000 P15Y 35000000 Equity<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Merck certificate of incorporation authorizes 6,500,000,000 shares of common stock and 20,000,000 shares of preferred stock.</span></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capital Stock</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div> 6500000000 20000000 <div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of common stock and treasury stock transactions (shares in millions) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.624%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.281%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury<br/>Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,049</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuances </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,039</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Issuances primarily reflect activity under share-based compensation plans.</span></div> 3577000000 1049000000 3577000000 1047000000 3577000000 1038000000 0 0 0 11000000 0 16000000 0 10000000 0 9000000 0 7000000 3577000000 1039000000 3577000000 1049000000 3577000000 1047000000 Share-Based Compensation PlansThe Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees <div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant. These plans were approved by the Company’s shareholders.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, 87 million shares collectively were authorized for future grants under the Company’s share-based compensation plans. These awards are settled with treasury shares.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Employee stock options are granted to purchase shares of Company stock at the fair market value at the time of grant. These awards generally vest one-third each year over a three-year period, with a contractual term of 7-10 years. RSUs are stock awards that are granted to employees and entitle the holder to shares of common stock as the awards vest. The fair value of the stock option and RSU awards is determined and fixed on the grant date based on the Company’s stock price. PSUs are stock awards where the ultimate number of shares issued will be contingent on the Company’s performance against a pre-set objective or set of objectives. The fair value of each PSU is determined on the date of grant based on the Company’s stock price. For RSUs and PSUs, dividends declared during the vesting period are payable to the employees only upon vesting. Over the PSU performance period, the number of shares of stock that are expected to be issued will be adjusted based on the probability of achievement of a performance target and final compensation expense will be recognized based on the ultimate number of shares issued. RSU and PSU distributions will be in shares of Company stock after the end of the vesting or performance period, subject to the terms applicable to such awards. PSU awards generally vest after three years. RSU awards generally vest one-third each year over a three-year period.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total pretax share-based compensation cost recorded in 2022, 2021 and 2020 was $541 million, $498 million and $475 million, respectively. The amounts in 2021 and 2020 include $479 million and $441 million, respectively, related to continuing operations. Income tax benefits for share-based compensation expense recognized in 2022, 2021 and 2020 were $78 million, $69 million and $65 million, respectively.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model for determining the fair value of option grants. In applying this model, the Company uses both historical data and current market data to estimate the fair value of its options. The Black-Scholes model requires several assumptions including expected dividend yield, risk-free interest rate, volatility, and term of the options. The expected dividend yield is based on historical patterns of dividend payments. The risk-free interest rate is based on the rate at grant date of zero-coupon U.S. Treasury Notes with a term equal to the expected term of the option. Expected volatility is estimated using a blend of historical and implied volatility. The historical component is based on historical monthly price changes. The implied volatility is obtained from market data on the Company’s traded options. The expected life represents the amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The weighted average exercise price of options granted in 2022, 2021 and 2020 was $87.10, $75.99 and $77.67 per option, respectively. The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.09</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,730</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77.58</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,895</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022, there was $813 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted average period of 1.9 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div> 87000000 P3Y P7Y P10Y P3Y P3Y 541000000 498000000 475000000 479000000 441000000 78000000 69000000 65000000 87.10 75.99 77.67 The weighted average fair value of options granted in 2022, 2021 and 2020 was $15.45, $9.80 and $9.93 per option, respectively, and were determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">22.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.8</span></td></tr></table> 15.45 9.80 9.93 0.031 0.031 0.031 0.030 0.010 0.004 0.225 0.209 0.221 P5Y10M24D P5Y10M24D P5Y9M18D <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information relative to stock option plan activity (options in thousands) is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding January 1, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,572 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.27 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,326</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6,317)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">60.77</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(862)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">73.11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,719</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">554</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested and expected to vest December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,199</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">70.09</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">539</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,730</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.4</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">399</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 18572000 65.27 2326000 87.10 6317000 60.77 862000 73.11 13719000 70.55 P6Y6M 554000000 13199000 70.09 P6Y4M24D 539000000 8730000 65.24 P5Y4M24D 399000000 <div style="margin-bottom:3pt;margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional information pertaining to stock option plans is provided in the table below:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intrinsic value of stock options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of stock options vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">384</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 225000000 106000000 51000000 30000000 27000000 25000000 384000000 202000000 89000000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A summary of nonvested RSU and PSU activity (shares in thousands) is as follows:</span></div><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.351%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.461%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number<br/>of Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nonvested January 1, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,790 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">951</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">88.52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">75.40</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(725)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">87.87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.65</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(171)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">77.58</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nonvested December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">81.25</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected to vest December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,254</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">80.96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,895</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">78.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11790000 74.88 1966000 77.13 7170000 87.12 951000 88.52 5150000 75.40 725000 87.87 1110000 78.65 171000 77.58 12700000 81.25 2021000 78.60 11254000 80.96 1895000 78.26 813000000 P1Y10M24D Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. In addition, the Company provides medical benefits, principally to its eligible U.S. retirees and their dependents, through its other postretirement benefit plans. The Company uses December 31 as the year-end measurement date for all of its pension plans and other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net Periodic Benefit Cost</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 6), termination charges were recorded in 2022, 2021 and 2020 on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. An increase in lump sum payments to U.S. pension plan participants also contributed to the settlements recorded during 2022 and 2021.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note 15), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Obligations and Funded Status</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January 1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,613 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,458 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December 31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(760)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(210)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(315)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, the accumulated benefit obligation was $17.2 billion and $24.9 billion, respectively, for all pension plans, of which $9.7 billion and $13.8 billion, respectively, related to U.S. pension plans.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Plan Assets</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Entities are required to use a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Quoted prices (unadjusted) in active markets for identical assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> — Unobservable inputs that are supported by little or no market activity. The Level 3 assets are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as instruments for which the determination of fair value requires significant judgment or estimation. At December 31, 2022 and 2021, $765 million and $943 million, respectively, or approximately 4% of the Company’s pension investments were categorized as Level 3 assets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,654</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,898 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,007 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,293 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,195 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established investment guidelines for its U.S. pension and other postretirement plans to create an asset allocation that is expected to deliver a rate of return sufficient to meet the long-term obligation of each plan, given an acceptable level of risk. The target investment portfolio of the Company’s U.S. pension and other postretirement benefit plans is allocated 25% to 40% in U.S. equities, 10% to 20% in international equities, 35% to 45% in fixed-income investments, and up to 8% in cash and other investments. The portfolio’s equity weighting is consistent with the long-term nature of the plans’ benefit obligations. The expected annual standard deviation of </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">returns of the target portfolio, which approximates 10%, reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests. For international pension plans, the targeted investment portfolio varies based on the duration of pension liabilities and local government rules and regulations. Although a significant percentage of plan assets are invested in U.S. equities, concentration risk is mitigated through the use of strategies that are diversified within management guidelines.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Contributions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contributions during 2023 are expected to be approximately $270 million for U.S. pension plans, approximately $150 million for international pension plans and approximately $20 million for other postretirement benefit plans.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expected Benefit Payments</span></div><div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 — 2032</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are based on the same assumptions used to measure the benefit obligations and include estimated future employee service.</span></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts Recognized in Other Comprehensive Income</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net gain/loss amounts reflect differences between expected and actual returns on plan assets as well as the effects of changes in actuarial assumptions. Net gain/loss amounts in excess of certain thresholds are amortized into net periodic benefit cost over the average remaining service life of employees. The following amounts were reflected as components of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Actuarial Assumptions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Pension and Other<br/>Postretirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For both the pension and other postretirement benefit plans, the discount rate is evaluated on measurement dates and modified to reflect the prevailing market rate of a portfolio of high-quality fixed-income debt instruments that would provide the future cash flows needed to pay the benefits included in the benefit obligation as they come due. The expected rate of return for both the pension and other postretirement benefit plans represents the average rate of return to be earned on plan assets over the period the benefits included in the benefit obligation are to be paid and is determined on a plan basis. The expected rate of return for each plan is developed considering long-term historical returns data, current market conditions, and actual returns on the plan assets. Using this reference information, the long-term return expectations for each asset category and a weighted-average expected return for each plan’s target portfolio is developed according to the allocation among those investment categories. The expected portfolio performance reflects the contribution of active management as appropriate. For 2023, the expected rate of return for the Company’s U.S. pension and other postretirement benefit plans will be 7.00%, as compared to 6.70% in 2022. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Savings Plans</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also maintains defined contribution savings plans in the U.S. The Company matches a percentage of each employee’s contributions consistent with the provisions of the plan for which the employee is eligible. Total employer contributions to these plans in 2022, 2021 and 2020 were $175 million, $158 million and $158 million, respectively.</span></div> <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The net periodic benefit cost (credit) for pension and other postretirement benefit plans (including certain costs reported as part of discontinued operations) consisted of the following components:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.035%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.973%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.134%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.469%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement Benefits</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(753)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(755)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(774)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">425</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(93)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 372000000 403000000 360000000 283000000 328000000 297000000 48000000 48000000 52000000 457000000 404000000 431000000 145000000 123000000 136000000 46000000 45000000 57000000 753000000 755000000 774000000 383000000 416000000 414000000 86000000 79000000 75000000 -32000000 -38000000 -49000000 -14000000 -16000000 -18000000 -57000000 -63000000 -73000000 -128000000 -298000000 -303000000 -96000000 -142000000 -127000000 43000000 42000000 18000000 2000000 56000000 10000000 1000000 5000000 3000000 0 37000000 2000000 -12000000 -16000000 -10000000 0 26000000 0 1000000 29000000 4000000 -239000000 -216000000 -13000000 -1000000 -8000000 -15000000 0 0 0 425000000 600000000 304000000 129000000 148000000 146000000 -93000000 -83000000 -59000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in plan assets and benefit obligations, the funded status and the amounts recorded at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:43.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.453%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,067</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,672 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,195</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,009 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(671)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,195 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation January 1</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13,999</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,613 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,458 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">457</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">145</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actuarial (gains) losses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3,283)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(240)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(392)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(90)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effects of exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan amendments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(918)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefit obligation December 31</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,854</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,999 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,575 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Funded status December 31</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(760)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(932)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(210)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,052</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(706)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(877)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(315)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(202)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(241)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Actuarial (gains) losses primarily reflect changes in discount rates.</span></div> 13067000000 12672000000 12195000000 12009000000 1292000000 1221000000 -3129000000 1250000000 -2793000000 891000000 -306000000 118000000 293000000 305000000 155000000 189000000 46000000 33000000 0 0 -848000000 -671000000 0 0 219000000 219000000 250000000 233000000 90000000 86000000 918000000 941000000 16000000 55000000 0 0 0 0 0 55000000 0 0 0 0 30000000 120000000 5000000 6000000 9094000000 13067000000 8473000000 12195000000 947000000 1292000000 13999000000 14613000000 11575000000 12458000000 1541000000 1607000000 372000000 403000000 283000000 328000000 48000000 48000000 457000000 404000000 145000000 123000000 46000000 45000000 3851000000 332000000 3283000000 240000000 392000000 103000000 219000000 219000000 250000000 233000000 90000000 86000000 0 0 -732000000 -678000000 -1000000 -1000000 0 0 4000000 4000000 0 0 -12000000 -15000000 0 38000000 0 12000000 2000000 56000000 1000000 5000000 0 37000000 918000000 941000000 16000000 55000000 0 0 0 0 0 118000000 0 0 0 0 28000000 19000000 5000000 6000000 9854000000 13999000000 7755000000 11575000000 1157000000 1541000000 -760000000 -932000000 718000000 620000000 -210000000 -249000000 5000000 9000000 1052000000 1395000000 0 0 59000000 64000000 19000000 22000000 8000000 8000000 706000000 877000000 315000000 753000000 202000000 241000000 17200000000 24900000000 9700000000 13800000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information related to the funded status of selected pension plans at December 31 is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.803%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.073%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.075%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with a projected benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,186</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,013 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,779</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,507 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,445</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension plans with an accumulated benefit obligation in excess of plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9,081</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,916 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,226</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,421</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,072 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">948</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9186000000 13013000000 2779000000 2507000000 8421000000 12072000000 2445000000 1731000000 9081000000 12916000000 1226000000 2462000000 8421000000 12072000000 948000000 1723000000 765000000 943000000 0.04 0.04 <div style="margin-bottom:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s pension plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.111%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">49</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">98</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">147</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">211</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,443</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,654</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,035 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">707</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">131</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,956</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,934</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,438</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,005 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,216</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,495</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,379</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9,094</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,898 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,007 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,067 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">375</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,957</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,656</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">130</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,025 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">129</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">146</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other fixed income obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">21</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">448</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Insurance contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">780</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">982 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">943</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">436</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,473</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,387 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,293 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">578 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,195 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The plans’ Level 3 investments in insurance contracts are generally valued using a crediting rate that approximates market returns and invest in underlying securities whose market values are unobservable and determined using pricing models, discounted cash flow methodologies, or similar techniques.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of the Company’s other postretirement benefit plan assets at December 31 by asset category are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NAV </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Investment funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets equities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">257</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">279</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging markets equities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Real estate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">14</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Developed markets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Government and agency obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">212</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Corporate obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">137</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other Investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Plan assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">231</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">363</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">353</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">947</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">468 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Certain investments that were measured at net asset value (NAV) per share or its equivalent have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the fair value of plan assets at December 31, 2022 and 2021.</span></div> 49000000 0 0 98000000 147000000 3000000 0 0 289000000 292000000 211000000 0 0 2443000000 2654000000 236000000 0 0 3799000000 4035000000 0 0 0 707000000 707000000 0 0 0 919000000 919000000 0 0 0 131000000 131000000 0 0 0 0 0 1956000000 0 0 0 1956000000 2915000000 0 0 0 2915000000 0 1934000000 0 0 1934000000 0 2870000000 0 0 2870000000 0 1438000000 0 0 1438000000 0 2005000000 0 0 2005000000 0 22000000 0 0 22000000 0 23000000 0 0 23000000 0 101000000 0 0 101000000 0 0 0 0 0 0 0 4000000 0 4000000 2000000 0 6000000 0 8000000 2216000000 3495000000 4000000 3379000000 9094000000 3156000000 4898000000 6000000 5007000000 13067000000 57000000 8000000 0 13000000 78000000 82000000 10000000 0 18000000 110000000 375000000 2957000000 0 90000000 3422000000 531000000 4292000000 0 121000000 4944000000 177000000 2656000000 0 130000000 2963000000 240000000 4025000000 0 171000000 4436000000 52000000 0 0 59000000 111000000 137000000 0 0 72000000 209000000 8000000 9000000 0 129000000 146000000 9000000 8000000 0 171000000 188000000 10000000 7000000 0 4000000 21000000 15000000 8000000 0 3000000 26000000 0 1000000 0 10000000 11000000 0 1000000 0 16000000 17000000 263000000 0 0 0 263000000 369000000 0 0 0 369000000 0 448000000 0 0 448000000 3000000 591000000 0 3000000 597000000 0 157000000 0 0 157000000 0 223000000 0 2000000 225000000 0 69000000 0 0 69000000 0 90000000 0 0 90000000 0 18000000 761000000 1000000 780000000 0 44000000 937000000 1000000 982000000 1000000 3000000 0 0 4000000 1000000 1000000 0 0 2000000 943000000 6333000000 761000000 436000000 8473000000 1387000000 9293000000 937000000 578000000 12195000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides a summary of the changes in fair value, including transfers in and/or out, of all financial assets measured at fair value using significant unobservable inputs (Level 3) for the Company’s pension plan assets:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:25.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.246%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.604%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.255%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Insurance<br/>Contracts</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Real<br/>Estate</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Pension Plans</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets sold during the year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International Pension Plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Actual return on plan assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relating to assets still held at December 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases and sales, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfers into Level 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">761</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 6000000 6000000 0 0 7000000 7000000 0 0 -3000000 -3000000 0 0 -5000000 -5000000 0 0 2000000 2000000 0 0 7000000 7000000 0 0 -1000000 -1000000 0 0 -3000000 -3000000 0 0 4000000 4000000 0 0 6000000 6000000 937000000 0 0 937000000 935000000 0 0 935000000 -147000000 0 0 -147000000 -34000000 0 0 -34000000 -39000000 0 -39000000 -42000000 0 0 -42000000 10000000 0 10000000 78000000 0 0 78000000 761000000 0 0 761000000 937000000 0 0 937000000 2000000 0 0 8000000 10000000 11000000 0 0 28000000 39000000 22000000 0 0 257000000 279000000 24000000 0 0 378000000 402000000 0 0 0 74000000 74000000 0 0 0 92000000 92000000 0 0 0 14000000 14000000 0 0 0 0 0 1000000 0 0 0 1000000 1000000 0 0 0 1000000 206000000 0 0 0 206000000 290000000 0 0 0 290000000 0 212000000 0 0 212000000 0 275000000 0 0 275000000 0 137000000 0 0 137000000 0 191000000 0 0 191000000 0 2000000 0 0 2000000 0 2000000 0 0 2000000 0 12000000 0 0 12000000 0 0 0 0 0 231000000 363000000 0 353000000 947000000 326000000 468000000 0 498000000 1292000000 0.25 0.40 0.10 0.20 0.35 0.45 0.08 0.10 270000000 150000000 20000000 <div style="margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected benefit payments are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Pension Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International Pension<br/>Benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Postretirement<br/>Benefits</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028 — 2032</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,948 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 627000000 271000000 84000000 634000000 257000000 86000000 650000000 262000000 87000000 676000000 283000000 89000000 694000000 297000000 90000000 3948000000 1704000000 474000000 The following amounts were reflected as components of <span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:28.690%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.985%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.990%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pension Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Postretirement<br/>Benefit Plans</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (loss) gain arising during the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(424)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service (cost) credit arising during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss (gain) amortization included in benefit cost</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(43)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prior service credit amortization included in benefit cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(14)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements and curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">347</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">83</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -42000000 813000000 -472000000 116000000 772000000 -424000000 0 156000000 199000000 0 0 0 4000000 4000000 -64000000 0 0 0 42000000 -813000000 472000000 -112000000 -768000000 360000000 0 -156000000 -199000000 -128000000 -298000000 -303000000 -96000000 -142000000 -127000000 43000000 42000000 18000000 -32000000 -38000000 -49000000 -14000000 -16000000 -18000000 -57000000 -63000000 -73000000 251000000 232000000 23000000 1000000 -18000000 15000000 -1000000 -29000000 -4000000 347000000 492000000 277000000 83000000 108000000 124000000 -101000000 -134000000 -95000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company reassesses its benefit plan assumptions on a regular basis. The weighted average assumptions used in determining U.S. pension and other postretirement benefit plan and international pension plan information are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:33.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.189%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Pension and Other<br/>Postretirement Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International Pension Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net periodic benefit cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.40 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.00</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.90</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salary growth rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.60</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.70 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3.30</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.00 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0300 0.0270 0.0340 0.0150 0.0110 0.0150 0.0670 0.0670 0.0730 0.0370 0.0380 0.0440 0.0460 0.0460 0.0420 0.0290 0.0280 0.0280 0.0500 0.0470 0.0490 0.0300 0.0300 0.0280 0.0550 0.0300 0.0270 0.0390 0.0150 0.0110 0.0460 0.0460 0.0460 0.0320 0.0290 0.0280 0.0530 0.0500 0.0470 0.0330 0.0300 0.0300 0.0700 0.0670 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The health care cost trend rate assumptions for other postretirement benefit plans are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.188%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health care cost trend rate assumed for next year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4.5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Year that the trend rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2038</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2032</span></td></tr></table></div> 0.078 0.064 0.045 0.045 175000000 158000000 158000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140 million will be recorded in the first quarter of 2023 from ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid was $937 million in 2022, $779 million in 2021 and $822 million in 2020.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(157)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">962</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">237</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,419</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(279)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,501</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,341)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(890)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates gains of approximately $140 million will be recorded in the first quarter of 2023 from ownership interests in investment funds.</span></div> 157000000 36000000 59000000 962000000 806000000 831000000 -237000000 -297000000 -145000000 -1419000000 1940000000 1338000000 -279000000 -212000000 -339000000 681000000 256000000 130000000 -1501000000 1341000000 890000000 140000000 937000000 779000000 822000000 Taxes on Income<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s remaining transition tax liability under the Tax Cuts and Jobs Act (TCJA) of 2017, which has been reduced by payments and the utilization of foreign tax credits, was $2.2 billion at December 31, 2022, of which $732 million is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income taxes payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the remainder of $1.5 billion is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of the transition tax under the TCJA, the Company is no longer indefinitely reinvested with respect to its undistributed earnings from foreign subsidiaries and has provided a deferred tax liability for foreign withholding taxes that would apply. The Company remains indefinitely reinvested with respect to its financial statement basis in excess of tax basis of its foreign subsidiaries. A determination of the deferred tax liability with respect to this basis difference is not practicable. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The foreign earnings tax rate differentials in the tax rate reconciliation above primarily reflect the impacts of operations in jurisdictions with different tax rates than the U.S., particularly Ireland and Switzerland, as well as Singapore and Puerto Rico which operate under tax incentive grants (which begin to expire in 2025), thereby yielding </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">a favorable impact on the effective tax rate compared with the U.S. statutory rate of 21%. The Company has an additional Cantonal tax holiday in Switzerland that provides for a tax rate reduction and is effective through 2032. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,011</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">912</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,006</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,749 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,795</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has net operating loss (NOL) carryforwards in several jurisdictions. As of December 31, 2022, $349 million of deferred tax assets on NOL carryforwards relate to foreign jurisdictions. Valuation allowances of $345 million have been established on these foreign NOL carryforwards and other foreign deferred tax assets. In addition, the Company has $563 million of deferred tax assets relating to various U.S. tax credit carryforwards and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">NOL carryforwards. Valuation allowances of $247 million have been established on these U.S. tax credit carryforwards and NOL carryforwards. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid in 2022, 2021 and 2020 (including amounts attributable to discontinued operations in 2021 and 2020) were $3.2 billion, $2.4 billion and $2.7 billion, respectively. Income taxes paid consisted of:</span></div><div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax benefits relating to stock option exercises were $45 million in 2022, $21 million in 2021 and $12 million in 2020. </span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Amount in 2021 reflects a settlement with the IRS discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the Company were to recognize the unrecognized tax benefits of $1.8 billion at December 31, 2022, the income tax provision would reflect a favorable net impact of $1.8 billion.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is under examination by numerous tax authorities in various jurisdictions globally. The Company believes that it is reasonably possible that the total amount of unrecognized tax benefits as of December 31, 2022 could decrease by up to approximately $31 million in the next 12 months as a result of various audit closures, settlements or the expiration of the statute of limitations. The ultimate finalization of the Company’s examinations with relevant taxing authorities can include formal administrative and legal proceedings, which could have a significant impact on the timing of the reversal of unrecognized tax benefits. The Company believes that its reserves for uncertain tax positions are adequate to cover existing risks or exposures. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and penalties associated with uncertain tax positions amounted to an expense (benefit) of $54 million in 2022, $(37) million in 2021 and $16 million in 2020. These amounts reflect the beneficial impacts of various tax settlements, including the settlement discussed below. Liabilities for accrued interest and penalties were $256 million and $192 million as of December 31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The IRS is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018. In addition, various state and foreign tax examinations are in progress and for these jurisdictions, the Company’s income tax returns are open for examination for the period 2003 through 2022.</span></div> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between the effective tax rate for income from continuing operations and the U.S. statutory rate is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:35.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.078%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. statutory rate applied to income from continuing operations before taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,453</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21.0</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,915 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,231 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differential arising from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(11.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GILTI and the foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">462</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D tax credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">108</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of VelosBio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Pandion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of OncoImmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11.7</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.0 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div>Where applicable, the impact of changes in uncertain tax positions is reflected in the reconciling items above. 3453000000 0.210 2915000000 0.210 1231000000 0.210 -1835000000 -0.111 -1446000000 -0.104 -965000000 -0.165 462000000 0.028 -75000000 -0.005 349000000 0.060 -110000000 -0.007 2000000 0 57000000 0.010 81000000 0.005 81000000 0.006 108000000 0.018 -10000000 -0.001 -275000000 -0.020 -13000000 -0.002 108000000 0.007 102000000 0.007 37000000 0.006 11000000 0.001 61000000 0.004 105000000 0.018 0 0 -9000000 -0.001 559000000 0.095 0 0 356000000 0.026 0 0 0 0 0 0 97000000 0.017 -80000000 -0.005 -29000000 -0.001 -9000000 -0.002 1918000000 0.117 1521000000 0.110 1340000000 0.229 2200000000 732000000 1500000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income from continuing operations before taxes consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,011</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,433</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,677 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1011000000 1854000000 -3814000000 15433000000 12025000000 9677000000 16444000000 13879000000 5863000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Taxes on income from continuing operations consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,265</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,164</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">57</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,486</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,906 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Deferred provision</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,568)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(566)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,918</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,521 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,340 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2265000000 74000000 893000000 1164000000 1273000000 969000000 57000000 -13000000 44000000 3486000000 1334000000 1906000000 -1510000000 240000000 -605000000 71000000 -77000000 64000000 -129000000 24000000 -25000000 -1568000000 187000000 -566000000 1918000000 1521000000 1340000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income taxes at December 31 consisted of:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.921%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product intangibles and licenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,575</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,207 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">92</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pensions and other postretirement benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">372</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">284</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">91</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses and other tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">912</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">867 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">267</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,605</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,557 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(599)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,006</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,298</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,019 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,292</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,749 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,795</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,441 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 2575000000 0 3207000000 1341000000 274000000 43000000 423000000 119000000 370000000 0 657000000 0 589000000 0 92000000 0 335000000 372000000 284000000 487000000 338000000 335000000 301000000 91000000 75000000 912000000 867000000 511000000 267000000 434000000 180000000 3605000000 4298000000 2557000000 5019000000 599000000 287000000 3006000000 4298000000 2270000000 5019000000 1292000000 2749000000 503000000 692000000 1795000000 3441000000 349000000 345000000 563000000 247000000 3200000000 2400000000 2700000000 Income taxes paid consisted of:<div style="margin-top:6pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,211 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,348</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,201 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,763 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,412 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes TCJA transition tax payments.</span></div> 1891000000 1211000000 977000000 1348000000 1201000000 1763000000 3239000000 2412000000 2740000000 45000000 21000000 12000000 <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,529</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to current year positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions related to prior year positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">48</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance December 31</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,835</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,529 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)    Amount in 2021 reflects a settlement with the IRS discussed below. 1529000000 1537000000 1225000000 344000000 306000000 298000000 48000000 63000000 110000000 40000000 230000000 4000000 6000000 46000000 70000000 40000000 58000000 22000000 0 43000000 0 1835000000 1529000000 1537000000 1800000000 1800000000 31000000 54000000 -37000000 16000000 256000000 192000000 190000000 172000000 18000000 236000000 207000000 29000000 Earnings per Share<div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,542</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.79 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.14 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2022, 2021 and 2020, 2 million, 9 million and 5 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</span></div> <div style="margin-bottom:6pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share (shares in millions) are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,345 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,519</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,067 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,542</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.01 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.16 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.79 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.00 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.71</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.14 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.78 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Issuable primarily under share-based compensation plans.</span></div> 14519000000 12345000000 4519000000 0 704000000 2548000000 14519000000 14519000000 13049000000 13049000000 7067000000 7067000000 2532000000 2530000000 2530000000 10000000 8000000 11000000 2542000000 2538000000 2541000000 5.73 4.88 1.79 0 0.28 1.01 5.73 5.16 2.79 5.71 4.86 1.78 0 0.28 1.00 5.71 5.14 2.78 2000000 9000000 5000000 Other Comprehensive Income (Loss)<div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,405 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note 3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(612)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(359)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.</span></div> <div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.243%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(383)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(633)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">293 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(297)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(279)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2020, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">333 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,737 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,766 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(526)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,405 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,240 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">658 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">516 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">410 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,769 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(423)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,756 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note 3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at December 31, 2021, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">70</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(584)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">170</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">541</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">82</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(446)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">163</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">87</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(612)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">253</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(359)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">335</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(603)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Balance at December 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">73</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:700;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">    Primarily relates to foreign currency cash flow hedges that were reclassified from</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized gains on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 14).</span></div><div style="margin-top:2pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes pension plan net loss of $3.1 billion and $3.6 billion at December 31, 2022 and 2021, respectively, and other postretirement benefit plan net gain of $446 million and $473 million at December 31, 2022 and 2021, respectively, as well as pension plan prior service credit of $152 million and $190 million at December 31, 2022 and 2021, respectively, and other postretirement benefit plan prior service credit of $135 million and $181 million at December 31, 2022 and 2021, respectively.</span></div> 31000000 18000000 -4261000000 -1981000000 -6193000000 -383000000 3000000 -633000000 64000000 -949000000 -84000000 0 -120000000 -89000000 -293000000 -299000000 3000000 -513000000 153000000 -656000000 -2000000 21000000 -306000000 0 -287000000 0 0 -72000000 0 -72000000 -2000000 21000000 -234000000 0 -215000000 -297000000 -18000000 -279000000 153000000 -441000000 -266000000 0 -4540000000 -1828000000 -6634000000 333000000 0 1737000000 -304000000 1766000000 75000000 0 332000000 119000000 526000000 258000000 0 1405000000 -423000000 1240000000 -192000000 0 -466000000 0 -658000000 -40000000 0 -102000000 0 -142000000 -152000000 0 -364000000 0 -516000000 410000000 0 1769000000 -423000000 1756000000 0 0 28000000 421000000 449000000 144000000 0 -2743000000 -1830000000 -4429000000 684000000 0 70000000 -584000000 170000000 143000000 0 -12000000 19000000 150000000 541000000 0 82000000 -603000000 20000000 775000000 0 -329000000 0 446000000 163000000 0 -76000000 0 87000000 612000000 0 -253000000 0 359000000 -71000000 0 335000000 -603000000 -339000000 73000000 0 -2408000000 -2433000000 -4768000000 3100000000 3600000000 -446000000 -473000000 -152000000 -190000000 -135000000 -181000000 Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company previously had a Healthcare Services segment that provided services and solutions focused on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company divested the remaining businesses in this segment during the first quarter of 2020.</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">579</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,832</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,703 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,744</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,425 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,279 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,588 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,930 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(6)    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. </span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,582</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,568</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38,815</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income/loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,993</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,279 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.</span></div> 2 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:30.674%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.574%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.512%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12,686</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">8,251</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">20,937</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,765 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,028 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">584</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">532</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,116</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">989 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">579</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">297</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">876</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">43</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">166</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,065</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,832</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6,897</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,938 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R II/Varivax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,724</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">518</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,135 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,878 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">508</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">275</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">783</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">486 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">311 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">797 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">346</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">256</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">602</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">893 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,087 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">95</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">173</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">922</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">762</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,685</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">762 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">583 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">240</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">428</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">119 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">241</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">22</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">263</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">239</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">187</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">185</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">168</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">89</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">169</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">329</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">341</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">259 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">238</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,523</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">4,161</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">632 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">952 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">274</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">359</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">633</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">531 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">79</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">179</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">258</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">706</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,248</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,813</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,920 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,836 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">355</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,344</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,700</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,597 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,964 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">477 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">969</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,282</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,249</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,118 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">882 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">24,989</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,016</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">52,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,353 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42,754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,600 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36,610 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">710</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,590</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,300</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">667 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,295 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">612 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,939 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,112</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,138</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2,250</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,273 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,764 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,822</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">3,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">5,550</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,758 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,810 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,219 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,703 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">26,811</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">30,744</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">57,555</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,159 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,163 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,517 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,819 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,336 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">395</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,333</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,728</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">382 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">32,077</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22,425 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,279 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,588 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21,930 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.22pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.27pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%">    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020. </span></div>(6)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements. 12686000000 8251000000 20937000000 9765000000 7421000000 17186000000 8352000000 6028000000 14380000000 584000000 532000000 1116000000 515000000 473000000 989000000 417000000 308000000 725000000 579000000 297000000 876000000 417000000 287000000 704000000 359000000 220000000 580000000 123000000 43000000 166000000 0 17000000 17000000 0 0 0 2065000000 4832000000 6897000000 1881000000 3792000000 5673000000 1755000000 2184000000 3938000000 1724000000 518000000 2241000000 1629000000 506000000 2135000000 1378000000 500000000 1878000000 508000000 275000000 783000000 473000000 334000000 807000000 486000000 311000000 797000000 346000000 256000000 602000000 547000000 346000000 893000000 727000000 359000000 1087000000 95000000 78000000 173000000 100000000 79000000 179000000 103000000 67000000 170000000 922000000 762000000 1685000000 762000000 770000000 1532000000 583000000 615000000 1198000000 188000000 240000000 428000000 153000000 218000000 370000000 119000000 162000000 281000000 241000000 22000000 263000000 166000000 10000000 175000000 102000000 7000000 110000000 1000000 238000000 239000000 2000000 258000000 259000000 2000000 248000000 251000000 51000000 187000000 238000000 60000000 199000000 259000000 42000000 287000000 329000000 4000000 185000000 189000000 -5000000 207000000 202000000 9000000 202000000 211000000 6000000 168000000 174000000 4000000 208000000 212000000 7000000 207000000 213000000 89000000 79000000 169000000 4000000 -5000000 -1000000 74000000 56000000 130000000 329000000 12000000 341000000 312000000 30000000 342000000 259000000 22000000 281000000 0 238000000 238000000 0 252000000 252000000 0 220000000 220000000 1523000000 4161000000 5684000000 632000000 320000000 952000000 0 0 0 274000000 359000000 633000000 294000000 474000000 769000000 326000000 531000000 857000000 79000000 179000000 258000000 78000000 241000000 318000000 81000000 247000000 327000000 0 706000000 706000000 0 825000000 825000000 0 838000000 838000000 0 207000000 207000000 0 299000000 299000000 0 330000000 330000000 1248000000 1565000000 2813000000 1404000000 1920000000 3324000000 1470000000 1836000000 3306000000 355000000 1344000000 1700000000 367000000 1597000000 1964000000 477000000 1494000000 1971000000 969000000 1282000000 2249000000 841000000 1275000000 2118000000 882000000 1321000000 2202000000 24989000000 27016000000 52005000000 20401000000 22353000000 42754000000 18010000000 18600000000 36610000000 710000000 2590000000 3300000000 667000000 2628000000 3295000000 612000000 2327000000 2939000000 1112000000 1138000000 2250000000 1091000000 1182000000 2273000000 872000000 892000000 1764000000 1822000000 3728000000 5550000000 1758000000 3810000000 5568000000 1484000000 3219000000 4703000000 0 0 0 0 0 0 23000000 0 23000000 26811000000 30744000000 57555000000 22159000000 26163000000 48322000000 19517000000 21819000000 41336000000 395000000 1333000000 1728000000 266000000 116000000 382000000 71000000 111000000 182000000 27206000000 32077000000 59283000000 22425000000 26279000000 48704000000 19588000000 21930000000 41518000000 810000000 -203000000 -19000000 165000000 218000000 54000000 <div style="margin-bottom:3pt;margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">27,206</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">14,493</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,341 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,547 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,191</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,751 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,726 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,602 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,614</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,407 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,582</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,568</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">59,283</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,704 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,518 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 27206000000 22425000000 19588000000 14493000000 13341000000 11547000000 5191000000 4378000000 2751000000 3629000000 2726000000 2602000000 3614000000 2407000000 2113000000 2582000000 2206000000 1890000000 2568000000 1221000000 1027000000 59283000000 48704000000 41518000000 <div style="margin-bottom:3pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Years Ended December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">36,852</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,963</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,950 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,669 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">38,815</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,776 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,160</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">157</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(2,085)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,636)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,817)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(1,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,519)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(13,011)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,692)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,911)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5,651)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,394)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">16,444</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,879 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 36852000000 30977000000 26106000000 1963000000 1950000000 1669000000 0 0 1000000 38815000000 32927000000 27776000000 1160000000 156000000 75000000 157000000 36000000 59000000 962000000 806000000 831000000 2085000000 1636000000 1817000000 1642000000 1414000000 1519000000 13011000000 11692000000 12911000000 337000000 661000000 575000000 5651000000 3031000000 4394000000 16444000000 13879000000 5863000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity income/loss from affiliates and depreciation included in segment profits is as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:37.423%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">182</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity income from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Year Ended December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Included in segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity loss from affiliates</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 39000000 0 0 39000000 5000000 177000000 0 182000000 11000000 0 0 11000000 6000000 158000000 0 164000000 -6000000 0 0 -6000000 6000000 143000000 1000000 150000000 <div style="margin-bottom:3pt;margin-top:3pt;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property, plant and equipment, net, by geographic area where located is as follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.412%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.874%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.357%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">December 31</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,891</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,993</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">966</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">857 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">225</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">207</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">135</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">21,422</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,279 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,000 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12891000000 11759000000 10394000000 6993000000 6081000000 5314000000 966000000 857000000 737000000 225000000 199000000 169000000 207000000 220000000 216000000 135000000 159000000 166000000 5000000 4000000 4000000 21422000000 19279000000 17000000000 PricewaterhouseCoopers LLP Florham Park, New Jersey 238 EXCEL 160 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,F"6%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #)@EA6K/['*.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*'%*#R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE>FS*V!QCX8NGW MIT_@5GNAAX#/8? 8R&)\F%S71Z']AIV)O "(^HQ.Q3(E^M0\#L$I2M=P J_T MASHA\*I:@T-21I&"&5CXAL'[S]!EF-& '3KL*4)=UL#D M/-%?IJZ%.V"&$087OPMH%F*N_HG-'6#7Y!3MDAK'L1R;G$L[U/#VM'_)ZQ:V MCZ1ZC>E5M((N'C?L-OFUV3X>=DSRBC=%Q0N^.O!:I+-:O\^N/_SNPFXP]FC_ ML?%-4+;PZU_(+U!+ P04 " #)@EA6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,F"6%8S'G F4PD -9' 8 >&PO=V]R:W-H965T&UL MM9QM;^,V%D;_"N'M%E-@$NO53J9) $=.=M.9I$8\;3&[V ^,1,?"2*)+T4G\ M[Y>4;--,*4I"K_NAX[=[;)U0TGU$VA>OE'TOEX1P])9G17DY6'*^^C05BN&,%)591G0\]Q1L,T^TI>RX/;2&[*$Z7?Y9V[Y'+@R$]$,A)SB<#BGQ<2 MD2R3)/$Y_MQ"!_OWE(6'MW?TVVKCQ<8\X9)$-/LC3?CR43UO* MU[+<,;V[MC7^WK)?\?RFK:'Q6NPL'-T5]:XJA_Q_OXA7H3M.\O)_)N4U,C C MY?'@4[G",;D3'VM57S] ,,U/N/<3=O,S*8HUSM C65'&3:+L',[6)KV1M:JO*""8 M)FJT%S7J)FI&6$H3>>1"XA!J'%,MI-VQJO%@9:WO*PT(IDD;[Z6-K9L:K1F3 MSF[3,A:#ZQO!S"K.3CLY<;T3WS49LQ;V-08$TXR=[8V==3Q>,2RZI>K(W[Q/ MVED+G)7&G=):UM<6$$RS=;ZW=6[=PIN"IWPCAE=&T,,Z?R+,9,G.<$]&X=@X MJ*QU?34!P31-KJ/:-J>+J$?RG)9$Q=_K#_8CSE<_HXB> M?A1]2GQJ,FB']54(1=,='K2^;A>'DR01]/+C[@:J^K)?"[--.]+U1N@&EUPR M1&M>H,D+*8\R])6^%D:-=MPC7K[BC=&:M;"W M-2":;DVE M?:*?_%VIR+TZC4-F/T10P@\PBT,Q]^,6H#[?^A:+HVE0!<>P__ M7MN,EEPT(_])5^+@E9BEV8G.V!F%1F^@N0"*IGM3R<"UM_353CEA!#=KL@/. MG3.C)-!, $73):E4X-J;^2]4-K:S)2UL'4@+9!PX)X'C.$9;H&$ BJ;;4G' MM7?PVUU1M N4B9ZVNK!Q'+(//CO2\$_?,V$3J,T.RFB>2ZDSSF-OZ,//SBGH5-_SI5(N"\X6Q/39='( M3NUM\QB9PE.9PK-' 9%0D[1X1O--_D0SD\06P/VC\=J:O:JO)"B:+DF%!L_> MX>_&&+IYBY>X>":-P:L%]/!M?F.T!9H+H&BZ+94+O$ZYX'#O$J>')1;OA7Y= M<]&W%7+(&?5!=OK1EA96-#D9]G+EA?Y9>.X%H_'%\$5S=HQ4X*E4X'5*!;/U M4Y;&Z#:CV'BIR$[I[0]^Z(14 O$X!X ^292??"Q$Q MQ9$?EZ)C2]!=6:[-9\T6YC=2&KV !@ HFNY-!0#/WK]OO?U.,]&6859?9V.F M[;YN(3U0HRS0( !%TV6I(.#9>_C=H6M[Q;N^9EN='D5WNS9+LQ.;AAAH(("B MZ=94(/ Z!@).6#VG+^<&\$ZCT9J=V&0-- 5 T71K*@5XG5) M3NB2(2G9\J, M76P+YPMFHB&9Q#$1((%):J31'V@.@*+I_E0.\#I-&\QSG&7H>EV*ITOS'FKG M-$ZPV.MZVSI&G^^K/M_O-'=PDQ/V+ ]H_Q($OI1-V@H7QF'7 FS49J_KO>S@ M&)V_KSI_W]ZPWT6WCVBR3E).&9IP3D3W6B7UVPP;.]@67M,,N[VLM[1C! !? M!0"_4P"8+T6O9AUA=DSS" .=#X"BZ;(.5@G9._])3HJDFBQN'%)V0+,FV/4_ MQ[C^[ZOVW[>WZOLI]<-5"+?B0>,AOP76M&3#7M;;V#$:?U\U_G['14%;8]LE M+\W.[+C;;T9CH-T_%$TWIKI_OUOW+Z0Q(>RN2,@;^DS,QRX[2B9>WW7T8W;^ONG_?WJOOQEEY,",@FM GN5!A040 ,$]IME!GC+YMZDF%:A O MQ/F7+\ENA=L](54NHXOZRM*29HE(M8A3]$20./$DZ!YOD.?7JT$_;I]8B,XX M0:^IZ'PD;'M=+R4EPD6BKN[)2U=I62USEJ]-"^1Z#DKP1KQN(4).51QGM*RN M0\L[BWH?V\BC4BR7U]8&1&V)6-/*G\CNH/\56>\>TY1%X^=_Z)'JAH MDE"R)E)\8/S+0Z:0")0VA:+I#E6F\>L4 +MF&#*G1*"T*11-7S:L4D_0,KO1 M?:ZHA=1U=$=V3N]5Q<>(/X&*/X$]KK3/#K4 [A\_HP9/H(D'BJ9[4HDGL$>5 M[A-$+:"F"2)[66];QX@\@8H\@3VQN*=GX_#=OC0RR@*=[@"E3:%HNL.#;T0$ M\&>* #+?1*"T*11-]ZG24F"/-WW.%'92U]$=V3F]_1TC.P4J.P7VP-/A3&$' MB#/%L,$3:%J"HNF>5%H*[+FFQYFB99U4TYD"-%- T71;*E,$+?T/K*!9@HHFNY098K@")DB ,T4H+0I%$W_JIW*%"%8IF@A=1W=D9W3^PMX MQ\@4H:9H\ 2:*:!HNB>5*4*H3-$":CI3V,MZVSI&I@A5I@C; M,H7_ONORC9G"SNE[9 .E3:%HND.5*<(C9(H0-%. TJ90--WGP;>RP3)%"ZGK MZ([LG-[^CI$I0I4IPK^;*5H \NJ3/YH818&&"BB:+DJ%BA J5+2 &D\5H*$" MBE;;&A[\$(INKTCWV#_4SY7 M_P=02P,$% @ R8)85JG&6(-! @ Q@4 !@ !X;"]W;W)K.[J)9X4#F )F^\$&KNY5J7,]]7:0Z< MJH$L09B=G41.M3%Q[ZL2@68NB!=^& 13GU,FO#AR:PG&D:QTP00D2%3%.<7W M)12RGGM#[[CPS/:YM@M^')5T#R^@OY<)&LOO5#+&02@F!4'8S;W%<+:<6G_G M\(-!K4[FQ&:RE?)@C8=L[@46" I(M56@9GB%>R@**V0P_K2:7G>D#3R=']77 M+G>3RY8JN)?%3Y;I?.[=>22#':T*_2SKK]#F,[%ZJ2R4^Y*Z\0T_>22ME):\ M#38$G(EFI&_M/9P&W%X("-N T'$W!SG*%=4TCE#6!*VW4;,3EZJ+-G!,V)_R MHM'L,A.GXT65,4T>1/-[S3U%OC:R=M-/6XEE(Q%>D!B&Y%$*G2OR1620_2_@ M&YX.*CQ"+<->Q16D S(:WI P",,>O5&7Y,CIC:Y-DOQ:;)5&\R1^G\NW41N? M5[-E,E,E36'NF3I0@*_@Q1\_#*?!YQ[6<<N@RB2RDKHILRZU:Y)+9K:_.?> M=+A'BGLF%"E@9T*#P:VY+&RZ1F-H6;I*W4IMZMY-<]-H :V#V=])J8^&/:!K MW?%?4$L#!!0 ( ,F"6%; G(45^@4 +$; 8 >&PO=V]R:W-H965T M&ULK5E=;]LV%/TKA%<4+9#:(O7IU#&01!U68&F#I-T>ACTP M$FT+E42/I)/LWX^4%'V0E.H,?HDMY=Q+GGLO+P_-U1-E/_B.$ &>B[SD%[.= M$/OSQ8(G.U)@/J=[4LK_;"@KL)"/;+O@>T9P6AD5^0(Y3K H<%;.UJOJW2U; MK^A!Y%E);AG@AZ+ [-\KDM.GBQF MTJP@)<]H"1C97,PNX7F, F50(?[(R!/O?0>*R@.E/]3#Y_1BYJ@9D9PD0KG M\N.17),\5Y[D//YIG,[:,95A__N+]U\K\I+, ^;DFN9_9JG87??B,-(5_Y2VC.J[_@J<$Z,Y ",&;F/@'FO@-09>%9F:2A6'& N\7C'Z!)A"2V_J2Q7,REK2STJ5]WO!Y'\S M:2?6U[3D-,]2+$@*[H7\D$D5@&[ YS*A!0$?P/?[&+Q[\QZ\ 5D);K(\E_GB MJX60HRL?BZ09Z:H>"8V,!!&XH:78$ URFX*O8$69CXY\R^:=T%I_(V2"$01O"8#+Y*H2J<_&Q(JC-_5[B M8.A!J!6!!>4&*-"*P(H:*X*P91!.EZ_<_[)R>P:VI"0,YU45X%3V_4RU K5% MVGB%YEP=3@; ME<@25M^+-"H6%$*>KW&Q^7*7H9W,LB6S_!D9P0Z).#"9*)"H56OCL33&=MU0 M8V%B@D KQMC$^.%(.J#3[?G.)(>JKX!W6;7CO >D[CEGH"36G#3>!H'T'7W9 M6% ?H.OIA&RP:.F,4.K)&#A)Z1L59&X5+G:<+\*'!':';B!T[*@G4U>R / C_E:Z7HFG-? M0KUKV% ^,@K4@G*]L0+MA F<5B9?Y!GN_W'SS/EXOKX?7=M@R/4CG9T)D\[& MTM>)%SBYL:]_)YR?@Q['2R%8]G 0^"$G0%#PA]=5H@T-6IFAAOA&>G,."TQ#@JBP;Y&\*2'[7,>8N+_4=I-C]3?N96^A9I MX?G0Z$L6&'*-3= "&S@;!J(3*G!:J?2#$&<\J>,@SY!=&,ZJ>I!ZK%[;JA=? M%O10"C- KZH.4Z(X>FA,B*GB+2#45QK#P'1:!TZ+G8DU4)4!.*8"(N.$8:T M"\QU/*-CF[#0"49D$.QT$%Q.'EBN,,\2\ FS4J:, YEV2:HH9 N_WV$VPMZZ M" 9V.YJGA-DS/ZG,7GOL.:FW^%3>AC^$=(H.32NZG_UN8FZ'"_@X_#_6CL@7ES2-]N[&@X#P0]B4;GI':2!1 M'S)'!EL3!><]H3QDVTE -"T!>RWE%:20,1=;%FTHJ)]U+2@TGL5.\Z'I7[PF M>@?GAT(5<)SEA^KWX:-ZZ;&-!)WTQ[.3>HM/Y6V8DTZFHFF9>M)&XME*4#\W M6E"RD1@E:*)D(QG9K5&G6]&T;CUQ(S$5I]%(_*,:B47>CE#MI"LZ6KJ^@E%@ MVPN,%-I04!=<%A0R4[CHW644A&VK.R$N3_92.-97 ^W;]M[ILKIMT=Y?P?.X MOCWJW-2763>8;3.9V)QLI$MG'LHXL_I^J'X0=%_=F#Q0(6A1?=T1++N) LC_ M;R@5+P]J@/:6;OT?4$L#!!0 ( ,F"6%:$,@8Y^0, *@- 8 >&PO M=V]R:W-H965T&ULK5==;]LV%/TKA%84"9!8WY*=V@9B:\,* M+&W0K-O#L =:HFTN%.F1E)WUUX^D9-66:"<%_&*)U+F'//=>7UZ.=XP_BS5" M$KR4A(J)LY9R<^>Z(E^C$HH!VR"JOBP9+Z%40[YRQ88C6!BCDKB!YR5N"3%U MIF,S]\BG8U9)@BEZY$!490GY?S-$V&[B^,Y^X@M>K:6><*?C#5RA)R2_;AZY M&KDM2X%+1 5F%'"TG#CW_EWF&P.#^ .CG3AX!UK*@K%G/?A83!Q/[P@1E$M- M =5CB^:($,VD]O%O0^JT:VK#P_<]^R]&O!*S@ +-&?D3%W(]<88.*- 25D1^ M8;M?42,HUGPY(\+\@EV#]1R05T*RLC%6.R@QK9_PI7'$@8&?G# (&H.@:Q"= M, @;@_"M!E%C$!G/U%*,'S(HX73,V0YPC59L^L4XTU@K^9CJN#])KKYB92>G M:L1. 6?'W*P-6[:_ .8 H> M,"$J>F+L2K47S>CFS;JS>MW@Q+I^ !X8E6L!?J8%*HX)7"6B51+LE;>&35A&Y?0\(4G^%X/Q5_W"R&Y^M_\;?-^ MS1[9V74QN1,;F*.)HX@%XEOD3-__Y"?>!YOG+DF678CLR*M1Z]7H'/OTDRJD MC?ONI>1X44FX( A(!AX0SY_!>UAN/BA_#VXT;F#S;+U"8E;0574[]:/8'XW= M[:'++*C0BSJHK(]*O21M04<:XU9C?#9S/LLUXIV4N?J-"7&]EZZ]H++J=_B" MQ)U-8GS)Y+DD678ALB/')JUCDU>3IZ+J<"7XFRJ65\3X=*7.5J .L )QO(7Z M$!,W@-8>YB@G4 B\Q#F4I^IDO6A\D .WJ=_)ICXF\KU.+EEX@M&)7$I;R>F/ M2-:*M59,E4JIJ],/:DU[>^RHF+^*R/J(6W]HESEL90[/RIPABI98@@V!U.@Q M06T"#&D!-APSU2RIA,(Y CE'A4)?Y4S(Z]8!L&1F%=E14SV G6F4$%@W945_U1UH&V*1OV-)%[8 MD60!14$'E/5!?AS:%?G>]\[&.ZNI+H3Y42'$=06L0]N&3NI*:.UAO/[NP[!; MZRTH/XV3CD8;5Q3Y)U0>]&_^^@/KX587PC><<,V*QT> [6Q[W;@W379G?J:O(:8U_DY3WV$> M(%]A*@!!2T7I#5(5"EY?"^J!9!O3*"^85&VW>5VKJQ3B&J"^+QF3^X%>H+V< M3?\'4$L#!!0 ( ,F"6%:)3R!DV < "DA 8 >&PO=V]R:W-H965T M&ULM9IK;]LZ$H;_"N$3='L )Q9)7=/$0)KLI4#:#9J>W<^, M1-M"9=&'HI)F?_T.)<6RQ4NR0/9#:UL>4N^,.?-PJ%P\"?FSV7"NT*]M53>7 MLXU2N_/%HLDW?,N:,['C-7RS$G++%'R4ZT6SDYP5W:!MM2!!$"^VK*QGRXON MVIU<7HA6567-[R1JVNV6R>?/O!)/ES,\>[GPO5QOE+ZP6%[LV)K?<_7'[D[" MI\5^EJ+<\KHI18TD7UW.KO#Y=4CT@,[B7R5_:@[>(^W*@Q _]84LT(IX MQ7.EIV#P\LBO>57IF4#'G\.DL_T]]<##]R^S_ZUS'IQY8 V_%M6_RT)M+F?I M#!5\Q=I*?1=/_^"#0Y&>+Q=5T_V/G@;;8(;RME%B.PP&!=NR[E_9KR$0!P-P MZ!A A@'DK0/H,(!VCO;*.K=NF&++"RF>D-36,)M^T\6F&PW>E+7^&>^5A&]+ M&*>6UZ)N1%463/$"?685JW..[KL%=(K^N+]!'T]^1R>HK-'7LJH@\,W%0L%] M]>A%/MSC9=+-1UTNMU+R M6J&KIN'*ZDX_/K2/UXEUWNQ8SB]GD#D-EX]\MOSP&XZ#3S;GWFFR(U?IWE7J MFWUYS9H-8G6!]U/%W50Z^Q^7F,19>+%X/'3'M$J#+-X; M'9%7WE6> MBQ8$0=G*.43PH>+H8PT9(E:(55 (NZ2!DHH*T3ZH55M!=1J&@,E)0G3^Z,7? M_18G\-LB[(8>9W L)[ MS78.V*U*G79;V5=-ANG>FK* MBI-X6LZM9C1PU#,\@A7[R:JW=TJV_989JO%.BC4L*KM4$YP93HTXFU8IQ2ZA M(V*QG[%C=N[VV0OA/-? ;[=MU6VC M"PZ)FY=,!]TJV&073K+4R#6+68HSXA \0@[[*><-]1S!QL8JVN09P:'!%(L9 M2$Y<:3B"#_O)]W"H<&0D('FURY0M MT*/;6QPU(M4K"\X$&PYQ-*TJ-C.:1B[=(__(:UUC+K8<*?:+^X-KP5EF;"]L M5H2X%WZ%%G:EJ?'S6ZR2.'4H' %'_I?6[K6?W(*RD%#C M)[>8T31Q9=1(/.(GWJU.^!\ZX6]<"6]!6)J$TRV.Q8P&<>;H]>A(.NHGW0U? M<0AD@8;%^4,O3NN9EP5FB='U6*QH&#IVCG0D'O43K^?Q-U'G;R,+-OCT\9#,/OX=P M6M":I---VVM6Q^Z/:*5^M/8K>,?*XA2TYFQ70A&SJK0P,Z3)M&!9S:!D.72. M;*5^MG[GBL$EZ',8=.N.5IV:@(QQD$X/'BUF$8U=1^!TY"CU<_3JH(,<^"^V ML&@W^IG9(X==EKUMIR8Q3\-#( VR;6:AZWR$CF2E?K(>)O]?NCY2/:,'OA*2 MPW:P&(X>].&XDIPUK7SNL\7JB@6M 0G3Z1;?8@>-2N9HD.C(8.IGL&[E)S+G M:#AZ.$=X'M!L#NW:/*:I+47!(,SF89;- T*/#>RI:^(YBL/42 J+68)=&TXZ M4ISZ*=[O.#QUO;'4=>ZNZR;+PRC+C/2Q(#_%J8-/X8C\T(]\C5%1*RDJ^&:M MVW$.X7<\13)Y'D^/BRPVB6.!A2/QP[?TN.X8AB:[H;6(C"=P/R1URB?G(T-:26^TL+?GBX#FV_B."KTRN2^@_*[Z"@<%9 M A[+_KE\_T&)7?=H^T$H);;=VPV';D]J _A^)81Z^:"?EN__.F+Y7U!+ P04 M " #)@EA6Q"2&5!$# # " & 'AL+W=OL".QB5>DCE1#^5,0,]N51*:DT)27B!!THEUV;^8#K6] M,?A.R5INM)&.9,'YH^[<)A/+T4"$D5AI!0R/%9D2QK008/QN-*UV2>VXV7Y1 MOS&Q0RP++,F4LQ\T4=G$&EHH(2FNF+KGZR^DB6>@]6+.I/E'Z]HV""T45U+Q MO'$&@IP6]1,_-7G8<.C[KSBXC8-[K(/7.'@FT)K,A'6-%8[&@J^1T-:@IALF M-\8;HJ&%WL6Y$C!+P4]%4UY(SFB"%4G0%6:XB F:F_HYG6%!"I4116/,SM G M]#"_1JRX6?.J7M-]90US]'KN.Z'>[3 MX]W[V^XV1-^FP&U3X!H][Q6]N8+@H3 5XBFZH06D@&*&9EQ24VD_+Q=2":BW M7UVAUMI^M[8^@Q>RQ#&96'#()!$K8D4?/_0#YW-7X/]);"L-7IL&[Y!Z=,G@ M1)OMAW<#2GBU4&G%X)S%O"I4YS;7@H$1U*^+513"?JXV(]HW"?Z9;''Z+:=_ MD/.V6,%>M,"# M@\!3GN=01G"4X\=S5&*!5IA5!)T"=,(9PT*B$M!E!N?MK N]U@\WJ)S>8(?\ ML,T6>-""!^\ QY7*N*!_(-N:W-#*3MQ:=;"YYP.G^>U0'V6Z!1^V\.$[X&M: M1*6LWN8/]Z"\01CV'6_@[I;W4:9;_,.6?WB0_QOA;K/UHB?X"4$L#!!0 ( ,F"6%89?^KL"@@ M "1$ 8 >&PO=V]R:W-H965T&ULO9QK;]LV%(;_"N$5 M70O4L4C=[#8)T-JZ%%C;(%FW#\,^*!(3"Y5%5Z*3]M^/DEW+I&C&7D[RI;[D MG.?P\HJBWEHZO6?5MWI.*4<_%D59GPWFG"_?CD9U.J>+I#YA2UJ*O]RP:I%P M\;&Z'=7+BB99F[0H1L2RO-$BRE&A>K58)-7/#[1@ M]V<#//CUQ65^.^?-%Z/STV5R2Z\H_[J\J,2GT9:2Y0M:UCDK445OS@;O\=O8 MMIJ$-N*OG-[7.^]1TY5KQKXU'SYF9P.K:1$M:,H;1")>[NB4%D5#$NWXOH$. MMC6;Q-WWO^AAVWG1F>NDIE-6_)UG?'XV& ]01F^25<$OV7U,-QUR&U[*BKK] M%]VO8]W) *6KFK/%)EFT8)&7Z]?DQV8@=A*PO2>!;!+(H0GV)L%6$@C9D^!L M$ARUPGA/@KM)<)4$V]^3X&T2/+6"NR?!WR3X:A_V51AO$L;M[*ZGHYW+6<*3 M\].*W:.JB1:TYDTKB#9;3&%>-MJ]XI7X:R[R^/F4E34K\BSA-$-77+P(87+$ M;E#P?97SGVB(OE[-T*L7K]$+E)?H4UX40G/UZ8B+Z@UCE&XJ?5A7(GLJ_I^EJL2K:<5ZW2O1,+#?S9AVXH^@/5NNHT0.#*M:K>E7] MW#L^L3G_,RN'*&4EKYB8U_(6?2PYK6C-E;:,A*RVVB);;9$6[NR!?Z"W>=D, MEUA=BJ1,*4HXFM'T!-GX#2(6GNA4M&9Z+;-9>>_.B6=9^'1TMRN:?A3VQV,Y M:-8/LB>>9\E103_*$4%$C@K[44,/3VPY*M)$N>[$54K&_;")LPV1QMK>CK7= MYMA[QOICF392H.B5&.#VW>OF<&UE,6=%1JOZ]U^']#^78K*16/KODRK[5S<' MMFE>F]/IVWJ9I/1L( 1L]YE5^O>')=4,09^D2K]!MZF2R6[\1:>/*FB3O1 MJ7%=P=TY6GS+\Y4%P=B,8U4&"0L.:7X(63&"A,5 ,$D][E8]KE$]ZQ-E*ITH M\[6:7A7BA/GZ#2IINUOAR0^JW92XO=$?.HYZ-C&VXECQ0,("2%AXR%A$D!5C M()@D'F\K'L\HGFE2SU&6W^49+;-:7-"D15*)W9?83:;K366]9]/TP>L/E&=; MZI)C+'^L:B!AP4'M#R%+1I"P& @FR<;?RL8WRF:[I6[5@>JY$$V-EJLJG8M= M5::3B]\?;DS&ZB)C+'NL7"!A 20LA(1%!XUL#%12DLMX*Y?Q@QNQJ^C'V(YC]0,)"R!A(20L@H3%QCF2Q#/9BF=B%,\L MK]>2:2R51^EGTC]0B'().S6VY5@!0<("2%@("8L@8;%YDB0%8:LS\"RCAJZ: M$]2P\6^S=J--$ MV1-7#0LT88YO>ZKUI@D;>IZM-"W2A;F>/_;5N>G'[<3((]Y9G9@\H_^&C<;J ML08<*&T&2@M :2$H+0*EQ5 T6:"=/XR--A^($;Y;&[ T?(!=74/ZT((6C0"I<50-%D_G;>+S>;N M_W#IL,85'3N6*AM05Q>4%H#20E!:=-#HQE U9=5TUBXV>[M7R[P,]E6&?&XF=Q8['&ZNMM3T#]6%!: $H+06D1*"TVSY2LHLZ5Q<]ERV*=Y=>[ M7@(U9D%I 2@M!*5%H+3X@:F2?P'7N;/DZ=Q9TG<:7:)N<\WUCQ6/IJ1BGP6@ M!4-06J0;,:RXCC%425D1G3=+'N/-8JT0-';JF+CJ[Q$T8;H?16I,5X?8JC>K M"7-M;Z*-!X1:,T8BB:KJ/-FR9-YLT1C;/I8 M_:_:J;D!1\L'U)L]K LA:-$(E!9#T63]=-XL,7NS1[ML9M[16RI0!Q>4%H#2 M0M+W7/NN'6C)&(HF2ZLS<(G9P 7R]TC?>^Q=3(%ZNJ"T )06@M(B4%ILG"A9 M0YU'3,P>,9R[1_KFXQ#;JI! ?6)06@!*"T%I$2@M?F"J9"EU1C$Q&\6/O]/ %HR!*5%F@YXI'=S+5!)^3[G_$IJ6YS<305]$8D62>^F/YJ_4B*]0?.ENT##JX9YVS1OIW3 M)*-5$R#^?L,8__6A>6;"]L$@Y_\!4$L#!!0 ( ,F"6%8@KM:&PO=V]R:W-H965T&ULK5513]LP$/XK5C9M(+$F M34-!+(U$6]#V@%11;7N8]N#&U\;"L8/MMO#O=W;2T*(4\0$E-3U5@<25I=(EM6CJ56@J#91Y4"G".(J& M84FY#++4^V8Z2]7:"BYAIHE9ER75SV,0:CL*^L'.<<]7A76.,$LKNH(YV%_5 M3*,5MBR,ER -5Y)H6(Z"Z_[5-''Q/N WAZW9FQ-7R4*I!V?\9*,@$VWAL.(,VI0/NSW?LM[YVK&5!#4R4^,.9+4;!94 8+.E:V'NU M_0%-/>>.+U?"^"_9UK'#."#YVEA5-F#<0%A#O"AC';S).(>^10?^,Q%$<=VQH M\GYXOP,^?3\\>J.:07L< \\W.,)W< )SJ_*'0@D&VGS=GHFBWN7 M:;C9[UM7S# Y#)IV!24O3'6=X=[#+D&OO$ :DJNUM/43:;VM!E][Z7GE'Z,V MUU+Z0E,+^QW5*RX-$;!$RJAW<1X078ME;5A5>?E8*(MBY*<%_E] NP!<7RIE M=X9+T/ZQLO]02P,$% @ R8)85J<9 :F5"@ *S8 !@ !X;"]W;W)K MX+JOF=+)JV\WQ;-;D*[K.FH_UAE;\FV7-UEG+W[*[6;-A-%O(0NMRAGT_ MFJVSHIJ0<':=A* I(Q5\%?6@&KSWARFU= M_Q!OKA:G$U_4B)8T;X6)C/^[IY>T+(4E7H^?O=')[C=%P>'K9^N?I?/]BT:Y.)_'$6]!EMBW;;_7#;[1W2%8PK\M&_O4>>JT_\?)MT];KOC"O MP;JHNO_98]\0@P(HLA3 ?0&L%P@L!4A?@+RT0- 7"&3+=*[(=DBS-CL[8?6# MQX2:6Q,O9&/*TMS]HA+]?M,R_FW!R[5GEW75U&6QR%JZ\&Y:_H]W:NO52^\R M:U;>9QX7C3?UOM^DWOMW'[QW7E%Y7XJRY'W6G,Q:7@-A9Y;WOW;1_1JV_!K" MWI>Z:E>-]ZE:T,78P(Q7?5=__%S_"^RTF-+\HT?0D8=]C($*7;Z\. **IR\O M[CN\(;O>(-(>L?6&:O,EJ]?>UPUE65M4=]ZY&!]%6]!&]@UOQ*+:BB]ZB:4[ MNI\+X)\3.>6XV60Y/9WPI-%0=D\G9[_\ T7^KU!3'M)8>B!CHV8.=LT9E[EA"R*"&$NHG##ZON"CU'O M]NE9PL79* Q!*\=0PX6'C,-#&DL/9&S47=&NNR)G')ZO:]86_Y/M!K5:5SH< MA CVXU"+-E.$(J*%9 J(8C2'@VV^J_W<6?N4\B;)"VOMY\!OXD"K/2 *Y_I0 M 411E,"UCW>UCYVUOZK:K+HK;OG@R)I&#(_U)BN8G/WR5<;N*)@!8K,J\R#1 MG#)%Q,>:3Y A%,,^)3N?$J=/O]=-X[WOQOF';J 7U3U]S@A\ZJ8_MT7[Y#4T MWS(YC(_$B(<<31Q]O7:%>_% MG/O6%)(F>6ZZSJJ%>/GGBB>F#=VV1)+"EC?)KI9ZX0' M7F]G'$5A%.N>F#(4SW5? %MA%%E\4?"&G-!R=L/[B4[%*F3!I\8U7YHUUN38 MFQI6(0R0[HPI"N:)[@P@&E@:^Z((";D1Z2N/- 96/# ;F/A&S4U5[(=ZS0%3 M. DL55<,A-P0).B.9_"*9W"1\F1V;SR>#KRRR&Z+4N8]D%+003'EH-;20UD; M-ZHB%;0'5?*\WHI)A$_YM+C/^+P)MJ )&M,HT"=]2(5]0O3X &3('\RD8U\4 MMR WN%SQ.;%J:U98,HV)&U,4&1$.J*)YH+L J.(DM'B@V 6YX>5/EBW$1-#W MR29[LG:(R1E3'.OS.* *S.%JBJ+8-EH5LB WL_# 8EN>,,7XK$72\3B:,$%A M@]$*>@9@16A,;*8(SXWI (4%%KB#"M P6Y N1I,::X^PB8SD%CW!!!-0P.U M %6,+'V$%8!@-X#\P5>1+^L4;%("KZ6^9 %40:P/'=T@V-U;WD P'Q+*^QXHQL)LQQ.0F=XFN!^OS-V\389,A4.(G1K\! M,H*POK0!9'-[SRDDP<&K-L>NY-+F+5X[$>BUT_U!K:6'LC9N:\50V(D3O*TW M19N5'GWD%+LHVBVSC/?0#/. Q#J5@[(@, 8-*,.6E3Y6\(+=\'*]91P(&RJB MXX9F=[22BR4!Z6N^B&K:.O\!>F<"B)&6]TI20"(PQK)TP@ICL!MCGKV20:]6 M](.9=+#X!]V#0 ?[.JV!,MU'0&/#'*PP![LQA^>XG-)%/]Z;K'R#KR:\S+'. M=( (^?KV;@JH<(QLM*! ".\#H=&RGG,1+2GC;Z[YLG*=R8B5NS5RYU7D0KD1 MP/1CE-Y?DVF,T 6Q!QD,ZS0U/N90:$3<:'3^TLV:EWM,]F_A )(I"D/=8:>E ML<,*H8@;H!*F/3!U21R.:?8BSR M-[=]B+E70[!>=5,S3?29 A A;*NWXA7BYI4=%G]OY%[BV^&00"R21$8L C(4 M!7JWII N08EE/4 4VI#H55#\N:BR*G^+WTZ4>O61\2&MI8>R-FYK!5S$#5QJ M8U%$6+.J63MM*5M[MS7CQGC;PBUJLI$110 ^D236R0.0\:1FP6.B,(OLP:SL MJ3L@XGE[06_!XR "[2/AT,A>D(SHYT8I)$-):%DB$L50Q,U08V LFF;+!X/$ M?JM?^SD)D,P3XX054 7# [/Q104%2H$;E-*B:5EQNY63:G M_,K'-7CF$^R'(4"2#%*/XIY@SQE6(79BJH78Y"L6XA:%]&55EPO*X'LD )[,?:1/J) L MBI#A%R3#R#*I!@IV C?LC$<3?:0L+[I%M/3/JS?VBS(FGQ!]A^\2$&'CG!P0 MQ;91-;C_\SQ H4[P0M1YW[/.A]%>X)L!( !) MQ3CZ!V3$3_2M=<@8CHEEL1PH[ E>AST\3?:7D7@K[/'OH(!S4&OIH:R-6U4! M3O "P'G)Y2^P7?=C#B!)C,-Y0(0CZ[!1D!.X(6?GV[9?(12[%<(>OTQ6,?R" M<(;HVPJ0"H>VV50Q3^!F'L.QY2X#['%L/_H DFFH;Q"F3D/C>XR*>T(W]^RR M7#?(AQGN%6,]W(]!@(3H%[I20(1);(G)4(%0Z :A3\LES>7FP:?'?F'Q+6NI M=]G?7N"4)]K@J&N)3S^WQ7U62E(7^Y[?J$##7%S<%M^#_@/$$^C\< FID'$: M#ZAP:+NOJM@I=+.3Z.>K*A<02+WW*>U>?1!Q_$;732@*(E^_J@NHD![>@&:* MYK;[AZ'"J]"-5R_WS\M:[X+>%54EK]HNO?_0C,F+?N5VP>/DW1P=>>^03V3A M=SB,A8@I(WEOY)]9M1&D_>L>D>2-E]NGOB MZ5P^YZ-]?H&.T^ZY)66F>XSJ2\;X*&Z\DBZY2?_CG%>,=4\F=6_:>B.?U;FM MV[9>RYS[L[/]02P,$% @ R8)85M=04H-7 M @ T@8 !D !X;"]W;W)K&ULK95+C]HP$,>_ MBI6NJEVI)2\>6PJ1=H%5>U@)@;8]5#V89$*L=>+4-K#]]AT[(0)MJ'+@$K_F M][=GQIY,#D*^J@Q D[><%VKJ9%J78]=5<08Y53U10H$KJ9 YU3B46U>5$FAB MH9R[@><-W9RRPHDF=FXIHXG8:: ME'0+:] OY5+BR&U4$I9#H9@HB(1TZCSXXT5H[*W!#P8'==(GQI.-$*]F\#V9 M.IXY$'"(M5&@V.QA!IP;(3S&GUK3:;8TX&G_J/YD?4=?-E3!3/"?+-'9U+EW M2 (IW7&]$H=O4/LS,'JQX,I^R:&R'8T<$N^4%GD-XPER5E0M?:OC< +X_0M M4 -!5R"L@; KT*^!?E=@4 /6=;?RW09N3C6-)E(O='ZO=@PN[SR'ND=#_1 (O"%KP67?< M;\'GW7&O!5]TQOTOY[B+66A2$32I"*Q>>$'O4O1_/6R4EOBB?K<%N-+LMVN: M*C-6)8UAZF 942#WX$0?/_A#[VM;N*\I-K^FV.)*8F>)"9O$A/]3CU: \6>Q M>2$QIJ4M"Y7 T J8TKR/1G@E]J>Q;3'QSTWF[TU\+SRW6;RW"0;WC4WEGWM2 M#TRU?Z9RRPI%.*1(>;T1UA!95=!JH$5I2\1&:"PXMIOA3P>D,<#U5 A]')BJ MT_S&HG]02P,$% @ R8)85OVMS4Q^!@ :P\ !D !X;"]W;W)K&ULE5?;;MPV$/T58@,$";#9M=?.!8EMP$X:) 42&W'3 M/A1]X%(CB35%*B3E]?;K>X:4M++K&.Z+O9+(X9DY9RX\VCA_%6JB*&X:8\/Q MK(ZQ?;MZ^6C=1V=G*4WEWX MDR/71:,M77@1NJ:1?GM&QFV.9_NSX<4W7=617RQ/CEI9T27%[^V%Q]-RM%+H MAFS0S@I/Y?'L=/_MV2&O3PM^U[0)D]^"/5D[=\4/GXOCV1X#(D,JL@6)?]?T MGHQA0X#QH[ MGY=L3SD3TE^QZ=?NS83J0G1-OQD(&FWS?WG3Q^$Q&U;]AE7"G0]**#_(*$^. MO-L(SZMAC7\D5]-N@-.62;F,'E\U]L63KS)VGH0KQ7E+7G*DPM$RPC)_7ZK> MREFVLOJ)E?V5^.)LK(/XQ194W#:P!*01UVK =;9ZT.('4@MQL#\7J[W5Z@%[ M!Z.?!\G>P4_LG?M*6OU/%]TTJ[?2YT$%)4 MQJT1N)JDB;50$B957H#%,B)I##+1!Z&M==>2TW)8#%:Z?&RLO>NJ6FC$G0.F MO&X3.0T56@%XF&._,EVA;276VAE7:<5HO&PU?[V6*JU+_(+\9H>I]:[H%*J9 M^&V'_NF3-ZO]U^^"<#OG&7OK<8YNI3%;9)Y%J2H$JV:PPE5!YU,R(!)QXP8K M !>H2OJ9BXM:HI(H@H\*:'C+:0;V*0&;B[4#/!"PJ;6JT_&>6N>C7!L:#678 M=XSU'P<,0=0=T(X>__?D/CZ38'QZ8,>P"E2B(H?(('.PTXID$3Q= P+SB2@E MC_$/:SATH+80Z^TM,N>B[!44T5%BP@^[&7FA@_,%='*+)?AI#,L#.?2@BR-@ M\(=^HP$A.E'XKD)PG:$@#6N0<7N*4O/37-0NM#I*P] =1&H3)O9&Z5Y*@P:F M^L9AUYJQHKLQ;V'XRGTQ$M<2Y-6D!L%^CW@Z9K7@J+HT>.!"/X0I@DP+) >,/\W=G-=1,M'8#XEN,H&YC4\)?MMJ^ M."_+U(LX;1"$L06)=:_>CYV/;F+7#^0]$M&R'?/R+(!H)$?Z)R0 MB[L*>LLD.A;=M%D,V/6CDT:7F?H:JE\3V2Q>?,=SE#U<(#0O7*N=AHY0M-Y6632C>6 M="FZ:TI94*30]J4.3QL=:_B5E0YPK9'(Y2*'$>=RKG(]PRDHZZ%OSU.YIMEK M0VD:LUD(F?M!D'W Q\2I):I($@)N2B9+1898CHK]=OO3E-JG+6QO!S' MZK ;JP?1\VY>-F ?@3P+$-Y7AR\'SQ?W3/]^N1?4$L#!!0 ( ,F"6%:/&3F.(24 ,!X 9 >&PO M=V]R:W-H965T*YD#D.V9 MB7=GQH+M2;!8[ !=VSHW%^WW3AF\?[<:Q_\OCQZ':N7T9+KO>M?#)IAOVY0B_#MO'H1]< M6=-+^^;Q]=75%X_WI6\???<-_>UV^.Z;;AH;W[K;H0C3?E\.AV>NZ>Z_??3D MD?[AM=_N1OS#X^^^Z^/&7_O; 7Y['%>I_=ZUP7=M,;C-MX]NGOSEV6?X M/#WP-^_N@_FYP).LN^X=_O*R_O;1%0+D&E>-N$()_]RYYZYI<"$ XQ^RYJ.X M);YH?];5?Z"SPUG697#/N^;OOAYWWS[ZZE%1NTTY->/K[OZO3L[S.:Y7=4V@ M_Q;W_.Q3V+&:PMCMY67X?>];_K=\+W@P+WQU=>*%:WGAFN#FC0C*%^58?O?- MT-T7 SX-J^$/=%1Z&X#S+1+ES3C IQ[>&[][P\0HNDUQ4U7=U(Z^W1:W7>,K M[\(WCT?8 Y]\7,EZSWB]ZQ/K/;DN?N[:<1>*[]O:U?D"CP&X".&U0OCL^L$5 M7[CJLGCZ9%5<7UU?/[#>TWCBI[3>TQ/K+1RS^*^;=1@'X)#_7CHQK_?9\GHH M-7\)?5FY;Q^!6 0WW+E'W_WIWYY\=<&^*0N2:K^]&]?73^Y_KIXNW-%%3]Q=;'Q;0EOE4T11O@# MR/$8"EBGF6I7C/!TR3O1FOC[\V[?E^VA*-NZ*)L&_^SATS"M@Z]].2 DOBWN M=[[:%25N-@Y=TR"DOAT='&8L?"A0$8WP?U=?%B_Q[Y6LNRX; @6P0V V&TH M23' 'P97N,:#="'DEWC"Q:5K!S_O<>EB?8"-?NL&/P+6[ELWA)WOT\.T!9YQ M'1SLB6?!7!:@XV*X+,RIFV+_?P<;%SX#2=_;0H0#."/!VV19/KJ[^N"*XP0# FZX( M.T#OKFMJ>)R8Y9S 63&; STFDG4(L#8Z76C5?T254.@.:ZZ)CP?&(T.3Y< M@ES"K\$SPZK0O00$P#$"L"00 !A]C2P,CZQ$PN([Q=X!=6MDI#))^(![P-$8 M.GH%^ 3)4M$'-1T$\+L&)-.IX?-IC_SOX.6J&VI\)HHP\HS^;#?GQ?V _(<< MB3*P*>'WNQ)H 8SEQUV! H@LY]Y7KJ=SPJD_$AQ_"A&*=P^,O1FZ/6$!CPHT+7PJ\@N&'T>_S@:WP*5D-9!)%V(/<$*.X)9%S!#Q_<" 0Z MP4NJ:T-ZJPS,6^\KD-:M V!\Y1A)]]W4*&$=4 A4.*Q?MFFOOO0UJA52GAO@ MXM)L?P9/NO=^Y"7/57WU;#M Y< "^PYU8WT'<@@.7S>AMA[>P>(;TC[+^&L1 M!N2T 9!D]#: .MX[U^H:49&23>'=]X!>T(6H+H@Y+\F^#35P0'-892*[+P]\ M>&$U."=C3T7"B.]# M%*5^&H!$02ETAEH9U.D@7"T4 $#/6?$158F#R/@:X8(%6T#/7+*%752"MUU7 MW_NFN2S>&A17'2GIMI:? "FH"8>I&LG$J)RS+A/=A]84#$\;>&6@_X2 7I*/ M -'$(*;.!?"<0Z8O<)THQKB0H)1%? FO'_8YRLTH^#FAGDB\+2M$J0Z+.E&H MO<>0B99%V6)%A^HU'8!5_<=H8F9%R]Q("^1'>4:E,9! FM5P&88/T+JC[*<]3QJKP80C#"A'9B(E5 L@"6!YX;W%6W+QZ_E-Q7J"4-87S(B$ 7 D&N..7&C?2 MS]%#)V<@?M)XX"2)=D1YQ*,=K..<'9@PQC1 E[W8@6/?',C[9%Z"< M.WW9[ M+[3;+"^4F,P2!KW:3V&O PI[>['O@%*X]4:$03^.2F[N8.6LPPRX\V&$8 -9 MGFBY0K<;\!E7_[C%D">$E749U _SHRH/ NX)FJ @6D4R"2CM]X,P'Y(8C'WDT7K!CY08,)I5\S NP8PI""&; !K V MX /,[S1(@+ Q<=&X&QPA:-P%#F):1*&SOGSZ&X)!UCNJLZ:[AP,B0.A" :?@ MR7-\-I"4H(B[?HU\#\:GJF@@KQOM$ MPX^!A &8@?*# 27',%D,WD?XK3F(TPC+@@&KP9T![@.1NG< "/RK9+?0\(/, M;Z!HP-UDG8#'ED4 1R!Y.Q<5IHOFBG,&ULM@<8W1 *KL-6[*OM$6=5N'LM3# M(T!>LL<.Z9S4+NI/U.3B*I.U^GT Y[ZP LW^3^/?N<;OP%'@8PU@W5OP@=5C M8+#10R'3L(LVG97L1D!5H\8 XOFWCD@>I1Z=MBEYP (B?BS.WP):"G% \LR M%2J3+6"B$[IKMQZ+X"J5U@K8._B-9Y^UO"M]@\]= +(NZ!QLKY"=C\/#'W)W M>]G__UA(<*,CMO_'U.&^&NI@3,#Y#PZF^>^!2 N$ Y%'Y:P6>=#7Y3U\*D"T MC=HU/:/RUT^CX=]NC3E"YM !(U^D.%AM8-MN((H"6YN'!$*PER7ODQE59@Y@ M&SQ>=,4C",98@-:.>MX&7A$P=/L\X-@/Y&8J?V5D0B6)FY3O>1WP(PI6/,>< M'DD.0H8HK,AL&X'K 86L2].V0;.4'TW>E=@M%6'W'E=%9<"IJTT6MB<#@IH2 M[2R+#/KE#=@$3&@2FBM0,!![D]=#D1U[Z)E2@\ ;#HJ9EPI$2&A<4=1?DHTE M@'AO=70BW!BC6GRC ])5'-E)OB+%3YUCMYSSCQPU5BE,!2P"E%Y]A:#%@LTNLR!3Y44,'@$)4W($Q3:N-)AY* M"8&X=+8B/(7NE-7(!^6+I4-*JFB/<9T>../DE"T"!BP'M B4NYT[R\O^#K*- MI-(P5X.:%&&@--PX^/4DGQB689E@YYI9?;#N[H*8P?NL+Y299FDNE;77Y*+ M7[:PM'B$E(LFKEU2?1_OULV4>S^M&U]QCJCFU"P29[;\L@K__Z%P3^G,3T/K MK^UPFFAHX:VNBV#7(",5.E:<%Y\9,?%B44*C/Z">(<1('EVV'Q(FVK 7^4L@2("_W% O7+ I%%3;H_8[)BMT$%!%Q1K MXKY)Z2,BC\W$92$OZ5[4Z7TS$3O &Q.7NV +/)@A,BS( MO(^Q89?%&ZITU+]->DZ%U(CS@SSSL)@O2^+'<^1K<3A?,T19PL;^#2-$>316 M-J(QIXB(ZBV KE7RNRN(,J5# *MT9<.><^54#(YV M0/,O!:.W9$93T'4KH"%:OXX.WNQ).5+E)]!KL?=/Z/?SX5PX8@]LR6)3H M@E 3,^KN!"Z*"W7H]YA!LA4$3#\B X* ]U1]"S9B\GM,9P^>$39RB7D$ETD/ M1-%/TRRBC#.1Y;Y$D4'GLN/L.FU)ZR$0GM77 /\AG&EJ-!B(T".HG<-"$YR4 M RF7UXN6#\Y4N(/ .2.%$$TT'+-#51S]JCO"^1ZS!6C7HYTG*V5RR"ZT:P M,E5/&X:K+P](IMP?C\=.K!VCRHBH.]#PG)WG'7]PF ]N / #BT;!8QQ&^!@ M^HTRJ?(61)E=]:[WC=IS%"2B&\6A;XR2 OB_UP0I C,2ZU(9V^^?W[.O040 M5H_,XBO[Q(^8,,0E7[MM2=4FVU>!L+W1L_Q-SX*[/?/=6Z!;AWE0M&!#*C/E M)_TQ/^EM?E*28'#N2G#W*MVA>*/G+J38]F9$/M["([]H>CL]@V3Q4OM.IZ2@ M(TBIQ[N@KCV1+%$,3<\1L5(ZV]#)$ -?Q@3HM-UI!IG6V&-+1%YQB651W"FI M_&0)N/+"#I:I=V^%+J!P,*^LG*KI>O#X+X ,%]BMD"O?F*(0/DTVB9)>IU_, MW>),;%5NPI'@S#"1/HC1SL&-#'._.P12T3V9VV"\=E&MSX^V8_'>/7#@E%Y& M.PJN0\I>)4UB1X: )E[9J.L_U+6H&P4M8'%E,]@D*8+VV*[>1BBEN' M]:(U-EH+[HGV [-COI:J*\H2?YAL3^PH$ O+>K@M*7-WPE^(1<4MQ$"A&,2:!T=F MN!@/ONP@Y(X5[HX+B1,X MPXXQ6VRM0&5Q<.5@$30_"X$0TV!8U#*,H."3]F7%1"TH5HC(R$6,^;E3* IYV3.5/SVPI@YTSC&4%3T$=)R@B14L*6$#>RK@\*:H&-:QHL]:%;LCT64@H*<> M6S"D1^8NH0C;4$N0"O&4,$(#"6DT=#>.%^#R#D4G.,PU$JXYV:=_.?L96*]" M7.-G_ L \F_5]V)@7(%L6U8QQ -[K 3_(>;&J(-(^#?W#R*YP&0*MX(A M&2;-%SZDJL[-'")9]V4+W(0O;R0\1/10!QR(N-&IFYZ\LOU5\J2\^8:DG ME\4K:7(7I<'.X4GO-_/;YLZ1T:%9SQ[U?.R!7!49H(L:E"'V_<374W<*LIP; M6AJ"XP"%M;(/3'KR(5ONM8Q^Y\L4 M97T_#5WOJ%H).PW$=P^_+HWO+-K19! ]DOC&@%:50K1L8S<"NT_M>JJWU,V! M:KR._28+MA!IBJ, J#C(_MMLG5HR[ 4NF]!E];\(6EI"<,SJ$%M\ D;2,_5: M]GW#Z:2L09=-&>7+V;<1]0V*LO/8M2&K8H*%)G7:,==CI$<1-])MH00NHA&R MZ6BL.W659VL>&R[(R;; *A^@4Z4S(CW. >D$ R> $%[V$?EGAN&$RLI1M@Q] M6L1$U0JPUD-/0G99O %"_=(!_9[\F8N_/D1;6\=,"')Q0P-,\,H+Y'QD6EOQ MR?[H0S*G"WWPX-ILI@:LR%WJS.$"["H58[(T HX!8DA\@8-SL9V,FCQ-]]J* M4D2-XX(L?L)/,NXPD\!B=0(2V!H0YBFK@\EE8HSKSQ'%GUU1?,I\^VSR#=(^ M%&R_Z;FG^-B3S\UC/Y<52)8;0!Y06?6Q^M%M-LBR&Q!#"+)IH1E2M+\N3X^)S,'#TX1V'(! M5U-/+B>+$/G!P%\OG/#Z\NK4"><(N<+4\6:\1_">E[T?R^@9VQ;RV%ZDC[A@ M&[1==@P/X;C**8/Q.WSE(]XZ?A$ 3"8Y&6&1]\GF[BNNW$O:]3MP/V_4<]TQ(KNOI^:$2=Y>:=+$$H]4#0OZCCJ6H5,4_ M1&\H3K*9J:F34U+).)B^F'PR"G[3_+9+TSX&%$].E-]*KWWJ8)E:+VY\B@VI M%R/U3?$09.-*&@Z&_[7HZTD[&$W@&V/%!B=O8MWV+&0WJLW+O/3:-0.A( MO<\$?)".)>#$489JM,7/)@JT>9![WQ;[WN(<:(ZE9R-FL*S@C/1\=& U5+F\8R=M65P=.USF09&MGX)P@=Z9-UDDP3I;V94Z]10 MF,[DI_:#-G;%RSSZBGOJBK;<2Z6Z+T?N)H+0@,UKC-USW:EY4]OWE*%,)2H+ MCZ*WM'%LII(23;X3I5]R?TV:2$7689<3#EBF?*\1Y=>?J4JT]IN5M3C"*MPA M2I)F*3;40X-)$%MF5+%UB;%SHL;N84.E1#H,0J7R&?O\&YY%ILGT?*]9PQW- MSY&F6 BDIU9C1>1"CAXK'(794' 7)[C44\9 %=OM ?644Z*)P.W033UWIGKI M"+ -)SGW+NJA,FLH)G!#E$;>))\ D7J.M/6NQ$)RQ[-T2I@P_8&D_K%LX5\3 M\G7HD1J%F%F7&T/J;%\U*;'PW%Q[#.Z'(2@U;R< ME\V/QMH9Z-(*:W^CJW9MUW1;BLPW0$J_EJ+Z6YN?),0EEXL4PU+#)P@>UQO< M14.3['/28J \K7^3YG3#A6@>6-WCP*!M_8.%U[!AQUGI5"6@4U\6OV*5 ^02 MJ8=Z)N\:Q',:DLEK*VD1),NP+]]AZB\VCW*_3#GA$J]1(5?^Q)08"TK4"NJKF'Z?:082)(RQR/=$S%;+/-5 M,MT3?95,#:8)#MM]>S0USWT],A+]//-ZXW"CQ$HG>CE*>Z&(!'C2K*!S+D@< MT5>:RZ%L=.9CIWA*P:&"'^N9G0?5I2_:'LD]MGR-79L/Q*C78>?'TY.<*.\. M94/7YARD;MA&&&TZ-M+"#M7[L#!/_\ %*CE3G!Q"MT6*W#*<&$:7?-/4FA9O MG@/0&%JF NQ]2:8EAEM7**+R>RE:BD[!8FX4VMA)M38C@J*DBK,9>;2.*$?$ M?-QX'O/HV 1ZP2WB&"=JKGG@TTA'9V;V9EM?W-,%:1E\V'D^S_;.<46FA/3G M?&1 E'0&=R7WH 3*5ZSFAUJFF[P370@SF&PX@(1>"YUG,DNN^3/JR^'F=3NG MH],[<%!S!1&A5OHMX"V\ \9QJD=^7J :$XMZIXQP<.DH#D4:6:'8XM3Z2[Q2 M2'2-ZH4]AP$K8!V74W298->)1=S9=2/$+])0?A+Y6:O\!]V=UZ>NEY!^G^,, MPB]=.SB<#>$J(UXZ4[FD-E#ZN6/:YL089QJI$5_[J%].7G%!,T%IL"'"$QLM MY8%#ZJN,X2?B,S[' *6[(^)-//9NC_BTZF2Z]*QVEZ>1%'.@JD_2)2XQ&T,O M&9LWCU_#+$5W$AM'FQW)B)TV,#,MN9([OFQ'%955MU1Y/L5B\S19.IW>N_-A MC%$94$\R]1 PBMA%64L\98YU=&N*WH9029M)-KC#YI=( 6$L.<$6&!#7[5#N MA3NC]WR@*P"40Y8FQI_C#0HT-H:>SXUM3%;!8@\4^9*2B$ZN':FR-[.69@)" MBBY9W$$XOBO9NY&+["CPHY.L=!Z=L:=S=9)SR(?!N=7+0H!--RUUKOP=V9^A M]O.I&G3!N6IJL2MQC][%YN?3[F;F@-Y>Q6L)I$>PY6XKNJ='O&N./6HPOMB_ MPC"F2L/1, Z$==BI@;>^)=>/-$ M&W4I[^1V#^FET+H-:[^LYT_A7)@/F>$82:U% PE6TZ9'5T9*3Y!DV$^!DD0R MY>6U$L,&7^85%6.?PIOF$$&B_&66V676]*2BM"#3XYD:S#"US,D?5,%9$-YG.>X93S!&M^Q.&/ MZF(?!P-F#Z5U)1-AV)0R#1$_IDES(6;3@IN!K6Q6BQ=Q\&U*PM'&%<7WD"'D*;W'*1PIA3 MP!WEKF)2&U[*-?I#O0PI^3/WT6=IBM@902;[.-$;IAXU2=8#:&"\9%U\P1QB M8HM/()BDYV)WGUD^2\')95[D;)@$$CP_5KN+J5^QVWN4#+;7YTBYE1EX?MU. MS"0>KTWIB]2")I%=5!>:PJ1 AVIN2_2E1!9GHDC5<2#AZ,)7?F@VXW LO=B# MP4$!9;T8 +MY["!=%/Z-INGO7+K52&]VB#?*Y1RBV1N;;0H?Y$M/:E4OB\AJ M-0]F57'.%QCBXADQ%!(&I.UT\X3QP1O6S<**47-@E2-V*T21(;4'7G<:>I)\ M09:G!X^Z'2\H&W.<^RMISI7,GHF3\@Z6XSZ4L!":4&0U+]?C-:G< =5W 95# M"B#UVM2%1&V6KDBF^>6QDT)Y4(186X2M []23:"H*VS&.=[S29,S68]*7DB@ MF 54!O8'A'BY5"[Q)+-4K)H_D5V"&V^^%3^67AGJU%,7N_%+XC0. UE=F2\0$2$708L0YL>LRIKG_0J5/) M[IX(-/#/Z*#MI_VI;;0Y _D(U.X%:PU#*B%NR+DD4M7GG;Z#XXNG120D=V:6 MLYWSXC0)MF2;V5CZT4"BWOJ5"9U)5%;0B2^Y7I_9%1N?S5"&',YF9]A6%'N;CFZXIGN MF']+=U(!#'+'9>INU,E]>F"&HO-IP/PH(3G=SRI M,E95E+62?'[U1]TX[A?OX:'ML'-KSV-0X]CHN+^X),P M>M+#U#*1WQVEAWX0TKG0"PJSKU, 7Z!L]-+WS)R"69(H9<91@4R-Z_2G;FS'GX=7%$!G$N>_ F6WC:@,!KK:H&O?8'2'(7N[,>7/[U] M>6[C*[V/=?YM%USBC:*:1LUR/T'WIRMZI)L'@=CXP!>UOYB?;C ?]G[!/\;_2:]3U']X7E5&R19FCBQ0)=?^:KU[T7KAD_\LA+V4QSW MM;#AH)KR**E.<[%$G[XAQ71IZBT"/HV. ^UO;F[/^7Z"TMY%KSEFY8AX8I79 MJ.EXWBN;@\D\&M;6OTWU5L0K(4"[TV7 -[^3Q*3Q8@'KR%B:C+:MW$JCU]*5 M:D+>=%'Y_%K@TZUI9ZG9*^;N5_'>M%E+QX,7A9]G?:DF7%\N,QR-T[MC%/H4 MCK+"Q+X@X!U2/)\R#U]+0[ZZPQJDDN[ =K55:@!;NN@UOU*R"UH)=Q]Y\^L1 MW8_<+#A_>^<'[GTI&TN]U0GO3,KP\^1!BMW2K)]\#1&.9,B7?:7/L,\8$"7S MP/D@+GWY1R^L:./#RD:6V5,+=:_5_#I/[+F6MB%AK#/+YTM<%SLSQ;6R%\RU MZLIQJR4HU\OBF:O*^#T0+ADP^KH+O(.*33NQ5.2\E4Z(Z27O^U(=O9BL""EA M1-%KQ0TS-W5'BLA<0O1FQ$D\]*[-E\G<3%LP^S3GP+;^AZ@7%U]]UL$_Q=D/ M-V^>G>O]%^6>O^="[]HI8F(Q4S; *#2QP:T/2)7$%NE:,O[R#VQ'&9,APXLQ M].N 4)/'G8!)NCMQO5+ "8Y.[9JC3>GNR?G.("SB?M/%1"L^30RD4NF85^+K M=OKH\^)-C>D>X719H+V$E1>L?4/W<&J# !IRR3^??7_[YCP?=]YTV94<)\\P M/J:J64SQ5 M3(Y_^E=SL&M9,P8ID_$+$)!F;'$(1W@0N$N9*SL&=R*FC@DJ9:&UQA .1>NH MM%7:P?)H6/.6H#5/;'*+%F>)"E%L<4[=\#(S%]U$5#;=]I@EI1=3.O[->)OT MXNQR.,=4;2:Z9??QY-]:)M&F_7(KF=]C&:K53,_$;\2X([:/D!<7Z5C*W5[F M?J,/>NR?PF=4&NT-9Z7;"A-;I4O__N7\]3/E_8V",\S%C^$]6;\M;E^V[XA5E)NKB-8WR_O3RV:O7Y]1=VZHWD"%I MEL@A%XKB-/C*Q@7I4-=8#32*!^ M75UV41\5XMC;33?6?+)WOE =CXGGI4OYTNU[I\@2C\-2@VC/%KRR\\?<8>0_C)V M/7U'[;H;QVY//^Y<"=$;/@"?;SI0O_(+;A"_M/B[_P%02P,$% @ R8)8 M5A_.]/YY"0 P1D !D !X;"]W;W)K&ULO5EM M;]RX$?XKQ%X0V(!NW]&*^V)[5^2\/#/SS(Q\MK7NVA=*!7%;E<:?CXH0ZC>3B4\+54D_MK4R M>));5\F CVXS\;53,N-+53F93Z='DTIJ,[HXX^\^NXLSVX12&_79"=]4E71W M[U1IM^>CV:C[XHO>%(&^F%R;*V]IH^?,C.1U,R2)4J#21!XM>->J_*D@3!C-]:F:-> M)5T<_MU)_X5]AR]KZ=5[6_Y39Z$X'YV,1*9RV93AB]W^5;7^K$A>:DO//\4V MGEVM1B)M?+!5>QD65-K$W_*VQ6%PX63ZQ(5Y>V'.=D=%;.5/,LB+,V>WPM%I M2*,_V%6^#>.TH:!G&O?"Q56MS8^?\ES87'QR&VF U&M9U6_%>SL^FP2H MH(.3M!7W+HJ;/R%N-AE^(NS3>W%OR_7 M/C@DSG\>0R+J63ZNAXKIC:]EJLY'J!:OW(T:7;S^878T??N,%\O>B^5STG]_ MV)X7]\F(OS5&B3G##+ _*I=>B]16=:D"@ J%$IYTVGV=H0!2FT)(D6E I=<- MU]KNQ.L?3N:SX[=>U,VZU&EY)P H,D,@LZ$A6!A"6O4CT$A%DR>O3LCW<^%B(1)7*L70M4$8MUX")F.ASFP00;IGD2L; M**30F?ZX((<$OLZUD3 ?IDKG)&ZA2Z UB??2%W#-IDIEG<_3WN>MGM]TXE@^AU&F A]!-BT(5\5+6,U,.G]K)&;I #Y%*$C13NW;Z1 M3ML&#D*GVYWVY(7*=*B,)%KI&3H8MI>5# M#V0>VO#L_$06E4W&D:#"1@JQ!T1W.E5^X,K!UZO+PP2MRS0Y&+5Q?(ERJZEK MT,+ C8./5Y<>9YDI,"I<"S 'Y@ U.$2J WHYG$51D7N@\G#WZ$D)]$%D]@Z5 MA3X>J(;ZYPE9CL)Y\("-2R$4DTT+-=$ 8-%4-KW\L?AFLA88^)CLE2NO(NZ0_NW8X"[]^-=,.G?,NYO=AF:)'8*$,T 9"W* 6N M;1104)RX5,$K4<6FG=L24QKI'(;YK2CL5MTHE_#7>RH[@'K5/:^I6]!O%HEO MT6D8/Y97#Q*8S MG<;^OBVH_*-V9O V4Y ?-0$2(M/%0#N:Y?QC94[IJ,@,)&!56\=I,D$A/='_ M"*VL2X;53>17W= MN P <0V1S[PK@,JHRBZSC$F-"N@%Q&Z::JVX#PPSS5$@(N\Q.%B_3"PM=$W)H\<]T7U:[RTWG=Q2KE6Y)U8;C77D14+'XNHA]9'4B-'O179 GB_%]H4@L#TM!.O_#P0L M,G(X$;+O$I1]XZ&&VPOW&B3LE';=\T&S\$*7%@ M?R5_>434%68!4!X7V;[6?82S1L5X=(D7V^Z ;2*4 [YD!:]6L]F^IZ=' ]># MP,ZK.->[O?=91(G'G[><$_8NUBN=JW M=CF=_C%KAT&Z3%-'F\2N^7:&EUIB=&<6;JV'M*8,?:EL$;_=(EO5AF YQ#-X MS=A0S^JVB0&<[?W=F"P)2Z0%+4Y,:LA]6@QI4NT*HIT,>,>A[8J[:;M?)1BK MD$@\5^U"#6G9\&W&P[;9[M:#9?<[U0"1']JZH,1^XF5)(GY5?.NKO&V'BJ[^ M+D,$!)!SAOUJ#8.$P9(H\D/K?>1 "-0VNS\:]:\9]E]*],NBX03)A@,&D4DD MD=7JZ!YGS&+2'B\7]QY,[T/_R N.I&TME+4R;GZ['/F3D.+<]ZIU$EAA!M)( MUV@]745CR9'./*2(7*F([G Z^>9;N:/*[1*:/=)1*DVM-/P,!=?]-*MH-+" MV-)N[D3>F+1U:"^7;V AI]!:FFLRF[2/00EHA"5'Y$\"B0/4+3#^C?@7=T=^ M"3DDJ)@0![/#F !7W'Q>(<56LSE^'R7+XR-4C:>U\>=8H-&@R*GO]YK6\SU:%80L/Q:B46R6IYL@?] M4T2Q5H@WOSHBAU;'@.)T?D*1&.QYJZE8')V^1%ZTA?@Y"IR2P-7J5/P=^?FF MDX#G3]DC[P7<[ =<]P$'4C-$[!A# \R4X&K]6Q]V_XGP=$HA CN&1V'X*M^27]VH9@*_X3#0U=F0[@>6YMZ#Z0@OZ_-A?_ U!+ P04 M" #)@EA69YM4S9(E ")?P &0 'AL+W=O2_BL=6GH"C $@'+SD*X(B98LCR^*2M#8V-O:AT%T RNIK^B $ M__K-HZX^ $(R[8A]F+$(=%=E9>6=7Q6^WV3%IW(M915\3N*T_.'%NJKR;U^^ M+,.U3$0YSG*9PC?+K$A$!7\6JY=E7D@1T4M)_'(VF9R]3(1*7_SX/7UV6_SX M?597L4KE;1&4=9*(8OM:QMGFAQ?3%^:#.[5:5_C!RQ^_S\5*WLOJM_RV@+]> MVE$BEO3_!Y>N"CDIO2^W> *UEDV2?\XR;ZX<4$"9*Q M#"L<0;Y9COFF\Z"]UE:KKF!F5O!ZMG?$:QF. M@_ET&,PFL]F>\>:6(W,:;[YCO-+ MLBI L/ZWCQ$\S4G_-*ALWY:Y".4/+T";2ED\RA<__N,_IF>3[_8LXL0NXF3? MZ'_!MOZ5\P4/:XGLSD6Z#4(0#Y76L@RJ+,CKHJPEZ*X;GD:IX 595F(1JW*- M8P39,I"?*UFD(@Y$'"N1AC!$60,5H@P*0U'8I2BV% E'$G0WELC%0L5 EBS'N(82*"T*D:[T(-FRDBF\&,9U)(,Z7Q:PMB 76_IZB(1M MP![A?^5G,+/P?B%5LH!%FQ$*^SB2A,NNUJJ(X-.BV@Z)_D3%P(HLE<.@R+8B MKK;T6I$M5164:U$TJ1IJ#J]P874.8HRC9F%8%X4$IB$G0UE48-"#95W5\+I\ M) )@TS_)R- !K U13>!Q_%.0=L [$3P=9SG.-6YLK(C+#-;WB(:5. I>X).L M8$2@-:K#BK1X#]#^$)%HH(=W:P5L#X16WSK40%?DPQ(?!1Q MC;PILGJU#L#[C+QM32/B-?(,R<6Y\ZRHEEFL,B*\+&F;841XS[BH.5:I6J);P+"]BL0=Y0;@4^ MN%'5FE[5._"/_[B83<^_*[MSC$%E@5M5O*5G8]J5!Y"94H2L*#=I\)-<%#4X M;C2T\V'P7A;A)]JQ>]B16J3!.QG7Z>BURBH)6P3_S4'X$C!Q=45+N\K&P^"7 M*AH'@\:CQT$89R7,*+0N2AJVH:I.-U%54!Q@8V%MJH UQ*S-:Y6C +*$,'DK MV#5DV6=0P1+V,BC02Y>T0<@9H\M#7VQQ_]-Z"4M'X6=2D@3& XZI/Y@C$F%WF; \W<9:U3P7H2B'FL^;Q28L41\PMG:A@Z73.,2(S0&!E[*U8@ZZ/I>!(LS"J.9N,+\Q>2!0_7,$0& M&F)-^2[0&S85$F62+P1M_V)ZT9=S?6'P(O*-O M4$6X5A(UPY$O!UD(,I& ABHZ$M9X(K)TY)\_@N4S]A) M8J'_@36+?(2EHX>;".*" P@"R5X6QB@ M)EZ2 'Y6X$TEN*2C,[I"(E2908\FXNU:+(2J7-3I[%6_- \ A[3/I@ M%!HWAW=8 :M"]J$TBA(CWAT:EC)*4O(QR+O[2ZX3.4E(=WU$CA@J4/60R:#7_T&_GOL],#X>]"NMA[TRG@)#ND/L'"@ M.TJ '2_;:X:!T)KH"!#<7?F)[ (8:!-Q1;X[,YD*;2BQ8T@O^KPP;-]0LAAF M$%.C1UELS6Z2S&>0;S(3*#F5!5H1DB.L M1HH2&1AZ@*].@R1-E'3[?EZ4PX MI#UEY!BR:T+X GV9GNYIQ0 C#@8*TC_0=9,BDYY%;G]M]@K4JPQB\=](N%I. ML<5Q>!GU1@<60(L6#B)%?QF!-<12W0C"0!+@NEI#3E-YY(#>KPJ1@+U>ZE52 M=8Y&%-$CAKQV9*T.3/<7\SC@AT7K%"@0BMMC>&6;&@EWG?IA;@/7>$"V-=9^ (D)I%[ MP]R^<-39N78-P*0$G)/3_ND@L%FG )Z#$,!^FE(#QFA]-A\7U3,OZY&I=J!& MPJ0?R MA_ "+.C;?#LEO$'6TM+PR>V<,O261HJQ[F56QL*N?O'%$( M\*6>"PA!4E;R,,/!'G0V;J\%Y'UO$!-Z)5(B]YW<5D4=B6"0PU9@:/E'G8C% M\;#EAC G'MU>CZ::L5L2,A']7C\2ZZP_6%(%#'0+A8>FX!CXYN;FYY&HM.M+M25&!13G%EK>PR\WV1%'&W01#3DA:3]LE[59=6) M.#X@E0].6,M@\($%1F#>0#XRB[/5UN8,.8PH)7E305E#V]F'$-B2 $M,Y"0% M*Z$J0K N10#R$@PR^/]CO9,*DX-63+.KDE-A@:T,T3]XM8NN)MI863N0U-%A,1]18Z8#W$ M?PI0G2K:@H>.+;ZTV#%KY>$TQU]6XS@Y\0@_.G/>\*D:QVQ\>:]I9[]O^IXVZ/J..!55N1&LP;T$2;4*:1K(5545W&VH K!J&NG1CVF MRBHG6EX:S]+:,0PVQ?YP_7XTFUR ?WHW.CV[.#GVR@=8]81P!YT1N[YME868 MO$+J>P)*,IU>3H/!U7_?XC^.*=V0Z1\@GX%*L$J/_@#%"50R4W8KF-L\F\[; M,2F!F $B4/TL%>5-,@ZBI>?8[])V.HK>7*7IFA)9"2PS4(R G4$D$Y0.$G): M!M".7TM;W3W G.CT^FCVZCGM"8^KJ#$& 59)9L2LT"\>8RG:%;)]PPQI59YC MLK$T^] R4ZP>G!J96!HZ&68EDH=7RZ[VN]H MV7?5?Q-D80:#K*?XW$L@T*B:>-&HVB:KXPC-5IV@>:4(5_,,>W];3J#AXQRV M_(!@P&[&3DLHD@"L58@,"&5N"BPM3^3'Y'%L[/[ATW=\"L5PM-:%['4MO=%\ MH&=UDG65$>'M-TN=(7ZU)1 M06#9U%H%?X_UX#U$/V7KT,3-NRVBK[=PG68%.>7#0J8^2>\&2A#H:#X_.32&.KEHA%O],137:)U$TLJL@4698%YCB4%L_Y:.#%F3]\(H6D_7 MQ<]^O=KF4VEZMN#&>]ICQ;.Z*E'/T+7O;HP-=5<,^?L@U$:D?T(C^[M!59'E MZVP1HP/ S!:$".*'PO1[.R$ M='UV<3XY]JJH+GX!SG2BE0;^XGFUWQ2)]EB '+C?6)L.KDRQ-H?1N8'!EA_7 MQG6E)$LS70P@J0%21%TN# M$>UZ@_.+R?]3;P#[->UTR7Z%P,S49Z>=/OAE&,H8\K;4U+BYXFD_IA)6#K.K M,"891_7" I;/Z79 MAOL7,4+/ @1C88^MR&)I@FD=-^@UA!@I\WS#(%)+T'1J M6@5M3N2'8$LQ02TP[R#?<_[J; :<7Y.)3F$#0;!!WT2JRH1"U!:PPMEW6 PD M\!B,!^4:\O@1>B"D["6P)@;SP!]8+P+>G'L:L-QF6IW7,3@'!%"0S<+!UUO@ M9Z6QX8/;R[?'X^#>(UV5SC?.34==]ZVC:*1S3?:C6%%.(U%$C+LJ9']8#9,8 M?RJP6O-(A41/[RA#=!V\8?"Z0%A?'+S?RJ(,[D'.%XM@\/K]_3'9-K OU%+O MC6VP-+JS,^%ODA<$$?\MKUHL>@O9@I*0W2'RH9'![$WZ^BPG>R#3 #)F%*4D MVTBJY?+ #%KB#IW+BCI8O(.7JO7@]BVOI&WX=MN\V>R;W3TZ3IEVSH)CP)8U MG _!6MPKPQX=<_A2ZU;NY"+._MC&P0#6GYN7R:R1/QBI=,2U=EEL$=X!KB\1 M0"CK-(8D% Y1MYIV59L1:T5LO5*OX;?Q_7@8O*DA/)6ZKJXC."[-<;-O!]1$ MI 0;42[L*U W8 U9A/5SC(\*%@637?6U][WXQX.9T%=XOJ32(8OI'8P=FVQ[ M7$N'QBFV,%\&\NM5.OV\G0R(V;\N$DRY0*7QGA-A4@,T?K/)-UI@C.23QX2Q MM3:%I$>PW06U%LAE)N*S2FJRE+.3;P+VW;9\$>/"R($K-ZJ#149UR/8$V]86 MJ8W!-_AP77W4<:@J"/0->@KV,<3^"WZ0<@7!<'VTV([<7T@,FTDI"%&-L@#N MPNX7XA8:7(BHE6/MP;X&,Y4=<8"5)00O&M6/QHC18S98Y(ZY/7UAG2^II(LD&9)(S@;QCJ"78/;9 M61#ZA3K.S P(\!6%"-Q)+K]UX>KTU9 #VBM1\BI"_ ?N"A!(VW84S$\F8&(, M:\M@=G$:W$08"RT5[92"K"!E@>?5?!L,IL?!S>W=/T22?W<=C!INZ&PX!UF\ M;9R,T&5.[3='GD>9SH(M,#F ('59QP$B.H^#^? "LLQKTU=B>$50B<\^ZQAE M,9@.+Z8GQQJ)8;C=9#(_>3$+'BBJ5O[B/(3?J^%T,@]^!B]!EFPP.PYFPQ/( M&Z\:8;A)4DGM@NET>#H](8;L$P,J+NYEJJ^C/CM9$#6[2*8CB?$G%6]K?4S$ ML(C\J$! O<%X4F?>MB9'6GH@E$&[ HQ/88 2^S_K3,UH0T<$ M)>,A2826*&F:'&R$L^4B:!"=$-$KAR =G!UWZ,US.OE:!N?CTV_(V+67>S:> M\!=FW9@+$$C-FQM=>JP^(1*S0@?N4@F,*M#C9*4TZC6FW<35KM U4)\8 M2UV(E6V9*"R*A2JGC2FW8#96J+1H)4*]8#"1.,^R,E@TS[82?(+['%GH&^#; M9NI7RI4[=60IU&=N(H;2V3X7:$%>%V [=?'R$@QUW)^9WF)Z!'3XL H#R-'? M-6#:(PO3[H%;^!!M2J<:D 6($]4JU2R)(NJEX$KK%&0+Y$9&9:/M&*M'0BU2 MA;6N,I4D=2HM3'ML:#\HL^6"&HN9/85%V:J&]@5Z^ 3L$'G^1E^W4+P-^B%J M_4'VDV81^92>5)RJ.XSF?>5!![2O.9J>G'>=L?.GR-&"2L9?Z%D;[O39 ,^V M9-A$.Q]-3\_L*@8>]:"#QU\$>#YO 9ZG?P_@F0K[2%Y#-X#4GQ45$MK'%OCC M-JZY!?MY&GU'%0)<#-993%Y"T<+;FX^<\7#0(UO0LG;S*:W#6&:4(Q<8$)6: M42"O>27,7V19F+<6MJQ*8&\A'E4Q]!:\!PZ1EU2MM - ;"#PD.@CUF$>VF@1 MCO1UDSO>LB:B'OI+)Z0UEI=TZ4=[9>\)E6)]6&C#YIYC=TEQG(L-#9!ER)O- M:6#C-5O 03,>14ZZ6OU0\'9UQ8@U+BT;D=LP'+C=X*/2.^0R4M&<='Z5DQH2 M%%Z)":R-J'Q9 T,+I(>T@Z2Q,-O3Z-I3..,%Q8U.4#^ SR%CR1 -+8#/XFT? M)1Y;'@<_/.;P6TA[VUSF"I!7<*\E3CR#I[+ M4G?X@O:3Y^V 1T28C8"X!%2D,W&[LO)[9NLKX[TRJLL6-KC78N3A02'ZZWX- MF4R.M2(S+SCID>[QY$V=-N]0Z=\TR/!=9/O1S!UI!+=/202,AC[,3.F.W%G1 M\TS*4'.0IRAS4"Y>':=6:#W.3AL2/3\U$FV.\=E%$=A=GW*'35EGN!5->N?> M2R9>DM= $N,:Y*21; MN5P^X2=I8_&2@Q6=Y;%NK%&@[6O*-KS<'82*>(S>+Q]] 8E/N-BOIM$Q;AR\ M$52LXW <3_J;+K$//>!-/I@ 8SU8^\W@'5"Z!^7B%B!W**9MK"$](ZJ^F;0^ M6)HY$F6J#>8.9V=X'5H9$NYNW85+<2S"0[ RLD<^(24G4=01EY M-H]GA*UD(K'*Y FRVPC.:>@=53 M69>A;93+Q-LD7^,!3,:+7%V?_#-X&%%?CI('>K3$>@*M#//?E H46.HDE^?F M19EUAWSK2,E]9UH3%9I[;34>?>+1V: X.G!=I3ECI2LP4G]JDF?OX"2V(2GE-5/; M(W9]=7PG-\;=436)[]OI #:!N\2'!.]KZB&5CN9 U %I:E;J6E>.QZ _JS(8 MW!9O;H^;97;#-PS)5*435Z\>8K$6-+0?'&+*EY.QLN'X0L9X;8&%FC: 163& MOC+O"P:_WCT\W!R[/G?[#+_-@MLI;K>-RT:V[^ZA]D&O2Y"A1X'W %0]92;^ M]KCWQ(S.3AQZ[>KR;O3K.T((:+'C*HVUCCY@2A<_>0+7OH2M+)2L<,5@0RLT MF7X8JZEUH"*9KK#FI5+=PL%(R"\FNF.G%O\FV0\_FK-'3?8PR69.Q!^4B(78 M@;T^X R6PT]Y%Q5X/:REBDTOQ)PK//[S1X)V0\S\GLJA$+,IPUI\Z>*(HP4U MYN"BVF2]3"U[<6J,ONN_O,5AS0Z:GJ^HZIN:;RA2U*WFJ_D:9YZ1K! +V/PI M2UD+]Z5%[QD 7V6.;B:.M;#VL@H+NUW<%RC)^/1 Z-?I^>10].]T/#G@FIAG M!7R=?X//34^^Z1Y=!GF;=#!->!JC3F@ SVU8>/-]>C MZ:MG*"#W'L$'[A&"S<;TS?S!&VSH\0&$NDXQ.'>H#=9-TBVN2M=IJW"L^6)! MCP1=P,A)\E5CV29EA23\@4%Q4_D"0QV$@0!5CH@=8 M)!RWT4?S.&MKW\'A' MF?F*"@1@("6%ON@+?6]I\3J.7-_(4O\,%EXA"M^.QZ>FN>J$QZ:GKL\ 44:B MZJ0!G?5Z7&SNL-K@=Y\)[#!S8MD,>G1;X+ R_\G9K 6:F#3+_*ILUOEOTD9( M8J$:2S#N"X'E"G-4$7(NC@8\2 [HA7 ,.POZ=8I!.=94:$2V[CJ#7A4L*CA M-O@-C/\E7^]@O*L779O#FG*)%_-5'B] #ZD7QXT_*W9F?NZ]VFMVN/#EW-E: MQ$L"TA 6^&>%]ZXQ/R JC[UCHNXFD&'S\)IG>S$,)OW@4C!)(\_,@07J)X20 M9.H(.N#?I'2 51A:8E+M94,,IA'56;4[%B".65V$#$T3#%YP --V:-,ZG4=- M:4CH(;OB;JO?3L3GS?EH(R&J;+\?_ BL+"&4U]&[^?/X MSWM%_]*YL9VGZ?UVGM,=!G^H& /N2B1B$8"9R&"_^(S)]&1B;\#"W<3UDV)]HX\XZ;=R6?6^U<:]KRHY<<:VC41Z$28^ MH7G"%:B^6T+:>XR&(;)6(QC'\3>]O5= ]^TRQKO>BRVR\'7W&&) M;A%LXG?\[J7 LU:L9?Q'X_1[:B]W:$?WF>Z[[.U!\XA.N42DX/V:KC1I:,_9 M"6G/CO.:3I5^PY&+9N.L>-HJYI#G$+R5PA8D'6SY.WGK5N9A.-"S - MC,+#$\(B7%:DKS& @?0N(6_Q\RK#W:O8%/)]PW0)'+:MZ*6.*AZ=3<]\3W%H MNKPW=#+^Q?C9-@<:EQX=>03H$%'?.XMOL]YJ?NAUVTHR%:?,0OM8H9\QL7%$ M%RKI!__TN55[3RU8GC-W=ZFK@!Q=G.XZQ-1&_",&Y:#\]"I+S=D*ARGA)IGC M_]"LT9R#,&K=?QJBJ9D/]:=M*8)!56/0F:H%N=8RP6P^R6!;:^15TU_YR(Q> MU[,&O8;9QXE&?H1A[-=0YT[#&X+/$R1LJJ5!0! M%6_X5&@4_(*4!I<)(K2%7SR1*^XR-$]R,'C_2J0BXJ<9Q]^X:VOA%<0TL*UQ M@9=KCI12?O)O]4)2T62 =2B0)=1P^"*CT;[.O%$G.9I-NT4O67B7_8KR<#7^ M2G7HN='6%VFG&F>G#3NG_";-_O()YJ0PPGSN8?O!_]3Z2)^!^.-<6F1A2O&KOF4G,_:ILWLO)G0\292R6Z6V,;H.YTTSTFT*F,@Y]B\0B<>!"+4H-G0T8N /,IGAP,O6*,-8UNS"H_R3/ +SFWN97TDGGMBCY@KR@J+B2I2_E!-8X M3MGC X_,JNDI(6S*9U2>]K4LC7C^3D4K256K5A\L^.46\DKSK49; X-T%MV/ MM1ZZBUWVW4"GP_]?P,,\%I"S#R" 2.M<49>S/ZK7^#OL*.&_3#W$EHE0,67P M*^+$3KNGX-SO1+3#T^XU?__"FFZOH6G6$7"#$A@!^%8R(#?X.5F\#0;\.7/, MPE(LY-M>GN?UQ(1;C[E_S:L@?#Q]->6$EW'>(PT&5QS&\BD^6G/WNKU2'YZA MZS/)F,W/SIIETX:% 1.JJ(%MK%K4;&^T+UCH$RRPVXUSGGT'AQQFFHM"201$,,FSO:0T0'AP &;AT4BF2.D OVGKID+ M>]L)C.L5YKN)Q$$F'IGISC/Q07NOGK]R'D3F>A"__M3$DHC2J_]Z9W9-M(96(] /U83Y6>#OP='M MWD+7IX8FW-]5Z$J]5:@$;S=@.!M?=-LL')FKA9_,,7I_H\C,Z-7*#BH[N,:2 MODW#P,;<'0Z\(T:(&<&PTW!0S'3:*(8Q#LQGT 8C/:QPZQD09(,D>,QJ2897 M/X]V3VYI_$[W,2KB>E@==J?=A9J=0J()($#&)[W1@KW%5,?A]Y=W]Z.K M[.-HIJ,RAHBY@K@'=6IT6YI]_X9/["GA65@%U?+&S1S7!PWP"'N"NN:Q]49O M5!]7$QT\$ZX#@A&*B'!3S65-#<&Y]@3GTMX7/WA]>7=]"7ML?K"+D+7+I:ZA MX5^7I;E3\QXUC'!*N(A;O/4$E)8\N:[*8WG$7C5.A%(3TRNS !TXE3%6;UD M\/6W5!*ZUY?Z#_U;V\WME.:Z=M,R-7=+ZMU$G,H2_ED]MSV=]-K3 ^?H:=@9 MAC1N\])@+8[G0!)V1X;E4!,%7$-K/_30S^UV)_X$'$ZW5,0ZG?!VL- &.6G4 MP@2KM$KN<^A'AGRM:(, =G3ZD#J$D%3,K3+JK>+MGHM:WS+*N E=1Y/VQ/M2 M.@ &IF*EE*FW)HJ=.)PW:399LXQ^Q \E0>L51RY.YU^V>5A^11M5^%YO/FE@ MD=C"NBNU9M[/YW#D#AR[W_<5N;NSG@9?&?=2P= M2!3_^K)[LOQDL%TFMU#3;8>]![1N=9KG@G=W*'GO6>!FA]2>!9Y?^/+PU<=] MN[=GV'MU_,LS GO+ ]%%RVW_[!2R;"$-*H69O^M>D5<]TGSHM2)ZC[T[141, MB \,$0KY]]\L\IP7A-@*/R_S8"!#*A,@LZBI^<,WXDYF9QK!P"?KAURF>0T/ M>0?@VTVAP>N'=]Z/%7TI7.$U'_CPL0G/4')XGFM0B*/M6TV,/9F>#;E%NN]2 MDRE88?^"DA;7IWBU!UZ9XW[4U__9*EPHZOO(TD&,S/IH=<0S(_ M>>(:DMEP>G[1O(;D=#K;>PG);'@&\<-3=Y T>4"1VB')-&7P?]>=(-/9^/2; MGMLZ_HK21*MQT\DU.^ZR<]-HXR*#)GNY^L]/>P\UI&I0FEKKJ^-QWV]GO_1^ M'ITPC%=T,H)8QK^4;C\-S._,7_+/J[O'^4?JW\,"\ A++)?PZF1\?OJ"&SWF MCRK+Z <'D??C_P%02P,$% @ MR8)85@D#?^DF$0 N#D !D !X;"]W;W)K&UL MW5MK';N[:K).]NKC?V1F7O;BI)Y0,XA$C$PP$]#VGI M7W]/-S 8S'!(T5[7O:E\X6N 1K_[- ^?S39AWRM5"%^VR1I_N)L713;;ZZO M\WBM-C+OFZU*\>3>9!M9X&NVNLZWF9)+GK1)KH>#P?1Z(W5Z]O(Y_W:7O7QN MRB+1J;K+1%YN-C+;W:K$/+XXB\ZJ'][IU;J@'ZY?/M_*E7JOBE^V=QF^77LJ M2[U1::Y-*C)U_^+L)OKF=DSC><"O6CWFP6=!DBR,^4!?7B]?G V((96HN" * M$F\/ZI5*$B($-CXZFF=^29H8?JZH_\"R0Y:%S-4KD_Q-+XOUB[/YF5BJ>UDF MQ3OS^#_*R3,A>K%)9>109C08U^L"B\FPPIU,RROLBPU.-><5+2)/(A]4W!>CJ">&@^'P"+V1EW;$]$:?+:WXY\TB+S(XR;^Z!+=DQ]UD*7"^ MR;]%+ABQ*OS&8KTQU4 2V/9HSK*,02U=PI>S#ZIP/_&XE0*MS!+1^*7)P59F1:JRO"]N#0;05ZUR M\$H@=W\@QV0J4>9+7.P MC0RX!#UA>!$PM-E 65HFR&5QK/)0%NR8U:XI@V"?N'*VY&7PM5:)_J3"=;VL;W8I M3/!)B@N32'S2BTN!FB(V2)]ZFT!3,HUA]F*W53#NZ]2K/=D=DNE1)XEH$<^#)0J^(O:%5FY ME/ST]>9>IY]T7_QL70$>1?9F5TMR(_YM-/%<\44AT&:-?NO2T5_@D$FY,N*" MWC>JT.F>FG0*MJPE;#.=4KY(*.R[&;*,8&::R]B9Q"HX4[&AW$$263W#-"=(U1,I MDB'&DL+IW2YQQ"@]@8P-(32%#]9]4&FI>CRCL7AH8VM-F><&Y$B#54"T0AV4 M*6W2]'?(K3*+UTPXI(4T"HA&%GRG]&919KE+6%"!0E@MK45#!9,;94_18S.1 M&I$=/X&*)(JD*(Y@)*&#'+%T9%+/?"LFK(DVA] M8%.G;.1ZU&A-RD \(78#8U3ZJ)("NU'@TN?#2 M7Y7;*C;:!GF6".#U;K4UIK]T.V/:CW?"X$5O'0ER2/%^3A0+"GH?!(( MX=;B!_@PZ 7UE=+LG2FP $GYQM/, )ISH?]2"P<_;6$;I#DQ0Z:7BB5UA;D MI+WCK$$#EA16P$F[!C"%8 M5NR_,SLHJT&9ZMP^8]P[MG!J,-BG:LV!(P"@]E($Z7'*3[A6?RT%SZ H*Z0[851%;T(P:2D3!DJ M^Y34YMF\9('!Z-0SVJD6+J)YM2!KYZ_:V$6@%JA6;*D3NUFCC50D$ITW@( MFE "*E)"BWTC_HXZYYK[4%M667CA3P-QTT(CXJJVX;F(>E$TQ?NS^3.\SH:3 MKO$>'4W&8OA,S,7/!I;>PSF6W&S [X-H3@1'(X1[")XNHDLQ?C84T70FAN.9 M>*] )5WU'(),;)Y?HL)I;GXH_T;SB8AF1!H1(.IB"!OA"6[U?&.\P;E MFGP?!NV[55RBU! &IU" @XK18(37X2P2=W)GR;1RQ4K5K3,505V:%@0YDUL\HMWV6Y'65=:I$VL7C]SJ7 MVG7B\[!KM0]>F3Z*2K$$1?Z!($8*J6+&+'7GW0Q" H24.A]-EBP?::^E[K^# MENUJOT$@3*;2!R0<<9'@@[0-)74':(^H\Q'R0>K$8KE=9G*@(O$!B2*GU+S6 M"XT,RML.E,!L.F+.P]9S#UG7 C_5H#OF7,O<$PO:TI'Y7CO9;.!MN^*;\DKM M5<]546VUB[R] 8FMZKN[/#=SOZ^[#)KG6CS;7 $( .BS#K>NB?5]Y;%NL(O- MK]3_0255&Z5M;")SE1:AM'RG;H8=5BH>3;"MH1EB@7LF?ZA/]%V,+;WWB:U7 MF'Q"W_C*=4MJC^7<) A68LSJ$;YH%5^A/.:<-5\CC .L]5R>L#K(BV 97KO: MQN,)J,Y;S@3;2O0'JMA-J;!@Y0Q\-F2/-J)/X=[2AMOVL M-F(OP)\%4MRC@?L$F7)80T8WO&*!H!(O"DIOV914VBZ_9C-;Q>_7;6,_J]]Q M6@X[G:"%[*&X[/4]@[V^IV>K_M?M?J;_I]W/G@A5FOJ:+= D5.QLTB[:IW5# MK@X!=U,.9L&?:$YL,T(\_KY^I"JI7[D=F4?C6A/_*>W(]+^S'7$F/!?S&?4B ML\$8KY/YH*-U '85T;,)H_"36H<)VH;A#(W(DGQ[U&+FL=7@78 M& 8"&DM:6\*A&S&*\>0O^-,E*P F\A<;JWWD.V^*7_ MOF^M\OTOS-F/$K*X8FAK"!TGHZE \-EZ%5#(P0J%D/4]J_K\ $BRQFHT#[5> M'3LLSJ:&T>7OM&9AN>W#W%5]/C#G!H78[(-WNXS^V-^JUT[L.@R<4Q20CT M-L_LNU@^!0PO3P3#UJV^" Q_,?JU:Q(TV]O>'P7X[*GM_086>V+5WP'&&IV8 MSZXM-&:O8WPLM:L2G90:P7 (OW4P+PL WD799.&RX>O^J(F;8;?90,6R.J2I M>J_C)V#U_GUC2;<*D"-I_'PZ&K6:D]DA$'T06=IT="JTM&B#YG1B2WNYH@-= M/A"F"/#EC*,B3!;U0P"B^SHK7_Y7(E$G^77E-N=B-([X=4@H;AZQTO>RJC_J M]'LCP]%<#"=8#>LTIE24.Z8,Q=B^D@\J\3O';!XH$8#\> QM,3 M83'@+MJ)\>PP+$:JP:CIR;OI-FV=@(FC,>VC1T#&(2;>GWX8$[Q/43RV>JZ>5*+22\ MXE:[K5=5%CK.Q9L[*FX_ELG.Y?QZ%]1/ZM&I0T)G-CNQ5@E\#$14O$ZK"V0, MVGMMU'YH%[&^*RC>R)5Z ' 6O&FMTP<*X!5/(.S8WL26*5W (Q>,P:!>$F"O M]L^+3,FB*IM;D.!4SLW J[_^^OJ[J^A95397]GJ ^@V*R\D(=7^Q=YVQ:U^[ M8MJV_C:1; P*08-(5D6:R")3^Z"&NTLNLT[!XS]G0I39F#X M8RF1!;EDDXE[]9(UXO8[-O[N6(50]A?T\IURIZSV%;]$Q]:EVZU0B;8A4)AJ MN$_7'5BHOFS).["VBC< 3Z68('&XC-.Q,]6 1#\W8!DW1HV-2@_!LNHF4R J M#9!A!:_X0'7(EE=TU6@72M2%&HA'LY.)O2":,IYUV_X.O33O+%D\>D7XU.ZL M)3%G!7^3M/,48__THN=OG1"9&C97KND.$C@46FM*=^KFJP<-@M3-@M"ZOM>Q M#4^[G5ODS^IH!+"A>*26D-GW=WI;=\B86M,&C3.4@[?(;"-UL>0;8]4=-$_H M(/*_=+?.J@,,20YI+_P=TV[0LPFAB:K4[Q5S MJB&CW@ (8C(8BNBT(W(^*T8U'\W$]+!B,.IBA'(Y%Q$&CL;/#H@1UN7:X%^P M7S6^9/0T9_0T:A9H&WP[?X^*I?J"':S@<(U::'?F@O[4//K3:,F/3%R?X1(P M7BN)<(/7K0+4,3 M+.UQ"A)@HBTFHYBR54$#C$"YG$=U3 "8?D@MF*VL>+787=7?B!D^Y@%%<&]] M"ZV#MW]]X_5D?/7T22-Z"E XG_OMG_[>K=IV]\J7_:;3_5/0UE9,@'EHQGC: MV*MP-UB5WMIH.0[C/+SDP]'@J)![C*RZR][-ZZS%:M3O^GO6=?!O.CCDBO\S M2$Z+/&W_6.=_]7]+O+'_QJN'V_\TOD6BURGYTSVF#OJSR9EM(*HOA=GR?_,6 MIBC,AC]2B5 9#<#S>X.X<+ M15N!QOOZ[>CD4LWJI3NVM2JPDQN;"D]_MKU MR-56R8PWE<4H'H]GHU+J:G!WPV.?[-V-:7RA*_7)"M>4I;2[]ZHPV]M!-.@& M/NOUQM/ Z.ZFEFOU1?E_U)\L_HUZ*9DN5>6TJ815^>W@/GK[?D+K><$_M=JZ M@W=!FJR,^4I_?LMN!V,"I J5>I(@\?.@/JBB($& \4#C8LQB]LB-L-,>,.!S'*7Z27=S?6;(6EU9!&+ZPJ[P8X79%1 MOGB+68U]_NZSU1+#Z:RF^<^+7*5'8L M8 0L/:"X _0^/BOQ%Y5>BR0:BG@I6)>W(( M[;5RXC_W*ZR"A_SW% 7A@,GI RAJWKI:INIV@+!PRCZHP=W//T6S\;LS\"<] M_,DYZ=^WS]GMI\$=R?RM M/14QKY_"\)603M32>F%R2$! %AG\60E=@6A) 2AR [?& 0C)O+%^HZPPM=>E M_D:"\%]\,&4MJ]W//RWB:/[.P=VK)I>')G1-71<[42E/,3^D4[<(;/JU*FM2 M6J>]VZN !_#"[#C>^!J"_+7X?:-=KQ!>I4CAR[IJ)"<,J' *35W(R@O+:V2A MOX7%A&K5Z")SI!@.,/8T+E^!N(93H1BH&:)%*MQ%4@>3.#+V>+):,2,7"P6XR<3XT-&3^<)V2?9 M:_$%_L1.I>K# #OMX7YC3;/>"-0#5:X0#%U-Z#+5AH/]E(8@,9@"$[VVSUPQ M><$5.:I6N!3H*>-Z: \BJVEARA^$3#KN# M*=@;Y)K"I"RZ]=,VD^0&$UO.G7)5J+:]TM\XF%0OY &^JQ5I3/R]%5_V M07)_X*%_Y^S].W/_;R5M: *>FPSD.BX)3A80?R$XF<;O\#:/\8B2!,]X/,5! M8).86*L*AQ3L>3)#XZ.I0'-P=9NCI9A/Q7)"'./P=,.+,_6 3K-F9KN5\5)$ MB-0GQ@BN@05[B?%4),FF5!6&#_=U]3>@ MH.R[KI#'@.6A;8:L>M $"0UDWA2BT+GJ8,&"R@_YAH;YV@3YU ^EN@X8F2@, M.HV7KBH_+Z+TSAU33TNF71U6Y<#DG T#AOF"V4JF*D:U)OP;>EW%[!2%# M""4SY(UON+! .W9;JI;4..4H)R$J7)/GH*_U##+(WA#] 73C%@^R:)3K2K/N M*G/0Z:66YA5695.Q:8F4 V/RQ)%N0_92G:+PV^->[_C^P%4T!#+SNB)?)')+ MN3OBEOK7['^-ZZMF3I\2J*!6H:!2NTD28I6@RLA(I+.0*,Z8B#QR>ZD=I7SBGTY4#[R@_M1W16NHJ MQ#H8<\_!,]6^MD&4ZW'V*W; %<*!9JT*JK,>A?9_]Y@CCLWQ; MMY]Y]CHAX#S :QMN&2M4DEQ[OGTY<>G0N?_-P 6BR56X$:+-46]"]-/=!_+8 MRC_4([$@;&6_[9OT5W1,K^J0C@M7>QMWXJ_P3BH?71^!?F$V/ZZN2QI/'M1N5F^HV5>W+3W)'++DKBCNE:_("7([%Y22.KWI)E]%B=B4N9^/%%<@+ MEY&]Z?I5RPB+H@B++N/Q\NHEW,\[H.ERMB_KD9BAD^H14T-%[10U4]1*O0PY MB9>'D.,Q<$PFR[.0PZHX)N3))'HUYAA;KZ@7FB^/&.>.;QHEXM07G-'!U[92 MP7'HFZ(3G$/#A[=^M/]L>1^^UNV7AV^>'^%W%)F%RK%U?#V?#H0-WQ'#'V]J M_G:W,MZ;DE^IS5"6%F">OF9T?^B _F/NW?\!4$L#!!0 ( ,F"6%8Q"VLX M:1X !MI 9 >&PO=V]R:W-H965T)%E>SE(:XFZB@+ M>+)5Y2&NX<]R]Z(ZEC).Z:-#_F(VG:Y>'.*L>/;C]W3O0_GC]ZJI\ZR0'TI1 M-8=#7#Z\DKFZ_^%9],S<^)CM]C7>>/'C]\=X)V]E_=OQ0PE_O;!0TNP@BRI3 MA2CE]H=G5]'+5PM\GU[X9R;O*^]:X$PV2OV.?]RD/SR;(D(RETF-$&+X=2>O M99XC($#C#PWSF1T2/_2O#?0W-'>8RR:NY+7*_Y6E]?Z'9^MG(I7;N,GKC^K^ M9ZGGLT1XB#GPPTQ_,"&\> MB+!\'=?QC]^7ZEZ4^#9 PPN:*GT-R&4%+LIM7<+3#+ZK?WR3%7&19'$N;HJJ M+AN@=UU]_Z(&T/C"BT2#><5@9@-@HIEXIXIZ7XF?BE2F(8 7@)-%;&80>S4[ M"?&U3"9B'HW%;#J;G8 WMQ.=$[SY(+PRNXN1!?R9BKA(Q<\RW67%3EPAAV1U M)BOQ.JN27%5-*<5_7VW@=>">_^DC"P^ZZ!\4)>IE=8P3^<,S$)E*EG?RV8]_ M_4NTFO[MQ)06=DJ+4]"?OG9? 49\&;U^W4MQK0['N'@ [BQ G"M1P[T,;B6U M4%L!^@,DI!#R<[*/BYT495Q+<5!WT@'.BEH"F>KV,Y#>#'[)N"Q@W&HLDKC: MBRTH%/YN&V>EN(OS!D:%H>*JDAIBGL6;+&<@$(#^* 28,8'&1?\ MIGF*6#>51#AW<9FIIA);2Z#,46(,?R1YDR(A4D M2C!!@W<#*@,FN#YJ\TF2#F0BP2AQDJBFJ'$*I:9RL.)9J5\:',1!?W(..Q=^X9N&2MK^*'0?%(&HI2%U3X:PV:"TFXHT> M]MH,^Q$!O', ?+[;PY P4KS),]"'J2&HV#.[CD%[Y[".4K"UZ^ "!"G@?E8 MA6JZI;\TDZN0.G!= QE%O(MQK<6= L(ABST0ES:DW9(([\ JB7,FU@^O@BLC9+QL.7# O?QC78V29/D1V1#@CMM\GM M1*0JSV,S%4<*;^8D)C#2ME2'+HE262@P<,2%59Q+D+!CF8&GD.4/-(IL2C46 M_XAAL4&5B@=9$"VO]QG]#5#@\TT&I%' 6/L,: '?P=0MF<8^;X.A!39%2DD1 M^\*);(O8 >:(RTE$ 7Z9/C_&)=#1:K!$#P#L7)?9IJE5*8"=D-8T,3'RP-.= M?Q P(OF X5CU6#UT7J#;R\"L=#$!Z!VMCSQRF+ MO-BA[D7CB9!X>#NG%)6 YM4V%,;N"!^7B&I!+HS&TWV2;. B-^A3529HLR<@[%9#U0&JB.GC.$K0"P+,?Z905 V^3+O:&5U ]/WU#<"# MT(<,/"S%_5[2RSBL;^]1K:&5)VR!!J@+R+YJU>(O)] >Y&HK*L6:" 18&EX) MWB3+YPU3.?T0CF:UJQ9@AML4(+EY]B>\0U:***]05' FO* #% *J7+V_?DML M C=S6$OP7^@!"/,MR2&0@LEOY-[C7B,_644PP?L!+'@Z]5X%C(2 ,E@/'+]0 M]:,S T4JR(4F5@/\00LG5G%U]<7X%!W:D^:9>?S!LN!9+[):&P6RYR.*3H,J MGGNWVH1%C<93THXG\)/G]_0Q_6T-O\@#@6E=(PIO$(50?Z0*OD:Z2;0YO#X^ M<;=(\C)F_H4P'%1PDS/3@ORC\SB@D'K1--X1R;836A'73#360E6S 26;072/ M\T+BD@TXP,L[U*%D#,AOH!6S"A:X\J /'[8[[U/,+X\]4)@EF'PV*E$I04W MUDJC*1+M_KM74&!W0)O"GP,O(,0(J(-3G&MU5+5VA5!_L O$,M5R+\G4D:IN M3=ISLCQHED_@]GO"=P0:7QWD.5G/H@*+C/0/ERS.*X71"E#C$>_6>(*=U3 6 M!C"K&I3&?NH2][=FXKF^/1XCK!BX0K\'IJO!U_]DYB3#9#G 20WZ/62:![D% M!DM!S>3 J"AN$,' 6NFES)[B-X[%JQ*F!7)UA*]!)U\#H6#)"^W$CL55@S%_ M[FX106[OLPI) 71FE68=!P\G[8\2=0R7,?M,H& MGXC,%7!$:A4H2 $J#@5&R7.K0D\*J),_5%G+D^((_Q"#CJ^;U/IU9E">41@> M\7/?JVJ[3<:LA*Z3=DPZ5.@W'=HD4(1;(H;E[^Q/TU5M0_W3&_33#%@(86BK@);:W;*$]O,9:2,-X&H/RNLYL.N!W6L[.\_Q M9&/O8I9]C)8@7C5ZQT"O3'3_N8L# O\V=[/ H M^;D<-XDX_=1H#-!6HO$#QWNLW4\L*EB/%!-5N7'9B>G 94-4,-S.94W7:+QK M]$>)Q>R3//NCP;7UTF_.S(?+"M0%-0U32V19+IPU;G]K+O1]4!&'^GQ4T(>7![X_CR(>\)1M49M?V)7@1UPH0D;3M4^9[8R MT0_E;4&G8\+ST7'(6*"MQ.K'>Y[MJ"$,1."NG,C91&*^-C:/,M4=+F]27Y.[)_K** M0PC&41EFEAOR(PA;L(?W!2>Q7XJK WJ#^,:'$B*8SV+T=Z#3N7B+Z8^/H8R2 M'"!>I=QCY9.J+P1V%)U_.:1^WP8C0P95B9^,3),4_13HHE^UQ/P7)1.IL"=> MRT0>-@!Z'E%E#G_0U;3]YR\PTHVCIBD:?30ILWUVK+I"Y23X3(P6ZW/Z=8F_ M9BN\CNA.-.=?\."G?@D91:O9N1C-+E?G8KY>"EKDV=\ZOQ'@+TK$FASWDO6F MRWL07<@ D2?.!&V72]@480SIFY4;4_OXB+Q_JG1QB!](6X35DNH^/GH$ 48T M-LG39L"6&U66ZI[4IA/&BAU>',[Z&S;8HXGX0QF?DKC<5@KP.]3C8$RM@VX' M&\A&X#1RR6Y=2E.H=-X+] /P%0 ;N[?-FP)A:"/JB:"GJ[W* Z8X;52)_B)J M8B0WL2#P.%JADZ2DN#R&F=8 /#@;$!LQ>ML-IDM!7C@.:H42 MI,$R<14GUZ&4,RNGYRY#SS"T"<.!CD9T.!BA' CHXST:;/'VYM7[CSPV8M%. M+7\5]!9,*ZW6U[03U_H.;+,"L;!I&"_G/XQ*2*]_AU C8V'1>6I@N%APR0E( M1,\[ZZT!,"')#@EJ0$ =1TZ92JPW;'2?3\C3>7A?_27-P:05V?%S!IASD!ZA M36!.W.99DI"9M<:,;!>^BJ<]%M4*S>P6@B"HUF-(]^LW!AO%;85'.,'HC\5BW2-P8L" MD34Y9B:/Y\S:)+!UX]EJ'MR)YFCS<0'=%/S5S:J3!1'MJ.]*]!1XG2JY*^6. MEG$CZWM).?UVAGZ@[-!3W-(.$@*P'_6G9CH?=MG!+8&WNO 2%9I?LH_ZAUD!HZ7@;$8KV<+,;N([)W5^.)B_3C,*PWKPGX8C5?32[&8>S>6R^@4 M) @:RD872%2 J9_:LN"F(';CU:5#%3"'06?SQ[']114&]-L^T,*#&N$<@+:+ M"R3X= 8_+\>S: F_Y[,U/L'+"&B_6 9L\@MP\M>RRI>N(2"P7@6\L!XO%U/$ M#@0B8)GI>'IQDD1?M@SSZ07"O 17V]RZ7.&=%0W/:.%+<'TY7JQ6%J=+NIR. M+R*D[V)./X%EX.9ZO%KC*\O%)=$V(F*/+Y=K8#2R^X#>1K6[,]@:5:VT2H\> M>T+5V+>EV"5TP"IAB2XQFVA0A#J]1IY"14YI;GM!@O:OK&YH52G%+TNTPU3, MKB3AD$@DO4T878/?F-7L^Y.B/C?YNCS7+CLI\6.I[K*4? 1NM"4;4?3ZDUX2 MQ=7A(.[X1.TX2OLF[3F6);*&U;@9N7L/[$(=K64AZF*H0+0=@_^DT:1J(J:K M,<^#,]/5!^P:&!XS$8PK_[\0NOI_C F6=I7:\$];10F9V/!R"]*BOZ9(5)U< +:-[ M\Q$<1J#5S\W/*+(_KUMTAHE);+!Z 6R!4$:KU3D'R1 -+\ZM3&-D;C!'NT/R M?$$*YH+T7]3C//;P)[H/I:UH69>2-3<77 J M)X-Y"&T-@NR/SC=0KPSF/)9@K];$D.OQQ11=A@78X@AM%_P&,SJ*QO,% !NM M+Z>4))G/*7T2C2^6E$%9T%-.'%$'CBK:/GH/B4_Z.]H-SH!JU8E,RQS&70!2 MB^G@2Z_[66+ 9KH* -:$:IY*MSU[\28R, +%.3$UJ4MG+9K$3;I0OP&4 M M@$88G:#1"%X[!SN_$*O6Z@]2H'QR"O*))!E1#@_99AA/AP-Q\_\Y^7T<4$IO MVCD&C'E=2001.3'SOKC\4=6JE4!E]9*7R/:G]J1XRT](>TW^CV:4=1[ZB;KV MRYUG#;^K?$](H-.:_6QFD\=S\DM'$:SC*7#PF 5I-+\X%Y<8=0^Q_FA^>N@V M&UWBP$&-UL^BW,IX)]&I/!Q@QE6MDM^!_!70&EMRBM0TEQ!AVJ A?D%"_#K< MJ.D:8FQ?PE!/@M>/<++S^9%^K6_H6I@8!LT*9BA=^T$QLP9KN.1.;3.F83%# MFA:?=,>72P16QZQX#@X826NYBPLL=.'RGR#B$WL/_1S\A-CD:V":RG^9<3VT MI$5YT-UB0*+ &1[KS+%2]N,]_:8LC*UT,4B[[L6E?J?-8.7%=IZR]M3.)1@YFF#^ M$'YGW\:J"C>Q((4'=C289K6/(1T\3Q4].6^L5&+.+BMXRT2,]#D%DN]+#,W8?"7A1^FYD/)'U;NPS T(HM4Z1BS M"@*E Z8?<98>_YUH\Y;I$OP!7'>0);G/QQC#/'!,+]<#J:[A M)]TK2NSMD&T*NTT'=642$&"U[G&;Q+KK:,*M:U5"7!G67C:J2"LQ[[P^!U^R MZUT:$^*AQ0 >\R5F/7=^I2(4+:XWH>7JLO,NWENONE-:B0_-)L^2G"KAU.?> MX1 T$!&$#I16@XC/&Y5W!#P& ".(]7+.D01ZHP#08P]4)BZR.UNL9E;C=*HT MI\PFZ_P9=2]V< "-1EMV\K3%\:S_)B<0FLV_":'H:Q"*^M4T$1P?A_J:VDCV M<2K.UAZN5!A<7J[,#=RA@JW<7'D<4\1,?;W=_AM M%4'RM]LIA,FX/G/!Z:8>)&PWZ3:^ WG#H=4 [.>&6)\T*XJ.97KP&2RN_0 M]%09S#TN ]BFB0MM"-^7TNQ9:&.JN<"BTQ2/(S3V]B9T:334,OJ:;677%EMF MZQ(0>'.Y"I:[BSJ^%#F>\*MONB' [M/I68='I<:A'7T)VE$T?0K>3T+[Z?B" M4'EEP YB7&OK>]YF@V%>5&7;]'Z+B#U"?M9&9[/U92CST66_R ^Y?J2DM&:9 M#FF6)1A>"_4LFES8'@<:8J*YHP->LFJPTX,6A,Y:,0X&T43".D# HR6F&(Q MZV!RWKR94K9#W@'*AXOE90G?<5S%[//&9=RH)W]+#F5ZPO[R)*W MT2K%.]]UZZ4AA!W*P<6F0;W3)P^; 4U16<.@0@D.I;M&J0S@*$+[94*CH_>U M^+G)3)88$3]H[7R(/X-M^%-6?KNE)]=9<6QT: J2V7VU*;HOTTX)1BQL$R'D M2N[O \Z6W.:4DY;3WS9Z0[Z>EX\Z19YO\0,18?NF2>WLL]T>LPNP$ K#!4*6 MWYO[[X$G#Z^]M"",\_>?#170:%5!:KO.R3R]E,9='C\L=E")/X(T,)QC17O'76,?S-8/8;M(?!6B$H! MR%BT]59MR(FG*,Q[2;,;L%/,XP8=X=0CT8 ^IKX+[46<)(2+"7[KX1:+IBY6 M,3H H69\"[OI1/R+[ \$SW5/;W-'CV@$9SOT(X\$U_L\]@Y? MVVGDR4.)-@-W)OF#?FK2'?="E29]01W(-UN=!NV5,EI36[P9VK^&/8PZB>&V MRJM"2S&F39,RVX2UZ 3X:P=B^2?/P-]X[F12 R#DF!^R<%9F#[Z;O*_WE)F; MV^OD*E%7;C)^;\,[;T>B7X;"XNU'-,*DNEY1>?S-8Y3QMS?Z=;>"2@D&F.[M M"O,,S/AXFA-Y6+K?>_JIT2=&"1E9X7#U]--6/;@*$B\]^8GA?,27 MY">^.A?0S0G,GA#'1^-IU.UFYKOSGBP(WN.G."FO?2>:TS,W^OQBJKTLLW\? M(_Q_P^S+XT2:]21/\%XTGEUTG_#=>4]5$N]%X_FJBQG?]DBKB_+/O^<7%A?[IK71PA,73EGLQG?5>1UZW'E[_"_BWEL7P8E_T7$4] M5]BMTG>-G2O^-2^-/Z. /-3SPN19KY9AZQGU<3&!UJ!9N#+J!\TN::)\K<*= MTG@P3J*+@35MH_0W2)MXXQ@_&!NIMR)C8@I!3VL)<\IG(+EW!\ M0];Q0OSZABTMD0VV70%D_+D+B79YT=$R0;^7-NH^++=#*.S7PJU 'K!Q>\VD$*GQQ'9=H2Z$:8=+!8-XZ]\&O?X,3UM1]>Z?#!N>V[YD, MR3\PGTHR"A?(U=V@ XU[G!)UV&C>J(;K)EZT_H^X:+#LZ;'_(O+W9YJZFW\L M'8G'*%JLSL7R0GQ@MD8+R\U9TTM;2UY2RQ:J%?>Q[W(A@QN9Q.$1\$ 8T,I74 E6I%\F0-[6K#& M^O@*=[Z1E_5H\9H^ZJQ4#W$.3X]F?0$JB-[R.W2FD92Z!+K%MDI[.H9*F\1$ MDJ8;\P[/'00/IU(Y!92(6S@#DUMKTWG1V6A#4P/.]G(V51!*TID<)L_@N%=7 M64FK0<"(I\A@Z5A]XJ.\O!TQ'(S&I-V>F_R##4;9X:"3\ZC+5*-5![MJ)K9E MMS=':M7T633S\^#NZ*FXT]C,JV3Z'/UCU3:2[4_Z_8#WQ;;(R/@5N?0"+U)MT]_4G=7 M>T]-:P/-R#D0K=TVY[U3R+P_\4W /9]MJ0G# H=+A\Y1)_>ELVZ(VU=:[,DCK>SO.>M;[)3- M#80E!Y"CK%8EVM"),VC9O+8'//NUKSM?)[28 M&3.26=:RQNY/S'3LEM@<=)QV3_U#1(%;Z0FU^'E3T8L(4\6UP!P982BH=F3Q MF#CWS*\=X2#@L"9FTZ)K@B,K<$#9PL2PH=4?34P*#1.9*<0:G(I#*VG.9NO5 M"EX5Y*@@9'X0NP9X ]IT"KN$'_BK/. 7M$'Q%:>F@#DLTIRP58;+VW7-!:8 M,AC3MNRCM =TQO9D M>*ALJ P*1EL\-L)P !0*79#%#'&?XU%GM5'3,(5*HV M5U F(NN<8V9X+TP,'F5)_B49F<+L,K@'#;%G5U!O]^!#MQ&-2NE\7DUYYR/. M"*LY\8JG'[O,\X]K&5&4AG'$ MLZUV>5SN,._0QTO:G)!$O!3ODO\ P*JP.2)RPZX 7%:IIDSD*UEBEZ3WF!F, M6F4!UY\E^%_[,3JL$V.*2NEVMWAF"99Q%GV'ROH[@A'-O^OS/#EUT2<%O97T M039\G-F !:RZVI54)=,,A!;.VR<-+(R[\9N2:UAN/5[%?':&?SP(E;WB?&"O M/@.C_CG*QON;26Q!1NM;VFQLMN28'3KNW%9_>U4?O;; 7:KLVVTUH, S=]H! MGZ:FH^Z*"A#=$4(T>#B,?6>391CZSL+0MW=Q'XVZ0T[AG 27GKV)>AM^'#?B MP0JI@.B6E#GO$!^8#'EKKMQK#A$:(IAWB*#V;+]]%_I-T>W5&)HA=0+$S)5Q MBIQ7U4:(?=^ FCV1TW#'E!$ YVVWCM:P*^EYJF,G*C66:\%%1F$R7_32YXMZ ML;!90F.(/+2Z:(>K@]$JEB?W<;ZUYRGT(F,G4'DN=ESYB3%:?-OXT-HB:E)- MAE8*W)4=*T0ZO>.0U2[ TLSPM*V@[;ZO V8D4P?L)(T17Y,? :+.#75G[:Z( M7_7I0UX0&2Y[)0W]^1RTUO$*>OAO/%[!'&GB&)H#IAZ-@/YW*G47 5+)2PCW M!E_Z+&_0G>2PDX*X":SRK3D:)=@K<:5-,I\[TMHE:9RV]N;)]J[5QT/$@5VL MY);H8'M@&Z8Y!<7LRD0GAHY)PVTL%1\\@TY3CTGAT-OM!@W.5PXV(82IU8'* MY;AWGB:\(+WG'/DI/4V=KTOE@613Y\2%'D;*O--ULB.GBII++SJ'2NGB:)S4NLN.WI&A6= MK+6IN*.MV22V-LB+8%3)A/7[HZ3B0D6+69 ]F,5,-TX*A0\&;%-5W.QN4.KM M/$JC@^!1;$KG!/V@\+O MK>W\@X]DI?4WO[DOYE'?$T*)N?,(G)9G_(12>B"B\?<>,SJZ](;=_P/Z78B= M8EEQBY^T_$,4KIQ'XP@*7/-&ND>]_8S[>(8>+]?2AB]L6]V,19 WUNEJ;TP, M*J':E;_L\] Q&/??,6![ Q9XMXX"RUON^&)F]!:,UR8T_Q-"#=9$3BA_*4_. MT*D@.[>X5\^HG#8"[2QQ!.C%2;XWOFF-V3O&*8,O6KG2PL^JP.(4("$F1SKL M0.>&G46\Q;P'61H#ZS-V!B\[AI<%O.R#\'9P*VPNM6T,PI_+E76&ZN&OMT)N M 0=O _HW,K4USW$>T2.P:)XQ6OSX0SKJ_W2&[N!(=W ._:/;^&YCZ/YS!Y16 MK%9H*+60:WI1UF$!>CT->?:?%.Z$$E1'!6RT+BQ<0!J/!VE8KP?7\,BW5'<. MC>"2,%41GAL(!;71.5H+UW%_E,$H9JP/3TU=2^^<96-()R/X53LNX9+7I/TB M/)"E\C:&6!(CZZY@$J<#!N,X)1#B2QW&(C@-O]S??0TJ<,DFV15ED<&+T MS&5#6 V5M0$R:%E4Z$I=$)FJ-L)Z7Z_AR!U<9+T!K(24H=U0ADB0O0I.KJ&M M\*#ELQ]3@[,UAA8E=SU85KI1Q,]TXSJESJF2.TQDY5-$ 0CCN>@UF ]O3+Q& M3"[/\R/7=!]\STNH7#;TY.&"_3?FM#(5@M MB:9P);'4"F&'W/3H9H 7A7 !\CTBPW1$#;)#A T[@N]/_O]H4K:*)B<7(7-8 M<\/#0*&)N#]S('FC:%[:WEM-(.FTYPK-)@PA*G\?0=NIC]+CG%NV[?U5O1V2 M7[C9"&5!XII,^[WK802F'3SMQNDZ-/N5=C0ZPF])LQJ-5Z#SM=;NL/$.CM-_ M\2]02P,$% @ R8)85@U%LGYC#@ ."D !D !X;"]W;W)K&ULQ5II<]M&$OTK4XHV95=!%&]2ENTJR<[A39QX;2=;E:W] M, 0&Y,2X/#.01/_Z?=V#DX04.]G:_2"1 &9Z^GA]@D]O<_/![I1RXBY-,OOL M9.=<\>3\W(8[E4H[R@N5X4F/^5[ M;\SSIWGI$IVI-T;8,DVEV5^K)+]]=C(YJ6^\U=N=HQOGSY\6*?=+\<;@ MZKRA$NE495;GF3 J?G9R-7ER/:?UO.!7K6YMY[L@239Y_H$N7D7/3L;$D$I4 MZ(B"Q,>->J&2A B!C8\5S9/F2-K8_5Y3_Y9EARP;:=6+//FGCMSNVW4T:\RIS,MGJ3*/OTW.$,6GD>5O2N/;WI/?0F4_$ZS]S.BF^R2$5] M N=@KN%P6G-X/7V0XDL5CL1L$HCI>#I]@-ZLD7C&]&:?(W$KJ[BR5CDK7FH; M)KDMC1+_NMI89X";?P_IP9\R'SZ%?.F)+62HGIW 6:PR-^KD^==?39;CRP=D MF#L]E?HB?<[)>(\@0/K;"N<)'5Y+]:?\'C;["87TVXO-GMAU1:^ MZYZ(-SL)[PE5Z70H$W&5Z10?WRN9N)UXGSM<7,M$9J$2?Y=9B<@@O+$GXE1, M%L%R,L>763!=KNG&.EBOI^(J_%AJJ\FQK9@&\]E$+/AS6;'_:/)8/)JO\6^) MO\7\<7,(\*32#9;,ZF,>31^+R2JXN%CQ,2LQG>!CWJ6TQ#\L7([OIS-E.J=, M"6RT+!.U\9SIO,K"I(R@LK!,RT120!) 6&;I.\6HZ'>X/.G-"EPVBMWX,^V( MS[@*J^TJ:I?HM)#:T%8!^%J<<:N X=,%5)-B 9-W8I-#Z\>LD]U)%R.VM8RB M2K4N[YR0"2CDT)Z5G>DI*Y-/+8PF<"1[Q&W/)PC19MG:3>0Q28+X;'#QR"HE M?LJ=$O/'HTKSO-A@L^Y@$3)TV! MO7G[M4R+RY>X7BXGXNNOUM/)]+*ZN@BFZ_:>OWIO9*1$)E-%:%ZO+L1R1GB> MSN=T#<#/+V;X-EM?B!]UB)RH/+Z"!9CDG$Z!8IGXEV>*C(4V2[-85FKMYF. M87F8?- ^VD.<;M:Z'%)L0/B6(H/ZD50UKCM(V96IS,3.AP@ Z8.B!RTU-X!@ MQMU;M4GR3_LD$*>ST4)L/.XOQ6_*;.2=%+@_'R]K?[@4[^" =\[D]& "(LV# M[Z2)P%9R7G^!H6C)N%U",ET;'1&4\0RJKQZ-Q%7E/S))]@'K[D4.]\SV8BEP)TZGHUES0(?( ^;@6]@W;?;= M2E*T,WI3^H!/'MS"-!CV\:LDB1-U!Q4,LMAZQN%N#C6O?SA;72P12"W2@E,F M5(5[#-TN1_.:+XBY<:@UZ;B=RE;GRYY(,HPC_:HGXK]!W03.>L M9PT$/O.<. ;LX K]H&C]L9.E1PE.FXRG2_$H4RET:; HTQLZ<#Y9?^&!YA\E M;.&E&GNI-E19\T%-_'S0;0EO+[3!T6>Y%;1\^L/ @<=>1[ M%*K8Y0B.,E.L)B<_Y1L4;#)]S)+J['??* 6LGW2CLZHFR9RFAPICB6.Q6EM;D@[;. =X)4@,G3J6+!=A.3M&[6'U M>DO,)E3,,BGK*R-/A:L.IUWI^ @$R>T6JT%3W9#41E$TK\]0-S(I&_ITI^;[ M$#?>$(W-_9$M+FZT)?\$O$)I=R(FM\<.L&1QC_;6A!%A$OV)&*BU#_IE6OBB M3B*\$ )8'E>:C(#BTZQPZ+BI.V"-DNE#73"6RL+)#QQYO/HI*B@9.W*:]XSN MFL$AYG06D8XYN"&(/*@$4I?B_)/E4$F9)-XI;I3A1,28%) G1H$<=TCK:\F M^IKSVL"R2D9$*2\7U3 =O4 +$2H-DY+\I.:-@E?A#P')-?$TAG4J'JL[1Q(, M^!^)'2 _JXR<"QS4D8'.J=>'TI@]68W)4\RR9>)\3.:#CL(!-$00I.#W!H_/\C@& 0)FCMZ* TA;QQ"/_>!1YY:#&%<+XCT "5X4.TGF)B:+(MEW M'9*,AQSG? 2LN(_STD#@CVCQH&1:SIF9@$8J2;C(BTKV&THLHTZYT*"FD<\7 M3+9)EIO2PFRH[CNQBS3+W3?U4P>V@Z60$[U\R& 5 R2-D@9%%.( !43K:ZI M5.>3?Q#KG;PB5\*++(E*BEKX82]K;$@07OE'&_K1V_N&E.*&A)M(C!/ M7E1[6)5<;(TO_&5GI55T5*+CQKF\1_FTLZ5 AGK&Z4^\OI(7O$[=%5P5=2OM;BKN8*U5S, Y'HA[_W#AV6_3OVUR*<7BTEKV.0YK1FVIPZ:((TNWRPTH^>#BC:U- M5$<";[RNI@LDT]R+T]<0L8R&C8@1_3)M[F9"CR*/#BG@ .11U4BR20LJZZ(?9)AU1*LO(TL7CJ:5+;YSW/W M!XFNM!Y^$11UHZK@[%-U/YER4UT648U7HV(:IT//$4"\K\W9K1,26680@;8< M&["V63>QX2!EN@,Q0X8K5:=ZX%H$]ZDPT[ZI8T,VNF_U79=IOA096G%LD2_* MRCW>)=J4<=/X#^3G)A0- ;]*@=.C*G@:W.<_L/R-YN:@;4QBI2(4UQ]JQT.9 M[+- B$+.S^A<&>UA,LIXWB&2NA.**2?C5$0,&AK:;B[HN60"M-YK3VTY.H8- M3$A%)#/4D&U5$^0'.0JJ$L 0ZSG*.HHG!"\[A"]VE9NJ$ZG 5A>M]O-B G+; M SX8_$E_"+ELUEEW:PUE9/,BJ;'ECR2%\_*NED.JQ!K^DP&-K:$*E29K'41S)[6! MGT?H<*Q"7IPA?W;'%44RJRW%/T'?.Y#/^*:":4*TE M2"_4K@_T%=T1Q6G7GH=&&@J(C=F0?>0G4@1IR:.$1(Y-GOI8V:D3JXB4E^[, M#Z?8=Z%.Q<1;0X2:7Q=#G:^504PDQ=/HLS1HX@\-U>6@KB4G]TUCQ.ETM6A$ M?:#"NQ>:*/XMYV0ZF]GCMP"K2\)#5O:-U0_']SO" 0[^2CWR?R\KNBQ3D$&W MP14!*0D M$>A]I_W+E1"-!!7_,H&G'#[0=QJQ(6,PW(>+G^,W#_641'#WU8Q">K..^Z'2 M=F!4>C?\Y6(]6OSM/M,9;3\0_[%.^D3^M\49'?N0F_9F)W\PBA6G%^,O]7W9 MAB/2-MF!0DVICHLKR@PR992\^/G75R_/)A<0* S)."&LK1E$ORXN)IWY93^" MD%;5+>DOUEQ#61]));V;0*4Q.2R^ZF:Q.H=50-?\-/"'D=&W*D.8I"$<8][E MB2(HH?_:E*X:2Z5EQKI'^=:\>:8I+]HXXVN_'"R@=\PZ_".TEZ8[#J[">,ZS MQ )M?M72^C<0[Z[>OCM[D?]Z-CT_U%$5GEH5=Y(&RH$A55=YK%N:4+%F+!BJ M(%N;,M'2#V^8&7_"U@<4Y"'*(?5II_-%6W:\[\&O&2=5_2A5.(?5'TU^.D,< M/UK:\TJ=@R^H2''.IV.)LWP2->#K-Y(J7Y[R6]G)Z/UP8.Q5UT; M2.7#W!%^>7#7S#WN$/ IP^Z5-)80(VWEH99_33$+>N=>TKUYT!NL\;U%GW&^ MM^1[B]Z]%=]KWDZ/AGX+==[Y-1MPM.7?[+$Q,N=_V-;<;7X6>.5_#=3S_P!02P,$% @ R8)85M*F\M8Z# KB !D !X;"]W;W)K&ULM5K;=C:!XB$)&9(@@%(R\[7[^D&2$F4;#]L]L&22 *-T[?3#= O=]I\LUNE6G%7 ME;5]=;%MV^;YS8W-MJJ2-M"-JO%DK4TE6UR:S8UMC)(Y3ZK*FS@,9S>5+.J+ MUR_YWF?S^J7NVK*HU6O;J(+OH;OQ:;;4LW;EZ_;.1&?5'M MOYK/!EVO>O=-B-9ISDWG);YWD^ ')42P^ MZ;K=6O%CG:O\6, -8 Y8XQ[KV_A1B>]5%H@DFH@XC.-'Y"6#[@G+2QZ4!Q7? M%S8KM>V,$O]^L[*M09S\YYRV3E9Z7A;ESG/;R$R]ND!R6&5NU<7K'[Z+9N&+ M1Y"F ]+T,>G_DY?^'LGB:*"_:OR5A!E5IJJ5,H-_1%%G90?'B\LHF(M549:4 MA7HM:MU"7MXI#*&A"2]S&2WG"/!A5$E(X7W&Q8SY1^;6\ M50;TB-5;AEH0$QSY\F"/['0B81XCD?I,N7/!!B6HP$SPI N$OY,11J$ M8PRT1#KG8?,0 \9JIC0W3I;]9Y".[1#RHSE_DJ'& Z8\(&(YX-\H6)"E5&?T M=:YJC?IQ$*%>+[)J.*.)$5(Q//703"SAE264CDZ4CA=XD/)?K [DF(. ZQ>+ 83P=VA!G]S3C0STV/$2OT-PN2LR,0 M%@BQB,-L,79/(G[X;H$(>T'I D?] EXQ(IK-11QQ0B]PFWXDX62V#/WS9R E M+HXUV1%L2FS4.DI>Z5MUU9.P/:0R4,NM- 4/(^KSU HY:+R<'+5>.Z(Z)DE+ M+!FQ!8C5_E)&,PD^RG._%^V6@:F[3!W1\X.6FO!C9Z#2T=ZI]%BW9XX@UR#^.PO,H-:4R1 M*=2.'P=;2-;_9ZSM:)D(/EPZL.]TU9!$=:>RC@!+L>[*DJW2U:#OO""I*"V; M3AH)JZK>#/B#Q>^@)R%@]L>3HK54Z6R1%\#FM!!?MM(TX@=9-2_$>[VM:%W3 M!.+9IR_OKW@M_/C[,!PJ]@SN0RC1XW&=O)KX.*.'% ^^*+.Y8,8Z*QKI8/3A MQ"79JCT0.%^3QP&B126EXLXH"FL[:$*64']V5.GQA..5>H- O%.FQ4YIA'9P M]T'8&\POC'*3G3FA2%/>8X. ",W@UEH2:."],)]6'3HWLSOA9L= M0)27,Z"<.@[,V1V 6/*K"B+]MY% 3M#L1O_V=6.>YRD85QC]&W!!"JS;UT# M.D(4Y?2D[_[&(?=P%[F7RJE@R8(K)3H+8Y*TC:K1F9:08!K-36G3X9=5]E0] M2I7"]J79HALW-JV)T%3D@<#B3#_-'EF\JSS@"#4%#]5;PX\288($-T4>6I M_&\$3=T6ZX)HV%K5]A6LA^%B8#TP$>[JTO(0!(1C *I2-!=%: QW[S&,T(@V MRDA/9'Z!8S=JLY%U\9?+T FG:%$A 10Z@=+9VUF1Z6CH&UR]Y%#US$QASW8@ M#[?#M!V9NV!_&-Q F5D!7._9 ]+=(2,'"[L'VKOL5X7H!]>09!^9Y*M]<"%Z MJ0XC OP>SB@Z)QLBV8&'[2QBLW:L.0&T B'K53JCT:"$6PY9WE)?TQE/NSOV MM6S(L]1J!.(W%[W]+#*F3U[H//1/#OP@YSBH^1C-L:BKK-C8;K5I73GP@I_Y M;W8LU(:J+1%+KR:V))4[$L)*R"9[U=- [Q:.'Y=EJ%*KWH[:!>-*EERY^+C+ MTP6%LZKQ3>A'3+$O NSF3&\04K0IA4<$'?70%ON:CD3H9 ]C4 8=2_:(!V2! M^&4D^P&HKLT;EJ(3P[S'[YM?05G..3-".2R_CXY ?"&2.$O=WMJ^$W&Q1M&< M4Y[UZ>^:S3[-\\)FNJM=?WS,(AW)HC8.ZQDF*WAN7PR8(>']3)995_;)])1& MJWM/)UF);QB1+/\GNBB TBV^H1"I6O-#/M4?G&7<@"$O7;. MI-"GE7<@)DJ"(+UA%;3O#F4.*]5E7 MZ_KZ FXM MIN*.9:-%*%IKN&4TA 6?+S.5=WX:- MF>H\FSRY8?"3>\O;WO3[+?,H(8=C29G_T?%6%4 *G:-4E+Z?*NIU*=W&U_ - M*LH(JSWDGG);TZGKKN$F$J':EW3$7U&Q#V1%2ML7L-D.T6(FO@7W]T_*^I=N MY? B6'3E8H/?VY ##QIY*TOWD$=3KPLLLK8RVW?TAW*/-]4G1O,,VMN._-G/ MI1ZRR$E]1W$'.T!N/?>C6FS >=]]L)D:UPSF%=J)729).AP?^W-E;!&2-!G= MC=QI-4BJ)QX!W6+H]L>A;9&$"/ M[$21\,%:J5=D7W]F]Z*.E\;+V00@J9 M.524PP:" IU?[+GWBT-PG6PWJ&T^V!X>'G3OC[;?.!7=29>_>!9=B4L139)T MQM_3Q4Q\/+#WFRPS=%Q Z#5/S#I#1'[DE7@1B21,O>B?==T/.A0534)W[,L' MZOA>IF[)>"E^'[]*.%LFGW'7=R7FV(;2W\FLH]Y!)$$DOA=Q,,,GZ?FAI_>& MWG(4?>OO"(=[DUH_Q,U(T*-SAA,/C!NL\6Z=3AKQR:>]\73AWBO$=,$'F0@C M=X"/BZ_4'#A=\\>>RR ME:@( QVE,YDNT%L8:7 M<3*<9@3GWDC>'+Q#KI39\)MR8G9XW+U.'NX.+^/?N'?0^^'N3?XG:394_4NU MQE1ZHW#ABG5_T>J&WTBC$VAUQ3^W:%N5H0%XOM:Z[2]H@>%?%%[_%U!+ P04 M " #)@EA6/JI:O6DH "#? &0 'AL+W=OMSVT:2_U=0OJTKJ8J6+=EY>/.H4N0X=M9.=):37.W5?1@"0Q(Q M"' Q@&3FK[_^=?>\0$B6L[=7]R&Q2 (S_9I^S\S7-UW_WFVL'8H/VZ9UWSS8 M#,/NKX\>N7)CM\:==#O;TB^KKM^:@3[VZT=NUUM3\4O;YM'9X\>?/]J:NGWP M[=?\W67_[=?=.#1U:R_[PHW;K>GWW]FFN_GFP>D#_\7;>KT9\,6C;[_>F;6] MLL,ON\N>/CT*HU3UUK:N[MJBMZMO'IR?_O6[IWB>'_BUMCX\/ MKZIO'CP&0+:QY8 1#/US;2]LTV @ N,?.N:#,"5>3/_VH[]@W F7I7'VHFM^ MJZMA\\V#+Q\4E5V9L1G>=C+S&<8KN\;Q_XL;>?:SLP=%.;JAV^K+!,&V M;N5?\T'ID+SPY>-;7CC3%\X8;IF(H7QN!O/MUWUW4_1XFD;#'XPJOTW U2V8 M%V;9=W4 _WZ]:.! M)L1KCTH=_#L9_.R6P4_/BC$:0!W#,/[G=G=X[XW)8GQ9/3 M17'V^.SLCO&>!/2?\'A/;D5_NZT'X"K(Y^1X7KNRZ=S8V^*_SI=NZ$F&_GN. M##+)T_E)L*[^ZG:FM-\\H(7C;']M'WS[[_]V^OGCK^Y X6E X>E=H_^S'/Q? M&[QXM[%$O^W.M/NB=D7=7G?-M:WHC^+:]'4WNJ)L3+V5<1J[IO=W?5=:6]$4 MKNA6A2E:,X#<94?+OK(]O=YB\37%T!4U,6DY.@+1N04-6S8CWL0@U5@.1:/ M[/'C0 N=5OXHD^QLCZ\Q<4DLMWU9TP\ ?&V@'>@G5]S0*_BWI(=)G16FJFK\ M2$_2\A]L[Y))U]VU[3T9,*[-"*,OG!2OVF(@PG2[NH46(B2'2"<"= "M1B+\ M>]OLZ33/MJ^%-LF@__YO7YZ=?O&5*U9U:UI& ME,@IJ"PP,"DLIC:HPMC3I[XHC=L4*U+2!/0/I"D%;N6'@AT)5E2T-D;GB$%+ M:'8F 1XA\NX:^T%$(I6!#(=%"K!0P"P;"TS(M+@.G_:%=4,-)$DN=IUS-9Z@ M]B*02?T@HP2>F.6F":Z(,<*=9:]B38MLQ.7;0#75I,02-@?GLAX%DP9,N M#!@D"-^Z^@]& G#M.CS/[&H,)'QG>AIR;$Q/M+C9$$E90IL,!9&-82%@-L0>3 :606KWLNR<2I)9K6BA3/B+=Z\% M#V>'H;&0:] Z%0LGJ(FR7(EV8U40]0;.31K%XL"W''MK& MBS%)!TD.+8H6*VU&)BN&B"0ZP #ZF^IWLMDT#BVMNJOJTC3T#LU"#"6"BZ$I M-R*[?:IAZE8\+-!M2>AMP>9K4S> _*0@%^10SP6APOKH$V51@,T&O!7@0 4# M90@:$T!>2!1AKVV=+!W/) )[9]Q @@QLB*XD4>VX71(?:1K5Y;W%U#J0)XY+ M'@BD78X#"^V>7$W_%O1C55_7U>,6JI*6%TK^W0U3HF48! M>@R%"HX:0]+&#N 7:EL(+"N<]C (;;>FRF'E]6&O33-"X-G^]K5[+P8GH;FO(N2 'ZC]&4_4U<03B\%_O]CM:%I\OBE/RB$\_9[:/90!Y\=XP04(*:0&VY9#WA7G'BP(UP_\.HGTGSQ M&/X$U##Y<.2(-*H@(,DLB6N2#6*+TJTM;"WVP5907-"-;H#E+[NQ'[P7Q=I6 MI7Y'VH46Y6I%-"=/;VUSBSYLX%,N@EB2;AG)M&"9>V>4E)I3U?O[V+-_NR)Q MIM^!N8E*(!"-H(H$7,B/8A(9Y&'3 >BZ+ 93;O8E/5J;PNW;JB=USE8 XE-U M8IX5[DKFWS.2Y^.:[(>2%.+Q(ZUL=N$N36L;:( WY+[5)'I#7[/H!H$EB\CX M,,) M8J?>>%>O^(W4'SG(B*$$4A*;GT"CXL+T'<491HTV@S5=[&^I: %^"O$A\H8GWZ9.[ODN]@:/K$);HP;E[O.@B(D*%$KG ]DAEL; M3<;/*[*-HM3P4$K:7TD/DY$JCGY]5_QR=?[S,=!S(]00L>I*;=K9TR^]3GUI M34/,>!54Y271PA,22_6\+.$"^:_.99[39\\^)]7QZO+\_)C@;PP;%IK"@'+7 ML'E>'%>)1[N1V4K#SB,;8^%LQ-UUXWHS9'Y0/OY>7!A>AG%D'Q#JPZ0;-O5. MW&$.$=AO%34#Z[ A">5U>ZD.>_%B=.SOOFK+D^+H\L6K8_A3Q,ZQ>HA\#_&4 MP,U,L]1!BL, MDK%/?"\B"I'74Y=0W)"(N)GBWI53Q+;B<;.<& T'I$\DZ2"TYNZT%5&H8A M,GN5GBY!4IWKWFP5+M)B#>P1X'NA3Y_3ZGKXM[I\OS0TQ169M7$@YS#X.5Y: M&9Q#<4UD(\'AY$ZU>;[KB6NWBBRKGV2X:\M9GIY0,:0G8;^#_%Z8IB8FMF1^ MO1(M?B 1)LRFRC15D^*63928\DC\ZG5OK01Q$DN*!4>(QW&K!.(52BI[;9MNM]6$@VG#^&L2 M[G7=6F\N)0D&3%W0&(5/&4PS8?DD.\,)C33 5S?NRK3=JBZN3LY/4A@58Q]3 M3W-:9L@"_+MEZSXL_01A^W$DDI";]7A&UK!R;5\] M!"RDKFA@Q$04K:OW0_9?(RZ?P134E//NGUV^(CF$5ULQBC*NS214E5' #.A2 M1$T&&E:O;M6&.1N2EJ^>W\$I80/B53Q._RYF]3%$F7QBTTO2L;C8P+]4EM(7 ML,;X*:'RQM9]F@'EF3QC\#ZBC3S)JZDE,D1PYT-:-@Z/A!9GBQJCZ868-_8! MGH0G6SCQLN#@[FX,T:^TM#9*=KZ!W51H/$SP>SC?5G48+_@_S$:.ZL/[\XF' M'7G?)2=="<#@=00Q0) U4BC3RRR\>)G7UW"F/?N8L1SSD=8V, U_DH>>2RZA M(\N99 2(L[];<3UI]*:&FF)!RN02I3T!ER=+%2_&$IKGS$Q0#%K8'<0,/L>7 M/ TF2R !:JS'QDCJV%0$&SQRL4W)*Z)R*? GWM%**6UPZ 0P=4'@&'.LIR\( M+^Z%=0J3JXF9US7]0^.LI'A"*U(7:1.5%5LJ.$62/HU+%CD3S<=R>LFSA4>A M[Z]1&F40/>2AVG&ABB!87D"XX-:-3Q M)#$PH_679CH2ZH88$,OS,;$Q"\;^3]!GVH88>\7SRT]TI)/KGZOFBN"II0*SNBPXQJAIF M_^W#RP:Q4OXCX'AS=5EKW#&' MV"%[QD+B2; []BABFX'3UQC0K/%,1>=15JEO]0 Y629$7M" ](90Y MLG_0O]MZ:8_%AP*NXH9*.6H5W%86,TX%F4!.@)+I1EU'_)AC7[7K]Z':1R!B M\95F=)*9EDA?M&.2ID(:G'1C)E?)/3,TN! MJ8MU2/7T*>&<5*RT9L*9#[@+G'87LF1YJ,=^<@64,T,%10^M4@G>R"Q\3BV. M+Y'=,I^P2;YA]TN>(8(\^>QPS ETIP+="P!%"Z+N2Q)19/#$ !\ 'HS@'""< M0-- &WJ11@#,*XQM^TS+<,7$L3L]YK!O;*[P3/30_QQ-L%_:>U- M8-CM_/HY22M\MDB2AUNS%H-DB]]9(A'Q0[=6:<)^PEH*]??R]L>G?6&7/<_[ M93KMQW'KV*BS%*I>#I#%P24>/'V2#SV%M0Y\OG52+X?WI>>6PL*I8R&?V7ML9(DH_CZ/P*)K:$WX"*SUCMZ8@VX*,UUX4G*^Z.HB:<,-1'U0H J7S+/4KD^)+VGN:Y6;JO ;XY' M>6-(I(JS=(@I)1?%[Q0@(%_&D(B)K)*?M]VU8$6RO:U=TO>"MH)8?3N$S2^H M"%2:6^=DIJ2?L,24PKYW 91&[;_S:1$_.V?RY-F'/H+R)62*\ :T*FAJ7Y:H MIHONHW4$54!CO)I'5X/DW2IR/='W)%[P[4X+:M=<*6:B3KH>(#B<;2.NJ11Y M,<]=*IE=4OA=D#BI1*?%$'Z"BR%!D$(=]V.>@/ ZR%W\F?16-^XT+LPUV1"Y MLI@C#N<]Z-\GCT7H&,"Q;4E JQFJ!5(P!\5&I:_3_Y\4I(Y#.(O5SM$@Q'708?>+L6'B=*"$@H:@ZL1L(M\:CD* M<5B<\PCUK^2SK\J:]C93P^.HS?]">'12?->3*BZ1/+U'!)655[SCZJ,@E&6T M0*"='4&JLE)\4.L7C/!TG$LD?$5;NT9?3--T-ULI!(QA>F_'JM/ARH-@1 M2?TX$D924C]=A(($TC3L9^RE0=*79+.R)1(DB=*BM>FU5Z#AT:I!I=JTMC\. M2<$,>43XR&V3P:LU![VTPPTL(E\.6CP6ZN W/D)@-/-2W(%E['IZK8'9-\%AZ@I(Q'OKN_NVB@3L/7@];%DAOB+O_8T1@2:X@>86526M]@L;5R-UGO8KP;&Q% M9"^ZFU9RDSIB<;/IBC5\G\"[BPV17$Q2'[AA M*\=OQCZRB@OPH;O']S)Y641/Q4-)R;$5DB0.>JLT:' V"#VW#9FE;?A))"2O M>?@#2'(6?V=%!@L/*]@^I(R]UKVOD072AYH0_<:Q0L.S^1\ M<1.#AFC?%U"Y&9C;_]#PMR);C,),DA$/XY#I*JWDU*^Y$2=DZI&B7_,H, X^ MW>]3G]*1S=V'7+<.F4E2!D1@SFH3VUA$X?M(W]PJM ]A-N(;(I U&T$?\$@W M]<[L.9$JWN\^&R)]581::4GTXD9AKX1H)/G%"978#[!2-=6*!EE>-(["K)/[ M<;.I"5S_3@RH-K;Q?9=C2^'D:FS@ G&";=?820.2KUB1'N;2JU8Y,NX+MY,* M(I(WJ+F7O+=CB)%;)E=970/LX5^Y17KD^FY7D$Y9N'J8KV'X[E M)WLA8FI.J4WAN4Y55/VXYI?Q&F-TL,8@WMX! E#T438F!"*0^FH$<2[>_IPF MYO(LD_BZ1+2]-P88U/>5L?X\N3CQZ<9)R@\KD&P/PD-77&:5/<=9FY/B^J3X ML=NT3@FK&2!:?KW9\:,S#YZ0<:F+=[D5N$>%^U1QNLL:S*4T+FW;NGUS;9#6 M&%LGEC$U,ZP:T4_%"UO-4)+:\:96C!J^\8O[H-.%Y'*XZ;C00X]:FJ';8[7[ MVL#=O9UA)@K'X TJTQCCI-^&)EG1Q.1&?-[-9<*P$\O> /U:VN!D MG3Y[]DQSA8]/980I6N ZY): U_9-E*C6X.M 12=>2][ OSJ) 7B"<9V6OO39^"?D9075DXD2A\7ZA M;4+6";H<0WL#QVF^^04 &$AAB?;- J50QYJK7.5Y'\X#@*&/GWWE_TU9ZLT< MFU![*(\4.Y#]Q9:_UI2HE!VY*K(.EU2_FJN]6\)W2&A$1>P<; M<5T(Z6./[WU6_$'=XO1IJAHU3Y);P?F4WL%:9Z8#_&D-B2V.#.R_ IOFAZ7_ MVH>AFSS0!H-S*X)1MVI1+#LUMK=#PIYZ-H;S:5P&1N:6O5.>YS5V&FAJRF*O ME1_()P;9YXF=[TN*?%:(_VCQN8=WI8G\#&!;DF]47+7"&'CA;>S??C#GGYXE M0>PF7A!$ANG=D*)]:$FFEDWM-LA0]1PQ8WUGV8(\OS(M$>0=_H!N43PG8T@# M5X3B#[;G?-\1?CE>%*2#D'"0_5*Q-\D(M[]_\[SX :G+?/Y0.D9)8BO;/.EU M3C?@*20G"\CGV>.O@JR>G7Z514A,N!A(9<"G"$[*X6GUPTW+'SSPW<9K;"F6 MZ--6E06J#>C(Z+GI#Y7^T"GRB%OEI>*C>*6/\'(MT]X+!-T9B M!E-9 %TS/ M,B1,$L&-R7W.-R-)=+\X["E:HQFP+O- A--B>7=52'QQ?MHLEU@EG Q">NDY>9H(Z!N- M^5UQ]-/S8IO P""Q,7 "1\!I1QF'F+>DNO*[77:_:B^=*$ T!)CP6"M/L MM7H8UZ:IL2%,LXC0@7R+=O=D#/Q/OQA BD4;&E"KWJZ>7;@/2NZ>Y36 M ?D??L.;;M X1XFQQ#B@8^WN[;);_Z[0K#AJLN\H73I)R1C2"^@!;WX!>Z,?B;^8"M M3\1>/#^_:A"L)I*6^@&I7E'I2M4)-D#IRF&AVVM"4[;X.]2S_20:F&N"7VAW MY,:UV:(@_N&8#(*V6+!MX'KQ0LLK(%G8P7=(,H'U3FUQ>X;1?:1B$MPDW@LV M=4&Q:6RN3P#6;$8IG?,.YRQU?,NL,0&5-GGYJK_'*WA>G%*2'#7VC_8V:&-V M KDI(=":4=I:@E*6HF3[XN\+]()VZ(\6[P9Y!69[8*[J!(]A)B9R?H%O5W_" ME1W^RF?%O4>N.WF3(PN B[WFW!SY5"7YDH4U/6G+7I1N3NU09_!M ^IN^X(9 M">?OV(QH$3AI?XRV_?#.07/=]=*FZ]ND.!.2U,K><<9KJSWJ>5E\4M[16(W9 MYFC=CJ&C.A-()9SP*_8+R/;D:^D%E,!+]FT#D:HW7*]#*BE"D[RIF\6SFJ4) M6\@3TZ^*6)VGP6^DD(,?7))F3F3%/]=E*_ L">T_J0 I^50#47U8$9?%W^+M M3CKZJ?:92/:B=@G.\S"3D.+,"2UX,-)I!=CO,C52I9$).;B1?94RB:<6_[LT MJ>IF=0ORNO+GQ9%H">T*]KM]EGO9HRB+%]9NAU9B,"VUSL=%%Y:A&AKON)?( M)VXE.^\.:<%.>"6%1[//I6/AY0$\,;@I(-DZ&G(2ZVQIAIYRH.M2RNT%/D9!APP;03D4,Y)H( MV.WRY9N&4QGKX&KS#D>7)E*-5CMLOE44EA'J^2_MWNO MNI-4GT[OSQR8$5U])KG)&&O=E=P,?81$X$8E_0&'=85:DA-Z1:-UJF.JOUI\7Q+ '3\JKOS@2+7-9SKNNV9/[M=NDD74Z.VM\)KXH M$JTM?Y$=#S8KB$=XC&=Z%&91T(ZU31>FDZ*%21'G'GFBC]5;;K'EWK4PG&:G M,(5W,41ES-M?$> FY;W;L6 D_':M^5S='3[^IZ+QG*S@#1^-HR29(1PG?V(S M;K0 NI?6==S4)KW[O(75^TJ3)$MJLN\AMJO0HY4OT]F%M. 2R!T)@+NIKBDN M4=Y1%\HL$UF^X0#2[AD+*R6KMC0;7U;6FD>0F73)XOJ]/P1?Q16 M\$+(T!V<1Q(3@9K(FAZAPL+LT<490XDD+9$09M_;1P:AE_+GU1'&P 5SH93VHWG/]/>4/CM-8VI8L MK?8SXQ@.Q 1UFP5!I_=!^.-B&"LQAS$';_/BN;OI_I))0\#9:=H0\*>!$>I7 MHM+EN*]ZGFX,'$9E:^L_O&4X%J;AC3C47 MA\$?6ET_82[QYL3*Z6$L>JH%LRVH8+]%>>4WUO)RXVWJV&);'+VZ?'OL&VS2 M0@A0>1=J17J0Q=$O5Y?O?CY.CC%)?077H4;BC^ CN!;YP93W\2L M1D=151",F7J,K'F\P-Y:D>5X+IX>\E9ONBX]-,[W'<883T M 2L/L;LX\[2)BPV/]_"+]7P_!8T6MU]F_AR/0(X#2%AI !2EJ%]^6;LHTV7V M;+]/7H?>A4 7*9_/X%&.>;>S>9V5;2GZI#G1NQ2CE(_JIMLQ]L2))]$8+1-P M2)A(_([]@]YZ-*4MVW^RI"9H,?$.=HW34IT$FA [ZFFLGC9FFN#]YCM GJ0; M0.2MH*5W6-,C2=HV\A ;(KGRWG'HZB'T^^AC?CW9+OA_Z6G_?5^11_A;US<5 M;PMX_N;B8J'?3OO/2$F<'^M.0C[OVE1U8]+-AZ^'ZF!S((]UK";?!,AS5.-I M=H<)VMNU"A^I'EJK5M*AARU7F#)(UT])D23-FO,Q-FDX" 6C+,GRJXNTPLV- MY.AL2$ZVE08G.4)A)MLDR7'M5(J9< N-!J"$VERDL>]5":6 8O=8^W!2!QB7 MHD4EE:,;%9)37,AIJ/G,0NG>WL9#)%)R_%%RQHDD(F&^.%!*,LO25!6?TN.*RPP+#O8]>LPES57DXB7I MMGB25IK4X&.,H:$;V1'*AONVK(U43[S[D"1 LOX)&VF0M>$LKR&WH MRBQ.O1IW.^$=%-]ES!;%NB7%[+[R@O*I-7E^Q&=-:9-B_:OG<]PI)Z/UFE\5/?ZE+T>\@K?6*&C#7.LU(;/NGG MT]$7=[TZK26(71+'\_>Q94V/-5U;))F*[VRSKL?M=,@%6-QP+\$+[F98%#^0 M1L"_+\=V;= =]PJ: 4_@/,EQC6#BBA3G'[9O9*T04 VIQ?=(&)PC;\GG64U/ MBA&@U(-+.@4# ,+00, LBX\"%T1.7F'7^J&ZUHFK>@O! JQA<4\&F 4S )+ MJJ2 \WI/Y*1%Q,>O4_F&D(5V1>>Z4MJ65-G&V%;J.13=;@V?#F:]$WTY"T6Z M/8,6K;QRH5#(/RFY=(D)9IU.B]GZT<;IVVM.75F\,X45Q@?YHD^XL) M\%N*)L;>UX[,$.O%+L/CI'B];XEQ?YA0OSCT#,ZQ1^GO!$%I#OREUY?IP7 ? M;1VY7^=(.B%#_Q,]V^G'JLK M=:#HG^3TFN;Y_P7^;DR0/SIP?9E$T&ZQ@SWOX7!W-W%X=.=:--Q]>S0F+1J? M)2T:M]7:[MFD<7"NU+MP%++O_=:2BEJ#PTM5XL%S"9L64 XMTGI ]O <97_. MW\$-*J%3YJ3X;8.>0KE@ :[7BI9DK5=XX)#K6J^4T$:WV#J7*N#Z[LM1]%!P M=C!CT@!G4>%0?NEE()>FT)UMR=G[^:4@B;),MEZEAU%.0?-83:X*^%?=N.(Q MK=/+$-@XB[)?K[%7<@CW&3S7]HJW@OE$AN]5',--,5 M I$FPZ/WZ#$P3@LY[J^%-@",3&@WI)=,9,65K_C#Y'#4V<)"-J^)--2-X3/WT8&KL_9=+DH@RN$$C@X$^UF"DP(QF'7T38\B7S\952ZR&1% V(QDW8OO&1I)YNP$HE/X H M89]H;GTTB7%(L;MPHA',AIN1,?]LO+H'13:Y*^D6NL]B>-!6GN;8$";YK9M< MA>U:G HAH,R,+8+$"YIEHR+O+=GJE,A*E &T:9A]&MBA"%Q"OUBOI_71@94\ M-_TK=5:CK,O50M-(?*XW_Z(:QTDM==@LLE9Q;#MC BYM>H@I;S(B/XENI.KDVJ<]^W)-O"EB@N)Y@T3F>B,OIZ^F=_3XBU6DMVN*+NKG?8BX MV9M"D.2Z""F]GN2C,AAT2U2:E&4/O;5\%#^%;XUF^_0X9=[&B0,4ZN68G0DS M.8>+3[^E_XV'MX8E!R#[RR,BMM>R?LDJ&N##9USP6(B;ZD%OX$(5S8L;YIX9 MB)M?Q=#4(L\K?T"5[O6MV^"V)&3A&-Q?C\4R%X^Q_5/>-F><@F,UIWVP(7IZ MWXX_Y)HOV[J4E]I1F56;N'18\-TRTO:$V-=0U;G1KW<&D8SRD*>,CX$/?< M1%LH]G\KYRF079$:HIS2+/$*7_Z@];#43\-IF A1K3M<.2R:NKV:)52/\>GZ M5"6KR&$DTY0U5.^0[=#1VA@+D:XAUD0X:E("]K!>E-L+#<3BC9\,-CD)LU=? M:F)&;INX.W)($E ^Y)#C.0:NK_[ER;/@]>'[OSR-7B!-<;L'N?"=IES'"KL] M$@P 'AE'/?4"JD[YY$.59(TG3&$>Y+G[8 M3Q7(D%_8J: &/S-HL 2A12(^L5-:W2X5B%L"=:")%!!V7"5A@]//@MR5\*/D8FC2%VN^_MI)'4?NB [?AANVS^5BZ?BX7,_]AD\)@N._ MHE=L/0;?G/C26WJ<<#]/NJHY6D'S!!N'?\V_\! M4$L#!!0 ( ,F"6%;+7P%,\P( - & 9 >&PO=V]R:W-H965TV(64;9?M >XN=WX8;Z1ZU 6 (2\E%WH2%,94HS#4:0$E MU6U9@<"37*J2&ERJ=:@K!31SH)*'213UPY(R$4S';F^IIF-9&\X$+!71=5E2 M]3H'+C>3( YV&W=L71B[$4['%5W#/9@OU5+A*FQ8,E:"T$P*HB"?!+-X-.]: M?^?PE<%&[]G$5K*2\M$N;K))$-F$@$-J+ /%US,L@'-+A&D\;3F#)J0%[ML[ M]H^N=JQE134L)/_&,E-,@F% ,LAIS7*4\0K2-NG$+9)$27*$K]-4UG%\G:.5D>^SE38*F__C4)&>HGN8PEZ( MD:YH"I, )UZ#>H9@>GH2]Z/+(PEVFP2[Q]B/?/K_P9&' L@MJ/21I* ,RUE* M#1"9$R92J2JIJ!_[VA12L9^@2;_5BZ)6Y']$%Q1KLH!4EB5ZXJPA&149=N" M%WZ!')2"S#NVR8)6S%!.[AUNMKO7!QD-"H:N\=!O84.$INY>:G*VC<$$#CCG M=N^<,$VH)KGDJ!IZY&;"/F+[B,C"\S_L6/^UGE-.10KD,Q6U33$FG59O,"!Q M*^I>[-F#-[LS),M:I07>>%?^'Q6')S% MT=[B8L\>G#>IXG6 <@4*K\1>4A?O)FX#O(6K%,->,/YJA=,JH)<_.SMP^-=[BG,B6HM=-2C>A:&"\XS6XCUS.O4F_N7NMO MJ5HS;#V''*%1>] +B/+ZZ1=&5DZS5M*@ CJSP+\<4-8!SW,IS6YA S1_8M-? M4$L#!!0 ( ,F"6%:FF6;]L0D -49 9 >&PO=V]R:W-H965TWU@+;!YK;%X7 ? M:(FVU95%EZ+LN'_]O1E2MAS;N=[U/FS6ELCAS)O'-T/Z=J/-EWJAE!4OR[*J M[WH+:U?O;F[J;*&6L@[U2E5X,]-F*2V^FOE-O3)*YCQI6=[$_?[X9BF+JG=_ MR\^>S/VM;FQ95.K)B+I9+J79/JI2;^YZ4:]]\*F8+RP]N+F_7E;V\^K) MX-O-SDI>+%55%[H21LWN>@_1N\VA.Y MFLFFM)_TYJ_*QS,B>YDN:_XK-F[L<- 365-;O?23X<&RJ-S_\L7CT)F0]L], MB/V$F/UV"[&7WTHK[V^-W@A#HV&-/G"H/!O.%14EY=D:O"TPS]X_+Z11UX^( M*Q?O]1*YKB7#]53*JKZ]L5B#1MYDWMZCLQ>?L1?%X@==V44M/E2YR@\-W,"Y MG8=QZ^%C_*;%;U46BD$4B+@?QV_8&^PB'K"]P1^(^$EN03 K'HR1U5SQYW\^ M3&MKP)9_G8K>V1Z>MDT[Z%V]DIFZZV&+U,JL5>_^ZZ^BT6C1(-U&;!9%MA"V,W4.9&V-_0M0 MB\QB,CB=?<'X H\O/SU_KJ^$K'*Q4H8UILJ46ZL=\L1#K!:9,A8R _I7TB>K M5&M5"K5;KO0??U5&D?)-Q[YA2X!,")\L );0BVG@+O=%H%( M$ZA#65(^O+=0!I8^ +3UZS1VH4WQ.U8"TF+6V,:H-D$N?V>7/YOX-AZYD28' MT+!8*VM+#-X4%EQ J:@;L_5NA>)#FP('7HNW-/L* M@P-3:$@7;%X'_K7SBAIUC&* /N3\"J[*G)IE7 D\,^/>,)+K+#+ M52B>3H:_61 /:3**9K$DDU7#3(:;/L:BKALF3UG2OB2<"VAS9<^MVQ4..8= M(*42?JAK$%'HZ:]N%PA0GA_,]L_J4W Q">#_*US\ZHQ#RZO_ A#T$)X3P)?0 M":!!ZR)754[+9"6"ST7>& 3+UBB;]-GQCK%N".E6:.K#C65=A,!Q)#JU?8N.UZ$&T]KUC"#E;\3W0* M'=\=] ">BM&T<1I!TTQJ]<'[^)14O IE9.Y!]+F7VY?LY0%(BB3LE)7"BJI<[1 M!Y'OK6*U,G*H;7Z:J_FN6P(CMVXP]([M! <-'#LPU2AZ&("."?0M204E1Y$U MQM"^]B68GU--J_U^/':!0/9%WT5Z&)B+Q*C?FH*V8@WA +M1Z7!L]*V"8P/Y MO!.G5DK%ME E-I\IZB_7,]HP!!6&N0@I4I8/_;TDU^'GAUQC05 MA9WR= !920M3%6O';L;*'2^\Q3,^'5@D-_@AU+=3=V'T=V7T=:99Y#^'SS#9 M-E8_:JOJMBWA> >=26^2NP$_"A4-&/MRSTNY$^;OAS9)YRE@&(YY>O$3/@5 MJ$'%P7P7;&<8[2"H$F(Y@]V2#HS0+ZZ4 FT?RKW'[-@\&=%3.@=0&VOT\H!Z M9RHQ.K5\W]N_2G!9S&A'\X&-U,?NE(C1HCZ2JV';J;:MVXGJJ!M;6\ "S(*3 MH7*9TY /R553O2B3%1"4J5K(=:&-3,*T[QR8A)/!V?7= MUF0)[31@CHHL*#C:Z T3X?N$8G=B22@TDT-)+$ -HVL/6Y ZD?7)?W2 M9GCWX6$^-VI.,?ZTI[+XFZP:":7QITT1I<$HB<6%&(_".!'?>0;$P2 >"V8; MXG2,S<7E.!A$R948]\,DH39XI@H:?9F.XRN1 .GH8+&CPZV(!D$23;!E@;)H.]C M'2)#-&L .P_^F@&[NINGE;ND8*J>R!2?MNBX7_A6BGM#7GI*-Z1_F,6N.C[[O5 MCB@7='0](#C41!%-"8-T>U=1DET14N,THYG)X@:!TF??$NC$-C' 27] M@HUTU.L-HD=!/"*:II">,6)+)R,W']OS]/61Y8.YJQ8 H.U3J?YU3PA-U>E\ MSW3&NZ9[G^H#:@2'F6\O!NC>\,0ISQ]=CFJ1/Q7#P0BZZ4]%'_F(/^>#)@JZ M-I8+\9OG&G=+T6 ;ESJ3KBAS*'5XZLKVIG/5OE0XNM(/"G39AG;!W;KOGNY^ MLWAP5_7[X>X'CQ]P\L7>%:6:82K4<=1#C\@_(K@O5J_XXA[-M]5+_KA0:&0, M#<#[F4;GY[_0 KM?G6U7MY7]>=F*V4KONZ*LGEUL6W;_8OKZV:YE;NLF5=[6>+.NJIW68NO M]>:ZV='_@UE_>-]5D0)7=5]9F^?%B]NE@00K*0RY8@9'C[(M_*HB! 0.,W#?.B MFY(&VI\-]/=,.VBYRQKYMBK^,U^UVU<7R858R75V*-J/U?W?I*8G)'C+JFCX M5=RK9X/X0BP/35OM]&!@L,M+]9Y]U7RP!B2+$P,\/WK6\W?K%R)G]JMK,5MU;2U;/-:@O>M M>"-+N&_4?"]$_!=3_Q0E>VV$>_*E5P- 5P#V0YC MSV#\QCL+\7NYG O?=82W\+PS\/R. S[#\T_ ^SBBM1'_?7,')D!C_F>*8@4O MF(9'J^A%L\^6\M4%EDDCZR_RXO5?_^)&B^_.8!MTV ;GH/\)\OHSX8N?MU*\ MK7;[K'P0VZRA]0" *W&GG]IK<'M^>EE]D75>;H0L\DU^5T@A=_NB>I"R$7DI M,)WX9?YISI/C^U+6+\58["T5>7Q2,0.7B\.*Q&X$2C ;L'=?U2V4!;3OL[HETE9Y MLX2YR,L#KL/SU"SNY@I#,&E#3^,IXM2Z*N!0&"IX6I4DDQ?"J&^WDEF0'P:: M.3K)ZSZ?"D5\RZ%'WMX#18^?8X6>/42_NPE M]#F-Z6YB7D)/(2P;S?T@C#$X$ '0<(-0N)XO7#\2 ?Y"@9OOON[AY( P"#K4 M6#!*+\#81H*D61SZ5_0:TFL2 N+J@%B&VC# ME/M@32O(%$W@"=$0$:$)2TA53#/#\5'@T$ M]T4BW+ ;;OE-=WL\_)YM5Z3QOU4;[*R*MFT'S]+2Z,^+*'KM/XSO@-M:J04/U:P ME=&5,\!JNR*]P5T#_!UDO/\_%3=%4S@G&-'*"Y"\8+B$.6SB,L2V?(<55 M[U,'_@.SER1Z1/68"G>+PVY/<3KL\H,"!-K8E-KCV&KGY$)Y:A! R+=U?G?0 M[&"A6NATF*P4'6PV->==Y2%[:TY:\ 27I 34;K-23V>9I0Z8R&IIE)LEKYP M^:9J)Z^,NCL\8:](;@A-ZM13?EW*O;&(AI$P7@="EH0\M1+."PC0M_ERR^C9 MBOEQ(&[E+W/E^.07HF<#^>-.G4-@FM&/SB[8:INY13[0W.DUA1' Y@-S2:SK M:B>^MSWT3YV'=M@P@2\_9U]UQ'2C.7/3*I7(*+#"3#]6):L)'#A-97P=$V@A M=,(@B)G,B&&-*"L.'NX05%[-Q4]W6'$*%Y[]_8'7X:2E/KP>8ID0_TE*L8SOBW?K-4P?KWPL-A:)J"GZ->(Y]K2S)*#X M(HK=J]&]CJ/[+%\!.9=\NGX-%_3J4TR1+G3T8_OZ6-(@[V;X9:?2Q MDJ2I"D6&"/LI3(38.2;SG23D=Q5K.A['L%Y \O-3C@P7N/*M8O]VG8L9 M@2@F#7'5_RU+!KJS4OIS/ ;!^^C:*";M TJ.I/N U#L;\(K0CG7_Q5KLNLE3 MU1BB=U/6X@E].U;?) QLS8L=9"L#Q7/<,.[T[OW \@YAS>)H<:5B9X_>8Y?T M-?(HSH8>J'L>92D?^Y0F@R565-RHY84TC/#B&1>A,H<^+R1#7O_I9KFLR1OV MX2*<;DTNML@SC@%STF&*WF<1)T:LC*1$B?I74Y-CU /_;@^,R93.DIB2*-_E M)(X3.MA]7@!:!T^N'N1KY/R*!ZJB4CG4]G:<<<-AL&/HT3&]*A]3SCNLMYQUZ4_TW;<# MD!QE9I0W_4/-.,%9RA\0@S;-L3.X/3>*EI>;1-H[L#V'HXY3?@]AO4\[&7@1 M($J1 6PZ3#]9:R?VIW$O'U.,D^C?G!_'[BUQE?M)W4C')A$3$$3>4PE(X8: M/MP-FVN]TM\AF.5UIF+PWPY(\E@A#@BM,['N86]S1+OU/8_;JCC(0CG7SH4*:?B*1=BM81P MS;*2@JYS1 MDA!E\1EY7X0P=5W=5;52V ?[(44KE6PS->_A#M8$)*LR,]L8&#K*U4PE\RPC M^CK6+Q/:TJ'9'/:ZF IT *%5^):504A7#!Y4DFU@FRR'=:J"5M[S*^N,NKR2 M*JT$Y$-#VD \I?==M8+V.9W_P /+K-F*-50%&@APJZJH-H:[AO^M7&[+_#<" MSSK9Y/# :R@$/-#$>G!(FO>R('7!)4I156A#O%6KD%AHL.SJE9;JZR7=#*;Z MQV&U,2DQ%#M7[N!1[W<91R'6LN6'TL W%X[=$/FT/>SY5X*.*R)X9D2NZW-7 M\5,9Y77:GH"5S1)IFLFLEX-TC6+EMI\T^Y%?&ZH<>JT;\PEI__JXQ M0\9V&3']>/,K1V8_5RT$\+2G^OB PPCC:-5VVUM:8:1WO-1(L<$91N12!.ED M< KGJ>K)%#W[)Q[Q$HX&4MIY,!K(P1 %U\"RVD/8QHS3M.PP/=<=!_T($I#Z M.1'B><^/QKFM$R/ #YR%'XIW.UEOV)8<0SZ5?L2(5NC_U/T4"0?]?Y3@I*0P M3IY\UJ7=%'],P:GW=X3< R)"Q.@*RS%K7"<-QS1W,_)="F%.;QVHN^_SKURI MXK*;->._T09JR=(A+<@VLEP^V(4I>RY_G'(.KWI.$B\F,*"K;ZMZSP[N!/3 M3R:@VU>IG#2F4UW] ;YJ ^P5%;0PG]]ER\\4>O?$=D.\,93^DN>/[_HZH;+- MZ?>RQF(AVVR1L1B+?^K:J??IO#>P/O5X]FJ1Z&I!9Z@L@T@1K<<1KN\$G&X& M_-GG<-U4>7PDP_1,X"2\N.ES",;&?05HF'X\W8IPDIT,C -G##%=2S@/7@SO MLG7!Q6^Q'#YR>FAZV*_D=$$40ZXAEF3 5:I.(AY=28/@">KOQC$;GY[;KK^@ MJ2(8I6!!AL?KE=*-"7( ,W7:%(5C[0M3$$S&8VR(*$U:I"=63R)2BZB4]_A2 MD0S0<9-$J]7:M@$#&A:KPE. M6)?2L0'&I;'Y^E BZ$ D)U4=/:.*YM[J?32;6 X>.?[5 2)OHM#6G KB%!(S!$Y7M#LHFBVG:K7JX>GL&26PDK:) MD+,AJUX6&(U85.VP'46B76ZOHDZ*R MZH%6ECG(_ C0OR[M5/)5$KRCGM2^12PSK:E&:%:9M)>1(_J&)O"Q;-:RYD> M]S75$0XM5RXISQIE7[8^6V)7-#Z2"XN9%JWJ\'AB)O3"RBAZ(\+^05D$E7:< MN361A[S)"G[6WC6:RBLB_3]U+^;_<]N++X!+D;$*8J5H#B)9!V.WLAAMK([V M*JA&[H]W*V9400^O)H%71=>;8-KQ)@SC."1 6B)N#UC46:-WOQN8H$;U$XP0 MT 7[4P@;[@[W-:9X&.C_T[P_%P=.25%9ZB+KS)TISAHQU@D5\ M=>8'4]S#Q9,RF/FIM:/FI[J9; 2$+OYLK6J@:@RJU3!&(=@X_,"E:=$I]SBY M"*+'F?[$*LBCC4K_ATHCYS(8[P0K$Y.[N*>$P=V8?OIM-9")Y!2QHX=\S1OG MWSY4)%AXOZ?R$=#?J;O(EO#WI*H'[;D_.<%]0L)U>J:S]\9)AKDWD6PL3M=4 MZ)XW$41W]W'OCR<;>!E#MJYY\42E ]<>23PF$DC[FIM.E"=P[=NJ)Q/^Z]P] MY?D_/%8Y&0^=N'3J_6S]@RVF'PU+E7[H=STL/N_\!=&P2A&H,B=7#OX_K_AC M><7QJ0ZR*=#?9BM7%C_%YH"PF0Z0Z*T]TV[_:/NLVC6FSN!:TN(PB%',7"T5 M?68#09K>=CQ.LV')(E!7:VIM(HWFL$;%0'Z4L]=ZUW"L!J'T,@IXWGTV^4&]D:Q-/VVWPD'EURA\_C15';=B- M80$(]L)G1$VP>$8*PN",FW#@R?BFIVX.C\;T3_D:1,A/<47IN;:#UKIP&+W# MGAY-^,FE\:_5<2%"L:,COJ-6*GM^SZ?@R+/E37=F V1V/;2]2( N;5)I[@U2 MV(F.2S5OIPQ965*@25NKJZRF?/%+ORY,1JI!:]EU.'<]MW8R"WXZICVF$7>5 M:?E59%EZ:=H\5Z2)#:=KPZ8L+&^=/>BPBLR#2B+[#>Q1O0=][[K6UY7C4 M#=/3,ER&/:PO?!IJN#>';*9CC %HMR41/41<(3:].ZP/A;Y5RPTU9B@1W!3( MK^G(4S;(56&@EAA%'NG8SM1&T925.U)B,FB2BA&J%P>KC=0&QHZD3DM>G["R M>B;H6!["U%Q:F]^=*##$[&QF)= YLE+S_J#,VT$SZO!;WYON,WC; MW)HSW= M2R]>=#O"9 7''4?.\1 W' XY(W7EXH]F'(Y^RKFOCN[N])[IZ^_N="/,G>,L M8% &Z)HLI_-+%40P!ZGUCKRV%Y-?3P*Z&HC(#SA.3B+Z'HH(+/$B3R0Q?8]$ M%$?)T>=GLE M_*D]] ESI*M=?)[ -!!@X/K -LT<\C"'$>9=+[S5ZU MIVYZZN*[YH-2?4^YZM];Y6ODIPA7:;7+]I["$,LVKJC=HT_$F^.V;:NG@HU< MWP%K5;RRKIW0XL_\!&*#UBYS-(+:E)IM5:RT,JEC7DPZ.'SZ: ?9(65 \8&L M"I0:\%0M434:%_F:S4%WG$8W"W2' @UB^@#,6K?Q9:^OZ4HX+$SQGQ\HK9"D[EG#A;52C%)6I;#;BC->$=N5D0\S>7MPMC;N;' M \'5<'N.-PK=-!6W@U-[,^+TE2[RGIGT5 A/A^/H/SJ=3)[$U^/"!X7K,U_U MZD[A>_:4H'V49Z [EWR \)*/$%[R(<)+.D9XR0<)+_DHX:4Z3-BAQP<*A]PQ M;'G2E-]T]O'3T>&YP>$@+X12P*#1^4XUV@V'YQ%!$N= 9_0\&+>K>7=EH7: M5PF8H(6K"/,#U0D=VMW!-Y:YLR-].OV%0(5C%8J!CDI'W1@*@G1?\5W^\_5R!].F+^O2IS._M M_FKASQ<+\4QX\YC>_'E ;^X\5&^N]:T_TSM,=8Y,>:0@Z;=X[BNX&GQ";X&: MY5-64)%W4U?W=(22H ;S2#V@WSR%6ZK>$NNM/[TQW!4*%3V!FC!00S61':T, M8>H,P( UH:+[F$/IF$-/H"12@R<(.DT)LVY(D&_X:1-$@7J7('Q;@N?HU,&F MFW)<2M(Y@*C*T( EX_JJ2B YZ\Q."_Z6F*G+]DP1:5.W^>_(2C@ M$ZEV)KB2=^V@MU*52:I#L3)[8[IQE8.;;KNM@0N7ID:1/=BA4C.PEM,QE(X^ MZ& 8(:$[G/LPYDCOU[^?Z_1+ ZK6T@S#BN$,*KR'3R^5(.QEUH4DVBU^,ZVU MU/#Y5!*;L<;>Y62CRC-:%O4<+[H:A@)D:J:<OH)_=S!@!U=1>(X[1_R*5O2Z4R]&<5*8:7X.H.O&KM,TC7! MRF/I]%- .YAPXD%73."=9"O#Y,5I.N.[-!6K@?.\/7QT*U4Y@!(H1Q\]/JT) M?U;QZ9ZVXJ"A,$RID^#4$>YIDY,Z\8L)59@06Y).5F7P?8I4;1]OU/ MRU)'#GO:^_[ML4DI#:/6=_FU5?NW\3QA#QG@]2.W,E16)>88!I_E46"XXKBD MT@'\0
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

2$@:RO M6!H'H;#H:ZP

2$OZR3R#.@2^LRSCBMFF44I4@,<]Y) CNEQ\WGW948,2-/ M.P4]/:J[XG BBB+=VX$]6C!A7#L&N79+XW@3%F^-E2.8G/"7=0QYSG-I3<:Y MI6443DP,:L)QK MK!S!Y(2_K(?( Y\+ZW85!Y9"$S%R4L.:KFEDZ9JPJ!V#43N%1BU+MRR0B )+ M]Z9A#Q5,L->.<:_=RCC@A 5@8^4()B?\95U&G@1=6KF)@).+ DZ)47X>!1)- M$-6.,:J= JF6=:M%$5&$Z=XE[,F!"?_:,0"V6QG'FK ,;*P

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

2$OZQ+R?.D2RLXSCXMY#-[J4$N1'MH M$\ZU9YQKKW"NKQ>P\A"0(EQ^26&/(TQ(VIZ1M+VW34EY+#<;*T$OZTKR MY.C2DM5?^31A#"F3JETVPUE[!6=]O5[KLE(H4/7%0Z@

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

2$E:SK6!CGJ; D;ZP

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

2$O:Q#\;9AJ( ECF/E""8G_&4M29ZY75JU M<U)WD,=VD5ZR^CFC"&E$E5+YMU#0H;'-'XHDC?O6_8@PP3#GE@'/(0C.-3 M6/ X5HY@&(8\!..X%99!CI4CF)SPES4J>0IW:2%/B%OI8TB95/6R6?^@H,&O M%_+$IX&4+RB_KK!G&B80\L @Y"$8YZRPX'&L','DA+^L-SP!E2.8G+"4-1K!."Z%I8ACY0@F-_:7 M4<1#GJ-=6(3-A+B4/H;Z,6URC%@+V]$KQ&Y9?G_[^N?T*K#'"5 Y@LD)&UF' MT!@GGK"X;ZP

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Ñ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end XML 161 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 162 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 163 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1424 692 1 false 247 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.merck.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 0000003 - Statement - Consolidated Statement of Income Sheet http://www.merck.com/role/ConsolidatedStatementofIncome Consolidated Statement of Income Statements 3 false false R4.htm 0000004 - Statement - Consolidated Statement of Comprehensive Income Sheet http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome Consolidated Statement of Comprehensive Income Statements 4 false false R5.htm 0000005 - Statement - Consolidated Balance Sheet Sheet http://www.merck.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheet Statements 5 false false R6.htm 0000006 - Statement - Consolidated Balance Sheet (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Consolidated Statement of Equity Sheet http://www.merck.com/role/ConsolidatedStatementofEquity Consolidated Statement of Equity Statements 7 false false R8.htm 0000008 - Statement - Consolidated Statement of Equity (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical Consolidated Statement of Equity (Parenthetical) Statements 8 false false R9.htm 0000009 - Statement - Consolidated Statement of Cash Flows Sheet http://www.merck.com/role/ConsolidatedStatementofCashFlows Consolidated Statement of Cash Flows Statements 9 false false R10.htm 0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical) Sheet http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical Consolidated Statement of Cash Flows (Parenthetical) Statements 10 false false R11.htm 0000011 - Disclosure - Nature of Operations Sheet http://www.merck.com/role/NatureofOperations Nature of Operations Notes 11 false false R12.htm 0000012 - Disclosure - Summary of Accounting Policies Sheet http://www.merck.com/role/SummaryofAccountingPolicies Summary of Accounting Policies Notes 12 false false R13.htm 0000013 - Disclosure - Spin-Off of Organon & Co. Sheet http://www.merck.com/role/SpinOffofOrganonCo Spin-Off of Organon & Co. Notes 13 false false R14.htm 0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements Acquisitions, Research Collaborations and Licensing Agreements Notes 14 false false R15.htm 0000015 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 15 false false R16.htm 0000016 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 16 false false R17.htm 0000017 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 17 false false R18.htm 0000018 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 18 false false R19.htm 0000019 - Disclosure - Goodwill and Other Intangibles Sheet http://www.merck.com/role/GoodwillandOtherIntangibles Goodwill and Other Intangibles Notes 19 false false R20.htm 0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeases Loans Payable, Long-Term Debt and Leases Notes 20 false false R21.htm 0000021 - Disclosure - Contingencies and Environmental Liabilities Sheet http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities Contingencies and Environmental Liabilities Notes 21 false false R22.htm 0000022 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 22 false false R23.htm 0000023 - Disclosure - Share-Based Compensation Plans Sheet http://www.merck.com/role/ShareBasedCompensationPlans Share-Based Compensation Plans Notes 23 false false R24.htm 0000024 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 24 false false R25.htm 0000025 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 25 false false R26.htm 0000026 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesonIncome Taxes on Income Notes 26 false false R27.htm 0000027 - Disclosure - Earnings per Share Sheet http://www.merck.com/role/EarningsperShare Earnings per Share Notes 27 false false R28.htm 0000028 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 28 false false R29.htm 0000029 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 29 false false R30.htm 0000030 - Disclosure - Summary of Accounting Policies (Policies) Sheet http://www.merck.com/role/SummaryofAccountingPoliciesPolicies Summary of Accounting Policies (Policies) Policies http://www.merck.com/role/SummaryofAccountingPolicies 30 false false R31.htm 0000031 - Disclosure - Spin-Off of Organon & Co. (Tables) Sheet http://www.merck.com/role/SpinOffofOrganonCoTables Spin-Off of Organon & Co. (Tables) Tables http://www.merck.com/role/SpinOffofOrganonCo 31 false false R32.htm 0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables Acquisitions, Research Collaborations and Licensing Agreements (Tables) Tables http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements 32 false false R33.htm 0000033 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 33 false false R34.htm 0000034 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 34 false false R35.htm 0000035 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 35 false false R36.htm 0000036 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 36 false false R37.htm 0000037 - Disclosure - Goodwill and Other Intangibles (Tables) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesTables Goodwill and Other Intangibles (Tables) Tables http://www.merck.com/role/GoodwillandOtherIntangibles 37 false false R38.htm 0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables Loans Payable, Long-Term Debt and Leases (Tables) Tables http://www.merck.com/role/LoansPayableLongTermDebtandLeases 38 false false R39.htm 0000039 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 39 false false R40.htm 0000040 - Disclosure - Share-Based Compensation Plans (Tables) Sheet http://www.merck.com/role/ShareBasedCompensationPlansTables Share-Based Compensation Plans (Tables) Tables http://www.merck.com/role/ShareBasedCompensationPlans 40 false false R41.htm 0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 41 false false R42.htm 0000042 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIncomeExpenseNet 42 false false R43.htm 0000043 - Disclosure - Taxes on Income (Tables) Sheet http://www.merck.com/role/TaxesonIncomeTables Taxes on Income (Tables) Tables http://www.merck.com/role/TaxesonIncome 43 false false R44.htm 0000044 - Disclosure - Earnings per Share (Tables) Sheet http://www.merck.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.merck.com/role/EarningsperShare 44 false false R45.htm 0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 45 false false R46.htm 0000046 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 46 false false R47.htm 0000047 - Disclosure - Nature of Operations (Details) Sheet http://www.merck.com/role/NatureofOperationsDetails Nature of Operations (Details) Details http://www.merck.com/role/NatureofOperations 47 false false R48.htm 0000048 - Disclosure - Summary of Accounting Policies (Details) Sheet http://www.merck.com/role/SummaryofAccountingPoliciesDetails Summary of Accounting Policies (Details) Details http://www.merck.com/role/SummaryofAccountingPoliciesPolicies 48 false false R49.htm 0000049 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details) Sheet http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails Spin-Off of Organon & Co. - Narrative (Details) Details 49 false false R50.htm 0000050 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) Sheet http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) Details 50 false false R51.htm 0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details) Details http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables 51 false false R52.htm 0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 52 false false R53.htm 0000053 - Disclosure - Collaborative Arrangements - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements - Narrative (Details) Details 53 false false R54.htm 0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails Collaborative Arrangements - Financial Information (Details) Details 54 false false R55.htm 0000055 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 56 false false R57.htm 0000057 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 57 false false R58.htm 0000058 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 58 false false R59.htm 0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 59 false false R60.htm 0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails Financial Instruments - Fair Value of Hedges (Details) Details 60 false false R61.htm 0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details) Details 61 false false R62.htm 0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 62 false false R63.htm 0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details) Details 63 false false R64.htm 0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 64 false false R65.htm 0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails Financial Instruments - Information on Debt and Equity Securities (Details) Details 65 false false R66.htm 0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 66 false false R67.htm 0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 67 false false R68.htm 0000068 - Disclosure - Inventories - Inventories (Details) Sheet http://www.merck.com/role/InventoriesInventoriesDetails Inventories - Inventories (Details) Details 68 false false R69.htm 0000069 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 69 false false R70.htm 0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails Goodwill and Other Intangibles - Goodwill Activity by Segment (Details) Details 70 false false R71.htm 0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails Goodwill and Other Intangibles - Narrative (Details) Details 71 false false R72.htm 0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details) Sheet http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails Goodwill and Other Intangibles - Other Intangibles (Details) Details 72 false false R73.htm 0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails Loans Payable, Long-Term Debt and Leases - Narrative (Details) Details 73 false false R74.htm 0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details) Details 74 false false R75.htm 0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details) Details 75 false false R76.htm 0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) Sheet http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details) Details 76 false false R77.htm 0000077 - Disclosure - Contingencies and Environmental Liabilities (Details) Sheet http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails Contingencies and Environmental Liabilities (Details) Details http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities 77 false false R78.htm 0000078 - Disclosure - Equity - Narrative (Details) Sheet http://www.merck.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 78 false false R79.htm 0000079 - Disclosure - Equity - Shareholders' Equity (Details) Sheet http://www.merck.com/role/EquityShareholdersEquityDetails Equity - Shareholders' Equity (Details) Details 79 false false R80.htm 0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails Share-Based Compensation Plans - Narrative (Details) Details 80 false false R81.htm 0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details) Details 81 false false R82.htm 0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details) Details 82 false false R83.htm 0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details) Details 83 false false R84.htm 0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details) Details 84 false false R85.htm 0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans - Narrative (Details) Details 85 false false R86.htm 0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details) Details 86 false false R87.htm 0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details) Details 87 false false R88.htm 0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details) Details 88 false false R89.htm 0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details) Details 89 false false R90.htm 0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details) Details 90 false false R91.htm 0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details) Details 91 false false R92.htm 0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details) Details 92 false false R93.htm 0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details) Details 93 false false R94.htm 0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details) Details 94 false false R95.htm 0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details) Details 95 false false R96.htm 0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 96 false false R97.htm 0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 97 false false R98.htm 0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) Sheet http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details) Details 98 false false R99.htm 0000099 - Disclosure - Taxes on Income - Narrative (Details) Sheet http://www.merck.com/role/TaxesonIncomeNarrativeDetails Taxes on Income - Narrative (Details) Details 99 false false R100.htm 0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details) Sheet http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails Taxes on Income - Income Before Taxes (Details) Details 100 false false R101.htm 0000101 - Disclosure - Taxes on Income - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails Taxes on Income - Taxes on Income (Details) Details 101 false false R102.htm 0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details) Sheet http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails Taxes on Income - Deferred Income Taxes (Details) Details 102 false false R103.htm 0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details) Sheet http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails Taxes on Income - Income Tax Authority (Details) Details 103 false false R104.htm 0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details) Sheet http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails Taxes on Income - Unrecognized Tax Benefits (Details) Details 104 false false R105.htm 0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails Earnings Per Share - Calculations of Earnings Per Share (Details) Details 105 false false R106.htm 0000106 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.merck.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 106 false false R107.htm 0000107 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 107 false false R108.htm 0000108 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 108 false false R109.htm 0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails Segment Reporting - Sales of Company's Products (Details) Details 109 false false R110.htm 0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails Segment Reporting - Consolidated Revenues by Geographic Area (Details) Details 110 false false R111.htm 0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details) Details 111 false false R112.htm 0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) Sheet http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details) Details 112 false false R113.htm 0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details) Details 113 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: mrk:RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - mrk-20221231.htm 4 mrk-20221231.htm ex23-consentofindependentr.htm ex241-powerofattorney11.htm ex242-certificationofboard.htm ex311-rule13ax14a15dx14ace.htm ex312-rule13ax14a15dx14ace.htm ex321-section1350certifica.htm ex322-section1350certifica.htm exhibit1013-plansepmrk2019.htm exhibit1023-2019annualceon.htm exhibit1024-2019annualrsut.htm exhibit1025-2020annualnqso.htm exhibit1026-2020annualceon.htm exhibit1027-2020annualrsut.htm exhibit1028-2020psutermsan.htm exhibit1029-2020annualceop.htm exhibit1030-2021annualceon.htm exhibit1031-2021annualpsut.htm exhibit1032-2021annualceop.htm exhibit1033-2021specialret.htm exhibit1034restrictedstock.htm exhibit1035-2022annualrsut.htm exhibit1036-2022annualpsut.htm exhibit1037-mrkchirfiguind.htm exhibit107-2017annualnqsot.htm exhibit108-2019annualnqsot.htm exhibit21-clean2x22x23.htm mrk-20221231.xsd mrk-20221231_cal.xml mrk-20221231_def.xml mrk-20221231_lab.xml mrk-20221231_pre.xml mrk-20221231_g1.jpg mrk-20221231_g2.jpg mrk-20221231_g3.jpg mrk-20221231_g4.jpg mrk-20221231_g5.jpg mrk-20221231_g6.jpg mrk-20221231_g7.gif mrk-20221231_g8.jpg mrk-20221231_g9.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 166 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrk-20221231.htm": { "axisCustom": 0, "axisStandard": 49, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 3171, "http://xbrl.sec.gov/dei/2022": 49 }, "contextCount": 1424, "dts": { "calculationLink": { "local": [ "mrk-20221231_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20221231_def.xml" ] }, "inline": { "local": [ "mrk-20221231.htm" ] }, "labelLink": { "local": [ "mrk-20221231_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20221231_pre.xml" ] }, "schema": { "local": [ "mrk-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 1160, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 75, "http://www.merck.com/20221231": 1, "http://xbrl.sec.gov/dei/2022": 4, "total": 80 }, "keyCustom": 96, "keyStandard": 596, "memberCustom": 146, "memberStandard": 94, "nsprefix": "mrk", "nsuri": "http://www.merck.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.merck.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000010 - Statement - Consolidated Statement of Cash Flows (Parenthetical)", "menuCat": "Statements", "order": "10", "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical", "shortName": "Consolidated Statement of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - Taxes on Income - Income Before Taxes (Details)", "menuCat": "Details", "order": "100", "role": "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails", "shortName": "Taxes on Income - Income Before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - Taxes on Income - Taxes on Income (Details)", "menuCat": "Details", "order": "101", "role": "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails", "shortName": "Taxes on Income - Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - Taxes on Income - Deferred Income Taxes (Details)", "menuCat": "Details", "order": "102", "role": "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails", "shortName": "Taxes on Income - Deferred Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesPaid", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000103 - Disclosure - Taxes on Income - Income Tax Authority (Details)", "menuCat": "Details", "order": "103", "role": "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "shortName": "Taxes on Income - Income Tax Authority (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000104 - Disclosure - Taxes on Income - Unrecognized Tax Benefits (Details)", "menuCat": "Details", "order": "104", "role": "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails", "shortName": "Taxes on Income - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000105 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)", "menuCat": "Details", "order": "105", "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000106 - Disclosure - Earnings Per Share - Narrative (Details)", "menuCat": "Details", "order": "106", "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000107 - Disclosure - Other Comprehensive Income (Loss) (Details)", "menuCat": "Details", "order": "107", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000108 - Disclosure - Segment Reporting - Narrative (Details)", "menuCat": "Details", "order": "108", "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R109": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000109 - Disclosure - Segment Reporting - Sales of Company's Products (Details)", "menuCat": "Details", "order": "109", "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "shortName": "Segment Reporting - Sales of Company's Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "mrk:IncreaseDecreaseInHedgeRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Nature of Operations", "menuCat": "Notes", "order": "11", "role": "http://www.merck.com/role/NatureofOperations", "shortName": "Nature of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000110 - Disclosure - Segment Reporting - Consolidated Revenues by Geographic Area (Details)", "menuCat": "Details", "order": "110", "role": "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "shortName": "Segment Reporting - Consolidated Revenues by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ia689dc2ff1e4458792332eba5e96c16b_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000111 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)", "menuCat": "Details", "order": "111", "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income Before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000112 - Disclosure - Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)", "menuCat": "Details", "order": "112", "role": "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "shortName": "Segment Reporting - Equity Loss from Affiliates and Depreciation Included in Segment Profits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "icb938a0339b9458a8fec2ab1c383d9cd_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000113 - Disclosure - Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)", "menuCat": "Details", "order": "113", "role": "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "shortName": "Segment Reporting - Property, Plant and Equipment, Net by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i2f49f49133634761b181692557d66dda_I20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Summary of Accounting Policies", "menuCat": "Notes", "order": "12", "role": "http://www.merck.com/role/SummaryofAccountingPolicies", "shortName": "Summary of Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Spin-Off of Organon & Co.", "menuCat": "Notes", "order": "13", "role": "http://www.merck.com/role/SpinOffofOrganonCo", "shortName": "Spin-Off of Organon & Co.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements", "menuCat": "Notes", "order": "14", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements", "shortName": "Acquisitions, Research Collaborations and Licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Collaborative Arrangements", "menuCat": "Notes", "order": "15", "role": "http://www.merck.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Restructuring", "menuCat": "Notes", "order": "16", "role": "http://www.merck.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Financial Instruments", "menuCat": "Notes", "order": "17", "role": "http://www.merck.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Inventories", "menuCat": "Notes", "order": "18", "role": "http://www.merck.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Goodwill and Other Intangibles", "menuCat": "Notes", "order": "19", "role": "http://www.merck.com/role/GoodwillandOtherIntangibles", "shortName": "Goodwill and Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.merck.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Loans Payable, Long-Term Debt and Leases", "menuCat": "Notes", "order": "20", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeases", "shortName": "Loans Payable, Long-Term Debt and Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Contingencies and Environmental Liabilities", "menuCat": "Notes", "order": "21", "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities", "shortName": "Contingencies and Environmental Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Equity", "menuCat": "Notes", "order": "22", "role": "http://www.merck.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Share-Based Compensation Plans", "menuCat": "Notes", "order": "23", "role": "http://www.merck.com/role/ShareBasedCompensationPlans", "shortName": "Share-Based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Pension and Other Postretirement Benefit Plans", "menuCat": "Notes", "order": "24", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Other (Income) Expense, Net", "menuCat": "Notes", "order": "25", "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "shortName": "Other (Income) Expense, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Taxes on Income", "menuCat": "Notes", "order": "26", "role": "http://www.merck.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Earnings per Share", "menuCat": "Notes", "order": "27", "role": "http://www.merck.com/role/EarningsperShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Other Comprehensive Income (Loss)", "menuCat": "Notes", "order": "28", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Segment Reporting", "menuCat": "Notes", "order": "29", "role": "http://www.merck.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statement of Income", "menuCat": "Statements", "order": "3", "role": "http://www.merck.com/role/ConsolidatedStatementofIncome", "shortName": "Consolidated Statement of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "mrk:CostsExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Summary of Accounting Policies (Policies)", "menuCat": "Policies", "order": "30", "role": "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies", "shortName": "Summary of Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Spin-Off of Organon & Co. (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.merck.com/role/SpinOffofOrganonCoTables", "shortName": "Spin-Off of Organon & Co. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables", "shortName": "Acquisitions, Research Collaborations and Licensing Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Collaborative Arrangements (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Restructuring (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.merck.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Financial Instruments (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.merck.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Inventories (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.merck.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Goodwill and Other Intangibles (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesTables", "shortName": "Goodwill and Other Intangibles (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Loans Payable, Long-Term Debt and Leases (Tables)", "menuCat": "Tables", "order": "38", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables", "shortName": "Loans Payable, Long-Term Debt and Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Equity (Tables)", "menuCat": "Tables", "order": "39", "role": "http://www.merck.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statement of Comprehensive Income", "menuCat": "Statements", "order": "4", "role": "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome", "shortName": "Consolidated Statement of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Share-Based Compensation Plans (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables", "shortName": "Share-Based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Other (Income) Expense, Net (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "shortName": "Other (Income) Expense, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Taxes on Income (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.merck.com/role/TaxesonIncomeTables", "shortName": "Taxes on Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Earnings per Share (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.merck.com/role/EarningsperShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Segment Reporting (Tables)", "menuCat": "Tables", "order": "46", "role": "http://www.merck.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Nature of Operations (Details)", "menuCat": "Details", "order": "47", "role": "http://www.merck.com/role/NatureofOperationsDetails", "shortName": "Nature of Operations (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "mrk:SalesDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Summary of Accounting Policies (Details)", "menuCat": "Details", "order": "48", "role": "http://www.merck.com/role/SummaryofAccountingPoliciesDetails", "shortName": "Summary of Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "mrk:SalesDiscounts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i05ee48b166b44fbaa88adeaa6cccbcca_I20210602", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details)", "menuCat": "Details", "order": "49", "role": "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "shortName": "Spin-Off of Organon & Co. - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i05ee48b166b44fbaa88adeaa6cccbcca_I20210602", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Balance Sheet", "menuCat": "Statements", "order": "5", "role": "http://www.merck.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheet", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)", "menuCat": "Details", "order": "50", "role": "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails", "shortName": "Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)", "menuCat": "Details", "order": "51", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "shortName": "Acquisitions, Research Collaborations and Licensing Agreements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i58fae9f157404c948f717699cc8b6041_D20200101-20201231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)", "menuCat": "Details", "order": "52", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions, Research Collaborations and Licensing Agreements - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ibfdc0787087a47d68adfea5ef5195bef_I20211119", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Collaborative Arrangements - Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "shortName": "Collaborative Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i0bd89ab9867a451bb7d8f5e7dd23cfa9_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Collaborative Arrangements - Financial Information (Details)", "menuCat": "Details", "order": "54", "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "shortName": "Collaborative Arrangements - Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ie0cbe6f30ebf448ca8dd317840d491e8_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Restructuring - Narrative (Details)", "menuCat": "Details", "order": "55", "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "menuCat": "Details", "order": "56", "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i395b7c2ea8cb4555838808489a3499b2_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Restructuring - Activities by Program (Details)", "menuCat": "Details", "order": "57", "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "shortName": "Restructuring - Activities by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:PaymentsForRestructuring", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Financial Instruments - Narrative (Details)", "menuCat": "Details", "order": "58", "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i966c0574579842adb1aad8f47b86bae5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "menuCat": "Details", "order": "59", "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i966c0574579842adb1aad8f47b86bae5_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Balance Sheet (Parenthetical)", "menuCat": "Statements", "order": "6", "role": "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "shortName": "Consolidated Balance Sheet (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Financial Instruments - Fair Value of Hedges (Details)", "menuCat": "Details", "order": "60", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails", "shortName": "Financial Instruments - Fair Value of Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i8b67792b7ecc4cd88fa3b8b53e2e1a89_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)", "menuCat": "Details", "order": "61", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated Between Those Derivatives That are Designated as Hedging Instruments and Those That are Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "menuCat": "Details", "order": "62", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)", "menuCat": "Details", "order": "63", "role": "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "shortName": "Financial Instruments - Location and Pretax (Gains) or Loss Amounts for Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i926eff1a8ec14b039e29169742609ad8_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ieead02c0663c47e4a289f16813bc7306_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "menuCat": "Details", "order": "64", "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ieead02c0663c47e4a289f16813bc7306_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Financial Instruments - Information on Debt and Equity Securities (Details)", "menuCat": "Details", "order": "65", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "shortName": "Financial Instruments - Information on Debt and Equity Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "menuCat": "Details", "order": "66", "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iba235620efd64c3b8e1fc94776a989c6_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "menuCat": "Details", "order": "67", "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Inventories - Inventories (Details)", "menuCat": "Details", "order": "68", "role": "http://www.merck.com/role/InventoriesInventoriesDetails", "shortName": "Inventories - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LIFOInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Inventories - Narrative (Details)", "menuCat": "Details", "order": "69", "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LIFOInventoryAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i50a206ace8ff4b2b880a7d891b6470c1_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Consolidated Statement of Equity", "menuCat": "Statements", "order": "7", "role": "http://www.merck.com/role/ConsolidatedStatementofEquity", "shortName": "Consolidated Statement of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i870984a7a0814cf9a460c7a4b331c37f_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)", "menuCat": "Details", "order": "70", "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "shortName": "Goodwill and Other Intangibles - Goodwill Activity by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i7decd1400c864cb5bee0b0259ca0474f_D20210101-20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Goodwill and Other Intangibles - Narrative (Details)", "menuCat": "Details", "order": "71", "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "shortName": "Goodwill and Other Intangibles - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i3bd68ccc0a164d5998cdbc87a8c81329_D20200101-20201231", "decimals": "-8", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Goodwill and Other Intangibles - Other Intangibles (Details)", "menuCat": "Details", "order": "72", "role": "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "shortName": "Goodwill and Other Intangibles - Other Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Loans Payable, Long-Term Debt and Leases - Narrative (Details)", "menuCat": "Details", "order": "73", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "shortName": "Loans Payable, Long-Term Debt and Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000074 - Disclosure - Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)", "menuCat": "Details", "order": "74", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "shortName": "Loans Payable, Long-Term Debt and Leases - Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iedd526ebaff749a5b3eafa6e57a81046_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:AssetsandLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)", "menuCat": "Details", "order": "75", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "shortName": "Loans Payable, Long-Term Debt and Leases - Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:AssetsandLiabilitiesLesseeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)", "menuCat": "Details", "order": "76", "role": "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails", "shortName": "Loans Payable, Long-Term Debt and Leases - Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Contingencies and Environmental Liabilities (Details)", "menuCat": "Details", "order": "77", "role": "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "shortName": "Contingencies and Environmental Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Equity - Narrative (Details)", "menuCat": "Details", "order": "78", "role": "http://www.merck.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Equity - Shareholders' Equity (Details)", "menuCat": "Details", "order": "79", "role": "http://www.merck.com/role/EquityShareholdersEquityDetails", "shortName": "Equity - Shareholders' Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i870984a7a0814cf9a460c7a4b331c37f_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statement of Equity (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical", "shortName": "Consolidated Statement of Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Share-Based Compensation Plans - Narrative (Details)", "menuCat": "Details", "order": "80", "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "shortName": "Share-Based Compensation Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)", "menuCat": "Details", "order": "81", "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails", "shortName": "Share-Based Compensation Plans - Assumptions Used to Determine Weighted-Average Fair Value of Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i5e30d57aa7714c7c991d4956adf482da_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)", "menuCat": "Details", "order": "82", "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails", "shortName": "Share-Based Compensation Plans - Summary of Information Relative to Stock Option Plan Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)", "menuCat": "Details", "order": "83", "role": "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails", "shortName": "Share-Based Compensation Plans - Additional Information Pertaining to Stock Option Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ied7d80ed2ab14e968047a6b71fb4fea8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)", "menuCat": "Details", "order": "84", "role": "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails", "shortName": "Share-Based Compensation Plans - Summary of Nonvested RSU and PSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ied7d80ed2ab14e968047a6b71fb4fea8_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)", "menuCat": "Details", "order": "85", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "menuCat": "Details", "order": "86", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Components of Net Periodic Benefit Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i047b115329a54c42a89e9abfb277e348_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)", "menuCat": "Details", "order": "87", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Obligation and Funded Status (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ieac41e3734b14c5880a3e1babce1d967_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)", "menuCat": "Details", "order": "88", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Accumulated and Projected Benefit Obligation in Excess of Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "mrk:ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ieac41e3734b14c5880a3e1babce1d967_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iebb1a8351aa841838361b44de4c7bef0_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)", "menuCat": "Details", "order": "89", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i2db1b4d2bd9c40969669b8308c8c2bfc_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Consolidated Statement of Cash Flows", "menuCat": "Statements", "order": "9", "role": "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "shortName": "Consolidated Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if1c3c2b238964beeb4fe2cc7ee98547f_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)", "menuCat": "Details", "order": "90", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "icedae49afe70492a8921f596e854194f_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)", "menuCat": "Details", "order": "91", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Fair Values of Other Postretirement Benefit Plan Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i44f98c489cc64681a483c72df528f6e3_I20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)", "menuCat": "Details", "order": "92", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Expected Benefit Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)", "menuCat": "Details", "order": "93", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Components of Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "ib96be59679d0488687e1689c7b3d047f_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i00c54d6e8143424db472e467e5653785_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)", "menuCat": "Details", "order": "94", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i00c54d6e8143424db472e467e5653785_D20220101-20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)", "menuCat": "Details", "order": "95", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "i26d66e8191e3489da8b88251530ce552_I20221231", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "menuCat": "Details", "order": "96", "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - Other (Income) Expense, Net - Narrative (Details)", "menuCat": "Details", "order": "97", "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "shortName": "Other (Income) Expense, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)", "menuCat": "Details", "order": "98", "role": "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails", "shortName": "Taxes on Income - Reconciliation Between Effective Tax Rate and US Statutory Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "iaf8fc8dc60ac4ca6b59f2a42ad4a7b23_D20220101-20221231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - Taxes on Income - Narrative (Details)", "menuCat": "Details", "order": "99", "role": "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "shortName": "Taxes on Income - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20221231.htm", "contextRef": "if0af637dd40e445c8087ffbd9b3638e5_I20221231", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 247, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLOMBIA", "terseLabel": "COLOMBIA" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r1004", "r1005", "r1006" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r1004", "r1005", "r1006" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r1004", "r1005", "r1006" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r1004", "r1005", "r1006" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r1007" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1002" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r1008" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1001" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r1009" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r1004", "r1005", "r1006" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1000" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1003" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mrk_A0.500Notesdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.500% Notes due 2024 [Member]", "label": "0.500% Notes due 2024 [Member]", "terseLabel": "0.500% Notes due 2024" } } }, "localname": "A0.500Notesdue2024Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A0.50eurodenominatednotesdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.50% euro-denominated notes due 2024 [Member]", "label": "0.50% euro-denominated notes due 2024 [Member]", "terseLabel": "0.50% euro-denominated notes due 2024" } } }, "localname": "A0.50eurodenominatednotesdue2024Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A075NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.75% Notes due 2026", "label": "0.75% Notes due 2026 [Member]", "terseLabel": "0.75% notes due 2026" } } }, "localname": "A075NotesDue2026Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.375Notesdue2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% Notes due 2036 [Member]", "label": "1.375% Notes due 2036 [Member]", "terseLabel": "1.375% Notes due 2036" } } }, "localname": "A1.375Notesdue2036Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.375eurodenominatednotesdue2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% euro-denominated notes due 2036 [Member]", "label": "1.375% euro-denominated notes due 2036 [Member]", "terseLabel": "1.375% euro-denominated notes due 2036" } } }, "localname": "A1.375eurodenominatednotesdue2036Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.875EuroNotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.875% Euro Notes Due 2026 [Member]", "label": "1.875% Euro Notes Due 2026 [Member]", "terseLabel": "1.875% euro-denominated notes due 2026" } } }, "localname": "A1.875EuroNotesDue2026Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.875Notesdue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.875% Notes due 2026 [Member]", "label": "1.875% Notes due 2026 [Member]", "terseLabel": "1.875% Notes due 2026" } } }, "localname": "A1.875Notesdue2026Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A145NotesDue2030Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.45% Notes Due 2030", "label": "1.45% Notes Due 2030 [Member]", "terseLabel": "1.45% notes due 2030" } } }, "localname": "A145NotesDue2030Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A170NotesDue2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.70% notes due 2027", "label": "1.70% notes due 2027 [Member]", "terseLabel": "1.70% notes due 2027" } } }, "localname": "A170NotesDue2027Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A190NotesDue2028Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.90% notes due 2028", "label": "1.90% notes due 2028 [Member]", "terseLabel": "1.90% notes due 2028" } } }, "localname": "A190NotesDue2028Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.35NotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.35% Notes Due 2022 [Member]", "label": "2.35% Notes Due 2022 [Member]", "terseLabel": "2.35% notes due 2022" } } }, "localname": "A2.35NotesDue2022Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.40NotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.40% Notes Due 2022 [Member]", "label": "2.40% Notes Due 2022 [Member]", "terseLabel": "2.40% Notes Due 2022" } } }, "localname": "A2.40NotesDue2022Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.500Notesdue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.500% Notes due 2034 [Member]", "label": "2.500% Notes due 2034 [Member]", "terseLabel": "2.500% Notes due 2034" } } }, "localname": "A2.500Notesdue2034Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A2.5EuroNotesDue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.5% Euro Notes Due 2034 [Member]", "label": "2.5% Euro Notes Due 2034 [Member]", "terseLabel": "2.50% euro-denominated notes due 2034" } } }, "localname": "A2.5EuroNotesDue2034Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.75NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.75% Notes Due 2025 [Member]", "label": "2.75% Notes Due 2025 [Member]", "terseLabel": "2.75% notes due 2025" } } }, "localname": "A2.75NotesDue2025Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.90NotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.90% Notes Due 2024", "label": "2.90% Notes Due 2024 [Member]", "terseLabel": "2.90% notes due 2024" } } }, "localname": "A2.90NotesDue2024Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A215NotesDue2031Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.15% notes due 2031", "label": "2.15% notes due 2031 [Member]", "terseLabel": "2.15% notes due 2031" } } }, "localname": "A215NotesDue2031Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A235NotesDue2040Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.35% Notes Due 2040", "label": "2.35% Notes Due 2040 [Member]", "terseLabel": "2.35% notes due 2040" } } }, "localname": "A235NotesDue2040Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A245NotesDue2050Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.45% Notes Due 2050", "label": "2.45% Notes Due 2050 [Member]", "terseLabel": "2.45% notes due 2050" } } }, "localname": "A245NotesDue2050Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A275NotesDue2051Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.75% notes due 2051", "label": "2.75% notes due 2051 [Member]", "terseLabel": "2.75% notes due 2051" } } }, "localname": "A275NotesDue2051Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A280NotesDue2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.80% Notes Due 2023 [Member]", "label": "2.80% Notes Due 2023 [Member]", "terseLabel": "2.80% notes due 2023" } } }, "localname": "A280NotesDue2023Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A290NotesDue2061Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.90% notes due 2061", "label": "2.90% notes due 2061 [Member]", "terseLabel": "2.90% notes due 2061" } } }, "localname": "A290NotesDue2061Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A3.40NotesDue2029Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.40% Notes Due 2029", "label": "3.40% Notes Due 2029 [Member]", "terseLabel": "3.40% notes due 2029" } } }, "localname": "A3.40NotesDue2029Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A3.70NotesDue2045Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.70% Notes Due 2045 [Member]", "label": "3.70% Notes Due 2045 [Member]", "terseLabel": "3.70% notes due 2045" } } }, "localname": "A3.70NotesDue2045Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A3.90NotesDue2039Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "3.90% Notes Due 2039", "label": "3.90% Notes Due 2039 [Member]", "terseLabel": "3.90% notes due 2039" } } }, "localname": "A3.90NotesDue2039Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A4.00NotesDue2049Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.00% Notes Due 2049", "label": "4.00% Notes Due 2049 [Member]", "terseLabel": "4.00% notes due 2049" } } }, "localname": "A4.00NotesDue2049Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A415NotesDue2043Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "4.15% Notes Due 2043 [Member]", "label": "4.15% Notes Due 2043 [Member]", "terseLabel": "4.15% notes due 2043" } } }, "localname": "A415NotesDue2043Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_A63DebenturesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six point three percentage debentures due on two thousand and twenty six.", "label": "6.3% Debentures Due 2026 [Member]", "terseLabel": "6.30% debentures due 2026" } } }, "localname": "A63DebenturesDue2026Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AcceleratedDepreciationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Depreciation [Member]", "label": "Accelerated Depreciation [Member]", "terseLabel": "Accelerated Depreciation" } } }, "localname": "AcceleratedDepreciationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "mrk_AcceleronPharmaIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acceleron Pharma Inc.", "label": "Acceleron Pharma Inc. [Member]", "terseLabel": "Acceleron Pharma Inc." } } }, "localname": "AcceleronPharmaIncMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AccrualForChargebacks": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for chargebacks reflected as a direction reduction to accounts receivable.", "label": "Accrual For Chargebacks", "terseLabel": "Accrual for chargebacks reflected as direct reduction to accounts receivable" } } }, "localname": "AccrualForChargebacks", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AccrualForRebates": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrual for rebates recorded as current liability.", "label": "Accrual For Rebates", "terseLabel": "Accrual for rebates included in accrued and other current liabilities" } } }, "localname": "AccrualForRebates", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to acquisitions, research collaborations and license agreements.", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "terseLabel": "Acquisitions, Research Collaborations and Licensing Agreements" } } }, "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreements" ], "xbrltype": "textBlockItemType" }, "mrk_AdempasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adempas", "label": "Adempas [Member]", "terseLabel": "Adempas" } } }, "localname": "AdempasMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueAdempasVerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Adempas/Verquvo", "label": "Alliance revenue - Adempas/Verquvo [Member]", "terseLabel": "Alliance revenue - Adempas/Verquvo" } } }, "localname": "AllianceRevenueAdempasVerquvoMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueKoselugoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "terseLabel": "Alliance revenue - Koselugo" } } }, "localname": "AllianceRevenueKoselugoMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "mrk_AlliancerevenueLynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Lynparza [Member]", "label": "Alliance revenue - Lynparza [Member]", "terseLabel": "Alliance revenue - Lynparza" } } }, "localname": "AlliancerevenueLynparzaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AmerisourceBergenCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AmerisourceBergen Corporation", "label": "AmerisourceBergen Corporation [Member]", "terseLabel": "AmerisourceBergen Corporation" } } }, "localname": "AmerisourceBergenCorporationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AnimalHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health [Member]", "label": "Animal Health [Member]", "terseLabel": "Animal Health" } } }, "localname": "AnimalHealthMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AnimalHealthsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health segment [Member]", "label": "Animal Health segment [Member]", "terseLabel": "Animal Health" } } }, "localname": "AnimalHealthsegmentMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "mrk_ArQuleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ArQule [Member]", "label": "ArQule [Member]", "terseLabel": "ArQule" } } }, "localname": "ArQuleMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ArtivaBiotherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Artiva Biotherapeutics, Inc.", "label": "Artiva Biotherapeutics, Inc. [Member]", "terseLabel": "Artiva Biotherapeutics, Inc." } } }, "localname": "ArtivaBiotherapeuticsIncMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net", "terseLabel": "Net assets acquired" } } }, "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Other Assets and Liabilities Recognized, Net", "label": "Asset Acquisition, Other Assets and Liabilities Recognized, Net", "terseLabel": "Other net assets (liabilities)" } } }, "localname": "AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AssetsandLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets and Liabilities, Lessee [Table Text Block]", "label": "Assets and Liabilities, Lessee [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "AssetsandLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "xbrltype": "textBlockItemType" }, "mrk_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.merck.com/20221231", "xbrltype": "stringItemType" }, "mrk_BayerAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer AG [Member]", "label": "Bayer AG [Member]", "terseLabel": "Bayer AG" } } }, "localname": "BayerAGMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BelsomraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belsomra [Member]", "label": "Belsomra [Member]", "terseLabel": "Belsomra" } } }, "localname": "BelsomraMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BridionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bridion [Member].", "label": "Bridion [Member]", "terseLabel": "Bridion" } } }, "localname": "BridionMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol Myers Squibb", "label": "Bristol Myers Squibb [Member]", "terseLabel": "Bristol Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "negatedTerseLabel": "Other net liabilities", "terseLabel": "Other assets and liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CancidasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cancidas [Member].", "label": "Cancidas [Member]", "terseLabel": "Cancidas" } } }, "localname": "CancidasMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CardinalHealthIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cardinal Health, Inc.", "label": "Cardinal Health, Inc. [Member]", "terseLabel": "Cardinal Health, Inc." } } }, "localname": "CardinalHealthIncMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ChargesRelatedToProgramDiscontinuation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charges related to program discontinuation", "label": "Charges related to program discontinuation", "terseLabel": "Charges related to program discontinuation" } } }, "localname": "ChargesRelatedToProgramDiscontinuation", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementNumberOfCollaborationTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Number Of Collaboration Targets", "label": "Collaborative Arrangement, Number Of Collaboration Targets", "terseLabel": "Number of collaboration targets" } } }, "localname": "CollaborativeArrangementNumberOfCollaborationTargets", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_CollaborativeArrangementNumberOfResearchPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Number Of Research Programs", "label": "Collaborative Arrangement, Number Of Research Programs", "terseLabel": "Number of research programs" } } }, "localname": "CollaborativeArrangementNumberOfResearchPrograms", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Preferred Stock Investment In Counterparty", "label": "Collaborative Arrangement, Preferred Stock Investment In Counterparty", "terseLabel": "Preferred stock investment in counterparty" } } }, "localname": "CollaborativeArrangementPreferredStockInvestmentInCounterparty", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementProfitSharing": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Profit Sharing", "label": "Collaborative Arrangement, Profit Sharing", "terseLabel": "Alliance revenue - profit sharing" } } }, "localname": "CollaborativeArrangementProfitSharing", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Regulatory Milestone Payments Accrued", "label": "Collaborative Arrangement, Regulatory Milestone Payments Accrued", "terseLabel": "Regulatory milestone payments accrued" } } }, "localname": "CollaborativeArrangementRegulatoryMilestonePaymentsAccrued", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments", "terseLabel": "Eligible future contingent development-related payments (up to)" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments", "terseLabel": "Regulatory milestones payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments", "terseLabel": "Sales milestone payments" } } }, "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementSalesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Sales, Net", "label": "Collaborative Arrangement, Sales, Net", "terseLabel": "Net sales by Merck" } } }, "localname": "CollaborativeArrangementSalesNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "terseLabel": "Collaborative Arrangements [Abstract]" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.merck.com/20221231", "xbrltype": "stringItemType" }, "mrk_CommercialandOtherLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commercial and Other Litigation [Member]", "label": "Commercial and Other Litigation [Member]", "terseLabel": "Commercial Litigation" } } }, "localname": "CommercialandOtherLitigationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mrk_CompanionAnimalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Companion Animals [Member]", "label": "Companion Animals [Member]", "terseLabel": "Companion Animals" } } }, "localname": "CompanionAnimalsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company pension investments which are categorized as level three assets percentage.", "label": "Company Pension Investments Which Are Categorized As Level Three Assets Percentage", "terseLabel": "Percentage of Company's pension investments categorized as level 3 assets" } } }, "localname": "CompanyPensionInvestmentsWhichAreCategorizedAsLevelThreeAssetsPercentage", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Line Items]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Table]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "mrk_ContingentConsiderationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discussion of the accounting policy for contingent consideration.", "label": "Contingent Consideration [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "localname": "ContingentConsiderationPolicyTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "mrk_ContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.", "label": "Contingent Payments Collaborative Arrangement", "terseLabel": "Contingent payments collaborative arrangement" } } }, "localname": "ContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CorporateObligationsFixedIncomeSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate obligations fixed income securities.", "label": "Corporate Obligations Fixed Income Securities [Member]", "terseLabel": "Corporate obligations" } } }, "localname": "CorporateObligationsFixedIncomeSecuritiesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_CorporateObligationsInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate obligations investment funds.", "label": "Corporate Obligations Investment Funds [Member]", "terseLabel": "Corporate obligations" } } }, "localname": "CorporateObligationsInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_CostsExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.", "label": "Costs Expenses And Other", "totalLabel": "Total costs, expenses and other" } } }, "localname": "CostsExpensesAndOther", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities and Equity Securities, FV-NI", "label": "Debt Securities and Equity Securities, FV-NI", "totalLabel": "Total debt and publicly traded equity securities, fair value" } } }, "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes And Other Assets, Noncurrent", "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mrk_DeferredIncomeTaxesAssetsAndLiabilitiesNetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes Assets And Liabilities Net [Table]", "label": "Deferred Income Taxes Assets And Liabilities Net [Table]", "terseLabel": "Deferred Income Taxes Assets And Liabilities Net [Table]" } } }, "localname": "DeferredIncomeTaxesAssetsAndLiabilitiesNetTable", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "mrk_DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carryforwards and other tax credit carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards And Other Tax Credit Carryforwards", "terseLabel": "Net operating losses and other tax credit carryforwards, Assets" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndOtherTaxCreditCarryforwards", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredTaxAssetsUnrecognizedTaxBenefits": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets unrecognized tax benefits.", "label": "Deferred Tax Assets Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits, Assets" } } }, "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredTaxLiabilitiesEquityMethodInvestment": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liabilities, Equity Method Investment", "label": "Deferred Tax Liabilities, Equity Method Investment", "terseLabel": "Equity method investments, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesEquityMethodInvestment", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from pensions and other postretirement benefits.", "label": "Deferred Tax Liabilities Pensions And Other Postretirement Benefit Plans", "terseLabel": "Pensions and other postretirement benefits, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesPensionsAndOtherPostretirementBenefitPlans", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic", "label": "Deferred tax assets credit loss carryforwards and NOL carryforwards domestic", "terseLabel": "Deferred tax assets relating to various U.S. tax credit carryforwards and NOL carryforwards" } } }, "localname": "DeferredtaxassetscreditlosscarryforwardsandNOLcarryforwardsdomestic", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DefinedBenefitPlanCashandOtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Defined Benefit Plan, Cash and Other Investments [Member]", "label": "Defined Benefit Plan, Cash and Other Investments [Member]", "terseLabel": "Cash And Other Investments" } } }, "localname": "DefinedBenefitPlanCashandOtherInvestmentsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_DefinedBenefitPlanOtherChangesPlanAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Changes in plan assets, not otherwise separately disclosed in the financial statements.", "label": "Defined Benefit Plan Other Changes Plan Assets", "terseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherChangesPlanAssets", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DerazantinibMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Derazantinib", "label": "Derazantinib [Member]", "terseLabel": "Derazantinib" } } }, "localname": "DerazantinibMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_DerivativeNotionalAmountMatured": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative Notional Amount Matured", "label": "Derivative Notional Amount Matured", "terseLabel": "Total notional amount of Interest rate derivatives matured" } } }, "localname": "DerivativeNotionalAmountMatured", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DevelopedMarketsEquitiesInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed markets equities investment funds.", "label": "Developed Markets Equities Investment Funds [Member]", "terseLabel": "Developed markets equities" } } }, "localname": "DevelopedMarketsEquitiesInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_DevelopedMarketsEquitySecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Developed markets equity securities.", "label": "Developed Markets Equity Securities [Member]", "terseLabel": "Developed markets" } } }, "localname": "DevelopedMarketsEquitySecuritiesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Milestones [Member]", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_DificidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dificid [Member]", "label": "Dificid [Member]", "terseLabel": "Dificid" } } }, "localname": "DificidMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net", "negatedTerseLabel": "Other (income) expense, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationsDistributionReceived": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group Including Discontinued Operations Distribution Received", "label": "Disposal Group Including Discontinued Operations Distribution Received", "terseLabel": "Distribution from Organon & Co." } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsDistributionReceived", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Research and Development Expenses", "label": "Disposal Group, Including Discontinued Operations, Research and Development Expenses", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Restructuring Costs", "label": "Disposal Group, Including Discontinued Operations, Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DunboyneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dunboyne", "label": "Dunboyne [Member]", "terseLabel": "Dunboyne" } } }, "localname": "DunboyneMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 11.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent", "label": "Effective Income Tax Rate Reconciliation, Asset Acquisition, Percent", "terseLabel": "Acquisition of VelosBio" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAssetAcquisitionPercent", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFour": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four", "label": "Effective Income Tax Rate Reconciliation, Business Combination Four", "terseLabel": "Acquisition of Pandion" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFour", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 12.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent", "label": "Effective Income Tax Rate Reconciliation, Business Combination Four, Percent", "terseLabel": "Acquisition of Pandion" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationFourPercent", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two", "label": "Effective Income Tax Rate Reconciliation, Business Combination Two", "terseLabel": "Acquisition of OncoImmune" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwo", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent", "label": "Effective Income Tax Rate Reconciliation, Business Combination Two, Percent", "terseLabel": "Acquisition of OncoImmune" } } }, "localname": "EffectiveIncomeTaxRateReconciliationBusinessCombinationTwoPercent", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]", "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Amount [Abstract]", "terseLabel": "Differential arising from:" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromAmountAbstract", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "stringItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]", "label": "Effective Income Tax Rate Reconciliation, Differential Arising From, Percent [Abstract]", "terseLabel": "Differential arising from:" } } }, "localname": "EffectiveIncomeTaxRateReconciliationDifferentialArisingFromPercentAbstract", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "stringItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Amount", "terseLabel": "GILTI and the foreign-derived intangible income deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionAmount", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "mrk_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent", "label": "Effective Income Tax Rate Reconciliation, Global Intangible Low Taxed Income Foreign Derived Intangible Income Deduction, Percent", "terseLabel": "GILTI and the foreign-derived intangible income deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncomeForeignDerivedIntangibleIncomeDeductionPercent", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "mrk_EisaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eisai [Member]", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_EmergingMarketsEquitiesInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging markets equities investment funds.", "label": "Emerging Markets Equities Investment Funds [Member]", "terseLabel": "Emerging markets equities" } } }, "localname": "EmergingMarketsEquitiesInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag", "label": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag", "terseLabel": "Environmental Loss Contingency Statement Of Financial Position Extensible Enumeration Not Disclosed Flag" } } }, "localname": "EnvironmentalLossContingencyStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will be noncash.", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "terseLabel": "Estimate of cumulative pre tax costs that will be noncash" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).", "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays", "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EurodominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro-dominated Notes [Member]", "label": "Euro-dominated Notes [Member]", "terseLabel": "Euro-denominated notes" } } }, "localname": "EurodominatedNotesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests.", "label": "Expected Annual Standard Deviation In Returns Of Target Portfolio Which Reflects Both Equity Allocation And Diversification Benefits Among Asset Classes In Which Portfolio Invests", "terseLabel": "Expected annual standard deviation in returns of the target portfolio which reflects both the equity allocation and the diversification benefits among the asset classes in which the portfolio invests" } } }, "localname": "ExpectedAnnualStandardDeviationInReturnsOfTargetPortfolioWhichReflectsBothEquityAllocationAndDiversificationBenefitsAmongAssetClassesInWhichPortfolioInvests", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "negatedTerseLabel": "Other" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_FirstCommercialSaleMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Commercial Sale Milestones", "label": "First Commercial Sale Milestones [Member]", "terseLabel": "First Commercial Sale Milestones" } } }, "localname": "FirstCommercialSaleMilestonesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five point eight five percentage notes due on two thousand and thirty nine.", "label": "Five Point Eight Five Percentage Notes Due On Two Thousand And Thirty Nine [Member]", "terseLabel": "5.85% notes due 2039" } } }, "localname": "FivePointEightFivePercentageNotesDueOnTwoThousandAndThirtyNineMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five point nine five percentage debentures due on two thousand and twenty eight.", "label": "Five Point Nine Five Percentage Debentures Due On Two Thousand And Twenty Eight [Member]", "terseLabel": "5.95% debentures due 2028" } } }, "localname": "FivePointNineFivePercentageDebenturesDueOnTwoThousandAndTwentyEightMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Five point seven five percentage notes due on two thousand and thirty six.", "label": "Five Point Seven Five Percentage Notes Due On Two Thousand And Thirty Six [Member]", "terseLabel": "5.75% notes due 2036" } } }, "localname": "FivePointSevenFivePercentageNotesDueOnTwoThousandAndThirtySixMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_FixedIncomeObligationsInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed income obligations investment funds.", "label": "Fixed Income Obligations Investment Funds [Member]", "terseLabel": "Other fixed income obligations" } } }, "localname": "FixedIncomeObligationsInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_GardasilGardasil9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gardasil/Gardasil 9 [Member].", "label": "Gardasil/Gardasil 9 [Member]", "terseLabel": "Gardasil/Gardasil 9" } } }, "localname": "GardasilGardasil9Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_GefapixantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "gefapixant", "label": "gefapixant [Member]", "terseLabel": "gefapixant" } } }, "localname": "GefapixantMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_GileadSciencesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gilead Sciences", "label": "Gilead Sciences [Member]", "terseLabel": "Gilead Sciences" } } }, "localname": "GileadSciencesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government and agency obligations fixed income securities.", "label": "Government And Agency Obligations Fixed Income Securities [Member]", "terseLabel": "Government and agency obligations" } } }, "localname": "GovernmentAndAgencyObligationsFixedIncomeSecuritiesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_GovernmentAndAgencyObligationsInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government and agency obligations investment funds.", "label": "Government And Agency Obligations Investment Funds [Member]", "terseLabel": "Government and agency obligations" } } }, "localname": "GovernmentAndAgencyObligationsInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_IAVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IAVI [Member]", "label": "IAVI [Member]", "terseLabel": "IAVI" } } }, "localname": "IAVIMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ImagoBioSciencesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Imago BioSciences, Inc.", "label": "Imago BioSciences, Inc. [Member]", "terseLabel": "Imago BioSciences, Inc." } } }, "localname": "ImagoBioSciencesIncMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_IncomeTaxLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Tax [Line Items]", "label": "Income Tax [Line Items]", "terseLabel": "Income Tax [Line Items]" } } }, "localname": "IncomeTaxLineItems", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "mrk_IncomeTaxRateReconciliationAssetAcquisition": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income Tax Rate Reconciliation, Asset Acquisition", "label": "Income Tax Rate Reconciliation, Asset Acquisition", "terseLabel": "Acquisition of VelosBio" } } }, "localname": "IncomeTaxRateReconciliationAssetAcquisition", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "mrk_IncomeTaxesPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Income Taxes Payable [Member]", "label": "Income Taxes Payable [Member]", "terseLabel": "Income Taxes Payable" } } }, "localname": "IncomeTaxesPayableMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_IncreaseDecreaseInHedgeRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Hedge Revenue", "label": "Increase (Decrease) In Hedge Revenue", "terseLabel": "Increase (decrease) in revenue hedging activities" } } }, "localname": "IncreaseDecreaseInHedgeRevenue", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InjectableFormulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "injectable formulation", "label": "injectable formulation [Member]", "terseLabel": "Injectable Formulation" } } }, "localname": "InjectableFormulationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InsuranceContractsOtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Insurance contracts other investments.", "label": "Insurance Contracts Other Investments [Member]", "terseLabel": "Insurance contracts", "verboseLabel": "Insurance Contracts" } } }, "localname": "InsuranceContractsOtherInvestmentsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_IntangibleAssetMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Asset, Measurement Input", "label": "Intangible Asset, Measurement Input", "terseLabel": "Present value discount rate", "verboseLabel": "Discount rate" } } }, "localname": "IntangibleAssetMeasurementInput", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "decimalItemType" }, "mrk_IntangibleAssetProductsAndProductRightsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Asset, Products and Product rights, Measurement Input", "label": "Intangible Asset, Products and Product rights, Measurement Input", "terseLabel": "Discount rate" } } }, "localname": "IntangibleAssetProductsAndProductRightsMeasurementInput", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "decimalItemType" }, "mrk_IntangibleAssetsExcludingGoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible Assets Excluding Goodwill [Line Items]", "label": "Intangible Assets Excluding Goodwill [Line Items]", "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]" } } }, "localname": "IntangibleAssetsExcludingGoodwillLineItems", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "Int\u2019l" } } }, "localname": "InternationalMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InvanzMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invanz [Member].", "label": "Invanz [Member]", "terseLabel": "Invanz" } } }, "localname": "InvanzMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories Produced in Preparation for Product Launches [Member]", "label": "Inventories Produced in Preparation for Product Launches [Member]", "terseLabel": "Inventories Produced in Preparation for Product Launches" } } }, "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryNetAndInventoryNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of current and noncurrent inventories.", "label": "Inventory Net And Inventory Noncurrent", "totalLabel": "Total current and noncurrent inventories" } } }, "localname": "InventoryNetAndInventoryNoncurrent", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Not Expected to be Sold Within One Year [Member]", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "terseLabel": "Inventory Not Expected to be Sold Within One Year" } } }, "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Table]", "label": "Inventory [Table]", "terseLabel": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_IsentressIsentressHDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Isentress/Isentress HD [Member].", "label": "Isentress/Isentress HD [Member]", "terseLabel": "Isentress/Isentress HD" } } }, "localname": "IsentressIsentressHDMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanumetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Janumet [Member].", "label": "Janumet [Member]", "terseLabel": "Janumet" } } }, "localname": "JanumetMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Januvia [Member] .", "label": "Januvia [Member]", "terseLabel": "Januvia" } } }, "localname": "JanuviaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_KeytrudaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Keytruda [Member]", "label": "Keytruda [Member]", "terseLabel": "Keytruda" } } }, "localname": "KeytrudaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LagevrioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lagevrio", "label": "Lagevrio [Member]", "terseLabel": "Lagevrio" } } }, "localname": "LagevrioMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LegalDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Defense Costs [Member]", "label": "Legal Defense Costs [Member]", "terseLabel": "Legal Defense Costs" } } }, "localname": "LegalDefenseCostsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mrk_LenvimaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lenvima [Member]", "label": "Lenvima [Member]", "terseLabel": "Alliance revenue - Lenvima", "verboseLabel": "Lenvima" } } }, "localname": "LenvimaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LesseeOperatingLeaseLeaseNotyetCommencedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Amount", "terseLabel": "Lessee, operating lease, lease not yet commenced, amount" } } }, "localname": "LesseeOperatingLeaseLeaseNotyetCommencedAmount", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LicenseOptionPaymentRelatedToCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License option payment related to collaborative arrangement", "label": "License option payment related to collaborative arrangement", "terseLabel": "License option payment related to collaborative arrangement" } } }, "localname": "LicenseOptionPaymentRelatedToCollaborativeArrangement", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LivestockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Livestock [Member]", "label": "Livestock [Member]", "terseLabel": "Livestock" } } }, "localname": "LivestockMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Debt, Current Maturities [Member]", "label": "Long Term Debt, Current Maturities [Member]", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtInterestPayableYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Interest Payable, Year Five", "label": "Long-term Debt, Interest Payable, Year Five", "terseLabel": "Long-term debt, interest payments in 2027" } } }, "localname": "LongTermDebtInterestPayableYearFive", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LongTermDebtInterestPayableYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Interest Payable, Year Four", "label": "Long-term Debt, Interest Payable, Year Four", "terseLabel": "Long-term debt, interest payments in 2026" } } }, "localname": "LongTermDebtInterestPayableYearFour", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LongTermDebtInterestPayableYearOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Interest Payable, Year One", "label": "Long-term Debt, Interest Payable, Year One", "terseLabel": "Long-term debt, interest payments in 2023" } } }, "localname": "LongTermDebtInterestPayableYearOne", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LongTermDebtInterestPayableYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Interest Payable, Year Three", "label": "Long-term Debt, Interest Payable, Year Three", "terseLabel": "Long-term debt, interest payments in 2025" } } }, "localname": "LongTermDebtInterestPayableYearThree", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LongTermDebtInterestPayableYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long-term Debt, Interest Payable, Year Two", "label": "Long-term Debt, Interest Payable, Year Two", "terseLabel": "Long-term debt, interest payments in 2024" } } }, "localname": "LongTermDebtInterestPayableYearTwo", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LossContingencyTrialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Trial Period", "label": "Loss Contingency, Trial Period", "terseLabel": "Loss contingency, trial period" } } }, "localname": "LossContingencyTrialPeriod", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "mrk_LynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lynparza [Member]", "label": "Lynparza [Member]", "terseLabel": "Lynparza" } } }, "localname": "LynparzaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ManufacturingAndSupplyAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing and supply agreements", "label": "Manufacturing and supply agreements [Member]", "terseLabel": "Manufacturing and supply agreements" } } }, "localname": "ManufacturingAndSupplyAgreementsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_McKessonCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "McKesson Corporation", "label": "McKesson Corporation [Member]", "terseLabel": "McKesson" } } }, "localname": "McKessonCorporationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_MilestonePaymentToBeMadeToCollaborativePartner": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment To Be Made to Collaborative Partner", "label": "Milestone Payment To Be Made to Collaborative Partner", "terseLabel": "Milestone payment to be made to collaborative partner" } } }, "localname": "MilestonePaymentToBeMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsMadetoCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Made to Collaborative Partner", "label": "Milestone Payments Made to Collaborative Partner", "terseLabel": "Milestone payments made to collaborative partner" } } }, "localname": "MilestonePaymentsMadetoCollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_ModernaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Moderna", "label": "Moderna [Member]", "terseLabel": "Moderna" } } }, "localname": "ModernaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mortgage and asset backed securities fixed income securities.", "label": "Mortgage And Asset Backed Securities Fixed Income Securities [Member]", "verboseLabel": "Mortgage and asset-backed securities" } } }, "localname": "MortgageAndAssetBackedSecuritiesFixedIncomeSecuritiesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_MovementinCommonStockandTreasuryStockRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Movement in Common Stock and Treasury Stock [Roll Forward]", "label": "Movement in Common Stock and Treasury Stock [Roll Forward]", "terseLabel": "Movement in Common Stock and Treasury Stock [Roll Forward]" } } }, "localname": "MovementinCommonStockandTreasuryStockRollForward", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "mrk_NemtabrutinibMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "nemtabrutinib", "label": "nemtabrutinib [Member]", "terseLabel": "nemtabrutinib" } } }, "localname": "NemtabrutinibMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_NotesSubjectToRepaymentAtOptionOfHolderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes Subject To Repayment At Option Of Holder [Member]", "label": "Notes Subject To Repayment At Option Of Holder [Member]", "terseLabel": "Notes Subject To Repayment At Option Of Holder" } } }, "localname": "NotesSubjectToRepaymentAtOptionOfHolderMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_NoxafilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noxafil [Member].", "label": "Noxafil [Member]", "terseLabel": "Noxafil" } } }, "localname": "NoxafilMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_NumberOfInterestRateDerivativesMatured": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of interest rate derivatives that matured during the period.", "label": "Number of Interest Rate Derivatives Matured", "terseLabel": "Number of interest rate derivatives matured" } } }, "localname": "NumberOfInterestRateDerivativesMatured", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.", "label": "Offsetting Assets And Liabilities [Table Text Block]", "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis" } } }, "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "mrk_OncoImmuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OncoImmune", "label": "OncoImmune [Member]", "terseLabel": "OncoImmune" } } }, "localname": "OncoImmuneMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OralAndInjectableFormulationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "oral and injectable formulations", "label": "oral and injectable formulations [Member]", "terseLabel": "Oral and Injectable Formulations" } } }, "localname": "OralAndInjectableFormulationsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OralFormulationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "oral formulation", "label": "oral formulation [Member]", "terseLabel": "Oral Formulation" } } }, "localname": "OralFormulationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OrganonCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organon & Co.", "label": "Organon & Co. [Member]", "terseLabel": "Organon & Co." } } }, "localname": "OrganonCoMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OrionCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orion Corporation", "label": "Orion Corporation [Member]", "terseLabel": "Orion Corporation" } } }, "localname": "OrionCorporationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OrnaTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orna Therapeutics", "label": "Orna Therapeutics [Member]", "terseLabel": "Orna Therapeutics" } } }, "localname": "OrnaTherapeuticsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax": { "auth_ref": [], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement And Curtailment Gain (Loss), Reclassification Adjustment From AOCI, Before Tax", "terseLabel": "Settlements and curtailments" } } }, "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanSettlementAndCurtailmentGainLossReclassificationAdjustmentFromAOCIBeforeTax", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other long term debt.", "label": "Other Long Term Debt [Member]", "terseLabel": "Other" } } }, "localname": "OtherLongTermDebtMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherNonoperatingIncomeExpenseOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other nonoperating income and expense items not separately disclosed.", "label": "Other Nonoperating Income Expense, Other", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpenseOther", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherPharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other pharmaceutical.", "label": "Other Pharmaceutical [Member]", "terseLabel": "Other pharmaceutical" } } }, "localname": "OtherPharmaceuticalMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherPostretirementBenefitPlanNetLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Postretirement Benefit Plan Net Loss [Member]", "label": "Other Postretirement Benefit Plan Net Loss [Member]", "terseLabel": "Other Postretirement Benefit Plan Net Gain" } } }, "localname": "OtherPostretirementBenefitPlanNetLossMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherPostretirementBenefitPlanPriorServiceCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Postretirement Benefit Plan Prior Service Cost [Member]", "label": "Other Postretirement Benefit Plan Prior Service Cost [Member]", "terseLabel": "Other Postretirement Benefit Plan Prior Service Credit" } } }, "localname": "OtherPostretirementBenefitPlanPriorServiceCostMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherVariableRateDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Variable Rate Debt [Member]", "label": "Other Variable Rate Debt [Member]", "terseLabel": "Other Variable Rate Debt" } } }, "localname": "OtherVariableRateDebtMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_PandionTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pandion Therapeutics", "label": "Pandion Therapeutics [Member]", "terseLabel": "Pandion Therapeutics" } } }, "localname": "PandionTherapeuticsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_PatentlitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent litigation [Member]", "label": "Patent litigation [Member]", "terseLabel": "Patent litigation" } } }, "localname": "PatentlitigationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mrk_PaymentsToAcquireBusinessFiveNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Business Five, Net of Cash Acquired", "label": "Payments to Acquire Business Five, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessFiveNetOfCashAcquired", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to Acquire Business Four, Net of Cash Acquired", "label": "Payments to Acquire Business Four, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of VelosBio Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mrk_PensionPlanNetLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension Plan Net Loss [Member]", "label": "Pension Plan Net Loss [Member]", "terseLabel": "Pension Plan Net Loss" } } }, "localname": "PensionPlanNetLossMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "mrk_PensionPlanPriorServiceCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pension Plan Prior Service Cost [Member]", "label": "Pension Plan Prior Service Cost [Member]", "terseLabel": "Pension Plan Prior Service Credit" } } }, "localname": "PensionPlanPriorServiceCostMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "mrk_PharmaceuticalsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical segment.", "label": "Pharmaceutical segment [Member]", "terseLabel": "Pharmaceutical segment", "verboseLabel": "Pharmaceutical" } } }, "localname": "PharmaceuticalsegmentMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "mrk_Pneumovax23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pneumovax 23[Member].", "label": "Pneumovax 23 [Member]", "terseLabel": "Pneumovax 23" } } }, "localname": "Pneumovax23Member", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PotentialFutureMilestonePaymentsRegulatory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Regulatory", "label": "Potential Future Milestone Payments Regulatory", "terseLabel": "Potential future regulatory milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsRegulatory", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PotentialFutureMilestonePaymentsSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Sales-Based", "label": "Potential Future Milestone Payments Sales-Based", "terseLabel": "Potential future sales-based milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsSalesBased", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PremiumOnSharesAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Premium on shares acquired", "label": "Premium on shares acquired", "terseLabel": "Premium on shares acquired" } } }, "localname": "PremiumOnSharesAcquired", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PrevymisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prevymis", "label": "Prevymis [Member]", "terseLabel": "Prevymis" } } }, "localname": "PrevymisMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrimaxinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primaxin [Member].", "label": "Primaxin [Member]", "terseLabel": "Primaxin" } } }, "localname": "PrimaxinMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProQuadMMRIIVarivaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ProQuad/M-M-R II/Varivax [Member].", "label": "ProQuad MMR II Varivax [Member]", "terseLabel": "ProQuad/M-M-R II/Varivax" } } }, "localname": "ProQuadMMRIIVarivaxMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProbableContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Probable Contingent Payments Collaborative Arrangement", "label": "Probable Contingent Payments Collaborative Arrangement", "terseLabel": "Probable contingent payments" } } }, "localname": "ProbableContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_ProfitShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit Share", "label": "Profit Share", "terseLabel": "Profit share" } } }, "localname": "ProfitShare", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_ProfitShareCounterparty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Profit Share Counterparty", "label": "Profit Share Counterparty", "terseLabel": "Profit share by counterparty" } } }, "localname": "ProfitShareCounterparty", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_RealEstateInvestmentFundsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real estate investment funds.", "label": "Real Estate Investment Funds [Member]", "verboseLabel": "Real Estate" } } }, "localname": "RealEstateInvestmentFundsMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "mrk_ReblozylMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reblozyl", "label": "Reblozyl [Member]", "terseLabel": "Reblozyl", "verboseLabel": "Alliance revenue - Reblozyl" } } }, "localname": "ReblozylMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RecognizedAsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recognized as.", "label": "Recognized As [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "RecognizedAsAbstract", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "stringItemType" }, "mrk_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory Milestones [Member]", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RemicadeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remicade [Member].", "label": "Remicade [Member]", "terseLabel": "Remicade" } } }, "localname": "RemicadeMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding", "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject to Funding", "terseLabel": "Additional funding by others, development costs subject to funding" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs", "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs", "terseLabel": "Additional funding by others, percentage of development costs" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off, Asset Acquisition Two", "terseLabel": "Charge for the acquisition of VelosBio Inc.", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "mrk_ResearchAndDevelopmentPaymentsMadeToACollaborativePartner": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Payments Made To a Collaborative Partner", "label": "Research and Development Payments Made To a Collaborative Partner", "terseLabel": "Research and development payments made to a collaborative partner" } } }, "localname": "ResearchAndDevelopmentPaymentsMadeToACollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and Development Payments To Be Made to a Collaborative Partners", "label": "Research and Development Payments To Be Made to a Collaborative Partners", "terseLabel": "Research and development payments to be made to a collaborative partners" } } }, "localname": "ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartners", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.", "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity", "terseLabel": "Non-cash activity" } } }, "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RevenuePerformanceObligationPaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Performance Obligation, Payment Terms", "label": "Revenue, Performance Obligation, Payment Terms", "terseLabel": "Payment terms" } } }, "localname": "RevenuePerformanceObligationPaymentTerms", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "mrk_RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date", "label": "Revenue Recognition, Goods, Goods Return Period After to Expiration Date", "terseLabel": "Product return period and expiration" } } }, "localname": "RevenueRecognitionGoodsGoodsReturnPeriodAftertoExpirationDate", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "mrk_RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date", "label": "Revenue Recognition, Goods, Goods Return Period Prior to Expiration Date", "terseLabel": "Product return period" } } }, "localname": "RevenueRecognitionGoodsGoodsReturnPeriodPriortoExpirationDate", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "mrk_RidgebackBiotherapeuticsLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ridgeback Biotherapeutics LP", "label": "Ridgeback Biotherapeutics LP [Member]", "terseLabel": "Ridgeback Biotherapeutics LP" } } }, "localname": "RidgebackBiotherapeuticsLPMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RotateqMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RotaTeq [Member]", "label": "Rotateq [Member]", "terseLabel": "RotaTeq" } } }, "localname": "RotateqMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RoyaltyPharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Pharma", "label": "Royalty Pharma [Member]", "terseLabel": "Royalty Pharma" } } }, "localname": "RoyaltyPharmaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RoyaltyRateDeductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Deduction, Percentage", "label": "Royalty Rate, Deduction, Percentage", "terseLabel": "Royalty rate, deduction, percentage" } } }, "localname": "RoyaltyRateDeductionPercentage", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_RoyaltyRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Percentage", "label": "Royalty Rate, Percentage", "terseLabel": "Royalty rate, percentage" } } }, "localname": "RoyaltyRatePercentage", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-Based Milestones [Member]", "label": "Sales-Based Milestones [Member]", "terseLabel": "Sales-Based Milestones" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales Discounts", "label": "Sales Discounts", "terseLabel": "Customer discounts" } } }, "localname": "SalesDiscounts", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SalesThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sales threshold", "label": "Sales threshold", "terseLabel": "Sales threshold" } } }, "localname": "SalesThreshold", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SanofiPasteurMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi Pasteur [Member]", "label": "Sanofi Pasteur [Member]", "terseLabel": "Sanofi Pasteur" } } }, "localname": "SanofiPasteurMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "mrk_ScheduleOfIncomeTaxesPaidTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Income Taxes Paid", "label": "Schedule of Income Taxes Paid [Table Text Block]", "terseLabel": "Income Taxes Paid" } } }, "localname": "ScheduleOfIncomeTaxesPaidTableTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "mrk_ScheduleOfOtherIntangiblesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Other Intangibles [Table]", "label": "Schedule Of Other Intangibles [Table]", "terseLabel": "Schedule Of Other Intangibles [Table]" } } }, "localname": "ScheduleOfOtherIntangiblesTable", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of accumulated and projected benefit obligations and fair value of plan assets for pension plans where the benefit obligations exceed the fair value of plan assets.", "label": "Schedule of Accumulated and Projected Benefit Obligation in Excess of Fair Value of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Accumulated and Projected Benefit Obligations in Excess of Fair Value of Plan Assets" } } }, "localname": "ScheduleofAccumulatedandProjectedBenefitObligationinExcessofFairValueofPlanAssetsTableTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "mrk_SeagenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seagen", "label": "Seagen [Member]", "terseLabel": "Seagen" } } }, "localname": "SeagenMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other net expenses not allocated to segments.", "label": "Segment Reporting Unallocated Other Expenses Net", "negatedLabel": "Other unallocated, net" } } }, "localname": "SegmentReportingUnallocatedOtherExpensesNet", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SentinelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sentinel [Member]", "label": "Sentinel [Member]", "terseLabel": "Sentinel" } } }, "localname": "SentinelMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Number", "terseLabel": "Number of Shares, Expected to Vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestNumber", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Expected to Vest, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedExpectedToVestWeightedAverageGrantDateFairValue", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "mrk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional information pertaining to stock option plans.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Table Text Block]", "terseLabel": "Additional Information Pertaining to Stock Option Plans" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresTableTextBlock", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.", "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]", "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd." } } }, "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SimponiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Simponi [Member].", "label": "Simponi [Member]", "terseLabel": "Simponi" } } }, "localname": "SimponiMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_SivextroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sivextro [Member]", "label": "Sivextro [Member]", "terseLabel": "Sivextro" } } }, "localname": "SivextroMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six point five five percentage notes due on two thousand and thirty seven.", "label": "Six Point Five Five Percentage Notes Due On Two Thousand And Thirty Seven [Member]", "terseLabel": "6.55% notes due 2037" } } }, "localname": "SixPointFiveFivePercentageNotesDueOnTwoThousandAndThirtySevenMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six point five zero percentage notes due on two thousand and thirty three.", "label": "Six Point Five Zero Percentage Notes Due On Two Thousand And Thirty Three [Member]", "terseLabel": "6.50% notes due 2033" } } }, "localname": "SixPointFiveZeroPercentageNotesDueOnTwoThousandAndThirtyThreeMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Six point four percentage debentures due on two thousand and twenty eight.", "label": "Six Point Four Percentage Debentures Due On Two Thousand And Twenty Eight [Member]", "terseLabel": "6.40% debentures due 2028" } } }, "localname": "SixPointFourPercentageDebenturesDueOnTwoThousandAndTwentyEightMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_SotaterceptMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "sotatercept", "label": "sotatercept [Member]", "terseLabel": "sotatercept" } } }, "localname": "SotaterceptMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "mrk_TermForPayingOffEnvironmentalLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term for paying off environmental liabilities.", "label": "Term For Paying Off Environmental Liabilities", "terseLabel": "Term for paying off environmental liabilities" } } }, "localname": "TermForPayingOffEnvironmentalLiabilities", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "durationItemType" }, "mrk_ThemisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Themis [Member]", "label": "Themis [Member]", "terseLabel": "Themis" } } }, "localname": "ThemisMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]", "label": "Three Point Six Zero Percentage Notes Due On Two Thousand And Forty Two [Member]", "terseLabel": "3.60% notes due 2042" } } }, "localname": "ThreePointSixZeroPercentageNotesDueOnTwoThousandAndFortyTwoMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "mrk_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition services agreement", "label": "Transition services agreement [Member]", "terseLabel": "Transition services agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_TukysaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tukysa", "label": "Tukysa [Member]", "terseLabel": "Tukysa" } } }, "localname": "TukysaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction", "label": "Unrecognized Tax Benefits, Decrease Resulting from Spinoff Transaction", "negatedTerseLabel": "Spin-off of Organon" } } }, "localname": "UnrecognizedTaxBenefitsDecreaseResultingFromSpinoffTransaction", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront and Milestone Payments Made to Collaborative Partner", "label": "Upfront and Milestone Payments Made to Collaborative Partner", "terseLabel": "Upfront and milestone payments made to collaborative partner" } } }, "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront and Milestone Payments to be Made to Collaborative Partner", "label": "Upfront and Milestone Payments to be Made to Collaborative Partner", "terseLabel": "Upfront and milestone payments to be made" } } }, "localname": "UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_UpfrontPaymentsMadeToLicenseOrCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront payments made to partner as part of a licensing or collaborative arrangement.", "label": "Upfront Payments Made To License or Collaborative Partner", "terseLabel": "Upfront and milestone payments" } } }, "localname": "UpfrontPaymentsMadeToLicenseOrCollaborativePartner", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_VaqtaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaqta [Member]", "label": "Vaqta [Member]", "terseLabel": "Vaqta" } } }, "localname": "VaqtaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VelosBioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "VelosBio", "label": "VelosBio [Member]", "terseLabel": "VelosBio" } } }, "localname": "VelosBioMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_VerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verquvo", "label": "Verquvo [Member]", "terseLabel": "Verquvo" } } }, "localname": "VerquvoMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ZerbaxaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zerbaxa [Member]", "label": "Zerbaxa [Member]", "terseLabel": "Zerbaxa" } } }, "localname": "ZerbaxaMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaantitrustlitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zetia antitrust litigation [Member]", "label": "Zetia antitrust litigation [Member]", "terseLabel": "Zetia antitrust litigation" } } }, "localname": "ZetiaantitrustlitigationMember", "nsuri": "http://www.merck.com/20221231", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (other than China and Japan)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r405", "r457", "r469", "r470", "r471", "r472", "r473", "r475", "r479", "r563", "r564", "r565", "r566", "r568", "r569", "r571", "r573", "r574", "r1079", "r1080" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r405", "r457", "r469", "r470", "r471", "r472", "r473", "r475", "r479", "r563", "r564", "r565", "r566", "r568", "r569", "r571", "r573", "r574", "r1079", "r1080" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r403", "r404", "r579", "r605", "r946", "r949" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r485", "r975", "r1082", "r1138" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r558", "r559", "r561", "r562", "r708", "r897", "r918", "r939", "r940", "r972", "r986", "r996", "r1081", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r558", "r559", "r561", "r562", "r708", "r897", "r918", "r939", "r940", "r972", "r986", "r996", "r1081", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r485", "r975", "r1082", "r1138" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r481", "r902", "r973", "r994", "r1076", "r1077", "r1082", "r1137" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r481", "r902", "r973", "r994", "r1076", "r1077", "r1082", "r1137" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r558", "r559", "r561", "r562", "r654", "r708", "r740", "r741", "r742", "r873", "r897", "r918", "r939", "r940", "r972", "r986", "r996", "r1070", "r1081", "r1127", "r1128", "r1129", "r1130", "r1131" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r558", "r559", "r561", "r562", "r654", "r708", "r740", "r741", "r742", "r873", "r897", "r918", "r939", "r940", "r972", "r986", "r996", "r1070", "r1081", "r1127", "r1128", "r1129", "r1130", "r1131" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r403", "r404", "r579", "r605", "r948", "r949" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r709", "r1049" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r424", "r709", "r1015", "r1049" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r499" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r482", "r483", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r974", "r995", "r1082" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r482", "r483", "r926", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r974", "r995", "r1082" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r424", "r709", "r1015", "r1016", "r1049" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r49", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r927" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r487", "r488" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $72 in 2022 and $62 in 2021)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r504" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Factored accounts receivable" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "auth_ref": [ "r560", "r962", "r1011", "r1012", "r1071", "r1073" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.", "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Accrued liabilities for environmental matters" } } }, "localname": "AccrualForEnvironmentalLossContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r33", "r303", "r324" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r71", "r78", "r261", "r1027", "r1028", "r1029" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r160", "r350" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r377", "r386", "r807", "r1028", "r1029" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r377", "r387", "r388", "r807", "r950", "r1027" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r373", "r374", "r375", "r377", "r387", "r388", "r1027" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Investments" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r72", "r78", "r1087" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "terseLabel": "Pension and other postretirement benefit plans, net loss and prior service (credit) included in AOCI" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r75", "r77", "r78", "r362", "r912", "r923", "r924" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r386", "r387", "r842", "r843", "r844", "r845", "r846", "r848" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r74", "r78", "r261", "r863", "r919", "r920", "r1027", "r1028", "r1029", "r1046", "r1047", "r1048" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r69", "r78", "r261", "r387", "r388", "r843", "r844", "r845", "r846", "r848", "r1027" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated useful life of intangible assets, acquired" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r41" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Other paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r750", "r751", "r752", "r1046", "r1047", "r1048", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Other Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r110", "r151" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "negatedTerseLabel": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r755" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising and Promotion Costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r756" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising and promotion costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r453", "r469", "r470", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other segments" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r744" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Pretax share-based compensation cost recorded" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r363", "r489", "r503" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r110", "r143", "r151" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense for intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r1105" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r989", "r1106", "r1107", "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration paid" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r989", "r1106", "r1107", "r1108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Transaction costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r1105" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r301", "r323", "r354", "r399", "r465", "r471", "r477", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r805", "r808", "r836", "r993", "r1079", "r1080", "r1124" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r345", "r367", "r399", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r805", "r808", "r836", "r993", "r1079", "r1080", "r1124" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r287" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r136" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, gross unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r137" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt securities, gross unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r491", "r510" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r135", "r490", "r510", "r906" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Foreign government bonds", "verboseLabel": "Debt securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r715", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r739", "r740", "r741", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r270", "r273" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "terseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r159" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r796", "r980", "r983" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r241", "r242", "r796", "r980", "r983" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r799", "r1036" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "negatedTerseLabel": "Business combination, contingent consideration arrangements, change in amount of contingent consideration liability", "terseLabel": "Contingent consideration liability, changes in estimated fair value", "verboseLabel": "Changes in estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r249", "r250", "r798" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Contingent consideration, ending balance", "periodStartLabel": "Contingent consideration, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r249", "r251" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Contingent consideration, liability, current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input, discount rate" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities", "verboseLabel": "Investments" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r244" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "verboseLabel": "In-process research and development (IPR&D)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r243", "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Products and product rights - Reblozyl (12 year useful life)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r243", "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r244" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed", "terseLabel": "Share-based compensation payments to settle equity awards attributable to precombination service" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r112", "r348", "r941" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r106", "r112", "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Year (includes $79, $71 and $103 of restricted cash at December 31, 2022, 2021 and 2020 included in Other current assets)", "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $71, $103 and $258 of restricted cash at January 1, 2022, 2021 and 2020 included in Other current assets)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r106", "r294" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r1018" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r106" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash used in financing activities" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r20", "r106" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash used in investing activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r20", "r106" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash provided by operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.", "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]", "terseLabel": "Obligation and Funded Status" } } }, "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementAccountingPolicy": { "auth_ref": [ "r802" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for collaborative arrangements.", "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementAccountingPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r800", "r801", "r804" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r803" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r1109" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r175", "r554", "r555", "r928", "r1078" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies and Environmental Liabilities" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r178", "r929" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies and Legal Defense Costs" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common stock, dividends declared (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r1046", "r1047", "r1116" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance December\u00a031 (in shares)", "periodStartLabel": "Balance January\u00a01 (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r40", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r80", "r382", "r384", "r392", "r908", "r914" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r97", "r391", "r907", "r913" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r118", "r119", "r292", "r293", "r485", "r927" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r118", "r119", "r292", "r293", "r485", "r925", "r927" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r118", "r119", "r292", "r293", "r485", "r927", "r1140" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r118", "r119", "r292", "r293", "r485" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Percentage of accounts receivable represented by customers with largest balances (as percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r118", "r119", "r292", "r293", "r485", "r927" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r258", "r951" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r159" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r976", "r978", "r1139" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r128", "r470", "r471", "r472", "r473", "r479", "r1052" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other", "verboseLabel": "Other profits" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92", "r902" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": { "auth_ref": [ "r169", "r170", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.", "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]", "terseLabel": "Restructuring Costs" } } }, "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r1043", "r1099", "r1101" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r1043", "r1099" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r238", "r779", "r787", "r1043" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r1043", "r1099", "r1101" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r117", "r485" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r356" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r182", "r397", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r592", "r599", "r600", "r602" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Loans Payable, Long-Term Debt and Leases" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r32", "r33", "r34", "r302", "r305", "r319", "r405", "r576", "r577", "r578", "r579", "r580", "r582", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r598", "r852", "r967", "r968", "r969", "r970", "r971", "r1041" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r296", "r298", "r576", "r852", "r968", "r969" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r590", "r835", "r968", "r969" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of loans payable and long-term debt, including current portion" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r57", "r577" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate", "verboseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r58", "r405", "r576", "r577", "r578", "r579", "r580", "r582", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r598", "r852", "r967", "r968", "r969", "r970", "r971", "r1041" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r58", "r187", "r190", "r191", "r192", "r295", "r296", "r298", "r317", "r405", "r576", "r577", "r578", "r579", "r580", "r582", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r598", "r601", "r852", "r967", "r968", "r969", "r970", "r971", "r1041" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-Term and Short-Term, Combined Amount", "terseLabel": "Debt, carrying amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Reasonably possible amount that liability for unrecognized tax benefits could decline up to in next 12 months (up to)" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r1043", "r1100", "r1101" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r238", "r1043", "r1100" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r238", "r780", "r786", "r787", "r1043" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes", "totalLabel": "Total deferred provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred provision" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r37", "r38", "r304", "r318", "r774" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Subtotal, Liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r760", "r761" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Taxes", "verboseLabel": "Deferred Income Taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r1043", "r1100", "r1101" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsEquityMethodInvestments": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.", "label": "Deferred Tax Assets, Equity Method Investments", "terseLabel": "Equity Method Investments, Assets" } } }, "localname": "DeferredTaxAssetsEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Product intangibles and licenses, Assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r775" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Subtotal, Assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets, in Process Research and Development", "terseLabel": "R&D capitalization, Assets" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory related, Assets" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r1097" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total deferred taxes" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "auth_ref": [ "r235", "r1098" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "terseLabel": "Deferred tax assets on NOL carryforwards relating to foreign jurisdictions" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other, Assets" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "auth_ref": [], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.", "label": "Deferred Tax Assets, Property, Plant and Equipment", "terseLabel": "Accelerated depreciation, Assets" } } }, "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "terseLabel": "Pensions and other postretirement benefits, Assets" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation", "terseLabel": "Compensation related, Assets" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r776" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance, Assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r226", "r1097" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "totalLabel": "Deferred income taxes, Liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "terseLabel": "Inventory related, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Product intangibles and licenses, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r235", "r1098" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Accelerated depreciation, Liabilities" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": { "auth_ref": [ "r663" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.", "label": "Defined Benefit Plan, Accumulated Benefit Obligation", "terseLabel": "Accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": { "auth_ref": [ "r645", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.", "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)", "terseLabel": "Actual return on plan assets" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]", "terseLabel": "Actual return on plan assets:" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod": { "auth_ref": [ "r659", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets sold.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Sold", "terseLabel": "Relating to assets sold during the year" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsSoldDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": { "auth_ref": [ "r659", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held", "terseLabel": "Relating to assets still held at December 31" } } }, "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanActuarialGainLoss": { "auth_ref": [ "r638" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.", "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)", "negatedLabel": "Actuarial (gains) losses" } } }, "localname": "DefinedBenefitPlanActuarialGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r631", "r670", "r696", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net loss (gain) amortization" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r631", "r671", "r697", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of unrecognized prior service cost" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r300", "r322", "r629", "r630", "r653", "r978" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Other Assets" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Salary growth rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": { "auth_ref": [ "r680" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": { "auth_ref": [ "r677" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r679", "r701" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets", "terseLabel": "Expected rate of return on plan assets", "verboseLabel": "Expected rate of return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": { "auth_ref": [ "r678" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase", "terseLabel": "Salary growth rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": { "auth_ref": [ "r680" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate", "terseLabel": "Interest crediting rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r633" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "periodEndLabel": "Benefit obligation December\u00a031", "periodStartLabel": "Benefit obligation January\u00a01" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": { "auth_ref": [ "r640", "r704" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": { "auth_ref": [ "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r682", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Information by defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Axis]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]" } } }, "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": { "auth_ref": [ "r976" ], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]", "terseLabel": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]", "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]" } } }, "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r647", "r657", "r700", "r976", "r977", "r978", "r979" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Company contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "auth_ref": [ "r685" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "terseLabel": "Termination benefits" } } }, "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCurtailments": { "auth_ref": [ "r635" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanCurtailments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDerivativeMember": { "auth_ref": [ "r976" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or other contract with one or more underlyings, notional amount or payment provision or both; can be settled net by means outside contract or delivery of asset; and with minimal or no initial net investment, in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Derivative [Member]", "terseLabel": "Derivatives" } } }, "localname": "DefinedBenefitPlanDerivativeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanDivestituresBenefitObligation": { "auth_ref": [ "r643" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in benefit obligation of defined benefit plan from disposal or classification as held-for-sale.", "label": "Defined Benefit Plan, Benefit Obligation, Divestiture", "negatedTerseLabel": "Spin-off of Organon" } } }, "localname": "DefinedBenefitPlanDivestituresBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDivestituresPlanAssets": { "auth_ref": [ "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in plan assets of defined benefit plan from disposal or classification as held-for-sale.", "label": "Defined Benefit Plan, Plan Assets, Divestiture", "negatedTerseLabel": "Spin-off of Organon" } } }, "localname": "DefinedBenefitPlanDivestituresPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesNonUsMember": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, not domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, Non-US [Member]", "terseLabel": "International equities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesNonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanEquitySecuritiesUsMember": { "auth_ref": [ "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Security representing ownership in corporation or other legal entity, domiciled in United States of America (US), for which ownership is represented by share of stock; in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.", "label": "Defined Benefit Plan, Equity Securities, US [Member]", "terseLabel": "U.S.\u00a0equities" } } }, "localname": "DefinedBenefitPlanEquitySecuritiesUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years", "terseLabel": "2028\u00a0\u2014\u00a02032" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One", "terseLabel": "2023" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five", "terseLabel": "2027" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four", "terseLabel": "2026" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three", "terseLabel": "2025" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": { "auth_ref": [ "r664" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two", "terseLabel": "2024" } } }, "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": { "auth_ref": [ "r665", "r979" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year", "terseLabel": "Expected contributions to the pension plans and other postretirement benefit plans during next fiscal year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r631", "r669", "r695", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": { "auth_ref": [ "r644", "r655", "r657", "r658", "r976", "r977", "r978" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.", "label": "Defined Benefit Plan, Plan Assets, Amount", "periodEndLabel": "Fair value of plan assets December\u00a031", "periodStartLabel": "Fair value of plan assets January\u00a01", "terseLabel": "Fair value of plan assets", "verboseLabel": "Plan assets at fair value" } } }, "localname": "DefinedBenefitPlanFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": { "auth_ref": [ "r639" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Effects of exchange rate changes" } } }, "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r629", "r653", "r978" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "totalLabel": "Funded status December\u00a031" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.", "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year", "terseLabel": "Health care cost trend rate assumed for next year" } } }, "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r631", "r636", "r668", "r694", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r666", "r692", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost (credit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanOtherChanges": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change, classified as other.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Other Change", "terseLabel": "Other" } } }, "localname": "DefinedBenefitPlanOtherChanges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": { "auth_ref": [ "r689", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": { "auth_ref": [ "r689", "r690", "r978" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation", "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, accumulated benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": { "auth_ref": [ "r689", "r690", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets", "terseLabel": "Pension plans with an accumulated benefit obligation in excess of plan assets, fair value of plan assets" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": { "auth_ref": [ "r1088" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.", "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation", "terseLabel": "Pension plans with a projected benefit obligation in excess of plan assets, projected benefit obligation" } } }, "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAmendments": { "auth_ref": [ "r641" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.", "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment", "terseLabel": "Plan amendments" } } }, "localname": "DefinedBenefitPlanPlanAmendments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": { "auth_ref": [ "r649", "r1089" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.", "label": "Defined Benefit Plan, Plan Assets, Benefits Paid", "negatedLabel": "Benefits paid" } } }, "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r646" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Effects of exchange rate changes" } } }, "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": { "auth_ref": [ "r654", "r978" ], "lang": { "en-us": { "role": { "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.", "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage", "terseLabel": "Target allocation" } } }, "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": { "auth_ref": [ "r660", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement", "terseLabel": "Purchases and sales, net" } } }, "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRealEstateMember": { "auth_ref": [ "r976", "r978" ], "lang": { "en-us": { "role": { "documentation": "Property composed of building, land and land improvement; in which defined benefit plan asset is invested.", "label": "Defined Benefit Plan, Real Estate [Member]", "terseLabel": "Real estate" } } }, "localname": "DefinedBenefitPlanRealEstateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r632", "r673", "r699" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r632", "r673", "r699" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 8.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r634", "r667", "r693", "r978", "r979" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": { "auth_ref": [ "r635" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement", "negatedLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": { "auth_ref": [ "r652" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.", "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement", "negatedLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanSettlementsPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": { "auth_ref": [ "r661", "r978" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.", "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3", "terseLabel": "Transfers into Level 3" } } }, "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": { "auth_ref": [ "r681" ], "lang": { "en-us": { "role": { "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.", "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate", "terseLabel": "Rate to which the cost trend rate is assumed to decline" } } }, "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]", "terseLabel": "Benefit obligation" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]", "terseLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]", "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]" } } }, "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r705" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Employer contributions to defined contribution savings plans" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r110", "r158" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r110", "r460" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortizationPolicyTextBlock": { "auth_ref": [ "r952" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for depreciation, depletion, and amortization of property and equipment costs, including methods used and estimated useful lives and how impairment of such assets is assessed and recognized.", "label": "Depreciation, Depletion, and Amortization [Policy Text Block]", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortizationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r66", "r67" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, asset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r65", "r67", "r369" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, asset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r368", "r371", "r835", "r949" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "netLabel": "Derivative assets", "terseLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "verboseLabel": "Fair Value of Derivative, Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Maximum planning cycle of hedges (less than)" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r67", "r281", "r370", "r947" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "negatedTerseLabel": "Cash collateral received, asset", "terseLabel": "Cash collateral received from counterparties" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r67", "r281", "r370", "r947" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "negatedLabel": "Cash collateral received, liability" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimSecurities": { "auth_ref": [ "r67", "r370", "r947" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset", "terseLabel": "Cash collateral advanced to counterparties" } } }, "localname": "DerivativeCollateralRightToReclaimSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r1112" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r1112" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r271", "r272", "r277", "r279", "r949" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r268", "r271", "r277", "r279", "r283", "r285", "r815" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r819" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Pre tax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r276", "r1113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r368", "r371", "r835", "r949" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "netLabel": "Derivative liabilities", "terseLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "verboseLabel": "Fair Value of Derivative, Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r66", "r67" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, liability" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r65", "r67", "r369" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedLabel": "Gross amount subject to offset in master netting arrangements not offset in the consolidated balance sheet, liability" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r810" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r1110", "r1111" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of derivative" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r274", "r277", "r280", "r282", "r285", "r820" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Products and product rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r714", "r745", "r746", "r748", "r754", "r987" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": { "auth_ref": [ "r6", "r7", "r18" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax", "totalLabel": "Income from discontinued operations before taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Income from Discontinued Operations (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Period of continuing involvement after disposal" } } }, "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": { "auth_ref": [ "r7", "r23", "r1103" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.", "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period", "terseLabel": "Tax provision" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r21", "r162" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Less: Cash and cash equivalents related to discontinued operations" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r19", "r344" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 5.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r19" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r19" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "auth_ref": [ "r19" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Expense", "terseLabel": "Disposal group, other expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r19", "r344" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r27", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Spin-Off of Organon & Co." } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCo" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r361", "r565", "r566", "r567", "r573", "r574", "r575", "r865", "r943", "r1044" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r49", "r565", "r566", "r567", "r573", "r574", "r575", "r865", "r1044" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r393", "r416", "r417", "r418", "r419", "r420", "r425", "r428", "r436", "r437", "r438", "r442", "r823", "r824", "r909", "r915", "r957" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "totalLabel": "Net Income (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0& Co., Inc. Common Shareholders" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r393", "r416", "r417", "r418", "r419", "r420", "r428", "r436", "r437", "r438", "r442", "r823", "r824", "r909", "r915", "r957" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "totalLabel": "Net Income (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r439", "r440", "r441", "r443" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsperShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r841" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r763" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Total, Tax Rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Tax\u00a0Rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r401", "r763", "r789" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowances" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign earnings" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to restructuring charges.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Percent", "terseLabel": "Restructuring" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseRestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "negatedTerseLabel": "R&D tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r1095", "r1102" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Tax settlements" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r747" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total pre tax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r747" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r744" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Income tax benefits related to share-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "auth_ref": [ "r749" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Tax benefits relating to stock option exercises" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EnvironmentalExitCostsReasonablyPossibleAdditionalLoss": { "auth_ref": [ "r557", "r561", "r562" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimate of reasonably possible loss exposure in excess of amount accrued for remediation, site restoration, postclosure, monitoring commitments, or other exit costs associated with the sale, disposal or abandonment of a particular property resulting from unanticipated contamination of the assets.", "label": "Environmental Exit Costs, Reasonably Possible Additional Loss", "terseLabel": "Aggregate possible expenditure on environmental matters in excess of amounts accrued" } } }, "localname": "EnvironmentalExitCostsReasonablyPossibleAdditionalLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r186", "r341", "r386", "r387", "r388", "r411", "r412", "r413", "r415", "r421", "r423", "r445", "r502", "r619", "r750", "r751", "r752", "r782", "r783", "r822", "r842", "r843", "r844", "r845", "r846", "r848", "r863", "r919", "r920", "r921" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r834" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities held through ownership interests in investment funds" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r355", "r834", "r944" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails": { "order": 2.0, "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r1056" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedTerseLabel": "Loss (income) from investments in equity securities, net" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r916", "r1056" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedTerseLabel": "(Gains) losses for equity securities held through ownership interests in investment funds" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r916", "r1056" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "verboseLabel": "Unrealized gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r138", "r320", "r997", "r998", "r999" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r496" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r497" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative downward price adjustment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r498" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative upward price adjustment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r826", "r827", "r832" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r590", "r657", "r658", "r659", "r660", "r661", "r662", "r827", "r870", "r871", "r872", "r968", "r969", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r826", "r827", "r829", "r830", "r833" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r590", "r657", "r662", "r827", "r870", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r590", "r657", "r662", "r827", "r871", "r968", "r969", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r590", "r657", "r658", "r659", "r660", "r661", "r662", "r827", "r872", "r968", "r969", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r289", "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summarized Information about the Changes in Liabilities for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasuredAtNetAssetValuePerShareMember": { "auth_ref": [ "r657", "r825", "r833" ], "lang": { "en-us": { "role": { "documentation": "Fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Measured at Net Asset Value Per Share [Member]", "terseLabel": "NAV" } } }, "localname": "FairValueMeasuredAtNetAssetValuePerShareMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r590", "r657", "r658", "r659", "r660", "r661", "r662", "r870", "r871", "r872", "r968", "r969", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r831", "r833" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r270", "r274", "r283" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r492", "r493", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r601", "r616", "r820", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r960", "r1053", "r1054", "r1055", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful life of intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r352", "r535" ], "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "Estimated aggregate amortization expense, 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "terseLabel": "Estimated aggregate amortization expense, 2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "Estimated aggregate amortization expense, 2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "Estimated aggregate amortization expense, 2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "Estimated aggregate amortization expense, 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r531", "r534", "r535", "r537", "r903", "r904" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Intangible Assets Excluding Goodwill [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r144", "r149" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r150", "r903" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r532" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-Lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible assets acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedIncomeInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investments that regularly generate a fixed amount of interest income. Examples include, but are not limited to, bonds, certificates of deposit, notes and debt securities.", "label": "Fixed Income Investments [Member]", "terseLabel": "Fixed Income Investments" } } }, "localname": "FixedIncomeInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign Jurisdiction" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r837", "r838", "r839", "r840" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r949", "r976", "r991" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Currency Options" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r1084", "r1139" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign government bonds" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "The number of issuer's shares to which the forward contract is indexed.", "label": "Forward Contract Indexed to Issuer's Equity, Indexed Shares", "terseLabel": "Forward contract indexed to issuer's equity, indexed shares (in shares)" } } }, "localname": "ForwardContractIndexedToIssuersEquityIndexedShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r1115" ], "lang": { "en-us": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r351", "r518", "r905", "r961", "r993", "r1058", "r1065" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, ending balance", "periodStartLabel": "Goodwill, beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r520", "r961" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangibles" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r529", "r530", "r961" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r519", "r526", "r961" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "terseLabel": "Accumulated goodwill impairment losses" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillOtherIncreaseDecrease": { "auth_ref": [ "r525" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Other Increase (Decrease)", "verboseLabel": "Other" } } }, "localname": "GoodwillOtherIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r816" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Carrying Amount of Hedged Liabilities" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r817" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase Included in the Carrying Amount" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r268", "r815" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of finite-lived intangible asset.", "label": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "ImpairmentOfIntangibleAssetFiniteLivedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes impairment of indefinite-lived intangible asset excluding goodwill.", "label": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "ImpairmentOfIntangibleAssetIndefiniteLivedExcludingGoodwillStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r110", "r154" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r1037", "r1069" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-Lived", "terseLabel": "Intangible asset impairment charge related to marketed product" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r1037", "r1069" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "verboseLabel": "IPR&D impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "IPR&D" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "auth_ref": [ "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.", "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "Acquired In-Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r90", "r111", "r255", "r416", "r417", "r418", "r419", "r434", "r438" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc.", "totalLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r253", "r256" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r400", "r788" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r84", "r299", "r313", "r336", "r465", "r470", "r476", "r479", "r910", "r959" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Income before taxes", "totalLabel": "Income from Continuing Operations Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r400", "r788" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r256", "r399", "r414", "r465", "r470", "r476", "r479", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r824", "r836", "r959", "r1079" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income from continuing operations", "totalLabel": "Net Income from Continuing Operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r82", "r311", "r314", "r332", "r393", "r414", "r416", "r417", "r418", "r419", "r428", "r436", "r437", "r824", "r909" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Income from Continuing Operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r82", "r332", "r335", "r393", "r414", "r416", "r417", "r418", "r419", "r428", "r436", "r437", "r438", "r824", "r909", "r915" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income from Continuing Operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r6", "r7", "r8", "r9", "r10", "r23", "r333", "r344", "r792" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income from discontinued operations, net of taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r6", "r7", "r8", "r9", "r10", "r18", "r23", "r253", "r256" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Income of discontinued operations attributable to noncontrolling interests" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r6", "r7", "r8", "r9", "r10", "r18", "r23", "r256" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 }, "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests", "totalLabel": "Income from discontinued operations, net of taxes attributable to parent" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r264", "r429", "r436", "r437" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Income from Discontinued Operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r85", "r110", "r139", "r312", "r331", "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "verboseLabel": "Equity income (loss) from affiliates" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r11", "r12", "r13", "r14", "r16", "r17", "r22", "r24", "r25", "r26", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r539", "r544" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r230", "r231", "r232", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r401", "r764", "r772", "r778", "r784", "r790", "r793", "r794", "r795" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r402", "r422", "r423", "r463", "r762", "r785", "r791", "r917" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 }, "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on Income from Continuing Operations", "totalLabel": "Taxes on income" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails", "http://www.merck.com/role/TaxesonIncomeTaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]", "terseLabel": "Amount" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r385", "r758", "r759", "r772", "r773", "r777", "r781" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Valuation allowances" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign earnings" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r763" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "U.S. statutory rate applied to income from continuing operations before taxes" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount", "terseLabel": "Restructuring" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State taxes" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedTerseLabel": "R&D tax credit" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxSettlements": { "auth_ref": [ "r1095" ], "calculation": { "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount", "terseLabel": "Tax settlements" } } }, "localname": "IncomeTaxReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeReconciliationBetweenEffectiveTaxRateandUSStatutoryRateDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r107", "r114" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeIncomeTaxAuthorityDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Net changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Noncurrent liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r533", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r146", "r153" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r149", "r899", "r900", "r901", "r903", "r953" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Acquired Intangibles" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r351" ], "calculation": { "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Carrying Amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r142", "r148" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangibles, Net", "totalLabel": "Net", "verboseLabel": "Other intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r297", "r316", "r389", "r459", "r851" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r1038" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r949", "r976", "r990" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r990" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap", "verboseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalUseSoftwarePolicy": { "auth_ref": [ "r155", "r156" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs incurred when both (1) the software is acquired, internally developed, or modified solely to meet the entity's internal needs, and (2) during the software's development or modification, no substantive plan exists or is being developed to market the software externally.", "label": "Internal Use Software, Policy [Policy Text Block]", "terseLabel": "Software Capitalization" } } }, "localname": "InternalUseSoftwarePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r1021" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r1025" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates current cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r1024" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r365", "r942", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (excludes inventories of $2,938 in 2022 and $2,194 in 2021 classified in Other assets - see Note\u00a08)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r1020" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventory classified in Other assets", "verboseLabel": "Other Assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/InventoriesInventoriesDetails", "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r347", "r364", "r444", "r514", "r516", "r517", "r898", "r954" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r1025" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Raw materials and work in process" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Inventory write-down" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r94", "r458" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r500", "r1136" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LIFOInventoryAmount": { "auth_ref": [ "r945" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of LIFO (last in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.", "label": "LIFO Inventory Amount", "terseLabel": "LIFO inventory amount" } } }, "localname": "LIFOInventoryAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r1019" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r1122" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Maturities of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails_1": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r862" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r1121" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, operating lease, renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r54", "r399", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r806", "r808", "r809", "r836", "r958", "r1079", "r1124", "r1125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r45", "r307", "r327", "r993", "r1042", "r1057", "r1118" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r56", "r346", "r399", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r806", "r808", "r809", "r836", "r993", "r1079", "r1124", "r1125" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Payables included in Accrued and other current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r287" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r29", "r30", "r31", "r34", "r35", "r399", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r806", "r808", "r809", "r836", "r1079", "r1124", "r1125" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Payables included in Other Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r1083" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]", "terseLabel": "License" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Available borrowing capacity under credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r60", "r1073" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Legal defense costs reserve" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r53" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-Term Debt, Current Maturities", "terseLabel": "Long-term debt, current maturities" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r180", "r405", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "Long-term debt, maturities, repayments of principal in 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r180", "r405", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Five", "terseLabel": "Long-term debt, maturities, repayments of principal in 2027" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r180", "r405", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "Long-term debt, maturities, repayments of principal in 2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r180", "r405", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "Long-term debt, maturities, repayments of principal in 2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r180", "r405", "r594" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "Long-term debt, maturities, repayments of principal in 2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r357" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "terseLabel": "Effective interest rate" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r58", "r181" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r176", "r177", "r556", "r558", "r559", "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r176", "r177", "r556", "r558", "r559", "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss contingency, claims settled (in cases)" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r1073", "r1074", "r1075" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Loss contingency, damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r176", "r177", "r556", "r558", "r559", "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Loss contingency, new claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [ "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Loss Contingency, Number of Plaintiffs", "terseLabel": "Loss contingency, number of plaintiffs" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r1074", "r1075" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss contingency, pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r159" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery, equipment and office furnishings" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery, equipment and office furnishings" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "verboseLabel": "Unallocated" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r1117" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r828" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r64", "r306", "r326", "r399", "r501", "r563", "r566", "r567", "r568", "r574", "r575", "r836" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions attributable to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r447", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/NatureofOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "auth_ref": [ "r106" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.", "label": "Net Cash Provided by (Used in) Discontinued Operations", "totalLabel": "Net Cash Flows Provided by Discontinued Operations" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]", "terseLabel": "Cash Flows from Discontinued Operations" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r1035" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net Cash (Used in) Provided by Financing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r1035" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net Cash Used in Investing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r106", "r108", "r111" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net Cash Provided by Operating Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r87", "r111", "r315", "r334", "r344", "r380", "r383", "r388", "r399", "r414", "r416", "r417", "r418", "r419", "r422", "r423", "r434", "r465", "r470", "r476", "r479", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r824", "r836", "r959", "r1079" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Attributable to Merck & Co., Inc.", "totalLabel": "Net Income Attributable to Merck & Co., Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r259", "r263", "r380", "r383", "r422", "r423", "r1029" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "verboseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r416", "r417", "r418", "r419", "r425", "r426", "r435", "r438", "r465", "r470", "r476", "r479", "r959" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Merck & Co., Inc., basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r427", "r430", "r431", "r432", "r433", "r435", "r438" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income attributable to Merck & Co., Inc., diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r631" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r253", "r619", "r1046", "r1047", "r1048" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r1051" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/NatureofOperationsDetails", "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r963", "r964", "r965", "r966" ], "lang": { "en-us": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Separation Costs" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r857", "r992" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease, cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r854" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability", "verboseLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r854" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r854" ], "calculation": { "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r856", "r858" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease, payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r853" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Other Assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r861", "r992" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r860", "r992" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term", "verboseLabel": "Weighted-average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesBalanceSheetInformationDetails", "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwardsValuationAllowance": { "auth_ref": [ "r233" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.", "label": "Operating Loss Carryforwards, Valuation Allowance", "terseLabel": "Valuation allowance on foreign NOL carryforwards" } } }, "localname": "OperatingLossCarryforwardsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r469", "r470", "r471", "r472", "r473", "r479" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "verboseLabel": "Total segment profits" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r366", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r270", "r283" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDeferredIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r353" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": { "auth_ref": [ "r73", "r75", "r674" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax", "negatedTerseLabel": "Prior service (cost) credit arising during the period" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": { "auth_ref": [ "r75", "r79", "r379", "r674" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax", "terseLabel": "Prior service credit amortization included in benefit cost" } } }, "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r373", "r374", "r376" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Net unrealized loss on investments, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r78", "r387", "r842", "r844", "r848", "r1027" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r78", "r81", "r387", "r842", "r844", "r848", "r1027" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r76", "r386" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r372", "r376" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r372", "r376", "r811", "r812", "r818" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r376", "r378" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Increase (decrease) in Sales as a result of AOCL reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r68" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r813" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r814" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r81", "r186", "r381", "r384", "r391", "r842", "r847", "r848", "r907", "r913", "r1027", "r1028" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r256", "r257", "r260", "r381", "r384" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax": { "auth_ref": [ "r72", "r75" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment and Tax", "negatedTotalLabel": "Total" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r72", "r75" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Benefit plan net gain (loss) and prior service credit (cost), net of amortization" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": { "auth_ref": [ "r70", "r75", "r206" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsAndTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax", "terseLabel": "Net loss (gain) amortization included in benefit cost" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax": { "auth_ref": [ "r75", "r79", "r379", "r1086" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net period benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, before Tax", "totalLabel": "Total" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": { "auth_ref": [ "r75", "r79", "r379", "r674" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.", "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax", "negatedTerseLabel": "Net loss (gain) amortization included in benefit cost" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r270", "r283" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "verboseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r199", "r221" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Licenses and other" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventorySupplies": { "auth_ref": [ "r1022" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.", "label": "Other Inventory, Supplies, Gross", "terseLabel": "Supplies" } } }, "localname": "OtherInventorySupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other investments.", "label": "Other Investments [Member]", "terseLabel": "Other", "verboseLabel": "Other" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r55", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r111" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedBetweenThoseDerivativesThatareDesignatedasHedgingInstrumentsandThoseThatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 5.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r201", "r629", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680", "r682", "r685", "r688", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r705", "r706", "r707", "r978", "r979", "r980", "r981", "r982" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r963", "r964", "r965", "r966" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r248" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r1030", "r1031" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r104" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r543", "r1034" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "(Payments) receipts, net" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r104" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": { "auth_ref": [ "r1031" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Three, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Pandion Therapeutics, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r1031" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Acceleron Pharma Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r100", "r797" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid for acquisition of business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r100" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Other acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "auth_ref": [ "r395", "r495" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.", "label": "Payments to Acquire Equity Securities, FV-NI", "negatedTerseLabel": "Purchase of Seagen Inc. common stock" } } }, "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Payments to acquire investment" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r134" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of securities and other investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r394", "r1106", "r1107", "r1108" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures", "terseLabel": "Payments to acquire productive assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r1073" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r654", "r656", "r662", "r681", "r683", "r684", "r685", "r686", "r687", "r702", "r703", "r705", "r711", "r978" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": { "auth_ref": [ "r33", "r629", "r630", "r653", "r978" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.", "label": "Liability, Defined Benefit Plan, Current", "negatedLabel": "Accrued and other current liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "auth_ref": [ "r36", "r629", "r630", "r653", "r978" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.", "label": "Liability, Defined Benefit Plan, Noncurrent", "negatedLabel": "Other Noncurrent Liabilities" } } }, "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r200", "r629", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680", "r682", "r685", "r688", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r705", "r706", "r710", "r978", "r979", "r983", "r984", "r985" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Benefits" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "PSUs" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanAssetCategoriesDomain": { "auth_ref": [ "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r682", "r976", "r977", "r978" ], "lang": { "en-us": { "role": { "documentation": "Defined benefit plan asset investment.", "label": "Defined Benefit Plan, Plan Assets, Category [Domain]", "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]" } } }, "localname": "PlanAssetCategoriesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1017" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r103" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r1032", "r1033" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-Term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r99" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales of securities and other investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Revenue related to the sale of the marketing rights" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r102", "r220" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "verboseLabel": "Cash received from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductionRelatedImpairmentsOrCharges": { "auth_ref": [ "r91" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Nonrecurring impairment charges related to the write-off of production-related equipment and inventory. This tag is used when an Entity charges this cost to cost of goods sold.", "label": "Production Related Impairments or Charges", "terseLabel": "Inventory write-off related to contract termination" } } }, "localname": "ProductionRelatedImpairmentsOrCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAdditions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Additions", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentAdditions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r159", "r349" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment (at cost)" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross [Abstract]", "terseLabel": "Property, Plant and Equipment (at cost)" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r161", "r329", "r911", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful life of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r1023" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [ "r1023" ], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r328", "r337", "r993" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "verboseLabel": "Receivables included in Other current assets" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r78", "r387", "r842", "r846", "r848", "r1027" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedTerseLabel": "Reclassification adjustments, pretax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r78", "r81", "r387", "r842", "r846", "r848", "r1027" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTotalLabel": "Reclassification adjustments, net of taxes" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r76", "r379", "r386" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r125", "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Segment Profits to Income Before Taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartiesAmountInCostOfSales": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.", "label": "Related Parties Amount in Cost of Sales", "terseLabel": "Related party amount in cost of sales" } } }, "localname": "RelatedPartiesAmountInCostOfSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r340", "r864", "r865", "r1123" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r223", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Compensation earned on arragement" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r224", "r225" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r147" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "verboseLabel": "Charge for the acquisition of Pandion Therapeutics, Inc." } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r222", "r339", "r1132" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 3.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r1018", "r1039", "r1133", "r1135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r1018", "r1039" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Funds collected from factoring of receivable, held in restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r541", "r543", "r546", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r542", "r545", "r549", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative costs since program inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r542", "r545", "r549", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected restructuring and related cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r542", "r545", "r549", "r551" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Expenses", "verboseLabel": "Total pretax restructuring costs" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r110", "r547", "r549", "r1072" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 4.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r169", "r173" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r542", "r543", "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r1013", "r1014" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes incurred restructuring and related costs.", "label": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Restructuring, Incurred Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r543", "r548" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r42", "r193", "r325", "r922", "r924", "r993" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r341", "r411", "r412", "r413", "r415", "r421", "r423", "r502", "r750", "r751", "r752", "r782", "r783", "r822", "r919", "r921" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r678", "r679", "r680", "r682", "r685", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r678", "r679", "r680", "r682", "r685", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r1090", "r1091", "r1092" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r200", "r201", "r629", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680", "r682", "r685", "r688", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r705", "r706", "r707", "r710", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r200", "r201", "r629", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680", "r682", "r685", "r688", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r705", "r706", "r707", "r710", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansAccumulatedandProjectedBenefitObligationinExcessofPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r955" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r88", "r338", "r565", "r566", "r567", "r573", "r574", "r575" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r390", "r399", "r456", "r457", "r469", "r474", "r475", "r481", "r482", "r485", "r501", "r563", "r564", "r566", "r567", "r568", "r570", "r572", "r574", "r575", "r836", "r910", "r1079" ], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales", "totalLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r859", "r992" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyIncomeNonoperating": { "auth_ref": [ "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Income, Nonoperating", "terseLabel": "Royalties" } } }, "localname": "RoyaltyIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Total sales" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r78", "r1119", "r1120" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in AOCI by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.", "label": "Schedule of Allocation of Plan Assets [Table Text Block]", "terseLabel": "Schedule of Allocation of Plan Assets" } } }, "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.", "label": "Defined Benefit Plan, Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted Average Assumptions Used in Determining Pension Plan and U.S. Pension and Other Postretirement Benefit Plan Information" } } }, "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Information on Investments in Debt and Equity Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r241", "r242", "r796" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsEstimatedFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r1109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r1109" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r58", "r187", "r190", "r191", "r192", "r295", "r296", "r298", "r317", "r968", "r970", "r1045" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-term Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Deferred Income Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.", "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of Other Comprehensive Income" } } }, "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofNetPeriodicBenefitCostDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansComponentsofOtherComprehensiveIncomeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofOtherPostretirementBenefitPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansFairValuesofPensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansObligationandFundedStatusDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofChangesinFairValueofCompanysLevel3PensionPlanAssetsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofExpectedBenefitPaymentsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofHealthCareCostTrendRateAssumptionsforOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansSummaryofWeightedAverageAssumptionsUsedinDeterminingPensionPlanandUSPensionandOtherPostretirementBenefitPlanInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r271", "r277", "r815" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Location and Pretax Gain or Loss Amounts for Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated Between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r11", "r12", "r13", "r14", "r16", "r17", "r22", "r24", "r25", "r26", "r163", "r164" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r1050" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculations of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsperShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "auth_ref": [ "r1085" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.", "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Company's Level 3 Pension Plan Assets" } } }, "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation Between Effective Tax Rate and U.S. Statutory Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.", "label": "Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]", "terseLabel": "Property, Plant and Equipment, Net by Geographic Area" } } }, "localname": "ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Sales of Company's Products" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.", "label": "Schedule of Expected Benefit Payments [Table Text Block]", "terseLabel": "Summary of Expected Benefit Payments" } } }, "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r826", "r827" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r144", "r149", "r903" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r961" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r961", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Goodwill Activity by Segment" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.", "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]", "terseLabel": "Summary of Health Care Cost Trend Rate Assumptions for Other Postretirement Benefit Plans" } } }, "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r1043" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Income Before Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Other Intangibles" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r28", "r46", "r47", "r48" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r1114" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of Net Investment Hedges" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r276", "r1113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r542", "r543", "r544", "r545", "r549", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r167", "r168", "r171" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r166", "r172" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r89", "r130" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Consolidated Revenues by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r83", "r132" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingPropertyPlantandEquipmentNetbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r123", "r124", "r126", "r141" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r123", "r124", "r126", "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Equity Loss from Affiliates and Depreciation Included in Segment Profits" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Summary of Nonvested RSU and PSU Activity" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r712", "r713", "r715", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r739", "r740", "r741", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r213", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summarized Information Relative to Stock Option Plan Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r183", "r184", "r185", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r358", "r359", "r360", "r446", "r603", "r604", "r605", "r607", "r611", "r616", "r618", "r972", "r1010", "r1040" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Summary of Common Stock and Treasury Stock Transactions" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r988", "r1096" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentContinuingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of an entity expected to operate in the foreseeable future.", "label": "Continuing Operations [Member]", "terseLabel": "Continuing Operations" } } }, "localname": "SegmentContinuingOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r2", "r3", "r4", "r5" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r453", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r485", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r545", "r551", "r961", "r1137" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r453", "r454", "r455", "r465", "r468", "r473", "r477", "r478", "r479", "r480", "r481", "r484", "r485", "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofIncome": { "order": 2.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/ConsolidatedStatementofIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/ConsolidatedStatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Pretax share-based compensation cost recorded, related to continuing operations", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofCashFlows", "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r987" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "terseLabel": "Period over which share-based payment awards vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r987" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Contractual term of options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r732" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of Shares, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r730" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Shares, Nonvested December 31 (in shares)", "periodStartLabel": "Number of Shares, Nonvested January 1 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r727", "r728" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Nonvested December 31 (in dollars per share)", "periodStartLabel": "Weighted Average Grant Date Fair Value, Nonvested January 1 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r731" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r741" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r740" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r742" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares collectively authorized for future grants under share-based compensation plans (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Options, Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r721" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r734" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Total intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options, Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r1094" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Number of Options, Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r733" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, Outstanding, December 31 (in shares)", "periodStartLabel": "Number of Options, Outstanding, January 1 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of\u00a0Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Options Outstanding, December 31 (in dollars per share)", "periodStartLabel": "Weighted Average Exercise Price, Options Outstanding, January 1 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r735" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of Options, Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r715", "r716", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r739", "r740", "r741", "r742", "r743" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofNonvestedRSUandPSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r724" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r725" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price, Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r723" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price of options granted (in dollars per share)", "verboseLabel": "Weighted Average Exercise Price, Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r718", "r737", "r738", "r739", "r740", "r743", "r753", "r754" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r1093" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Quantity of stock options that vest per year" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r739" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedtoDetermineWeightedAverageFairValueofOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r219" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r735" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r734" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAdditionalInformationPertainingtoStockOptionPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-Term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Weighted-average interest rate of commercial paper" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r308", "r309", "r321", "r1026" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r116", "r396" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Capitalized Software" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r343", "r453", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r479", "r485", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r540", "r545", "r551", "r961", "r1137" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesGoodwillActivitybySegmentDetails", "http://www.merck.com/role/SegmentReportingEquityLossfromAffiliatesandDepreciationIncludedinSegmentProfitsDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "http://www.merck.com/role/SummaryofAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r61", "r186", "r341", "r386", "r387", "r388", "r411", "r412", "r413", "r415", "r421", "r423", "r445", "r502", "r619", "r750", "r751", "r752", "r782", "r783", "r822", "r842", "r843", "r844", "r845", "r846", "r848", "r863", "r919", "r920", "r921" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandPretaxGainsorLossAmountsforDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r411", "r412", "r413", "r445", "r902" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r39", "r40", "r186", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "negatedTerseLabel": "Issuances (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r39", "r40", "r186", "r193", "r724" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Options, Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansSummaryofInformationRelativetoStockOptionPlanActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r40", "r43", "r44", "r133", "r993", "r1042", "r1057", "r1118" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "Stockholders' Equity before Treasury Stock", "totalLabel": "Stockholders' equity before deduction for treasury stock" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r253", "r254", "r262", "r341", "r342", "r387", "r411", "r412", "r413", "r415", "r421", "r502", "r619", "r750", "r751", "r752", "r782", "r783", "r822", "r842", "r843", "r848", "r863", "r920", "r921", "r1042", "r1057", "r1118" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet", "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r198", "r398", "r604", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r617", "r619", "r821" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSpinoffTransaction": { "auth_ref": [ "r197" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.", "label": "Stockholders' Equity Note, Spinoff Transaction", "terseLabel": "Spin-off of Organon & Co." } } }, "localname": "StockholdersEquityNoteSpinoffTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Share-based compensation plans and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r849", "r866" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r849", "r866" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r849", "r866" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": { "auth_ref": [ "r1104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability", "terseLabel": "Transition tax for accumulated foreign earnings, liability" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent": { "auth_ref": [ "r1104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as current.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Current", "terseLabel": "Transition tax liability, current" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent": { "auth_ref": [ "r1104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act, classified as noncurrent.", "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability, Noncurrent", "terseLabel": "Transition tax liability, noncurrent" } } }, "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails", "http://www.merck.com/role/GoodwillandOtherIntangiblesOtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r310", "r355", "r944" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "totalLabel": "Investments" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r492", "r493", "r601", "r616", "r820", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r1053", "r1054", "r1055", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity", "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r63", "r195", "r196" ], "calculation": { "http://www.merck.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r40", "r186", "r193" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Purchases of treasury stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r186", "r193", "r195" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ConsolidatedStatementofEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r1109" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicensingAgreementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r542", "r543", "r549", "r550" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r956", "r976", "r1134" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDebtandEquitySecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r757", "r766" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance December\u00a031", "periodStartLabel": "Balance January\u00a01", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r767" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions of prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r769" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements", "terseLabel": "Unrecognized tax benefits from adjustments related to examination" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails", "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r765" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Liabilities for accrued interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r765" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalties associated with uncertain tax positions, expense (benefit)" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r768" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions related to current year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r767" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions related to prior year positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r770" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Lapse of statute of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r771" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Favorable net impact to income tax provision if unrecognized tax benefits were recognized" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r122", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SummaryofAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r406", "r407", "r408", "r409", "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesandEnvironmentalLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r1117" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r288" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/GoodwillandOtherIntangiblesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/LoansPayableLongTermDebtandLeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r1050" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Common shares issuable (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r427", "r438" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common shares outstanding assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r425", "r438" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1000": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1001": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1002": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1003": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1004": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1005": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1006": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1007": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1008": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1009": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1010": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1011": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(1)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1012": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)(3)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1013": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1014": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1015": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1016": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r1017": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1018": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1019": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1020": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1021": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1022": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1023": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1024": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1025": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1026": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1027": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1028": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1029": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1030": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1031": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1032": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1033": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1034": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1035": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1036": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1037": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1038": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1039": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1040": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1041": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1042": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1043": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1044": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1045": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1046": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1047": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1048": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1049": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1050": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1051": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1052": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1053": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1054": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1055": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1056": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1057": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1058": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1059": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1060": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1061": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1062": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1063": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1064": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1065": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1066": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1067": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1068": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1069": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1070": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1071": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1072": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1073": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1074": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1075": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1076": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1077": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1078": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1079": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1080": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1081": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1082": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1083": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1084": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1085": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1086": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1087": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1088": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1089": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1090": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1091": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1092": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1093": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1094": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1095": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1096": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1097": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1098": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1099": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1100": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1111": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1112": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1113": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1114": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1115": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1118": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1119": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1123": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1125": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1129": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1137": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1138": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1140": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1141": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1142": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1143": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1144": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1145": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1146": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r1147": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "40", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=118172244&loc=d3e17916-109280", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=16397303&loc=d3e19379-109286", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "60", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r198": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(b)(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(ii)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14362-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "54B", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126972413&loc=SL7495116-110257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(b)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "350", "Subparagraph": "(a)", "Topic": "920", "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6571209&loc=d3e13703-110860", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r978": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r979": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r980": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r981": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r982": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r983": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r984": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r985": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r986": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r987": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r988": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r989": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r990": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r991": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r992": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r993": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r994": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r995": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r996": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r997": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r998": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r999": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" } }, "version": "2.2" } ZIP 167 0001628280-23-005061-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-005061-xbrl.zip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�D4ZI2B25G0Z8UXA @@D3[6L9:)?P-V@&!!M)-,-V/ MW_P6:=@6H @4/3"Y 8I.,+P(WM:?YH.J,&%>0QI\KT(UP*?ARDBGJ2*A10OX MX-; =R@MF-E=$HLPC)6B8MD^-IH5V1 M"RU'FL3Y8AAIHH1"XL&#]L!RE_#E@XX"F>M!*SC'X )X4WR(Y1ZZR'/B-:<> M+%]=KB<%O$R?@$DC:/=Y2^N";E(O+7$IF3E"PN3,*P/A#Z(HY%(]8C! M-?#_K?IBC-8C)/8?@1*/#D3G7]W;MK= MVX[YZ^+ZT]6O%QWPL! +V;U\OD=??6B-^A\>+ZGFM]::[/UQ?8\WGRT+%@.K M4Y4]QX0AH8,6#[(MJ@M4?;$"):KG[3.PN6'^F4*C+XZR^R'83N.T%-!ML-X9 MC92/FB^PXPA?*\=$#('COP,">K]F!-0IF:.O,;GJ?1%S)-1'Q(8J[.5 (4&! MGPUOU.B>!P&24"(V'?4F!>$,T-@F9S))MJP'.8N:04O=UQX92D85HF8C/8;/ M]Z.O0O;!V/X^"*N])H1U5#^FO$G/>%EPGBLCJKIHD>7"$* 95RL=RA2->115 MRMA*[**"41\ Y>3NH.]ZHI=J(GZ-XB_&WNI\]88RO%?""Z($:*ID$N-7^-KW M6&<"(UK3V)+DC),[T(-J)]='8WM6=.9N;+(JN?]8!-#/R!9C_UJA J!)KXP4 MW'-Q2-,D3,VQ]#-26F%DC&(Y2(US-Q.LJ(NYLR5C%@UE/%24813->(QB@/;" M"(QB,&S%2,':Z&[/#MRW Z^(KS?>,:Y\94=&L0_@4:+^"6AX= K('G8SL#5L#YI6.OB@2(-%-Q"B@9.U><6^3D.9]3 M/"+[211DZ?PC3]3S\G^'<2$J[M5V'P[_RS:M[%0&$SE-9C+L+U9#O"Z2R9X] M\4W%69MC)E*K..99K]+E,=?#Q* NW6<#$VC$]LM>: 97 @Z=EFD67,X\;0EF MY%C&\CZ6XZ%HBTT<&&8>* D<+L54R9BCE@ZKDA>*UM]O6:P37WLKU%R^=#F-'0J3TYP;FAG/O=\P*YAX0:[I2CG4 /1$"QYB'8!)LM + M,GJO^9)]1W=ZG*&\+H01)"OB]OS^8=?1E_LU?=7HS ^KHG".*HW M:0=^ID3\'2?B5Z@L.C/@%UF&"* _$)$'0>Q&DJ,(55D5@]3H@!Q<(@6&UO>A M'F@/@3=YD J'G83 2$,]1LX'Y@.>W)0VYO;S71YE*P1%HH'@3R.HP>RMVH6,);J^RS*$MYJYQF\Q7UQQ'S]\QT#@A@IA GNB$..N:V8@!"Q MJ; /G'\HFCU4N&GD'.'0Y@L69[C'!EN2HT#@W=_"U-]'2GQ-1GZW^@<143S.!I^ MYER#;\&:1NG#Q<:>&,&"@,$,YUN07N,0! N,#Z^RSOIB1ED3>K];#W)O'M0; M1.^=3YUV[^;JLML6K7:[<]UK7;8[SR#Z&1*G*,,,E1_47Q^?;(B\$.- QC4+ M:TBB .U,DR!N/#18;BP M .,.<-$9PIKE'-'+5U8>P:Q^2HP/6DVIQ]YNE1U\C*@:!Y?@C)9,P7\;"5@0 M"!.=#(T+B"X*HM7**$>C:B5JRMBG=TX7 "+AUG5G\S7A\D9]GX+QHG5^T;WL MWH)NJX1Q+\QJLN6+F-B!8"JHE8S1,47&A\8G$G\:916^393M&CB??S1;L MN($')+ <46X>)T$QSDS2R8^R?HIYJS$R !J5.C&H1Z,J49A^K#F:E%'2 9%< MAFR!G-1P#<9F(*"UB=8[ IY\:JP:@3TN[!9KGI$W FH\4R"9!D4J9GI(?@H\IPJ##' ND.$E5S(: LP6/>('4U-B& ME0.=K)6HT_GG.5YF?3M#-;/'5E!S+0\B!O"65%I-5WKX1$E+&SU-2YUBTFB>=/YX%5+9RP M@R=Q-NQ<5IPJAOAA7P(9PV3 #,U08:V]AEH3ORLW1*G[Z"W6HXV5C7@"49I:E3+K@&P+%/!WC!?@ M9GS*B5FP;,[=+><*&7%DZM7<\?PH#^2D0+"8 .#BQ('*'K**-\8]$8I%NO8 M:S_?Y6S-IJXJ^(8D2\50J%AL#GXD<57T8CM3XM22B#>E6#+(E)TBZXPHMA*, M(*/*3_(EV* [_.UP-_(J+IRE)"?[0 %XI(5A3[W9&@%<86I"98S<%I92+4X*X6,0]6%FGT"W;2/LL:2DHI%"-(%XT%+<3D-/ M_/#F<.],_'1C/EQ$H9J:SQ4CB.LX @X:+5OYM/OPBWMZZO.Y?GW7^+UI]B.3>=]M7G:S(ZP 1I7UW ZF[);<9^\/3% MIRX&R<1=]^H37;C]HQ;^G'S>0?WH]0LN:<>NKSYUV]W.K6A=GHOKFZMVY_SS M36?)36GLHA4VQRA'3U7VKUSXXQ1H-3G*PER,P)Y27V:J3M&8ZT=A1NXC==G(C:G< MGBV;;8010!L2"VG91)"A:%', ?[L&,>-XQ<8-+(%2.R9D^)&6]S -?H*%&%8 MX-3.P6GD(K<&%KDUFC4#\])IL2BRMLF\SH)4EL,E+;!D4C?0@KO'98!RB^^8 MFZL*[T&5D;GJ J71XI Z!U[() K!9@8G-(/)/^#&P\I5OF!PAQ<,9+!Y.%N^ M*,4%HCV1*)GLBQ)?CH8[S1/@.25C;XC1!7#((U-P#;N8#<#>SV**1B0R4%R( M#K;%%P[#N47*<8132;C\%.FSOS5#4AQR\552T-OB27J(G/+%K9/Q_DF"#32; M,B9D!R+W3 "#.I@,*#IM^_DS'[$34J)]JI=V/8T9,D>[#J-K!D_C>2:.,LTS MZ"8,XR3LYP(Z'*2#/5=+==032VHC4<]QJ[MRRW,*PY,E8G.=BG(!B%&,+M_F/!8*= M!'I-;/:W#("68R=ZU,_B1.4*HVK\[;Y,B*,7#\QZ8U8I4"PZ2E**%89I,*4G M T7 Q#EE 9/SMN"%\$T0T"X& 6>U' "\-/NP;7O+< .J?'G^TR.$I6=8'.;% M"$[V7#UHA+BD$Q4\J&U*HA5MA"G1X,E08CL2V@V*3#@M<*S^G=]TEN < M@C%A5;\ \:#LKY@X*4D"I1+Z\9N6@02\.=BB&?!YC\"VLF_EK60%UH%53(0QN% MY ?R!BK,J#,=5/Y0P^Y<[B[B\%GEO[ .!T>:R M+T ]#0F: 4),IR9_;*=EA/*3+L)SYO\,&_4[)^7]-2-E0\>S3H\E8\89E6' M(?8#0XM(@SA"@BBE>'(O!S/@H8>31]P!2T%+#600C+/T&ZIH5Q'%L9TJO]WC M6%$E^IJX&WN[]0;%L4O^<(T\!LKD+QOW8'B%Q8NHV/6VR:X;R@60 M$LX]1B#COI3=F1F8@T7?Y.9\\T1Y8"851G,ML"]_*CABS3WY;@7_"8$*,E>.$6S"?I4_VC 7"(0@N8;8$ M5PS+RO_:[+%N5G-1V?K-\K^(ENQEXT0!N85 M?809;9\A2LC(\AQ@9;21K=&;;3V\=)'8>F8"J#.Q8= +;,4_4:"U/Y\A:?SQ@*EEL.RF>,/V:LYC\ OL1FR.%!%96O11WN59(IYU MGAPYL2:S=!C%&(S%$.AB*[S:OC:[;X2Q3AV8TYPH922NQ=XYU5MF!7.$7'D/ MH7<7=-W.7^"8]:4J,;H9OLEBCI'DO$DVFX>\K*[P MW*T',ZUB1EB?R]76Z(L6L-.DH)5 3N;*-5Q,HD-6>%=.6D0N"4%&_6)_3>\7 M6UAFF28OC"RE*')+V]:PT6\,<'IWIJ!GU4D7_ 3,#> M#!"FZEV9\7/R<*[C\%2]:A%VRDEIIW"2BKJT4/\%/5)Y8J*Y:$:4Y'IL3R@E MJUR0P":Y2UB1RU4,:/]N?0-TX$GD@%UZ(6F+AAJSV5_.GS X2$V+JKQ9(?@X M.J(N'B4Z,"X"Z:DRV>64:.B/]MG\5H7-M. L.]UK_JF(1'S&++T;\\??G($9 MVN3\ASQV?V,B]DXJ?]'XU[>?$\[_/V?DEW-!_@:BOUCKO^5AYZL&8/,/-5@\ M^?OUGN=-Y[9WTVWWNG<=T;ZZZUQB_=JSI[P"![Q:/V+; %/R3\&X1R5;3?B$ M;GCZ5[M ?M8YSNS>Z&&3[LUHPHVM"W>18 MY+PO&1C'10ULT4T$JT]A37EO!!?S7#/);U@>97R"*2LE^U=1VR83VWK$WAO! MISY%O$>$#ZYQ5R4TR4$KZ3$6$,/0&.;WL3Q:@PV/SX 60!Q)F))LJN7!4[Q1 MY;%(U(HTF@F3&V59H)X\.98>*EEV9D(&JI'F-JW]JI?DIOO)6,_;0@UR? O! M6 S$A3XS9H4^.I@6#-8:T)J#:\&J.&\8 @G?3_F>^$%[UFL@-9VJ584#9]O@ M\V_*&?2*#%K8-BD$;(!B(__. U1S=X5)XXX3+/M[J[_\*9Q MN'OF[+T]2^77S#4^1>YQD&!/GHK.'&P((_>V2K]EAGC,BK>Z[\-?WJ06 ^9' M4?N$H7% 4TN_KVXF; TK+M?G_8!)#'5?4_L4TRK(L_A&Q,W NO C.LTC;A,I M0]% V>8Y,$8OD$S]XPP\:P_;=\42ZPB]K2@D+@I+G..=T0+P9* PW>^ G!ZK M@5VS#2Y^7,ZTZ'3#*.4X">XV 1L8:ZA\"R7,?R;2J_Z92%:/^6]%.FTX66US M5PI^E%^%K_\&AI8FET,3 S,2TR,#(Q86YN=6%L<'-U="YH=&WM?>E7&TFR[_?W5^1UW^Z! M\T09+6RFI\^1079KQF .R.[I]^6>5"F%:ERJTM0"Z/[U+R)RJ:Q%&P9)N.D/ M;51+5BZ1D;'\(N+7_SK_?-;[\ZK#1LG89U=?WG_JGK$W>V_?_M$\>_OVO'?. M?N]=?&(M9[_.>A$/8B_QPH#[;]]V+M^P-Z,DF;Q[^_;^_MZY;SIA=/NV=_T6 MFVJ]]<,P%LX@&;SY[5>\ O\7?/#;__GUO_;VV'GHIF,1),R-!$_$@*6Q%]RR M/P8B_L;V]M139^%D&GFWHX0U]AM-]D<8??/NN+R?>(DO?M/M_/I6_O[U+7WD MUWXXF/[VZ\"[8][@[V^\/C]J\<;)P?#H<-@:'A[QP^;P:'@RV#]I'C1YJ_X_ M=>CD6WAY[M\$[&M(;^:J^[89^&+W[:9_^.\4[>T,^]OSI MN[^U(X_[?ZO%,/E[L8B\H;P=>_\KWIU G^C7O>SG$;SL>X'0_98][3R,O+Z7 ML/J^TZSG^VGU<,(' UB$/5\,H:$C6'%H7%^,9//JJC48%V9?1&]F3L0+^\ 2 MZ]'SQB)FE^*>78=C'LQ8&2*7Q4L#A%UG5YWK#Y^O+]J79QUV\WO[NL.^7'9[ MK/U'^_J<]3K7%S?+#?FPZ1PW2D/65[=ER%\NSSO7K/=[YT<:U$7G^NR?[)>? MFL>G[.RS4V/=RS,'V%;]A-WT/L,M^-VY['6_=MC5I_;E<%-(-]/W2_G=Z)*/%<[JM/)>%$L=G6H=-H M%9L8\^@6^#(\]6[?L?M. ZH?ZWY[P0#Z_&X/KSPY3<@O+Z:*KJ.GZ6F_7U_B MZX6)J3M-G(B/G6GXT9C__3JYDM,?]9/=QG>O@7Y@V0%6-J(\6# XK3_;^$F+ E9,A)L&/I^ M>(^"1/N>1P/6$]$XI@?Q[H6(W&]ZBX:X10-7;]$$"!%_ \EX=] UGP=L!U^" MQUNG\LWNS17]VG48# ":&$]X,&4CCI\(PA3>'C <@ >]#%!,PG[%$Z#6<#C4 MS='0;O#BY^'0#,^%/<"]@$VB<)"ZLHV0<1:(^QI#4IX(HN<:FZ1]WW/]*4LB M/H /NK(;-?8YNN4!?-,,T$PDK-I9:#XU2".<(9HO+XH3&( _9.&0T5&T8_?P M'$0S_9[#VC#."71P O)((FK4@IZ$>\_W65^P2 Q%%$&WL/LFT7:.U@3[C/WP('"9_'YNX%F.8&!S.&:PN+#:LCT_#-4WCV_HQ(A1K MIE4''36,!4):)7\:\X<]R9".G(/Z\<^G*!?*"X?R0IF#58F3CV!^C07,#^XF MO.\+?;\?1K U]F ?^WP2BW?ZC]/"M^FE4]5:/TR2W3$EM/ MX Q(!@6N[]"MM\F@?*]U[)SLS[Z][]1GWGNB9M]2EV6W869B((R_OVF^*4R> M9)<38(JA[PT8W*D@/##S$[U\00'#[&/>OV4M8,@Y7YN@AY/1ML^'?.( M19X%WT\LVSX'U21QP2-WQ)KU&IV2CR 'Q62K=\Z/0RM2[@+)S@L'*U++W!GZ M@4CI'SQPF"(DPV;.!8BBBKR:9?)Z2P=VE8FJ+! LUM!>7WK42\M9$EM&])LA M8^8^NE_28 ^>F<^Y*3S'G 4$/A=H';+&(Q MLJ=O9MM>&LY1V?0B+ZYNR%G^SR@EJNK"H7(5H6V$W" U^ JB_ZL8>Z M><*>BC:WF]"KYV@'75]$W;_\U#J2_T,WV)AF*Y:3Y;CAF.[$$Y?^_1:$][X8 MW KZ!=($O\5A(($FT_PU(-9H3SQX<8*_. I6,3TA"3:[N$=4+N_M$GU+BL:U MHUO.7WF=/I!-D"9C$H6N&*218 ,1NY'7%V1\FD/CV63B:C!4#*6$>^\E(R]@ M)_MLP*>QPSYPS\>&\[.?&/NC&P8#\IS&:&F;VQ@;\RFPK#CU@2D%;!A&0^$E MV#B\B:V:%POKNH2XF%NB5MTY.2B:RYL'=/')I>-E+-9P>FR/P;S1<@Y)$COO M?.A>=GO=SY7221I,PUN0 ?UC&[KS.-5_>?=2^/BQOZH9SO Z* MJ9X49>;=W+K,.[YM;7B3E*.,WVPLH!')F4:1$'M3P2,VH>ZA'V$L A== \ 3 M04E->30U>BKR,!$,U%W05L6X+R*CL99/F,<0UBL)E4GH+!R([2*=+GJ" ^ZS M:W$G@A1]0 -B1O63XT,6HF-NRN(43L$XEAPK$DDX6P;Y7LV]29SL=#DNE3OL M5A5'_CI4U^%1 ',7(^]2OEE8RL[5S7:1HG+ND1$-9&P6"!29@).!A.?=>>@> M[4_I2=DP_.:@IO-;(TL%*?$Q^!7C*$DZTSY-Y(C [&+R#:.3D@U3'Q3& 8AZ MV%2?QZ!B6NY4F]T_#4!B%8YHF6+\8Q%F"_\%T3RP80"1\GM!TAFRGOLN& M?NHF*9>"LQ2&H43B(<1+ <> MC'),Y+Y&#@>MI7$*3!%>"\)@+Q)N&A%AZ'FPVD6^F>@^-G?AEKS$0,['MH(P M@6]#$XD_E5,BIU839@A3IN8DE$]',*5A $+_5"L3.&Y0.I(H]&V:)NV2IEY] MOB6G2 R' F$'A3D"729,@T2-(\!Q0-MX-1K0@N'7V!<')../[?95#?LCY\-N MQ1>W7NR3O44WH[Y^L,MNN2?'X8=QC/,4>00%)7+Q EP!["Y]6*K)+,;)A>7" M5;D?"?H>S( /M#S EM+ _,(%VCDLD0%QM$B ) W]H:\27<.[?8':(E&2#XOB MQ\^SD5]EYIE'S]5-#AETQ4%;3K;KW(']AT@A=8[T<(,G\IB,<9\"1YQP#T@Q M3?"00,321-D9BB<6CO8V!+[!X201:"_P H-PFG XJB(^&;$S_,X-@E^@G:ZE M);_*VT],?A\04R1/\FVF.;RBZ"ZS90&'M&B$H> =#M+]259FJ,@C%=A'5 M0('L@*+N1YX[ AFW&I7)M#-%5$BVE02UR(NY)$&UG HS\NOI.8O0K@2<&[^# M]).,7%P[>=Z I+19NFNV3@TPQ0V4C1?QM5-#(&!I0C34+GXQ#D#IERR Q$OYTACH'%WB"5HV1U6D< M0A&.2WIBP&60%(GO;@B2,,JB4I'4JDNM@%C6TS-S!?%-="R0I*!9/HFK2_IW M]IW]19+H_*VJ8Z&HE5 J3.^DRG8G2J%1F>=>NNRS5W@_#E&%7C6:2OY_%&6C MNQ5[?5BY;WNT>.^X?\^G<0$R^TQ!7"8B8KU@C.,C9_^D\1@L1N/0.3DX>G+\ M;;/E'!_-?O6[FFT\-:QWGRQ^\W ?%?>K8&:'SA(0D.= F2W'<=O]_E?/R!J+ ML7?+CGVY$<]B0/4C2RI8XY34FQ@#Z7OLDPM6.0A-G_$X%P^7*:XO%6]?]] MY(&@[N]=3$44LYO_I%Z_O^J1,8\VGGGI\8S=G&Y\';HC\=A5WY1X(%'YX2B( M3?2D^O64Z_Z#\L\;'H1#;Z^-_JLJF6&9R(4JNT\=**2DK *%-#?J_K1-$XD( M!K&T"\S7V_O"CE,F&X)TF)('E$O 'SP$'%/$,3H7X;%(##'8E8U%="NB&OPF MA*+WOV1:P-\NGW@)NKG4E;Q_TN7Q2#G!@T$-C19]3YHE,F8S5G$R :8*[*=RM=V@C/ MH-!]AWT!]N,#P8/TX?4)GC%)HSA%LSOLIC9R2U^PK]U:V< =*R #.M*1BR6^ M,E2&/GKA$-*+3G?I=#%;!+JD'BCT!>/U$0*!1KV[D"R7\B7I\YY$(2%3:O#Z MO;C#O6UX2,9>(I&07]Q\$KLQYM^$Q3KBO"G0\OXH$>A0FME]/L M *=NO)KH%^XRFH#%>.*'4]B\]R,\ MOUV!\*&9'K6G.-]>]]WWG&ZT#-M 2MN^ZZYNOFS#-)D=1V%/>,15'.7%([$4 M(?&Z[]9,/3EXU/;041[]6T%)))7IO$9&L"1GGZ<"L:R7+B2H53J%N3OR0+0; M,"77$9*0H2J6>$,/K\=ZQRC?7VS!-&1?(S!&(-2'=,@Q$IFARG6/-H$YL=8^%=RIMF;U;0:GC MWU#UDWG<)(R:]<-DI& @D\@#KH'YU(3K2;O,#D+.179AUV2NBT0&A,8>:;M. M+#/1]07L_X! )%F8EO69V+ QB4956%0="N'Z85QZP\+!P%"3$:F\)NZ+4RHX MWW.1'3J$PM&?<+GOIA*R3E@8G#L8/$*Q,9,2(6%DY$3EQ+TJJMNT4?]"2.SB M:.<#LM\O!&17DFW],53;,@F-3)#V.H[E61':6Q2BO>^T:$;/VI_.OGQJ8XPV M^_R!?>A>MC^I[,GPLSJ[\NR4RH_"16^[.-4KR*NVY4G9/_&$42J3+1G??(EU M?E6@03R!M F3Q%5Z ;BYC3Q/ U_$L;3ZWWNQ*+VA'_YJ\HWV:*<9!T6';"DR M3DGE'WT>O>UD/5#B&=G2MF8KU5M.D[927J--YXKF%E!&5+.$/_!6#L* M@J@\I-C$3^4!41U.I,D*"=7(47=):<6?YX M MX'\YB'Q6)P$)*9##%Z-:&IH<@9#YWD M_"M-V9&#H)/73-I1-R'+(Q?_#& MZ5CFU][_>;X/T%MV1@)Q2Z![-1;H01"J&&+J_)S!]45^/G&$3W&V;AWE8;2' M>. @2, T+3VSC8.?C=JMR&Q%^J)6]G]>@LS"U,<(#E;'C_[RTTG]E,CM_[*= M';RRA\WLL@=V\/,NW&V>+AGGL7@I7O2Z-IP5&8I:61))EV,A?*RB@IZ2B\!A ML#(;6<@N"$VDQH+Q06)0G1D#^]B?LK%,P4_;OORU&G*1>:,!6A4\PC.-XOY! MR9Z8Z@LPPTJ4LO*4/4_P_(&S.9'];&M$)%!=I,A>+>)N7FJ?(7I7B4@5227R MT7%VDI#8'8E!ZHOYTM121&3C*NVJ7"O09W54W=:V_AK#5\J_O*ES#"-1K2HF MN%V6- C6G:,-U/XX:#F'AT>/"3T\;#@']:6XB07SC#3Q=M]YVQBL=.\ZAL+E17G[_J MW'++HH[4*R/)S"<'/^PQ WG7KFBHKJX M?M*N7HO]GU\\+>^O14^IGCXB8+;3&X&2AA"5W1="S)+FMB>^J7&0T>'+H\#C M#07<$P4>.@=(@>23?RGD]V/R4B3ES7-3"FALG2!);F\\(U#MR='RX?"O7%)Z M>0[V'\,FORN&?KV<],AI;"QUR7\?.8Y;\&&3?VJ\AX MN>)KEB5IA:)CF[8_):,H3&]'E,2?P#FSRNJ^6J9>+5.OEJEM6(,Z"?45AJDB MDNAD+<+_JV%JO8:IQC[PNA^6N%^"-K4-NM1+MDP1!;^:IEY-4QLDP89SM/]J MF]H&;OIJFUK>-M5H.?N'K\:I5^/4-AFG&@=.J_%JG=INZU1S=>-4936&\G%R M0HGZ-I6]M:AFQD!I$>)20QD%G80YZ&!?)/<"8;OW(:9T<(%DA8SZCG5(D+1< M:;@KIOF+)B'%,S\+F!44]_KFT*SG:T*S5H8>5Z-9*^.]!F(B A6\JRM^H7GR M7F.P;R9 M9^'0Q:Z;AK%^B8]:.I@8]I&F;))9VH*AYF%=B5 M<00Y]CPONPWK=2\Z-X4 ?GGM\- Y/-+!"K*@WU06]*M"T)9.A#DM-YM.LRF' MJYK_K@B;'YA.^G/I),<#YQ,)?"8WX?EU^9[I;X%._X0QD]L;WF2.ND$HZ,20 M9UYYVG&[8:B%.OOB=6S6@\+RZNU:=C96;]9Y+LBEO^I\#[M_-!UMFVS7V:9( M)1G,?:&"83=>7M%A[6"*=7)O*W,$ZGP75$ 7LVG#+L.@I#CAI%:4]YH):HK$ M('5EN5XK8T9E:F^3]M>DG2JVBHG!*2LQ1?;!YD@C*W;0W@DUVMI2.W=7IFU+$SU M?CNOKJI7,YG,J+0SD#"EM=;*-W?=*,WRE57D:/2&,E@[M]ETFZI '^9_RBH+ MR@+:@1SK!&<;590[I'8SZ K8:L0"81242$27,PTES!$&HZYR,. M2NU$.>0P\*=Z*-8F=]A-_EN&E5#/,=,:+*RL)ZB+U%/F?(Q2QJ1RZD /[3-= MAA;K%JFA684-RSU2;YI9DZGJ*!&>R8DGI\^5TR<3QZF&J*1HL47/3J_BL.Z0 M4JKGXH7AD:N;+RJW*\"X]3)T1#867R,K>XF'B4>&"()Q/.B[P8?V2S 6 MR#55WZ0# .Y,BRGU*EM;Q-2UK*3I"\L\\,2+AU,:9\(?LB((2#SH]<3%"/N@ MGLM*[L_*H^LR'56>31_0Q0UQZBUBU =.@QACKW-]T;TT2<0Z%U>?/O]YT;GL M+9QDD]ZK7ICD^O$3]ALX'CF!M89@[0 8(0=E4;<:NV>H_RFI\'#RM$9@\#-#ZQ@F"BWQ="+ M8C2B!+"=(A(UE' G;PSX-"]C:K&:8\X8%O&$&R%K)Y?[-\OOB/EY?8$?5WE^ M1\*?S:E %@PC+0<5^4@VD-V<3-?.L2.[1H^NJ8U*+8JZGLZ*-.)WZ*T3@93> M0,ZWOC/B U+-O2#%I#AF8-Q-4!2V'7XS%ZR8[Z^8?L3.[4H)WR(R0PU(@EN% MK]++I=6H2H*"^7E2/_$F_E3WV9:AX39GPXB[LJJ66D4X!Y.0%O)^Y,%,>L7, M]J7U54=(;CK4-,DFC/$ 2YEPO15$68N*V#^^U@SM@\03TO(7NM,\1&%;^\L\ MBP,D&0?0F7UEZ201V_>P-6M6"[W@JDB2B&'NI):".EF4 C'0H* [_P[[6*9% M-P@DDY)117XJ"(,]FV90&T@3*O!N\F_CN1PS'TBWG PX9F?&M/G1$'XL">A9 M\UF7SYLU57]\,;F1;OB/(2$N.F D%[7VC-P/:#2,PK$T#H()\ M:3_V!A[L16F)B3UY /T;TX$Q3">81C+'H"UQ5FCMZ^+P!9Y(&: H63_T)"HV M8IW;Q7,ULXT2*^B+H4R,-N?$S2T'"N@B',KT;+@VR,V7_OKC3O75CJ&Y-/=X M@7^+Q=UU85E6X#[7 GUGXYQ+:M,\R"9,BR1F,9X^:J5Z%&PG*VTH>.1/B?9A MN_.^YWN)_>BN29!89A%Z9]/;I>(Z5#7""$RR5(2RJ4HFXJ)R:=S-NM*:-MFJ MIBBE9(T^PZJ6>0Z0PC\SK0[;#=QGZAP\.Y*+".OH@E"68QW(*#Y+7"W;' M'9JJ=_J[JLSNK:0Q?8/67V73C%7A/DFX:(%1IR$F 95#D%E"78X4JVJEP&,[ MKNS*X8%Q!$3B%M<$**S8%S6#TJ*3(21FSE3.4%Y8MTZ8T)>#,%&.[J(V_5\&=EN\Q;>J(03HE^YF'$H4Q&TYBD6W@&!P!_><'0@R]CZY1@/D;$ M!1P.\H3W4> F7Z66OF/OP90'C"2VC?8QJ 4D9]1,$ ;<1B3;B$3H>$0(?5,Y M&]NTM,B^",302V(Y8C+RFF*#]G,@R<,I.U::)GN$KEEA^,?O)@0"Y/$\J]3, MHU'&GE2;PHJ'-':V=%"O(@TM/H=GX\&>#)W06$]JC&I^]?O6\:M_D/7TJ[2> MLANM"&Z2=;59 E06#Z5E8;[&@%5K"@9@8_6I:87?!>+'I@A;3GC93Z #NU,% M#.NH "N$PZ'!@5@ (LEAUWJ!9:[07'"4=\A)[I/090YKMH9WI)]+*PHQA=LT3-5VS7FK:CD=GJQ*DK_$(F&J%IFE,+3W/C+>A^:) MZ4W+6U[K-$;1\[V:;;QL#/'7+:IOF6&(;WK7 MW?=?-#:M5-%R67#QCR"@ON+1YC#Z#\9-5XE!UE8>P8&SY:M_]F6H3^)+64\+ M(]RR2"OT,?R5*X"= R#;@I IPJA>)-%18;HK\;;($>$AE,*R&J'=KS407]&P M8@"X@>"$N[X?H5BK.K@3A,;*GD&ES>!>,6R/Q;"M:;=7$[07QT NNP8EGXG& MV=(B*A^E]3A$WQ$"YF%Z\$E:0CA#AZ"LH*(AS7IVM3P_7UC0VC NTN2 1V32 MSPLM,Y'M"X%$7XJ%<2N-_:" P;[,R0UJL!H\7E2*$OZ %EX/=FV"XT6]B<'> M+85,R+J_RM_M);+[ROVC^T\@JNJ]_L,YC;<0([D-7H6\D)_;=:$D\31(JE4) MI??;EFU3,;&2&/,:>>9?S7L7JFQWTLU@=E5N]]AV%;/=\EN*=/15=E1^/SWU M3OI!8_*^;E'!^/HAI0!Z\UOONGUY\Z%SW7[?_=3M_?F,H7D'E97@&RI-\B8V M]Y6&\.:V->C!<R-I7TI MJ3Q%C6:MQ=,X$6.2'/J^%X^$-->CTQVA1Y58*:[0I?A-]-<0GTM6@.<\P8G> MDIPGSV..U6FVF5C[?VT-DVDTG2/R9;3/+[J7:"MK][I?.^SJ\Q^=Z^>,N]^^ MPQTD=QTNKKF!$8G- 3H)[T54L+;@D])VW[VY(JO]]Z;'R$1QY#N1N$-]-S'6 M[U#&@".O0GEB"IW1C"F,:N9O5-AS04=*18<-GG.K>D/@9RB+QP@I)^4^EHEQ M5"XX4-Z-]^+?Z>!6!WX7=.XQ_R9[J70!6X'IZ8X7#/+P8>Y%QA,0J3P?\(H7 MD6LBD*Z\5.HI7$X&-@S-H/%B2=:Q=(F113D;9?WVK9%8GHN3-!X3#"XMNF>? MVG^\;Y_]$WC(I^[9G^S#YVM<\!OVY>KS);OI?KSL?NB>M2][[+ISTVOW.A@H MCJ;Y#]U+D&RZ[4]XX\NGWLV:%/D9MO++ZUNY?L[//%U:)E0EEI@QX(D$:0+/E6CLZ^Q]:3J9 MB"#F2CF,Z(+OD2'&:HX73K7V!/.&>@^L379A:&U@0J(0AH%<&OYUF'5NUDAB MKC$YW(!@)IA^*991/_ARC4#PUF"M,63(,IQ3-1,^]\;J/##@EN*LY/WB;")3G9RT2?S"FY+RJ'ZUJ2V M;=2UU0G]<"E0F24;J0WP/C3;"(4#Z$1"&*DX56&HKA>!?H02EJN18@88AK;& MQ01#VJ.RB:*XI*)FS4L8,6)3H-2+OB%R"KX 6P.Q9:* II!FXC0V [%:I)W0 M.-5(,CL=;_&[U,2@)MTLH30A25A$4D,UJ_,@W)004Q\XXLMV*.H74V,HJ%:$ M!M^A5."0P'=-:-[W4_HL*7^;$FPUMHG:CS6QY[@VTM-[S?SF;0",]0&>R7TW M]74R*<5<_Q;/Y7\EL%QF^U"!Y8.2XB#=>J0I1'G8IDVD$WHXB_?$$"/80]KN MGP<;?-8;]^$0D!\VP;_9!J+Y MQC"HO'-F(E-Q:E<-G.PF/6'VKC+8R'F&WM>/#?JSS$]R^$@116$@$"!58DS/ M"JZNWKL;#1S8+IPBTA"WL M$?:Y\^".>' +IZU+)%T_:;9JE@3X!.+/%A+6=J5?.+0(B[C9]A#5,.(I90;4 M\25C*W#FEY^:K=,_2C?H,C+[6XGU\J<,Q32A4LE$ A07S4\Y8O#)=)P&H-*I M"!9O#,(XG",@H(SX'5JT7,6_!\Q.!T2E K31"#\D3YTX' MIDAO+7 5PD 7B MUO>@0Q1GJM)#%P7,8GR!%*#0))=E8.!LR%T,_\5#JN+XJU6V3(<.GTP(:TI" MHBS3(%6^.W@=DQOB-).DEI<=C9]_2& :0N=[9#U\KLW9.%A+T;N7D)R ]F8' M\]_$I#:3F+ =UH<>&A:T ]ID.#=0:(LHXTQ"F4/S._5=T@[0C>5%*B$HWDPR M%UBVI;F+SFK0YI_SNG*H3^%496E:JNU,=A!KSL8Y$#TSL*(QK/"H MI[>H;A WD?=#68D^YB=2,Y7;JB=KYP.L&HJ@\Z+!4=Q3!C6L2RA3"-D R!+1 MS"BQI AA9@ R58'&W,-O\O[8)$7DHR?RF MAD!+F1!%.9/*+=\_N[E=R>,4&)V:*^7QM%)IQMX#S#6Y*RSF2G>JOUW+'8N4 M9T/F&IZ6,IC2QS$[! G>E'Y860.U\0*F7IKQ5/8YD%C3".>O)JT8=CT3PL+/ MJ4:"^5)K67$:HE1R_:3R981I?/C@\MYM?0N$ M;-H;_/V-U^='+=XX.1@>'0Y;P\,C?M@<'@U/!OLGS8,F;]7_I[[_Y@E,'X<5 M=@_]7*GP]/)/D*-7&!(,DOA[)>6 W;( MQ.?3=QZAR/?Z?NA^JR@%KI83*[ ?'A>:6 "7V7>:JQZD%2]^Y^0?+SGY!(/L M=FX8(@JOKC^?=.;H 9L6V048E?B#)#3WRV0%/16EY+0]#:[D\I>?V/!WW[G MF%@M9[ROL3FP,T_ENI;[2!ICRJ$7AL;#89',45E($&_G!:27RQAK'*U.9J1L MLG-R!F"'J5Z=+^[XO'+6.86N]2@6MI*Y\RD8\SG.-(E]\?+Q$J?KZO,3H5"_ M_Z,%>VQ#I150[#CCE[F4TY*&@7H43DZ&PZO"!KHZ06:2\FE))H/=JM6MU392FD.)>-H8D4K2NYMN+;+XY','1CLT=\SV#B7J8$1EB?5 M3_Q:'@M''ZQH?D\"U>8U+$^)6CH4:)PUV\XOLT MB3(:FMM(/*ZF88_0$YAE'\:23,WP!HM;"'+O2.:'K66H/8D+%W<>PO&2>^'? MB3VE&)NNBOP\0I\"*P,030>E5-7]M([;\JS;&'H#(2S5)2GTG,Y$RE-$:2B6 M'$=^&&1='>Y:.>@00Q.2M)*CR21,*,M[43"0TH Y$S7F5 6DE3^I;21ENI;W MGRE_RMK9VLIPXV=C:VTM9\X\W"OX'&45- E3C;M3[L""O_-9Y94C%%R$HBLT4C]GZWW>N82!>^( C.QM >6BD=V\)QO$ VEM(K GX\:$[) MYO!*KD*3E,W#:$I'#TJ"E/T68:YY,1XH4%6H ([D)0HEJ[NE&.Q"Z7Z5_C\+ M-ZO75P2A/ 61MK:&2+7!OJ")%"NIV($Z@;@ELRG"S#@N=5")R,B ]XA"E3Q- MKS,=VY,T64NV\S6;C3PQM&)G/LOXA6?AF9N@ MT.T1 9%"=0;6,] M8^'/,:BI=0$R<65DI>4X4&MDP[G&81BX9\.+L?-89[1712+>;,5M& M-PD_R9B,@R,2D3SI"8,<6 MEBB:>D9:2!Q[4O,J&E)5"GO90L$,138F-2WR4:D5R2U@'HM-Z#-J]E$@2P30 M?B2L_H $DEB5K8*MYFI, M7N4*E!?*KL(WRS8^W\MXLLC!O<*> NKZZTK:W4#3+.VC'-5693#*;/,Y>WQM M%ANLY6RGL%VK OE-]"TN>>KS2!\+^@A2L2FFPD$Q9<:SFOBK<9JY1$1KL_W[ MI.5(AG)!JJZIX7"F<.L6TSI701;QJF#]IZ#Q_)FK\MX-Y B$L9K/$!#9#NKF M2' *(63>1$(;B3*A2<\73Y-1&*G"0'/$[6I!6L^69/:>+FF).Z/$JF4=4/1] M(;I)0[+JAWH$)1*M?,8J(RI*>6#T!RSYW6ICN8!?QR83>4:!CAM&25GDHJ,' MIF.(U8^D+IU-286G.9]EA0R+FCS7L!_7O/. *?IA3'5$AI5;[+'.N$UPE\6) M.%75J#$&',I2LS+*52>&CC.JHR2VN(=@LZ0F<"4KD6P1*#YEB)0(+Z88L$$V MNPHVJ3-ZZNV71<#;[@DCV.ODH=#-.%3Y[67,9-CW,?Z6W'HUC3LTL%'NV]_N MBVD8#+3M+X-OP@@E:MS>G)(!>8ER-EN<2):#KBIH9GW+,_IU'_.*ZH.MR )( MM$MBZ7+"#-W --8 4%[OYL**C<+W.:7&^(XS^60#-M/+T$)/9V>,Y+2^!ZS5 M^%FIU &GDIKN\J&[9)'H1F2ZO<7:+/+:0F#W9D@&AL;@7>%@ Z M%79^M+@W"EB1JF^E2I,QQE5+I:GZU"QXD>4'3H!&T9HEYP"#;XP#H#FK1^1 MFC#@S[;3\<3.&?43+V?_O_4$L#!!0 ( M ,F"6%:F=!?7IBX ,L] 0 > 97AH:6)I=#$P,S(M,C R,6%N;G5A;&-E M;W N:'1M[7W9=MO(M>C[_8HZ[M,=:5T*YJ3)ZO1:-$5W\\0:ED2[D_MR5A$H MBHA!@,$@B?GZN_>N 040I"B)$FE'>4A;!%#CGL=?_^OTHCOXQV6/C=-)P"Z_ M?/S<[[)W>^_?_]GJOG]_.CAE?PS./K.V4V^P0]\W?LW3A- MIQ_>O[^[NW/N6DX4W[P?7+W'H=KO@RA*A..EWKO??L5?X/\%]W[[/[_^U]X> M.XW<;"+"E+FQX*GP6);XX0W[TQ/)-[:WI][J1M-9[-^,4]:L-UOLSRC^YM]R M^3SUTT#\IL?Y];W\^]?W-,FOP\B;_?:KY]\RW_OK.]\;'GH-KWZXW_+:[<:1 MQ]WCH;O?/&J.#@Y:=;?^OPU8Y'MX77Z3I+- _/7=Q _WQ@+G_]!J.8WF-#VY M\[UT_*%1K__\KO!J*N[3/1[X-^$'6C \'46P/?78C8(H_O!3G?YW@D_V1GSB M![,/?^G$/@_^4DO@:/<2$?LC^3CQ_RT^',.,]->=7,4A?!SXH="KDNOHW8_] MH9^R1MUI-7]]CQ_HS!;OL77VZ MN#KKG'=[[/J/SE6/?3GO#UCGS\[5*1OTKLZN5]OS0M6[/G+^6GO MB@W^Z/TP.SKK777_QG[YJ75TPKH73HWUS[L.4*7&,;L>7, C^+MW/NA_[;'+ MSYWSA?N>\/@&J$H:33_4G?UINA+(&Z+CU.<(C^!3%$QZZ@EV/>2S8E]!/ M$[;SRT]'S6;]Y/+Z2T+_;)SL,GQ\ _R?>#7<:,QXZ+$D&_Y3N"E+(Y:.!1M% M01#=(2/OW/'88P,13Q)Z$9^>B=C]IG$H0AP*78U#*8 M_@V0XM_"T@(>LAW\ M"%YOG\@O^]>7]->NPV #,,1DRL,9&W.<(HPR^-ICN $?5AFBF(+K2J8 IM%H MI(>CK5WCCQ>CD=F>"QC#_9!-X\C+7#E&Q#@+Q5V-(01/!8%QC4VS8>"[P8RE M,?=@0EPIQF@^8@S\5=-S)3>5F,)T3GY<=)"AL(1BP:,>(4._8* M3T$TTM\YK /[G,("IP 'J:C1"/H0[OP@8$/!8C$2<0S+PM4GL"8?L)0'W0@> MPF4+^LB,7:.[@37C?_@(:&OQ.0YQ)29P,+B=+MPN7#;<3T#;-4/CU_HU A3K MI-4"';6-!\232FHVX?=[DGP=.ON-HY]/4"Z3/QS('^;I794X]P12V7P)4KGT MH]]^3?DP$/K;810#KNT!50CX-!$?]#].2INACT[43,,H3:/)!Z3 Y>TA09:/ M3^:X2@K+2;T2TW'HT?O4FW_6/G*.ZXL?UYW&PF=K&O8]+5DN&TXF 4C[Z[O6 MN]+A28XT!1(;!;['D+:>J$=X)Z4GBF1_:$[O&3["_[:_TQP6P-0%' M#E/09TC;J0 Y7,%D:Q%,OB<18UTJ[=M'J]DEVT:072 Q%R:MK[K4 HCN.VWZ M[+L1/(_7+2&J==.M6=2A3%.7/)=XO>0% Q6EQZ\H53T>,C9&O!;8<C,$GEDCAM-Z$DR M=>F_W\+H+A#>C:"_)CSD-[@9!-ET5OP-P#?>$_=^DN)?' 7\A-Z0()S_N$=P M+Y_M$L1+&,<;I$?.VVU](FLH';Q6>*P3]P/<.#B':3&\NI&H4<^VP1MC$L'8Q,^ U*69 $0 MJY"-HG@D_!0'AR]Q5/.A\V@IL6@);SC'AWG+$D U:7))(^Q2*-%HL;SU7E6T2W3E:C206.MCG)8WN! MKB#&X5!#GH!: M:3F);TI'-O7]F22H=V>+>#3(@ BX< MY@V>9@RZM #Y=A1'$SHCN+P$Y%2**(2SGEJ1#;$(>$IG&;&=QBX;!9F;9EQ* MQ%+*A16%.,F8AW"' +0P!UQHDB4R$(%^ 4'G^(3M-'=I0A\NTZ6Y$OC8'_DN MF@&R< KOAP@0+FA7B9*[@:F1H@3KAEL1H%RA4)W48,XTYE$,=X$\4.Z)//)( MU6"T+,G@H.&S, KW8N%F,4&%/@=K7*25J5YC:Q<>R9\8"/ X5ABE,#<,D08S M>23R:#541G!DZDPB^78,1QJ%(,W/M): ^P9M(HVCP 9H4A[IZ-7T;7E$8C02 M&$E1.B-04J(L3-4^0MP'C(V_QAY=&,[&OC@@^/[>Z5S6<#WR/.Q1 G'C)P$9 M6/0P:O;]77;#?;F/($H2/*?8I^A2 A<_Q!O Y=+$4@MF"1XN7!?>RMU8T'QP M @' LHSF\KH0YG3)00%.MXC7 -IAS)/B'0/$ZU3RQ031$PCAE/L @5F*C %CKZ;* M;E#F4KC5FP@6RH%["-3__=#$:DTYL*>83\>LB_-<8Q@/C-.W%-\WB7IM4/<) MXZ**[O&M S7\18%;;I(">FB!!D/1.AJ]NFC]!DPV,.51%UL$2YX*#@1 NAO[ M[ABDV.IH4J9=)*)"=JV$H_8+JVAOT&5#UZ4 [O 'B#;IV,4[DUP%Q* - ENK M?6*B2,?YTER]-)8EN0H&"Y[X:2H$"7.W/,B4M%_!(@?75P4P'2G[)@8+QR5% MBZ'QTYBD\,TD GE2C@RR( 7++M#2X >>HHUB;"T:MU".'2;U+^0RHXH$E3*D?:J6D5@JOUL>S\/KP2_0%D#"@R3L)HBLZ9NI._2$4>H2(\.S1=!H6 MC1))Q>J#5.UNQ<*L+.W7SS_APR1"/7ONDX6+L/]_'.>[NQ%[0X"#;WL$"A]X M<,=G22DRZ.'\L0>FW4! \%'=.3YJ/24LHWGLM _6'P\,P]8/VVL?MG7D- X. MUAUF7">;W[(0D(KG5<%Y!\X*T2 O'IM73:([P^%7WX@C#X?EK;KQU;:[B,8T M#BW9X;7.HX&8T@M\]MD' E[A%5TA)'9M,--H.XW]K86:RQ&\'!>@YKF(]=TA MSN1&A"O@3>7E'I&5=DMW]GO [Z-KD,3&?\.'CXT*_T% _"IRQ^()$&[B#Q<3 M@I61X-%$M*A]S2E2^\Z+9VTN0)8$I&3V_T0H7+Z:ZGBT/8O_&/L@P0=[9S,1 M)^SZ7YD_'#Z6.RR#BK5>^ORY;827R@#U:!PF)HM2_?74Z]_<-LZC6PXWD*SS MSG]$BGG-PVCD[W705V6=UJ.R#JK,/PT ASF%$\"AM1[KTL/#O[H;U3:$I"+T M$FF%6&XE& H[A9LL%M+Q2IY4+B,"X26@P2))T$D)K\5BA'G ;"+B&Q'7X&\* M8?3_388,_-OE4S]%=YGZI>CG='DR5I[TT*NAB63H2R-([C''GT,";CTH;A<- MCB.!-I<:Y77CG_BOP$_M?V;3&AOR\%N<35-W5F.!#_17#V1Y9@N^1;@3'BM? M(GDDP]F"@YNMP6<" '0\'ZO::#EO]N\Y"V7)KKPE9G#.I@ K0*R5ZU=ZQ#&T M@XH9..P+4+0 X!S$&'](H1W3+$XRM.8#$G60^@:"?>W7YDWGB8J#0#\\$L8T M4-;0*$!O'H;ZHL]>>G$,9L"2U NEM6 % XR@0,OA;43F4?F1=)E/XXBB6FKP M^9VX190VI".G*K%(R:UNIL1E3/@W85&,I&AOM-Q)AWJUII3#JFZE)]D;&_-% M@8 Z-]_,_TN0B]PUY&T2F\VK;D/,M0/9E4#YS$7Q;$N2)[">E8IIQ5!IEH@4_<_I&$&K,\5"5/X] M^_A&O%\-1@IA>1N'CSP*)P\SKR!*),+KLF!&"R%7LJ^R^:R/SF0 M0Q3X.[8 M!SW 8TH)H*A5ANIZZH]\_#W1;".EH]%+6Q90\:+B_ILVO2HH1RG,02"B=,4K MD69QN'&HWFI)9'!]M?$#RM$^MU%AN!-9'J)0Y&8(KFL2FL GVQC HEM5YL]& M3U#Y^3?D-K+NH8S19\,(N(Z,1)H"DQ14?U"XOC36[6 ^@\A_V#65'F.11]GC MBK2Q+Y&5&X<"$)YXFY7N9TV3&+HE8YY5Q+-.LG&#*)G[P@K%@JVF8S*(F/Q! M3J43 ]]%^N=0()B>PN6!F\E\" K'PK.#S6. 6&7<5#UR,8F M\]U4:=Z74<6.7R%>O1J!.MN!/@T"R**:@LIZLMG2V[_;/1H!6./!"X:I?[S"C 690%F!;$&3OK+3\>-$X*U_\MV M=O"7/1QFE]VS_9]WX6GK9%4_QH/W\/U>:M-Y)"E1UTI2YVK$@T]4FMDZZ0?P M@$<3D <)!06,J;U@PIGPJBNHX!J',S:1#2@(X>=GJR']6+8; %3!8V1E5"(" M=.>IZ3T")ZPD)ZM6W>-(RFL_>TMM6U1-H(SL^\Z&]*#NEDB@9(^I5ATVK HM MT&>JY,^**B_%I%:[:D_BCH67!6*YJ+H2X-B1SW9OOD<4\]Y$_PG3.\YJM(.G MO:(QKJ&TMM=-'MUO.?N'C:+>?XZ&@;LSR?E^S8/I!1_46 M;[=>/@)]00_*^;INOT<\>'3^PX/'N[Z4R6=FFQYA:DG99&?GZ"D#RO'+IZ L MZ* A2?&ED;,6U>S];F!^WW:CO5J&+Z:>?S;2^W_O T'Y8:$:6-U\(T[UXROW MX:R^B/K/WST4UU]>FJT^.P)=MC,8@^:$P1^[WPD82VC;DH2UYGX.@=\?[!UM MHD0"P=Z!LX^P1Y[O[P7P?D#ZB4"\>0I*B:EMDHRV-"\5X/7X!K.H?U-W/3QBGHF[EI M17-3L^W4#U[=WO1=T\8WJ]/+69V:^TZ[^69VVEJS4U5-PO8\*SBF,H4;*?9< M5@@3 )<80S8CF>Z;1H5XKZ%([P1&M-Y%6*S !;@3,KTYT0++D,@L5=TN#2V'=SHJ^7H* MD'HQ&K'(=;,XT0_I1=,C'&M5ROI5NFQ5-,J-CSM<5P0P/ZFD0)UWAT4#SL5= MX5WY]]R+UJI.J7<-K ?FMHI?ZH)\_;];O3/"*'UDWXR%@/2T,,050N&W-:FZ+#HTOS"O -)(R!L@$@&6)B(G,]]FYWY4Q]05Z MO*Q0"QOTSWK7I1QU^=O!@7-PJ /W91_$F>R#6!6H.L<"EHS<:CFMEMRN&OY9 MJ28_*I ,EP))@?0MAQ"8IG#:Q4MYSMFW0?5>8\[@EB;Y&/;F18*XA.1S\V>. MB(:A\(K?):^!IONEN]6(.N_[JT;391[!E6=UGD/EGPQ$6R7&];8E>\1I'^,) MG*DTT,TVIG18)YQA/^&;RE*)NIX#-1K&:N& 7)@KDJ2<%(=Y%#.Y)K'P,E>V M-;8J0E26+C?UC4T%I?*H6/BN6@'K;.290/^U_[9_VSD]?LHQ*!:UI2K7T997_Q4%7^ M+M9(!^:C:X11+FD^D%[1A'N 84@!9)T,T/JQ%@RF5JLP@)HN4XB;4@@HMQR% MP4QOQ<)MAUT7YS(4A%:.M<+@5F531M6.0#8$P,Q<+(NFV'=D<7Y'ZTIR:++9&I=Q,53=Y?*X\/EGZ3 U$S5C+(_IV!1&']4=4,KZ0(PNO M7%Y_495M*38'SM+'*A'Q2/BI;'PN[J<^]6,(H^6@XP+YU1_)8E:AO%,U)]%] M>#(K%X6K'.TA6JXE(PU?V+V"IWXRFM$^4WZ?]W9 X$$/)%Y&- 0%7#:Z?U'2 MW) EEHK4>9]^W 2!WA;Z?.BTR24XZ%V=]<]-2:S>V>7GBW^<]D3.7L^KBV^,=)4K=.:LP]LTR0!Q^VSCR:X#R ;ON/ M"P9:*[9M21T/PVM/!4_'6\UD+<3R *X!]CQ<\R)V6R,CIZU5K((=4K['+P#M M$$]!LR/GW J(HM3%Y=ABKZ6V$%F<$J&!8=%0._8#L5!IDMN+R2R:8-W>W#X% MRU$T9#&ADD6RD2@E+(!-S)?N3;!V;\QZ9M9$UB65]B^])+)C5:QB%;*TME.& M@58B2L_UH&[$'+Q6.O0JCOU'T*$S/P$8 4U[DV6$'BOQHWT& 3 +I!E!!#ZP M:7A4(Z@'5HN("(=F/ H$/A'XM^;W@RQ],80 M$H-\3,)%S40(P6.4U6&A\*]D3!$DIL<=CNF92P84#L7(3Q.Y8SRDO-.#_=XT MCH"Q3IXCQ9?+E^&L*3FMEHO;2\3TT)OOT9,WWK%Y,R[VT>J"OXEM@$!LD0QV6 L0D(UDN_R&1'TL% M_Y-V<"MW8/6-K6ECF N@C(-10 -Y:S^+&^[.E'^BIR+YT"MCU&]J83O#$4"H M=L<%BC8N-K"0E"2EGSE0C)L0E'47O:G#+$&Z1[0CN@M%G(S]J7$(D>,":0:V MC?9!DL:QBG7[K:TB"9EF\31*1#(OUBO_D/7^)$NH:#&VOXENR4]3(]PE%+_) MHDPAG_4-OF)M5);KEM0".[JIJN^6O-_9ZS$^A.&)@,WF$5BI)+:FXNL;S'U' MA1O,G2#R#M9 [;'Z_QU6[I\Y%[GZ\%5_^,7[=:8:^VQJCMZ0W+A#]= HKE- MGHU/QHU0Z:S6AA3!@?84NY\,A>X"[DFQ23)_;K5"46[J4N/OHJ?:%CQ,0PKU M(0EJROE?Z9@M=*$T#56^UD!81,N%\=2&@I.#_FZ,0J1:X$X8@7C&W:)/W6S. M3Q*8=]?XY7.9)G\'XP!0S$HB[-*%+GJ@[?@F^3. 7(Y QD3Y4!I@[&KT0;%P MOW7R+F[.XS&;P:J+_&FA+[U*$+0[++$OY0XSUK=Y5(3LJEY@$6JSVEU=EF53 M?H_6.!^N/\7]DKB[H+.S=G_YJ5Q\&&E-@U:?9ODME/O6OX24^$C;[X_70F0[ MK+Y%":Z 9U%HFOXMD!25BF9;'Z/Y/J(6"!;5I[PB=-'Z6RF4DAG88%(!8VP5 MV*!8$8U(H7HZ%KWAS]8Y3B3^?/4QW4L!GN[;C(RP"T)SB.K(UO@JV2VM546+ M5JZ5F%EU:V?;'#37GUH9,NV0<*F+$*"[;C91W2RKV'A-X:%MZJ3(+VWS,-;0 M_XS U:];TRFPJ8*T!U>=\^M/O:O.Q_[G_N ?+Q@/M5_9!;#Y\MV^%F2, G"3 M5;# ET!+3S(NK1.F,U^_ICM\%$+ 4?T'$-8F#T["($_0B$"DGU(Q?"'_4#E^ M0\4NE$\NX'>)="HDKHHB*"QG5)#A*UGDBEZNNE.OM*8=/@FA&I0&/3]:11#B MYC!M2U -/06$:KW/O>[@ZN*\WV6=;K=W.4!%_1F&T"==W0,CO2H*#BPA:L)G M9/-#&W<225,Z9F63"]H3+K 6&140^+="QMIX$3 ?4A8IS"R7[Q!1 9-&&9FD M9-=.M/-ACL50YP)K#SA]$("N!J@I,%DCCD+?5;UT*<;G7QDJF#/,R$!KG[)= M3CG&\?A32C@-EP[CL']$&7HZ!#RTABAZON?TK'^.YL#.H/^UQRXO_NQ=O60R MRI8Q2EX= MF)C[L7$GQ2I5$3[Q8_)OA=*[JSI7M>#SJ"'22^Z*_QYM]_YC ^^?!YOVK@:=_CGK7IQ=?NZ3(^EK_T+V MDG_=W,9#Y^#-EP1:*@JOUWG5F"YHC$..J8P;;,-7&==FE;8!N3;*IC+L2/E M;A7]NM4VM<2B9E,9]0H$3";:7>7?2VOG5(0)5PIQ3#\$/ME.K>$6FKFR6@L\-L:99Q:>[6VD,?LX6FI@PBX M/U&TU40.E0^E&'@02W.TWO[(#V&K>'DR?"DQ"45%/YYMN9 YG1$F+Y)I(?:' MB\L*K_DG-2%K!R_1AT M0A0O71V 9^+MT"_P,*B0QJS\%[HEM/W1'6*-!7M2%_R&YEF8 7 "0_9$*;!% M.G6RQ&S$&I%PH'FB _3L$ESE>6D(KR;=H)&TE\D(E;2&JF7O7K@9V; _<0S; MV^&)RIA3,7 Q.F=&4FE%T-Z5_8-A#\^'\47RX];DVS>W!LYE*)JVY1A*C:#T M45.\9;"_PW>14/+ )4>"35'_DBPE>G,!B+FI1P:2D76C] EYW$G4CHN!L#9\ M3NEE T]L9[B+Z*/=<\7P,3+?5$-W%7!KLXF!;]@E07CN57SH$.G<0'7X!M/Z MDR%0?CFQY&[VV/*\89$E'^I45N')>U=IZ4%&). M!4!9*"+J %ZB22\:JUZ-MILKR;,U\0!*&U-%"\T5JX*%FQ,FI9E56. *G BM M-#IKJ1@VB4&N@+D^!9'W[MTQ#V^ O[H$R8WC5KMF"7MK$'6V#9ZVQC]>A"X6/L>Z)GC,))(5A403?#.BJ#;R M]?MD(WTIG)2MUW_8XKF/0$F@BD&6D$I,XL"V6 RT-]U4,#11YQ8L)KD8L@34 M=QJ[)/VC:\Z/50D@?)CF;KT&8FTH]Q76C4&M+D6FEG>,&_@!6=Z6Y/L!?DE%Q[(^F0"Q9*-A MWK&I9TVFI8](;@_J=6G%P@0/*Q?U<=8ZD,30*URRVI4L=A7QR55&L2?9]_(3 MKBTS\*%I0#GW%QKZ=E^__M:F?!1;$OAB\E2Z?W3.?^_M]<_WNA?G@ZN+SZ_M MF'Z%>-9JY/RBT[J5P2'49?:Z1-X!5/:Z,$@75*2 M%&>5F5]SA9BK,SX3/M%IGZ&9BGZ<<.!_L12 M0792L6PDJ'6;V7;5!1!T2-A MU=!X()5Q<8FO,ZL@ /+L.)*%%V7B'0HRRU*Q46A0MA=L5(%9(XD5$U@!1@NJ M<"O06)C_2WT42I'RI1H=ZTCEV[(JA7_?EA!!]!80A;KN=2F9KUT_[EA.V,T5 M3WYU8]W1*_A]%R0O%V-_D-2J,-W'A@&%I:!BH/ADF58B"J66J>@*4C2,N%-( M[B(8,$Y23^@28\ DT+$GEQ:+-"JY, LY^C590!=S@S'=6NDZUZ8HFUU]CQ=Q4F+&[* L\R^)"DV-%!A*[8YV-H2K"4:B.4,X%PQ!&68SG M5Y,*L%W\EF+"EY2NQ>*WM;R2Z0 K223S!+I@ML MJ*M'EQ=0^1%TX;F#;4W]]YWO#0Z_AU0_W6UZ[W3CRN'L\=/>;1\W1 MP4&K[M;_MU%_MX;XN8.*X#G]WG-[,RX@K,?42N%A/IMK:@OO;,,K?()&^D T MHKD*ISYW':6.],,@:\:(8NF<:E MS #RQ!'(;[(_UOQ:17@#'(4$ KM(':;)<-\4>D#UE0\#E.JF*/90HF;>+N]N M'"T:J"(ZZ4P7_9(8DY-.F:_CRZZ,RAL%JBV&/'OB5@315/JEX!0S]%V1J%(# MP2O 8\&"8#S^)F@ VQP91[B4)(_:&.Z60 I62V$AEIMA\2*5I?[:"H_Z@V,] MLX+9OL:6A"7IDK\2CZ1A9CXOPKZPXIL^R2 MF@^X8.IP$(A;OJS164&E:S])=%NWQ7-5FGR*!TY26[)ZNE[57DI(JF+NLAI@' M?B=IE@P ]S5&IAJ>T*&4FDV3:U\/DG+#0UW>3*6!?S"/?KW J+.9>8Z1G)) MC11G*X9/T805P^_)V*9E TN>454_>Q(E*452A5C_@91]@2XN3 B_ M! $=HDP4YG;P%E?'L$'@)]Y+.S/:\AT<("]](4HBCY8%>,GY8W/H8P97> MB>!6["E=V2Q5%,\1UA1:A8'H.*BHJ5ZGQ7SG3]V.M3919R::#0E_QAX$8$[GB4\%:3%@LBCB R!B]TV$O AD)Q5OJ9>E MR.V#DO]CUO\R%6$;3PE->2:LMK<-5K5AOZ2L:#B5H9'%/*-0W)!%%".9.-YX M6!FWD0=P8WRCI'#ZNHF73[/T58J0;\;8@U*)!^QYL5[Q 'S6GU*DX$=3+0J* M;XVT ^EH6]' (0,<= U&;HI&(ZO6"")CJ+I(JNRE770J1 MJXDI"F*&KY6S_6117IXK/3AKA<&K5,"8EV)DM;$*0V@YHJ%EM3*2;W?LBY&5 MD7$AP^-?A)!N E"W3DI$0-7U6[N@A28B6&*(4]<#T.+*C#W+4:"NRI34SR_Q M*WHR+X&DH$\/),(_,F#%6'@MRF)7]<0TO%L7H%>P(WUVQMP9"ZRU32)J*F++ M-*5,/[))%>46S@$VK8STE23QI8Y6-L"JFO-RA)+YBFQ3ZECDJU)_DIA@7DM, M,BW: .)05O0GM*30<(^$%5G1'LV? DUHB&&@057V,UZ'R-!^2LC)CR;>]N>J M23R:+)?3#U)IQD9)8\@3V=J5J!P.:]&W"B);!#U)[UX>&6C4G%PTC$N@^!J%9Z%1P#F''A6^O\F_'Y/ M.OSVG?9!Z^<3=.XJ#Z#\8=Y#^&[5P9<[%X\?\FL_ K4 NO[CA?%^J$&7T*D MO%5%@G(+?\&J7UM$%&L%FRM@;56ZN$GTQ)O/ AYK)J$9DLJ0,"T-RA497M11 M4!WY62@:\]H>A$#<&,GLC'1C$]O957'P%@D[5;D:R0M$_J\*^$5^K.K+>7(C MPMC>%\B0; =U>@0_%7IDOD2P&XMYL)/>-)ZEXRA6/7Z62.35LK8^-,D!?+0< MW("\@'@R1[\3LCJ@/PW#IG2L5^- [V .8"O?P>_S_(A2T1$]@27B6V.LEG+J MV- B&1 B4,HB2 M3#:AKT*XISKX-DAR'BY_J1I"33 ECN0M+M,O=1GQ)(=!JAF+& 6HDYGL&-,Y MQP97?,N +(%A0OEE7G[(*CI3U]'4R)AG9-LN#Z,"Z)*=L,PD4AT09%:?:GA/ MKL*:#F\TT:D\L.<>BED4>MJ"F$>)P@YE1+J-JI(<^:ER9UMTB;99V:G,FLLW M"OD0JWEJIEU2S=,0 MMGS SQ!#P+F5*%H*"*KP': 5OUF*3:F:*U.JC['46CI0U52+PIDL3W,*$(O& M,'D&F/ACG JM12LBW]2R,R%'J;!=]SL5=4]VG^#09P]Z]/7>K1(2I@55V2FK MTG-TV#;2+Z0J<[1D>=""PY9"'?#^@+NB"'<&%!4 TD&KQ&SM)L%5]OJ7,M4@ M890Z9MOSKXK%GCX9N_R5LL9;'G9[_"VB0PLJL>?[IS2)1^_82YEQ6%?0O5ZH"+RVN"YE536=YC/V M"_FJY23]0F1T: )144\-?+(E(%O$&A1!.7JYV2Q$=L^UCS$1WF-A$K1JM "L M/R8#M#!4ZB[&A8>F/+X=2%Y3H0>UO(\2B17ZK[R1+T]T!2G]+A;5'I)+8D++ MKLEFGC5= H0'-3A0\L.8+"C\!M@X!O!0>0^LH* MXOBB, 9FE&MH-.7'4.). M'DWF\BEW44R22ETH(P!)]E(E$JNW9 =;D-)BNI&.3& 1Q0^IV"+ZMPP6HG]: MP41H@5?1@%9 48VEPAV' +LW,_D.9;DIL'(EQ&\(W"55\$#WEX;0#_2":FWP M[K=D8UBH_%RQC&S$"D]HY07R]6_M*5%:/)Q=?N,8WZJ.W3[U7WYJ'-1/K+/7 M=RF\FGHF;U%F]2787*RB.8-491!=.SFZ8HS0L')6>[YO(> "CCGV)TJMIM[8 M)EIMU?D/8O 2; __B3:$O 96 TF: M:T6)N@&72##-AB U8@&AF&..AF4@T3D?"F4>YT+<$(NY1AG83S?)8DX?: *6 MWUY.QQ?1XT1NIZ9^1^TPIXEPI8D*@-"OD0:GU;6220:'*#(C[/8N,.##"GS+ MN=O6W_42XWK\VY9/L!_:F:"(Q)BM666)P9G]YR/Y!]'R.T5?*4C)E2 M*I"QZT^+:-@.Q>_],/)F\)]Q.@E^^_]02P,$% @ R8)85LXX\#K7' MKYP !X !E>&AI8FET,3 S,RTR,#(QRI*,+QOOKSWOIEEJ6 M#)YLP Z5J2D"MM0WO=?GO>CMWTXO>L,_+_MBDDT#=!3VSM[NW]\["W MMW?Q5%[OR.&B0Q3G>DHE,'>7O]\2VQ-LBP^WMN;S6;MV6$[2F[V MAE=[.-317A!%J6K[F;_U[BU^ C^5]-_]U]N_[>Z*T\C+IRK,A)%,\3?3/)Q,'^P:'X9Y1\T[>2O\]T%JAW=IRW>_SWVSV: MY.TH\N?OWOKZ5FC_'UM:C<='A^.71P>'^_M'^R]]*5]W#KS7XX..UY%J_^7_ M=F"1>W YWY-F\T#]8VNJP]V)POF/#U_&VLR=9?MRD#? MA,>T6OAV','>S-=>%$3)\6_[]-\)?K,[EE,=S(__WDVT#/[>2N%<=U.5Z#%_ MG>I_J^,W,"/]->,EO(*; QTJNR1>1_]NHDZDMI\EZX33 M2MY5;VV^R8.#5LD/VEW[Q4K[&_:OSJ[%AXNK35T@4&9'7/6'_?/AX.( M7@UZP_ZIN!Y>]/Y'?#D?#,7'J^[Y\'I3M_#E_+1_)8:?^N*L?P5+_OVWP]U;[9T^;E[7MO+*K0TE)]INV$O&1V5V AFGZMC^O<5 M%#QZ*4BS3TNN&W0(EU&"'X'Y(C.!)Y)^A[PRJKQ9;&\VT33+[9*MCU:GC'M/ M8H M&,GU\!6:WG"#+X@#RVSAJ(;J/^E89!^0RD"$-J:9Q M$,V52JT/TXNF0)/SEM P4YJ/4NUKF6B5\B=R/(;U@)A+T;['3_X5:3B06Q@> M3'U8W!@6EP*-$7@SFA>#JC ED0$>@B_>JU"-\6[X9JJS3"F,?!_DDQ%/W=.=EI=D4- M)[&P>7%D>4G#,8?9\2[B/4\F<8D*!NU');VF24\JAW#8:1^\QEU_[)_WK[J? MP>W_<'%UUD588_5C7 E36G;74QWUV>7%U;![/A3G%\-!KU^Q/Y^0\84@C('X M723J_W*-K#6/IX"5: 1*/@3+GCRU=YG$IQ]N1ZNX_B" MZ$; 58R^G$7)#4B[ZTR&@9J+F0*9!J(#C)1M!*GI&?_^V]$K_H& ]93N2/F& MMA=-Z9LT]NC?;V$T"Y1_H^BOJ0SE#9(L/B54%NYG\,22776GR3K+ZZ:LF&.@G8;7F9_0A"H)H1AN,D\A3/@)%H#F\1(] M<9 =N?39E0>$)USB2V*FLXD.Q9M]XH 1ZX>J0'J0K3!0I\"%Z0 M[QV-<"[@PSS($*7[$"5CI0G?,JJSN+&N>'[@HWIUL*B2.J^?^N%UUZV2WK3? MT*8=9/42AHW\QUW81.<( 2MD:0.9NW!A,H"3(<#$LV+[OH/01*# 8P)? M+.@\$K<1>;WDD*0E!%S=(U\Z3J3' M\4&13B1JLYD. AA,D !4OK&R)7P(;HJ7!Y*Y$JYUSR2)8$$PZ0^P[3:!D=YO M"B.=ZEL-A^"+/JBQ6QG >:3KX:539I>LB=Y;PK?K5.4Z2U+RO"2'B]&QP?LG M48#$NVTQEX7.1A2R-P44 M?BGG%+0&IDIS8/-R)+NVJ?15BS1*E*/^ !4$NT.'!C@MA!V#=R-9.^'VK$JI MR3\)"A@@OY::D4(*E28Z"Y&.[(EPNC^<_02Y=N;Z!1@ M&MJ6F1,6T<45E)N^=S@8+0<%OW#8H?) VJ DLH_+'C)[IQ<'FG@$>'SI1@3./%##-% 9X!V/Z* M=V&Y',R&:%JUK2O[;7I&L*#8!*3-[*[,V"[71XMJ (F>F=PXW12Y<;3_IDN/ M/] R]-1:1 >H+73I;BQ;@/N7):B#PBA#,D&?'U=N=*1#:9:AT0DTZMP:S$#% M7K$MHC9QK*5,72R$%B&#B>6PU+V98(E8X))H9%NHMBD,%"I]=% M^DG?X,'&4!+5$8:)DL#'5^JFC:.U1:>-@^UVMO7.TIVT%A1_(3K MFHZ)SH6 M$LSP4)RSSG0@I ]2"D_"PE]C6)!&)A\3GF MQ[%.4 ;*PLU)]1T\%I#9\+-Z MZ9+#:W$F#GPOISAZ,L6S@ _F8A;E()J,4 >50NN;2)_M,"O><4#< DB\F_> MG"#4@9(>!%N>X/&T6*HOE_]D]YS.^LT+)&9#^-R=%[ M]O*OOW[YQR[6=>G%7H$MD,>3A4ZO[XPA4\QQO N*-$K^4FXY14L2! MS-7H)93G9H>_/NX)L+31IB:Z6'PR"&FQK!!Y10.7K??'."V,:MW<$ZA)7'Q0?3/ M+C]?_'G6/Q\^+_1[8+!FYD(BZ$7Z)Q21K'**I/KWPB(T&"?$VYS3&NS0Q2\D^Y&UPT<5J@2-PSQ0:U );=% DJM3((E?)%HT$-%: M)K &+!BDJ BLEX4$9]=>0_/K)I'Q)&W1-WEX"\/#E4T(%Y/T-NFI<%Y80DT& MU$Y!^0X*QI/["'A4T-H9L5MDU\I\"XX+XW0\Y8K,^^K@9V7>C4'/KX'B MUN+/_F=,:^&G)A@(G0^B)3L8-1Q'YV]6C( (GASB AI\=!.6 MBK#B@")H<+US:7'0%&=#$3C.3#*6$U>#A<&,((24XYNZH3ARE*,QNXBT:]C7 MRC/5QZN%]AAZ2]14:@KG_1*,SULP;DRL8!#>1D$>9DB5PU*0K,O 8-(N49X:B4YQQ*BMFYF-HYOH*C)$7#B M"$#=*L-5I M!$ )&%2Z9L+?T8844V\!&(8\:Q: -!9/X.'RY*.&6&8CI=\F^ M;FB14NT0M*,9+5S*T0655K1F5#_[!9''C\XF%\'UDF'$W,OXN$B)CI;'.-UB MY#CB4NSC1 4$DRXM3S9IYOOE+7*4PO:R^BU+Q:#[2+2K0]F&W2-NK.T,&813NQBI!^)A@*4L*?IYI ME18&&'M-J0@T"0?.N2G](O&>,I]/X=HDRF\FXE/!?2F[ZK_4\\^DGCE M,CAOPJ$WQ'MQ[-P1H@EV?0^HW!5Q@U5@@[^H(,H%MS$EE%D"8?79)")FL@D' M%OCXTKYNMZPZ*3=H-/&" M,44P$@*0+]@)0LSA0H+BBQ#A:(=9#^^@_$/S!6<;<+@J%6JA$L5X>O^&;?$6 M%"SOB@RGQ)U0[9"5%L+9NL6>3[V&.\YJ6H93%5* M_9*'/Y,\W)@0W:F2V60#1:&)]+/I@&O<% \$%@P4FY'SD4:8D(/QNI1#\BRH MRD7_\C%XKL((I$.QH@IN5P\\5C0MG4-MIA6;3;F"3=EKB8\HOVKF9,N,,&45 MTR([MMS, PKV*4CIN6> 77#[_I$(M-:5QRG8P@T]F:?*C;Z"A1N%U4K(,I3J!1%U&XVXQ,HKSL?C M\S&"I2DUTG)P4U8C2BY3/^GC@]!\MUF1+5JI) MXC0WR-_8Y&LNUF4.',GA1X169X9U!9Q= 454\Z5KAT*KUGPW?(38!R$JG)I> M9(/#+.;X'BJ\\60Z,6Z,61V>:5&X4BFW&4L-NDHFWU0F0%#G13$VK"0%26,R MNTGVPBUWA87 MX3*27'&(UB**!-LHX*:VZ-56K"OI_-G2IC$UR2"NRS3YHGD+=9'9YF '5?R$ MXNSZM'[S#KNNVI10X$G;QP,+,0 ?K$LE^+?GI/5:K(^]UY6K*MA_I9UJJ_?K MCZ\HS8Q\3DU;5J (GY/^G->+.YX]-K?V[C.=0]-]Y@_*(OK*641KT53]A6Q= M6(%>/]LQ!$P$3'98EP*5HM MQRR/#: PB_,DCE+;T:DJ\J_12G6NIU)!3'Z/$>HG(ZYE^V)D^B:/\C-*SE_2D^BQ ML_,?9L&#E^T7M._A5??\^D/_JOM^\'DP_/-YY>0/:ZTYD.TR;&T/FHD4/7(& MEHN8PC29(AMSG7Q9J&7O2)J*JWY.$ORZ=@I\T7Y)*K3_N=\;7EV<#WJBV^OU M+X?=\U[_N='ABE72OO) (5 -N"GV)N#(- Y'KR"066G6(&E7>G(;9,G4/W'$ MU>TG2.8=R& 5@,&31*'V3'0Z2JB($Y43.66HFDRI.(C]3'LZ1A_>6)C+AFE3 MOS),?84OG2&L&\"--(K=5$A[9K=Y,_!K1/W#J1U&.5HZ3S,U MI0#$*-#IQ+ABZ EAE+TQZ"L%9P3CG/,E/0]1/3XV<:Y;.*Q?-KPRT=ONZ=G@ M?' -2JJQ,^'/P_JF(R87$\=H]UE,%-DD2W)VMGRV$6.4!^2XQ"^ OXJ/2J<%CB&M:J-6,+4,0HQI\;;"3*:-GA=PL:]HK: VTJ) M3'Y3H8&<1\K\67(BGR@L/]'L4.<$G&([4?('0^/2%45X9GS@C$O;(W5Z!I3%YBAC=;C#^3V$$"#N"AX$K&VD0]^2$VP:R"9%X9O;'BM% M/U@"%BP^7U8/6X 7=H-Q!"^0F MY8]0(/5DK>^?U^^%YPK VUF&H9O&QE=1< M-E#"C,M,6CU8N=T _6UVLJ39-JR6!)%77C!<)NV77+-I66;P)(KJM<589M9 MHI$)4Z$(W_9P1'>X4,%S,&9C#IX?]1,P[&5;'*2DD4Q;SVD$(S2<-Z:5&0U) M2:&5L$GF?#UK*'+ M+P;"/K3BLGLUQ&)H? ]/61 M>A?GH.IZSZPR^GPA#RY1]*X9CXC;-,"NLB#( MR$"!G*!D0K@8[W+@"I;Q5C!6$BG1;"3CLN6.YT<%WI(!X6>*3#P;$W#NY^8Q M'O)T-E,J7+00__A:B >3SECR'TFHAJ%00:F4DQJF$G=%$]N5$L=75 7#+P7T MC5.S[HD2*PFIOZKRTV(+=RKQ4%LLB#+@>=RXJ6$@A+AHQ0AGZBVV6W"!)OR& M@?:Y.5&GKTJ,7HP+6B&'3Q&:Y3;BC.<8>5,,05EOK(>6X5V/+I#6C4 XW3;, MDW34$'ZRM+L[9R.;-C,8QH^H9S0E#F &+C[1:KVE:1XFN:=TFCKA@8]!-)*! M^ PZ:1?+N"K*)9HJ+/<0MUJ*ZWGHB=]_>WEP(CY=F5_.HE#-S>\-(XA+#MK? M)WA?O#ST#AX!T?U53]-<3[/FU\[9!BV;^EJ\[VE#LYK,.7B%!&<^X1=]T$?+ M-GS?FS(VX"T:EQ>?![U!_UITST_%Y=5%KW_ZY:I??]WAYBR8>@T]U1J61-RR MHH$T=SYRWLRQPDLT\-+ZJS/N?U,& X%5I\L4+AA3@=ZZ43J?A#F:!+72IHE MZ:MO;I4AF68*;=-+N6@8:P/0U604'NN",9BZL M@,?'G0+D#E]16ZL*;T"&DU'E)J"BCI:Z2(# 7#RP[+"+7HQ5,2G&' J_C)R_ M)0/1$RQR C%A0IS9U#^FZE(8,3+LM/^!^Y1,O GZTN!^1O3P6F +A/E8FAK4 M%O5ZX'>P<,*%\9J+KEY)A$M)RS8&HYT%FF* P;9U"# M>36_9$DEDMDU0U)PYNI6-MFL&R/]3HN$B175%9D9:TY0Z*R[=UEGW_0N,]*U M%'^52C6F2* %XU]Q6J1I]F'D=IEIQ;!FNI"24H$,P?ECF8,%?]1CV^*]96:H M%%Z>),9Q-)$?EL6%#*9L*X*#PEWZ?8E0ENPC8,$@=_!D[UQ/1WF2*FL,R:;A M=T?! $=8A!PI,9)_Y7F M&'9OS3O[^+TMQ?;\AT<(*_>P*#/IQ :S95]-W6K,G\AF*KA5NZ;Y:+%453U' M6%/H=#&FXR#GUZ[349[U4V?QRUZ^00 ;FO0LK)PTG)+>!!^26G4?U6T@ 6^/ M=V@%_,"G8 Q$9'Q4:#*+,BH.753SK-L+#6?[B)GLX_J4MLULG:[CZ@M 'B,? M9!/DW<'&R+NNM2>7ZO & 6B1+;ZAZ _*K+G0(/11S91G3RB'FT,H1?N4FEWL M4(@K!MR>M/ @)S #MJT"\Q<[33>:P*X%G#Y@ +.)B@7J&H8S!CC<@K8B3H=H MI#' HV1>1F&QRD1SCWG'5J?7?5%* 0@JG9EHIEV6D;L/FO!_9?W/GG:/-H9V M;8?T!2]DL5V#F\\9XKLIT;@K T8E2VTD.R+R^I,!;X$ MS#&35 -3 DV%K=N;:#46_3OEY<2#%_@B$Y4\>XFY.68A4J[M9MP#1S15P3U8 MFGE>0#X>9U,XZ+EY=D44M7RJ7[&D^A)$"R9;@ GX*0\ /A;R8B$>K:IEE<4,UVS0*LY0-"4PP)\AO>^D%B1X]O2Y.<;L(+0$ M0$19(8%%>JE"WQ6XN[5,U+0J8";0OGG)KDZ\?(HI/5[YHGG.U/S7YK^F3T]76NWH/ MTC5F2)OB 9_/3Q5P^1(C4&RC]XV$;?-B[)U(T%0QND#0',"2>3:)$M-'!ZU72)EQ0+N:I1D=?.)],7,X3])< MAF7!NE\PQR9'SD",!E%J7@9^'ZNNE6V8 +A=05G/3(YBF528EL\^D+-:4K]; M7."0"5Y5D H]_I02 OWR9,R+WVQQDF4"5;"I&QVHO2T2EIE&II"<2_/,^U\I MJM:RV>X"58!YT[0S]TC-H]"W&%OY CK8(3H#U=Q-%@,Z,Y%;1Q[0-AM;\SAS MZ<*3'5'];O&NWRHCDGF$=5T8\3'="#:8Q+$/F H"&:HH7S,UGT?\$L=J>-\( M(JH,J%9D2J[-H!C50J"5(ZB='0/BVJ@M 71.1Z7,BG5\S!I8):3&(4[1R$(: M2@/0C9#SP4)&1-- ;40*!/QPV8HH M?G+?F?!KG=V \S99^UBFR$G7:.+M?$<86CP8A[9[+V5'61:^&$HT':YL6Z:B M&FF1K>\/M;?%O50'ZB^0GJK274&*A@#IH&&LD<0DW?*U=OW!):?@IOQN8Q=L MON*NB#;2^Z$ C:\,5.S$A9>-?XFUGG]YY$W/CMT;1?X<_IEDT^#=_P-02P,$ M% @ R8)85N&BY+/@8 #2," !X !E>&AI8FET,3 S-')EE3VVC6[_?[5^BFZ^V!*N&P)B&9F2HWD(2>#J& I*<_ MO25+CT$36?*59(CGK[]G>S8MQDD(.,M\F [6]FQG/^=W_OY_#]\>7/QU>A1< MU9,L.'WWVQ_'!\&CC<>/_]PY>/SX\.(P>'WQYH]@=["Y%5R445ZE=5KD4?;X M\=')H^#155U/GS]^?'-S,[C9&13EY>.+L\?XJMW'65%4:I#4R:-__AU_@?]7 M4?+/__/W_[NQ$1P6\6RB\CJ(2Q75*@EF59I?!G\FJOH0;&S(70?%=%ZFEU=U ML+VYO1/\690?TNN(K]=IG:E_ZO?\_3'__??'])&_CXID_L^_)^EUD";_>)1& MFUNC^.G^;K2[O;?[9+0Y>C;>?9JH4;*WO;F_L_OT?[=@D(_A=GZFJN>9^L>C M29IO7"G\_O.=G<'6]K1^<9,F]=7SKX%7-L;1),WFS_\V+-,H^UM8P>)O M5*I,QWRY2O^KGN_#F.BO&Q[G4W@X2W.EQ\TC/?IXE8[2.MC:'.SL^N/L'F$, M2ZK*1[VS6^*I)29VD4Y4%9RHF^"LF$1YSQ2WMI::X\71V9OS8'AR&!R\/3D\ MOCA^>W*^\H.&8[T='/W[Z.#=Q?'[H^#@]?#X[,WP)#@[.K\X.SZX.#H,SB_> M'OPK>'=R?!&\.AN>7*S\G-Z='!Z=!1>OCX(W1V=W^L?PI'=FAN@&FX;P]+4DK:99-'^>YC2245;$'UY?TT2A)@3!N9&@,3> (+0,N?0,MWNM+' SWN^__Z"V]EMI\-]I_A.KPZ.CDZ&_YQ3P/;[5R6X(TJXP_Z MW!5X[O)X$*S55PI^?+:]O?GBH)A,HWQ.?VV]6 ^NHBJX!.F&DJ@N@GDQ"_#N M,U7591KCK^YO""M H2+>>< MAX(AWFP>G<[*:@:?Q@_C1[M'SU23(V6GUTJ&! $%S@$\\4 M_JAFH_^HV'P+N,2D"J(\">(B3TBT5T$QIFOT-$8&CT$\RXO8::CHJZ+R?,](+?F8)'[\649 M]/[^X,G^#@ZZAM'428-I#V@^C^ND?6T7F,9F_^7-P5;OM3MZ[6,:,@\;%J8" MGO"/1SN/&FM'' Y83U 569H$R,!>R"78N^85X8O/MZO M([ZS^PS=,RO?WH/5>(6L+[B83]6OO^P]>V'.E*Q?_]*4_)+O8VU:TH36!MGG M1C#,\UF4>0OS^8=GM9=AT1$Y!%OM+H[(:J] ]T%X$\V#G1 MT>VN:'^G$\K@2%1=EA+K*\QFH["7>]>B?[T&M0V\#GN:O M<)"W=P9[W^;"G!8E_@1Z550'N$K59W \41ZZA<*W=[AN8P8[RY^@A2OS#1ZO M[J5!(ZQ];!Z3@KFT#OL9UWKT>\].W1Q8&][WQ=VOTOQL?["YL_4Y2O/^76NW MGTRN=Z+ZW79\>52^J\=?Y\W!YK-/\;PBO 1;_[R.P&2?!S=J5*4UV-IUL(;^?9KDK[_L M/N7_0U__A)ZH^(%!7$SH2C6-Z;\?\N(F4\FEHK^ H4272($XRGKN_P8C+C?4 MQY0$\@9Y42JZ@T=M?]R@J?*U=9HD3PO'3Y=@=KU>O 4G9['[[UZ/7/=.OP3> M4]S0/*=E$:MD5J(KI8K+=*22H,@7;:%=)UQHQQ5TD]97:1[L;P9)-*]@[5Y& M:89O]E>VSS^T\&W!!(0C',=95J.3YF51CE5:X\O%LV0>;/MM/F_'%HB93C&P MM[OD_K>>R0V>'X3]=$Z5X/3N'] M1?*P'F+@GIYWE\>$#E*B,_X+* VMA)NK-+YBCV6?*W5LCSC2"EQ4<$)2U"C@ MZC5\9R"?=$@FR^@*4K"C3:*'L[HJ;G+MWQP5'X-H5%RK,% ?B3 CUZD*/.$Z M3=@=.D01"M\\/@Y&"I@&?/0$/E^0L4/R&FAY.@690(S?G1#?.BZCF,.[,(8( M)0H-)3@ !^!I+Z.,EBAZH'I])!IT*%*4#;@ MZ,7XJ\@^ZYHBZE-TMO3%!'].X9$DA7_!T9_"6TH=_Z"KW@F6PTI'G(@*I"$H MM5$>*Q)SP30J(U XIE?!\=K!>A@D>M&4731#-O!PB70SQD_"9ZZ*#/1C$PP" M,6K"0.F8@RT\,#BC2%_ZY3RJ:03:]&A.-T@$B[@'!8S@ATF1@LH1TFR+&8IPT *(496!BLH< M%K<*43F$OR,B95858./Q:V B 5<=SR.F.,6PJ:@ M:G*,*P,;)\X)NL]CQF2;P9C@1^'$J!C!:#].42T.@[Q8O$UQ"<=#'J)%1BZ' MJR;?A$$,<01V31>^#MXVBU5S+W,5JZJ*RKDY#7H/X;X*.&4UGM-$Z^@C#H1X M/.T"GAHZTB-@9,)2%Y_,]XNTX9Z8]G?.;@]6D-TZE+)V[E&".=SK#\N WZ' MOQ9_:5/:!VMI'F)P1K MGT$.%*S-FI%L5^GRAO":A@!3A2]-1=O1^J,[$\PWP-G@$(5_=G(467) @.X#@ ZP_6G" [Z9'K M_6O^>IT_EQ2PM'E1HYT(AZ6>H3#6F0&Q^40LGZ!AB>C3UB,.J4NC39XK4E*#K<'NYOYP8V;!YZWZ[D:\@BX8D1^K/& M\!1^S34="E1- P4C*5@U1(<9=1[.S'@ M ;+? 7YIH)GN%C#=WI4-&YJO88"PCKW;U&37M '"J\=I"?9'$K'I4Y'TN I M>L/_C\D_JHW$GD4S:D45@94"_'V"\X0?YL%-,.W+E:<%9_,]+E$#IM6JEM=L8$?M?[2/1J"HR.*B?F@G/_W]56A9_ MJ39&<+H^;$1CH(7G4783S:M&Q.[GUA%X!JK';(K, MR6H5#[%(C3Q9K1FY+DLS4E^S!@X6J[*.X,?KM- :*CLZINRUR-)XWF6N.QX MY+U;3U]4P2G>G2H.N9SJ< ^Y-9S%TN]7>26L#BY;>1^\MR/!]^#5SH181?B;%Z5\X"KTW># JW%[J@+U<(2K$U"PMY:[Q2,+!CA[< M\WL\MJ%=I82X5.6EY7O#[3^TO[GBM!7T"5G08UY]J9@!A$9_ IJ=369LIG6) M]5"4/-?!3-Y(>L-(67_DUXUU](BS9K'*PU6JK%"IRN[@R3XN!!:,'9\,L5 L M>/LR.'IS^L?;O]X<+:BP6D;PW]G>/9"^<"S!?<>F:4HKT/M##%#E"P:1G7(3L5M*&T"IC$VEDH4DW^O<6!NR5[+D:*DV8]J:0:+X4^B_(['N M&+B<,Z&+7*S#&?G:M4UT]5+5WBER[=@=,YI\$+=T"O5KMNU4DE,@D3O\] N]WB"IBP2S#J M=":\Y$95'/Y"0W5=G\UH681>M:",ZLAE.?28X47VLTC:_>XVS[U67Y7%[/)* M?- E?K)@,O2&:@*!Z. D<5[4\$,C).B5T?K<\.9*T?+"FN'2\I!!K0 SHD[) M>8B;LI;"ZR.3^CDS MOT?Y#!WPLI5]23.=!RJT\4J5%_1C8[A/!I3I!B+E%[K'J)Q?XQ'@&?WP:V0PPJU8;Q[!>5X6O*(M9P([G"3.!BM,XB#Y_ Y=(7.*K-SG2=.@GF0\V9,F)78&TX3P'# MQ E&;0(*7.+;X+:UF(?R9,]D+I7J$A<;"_H;8UDZ/>:'$;@KF!ZCHOIJE65K M,E,"%E$"-X3!+M;*1[/:,HC^J"'&1_$2HR)A,IRCE >_A7C6CSKYB>N$(M[R M2=*1A".G"L(K-">%Y]4M[C.<%_.)!6NE4]Z8S59!EE:+YF?,C$HY\O&V^39U MB=J50QA?SC>L1.DW:#Y3J= !X<0[MS_#4"N:)/$FK;"F91;7*\=C6M:MFUDG M["8#8[8NH)% ME_1>RK^LT".D8D&4RE I)K^>K[NM5/S.ROK$0]@K%L#<'NZ3$7IP-3\Y? M'IT-?SO^X_CBKQ\ZDS,7'P55 M&X7\-1 R*!,E+ [>D>;.#Z$;Q\,0.4H7$4]9=%.QZ5G%Y+8CD>OFB+9K"ZR2 M\8.GIKQ?';+>&FQ2/P^.35#TW69^3$Y0*LL<0+!*3* MJFEPX D9I*&N!77T0;5#3*S74=Y6'A>8MQA]#(&V*0DRS:M9B6F4H2Z%YT-B1Z:W&(7C.89Y9Y^CJJ]DI-4)VU M/PH\K4ZC:142Z7P8+J^+8@/&POHV!?6S.D5K)\C2R'&TXX*T7H=Z-0Z/_6B5 MMOY1,:^TEQZO8TXHXA,H-LZD2@JV:D:STO513?VZ9^-"+H>>#PBQ1M+KNR=S MVQ' .-X$CT&.)M84AH[VFN3IENR!A&."5JJ), M^;607A5D%$NA!CEZ6+),*[?TL]<:=QQ"9)3;PG6[+UU6H"!&Y F'1)-"J@@G M,&$6RJ74A.,&V@IH*J:KRUE,264V[ZIP\D9UA*]O.\CHQE)M$L>XQKF)+_JD MT=YY?'5\E2JT7JDT'&E[ED7$#,26'P0O^>1.BE+1D4:2E%(38CQN'!D>@^.$ MM[*,+W(5_&<&?"1)Q0?>2]"WT@#\@'X.I2WFEB6[KI.ZW6)%77O.DV6>U[T: M"P=^W[[PU9)?IVY,&(2$NB9M-/JH63QNO%OE3X4%+4<#[CVKHB"(R.V$/"TJ M2RRMG7"A-=66 LLMRKG^X*T"TH<><.1,'_! 46HH&9&K.L;:*3X&P7&N*ZDN M*;6:#O&LOBI*6,3E9 '_D)9:B&/>-QBKE'_-%)"2$RS&^# %B^RL\$WM\SJ: MTRG%PT(*8GH:-(U.;DMA6!-1QA&"D[[N(&.C\J(G!U:WW5W]HWIL^W6-4DNV78A MC6Z;ZBVU]F/C3(QL=?H3>-LXC3E;QYTB2S/:_8]2&C_D6(WRM5HR\18?Y#7' M**2*^9]]"V7\JY/"*B@-T0/\ *)LJC\+-X MQL_TG:IR"02IBJW:93;0/12\\8*0)06VI.16-B;EOG6BX/P01A=L)TP,<1)C MV1-7S680EDK%(,DH'@!&-OYR1050'"I =3V!HK]:$O?"(2%75&%AFW#R@ M<8H_.<.EIQ"9R$B)M%'>JUS/]UCHD"N M'K56K8LX=:H/,0-JP_D&"UA&8 2-'"4EUJXC2I.HYO8)M,?$4-,X4&LDU$'3 MQGHH3:.ZFMMH[8P68@ERG61T2K%@^9I*[$@JI3[887"Y(-H6A#>%A"8\'XI-O15U(SP6 J$77M_$[@SKC.C'37H70]C'EC^=HMR,M"%:K?2=%KY M]+P4IPLY<0;&!BP/_8@53][6H9![ ,9J"]B%T9(>@YF%70@X'C=M](2Q2;:$ MG.7'IAB0QGDGZ13\7I@AF_@1OK3(,&- Y_W(\/$)V"5M87?LT$PU$QY\"VZQ M)^7'-C7^\FR$Q@%N:OZ1Q;*!96WO1,NX;+[@$PS&KA26?F\8?3F.99B7+/V@%KX/;R4UA^0L,T!V^-#S MR.G4C>^9P'RC@D#>,2 QPCB#YQ000(F$"FF0;U5DX$ZIX"06A(E$Q1G:9L2> MR&QQD3A^9BS\D'F+]U67V_7UKE3=10UK#O%X'P!-B"#%0_VN@F/QL.6[+B>, M>72@2PL9"NW-*B71M"G0/1DL2*Q>^">/)@J=31.%=@WH&/ 6C,-E^D\.OZA, M3:_0.\!J>6A2T4B"TA8: 96I%L MCY"%"5S.6"+:0AY'UXA'8%$V]<*+_5M96$,--=HRWHR*BX &E6G_N:PXZ';< MR<9W[#'IQ-J@DXFCL,1I^7XS!)/',C\TP^E$1 EZ(JI:'!04>.56&M8&H(2"68W/[FS](:<-]E2HOPR_WMQ?S2Z=M M[%!.DJ#EG4LMWBG[N,MJ=3BH3K*J+ 4B-#H>4*!*O_,)\I0 #P7AX>'(95[B MNR^1!)P"R3SEYK[LF&,F@NE=55TU*%HL-$..$8>:(G\9#45ZWFTF2W%LC6<8 ML@Z]U[.7C-A%9'%5VH.GJLDKH[(QD7+6@42@])I1)CP\SK[$**A2V*<(K7:P M.LMN'M'Z'.>8P5+BJKH&/7R=4S,,T'WU@5T T246:)*/GY 8W1XR__FSE\?BFR%6=-]%77>!6LZQL1+#FJ ^"'%[D(3_NKP M(I+(=9M4N$%#/V\Q%B'>AFI,FIAV2 TFY!A^0-3*6(-(W$!_Y9Q"4"J/*#XI M-)5>1_&<\T#918M-H@P?,2[WQIB6510T!^Y1$])J207A1U '[JO2\2[,I_+?[9!8W][O1/ !]5\:28*.,7.JY\8!Q?H+U.$U4*=$7K.)L&#.$+UJ145BK MQ,K>'UY9U2@\NLP!Q/BB)%::[S[2B[C%#5G:!Y)*4B:_?EK@^Y'=PSQ36#-*;6!=I2W]@5D5)M< WVF*I;'<(B"*&ZFM=3"LZYP3\EYEQ0@^?RIGZ2WE687!SMY6<#( MJICD:EYC#[W3] /\?D*5J7]&&6[KJM)YLOJ+N:38,AS_24:)??V R3$3LF&]_[#M)S/*-PGTU0URA;79_G M)@RWY"BL>1!=C3=C\B\.A).?"Z-A5>O+)\:SRJ*KE, M!1\,D"OWG.W1*_U73Y2/?"B2[*!+?'HTPV:.@:RZ[?716"-GB9P5TIO;SK[M MRW)ZB K!!P5 EC-NNS#UNJ[:R2=29NID:G7%62G9$,CN@X "_/K+SNZ+(;5> MIG_B9X%[77!5RZ(NSS]S1!HY(BM4J*TK.E^]?7]T=G)\\BKX8_CG:NS7@V6) M (DD13PCIM1H)5'D&>%_:\%U _IMC>YGP\5&JKY1$FXC)LE^+/>=I@<@>A2G MI=)=]A1F3,0&=8Q24*5P&O]-3C'\PTL]<1UFG!WK(PNB,S"^*H 5;!3C#4DJ9(<,7\9'QXG7!04CM5C MEY4(%!78Q9JQ&[ABXN?.&H7>4VAGC2A;!HONJ$(V,6S*M'(".ZM"'=]-25ZP M=FQ;L*9@8'GT]$UWK)%R-"K:?9%V(%A+-CM@"PI,-P9!._?S@D1*C:7D01[1 M^I^_=?I7;KK)N:3NNW"T6& H411\4R@6J+..J30&<^4D%9,(D-"B/@]?A[A7 M!LYD-5_U,V7I&Q/=JR.[MYX,GNY1PZJC]S\15G2"IY5N!CG3"%[NG(Z0O-J4 M3*7DA"N7J$38>0$%J6PG#2G+RS@"Y:&HS'(1WEP,2S55!5<8,N"82#0'==I^ M1A!<7&@N^,XH94>CHQG@RW\JTRV*7"&2W![L/L6E^'-X##2Y&EOU@,4>+3" M*+B)J)BA"6,W#E#H@ :F?;R:/$2#,Y:FA3LJI@0P2OU/%;M]9F!L=* H9#PQ44O/LBP37_"G%\.3@:#7V;06J(+2KEC)&_!*!$)U"Z#M%P#*I0"*+4(1I%6A (:<) M%<)XD$N1ZZ6)Y,6"9IIQ;5OR%P)Y45I96>1I+)53B.!@_<6E:^GUN1T[7B,1 M/S8=G5?H4!!#B9O9^&^0&7M&8O_7#8@ 8HO@BC->BWE;-:]J-0FPK>4H2ZLK ML?=1%4!';B>J)X;]4C#A\9M4008G)VI[1%>D:=?WQ\Q6B)?I0J[AX9OCD^/S MBS/J"?@#N;R%94W0UX9 #1;?2P"&1?AK==DXUCCM7'M'W,)V+QRO=0?M[J+Z MT*28C6K$+2<2M^IZ:.'$-#V'[!\T;BEZ%Z/DSC*E\ M5>"/V5(1>.Q(@UX?F<(_7>G'(6#,/T 4KTL1@RX #=S4>A[VE*(S#EIXU=HZ MMR!'^W\)CRW2Z M[7T&?0W]Y(1@)PY@?*/[NAQQ^23$.,M3BKUJ,ALI]FER_CGK2=5DWUA<3A2[/X#J-@O-Y'@>__O)D^T7P^DS^\:;(U5S^W?$&S)) MG/I5KTG%5Z?)/QZET>;6*'ZZOQOM;N_M/AEMCIZ-=Y\F:I3L;6_N[^P^_=^G MC[[<*;S[;+#_I,,I;&Z-RDNXNRZFS[<'>].ZD1:\.VAW4)P]^%PHIR<5%GV*B0/)K)0X MU)F*B]E4%P@=N'AQ>!E_R%+**C)=VOD]>/4<)D0R%IY&G#+@C/I-+T$(Y53J M>498&]4MH0%S?@:;K3.$JEH6S9^G9'!MC#+@'2_0@XK27985#IBU_(8!?MTS,Z^4MNU'RY [<"D^A)6N'^%R@%:#INVI8Y M6WB"WMC:M$,%HK[@8VB5'7GPMX+P:L?!H:[B]9IOF_M-]VTWY4I>)?TO),\3 M%4E'?R2WA[C^C5J N(V(%>43"/4$+_*9AR4KAY M?9E0_$9II@2$%CO+@/:-#M(I5A95RLWN)ZVKYT6T[J;##97ZO=&-; SWD)P! MVZ,<49"C,KY"[=6<@A#S(&<(($KM=ZC^&]>#P$;+#VSN"<,2'S*.H=)Q>&K& M"%M^612)1JFB8F0R(SB#KQK "?G<03,XZ;_S#J:Z&9+*_NB M\_G0:L,A\A ZB=7G$M76UF"K>TE\+^T^K=S]4MK6I[IGO_RC#:_L8(E!75]1)4=7DJ\DQM="V$N]B MA8F=%8,EI$%NQ>>_9(EF%#-R3 MN6!C")E>2&9 #/H7U#F[\0;=[5'P^$9M[G]22VAVL>:KW^V3K+*'&Y[53C<4!M5;26W@]>! M.KM&Y7RF7>6U48F)$G7*M-'2V2#\ZA8 E4N*68+Z;IE*8\RF0NX'B9JJSF(C MXKL\B3LKTI8Q8W%X_(G2Z^48U _)P!B+H;&*NZO$($[_5UEYJ MX-_E =U=E0.J[3AMZ.E3R7DM6GR)IY2ZW1B34'HQ5,WR4%O^89'^W;8,>'EK M?V>7&[)PF6^(<2ZY32(29B,;@-&W5F M1,X01IFXN*H"M3<4=[9#4JXN8?.Q4(=[&7-XJ%XEA%8P4^N,+J7/3F<^\M6%,N[)=4PS^&S]P4. MGX=XT7U%G$PT<+4&32]ZGH+.GL9+3.-E7ZCRLZE_=["_JM2_,OXP+T81DDN+ MP7"7#%DQU[80&&X$A'@X2I?O<0=7QMZGIBQ^)-0D]7%"5R'-_1Q?9B/)3$6V$0>XHH:0UQ%9U &PY,,-S6I?V/=X6E;& M)C^X2M78"6TQUM$"1(YO>-%7QLY$)ON*[04J/*]4MB M0+8(J#'6((I&*LIV MF41-NY'O&6U9502^'@:O9Q/0P,]45DO%$/B1;C,'E%C'KLN.6,C0#33*D>!=_0B)*302++PK>RQYHYC;G- M)NIBT*7,N;XSS>7?44*.')VYC5G;%7.P:8D@A=_E:5\9@]N"X'^V5M$T5FO. MJT$[Q"+)HB#!U]Z2E=:9>3:)/FYPJMG>8/?)SO^\P'1(R3WC']JY:8^6??GB MM+;]3TMKZS]R]WN\'$'=H2WX-,Y*X5*I6KB1%-_JR*:B'#/"++E.DYE&$399 MWZ'6;F[PB$CTE;TF@O+-X.1A1Q[8=\D!5L:E<)SKS2>R][:_>5;\G"+!8[&AJKK9]NGV,W*;E^DN M4J7NG_[[S?.CXU-.WY++*G/2L/BZH[3NTK ^M(M^L9(H<]YPPB,[?^_Z'.*.RW7J%%D%\/J2+V] M=9L]69J.=2C>/'0#'-0]-URD1>0$ M;7DL3J(8JPASJ:(EB(#S=S91W#YK4K8D[VKK64 Y3U4'D4CC#@F+J+(L;"LT%QQOPR/Q;D[<,\N.@ _^;G8E(K:/IVX*UR@-Z4H: MI"/*=' 3^4GV[G["*%(0RYHI+]C>528-_W1W4 95..M=^TD1RSL=%RD'H.K= M4#_S<8\ZG12@"5"/CNF4&\L[J^A4L"P([Z]MK9,":CII%Z63E,S&N\U>B @B MF("VJ=R$P,$_BIU]Y2@Y"I M2Q.G<4K[J(I4E81B[OB!#F5#OD*$]GYI]JT+%"L"JS,4W>2P E>4\,(I4PK0 M$V4)UC ;$#T>NE9>/\G90[#:B>OGX$HVW9B#N,&"2&MWG$^V2*@@U5C#2"XM MEQOC,2 =(@=R[-F&8\0]&^SK*Q5*CG:H@%QXIFW&SB)E.J!T9 FS\590?I/S. M?"Z3>)8KM]R/^9W]"-LBJPHP=6>D]1$&XBC###BJ,0IMNPNI08PR=QXC-2]T M6P]NM$ M@ M0"O%WA,K(5/W5H/"W\"*JBR+2+==T9%W4^Y)P3FE?@FS,'=")_(!=*6#G&"! M>F5Q7.\&.JCM6VN M1F=Y;/7[!%!9$<;34S3+Z'@<(_&5I7;&"0LO+41)LG+W!11DP+S4#%X1.N6/ M**\3:MUGF\AYWW"!4*/K*,UT&R57 C*8P'H8&)I3VV'B*KP4Q)C&VN.Y"$ M?J&J\SNF.,AK;+\2K:_P3!C:W,RG;ZS+(IU]PP)Y&21*EF94[M! S[6VTQ*Y MD8- H!N]VPCSK@7&T8-/!"I&=(B*A$T+$C=8BS^9 +*MO?8][V=1+&CUY M*&+&*1^!CD]1/D%5)^GQ#MPGNK$LLLKMUD?8:S+XU.JC8GH M2$-[Z0S'I%UM<-8N/'0!\OTU;M;F 7ID"X)!_AR4(]?BZO!,ABZ3Q3)Q+W8Y MHKQ##8TCN)TZCA#(=3@FZ5\W1.[D?]]_)MU=K!D&6@"Y&$ZFS!2\+7N MS"5#H+/1/8X?>KLEE;_LR,ZB*M4PF!0)C(R[9(G@4[X>UA&J\?3(O6!4#J1QT1LKY1I"VQ1QSD#$"O0-0P2/5;CC:!K%:%L;W3_6VJ+8!SW-,1W #G**8S6\8@5" M ]V0%2=8-_1O!J^A?SK@-EBF(#!5#L!-""(TOLKAO%[.^9[R.C4Y@#&?\OM/ MYB;J3T"+YOSKYW2#(-X_^F?U #0G-4 EXVPA4 *FE0.#^J\N(9$H$ZR7W67, M)I*E=E=:^F;;]=;[IY)0KO'.<=7W>]A>RUJ MYG"53G1_NMQ%3%KV>[H'N/;;-C>%3-J*]$H)D7."TJX? M1H@(X]EDQL,@3R.\' NM=.?K"3J8X2KVC>;558FTR2;G\UP'N+LJ'6RK9[[7 MCY.C/"W)X8D9F>R?9Y\\9P1TN;93,BS1A\82GSWHGW8DF];9[N#I-V.=[=^! M=?;EG8"_P/BYT]9?%T=G;\Z#X M71R_/PH.7@^/S]X,3X*SH_.+L^.#BZ/#X/SB[<&_@G'167#Q^BAX(:7UR()C6\*^C$YHSS^_TCV%_;[0[#(@^&>SN M/+OMC"\TEQNM[@:;6P_7NG-UNMT]&^P_PW5X=71R=#;\8_"I2M6=-C7JQE)O M=)K0PHD-XZ@RO2Y!LF!7HH9NQB$=1'(WR=!G#I [AVUMQ$-+:-/%VGF(A:]Y MM!E!7H $W]5UR9L7_N &C6[K[F2;@2&P7>KU&J.72Y6L:;K+0!3F5O?;=(/S M\7)@?@K"<]MU,#_A'[Z*@QE8U^ZMXOG6:S6G76KEI4Q4N0%TF4732CW7 M_WC1&!H]]$+@PT3C046X.5A<;+[\HL6S:QA.G318^H N/:Z3]C7,H]GLO[PY MV.J]=D>O?4Q#YF'#RE3 ,?[Q:.=18_&XA?BT)@,K"9"[O9!+"+36N")<\_GV M]&. E_"_.X.G3WVG*[ZS^Q#=+3O=OHW1;^_!:KQ"QAA*DOK,H9+UZU\: MR?#\/M:F)6IH;9"Y;@3#/)]%F;QR M5M7BC]_N.@H-4W.+@4$^^WAL!BS*OG"-O=?\2(>VY>:F#"^\Z]$_WTLG!SS0 M7^$L;^U_F\MR*F6AY$W"-:H^@^6)^M M%;Z]H[4$-]A9_@@M7)POY96N+KRU M,^A2X!YLP=!P:Q^FQZ1X?I)W>0GW6MM?0BO[Z+Z5XV?[@\V=K<_1C??O6HG] M9**\$PWO-OKE43WZM-C!7?DXZ%@>OSE]>W8Q/+D(3MY>'!\<>=K-/;LV:$!B MTY.O0F>AJ*\!!O_O([ 5)\' M-VI4I5BT40=K5W4]IF^O:2Z*(NVA$#=#MZ2("+T;(B=M=\^6T,N[&\&232O8"5>1FF&;_;7J<_+ ML_!ME/3'< SH:K'A-.T?,@_>BMNN8R2#S6<+O2_]?+\[;W)WT=L6/74K;M_6 MLWMPZG8[+XI[&FM/5@A%$%OQ<].SF/^2O"O& M,JH7.43']HA3B6L5*#@AJ40;L6_%0#[ID$R6T16D8%_I0U=E=86)'CI]J/BH M$^'51Z+-R/6.2ADP^36'* ;AL\?'@L06!"LJ5=>90;#Q:%HP:S"M1L"FN"C"1[0KB]DMK3GN)#]ZQ2GV MMQ6BV/UM7(9#"=X'1R!ZKZ.,ZM(?EE2=C!FQ4YU&H.0!T6))1 E:ATWTM/7\"+9; M(MYW%:*VA^EE1,JL+6 ^/GS-I&(Z93;"3!@8Q8P2/][F)>PXF.,6PJ94G!+# MO0,=W#6/'Y-]Q2#E)L&$1OMQBGHN5A MWJ:XA.,A#W&[]IQ73;XI17M3NZ8+ M7\>5V,V]S!6B96*=^MA62NCJ(RPBJ:0,IHX^VOIIW 6=;&?KEZI;3N;[+O7V MEN#T=\YN#U:0W3J4LG;N48(YW.L/RX#?N1UJF](> 09,(EC%B*.H]\M]A#[; MR#^S*@JP3K0_U^"DDT'!0&6A#UWK?^Z:<);=P+=SY(_7CM;7F_I*%.0S3!UW M&N_"O]H,$\G8=@>USR '"M9FS9"TJW1Y0WA-0_ Q(;0*ZX$Z\&E.[D M*.0RU4)$NU"%*;&NI8<2@FRY@45#P')&Y^Q;QDK6D72Y*#@0,#1LTIK7P/H] M*%72(]?[U_SU.G_.(,]ALGT-VC *8QWBC\TG8OD$#4LW"7-Z$6._,#EI[P;G M@^ "T2)FP#+/G!+;%WRU*% 'UBE9-!TRM].[L.Z(ZVHT%'WDT:B MC%Q09W\=W@]^"I9&4O8*"1:VO)$L' BZAY4@0#-<92#,E5@ :D' +?"0$R 6 M%;Z0EN8?=N*_@J5!^JJP8J(5 [%'M**Y DW>Y*K7J6JBT%P MSGE7,4)9AMZW!9&!6"0\,9IS6QM%X#V.Z>"VZV7PCU9/2F2*(]'=9?2D6KIW M6J996:Y9*20[NDZ$JZYJE:N@ 5F)%;47OGG[YN4DY:S95]M]. M#'B ['> 7QIHIKN%+97[5C9L:+YNJ7SO-C79-6V \.IQ6H+]D41L^E0D/:X8 M+]9"1\FUSD4S:D4530B*:&( B&Z*698X;4SINU=1PD:&2:F'%VI@55@U7_9J M0$81O?V2W')JYZM:O'/_4_K#QJ&IZ2S-@G;C]Y!O%1_KRC/,? M4SH=K8QT>C9@S_NY=00Z+74>-/.WD?"J-2/796GQG9J]-6+!MKTV0*\: 9:] M%@;#J6&N=U6[$'B%!HNQK5G)8^! 3,G[#0;&N*_[J6FH]BD]5JASCF^UZ8*A M(4D?#6[%#=[@P>CPEOS%+BJ;(6H<&<'E\&<$48O MZ\ ">%BU4>K@=*V;U+E57GZ]-]S^0_N;*TX[ZR9;!6X&V+6CM,T5Z[J%K>M@ M)F\D=R!73L';5XUU](BS9M7)PY6[@R3[UU3PZ>W-\,L2*K^#MR^#H MS>D?;_]Z<[2@5&H9P7]G>_= ^L*QQ/<7@4T@R$**/O QV432.@*D994"$91@ M2YE*8+01_E.D\!84EQ@CU;&/W]^;T$>CFABL!%9SR14!CTC9<>+5C8C=4MH M2F6AA9*%)-_KW%@;LE>RM VV?'>+U@R<)APLUAT#E],F3*VM<7@NBQ!U5^=J MU373U 2W?@+I Q<0?T:K4+4)U4 M(I,P\7N4S]!QN\692F&7;-1)37C)#:PX+(9&ZWH_6R#JZ%@+RJCV^FO18X8= MV<]2AX)>CYOG81,P(G%#E]S0G"C1&ZJ)!:*/DR1Z4<,/C:A@$W?288@:THK@ MTVL)](%F 99$G9+_$/=E+8771R;G*M2A1^Q?6]!W6 M"XZ0[.DDN< (<(E0 *@Z_(=^VLSOLTSOXW9?TDSG@0IMO%+E!?W8&.L31NB $Q=Q;_A&OSQ_ MY[KD1G6WLN)NJ8$# N2R;!($3DZ@9([&U"S=C8ML,Z; MIX"1X@0#-PS2BF]##*V8A_)DSR0O<0L7*LYOC&7I#)D?1N:N8(:,BNJK51:O MTFJ.[DAPL(L5CJ!-V/ZODY^X?BCB+9\D'4DX M[H7RY5$8I$>PBPPZN4QH0:$THQ'6NL:NE M_- I_JL7?#U,*VD9M>)'?J$MZ=6\(@T4&W,AV#!FKV A);U7$(+5QRGW8$$\3%2* MR36G->0J_6B:'I?2K5?JYJQ&81&2Q9PT7G%=983O3,R^ NGF:HQPG(S:ZOX#;1LD[D0@(#N$*ZHA:3XS94P+,R<7)4[>O8W.50$KY!6T2_= GL$[4R-6 M/Y2X0K'$S<$N:1(79\.3\Y='9\/?CO\XOOCKAXX@GFH#Q\M20TUX7V0PX>IEJV&3GA]"-IXRD5:WP".I%2_I_%>M^ M:WZN7CO'VW+ZG\E[2\'%?K^<[?WJ,+:MP2:E"5T,_QW\>7SQ^O7;/PZ/3U[] MT(SMC'R)F;1R8,^U !MU-N)PM0;N6-O5+A850LI\C@O,H(L^(C0[I>.9IE2A M+LKDRZ8,D7,*9[EMKXLW;)125Y)B78FI"4%OJ-9G>ZM"B&-17\C,4QM1PS0- MYO6/@GBJ$SI:)2TZ,X,+O:+8X'P$!LH< R*H= =9&CG^7ER0UNM0O1-4;VP. MIHU0U \K[2S&ZYB=B)7R HHN]3JP53.:E:[4::IY/1L7>#U**&.T9$<8'!.LKW5:CU, "EAMK?,U\1,=B].6+#06/FNM MV(O^'A?:=M?G.K5,[.)#X4LM]J0%N4G0"VV)8-D-#V!3A$#]QTM5E"F_*L^K MQ^-F$QIQ@&7KM'*+$'N-0L@EC659>SF-*;; 90X60PZEA3WW;8]LVHD. :YR;2Y9-&>^?QU?%5 MJJZY@0/3]@P;OV(A,9N4@^ EGUSLU4%'&DE2BAZ(\;CA3'@,CI-MZX$=A?X# M]GB5I.**[27H6VD &TZ#N6T[0S<-JG6=7NR6S>DJ:)XL\[SNU5@X\!6QI1Y: M,6/11\WB<>/=>G-*<6_9N[CWK(Q+-T7N?5N66.0YX9)?JG*,L(73 MO-GYN%= ^D7PCISI*X&W#9A%KNI07Z?X& 3'N:[IN:0D7SK$L_JJ*&$1EY,% M_$-::B'.O2HY$Y@I("V=1H2A.RM\4_N\CN;VQ\6I&MDWZB.ZLU,VUU M=VIEFPX/.62@?*V6C-S%!WG-,8NI=ONE2BB;\MCT5J4"ZA;;^4 MLTI$1 &[(7Y K9HQG.\G6] OU$84G^D[5>426$85V_7+;*![*'CC!:M)2CU) MR:UL:,1]ZT3!^2' *-A.F!A"\,6R)ZZ:S7 @3LCB5%H6MF'>Z]6'RU M).Z%0T*XDLNK,:,Y=Q^'LT!0 O8X@&J83F:3 &NX9L3%W#.E,0<,3?7(T9*3 MN2Q8P23Z2*]U^YM3V%X'(UP]:JU:%W'JU,%A(LZ&\PT6L P'"!HY2DJLHD:\ M(%'-[1-HCXFAIA&)UDBH@Z:-E3F:1G5=L=':&;?"$N0Z]S.CD*1\325V))52 M'^PPN' -;0M"/D)"$YZ.9-:>(9%F]Q0;^BKUE;;MSMO[:[JRR8P:]*Z',0\L M?[M%.1GHDJE;:3JM?'I>BM.%G+\!8P.6AY[4BB=O*R)T$W9;2BV,EO083'#K MPF+QN&FCS8C-]20,)S]$PM HSCM)I^#WP@S9Q(_PI44FK<#%E3TY+=9T6LRJ;=P0<)7O);UO'3'&,B@$VI$,R81=; MENJ6\ST4H@_Q8EU:U,!QE&;';\?'OS8(4B7UH &4;S7;$ENPX>#5\"8J.]R\!JEUUD1@8KP MVRQE$?BOC:W@7RI/LQO,9@AI3+^C9@T&,!HVPT&P^71SA].]&6;:-$:MFA:6 M!6)9UHH6Q7R*R8FS7">I&!:E7 :EG0[ZV;]5).T<#X1)XF3 D2S]H!:^#V\E M-8?D+#- =OC0\\CIU(WOF<"TEX+PPS$@,=*]P9O0!@G5IN\7&(FWL )T+$"&[I MNRJZ?. R2IK%(22^*FQYC]!;/Q@A]Y-%'H:IDHU.I!PE;8 M21ZEJ_S)P0>5J>D5VL:LE(8F'WB4$B=IQO6,\JJ--8Q)U 33P8!#\AJ0[L0X M8K G_JORZBJ=AL%_BE% AA&W9N[7%]C4*$I\3/3B-/SHUKK(4 MB,#B>$"!*OW6(2@) CP4A":'(Y=Y2;RA1!)P:@OSE'O>89@]]%[/GCUB%Y%%)6D/G@H.KXR:R43* MF1(2-=-K1DGDW%F>H@U5"OL4H:T/L>9@;"4N*JN$P*^SNDD!B:^ M^L!NB^@2:QLI+D$XAFX3EGX%VBQOO#^2UPJSI MOC (EF%-^]N+6=,QILMR( ;$#ZGC%YKP5X<7D42NVZ3"[0WZ>8NQ8O$V5#[3 MQ/03:C AQU@%HE;&@D7B!OHKYQ0V4WE$,56AJ?0ZBN>RR9/B("1,T MQK2LHJ Y<(^:D%9+*@@_@CIP7S7(=T%S[W52>*XMP ,GWLJF&&UI<*CRE"N% M_@16G91@7&4/2Y5_W9X&2H=2LM?&^G12M!H$,-;;ZA0+EF4HA.'XD'?^1F;I M'6ST59%PA9G8VN+"H,93KA$'[SBPU/$.IF_QR/?)+.YU=Z-Y /K;C"7!IC2% M 7+CM>.<"NLEFZA2(D98 -DP9@B=LR)3OE:)E;T_O+B\K_K>N]#D24!J(-HS M2B)[<'J4.C@GHBG9;9P1TA95VO,B@FT ;&9J<5QNL&[&"$V2K2ZV':=VL(^+ MD]\,Y!UF<6 LC? #"-H;R3(NIE(2Z8LO5Q$WGK60=[&W*YR1U7WA!KB.%*E56/OD=4K]'K,"\U(I\A6ENUO!R0"H8I*K>8T=Z$[3#_#["15U_AEEN*VG M*L^K>78=@4 SX9"M_=V]W4])]?G^F-]]57K?SOQTI?<%%=!JCWQ(66CDI5ZL MC7:D22SM0[LEF@Y"64 )NCNK=46-&F<5/T>\^[0$,N-8 V%FSZ5;;91512N MU? 5F&8 VI>@F9WTPQ6KQ'@%/,ZKM?1??]EZLOF">I/9U!V*)TR)=OF-S= > ML6.R\;WO(#W',PI1VJ1ZC5'5]7EN87!+7L6:!W#5>#,F+.- .&&[,!I6M;Y\ M,C^K?&KBM#:KL3*"X-!M;NFMDLO47<( N=[2V1Z]TG_U1";)AR()&KHLJ4.VAU&OZZJ=,"/%P4YV M65=LF!(D@>P^2#W]K[_L[+X84N]B^B=^%KC7!5?B+&J3_#.OI9'7LD+E];H* M]=7;]T=G)\$7JV%EPWH-_6Z'XV M7&RDZALEX39BDNS'P+QV$HH5JOSKC'#H1OI U:>\-5(\YE33/],^ M/JQS54YB+0CMK1!D^ M6"A(5;V)85.F$1+8617J^&X:]8*U8]N"-06#:*.G;WI+C92C4='NB[0#P5JR MV0%;4&"*- C:N9_+)%)J+&4:\HC6__RMT[]RRTK.?W7?A:/%HDB)HN";0K% MG75,I:V6*R>I $8P>!9U2?A1F?'J<..M)X.G>]3 Y^C]3Z03G69H^96!$32L ME#M)(SZI-@Y2*7S@^ADJ5'5>0&$'VUE BL,RCBEX:":S7-@QEV1294_!=6Z, MOB0\RD'AM9\1)!47IPB^,TK9=>3P>GSY?5/DYN#.4N)7YE4_DYZ^-::[0EQW M>[#[%)?BS^$QL-T?FM_^U84Z$ 4W$55--&';Q@$><5";M&-6&4(TQNC1'T<'%V=O3XX/@N'!P='IQ?#DX&@U]FT%RBVT?Y72//Q:A! ] M.>CP1&PX*74B,T[TI2K0R$5.WR7$"R$_(!=F$\F+VU6H28"?'49965V*DH[:'WM=.%$N,U:5@=^,WJ50-3D[4=F.N M2)^J[X^9K1 OTQ5CP\,WQR?'YQ=GU ;O!_)3"\N:H(,,$2$LD)@ ZHKPUQ:1 M\89QKKAV:;@5]%X,7>L.VD=%A:A),1O5B---)&XMLM#BEFEZ#MFI9WQ)]"Y& MA9UE2@.A73LQ;59Q2@-X M%WU0>6#<-_RGY2*\JF$3>HZ-TZYB4YEAW)44'-JUMTG"BE-ZVL#]I,N9_N,: MU$#ZD$_1LJZ%XSEANRRZ"7$>.!X17=K4MK7-KG[33EH#?(BW'O:RB5@N4D-#A\&+OC M <-CQSGBI&*="=]JLYU]OXJ]S\"\H7.;H/+$:XMO=%^7(P"@Q 5G>KIUKSB!Q_VD_6NC=1,-=NXJ^ M(LXRA\& P3^+%G:-_7HB]"$C&Y:0TZJ)!M'TM*E@>W-KWZYZ8,LS.'*@P1K= M^M1&4HWYGD7RD(PG"ABJ$EXH*0A_P/'80./.V^=BHM";$ERG47 ^S^/@UU^> M;+\(7I_)/]X4N9K+OSO>@'D,",+>GSLSB;6*'ZZOQOM;N_M/AEMCIZ-=Y\F:I3L;6_N[^P^_=_M MO4=?[L[:?3;8?]+ASFHL>5U,GV\/]IK+_71WT&Y +C\Z)(@;K,KE:6F(*$Y] M%+2YE'XY/#T].CD\_GP\^%TKJ287=GV+F0#(K)1!UIN)B M-M450@QA^RE-**3)-S?@]>/8<)D;R&IQ%<#;BL?M-+$&@Y5>B>$4!( M=8M3TYR?P6;K#*':ET7SYRD9;QNC#%C3"W2XHZ8@RPH'3,[@[M/!]I-GC5=X M>_6DM4^;@YV]+]2H%^W3,SKY2V[4?+D#MP*3Z,E:X=X1*&1H.F[>ECE;>(+> MV.*T0P5J0\''T"I.\N!O!8'LCH-#77SM]:XV]YOFU6[.E;Q*>D=(HBUB8>R=%ZX]RP39$H!SBI8TIQ-,-J*Y<=OHY:.84$_LI- MHT4UIQ#EF#Q,IJ>*)&!Z-K7)X#0G&#-)_4.,ZA;AHH.%5Y@*209K8.P[8=Y. M4+1EJK )JN%LEU28/YT3?8(2O;IL+C>@=*$ /'@0H)@-B'CF(ED!)1GB#;J>OV&KC;N M?S'K05T=12=%59/?)\?<0MN&NXL)8%-B!M'):!%9L'NMS2-9A@W=10'G@MTL M9'K)[6_(O6=8\@M\IG@UF0$Q4F%0WZCL6FU0\SD[4N4O(PPI=T %:37(2ZF' MZ>B3[477Y6"(4B@N,@=Q50,6-@9.VB,%R1&C^/.F01TPZ?8GM81J'VN^_MDZR2ISN.U5X7!#;52UE=P.7@?J[!K5 M\YE6C]=&)29*U#G31DMG@_"K6P!4+REF">J[92I-)9L*N1]P:JHZBXV([_(D M[JS,2TV4T.GF&]6,R,,)JZ"SB;FJQR-,_%9;>ZF!?Y<' M='=5#JBVX[2AIT\EY\AH\26>4FK18TQ":2!1->M#;?V';4_@]I+ RUO[.[O< M18;K5+[+3=Y;L4U^&0&=^1L\+J-9PO "^C^;%W@8CI,=P!CN:0@ M-R+ ZO:Z(!9M*4N$;9/GW%H,# %I2)Y.)-L VZAVSJ;,LM!'B>+3P]Z-_4H(F>8EJB> MB:]M_[#S&R1@H^FT2(EL/.2T-"+)B M]-%T?/JDXCN!X+Q10!3/,B(K^(D:1O>R)X?SB-F*8GFWI!KF.7SVOL#A\Q O MNJ^(DXD&KM:@Z47/4]#9TWB):;SL"U5^-O7O.HD *T;]*^,/\V(4(;FT&,-X MR9 5%&0(B'HW3Y'G=P9>Q]ZB3C1T)-@B GAQ72D=#Q9382UG0TPFQ= MV PA@%0OB^O(>D'QJQU175UO&W& *VH(>1V111T RT?5:8&=^H*YLX4Z1V>%K M'3;7P6O]T\NTG?) 5;&+72<:Q(CLO<2<9H4Z>?E>+DX81__#KV8<811 M#2IP2,MX-D'(KMCZ"IT6Y2+/M.P4+Q.+#575S7Y*MY^1VSPA=Y'.<_\$W&]" M'AV?<@:[I,IBD>0[#-)^2J+KDM"-J[ 2/?"+':N ;,SH8E)@<8=Y0J3M?U:J M$!:A&^"@[KGAHB0R6 /*B8H:]JKF@92RJ?]PWDCG=_L%-P"OK-70\5W.^NP! MC!G-'=N%_>5KD1,ZQX;.ZR;Q]%L_,=N])^;8M^E/J?UL1VXVYSB!5HBBK%8N M2_E;M9#J6TE%IZ:V73*Q$LJX]AXA]:F(*4R7! FE&+0V>>HTB:=$F-$ZGL&T MYB0(BRUD0,6ZCTC7"=&YM^:0P"SIF'2N#FEW?EH0>3Q(LSQR HL\%B>9B56$ MN52-4DG\^3N;S&R?-6E%DANT]2R@O)RJ@TBDNX2X[E59%KG"%*(6_7X]1GMO M+I8E#[85F@N.M^&1>#[DN7:QU/WFVN4+W0EMM$193JXB?Q$ M<'<_810IB&7-E!=L[RJ3AG^Z.RB#*GKUKOVDB.7=,(N4 U#U;JA1^+A'G4X* MT 2HD<1TRAW;G55TJBP6A*#7MM9) 34MJHO229QE%XF-L$>$8TMHT%02P?AM M(!G2*=;^Z_SZ5\.A3R(5\ABGB_-/O613,5@=49+FUR6('G27CAE$E7[XFR!&N8L88> M#UTNKI_D#!=8[<3UX>0=Q@032P.Q8E6R14D&I 7"27ELN-\0>0#I$# M.?9LPS'BG@WVJ)8*)4<[5$ NO#EUH::J^&OE#*FCA- W4$E6ZC/Y#4F&'O)* MJS@K*LS5AO7\'NGHPL& DL:J$Y1BW/>0\Y#U,E%F3N/D9H7NO> $>5<]H): MK-_&EEVD# D]4BX/\?7?RM$XG6^EQM\T0M@R[1'M:C!/6&M8I %:*39(6 F9 MNK<:%/X&5E1E642Z[8J.O)MR3PK.>_3+;(6Y$QJ/CPDL;*:+-!! M;7-5X_1TFH#66E3A,01=$PP!Q*MS5$K'M".?1CO/':VK[49)W9A+J,[EU M3C2JZU-]I>I.Q54=E9?*:S-G\N!W^D9$I1F+UH0JAI1;PK;68?^M?XW"-CUU MQR34[VD5)W&Z/E=KJ[D% FMRG<6U>PSXQ6YP7QZVDPH6P[GX^#)[SP8[VP\* M,7/W:#'+@Q_?)T[(BO N%EY:B))DY18!*,B >:D9G*_0*=%#>9U0?SG;Z,*PV8LA3$+-!"O]'"6\YNR&LR4Q'#MNDU&Z!=3.K]CBH.\ MQC;5T/H*SX31VLU\^L:Z+++7-RR0ET%>9&E&*?D-M%AK.RV1OS<(!*K0NXTP MWEJ $3UX?&$3D _9*2+P.2%$W&@M\FP.Q++ZUO>XETV]I-$XAB)FG/(1Z/@4 MY1-4-?>:J:^:JC[C6Y(>[\!;HAO+HG_<;GV$O2:#3ZT^"J0'TC.TE\YP3-K5 M!F?MPI.BY/MKW*S- _3(%@3[^SE(/*[%U>&9#%TFBZ7,7NQR1'F'&KY%<"IU M'"]$7MRO7HZ4=GU@*TVM:^J&G.Q)9BVAU 94&Z-&(NDX?;9N/!5'V"$FUJ)9 M(VOI6E5=Z_H#DYI=5PM8CZE-DQP&0X$3#2IM?_75Q^@R2O.*MP^LS$HZLG8I MH%ZF!)P.AOF";Y;R=4_L1O[W\6_6V<&293 $D(?I;,+(N->Z?90,@P8YI6, -KL0>VI:;A#L,'*2I11;HH:_(+:R8#B[!#D1[(3!]N;VCJ=(ZC.A M="Z/"=I>*=.^U@)M OXU M(N$R4=AK'@3(#25E2Y 9K2)X-1J\"37\&\WHF5)-$?>$ LBH0NK* ;*838HX M"AEZFY1\B.RQ.G<<3:,8S6NC_L=:8103H:>)HX,K07YQ+-I6K$-H/!8RY 22 MA?[-&"OT3P>#!2L5!$W)P6$)08K&5SDIR8-4'K'WW\^-S& !!1I M3L%^3C<(R/NC?U8/0'92!E0R'!36\V-F.?"H_^HJ$@DTP7K97<:$(EEJ=Z6E MO[-=;[U_*@GE&N\%IBU/(I*U+KY0<.2?$Y_IAY,BAS:9L M<>O0VS'+K_OX;L43">5WC!XX#<.X:0.&V?5MU@MI\8.=@]:0.&B/*W27.5@^ M5H2M\!Z_+,JQ2C$H\@#[:W%";'2V5H(\9KF)_8UY=E4@[9_(_SW6,NZO8P;8DYGO]4#G*TY)\ MGIB4R2YZ=LMS4D"7=SLEVQ+=:"SQV8G^:4>R@> @YM;^DNT,/N\I;0SN#IX^ MK#'X>%0D<_C/53W)_OG_ 5!+ P04 " #)@EA6AY VD.^Y "BXP0 '@ M &5X:&EB:70Q,#,U+3(P,C)A;FYU86QRR]:5,;6;8N_/W]%7FK MXE1#O$+%X F[3T?(@&VJ;!:-B' >GGUZ_/SX(?MGZ_?<_]PY^__WP MXC!X=_'A??"DN[T37&0JR:,B2A,5__[[T-\TN M?[\X^QT?]>3W.$USW0V+\)=__!V_@7^U"O_Q__W]_VQM!8?IH!SKI @&F5:% M#H,RCY++X,]0YU?!UI9<=9!.IEET.2J"W>W=O>#/-+N*KA7_7D1%K/]AGO/W MW_GSWW^GE_R]GX;3?_P]C*Z#*/SO7Z+^O@YW]I[IG1=/=YX\'[[8?_)D^&Q_ M.'RF^\.G.WKO_^[ ('^'R_F>O)C&^K]_&4?)UDCC^U_N[75W=B?%JYLH+$8O M=[:W_^L7NO0??Q^F20'OR^!^_I,?TWA8H;\46RJ.+I.7-*5?^%;S\R"-T^SE MK]OT?Z_PEZVA&D?Q].7?>EFDXK]U[>T^HXVTW[S^^[KT/+H[./IP'O9/#X.#CR>'QQ?''D_.E'SM0]VYP M=G1^<79\<'%T&)Q??#SX9_#IY/@B>'O6.[D(WGP\"P[>'9^].0[>?CH^.?RX M]%/Z=')X=!9OKG561 ,5RW(4Z42.[Y-G MW2=[+VX[P3_H-S/DB0I#8'E;L1X">WD&BTI;%R4A;-O+K;UGP'$G=^ 2WW7W MCKMFW#__[:\J*[/[HKO_ M?A[=')T5GO_<\9UY/65>D&'W0VN#*TG"(M)X-N ML%&,-'SY8G=W^]5!.IZH9$J?=EYM!B.5!Y<@-U'&%6DP39%% _SV MO !B#3XEP)\WY"%GYY_L ]2-RL(@G^A!-(S@\BB!!T1Y$!H)ZMT4]/!B>^ND MS/(27HTOQI>VCYY/8H+<(KK6,IS36"4=>-<@+G$O IA2D)?]+3AE^'Z=:7CF M,,UP0EDP2,NDR*:5A< GF)%T@^ "QVR'&, '>-R_], .#EC5.(?WA/"T)"0M M(P_2(?V&SZ*?X$.N@[=QVE=Q<&'O.+!WU,>,I,0*2_L+&E. Y>U-)AHN^!*\ MKDR(7N?-Z%,2ZQR&B*MQ$\&P0CT$DFGN4"<8J$E4 !?Z#Q(!#:/,S84X(9E) MI@.@ELIC>.[=6W2+5O8W5E^VF-\]!]UE][]>H3K#7SSC+YH,LDT+NCMO?7*K M=O1-OQ6J'VLSNGZ:A3K; A80JTFN7YH_7M6&33?!FF27L K]M"C2\S#_+A/;WN\_V]W!"!8RF"&OBJ$MS_;T(F[\]V>Z^>/%\YL_;W9V9O\U[ M[--GW?V=O84>^SL-F8<-"Y,#9_KO7_9^J:T=\=GM+JQ&D*=Q% :&D\KOL+FM M/PN??KD[^1( PWPOWO=Y\^-*.,5Q:>W4]I/%BV[3U%+1%8<7$PG^K=?G[YX M9:E+5G+V(I'.OGJKU!!TM$K(I[>"7I*4*JXLT3<2U'*OQ3R*.00C];M1S'(O M0SM)],K+,B^"O0Z:XKMM1&%&9&Y[0MKKMQ'*=L Z\/=8[-A MD@MPA[U'2$+MR_(FRO*"Q$80[.UU]_;V_FM-*1ZE/%E3BBS+N4:C])M)10R; M.6KJZA+3T\6)Z?9E6G%RNQA%F:&VURI6R4 WJ>UWLIE_I#MTACNCX@!\*GKD M3S7Z7SSO[N_O?HW1O_^BN[\]^^>[6^??<*2_L^EZ&Q_@D?XR>RMWN\]Q]S.$K)8QQD^M]EE,'#R6N7FC[! M7-4E[B..LIA6OT.?ZI;^$I%AL44^[)RNX%&[+[=HJOS;)DV2IX7CIY]@=HO% M4)X^NY6\[A"1::75K>WN[L\@UG;:> -<+KVAE9EDZ4"'989.YWR017T=!FDR M;]/=RI*[VWGB;Z)B%"7!_G80JFD.J_U&13$^N;H7L]SS>GX4\:ZVRV60FJ\9@PS$3'A3_!@4$WQ\TH&HPX M1#,K(#5TE(HD#S]JH) (51#X]1K>TY57>I0?Q_0+G0&D^HD\+$5-!!4NIGI^ M;2/^Y9X$!UDK&*&<$3(B.P%;"!T:#ZEO\%<"DB#+519I&RIS[LI@@YZB3/S* M]_*XZ"*,8Y3>)";:U$^_!*J?7NM.H+_0X5=^B OXSG44P-BF]A/@E\(O)!"05S=!?;;YTF*F!Q.;RD4(Y1VO8U[#>>8DY01-8 MBEP71:PITEEG&B# ]E\%"NX!)610QHJY$L;1O,7-TC)!2N[.9 I-%K!ZO.3U M$O&2_5U"P#5" @O0%^*_+5.V!X%#71 MEODQQ*\CN"6,X"\@_0D\)3-'G'ZM4+ 0*Y$X'2J0N*"3HSW&;&2B,@5JT&04 M'&\<;':"T"R:=HMFCPWVP0!$-7VW$=#CJ?SP(!&\7R9 MA_.H)@I,@?Z4+I"L!IPF)Q' %^,TX60!.,VG:FI.:%X"TW%/,F,;JU#C! 4N+ 1'R\'LL6]DR6 M)B8:Y$9,H/(%H_TR066]$R3I_&T:9$ >YGH@-H%I!HBZ3XP,F&I\RGS M\\(ZNLMS6G%V>["$[-8[*1OGE9-@B7OS?AGP)Q3XUZ*GU*5]L.&E]@"+,H:% M7*>OZ53 $4>*!P*MJ"C .M&(WC#I/O .8,8=H_;0S;77X3CR2@Z51_+'&T>; MFW5]105).>[#,4(V:)E0DV'B,<:$)#ZP[AY2"S?*>EZ1KW15AO".AE!5-HUR MZ\\$<]!P-CA$X9^M'(7B64:(F/B6,"76M+K9J<^22"&"T6B%\[ R712#%!3B"#7=2JRU2JV^K.]M=DD(J#'FI1E/ M$#'Y/C/@D8[#2K8;79E7+C5\_D)]V3K3,27:'Q=Z3&ERN#R)3(ZHB.FB*4^] M$V@$!=$EV!V4M#_,TC&?*I@!'+AH0DOG)[!M>M)J -8%CL_0 M+&O!4N&1ATLD6-@G@,>"E(LX0NW@?B4(G!D\WI>&N1(+0"T(N 42.;HV<0JB MI56)G?@ONJR,OBJLF,Z*F1^?%<,5:/)R3@[24).:2KFR ]2_6/7"9-EN<,XI MO*#UQM-.Y=VYO U9)-S11Y_9$.["M_FF0XJJ::!A)"FKANB4 ZY"(P&! R<, MF6)?='<9/:F6_I6.:>:.:^8:CQW]3@<3-N Z@O=O5#-2_7EO&I:*0@4G/?.$ MF2(:/*23E$N(7F;(D*)KW:BI<0$0CGRX6U0_3V,8]UW+9._*7>Z@.W MO]I20UB:ERJ^4=.\^OKO6OVS"(^Y)X["IH<8&^CT-21Q;G/.CXCDM+8;7J$) M$IM=%)I=I(^N$94[("IGGH=.S5ZQ8@NH?^;AJ@M9.C8B88?H)D.O,]N )/-' M >A<\.^0/.?&M)]!ZE89S!78EB"5QSA/^&(:W*1EC&K4M8:WZH3?.U(AFX:9 MN!WQ@7C^T.D%JU;5F()AF>'416&:K7\Y^>J]U2AEM #\P7@S9_DW*\R-O)LY MIK7KNJO]T4O4HZ61J"^Z',3:<)W<1ZG1JMDY,V%/2QP-IFTN!L]K@9QGY_FK/#C%J]'?C4+GU(3! MN)##+99YODYR.>CPL]-1@L]N)/@<_/4<:)/$,]Q]QN:A>=(;D)S)( +M_8Q, M3G1(U2U-4S/2(XDI2@0PDB0TJBZYK)#IP7\W?ZPS>L;9K5>8W5_8?8GJRYYT MG^WC0F#AZ/%)#PM&@X]O@J,/I^\__O7AZ.3BF[C<=]N[>V*.QQ+A]93.^M$$ M$=]!?W(8#4EI+=@V!M:01V$$NG>'$A?BB%38+/A7&L%3D#=@>,TXI__X;'W3 M5N+SXT$A8(E&MB+G7H"\MFE'"6]0E6>(>GST7H MC4B=88.AYE>A@X5XF&>!<.#+@Z$'U%90$KQA$"+ >DVD!T$\ " MQGE:'=S.+JZ3T91Z=AU/E(FO4Z#"7U17U]8)3L%2#XX75 6^&VTONRJP? 'W MMSK1&0J>,M;W*?^[00LGN,,1&XH=@*8"6KD4;0!]%X]%"KINK;Y5>RJ[I?F\ M(R$;\67.#M%L&(O4Z,UMZK;S27EA'"^,5Y^MG6J^P&+4?5HT0'=Z<7R&G:%; M#CB,'AGSI\I;Z:/A;J1XD'TQP+28#C^7L\42],?"Q63TT]0X(E5G296!U-PB M["S@L2S(')[O/A+FL'P1]./D.HW+I$#_UH5S\-P[G_ )V(I&,6];CDUDIQ%A MLLAB'*7F@._P<6\Y\GF'#P-Z J.DM D\UF]@&4VKCWXCWVQJ^W4=P1KY>*9S M(%XZX)D>9F#V6!=YIJ_3*W+5DWLB(TL$GJ.UL9H4N1TPZ))9YE%E"!W1A=QM M=G**'U#"QPR8@,HU.CF3K9PLIH)(@[\)HWP0ISGH"?8SS8@?R#E^Z41GUHT? M1X6$@@/TWB>8L4G7$;M@9LZH&K$L-TS) M25/?I86V2)&2%K.BQUE2/B>?.3#VZY*KT?-5N?RM:3-[J].F:OITFP!;)"4; M1!J.S2=:CZAG23$;]?%BAPJW)8!M5[YLI2=8H>M&A#.?[<:JN*V*49:6ER/Q MR&?XRI3E3674-BR*CD/2G=,"OJ@%2&?FS6W)HV(GBZLMEG'7P^TGI*K^#CA0E_[3%:"@1H7 ER+6**#]%7WN*/6S1YR*H< MK=I&QP5M=9+2E[6A[CWKX*Q@6B871)A&;>7*,Y!JKS"FVG30WMCJJ5<"R79:#8 MTUL."MYILF7[F!EJWMH)^F6!B9,\'N2M0 K$TY&1F#&%96$\6/P&Y)PY<%G: M%$I)\K3>X,">GW=6U\W9\%LV3=111%,;K1#!=]=)OY?K9?7TUN5+13H'07&_ M8>)O,V;-P9VELS0BKLQ#K".88DRQXP>MKC+.]P- MLRFFDFZ44P)7'SCFR%_5>K @GT0H"88=^ MT6/_/PZ6/6?G3!<@32FLN&Q\V*F G AC!GH7;\"W64LK9B)5U+)UBLY#3-'Y M6LM6;,#[M6Y]>V^Y#=R?8]>^\6-^-Z.T&M,4^8OYR!UC_SHF:$Q>S%R>JW"( MLTD5A4R1M >5 :GD9,QN*""52QT\?2H:5A&@SQ QHH,I7$CJF4T"[&^RPH!W MD-]/?N ,KSO!02HK[ADS++G;(.IY+O-85A; MNKK3\.N6LO E)L>-G.R;O<9?J0*;?/>P^3O0P M@H-,*\-2@)O'OC#L8F-* ^,QDS1U9BE/6G'\'1"#F*WHL/*:;$X,0TR,< ) M%3_W4$6@8:CL"F@-1E_:X"A%4D.3\$C%TW + W?DB-C!2$IL@2L.@L^A]D9139HX=Y6T MKXVN1+V:-C@'BC(ID^##^6'SYCDE<(_3+[D\-7$[.]VG7!.'#3^''& YLB+G M?NT=?TQ^,SX94D; ]X)6K5A&2,T-@(AP0A"PFU]M68&NJ4G^)5]8ST\URAU]I(Z M'W.VXA_+PP6WN_O/J08O!=WYC!P6]UN$?ZO5C>?4&^U/3!E3> MUE;"VZR[%:G)A*_NF;1YP'B_<\M1'H49>E_EE)&*(S$VHC3%3'+*7O2AA+Q; M21DM!)=(#=!AO@7OWNJGR ;=A>NLHX>8=01*# HD//5$O4=?]*"D'K$76HV# ML<;M[OP2C20^^NCZ".#03>5-0)26+J:V!GB:0IF:#C*,HJ&4PWQOI&C) M MN/"(\V8YW\E#5T3&@N4Q<'(JIPTIR@!ZPZ&)=5&@CF99HJETHU#4-0XTP_3I MQ L'*3 /532FPG['!KYZ :(,QK^QM[W)./VB\P[5 )C6)4@%@O#.21#0H:]( M%;3GP):.20T>E.)$&D39H!RC]P,5Y-I#_#'/&03;^M8)*].WWN)!42)ZFA-Y M]43QML=R6!W&;%=GZ#HR8 M##],J M,S:^-&E**;:W3(0*61%IJ7]'T'5">)MZJ(V+T?J%LZHN)B!BH$P:( M_H+:FP2"8G63 MO?OX_O#XY.VC/M9GE/3*X,]#L=.DSVC%=6)J:(4]X+I&'='6RWTO^2,0XMLU Q-JZLCB@'MCT5ZU,4)8J+ M"+4PT%"5EYB,"])X',7NR"3E^)RDYF H*#=9S::*"WNC:,Z E(9/MD;B,!+ FA\K($@R9H'F,RA>#M99PF"&0"FY5+@K6) M316@GQ8&[0Y?T;(X+1%*' O36B.T9-['K17:.S)XZ-6< (FB!XNI.#?Y7 1\)($E1G'NA;SP!\@?XA6T/:R!G9 M-.",/E"ZZ7O!DV6>U[X:

^));$?:NE59>[^F)8/&Z\WV&$ $(;*3WD'R15 M% 01Y811R6R680!QS$T>"-<>6&Z:36LF\&P!66U[XLF964U/TLRTL1*Y:FI2 M6L5'-SB6-">^4(BX+$9I!HNXF"S@+Z+,"'&TW=4EUPGS"8@H0VV A2[DX'6S MPB$8A=>MXHT."1CPV:BQG%AA#L#<@WN,3;?.A'"@0$07LAO@!Q0BP[JP:1*1O M;/AV%E5E"W2OR]FJ760#?:+@C1?<*?'(DY*;NX1Q_ZEC#?1#*4:PG3 Q[!P[ MD#WQU6QN .5A'H"1C=^,",B879BHKH>8KZ*-?,0W4'P ]:V!0 ?PV@PHKD+) M7DZ+:1>G(HMYZZ6,5W!UDNB7OA'2%JAB&/%Z);W#A:PW&&6,\2PLF.('>)$-7=WH#TFAIKI0;=!0ATT;J?5VCEAR1W(39+1T5!R_O!M.G0CR;6^C52U8*;[TEYW*;&7Q4;H4; M=LH+?-X MVE)388'@ZK( >1#'WNB8X$#78?C%PO#+1>LF)NSQGSI?,ZQGO@4DRCM&/RGT MB5@?4R]$4FOXV=8>KFGU+H?'?FEB+$L48GEJ"A5[%[W@].SX<^_@<8=-?0Z) M61B@E!5L_^_"BX.W($[2"0KL=ZASG*4*%+O79<2*RS^W=H)_ZB2*;S#!K4-C M^@/MH6F'S-%>-]A^OKVW1YY<\LGFQ@/IFK/[^:]W\WV(.37!Q)W\@"$W"+*4K?F?<\O)244]*.7+I*/J+[43[!@>C*RD%0K(:M$C34ZR,8(Z!B"A(6G8.PP-A\Y9*1C/1FA1X-- MB8Y-,^M'Q$GJT5AK0PG;':" >A>_]$)5@)T")"8S%D& MQ)^M+["!F%(!@5@S4;UZ@DY@08E>:)U@ZSEJ=MM!G74 \PH[8D.155PK:*35 M&ZIK; _4+'D0FSUW;6!-:^:&P6G5&K@.B"!6B]R0OQ*E"P>)$71HCD.PVG_PL&Z20..;A1@[EQ>.* MUI*HC).9=[_&'A=C<_O;CZ2JZF=U[5B$7^[OSN>73%9D&?:$DB2__%SPUD[9 M+Y_ER\-!36)8[DX@@G4B@6(-99I=*CPP*HDU\90 B8(Z4>+(95X2;\@H%=V! MX%6;8$E6?XZ@MWGM1(M]8H^C9/*KZC+:$UGQR/.Q%&?3&.>9RJ_8;4$E$0'%):ART^02$*N?J8K9Y:T/H>,@&M%7 MG[!#TD*%^=@@[=SY49 MRDH];6EPJ).(\9/^!%8=9J"FWS,RRE^WIX$244KVVM!0)T6K00 CGH5)L6!9 MQIT$V#M_([.L$#9Z/4BXPDP<\F)JJYPIUXB#=QQ8:GD&GV_QR,^260$U0[XQ M/"#@.BEIYZODP;;S/*(GLWL^C8+1X$4W);N.,D*:H,C:\"+8NL)F)P_2^ MP:H1*S1)MOK-&84T0)D:*K-*4_,"L/00=XDULNEP+N[QKG ^@O.AM@48__ MTX0*IKF.>E!+QRV"7E$DG$3X-D[[\/I3H26N/>P$>T]W@A/$BA@G>EJD-TEP M&EW!]R=4,?ZGBG%;3W62Y-/X6H% LX[UG?TG3Y_<)=5G]9C?SX)\O9WY&2XMFHSU"E0XK]'2?_MUY]GV M*U1CO-0=\DQ/Z.SR$]LPM-C&K[P'S_.@Y+YK-JF>72#MKP\8R'-^7L6&9/!* M(ECUR9BP;/ 7A+_3D_/-Q9/Y6>73XR#1R)@5)WNG?8)Q<+FEMTHN6W4( ^1J M0V][S$K_-2/&13X42= P94DS-,-ZA%U674)]Z+NJKI&W1-X*F5((*),.B@9QXL3WT 9Q317H'.P6C%!6P270:EP7,Q'82,FR7XL_YG& M)TWEYY.,F@TQU@;(G(%M9T!ILU+LC7^34PP_5!(O?(<99_1ZW6/6Z6X/,=T- M$Q9!8QB,4F#@6^EP"ZL12)7!7IB8&/ZF%I\UR$ND+DX)AZ TGEFL3M9>.C1) M?_O)>EYY\U,*HAN*$_H--)5RVJ93MD\/26&/LCN5N] Z[E.&#Y9W4BUV:(6+ M[>8(UG&.EIF?_#Z'XMDB9/W.HK-[P%.<$MO7GAY,9U9T%%"',C86X>"DF-@. MZM&TFLLDNL50BFOD%J.U5P^<^?8P8D.Z?CQQM%C**K$O?%)'_ ;>.D;H*B U MU6DW5+8D>/(Z7(O0N@A='AFZ\ZS[_"DU]3WZO$9G,6F&CE]9T"JR4JQ,9D$]XE-?X MSKU&T%]\ 'UX3S]*0F.'>P]?G\C&B5RB([G;?4+ E7_VCN%,+L=6W6.A2 -( M0 4WBE+JZ\TFAAY2FT5@S)U,MA:?@TIB#$@Z8RQW$:K!-!J2UYAR-)*#,Y^9 MV@L]& L9#PQ44N3<@Z3YX?HHUCP$_[LT!]':ET?OCPXNSCZ>'!\$O8.#H].+ MWLG!T7+LVQ+DXAN7*65N5!/5.^B<01\F@IU)'0SI^"),\\" $8E*C9 G" %" MKCVO*:Q8LGQF?!N3_'9PO"B]*TN3:"!55XC^X/RVF:^[SW+_M3Q&(F]L#'B/ M,"$9[I%@9U-]@LRXHO;/?KL%($!<$EQQQGJQ3\NG>:'' 4P()'B4C\3N1E4 M':JMO75"5NI>(!9DJH(./GTXN_MHZ/STZ.'Z# M?.CT].CD\/A_EV/G[I$+.9 D:SU[9<+D=G>%UKZ^[(-=]R84&?\2O#8)F%[P MP0!\B>\:.!95'E$L(_%ZD.#E'"ZFH'E8>[#7VB>.AO8^#]Z;"KU;!VO;II@D M-9ZK!;"'<76<5X("V#XGJ'>%\RK*C<>".R"X-V)[ 1NU04X27F/#-(;72+.0 M$7G\&D0NDA?LB:$:8."=EHEF5,;G+$A7%P@M)L4.P%8V%;GS@?=.,B\W$T*IDTQMPP/D\J M1P_3LE]@#U/2"MR1[#CT0J,"=-BU;WV3]"P&>2]C;> 0+TMQCJ)1$Q5M85G" M;\PC=FEX!2P3U-=:SFZU?4B/6,Q K*+,PEZJ*YT$UAW('YWBP:O:J0-0LK.C MK7A99CAH*PWHN+5WI0*:$_N:+::(>UJ&::!-A'%.D%46HB1YP7O@;!VQDNMD_2DH%YH5-QW,#$ MC:/9PAVZ*B^X[<@TP#RR%:NF1)6S-QA\')_'FK./=P47->Z'/:7 JM=2)F]L MG5]+9T(W!/^HC.I?N5V8?G.L':D\S<8=B\:)$7P>,-QVG"!6,%:;\:6NYJ'J MIW/76;!'#'$18*9$ ?")_N,2A &5[( RB2AMPARSOF;'-I>.P/4QX5 @\)V9 M@ZL0QC9#8A20$[[2E[3P?O,&B?M/^]'H;$IGN&U7T??(M28PF#PJ2M3FET2& MWF?(L]+!L0834W?FZF!W>V??;43@ZK8X.&507/T2Z%JVG:>U&8@?286D3 +J MOR:Y2>^!8K;01539^G2L,6P87$G7KO6_KI;C=H"!7!6$U?1N0! MVNJ#477U"D,ZJ#O(L@*!"0T^>=[=??:B]HC*7CUK[--V=^_I-[+O>?OT@BA_ MP8V:+D9P2S")&=ELW, +90Q-Q\_GM+2%%/3!%:T>:E D4B9#ITK)C:^I\1)\ M.#3E_<$&?N\Z ?+UM@N@GXLICY*VV9( CFJJIYV2'U:< 5;I0!!:!+ZK'A!4 M#/MI4E: L071P(JA)H0LZCXH&*5@-0EZI(7#1Z/&F!P",$6<8Z(C6C\>(%75 M^WN@8Q:^Q8"3YE1UMDI;@^1PCIKK+!"'5C2P4=3) N$0V9 M'$0$#('KD9I>MZ(%>T44.(;95(D9MB_HE<+-EJ9QF.!"O$7"E)V?#>&&CU,!<+ZA"WYT3W4&M7EXVEUBW M9$<@1"K0P*9+E:>=4A-AX5I'QZ>67Y%8YKP@DK3G5&Z/:4FYO?[T_).]WKVF MO:)&UF7QKX$!'^,A0 U0Z%>7&#]-)GFYET%X7?W3:OD MR,?_K#9ZS:HJPM"J",PSI!,UV^=V,;BG6:>&)&V11+QDZ#XPCYO9-.MIHML- MK>R;Z/.^U89#Y"%$B?G7'JJ=G>Y.^Y)4G<#[M'(_]Z3MW-7Y^^TOK?E\NWN4 M>B)'T6D$\QM66E T%#\U9'IQ!^:U^$3%S1:K&P&P5YO39P^M:GO\ED$AF/U@ MUH/JO7S(TYCF!7F"$LQ>I> )Y4^W,8&-P:; -,6TB"S852 ]&GF O Q;IKN* MYKZ&9GKA[4](*O>PY!=87;_9HB"8!L6-CJ_UUAAH:N1&JJO+"$-*/-A*6@WR M6YIA>OID<]%-F2CB8(K3S$-B-I"8M8&3]DB9-HA=_G73H,XNPTTO0T< V*FO MH4>215I09FU+\P1?>[0%P_6,4=54^ M$;&2E+BW-)28&%)LV+$>)?JL!?C9:V17S[:WJ=$#O #+>498P9]W M]O>><'X8BD5A"5WLB@3, 3P09@$,);\ VRO=!U1LL58+ :_ M^ZS)NT@X:RH6%U>>HO:&XLZU>TOT)6P^UH)U P-.6G,N-E*E:#W(X^3Z5JB M>Y>1,\Q(U(J);VS_3NL[2,"JR22-Z-A4$!6CA+3D2VQ A4PQU]4X>BU1@%UY MG"NPDN?CV9*=C[KCLWI4JDX@H#>*AR(M(^)*-77#M3.WE,/%"&Q%L;Q;4 VK M.'R>?H/#YSX>]+,B3C8:N%R#I@>]C$!GCP8+3./-K%#E5Y_^)UX>P)*=_J7Q MAU5B%!UR:3%*]H(A*\G7M=@X?@2$>#A*EU7J:BF[% 2Y5$_(F(HLZ -:@^:%9 MZPL[&$5ZZ(5?&*AK#IS, R:CI3'6D1&\99V6ZN]S'<\)7X+0W9[KB.KQV+U!!5QX1-JD5Q2FF59^%+VJO)IL)>Y M5%4,#&0)%T5'B?Q-=0=X8CAW&?.62VI?&\G<='+Y:\K74GE"/ M50RO6!AD9';X6(_-M?#:*O6Q2*TDNMR2>-6:7#567[8XF^II]\FSO?]ZA1E_ MDE[%7S33KWY9].'S,[?V[Y:Y-9MB?RYUSDHGPHVD&$Q+Q@_E01%TRW44E@8" MV^8]=XP$OD$2D0@A6_8"4<_(^IV67*65Y !+XQ8Z3LP1HV-?2<2IG\AJ7DXE M%Z)A8;.B_J';MN MIY';/"'?(YWGYQ_@V2;DT?$I)[!+JBQ66G_"(.U=$ET7A'1=AI68@4G=L@K( MQJPN)B47WS%/B+3]KTH5XOJ&T^^5)/2M6_3 CL(L!P/#AS;_O9CEN/6ZY5%G MUC:&U9(>>NLV5V1I-#3A8GO3#7!0GVZX3(D,UH!RHE3-7K65R4HZS->>2/2[ M^XK&BH#XQFIH>2]G?4;R@N=8Z/W39MX^M I9G56TA]2@<4I@O]*G1_ MDSGCQ&4'8VI4A(FWG 3AT*LL;%T[B;11B,F]M40"LR0R:5T=TNZJ:4'D\2#- M\L@++/)8O&0F5A&F4D=*!>;GGUPRL[O7IA5);M#.BX#R\+8_$JSFYS"X[HJ14=[,M6:Y)GJ:C8:U\ MH2VQC4B4S\&-JB:"^_L)HXA +!NF/&=[E_EH5*F[Y610C:_9M?6)6-P-,T\Y M %7OIJ\&5ZPPMBB280J: #68,3 =WBIZ519S0M ;.YND@-K6]6GF)[L3YCG,!:K[TE M3S[6ES:6X)6?4:6CS@B"W_.V'?9LS3'BTP9[5#.-DJ,9*B 7WI3ZG%-1_+7VAM120E@U M4$E6&II\0))AQO&*\D&NYBN?HPH./DH;+#NK)8$\),DKN?3U-#4] M2:PHY[(7U&*K[:W91GK-@0LCJI ,0=<$0P!!+SV5TC/MR*?1S'-'ZVJW5I+< M]JY20GTVM\Z+1K6]:E:INE=Q5:CL4E?:3]H\^+U9(Z+2C'EK0A5#VB]AVVBQ M_S9_1&&;F;IG$IKG-(J3.%V?J[7UU$&#U;G._-H]A@!C-WA5'C:3"N:CN53A M99Z^Z.[MWBO"S/='BUF\R4FLH M11$S3OD(3'R*\@GR@GM0%:.ZJL^(EZ3'>X"7Z,9RZ!^W6Q^=F29#];16<2$K M(#T]]],9CLFXVH#6+AH(O?6+C7F 'MF4L,._!HG'M[A:/),=G\EB*7,E=MFG MO$,#WR+(E2:.UT%>/%N][&OC^L 6NT;7-(UZV9/,6D)F#*@F1HU$TG'Z!O38 M4W&$'6)B+9HULI:^5=6VKH_XJ+EU=5TO,+5IG,!@*'!BD.G=MU7U45VJ*,EY M^\#*S*531B58\;*O39M MY60(1!OMXWC4VRWIYEE+=A954G:"<1K"R+A9F @^73G-;:$JSS[BS& */>$G MW&S\;WL/B(>8E+GL9DFX,/#ESK/O@'RY_X0G_/6V3!6-=-_S('%3ZH9+:;]Z MF.X*)?E=,=DM0.;K!=%6']K\#@^/$=F]]SZX.#K[ M>V&QI@_2A#4FSLW9W=[=I01)U&RHIR*JBXAD%KQ%T/=\,>RR-A3B#NJZ&*'+ M?2U-U$L'?CVP S)%J*0JF^IBVQG"M+7F@A+$6:?_XL J_2"7?"O;:?=BY..! MNR5!872/C11H?4)08CG]^271 E[URS].D5_X/+%/9IAQF\68''DY9UG[V7-L M]F(#M?/DW*_7$BWAULQ>VOO:B MDGGXQ3[YNP*D (QIC."9+B*5!$!OWZF,B3MX<'V4E#(9JI4T _*$&JN1(GLY MA?EI@S!VZ#V-B1^/P@ 8/!H;\93[4^2CM(Q#3M'Q0WOPUU"3XU-*;3GA#EXS M2F_DT#) LCW3?F\T]BE4)F=GM.3:9#L%8(53''//-UPW0@H.!K#X_^%61J8H M6^*VID6<-'PQ)6_H+9UYJ1194,='2MP7^\.\3X+!F&N39E<484 _#:@B^5#; M$0PJ#=?]:-2PD)-(9DAP2$5VLZF9FQ"UDJKA2;D::_'&BY)3\2C.:_YIE^+QRU8T'U.>!/6' 13P._Z[:-?5OMX$S*04\ P"],:)*Y]*&9",:(JPE?E$_G3 M#P8V>HG7DR-7E0KN#%?V4ZB _)"-AM%$%]1LE*1.QQ+&E/TP<=R4 MHP%U<%HGP3,56&A5,NJ2Y-1Y< ;4Y%YR4B\YK('Y=91$DE8A#B0[3WY$L ,4 MS30EI@>1NY/L.4Z1[[ND<%]E&O MY!)*YNM5)#"40DUYY8<,M==,VPH50YN=JEYLF\'UP:B.6$4:#H&JD7+AQS\^ MU^27<<@CD6;5J&\^2"?:1G'F'S8C/5>:YSY?.OHNDQBQL+PB-S1BPR;K0Q0-XQDHJ M3$9CS[%D *- #_AE(H%PKQ2K0V6T20A7 >L"6Q.K=-#3H1/"4S<\<*)( ,,8 MJ$P&!Q.GL*3F=R5H58;$*9!;2+$_@:SK>*BH4%_\&5[!GGNX -(FJ4 Y2E2] M7PW\YM45,WS S]@V%?DF@E8,HR6Q45+5=X9JK&ZU+EI!Y*A:LIU-$W8 M3L?^.:\'B:3MVKH54O/TC#Q%7DST94#U"&R LE,P60 1)(?^ M2TPV$#[Z7R7,(Y1^7C<$[VYR601OP%8CV<+J^J"]6FEQ#ZPX&2]/H,&0,=)% MO3M?-318V;&*3\>XACTYZ,62E'U>*(XBT3M(2@.QL>U"@#Q&$-;,>:^<;5%) MN,& 06P(&A1#(GER)F"&J7^26H@?T5DSN+ID SROP%7CT*QR]S)H*K>GWDZ M6!EIF+F@M &SR&-K#MI("]6QR"Y:_^(U(P39K:[KCQ7/O_/T<5HO58:Z0LS0 M0(70Q2*C*-TKY' B[A=\'=D>UV83S:>A*7'!;=-)$&OE>DWZ"AE?/T;H)@<* M&*>@8$HC\?U7K;7[%(;B FQ3K#^KEP&A,BU$J&W'9IT0UGCM-[/N>V+4''K= M4N]=-WO!A"-QYV(V>,/M_0$> M.JTO3V3:&JXZ*DS'!^=P2NZN:EOP%^1;L4.7P^V'O4!]BPNV,KQG&)<#*1*! M>XH;K:6JA%4XKG\P0+CU[-?@,(U1";2X7@)?B!=6/"Z.M#3J MN%_4>AGCZ0WKAWPXL )<;V:/G;AU9CA@S9FE/*I)8>*6A/]$56A>!8?YDB#$ M8"*$0OKPST)[IN_K)DNP47F0H)^!)VY8/*KG01]/I8BO<>3+K5 MR/_]JY;CBR<)2W4FDD"2RFGD\K\,K-ST2F<6X]+FIP^]4B3J58ZF[9SB0L3< MU9)C+&FH'EI0)!M0\ 98S"B&\7+G9,R;HFA3T,[NV 9QEA?0L#TL3DYW[IAC MVN&2Q@H(*@+%I+E_IFM3Z)BX&")=MT]R0W-ST\ AA!ZZ M8<=!I%T+>RN("FSE:JW@#&OVT*(0&YK7TZ_Y,I9T598;+N]W[!$/(GDQ:H!J M(N(]^#/?OY%;HA$J0="S]\35Z_O;!A1MXMBCJ!\5HC(GA,)KU!W*!H(]HTZ,IF MR9H/-(BKQ2@">8,J$4NOC0CN-K@=T61"G,5 =9A+!;T2*W[E#6./,-&4+*>< M6D(M0 R"73?XRREW5UI/<&_&46+[>_C/E[*Z8*BQ6L7"P.8"W.J?-;_,KHT" MJ!^:A@>3*#>QYBIJIVBZWE-]&,YHC$?-",L:C)]+S*C2B\5KQ%G3G83=;4]" MO1^N1@PQO''@P/\M;&"=N2R@(XMZS HQ%XM'N;0A7%DY?;!$#6 MTDA@L!:E1P3+:0^B7X 1.%YEM.B*Q3I3[J4"9H=@&8Z8E>I"XU?=]7R97I7X.387Y!X< I M&38H44P6H;\[W&J@BB?J@@!^H;V!!K4:@'3J(.5 7HVK@MLI[4WZ*C8-":F> MNN/I(/05F21N:S$(@6XH);S1&NIX+6HP:5W\FXXF+&5J,_M+Z(X 7/I>&R-. M/5(%HQ#0QML65+2\WH88K%'1B S0@%D9Z5BE3 !< JI"EX,+QY(_<1\G>CP MIG['\S/WX#1ET#P7C:7$VSPUF.2SLM+I<.FDTWO8\Q(XPNJ*&7MH$#D$#BBJ MXG(ZCY)++% $_L6+@%R0+!*A:).H@LY!4:,05@NTJ+P8/3N^;B2!A(*3"=%!2>_#@F,NL:2R6RU2NL?GA[+(,&/M.-G=1Y_G*._D?&BSDD[60U6X6/"P*1T=JU% M%32I!FSTV:X-WKH86ZH9B[LMW;7NOO7]M0VD===>R?9/XA:>B<:^V9C2BDP M.9-IN^"WO++I!600#]4 O4NF>Z_IY)95$KB\'-S4*F_"R7)2'%"?<*@1-LN# M7D&\CD,G5?/9C9==6Z2DY%S6@"K)90JWS#[XZQ2$Q0[7_:$S.$0OCCI;DI3( MA27%RCFJ]3.L@C)1 KGL5@6AJ6I7H&\&^X^0:R?-T*5F;*DYYQ%1XVA\):C1 M+3$41,;L@?S/$B(PA-=J)"Z!!HUO+$8-=+6OGU<%?8JPYLO"CHGJ:M#N@,FC M?BU=!51D7SNP9_^@KPIR5 ?V)4I[^VSD^/#H[?'!_< M"@>%'T\^7N"U/?JF<4[^\?>"VTD:JD?__M8 X[V37+\T?[RJ@?K33:^J=(7- M$NHP_[BH_/.K1F>M NBV",V;Y>PL]]G<:,@\;5B8'W>:_?]G[Q2X>&&Z7&6:N;@E=](?XOU>RJB3FMK&I M!#+2* P,WGW]QU$8QOKGG^S= MI^C(9F>1)3E9W1^P<(SN_WA6MN?TUU:H?/QXD@)3AP%77?"+4/&*$>ON8DL: M7\*-:A%B_;DTN?"JS93WS^J:]B[5.]9Z8\B72Z,7G*JIB3FS@;J@T;[LLVVW M0# B[&QQ4Y\N&5.FT /T]2+FZ@+N39H0!CH,3$:DK+4&M3[RQMX&Q6 MB9DO]J$JO'6XCI3886!89*"9U(!QVYT@O&HU7V*4S)P1NP[($JM99S;$A;&? M&;=7 H*7RO;H)CEZFS(.>FC5[F><]H_>TE]#)S, (V R!0@_ H#EI MCRI6J),"7FF9!7 N2^J2)H279S[0BKF@TGS3]=L,-N#O*(]^^W7WR=ZK)#A1 M U8F0QU\5K!J.M^HG3;?*SBQ1)8]%UM#EKS:I,DM7[&2(N<^D2!\ MQ-F-9"))WBTFP4\_HNX+0/= T;R+WMN*"WP?C.N36(&MV/ M&0P+ZV"J90+MF/\V=F.5-U51)^:84KU^T,,I@4%2YBFEI/I@ M 9D#73'-7CF5=*4-FN,AT2_N$>4.F--C@V7<4'Y&Y5^CL4?^+<1WR\DD==X. MQ%$^'/L,CA/F*WM-CS@Q@ Z=)1:51_>OJ"^WQZK$0&V\^@X6_S3>5T3%K'42 M?$25,CB4U)JO8#@_=3ISE!C2C5V.$"9;4F2QVO_+S\+C.^842R(#\9;*=@ZR M_0=K#=(I=P@9A*G)BQ#RRE;EL>7^Q^?<>&0J32#V=GM);$O3 L%;GZ_BBW?7.CP]$I=L,#F*5Y\%'/![!SA/*IH)% MWNX$>%5PQFZ'%-CLVQ)39I_LBSM"VE%95;(!NO"#"(.>V-:[LIU4#E*0!9G4 M3/0&1;"[O;USO[T''^*9FQ<+]4(/AJWD][O"P7&U#(:KA=S9PRP'9A5UZZ7C MVHUQKC35O)ASR@!?Z21RK,#UG3&<*.? [*VFC+ZY*^9!Q6VQC-/7<_?6)V3UI=$3=39$?D4] M\MJUHS,DY[J-/A;97%YRL8@I$3'E.&!8?4BS2]17P/Z+]?0A2D(\.L#S&7@K MGG9\MUF;)#2*UJ(IX$LV60RFM4W+XEP/N82W7H8[TO%$ZMVNT+R6WRE4:913 M!V "AGE9S"XV HGNN]2)&!,_Y]]CW$B/.#CSV2"YSL(&6ZNI*Z2F M(P*X,VXM4C9GL=\'R4#FV0UOI5>S%Q8,/L(*W[/M<%$S%J0#;J6YM/N5$RZ. M"P-2)Q-HOL0?FR\8*Z:&$7(!!&GIJ2QE-\.\R ME6P+? 8NW%]I=B6_6WP+XTX]^>O\R+I3L> E2K"%6$Y2 XR_RU%0RI(RG&? MT25EK5CFP$A(A 27I6)WLPL2NR#NC#%3>IQY+:Z#[,)<=+:%%L, UCBL. L^ M%*9C/# #H7,I+"(:E](=U+TE^QB39QS2DARKA/V \U-=WQ)Y+L>H3)?K0IT?&>/(HTC;)D#Q0NR95%$R&,\EM M+JC0IN6Q]<>,4Z0?/<#M[W%8]HR1.F"$P"G&P<[VUC^M>EZ__7_@'!:8K-5R MU__ &3OP_<"Y%D@)!F92URJ*&9>C"$9%,2&?, 57Z)^;FYLN\,$N$"A][AA> M4Q^$L!B6JRE6,DL2J$G)PWV8M.F% BI:0Y_;T7A'C*'TZ;"*T0ED-E/5YK_.TY)H Z'YJ7O>#3P7R_UJR3*^W*@P,KZ!&Q\YL4!"I)=I M28+,=FUT! <$X!&L=S/0S!&V0T#=26?SM ;L6\U]4HA:0#(&URD1G>#R=>8E MJ7+"EJG1)YA9<04B$K< \KN*C8&:H#>,JO9MBVM%X(!M[5*0&9%^F6"1?D+( MQ4-L .$"SAULO;.EQQ-J@< HCZ@8) :!PW50@[-(UV$6F+U_Y0B_EPLG, D/ M@ISZV;"L\];=O&>;T8)3Y18Y"E/_"'VX:!2!+Z*T(OQ9ID)/@P<-W>/%^73< M3V,C6S^<_=,(4U5P[+9-F*+(3J:@71LI2D8"_?6_\'RZ&AXE#B3BY!8NC94$ M9:8Q4 BX+#X03&6[Y;597Z&FT%4E?85^QP@5[YP^2A[:8$J?#%??(M6S.RK& M\1*[TNQ [8! MS\L^DAN)H!=[O:T#0P['W/X1%Z#G!!]&>W;V]Y\'&P?%:#/8\.*)S2NM&DJD M!?/9\( DB6^ZDE_3<:CQD'HL\C%6D-TA1W79,U0-)MC]+-S,\X%F,#=M$HC( M+0S)8@%ZJPZV. T:&);9B_C(J/2UCB^CRS[M6TP $T"0UIXNB-7(+3=N,Z>S M=WQ'5^%@<4&]!]F"D1-,?O!RWX3Z@P\FCM43X&_;8?B,JK\SE8GI"(="0,'- MO910DKK\)<]VP/NFB)N-AFM$".K1F/_ND*W#;_N/;:YH4JC8M4RQ8 [C?X5[ MG"USJG@GPSN-0V_8':_^Q71<&P,%5.!!*=.O49+BI26\-K$E2;+;PVOD#4U\ M1,\.-[C].*A; L.I%PV<>CUWUF;7HBP^4_^)XC6'7Q8.?U #X G=UH;Y@YD">IX-(%3Z2 M!_#FJ IP?"9M=."J4^K)+(RKUG[#N)OK<,T+/= (N9D]]+ZQ=]ZR$\KB("(D M9E9DUE]Y/%PAO:FF0^@&VWVUO03 ].GZ"L@QR;T=1E\T0UO,S,("=4*>?:VS M=EJW(!(57 BN95D5:F[?5QOUG8^.T&&@A=@TXS*5%1T+T&&1$VSEI,"UM2A\ M9>(E+% *)W=%X[AQ9GIVZ>4:\H:--0RJQG%;8\6^I/G1^RJ7ZPS MD72D-FV*93!T6Z;'92(97Z++MPWAZS7#M3.TKCN6,1@A=_'9K[VA:V_HVANZ M]H8^2'9WH!*U=H8NCT5PX>-\#06G[2N1=I9QU@NA"F::&@'GJ N!WJ@FHV!C M?]-H:#\78_!A+NC1%[2O:NV3C%B.[N&X9;?BA-H M,0+)M)PZ9+T.X3==)F;J[F#B+R%,"JZ:$J ? B1A<0CZ+G .K)1[2'Z$_4?5 M(2F0C/D=\\>Q_RG.PY:+%-((B&#I=#S$I;#V$,X3QHZYY>[A4B8&*A4,'??. M)JA7X>XJ*P;KU.$7QK9<'JRL.=O]9A,V!NRTXSO3;K,AV84["%I M&;1M?&=\&IOK XX'?'=]P._B1<2ZCQK8BN<@UC/./YROG-O.LL?0-+'F;C:L M.<@UED7T*WV@*_R@3ML&XB,?11-;A^7)5W.>X<\-#F-S9[RA1#WHF.*I)7P! M[_1OTHEE9Q^N LX,O=OF8#H.4E>CC-^01F/?CY)>WBJIX(K )6BU5(9)OZ12 M;:A-=Y$YZDE*&HK.*H>>UY3\YT8AJ);VW4$#Z 0;_=J+3<^0FPQ;;YB6-4<=!)315^2!O!1I%>:O9A^VG4WI,. M%19M""13$"PLC>:0FLG]\%_!FPJT3M73N+8RL0G'&-+,_C6D,*"'.TT4)I?7 MI"&F;)2%[DBJQJ"00NB$:C\&T77$#2E-@17V=&08&ULU 324T/(#_?O57_P] M44&64O5(:.L36'U46-&;6>F([=W[&L&;W2[:S(>6\V I/.\0>!.-".FG-A < M0EW5!:K.;5N9+L([#BBR8X*0^:3DDT-)^"P\9Q)?,,(C-J *HU!*DE4B%25\ MTF&3O;Z59O4]?F1,(#[)TH" M=E)R>A%NH,(,.M]3>K@-=W*$&&6HIE;GPR[)XW(\>T!H:$_K7*.%:319A;12 MKU0V#:D>E%SI3)1L9M-09@[AVUC$BM#T.N&RACQ#W7&0V$T3L%S'\:T.K&*4 MI>7ER$6._2^X"1GP6W86->&X9YT\%]PF#;&>;K-@TB.C@I'5@9C$J(_2O>37 MKPQ4FIT+Z(0*:EV _*S#><6#DHO(=:IR'?56X(I;8&VNV="<+,?5/F+U5H,K M,MG%9*3H5*:53 7<\%QLW)V=C=":Q4X+FM'.)DRU)$<(:BCY/DC@#1FYBP"D MQ)!0W'O0@ <87:;2'0=^))$]&V:,D?E69.-F!)M&/@"YE_=,@A,5FZG)O(F& M#MG<-3: -?N?4O?U8)7<$K-2]9++$L%R#A#O>.7C<9HSEI"WUY-5(^-/B*Q3 M!0B&FGT*$HY4,H &>8/B%?Z+%HT%N.^(KI9+ Z1+QFP<:(U+0J B9*@CU&6' M4!D3!L24KE%>"BHZ*@G?Q 4R0I"2 Q1#=(O]Q%=V4!4,,P4V?SG!PW^47(*X M&CUX:71')(3W[**D#P7:?Y#QGZ%BWJTQ M5'09*_*JX.^$F9*PZ8EH]U'P[Q+;E +S*'.W[_!4?M"@+/@/)))K? P,0+X) M-''Y@;RR1-;\KS($JXG:HQ"R6R*W:^JGA1LL(;/2[KCXH4T6$/T,-^T^>857 MY654:/,Y1A0(>3N2GC>=!T\6 M,K95DG6S+27DE^BT- 5;#72E-KBY3*,X@(6E0T?N-%0$2Y(06,Z ECO5$3": MJ@'Y]+'_&*X7?F7 WD3'9"H--34AXBP D!\=@U]F\?M4B'X)+%VSV*T6+='7 M- 4SR*!-MI@(?@0L?8M@[?:%;=7F NCU!2$K8]: J*-CD+*\".W K[2NM)\T<3LI'8 ^BF4;Q.;?Z.N7XC6,^' MGM?\F)(!'ZFC[N+=4?#QS9NC,_@WP ]DN?_9.SL,#CZ>G%\<7WRZ.#H/>L'I MV?'GWH5^?:L M=W(1',+MZ,J:_<;C\^!#[_ H./_T^@]X2'#Q,7A[=')TUGL?G'UZCR\]^>W7 MG>?/7@5[>\_,[?3:'KS^XX'WMD_CRXL1NC! MAS=>7-$-Z.P(_CW'UWHS._EX 3^\/3Z_.#H[.@QZ%W2#=P'_>/97\/',_/KF MX]G1\=N3]JMDV!_>=(+>R6$'/\&+X8X.3/S@G7]3[^R(WN\MR,?/,,3CM^\N MO ?!)-["BI_ 9QE 94UK,S!;U>';/WXX[9W\Y:[[GT_'>!6\ZO3LX^=CV([3 M3Z_?'Q_ ?3#(#[T+7.'>ZX^?ZF^"Z9^_@Q'3MN-NP'7G%Q\/_FG?"./\=/+^ MZ/R\=B+/2:]JNKW M;JWX9.IS73 MU?D]-MN+\VQ[FP%WX/F87\N.!TKBI+2M%8\7U:.:M!:/ MLV+)YL3U:PD%")L^&V> \'XEI";!$LEF:<42P,:%S>!J,2)*KH(N5:#]T\S$ M8*1MC(WRT^5I;'._278U8!>^!GP)CX6.B=MXLZ,T/Y.L,SOYS'JS9F6\F[4V M^$GTO+X>J7C8J2&2>#!3D@Z'O972E'HL^4Y"Q&@*)I@&*?E;'IN0//?9*?JF MFBA \ %RWB5!'GW9@I6"W:IQG-9)2PJ%F3$,FY<4GIF":G%I@2-4EM'>V?1A M2A61;7(=C[B#C;CR:+U,0-RBN4B4C=K44'^4J:2O6 _N4+-KIPSB)?UF=O /9-73%Y>#=?+69^5F8I*Q,94!7\*BI?8LD_L[B1"J>SS6(;I73>?( M^7-[\,)]+M,]9&;&-3U>]R5?D6KP,I^KH'<=3M' .Q+S.[&T(K2;W"="D,.T M2,R:)?"2QFYY+>$(>P3YG%3:,:TPY69JS.G'WEBM I>+]IAH;),LO:?(RLR[]E*-[%B4A(:L%(U[+R9.J\8[%RM0JF"%H:NTPI"9^/=1G^2 M&DY/ALRA4]MOSA,.F9XH[ P@1@-IX9:.54"8."IN3L&<2SC)P/RC?-0\11M2 MC#6G"&NSH5Z#ZHA?H9RA'*I:L91(/&R@9$_Q1$66W<"B4@\J[GM&"B0+:4X* M'DP#U=ZJSZ6)XBLJ552%?2$E;<]^6\=!@S%=6.0XL_*V"HH2O@M,_5+^(X*^ M2J[LVAJKB"$6K=ZJJU>!>%91;"OA[$K"310WD!4VNY*G3ANI+&.HR>TNZ6YB MOO [J"$NW3%.*?'Z"DF'B_P;J@WWK<)>XDC0%@BX9J71.ZI;4ZWEGVV%4-]5 MSKSUR=(VRZ+:PVI>".M;F)D.!*6F=/ADG,;(LB>J,:Z9IFLF8LPT*:'-$K/' M@FCVM>)C8!_G-;/C5K-]7=QH;9IK1V,W?/I0I3]K=WCE 'S*T!ZK'U>[@96L MBE: 3ZL)5KR!?BY(S3/8+BTC-/IIJU.3Z*\HE:V*O-JRF+X/TBSF0YE"ZI8BQ)FZER1$% V MXUC#V)E-5 W-NL^AXQYIW$'F>51H=S>DU,7LBKN[EQK^HXX4(SD1[ERLH@,@ MD\U"M^9MW=(JRX\O\](XQ MX8<3KEYG.:^SG-=P[S^T! S>,^XO>T?JU"-[.^# 3$2NMX M%_/3"J@M4!)6?(,9]<4D6]_+5N3CE,BO&6&D<64 9HYG"O&=FS@O' :Z>@N&)UL,XW?PZ-M@_2&)N9PXJ0 MAKIC;?!9W2FDRP3HYS'U':XY^L*4> :=( M\*#:N^1:#3AJ@Q@9H1XGQ)*PI\,T2Q'M$WN#PI-2\L5%25Y2PPOV/*"5:<)R M9MC._*;1;)F.>VK,28(4J;/>;G+]-Q2(M4X^6R?/"Q63K,S7)+@FP?LCP?]H4&9,>?^:%)>)%->0%#5B/=0) M&(-7:^R)931\U_Z2[^XO>71NDM=3#)#KB4T#JN7USLS>XZ5B.'4VURG!0))@ M_#Y.G/:*GG_I^R(!7\5=*R5;M]HKH](=W3NNW7(E"6=Q\BH6%&NC4W#!/)2ERN-+',2A2A#\/58WG'+CV@2,];C/@1%&.[+Q,UA%=:E-+KJ7 M$/2W?&[W6!BT:#R5#F7&A\O %%/)=X=Y1M6,$ZT-1A-=W38%KUI"W+@US*;V M-6H_%/8Q?B>%!\\M[UA;=1IK;+4&RZ#;%_!&(6XT: ;,/&"W_E!)B3 '.YU@ M=WMGO\MH"])0JY),Y+6L\!&Z_?X5IE,JB4+,%@MU \[A@LA3L*AG/)]R6RF5 MV2%.WS7=K]*3T-_]@,&Z3), *S=:2N\7+0,ME!)4ZO-&7+ MR_67,GDI8JOQLS><6>!W7=ZT%>;(6ORV\63-<5LP, EYD M@#>9'K^4J@@3DBI%>!:?N,0^S)3@#;AWN$!-2D%1FOLSXNH8F'V\PKB][:3R M^;=?=Y\\?56@Y_):Y47)I+$58H[1U54Y1LO_*DK RE= ,!JHB$TSW+DKK6,X M3"K0.=;WE:&[YU*!/9;B5V%ZAP%Z_Z M41"7ESHIZ;<$[J#RG*P,QCH!PS,&:N+K81O@D==1%"IOD 75+LD@"YC$.KMJ,7GW!@Q! M.+O++>_6.M=JTV!6@9)82A)\3"K7A?J"V?](R*O?3>FO:DVG1/>HC69H.Q.\ MP=+_$68&;_V[A%$CI-6#5SCNI':O=MCIMCCR@JJV17IW;NP[J=%KS7<1S?/A7W65._8$P[\%H"$] )=1^F&@2\0($:_O5M'Q^9;O$6%E8E MT^56+M;Z[6K38*;ULNNWCXT$U[FR=2(M,2]#Q>M.;ZO;^/V.KI _ M58;!-2KT8&A=!"D@SX&1',:7P.*.LW9UXN1>?QHP*K=M%R;= 0O"'[34+[XI M@7[17W0VP CC0)5&U6!YPB"O*- (]Z6:]"Q8A6%:]@N$QRNY29_$MZMC]]QI M'N@APT:PFZY2[,*"5X:7]K%=$\$[X.\X?13@FB#554SMP:@7X$4K)L;\'E+5 M=HK^_6U@&3X(CB#C>#@XG&IK%QESK*W^05XI$EZFS^X1$&&$7QR9//9:@C@F M<$>%ER5.P!8V3YS5BS\^YS+SV]>TL@V,<0%78P>@ B%V877*1*($P1@1,2,5 MYQ7$3(;J323%UT)#N47#QG!5VIP@JG4FS;;J*/:R.'4G?67-)?$8MARMQ:*T MZ?Y#1K5<8$MPC!X*O/=[C(GZL56PW=[AT*B+'5.ZC(WV;B@ J!-0^(@ RYP* MN;0:C)J[:C;5Y,QWOF:+Z;\>Y%,-Q=1AEO"85J>P9+'N&RLRV<4A>AU".O%9 M52]SV=G9"#=]SMN9DX $G$YSH,S@QI(,P2$0K2,K!B(S'364A;UGP%5AZ96H MF\'$G]WS@?M[K,C&S5!LI'?%.:W BDQU!K!C^R;;2CI!:B;RS;2)EE -C')\ M-$KP(FD7+"#W!MB^K8>"@=QUI,?(O+F!4O:PG(7H78,B[O0[&Q:QTF.RT6BU M4CG%F'A5^+UJS1;%F&[KG6?;+= UIKTRC#/!M@O<#+4^BS7TU.*F7YE9VN&BVL&,#]UOY7MW6ZNHZ4-/P0_+['UVYJ'?;Z M>A9_#/ORX$->*Q:\7411:FV;[B-"N>I5Z,-$J M:U5JY(Q.?90FJA=[K48J5X$E9%!1$T)H,HFUHA22MHLMCZB&* 5%.(ZC7'6S M2"6J&^J;Z+=?GSUY-=;9X*H+RB;HC+>E *.;^NLJ[IISV8BZNMNI9 G/\<%7 MRO+N5I7'[NC6=&(]*YVX8QS9>"NY+]!A@2[VD8ICG5QJ8Q-$(0:)&H&FOLK) M[TVQN9.T&^P^P8MVM[?W\=L3VG?0U]_$"@R$]W:P!ZEBR\[D0=@K>PF\<6RZ MB$5C04?#U3H%?9O"$8C5?695Y&#C9J03\A>@VA8(_KS0LDEJ$ MV1SR,&!D,(JQ@BU++L%TO%0\H@Z_!ED.7')YQ6Q'Y1&(6:@*OEMZ#5X?R2TM^Y7K?EETZ'W, MC)C(91^**%17M#KJ7^45+3Y,BQX*_^3\,59798TB: [^_GV"N0)9\W\,N[J MLY,PQ\*(-/[R&L-Y&2R+S"ZD/@NP WB7OH0)(>)?H>#+RS+XI\8?L/X5AU-. M2CR6&0(XTO(QSX(;^NI21; D,%(@?[@\F<*^7^DBNH)71+ ,_:B 8=99V%K) MG:GDHLQ=%[2NLZV7FTKS3.GXH?N=?KREMDXP^\DL8%; O][_.Y<.[P08Z&=$ MP8_ZBQXS@*%MA^NUAR9'>A1S-)5"GSFVJG?).FC.\/E G[?*0F.1<2OAON0N MV&?SM5'@;5K/I+"!KG603B+=GE/V!G8U.-]Z8=K3L>F06X1*D[9#-PT)VM F M,%';=^^5^,PCX[P_L/$++T[#4Z?0,.A8"1E4&1H^>%6&00UGLYK%I7?"7<<4 MYX;AG$F278[/^( J9?#;KWLO7L$KP:(\3@9=1(7@K$&,X>GO,,1G*6( M O)/G211?(/HJIW@Y(]@^_GVWEZ'YM)CG$=0+?5D!#IPD)0$3RKMX6%/!R7Z M6#%T3=C(0 ([6_O;+[:>/]G> GK:[@:]:B;\X'Y7OII#UY_"%JAL,#+4) $B M%WN*X$!9ZT+U,K^FS#H%J MZ2]^H_L\X'?RU]U1,8Y7VS2]R.#U8-!GN#]-OWW7CY6?U0C DPG(<]((MPS4E'X3.SH8'Q&H99=G?PA\E*W*3GR1[A0-F MS&H?PK7ZF[D1V%1Q@QF;?GZB.>+U\U7@,S1E5:811;)KW<[KB8WTC<,XME(! M&$N995R64\V'.#X?Z^"+O-R6CM9E]),:[G$4E'>6R3EV#Y MCDX&R'3\F=?7M5,M)C)MXJH;5[^)!06P$."@-5JI1?[M0G2# S6A7'%LW,<$ M0A!-8#B3T\Y#LZZW\$0&:Y;3R=;,&SGEY.)'S"(@SEA!YFZ;PVHSL[.J#G.F MP9I/@G,8&"SQ@?AH2(Z]UR#,LQ59C#E0^)E5[(@X64?0L+.] MR[2=!QMR*EMNL&RF[MYOR2F7I]6.BM-:&Z1*QYS+!LM89>SD1_ P3*I+B@Z( M_$O65T*X[QHU(?I*HYDVL7EU;?,4_FLF*YF%\$]63(.-O>W-(%33EOQ"+"]4%^ J6METB]K$12_:K%9A=DB'&<70+8O M,Y(?^BSZS)VS29HI$2LRS(%V,(.NMC/'.(8#G9^5\C,0PJ98$F6)5@)6+;FE M-9NIBY4O_I;8I&F38\59F[/XAR&UEI9WO:SU0EXS*S\=O2"&>,FC1\XJV@%8 )&<()XX!%6+0JMQSR=(!K(,"YQ&-57 MS=#\O2X+U8W>Z&]N[-J:C8_H*,$[NT&]_H/M63"U4\K)[-\2ZFY4R_N3&J@$ M#_EEJ4C4^EHTCCZJ*S%;8V2B2J64;5\> M4*L743N$E]A3/<-J-"6KA#-Q#:=/[C,7(I:C]88V2E[SNO]H<%D8'/K(K6E,!OP_+.)XV8C.LRJ)J5E4TVA_-&F?4=!K.FX[HXR:- M1N$P\ N0^""I\]@H;KH6Q M:=/QTJK9#FI#]!]7B>VVJIYO[9M&@TVW2U'NH2W@TL#U"3=O-J "@RJO"33LS&-@$PU*H/Q"V":Q)H]!2;M.;M'9P3YI=JB3Z MCV*P9%AS$T5RW\2(56?PWVUE>F"]K+;(7J$6G)=QD3.X3Z!"9$)^\]*919&> M+NY"4(,!V"B=.DG+FO'#=2A3&LJ4#CCV#\\YX*K)#M)#ZPLZ\]Y@JSIALS'? M0EYSN4D+&\(9YB-)1AZNO1B]TC9:>F@:$]$8HVFL??2-*F*/9\>.F(0D'G*H M"A6<9M&U&DSKC3+-\9K?*'.M)E75I#\4+,-RJTF/+2_TL5$@^7:7CP27;_W^ M7WO?VMS&D6SY5SJNXWK)") KBK(LK6(W@I9D6_9(]I5DSYW]LM% %X 2&MV8 M?I""?OWFR7V9YNGZ6NPB7VM6V\V)53RSE9D@K^BKJ?<8L9$CPUJ[WW?*:^)^_9E*WEGG.,$M@QTPWG@Z8J(@I39 AK2I763'#CQ^$RS M=TT*?',\._[,+=K[_E'P(3-UX79OMP^=](PG5Y)=$\-HRM\ S!M+32VH]+$1 M>TU!P2_0=Y%7_8YT=)?E TYM9^ M,9BG$V7!O$*$P191A($#C;=]M*ZI5I#?HLD%YCW8.6VCH=NV2)=C.VO+%C'! M2:C Q:"S,L]E"$?,\<\G2@W"XD"9&/QVSK#_&R+8T5E MJOSY2\ZYH03#6!J;8@/A:%C@&!WU(IZ=:",2$*]27<"!I[.EK9 YEQEM4K"$@E[^$,Z'&IWB>2YH^JM!P)_A,QUD+L]Z+5S3_@# M.6*6\S+/O+41\:*'*G!29X7SSKU'8^1S!'.[M +STY HB3>)R+Q<(MR:5<+? MFVTDAH\DT$ZS/;:<3EZ7$\MOKENNY^X2R+V8"TV7-X;<8VJR56"=%,KV90%0 M?%>.DX:6G!GM*\C"^YU8Y_<;$)UC! M//P.$Q #2V>S@*%64 M[U4;G:0>B$27A. 4'*,VSA!$>.O6[E!DM M5[NR<9DG'B#M )B\F[#3_5&P;GK3\-Y#(V+RVEQ@7W99VQM/U;.;\_8D!S@@ MC#:?=BC:,V6TT52R&F7+78E)%)BW:: ;$?=:\%.\CO4%.[K*V:3IVA-ZI*1H MZR8,+;2L[N&B9$7?8/A79:,9ECO&:KQV27)^#Q4&]'E+TP%@"GT%8\_GB3"* M&H"415D.<7LD5^&"Z.G2?H'8-$5)A@D>*&B_RAN$0@>M( MVX&V,1<&@%A2#V6\KJ\- Y1LQ VB\65[#-@FWBACN\P/["4&FM/8#.CY#-;. M=D'JJ _>W]AC3VL^YZ)3[ L@;4Q=9!1>&=H3-R9:K!_7#A7H40Q(HTW/DBJ5 ML?.2GDFNSU8KA,>/MNM44X!I::'E>EX-#[*5E!0*':/U4F3B_* ^\JC0?%1F MRJ6T)%DVJ](+-FR M U>B+9.R;D:]Q12Y1*Z\KD("S*B? MS]*!(8J^=G+::R)H9U"9K&+LF0=5CE-:+Z&&7E1@CN<7"T9^P2F^DI*S+/SG MY<(X/:47]Q"9S+;3BL]"=Q2OG;QIX%-=&'R'FC)H'YT'>)L1\!IN$)F4"^2- M) R<(S*5.5+WA)LE/\#N_&3K37OW@FOYN;=S$G&I!YW(YZ(G+\V%B20>"<:I MY5)7LI.&F\0RHH9QQM*V2;M2HUFC\5C(]^G8PGQ%D\+R,KW%Y1.?X]6AI$/1 MR-7^0,A-27-7Y8ZWVM"HE//MXDG>N1>YS.JK2_9M-]_VX_2QS]>6=AV MJ_1W4S%IJG*^@C25-G-0C!8@E*7-B3[H^2$>%.<4$HI6&/CI$9/",D'LU^@5 M.@,MKQ+I8BAK,P'QJUG4=+*JP2\,XR,M5BESNX+V*ED8VNU:8?N=V0^V$-;@ M8M8N5RTCDO''K 7[*]^_,J3",G 9CW3HQX8Y;\DT6;!ILF!26=+Y-,+XST@- M5^KF.,VLL ?79H48EN/HI8FC#X&DMS.=>%JZ2H_H_RP113+#Y0E9.G-N$S^4 M=B3:GMUS84S(P^DAJW216C(3TW>0*N$3ID\R(+CRB"^G_R^26G\;^4_TS 49 M?-(.TG4@V*7KUZDC^Q5R:QIF')6GU,09Q%A)<_F%?$K)QK92.F0:WJJM=:C7 M<(\(OB/5[O]NOD('$XNOIXK&1%^DW:G2"4R6+U"-F3-!W8<.GI(FM%N1QS2@0- M-4Z=#=H'5ONY)0M+?U4W4TW6>(VC$HN._H;U9,C^I&?)ZIA1KT;T[@M0;!=, MU@R9>4?=;_#!B3XD;RF/TM_X673YW"VCE0R'"-$;+\D $U5'_%\_'K59MFER M5K182_/N(IO3D*!M*N#RXK$%L;2^*-7[6+HS&G*:9/T%-$U-ELYU-OH+;O$1*X[7EJ?PAFOJ],&3 MCG_*_VB";.G0+UJQ,?6Y$ MJXK&CE5>YMIY!R)>GT(+B).0MC3A<:>3.[:@16"UW^L!@&@SL?P"==AHW.$0F+/I.LT[M)U.0>T-U#WP2%Y1CM/7LZ M[Z4BE7XS%;D,T[VU^RMEIS]R']0KI>T$M3RV#IN<+0U>'AK!?6=UN$3! +<= M%^[)HF[\"Y(#6.'EG#:WT<;##F.]2ZMVG5H8\^"GEW_$-U5;V>^E?Q7-<-;R M2.@BK\;F0\JL]SR2V@(LF1V]EZ(&/ E+P]4,:,9HI.D@0'=:-_YX!]YD17WC M]:J\=PR?:P][M-!J7_9@-F_'_*2+=&%S.IYQJ("$O47M!1E+,3OV>:Q<9U#0 M(%FTD!B5UJ"9]\EMUSCQ;=^4TTW9.PA"NN!E S$(,GNHBO1Z*M/=(^T8\63D M=F%'8K.WX3$SIR.U^(-?K>)"N:K92%L4?76T9&F2R5'5?[WF[[.QMHL< M;3S5.+7%J=]M0"0!I6ZZ$/%V[PXT^@0-"FM@) J(SO+I$?[#TXJWD:9*Q4<\ M\NO$[ST-:D',M1FT;BRW@?L4['J07)O:3Y-[B%-"F,6T.-)_.SL]:I1P80L> M.)$V4Y2Y;O'X Y))CR*!X3A@* F#KG-5$?D8)'Z!X*X<5Q9E/=JV/O6$0RNL M:>F(LW^]@I:91OA=V[!Z2W>.LZY9K9\2FDKOBXY59$6FP*<<)[] 2_*=8N&, MW4TCM=;\[PLRNF \R9(5FZGS#C%SU/>U,G0Z>^>J='1WKC0ZZSDC1-[.\]&@ MXLR[5+-KH2Z/\!\1:)AK9!-6),GO=C7]LGGC>U),V7S#5(_:(75JH@'U!J>J M0GF.ODO7K_O3JQ%G;7H[[#CY#=L!%X?9.H\+(VZ$,';<$=[XMG;%[2\%#YN( M=(NJ[^X"K_UF %CDP3716;Q_R%5NV8FXA46G8Q^W+GZV'Z6%P5%\5^/=K_MD MV/?G:GO9P(HSL.)\65:< ;#>!ZR;]W92#G#U&W68O3E9:S?'@=\M!._J!O3S MNA1ZLP.\%)5M[_+(,01"@FQ<@&3&T;.8RM#787RM/RH;GYL*%V4+N!->66E4 MZ_&'M%BX>'AT9URMHXB):UP?$9P$P$W2XG)&LLBR%0)O%VP>=<]U;1N$'A"5G$"AV([#Q(0XZ)O.U%6R Q%S?*\BF MERA?C[JH3!=;0 QB*["!#T8UA-#M\28 T%+2B;=:B M21?S4L/I0H&ZD:\8(=P!5P1"XPJC.A)X_94X>&,1CZ19LB^AF49>"EFAN&0/ MP7.Y41-64!?>KI4(')[O !*[]1&*2ZH?PUT/31Y8TNY^F1A1))%$,3!3P:XC]/\2M]S.NCO*DF8/>]N>=53\DO^B*!(!(_,C'.-5 >K8 MI@6UKM#T;E29V(:GERE2=K 79^#>H#O'NVT<2_&.8+6XSMK,UR?6UA&2.&6*EP M($0$=?0-6U .$14_%-ML=:ZI0\Z1$(C\&)>76,\:B 5CB];P5P$JZ%%W^()V MWH"4NO.,[V]C(*U2QWDCVU73HZ':6[9O9]6^$4/[RQRXO#X=(,]8%[/=I[O8 MCP7UAPKFJQ9G$AMM.RC]U%KT>,L+ $9-#:\,5WDL8OQAQQIV];08+-FM( :? M\,0$&&5HK V@T8%A)+,PYSSLI8(% $:X#"4/[BZ] PP#N40\.! \EB923DK M! "M>,3.2/A-H .MH]4&A#4S5>YNH,(WXP'Q%N*V >CL*'HSS'=^A9O*:$2C M+2"J.^9;[/DK-T@OG;4Z;%:?7QW\2 .8HSSF.J089F#'BO>G$0_3^TR29GWO@NHG6K2$Y)]35%[PJRAR-V4R7OYY7)%V"VSY93?E8-^A;20GMC$2 MS>;X,\:MMC-NENRS_H%6]KVH#S-&_-)8S8D8N^2TX]Q(Z'V/%04>7OC R7 M53FY3FCX;@9^OY35F:[=J5%\M7>'DK0;R>WYD5V6;VV:)E>FA;2>M[-\!5OE&'K9X3-S;O)R MY20W\.V XD.<(AQ,*// +$ '[E:=8!OV]Z"==VGG5P;&.%ET67VS-?3 8'[' MY? B^;\&>6;9S9;#;2-'C[GE9L(=H3"_9O;6/\]>OWKQZB$2'-D7:C6%735@5(+A@ 1#MNK4$@ZT,YVWOW.1RS-T8(7G213E7+SB-8 M,UR:%5$OD!JA2IT@JPH&/%R0ND?)V5''W-2Q9%X/9HJAKR<5F4*@51/O%D,# M<5TT23GH;VK0Q&GA,6>"6B9 ^UR!G!LS!Y'VAT%'VREIGSQ?._X:9)>4*S+_ M %B3Q1EF1^!YLDIG8IL',A &O&$,,?YC"9[0=*_U6W<4B&^QM=:A%RMZ;O)5 M] SZ9HD5R*P%N,EDOIJ9+MRV!L*E:G,N8\!NK:A2N_/.>6BC;01LD.GA(81V MC2Y(<-F0V0L9F+?, @%BQ&;XE'7N&5A6)T(2C%Y ML-:QA$[-A7%T31+2B5F[)!C.8^9E\W:=*C^"B$XAH6F]2)B928Y>XJA&.3L- MZ]1T* 3%#,-\V*-W8.W4O\OC#' M/N.5OT&=^9H_S2O^YQ_T>/D"=1 +DZ,(HD' %_1$>29K5<_ O6;UJOWWW[S M\/3)BV?TS\F3AZ???G/ZR-W&7[VD%V(K_M%2_V=UX)P6!KWC-\?)F^=/@=16 MRDCT ;L*-?_BXN*X-I/C67E^AV;]P!Y^^\W)PWM/-O_;"\^Y"$PYXP/J/FY, M>"M8+>D5>Y$1.R,:',2X2R.]>ZB[T=0^3_^RK!NV&KEZ;=%*1)]&-SFPQ^9X M!-*M97)R[^C7P[LW9O8P^>NCQI!^1 ,C;5\[/&5]YP;M_(J"YE=9$A_R;_\ M7*?_R>]5R3B8ME]K]C8/P5FGG^D8@?FP90=7O#!",P@ D'*XD.>E)4G*Z44QH?]^'/Q3K/<^.;>K M/6S>FTG+W*\.9TH;ULG1XWN/CKY_<.^(1N;>79I21B< X(#9#"8:K%;-T?*F MKMC!&*.0[!3PD6+?*I8Z]6._W&MA'YEB0EMX.M/7EQ$#8Y.^ MEZ:5S##KD2,]WNUB8JHBT,SSO_5P1,D-N2]Q25)KYI_'CC@R:RR M==V&7 SS?F6[Z2FO#5*PN9+![]3X,F/%X@""MHB2B3E95O#PQR$>POY+%Q/I MEE9U[93?]-I>L"/V'49(24 397$67%LMR 4B^N"FK#2WI]HL^/;Q._! W-%7 MD*9J!]J.FZA)KJ1 OYI:DYYD86N %=ALP(8S5FI!H_D[+'@!J]:S[+OLS,)8 M.87,H_K6O22%0O-TH&E3)>)7S>S/AI=J7PX>,0#BZL\-B[.=HAUKRUI2$!JI.*M*VE M5W=!TG.]^Y';_N^63F8 W&VYXK^BIG==ZES%[<(@ZE5O;8&F#6PZ'5SFP(49 M(WBP(]+@PX4AWC#@S@?<^8 [_SL-F[G-[6I%W]]P9./79+WTX>AWVF09 .I? M$*#>[=$-PZD<&$CE$F6)O^PF( [0 UQ M3?CL;UBG\&ZE68F:,GGIZ$9AI-9-Q;ZFX9Z6<-P4\YH40V95=GBU8GQN)D2$,U2,6EBC5 MP558OCJ) H?>%V5\"?%@L?8-98<^%%.XW[HZ;I^PG&-;7W^%5FYMEPU@'$TR M:3GPBH+S.=EF=CF^]<6@KVGL_EX)Z3V)#*TYH%UA:J:TN,0\3!%SIA4UM1PF M329I0FNL06G"I+#G!FEA9G+.!1EI.(LR96Y;]N8:'ERR0.D7.GB!LRY-:HMD M5;)(9P9_8LRM30Q,X0]P;J(TEG5K&'[DPO^!"8-BX"?2(M9EFQGAM&QT#?,T MZA.YL!]9[$F:G'.-Y*5E%ZIO0X-2;?"7YI;+>M'ZH.:XE4*V?R617S*^4Y&2 M5('KR4"SDMDCEE2(&@GD43+&>[&B MF'W:-T?8+U/F"4B364G"6G!%PIS9>"=KN=1"FR-45Y@)/"H5%W+AFVDK@?Z< MIW6H5U2.M7@-FWX 8JZ0ZC%E4X^NIK? ;JRIRPH! M_P.?K\IT8FG]%E7(22DFQI2=2Q&3=*//L+F[4>.1Q(>[W;S3(>([HJ<&D'P/XMF'*G(( M H0HC$\,^66>.7QL.D7& NIP'_?N!O-NQMM]S2'^RJ/=[48]+GJ,V#C05RBG M$/TD./Q>M1!?$0X=80'W9<5\W0K_4(&:\E7,43*6DA.\%J"%8QV?OV/X(Z:2UNTOG1&O GRWZ5]GNYZI$!%=

V2B=JM6JJ(&N?>YU[''D*7 M@,10KJ"FV,H%7I_V*#:A&7;N5PS@Y#"=1UL>>N!F_&;XA\"@\9E;M/?]88C@ M0OI@Y'P1QM9]20M(LR;D>F=?,TV\S(>.\<19YH=>L2N)O7]J-),'L:=VE^U\ MR&UR3_,$=J@: G,U74*:'<._K>BJXLAU:YP6"Z=DNI5[6 7YG[CXND]X"MVT&Y4_>[1?<2AJRA97=UX[.037>)\?&3\3H35(_*=8E1)3SU-5SA: MPZ&P,(W0'L.Y(62?FS[+;HRDVS!68KI_<'5K_(&!^85:9-:>!.[ 55<.%&"( M$@*T03U@70F*Z@":/.S3'P\GH^%D]#>?C(8]M;^G4IO355F985O]XO[K[7OH MZ^!U@ZI_ QL6^\);^(!IEU!?\9W>4*/L+LFSXG/2GBB(KP^Z.P 2!QD=RQ=3 M8F* :/2-EBC')H9#C(XNRW@@T^F$[M18.*A#.W\\^RQU$P8K^:99 MR4)EW/.=]!>P"N%_M=2%*7LV?F=Z6N>$]VM%EXH7_>]/#TX.#Z:Q7(V84)E= M%A*P$023/$)B%\K,%]- [63;B^QR?KA6P(&.X>7MO4%0'@D78-@@Z)(Q0!E@ M\#MSJL"&.LQ^WM7X3.:Q@G@SU\-5=R+::"K3C+7_2CTR 4W)'QF1BR4 M@@-"<*PN)U:A)[0'9^6%?\*AQ#V]V&#_<66MUU%1:]SZRY^]0@&!03LZEM+A M&(A++7@RV;_R_+8M3[2RI^%,3-OVS,7!XYNUEAD=O&>^&!*_:MU[XKYN6*%F M9TC1G%8>NA%"L@S\1_STI@7:S?'L2P?:G>ZK1SOCW.K!\.79I=ZY2W>:N(D6 M4&BW7LZ2EMC6V;Q$+/TDUJ"_"PW;QH+7,3VW-FX=+ZM=C]YNP7(TX(KDB8>R M$=2FLU1J&82Q"95U,* 793)N:R!WZR1+UV*5\5L570:_0EEK$$* X"K$5YF/ M=7\VTN[Z[;0IU'&3-]17>T7<%]>%8V6JE,)R[,%WJFULZ#[8NQ="[2MFJ?CP M.=>/=T3W@R#SVCRM@L&JE1N V*A3J]"'C*7&61+;WYC,RSSC6HDC[LM$Z[7% MJL$J#:5(!!+]QZ2?6OXL!19'$FI()_@8D(-E%>:&?A##(,8%Q7\=D:G#M=C8 MK\@5$[5$@(O?,( ]!TRNG-!=M*PD+YIM&28E4%0$[%0Q2W"F06I 7@(W-<*V M,2_;&?L>5VBOG1AW"I"9JX&%8F/#%[$3^#\]?R5;DIC!F.[P:'DG'_^T H9$ MBZ8EDB8%B^/-9RE8"55/EDP:1^9&KFA%1%&J"VZDL(^56VF.,#45,;9Q#&CD M$R>SZ-#7X8>^TR;$61#U"-IHEEH2,.UM?CVXVEZQ#*(NJ7"*4Y2J*9:1;MRC M9&G<3':6WH$8P1")N5URK@8/!:%NG(M.,_Z*3-="*+)W=/O8[MW-*^&BPT2)1Q!6. M/]6$BY>,6>^ZLTL\NL?)F3N)=1KL3F$2S4X3VD#:VDAODYIW@:Q<84GS'W0@ M61WQIRPE;=& HM==X+[A0<=U_@LI:L>*6/A[[I\D:T-J>N".'>(+ _+J[XP> MY.5YNB [5,*6-QM\-1#.W'E9- /CS WRJ'U5!(0;?#.[JB1\4O*90$48?O\8 MAI@.&4Q4#.%S\<*4=Y879G^DIYS1N?J=23ZDR1^PXL=E<@9&CF^_.?WN],G" MS-+D%_/!+FX]'\S>M?*&S@65>6>:=V9)8H \M(:.):]2DD00 M=YXG$SI(T#5Z,20R+[_]YO[#QT]L3N>HDE-!S*RJ*@GYYV6 MTS!QT]OCY,TB3S,R%FIF>Y1Q1+YIK_&-F4<=V(V\&A SU[8SRK:9)V?3BAHT M@&9NHM+9KGO?IN^_GM#>I>QW@J+Q<2YVOC]?KO)R'5QIDD#H?-\S1. DJD4] M_&"N%9A +$"BC=,4V82E%LC=_F)^E;Y& R!7JAS%\1Y)ML^M3^9.45[MI89K$E=["CQ=FC& <**--]^$<)OG8J3L]/?[N MAF7\GQQOC=+&U=+.I%K::ZF%=N!KI1VR5_ODY,D5JY5UO^>_2-F0@%C:3Z72 MFGSKZZ\=^=_E!V6Q.$[KU?L[- ?W+Y^#?HF]Y&C;H)>DNKO##:&6L9M7_,\_ M2);EBZ?SM"A,#B)U _(,?$4ZXYFM5YAB'N1OOWEX^N3%,_KGY,G#4S*P'[G; M^"M@H.X^F':K6L+6J52V*QO0#A)Q"WJ)R8,%RS:"%I_R,S?MUB7(, MOYK"YA=(;QDEKWY)[GU_[_34IZ8P& Y$FZLY8+0:ZO4U*$E-/[STZ^O[!O2,:LWM#'&F((PUY*C?KU+VB,\%PW+Z)N\PNYS^-$Y\/SOQ> ML[SK00#.Y/=1NZ1N5ZM<0:81=OU5"E 7ME?.%W&8"8=41V5CY'>\\#PXP37_ METSU6S&$/<]%S *TYT0513]",2;_ZT0K'I#YL9MN3X[R\0E-X;L9@VY6'OW' M]*-W>@[^U1U1?S;U&.WMC, CQE"U9)B!_Y A?;A]5I&\HXJ0EN3BH!%XF#P? MHN)_^YR0R"@ND-.4M>!21!D%]>X8<1AM('*!%>*&.6"O!7;20WMKP?9B,59 M)R)[F8_&995G:C:B@;QX@0H':3KS6/EOA2^X[J*G8D]8Q20:==UJ%DJG!%C( M6Y/(F\]!,W1)N<2VD',G&,)Y 0?9V*J+J8>$I8Y?I:>@/)8EP58\PTL=O* 3 M(^01Y_;2?V7F>]1)Y9G1NBF<6V+_:-A&<6J"90-> M%NDIT(#J>9399@(.CZ<[4)2OSUWYJ.$1!K7X]1[MR5E(F\-JQ*.&"[T)^*+K$M>C/'Q;X:>- M(>8@+RFT4'#.K4@/RIVU*0-;H\Q(;7'T"NTH#0;)%67,B4#" M6FD+Y5*9@3%76@TFQ9*9B=\!M@&V]^F?K81A3L N>96 M@S8:Y7_N;S([AK^?<""=S>>[/R]%[T3Q2<^D"JZ'J MW#/M)T6Z[@AO@\+=4T9'-L@8Z"XRC^TL6B8$S9+STMX9Q_,>ST5>E[NW^Y$D MMP45XR(*.\ 8#I9@"Q];8+]JI'*Z<]%G9G0LL;$_];!/LL%J'N5-C*=U\J1$ M)%7&,Y0ZRB'$) ,Y3#YN.V M"MZ6^H /B6W+X@VY$ENU5V2/;1F9,3NTI\:ZXDG8EVGHK2-GU%Y>SF8E:=KH ML@9DP%%/=RV+D'=B8]IX1E1?(@#I+O[GD!A^A>@4P-0J0L@!"5($E86E[TP- MP,#!&3HK-.$ VEA2U4:LG2V*QD YTQ]@WD(Q@^Q=RXF>@')K;&*2,O+ZLCLX M-712S@J.M87[,0\>^9,3KFC^QP;.'G\ MZ+NA1L(M[_;V!?K*+TNAV.B6)] -15#K(\_?"T4_Y3HD(DEOD%;*D,8+.=N* M(<=,7(FO0$#?Z5>Z.;C;2&91P(N3\V"2%.K@\6>6[59)G,S?J0P=BB1H[+A7 M R%*\?>ON%EJFS9K.D:C2O#I$T#B)CAFY&!DY@A0*F6!_TQSY%=^6?W.9Z'- M A@=@C8F;/,!S"%J-$2-ANRCOS,F=&$R=[/-+@S^ H;IQH1OZP1\U!GB_E_3U.SUX_]0#"Q]^G4^E#QIR1I"S M]<,/GJ8(--$D=K60?%@Y">D01\PN-7MSMM!;;Z%+O?Y\C1)?U'87[%97B.EX M:3J5"Z,C#77*=6._PV,?CTAPYFBYGU0+\[&;)F8:C\9P8X1&RO(J_J&I/Y5> MI1N.!:!+L!-Z!NZ(C1=^/&WV5[<)VN:#J>BPD T[X4W9";_20S>VPK@@X.Y@ MNZV[@39?R,[=#0+.(-DN/$-7@WIGI$1]/5KM#C%?]P''U$6K&HMN=&!&/D.' MF%RHVR]9!4L5U\J/) MV)\%LDUJZX\.$IR\<8Y]1[9)/[TY"V[$ VL/71!<3J+YNE-8L.@$CY555*\+ M^/'NX#B?^8J)%).(-Q1%$S74OB72'D<=J&'4,OA(I$1N%5S[C/P4&E"IQRM. M3+*/T%GE&<$C96P$TLZ>\3);;QW8Y+N3A ?&!3C+MPQB3WLT_G[ MA3$]>:.-*6/RPV$/NN(>]#:U%^EP$!NVGR^__73!"(%-;5O5N;'95;!3?*^= ME!O4ZL'/SZFCG#7V?!<&B6E?]X5;<<$O?];JY]WN!.:+O.MZ7XU>4^]W4O9< MW]"UB2Q8\ 1ZKKY!UUU1U\TA$3?=V/[:N&X&O'Q?3%NR:]8#8/XF[E[#IAUU M6ZH30UQ]I#4@GQJMF:N4-=>EXJ6-4M:!*Z-=-R95U!2&%3"_"Z@ MLKN#4-B-ZM,CK=)R\V2;8L:%T+UL^,19X>AD_%S%-EE:US12(>CMZ_Q=1JW< MP9O3./]S3H=5H6:>>XAI8:[7(&Z&XQ)6@Y)?67M(XKX"A ?,W]]EG>6JRJG- M/+8UV(GTQ:6X. 8D6DYT9 >N\JD+="]G(+)+-6D+_;%1J+<.!)K3YHV X\11 M0/W.S8RQ9'QR[M9)N0HD3D_OETP7#SUS__;3[QF1O'T28H+W(3 _!.:'P/S? M:'S^L:A(@URCI-A@6WY>V[)?B_E.VQ-#*>:A%//V4LQ]0WK0X#LU>,&Y"&=5 M.DZ>+V'(!3SFH,Z_M#K_2ET%;Z/H,;OCA5O&U4?[I,YY5[Q-?>V%3]FGUVMH M5LO$^<,0M\/A@Y!7(75'D#M92'F(J[30*_50G,@U8MNBC,#B?=K>$->6$$-@ M\'%D/V[3\I7N_"@AL10<2IG6G?,A9JE"*J$0UMU;.H27N[)+4GV"@4>:V\3Y M*SDXS^A1J#L1U;+CH:0N.58H*UGX=F6YW3I2<4$.G?L#) 2-KN$;.HP.MED[ M:10VAOS4K$56#G6+*0!UZPGO#%2&"@_O,2]C!XI;NXGCWWJPQD4.'99%IUKA M2:RX!H^?]7[Q3NY9)G^'VGWNI<_:<6JW@0S"I9I9$&@1A=YP6E91/)[^.,?* M#4R)7J)V)#BH6P5-?VD+R! G(S[G;/?U*&K=,Q3]:=S._ES3X>EKO^./KM?[ M4?+4(%<\3WY(B\4UQD)22(-IT;%".G257K!\$M2>A3H*V1L>!1'R[JMH[>(/ MSC-!U1-6&C+J8D$%7<^01:4PJ R*1Z&3>V92JC2Y.?MX=,,0;-EN+?U*3<_* MY1!TN8DFQ6Y2X*^(G^A?@?HWKCH0D^72<7'[F5/K;T]092-U9#IKOF$[A%<4 M*=W)]0Z5#U#07ET@&==4OD9I/[WA5NU=E@V'UU38XSE!6AFEQ>#:WU,V5RFD=:LFJ?_HX MJ-VT\GIP<+7IP:796SI^+CAF92H/'E\^D"6V)+M=&6=Z))V MT^$#?#J8; $)<=XY#$R8_,Q[;7E%NL+4J+)+XT$B:'HNP:E[[U@4SA59C9<_2-F68T(+0IVU)=DD\B'?228ZY15Y6/DSJ&&([U M^'YA!;Y*]?L7"!0I]4[A3RRUA\RF:R6M00' M!SXN@#HJM-5U1R0E#PLRA!]1N>\H!3%SS28PD,Q+99X)Y.0ZD)?E6QR(_5J5 MJPI'VL,M8N%!O9<.W/X^.2_CDC>"NI21PQ91.1G#H"K=%K]:G*N?(-MFB.H- M4;TAJO=WGG*J=M:FU\"4#<#' ?CXMTOIG]8T13H21K_ZQQ3"\B78Q'FVS__T?=OS89">G#\W)H^].'GP_??3X MP8/IP\?3Z4,SGGYW8D[_W\GC__CKQO3IZ?')[3"F'S\\/OGN]&-LZ0>/CA_? MV_WSQ]K2UWCL5COFX7^$2;O6'BC#LF\/W%@'5]P6)DSI_*6H4W[__?FK9R_^ M.WFZX#YMW^E>/G_]]%=7T^4WU'1Y]70W/^VMZ]Z;WY\_?7'VC^35;V]? M/'V>_/C;Z^3YR]__\=N_GC]_0UU-GCU_]?+L]:]WI\-GKW]X_LNS-S^]^//Y MZ^>O?_W'M]^F6T[O/2$;*Z]-32:/4*_00^6' M(L.=JXI>F!PG[]*B3:OD_KV3QPBHG#YX6XM+Z:UO:$ 6*3U= M;[6=R?"_UC(8+QR61VU H850WR7^P,!(T.G3:KJNA.XWYV[^\__N%?;,%(7I M2QX"=IAHDJ)%6R1=D1LE^)[^5\@=YRC(GFRL@F.LUGM/DF=@QL^SNG&KB=8" M'6)RK-3[CY^0!,^,=RP<5VL3!'Z9)& M, ;5 .][ZBL'?,GA.?3J[\^.7/K8>\GRB(QY$LE<%^",MHH1;S]ICO-QE;19 MCA(5NH/0^M&E]<6T7/=0P>?$VZ?X7F TIU[/8"9:#LX5==V8Y1+:B-8_S<$2 M^I#588.KLFT:DZ;2*:'N9 /;5NEO<'W\N:&BJK28;7-P#&9@\()&'"0.$'!Z M<.+Q ,^$5%HIHS@*7[.3ZC4>PCA!>L1DC@1E4O-OVK'4+&"E_T9\6*8APX>V MF>>!\MV7X9S;51W!"03$*:4I)))[DOS"=N%:#<,H;"O6T&]2XX=:& BK'%!" MRSEDPM,EWLBFPYP9(QN%;) 1!"%IM.:7M 7@V_'+V<_G]4W/HSI>;S?_;I96 M_]R;S-Z7QV,90:9Y- 6B8/?;O]']^,+?##;,I :P%SY55QBV;N@OB-YMMI#_ M_A"BKA+*R#// M7^"J$MWG9OD6+[/;_OR_W=[KUS92@%H!?@Q33 "":RX@,9N9*AT%X](EMB6O M-'NTQO9[%(M:&4CH1^0=7-,>;,K5O@#!C;?EMX<(3A #M5F]:HN%%KF+3_QD ML2?G..3GZ:R>5C;QKL#@86,B337HC?<1@HAC-5WC634?$/Q0ZY'.,NS,EO0/D)W!>'0 [7XH.J\1:"=[B>YD%->O6AQ"&\JD0S:26RRJ-)I M(P?T0E]=P0/6/=E]MA/=W5W!SX3E.+ ^ML6TY?.6AS&XX]$.W &#/I2H'=.K M?#V1(AXVS&NE%',1;C\QD=UK!5_"U1@[-9!=25?>Y7X0*+2DE^*(XT$U/Y1, MT#1-GFF.P+9RQ74[GO@;V?1#>4"7K2<)&?1Q8NK:86@N>4?O/"?7^T.93SY, M50:QD_ I'06/C-1"Q-&AT2JK*+?L"E0ZR]-N07#O!V4/F_M>U7"?5$.D6S>W M]]NQF]\Y]>"F $Z03F10G9WU AE<.;R#U*@L>O M.$[T#=WXM^NKMLMZM_*L[U;&V&6M/+\H9YQC*(M$C"U\U\"2.4]6:2Z9VL&VNK5LG_3N,G%LVG+OM$C]L;(W4/;9*[,'B]A&[ MI"YS$Q5OCRP-,0!BGY\S/U"N@:1S#<1NFB6K\L)4'$CP=@#M]V470JR-<7F] M(P>CA3T0/ /Z=KEXVZN1,9:9B<5)A.:5*5FZ/1AQQB(]>0E^5JU4K]X*;81: M'E*4WKWE#S],G:;LHN%P? EQO6F(<)[:92RH\A+7AAYSZ,>FHIT^.G[TZ):F MH@WHV2^&GKWA>\^="JQOW^Y.:;M[669%QY&D=L?1BMEMS5^V@[\46BK&(<'( M+ RR3K+D]'1T>GJ:_*L)!UIY=,H&6R'NND1./(7'09:KN;O%[0>_:V.7_>F" M<5@66"$&)D@'?B5F)%N3]3E9*$ DDN+GZNU;3ETVF,FWW&[\2M;NGYHTQ;Z= MDIG':,G>UA7[K^"S(GN:C#5D:M%R/:;E^I] BY@4OJ2I$F97-L1%9/)SU=2X<+EC9;"%RZI=)J]PJO) SLDQ:E]NR_,5' MI MSH]5C#DGQ@D3HFJN2,8O>.4[835*TR[%P:C@KP86XR@XS*W=? ^ MU=DE9-.)8D)MAN7A7&];]PH7CK')%B1>QOLAH,582V-J467.:2OL;%X[3AR# M_.Z5W^?O334!'\VJLI._;IS='%_!JQ+$0U'?I%H$,]V(*N1TWUZ:L*\>P>BA M&M##2:\*PV4Y]TRH-R(#=_-(W?-?_$SLK=;;;&^32]';T,:B* MF>6NR'+3[-JEHRB%YX,^VYYE![,@'$L=H]5!9J;42D0L@+*X69C)MVK:JQ\Y MH,6_:"+.AH/@$/$P^H:F()J/A-T =4M_871;L*:8?)Q6J.24L6'UUY''GS3> M^:7R>4D!_&0@@_#NSPQ(-GX^1W5LV^Q,&17/"Z>KT;\_^#0SJ>AD;K9<;U2@ M^J+RO"'.D9HPG/(G4NSZP--VNCEERQ=.&4+/_6*5^1P_\D6 MOVX(Y$M*:B+?HPWU4EI6UY;9,DF]Z,&Y95]M%L$ DBM+I>[,]!,.[SY-T#N2;W)P=T(F.&]V5\X8;'V[P[3&9,+B3^:3R'5ZM[ M$+P',@X%YP!?IL%I1NC'5FL-]C3 3I&-;1P@6&F&.&3P4$IO5G0"G/"N@&^E MI4X8MN39*?M(U\[.H+-ZN)(6JB162"I=QTB7/6IQK&!L*L:G21:T7HJ*8C$/K>E9= MI6>RPUUR'.Q[%+(ND,;3''6SO';U.&.,=0V\3,' 35 )R6II@L7$(Z+AI8\9 MC6'=T+KY$9Z#"C8:?0F(!<_#"@=Y&O!:)DLV_*Y]A./Y)6LD9R.'D0^:O*(Y35!@]&Z6 MO8A*3=4VH@%(3V%TA:2PZI;A ERC+<(_7=>V7JAH(\I!Q@496C-="/(&>BGD M%14'&V<"@A<#F70V 9:1EL_#KJGDGI@YW6HZVY?HU*-$#+41Y)>V@"CQ-]A] M?8+%@I0G+0JR1^IU)JE"6'CB+XY_+2M!KAQMK$#$^=@D=B-%4[7 C5RX2%\4 MF;T[ F$]R*;;KSGKV?4ET_WUDM/<-@N9]AC\U&F'FN4)K D>0I#8==1$C-H, MM[I\J@43V,2L=X-&@$;X^3CYM61^\GIAR;C8]$+'>56DAKUWI1YUO2T@B2"Y M8%A5DZ"P9[W-[8+%%QY^F6)IY6M=")"_&QUK @P&Q3F?IFUMOG"<23+:#I-Q M)^C!DED(JL%N%^+W&DUH;MC;PS$$!5@]TDZES\-3E>;0,$DH M-4Q8;MGKE;LT221V>DBZYC*Z &!$#[>'W01=5H9)0ZCG0#V^L'"8# 5 MA?<>^'&9II:VL+1:F*R.K#*V\QM/.#)*%ND*2\.\TZS-L*[QUG(;LJ0S7!O[ M38VS0).F[:U[0YW,T,6EWUS9%'X&<@QJ7EV0C(_)_,3TPTQP&;'N MQ*/4JO3B^^Y(=-67#+L%J(9H>_B%M?F?HLWI[QX"!D303=_3/C>5),^98G[. M)T\(-WMM9/EWDZ/Y%-RL^53"1)*F82 LJI/3431PKY#@BY& &R\N+V\S)>-?()SP^B\ZC MKUNN6OI"Q2D2&I#4A$R>L2E?S>A3+^D'*V45KR&_5LN\&%!?T96;O\$_L&O1X2 /WI1G)=Y2Q9?M4XBA2'2%),1>;53^W*X M?4FS_ED6O*-7E+MQRY3%$#$VE7T66IQS1KLV2B$F5=K0!]3:%;W%K6@+S3M3 M0E*(UAZQ"IK4UE++-A "4\>86:GA KNUU-86IJ/ I\E5D>WF8ING3'A(1],6 MWC+H^HTV\[NI,;1JA9R _@S5=WTJ6G)P,3>\S,J*F0ZDAX?<,"&>"OEN$YJB MW#2'.%8OI4N8K!O):B;OB)P\&=QX]K0'>C;;Y0>VC&#C)FEA8> M/.F##$QEEJEE2^\JFN K4P2W_?E?"(7TU_= QP"R2^F);HCL*I+Y-O<5TYEI M18L#<+0L1KZTHO=X!J+=[]C3=IU=PGLCMFNI-T$(E M4H@X/]A.MZN0#=4>\>E!\X\-+6FS7>D[PCO1.]QKZM>5W[3YO(W$Y4%)W)Q% M#*#1:P/2<*9_W[J4H]D>PQQU5^]=U8/M,-@.@^TP//\+0IQ,VLPOU6A9Z[CY MX8:F.RX_-_FU""J,S8=":3"-._V4"FU&C-XI&;J#/=51O%]'"<;>(:S.8^T> MW6(N;[ELTWM&H\\6V!IE,.]FQ MJ7?M<]084K/:;])PRM-&P;8SIH1VOH29(\NZ3I;^\:/KSVUG6X@GFIVQ_'*F M^%MQ8V@SM9-0^CM:9K=9)F[[\[\ -BIY9NMT3,>Y9OVESYSTK30$V\#*5"CT MP\];TJLKFR(6W%@3JO94(-(S=/:P4[-TEN\$=MWSL34K8D7<.VB'8T,(1W3%-? (SFU8*_0DI=NL&E M]:GTZ=Q7-O56JYR:.A8V4'<=V:QCXYT?LR6*PK:G M%#&I>P?.CJ$N1*=;C@1*NRI' 29'UV<8F@E'&NIO8"YD.7[=5> M'2!3)X:D9SR@BPYC-X^GEMOPRTSRLK9"0H0&3OPP3&08+EO=-W\ARS3ZYFFOY8<(.MW-VGQ8LJ0O![=-R@:UT7MQ5-%S04.J6FCH+ MB#3CY]H:1AR;0^5%0;(UMZM$D4E-M'9YM6 I[H1^8)VLVFI5UJ;N'F$'EK2! M)6U@2?MB.+:'I$F^_>;^R<,GB[(HEQ8@XI0V_@6<6^?,UYF[="0'M+Y#BC5. M'08<4SX%3BU.)WSP*!H<^E2;!2G96@F!0RUW@',!O75@VIH!Q#&[:ORZ8^X#,G='4SR)8]BCI?^,RL%(FFL_+\VF&J;\ M.C5G.7)72=:%KCR7T- J=5FD(I+*UG91.IW0EQAY0)0CLLG;CU^C>7/OHF7= MR2BJ-W13FYW;A:10+%G#N!P1K9\Z$S:\/+K2-X/;)8D0I@D*32IQ9>R5DV:@ MSE6M.F66 HC 0'160)*=MSE<798'9-#4BS:K\2A21+=9&N^:M MAAZD6FMG# M\TAJ+&17LQ!@EUH@):Y#Z='9&UGF-FR'42^_.61):W9T5$EV[\YHX\13?*=U MU$R%M OHOZU[II=L%(07Y1-N4R"GB"S=!%7*NR(E#XKCA70+^YET!"L$MCY#JFC M#7$MJ5PK;,Q%XR97O8G_HX[>G)%,Y>5JR:$>AL[D=>ENF&D&4'21^TEP=.*A M=RU_ZK1=DZ]' J^5E9#,6C9&C=:R%CM40MD[QXK[L[8FSP1A.;4#-N9:F@F% MLFG=*X35!8.HTWJ'T;N<- >;P*PPD4^U*[:AY;-JH]Q9+\9M7; M@4*5)HG?TS;5TDE<(DHHT]ER#[@,*2PZ\;)S:%%,0K#)>1E'TZBG*9VKZ@T" M]L_@C103[S\^2H"^D+2\?/[ZZ:]D0Y\^HF7\V_$H>?'JZ2?+-?^[.W.?'I_\ MA$UQ!1G^&8KD=9G>VA)KOYK"YA>H93;B1_X"LI/U'=)5?QR_.3X[3NY]?^_T M]'.=QX9%.2S*F[(HO[MW_/@:JU*^8HZBYG\=/7AT?/^+]?J2E;H_.-SU@#R^ M(A?)C0DI_\]QF:WIGWFSS/_/_P=02P,$% @ R8)85EA&@-D'=P 2/X" M !X !E>&AI8FET,3 S-BTR,#(R86YN=6%L<'-U="YH=&WLO6MSVTBR)OS] M_158]TX?*99BZVI;]IR)D"79K1Y;]I%D]_3[9:,(%$6,08"#BV3VK]^\U04@ M0%%N6:)I[<;IL4@0*%1E9>7ER2?__K^.WA]>_/'A.!B5XR3X\/'5VY/#X,G& M+[_\OG/XRR]'%T?!KQ?OW@:[_N=?I9?_G)Q]@O>:O>7),L*W8_*Z,D__HZ?P'^UBO[Q__W]?VUL!$=9 M6(UU6@9AKE6IHZ JXO0R^#W2Q>=@8T.N.LPFTSR^')7!]N;V3O![EG^.KQ1_ M7\9EHO]A[O/W7_COO_]"#_G[((NF__A[%%\%[L MAH.]P?;6?OCL6;BYM_ULL/5_MV"0O\#E_)NBG";ZOY^,XW1CI/'Y+W9V^EO; MD_+E=1R5HQ=;FYM_>T*7_N/OPRPMX7DY_)[_R;>9N5FIOY0;*HDOTQ?T2D_X MI^;K,$NR_,5/F_3_7N(W&T,UCI/IB_\ZR&.5_%>O@,G?*'0>#_GK(OY3O]B' M,=%?USS.9_#C)$ZU&3>/]/C+*![$9;"UV=]Y6A]G^PA#F%*=/^E\NP5^M<"+ M7<1C702G^CHXR\8J[7C%K:V%WO'-V_>O#MX&%\=G[\Z#@].CX/#]Z=')QW=P>G@< MG/]Z<'83L]?X2EK3?"TY.#_N@#[;V M\5_'IQ+M[#11_>'IQV3H+=N?U-NWO-=U%<3!(U?1&G-))!DH6?7U[I MO(Q#E;/;W)N5">Z>V,#M;^#M>@3B- M8/9?;&QO]_>V)K?0%7>Z""=],_+[?_K+VMQL[?5WG^,\O#D^/3X[>-L/[F=D MNZWS\D[GX6C!217 )IR>> M=&463+,JP*O5MP8RD'P07^$[V%0+X V[W;QW:P8%>&A?PG CNED9DD10X MC?@=WHN^@C\*';Q)LH%*@@O[BT/[B^:84>#8N&E_P,PKP/0?3"8:+OCR\T]; M3S=?OJJ]%3W3>ZV/::(+&"=.R74,8XOT$&1K=AE[0:@F<0EZYT^4%QI+59@+ M\:WD=4!.0+!JM^$)N.7N.(1'#?+XK^V*_@T&4*N2':LO&ZQ5G_7W=F#;H\W% M'SSE#V;5<)NI]A4:_.E=:/"6'Y5JD&CS_2#+(YUOP-PG:E+H%^8?+QL#IA^] ME+L-LK+,QB_P-&B^ AX._/7+F0.MA'&64>.\Z]-7OY31['>[S_O[F]U?;_:W M.K^[H]O^0D/F83G[C:SE!7FQ/ MO@0@P@'^[T[_V;.ZF8-W;Q>R![%B\9 (+J83_?-/>\]?6KF3F?SZ26(S;^5F ML5T5X=FQ$1RD::62VA0^"ER[P!V!#_XH<%\O<+^IM!]L]3!,L?T5 B<*?\YD M_4@BR58?F,1Q%MU2*/_Z1-Z5V-XTO3S2.1;(4\]'IT%O]Y_MS?CM_.$22#T9 MO5M;+Q>VE);]Y8XT^#L[_':[#=/6[NQ?R&Y;S"[\*F/R\4??]8\Z7*':#39G M-L->?_?[\B3V[]KD_[[U^"TUVRUBA ^I)CMBA.\^O#^[P%#UZ?N+D\-C.K ? M-#I'T2,*M@6Y_D\5YW!K"KAE@1H.XWRL,':53 ,5AAJ6/R[[P1_P_<.-F64L MTF&6*PPUO:A2D%"\ZLD_WGT\OWC(V0R2[#* JR0JF.67*@W.2Y4F>AI!9ZX?9F+XI)B'][^."KF!9=A]NT ;@[]9)]%G8 M<1'IJ_[C@L&"O89#-+NF69GD6:BC*L>P;!'F\4!'(/?SI-[-*D6%7<#Z.BY' M<1KL;P:1FA;]X+6*$[QQ?1FZ@MAS;Q:,U1346E$E)<9[AUD^U'&)-S?A;_/# M9CCVEC;KYE>M\&[#L?QW!9(ZG-:36CM/'^ZT6IZ4UO9N_^D^3L31\>N34TY4 M@ZAD.4MCE4^RPJRJB?C7O>'Y9NE>ZTK#W1N7>2;#Y3%I.=1-.]+-(]5GL+4%2B=DG4&[7/\X7RYY-3+I6^! MT12D&H\^D%4XJ>.K.()S>C"E*_G&\+<")TU=VC,QK4A2X:\"WY).6;DKR3R( M3:FB08)*,"P(5P#+-C$@TCD M.E$E+4@6K&VMXX/*O I+6J6B!XM7@$T%5U1HQ,$OE23\X5B%!\)Q"G88)O'Q M'O38'CP.QI%OT*TUZL*BA$]Q(#%(2DAC*&!VXR%X_S D%8)]7HC9!KJ13&U\ M#5@Y& X997 #6)5<93FL%^I2?D74I(0""*JT*BJ5X,_2+(6'AU5.DF:FQ;^Q MOM)DTN_MOPS6MM?A._XH L0;Y9F)3P<[E$FT\"\!\R0$74W$?P\](]5D:5@ M#DZ-F8GOBU.79XF_2\@!H:60Q^^L!\,$9UQNR+8HB$&**SM2*>P^V(1%53 @ M QZLS=!WUQO3RKKG3)O5*41^8)0#C?8Y(DD0X9# ^R9R&YS$M3V^E1X.X:UI M7WL+R\.@L>&G>42R@R\:?.R#K76I4YB0Q$8"4'&X7T]@'<)XDN BPD!XO7P! M2/1E7"043#"/ZM_L!O^ "F&Y#\$/YS7TU0<%_E>Y7"<@[%M$7.&)ENMA J)N M#B-5EBI.2472WC G7O/,Q+>\S$#1$%P(/4]"#-$\!!,%AV6N)J/@D'8CWA]. MPA//67H4Y^]$G%_'"%\C&V6Y9-C98(AEA(]4"9R MP95N&H9AZ,=9G'80^%/51)6/%)V'(,>*(>($XQ&W9+?&?^\BZV M@'?S'7;='S?%W6T*AW%9KCT1J9( G"#1UZ,8A%AU (&#V,*'%Q30W4-YQL"HK:$!1>661!DO&=P849@CW3Y:'S05-4 ML+GPK/5/SYG+UG*1W M/U&#(L.PR6W+Y/B_H]Q9A)=Z8P!+^WF#5O>%2J[5M&B@I;Y1=9ZM>[I?^,7S MK?[6YM[7H"^V]_N[3^\>QPVWW7RV>^>WW7G>WWKZ].[AX<]N0'JT?']+J NO/\3;VL'892#P:=8-^3^1@3E_4S6UK-."^6!9NLXB8.W,6C^ MVTZ8 1H]M/QM@0[L

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�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�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�<3]<6>SH"UV6' CADQ3#3^TWW?\*-\/$_:WJ3?'99.T;K<*U5CJOAR M:&MHH(?(23_J^,%YD3Z'8&D*QT^H;H8]6;VC-G!!2\I;XQ7+,;.- SYXFFGB MR5VNCJ^WC,\D8CXO$FXA?U^TC,T[ # 8ZMYU\7_2)BGQ(HR'.H[355)3R$( M3Q7#)4 ,JKQLTU;0F;A@TL*\RG#QUH/'7_ MT:($@PM,&K2SL\CN>8E#-Z@?6QWA_AMA^ WLLQAUN1P;[%_LX!893C0,] M@[T5=/U]_3ER'A#-^4MLEU,TK/KZ]!4 NFSV1$[QU-+!(F=8Y?2<3K:G/]S; M/ZCJXA_AZQ$DF6*EKI@JTS(HDB(\*7>>R^@+Y\$T- I,< :Q^Z#I+&1'HHBP M;W=V_J9(1:S_J_8)D!$(8Q .CBCN9R<[L&E9""^9]">GQ*HVOF M(RU:BH)V8])G^1RPYMPVK%%*TO)2@J_@J$UU#),LR?0PR5('F)+$ *PG6:$V M2?^B48QQ6@NY:AE%MF4 N+7=B2I;X!DD(38(>6L*T;7Z&^1#'ZQ+6>O=>V+Z MXW>NZSQ%U.]1[3(GZH+3JOW MHX\]R%[VYELR]CAK*O68-CXFQ0'6_2 M+3R[P"0K-1!-;?T6RR'MWY*),A]TZ+I5G]5Q/_*9$R@*'[O'DP;-I$M0E(FA+GMGX+*T@8((Y M3WW=<35NVDW+W$/183Z8WC-$A?KT=U-7>=%JN4#W+%S>WG?? M5"7]G9%_9;[>+08 6LM"_4G_"B)8HV*1+ '0DU0I6CT\(&8K5*M@8>.)G.M8 MP%'J'>6/EYV&81^T!KZ\67UN6A2Y8WMD^[J?#8N(RB:3@)53[C%;H6I1)WU MQ^],*BIK7_3W/5'@5C[3 W\0&U0QN:>@JS8 //-!_A:+RIOR4W!#.R/D$)"L MA&P'<6">A8H2\6X-25VO8((+)X,%W4C!^XWOQE5&[D6&'S'Q3'CI%WG4\:TI MAOGP>U?X&H(/]+=ULXUK2;_ M\EG!17>+3^\NW :N:V*R062EGH0 " .0 (BS@P*-(P]!G,/EL_VE;9C*]2R M>WW7'$\WZHM\R#[ZDLWN^'#C&P%NFIS]'CMS-\H8@-0/!#0ME:;% -S(*@<@ M>A!?P,

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�G(=X#'V/OB?RZR66V+5V;RSBE$6&80>+Y(42,I%"1FFXH M$R<$>U1*W^B\XL5SYT9/E6C5*82YAZD-5+]G;Z#Z(]-%K?GM<,W-?60#$9C( MUV6$A)6WZHR^'5ZG]M63>8_.B-CV IW[M7T7S=_(C^QA]U#[5,/(9PFB(62! M8(I2)%%&$?=@\O]S]Z[-C>-(NO!?0<3[[IZ>"*.7%Y $8C^Y;KUU3G6YWBK/ M3&ST!P6N-F=DTBM*[O+^^A?@1:)L70 *I+FG8\9E2R20^8!\D$@D,@4A*,8A M"B+K\IE[+<^-5%KA[,MD[N-TFE$NTGYD3FGE\ICOXJBV%U3"W&]OLA*8!]7H MU[X\?,&P5+C)&$817!E*)4OXXL M@!AE(8PE413%-(U5[+)0.=_EW-[3K8C@CT9 QQ6(!3KAGL 7BY3'"X"\\I0,;>=20JSC M3S_(5?ZDEZI/LOI:KC_(*K\K3&JLZ^H_I+C+B[O/1;5>U0O::NO3J6[4I[R@ M!<_I\IM-R%_*)D:]%GUW6EO$6:1XFL HE1BBE'&($XY@ MF'",(TH22MT2M\Q!J[E1=^M W;E8/RHE>9,1NH>0B6L".XP K4"+$NC!-)3. MW_(IOV>KE;/6N8Z;3F%[F3V_$\AQ7B=G.0=QQ'GB.V$-:_]$2^ M G0-.JF;W&(>#WRXH.3KZ(=5G],> G&!X=5Q$*>;AW'15[DV[7];E4^YD.+= MU)Z&P3+2YH;UL@PNC,\NG[>'=']]/0U-P>_S4'>1:!8PM-(0(Y( M %& $DAX',& ())*(0.$:9<__=;>\#K5I]4KMI\)_78"L\N(9D[/-GD!S;CW MLQN8HBNR5@I4O4/UA6O6P).#8<=G%V,[47WW!JU^"H)/?X-?/^]E'?#'5C:H M>"*GDUU-RD4V2K^D'JM[AM;^.K$6;0,Q9WM%UVROY6]Z#;W_G_D555%N_+U6.YZI?+3A*E"!<8*H4T_:3*U"6F<6W^ MI)BF<998A^ >[65NA-,):A^2>AS T^SA#9:1^:*3$?2$'' J_CA,]G&\7N": M**KW$&Q^HGO/HG BUO?XO9-%_IX5OQ\'?/YB7Z57J_.%5?:]_%]T Y_7\J%: M9#@F-$T95&E ()(,0X8$A2S&&8L#*K!CO3V/PLV-7P_54:IZ>=#W%7QQV^F\.N-^FO5I /H'9)[M4G\\>?:')33,GW)J_4B2(7, M,B2@%$(O[85$D,81@EAF-%*()5G@%/?N2:ZY312[=.^U7E>@U@R6"FK=FOP9 M5V#OS.E60=!I"/[8Z0@^%MKL:TP(Q[G"U\C;31-O,)XCSQ!O,Y3N*5?] N\K MXZHGJ:9-N.H7RE?Y5CTW/VQ"^*TLQ9_YY8J4MT9_LS^5U[_I& KZL!3UC:0 MVU&*9R#'WO<9AJ$SK3B@XHE=;'JYX;_33"NJ:3LX79 MCFQ& 6]DRNG+_+] &Q5GQ!Z_+*XS7-XRR-GV.W'N.$-5 M11VE6RI3R-M410K_;O^ M3&QX[=%8E]N2LJ9H8EL@TS[Z[##XIPG)"Z0C4T^'YB=3#G8GX:7 V(?D70S0 M1.%X5H\=;1\\\\2=>_8\%98YB=^)0+[#]TT6Q'=2['X W^D+AQ9HZ8HK?M)" MO6].@>7%W>X8V+9Z^+=R93ZX7J]7.=NL:RXOOVK]]$U:UV4=2ZUI3U;K!18Q MQVD6PR#$VD1D4FHJI@)B'C$2)D&8!@T^V MCC:^*<$9%A!EH81(8 IIEBH8Z$$/<)9PSKA;U9XW']^)JAGGO?'EN_$MYS6^ M=LN+MQ^UD4V"]F5L#@V>>">OZK6*7K+U&-\E+^\*4TSUL]#V:*YR MNBWVU-4[NR[$%_UQF^-4?Z=-5_&Y$"9*M:L&];)0U$*%DN,0(6U7<&Z.!S#( M4D3U#)0J+F*):>@8"32A]/.+*_IMVY6ZJ%O\M<(^227Y6.]7_7+ MYV_?_Y4^//[[!\?*SE,^%VYQ"#,;ZZG"&GIJ7X&=XJ"O>5M-#VRK$IK'H:<] M:-4WLUP'0%-R#[PJR><_7&+"@?,.33\T-> MM2",?"/(?4/5F;9^^&"[;G7"]VOZU M$_D*]#0:\_"J%7"CG4\]W?L;'T&U@N;\*5.[9@8FF7MX7);/4OZ0JZ>$\;QTQU?D;4CD>G M'Z>QPV?J,:A5 -_H<^W N5ZM]"5U-.L5:$6^,I[JCG8]9L/SBJ>OO'E^A)HV MPYY7(%_EXO/;^N"=Y[WC8)^+ZS8RX/LV,& APS@,6$(A43&%*(D%9$$:P"1" M&0LC&68(=\:I]4[CV6X'&*/C1_H,"]AQ0MMZU\\/@I/MX;T\#&JRJFX1_7X> MT2';;]80^=M,.]_EU%MCUB -?X3,%VT:TN2_WI7/OV;OJUYW_4ON]?\8&.3O,ZGU.A>VY/7 M# COC7Y-@L <$WXO*/7?MI8>Q#N1MVYW]:LY4+"*6Q)(P M#%,LB-E5S/2*B>L_LR2AL69%272B*]]RV_Z";W7B[_J!UU* MDZORAUQKP[*N3[ 0,4NI3"*8I3'3C)>&D/!(095F:91&",?**0+=K?NY4=Y6 MUCI>JS("#Z@2XS@$0_2C;7*>[/R-]SAM@#F_Q6G5RD [\+YP6R',VV M0V!:6F<70C3ZQI]!Q\@'/EN@XVYEG5#?ES%UJ(MI;:832KXRC4Y=>^F2[Z_% M:AO(NMN'J[Z72W/Z\T^Z$B_20>"$1(R' L:A.?HNLAC24 EM%\5QJ"C-(J2& MK?]<19D;;?3E[V]ZNS+'\+%Q7?V-B?B$2\&CP .C"6A5F2BEQU!,O:\3G05Y MHT7C4,".KR 'M^B^?_ I?Y+?RKQ8_] &>E'_)?437JSIG:P==1\V\J:X_;.\ MO2\WE;;"M<5V>Y^OUL\_\I^MXY?$<9H02B!&5)M8.-:_98K %/,L"V+$&+=. M)N)!GKG1:O)KEOP+*/H>Y-3>W>YC@,[O7TP,^\C<:N0'M3J@U@C4 EHOT"@&M&8#MD=\C)?]3LK$XS;1IDL]7(_U^%7U^*GZ@]WX M[5XFDRA%C]^Z&S_S_W4S?E7^TU.V%(\HG]C+\='+9-L^'B'I[Q#Y;/;2E45] MW.VQ/BIN:G^_,%4%83+)DLPD'#7[ZU+H20_%D">9,COL.%1LV#+B9+]SF]Q^ M;!X>Z.K96+%_EZ8BAK9@KY_DRKRE/46 T<3$DGV0QBV1%W7*!U,40[_ M9_0 MO+A__?7'K]M/K4IYZ16\*EQ&7;'[)IEAM6>'E?6YSN M]8T6$E90'%\UV-U^2>XKO19I$FG9MG>$_>"*A*GL;;C(V\(CLQ"EX W,-//&5"\ M)NPYUM<;Y-TYH_;A]#GG;G+W-WS(J\>RHLO?5N7F<9N!Q^R/-QEZI-@EZ/DN M3;EQOMZL]"5U5M1%R$)$)6$0\U) M"+@1T7[1>N&HG/DG,.LKLY?O;']DWD\Z,O:>A.E&:"(G MPL@CY>1 \ /N"=_!A1U,YC;P T3?8^"IQ8'. GEGGN3O\M&DD&NZ?5DW(XLH MB0(S93$N]+RE,D@(0S!-.$4LC(.0.A7>M>AS;G-3*S+8RNRX5+= V7*9[A>[ ML;<(7\(V03T2>X!\KIQV/6X/P:NUN,.M[J9SM](OU377,^BFSB9 "_%M M5?ZCSB7^*F-$7GS\:3(6EFI;KZE4QM'3!.6]\'31"%-,9 0#E.I5?!H)R.(@ M@ S'8<"C..$IM;6M1Y9U=@37V\SO*5S[,+)EIY: &UEBL@ M=K.U'EGZX@EYW#XA;8884/9XP5RAS)/QU#T9C_4N2?-DF CIQW:?Y+$^-_+G MO=3=K._EP=:DQM-DGM%?'VW4TU[I1,-]8BTTM@23+98F@K*_FIJJR\'G7N1J M5<=$]=*2=I^VN5;>T\=\39=U8M/B2;_MY>JY<89@BE3,!8(B"4-CX"C(1)I" MHI\?3F7,@]CU',P%XLS-AME*UR6JNNHG,W8^'7/)0-DMYJ:#?_RMV%KD>AND MI\H5V(KL]<"+!]3\'8"Y1)BI#\1X .[ 1D?K0YU7]7%#7[3G+ZBR^M"7 L3 MFE&MC;_L2;:]=^EU,\*1"!6&-&$J9[ ,Z0&082PADGJ]3E+%84S"E!.4D(2Z MU3T>:S2F<3&^Z5C8NA]'0GAT1V0+[F\]D2]\3 M.RH'P/+:93FDD4M#*U_6#-#]_E:6XL]\N7SIE,RX"K#$,(E,RNT(!Y!0):!0 M$6.$QY308%B8I;4,D,T?'H2?>F?/HP%B(@62I% J4,M'%M3JC31)F(RC!6))0D MS9!+%=##W3A1V015/+SW['2[R)\R(H8[[";Z>2%_BR4,PR=1' M)M^MZJ 7LVZT?Y72J &@;T-J"$"-07=OBP)H8>A?VUZQ1>*J.[&"KNZ<[Q_&2ML8F:V3J=?Q[Y*:8#%Q8VKS;E;FD(*^X&MIL@$U?[ZC5=XF M2D8HE#2D"-*(IQ!)@B!.: 09BE(I8HZSR"G_@#?)YL9KN_C*NI)W(V[];O;E M'Y;;VM]PVA'BFPS2R(SI:7R\4"OYO,)T:D7FC_[_1G_K!YN+Z[6]5US[[+.Q-.6:Z>?\^7LEJ7A6S+ M#E:+$*4HI&D <1QH,D>40T*3 )IR!%$2(1G&UIZYD62<&ZWO1 4/G:P5>&RE MM7>6C#6DYYUI,QBHD:E]3\/]XIJ-DG6ZM9Z:5Z!5%&PU!;V!WNK:%>R<-R=?%@CC\@)5]58/4_FD1H9NK[C:>RNAF9$:@-QO\KU(@YI M' 01A0E7'"*2I1!+'$&*&:>"H( 2[!8:VV]^?I&OG73&R_&+_&D.W?QKBUY_%!+4?A0"OJ15E:N\20W7Q#6U)YP@J&23I_-? M_Y\P#?X=_\4UB5)O>!*5$9)F MXW".G=A#S&XY.A2'D R,.J>LM752OZ8FS0[U6ZG4RJ /7#*/-KC:M M9F&S%GNO%V=F!U%*9<(\(QBGD2;0 .FE$)&:3Q&-1"P"' KI\H8>[F9N[^KM MB@II#H8VY94?&V'=7MLC@-J]P)?#-/*KO"T]W4IX!5H9_;W5IS'P]'X?Z632 M-_VTHB_?^3-77YA&\GJSOB]-"=SKGWFUH"&G+$ 1 %WSDA M]SMYFV20!Q4]F@7R\-7N#M3O)JWWIHX:N"OR.F2@+$55__@NUYN5V?W/2W&M M]!NX+C_^?,R;W%T?]&)N(5."1:0-=ZD;-K6\%*0R2:"B3 6*,9ZE5@>X+Y9D M;E3R;56:X FPJ@4WF?*UY/6*2V[EMG>5739(YQV?DT$_,C.U>H">(E?U(9&J M_0\*Y>%G[D[D0 MO<#0=Q3Z:7!H[4FZDN]H)<7[\L&FDM--D['];[): M2U/-PIRX-(E6;DOSTAO; 'V#/K7M5" &HLKT**Q]^!\[#TX MYF-]U0Z5*W#TZ?-9J/2-!]=;-=2WTF/BDJMO/%ROZ[J^M4"#C^"^*$K](3?4 MG6L305:[W&4+C%F:9(S#2)((HC!ED"2!_I%E69B(A&8D612U@.+6*6^85?]6 M'$@:#GPEQ8A\^)@7L%3*[/'=K.YHX5IZR1I_NSG**YQO67RIE_OS"O1T&+/: M_6FH1JMS?Z3;-ZYP?QJ,\[7MS]Q_B<_\2UE5G[0*33F6C>;&75I[O:HQT8V\ M)MM%PE46QS&#- KK?/,*$A43J-(L(2&AJ>0#BC%9]S\W*[YU'YOA!SOA>V4? MP"]Y 82),5E5QG,&*J.&<[B!VR"Y^.9'@7X:I_TO1O:_G "_/I0(:A4:^]FW M2]\9/*^^?OO>WV 3P!F:P[L#[LT,WC;0S=75'K62NYBOUK#4EL]#M2 B2EB2 M*"@%DIK\0DU^^E=(XEB;<%PJQ*WK0]EV.C?&Z]:>IM"F0X"L-<;6#GZOR$WC MRZ_YJ!.Z%Z%ZM5W1WXZ$JK-SWBNZT_KA+T5YB+?=&J[SCO7S34WM0[=6[H"[ MW/[>8?9K5Q:XK0K\=6,R"=ZH>DJH>FO]>J)8Q)&,2!A(&,5U(%B001H&"8RR M,,H23"A"RL5Z=>I];DS>%5+6T^Q#632&:07*G=2U[=I\[&BPNHV*G;DZ&M8C M<_^KPM6-Y,:_T6JC#&KEDG?Y#3Z&- M[Y,N#:7^N)=R7:=5%?6.)%WNBD)5[Y[WJM=59\K7-2>%51JG(D@E5$HO\A&E M(:2*24@QCP6/XS"-B/OZ?G2YY\:M^^4A*XOZD,..B$_U6+AX%&8UV&.[6OV/ M\T!7Q&2H>W5AC"_U&[@^)AN*PRZ3Z;H?-I4U*4]^E^O[LBXX4:V-L#=_%IJ7 M[_/'-D&3GE 7(L(I8XC!)*0I1&%HTG-C_2=5<29$$LC8:3*R[GENTTF;Y^>A MEOP*E)W$QJ/7R=^=H9*T^, M:]_OI)SI#,=+UG-OP-U%_&Y3Y86LJO?E \N+F@O;0$!3-4?H]G.5TUUZ;ZYE M6LE^#A']Q>9!4ZDYAGHHQX@Y%XE0F,:*2ACQ,(9($0ZQP#$DBD1)D(J4(>00 M$3"9X#,-)6B._!9R#9:N*;^G&W-">,)EI&>VA&40\41!2B6#*HAC',1AP$*K MT\/S&NS)"U;072&%WF!?F=&?VXB?W^&8W3B./!-W^H*>PE=@IS+HZ]S5S.BT M!K_T]/H+:#6_:@_\=Q?KY\(ZI_T;/1?V>S2S>SXFVN"9V7/BM%$TZ9B=V&6: M1H[)MJ@FA;6_OS5MQ[Y"4=_?F^C9S\4VW=U-KYKN]W*Y_%2N3 RM-D6Q-DP2 M I50"")!,62$*!@HK$B29"R-G"IC#1=E;O;&X>C*1AN3:.9$Q76C%6C5=(%J/,E6 '$JT9UX>(*BBE\-"3_4R9NNMJXVQT(>$PZ\+8'/<3A')_U.Z:W+X_D* M]!/F-ZJ#5G>P4[[VBQ@36@, 6@3,2>,& ]""L)^;M\$!=$#XG#*F'CQOT\QD M@D\\-4T](*^GL\DE&%"ALSV7?%T4&[K\88(%]9KC@WQJJEU]+IJL(M6-:F;@ M;^5JK73GY=_O]?3Y_ZI'V*%ZZHS5F.%FY/\E3/VK MIX*M_P,>GE/%7>,PH$]V/\1\E[J&]-KDCIH^[IVNBQBGH4B3 ,8 M(*D@8MHZ9THPJ!1FF<(\"4.G(XS'.IJ;8=Q)USJ?#*&*K>A#W4\OL'5U%@U' M;#+7SA78 M=(.8;?Y3 .WKTD+[IY(Y_&866/>R".7.]K2_$_)%VN[]_3E7Q? M5NO;E2R$J9S=!I=\E3_7G_**T^5_2KI::(9(DBCB)GTG@RC-,H@S)2$->$*5 M$"&73JGP+Q-G;A33R ZX%AYP+3U8&_'!RJ1)I(T"0)4FHOCG&CQK!2[=@G0: MNZ%;D6.-R)ML2;9#9+0!1AU0ZP.,0KN(/J,3:)0"_WEJF#SL3@Y!=[1=2B=A MWGBW<@APYW%FW6RJ]E;3[*%UDK M7QPU_TUWM#9YI;=>[86,HH"$$8,I)0E$61)#RBB&*M$KG32D<4RL';;S4V]N M4\6KI ZUR'46][T=M(\O\C=?E YNGD-CX22=G] SFNB:Q,[,,@$T.Y0 NO6# M]G!JH]K7&JE=>N@M6%<'TD/;/='_HQ]4>U?H_(2?H0/T_XX'U\G+.=_GXH1O M*O.5JLH-T5TBSOCQEQ)+O.GIO[D MO5R*9MNH4PUPK9N;H^$P^G;^@XLQ'=E:VLD'C( C5.P\B8"GI?OA/B9=D9]4 M\^5"^_3%0VL:E:LZ!>0'R=:WNHT/Y0/-BP6-,(\RQ2&.J%[(\CC4MD,DH:#& M1QEDB%"G8KU'^ID;3]1B0I-5%QA!KX 1%?S1".MX6.P8M'84X &PT9=,!JM; M5ZP&E+ YB82W C.'>YFX_,M)55\79SE]^:6;GO4&Z]=RW01K[H=B"GO\J6X[H9:26#U3NPG/AF91GY; ME575[9%6N\CLL@GEUJ;%0Q.C7;0QVG1G95:@*->]*TV\B'Y\*JV[,*(#UB04 M Y7)*';5A)D,W7JU&V'7'5E_HS9Y#'XM^I5M-/U6&6-!?LH+/2XY7?96TG5H M?@/#&%N^3D![WPFVZ_V--HB=H#F^;^S6C/L>QO6#[JIYDM_)U9TLWI>KQ[+) M\_>[-*EL%S0(*<^R!')S"!4%A$,21PG, H$0"1A!L=5VL5UW<[/(7DD,>B+; M.T(M<#[O0?>+WLBD=A(X\$Y7/Z?HORS^"%I5192?*ZJC7Z&6<2I M8"*#:40RB @3D%"509IP2C*:$B*LW&-G>YH;T3;" B,M_*<1%W3R@D9@.ZHX MC_!IGO6*V\@4.QPR:U*PAN. =5=)_NM=^?1ONHW&L-._[.RY\RU/0A+6"G;\ M8'^#NS56.^Z_E=IZE^M\U3C]=V$M>@E@"F&UDQU7$<4I5S"48:*7O9& .)$9 M)(D(&",D5(E56F3'?N=&&\U.X;[L>^%B]2'EWVCN8*RY#,-YJVTD<$?F%CM< MC>@#;#D7@.V-NI& GLBZ\PFXD\TW +83QI]+:Y-9@0-4[)N#0VX?7.!EI2<3 M^4$V_WXNKCE?;?344B?UOZ4_9?6-/M?5."3E)).QT.MR9M)$B13B2"H8XS#( M@I3Q-'3:(G'H>VZ30%L*=&U$!(^-C,XE5*R!MW-'C@3GR+3?20U^Z>3^BW$" MMP#70H-O9P >4KO$%2I_]4>L>YZZAH@K) ?J@#@WX6ZR_E8^R551QZ(4XEHO ME?GSKL1?]2G_V?7W0_+-JDYIVDWL$0^SE./ZW E$,@PADPY:$*-8_J; J M(GV1%'-CLITB]5%?6JL"RITN]D;6\)$Y;]-.@O?(5->#VB0,:+3H50JM0*U' MQWT[3088O!>\)=;F[R1C,I$Q?/8U *H>F[P9FVJKD:>#[!=C><)"'M[V9/;R MQ>KWK>?+&W.?E>J,3JSVV#[)WI9I5YVQ]WU9-,?"JX4@*&.(AE H4W@E0 A2 MF1$8A&F8122-);Y:%>BE/>E;=-7.,Q$@T;C_"0T-L8CSS][XN_O MZ[?(WRBPIT.;#V=LY.VGG+%'8*+99H21<)IM+H'QQ$0SJ-G)YIA+E.Y/+Q>U M,S1"C:V[@&J*0I(FA,-8T-B8] /*>HNI MVK4\<;S4*Y5>QT*]OF38:_M-UH6XOV@3\ZX?-A*'0O\O"2"/N8!(VWFF^!J! M<2))'"881ZE3JOTC_0!KY+7Z-C\>-%TL8/+W? MQWJ9]%T_H^K+]_[_EV*SK O@?-G.V$;PO6.X@ZK1'X+8?C:_ +B1^> 59K># M,!LT[1]!Q>/T_[*'R,@>.73J,$K;'73\7CYMU]44^R674/(S2HI?9I MTOC!SY?Y;K_*FIDLOT!92O M%['F2QZ@!"8B1A"%:09IBAD,0YDP)$2 LL@Y>XA-SW,CS3W!:V=L*SK8R0[^ MZ*1W7,+9CX<=7XZ"\LC,Z O@8:E'7,#RF8[$JM_I4Y2XP'$P;8E3 _X+O7XJ M5S*_*QH_-G^^U1-LM:P)UIQ,,.'#"Z5XF :<01[A "+)8JB-1@[#A%"$,JP0 MOK#6MHLX1/WI1RKE,R-[^[6HF7#96M-VNJ 1A].^ML7=A6 M'] I!'H:U8=OP"]&J>,I3KV6B+5'=X)2L1;"S*9DK#UP+J5C'5IUC_32'4O= M;C^H67-\?6*CZ?VKAJ79/FS]4(P$88AI @-,-=&F$8-$Q=J.#'$H.&Y\:KS:FC1E;[L")WT$]3YNA0CL^0M>S[YR1,5'$?WSJ%:1F8/\EM9Z88 MP'=I=,V739&H=YM*3U]5];Y\8'E1?_1)/YAMD?-%&LD0I8K". M-N2450A(@ M!A45:1H0%I'(.C+X18!]TVMEI]PX'@;H_/0R+>PCSS=; M97I83]55 MO+R3Z:H?>@-DKT:AOU:'.:?,?%H6:XV"ONCN0X02)*F-#?+I[DBI47;LV][-GES>CW/]X+ O\D&P4_ MS=ZUZX: +<@7;7=> MV;;78:04V,6R-V_>?H6YW'@!IWH_-5KW/8YCP&A>4F MY]';!V0*#E'RM5S+ZL-&1D$PS=.EZ[WI.![*7I/7SFP&DU[Q.-& M=0YJO5)O'-*:4[_DE.G%N@D9J<\=[*)&DF73[AY*VM/CUS[Q:4)E@J6() M Y*%$"F*(:8IAW&<)0FB099RISBV@[W,C>F.9A"I7\#^W[W*IOLW_6'T3:KZDGM,7#R.6W\I2_)DOE]_U M:'XJ5Z;&Z2),<(AY0F <9IDYB8D@"8F F!$E".%4I$XFUH$^YD8JG8C@#R,D M:*5TI(A#6-H1Q(4(C4P/KN XO^PGU/?TJA_J8=(7_82*+U_S4Y<.>\G?UX'; MGXN_%BM)E_E_2]%%@]X4_R'%G12?U_+A<[$]UEE_&)IR?RK&$86*QEC;%TD$ MJ10(2AFD" LF' MES8WC#,_TE61%W?5-[FJ#V-^R)<;\OIUKY'[1Z7$[ M!%K4!K8KT$H[RF%)2V0\,=VYWB9E-$O57S*7[6WC!%K73JE>P' 7&!K+&&.. M0J@$-2DR5 AI@A,8(D6(_I('L57TPH5RS(W17H16_TTNR^I=7OJ-V3TV)N?W M)"=">FS.LH[*K74!/65&BJ(^-B)^PZ<]C,SLXJ8'C)#W>.DSN%X8*'VL]5E% M2)^!P#4T^EQSPZQI8Y&@[F]ANX'FRM"T[G=3@=@/BI=WM>/^)A/S)-2M->87S)XGX;=_>Q?"Z>=$OE M*I?5MU4I-ER*O- =/]*FP(DJ5\WGZR]T4V@+HJLC1U)MOL8A@41&""*'J!3Q&S8]%0!6I?VNS7HM+%?[ \>KO.^ERD& M860F'HK_@*CRP0-A[W*98D F\K>,-S!.SI9+$3WA:1G<]&1NEDN5[_M8+FYK MV&KD^N;]Y_X^VVWYC9J4+E_E^D891T\O)BF6..(90C!1J3D_&@20!4Q!%4I. MI! RS)C+FL.A[[E-2]=_N@)%\\YQ+7CSC9;J M8]:*;3BM%0_L)-_RFY&^^_XXUNX%S@: YJOJF4O7TY9"&P#*J_IH0]KP5R$I MZK*IIHRA(&90T#IM=91!1D@&4Q4K3J($18I?6B$IFJ?[H"GX$UU>(2ER2A/D M":&16>=XA:1HH@I)T2B)@D[U].85DJ+3:8)L;G%C""'S15N<]5-><;K\3TE7 M'POQ0=L-"Q1B&;.,PI"E*408"TC# ,,TH0G+DAAG++6AAE.=S(T36CE!(R@P MD@(M*C"RVA'%24A/,X0OH$:FAD$865."#0@'N*"2_->[\NG?].T-#>A?=F__ MR48G>>UMU.K>=ZMK!YH">9&OY9?\R>3N7>M1S?7"JCEI_$5;'R;HO=(O?A8G MH7[Q)9)Q)GC+L5C71HM.Y$<%.T.XH_L>??+FI*PKOSJX9 M\>MS(J[A,5;C8&E/>$9W;,.B%A?6\H+7*%M!ZFY?.&#DR]"PZ7):B\,!A%>F MA\N]PZCI9;MZ%;1]Y;HW;B'3%&.)$0QQJ*DI5 K2@"C(<)@P)#F3B5,PGTVG M,DH89S'4:V\.49!P2)BVN#F.<9@Q#7<8+=8F/>4;/=W; MKL<#>YQ'V6XJ]8W7Z/OO+V;/QAGXRVM+Q6/A)A>,/$VE5EU..I6Z@/!R*G6Z M=^A4VNP7/^]L28QCJ1"/8:!BS>4\B2')@@R*F+ 4R8PBYN3G>]W%W*;)K807 MF.D'@+1EDDO@&9TWG) 90!''E/=&"*\ZF/CU/Z;@ZY?]Z)4#4QRN2_[/]BCS MQ__:Y.MGDT7QQV->E$K5I=DHKT.=8A$%-,TPI#0SMH0) I>8F#)II@!.E,H M.>4TM.QX;C1@)(1:1+-'5D=_EL7NF+AC,D-;[.TX8@Q$1V:.OLC_"S1"UQE0 MKT K-^@)[C$UH2-4OG(1VG8[;?)!1S!>91MTO=\K4YE/?SPN\_7[4G/CJM(= M?3=!;.&"QCR+(A1!@FD&$18,4A41&*6$1DB*@ 56^PU#!9@=[G0&YGP;$D MN?/M#,SL8W$*^FM9"&F"=,W:KZUSL9?W__T]7=W):D&Y4)'0]!=%5)KS>Q&D M@5ZZ91'5B[4L5&'H='[/IW!S(\D]&1US^_@<,SO>?*N1&)E3[?,[["D'6NVN MP'[]DE9!CZD?QL3?5VXBGZ)-F\AH!%!?93T:HX]+BPQ\EWIQOY'5)PW)QY^: M[0JZ?+^IUEK 59VXNRSNZBVSQM%7)^]>A#(6@J8(!BK5Y(XR 0E!$B922,P# M'@6I&E9K8(@XOQ1NJ!ZP27@>B]B,$B8-ZIE< EPQTL:7-3JP-S$1O-BW1R.^YY7 M_WSWO,TXHU0@>8HQS%060!0I!+&($4RIXIDYVX&(TT&U$WW-C5SW1 5&UN'Y M?4Y!;,>&GH ;F>H&8N:>"O@\&K[2_9[H:=J4ON=5?I6VU^*68931*[+2AEXN MH@"1(. (9BSE$%&$(48DT9QALI9'6-)5/>1O?N]S)Z\8- M![ D"=?F;9A!IC+5E*BF%!/]&Q4I4P'AF6,HT65H3A,X](T^F]FL GEA-OB; M0_C7G*\V^E=C%Y5U9-$8@-MQ\&4@CDR]/>&N0"N>/\(]KKHGGCW0P:3T>ES! MEZQZXLJ!::XN4I"P@,)<\@"O5" RNDUW!8<(494A([E5"QZ71N M_/)B-TT+W4\S?$$XK-4(V)&.;UQ'9AX?D#H3D M&GEC(JLM)J<@%A)=\Y'3O M,%+ZD%>/9467OZW*S6/UN6@#^?7'6K]U7NB5_LVC;)BP,I\NRVJSZE6ZQMK\ M(3RA4,1AJ F+A1!32F$2!"RF6_%8V5';E",P M,NUUJH!&E[JJ5GNTJ*\.V.ES!78:@3]&J5/N"U]/E'FQ.)/2J2_P7E*MMW:' MT;"IX\?+N\)4\KNE/]_)0JI\7=W>T_7?R\U2?'[03_AZ&T72QH\L,*1QRVN93?:QO GN M6M.?X'%5/N5U<&RNP*:G=?TM:_4&?TK- KLOW>AZX)C:D?3X(S4R-?<5J./M M.A5,)?4UJ)4 C19@%Y_7!>;Y8^/+@/3$P0.%F)1Y+P/J)=]>V)I[YOK_38O- M@URWGB49H"A1',-$$0Z1X &D+),019021AF.[4J,O&IY;ES8"F>?J7P?I]-D M=)'V(_-+*]> 7.W["-@G8!^,Q$19U5\B(_'$9R@\G70P*[3:8\0. 'QZG" V]T#,^>5*YG?%;^5^H4NS&SS0;+U MKL^N3 ]G @6A@$0*8C+X8$@"$4,>$15&6!(EG?)36?4Z-YNI%1K<;:4&K"R$ M(RG9 6['2=YA'-OOIL7K".GY"NSDKD]0Z4O&R,'K@I&O)'E6?4Z;)<\%AE=I M\IQN=E^$_?51"UR8;8S?\Z6LUF4A=WG$W\G?J9"WY?MRJ:\OC:_M27^]6A?Z M/8D2$0:)4#"0*C7I0! D*4U@S+) !$2$(;9*!W*1%',CJE:1>BOOH5,%//82 M[C,)'K0Z]HN?X2-T?JDX">YCNZUZD&^U -_V(3>:F%_W= &M,E.,A?VB=9(Q MF6B!.^+8.*V(+\;TQ.IY>-N3K;0O5K^_*K^\L:$IZ-ISNM>;]7UIS)@/Y8.V MQ!L M=$>PM3.&?2 V\BPQ#*P!B>I.(^$M7=V1;B9.6G=:V=>IZ\Y8%SV*54A[ A$NL#=HO;<'&K0)@IX''FEK# MH/-55LNQ]VDK:PV#YE5QK8'-#+1U'AYIOC*=W*B7V7T_%T*J.GG^TIQQ?YV9 M.@I1F-;U TD40L11 GA#+*,)$E 4WU[XIAD_0)QYK>S\?G;]SK<[T,=B-+H M!7B3R<71;+IDF"Q-JXF@']O\VB%=JM=%.DP88*=+F]5CY)SC'F#U9 5;K:ARWGC,X^!\%GXD?/$HW?;X(_] > M3#,Q0C<#CVS*5?Y4;W75^U[:)J?+&[;,[^I>;LOO1^^V:CLC]YW[[AX%P! M:I;FHXV'W2PZSD,_\@2Y$[IQ>EV!'QOV#]D];5&9!7IUK=6W#W M;NU2Y=;S9*^P:Y-<.I4(Q4HJF(4F6Q(Q9ZU(&D$6,!Q1F@1I:AVZ=Z:ONF'I7^+H09M&QMQV\2T]PS?2%E*\7L8I)$BD) M U-#57,PASB5'*89"0.14*J44Q3*!;+,C:-[EE)/ESJ(M-6F%T2QEQVDT\@Q M_.V2<72U6$<=G>E,6.\#\S38\)V MKKF>VS?&YA8W[S_?EHW'Z&.USA_,9WKMU3B;311S7;12R=5*B@45*!,H4#!E M@947V=&Z]]63:87X]K?[)\N!GH]*[:P5$#K MU>3%^S-?W^NO"Y/U*8S 0UFL[RL@.]7;$P2K+6B=^^A: V6^K.ARN/=HY.?J M@IGCC9^6-YEF]G8*7FT4M,.^TQVT3T"C_A78 E!O0[0[5,WCTT-AY.EIQ'$; MIB:K1@_7J<<2?]NI MPS^JHU-_(W)S4*>-#3V*LD^V=H/*&]M:=CLQ6[J!\9KM'.^_)*7/SJ&22<(E MB6"6XL@D$#/%WL-4&^QA%BC$DC!RRM.]W_Q,F6>HQ^,%=G9\,AR1D5G#'HR! M"75& 9'_["-CO @U&8J(] MGW./@M.NSD%E3^SA[%\_V8[-03'[^S.'+QA81ON>KN0[6DEA L-D4=4#V@NE M>/>\NZ0]PW?])UV)AN1Z*[-ZK^CVGA8WCW5VZ;]IBT5JR^6;7L:58B&%TB9% MI)<[<:3M"Q29,HXLAD(%^C\I4K4+&K*S-:82?4"TT<@$^75C1MZ$"M<*:FN_ MD=B$!(.J_NCXL:^W?0SLC*99#>U$@0)&'U@K!/I*]\.: 'L&_>M:S4&M^G;) MU]]E:O;)UUI_T *P?5;TH]* X+'X]\3#YJM,^%1B3UM0?.+!>%5Z?.K^W29 M(?/%QV*M>](K[L]"][/U)3;TNHA$$$8RXU#12$%$,P))DG+(8BII&J11AJU. M,9[M:6[V=R-L[4W:%Q(5M[+7T4,2L*=8:C0.<6$G^ZUWY M]&^ZC88.]2\[%CS?\B2T9:U@QS/V-URZ55Y]HOGJ;W2YZ9574RH*6$I2F 0H MA@BS5/."1!"'&JBO-]J\/*'V\1W'4S<-\.,MESG58J_DDRQTD\_%(UW] M-VV]-;%*D5(\,ND1#)5$ :0RIC"*>$AP*"0E5E1RMJ>YT4@G+&BE!1!T CMX MODYB:^$+](78V+[!XV -\1>>1,W!?^@+O:G\B9>@Z.9LM$'FE//QY/W3.2-M MU-AS3EK=,+"@>5FMJ^NJ*GENO&Q_S]?W'W_FZYM55_9N%SEYLU]/O?I6+G/^ MO*LA*56<8D4HI"Q%$ FE[;<(1U!21J(0JT2HS*GVN3?1YL;2KVON.@9H>!PU M.T/P;<9B9/ZOE0([K>HH3V#TTJ\0V%8([862ZX_WE;L"C7K@C_;?4>J"^D?? M5VEW?X)-6P7>.Z"O"L;[[\'=2/XJ']:4K3;KO,A9:XA0R5-%TA"F:9)"Q'D& M*0HI3 DB:9 RK+G:UC0^T/[R$>(]/='A0##-Q#F-B; MM1=B,Y$Q:_>X.%FM)Q0_8:L>NFLR"_6$R'V[]-1E PZ+RSLSP-_E8[DRR0?^ M6M!EC:P4]6[%QR8EDTFKLB"!"D(21I $F:EN+ DD(=+K>TJ9BJG,4!+;[7P[ M]CR_C>MF.W*S$[G.6>5P_-D!]O,,Z!O*B3:*&ZG!5FS0D[O=\.TD-\PP+P?4 M!]SNSO$FZ+K0P_3\M5R;%KEN?ETR^:-Q[;H;L5OPZPTZG0'MRS.@ &B6 U@(8->Q) MRG54SD\#(V(]\E3@#/, 0]H5;_N)843<)YH<1L#?::88B.")V<*UQ-H4T,#*S=)E'9YEW=EO+YKF>.D;&7C*.=OWJJT1E[8=+E9RI5;S1Z-<3J07DQ?$W:IG$\ MT3YP]15B>HDHTX:->@#M52BHCS8';AG2ZM[\WP25/M&E6:;5#NSQ/,:E1H%%MD*L 1IA@&2B0084H@ MSE0*,YFF1*1,)318K$N3N]UN*VM2\9VH?JO$>(S2Y+YNQ :_= K\Q82N&U6O MFB2>/8UKRM_A47_ON%DY[?-BN:$YVZ=@[$W/@Z-\]7*(KPZ-^_X=#0J'GB93 M1JDKFM2!T4Q5#1P>=T;?9!A][9Y.*_RT.ZQO,C"O=F'?1HH+"POOS]W&TI9: MSB_Z95ANKY'5@HI,A2C&4!&A5S188DAB1*!,(D1I&$HFA]4;MNM_;HN86DZ3 MV,NY>IXC[G83S(AHCCQ#V"XTKD #N9DH:G5ZUYLX["8ST @UC=T0]5WJV++W MMZF [ ;-T<+(CLUOL6=PJP4Q[@2C MW%"WC=UXN7IJO(_"R#RYCW9C+C=#T0063N.'<4+-N^O%KO+6 MS# N?+>I-FO6 I"2D)4AC'5/-C%#%( X4A2T,NDC14"7+R<'N0:7:A70.157?T'K)P]W#Z&TXX^)QZDD2FUTP;TU#&%9[:C]GY_U+8Z78&> M5J!6RQ_9>L38$P'[D&A24O8(X4NB]MFTIW2EVO)ZE*OU\S?]<*_UC&&<"H^F MMX6V5U$K2B\92X\/@1VOC@/LR/1Y,&MI)[C^S8A>&ZI;X4?,7'H6L+%REQ[O^&VS MEYX%Y&S^TO,M#$W8\EXWLC*+>R%__A_YO @0BUC&8R@2CB&*$PD)%1A*IF22 MJ)@39<531WN8&QVUZ49:*4$M)M!RNB9F>0GD:;;Q L_8[D!79 8D8#FB_06) M5UZV.''"E2,*O4ZT.)48\42@,W%(%'NO*ZLF=](1$)QEHBGN[;@X<032.>$ P53"@$3=ULP3$ M0O\(19;%+ P49TYULR["<](XY#'0M-U3N1RCD=FR5U>\J_C12>ES)^0T#MZV M/(YT,_'>QFEE7V]BG+G>C5JKU7KQ1:],BNL'NTPIU[^R9J]P/&-VL"GI[+U?T46[6.>^R=\N, M!2P6 4PB0B#B.(%,L Q2QJ-4:Y5P3FS/$1WN8FYOK)$2],6T/YYR!,/3;ZX? M9$9^>U^!,N#PSA%T[,_H7([25.M[3[E1;Z67_(GDZ>W*Q_<^(7>/?]._U&NWIOR7=<_\VK!F(AP@@F,LS"" MB*844IX(2$(1(X)3IH13:)A#WW,CPD9T6,O>JV[=ND=-1$0M/Z@5 '\8%1P3 M;;H,C-TZ9R2X1V97KT@[KXD&8.9IF>32\Z0KIP&0O%Q,#6GBTFBPLUG.JV-I MSNN FT7 XS2*DA0J%2J(TC342[-(0(5PPF,>T,PN^:=WR>9&C?W394T-!':R M5D*U*Y; 7A=+:..=',G3W[#;4>N;#.;(Q/MZ'$_7O*A.%KTX.XX7!*MYPMQ[ M&-NEX3J61 MMFQINH32;JKMI99VO-6=R+^4Q=VM7#U\D&S=;<7HB<),#R8QR">]M%BH1$8D M9!RJ.$8014D J5 )#+!*54!BC.WV4BW[FQN!&Y&A[N@!""WT%J6Y&OFGQ!1FJ_0-ISMF= )^)K M'\ Z<;4#3"=XVJ:5R3C:0:4^/[O<-K0 P%+_6:[J&BT]R_Y#7O%E:<*D=R>Z MLC3(.-7$' 8!U19WFD$<8@43$8H@"+E4H5-I^Y\;9>Z+O+:Y=,_G;PV_G MX1@)U)')^RB>8"9T W[V)80QV4\C;_$$: MFFS/?[R3A53YNMN;C;,X)E&*8:R4@B@C IJSQ#"5J4!8*)P*JRRBMAW.C:M^ MR$?:G( 94FOD++QVM.03M)&Y2(L*U[E)9+ 3%G32>ER6ND+CB77.=C1WED$H=)&F%(6&*"?A&%C&I.X1('2"2A8MRZKMS1 M7N9&'ZV@ Z.)CH-Y?OWI!:*1R>(0.@/\@\=ALE]=>H%KHC6ETT/EM'@\B\*) M)>/Q>R=;*)X5O[\\/'_Q,)/JY0%9DS2DCE^1(@P#JCC4_\00(:8@DUQ;5BF- ML%0XH=3IU,.QCN;&@:].ES=Y5(:$"QW%ULZ.\H'8R)0X#"QGL^D<$I[,I:/= M3&HFG5/VI7ET]OJA)T4_E \T+Q:_/?WX1R.=Y:O^"JW3K_8E&(S\*MNJ/^#,Y[ZN%QSU;!N:^(3GOOBO M#W:^^'YP9HF\D*)=V9ACW[MZVET 1*)B%20(:DLF@BB42+^(*=$O8LABBGD6 M(B?GQODNY_:*]DJ,.R>-.(>NW9SL%[.17^E6V,ZA46>%N ([@4=P<-CCXR\G MQ+D.I\X%80G @1P0MG>ZS^CO-4]=KR1]7PJYT+-V*GBLH% 20X1C!G%, AAC MA F*4$IE9#NC]QN>&UT8V8 1#ACI["?T/;#.3^A#(1A[G\5.>Z?Y_)"J@^;S MO88FF\\/B=^?SP]^/VP^[V_G?I-Z2(LUO9/O)#6I!?^F?YJ-W6Z?UZ3<700L M% D2!*HX1!!)'$*2\@3&*J,"AVE*J-.6J[,$M J#38!L!LG?5R4) SC;#8"@]F1#N_4]J40R&YZ6! M,;RA8138'!ZZ9M5Z1?EZD<2QR *9P"PD"B*3"X^%00!1IK"(F&0L=3JLL]_\ MW,AK2&J[%X#9$=%P&$9FF?8PX!^=:!Y7&8=U]D0'+QJ?]%T_K-C+%_G(58-K M4;RH>E%7@;UYK%-I%G?OZ6.^IDM3MCC@(HYI&NOW-M5O,(Y"R((XAD$2J8P' M*@I"Y9I:RK9SJP=[^G+_D]XS=5XJ2#1:F:8M%;T;O#Q'7-B3:= M:VZ*39RJRCVDTH0C@/Z*3-AV/'5]"4= #I26<&W!6R;U-OY)+I]-78N[(O]O M*6Y7M*@T3^JOJVLAZ"TZK/5;6A&IPZ8JHM;UI44BRDMDO"1 J8D=B4 MH9 !I%$60IY1GF8XQCRY-,VZ5X'G9@/U#Q#S_@G5[6F'NO[[>JW7&?*_-L9? M0KG&W6]1)$7V22!N] T_>LGG)^>:9VOX^+'67/Z2$8F>@/YWC? M:0MVZH*^OE=@IW$O*%A_WBG=UMWH"D<;O4=- C_*"(V7(=ZON&^=/GX4\"UR MRX_3K]>*Y MS3HF(WJU$\]+A;@7.%L;YW[1&SL"P+H:G/EBI\-D]=\.(S=NU;<7?8UG1Y6^KZZ2M M5\1B)Z]]Y+''(3O-@&\W$&-'5+1*@5JK?O'COF)@IUE=;7DW;#WM.L/5(<#> MX_C9AYJ_S3A.%)L^Z7@ZQ;;[A_U$,+S'SB:+GO4J#6R@0_@9Y>X+H"M6:@ M5JW;8-@I]P8C9S\/O\4(3C0+=R-YZ%7[LQY)JD?RX$NWKD>R>?'T_9V2O_J9 MA'UC?F(*]M;59!.P;W#ZTZ_WMMTGW[\6JYW7C_[LCAQWNUIZTM\LS7;6)PW* MC\>\*)7J.0<781*05*D8AK$*3-40"8DIUBN"* O3.(RPI-U>^:W=S'N91 ,V MT&^GV"/2@D(MJ9ET;U9WM"@+>QJ^<(S.3YL30#[-9-E7I';?=:J8\P#M=OQ6 M&V!>=-#JT]^9F6QD[*?%Z49HHLEPY)%RFO_\@'MBUKNP@\GF.C] ]& M'IS^.S7E[DUHS7?9[]]KVO%DA%$1ZQ4ZK- M^1@/#VQW'T.[':S)1F;DV>]EP'NKRW.;SO"F&"F:?3!F(T2VN\OR9E'N@V$[ M%?$^O-&!52X.)E1?I%0F&4F=46HC]0 M)_%9KN3:1#LT,_=P*,_\LZ^S;ZQ*T;FQC0I9;1[:7D;";62[' M=^0IXV#1C%UNPROP5?,:K>Z[;1^/-31.0N.K(,;A3J:M;G%2T5>E*DY?[>[@ M^5P\T>*_V]/_48!(%J<"1AB'$(7:G*6<9Q#%L529YFR69+8[)/V&Y\88C6SV MZ_@]D,[[2X:J/O++W(@U(%?;GOKV3HFA,$SD8G@!AR=G^2&E3RS]]RZ?;"%_ M2,C^LOS@]SX-P-X<U?M0C4WV%Q\6U7A/ MS"6FVBR>@PEMP&,5UDX66+L"+097H$'!N'H:'*[ ]@%KH6@N 08,8- -1QC MVY6CC^.H!NMXTL_ $AY]:.Q,[/'%&! 9I<6X,YZ<>D%[6WY;E9J('W;Q68V- MEB"XO_1\;P8'8E]PA M^,4._/.K!?^0CCPAO"&:#H%"WE&=*@SH.])O/&F;U4H_8 N,(V4RZT.,@]H[GD#,4 85%BB6"8ECXI1T M^GA7 MT;1%.LXJ_*H\Q_D[+CGS^J6L*A,$\;%.$/"[7-^7HA<0N!"<4X91##,J*40X M#"!-%($A5J%*XBR(%77;4+/J=W[[:XV@>H59G]W\9:GE_TL3'T25JH__N3*) MW0#8D8IW4$=W&3A[8N*HO^YL891N3Z).U.:-"7VMZ/8@/V>9>49PA' M9I"R0R_?H:=Z @_8\;:!T=X7Y1G.B1Q1YV#UXWYRP.:$[\FFE;^->MN=WFZ?:<94R 2AD+(TA"CB*609(3 1 4Y0)GC*K0* MK'N<&Q/O).VE.W#H[N MY5!'MPOTUDZJ,0 =WU5EDT_99D/!>_[D XA-E$"YW_.L,B@?@,0UA?*A)@:6 M?Z7\/B_DZEG;7\955J>N^6U55M4B51&5VO#1*U.6F'HT%&(6,+T\Q5G(DE J MXG3,[WA7 M((4H9L0I4>UEXLR-?SY6Z_RA#H&A=W>K.A<'H#TU@&STN!IP;/C"@;.CJ>F& M8V0J:Q2!M29@ITJ3.NJJ/OO%ZQ#>GE9C'"KV Z@G.KQ0F$DITP]P+VG54ZN^ M*@6WO]ZP97[71@LF2H19C"%&L,;%W0^"L'YBL[';QVXK\'OI=@L MY8WZ2/6:5"](O\E5=T8CYR8C;;[LZURJR>B=UJW?RYB9 MR#2$)&$AS.(L5:%>^&..G'8[ALDQ-\/[/5WR[=YIJ4"GC#FSU9SR?M=W.[\V1MT]ES^5J_+"=W_5Y MD>E'6RH2P%"OP"&2%$.B4@)9G&(5HPR3A+H0Z 6RS(U$:U5@J>"F:C/S:LNO M4<=L2\A6(1-1T>6>*>[ LM[!Z/:"GMUX]I*1M./:B<9G9+[=#HW6H_%A@)O> MT'SL#TUOXZ@>FB]GA\:9<#V ZHET+Y%D4N+U -E+\O71Y(#R05+)U:K.?=DX M3HXDQ%QD4C.LY!RJB"00820AP1F#,5%Q@K-4!%Q8%P>R['1NE+J7$]9D_&+; MG+ N=<:=<#_-BV.A.?X*NA:Y3JS;YO\_FG!W!% =RNZ, .Y4174ZD,V3VJ;F MWQQ[@CTE'W*%ZU0Q'-NFIBMUXZC<7B$;UWLOK$_9^KS;9@^%71TI3->5LU_$ MA"-$$@X%T5R/*$\@#16" J<))4P0PAT/T/@2;6[3PIFRBV,/E)WE_#;PCSR/ M] IDMFJ!7UK%_G(%[ MI-B,(_NA4]'KHQS?NO@MM7B[8VU3C] ;HT9*=_GJX M($/#MU*W)=?YJDG]LW-B5_M^[2Z#)DD3Q$D$,5<<(D6E_BU3,$E0A E%+%/, M.76#FPQSX^/GD7$>F8A/0EQOD(T0BW\!9#ZS13A*,'T: MB6$0'YD9AG73@CT8^RY.$IY$\34S>\!F9>NRA ML288*]5/48ANH$Q)RL%*O>_WM+G9W/'Z73[+8R._-(M@83;^5 MI:CJ']_E>K-JTQ=^TS]6ZU*;8GECH,LU.-C+W#<[(1FL@+.OI(.?E'O:![PFEZ M6?N3>5*]P-!WK_IIT'T6:[/O5K?E-?^OC3:+WVTJ;097U:?\27Z5ZQOUGE;W M[7=BD5*A$AK$,*%(0(1%!&F81% ARC*:RHP*XEB-U$T"JQ=T^NJCM7A5/6XF M!NEZ]?]MEO+*N.U^O0*%B5Q0H*[R0EL]['G3<83.3V$C #[-G-4);LBM%0]T ML@,C_!7XVD!M%.@N&0]J^SEI/,@GFH1\0^\TYPQ#[\0DX]C@9+/*,$7[T\C M%@;&O4F^I%65JYS7CY])DW?-]?.XJ;/^UOX6DP!^)>]-_>TGV3B;WS?G]9OY MK);IEOY.U\R)./UE2+K1A\MT6H5/4;0C0"\KY ZGZ)-&V,W JBO@N[&Z,-7!IL?ZY+_ M\[Y\$([]3^W@ZTSVE;8._]&D M#OY3ZP%J12R/TOL.D[5WQE#@#^^"X1MW#]EOK- ;+ -.=^\OG 7'"IK+F7#L MFO$56GU3EMO[JKK1'[HN4A,@MKI3[%O1\(+O_#2J_+'*6&^53VHTF.>"YP&F M.90H(1"G6/$FP@D,4DRS(&%QF#GEO!A2V*F1[%>ZI,43N"O6/S;?37[I:R.& M/0ZL'=-.9;@&IN73,7EEC&#?J[M[3"L\JISE].M&NOM=H/628 ML_^Q&2P^VJ.H+QQ8[1_TRQ'9 _39;^WY(,M2RC.!-LWYT-NMG(L@$CA$"4PB M'$.-"LZ-0A)UJ#2%8/MVCW*XN;,[6FE\>9:L> M<+F+!1)Q3%$B QAE1#O'BAR2)(JAP%DN9!QDJ;".TKW8V]3(X$#@=G'PTB:R MIP?:EYT%O&(X,$&,#I]#+5V?,(Y51O=BH>1_ MH,O;E4ZA_>W'>LY)Q$66(T@(S2%&L80TBBB,PCA-!*6,A4Z+4Q\AIK;@:!V@ MZN@>"*7%#-SO])B!8J>)IJN'1A=],ZYF'78\'^TS8I9GI0./P]#GIGH(M/S@ MK1F"6H6G.O>[$M;C6>D54/DZ-^TCPKAGJ%> ].P\]9JV^G%CX^[[9GW/%JLJ MQCTLMEA8])Q.*-?E1Q MLUP:[]"ZL&%361-%NK(@1Y GA$ 8FAPJ91KP!DJ!T(^!I_I_I9-2YWZWH\;R_\+0OOT3C MNJ(Z$*:3>132F.0)A4($F3(2\A1F&8LA$A@K8T'PF#FEH[[4X=1XP"3ZH3OQ MKG4./$+7CA)\8C8P.=@6$IF!4U[6.CNT 7RGVY">>*=!',R;[JB[%_:(.ZW\ M9:^V,^_U/+A1C7_*WQ12+#;O*3=N);_3GXO[[?WK=5&L?RQ6=V^H^M1T.G41 M!UE.XQ@&TL0#,L5$.,]A%(LXB3%*&'6R0UPZGQHKW3S2Q=+4JV"-J(#7LH+M M2HT X$8QD->:.9[/N R,Y;G,0' /?1ZCQ#9^PA63Z8,;(#G;"@T9ZCP%W+D+(")$EB<8JC<#B E5 M/XF$JW^R.!(LXS3LEY#X>5]38[!6_MJ]L,Y>&38@V]&3)^@&9J/>J/5/\GL> M#]]9>T_T]#)I>,^K?#:O;L4Y9R%"$ M),QB&6HW.0(IS27,8X:#) NX8AK'?9I+_U.CEQO.Y5*[+:N]B) /A>1-8NR6 M-LZ;.:<1L=[;#87S\%N]?<6+ENPST$@_,YNYS6&Q=J\[NC[0^=O@.?4^]GZO M#S0GMG^]FNGKCZ:8<\OUM=CJ3OU#%H]RGH9)DM*80Q0(IHOT!)#@^I(J03%F M>1BXUQL^U97+U!JOP/"!I*"H1)T!)N\6*^, Q*AZGCM&K9Z$.HHXSJ,HA@3I MTIU(")CE"F^**$Y8WDCI7&K4&WXZQ!H!R8LAI!S4YV]X^6V":IR!"^$,YH^:H5 M;MWON-7!7>%X5@_KL>U^IKC]^N]JH3VK!EE4QW'*NO:HR MCA/($Y9!G(8,9F%.8!*)D L9TC!RLJLN=SDURRGFY68/-=PE*);S) M4*I^OJ?%WZ5)'U'H8L*.!I?%*-B1EE]L!V:K1M@JJ>C7&LV]P)@&,^=175[4%0&_:6\"[=)K M/'KG0B*6,ZQO)@,.<1+FD(0LAC&-" LRE,:QT\UD/S&F1EB5Z^.K2N)?F@*= M)@&OHU'5;U0L+:S!L1[:W*H5T+150=[6H2E]^JI6XQ?PI]%D&(?TZ\#T98WU M$V)UYIZ(I!V:HRA8JN]Y\YD^Z>:;^+,(A5$D> 11SF.(8Y%" M%K 0LBP/(D'C$"78-A/)Y>ZFQGW'L8&+6NI=AC2W2$!+S+L9SS^2 S/;'L0J MNJ\1&-026T3Y]4'1/BV)7S1'RDOB 56GY"3V('5D)[%H9+3T)/8*M?.3.+S5 M,HSR!1' *EDX]^80; M6^LJX5]TRKV&JEF*1!()F"=40(P9@8RG.40!2F6(@BQ @0U5'[4[-9[^JK]: MM=YQN@2_2ZH]VLT%Y\52])W@=5//%9 ,?1+9%PWKJ7=&]R[C3;W2,MS4O_9& MVW%KHTS*,RHT,_+D! MC") :^+( =>,F-V>RU40]L\!J5O;BBYWZMVH>#KVO1D M'^/>BG:I^>S2L_/AGH[^N\#4P]I27RJ?*^/Q]O4[+22CI13-0=@N>)JD) UB MC&$2)!+B($]@)F4,61)%F/.-,C%"4I-**"6M9V6OS>X>Q7#IH= M#XTW%(,3EAZ%U]>,@GL8@1?P?(467"?,N.$&7H![%H+@I]5^%'LF&_87*;;< M9&?\(LOM4E\AZ$N%#_2A5%+>/#PL%US?E>HSAJTN_?=A<;^HS@S+>2H02;B@ M,,*Z= +),DAU$1S,!(T%27$<(+>KS &DG-YUIQ%;NXV5E;CZQ^5>8#<6'F)< M[:CYI<9J'+[N*'6PTQ#L-*R\F'<#N]<2?-V/\0>+,7;F^ %'P1/Q#R'AJ*O! M@! ?+Q%#=N4K!O=T8=AYDD1!%. ,1B)+U1*0A9 &+(4RB:,X%SS(DL"E+JMM MQT[F]@AU674YYX>FG#.KPT>Y$A2\JK+=_7)M/.Z9 ; TJ > =6 J/AV+>[9L M-GCUY@+.'N)QNT$;+!KW3+9 +?<$2L) JELHCM3.F"!).I,S5?Q#E3D<%IWJ9V@G >ZE@HY8^&=WX69+, MM:@,S2BU?,:PN]ENOJ]U]9(A OF[@/#%$B?[&)<2NM1\-O\['W;W5GM-GV1Q M\UO]@:8T820D%,:"(8C3)%-S.]1N6#DF,:$XE%9G@<]:GMJD-L*!F]_LG8P. M@>J>R5>I/_#L;33OX6=U"(&]FU5O*$;RLK*'Q,G=ZJ3:'=Y6A\^/YFQU4LRV MK]7I!_K9%=\*XV+S]'6SYG__&UUNI2G44U0'>+]+M9B(>9:G2*J-$"1(&1>8 M( Q9SC'D84:0D)1%2+B=C-ET.[VCKD9J4&JQ0:E/-TOPH)K_KL\XW2P2*^3M M#!1O:([#>#L8C;PS8"2>@4;F6;7OJ<3V9[RX@.3)EK'JM3/&BI MHZQO-IMBP;8;<^*Z6:N94"BV^0N]?_BKFAJ_FCH>O[J1S2&P><#3B.&:V!>;B'U2HOVRS/ /JL% MSV"+?P[9'9=F3:AW3Z>F'^O'FF_5*GZ*;=$JK% M99JD01;#+*088L:1VD/R".8,L1@%2:1(U67*7^QQ:C2P%Q@<2 S84W^?M,NX MVS&"5S0'9HEK@70F"6MP/!''Y?Y&)1-K]8\)QO[%?J13AVH>>=-69Q%)&"9A MG'"(HUBG$$\R13QJQQACPA#G* W"T(5N.OJ:&M%\6'"=):4TB0O7[K'@7;#: ML8DGL ;FD2:,^\@!?X!C:PL\/%%'5T^CDH:%RL=T8?.*KTOWF_MUL5G\T_"1 M*<"]+K[*XE'-'+V5K"X\YTQ@DB51 #,:*@X)"(4DENHGQ)- _5%O"*]+@FTC MQM3HI2VS=L/9MCU['K0*H*QT,-?TU][.6XV4Y37:X/@/?<]V\N;^>$",&J#6 M8[PK?!_>H_K/;6B FXXB1 M" 9!&BM#BRL;*PDP%#E3OQ419XE;PNW3_4R- /=B B/G%1%%9X"UHS,/< W, M5[V01-= 9U6XL1.8'UF3FS#U#]UHFEE*KD3VRHY)$\\>,W;3KQG.WOOEL0?I93;4 M>RV!5A.T]-P]NM=T!K2NIEY\2UO0J#OHGMOG> RW*? MG#P Z;(!WE?U@4FP$JN']^^!^O9F%PLH%/Z=QA[!X\/II5>TK( MMOEZ\N_N"19U5*5)TO"5RQ4M%FMSYA63!%,1IC -4!GZM- 2$*[%2K MG82Q^\&^Z1BUU]@W^O.+U*(NE@M#R6^^Z^PKMZM6 ?GJ#E>[ZIHG;I;+]0^= MX7@N,X)XJGW :* LBD@G5LTH@RD)&.,D4=M*ISIXUXLT-7K820AH(Z)C*@L/ MPV2W3QP7_(%9Z%V>2YWT73:>J#JFT6SP#K6;@4H_?9K;:%C%/U9>)/OQVVEI MKFJW/MU7_2'O+:WCU0*-G.71%X#/DSYZ:[D?2U?-OJ>+PH1*[+,ES0FC+,RB M!-(LBB'.HQ02BD(8Z@21." \SJ1+6,/9GIPX=800AV^Z#T"[*V$Z@FE'D5X@ M&GH?6.>?U5)6(5%@+Z<_SKH(A2^ ,#]/%3QD9SV<@>0=76I#=E4:9\,F2$#MZ0/"U"(0 M91A!' <2LCC-((TB*5(L49Q:U9'NZ&-JC&[$!+60@Z_.]4B-Y9_3!S$WAYQN++J<<,Z\.9[C3;?H!\XV%Q[UD*Y$ MT?#]>F7,]+DR@[F"*H,YEZ94G2X4395)S!*))>9$9DXA[>V3L MK% _,I<=I2RHIZ_0E ^4I.8'$$+E)VMV\7#Z2$\IVYB Y]7P_6MF=.N^/ M#>E&'AX=JE]^E9O-TIAZY9SF-$L3E$&5-V"K-JN?'NJ< 7K#^G:QW&ZD,%O<>1ZF*([#!(HH M"B!.D@1F..<029P&&4%A' KW"V0'":9&?O7\-(GS]^*#O?S@E3*KQ'JYI$5I M3A>-L>68/=M]H%RND >"?V"./,Q8='X #">"6HGJE-#W37 / +U>_+KT_P+W MO#W@.7VMVZ>AO@$=Q>*15EQ<;@IS /%E4?[=^'QE.,E2DH>0HA I$LPS2(. M0Y*G010JDU"FC@D*SGI$48EJ+YR73>BJMWB78^MXGEP[=C""V0#4\4> MK9V4X.LEM-S3+UY"PE'LU!/97;_VA&.G&S182ITNVTUIWW*T=O3#:E=II0=LW M:6>>Z&>9_+9>BQ^+Y?+#8B5O-_*^G 2TZ9>$*-!@G,!,X[TN6P00X89AG$N)4649AFU M"N,[V?K4)G)+0(>HV6>87;8FKD)BX&G;DJU/#/$S-!P"B:]!9:QH8A=TW$** MSVG?%5?\[)WQ@HO/B7L087SVH9X^[TWTXZ?\#2V_OU^N?^P*@,])&N22_OK$J9T]=IJT8T0%*BD#"8!P&#..4,4D8$ MC&@8\"B*L R=Z@M>@^\W*_%6V]/K!WUDTFR.)<-,6;Z0I4*GW=0I MWN,PA3)$+&("HM>I\:JMY^_F&K,;UW#(FP0MIOVWG$;F MN5Z 6 MF\C>ELP#;**=4/(6XV#3Y\AQ#0XP/(]E<'GYRN.XWTWZ+ M+S-.XY],MO0$/Y2BH*UI?6[Y+"QWIRTPZL[ 3N%9*US7HTOW\,/B^W#4OZ O M<[8Z&.!GCV:'Z]']KO;T&M9*CJ7/>/3]TK?U9UGH6Z?WZ\*4'"YOA%AH^>CR M_78EM'Q/U1]:#9D,,E^W['^E;J%^;AX&J>2QVO7F,M%ED9"RF6D60!R&41[P M1&"6VWJ[O80"4S._]XJ O))0)]0S-1G+0D\I*#VN& \B)BC>;<\I*@MQUG M7E2.?J< 7^12[V8_TV+S]$W)62KIE!CUO2_&"0_SG,$U5IAXVIIV M]S7J[M)*[>,-HMU+/3,;R(UBM<5:+/AAU<3RW4^=$UE^4516E'3Y*:]_\>XG M7VZ%"9XN'A?<) /5"937*\5V9313VW(JO*IK*Z)^J >!:]X(=4J\XO9HE5[-YW6?@7*2CWS M>\>$"Y['W(X%7W D!^9-/8B-:N"H!FX):F7 JT8_[:Y1__*7&=@I"6HMC:T+ M=GIZS XQS #XRBGA6;IQ,U$, ^VS_!4#==/7"M59=OAFJ\\@E?5<+U.Z"]T[ MKW\.YES9H6JX8RBB.(-8B@AF21;".$9YAC-&6>:4(\>VXZF1?2,<*-H*F-O= MHC:]W,G<>A1L;57_V Y_QG6$9F/(:DEG8 ?[FRYP>UBP;DAY,V8MNQW9KG4# MX[F)Z_C^%46;7E\N^?'ZN.3'IZJ@D-KYYW*AI)3E[:JBXKF(18H2BF"2!0+B M* HA2\(4BIB0-(WC(!!Q5$:O.YUG+K6:JSJU:):]W M3*@ZQ #;$>=+#=J_3+&FXV'>UJ4)*ET]EVH:9B!\%FKR+.'X99J&@?ADD::! MNG);0X1K>A(_;!GH;,-CD(AE]1IYO_%Y]PGKZE@],Y4BC2YB(.,9B%-*222$XA9 MGD,F!8,\0R*)\@BGQ*K$T(FVIS9EJR)8E7Q.29U/X79YJEZ!QL"SU 4(IREZ M1N5>L_.XK=$FYADEVG/RW"-]0RD>U?Q>%T__O2[^OO.?UOL_^N-WM0DI%G19 MSG,A,26401'I"TT11Y"&"8(4H82@+ BSU#&4PJ+7J4UA)1NX;X0SIQP_E/3: M@'ZHY'<-L;!!WF[KXQW/@4E@)^\,_'>-81-R84Z/%-([L7V&6#B@Y"W$PJ;/ MD4,L'&!X'F+A\G+O&U&=]$BU_;@04KQ^^D/M+&Y7)F&K*4\AQ;XZQ2X]#TMP M'H2QV@3(C.OX3656D""$>AV#_?;3GZ6 MJU+?6*V$"0WXO%96E]PLJC#/0R^NSVK4=W&<"UE^5"INBT*[6/*0?2T _4CTZ@[4J\P'N]0_3;>CY%?;TO535F^ M6=^SQ:H)I:_SO=T*U<$B7^B@^RI;U W_QU8)*)3,+6G4WY1=+_1V6_WAG7KD MD2ZEJ0A)TS1D,8>YR&*(LU! $H4<1B(G492F,B5.=1"&%7=JAJ YO=*G\%S_ M(/>"NI'WP&-LQ^K3&;F!Z;Y1%+0T-;E2FB2*;66K%'2=6@Z?HUY7^7 MXJM.[F+Z?+_XJ0]Q=9WT_2_K RV>!V&8!SD,0EWK+Z <9I1A&+ \XIGZ'17< M+N_ME9*XD-$XZ7$;90R!F#2CD!E]0+F3W?Y<\9I!NGQ6.Q+P Z\".\1U3@BC M!Z@4 7NA@5$%5+JT?^]^U'O-D-@?!(\T-",=$S^?%.#9I "Y&:)%-43[W__J MYR#9 Z =Q\S7M#[:(;0'"-I'U#Z:Z^F^=?] %T55*.I6?;RKNT6S@-ZN3#3S M8B,_+!ZEV,4A-N4R6R6F*M$^%=K!NY#?]0[Q45:_?/=SH_^I&GVW4O.CNKF< MHX0)CI,4>U1T%7;6E0J(A<_Z8! M AHDP*M]X'(#QB\S<%#.K6;Y=0$.,&E^_^<>%M#"Q3%!QPM]@W8[P.E_60/; M!-/_J-S]^%YT3'TY!KZ,$N-Z&K[H0#US77Q9:7HX]T2_8O1QO9'EVZU4'Q"I M;6>),XY#)B%/4K7GC&,)69R%D*]@I>4$8BN! MEM3!)^4,D!8^/-?#,S"_5\@8$<';&ID^;CMG(')PV+D>JI'V8*<@\^2CTXU! MEW?.F3?'\\OI%OW (^?"H]>6E'JS7NK< P5=?EG)3)C$$>YSK#'D.0H2B#-$$XQXK_ FH5.=:G\ZEQHSFDYSNQ 16/VE]*Z"2= M7%=3DL4#+=ROWYT&Q,X:'PKF@3FV51VHG6U^GPOU=UINM-.#W.BJ:\3Y0Z2%[M+V7);+H^H5*%MF#&,;N?E-'4KJG2=:EJ??E,&_KZ M)%PI.=/9LTPI*EZEWO)HO@^!OR_[WJMLXVX AH#UV0YAD$[Z+0\WW)P"Z-I5 M-3#>TME>)T7?TW^%K*Y]9H(E%N7?7\L5 M_WY/B[\WE<8$BC/$$R@X3B&.0P8IC@-("0M2G?Y6_0V#K>C$\L(.[89Q*9+ K+E/IL?]KI!]=S]XLKV/%3;TK5P3)4<7010FE1':<9DSJC0 MGF@AQ"B/(!-A!"47J4BBD+(PZUUDZWE_4V.\PR)0WU3[3FFD;%&V8SN/V U, M:NZP756>8RGS@G,4H MSZ,,)A)QB,- 0A+( $;*N,H90RGC3O5;.WN;&HDTLO6BCFY<+0\%?:$U]!F> M)5#NQVKL:]S#*1NUGYTE6;W4=T?&-OJ*>+DNE4GS3?[#*,%,T$2F1-C&!E[H:VH4\6V]H4L=(VA$!=3(6@4LJ^Z510<*1== M[+0J=3D7K8E]F-PE^+N)PS.H@Y/'+NJE$154LH+??>-F'V;H$;^1P@VOP-$I M^- 2F8X@Q$LMC!:,:*E*.RC1]A7W1.&?B[50>T%=Y*:NX5[6-T$RQ#155A>D M88 AQBB!%,4I%")-&1&"D-@J#4IG+U.CV5I08W/5DCK>M'6#VDVAWJ :F#Q[ MH>24.OPB"E>D#C_?]FBIPR^JUTX=?OGA'I;6HGQ8EW3Y6['>/MRNZHP0IRNY MJ-]NB@7;UCD-I4XB,0_BE$+,^G^S,_TA96&TCXC^T65>K HPN8*?,V?B5 M@[%J%!IQ=!QLPQ%':2SC<=C1V\5X)JHG, YL6%]MNI=F?F<* MRG[]+I=+[1='5T_S)(KB&"<2"IEPB&6>0L+3$(:"))',9(Y#9EN=^7GS4UN1 M*@F!$1'4,MI7:#X!7_>B MZENTF1?ZM/NMK/[W=G7#>:'HH94H>Y[+-,HSH0N@:A MB'.G^"Z;3J-0+_H@LW M-QC;E/GI4;+9'B)O%9LMNARY8+,]",_K-3N\VX^-_E@5NS3^W^C/VONJ;'HL MO\ARN]1YD734Z^=BL2X^2_5?_>SG=;DPULRDC1W+*_E0RRKV3=J=:TO4A]T&$L_7Q=@0W^"AT9:?=?QH!4!3Y(6CKSF M913M>&^TD1F'%]OJZ)0 C0=JJ4MOU92Y4ZDZ[#!*@4HK\\I.+W_4Z1-E3]3J M1:11J= ZO 3)FV2#BB:\ZNQJ5 MAVR4/N87JW=Z>K#R[\H.6WI^:MS22*_-M;W\^E]:@[HXFZ/GJ]MX MV%'/<"@/3$96 (,_C?Q@$(^X?M#Y\JIUZWQ<-]M>P#SSN^W72C^N^R!5F[(^ M>%_=&3?371;@)L;H[59^5/U]^R&7C_+W]6KSO9Q'48CBC",8288A#A(":R*^W&*/2X+5@'1/BU>WUW#Y622[>K'5@.C=5 M5)3)^6U]6Y9;121-Q@SSVRKKRSQF>:CH,(59B"3$G*204AS#G(0X2$D*T"6%32ZOFZ,%K\1VG*,.LYW/RMK'+HZ-2BU8^.^41[C)SE M?G70\1AZ%UL/12,]N-T/Q6TS%._JH6C^5FGA<7_;&T%?NUYW <;="_<&Z-D. MN7]+_0CSW>IQ4:Q7QF]H^>[G8J-C2\LOBJ[7*V6S/GU>EZ9^U(T0B\J)66<+ MG:,XSE.*,)2$QA!C760X#3*8IU&41#3&+'!*I]=/C*D1Y\W=76'N7/0-2%5O M3OY\D"LELXYU4CL^V=93!WMHL?2=I?S)=;%TM2.LHD1*G0Y4WXJYL6C/X;1C MTN$':7 /DC;Z6@-@5-!UZ1LE0*,%V*L!M![^^/0Z'#UQ:D\A1N75ZX ZYM8K M6^M1+2\,XGU1JBBHC]G5#IQD(N.0HU1 '"?:X P1S*-0BCP6C,32NEC>R2ZF MQHOAKT%\6"LO"AP*P9V&L9NS_( S,!^=PJ5/I;S3 #D4RKL:J)%\CYT^)+9T0=)7)._WB>%7R.@4_*)+7_63?^]H57?$%7>[34)K<%B)(:91+!DD6)SIG M"(,983',LCP+*=%;[L3MJO9D/U-CNIV8K42TO3*'G,/5]H[V:K0&OYYU!ZK' MQ6PG#-[N9$_W,O)U;*>JSV]BNQ]W-W9^7RQEN5FO9'.X]SL5Q$!P^U[&I'*&15 M);-=\.NADM_>(G 9C,MVU$ 0#\PP>W0;L<'O-;J'Y=0^#XFNO1$V$,HC66;> MT':RVGI@UF'*N;0VFGW70\6VT=?G]9ZWTNO5G=!+SK[7+$BP0D/)(&<4K46(!)"AHF$D10I3?((Q<1J+;A.C*DM#2:; MU$9GDQ)*CUF5%L9H,@/%3I?:O;K21I\BNN?X[3EJ=F;H\&,Q\!IRF-1K!FHE MGH9)X7L=7+ZNJ_L),>YE]55 /;NJOJZU?FQYYF;\HP*@B@?;9?+[E.^,]<;) M^MW/C5R9L\H/BW(SSS))" E3B&*60QS@$&8A#V"@C.HP$WF$2>A"H1YEFQJO M=GFC[/6;@9V&FF+W>]5&2?#G7DWP;J4,K"H&VG&3[_,CL&/D%QK:@6GZQ4;5 MF>('P-\3[_N4;-3%8 !(CU>((;KHMVS\37Y?<&71[ZZ2TE &0E_#BP3B2*T! M+,\I%"S)!,T2$4=.Q78.FY\:>3?2N9'L$61V/-D?B(&IKA%L@#"6TSI[HI>C MQD=EB-.*'4_R,T_UG*=TN:W*>"V7ZQ^*$&2Y3]C>Y)7#'+$(Y1CR,&<0XX1 MPDD$<2@)U=GZ.',JSV#3Z=3F]-=W;T#C/#\#00@1F8&=(F"OBFC:%@=B<9!]Q\48]-E^,2D@,(SVC*Y5UO=[KEJ9SD!.4BPXC -*];W^OQ?$%;H/+ MX=/$.P(UW'WQR5Y?^OZX"PJ+^^3.U]WOEV]7&_7%&/\\'5'WN]J)J99U1[>K MA^UFG@9)(J0((4Y"I+=" "QJPE.<"6^A>T9J8!+?2UH%-,] 2UA@I/4'G/V]ND< 1[I+OP9(I^MS M2V@ZKLPOM3#:-;FE*NVK<=M7W//SOUFORO5R(4N LQCE7VZ\D M48N4$!32+$:0Y8E,H@AAA:YM>OYSG4QM=3J0$QA!>V3G/PMI-X/Z FI@ZNR% MD5-N_DL@7)&:_VS3HV7FOZ1<.S'_Q6=[YI_9LE+^8ZO(X]VC^D]]V,P(#9E( M,ACQC$$(8^ MA3M"9H!#_$X(?*5S.=G'N%E;NM1\EIRE\V'WS.1O:S.P2G[W;B7>JCW!/$\# M)&4D82-DDS52B0G>6N^.S@/9 M/=>]P#/P/'=&QBE;>:?VO1*6GVYQM)SEG0JUTY9W/^A^IO1))^#6"= +^5W? MT3_**CF=COM\7M+]J]QLEF9_<+,2;[;%ABZ6^E^_*>M!O_%%\B4MRT6^J/(_ MW8C_W58I[G2ZS)M/;VY?RWQ=R&_TYUQ2@7D2"!AD*84XC2+()$\@HWF69P'' MH?UIU8MI,35"VJM676/QO7:6Y_$O^U%6'<#;>O4E>?DLOF MF 5SGJ=Q"M7^*X:8*D,JBU (>9R+((E8B+C5L>KSIJ=GXE32V2\Y1U!=MC'Z M S#TZ4DM6(\,&4<@V"^&_<$8:86R!\5I@3BM=P=K'[TP&I6>%K3-;V>><">= M@YC)FZ)0PV"(\'.Q5N2HL[$M5G=S&68LCW$,49H0B!F7D"1,<1%#3(0)2]+$ MRB7;NL>I4=3-M:.ZB//U%;C-]^U46>26NNA!^S)$.YZY>X*=.5 V2V3(\(_] %9N\K47A=P M\19CK,I3U^#KOQ15+VE>JC;5-=!U%*NZJME^]%L5Q)J'.(K4YB@+ M( GC%+*8! REL<@HG6_6&[JT8]&J62][73W^4NNIF M':*WNKOAF\6CR7&ERXPL5EOUNSK#B:Z8S6C&(EU:-Q'Z,HU3HNOK$HB8C$G$ M8X%"XC(QKQ-G:A-::0.T.N"55D,9.;^ 1C-MZ>RT GNU]'*\5PWL=7,CA"N' MU8Y(QANL@0EH-T[MT=F/V:EQFCF.DC.)^0'7$_E=*L[$JNQM5U3!K!S\YH"I M@OM5\CI5^_O'CXLY27G* AI 89)IQAF'-$P#M5>*XX AS/+8J>#8J4XF-]^W M;+G@RR>@N%0?<50UN4&Y$]K1%#B%JZ49<"5:0YL %3![^6;@_=_@Q]N9CLPI MNBXFW]0\MG2W_5L/P*X7:G9)Z6142NU6])A4+SQ]K6/4%ZFS>')="V=U M9](+&Q\!4S#;. /,@S!%(D[5#BO2-6=0R!0])!%DG!'"!1("._DV._0]-0)N MN]T<"%_GTJZ<<(S\M:.-XQ&-R[C8<N7=3;!:/]/5BK7V_ 7QWJSW?#VTU)?D$;F(&Z\.H1 MEGP!./MH/'\ CA2&U^O#1J,_Q7M-2 M4_/]@UR5E4\0XFR+<-4[>35YA,CDD F@QA&,8VQ8%Q1M%.-B7'% MGQK?-[*"6EC02 N,N+/=OP5XM5@!H:,UBQ(\R,($;\M?' W7<;\52]MWLE_ MT.:S5@H:K4!;]784=*G=Y-H/UOH# \ ,U!#L/Q03YU'!, ,7/B^/QOB+C*$O M>WY]P3G6:WSONWT.'0)?\7H MXWHC=7L:[EU.?(E%F@D81DSJ:DW:-R=A,,EQRA#!#&$K+^:./B;'4$K*?P=& M3J $!5I2AU.",T!:G*M<#\_ O',*F3X'*6<@D6_>"8Y,*C?7T3FJA9G?S@5.1(E<>@>NX;_2F5M;DIJ.ICL:+% MD_&7UI7%]96SVG^K5YO+OCD.8HP#'.I\ QABCG-(<%7M+B1"@7'(H:!9#') ,AEI![>$T%3F M(K2[FYC:D(_B&&.&O$Z[LYG6N-KZ@$QBM 9W)&GGHNB8HO50UL\;=6?@4#W0 MZ.?3!67P0?#FQS*,UALT V/&Y9U@'YN6]M+/=B?Y. M8-!([(]H'=#Q1)@V/8Y*? X0'!.8RZL]KW[EG=[?-K5,PS!),4T@(:FR1U&4 M0AI( I$D64!)1'/JE@:MW?K4R*46SK5RZ6GD+.\I^^(Q]#6B-13NUWJG5/9U MZW;0]KB78J?4>G9G=?*A:QUYW]-%\3==%OZ_U!IH3!+M96?&[^N&;JK+,/58 ME?."+EL!6S)=J+4!@E!*4P0BB$.!489D0P&%'&,I9& MD4A1/V?@4>2?'-FT_%PU , @ &H(0 N#&=BC8)YN% ;MP$?M'=OZ2XU%7Q_D M<3XI2XZ<[HHP[->3_Q<<6X=OW] M;;T6/Q;+916:Y,:2[5:MEOG3SH9\KK62/H MM9$PA\"ZKA:]X1J1U:V1NH)N3^+@G18/>WDA^CJIZGF:.?UX#R\(G=&SE2G) MI-FMTGPJ.FI<+Q92%\Y;WZT6_Y3BH]S,@S"+91!(G>HM@3C),:19*B /Z%TQ(!;.%H/#/##Y&%D/\[A5 MH%=*&!.QI0;8ZS$#2I/!A\#!F6/PH1@K3&:@(7'S!KD*S2YGD7X-C^=+?G,M \Y1DH0PSB("<<1SF,4(PU"D$4_R-&'"R0X]V]/4%I%= M*KB')A7<=(+O^BV ,E#'OA7;2%]6]E#//U^[TKKH'/]S3R]>]%E9]? M^UY^Y;HL6SKB8XYYD+!([449XA%4_U(F0Y[F,,BXB!4Y1+&=U_ZIQJ?&!+O$ M1@]*N'X9GPQF=K.^+Q(#3_,="%7 SZVIH*FO%M[0A\6&+K6-NG.V:P<.Z3W) M[>I1_?:PO(+_G%!MQ#QG@C)-OTC^I[92Y[(^'3S3;W*_7Q"BHS)P2:I_N9FH3OI82O.F7YNT,EG;3_WJ$ M!B:"9^ ,D.6M&P1/<_M,)Z/.\FY%C^?[A:=[Q>3%[[;%>A_U$N'Z:XU3$G"2 M44B$LO=Q$.?JIS2!F2 !X3R0@;2:^=W=3&WF*T'1OP.I9(5"KM;WBY7)(;8R MT57"1%=%V"D.[1R^%@?(7E ;F V4C/\.M)0'$6@1[A>T=PXLI[@]#Z"-%KK7 M%SS7\+T+F'1'\)U[>H=ID3#,=FFMO+ M8Z==,__YIGI5(NH:ZQ_5QU@[HG-.&./:%4G(#.)<\5=&4 BY3B1#.4HH=DJ8 M/H204V,Z(RG0HO:-!1AB).VX\:7'9V J=1F:$5..7<;NQ1.+=8CX+Y(^[#+( M_I*$6?1U!? MGXOUXT)(\?KICU*ST.Y:?W^K_W91\BI7BA3[5"GS+(W2@% $(Y(QB)6)"6F. M8\@CRO(\QP%Q\S"]2IJI4AE=XD!1LO^9'64,1CC MQ+511-N"K_ZHQN&7DWXK,]#6J)6.RN\A[-7(>CR<[2_+Z(>V5\-VZC#W^D9[ M>^8N5JI;N5(_;/31PLW]>KO:M,(";E>OZ;*JIROE9E>L75"9TX!R*' D=;7& M -(XCJ!,XAAAE/,HG%;Q>U?92:KK%41,ZR=G41,0WT/%D!" MN(0))AF6>4H%<4IE=;J;J5%C(QRXT]*Y[G!/ FF[O;T6GL'WMK6 ,[ #R<@X M [\5Z]*K*W,7%-ZVMB<[&7E?VZ7H\TUMY]/NCH]O="4KMBZJ_'C[X[>/6^TG M9*I/2M6@MOSN"GI?SBD+12+S!"*J> $S'D$6<091$H:*$TB>$*MSL#Z=3XTH M*CGU\ES4DH*'6E1[;S_G$>CFDJ%Q'7H/VA:]?3]Q M.23J(_EA>D;?R3FS+WP=+IO.38[FR-E7V;9[9^\VW%8)KNW/XFG^YM.].LU=0HD_&YZ,T4._&7 MGA/GXSPC>9P@0:#:3*G_<)I#AI, LC3A,E6;*(JL3OWW34YNXGQ?K*CCK/EH M.VN?4^:CORGS<>0I\_'LE/G8<\HTVYPFR=C-2MPJHV=UMV!+ M6:6%:?Y4>1'/)0IR+M5J%(:Z\D_ ,DAIE,,\0.YU06/<\M0G82.=V M7&$/M-T)QB#P#3RC=_D$JP#M1NHZE=1LEV]PG+@#9P0]G878]SOJ\8@S',UTR^7E;^D^-]MN=&;_CH^ M.,UPE(0YA2&3^L)&(+5##T)(.,J#G*0X)E;I4=VZG1K9*,CEXFX%WFR+PCC? MM60'>^'=^,9R!.QHQS^N [-/2V#P#-Z]W.!FLRD6;+LQ.?$W:_"9%OK7_C-C MN"'HB:X-#-!?*@]:E142V<&]44VU]''U&9J)2:HY9P!+:G"$6A9[:9O%Z#=D]@33 -/Y5X( M64]K"PPZCDC5V]6\5C_LIW-7FZ-,:@NEFJEM\ZB[?\=KN2S7]P5MDED1GC*U M#8"21ASBA&:01#&'**8,\SA#B%FMO<^;GMIT;J2S=PTX@JI[QEX'P, 3M1&L M1^ZI(Q#LO1_Z@S&2;X,]*$YN"Z?U[G!*.'IA-)>#TX*V'0K./''U@<5O=+'2 M]:,_RHT.(GB_7/_0-:IDM3>LOS2"2"S2G$),8IUF3]%31B.I#9"8$)8G,G&Z MR''L?VKTM2]:Z[AW<,7=^;S"-YHC'EQHT<$K+?POI@S(K,HMI54P!0+E;)3S M"A<$_1]<6/7^4B<8+M!T'&4X-=,C6RCZ-4;(I-43.JU>V*1G3&@N0L92R"E7 MVZ8DCB#)90BS+,($1R10Z%CG"CW3R=28RHCY[W7BQBHS:.B2&?0N[5\?* 7A#^( OHI6=] MA636UP+-K<"[G_R[=DG]H@CYC?FIK!_^Q):+N^J#933EBC S&$4!@E@B!$F< M8QC$1"12"LQ"IZP:7J2:&L.^RW/)JQK%LA8?%$I^4/WL7H[%P\#9F8VC#\? M='XZJ+/YUU[DV?,[LO859,L.'3)T\PJL!POC["/3"X=T7@'CY?#.:QIW-UP_ MR-7CXGYW&"A3F6*.8!Y0 7&:*4.5IP0&%(62:(>E()P_RH*M;>S5@[9=YFR[ MA^&F;BV>OMR MN3"%[POY*%?*]H+@2N@N&_*] 1F8[FNY>MCK1Q^/M9'>&XF1+'-K1)QL\9-: M=QC@A\^/9G6?%+-M:I]^P)VFOV[O[VGQ]"G_JI:&1;[@=+6YX<:[?K&Z,^ZJ M"UE^4$O)[4;>E_.$9!D.TARF(@\ASG1=HC3/U'\$8U@@QNU+E#CV/37ZJL77 M<8HM! ]"H /[42@"CAO@=-<61V/]GJJVUX6^3?@ZF7GW\T'RC13OMYMM(9L_5$E5R_>+1_E^47*Z M_!])B_+;=UE(FBNNGH+'- T:H%*K_U? M*\UFP*@!M%I :VG2/K&YLOU^ MG/[[8K4N%INGIM#IG%*6D#A*((D2#C$11+%T1&$J$8LCDJ>$.Q4N..Y@:AS[ M47T.NMKC>KG4IDTCIN/9]S,8[8CR&G"&-L%UZ87OZZ7ZE,K_,%6RM(?F41#& M&?#\4=HY@#Q1T[/F1Z68<\H=4\79YWK6/&G2/W[*=\D?F]R/NWR:B 29"+,0 M!CQ-=8(^ 9F^/\,)CK%@ @72RN' I=.I48.'/)G]!\".0'S#.CBIC)]YU 4B M7Y4[;+H80I$E% W3*(NHLP-;IJ- ;^A-0HP-0<^KC MIP^ M\4'A5P:Q?0*GM?7R?^[+1:E6/#N/.N^!L]Z&SG@D R_8:Q&0]?K:#)^ M[!0 6@-PH,+N:M_KAK G@/ZV?JX"C+W)ZPG0B>U[LTA\>NG^H]UJ2$2RE B"8,XC90I%RG.#*6FT"B1 )0D M 0P9B2'.0@(I80**+&4B2"3"A+C0XMF>ID9^C:# 2.K&9N?AM.,L+R -S$R' M^,Q )>8 ,3P7P?#$,.?[&95'+JI[S!:77W#/4'"S%0LU*KJ4\)R0**%I3&$> M(P)QG&"8I9%07)"+))&"I<@JA]I1NU.;[[5H0,MFGWF@#53WW+Y"_8%GLI7F M3AD%3NC9*XM NYW1,@><$+Z=+>#4GWLFZ)&K4BWD^GJK/+SQJA<+*664"80A M33)]C)-BJ ^7(9N;8]=\/I?@M5N+?8(V\$1N M\-*R#I'ZQQ()7]F +G4W;H(@2^6?Y0RR?:_G28.ZIE.>1C)F:8:L@]7/=#*U^6K$/(HL M3AS"L,]AV3U9?2$T\+0]"4Z?8/5S*#D$JWM :R0_[)ZHN06K7X"C*UC]W*OC M!:M?$/X@6/W2L^[\IUWR/J\7J\U'9?&8?T@U\NJSN)-O)5,_;-77\'8K/ZV^ M_5A_^[[>EG0E;E;BVP_UMZ=WB[OOC96>A$P9+FD$9:13N&.BPVPB"6DJDHP@ M05.[6A->I9H:P\:_$C4;Q$Z'9DID]OSA;\0NT_*+C,/ /&Z,?CU6 '\C:+]DO,A(CK3&F!%\,".ZTB.: MFW_O1_1HNJF-]T:-Z*894?U_FVI$I=;S5S^KDG?$.Y8Q?WV-MNYYAZ>]4/IO MO-^N__6V5 *4Y0W_QW91.9N]69>;3[GY12%%E=+49+^@O/ES.=?U"&(:QQ 1 MD:C-A]!UFU@(0TQ(B%.4);&3_WI/.::V>K;D WSM[-_>=S3LSAI&P'C@E;'1 M +14F($VZ&\Z07<^M+@2,D\G''VE&/4XY$JHCL].KFW.F_>".<0IYP&3*.9! M"L,LT7>7-(*$D10R&M*$Y0%GPJDRR]F>ID=I]>U\6=W.FV/1TIR65C\Z'I&> MA]B.Q;P -S!/G?9HF(%*T$$=&@ZQ&,ZAH>[GI1T:#M6U<&@X>J%OL3B^I&5I M0L$U];Q7HMZL^:)* [51MMQBK7U4YRRD683R$-(0Q1!+J0@CB 0,A8RR-&$L$;8CC2%P&YA#CD4&>CZ FT]O;F=U5KH-J.2>@2YX M>Y2.<\/*6PTYRVY'+B;G!L;SJG*.[_>N7FEJQ:L=XEOY*)?K!WVJH4.=5Z6< MIIA#6G*&(OKG.UR@Z M61ZFBBR(205QN]=_;9!MF=[3 MMSDXO;<0:TD*:E&]E@*]C(B_0J =?8U=!O2RVB>*@%J\U(^C_U@5DJ_O5HM_ MFOBEQA7M=L6UE2I+U?=VJ5WS]1KQ6:T+Q6YU:.) RSFE42I2%D/&4V50IE$ M:89#F*8R30D/"8J1 M1J59GR >L['7MON1]J?-=UG:CW)B0 M<_-KQ3/F(+'Q+(H3EE)EBQ&4IVJ#G6)(>,YASO,\"!A)!7:*^';K?FHT\?'F M;VX,X8BV'7,,A^' C*(%!T9$T(@.Z$;7.ZL27-1_4_)7]PD#Q&?TP\X3!3EV M/BHU]0/FF+)ZMM(WZ4]3B?!V56X*X^Y4JOVM+JBF3*<;KOZD3"59OEV4?+G6 M\I155H249$0$<0SCE#'-:@2R/%,;3AF$:88R+(B5@_G5DDR-X/:*@)8FYB2G MU@7LE0$M;?IEM.@_@G9,.YL:82K!'#>-W6!:7P7X@6CXJX!:SLI?!!A)P2N-VB\#6'=6N/B[ M$.CH:^P+@, M4!XH2RP3E$"L/7 )#R6,&49"<0@EJ9,;6@\9)D1FN$ 47)O/__( V9I<@\(^N+%U*DN_R150"0T^Z,LS$($O4D_.Q7)19Q;; M'?>_4H-B?OK%).NOM >5^G5I1=#D'ZC;-$@ #<60N?RMQV&PM/V7)7CA#/W6 M$%U.QF_?5#^*5=_;^EY^HS\//T3UBS=JVZVYO+[PG>,,TR#7.BRJO];;4VU].8^4U<(?4:/^@^5'C/0*#(#-_>ZTI _TG/&T!/5V?<[ M*L$YPW%,:^X-7)&AY;5:,\6;];WV2#'=W!2%KC.K=[FOG_:/U!5-;G0NW$\/ MYBKT;\J6E3J(K"F!\FVM?_5INRDW="64"?5Q:[97*4IR3'D"JY1E%-$(P2&0$<13DD.0RA5D@I(QHGB"[9"!7RC&U)6LO M:6UVFA(R^QOIW66*^-]MN3'\M=O3JQ^66Z'82JUCF^^RJKM@'NXV8+V.J]T2 M-<)H#;SB5!J G0JSXU&2.DQH-Y@G#E[\K1M7HNEI&>@KQ:BL?B54QR1];7/N MZ9C>?/K;[=N U!:80.(;!/!=0;BI'2^5S\&)S2\)S4MB.5 MSN'SHZ7#.2EF.Z7-Z0?ZWJ4_RM56.UH3AK*IX;5XU/#5^^4J7KG[5.XRBB*KVA3)EB4X$FI,(9E&B2%B$H8@#F@1!-M^L M-W0Y($:[YJ>)D:W'@+OF@SL'5"+YO/X_5-+;37_=[,B7^H?*/+^_/_K[%6$@ M>A]QAGC M<6[\*A.(*6*0A$$ $Y3D*!4!%8F37Z5/X:;&B]KK>;M21NO2!(^]6IJ;X3NE MB+X>%CM7KW(&5M)L5HLCO?I$J_@::3O6>:GQ&YBYJLB8 [V:"[#J@E]M4)5V M0*O7[%BUAKN_FL+KX%D>#'TPZC7AQ1#X^PS'\27:^$$\GD$]&?KCNP_W+?$N M^*ARNN:1%*;.61['RAQCVD5+ZC3#<9*2-%%[9&9U>_:\Z:F1\TXZ-[_V$YA= MWA[W1V)@FO,'@OT&N3\8(^V0[4%QVBJ?UKMCKWSTPFB;Y=."MG?+9YZXMDIM MY6OR*?^ZN%L9AEMM_EBM62F+1]W/[>IANRG??-=W..5MR^'*2/%-_MR\5BK\ M?WU/UM2O[LY9= M7X*T3N3U']1"15=/_['WCCRHLE2IV;?6K:=QM[S@?\'1'/HBOU4EMU+.U,O= MJP?:^H%*P5E[T-LNJQ7Y :TH,)H.4DC7[R!XK[+K2;P7*L'K%]SS]7D]]W.- MNZRVE'5&C3?KU6:QVBY6=W65=9W !J$@0BE5ZT$4)A#+((4D9@%,9$BER%*. M4>QRV'BYRZD=0^HCB7H?:U+5[&4&>Z'!S693+-AV8PA@LP:_RX+__2__%B3H MK\:E5KWVJ_&'/Y_,O^\0X2@/@CSF,,T"#G&,4[5X9[KN,I4H3AG-N=.9N>94"]Q^>9OC+.)I1A.8\R2#6/$:I$DL M($L%([E4_S^*;4]3;#N=&IT9*>V/%:RQO7SJ,@1B _/0J> T4)]%UU:Z\W[+ M"57[8YPAT!W+!6*_X7G0:%:!ES.P6BMNUTK\6)02E/*!*JZ0RR<@JF#[O7>@ M4IVN^((N0:F$-1ZEI:?"1JZX=AP@63O.1!3&A091!]7]86U,9 MS*B4,&&2*QXE/,!6VV6[[J9&2FUI37RM7NMU?I'%3O!ZI^+&11= MR,A?U . MS#X'**YSL!?UTJ;9F77L,/%$-Q+_5?M[3"UU0GU7Y_%WS^5=\);)[]X^MFBE? M)=\6)M7FQ_7JC[*) XNR-,EI!$-]>8QCRB'3V45PE CU&T4H,KHNA5U'[U-C M%\7ALJBV1W0)I!;R V6 M3*ZK[Q=.(V"[$YBS!U,A-?9^Q&Y6Y@VY' M9X-".3"E5;+/P$YZ8,2?M7,_;-: 2?"9+L0,:!V 4<(?J?7&SQ.QN?<_*KGU MAN>8X/HWY,MRVR=%_Z#^6'!C1G>L[V Q"7[OM2FA?P%YS1M6#C=:!TF"VV:D^ M7]@FZX#ALBW6]7)?>F*;#^O5G;Y$NEF)K]_7Q4;__&9]SW3G56*I><3C,):* ME1)!M<.K,KR(C!&,I624\QPEL6.A&IMNIT=0;#,#O$FZ17LDW;+$VY:*?*,X M.!=I +7(\/_G[EV;(\>1L]&_@@B_MGLB"F->0!*T/ZEO\VJCIZ73K5W'.?.A M E>)WE*53%;UM/SK#\!+%>O& E@@Q77LSHRZ11*93Y(/$HE$YH.2L\P@**4N M_S@#C>#."_+:(>6,CXP&'9F0;( X9B2KNZ^H!%'%V^N 2LH$3I"B&Y+J$C6$ M!C!EV(,\D#0,!8]C;-\+M#W"U(BF2J;LJG"#+,8XBP;NXK MB("1SQ"+$S^,H\ TT?S4 %/[BG]$GPNC]C%Y ,_!6WT+A1GW$C MH<5A_I.XF.>"7XO/2'G?>V^-HW3M+M4[4K-/WC9:&G:7T.V4Z\[K[*GK]VPA MBO5J*>I@T,/JO?B=5D.Z9[DZZ6:7H/$$RSE'/J!1ZHJQUAP MY9L($E,%J!>%U)34[(:>&MUMI0X?5N"] +_70.^)#^X'!MJ<@(<#?"1J=@N\%8/WPZZ#VRT? M.!KK]U.T/1_T?$*/JE3/Y''U/EM]9YE0>A6W2]8L6".>1JDG(.4RA0AY:E+@ M D'*>)*H68%Q8G3BIG.4J?%_*2AH26ISLKL;S\MD[@2E@7G[#$ ]RCZ?1\JB MPI4+Q,8J=F7Y:MF5O+H$1%?UJ[/WCE<(ZY+X>S6Q+EYL3X/W^4IFZ[)3R0<= M_A.Y]NU>YY&'J8=0 %-"=>5Z%$&<"L6)'J&$1(Q%U)@$SXPQ-0JLQ*Q:3.DD M5M:2U?SK/@?H919T -/ '%@C5(H(/CB%QYSZ', T$O'9PV5%?1> Z""^. M1GL71&^3WJ5+>QX38JSJ_B'X\49ML>O>4T_,@C,OHDD,?=U1&L640B(2#R:( MQ 11YLG$ZDBCW?!3(\I/SR^+U:L0>UD)MD>&[ Q@M@\R'*P#$VM+<' JY:-H M-Y0Z71-H@+V5?G"Z.HUD-_BXIY-Z 7-T6JG?4UQELM75-?6/_YFMGQ3/_E?9 MAZZ^Y(XNLL=R@KQ=?OJIO,WB3NXJ8+3JN41^&-/ 3Z$O4@J18DB(?8)A',5^ MQ(*4Q,&5V6^.))T:C3;E35_*#_Q/I1D@X*51#M#Z^U]MU=.E842IH#XZM%=7 M1NI2JC^:4JJM7UV;:N?J+3$C\$G8?F"N/WT$8Z_6;?DN;%7=7GFW]R9\VKX) MK7I-,Z/B30X2 AW;9; D0E=ROG'BH6.X+RR8_LV7M 08<>Z$( M(IC&@82(8!^F7L@@X@\JDU!#7P &CS!4 M@O4(JQZ 8!-0Z O&:'&$ U 3"4"$.$0@ZIC*2BI)#&GB=2RQ-LYP::&B,U%&A&5YU4*"?ZH_SO(4?Y+B#BKTGMFF)%K\W8K>UR1]\+U_>C@ M@Y96E^LJ*Q=EQ=\?U',^KIY)MISC,(HH2XDB RSUOS@D :50TA@1*CE/S!K\ M&HPU-5+8$Q5H68$6%OQ1B6MYR*L+9#.R< 3=P'S1&S5KJC# PQ%;=(TT*F$8 MJ'S(&2:WV-%&D:_GW\2+>F&>2"%N'G-1%N]M;UY\52](_6XC&:,TP012Z@M= M.4A DJ(4!B@(/8$EEPR9$(C5J-.CDIV40(MI22)VD'?3R6! #DXLUA@:4THO M3+K(13VP12SJ3SM2L1MK%'KII7Y#-/UNM@^7_/5%";QX<$*D%#HN"A''!!#5.@.XEP=2HJ%:B/-SX?)@37;A*A^YG MK,MQG<%-,#")M=$_RM15#O;YYB-3?L4,V7<2PDZ)\;6VL%07M"$!+4S*RM*MZYIS?"4PVRJF M+6SJOF;K)]WB[*5NK]@": ;,7E6'<\RD[.YJ7IN&4N/.I=/0^=S\/2WI>IS. M/*C=_^DG6VQXMGQL:G-_V1;^(['/44(EC 5'$,5) &E**.1Q@DDH*4H2X\0@ M\V&G-N<>-:$ 6]E;1>:_V-9@M+3%Y0C5, @/OLD_!7 M3H<. O)8QT6=@6UW MD-0:LZZ3I>8/&^^HJ;6">V=/[>_N>3)+/_Z&J7FHR/2+]D%-.AFO6RH_J#FF MJ-K=E3\25EU2K.<>)3Y"TM,%7#!$5,00Z\0,%H<1"=,X2NS:)O248VKS0DL\ MP)1\ML>T>EK#;!4T L8#SPRE!J"E@BZ#V5("M+28@;8QM"(.CVI=AZ2K,UL] MI1CW\-9U4!V=XKKRH'%\I97_^G(N1O MHM@LUK?+#Z1XNMNL%^15^QRL"LNC7(G00[-8#2H^Q27&H"M"I ZP(J9<"M(E5MD+L1#6+NDX]CF)%\ M="=?#'CWHK/V\VSQ"C1- ]&<*R_$"\GWNE3^XNC(P_56Z/#ZKWCX:*N ZP%H MKPH9J5B4_J_5(&:>:2\:\F&("$^Z%$(DX@,3#"?1)P".9A@11RTKW MIX:9VOQ5"C7K57'Z#(YF[OOUZ P\CVQ;WNM9HSD@6PKIOJ_]:1 <=[ _&.1- M>M6?5O1<5_HS5]M[O7\C_[TF]=D^STL4\088,I)0B-+4@S0-?(@Y%1%.,4>! M-'5C6\^=VG==BF;NQK01NNPH]M1[X"^VE*K'X<^V[N8^64\,1G*R#+&P\G]. M:-SAT+2O'LU#.2%BV^4X]>M^/L3G;)FMQ1?ELO##Z&:K-$N[I_3<0T$0I8'0 M^2.!)AX&4Q9Q*)*0!0)'*.%6[>/M19@:1[4K%[7EM'-#>IC"S$49%N"!R; 2 M'I;2'W>95PZ?+?;6SDU_^!PY/CT$&-4IZ@_0H<-TQ9/LG:GM%OWO@NB&9'HV MTV4^_KIWR9;,N='W^)2S;/EXWM29,6V\V*U:.!) MFJ H(= 7NLU8R$+ED#$* S])$IE*'%,V7XI'K<>#F7,VA)Q&'WA:?>!'T@Z\ MB#-W> :QX&6O\^IKI^!>3( &^Y#)H!+3D[7 (-T^;]2BQ'6!-U23&9A9$!5#:K M(Y/']231AM<;:LY$45,\OSM@[R.NWZ?Z7>FKF*6,1()#$6($D>0>)#3U(/9E MPM.(XSBQ8]@!A)P:_7[?/.N-XO\I"4"N\N>*= E=;=9 S9;@PY/.;"_T%G,+ M!J NU?E8:Z6_=NKVQ MU>322XJIS1YERWK=Z1SPLH7]\U:1&+GNO7YG!$6)H$4,*0>A8A('U(2Z[,@ 1)1$J4!X38L>'J8J=%< M(R5HQ+0CKS-8FK'3]0@-3#]'X S0+Z<;!$>T6T';'UJU,H 9>;B&=6 J<8"H?=T("XA<574P&7+O8CXV+)BP^KY^?5LJRAI#/>Y]@/U;H,"QAA%BIW!"D&"KP(^@GS M/1_CT/-)DQAA1D3GANJ1VS P_90G=(2IE+*67G"R6'R^@4D7*6OGQMFW 3V"\H>I;!?NMX^[^KK MZB>1V:+I*DH98SXG,*6(0T21A%3O":320Q%.0D+,T]CWGCPU'Z06SCSW91^G M[J_Z*NT'_HQKN7HDM.\C8)ZVTQN)D?)M#A%Q=*[OI-H=>2W[UX^6D')2S'8F MR>D+^O8MV=+6-BX2L!@C!!.I2R6)!,,41U3!$T988)HDTFH]=#3"U(BG/7?: M]B,Y!,_,M[@*DH'9J(W& .&/LZH[:S-R^/R1FXN<4>^XI"H3ZBMT?DC[%$VMXC9(O)?- M^_6RD:TYO:ZD^5OBYL?)%OHI ;XIL*0H=;:79DM2U].K4W;W,W>T4.?=]*A,_22'#"5>K M&*GFHB@)(/-9K(M"QV$2V,Q /628VN322G=F_=.=^QB#AZ%254H8Z[J"B,@4 M8HH0]&A"*8E"F031_$7DV8I_7Y-\/0F3',HSOF%F@(K';*F=/T")NH6=3X1S M9BL2!3*)I5KO"XH@"CT.:413*/W4#T+.DU3*VE:?EH:;DJ-8JI'F+>PDEGQ4 M(YGY3P/#/K!KU$@/6N+/SI[9:*W'W3D[5P#HR(_I(\&H+LH5$!UZ']<\JF]# M.K7,UDY,>2)$K5II0"+I045Q.O(9!)!PKCO2!4FB_BA98K3K>OKQ4W,'MM+5 M!V)LL[SVL3-.XO8>/W#3NE&+'#>-.7M7S@V5/ M@F\6XDY^S(J754$6O^6KS4MQNZQ[#JB_9B5G; 2_>ZGI0O]Z]2RVDKROINGO M3T+H!I@WG)?Q-[+0=R]6^FQ/L3N*)Q,>CK3S8:6_)36_PFA@2X+2-/S#+VMM]T,.:;V@, M5_3_!AJ,.\>\G8F.)K(W%&5JK57_)HJUKK=P7ZZ\+[>^C#V9>"F.H$^X#Q$- MJ)I#HP *2EE(_23Q/*MHW&0TF]K,:MI@M5)SXMU5;=^R@7>5WO+=F?XVE&&/ MU?K%4^]=A=+_ID:K/>W_UEM>SO7ZQ]@C&\JAGU Q&ENKJ$X"E$,2&0LE1 YOF)CSR!F%W6Q\41IS;[5H2WDZ]=M<9N4KT, MMMEDYQ3"@2>AK:R@%';P##MC;!P1].7Q1B5.8_4/"J;/W"U"0'V6!@S(MS+H=D(%1S$C).=1#AZUJ M+-L" RWQS'&O3BM@W#40,AAS['Y"YC"<:"]D<;,=0Q7Y>OY-NVTW/[-B3ICD M/.(4L@1%$(5!"@E*/"A)ZB&6$!+YL0D#[3UU:@RC U=9LQ5P?Y#"VNX M9;@/6S='] 9CA W"'C@84\!)O;L^<75#Z_-6?]I]VOO/&N73/2E^\VF>_F7? MNDZ%4#<]W2SY1_%#+%8OY7IIVVI7E^5KEDD/3_EJ\_AT(J_@/_-LO1;+.RGG MRE' PE/> TX$@2B-(IAZ(H$)\PGU8\I0%,_5DHJNS&M"N171YBMH"SI@(I1: MKSY6Z<6ZQ"K9]3C6:<4QMYIV\I?D&)K%& MM?+H4TLYT&I6KDMPM )WM8;@=#96K25<2>FR6-8P!G!69LNQ>",7Z!H&W./2 M7@.-T_.D;%[.V:_EV=LZ2[T68XZ\4'JIQ##UHQ2B)$Y@RB6#*<4D(&J522*K MUFT=8TW-N[M7#WI2B_BRQ.FZEKNJN]/_U% 7UF84[ C!@=FTD;(IP%,).MO2 MJ,.SH)?Q<'6DLV.D<4]F7E;YZ("EP2W]V*/:P_^R*HK/2M#3^_Q?Q?I.ZIZV MZVK=J=-6'E8Z**97HJO%HBPMICYJ4:SG.(X#3G1?6IH@B#CR("8\@EX8I]@/ MDHAC;$,YK@6<&D]]4=/"OX-*2TU5O)TMM-IE"Y&6;CH*MMS3#F2U>I:Q+^?F M-V/!MS3JP-196_*=5NX7H+_^[JG4S"U_5%I9GH6XTJ*F<8FQ[#1X%&)8$_4(.+A UEEXX2IA1@XF MN #N.'3@Y*E]R;DR- MA9;J.WKF((I\&0>I#+_$D1!)12!GG$!&* M>"S\E"7,CGG/CC4]6JV^RU)6T!+6:B/(!&13,G0"W>!,UQ.U'A1V$0]G_'1^ MI)')YZ+*Q\QR^1;[TKWW^>K_V1#^^^_?;F__1O+L!_E9%X9,4Z[?$0(]$E&( M?)% C%BH XW"CR(O]E*CJIJ=HTR-*FI!_^UW^#O\!FYO_ZV6UKS"[7E N\G! M&4P#TT(M(U!"*GQ +6:/4L#G@3(O"^P$L)%*!)][M5S7#+Z(24?]X//WCE9+ M^*+X[;K"ER^V9\1/4E;ERRK'3"VKORG>W>^&=V*WY^'/U;U0K\IR/4?"2R*1 M2K7(52M=1!("4X*5T\4\0I.4^#)-3)GS:FFFQK W^_OM=TJMV^?GS=*P\(@; M"UVFXE%Q'YBRM[HTJU!=(U2K<]!<='9RHQPHG6:@UFI,(YE/ Z,::Z3I8@RC M6Q_E ?VD"1 M)Z6D:@6 /0^BE!*(8YG )(RD^G\0L]1JWZ]KL.G-6I6L(-\*"]XMJ\T=LEBL M_M3GHLN<,K[:T+7<+ !I;E&7_)\DJ%NO!F7ZTO^)FS_[EOD)G18R"S^XPGW@ M66L+^4[.&2!261O<["'^(1<\6P.]13(#'UP?M#%!RU%THG.H4<,3)DH?QB>, M[NE'2_7!PN)A5>=$_$[ROXMRF^N[;F)=GE%3_,10D$0>Y%'J0X3C&!(D(QBE M,B4\PA@'W*X?F=&X1I_,J,W)]A*CBJV@)?.LRKV);/E#%.M2-SOZ,;.$&0^Y M0W>DR$?347N]:M*DP$YDL)/9'?E80>2(A];[ M.ZNE'K3<%4 B"&F2,.@'+((H\:ARH<($1J&O^S=[8<*,X@%&HTW-:9Q C%F!-)$))@EGF2>49?WKD&F1A([ M.74G4-M,EDXXN[G!%4@#4X(U/E9']RX!<,5)OK./'NU@WR7EVN?\+EYKOYM0 MG^A]+Y;JAW5YF)<43\H3+Q-!;G=^>+WW%:G52DAIJ+YYHO<.O "2E#-( QK% MOA_Z(O1,]PXLQYX:*90]EF^633[5K>V:I0_\ES<&!@1U8!)I*@'4HC=% #3* MY!3*/?9T;>$V#_$/"/M( 7WW\%N%[WL"V!&LMWWB:*'YGJJV _%]'V$_0=Q) M68BUKDA3GB_4+=9:A9?* K*[.KVI'^(TIACZ/A=Z/SF%)/8)].-$!AB1-$5& MI_UL!Y[:U'"[E*O\N4[ 78*/0F_]EYME]ZMJ;[D WS?TOP1;ZVC-[Z308>.O ME;KMNH %( 7(I#X)_@K^%+EZ@))3_4(?S5D"4A[@>$^*S&+.L;+HY0EG*#L- M/-OLQ*X.:!?E5-Z2W*8Z\G48F\\R0V$]TA2C!-PL2%Z>,*O*\9;GS79?Q\OV MZRAV7\=S]74L:VN1KJ_C9?_KT#M@5'\=CG*7^N#?,4-9/6ZTZ:F/DNVYJ=?] M5\8UOZC9\%;]6,R1QP7F#$,1T 2BD"&8IIX/$Y'X2>@%S/.L\LB/AYC:9--J MKZ%E!*60?>.7.R M@Y:]X!F8XRV1Z1^G/%+>=7!R-\#;1"2/%#P;ACR^LD]0 M@JYW>Q_*JZUBF[N_^ORWK[?S@ 0R\40,?4(81,B/((V# (:ICV,_"#SJ*6=S MM28+DU"$P8A6'_YVW &G4SV&FC[INERAO6SH(F.+5[#."5OW_=WI>NOC>PO2SW^#7V]=HVD3=W",ZFC1 M!@?H6@88+)#J#"N8/&?$8(*%6OLA!)L;I]8DX^NJC'&(NCON/! X8HCHD]JZ M*;HNE(W](((D3;Q(DL0G-+;O@CJ:_#9?Z'B]4P^[7Y>EHBNQP5_(#>)@C]15#B5-=S]A/8!HB_9ZD@DDO1#2R[KLZX7=C^&ZM76_&1\'* MH",(_R'>#<-USA2M/?3R:;3&)5L,U(\E"O\('4G.&&[R'4<.Y?Y?TE'DC#G& MZQAR3@#[]:^2[%GD+-/MS*H=G=W.?W/Z62:!ET0)C"A5B]\HP!"'A,# %W$0 M$M]+$Z/ZV&;#32WDM9,8[$0U7X09X'MY/>L6M8&IO 78;C.WE;5COY5N@*'Y M*M8MEB,M8:_&U&KY:@Y1Q]K5X"&C+5S-%6JO6BWNZKED%64YLM_$4N1D47:1 M?,Z6F6+]5A X8?ZL%D:P)0)"45$8ZE6&;X,K.K:F@T[ M-1ZNI9Z!QTKN\D,@>Y);NOUFZ!OZ[,XQ'=KA;N#\K07GOM"@EMJA@VR%DBOO MUFS0<5U3*R"._$J[N_N1TXFSM1_*##$BN)0*GR8(EV;BQ,A(C\DDD?-4;4'-.G;T\!W59"8(^E$M*&'3HY>RMBP8*._(= MZ^U*XAAY'I&0>RR%2(0)I!0)F 1A%,9$J*DUM.L*,J47:^QF(4K@0K\7:NF9 M/9<5T6QW^<:VOT1)DC)%)P'3K2P1\B )_!"F$D6$A]Q+I561U0E:?YQ%\*7/ MOZ&-?[#WP\R[FZ#5!W8/3[>):;T&>RKLI9&JR[83R,UV CEW:ZL[J#L_U\F,[QIN=Y5.&N*L/SFO;+A\":D;\SL :F[*.VRZ6H<"6A M$K9";ZB>RV= &:3?\N%8;]AK^8S:W7V6S]W4LTK5#Y(M=)KSYU7^G2S$?J9- MJ]CV;_FJ*/ZZS 59Z,:IND+0>R%7N2ZL-2>""HI(#+U(G[3D?@PIQA3*- UC M*2+...^Q!G9,DRAG8 M*@B5L%"K.-OK35#J!7:*U66S:*F;KC'HL'*62ZQ=E=AR(M.XM;A1$2',$B,(4G" ,:AHFCDH9!Z MH>GV^YDQIA9NT%+^,UAJ.0'?"* E-=\N/@?DY7UV!_ ,3'(5,J6(X&.-3(\= M]7,0F6^C.X!JI+WS4Y"YV2>_@$''YOBY.T?;$;\@>GL;_-*EOR$-$XP]9-G8VWCLZ2V%+_56TI.1=1550T,$ M'N.I\%*8$+V7DOH1)%@F4)! QE1&. RLCCL.8H:1*N"^F1$,??LAH!UX:KNY M^W![U!CRGN3EF4IG^4V]$7)7V-9PW+&KW-K!<:+DK>4#[#WD+ZOEHUK;/VO/ MO*ZF^SM9UPYZ_7TPB=* D!2&'O8A"BB#)(@\R%C*./(]1#SC9%6#\:9&35]6 M9%F %_):?D ZIX=5@H.75=XTFE@HO:"2YKD\T&GN-9K@?]G)=HSJP*RDI05: M7*#EW1;5!CN1>[C?)D":N^*. 1W)+7OAC"TP_;_FH_B#R<@+03=W%1U']5_?C)<73C6[PD*U?YU3!S%C@P=CS M=#$G$4(B!(4T%#SF*$A9D)JR=H_QI\;B2CS(RFIHM8#FU-('_I%LHN1=T+0%2(_ M?>-X$?).P?<"Y-U7]HN/GXB?Z#%:E1QYC+T(21@D)% N,XTA1H1#GDJ?1>J7 M/+#JI'%IP*EQWZG :]T>\)T.P%H6@;B(MUG@U26* Y-D!W3E;AGXPZ0O+4Z*,6#FCIP.U',[(XQJN;%:Y"8>CM%D, MC#_PL\J>^)(+P7Y]7/WX-W5/]1&K'W;?[O&31OE(SRK0?(WG+[!?PWS/?MZO MLN7ZL_J@]3]UTU+R*!I7XD[W,GUX6FUTP;2;)7]XRG)=,^V':(H>1"B*(DR8 M_CIC];'JSC@>3F!"?1$EPO,0,=[K<"#/U#[Q^-)C20.C MN-[%D:8V@6E!]7[]_OZ%74.XR_":+6R=@#;P]-,3+^LE[$4L'*U=SX\SZJ+U MHKJ'J]7+-]@O4S_6,^!#3I95XXYO0J>TS%/,PR#4[2$YECH]7D L,%5D$<8\ M"E L"39=L9X;9&K$T,@)=H*"2E+S=>Q90"\O:5W -# 5]$#(:J%["8)>:]ZS M#QUM^7M)K?9*^.*U_?R SZM<9(_+#_KD=?[:G(&)&4H$32 AOEKI^GX ,4\X MI"%BH8?3(.96P>Y3@TSM(Z]E!']1!%KPC)G7G>R$TFRZOQ:@@3_O!IL'\A/< M;-0R)-?9!.ZSA+M@<#3)GQQBU/F]2\G#J;WSVGX?_'%_05W C*T%_[Q1SH-H M?E'WKO]_!B$[DN@)OQF-# _JT'[$R4ZEC1*@TF+WVTJ/&="*Z B7.R:Z#DE'7-53B%'9 M[#J@#OGNRJ?9KW.^J#=ATW/8LWL2?#-0MS)TV7]OZ]7[.]U>?XFQ_&P97$48C]B"":A=EFD ME)!PIEP6)**(I0CAU"J0>;U(4R. [YOG9Y*7Q3C:?8V_B455D7B] J52=3N/ MJ_\JNNJUO3U HU; MA]H9@$R4N2YX _D9U4Y3G>J7ZKWZ74N1$1%G&+((P]!E,084DH" MZ#'D!ZF'$ JDY=+QS%!3X]>M8" 7Y5G=6:^R>AW8&J\+'2 V_-JO%+**,I5B MZD-#M:!.EW87P'"W?#LWT-A+M L*GUB&7;JC'TM\%7_>,*:C6=GR\3Y?+=6/ MK"H">K]:9.RU^O=NS@\(\[CZ!X:,*A\N9HH[]'%SYJ$@".,P3J55)-I6@*DQ MRC>A\P06K^"&KUYT2&2GC7+5R)*3G%NRB[5-S#AG2*0'9B(E>AO7?>%GH!(< M_%'_=Q!7JR]ZCJC+>OA1":TO.(U#*['?%%OBGDPH2F&<1ESG MVGB0)G$*$ZS>49)ZTL/FQ>9.#C$U @N.CC[%OL41L=,P=C.2&W &YIQ3N/0Y M0W<:((LS=%<#-5+RI-6+9'>&KA."KC-TIV\<[PQ=I^![9^BZK^SGW/VV6O$_ MLX7ND'2KS+]\S-3ZLO0?;Y]?2);KEV+NHX"&$45B4'?SYD$(8Q)@)+T$ MA;'5/J+)H%/CP)V@@&A)0;855;?UR!]MZQ@;(6_FMKG&6-&0X[J@=F <.AU6=W;-QB59S_*$/9O)%OJ,Y9J;;0N/;L[ M69WGNSM5,NW3S[7^HY+GTU+-857;B;F'0HD3$4+FLQ B&2&(A?+4,,="XB@, M!+%J".E4NJEQVTZY&=#JU4=<9V"KHTX9KH^_KLZ<*/YCIRIHZ6J9@^WV+3"- MM+V1;023\#6_EG53_AE@K#AB>O -$9F]I+,#)G]H;HF!G[ M/ZH?_S6MUC)1?%8N^=]T1\F/6<$6JV*3BWG((Q%0'$'* @%1B##$4OX;?-!C;%MQ9K:+]0O8FK&8.\0&)JR6H#.@ M106EK& GK#M6,@/%$0%=&&Q4KC%3_)!6#.^RW^RXU_Z8HB3U(GP5:^W)-14T MDB!))<8PYCKX%U(.,>,4,A8)+PGC)*)&[8&[!IF:#U3+6>7.*4DMVA5T8GEY MS\,%0@.SPTEP>FQ[G$7)?./#!5HC;7WT1,UJ$^02'!W;(&=O'6TCY)+P[:V0 MB]?V[#%[IBN#'N";8 M2%)G,6-4+E__7IECK%^>S4D,WYJB%4CY>^9S[5;'. ME=>7EZOAUNF(XO,J5U(W"^9=3T(<>3)@0GEH4BJFI3*%U(M2R(A()>$)#E'< MH\7DVVIE]"F.WYM2?X&Z^R1X]Z@D_@60]C*LJJ8LN&[/3>MS2TPI;ME8]VW? M)C.?]!_@Y1BI-?"E6IEZY7[JH-M>9/40,K###&BZ QJU8?IG3L.2KOH9OZTR MXS9,GH3ACCHR3T.J?A-Y):IZCI)4&4$MF$HYZY/9N]^JV>9C)J70[3TRHMC2 M2[T $0EY2!E$$8HA3D(*$4O22$1,_<$J<[6G'%-;#C6E! 3)E]GRT3)VTM<8 M9A/8"! ///-\JAH\[.8;G4NOY07[*LU 8X?#Z]J*S71$>>,R>>)*A!W-"'VE M&)7*KX3JD(.O?5S/MJ-;-B\>5LW(0K'T;@)X6'T@Q=-]OOJ1*3?Y_>M?"\%O MEW\K$^K*1;0E-%_(3I%#(DO4"DT M9 )&/0T@"QF$4A1$)0II(;M2] M:$@AIT:[+1WUJB5[E9=L-,7_-%H[+)]Z( &<=5I= @1QVU*.B#(1_U+AQS+=?IR ML=L5V64;4$$E\9,0^C3QU"S$&20\HE#X7A(0GB)BUY[9;OBIS2][>;A5_&.G MA;-LYI.&,*/TX> =F*P[,YR+UC[J0 U$^@$W>.;SR<$GD@/=!8QY-G3G4US5 M?E,C;9ZKL@":7S^0!=-=I16_UA?=T47V6/IO_ZD6"D]KP6]^* 9^%$I:H3L( M?L@%S_0->NDP)P$-*$\)Q#).%2L&%!*?,BC]*$&!QPF-K6JN#"[QU(BT$1*P M1DJ@&S!>6V3.M9W-2'=2UAN8IT]']%OZ@M)M;FF\O72G\PPT6L-:;;!](;:* MEX&:(4O=#62DP:KBN9;WC0OH#03_Y5I[0PU\;06P#ZN%^L4J+Y/#6^6/"C5I MZC:G9WY=5DHF92'?HJQU,X]]PEC@2QCBA$'$>0!))# ,0A8*G_LDQ5:1(_W1G ^&93UMN:=. Y:@1K7E%4 MS#7@SHN,.1/PC8J.N0;X?!$RYR/U3&,7:B$EMB&C+[HO=I/U^MH4D?VX$;J. M[&?UEB%$@EF==335H"IT;_Z&&++['9; MR,UH>4@@!R;=2O19*UA>2C\#6_EG.LQ.!;@G&:^+66L='";&]T3/5:J\[?#C M)L_W!.D=SN<$72X](G%*8\E1 A%NAJBPE,?<9]*G%,J96/ M>V:;&N%4P10M*+Q=@EI4VV2H+G3-6,<9 M9@.3S4[."K-LB]D +<>,0'&6(M0UULBY/@9J'R?MF-S4M^( TWG^R\>;QUQ4 ML:*F&:$( BYH"FD0$(AP%$+*.8=4I"&./<:BF%O%9,Z--#7:V H*=I+:EAHX M!ZIAU,4%5$.'5TZ@- !/7(3"65F!<^.,7%'@@KK'Q00NW="_"?'GK-"]A42> MK?AG]7?%G$61E&$B8$+4OY"74D@\&:B%3!B'W&=8,&K;A?AHE*GQP;;);B4I MJ$0%I:SVC8B/0>WF!&=0#;U4Z8-2KV;$9U&XJAOQ\5-';T=\5K%3_8C/7VQ? M..0[68BB[%WS>Z9^6J^6HIFPTI0'C# U]P=JV8#"2#D .)10!BAAD8P\GAJ% M-;N'F=HG7TI:]W_:R6I>%Z,#T.ZOW1U, W_NIQ'J44*D RKS(B)N(!NIC$A? MZ*SJB%Q&I*.22,?-H]42N:Q NYJ(P=7]UD>?ZO.RBFB;#E\9VVY.("\.HD#[ M0]A+( HD@\KF'*9$A $3'O-CSV:-U#G:U$BR% XT(H.7JO;"\VH)2MG!S7J= M9W2S+AOCK5?@=Y&SO__+/RE(_N-?R//+?ZBK?]6=IMBO>_<]K1;*/)8KKFXS MF:VZG($_,/5N$5>"5I#-0&6+(;:4C%!QM CK'FO4A9B1VH>+,;.;>J9EGNPO MV$KB>?^ZNZ3>]K[YD^2\[C[XZ:?Z_+)"%+?+RFDLRRG>+M4WJM:/K*Q"-UL&V%]_(WZ2LXV3M6J]UTC2UF8*NZ M+D]5*:]GPN:5*55WF.HYHJ%<)7^.(?*XZ: C&N$H073,L7N$'U8Z+2/7*-8K M/^0Q&7*/02CP8,XE"CDA N=$\=/+I4YLPBIV %LOF(\P, @O7 M(#$PN[9 Z!-$.$+#(G9P#2HCA0Q,7A&[\, YI;NB D?WC!<,."?N7@S@[$7] M/.Z#LU9?-_J9=_)CMMBHORT)L[C;K O=_E5Y_?.$^ER(,((^U_5Q D)@2B(* M0^3)!/D>0KJII'EU=LOQK6AMA'+MS4%*5JWMBU)>L-H)K)NP;9[U#URKI%VI M=UESX?EL)B>V,O-P![3 P'3:2 X:*U2RZV5()39HR3T#M4;N7,Z>R#GR'FU' M']41[ G-H4_7]S'7=G;[DBW%[5H\%W.1^$% L >3.$@@BJ0'4Y$&4,0\2'WF MQX3V[,^V'6-JKMI.1/"'%A*44O;NC[;#THR/KD1HZ!U@2W"NZ#)VI+[S7F&[ M$=ZHX]>1BN?[=AU?VC,7;%44'\H*+%5-MCYL:;VT9=5_ENRSD E+?BCDM?R\^]"V8P& M'&$W,!WTA\T^2>PR(*[2Q#I&&C=1[++*1ZEB!K?8!V_.'3F^S^OL]^\Z['V[ M_"&JNG.WRP^ZMJW(7TB^?IV+($Y#+U!.1"J)CO0012E!! ,2$T4R81!QX]8T MUXDR-=K92EUO'&1;N770F+4D-X^37&FLRR&F\4PP,'N=+=DP SO#E,J G39 M'S-X"\.81[O&,]!(H;%A#6455'.#;4<$[LH!1@O7N0&B'=MS],1K*R+I 9;J M!7C]L,EUI>ZR6,:N)&::$!F*.(:QEW"(T@@I)SE,8!SQA$OF,R1ZUCGJ'GAJ M4U-YI1*[:>M="ST M=ET&:)CFLK9H.:_S M8P;&^9H\AO=?D15$+^_LTL.=W6WGR5;Q.7TNE57-NY[].4D\#P58\5B08HAX MC" .:0(C/_)P&"7"9](Z%V@04:=&?XUP8)%) =Z]"I+;[F<,:%=#ZIR$M88F MV^M3>EJM=5L*S\#V'= Z.T[E&=0L+A-XAA%T_+2=00$_F:PS[(@]6@N3M1I& M-RVNZI#6619)S)D?AC$428(@B@B#&,4,^D*@,% >+\%&4>'S0TR-VRLIP4Y, MBV:YIS&\'%2Y'IF!>?0(E#ZMA$^C8]%(^&J4QFHC;(^670OA3B"Z&@B?OG&\ M]L&=@N\U#^Z^LN=1G__>9.O7[X)M\JHY^]^^WNJBF97;/D<12Q%2-.>14'$= MX9Y:W*,(A@C+6(A41KZ5/]P]W-1XKY(6%%MQP9-8<+!^RE>;QR>P^G.IA'C* M7G3B>UF2NDQM;L6LY6;);0_U=!O$S)%U!_/ )%HCO)-4.9=_@U]O9V GKL-C M/4:PN#K7TSW8N =[C!0_.MEC=I>]8[4M"B4*YGA%#8] MW*RS()D[6B[ &LG5Z@>:E;=U"8T.?^OLK:-Y7)>$;_M<%Z_MYW6=V]EI5IB2 M^'%,!:14>UWJWS#UA(!8($%XF,:)CVV\KN[AID:(9S^M/+8Z0+G* M84$6UR0\VQG&<']B*+@')J<+2'\W1OJ*[5T+Q)SO\9J,_48;O1:PG-_MM7F( M_6KQX4D\9TUYI-#CB. P@"@*=%5QDD(B4P:CD*JSP]M0W7]7UA6&DE9PI'%9KMU,Z=ZS7]BX?;8UV M2LCVNNSD[X?SH)JFX5EI\(.T+$XI\5#B03^E6-<,IA!33*"O_CHE04@(MJL? M'T\/:/GVI=EOF4RO]GP3+TU-^NU M(H[R\9\7Y''N"R&YB#",TU"?HHDQI!)', Y%F@I!,4Z,]B:[AYD.QHY5GOJQ:NSZSP=7] MG+.RFXE."_\5J>;/DY57WJV*=BW665_EBNT[3Q0W_ MKTWE<;P7:GH3BJH6I"@RF;$JS6S[>]TR]('\G'O4]WU/$LA]3[ETU(]A&O.R M CP)4YZR1)#Y4CP2G65F7MSD;;0Q^B;3ZIL\TFG QF1:G/SM]LFN<;#J2?\%+)0Z&H6/E:36A) 'W/) M,$E03,R3:[:/G9Q_K"2SR S9P7,Y:-I/Z:'=7"54GY28G>(623"] !@K[<4( M"+LTER-]NQ);=A>/E\IR).!>\LKQ;WNV27E0>A>Z1OT\93*B7AK!)"8I1'X4 M09RF#/K::0S_]H.H+I,./T!&)AP M&L%Z.#2'[XLQY?0'8R3*,0?%BG1.Z]U!.@U3,M??B1KL3W1.H]B%L1,>5B$QPE$ M-!4P)6D*(X34:BU*:$*,H<' I,M RM\ZZSZJ_5I?IBLU<9W7F M50>HLGISGV('4S#&T(U/WO+E&=H_OKZ40IWUT(('5''4M0)HUSNEPJC=.,7L MG9U /Y6A[/_635>?/K5I50L(:@G!N]6.UCX\94M2 M[NG\A;R0I>',>1K1[MGK:IP&GD'V('+GWW>JW46[+?,D(S19E[M/O@A2;7/"[Y3>=#Y5GRT?=!;$XR##T M?(FP'U/HXUA7&/-22*GO01%ZQ)->*!*SA*5!I)L:>7Q6%+%D&5F 2J>2+EI: M@48M0-;M@E3*^R)@JVC9([1W)JD+HQMZUV]ERJ$]Y%:.:7LE=/I>]9.RE^@)*()GJO M#"<0>0)!@FD,>1 +%J. (LQLF/_,.%/C\*V8H)'3,M_K#)Q<)$(YS @F48 A M\F4$:21B**F'TB1(0AR+N?+GZ6I$0-OC#9PU!XI*2O"2KV3F"E6SFJ%O#YQ M\+C,_D?P6Z[&44Z_IO*:^]E_;S+%]OMS0%DC4O"/=?GT!_*SNGJ>X,B+/,ZA M2!&#B"J2)J&'8<0H1HI/./&M:I@/*NW46+X1$*S)3]W>4-@2TK"V-:.UR5AL M8')L] 0M1<%.4]!6M?'2&V6/W/5:WS*OMWH%E,KU7>ZH=A33."+L864=E?9' M@?UP\AAGT)'+SN\W%-?2[W<1]^['L0,9Y '/M"GR,.8D_0B'CC ME)V_*.K4)I^;Q\>\/+,"MH(V,8:6$B/5H;]L:(N]UC>W"L\. M7X0)U*$W-LM;UZ&_+.@_1AUZ8\"=U:$W'['?Y+/?\ZGJ='RS63^M%?/'N=9\;(JR.*W M?+5YN5VRQ48W3E=_R\JFJ1O!ZWC.:OEA5:R+._G;:L6+[^59$,\77AQ[4"#, M(.)"Z$Q%!OTH"$),PYC'1FU,'<@R-4;2\ND]+UU$T#(:LJ/^\ X> MV8](;Y]?2)9K?U!WOUNK-S7;ABD^9\ML+1;9#^4W")FR@)!8K>T# 5&BEOH$ M1Q+*&&$?Q30.F%4)5L-QIT:0.U&KD#'(MGH IJ:X1P%RL="U*,!Z!9Y)_G>A M?W[)5WS#+"M!FYK&C#T' 'Q@IMQ)7#78W")?"3T#E=CPBY;;'2-: N6(_4Q' M'97I+*$X9#7;VZ]-=OLJUKLJ??]7\$=1W"YO&-L\;\I/LJL*PD'Z4QP)PA%A M,/ ]"E'L(XB#%$$1^DG"U6J5R)X5I]T).35N_"2E8.6WJG1L-_"NM.R;S>;0 MJH9AS#>VU= !S%9NVTE#Z>,:+27!J0(Y=;..=UK37T;*<7-O#>>I;@Y%?*., M-_<@GT]\&V"LGM$$P7)!"O7XOR[S[;[= _E9E[\I;HMOZO>KI1KT]5Z-KN>Q M>UG;<,8Q= V'#HZ40\S1=KE/@SOL*?2TD_^&\G+ M#+-ORG/6S0F:D[N21Y2R$,I$%R B@L"44Q^&%&M<0Q;[R)1'.\:9&HE6:]9& M5J"%+5LVF'-!%ZB7^=,15 .3YSF4>E!G%USFO.D(MI%(LS]\5I1I $H'7W;= M/1I9&JC09DJ3R^UILLRZ+;(RX>F;*(2Z^:G5Y%#];9F/R\2R$#>/N2@3IXI= M]##U(P_Y-(0$H1@B%$J8^BF#89BP%"ZEP] MLE_@NXS -R'UF_4ZS^AF74;65U\5'*OE6D&C[G^\7:II1!3KN4<(B\+0AQ%+ M H@$PKH5KX2,>W:N^RO0UY*'U?-SMNUD\:',P7L42Y:)0N?D+5:Z)$=K84!0A"@BD,>Z1!KV M?4BB&,&0H#00,DP#:74,VV[XJ:T%]N2M6F0N?V3Y:EEZ48OV25P[$K2TBAD# M#H?UP/37$KP$>1_VG>QFOKPU]?7#S1'O60X^*NGU ^:0\7H^I1_=Z5SB/[/% MHLK7$[R5@K%+X=/4.P^XA^* IM +90B1)"FD."+0]T,<8JY(#W$;IC,>>6HD MU\Z/>JR5:.<"*P,5MOQF;@8S:AL$W(%9K9%Y!AJI9WNY:*V<8"VY.SZS!LL1 ME9F/.RJ+6<-Q2&#V#[ /Z#;K9<60'\4/L5B]E.=:=Z=>-6_FA*T?5O:Z#15 MOM,%L)7QZOE-WI'+(>8I6WY@>M^&H77X-\F/BK8Q[_GO(K-%+ ?,JODE5\_:ULV1&0'UVD MT2+X;P5V.^3_9C*XV"/X0;)%%7G32]35LCS<(C_^WD CO@:^4@"T-9B5Y;K/PW[EWH Q>(/L M#%P>_0WW!8RAZ=X5,'],WTI&*R8$+SXK=6Z+8D.4JG?RRVKY^"#R9YV@-!=Q M0"/J49AP%$&4! B2A%/()0V$)"Q$U*I<]N4AI[:H:R0&VN@@JV6NEG"FR9<6 M@)O1F%L8!V:N?01O6PAJ@:&6N#N1M4=9(U-XG)4VNCC@R.6-3 $X+G%D?&?_ MC]T$>*:?P(XE@FD"MI H3\) ZMF.;,.%.CEWK> MKJNE5>712I:YIF#:.8QIPE/L(0\&J>YY)40*4XD3&"&"B*_^1QB>OY3-N+ZO M2;X>#>G#,8?#^SU9E.SS%[+%F]JE11M^U[E#UU/9TU^7]9KO/JUQDC\L/FSP72_;ZD)-E M09B.=_Q&LJ7V\M\+J:YY(#_G/!%!D# !693Z$,7*X4ZY)R -N/*YDSC"7,R7 M98EE0\*P&-WH2TBK+Z$MPW ?Q*>?[$F'CWIM/-O@;L8@KK$F#FB(%L1AZ5E7I O+]E2W*[%2Z" M%'&>1E $5'?K#GU(>"AU4GH@A"!>@.QJ6SL3;6ISQKT^AMH-_&H)9]=:@TUM%'-YH*W,=7 $\&)#EVS\N?M+VK59OO-6+11WV_MURBX M_2N7I:I6 5X00P_IR$9 4.AA.Q8_/=#4.%E+UE0+[+5G>!914PJ] M'J?!"9'JU(9&QADH,:O$=,EJW4 XXZ@SPXS,.-W*'O/'A>NO\P*KG ;%24)[ MI65Z5T53^JAC&<98SRG"@J&$0!HR11 $8TBE#'0S$\1$0@7#I(^;9S#VU#BC M*L)SC8=F KB="^88QK%\K#ICJI2[]*#:V,[ 3GCW[I,%8H[](Y.1W\0!LH#D MG(=C\XB>[4/T@>LE67P3/\1R([Z+_$?&Q.VW[W7IKR!*/1HQ#T9>G$(DI0>I MSHM",4THXM(+N%$93\/QID9.C;B@EA?4 H-W2F3+/=U+4)M1E$, !Z:E;NP< MUEBSA,95PX\+HXW;Z,-,]:,&'X:W]>,6O3FS._G\^E7\^6%!LN?B<[80_.NF M?.F]P)6VXQD3V,VXQC&8 _--B>.'-HY*8%!)#$J1U=^40KNC' N$'-&.R8BC M4H\%!(?T8W-K7_>F:4]QOUID['577204.$F(1V% L0<133V(I?HI# 4E?A)1 MQ45VCLV9D:9&-SM!+9=;Y[$T]5P<(#2XS]+(. .5E."/^K^#5&&YB(DS9^7< M.".[*1?4/790+MW0.R_[L"G-5[&^DSI#"DGNI:E,(4,LABA,4I@&2$(A9)RD M42HDPS;GWSK&LN*&$P1=5B5K3SU5J6X'AQ]L\YQ/6L#,T9QA.S G-+1 M>&M6-O!:21VRF1T!?4_RR214A+E.LK'W*U0 M\_U>N,J^.E%KF[F56M2DG33QV/N]G)-Z8_E>&;J8LSCF<4A#&/F<0*3;C^)( M.1($<\D"[B=>[)E6&[I6F*G1@4WVCG7!22?6ZV:7L6TRUA:23LUI9VEN[72S MW4[:5ZA)R0&E2B/:Q[S8SIAV&JEXSDTKQZ*VG.Z^N&O.>%BJ0OVV^E$\OZQR MDK\"GDEUIU#,6Y]5?C'^)!T5IG=EEXY".%I1B*,84L(P M1#3659FQA%X:,A]%4L3,MZQ#8*>()HB=,F"G MC75UFFL,:;:8'\\\ \^E6\LTJNBZB.]J,_URTDXS2ROU*6;C %QWM6VN$6;L M4C<.@#M1^<;%4^W7-/>KM>+X3)O)8[ M_$HZ[QNLI? MY\IL*"8DAB3E B(1>9 ($4'/9PD*PR1" 35=O9@/.[EU2B,YD*7H(-^*"IX; M-Y^VMAB,L+D6'@'9@F=\A64H.MV*"1&^P$'P19\R7$, B/M%APA+25 M;V\/6(<7;_&PT?QU>P7;GGF/N_OYX-_9D^";A;B3W\6C?O0WH=9_Z[+5RK9A MV?O7^I>[+=TDQJE(/ D%#XAB?QG"--:]HF04IY'TI2>LSJ'UE&-JT\&G_][H MU769:E(NFF^D5,LJLJX3;C^*EURPK(KJWB[98L,K[[Q63/N$G>>7G!K1S/$> MP30#3R6-!GJYTP"]50*TM)AI5[RYXH^',B(RR+[^E9@ZN M];6/LZ-9+K+Y)]T1_+4J4+$;[;N:U3?%/&!^B*.4P"1$%*(D#2#V>*BSCJC$ MOO*AS=IW7QIH($\Q2" M_?JX^O%OZA$5Z:@?=EQS\<&CD(FI>@U;&%_?S^LJXZJMD&L]R%Q*ST>^])57 MI5;2B(2I/MW/H4 ^BRAFF(C0QJLZ,\[4R."&L5R7>-QM+-2'5[8;%M:]Y,XA M;.;R.,!M8$*HMMI:(LX:.A&7+KGNPBO&(LP &(@@4%212K:T8@]+STCB@B''?N!G]X<.G]OT_;N4S#^,< M 78Y#'8-# -_SCL$+I][N@R%>=SJ&DA&BDX9O!Q6D:=S*G?$EXYN&2V*=$[8 M=JSH[#5]CT0T)?=UU6O=C++:8A!\M\/0)#SNM^K=^DB5YS0/?5]RCWJ0(R1U MHC2'J52K'!Q2BKPPQ+YG=8C=F613X[\ZY[<,&+75:FWUM3.!ZUA2E>-1F';% MMC[-X>HUH(3%S,0U&V+)OOP:\ M_1JL6J_!LGH-UM5K<&#ZE^Z,\($-;>9;OXGY!IZ^]UO1F'['PV?T.\?:V7$C M5W*-?#S),9S'QYE<#]"S%TZ]S?1YE7\3NA .6V]T5<1Y@N(0$QI"+Q(5^]Q01E_WJ"6XWS6B_@)RP43VLJ[HV++KS3EHS=CS M*KA&VKAO]HSE*@=[0CKL:7,!!E>=;,X-,V[_F@O*'G6MN71]/U+X)*70>4=B M6W7FF_KJO@FM1;G'J6OIK3\+]42R*,.D>G]Z[^*Y>G>02!*IH/9]M22(0DBQ M^B/R64I%F5)D5<[!@4Q36PS\]=?OOX*B$14HUA> O+PL,IW#O6I:#98^!MLE M!>YDAVG&3"PN;T=C(=AMZ=Z;1IE5A"V@9P;Y&L[(\>:44V&IU>-.V M+:T[NG0(MR-F=2'1J"3L$,)#OG;Y:#MJ9SJ"D+_._W(_IXJ9.?49E"36\6:* M(*9^ H4G993&"9*^T=;3[I%3(]:_D!>R-"/$%B[=?-9/VX'IZ"\W]S=?KR>/ M8]TZ-G_KBZM/O_[#[JMO/6J4C_98].:;._&;:Q/G](?ZN,S^1_!;KI/VI)JI MZZ+S[+\W6:[^M%=\7OUN\ZP/W>B%VS87BY#40S25D$680>4D$4ABPB'#6(8I MXC*55AW_',LWM8^YG=*U4Q#L-&S:2C0Z'O67J-7LFVGGQNIFWM(;VG)@JG)F MQI&R]9SB[SR+SXUT;Y3=YQ3:\UE_;H?I6PDZSWX0[?&5CYU'/D]3B@GT,$K4 MJC@4$#/EBODIC64L>>)SHZ,T9YX_->[>B5=_M9:-F [A,R/1*T 9F 0M\.A1 M?_FDULYJ+.\_?>0ZRB=5.ZZ5?/HR^QR=F^#7U/NZ6HOBXZ:,5=7I%DQ$7'HD MA2QFZO/U$(:IEV)($XZ0QWA$8Z,:R!UC3.T3UE+^,UAJ.0'?"* E-4]8.0=D M]X?L")Z!/^8*F5)$\+%&ID=.SSF(S%-['$ U4H;/*?Z#6U9">)U=TF]Y7#S)\GYW4L9A[[; MK(NU\M:SY6-=5)AZ"!$>4$@B3V\>A@SB& F8J*4MD3[CB$;V#=>=RVGSA8S7 MJKV23:^3:KEGH"7YK&GA#JYH*N[>XBSFB#."($\\"E$0,YBR-((8DR 4290$ M/+#M^SX!>P_?,?Z2M9M.\N":)O+N[6T8SGA+"PX=T-""PU+R_89U+?7*0X:M MZVH50:GC[(S%75OCT9ZJ\/5YU3N.$!]]A;[V$IWI;E[ MY77E=?>9#^JB>C&,]8)"9Q-AH5L@"ZGXA*,(1HBD?DQC?4C*-/#21X"ID:JEY$N!W6&AGY@BK)&75W9(R+4"WSS<-'01A@IEC2, M,:R"3M<@V1&1ZO78T<)5URC=CF5=]9SA\EIUUI70&X/*\HM6U\5YD&+!(IS" M((XY1(A%RJ5-&(Q$A 1//)S&5FD;UP@SM>FHE'.H/-2S%C'S?L?">>"YQSSS MM#)&F3VAU=GK!?M&&:>7\!TQU?2L*)/+,;T$6I_DTHO/[!D*T.N#I]5"W5%4 MA=%*=I\++TU\?73(H_H0D42ZS;7/8)B0T NH8E."FT-$#Q;1@-/#&7VM^P>) M'L8@QS( 2,L (&L'"E]T9>U=*13+L, 9R U# E<@.%(XH"7AOX)*QEG5=\!A M'* ;!E#>7< MX^VL YU#T49N6><>U.,>=P.,<]#C:>[W3[;N>]#]Z$OI!%J(L MB5RL\XPI]TW_0@FZ_Q>M*^>QQT(OY0'THC2"*,8QI"*,8$0H#WQ&8Q$D]HMV MIS).;:JH5-2[,(V2U3+S0_ES :HF=4^SJK-%2Y&2@W9JEK_O$PUP^P;8! G> MS*ZCQ Z.37K6E+-#.\Y.&7?_CH'[E@QH(:?1![<2OD%08A"(3\IFCD[5,6I0OH-(AQPE("0QEYND@V@B2B,10H MIHQ(AAF+YS]$3E>F,[8KJ-N#_B\!VVQJ= 7@P'/<#KG[+7*?=LA][4#.OB:- M 22NZM)T#35N;1H#I8_JTYC<1PE,>))"A)7G2T+.H)0\8@R%E"=& M<>YS TQM[NK. S##[/*\$?HH2??<=2.?-J_24&Z7NLYMN459"O?P1);U ;?/JUR* M;*W[9]^7IW?GL<^AQT#\G_,4Y(]S>)L[/35XAP19;-ZO56=J??FJIQ5Q- M9SR1,H$")VI&HYX/"4X1#%'H8_7W 0DM9[3N :I!CPNUI*(*;DJ%@ILGR*=1%/"$;W/7S;=^G\%B8F\W/ M#B <Z+> M R:^/PFQUD=MRLGF9U;,<>A'/$D$Y G3C?*"".(HB"'V:()"+PVXC&QV*,\- M-+5X32TG* 4%C:3@#RVK93;Y66S-R,,%8@/31C^PK GC$A*.J.+L,*.2Q"5E M#^GAXO7]B&&O2T^9S;;0<_B-/K=7%B'6G< 6JV*3MTJ'TSC0U70\*)!$$''U M$V:>8HY8(I+XS$^951)S'R&F1BAFW:;AQ)1R[*5&E<*.GCPUQJJ%,]^&L?,F%WWE>:.V M&%?"=[Z1QK4/MO<.3:K8O-\4V5(4Q8?5,\V6Y5_I9*PY3X(D]'@"9>AA724R MABF2$:385^MD/PVDE*:^Y!5R3,WS+-L=%5D91%(,?:]K *\,^R->:Y++;NM( M0 ],L>;EN1I=0$N9,A%X'(.8>]$C&68DGWM( UGYZPY@[?#NKWGZ:&L!!Q"T M5PXN'F<_47T44N2Y[A?WL^HJ=]?L).E)\ /)\U>YRG4.@:ZE4:4-D)]5(=Z] MW\YEDE >1CJTFU U;05435LAAS)1TU:$N(R]V'3:F[5JE:!>Z*7 MIUJJG7)]1Z7<_B5O83SS>?)-C#C2K+DUIOZ^2&7,_:]P_W,S^"(='7EQCGK' MI.INK-&F6.?PM"=<]P]W&.93(]9KTU,;&*U*9PB3+!/J='Y4"?23&VZ/1,RTI]W$R0ZN2=87%$G\#IS7A'6&\)(;Q/2RT&7[9'FJ@RQ?_[4 C?A].U&YMJT9 M=T_"8H.GX)1* $T5H%$#;/70!W :34JR;W2I>V2!03)R!@?>>;,MUW*^4:NN M@> ^W^AKJ '[328W3"UR-V4R4GT0]?DE%T]B66R#??6&TYU4"XPYXY''&$4P M)4D"44I#2*-$S1@IBB*6XEA$1NW9>XX_->)OB5^OR5E;@7+Y;C<#V!K$C-<' MA'E@MFXCW)PR;R/5CIX(Z;>X+GB'%M1Q^51WM"<\B.?1_3C_/4 M W-!"O%15/^]7:KQ=7)-<4]>]13_D!,NY@F67IC*%%*JO6$_H) &.( QE2CQ M?$)#:;1G8#?LU!BN% J06E+P4HEJQVF&@)M1F7L8!V:P1F#PKA'Y%YV9U4@- M:K%GH!3<'6W9 >6(K0P''96D[( XY";+NZ]=TW=Y@C?K=9[137DB]?,J%]GC M>I9 M'8@;4-:ID=^'U;)8+3)>>A^UMN4"<2<_T KT7>2[-[;M,O]-33@P\;;;75]: M].]T!>L5J+5M%30ZMOE(X8#!#.0\(.!>TC<*"0P&^?F@P'!#]MWVD]E2\%:W MV ^;?$VR11GHGJ.8QXS+",8QIA!1&D*<)!SBB.H"T3Z51-B5R.@>T(A41BV1 MT9;.=@NN$UK3/;:KX1HM544+"MI=HV?;/]W11?98YP2^:QRM7T#C:@&Y4LO] MG6(N]]),\'.V6=8YV,B[82:*'V]W&=WEBFMNBF+S7-7^^:NN)T063 <'LN7C M5[&N2@!EK+Y>=Z[6%25TNY(OJ^7C@\B?OXGU)E_>+:O,B7G,,<.A/O"(@@2B MB(60^IA X2=Q$-!(Q-RWZW@QM,@V'_ X73,:>4%>=C62("\%!G6/U3IQZ5HF M=&QXG_I^&,0")A)C;7@*<1 Q2#SD\3A2WZE=!&=*9A^E3]D_HM'[3J!O9\HW MF8);ZH*_E@4)=PJ74?1&Y>U]6ND9V+X36F^H%:\;G>DU5O-VZ"$N904[F+.' M,=E@L[YC<=_8;Q@&_,N>QT#C]MP^+1^BG*%<.4+SU$\\R9(44DQCB$BL#\?Y M'#*.D!=$/"3I_T_>FS8WCF/IPG\%$1,SMRI"J.$"+GCGDW.KSHFJ=$:FLSOF MU@<%5IO=LN@FI:ST_/H7X")1ED0!%$BSXT;,=#EMDCCG ?G@X. LH4T/LX.G M6RT.$Q2LJXKB 58+-V@I. 3/\"!S*"1C'U-65/E @=AB'$4PM + ]T!SU>?:4*@'WMIY$F1 M!F8]K(X?/3<#KI7./+OC!53]'^5U (S\1;:"#2B*\@($\SR5X6!,E&QR\86P M2A YK6Y/EL>+&R9+U3@M:#??XLP5SKRGRA"YE9^+_'O&E:7R59DD&5G=%KJC M;T'89DM6VC9ITB:;&_>5/-Y5=:.:"NN((4)HXL-0,@213 FD'D90>IB%"4(H M)591NJ-*.S=&[,@-:"WX]?Y;AY,[V/W[.E/V*EM7K6M59:'5%C3J5N&Z'8U! M=[;?7)IM%TYD][,PG@_:H:RO[<)V#[N!!WR$00=7/!7J)MVZ^YWXKA:RJO]K MI_)^*])=KL;3,<2K9>!Y[,840&EC$/M+ T@25(/>DB0 M*(XQ9S&W+(%ZO51S6SY:I2JFZ:C5[>"QV%&0#B5H=*N.LFKM%D#K!_ZH-;1, MX',SUV:KS.0S./)J,N7D#2G)Z@YL=S5:'<@T==%6=S">J.+J\.$#"G>MOV=% MOJ[VB:LJ#UR-IU81L6;/7]76L9+A5GY0:\Y:+T:?\[HDE0XI69<978GW:[7+ M+*H521<;JY,3!?^P(O=+GU/I>3B!5,0I1(1QB(4O8(23T"E UNU@=;;HGK5J"_*9:?0;*9_ MY!7E_[69MZAL-I\26CD@C+MQW_ILF&.H[N-2?EQ_+O*_5T$2C9MJ'Y=;?B!9\5>R MVHI;V41?B"H1_<-VS077I+,MZS]5Z1#[3!0B/1]SX4%6]4N71$":8@\*2D,L M.8J%;^5/&E/8N9')7J7*5U&+#VKY[?Q%HTZQF1MI+A,W,MLU:E8-=UM%3P2Z MZ^:\2EE0:5N=8NQCY1;'L[V[8LQLHREFR)%+:E11)_5430'Z2P?6)&,.7(OR MQ\=\_76CGO0N^YYQL>;E9U%4+8/?";92_^%+SD(O%9$/HY#'^HR"0Q**%,8) MPE3&E"7"-OU2:>YROUCQ(\B:)N&6_9,=YH M-@SIWS'&8]-X#>_7&MZ=Q M]%E W9E^ 5FR'#&P!DBLF-1ER6D:T .&(V6SN M'<90:E>=;<1OV7?=B'RCWAF]GZ[I4?>\82GF/@N4OD?%@*SZ=2IA*F//4@"A+==390AHT7!A'5 M^6K"RIPY?/S<*&(O'6!*O $=9??(&0L=TEW]2 M2NBC?V5U5PV[ZAO^DJ_4:.4R8DG(/!% [@<((LPIQ)@*&%#"_$"JOWG8KEJ" M*]&,/HE)ZRH<2 ](4_JBF^53DUHV'G M9LQ]W3X^DN)9NZ?W4H-6;,MZ:&; F[&M>SA'YM*.P*>@!'^,4V#,"B97M<+, M!IVV[)<5$$<5O.SN'D9,[Q^?5OFS$$WM[\JG]8;HW/?\\4FLR\IO?T=^-+[\ MNHB8*%A6BEM9N<1NZWSY)0]P&F"40,Z(VG"F$8)$IB%,(JGVFR0,O32PX2YG MDLV-WG2;M#8]#!2B*8NA+)C*[0[R2FH@&ETL^<[=?)I1XJO,TMBLJ96 E1:Z M@.YQ&'^K@5ZA:O$75?.[1DEW3.H<74=DZTZN2?G8.9PO*=O] ".RNK)WORL# M5_";JIE;57.C^W>=A/8IW_R/Z&26+2G"7AK[ L9Q++2_(8288 E#F6*/>YP) M;-6C831)9\?Z54F3IT)4G16WZV(G:=76H55%\;[^6=0+0UTQ=MVJ?[!"E OP MY>NW*JKCL_ZO1:O-\5\3AXO'V)/_VHO)3C]0*=BD(.OH[&>Q 7N=%N#F41N! M$Z\NU\ _Y6HS2,[YK3[7P#UH-;IJP('.D)."=#Z*-\_[2YIOII*N61QOMYMR MHWA/F:ETFII&D?,N:U+ MG[:Z*(FR9/_CW_S8^Z]&=DLGRS@3:NB4>?5IFG %Z:K8749T#?F3*TV]I-RV M%D-'6?"'5A,(.:U[:52@C]Q1XXXVI/):\<_M][:05H1H M0F,_AAS' 42I6@?2Q(\@I2F*0QE2+S9*"3IZ\MP(NQ'.IN)8%Z=^4KU*^Y%Y ML)%K4,VU+@(V)=<&(C%9Q;7^5\&RX-H)97OKK76OG[# MZC!GFA=5)^8.S7W)[A^JH/5.7/OOY$?VN'V\N;\OJDB&JF=O182_9^JG3;X6 M#2.6RR#V:!3R"*:((H@\@2!%PH,B]IC'@]17=JHI48TDX]PHKVZ!_-B*J1O% M633'&',R+[/I#*9H9%X^T/#0MU$K"926AUE*C:)@IRFH5&V,UYVRK1D[@XDV M7S1F,.$3+3^O.?%62]O(4]*S2(XU\F3+[MLE6TR459UY=7&J:XV75_Y.RG^(:KH MPZ^";8OJNF5,64QC',$P11%$4O>%]1F%(DU0A/R4I%C:M9.95'X;DIJFM\S' MRKLYH)76M/-NYNJ:[5R.;&&T>H..XHO.T0CHZMYDNH!6^^J$K*,_: #8U=/? MI<;L40![&-SYQ5YE]ARYRZ:5?5(OVJM,RTOGVNL(\>K'-Q]UI\EUF;$J*7SI M)P3C$/LP#C"&* X"B%,_A&'DH8"'?D1\]$HG.(>2SFV#O#>G=W+612 .//ZO M=JCS8IHG/]<9/GG_FD<[BY>OP2P/=T[/ROS.=U[(^:]ZQ',:[A%/>21! >Q]C4DWIFC+D1 M?26FN3?L''*7W98.\!B9.RL)JTZ!52L&H(4<<#9T#B)SAY\#J"9RV-60K31D M&PT95\+^XL;%=@&$'A?9N3LG M&?=5]>].57TI$NRG201#&DN(A&(]$LH(DD"F,4GB0,96Z?P&8\Z-^ZJFH'5= MB[N#JA8#VQV8P&YFJCH&X$V3G 6\;8 M8TSB5(=.^1"A&"LCF!(8!P&*$QPCZ1O%>%XAP]Q6BU:%NBA*605**?HI=\[^ MZO@KKR@F&WH6.F2NC"WG,6=@9,(_!%_+KP\1:PV:?I&M#GI23,ZBAUC80Q%T M9W%;2S"U!3X4HA,6^>!'#2WKM\F*RO.J&?NK,@W+O/A-OQ9JI&:7*@+.N,\] MZ(O0@XB("%+,, R"B$HA*!'G$B0L1&D-P7)W0_-:!1=1)^5!WI%4VY/.W4EN+ M33.@]?V-(K[OE;VAV_Y4C8.V@M\^->V RJ4,!951BB$*)5,410.8XH1#+Y4Q M)4$41<2SJJY^C31S(Z]/8E.5+07;LMX2RE830':J6!99OVJVS"AMLCD8F>RT M'J!51!^W__2MGH>?P4X=L-=G ;H:@;U*#DNVNT#652WWJV29MLB["]B.JK\[ M>>@PSKTC/]YNJ]CG_\YIJ0:[E8'G)W<%6=?-U]0%'_+BAK'MX[:J%Z+^);+[ M]7M2K)5X91L=]KQD/*$^#R/(D4QUX18":13%D'@A\4,2!Y1;E19T)]KBS JM7$CJ(=3JX97[_.E(U,WKKNEM:JVF]KO313 M+T!G$N^:2>SH!1K%P/O=)/YV<1*M6=P]WHXHW:%@D_*[>T!?DOT(([Q.D.VO MZL*-;L8DBBSG2Q[',8F2 '))*41Q(B'VO0@F:2!C3WB)Y&S*R-I#\>:V NQJ MHNRC*RN!FP9(5=.CTK+KD>,)-3QU>[5I&ONHS6'@;*UDU5NO4K/JD:(G7WW: M4F2;;>$R"V2<*9E)U.P+X?ZE0F5/ ^LZ/O;,*,,6"1V!]G%=;HHJ>/"W;"T^ M;L1CN>0>YRP@$11$!! %3$ <"!_&3 @4Q@GBPLK9M@B6E'B2"DY@A+ ' MD4Y3H20FD/HR)8B$*/5EVYCISF+C92^*T3=YV(CI;H+56BM!U!M37K&G&C O MAANGD6"><'=4@EK^1;T)*A>G-T/=JBU$*C.ML^UQN.L9CJ>KK MDZ/,;1=2":G=!Y685VQ"3F-J>#1[+5)C'[D. ,G^%+4/!%>GHR?'F/;4LT_- MH]/,WHOM[%,6 13E@B(HI##-(XB&/,HB7S$1&J6SC9< MA+G1AO8YUMVM 6E$-T]B'3@+_5PR#;8C$\W19F]Q5!_HYEQ]H+Y6V:ZFP#S- M>/RIF"@+>:PIL+-OY.L6[R=!7/FF8H=F$UJSO?]-=//<1 M$%Z(,8N8K[;;"8&Z5AZD08BA+P/!4RY#*KWE1C>W,#,USXQCM6KL1ALQ^J'J M*I2WPH)5U2!W8$#*.6Q33C@+U#I-/:W<2@DK$46)J+J#@R*H_-\JD=OT%55]:]IX]JD\O]M7DFGHI.)8^PS*!B#()$28I3#V4PB@,H\BG49*F M1L5X; >>FQW_[9>OOX#[G>C5B0/1\C]WDO+L>,-X#LR(9 QD1V:6;U_!7F;0 M"EV7_-F+?;GZCS7=V&+EB'^,AYV4D&S!>,E0UO>[#)VKXR^45?I1Z;K6):9U MHDQ9]5-^7@9Q(KDG$NCSF$,4*SL'!O MRNA8$I)@Q/2&+8V40>8Q3^W: @1QB-+8\[&/H]B&TO1#Y\916B8[/JJ@,2,8 M6X5'9HQ>7:TIH*NN2D'VE7B9=?W<'?AH97OBR8\FVUR1[)1OQ%D-7F MX:WZKG5[U+M"K/D7]6M??70Q30E/(:<^T5$?'J3$YU"$<<"82$,OM2K39R_" MW#Y1+91N8OWG0\8>P.9! *;[&V^TP*#0?\Q*??"AW8/Z.BZ8DL2RNM6 F3+C M@''Q'YDQ3M6@6H!6 5!K +0*=<_I2@F@M7 9 SH40&?AH=8"3!PY.A2@XZ#2 MP4^R/_?M[.36O-K,/7?:\^S+GWS8KGGKGH@#XJ,48//C1E_/>DDRO=:F!\^#IF-RX>_(V,\,OMU'48ZZK>&MZ- MIQX3J%084#UZ"/#F1[XC3\!$Y[T7W_-.83(@M2J.:E)? 5_/ >^0ITYVNGN% MRMVCW6L>8[^6?!&E4#<\J+'>B>]BE5Y54LQM76D5J;XVOE=EUS85/"IE MM*U-E"W>;>'X5"MD3G_#9^[RZC/)?(R\!AU,14>+77]+H/4 =WHJ#KMI?IYN M*LS7HTFF9*)5:;RIL5JCKH:T9Z4:_NS)UJNKU>^N6M<_;)B?Z$.VSC:BJJC_ M4;VW=4G])AKJ,2\VV?]6[_+[']KY*_Y'R7CW9[Z,DHA0[D40BR"%*.0>I,CS M810()%@Q!3%@ MD9?RA-/$1Z$5/5X<<6Y46!=GUSDR]TI@4)SH&?!35M5F_WG/BFM=N62MK/Y6 M,.%+9K=*JOLO?A.Y=+_C-=U&0>_'^ARA85HK/1<;$,L6<^E[$8!!C!E&" M!2013F% TD2D@0Q8:)4=.:'L<^/*5E9 :F$5(=;2@B7&] M%RA*\*2XM$I =UW3R^';HK,8N! 4JO="O2TBB2$55"V/Q M#IEXC+*E=$/Y, MWY=I OMW;TPC+FCE!97 AP7?_I7>$[/U>:9S/_)*;U(UKAQ>-N[".S5A#3GW MLS=5@3F'DL\@7G#4*;$N33>""*X"JZIN5-66L_EE^9ED?,F#(/)D&D&?)+KK M*>(0\SB$?DS35(24H3!JB^B8;@/-AC9BK<.B.2.O6*UTX$F)=VUXU!F\33=W M#C%\S5"HNBE?)?<"[/#]W(>O@P"H?K!&"WLZ,^PK!SOU@W$YQ.G"_8[ MR5:ZV=V'O-!=G@Z35!JGF*;9HHS_MV,MZ-LQ8;$R,1V>S@[RW M!=CI F5>P+H1W4Z#*KC3':$-Q\NWFBR \6SV_$QM1/&;K2AZ2%7\EJZWX]J0MQ\H:O.%_W];Q0&_KJOC9 M=U%[KY=!'"4QPS&,.0X@PAZ&1%*BK+B0^V'DI5%J57=^+$'GYM#:RP>VE?R- M(XOL-+#CT-$FV(QKYS!M(W-RK6(W&_G/6DG0: FZ:@*M)Z@478!:U=I) /;* M+D#G+:CU=HP^GGV,Y_MMD?-Y0>;&[EI.R,6Z%16LM:SF ML7YGP>QG8U<0C2L"_ZS3561]^T#*>Y%N924!1&-?8A\&NG_\:#Z%X:! M3X,T\2B*?,O6S<>#S(W^#F2L' *642HGD0Q90*@4(>0A(PI)CT*>VA[KG6WF9\FQ=/.E!;='*//F0_=)BB#GL[*G^5Q") "64PI(%0IF3*(?&H M#PF-(H91$@:><5%AR['G1K$[\8?ED]HB?]GN'!'/D4ED#V4W=[22'=3"6Y4@ MNQIK<_-U1,PGLFI/OL9 5MC7L:^=4P9'6:,#4>NQ?FV?.)E1/%#5KJT\]!$# M P=.-=FNPQ5NY=OZ+VKI^;C^GJ^^5S$/-[JEB;KM*2_):DD8IBE6ZT*=959-X)KDS^>F!=R8[Z?> MP/:E@NW='K;/[F&SR'=W!M]42>U7P&B7MFZ$3%]N>O\#IDM -U+D(,O<[(Z! MD6>,%5NR^I 7[]??LR*O:K"0E4YTJOF\*9N\)%&(D]@+(),L@B@)!21IF$(B MXE!2F9"86Q4L-AUX;GQ;R:T,I%6G6XS,"R"Z6H!'LM'"6,:=F>%Q'H\\A3).;YFK]\ MZ*$H(C+AH4!6.=Z#I)@;HVDEH([04-8CW2PT=^WB/(N=*GK_]]0JHY.0U/L< M6Y9"'C1G9F0W^DR,S'S5)&@%JAX3"]#H\-S4O-#2.JS%? U8KHHW#Y)AVFK/ MU\!T5![ZJH<-(\F_"'ZO"/>=*+/[IF7YCZQ01(^OGQ+/G]K$WXH%6/K-/_!1H_=_UE5",O9TR1<'X$^[1]\1W M6PKVRWW^_3_57?4GJW[8?ZFGGC7)Y]FC1/M-]ETR;"VNCR?OR(^;[>8AUZ;= M)S5SU=+!8I8&*.%J&Y(D$,5I &E,N4XZ1HR+()'@25?LRPJ_7+4-[AA&&)_T M)D'/= UGG$;J/%-D+J[^\ MORH,RC=9KH,RSX<"OLJ\DX@&6/@>C +=IB#!'&**(L@YCTC*:.#YS*QVVPQG M?IIZ;6>;&C2E3RV"FZ>8\?XU;8:S./(">;;:?B4V:#5NZMINE,Z@41JT6H.. MV@O0* YS*1?=AS1\T%>4^E5>B&N;++S:B_':[1A>X05QT,!AE.FR;O7@5HI7 M;@HQ"J27VT>,,ZR]]_C]>J,VLQ^RE2C>DHVXSXOG)8N]2'A) #TNE3T91:G: M>P8Q]'D:8\)"(6.CY-$SSY^;_5>+""H902NDN2OY%(*7WC,/ PQ&D<022YT 6< M==,7*@6-U 80&Q>Z.'CRW#[31CAS^^L0I\NF\V#M1_X8&[D&Y >(F!N*PY& M8B*K[B4BCE+T3JK=8QT=7C^9'7-2S*[%;]/; M["B$Z=I>RAC^]G4I4$C\T)>Z%1W6O99\B#WNP2#F'O,I(BCQ3%AB_\BY$<$W MW>R*@Z]JZ3-U&G;PZ?_BAVD]\D?][=/'N_?OP->[F[OW7Z__>(]U[-D--!?7 MGV?SC_V7V7G4)!_?L>CM]W7B+P/CX/=I*+O2>CI+G&( M6.#[,/"]!"*1(HA#[$'/]PA.D0C#R"[PW6C8N7V*':DM(]?-4#9;GMUC-_(' MW1%XT:DC"O9"@S]:L1T>/-OAY"HLW6S0:>/0K8 X"CRWNWM IR)-$B"P*-V M2C ]L%. 2U([;#S&-+H%QE'IL..VWF ML2481YG'MOOV0=358ZM.TVH";#G+;!X,&XO6C>J0JZP@8AVZ< M!+&?2EQ ,S9IV*%B%;W1I_J@\(V3#YPL?J-/G6X 1^]U([6$O]!5]7:[*3=D MS;/U?6_CYL@/9,!##J4(*$2>AR#VO0"2,, LB20/)5T^5<7]OFY(L3&S4R:2 MWN:K>JG#>!_8Q2;?C9*@H^4"_#=9;TGQ#/QI>G\[>GT0H6D0(@;5^A% %.M: M.CA2;Q-A"9:"^4(9N#7T[]>!F^_*T&LSMU7DG6.5P >&_ULMC9I7/\'68 MT*P_US#>M%_\P8LRGU;Q;N=LJC;QCJ2>5XMXMU-AW1[>\?!##]"9WG U)Q0^ MCI*(T 0FJ2Z-A$0"*5&;)9^D?A+X,A*>5;WV@Z?/;9/4"&=[%-[%R_3$>R * MHQ]L5W(Y/,GIU=C9$77WV1.?1)]0Z_C ^=1%0\O3UGDP'S(=1?5;]EWW>5"D M<)_1E:C;L+_@AF^ED-O5;YE4&QR;[+'JW+>M9 0K):3.:LYV&@%2J;2H\Y[[SCW<3YVAUW:B"1G[ M[*G--:SU@)4B8*])G4U8GC#B:G6 UL=E.=SK4756(O<*428NFWL]:,>E=!T\ MTSZ>YZM03VI30S!&+"#,@[XN'H'BR(,TB%+HZUIRPD>)"(T;*W0?/#<^K&4S M#VLY *F?K:Y1?72'L!9K0%3/@?KF83U#89@HKN?"2V 5SW-*U9Z GH/+)XOH M.25D-Z3GY-_M&46QEBCJ;&6R:EZ:(/#\D%8Q_TP99PD5$',4P\1# 4IIQ#DV MBD@^\_RY\8L2\3_^3>TID_\R3 DZA]MEKKD2C9$IYT"Z AYBZ=4J? MCX^/V[5%GZ4KYN0R;4Z#],CLNE,"=*J$:CW H2*+DT5L[*H873$;%H'@D\S* M5''CX\V.7:SYU:#VA:8/?_ATD>Q7 W 0^'[]TX9Y1ZOJ0/IPI1 /8EWN)*B: M[9#RX<,J_U-7E1>_DFRM?ZED6I&RS&16U[2NNC,J>9?=3.W;WW1PZX%BEIF'[J;8S*7Z*A,W\J)8EW [4*HEX)^T"C\O@%8-:-U MI=P":/5V?WVIXZ)I>:O4=.=V=8Z\(Q^L.[DF=<@ZA_.E=];] ,,6@=_56E-D M9+5;;];W'S?BL>E_OHPQ"WW$,/13PB!BB"AFYPC&,DT%IZD7IM2L%*S9@#;? M_3257+^I[6 30-2-4=VB-[@N^K\*(.H*"2M(1CL?-0'%$8!<&FY25 MS!1_236&=PWCCR^BW!1;ICN2Z<[=3%=\X6_SWV%-V]_['1 M_Z0K\7ZM]E!UMI7. \>[I&I]A5GVIJJ MQYP*1P0_BHB3+@MC@OQR,1EUK($9+^Q!\.U*W,JZ'NK?,MXI47*[_E7D]P5Y M>LC8C=YRZU::531$'0/Q1Z+>HTUQD?>X/0J*V7I4[IIWS] M;.58["E*)/ MFZCP"I-RE*WP&C(,7"XWZAD/^4K=46JVW3R_$5(->J<%VQ;/U=^7.)7$CR/= M^RE)(:(LA!@+"D40I30-H\CS_>4FWY"5X3IG,JK5 K4;>T3.Z@C]?X"HQ :T MDAMP-=^L.EBK&CPU:H!2WV*Y1AE-B.'BXAKFL5>% X3?'R#1S'T MB"00\<2#-(E#R (2=-:D88>*(3/K'FI1$C-1^21YF-PWL*T!*W1%)_T?STG>R M4GO)]LP%)2G!"<90$!(KSF $4NSIJEH(1;%$PC).H6^PN5%&=4:M=]A,_R#V MXEKV&.C#UXP^7*$V,GOL *M^Z$@ZPHF6"22N^@KT#35M4P$#I8\Z"IC<8U_U MZFW^712[0MP\8,+W:0@Y53L>A&(.:9Q*J-Z3F#+?1Q$V+G=U\.39<8(6SJ3Z M]@7 ^K_[JV 8^R,W1<"JFM5);0>5L3I\TF3UJTXJT"U<=?H"5W;^35EN'^LR M#M]T 0BR8ML5V63K^T]B\[DJJ9.QYGIM,[S(8ZQ"^46Y>5L(GNF[=$#EDF _ M$3*4$+,(0\1\ DF$/1C'&'N42H]0HUXATXH]-\IHA02LE1(42LQK-R&CS/C0 MW?-K?*PS2K?O2$[_:L@]3&W6F-. MV&A[ME&$?N7-WY@3<7D7.>KH]CE@OZLU4I]D9NNW^>-COJY\8FI#<> C^Y*O MM,M?%RY:^E3ZDE$.?<9\B (90!RG/HRBQ M2$O&4&R>UV@X^MW6FE5^?_-4: MU&[@:D=VZ!D&?V@]0*.(13*H]03U+RACPS[RLC!+Q,U3O<9$?J($KQ%FP"JQ M:RB$/>EJQ!ZEEYL=4HXL=L-!)[6X[8!X:3%;WFWO1JUC7_Z:K[9JK2SJ MQO3ED@D4I%Z0P)1JLS:5!)*0<\A]+.,H92(.C4Y=SHXP-^JIA00[*4$MIKEW M]32.E[VL5Z,S,H'8 F/E=.U5?I#S]?03)W/"]BK4=<;V7VB_!62N0"^/,[9,^%!4T MLIIO?/H@32,F<9KHGKH:4L]/82JIHLM >CY%L4AP:)9CZ1#4:9(K#X5U ^?E M3;HCB,:VMDZ^<@-J7O6!9;Z_=@3:1%OIT^#]XF:?; !%SY:X[^[)=K\&*G0W MNB:7#]O3UFE!N^2A-T1-(Q-?'X30%NH-YUE=D6L?3%V^>5;_>,I+LE)VZ_:I M5(]8;76==WU-KG?C6\%OGYKDHO*W;"VJ?-=EB$0J2!S!(/(81(G4E)OX4,8D ME8'/$TRM-L83RCZW];!)(-SIO@"-]J!2O]H:[@'H)'Q4J1HM!J &H3V;YRMC[8MXA9=YSZ* TAC%(?22-(8HE@)B&A,H MTB!)1,QB9&=2#Q-C;I1R.L*JUD0?[K:_WRLSZ$3]RKDS8Z7Q9V1DSAIO,AQ$ MKME@.5HDFI$0KQQ99@/4Y4@QJZ>Y(M2ZY%\UFS!VL7E+ M-N(^UP5@;GYDY9+Y44@"R91]X$N($N[IE,00AL23 1-)C.25YL+9L>?VQ9]> M&O7_[CH=-@H\@S^T E?OILY/RU"KPPG8KV*"#,+9@9EQ$;'1;([S([^R 7(1 MDLO6R.5'#'0R#VW>_8%DQ5_):BLZN3Q?LO(?'PJQR\^I=&HUI&*)60NF=OG;!GG\@Y_CP;NL[G-'MC M^^"U(K#2!'2U!1UU]8EI][I&95#IO !::U"IW4W[7 "M.="J[Y,XW:9N3C9/ MKHX(1I=WVK.&J> _.K28;&#[:-<;QHJZ[N(70=6CRF44A+$0*(5A[%.UMC & M4X]$4$0BBA,6ADEJ=!)Z\NES6P<: 2N?45&+J%8$?12M>"-; Z+_KG[4X1EY MY5.J:CXK,EEEA&:K;*-,!O-@Q&.T^QG^:@Q'9N,6/B4<:*2[!@SS>,RK0)DH M"O/4NZ4VT/K+Y+K=U?[4';4 MB-X.G+X>]89/FJY]O9UJ!YWM+6^U3Z5\U[Q!.BPP+YYRO3?G;YZ_"*EL7J7: M_D6GOA\PC\60AVD(41!$D*9"9W_[DGA">D08U;6R&G5N-+T3''0EU]O@G>SF MZ9?FV/=3]VB(CNWYO0RFHG"7_14&(34HI]-\E,GR/*T5[^9^VM\\?I&^HZB: M*J)YNZX]>DF(PHA$RHJ,8EWE*/ @P;H.7X#32,HT\! 9JPY?KV2SX[1&MI$+ M[/7/UM 3K@GFX%7.OWK+Y)V*S]G-XNL5P3-"_!7JW/7+-=M2=D9P7E.MSFP M9SS^J /)_[<:Z%;J=L.E[C%/E0C80)1@H3N=19#0F7DAS'!<>PO MU^)>+SF#N?K+FIWLEYL^ =$2_FI[/3L)@ KX* MV%>EV([D>F?;::8^*G]> FP\ACP[\FMSX"5(#%CNXB.&\=AO^\.'FS4_;D>S M3/U8Q)YN8,6]I*ZJ@1.A#,X0I[%'62(2SZ:!U:4!K:S'"7I7W>DQ0$?J7;FN MS;,=6UV$VHRB7 (X,B]9HF9-/J90.&*TGT*=^( M\MU6*/3B)B28)=R/B;)_0D]X$,5"0,Q2O7&50<(8Y=2LD.+Y(>:VY?1^2:)_ M!VLM)^!; ;2D%L>9IV$T.."]&IR1":'&Y=,!+@,J\9P!R.+0]VJ@)CJ9. 68 MH[/=7@CZ#GA/WSC=*6^OX ='O?U7#C28\O6]HI#'=X)N[M0CJOAEPJA(./-@ M0G2IV"3F$(N$0.P)GX8L\%)I5,VM;Y"Y<5S57%@+";24"Z#E'!0H?A)10UOH M2IS&MG\T1'=V$-D;03T8N#)\3@TQK;'3H^21@=-W[6!OCR@*P>_(CSIF_]<\ MYW]FJY6RH#ZJ16!]G]&5J/^T]"3Q$AW>@<,HA CY#-((81@&A)&42Q;RP-(Q M;SSXW$CBSX&07D\3T_E=@Z M7F&73M**7B&]%_X2U$-\/]:8N7/^F \]M??'&I03[A_[9PS8KL6AXDAEQ.HR M2H>FM!_B0# IH90I@RCR$YABC*OXW1CYQ,/"-]ZRG1UF;FP5_Q)Z_P[X3M@A M>[?SF!KLWYP@-3+E*)#^'>S%!.^NV,>=!\MB+^<$M*DBS;(?X"E7JR'8/.C\ MD">A'JQ&O1R!BDY3)NPXI,VMVH/XCKQR55"-T?3ZAK:N\M+*_Z0[#2VE#(,(QVJ#)O7!FN=S2)#:I1$9Z CSR=I8G,V?WJ8N9W( M?]W2:AA7OJ,*RJ%>(EN 7L4?I(4&GF MHLSNUSHNK_7-D,A'THL@X@E2QC+FD'(20X\0YA/*4&!WV'1BC+DMU>]$D7U7 M6_/ORG[\E&_ NYV\.OWU+X+?Z[#AC^MR4]11_-;K]Q'*QNOX-=B-OIY?AFJ< MU?X<*.Y6_:,1IE[]SZEXP@HX>^E ;\.+K+DW0N:%V&70O5/_*3<9NUES76=- MC?PBI1,A%! 6_SI4!_;+W"3AZ[("CLG7V2%9_$62U>6@,A" F4QXA8G'5=A62.QSSY=)" D1$B+J"T@#+X$1$CQ5 M&'M>8M1RVJU8<^/&0ZVT%=/V]ZG5*L$F!U=;E8ZFU,RXG'ZB1J;MXSG:J=3, M4I,:!_3WVTY@-7-=U48U.-V"[LCN="34I.:G6R!?6J&.GSZ,X.O^!_GC4R$> MQ+K,OC=FL!Y=";@B99G)C-7U(?G?M^5&"Z/ENKE]^_&SOD7]859KF,%W=P4^U]C\#K?\"G,[-?HD+V -3+T : MFD7K!E%*NUME7FNZ'*U'DXL_Z\CF*8A"GV)?9)8-63M&VQN6Y-65FW'DEI: MD.W$M5M^>D$V6RI<03H23G.1.F7?&1TSS#N M^+;6I93OU]G_5F?W#3V5.Z^R(C.R:K+EVU+I-W4Q[V42!#1..84TBK'N]M;NN?[[IDZ&./ZVYDUQ-L'?_V#JTIM'_:^E=BV$7N1#GB8,HE07 M3^,XA3@5B$N<(LRL.F,/DF)VY*HD^__ Q\>G[:9#J99I]X.FPXP^1P=Y9.*L MY5]T?,25"HM=':CG!>BJ 6H]0*V(P]S^:W!TE?P_2(9IJP-< ]-1^8"K'C8P MS%-L]OOKF^\D6U6!"[G:@3_FZVZ-IG?92G_SRR#%)$Y$ L- 1Q]@+X(T#!!, M"(K#*%2[6L%LW+'6$LS-GZJK2F:U44,VFR*CVTUU4J.V<+^+@OT#_ =Y?/HO M\#;_I3)^U/_R6A'+4%'KF3)CS%'Q'YDM-?2-/=FT4J,_/M J@JX,NY]L/ MOGW0Z5 786D6H\_;<#J4'B.PED'/V@8-;XGQ5K153 M7I+5KT6^??I8]=A3@U3%O=?*9%,[U<9ZR]>_JNUM073=E!O^F*VSYKN2MG$3F0W#(1S]TLFK'5Z\S-R 37*@4JK2K3MM8+=!4#.\T6X-?._!UJ M!QKU'*8*.H?<57JA.\&F34ET#NA1&J/[$9QU6&!L^ZA[.^Q^NV_ML/3"E/E4 M4;=4.V#%Y)) PB(?8DEY',01"YA1Q:IAP\^-K3NR MI$GN0[::_NLM W$89D M/!J\8Q/NZ5X+';R/N]>,VF[! +;Q.B[T#?[:31<,@#'HNV#RE(%IG$.;>5?_ M\U>=ZK2^5Y9UEG-_*4F:L-3W8>()M0E.8P%3RCF,120CA .*D%52N$OAYD:. M;]5*5A"VT2V5JP+&N01YW4'(,M'3Y0R:\>9KS8)A&<0"E)P,_];FD9I7O>L:8&_VVXOUG^P/ MYNF3YW#L9T]'Z(Q,@B> &9!@>@XA\RQ3!TA-E&K:AYBC$JD7P.A).SUWYV2Y MIQ=$[R:@7KITZ!:^+=NS.T#_E&]NI2S%YG.^RMCS^Y5@56=&H3\( $ M7A+!(&!(G^8$D!)*8>RK;7PB J:;!5DV2[26PNA5G[1I8E5,2K=*U"U0RRW] MNY)8'Z[FE1H@6X-'4BKV!FNQJ0P@LE_A2MV)J'.EKG;(NDF-E*BQF #E@Q"; M!5BU,-GZ">QGV]19,,X,3N4Q:*7OA@]]W<_A[_7,?6IFKF.;Z/2A1B&]2?F0 MK=4\96K;TJG?I(L\U5"X=#,,!MR9K\%>@HD=#H,A.O8Z#'^4'3&7Q6:YST95 MS_FX$8]EU7 GC5,IDI3K4E ^1(00B%,L8<)HY#$O3#DVBK,\/\3<[- #*4$E MIE7_HAXP^VG-#40CL]8 =(QIYC( ?2RB[NXPB/K7GCUZ'CP).5Q6K/WV#:X< M&"]3-7'\*MBVJ)(O_I;I%@*;+X+P;/7\3FB'EUI&Z$I\(%GQ5[+:BF]/>JO[ MN3V"C(>BJ"+2.H%)R 6HU0:5G)Q%\ 6I5 MG4>5CSD3KH*=QA!QVDBI$4$^"K,:G$G(G"[ 6\G>A1./[[,UEZH6A M3TD,@\2/U'X_3""1$8>")TRM-LHH]9&I ]1FX+DM%PU_/%9B=E>'1;?YN+D; MT&H2+GM/QX)V_-/Z?3WTCN"+IA/A+"Y]W4LI"=RR3I$W,I/.P2V M'N>MU>,F\^@.4;+KYAUT_X!JJ<$O!YV7H[9R/68IC]4.0@B$(2(\@)CC$/JI M])*82)*FD7')U--CS(W6@^-.\)%%L= S0%[F:P?PC$S-0:>U>=-#,!I23_4, M1!9%5:^':B)N'0:978'5?C#ZJJR>N7.Z4JO]HA_46[UPZ0@)[FT%$S7@_PA2 MW/V9+V,_\N(TB2&-B:_K\$ME^G)E"0/MQI\=57H!N;'% !/I.,+X#6 "@5)DI8/X_=%*GJ)T:?3Y+Z>6BLTM-[ M'G-%F=&ZG=';K;(Z7[N$DBF 48P21CV.(A?2@SV-.12Q% MQ,.KFIBJ0:R8:*KBWX"WKM*-?3>(DU":V137 C2ER[XU+G39BUQ6!Z9-7LAJ ME?^I@Q9'[&O:P66LKJ9ZB-?M:=I1\F)'T^ZU3HNM+H/4]R.<4"BH3H.0,5(D M$$IEA @2*2LDI9[GH)#JW"R2@P*=B@7:7%TW]5"7+$@]X2$,0^8Q1:TQ44:> MP# )PU!PRCPIO.53E=OR=4.*S638OAQS/(3?-*'-_TW66U(\_\>_^;'W7[X; M>,,P2%GD>Y#2@$/$8P%)+ 3T<>BE)$G2,!(-O._7AL'JSL!M1QP?VG>"5<9! MC6WH"%RSM6-?QVG5NE#D4Q#VW@EVZ_&HSMG.*^FN>\S^S MU:JNFZM>@8RN1+UNOOSW,J%Q['%?0D&(LGF#)(!8IB&,/ ]Y"4FCP+O@Z]D67/E@>]_E[9KE'Q\?M^N=]S*.?$2%A$'5H9)+ M#Y(D"& B6> '&,G4-^K <.KAP3AYUH _R81U"8 M>S*O@60B7Z;!RV'EPSRGC+/7N,FSZ9YIR+J!1'R,"1* M![7E#@.8BM"' 24)C63H1\2HGD/_,'-CIL];JBRSU3/8%(0K,^$HF^6Z+!4C MZG*'V,@D=IPIXBZ$RPR$D9(TIOSJS12]E"CAA GVY;!U_[NW=9G$;'V_JY/8 MM+G;M5@1Y3OU0[G)V))1PIF4(8PC&D*$60PICI4U@U+))$EX2H4-75PAR]PX MI97+CCJNF0PS?ID(XI%)Z+!>?]5R=*_*OEQLV;8@W?>+TKN^BW-C35@.4'7$ M:M=(,BGU.8#L)3^Z>*3]INY#]EU\SK/UYGUV_["I_B74:ZY,YGO1!NG>KN_^ MS.\>\FU)UESM,>\>LF+S_"G;&?.A8&'@>PF,B$PA"L,$XIA@R"+/BP1G/I/4 M="/H0J"YT6GT2_HB$2&T*+OE9(HN;SVG!GYDDM4*@$H?4"D$ZE_L5.J$\M^N M=2 N:/4"2C%0:P:T:@.VNTZFS'R+//743;2MKF;LJ9I"44VAK'ZQG\+]%Y6O MP49-X::=0OW_FWH*UTI%1[%%+G'NV)L73[E: M?,4[03='6V(L$B9$XL'83[E.(:&0)@Q#3W">>!%A";;J7]$[VMR6M)VPS4>H M/SB:K[FEMZ$?8;--@3/<1EZ1]I!I0;Y+X+?ZRX0HLSNU]6U M=[J:Q#+V$^[%/H%A2A.(>,@@3CB%B'H>IFI!D=+*?3&>J'/CKGW]%V7_[75= M@#:JIE(7M/HN=/'K3B'!5F>@E09_5"H:VH83O!9FG#F/R1Y["S#E/%M3]/A3 MX(C?1Q1TTL5A?,!?KBP3C.BLOT]9;A_K/@S?=+UVLF*Z\X8:^I/8U"78,]9< M_S8O-^^:5KQ?U+JYY)ACFO(8QEXJ(&("0R)#!(GOXY@)&0?,*!!@'/'FMORT ML@%M3-;*UYO-D9>'\ZT$]HK![Y5/3'VZE6Y$*V"N_NTB@NPF]8O M?=/JHNN0 _3'ZTITC7"OW;7( ; &78U^ M"+8B99G)C'7/'.[(CZ4O" \1\B!+HP BXGDP36,$8TQ2QGU*<6Q%\M<(,S=* M;[+4N\JT#=%_6E6G?,U17O%")4!V!0"57:KNWI ? ]+;A\ZIV0(PU4R-3/?U M)!WH<=@Z?='.TI$ZN[_<]4S/L"3[*W%UF8X_5)3I$_>O!.UDBO^USW01P'*R MU:=._;N5^G,5BF@EECY,PR"$B'OJIY@'D,L0QYQ%F$:13;JNS>!6E#M!&F_S MY5;1$[S;;C??B;[0#3ETZNJ '%^K>1D2O.(.[>FC54ZW-]ZG"BL%NMV0/^=% MG3>\V109W6ZJ(LR;''Q27[S>[.95=VN=SB"4X ZKF Q!?)1(E@M#OV+HBADH M_;$JAL\84,O2_R5-HO?;(N_4BXO;X[> ):'..4!$"H@H#2"EG,$DC0/FLY@A M:73\=FF@N=F:E:C_#H02%G*QSG5U:=U(Z*#.96Q1Q+$/Y,MA(ZZ@&YG%&M2T MG(=%'.,A=2_[(+,H?ND(NHG",:Z!T*X.I@$N?<4P^VZ?KB*F@1('93%-KA]F M8^Z+S'_(BYM'O1K_;_UV4B^-1( 9C-,D@4A$0IF66'? ]%B0!)SAP"H7]NQ( MEAH[R[ M?U%HS0QL)V_?R.N0$3K6ANY%S1U9M>?'F=2$O:CN2WOU\@TC5!W^G6QT*,ES M=6!W)WYLWB@=_K'DDM!0T@@&3-?<(D)Q+H\Q]+ ,?$P]/Y%6G#M AKFQ\5?V M(/A6;0K5WK&16(=%J7^]J*8[O/+ D)DR8YV1\1^9CTS*%K=*-#$00.L!*D4< MAD-< >,4%8S/2#"?*L;]$%E5,K[P*#NJY");OE]OU.-N.%=O;MG\Y[=L+?PE M8S0@@B309]H Y:FG#% O@C&C$0\2GOH\,"'#WE'F1G>UH* 1<='^ +2PX-:T MPD _L/W/3D MN7W@C7#F#J5#G"X[W09K/_+WVL@UP*5VB("Y#VTP$A,YS8P1L?*0G=2ZQR5V M>/UD/K"38G:=7J$O.@C>;)"^QY1H=[Y6LUF[FLPK_JD(;W/YYT MC=-*W4L/O9!TW69%<>>A)')<^;X MFW/RV/,P$75WL04RKZ.-K2?(5:;AM<#VK Z#'CO9(G*-TMVUYJKG##M15-8T M$X)7<75?Q%/34_!6?GW(B\V=*!YUDOHR\&@4!*$'&0T81%R$D/A) (.$AE'( M8\IBJSZ 1J/.;?'1P:;L0?U&YUJ 4HL*U;B/@.9%D?^I)L7RC- ,>[-30>>( MCK]%KN2M WQ_VHNLZ.EG4$D-M=A5[0IWIWY6,#DZYS,;<]*3/2L87I[EV=WL M*F%8LR#;"/Y%;+;%^G;=I+;I&OT\(E[,<01#WPL@PHA!0I@/*:)^$",9,R]L M Z',^,EF>*./ZC L:NSSOD964%3"ZF)53^J"0=U,K2;"C*J<@_N:V;L[K&O9 MV[0%!;G^^QA]$JRQ&RWWMF?H5\ZLO0S*Y;Q9@V<,3<&J\TX:NVZ)DRA->4BA MYT5JDQ]015]!$D$/>5$J"8V5[657%_C@^7,SHUKQ@*CEL\V3.@2/^E1RXF'( M$H4@0@(KVA<^%"C$ 8LBG$:1'?G<+H!EG7_%.C4S+.S3>7T!C0#;7 M29V=)6P=/GWBG*R3JAVG79V^;!COW>E^ 9_T5+;]$SB*0D]X4!+D0\1( M/8 M1^I3QJ$,"!81C6V([^4 5>?KQGK[,_N[C;_N.Y;&-EB!\QM;V2D$11#)%46ZX4H1C& M/ T\S$D2ID;QY"\?/+NOM9+-W&-] -+EDX"AJH_]859B#3@=/5#?W!$_%(:) M'.P77@(KU_@I57M73^;*/B5DUT5]\N\#7<^-Y^@NOV'_W&:%>+,MU1ZL M+.\4*J)*YWY+RH?FCWP9R%1PGX0PPBR%*%*;I314[,-Y)"(1AR3VY8!\-TLQ M!NP')LF"T^*5657W()?@,UES_>/=@RC(D]AN,E8U<&2_[(I4,*44((U6EHYK MRYDS=&&/,!$3.;-;W_4F!XUXH!4>5-+O2E5H#=IKSJ-N[]<>AITK#[?EZ-/Z MNH=!<^3U'OB88=SX16S44_2 VNVD2W-6D9$>"1*)*8))&&&(4AI!&F.F-E!> MQ%B0I$ED50+^]#!SL\3V4M9.U;H^KD6DZ054S>CI>JQ&9J$A,%D333\*COCD MS""3TD:_HB_9X<+50QW%WW4L0/&L"Q=MBT+]8QGZ,4:<(1BE0O>,>;V^>]$!&U--,'U"7P=WC+D4.L4L)[O1X%(*/13K*DU M]6%*U3\#R@,O](2?BG3Y710TGPC:[ECC@5N#>.&8RAA$4V?R5<",[E!NI%N MO7PNO86+O\ED5CSW,YR^U]U.I_4VA,XO?B?J_']>ZG+GX(M0@ M6[%D":6:7'6'ND!R=&%H0W^U _+@&E;2@$=<9;N8>-'?X M3>13NPI'*X^;&30]/K@+#YC,*V>F2-=/9WC'E8:IKL2XRLMMT:EB$C"/\H1P M&&.)( K4_Y"$!S!$6*;<0SQ&1FF0)H/-CV=K6:W+Q?0B:FE578G35.85V,L) M_ABEQ(L)(JYMKE-#O8[QU:/T62NL[YYA5-&66KJ5.BKTX[K<%-O:C[9[O4.$ M@D"$% KN,X@$CF$:^1%4F]F IS()P\2W(8S+0\Z--KKUJ'[+U_=U6'G5M:\C MOAVC& !OQBMNX1R978Z0O#N%Y*B%I8L_S9"Q\ 64DM#>>,(B9I##T(Q(G(B8Q-RJU<_KQ<^.)5CI+%GB! MF=F'/QR)D;_U5K 1/N[3.COZGE\\?-)/^+1B+[_:,U<-"/76T4R?\VR]^9K] M^+^BR#\+-?G*,+P7;9^(V_7=G_G=0[XM%6,KEOB0%YMG]:OF'45!$NB6.)"$ M"$,DF80XCH5NX\A\&B(99VS50"H!6*:"T I5:U:\'1,-?/5,6(?13SMA4 M8[I< 5=P'"08.'NHL[/-&UIN"L(V2R\FDB0B@D&D MJ\=+AB#U_52M=$GJBT#(V+ M!LW%2>=+.,8[Z-R-]-KGG"]5-CCF/+IE8+F:K'S*2[+ZM?Z <=]$]W71WT81=.Z^V<"64KHK<#)1BVGHW MUT%U5/KFRL>YJO#U8;OF@G]56XMM>2OU;Y:^)%@WZH ^8@%$) P@1D1 SZ,H M"D7H)8E5 W*30:W(<(+&X[6$H*Q$!.\$JZS<__@W/_;^*_2OK>9U G1#ZG,, MY=@\=[)Z5X/M3]_6LOKI9U"+7Z70JBO&+-QU'J[1"G:=&/*5"W6=!^%R@:Z> M>Z_<^OWV\;&44W/ B4LV$F[J,K% M@3]JB:T]SCU(FYHD;O ;W309#MT ,^4R)L[,E9ZA)C9;+BM];+X8W#.PK";Y M\7:[*6_6_+]S6MZPS:T,/#^Y*\BZK@>E+M!=Z)E:1K8KO7-0_Q+9_?H]*=8Z M(FG7A_GMKA2"C$(_\&'(N79-)PDD G$8DBCA,14A]>WJ=IY%I4?.A5JZ*,M7J :7? G1F3E^A6^ATU .-?J!5 M\*!-_5O7I2%&P]]5W5/G\DU;.'4L>(\JKXXVT("LIP!%;=Q$X$5>LW,)"4H2 M/\6*TT,)$<<>I#+@$(DX";3+R\/&15Q/#S$WC@Y^0=%AY%WD623LG(;Q\D;X M>G!&)L8:EWT\E19R2$;3:8 L4IFN!FJBC?(IP!RE+?5"T)>O=/K&Z1*5>@4_ MR%#JOW*((X_IP\C;)SWI38W&+Z(BU;O\;;Y2U^7Z[/*[N"D*W;M+7["4B<=" M$F,8!$19N,J>U;E*":04!3*E D5F=10'2S W=FR4 'FE!6B:.H&BUD.? ;"N M)H#L5;%QGPV9*Q-GX\@S,+I+-+2+9I87GX7Z7_Y%M%4J6?6FWO"_;\N-'N.=*%F156(M212A M%$4Q]!*9J@6(,$A$%$ _(#[F2%+J63;4M!-@;NO/2Z&M.VE:XF_F$!D3U9'7 ME)?R+JK6P*1H-I9@+S_XXW.^RMCS.-50AD+HK/>FY? 3M^$.RM,@>>=?3LS6.^K;MPU_+O'(?6I>'ZT38C,F<8CLQ:+[!Z7@ M*JAD MK8%TQTQ&F#BBH?ZQ)N4<([5?$HS9305??NL]5PZ.]!=%(?CN#+RS%"Y%DA+$ MHQ2F/%#60L ]F!(2P5"2 $<1$S*EEA'^9P>S^N@GB.S_NJ75,(OAQD$OMF8? MO2O$1O[\6S&K<]J.B N=N52Z;;%]$0]W$?KGAYHZ,O^BTB>"*SJ69\99VY;F)V8^LQ$RVF; MJ'T:34,CYGJ,QK9?=O T(HX00'8!!66X+?K+YIL"K6->D/*K/RVSJG.6M*C?UP_;3?JSTI5=5?EIWU+5DS' M@JD?O^2KU8>\^),4?)F*A I?A# -B(3(1Q225+&*SSFC)$WCE%JU>QM=XKFQ MTMY_>+#+ JW20%E%.[5!I?<"=#4'E>K@4'?U[>ZU!W]H_4$#@&5BPOBOD!F! MSNK%&)F*9_1.6%/\9//D:+$87]Y)EYW)X'^Y@$TW\+5]7KX(W;:!;;9:GB93 M]\VS;HEZ*]_FY:;3*0J16/J)[A0E,$0L1)"F"8'"#P(?<1;&=F7#!\@PM^7J M[0,I[D6=I?#U21DLFH&JZ!7]@]J&'FBFA?6+,)\YL M21EY.D9>)+J=9 Y!;Q30B%*& GN^1NB$\\5(!?20"Y*4TD<2H;L&5LYZ&BP (UNBTX4FCNJO!)-1W0Y5(I) M*?-*J%[2YK6/8!F]5TQ MVB3!,>(8P4AB1:\^XS 520Q%G(:8"2R\U,Z5.YZLU9M'8]0]GB"J1FM M%I\[25^YA)]SR"]7_G,_Y+"E1YN9HF 967TFBNN:G%?,./%]S"!)$P&1I!AB MG^E#0.X)1)@71E:+QLE1YD;W>R'!DY;2CN5/ VG&SU?#,S*S=I"I!!RA^5$O M!(X8[/08DW)/KYHO6:/_8OM$X[=5,>1[9:^JG\J,-Q61Z]R9O6N,TP0',O$A MIEQ"%&*A:""F,&41YC0B?LJ,?)KF0\Z/"5JIP8'8YJFJAE#WT\,X ([.%:>Q ML\K1&OSJ&N?ZNL=UHN1>7=1\6Y8:T5R"S8, A#&=J*-MUZ<:8ET#B.WG@74U M_,5-BJ\=?CTYO88/FBR)UTZQ;M:NY9T#XS6R=;81NH:C,A(WZL7(Z$I;CV)3 MWCSFQ2;[WVK0)NS]?P0I/JAKES@@A(2QA"1!B6YO2R'!'H:,\50$-):(&O4& MOTZ,N?'\^W*3/58Y\>3^OJA"7 'IB-_VZU@ ]=HFEE$1PR;*,-1A=/C'CE^H M%("5!F"O JAT6%3),:S:M'>T60"M"-":. Q&N I)5Q$&PX28-FS@*J".8@&N M>YHK-^MG]71-T>K'\F_9YJ%3SZRYZI:NLOLZG_^C$H>)LBG4WPC;\L;G(O][ M]W;<424()IS$,1*"XER<)Q"RAD.L#+YZPB#"K;.+746-NW-WH#)ZTTN!/ MI34@.N>P%G_GKLUW"F@_GZ@TUX:3O@V02OE%[VW7^GHG><6&NH'G]N*\BH>X M?9/TO^H7J5L_L[WV]N!%>K][D:J[;IH7:8?"B=O&]!E/.8^CN9,G4>*5/OHY9X17R?^^#($9R.(#6X=1C%ABS'G1C>MR%60;T=H.ZHQ =N, M:AQ#.#+5G$.OK0FB[,C:CSMJ63,+S!Q1DC-.V7-[7BVFX1%@I@JGO.@LK12B (_@90%D4[F(V%"/8(3 M*S?&S/2;&\56ND.JE0==@$ '(1V_W[VN00E4,"W://\.4DWGXXW""C1@+< . MKA/!4A5D0&/6+6-F$ CU+_%*FRTN,Y-Z1@M9_>Z],7Q'W\SM';5/89GGF^ J M/69FVDV;>C,SY<^E]0(Q21'D@4_47W 2"B/OCLV@LS,&MD]/JVI^R0J\(>IO3"A6%6*CF%/F MQ:-E>)(Q^)<#E,: =.1EJQ:YVGT=5&&KQ;9)@AP.K$57F1$ GBA6R1W0=DUH M+!'K:TMC^JCI&M58*G?0NL;VWF$[U]_4@VOG?]LQ/4D1#P(40$S#$*(0$4@I M%U#Z1&T?D7I*8.4R.QIA;H3]F[A73,V%K!IQ5 5P07&AP[HAEF:;EJL0&IE_ M]V%7>RGW!;/=F>MG,7!D,!\_?U*3]:QZ+XW&\Q<._+[SLMP%.S+%(6^>/Y'- MMJ@2RMM?UR=%7A)1J$X088N8!Y>D^KHU\M)6'E4,AM"F,>1I(@^#P*3+ MC7X.;N5Q;O6['WRUU=(5_RR*_/MRM5HD LDLSSG / \!"E,$" P1R$B:8.S'F7P8F=\ MT%E_7MK(VGES0FTB_\VN[UE=."=8CKTXMYNXQISK;XH"'MX*5FGMLK?% UVN M%_7Q-4($X"E'RI>+&2 R2P$1A'&)9TE4";&6@[;QH-O_\T MMEJ'DB=Q-0T;+T7+>XBH@/IJ"Y1#A#B$PV31X,E.9H[\A@;Z/,H;O-I9L&2_ M[[G./XMJV:2!ZH/1JT(GA>[4D4*:I$)@ J*(2>72 M%K3H^]HH8V]KT*;HE\YI/#938$8DGH#US"Z.F+IHH]BB,YUBBG'/<^NHV$)R M0EW%^A93G3O]NJ'K4JK7_D]1?1=BW4@0RK MN Q'.8SRE&606-6/=+#AVBAL9W"P7%=%4!L9Q)>>SQR?"C,*\PRP9RH[B^>EEK3_2-NM V-1">VK:7A1;'0B^')V_"8Y% M&L^ MS.-XQ;\X@.)QA"-GR8TOY5C0GQ%*]%$FU]T$;C[8J4:ETUFV\[A(#1, MT@Q*7;6* )1E(:"018#A*"8)@F'.K7P^HUZOC2IW1M?RQ3VS_]8EW#JG[7-M+]L%9O MN"BKMDR7UBZY78L%HGF21S0&3)(0( @YH!2E0+ 0"9B(3/#4=-=QO+MK(Z3] MBE5>+\0L6ZMUH;TFZW^YUAM)ANZ<(>;C&Y33(CG':E9OV:\S>%^.KQ9(4D9/ MBJ+Y'N:T:,ZTG3D!JE9[F^8@#6QS&MQDMAU/\P'U-S\M6KDHG3X\TG4=V"\? MZ*IL=^.9(EP>BP20"",=5'.0Q30'L2 PPWE(*>;FRJ:GNK@VWMU9&;1FVDAN MGL1PG%,O1\8SCSX#Q2'AXPPZ-@*DEZ(T$S\ZH&6I)#H$Q*!RZ,F&,RJ%#AE^ MJ PZ>*5CGD=7L_YP16;WZ_8L>AN@OZ[>"ZU(NM*N\%;-QL]]>^4;+UB**(XH M S!%4+FG/%+N*K+Z^"LC,UV-2ZH8^/JZ7( M=8&[96U[H)^65H9WJ[,;BL=6$;8,F)#%1@05_2$,&=G/K)O%Z;]L+CU_!]Y) M*73U05T,M9XQ96*@;3Q:Y QH%;1C"G:#.FYSH[5*MU-6@?("^U2I+9/:-F_J MBP]8GZ7&>.G$Q>L9W.P,_JFYOAFE$T*8TW\+_1(7S9?^=,-@V:X03U> MH/>]FA%/N.7E=TJFVA;S9.6\6V=^H7ZVO>:Y.[=/R>O\26PJQ5SK;[H&57E< M?T-P01-*4D"2G DF%111,9!+"C.*(WB)&$VGX21_JZ-VGOFUH?>[]34%#43 MU-;;D?T8UF:D/2&"GLFW#UY3;L^G^ITA+A,QX%AOLS*9X="/&:Q MT$'T@=JP5J.IY3VWZ[Q;7J-9#'F(!& R4BXGXXII.-=:,((G$ 9ULX M/O&63>\UXUJSY? .EY]M&SLN-&S%U^*SJ/7C[^A& MJ\N\V6XVJH\%A%D8Q9%0=)TG "$>@2P-"8"0T)AAS*&P.J=SOJMK8VM]0K8J M@DUC:_#8&'L3\,97]G5X)RT7^Y\^F[O'[Y9JNN?(Q7^N5^5JA M:I=5"!G!A,D02$Y#@.(T!)0E&- PY +%,64DL2$1>Q.NC5RT^<'[5?&];-:A M=J8'>]OUDM6;_2[4;GG ,AQUF"\S2O(["YZI2A>+KR>A,U_+W;YHR\J_/#T? M/I)$W4&*T:@ M-J# +)(1BA4?TES%Q3F4(%.L"%)*,*0QAYDP8D;S+J^-";71?PFTV:!G]Z'D M#;+0N8W6@^ MN1VK@1VH[]BU=%G6[.I!MT+(Q$*D81(:E6>VZ_;:.+Q7.GYW+(#W;0_HWGB7VO&C\V"RXND#7>]+ MGCM@.ZN# [/[!1N\ &NSXND#X)FH_;-XU"J_&M_=$US=TRIXH#\#)M1_N= G M7:I[$N5)7TU/?_.3+;6:CM%@XNMQC>;<;75=H"'RZW6K:?2%5"QQY:N M/@OU9*UOU[TZG5U(CB.(J20I2!*A/C0Y92!CD@#U?>$PA6F6H.PR68$Q$Z[M MH]/8J]XQ;7#0%I1N*T/_?JFXP.A\&*[:>D79]VKNY-("=\HTG=5R$WRA^GR6 M3K7X(JJJJ9#A97W%?0:\20N,&O"+E05, 1H7%C"^D[V/?KM13UJW/Z9^[ Z* M"9Q$C# @.8\ B@@&5$(),(QH&"))8G.)X--=7!L-UE8&/3/-W< S&([[TI9'#AO<]QI$K[6GM M;B,>EMN'VW5=#*Q\S?^W76Y$OJ"))#R#"0@%@P!QB@"# @,A6(0%C.,$&8FC M#/1Q;<36FJD]N[(V5$57C:7F[_ Y.,\K.AN M!(D!OCO7,,01F&2A"#C.%$4B)&*@',,("8R043B M*+5*(C#H\]HH\:#^>.ZE>KN1#^@)0L^$.5:]?<*=&P> YBC5/J6QY1X!(-3E'B(ATUXZ(S+;'&AZ6-B&1>> M'/A@0'C88L9(\*2IAR'@Z4M<1=)++76G=XFZDS/*TT-@JA?TB_.;9CI\0/3-/\"),/--\!T=MG0RO F4O1."9Y,M,QV(LQT+O 1,RT05,W0&TU-&;C%C4HK98 Y340S;7")! MUXE0[ ^9[,^8O*ZJS9)MJ[J\?/%)C5)=I$:L;OKMG;J\^KF0*,MP'.8@D5JP M/::H$>5,PU02&,L<$:/%HW;J)[GR/U_O/T4?WTQV_=;]0_C);BC]_^#U!+ P04 " #)@EA6!!^0 M"3UT 0!^(1$ % &UR:RTR,#(R,3(S,5]P&ULW+U;ED*2>Y^9%T1=LBBT04 -@+*T?_UD 2 )DB ( K6X M%D]W;,NFI%5Y^2HK;Y7UK__S^_GDIV\X7XQGTW_[&_^9_>TGG*99'D_/_NUO M?WQ^"^YO__/?_\?_^-?_"^!_O_SXVT^O9^GB'*?+GU[-,2PQ__37>/GEIW]D M7/SY4YG/SG_ZQVS^Y_A; /CWU5]Z-?OZ8SX^^[+\23 A;__N_%],<,Q)C2"S ME*"X"Q#1<) 2 Q-1,A'*_W/V+T5$;1$CJ"(R_;%2P,GD@$>%OMB@M)"KCT[& MTS__I?XCA@7^1,Q-%ZO__+>_?5DNO_[++[_\]==?/W^/\\G/L_G9+X(Q^75C+#P(9Q56E=_=_GC*_[; MWQ;C\Z^3JY]]F6/YM[^=S_^D)87@8KW@_WW]=W^Y7OOK'!<$EQ6OO]$/-I^H MBQU!!WY?XC3CFKG+)2:S=.,/3:IH9_/+OSD)$2>KGXXRCD>K+[^(B^4\I.6( M9\V]31Q(=@648I%P)37DH)(7R7$>PDVV*\T+(GJEB06FG\]FWWZA#_]295'_ M9264E4#N++<6S'%T7VZ\=],RFY^OY/DYQ F.LG0J%JO 94-;(R<+7B)M*$4; M*5B5M$TGL7#?RC>YV5;TBWGZ:3;/.">+;?UIJ[E]$5ETNRN;CZD\>BXF(! M9R%\';W&2#R0,%;SQ!H8.%DN+G]RC9#[J>@/'VTT.VLJYL$!Y?=PCJ]GYV$\'85B;5)"0[26 MCEB?"P1C,SC+"C>9F\14IW"YIJ4?T+32\5[('"GP'H%#1_SH!?M9,_;[;(F+ M?(&D1_5W/(\X'P7E0HR!0>:9/#?),W@7+7EN06$6V?HB'O 8]GU_2$ X5G.S MQF+L&PK\9V?U%@]FPX,R] >9SL -N:"*_@^B\P5L2C:*+*QT[A HW//]@Z @ MG@\46HBQ;RB(FW"6EW!&$14/.1"(.3ECC@4(7E-00KX99BZ+4?P0*-SS_8.@ M()\/%%J(L6\H\)_E-ISE)9R3"R71Z0D.@ZVAO2:A: ?:9\]*$=I&?9A5V/G] M@Z"@G@\46HBQ1RC%:=>K=[/$=(\%FDJY(& Y3/]V5$VDC@FNJW7Y&6S0EZ09@YL-)H7)Q5S M^R*0P\%15QM48'JD[G8 XM&"' @ 7DRG%V'R$;_.YLM1B%)FIQE$GT$>DB]H'IB7@7W=KQ(8?+_ M8IA?\L"8*LPP S;[6B8*'$+,&D3TY"(5^H9@NQE4N&R.HA-*%6PXQCB?X^\4ZT"K!E. 3"%XHT I60K B@B&W*11--E">!H[;*QX$ M"O-L0'&20 V80.57$0\+)*_K7]_//L[^F(PS%HK8!,M,"E#(6?-8UA6^Q;_;!\&'N>8#E%TD-"S(?98ADF_]_XZZM9QI&BH-QR ME\#4WDE5"D*0D0+XF&+RW'O#3DNFW[_V86AY/NG31E+N.R]2>9AC6-'M%.HL M4@)IE*E16 #O%7& &'+TL2:"3\N%;*UV&!Z>3_;T:$GVC(#:43SY\&4VO0R_ M5# 8#"/:1:&SD7,&T6@Z*HOAWG"93#[-];B]XF%(>#[)TI,D.HBSX]TTS>9? M9_.50%8GX:O9Q70Y_[$"=RT188@11)29CD*R;#[X $5'H] :^DD+IV,O$8=A MYOFD3UO+?1 P^AR^O\LDJ7$9KV\M;/:#SB$[AIQ\*4E"$II!0"-!LH0\1.]8 M:@&@>Y8_##K/)ZG:3M8]@^83IHLYL<)%_#Q>3G!$#&LL=&QJ1]92A40^MR?9 M<.,S>5*)D^D\"2>W5SP,&L\GM7J21'M&P^=YJ+?)/OTXC[/)*"5IK26'RF1& M1VB,&J(3"GCBQ$0,1OG3H'!CN<-P\'RRJRN50^#Q//)GIXLV4%X&*]FY^?54YJE/S]] M(4$NWE\LZZ7)BO:1-(F97!)X;BTHYPGG10M@,CH3;51!G5;:?YB&PU#SW/*I MS:0^" Q]N(B3<7H[F87EB/L2HK >O*P5)F04J445(4JTSJ2B M@S -64(-HB0- M2CN22'*6@G5B")4K4K5H KBU[&$@>3Y)U=-E.PAP;)KCULU.U1$GG5PL1ID7 ME8QDP$,ARYBXAJ"3 6>LX)(G(WR+SJ'=JQ\&E>>3=6TFZ4$@YMV4OA;27&GY8OV;'H8?AX;HG5 MX^4Z"%A\.@^3RGF,2P7,!A:--\F*W 6-Q8] M#!;/)ZEZJEP' 8LWYS@_H_/QU_GLK^47"NB_ANF/DM@*%23 MJ[IE,J[4=KK3&@#V+'X83)Y/SK65G'N&R[M4YB\N\IC^Q(OE$A=KE;R=A+.1 MRBZH8",@>5%U@)(DR;@"V2)%;9HV@3ZMD_7^M0\#R_/)QC:2\B!,RZ2B[D+H%-A0,1KRA4TQQLR86"^A+1M@AQMM<\#!O/+>=ZM%1[QL0+DD>N M,EF!N42F4P@"6-8.5$ Z)PTJL$ADRZ"S<_8D.-Q8[K!+F,\GMWJ\+ =RL>[Z M=N!;^LEBE!ARYHNH+2QDVS Q\%(QB"6AMI)):TX;HWC/PHA)/Q MBMB8A\F[:<;O_PM_C(PP/.IZM[@D12(A!RGP7"=9^*@-6HNV1>'NUK*' >39 MY5!/D.U K,CBNI,2\\L?'RLE.$WX&;\O7](?_G.4!).I3M")OH9@TB+]FS5@ M-?TB;'3*M1E_^R IAX'H^:15N]%!,V#]ZR]WY$P\_WG4V.M5R+8EO)O$'C3] M^LXG3A^"O9^J$V=AKV:.W5K@:J1RR-:R)#(0?W2,.)FJI; @8A+H3/#L=D%K M]^BV>[Y_4ARRCJY7;4Y69AVYJK>'0YW-RCT$D00XPU4J: *>.%)L:[%^AD8U MT]*-\.-($?8=@:[)_FTS.9^LCC/6Y6IP(OT#LX)@8JCC,E6.4?*@3^L^O[5@ M/U.BND3 4:(CN?G[_((!>,V608LN'I#KUZE,%X!\]H9)W*.^K0ZZHWE M^AD&U24"CA#C( _P5[/I8C89Y^JBK.[;5,=E5JKG0L>W M9]@?)=4!/';P:K98+EY,\YOO7W&ZP,65, Q'YW),$+6K4XF2!J\Y!2M!D"OD M4[&E-3KNHZ7?P>9=H*6)U >"GO?EU]DL5VX^X?S;..'BTVR21R*98GA"<"XR M4%EG"J>5!-H"1L?@?=P[JN-8_.RFIE][TT;;.R#40/0# -$GG$QJRP!.<1XF MQ,R+?#Z>K@9AU2ZUC=1&$CU93\=!:TW.=R8_+M:.:2&>H$7!VH9 ! ^TB:(0*^$#^OZ;B>S+Y6@W[)3+VSP534P+0DY]ZS!%YJ#9() M)4S**81]UZ>.LAG1ZMO8MKS9 "1JE($:8-G7F%IW;I&W@,D5;1UZ(O;?QC@'/?HKZ&\3;2FCF9UZW[%( 6Y\#G7&<+ M1X\LBZ#9K4S%SJ+$SH_W,XJW$T"T$>#Q1F6V#),F1F4-X-]FB\5;DMBKV910 M?4' ?K]&^&RZ>(EE-L?UG_L()M' M]G840E(R1P?&DW059P5"#)8"724LY\&AW]>+$9*L4Z3(*P OB"NE710Y*\70=P+A.Z3TZY1U![_3 M9#X M^SA741_8G)1QSU\J-S';G:N\<&8S'U2V,?UNGF.?*\.< N5&@E([DJY#A%U9E[I+UEN^[&G\,*&\0T,_+&UT"ZWCY M#L#:O0GS*2%[\0'GJQEW+\-BG*[$(EW 8(J&7%/L"I4"+YD$U%[%(.H-O-:U MU[T$]?041Y?H::> 9B:A[T!8G/%X8K7D52"K*7D4$I]P2AK2VYG,B SJIC) MF";1&E^/)+'?#I*&X'BTWW:\I@8 Q)W'^P$>P*4#<)/YC,F5Z (@^EH=\@RB MB $TQQ*DL-JPUBT"31GHMU.E.Q#WI^4!0'RG6$?.Y,(P(C&!&51B%D)]'8[S MA"XYB\*W3GOO)*3?FDMWD#M=Z@-T^EZ/)Q=+S%<"RBQFS92 '%B=NR&('1GJ M):@D@LZ,.=8Z@_T 23V]JO64CM\I2AB .3K(H=CPN+:W/*)*RFC0K"0*HY&# MLTH#C\K5APMEYONF<'7F_&T3.2SW[R2('., 'JVOP0%R?[[G-JM%)$0;R$ZL^"V+5FJ)X"2'%/C-WQX#TR=R[[D#:G0X' -=[Q#AB6D4IF*MO8)%K M@39 -$$!U]$:QI'[O:^ -#R+A^72M819"]DW<^N>X-YGG:\VQR\X78R_8>M+ MH+L^WMF-T 9?KY',,"7^/ZURO9%0JJN$)1AU)3R.6C MA^ IU(XV)N%9T$ZVSL6=3G6_'MI3PO.)-3QP3+\*BR]O)[.__@/S&?X:QM/Z MPQ>%%O^(:1(6BZMG+$DE))F1T>166-K WM0T0K98G[%TD&61R&V6[6_/MJ2_ M7S/\U-A[!/0[!<+ -\&+;V$\J9T4;V?S3V&"FR?YQKAXD?_K8K&LENE2/?4= M5[3H! 2]&KBD!9UE@O1A%3>H1!1RWZC4UAO@,;3W:^0'#/[. #!PX'^H/UCM MZ-6?^C C.>-R/%^=Q9N>^0^3,-TE!HF),6%( H;5D4.\@&,N@];>%"N5#OB4 M!\$)K/2;-ACPMG@J>/1Z7_$009!9P/'9=/TD4?KQ>4X\UY>*UH=A_:_)&B]W MY< REQPYAU*'/JM2YWLQH\ HJ5)*@J-I?5&M&T[ZO20TX%WR1. 8^%%RI81= MMU(^K'0\TLYQ%6OR,ZBJ@2PAJB@@.RN=2#K'\)2NTP$D]WO!:,"@;ZWN ?0< M[.#TVN=#*50@N=F$=)H)2SY?R1ER3"8481%9ZS; />3TZ[ \9;*FE4X&7_MX M&@S&\OJV+$HA)#8P\ M@^)<(A>A-9 M+%^%^?S'>'KVGV%R@2.F"I.)9RB*>?+6##F)0A@@&3$N+1/HFKLXAQ V!"R= M!(#;+DUS;0P 8I^^4!SP&>?G[Z;?P"=+.L!X.5%2K,+HOLC)J0M0%$CN?67+WXSASEE1HA7 M==Y9% 49[ > H[H%IO1'?A +(VV2I?\Y M8((<015S?2=))C JR^(QH@SM9X)=K]]O@K0]3HZ6[=&X^(;S.&N9J[PAE)'B MKL8)"H1=E20H;@@D TC&.*L+5UET,L7R!A7]9A3;H^1$.0_ AMPDGA>1M(D& MF P4+4B3:J[4@! ,M?16>]6ZK/EX?'0V_J>#T^9HZ0X@)?SW,/\35TGMZXZ M.IUHPXW@L@B.!:0KC)ST^J!KCA)BD-I'FP)INC%6]E,T!%>W2=S=4/ #L# ? MYG6H[_)'K94OZYA8BOM6 \9_G=?FDTN!15ZL*DL.!4B<*.3"R4P MUWS*\F&4#<$#;@*K#A0Q 'C]%J9YI)D7RBH!,64Z="6O598D(8CHBF6!1]_Z MW*KK]IN=Z4*?LQ.%.P! O+P@J=7K0B22=^=?Y[-OJTSZ8B65D74L>F8E:%'+ MLO6QR,B-I,-=ZV T%B9;GUI[">KWT'H""+53QP"P]?= IWB_,<=68TL"40* M[A:.D:DT]QXT(G)F#&&@*TGB.RGJ-_$T!-@JZ%"!I :>)'2 MQ?G%I';%O$8B(HU7NJ)_G^"F]_/%>6V.^^?JY_P@9\R; .$J8 [ B[TCH65(L1R\%3\V+LP_3U>^\^X;@::Z$ 0#K]6;9K4>B M+N^B;9B\+@G$K%70D8&VC/:,=PJOWV'U#6'6E4H& M@+8U_2.1BL\*"Q2LUWL#-^3,<0%&2I\R\A)4Z_'SZY7[G3O?O&GV48(<@"OS MVSC$\61]Z7N:/RUGZ<\OLPD)?5$=M.6/Z_LL9"W)Q2?//I$E5=E'"EF+!$-1 MJK:N/OS:O-)R(&V#F>+232E+*U=X>LN3 44#@G M(.IL$54LB;5VOK>6'PQL3M+H'4?H./$. !F7#< ?PH_:87/)11'H9*6=65Y? MP;*N%B(9,&^#",K*HCI(1.Z@I-]3K".\-!#Z *"S$^X+P84 MCQI%V > 'MH#\XL;L>,E(QJ%D\5D( /* M06$RX$,N@"QHFXO0(K:>1GHO,?U6-;HS/PU$/P ,O1Y_&V>0O(UU M%I>KTP"0D7!$!"]ED;0S"H_M7\#924J_A8JNW)T&8A\ >G;84"6$2"E:**6^ ME'K4:J&(#IVB,@P23]GQ=@ M8_+D$B0%02+6M^JP*)*2;][P?6+MXRG<[NY U4@5 P#5J]GY^6RZXF<][\1Z M]!J+KX]22_(S=8 0N 61.154_ M#),/84PG]:OP=4S>_19;(X^9B>P2\)CKTY:&).,D'=-$C]+6R(+-\]8/4M5W M);83,#56Q@#@]1&783S%?/F^UHU&X#).XYKA\!25I@">U;=8<]TPEA.#F6-@ MR,D1; VOAZGJ>P)H)_!JK(P!P&N+@T.&Z8Y$R Z5SI X_4-%72"8;($+P1GY M"T:[UG7:1Y+8K^O>E5WK4$T#0.%=J;W$,IOCYSHJ^F+^8VVYD86LA8F0F(N@ M&"/'E/84H'(8BTK9E]8=W <1UJ]?WQ'BVJMD -G2&\2OG8*US^F5,T*7 #KY MU3!##H%%#L[XS'VR4KG6U>'[:.DWT=X1FIH(?I"&:A1\0C2U3)"\ U6?W8F" M.V)(%.9"+LZV?ESV+A7]7A)X,A/T*&$/P-[\?3R=S8GN=U."("Z6(Y,%E\(Q MX)Z1=RBS!U>2 R%]%C+X+%7S>4RW:!A,(:^[+-1)8A^DE2$7;WU19N=K%C5U M.YLNB0KZXMD5UXY3O('&DO\G283.:(B:_BUSIEEQ*+>><^[,,AU#>;_6K*=$ M:>3N[.I+SN',N=)QVA! M")] :6LA&H' =/#22.F";'W3[K>&C%:C,L, M \'"D,77IMY84P9TMG7,#2J96@_CW$%&WV6DCE%UJN '@)VMXA<=%^_G*YGE M5?KE \X_?2%!C]#7M^Z($:DQ4I@N')#0+"0NN6;:9^W:#S%[D*R^:T@=8ZNU M8H:%M17]BQ<7RR\4B_\3\RAK9%(57\L1@6(5P<$7RX Q$9QWY+(V;V/>0T[? M9:*GP]9)BA@BIMXM%A?$!J.0I#[3"99EOA[>$!,9Y"QC4@*S$LV'4=]#2M\% MH*?&TA$*& ".=M0@UNR,HN6%1:"'X08:=G]3>+?*Z!Z,BD5(*S'J)"#2J8!-X+,J;9LV*U M3KKY\,*;% PF'] ("W=3[$?+>P"GU17U:XG4AI_9%.L[C-_'BU%ARC"F!<3" M2"XH5X\O!G"96V8XLZKY0V)["1H(EH[0]'V@.5GL \#0+1Y>S\[#>#J2N3 > M0BV&IE)GKTN(D;RXS L&68Q&WKI=="M9;Z *"SY?/_'<\CSD?) M^A0,66&=LZ-=E>OC(LZOQF)I76(6MOGKN[>)Z!ZFI-]D='OP-)#W %!S0&/\AC&* M%8(6,0,=[#6_H!FX1)95*Z.28$ZKTOS9S$.)ZS<9W8%AZD0K@[C!OB.!M6&% M!(*QU$L_@F(/94* Z&4$H[Q(T4:4HG43Q+W$])N1;@^H-E(?@+W:W<>WX24J M)ERT%FRJ;:HYU;$SK !+&JWPWI3FSS_OHZ??5'1[$#63_0!P=!6^_D9G^#OZ MU\5(R10H?*!(-2*"2G705:3X@*@;2#-$P$'2?@ 4"$SMEJ M-?$UKG]]-[V;:/U(>^'M;/Y7F.<18F0Q)49[*92Z R0X9C/PH+/)B@LRJX*G @(0D=IHDV %!Q@)6)2M++ESGUE#GZ+U%&X&G+$#%^C8) M]Q*2E(;G8#GMB\98:C9=H;,LV%-"K+F6!H"\JQFY6X6'5V'Q911E,#K4]YA+ MX,1'L1"%5Q!SPJP]MURWCAWNHZ7?7-A3(JR)-AZ/*K]&U13/:GZN?5)LU<#\ M(I&HB)17LQIA+[_,\B@:*167!K*T@4+WJ,EM-F2J2V%>6"5-:#TZYA"Z^DV5 M/27>FFMI$-B[*Z_?9TO\]'4\G97R>1ZFB[!Z+'R4&1'/Z@1>E\C!E"9#,#X! MRX'5^XVQE-;X.Y2V?C-M_08+#;0U@)/UAD-ZV-7MH*U64D'VJR&KRH'+QH!, M*N@4F6+-(]M'$]GO1?S> HKF^AM$Y>KV5(Q+L;XEP;\>+]8LDVH7]['\'VO! MCWBP.A>'X*-AH!A&"%JX*NSH2":L-&^7;T5[OY?YGQ+0O6A[H [!*I0;H70I M!]JA(:M$C(0 S@M)_VF%2TN\[JOT>]X_7Q:F@^CRTG+;/TE,D MIP$+(]>F2 Y!U>EG6)0IW&/FSW@NSW7]]?\LX':NZA.3VF^FV^;SR2XVM9R@ M\L#'.[[R]*2S5/;<>6'!1R;HF)5".R"TQ.I8BIK]"99E@SJV[@)YDOM/6UFN MZ[>Z-O?<:4M/Z)<\*@9=#!3G8:S]'2):B+6'%7G"Y)E('%NGO0^A:R"5YV:X MV=.(WD8WS^F&9LVYOIW,_EJT,U_7G^S,:-U#=7M3=;70-=)(UR$C ]2"SC*F MR(]C7@+G2CI9PX+KAZ=JQGZ'" 8*W5.,671>D[=XZD?9H MM1B-JQLNIJCZL+ W$'U&X"H[;X.):)J_Z=P!'_VV_3SQ=N@="(/:#&]G\Q?G M==?_E4@2?*8-K;BF?TL. 8LHP64GLVH=/MU+3+]6NG^T%\^,"X6OHDQ0-MCZT(P'KGD(F)BULGGCT-;Z_9J^P6'L:-4, M %:_SF;YK_%D\F)* EJ&Z=F8W)<7BP5)\_QK&,^KF$:Y\8.H:O?KLC!P;"Y*@< SW6R[1.FB_E*4&^__3[^-8RGJP9D MK=!ZI2,@\GK1B"?PAM-6P\"+X=GXYE<_]]'3;POEX.#83'7#J41^))42'5]H MA[W&;SB9?:WR7FVQRYZ^5:'U\YXJ(VF\;Q=(6&?Y \ MECA]7\K(VAB=0P&<5;_G.3&11F:#]-LS4._C9R#0WVO$.FUX>E\ M_F=S[J__YGH8YN>_9B-$XQ.6!%&Z BH5!QZ=ALP<1V3"T8\?*!\\$:G]]I<. M9FL,$1@#<&U>;Y9=J^-S^/[F^U><+O E3K&,EZ/L4I$E(5BK/2C':./'6)^T M-4F@E<&6UDF%!TCJMR]U,'CN0H$#P..JZOPR+.J]A//*R#J>-4'YF)0#)0)Y M:MP&VE_2@)0N&6:DC*;Y0XL[*>FWB71PZ&N@KD'T1Z_,?JV6D.S6LMQLHY%E MA@4?ZI B+LGS<20=QRRDH"2:+(UUG=S%W$5,O[VC@P-?&Z4-HF_Y;GOCE= V M@_VN)&:M]8XB5TC>DX-A#2?>-'GF/'N7M(DYMVX_.)RZGKM$!P?1CO0Z@(/Z M+F=W']P:2169"^1W9._K_0%CR?E0M \S"Q1.^I13]V-E[M(UM/D<;3#Q(/1. M5-! #>7E*UVT94=)25HV8FV#K(.\,LG+)TM;U1GFM(XLM9Y3O)>@H0WE>"*@ M':N2@2+L7O*%-\WA:")ZHKD$B<17A7XEQ>Y-E\E MR0LDI\A,"54@I*@ L\S<.JZ8 M:WVA]Q'D#6VFQQ,AL8VZG@$2-V+\'92+.! ^09>+DVQ8R M]]T?Q_=1-[09'KW@\$AE#2(8.;S!>M?E@)%F*%&0*\(R.E"RWH*.!:%H'F** MP6-HW9MT&L7]!B]/W,[^A,H]WJ;.:.MT">6:*UC<(UQ=B)>L.%3/&?GQ8II?S2837(T"7;PO:[&N)#"R2BL="@5L MOM1[(]Q!3,2D=D5+5;(.S:\X'D%FOZGPIT9GQVH:4GRM/5NJ,H@DG.:*X-1MTX*/9+$?M/G@X'HZ>KK'Z3U MVL6]'+Z=7Q*A-N10DUB]BN1:*^F0D3-3]*T)4SNOUCQNU7XS MY4\$N8Z5,72TC;_MV$X&M8K.,\"5+Z*1$:LA@R,G12;%..?I)+3M6K7?6P2# M0-O)RN@?;0]:<%S<95%F[9WDB7S?U60&RR!R=&2^5Y>.,2;=>69G#WW]7C$8 MRM%[JN*&$6!ON'L[FV\'::OBZ Z)CK)R1DC'2(CUTH[A"D(N HJ0]9I8L-YV ME>PYD,2>;Q?TA,XN]#<(@!XNSYWU3ZN9S5%P8$8G4(4+\!XC:&$Y,AZCCZV3 M0:=1?!A\_T^IW3RA=H=;W7X[GH9IVBU<*:O_+,B[$;$^(A,C!($6DE(H&>.H MO7T:_.ZALM],^U-7MUNI:PA)RZTCXR-^W9PE[\NG+[/YDGS?\]<8JPQYH%V= M0!3AB"G+P24F 4UF&KU3G#7/!1U"V""KW,W0L2>%WD95 \#?-B._S:9G5WSP M%(1>#<@(1M"9XC)XX02(VCP59 F^^42)^V@99#6[*Y0U4<@@_,;M_?)NL;@@ M<>$MGE!9)@P=!L*O[F#X!+[.8Q$B":\\]Q%;O_?X,%6#K%H_A5%KH*0>+5K- M8[T>+[[.%F'RZWQV\?5JYC;]-*U]5\S7KNOV"VOKJ[:81Z*^G\&1O)-0#*C$ M$@2= F2!#*-5)J2'GIMH0<<@2].M(?CD"AO <;N5+"!#?S%/7\*"]MO6VRZC MJ 63Z#DD&21M-R7!!4>QG44I;4FE%-/:)CY(U2"KT9W9Q+9*&L9A?.54['K2 M?,0I0.-6*G#HL=ZX".1FU'9U9S576@K5_+W0_10-LK;<-> :*&<88-MN-JHL MO/^ZLN!OON,\C4F4(\>9CSQ[")D12Y)L=[ F00Z83$$M5&R=5'F0J$'6EI_" M[SM=14,X6;<8VC+@JS3\#B&. EEJVDG$CV(*5!0,@B$+GA,OC M778D.$7@ MB8.L/C\%'ENK;P#H/%R:.[/LW@;EA8[ ;;+$K7,0?/+@K?8F:Y55:'W#Y32* M!UF?[@J[3ZC6@+J]ONW3Z;=@4)Y1TG^'F8=C]K%(B Y*>N8!@=>* Z"HU=12E&:OR)Y M$L&#+/ \,92[T>Y H;S#-;J/61.3K^,:A"B^WO6HTQ-4!N;0%J%3=JYU'^9) M! ^R>/3$4.Y&NP. \J/$.]+*Y%C(07/%D%@]3Q"X4A -%NF$I/.HM4/Q* (' M663J$*K=:6\ 4=F;4C!1V/#F>_H2IF?XD0*)]]/*;_U?O1'_+4QP-56X5M'2 M$O.J;7J:;_Y@ZT^.1.9.QZ# 2#IME H(UDZUCM@[8Z+=TU5E$ MU[?"!V".3V+V \['LWQW*-FF!+TMUK6H1TF4$J1!$*N$>.W9CMIZL,PS8:-W M,;4><_2T'/9;<^MLIPP8)@,X.$ZS&!K)9Z.0 Y!'1[&(8^"#9,!-S)HXYHRU M;E;H_C#HK,8W3(@_2HE'(_;K:B.1!.;+-B^B'=XYM!' ;;:9$A@-SQ!"+:L' M8<&1RP?!:ZL"<:Y]\S?33B6ZWYI@9_A]6F4^=]=EI!W+*=2!J$H2LS[0$;.: M'ZUUL<9X@]$].ZO;635PJ%;W$4H\T>J^F6[W]?SK+W?4\!O]8/5;J]^I?_,C MEI_JKW]\?'=CC7.&\#L M JC("IW4R8%4W,I4;+:L=39T'ST-GLC>VARC6*Q-RDB0VC!0VG.(*G+@M F] M4*8D;-T4=I."?DMJS32_XYGI8\7<[*AL:71^K[/+<%:V4IF/MRP[/G*Z^7B( MLD8VXOW\+$S'_US[0U<6J\)TFC]L4?Z^;%+Q87(%KFM(<6V0!%*[76J&4V8. MCO,$-DJ7%#>JL-;YC":$GYS%7RGI_9:21D*PJ)0WM+'0UG?3+7@O:4ODH#,Z M[D/[ >QWJ.C7^CP]IN[DYT_3RR!-U:>+\_,P_S$KFW>O**KY0))-M;WS\39K MW]=.-UX'T]K(BMU=Y@I&(;"48S1@LX@4S3E3NY =U,;.H#Q!*;<.<.ZGYN2W MLL=GTW$AAW&ZO+O(9Q+FRTGM\B\E&"!@9T\?"ERS29+>A@ MOMX4VBO+HHX0$I9Z*D>(H0Y53]$4DZ-$V?JRV*DT]VO#NL3@WE1JU]H=I,E; MC8);C%<,4NB+1-Z7.N,ZQ-F&[3#-OXT33A>U1^ELCFLG]@C#>/12IYO/-EPV M,K*7 _E>S;L&'U]L<6G5?X=D)*:9D :T*='\D)8C8R0*X1E4/-56L; M^S@*3YE!\+!B7EPJ!J_58CJ&S7R>I M&WSM+!YVJ;]!6JNK&L>[:67_6)]HYV=.MUT/4]8;S\;?5\;2U$H'@/S"? MW;G?LP;!%>BRB4ZR"K50DQCH.,0@!$1,2 ZR,DZVKJF=0.ZI9FZ72G;M#.]4 MX())<*PP4(5.]!!U?0TSYZA+%CFWELJ!I/6<(GLBI-TV;UWH;9 6K=XOG1*& MCZL\;O_MT^W7O;0T,EN7W_^Q RSHI?"<19#%T=&DF278H*DSW'C1JH@L2N,- MN(><4\W.CD]OG<+)8,:0@;'B0"41P>7LH$C4(:G"E&I] 7$?/?T:F%:8N&U MFFE@D%;CU]DL_S6F,'6:-P]:+"E*'*HE.FBQZYUA3?*% M>Q+":H FBPP\YD+; ]'5VRC.M+Y\\3@*^[56W6'KMOWJ4&^#M&B_S<)T\2'\ MJ.\R;X^YKM6R>K7O&+OV\#=/MVZ/I+M9 !B7.P#G"0$JUSLVDJ"@+ OD"&L# M(5#@'[VQAK6^&;Z;DI-[(6Y\]1KFQBG/B^+UC7@ZN.LS=\X;10[G>&T]I"1MORS?3;>#Z;UI R3'X;ASB> MK.=Z'E-;._#336[ ',%%(W-3IQZ/EY>Q_PU2=L7]/AM=,$'BBHX]52R$Q#(D M8:4*,NJLFE_(?PR!IU?P#ECL>@/Q&)WVFH/QR=4KD C1YPR8DG:V8!:Q?1'O M,13V:\JZP];=NEYG>ANDX:NW&I<_CC!KF[]XNM':14$CD[3^]/5]T6A8R5)# MKD4-984"+S" ])SGC-*6YI7RFQ2AWU_F4UHLRW67_Y]ML1=N&2%L62R M@:(,)UP&A.#J)S)-_9J\ "G24B-:\JG49Q@Q[VPU9_N;WZ]6:* MS'MOD/:1B*Q>OE?@BB/Y23KV5R4>[T/(*.JLVELN5=]6# MM)*%9PG"*@5*9T=';900C$S1>"UX:3YT]G#R3GXI9:V'%_OTL#-0<<(D4S=P M*0I-#M(F;@I\]-_XYGN5 M-?Z.RR/LW^[OG&[K#J"OU2R(ZY4(!YO%KD]>6Y]J2EJ##C6K6J_'^I0\:&^$ M]#HE^GGC/;N?HE.MU\VOK_YKL\3.H"G&DFWA8&I#D$I8!_A*"X9K)I03.:K6 MCO&C".QYYD,[[-PV3=VI:9#VZ'/XCHO9=,WP$7;HYM\_W?[LH:=9CU7]-*VS MXTSC@5L;E 5F!/G=+M4Y?$8#G[QZK-IBXVV/52 .#M!UOPGPZGIXMON)\ M%<<>DTB__8D&*?6]5+5*KF\6^;!9Y'K<60K&<,/ >U4O$!@Z$+A%,)(%P9 S M;/X>[7VTG#R9_]9WMWIIK NAIHP1Z_51KA)$:3P(XCU*$9C&UK;C7F)Z3JBW MP,&="?E-!#](D['RIVJ4.<=:3Y-J6[/;(;M:)=KJ,XY)AOHD- O*UWX< M7F^',M#(F-(F1:>;OUWW $V#JM ]!@$[JOGMA#](:_()SVK"Z"-^G"@X!% <6"KK<+$@@>LF?HE.:M.=U'SV G7SX&$7?] MF48*&, S&COF1*UWZ8]1#,YYQB(4KV.=S800L=Z."20?1AZ@9JV[U^ZGIM\' M;CL"4B/A#P!&;V=S')]-7UW0VE/:#O,P79!T-@/ 5O\YV>9O:RP/4Y;D9"&$ M((C1$.O%*/I'?3 R\>W68*(TI4==*+ MKV\[("?7T9$YM\JQ9#FB3ET\E_P@8?V^-=O52=I<)0/ V=5]]CNN@2Y$?##@ MM$LDJ=6012& &1N%5"Q)W;ZHMYN6?I]T[0A-300_$ M5K=?;C,BR9WDQ PH M20Z!N,"W)+AZ?:H* MYA_CY9=7%XOE[+PVNMWDCIL0DPX2*'RAJ"72O\4B-%@LECDT1;/VX^(>0V&_ MSXYVA+8.E30 "+Y&6CF-5TJB?Y_@Y1#B\YJX^^?.Z#G*8,F93,#15)?2U7%1 MMH Q3F:E&++<&H='D-GO&Z(=@;%K=0T D2_R-R1>ZCCWU:6'V^PH7X(6Y!TH M5T>4A3JLC"L-DMP'[0T645JW9S] 4K_O?G:$M)9J& "JWDWI6],P^6.!GV9E M^1>)=I/$D4(F48=7%>=7;WF1P98.05- DR.K&Z1U">Q>8@[+Q+)G!J4VLA\ MB/8,$;K\K0UC*K+$'=+N$/4?GB7PEB$8H;*2I;[%VSI!<3!QAX'LN>7[N]'- M $!WFYNWX^EXB;^-OV'>,(0Q"SK+-7"3R>4D@TRFV/CZSKW0.FM67.MRTH-$ M'0:RYU8+:*N+08#KPWR6<''U+DA]K8D"GLGLZW5\/?*YI)AX@:BM)9&A 1=( M;MQ:98R2S(?V&8T#"#L,9,\MU]]>)ST";?V\Q&8TS+(69<=Y\RS7;8\R%(W( MF(%HG:WO<)',)*,X)>8HC56H;M_ANN?%D4-6.PPZSR55WY&4!V"@=N^!S1VK MS58H##463D:6.*!379/-#3X"RY@D+][FV'I,WP%D'8:PYY:^;ZV/ 4#LOO=I M;DF0'$<>77#(@.3CZ];)X"P6R$PH2:QITWQ2T*&T'0:VYY;H[T0S T#<[K$[ M[[]NDGGOIHF8))978R(V+%J62LY2D&.I6,TK)W N MAL/G5@+H6E\#@.0JQT=!S:PFES'7"L>;[^/E^_GE0ZO73U.\G]]X+&='QXEE M-@R04_:'02N[QU2>:>#A;SB MH#(";=":''(90G3$&0:52E&)* MK<;E8.M\0T9'@F09K-'6%,&C;=[[?1\MA[7K/K]J0P/)#P!!'^;CV?P#TC_S M1TR3L%B,RSBMU9/_ZV+= /,:%VD^7CDB(VFEJN,&$QEA MAY9!%LQY.OU-L:V'#=VDX# 4/;?:P@E2'@!&?L>_MN0RGTWI7]/Z$>&U';YC MC95A=':3]RCKU"7E)41='_XM)NDDI'2I]3GX6!H/P]ES*R]TJJEAWM/\.IZ^ M+V56WL_/PG0V?37['(Y\VNO>3S6XD7D0E0T',:^\[0O,[[]N2@75![\,"'^= MSRZ^7@/.*FMF+Z)2 M6D4'LE;N%-)>CBEJB#9[5F?V)MVZ2Z0'-OL?Z=P5TN_D"0>.H4%:YQ?IOR_& MBQ6+5Q7OK<0__;2^_35.=3+)].S%V1S7A]71-OS$!4^W]"TY;G0>[+CD6J%7 MFURVJ+W:)+&^N%=,AI"TJ/$R19A!A004ZE@C2BO]T\<$]WTP,+M;-\]R\US;_/ MR&?9_=O;=]-O;858A-'2<5!&:?*MO*%M61)X5F*(!K61K6/^#MGIQR*V1]O] M!K!?! S2&-XHCAYM '=]Y72C]R!MC9S%&^NL'GY8/5%S74.^@F'PJU04!X:) MU.W103#!@9:J/CBHG0FM2ZH'$]?21=RYY*KH?@U][1QG,2/(>CM426/ E4(" M(3$P(Z4VS9_Q?"2)_;IXW:!JGW?76FL#2,/?PUZ-,N??\.6/S_2=:M<7RVL6 M!0]:L5I^8GKU?%1]E2 Z2"BB-.0KI]R\L^SQ9/8[6ZI7<#;3WB!/U+<4STW3 M.$S>32O/IT46>SYV^OEZ**7-'J6?C[^M?*NM]0A[_X'YK*+P"GN[GB'PDJOZ M;&;6@J#AM00G8H)DA?(Q.E)MZUZ $\AM9_5^Q^7U=)"Z,B[>35^D='%^L=JP M^V9TWW)53?'(1*VQ:5U[BK'V;C(#=!Q$0IS,B;>^9]X%'SUGWY\(P_=;TIX0 M,2A?X&T8S_\S3"YP(_8M75Q5'1;TQR[MVP>\/(?NV:_8SF?&I"=:F3X!O?7,)Y6Y^V>#7=])&W%T);1SN**9"MKN= 4 M(-DRL#P[X8JG_[5^5Z8Y$_T."QVHT>T8"X/:#*M YEH*B]]GM>=\?#9=):H6 MG;IL7%A'@HM@I*2S*G%28922PJ.D!=?,B=2=Z]\CX_V.5^U_TST7S UJH[[X M%L:3RLO;V?Q3F. G3!?SE9YJPPFQ/AGOXM=))W42"%QC!L5)8\$J"SPPSF5V MQ;C64RY.I;G?>;#];X\GT/2@D'T5Q>QR.O^.H8HXOY]^K&*HA8V783&^[8QF MS4,T=/0:]!94-@P"H@=-Z$Q&(Q;?7:=< P;Z'3O;/^:?&@,#V !7+!_ Z1_3 M6:S5O,KPN^G7B^4M2W!M!%SVIO:A9UZ?*$*1P>?5_1LT*FDO.+9NL>V"CWYG MX_:U'7I'Q" KO9=//UQF((XI\-[]QNEUW0?H:E3.O7KX8@?64,AHD@WUBB<% MGNW;-H**_NWV?3L,\[/7V-^N73S]:C>&C6S!F7 M.W"HN0XI)PZ1(?E9&2,XHR*Y74:0>Q=%/_"GI.:< MD)\EHZBU3L4/TCNPVM*O2GF?6FF'>,O 2HS*I60AN_KN D=! 4N=$:B9=HHQ+5)YP! ]9KV^.P&;P:8S(0_ MU5KSL)FS,3U;V?A+%G_\/=3+%4-5\T?W4-'*!U@MO\Z^N_Z8AZCKUP4Z 17WNSY-%3)(V[%[)/UJ /WQ MP^T>_&:#*7>/H[OAN+OU:56O3UZONWWG=T59K)11B'ASFH(.UL0<5'U4@H%2 MO$Y Y!E01RMC(@9D<^@K-,*.?HI]W-_6C!0?\C[)X(O7M,ZE,#80 ! MQ"[NMQ6PS?VFE^#V05-G/T66;;T);NO4$SIR@N9@LPJ&^:2T[:ZU_%BJ>XYN MAP7W#A7>_MB]ZR\EL',RY:U6+D5L:Y10G*UO@<4ZQEH:T+IX M)'_.DDDX("_S!*3V'%,_/>B'"(%G8/3OV??62EF*UQ"(J;KO.7A$ :Q(P5)1 MOJ3NIJ@\AM*>+\,-U[@W4.P@0\4/=:P!;=%-1\D'$O$G_C%,MX>5K@ M^-@53@\C3^*I45!Y SMU)-#E^CMRH\YJS0HZX$F7ZAH8"!H]A"B\2UJ'P%M? MWG@$>4WGKVRDOYZC=7,K%6\3UMLZLM@,*@@%,=796MY[96)B1K:N=AY(6K\! M7E=(VCL5I9&>!G!BO_I2O97%ZMWL_\)$Q\B&M_=Q,CY;3]2^ZLA^7ZI=N.K7 M>'M1+4&]EG:Q6/_6[4Y(I[TKQ0(O]3).KK/?%)T&'#$9PR0SO'7#5Y?\]!O: M/170!X.(OB.\S8:?E:V)1W1HWB^6\?3-]_KV_.SZ(L]L2SZW#45TPOMHP&3G M0:&VX&-4%.QR9,K)K(L^)+KKELQ^([NN,3\T/0_@0-BZ@3F9;&X/O[^?NV2L MT#(7$%(A*-( ^, 2)"Y-U$$;T_SVQ>,H[#=D>WKOI+G6!H7)-Z70GJ0H='PV M73T4.%W>N0.VN#[![N,_6)>RL'4HK9/U'H@ VJ4&G$+/,MHZ+*@SU+;AH=^9 M)4^/ZQXT/RSD?_^Z?1I=9G=N9] %&N.3@2*B!F4+@M>&H@\B7SH,4;/NNMT/ M(K'?L1\]X+:YW@8%R]?$U/2:N[KMSNO[B(NM!V"FCY@3RJ4,*:8$O';5JNPR M>,=KO=,(Q5VH_^RPT;DI,_V.\'AZJ/>)A4%MBJTB_A^+NX\:F:QS* :R4W5D M7&0DY^2!\V*CE1BLZ>XQ@[VD]3M_HP=?N9F>!@6__\ P67YY14)?C;LGV>>/ M]5WDVT% YEQ)'4!H564H-424J;8$6YNX53IW-RSU,!K[G8#Q](#L0'.#+*MM MKF=7NU_]H^D"?\?ET26T?5\[O5QV,*V-2F-;ZQ'H-DM>5W&Y]%(+H&B M&,[[.MDA%65XKJU$W?5%/H;2?LMC#='TP"C#+A0W2./U.7S'Q6RZYO%HH[7K M*Z<;JP=I:S:09[W ]QU'(1U'+KEZORTS!BJZ"%ZLWL]S24IG?(ZMDVM[R&F= M>[P*6&BU>C;OG49HM= RA9KQYX9<2&\A9#JWF99U!I90PG;G8CV>WKX'][3! MU$,YQ,XT.*@@8,WB2RRS^36[K^F7Q7*<:JF6?CX^N\UN<(6IHATXIDG.WA;P MN?8;JHSMQ4+"M,==LNAYR?,7NQI'8))9N9XE, MB $]1>B<@G.5&;DP)3!@L4Z"M5S;W-ULWT>3VV\]O7NX=JN_04'U]88 8O" MAR*L,<[4Q]299 F4]1&<*!&R,<45#'22=#G!XQ&D]ELQ[QZBW>EM(!U+6SL/ M%Q_"^'9BLW!>+P\$D-*33U/+3KZ05+TN"9/+*M^>AKZW\^B!Y?HM5+>&4U=R M'I1E^V,ZOZK8$',;N[WX.)M,R-VH5UANWTUTR3J6$CCG2)(N:O#)>D@F.8]< M\Z*[BW,>2VV_%>CN[5NGVAMD1N9-F$_'T[/%5YROKJ<;X/EH:)F5NK5#' M@M>PZ/5X+-(" M0WOR,)TI;9#FZ<&6AZ.+7OL_VJCV]0C*NYEVE%*63@=./K<7%"%&#T%A 2^E M,AYC+OZY3#LZ[O'D(I0OQBNPG-,!S>F4=D(G,$6CR3(J9[NK=3W#E[-/P,^> M9I'.53=(X_4)SVK+PT?\.IO7TM[Q$Y)V?ZC!6*0#*&QDF&XO=04Q:=!FG05$ MX25!S H(#CFP&(,V2=K8_N6E>VAIZ%M-E[2-_C'.!._5(W/KR^;?<'J!;VG3 MO2&ASJ=A\NIBL23TSQ_RS'A4_J$3(/IY?+)?S<5SYJ[--$>95 M[7:M3^&\_/$KSL[FX>L7\FOG&+:'YTEN#!T A159)R)$B-9:L"P9F3U*D;N; M:=25VZ?#=]-\WC;^-\$29WSZ'UO_[8 MNM+ 0I'5\V*8$RBE+'@O#!BN"AU T7QQJ=7:]Q&<:38_(5]W_K])3%@72VNE$P/PO3\3]7"UV?Y^M++1^V&-AZ M5O[ZK?GKU+]D3B=.V*V/+RE6%#@6."0L]26![')HG85M0OBI!OKWB_.(\RU7 MZ=(Y&M%N,3;8 AP3[>O$"D1.VSR+4-V@)%&VOJMZ+S$]WS)X=K[J6GG.M*N&B]Q=?#??E=OE0T?U5(#HBH@ MQ?HNJP>O*6K+Q2M!/TK,=N?X/41=O[:K$5KN=]R:*J?'B&4Q7XX^UODJ+[Z/ M%V2L$W?64G!EZFC7G#D$Y!&$*EHHI5G$@V;[T5>WT$3_=8VD&POVG'#O2)NS M4T4[!#S\'>O9.R+"4E;:@N9:U-X0!C'*"($IXVKW;#ALBO,AB%@OV0\F3E#6 M;74?(;F>%?YW@O_YQ?F&\%0T>NW)HQ)&@>+:02B: _)LC;%6.'G0L?* RF\L MVK/2CU'9K(7\^E9\^+Y%N*]7BE1D4*(E5[TD0Z@7A'\5BY9*9A4OSV MHOT4FYHI_FCY]:SXJT#M.M44)BO3IZV7.5%0%5@B]**T$)1!8%H[P>GWO&_A M MQ+0,_5Q^Y=@C:B[QL_ZT!\FX77L_,PGHZ(;9-U)/?:UDD ,G+PUAD@D:#@ MH8AD#FIK>P@_]Q'0WTG22+&SUE+N$2IIG8P>_?%I)!+S4F("6U""8JRFH7T= M V98]):[S/>5W1:8?CZ;??ME\\4U-#;_<8V,Z_5ZA$$;I_$Q2INUEV#/0'@Q'9^'R7HRXTTF%$-+9RF1KKBO4_1),"0,T%9[ M\K*0198.@,&]"PRBN_9$$+21W@".BP_S.MUN^:..-5[647K_?3'^NG[E\3-] M8F4H2;,Q%*R>FJ\7J;,'EQ."*+D$1!^9;MWI>@!9/?<&/HUKTEH]0T9<96BS M+5WQ0DCM 6UV]6:%A:B4@5IZP/+_L_=N2V[EN)KPJTS\]]B;YT/$W-BNJMZ. M<94]MKL[8FXR> !M=2LEMZ1TE_?3#ZB4\GQ8DBAQI>>/CG;9SJI%$/A( B3P M(2;,S7OC#1"K[^G5' I#H;:G748 M=<7I-')[,MF:RXL\*1X3;])]4Z:!P@" M"["B2U(E1 I"&Z/JM@0C!="^!IXWT_8(L/)[(/7-P>L?OX=_S!=OIF%Y M&8PRCU[(9(%A939TY"[X2IG#= DAV,A*\TRF'<3KG(%^&E_K6.8:-Q*O)_9' M.-\NX*0%JX36Y#BDRH<2.3@1&&23R8UP5KC4^J3<4<2^1^G1H#(\C*;^U8+OOO)L^_()WF[PO/EF6'DV10= M(21,H+(GY\8D!HP;Y26G2=\EVWJ89G*W8?NR^QWY!#ZV&7HC+$QQ6:O;UEW# MSJ+GR0N6@*14H R)3UJ)I##AO&3.237DFOWV5_ML0DTN*Q4 M?/,U++Y@#.F?RS/)O+4H.0A?<^6,MK78W(!5,F?+A$_YN6J71S_>)T0\)1H. MU^EH0/&1A%_A\BRQ8&P1 @JSEDYFFD%4E@Y.F[P/R:*YVP+I&4!L/MSG#;\/ M&/;196<@;/A8-LTDJUG^,I_GY?J7C[BZ6,P^X&(RSQ_HE\5J_NN?WR:7Q;6_ MT$S/)-=<*SI?L?ITRO*:6$<;8D%>!(\6U=W.N ^"YB A^KS$G!)@I[/1"P'C MJT+CW9NH]IP4&P*($"LAE@D00VW"SEB4SJ!6?LC+\4%"]+FJ&B,8#[?1.,!( MLUD3H\P2OH_3R9?U7#8-IS_C@C2I-)->V S690%*:DG3R?6:V$21@^1>#F'^ M'SI>GUBL \3::GX$%TZ//E[\=8GE8OIN4NIN7:+-*&M*""T01I/SJ1;&B,"3 MC-GZV)K*;H!8?9INGPISQ[+/""#W"]+(Z9*8[ R1,^UK2UM;29RX=Q ]4^"5 MM"SEDK@RC;%U<_P^C;!/#:*]-3X"M+S*WPG_DR4I9=-=ZBQ9+Z4U'&S(M>>9 M4133&@3G:/.UQ9DL6E]]WY>B3\?J4R/G0.V/ #^/7\_>V$$=TYP)[6E-R$ J M,O5RWDL0Z(0(J-&;UNTBAL@U[ J3O720-3?1.-E]ODUF[TN9ES6'4J5/^B,L M:ACR'0]@]WG^HPW8?7:4O!&[S_IFN\+M O,U?]JZ>\CRVWP9IG]9S"^^79.X M!'*"C @)O(\.%!8!D26*XWC6RF6N56[=TG1'$0_=RRZ;#US7<(1I#40^?46L MKN&KG->Q;YA>\P8N7_^X+0I]8GI1<](>%OWRQ2KJ8E#Q#,9F7GL9: A6(1@5 MBF,1,>?63MF)IM;W9?J8B+Z[J8X1*QW=@8R3LW?X)4Q_7;-KKO-0;!#%&%:Y M&;P'I;0B)P8]%"E*DN34&..>@/FV_)@^?8EP^LTUL!\8< Q=MT<&B'D;ZW0& MUJ74FW22:)CG13CPUJPSS@-X23.P%(TSBJZR<$_5-3^/JINC]8'4P>::-]!= MYZO8*U]HD]\3A<9BLP8GO0(5JP/,*YE<\-[(6)3'(6^5=S[;S[[[VV7>1DEC M(#Q;(]ODXD6NE**E( EM*=;-M*O%S$VQ,63+6["7[$: =^1&]^,\)O:WRQC MM%D#%*]:"HE)3JDU*%:)7Y)GP(MUPJO"I!A4.O&RV/-V,M8C['F[:*XWB=HM M]C?EC&*1O'?C PF>/'GTQ5K0LECMD%F,3SF:+Y@];R>3/MXO^>AO^%ON; M,=IR)S,X.MEH^HG5DR\!SZH$;RIKY*"7LY?'GK>WX??6WPCNFC_BNFODA[!8 M_?B\"+,E!?%5[W4#3"0O1\X@Q>KZ+;M^F/JPEM*Z.TLLM-LX H:L94KH51+ 7%]0"\#!NM;W!]'- <0<^=O>AUPRIM> @?VCLOLPZ8W:7FEBK]^T,?KM8I*]A MB5=KYNZ4MO>@*;'"',TB1E49/$A#]1>GD28DK6-\4.;12W#K&2 ?M M5/:.)O9]_GT^]KDZV+D+?J.4., M)193^='7Y:)"T *GX+GHHD2T@F77FN7P0)%_]KNP9O@_&2Y&L PVY=&_D;UN MW'%/<'FF9.8F,@M"*0_*D#I=$0BEL!B*2H&+UJ55CPKSL\>1;:#;QI:C .5- MZ2\]JK>S2LKWOJRYL\Z*2UQYF@'WWI'#KSDX2^N-_I@\5U'0"CS>V_?#0O7E MM7LY(&UIVQ& ]9>'5MR;BT4UVED662KF..2,M8LH1:?19PDY>D%_GY#+UIOH M4_+TH5YX:1!M9M%QH//S_.&9Q) $J\_*W@7R5!R/$'+,D)/B+B13,C9G<'A4 MFCY\#B\0F2VL.09<#@\SWZ^^XF)+8N"9R27Z $(435%F59P)M:X7"@U.M M*23V%+4/S\2+0_0)R4>21Z @P@!3R-#* M)'495,!SG.-B(^7+XC;8!6<'[/;[6'!L?LT?\]6#<[MS.-\X@Z^T3!&P+J+F M%)2<01D3P"LZ765DCMRZY(MHW:BPD>A]'PZ[H?E$MAX;Q)][(:)#\GU9\[E^ MFD_SF7-&6B,=J(@&E! ,@K>29EZ,X+9Z'JT9*0\0M_O&?'IX'?(:>("M7Q:L M_X(S^MUT'4B=3V:3JNA*JK4-3K+F*3FK@$G!:?J1@4?CP5&LXM$'HW$0\19BEE9S!ID+3R$Y MG:F.EGU9>%XM+C:%6.N#[(P)%YF4 M'.CP0E A1@A.90@PS?D:)ORL8+P^TA%GPY6%W?@EXJ?;,J_T * M8Y".$H<2+!9&47(J$%#1B>,P*"]TT&5(NXI#Y>B;I_&"\'JX%7='K+]$[ R_ MU.>CSUV>K,#U>@NBE>M_-E\O?'GM-^&5]!'VH]77O+U:7F8.OL/D? M?PY_GDDA4'L5R03K-RLEZV.MA5!29$ER+N))&(_;3*>[=WW*&[]18&*LRX/F M\6LIF%;ORYY:.:ND\%$Y#8RQ4OGF*%CF48&1@1G+.5K?/&/J.%/I[KSW718G MQL((;A '3+,^-;^O3\UG(?C A"8/+U(XK:0WX#FWP+7C)204B;>^"=]%ONZ> M_,G >S2KC6"3WF5N-Q,>/C^2\' FHF/H-0-F:JOBQ 0$F22D0B>42M&1$CJB M=L@@"DG:S6G 2>S!<-- M(BMDK73K,+69\'USOE\&W@^Q=[-MOF5VX:OTKXO))1_=U97^&UK-(=\^Z M(??5PM E##=1_J*^6**[\MVW)OF M>_WCQI\N:5=L<$8RB@Y,YJ*R$Q6(REOP0FM&D0'3IO4K^ZXR]DT@.2+"[C%V M'--X(W E'GX6?47;Q.S+AD%KMM;BY_FFT_!O\\7ZDI\F_YD&N:19YBN4]ZPQ2EK M$G-%0_'UMB9G#D$5!49X9DO)(9?6]61-!.]-1WQRP+6#_)[6[_S:_G'^(TQ7 M/SY\#8OSL*$H=%+SP N"E)7J$.D7IP*C+42D3.& 5\D^X_@^\ND7"Z]]C3MO MI^DQLAG+@CF%4$#KFE9"APK$X#*X9+3G.I$0:L@V=RPVXZ.E9I[D'&ZB]A=# M2\R=RG5O!H[78D>(:5^Z.L=.U$= M'0@-]-D=$>MJF\6WS27F9@;)$&A%K#62I9;;, H!4D9(6H24>)&H^2!$//3U M/BD^IT+$P?KLC(A/D_3U(LS^%TXO9J\G\Q6FK_2/;VNO.ZUA'J9OYN]6>=M0 M1-#^QVH7&@H+:SH>@C.:?E%6Y1@(\'?;&CX(E1V'[9,/C%9 MKN;3WW_0USZ1AQ_CMB[LJ&+[@E8O%HI;%D#JXS*"0*8B:?F'* M!.42IA\#;6E614"M MM6>J2'7WW?X1J]_\:A^VM5/9?6_]=;;\VU=_>[N16@JO%#H)Q=47JD#A5- R M "JTC(NBI1MB]>LO#KNM8B_3Y'LJ;@1OR?75Z'VY\<"TOLDM 8W@G$$HKG;@ ME0F"RK(>4Y9"':N,;]U$^T%!^I8JG323X7!#C !--\2O2:-_S&?A^F]N-&*] M:I5:C'-<.9 NT*GH,ZVWFJD?98Q&&0P&MD8>/[8O[V-[I7F7L0"PKEZZU,HHM,"(0>M@D[6E]2:U*VE M_'VA>U2@S4=B]1$@_H%\Z.VK64G!6R'!6!9KYH:!6+@$9C-&%=<)2(WA^Z@P M?5,A3HG%-O88 ; NF^=\N*]Z0>8UL#C1=Q-Q+;,+C(!%ZGO,-@;!,(CM:9'>K$W7"96_3Z:X7,UG5Y?W-J8B.$L@:(NG:=26UYD. M %YT5M(AQS2( N_Q(48)DWT-.6^OU=Y)QOCE8EI__N/>+!@I@%N1 ;74-:W- MD6:BA%(['#ENM!!^ #8>'Z&O_K\-KEZG588KXW"\.\1N,0PAK? M+&=P.CL046#4*2HS**OO\1'ZWG\=#QF-=-H9&;]-%DM2S7DM8YV$:9W4O>D@ M*B,=*#RNMM3P"1_>!X&#MJD7& ME>;,@&&N9C522.!RH&C %6ESLMFXUM>ACXC2ET_FI&%4"V.,%%/UMPN\6H J M9Q90U%ZBM$@DT@*,(4-6QC$?&"W"UL'3LT*-H^+Z(-,/@-/^=NB=*)023G$Q MGUV6A%VGL$3O<\X^0O"5E#*;!#$%"4+S;*0VI*@A*:F/?7]\L#C A//&^NR, MB<]?\7QRY:U%5Y(AQYU)S4$E&R#P4"EPI2O%AGK3, '-[_9-QHZGNWWUEOO M/6#QO^DHWLBMBBC6\]H?75?OG+PMIX2&+'CMY,;9V5)\4J*\WTLSLP^"T MAPU& *@G^Z!(IO9C#M$WAM4 L48)KGU ,(BF M9'^+]"8)J.D"ZS5'H:%(P2?PVI+0IF9?"<=!AU)[RCOE^*!+FN=( +8#]B6$ M/!F+Q'X*'@,JMH]=):"WA4&1V9.+1WZ]\XP#4Q0;+6TBR8!L^D!9MB)+>XB&!:IYH_+$GG MI/&#+?P,9/90=^^:O//P9?YZ,M]6F]\H([:6F_J,CBFQZGHY"*@U!!,MYE0) M#Y4B.VJ,#=,[?;XN%-FKL_BSS),= DHS%1'%95I)0[2PYV4D(T!B\ MD)BS#,,>:@[F<#C:TTUC5#14:&_&L5F:OST_OYAMG7:3=6(A"+#DH8.2$<$7 MQH!K(Z-E(<5!-"]WO]LWXZRQ^0]26F>#_PVG\R4A=QM6U[ZTM=#(BOIB27X2 M."88'6O!1Q1))S.$I^/V5_MFA#4V]@$*ZUW$<#&+\Q]7($7MLLHVTUZT)AVB M4\L%I@"=X]JQ'-(@'_#V5_N^J38V]0$*ZWSE]&$QSQ=I]7[Q"1??)VG#L)-GI($>L2$K'VYXQ0R3&9,0G3W2#A$.S<%Z#?U?7A-KT/D ,5W-M' M7(0I3>#M[!^8UEW5?ILOSFNUSHTR:"=U$88S\#DZ4"5X")8\(*%1LJ!]-FY( M4=R H;HCXU!CSH^GV1$ Y<8,MA7R%ADK(=:#F +EY#)$,CQD'KU2Y"?;]%SC MN4<_WN^AXSA@.$Q[O:\?'X+Q]BU(<:EM;?GH*#A2R!!"8 YLD3%:45AQ8@ ( MGABB'X]U>RBTTF1G0+QY_[>WOW"_C9QJRV^N(ABF:J5$39/5U35'I9-W+EL] MA"KTUD?[$4^W-_K^VNJ=Y7_QSQ_+;?\%G9(2"FMOU_H"4YL..D-HE0F#0Y6]=]:YLOD-4J9WBAER18G1-= \4,&7KR8[&!TN34'?Y M@EH1?1Z%!KJ]G0_05^>8\#IX_I6BY-6/WW'U=4XNZG= MGX-422J0*.C(MHE4PI(&RU!RSXQ&,\2]V>MY["@ :6FKIY[(=E'<"'*O?IO, M)BM\-_F.I)55F'V9T%Z\?FZ@/?KW\(_YXLTTT-Z]YEBUQ:#U$ES(%*=G6:F+ MDJ]IBA2.">:E34.VF!T2LG80;QBT?HX6S\>RVK@!>3VQ&PM7L1*#X!PP\;+<1P')3KX7Y,Z:OL_ET_N7' MQ\F7KU=$IM'$(%E0P"M'ABHJ0M0^@F:%92ZM*L/*'G: X3,BC19VA\-A?CS; MC !JGR[B$O]U49W6[Y6+]XJTDNE"OD4!EVK7M2(]!%,X1.1>NN1(18,Z[>X ML4=$&0:ME]W%N:4UQ@FJSALX?&1P";!W;H=_07;U=X3OZF"[*HI(#Y6+7C:U\@)NCD#R$+8;),O#%Z MGI)G&(A^CM8ZS>PR HP]2:MP5K1+:+.":+&6T0;R_E1]WF#2Z%B^K+U\62'^%UXRO M-W3P$:?TH_PA_%AWOCBS2HCL703#56W-K6I!#4,HB*(HE9C40U)$CBWGZ#CG M#L/IZ$S[@F'^ (GYE0IJJRUA2H"24DTF%Z2"=5N7X$UFJ62OA[!@'DF\T1'K M]05U*T.^8"P_0+M^I8*BF!3D5P/#5$#YQ,BWXAX\17PJ\"B#&)3)=1SQ^I:: MC0[+K0PY4BQ_V,KR:35/_[Q^V'X[N]FW]4Q[9D5E)O,%=8TZ"WC2.$U7V)"1 M?"Y=#H#L,"GZUL6=%)E',,L((JKMPOD\WQ"_;A+'ZMS7=_AGB@X%#)42P+K: MN*WFZ1K,P(UP&K,N7+6^^'E6J+XU>D>+K-H:8P3HNEO->+L[1FT]>"G6C2Z$ M;^;+U5EADL7($9)+I$3C*8CTIJH3F97<&G*]&V-N3U'[\A,>#8FG,%QO"HF[ M;#OK%;99>)D\D'>3$"=3^ADNZ6<7YYC_P-69$3YGI"D)SRTH70._8FOJCW.R M!&\E#JG]V6_TOG171SEN3V"&$6R$#]^9W? NZJ7#@A;2Y_D'7)3YXORW^>)] MY>)8OIF?UYNUM95_#8L9YC.1N!*.MGTLUH.R2E5=1^#)%F5SS$*WODUO.H&^ MM=0GOA@]A9&[MP_<>^*OS+ZQ^7/Z!_,554?,'WY<9'ZRFS M/+/>4WA7&^@I4[MI(8?@6 )7@G;(6?1^2,[JJ>7NG*A_E/U[U+;_"=?%77U\ MNHBULO+S?//OG9F2LS96 #/KM&2?Z5!$#TYPPRATH--1=EH;S\G>.;'WQ:R/ MIACHO$;^^HT,00J9W;_,^SUD_#R_=1_S(2Q6LTIDXVS4/FA(+&::8&;@,4C0 M+)42HF-:J $@WVOPSCEQ1T'I\:W0_;)U^ZBWG==C]WQGW'ET168*+80 %4E] M@>0BVAH_8.1OE2+>H1]'W"$*Y>Y=TUU?!R[.(.H5:6A9T4*#" M.I40ZXK0*+E4/"O5.#)[2IYAR'HY+T?-;3#>P^_S_#4^M?6R4&S& -+X $H7 MA."Y!"5R0*&4=7?YUW<] )\68!BR7M;+SVFLT1ER=Z?VS,PDST9':<%9FRHG ML +O8P(=A-:UDY\K0YAT=QMU&+A>SOO.D?4^RBCW_LIY]=!$EV>:COV"&<$& M7?DHD@=?:VEC],Q+6;S&_>]RADHQ#'$OYQWGQ'89-0*?F.49[EO;TTM47O[6S^(TQ7/SZ&%5[? MA%-8PY)GJ("._TP^YKH13*QW+Q)]5K98/^1:XL&/#\L ?V$/$P=K<3PP^ 77 M:4#SVML-5G]N).HLSP3' TK/("0]=;-% O1.@6"(@NOM132BL9G MTYZB#L/@R[EO/Z7E1@#0H:ED9U$7[J020*DKZ?A6"4 *N=2> M+)"-B/59U(!+3 /ZDKFP624VI##ND<\/P\K+NGEOH_KY-N-NR]D62M/YRX*6CQ]*7>OG3[_>WY6N!!)DQ/(4TF@@A'@@B+M+?89&W18EO9QG_K&OG[7)Y08-=I=R&!I?S@7ZB>PU D2NI?ZPH$5V1INT-$F7 M6OKMZEIR% #3=FT#H[\0=/;GUFV)KDK0!D9(: A#2423J,0PNG&>+HY_C#DOV/E-<7\BF+(\ 7_NL1R,7TW*;3G.JZRTAFXYG4M9%4S7PID9H1* @TS M@_K+[I+U=H"\PZAH7]XM_,EL. *\/G"[,,*\6YX@QBE+0D MG3/@:BJ@D*QP+(IQU7K;VT/,8>A\>1?]Q[;8.$%YG1CX-M,\)V42[CD3#Q($ MUGBG/+Z0S[AA6:KHP2=70*&O3764 \LC1FNCI<5[?# ?:WK#%L'+>>@8.T*Z MWB[+W.C6C#W)C1L MB;R<9Y;QH:#S1?F>BKBOA4>SUFNPGZT[6^3/S?RIO\SG^=^3Z?0L.YT*20K(D8&J MV;:AH(/H??KGVEZ4;DDK^:JA*>-WN5:=FA &13@@TKD(7EC:HLWRYM??!T@[S#LO;P' MGY/9<*QN[2.![XW6;K_6W;V>OSFLQ44WB?3I6YFMWS!/-+5AZ^#E/5N-$1GC.?VWC6.J0[3.?KG>-I;O%YO$F+,2 MF/516-#,UI=@CN!%;3.L,@NE%DNXUG?/@P0;AMF7]SC6WBHC<"H>6(B?D!1- M\YO^N';';] 8W""VKKE8T_GR@DQ<,Q;"+.&:Y."/^;:A;#Z3DEEGD@&1#(*J MG0F##PE8L2Y$CEYBZV9 QY[3,("_O%>\46%AG&MC[_N8-V%94VAK1L_W,%WG M_'L>D/;V]]_QP7Z9__ MD>;GE]^^H;3EMB#A5FWG,M3%5C-Y*1YX]66!EP'#K\O5Y+RZ:K^1H_:W,+W M>;F]2,/#E^>K,)DN;ZMD.3G_-GWN0KB3H/]YK=6[^M[(>P_+(]0P_KG"62;_ MJOFQ3ZN%SGW)Z)Z+/,FMSTB I400$AE0 ,L^$F*'31'_\8?D+"@U-P MTU?,%U-\7Q[8@Y:O?]PLQJFGV!FCO2@:?@2$W,)Y0A,3IH137,QG'[Z&Q7EX M.TN_8R49.7-9.1>5!%L;AZB<&$3F0Z6\0X9.B."'E.@]]OWQP>( $\X;Z[,W M)A;_F[;FC=PR.:>M>.;PRA[7J#M]]7; M" Z7WS'42\X:_+R=?;M8?:;_;KU3HA66&X\0M' MR,=DZ8N;D[HL30#-8ZH=% )Y=DR!=5+R&#.Y M=H#RI"IO!/ENE>M7=/:"7FG?7'=!08_VZ*X6"RV_%W+W\/BG[BJ_^4G3!>+];]WYHJ+":VO M?*BT%25+%@R>@Z"]R N6/=-\S&ODN0F.+J@>X9)I"I*QIB(?K?Q0:^,2NDS; MBZ;M1:P3.KB&9*5GWHJ,(T9'6,, M#K)/-:^;17!>(&CNM,7H-=K6G9)/.L%!"Z)/,>+X-O<6(/G)5M -,H8;/SR3 M-@G!I0)4@0Y!82IAHY.08]32%V%9&G,!P,.S&K16^A0LCF6M-(!#_UK%TS$X M*!MHMP@"-..T<:B@(#B>@:,-A?Q'EOV0GDGCX>GH4_JX#_K':>2?['2HTV4@AE9"OUCS$?!4.3WJ8D6A, M"B4Z"GB"]8KB'Q_ ,64@NI)+2%KYV)H_9"?OF_YYR-Y>'IN*L,0^__,LVQ3RW?<%*LW="?. MO9OD-N <-TZ[D&4SE/&*VUFSGO/ [ M4]D0AU2O=_/;C_6:<7EOBDDY8R4+$'G-IQ:)G.":?:8#9\HCK1$Q)-+9<_AA MH'HY+WNGLL0H*Z8?ZXR[_",L+O]R_R+GX=\^O"YYSWD<6$K\5&_AY55=I]6: MBUCK4T*MC:+? _W)0G$JN>""-6$(@>BS [4K 'Y\J%G^8SY+C_SX)N/+9;XB MYA1S=\?!=+E:D MVXL9?8F,L/KQ1SB_K ]0212A*;#2Q0M0(9#\A7X)%HOWP>HD!]VOT WL$I_ MNL;I8V./I7ZX#Q;F#0W3&5@?\=O%(GT-2[RBO[@[I4W9@';:(!H-#)FJ#7Q5 M[95$?Q0*DXG2&"$:H&VP0'T@V,;F\V,;H'<-:=WP_P_.,(5-54AQALE,T7"2 M/)/P$"(QENWDJ+G2'PZV09)ENQ> M?#O#(\6V&"1$[0I(J;EWQ@O'AA (W/IHGR3=TQA]?^UU-OO'2?Z",:1_OI[, MZUMH^(87JTE:OONPF4LP)BD?D#8I^D5Y[\!)3""+]#H4@^(NH^_#G>Z?&:=/ MKNIIP-%4Q[VWB<5DN9I/?R>X+S_]ZV(2XV8.S-E8M&'@':L4&;73:RHTDG0): M"PE4TA&\"@9X45E$ETL>UF%A&+KN"] O=CG_FH=(7ET*!EB0=#3B,;G^UN[T/-=&\B;YZ6QIGWR?G M6\&S,R$$*P%3K ^P-D%D4H(IVG'-HDPXR- W/]HO.#V"G??65M<*I_7U2<;S M;V&Y96 +&"+7G%QD].0*.0JIC&5@;0XZ2\^DSP,,?>NC_0+2]H;>7UN=U_/? MEQOQS.4;"ZG"FLA F[R^%@OD920/S";!BW'!-6?Q>%"0L? P M=8T-VYEJ!'B[K[SPL+XVR\EDS;R6%JRLS;BE+Q0UV0PIUB7)&2VHUDC<4<2^ M+_0-0'&WT/F(%NI\M'T*4UR^#DO,OT_H=ZOY#+>S"(JYK&T!M#05A8JB\Q(# MF"AXDE)&X>2 8^[Q$?K"Y*A&G3?7\ @VJL>V_!O*^OMD]?5#O5G^/'_LW]Z^ M+J9D8XH9(I)OKQ1Y!D%$#E(I1VZ%,H&UWL5:RM_WBO84V.UN]>Y._Y>+:?WY MC_OK5C)52K90)"U>99.%8"E@598[[GT4*@_9&1\?H:^3=ZJ=L9&&1[PS;D/= M4J)40D*0@@(@+00X0:Z(*$(X\G*EUW/6X4Q[5Y[6&8$.'N@7]CVM348 MEQ,KD(V(H"H)E/=.0"$EE1PPV[LY;@=#[%%A^M(=G1)=;>PQ F ]0>'T^L?O MX1_SQ9MI6"[7D53(T3*'%HRP"50MNW8B)_ B"89))%D&)>/N +4=Q.N[M8WL M?N189ATW8J\G=B._A17/$L>:B6+7]/,%@O("F*1UKM +;,Z,N*.(?:>=C36O0%J(($31'EU02KFAVE%-Y%'T@CFKJ M!T_B??0^ M"\#M/:WOW35\35N_IO;YO%6 M2MD8/X_)TM>I&]FYVL1@(P7>9C&:$)+,6D/E5J[UDAFBRAX\]Z)PY!A*<\[M M1Z7IW)6AB;4'0&@/U8\ 1&L:LGL;_&8CCDDJSQ-H24&V8LE1&*08%*X3HP!) M6M_Z 'Q"G/'!:!^+SX^C_A$@ZIVD3F$UF6.MI-<_KMJ2D9YT\3Z" M6-\+"I$@L$@JLVBS2EJKU+HGX+-"]26S'=G)V-:$X\7DC9YFNBCM?%; 8[$T M(9J5Y]R"11YIX7IC?6OJAF>%ZKO3-0;!,(CM:9'QOC(59D3BQ0!7%+\HC1*< M5Q8<.A]RCLK)(66,![XRG1HD^YIQV+O2+CH=;V9&#D%%'=<)DS2+0)Y"U$X! M"YI)9814.0Y QH&9&4=[W3X>,AKIM#=O1CVZU]NH).&4T@&$"@D4\GH1IPLP M8SRC4]PRZX8QKKKKGWT%QG@_\^F4W.+\ZW#YVZ9!18H#@,M<8N0. Q M #>^I&(DEW[0$_$S)K\U:&>C[V.R>0O]]39\^/.&X+PXR0MY.;(6YZLH,X2B M,NUT6C-/SG:1@_J=/V?XFX-V)$EI8?B]]=>=JVVVG$\G>:WI-=/G>M\KM.TE MIVLWY,H'K UYO";07'3*AF81I1[4+^M9MK:'1N_;PF%$3D,#XXP.7AN'/-F0 MM0L"L*0:5QE:':HD*(PI5HNY^+![N9T!UKN:O85-GX3('@H>P:W9^V_KH&WV MY1-^N9D6)9E@/EH#08?*PND-15F>0?&5F#QF)]*@@&67]X"'11D39/:Q\=U7 M@ 8*'P%N/I$)UKONEKQZ.YW+]S::"[)L(>NDR'UW KPI6.L*DW*))8^M,\^> M%*AOBY:1G&SM33<&'%[*OEF8H10L AT8\AK) 2PU;/0>DLHL&IJ62:W?PF\) MT)GQMIUA[T)F;RUWOIO]\#4LSD-:,Z&%Z?)R&MN+Q"BL]-*!4(H.?!,\^, - M9%7OGJ6H^<8#+F>?&*(S'/8WVKR]!D>P5S38?=]=]65(CCE42H)+OEXR2#JY M5>:0BS.%^\@B;WW$M92_WM[=NOD=\6>T,MT,-,@(LOG<\7J\E_KPUXEF74+"L-7*]KOC0M#UXRF.2=M:4<(5O[46'Z5A"/ M!F=MC-7Y.+W*5=ANR[^'C*O;I?:U_'ZVKCM,MKC$0421:#$)!KYZT4F00RU] MR2P,20W98$00?=^M\_L#5 MKW^FZ46FN/VJ_3E+3#NG+22O:4Y!(\3D.47H!1W+.8G2NK7\$+GZYH%T!^;1 M3-B=['I3>_W^6]729HU]1%I@F!\G!#M#\D>PW>]^&V.Q1/8[01;)=/,!#0LCM#Q6RJ- /,V)K89WQ=9706U*P(58HG M]Z/Q1OFT1)V?3[H#\PAVZUW?-?\1IJL?'VE=?&W6%2A42LY!8#8GY0N6E';#SP.C# /2S_M6T=@.W>]5!C_N)<>]]<6"X,@J M#X^$6%A-Z?$N!5&BBV( NEJ_P?Z\KQ5'M,\(G+"/^!UG%[@\8RPRSK& %UJ2 M\T@[<<@%(5F>=9 L&=XZ^7<[]C"$_;RO% ?98@P8NMR'WY*JSI$T-M^F.Y\I ME4PL%(<(9VO2=%T,M4>))6?0FZ*]B:VY=1\59AC*?MY7B;;6:@:[__F?]^Q! M\_SG^D?KG]3_ZB.6_U'_^=>/;V]]_YQ.^W_^!TWD\MN/ZIA"EC!+DS!].ROS MQ?DENP^NPF2ZO#VAY>3\V_2Y/E![#?.?US.Z.]?-:/?@UGQV^.<*9QGS_]?^ M!6CY*M:F]&EU9H(W+I#'Y1RO.7F&L.E-ABB4%8;QHMB0QGG/#G1P%OD1TA&9 M\<98#=K6[MS",G"TD8.T.6IE=<+0^@QM/XL^.7?ML74OG[VOO4=P3E]N^5<5 M ^]NLN4%3A%WC@6X"+7W0T@0..DXU ,E,,.\;?\L\:@XG9/H.R/EWIM$&[.- M%X';<@7#T-;DPAB< .6E!8^2YF9-C#H6G^]VXCP6!L=0V=/,[,/@M(<-1@"H M=1K-MEV$#Y'B)@\JR0S**@074@052!N&JZS,(":%74[?Z^%'"99]C'KWV-Q3 MPUT?/J^#KN7J?;DYA9BM4Z:VN\QNG>%'039Z!5J8&$)6(JM!9 L[E?#<$:)O MFOGQH'*8MD:V"_X M':?S;U5_FUEM5Q:YC\SG F-K$FCI#XZ]L&@*BDKKMS=DJP&U[7/BM4WW?QX M@&MMD1%X3H_SI@N7*%(ID%5QH&HGD6"S@HS),NFX%;KU)<9!;0V.=E".+ QL M8K"1 F^S1(4W27$MZV5V(:_2D'^9$NF(IU(#'L_5_]_68!=K#V]KL(OJ1P"B M-:_^FXM%5>5M4GU#^ZTCS3C%*40IC(%W@D,4FN7BN"RZ=0'I8[*,#T#[V/JA MA@:'*GX$ 'J5TOR"=O /X4?=F:L/>5GI<*/X=220'OE4E^%R!=V?#\4D4M=-G=42,/(B M,\0BZQMLT3))2V*W?C%_3J:^4>0Q][%6ANA._$B+!1??:I/OVK%M[2=HRX5) M53G),5*.S> *A3L" Y/2QRQT&]+'^V/W!="2&;!>Z9!94<;N2T2#/>*>^F4O[M7/9@R2LM=H; KY-EF&R;<7.%$2.=K*6F^W,9P3FC03*3Z20WN=RM\WG0^#<^ MV9'>_.AFWU=SG0W^.OS Q:N_;)UV$VV0.4"V.E<.P4+GJ5+ +6.>,6><&Y+# M?NNC?9R.TQA]?^WUKI29Y"\80_KGZ\F\.MSAVYI3>%A?F^7D MO'*T4(C .!C2WE[ MW L9.4L,N#,*E*83PA45P=OH#?T2,-!T4X/'BE^X/1GU"'1>AU$B?G,I@W^7/X3:]#Y #%=S[RF\ZG=17G,5EA>N['S/2XG]O+ZZ2=BD*:4$F*VO= M(:' #4^7O9^]5!0^"(?HE)5:VB$PN/G1?I>%1S#[WMKJ;.:_X>)?%]^W^&0^ M)BEITK[4/IZF-G_/%"K&VB/42YFC]P/,?.NC_:[]VIMY?VUU-O.[\ 6_+R97 MDI-XWKI4^[76EA1%T?'D)5B?*WMBD<4/N?N__=4^X<1Q#'V OGI;^K8CPC+/ M7G&25R4/RF9#)P[/]=CA&)A&SH:LZ#W\N.8LSD>R]/[Z&O&UU5Z$)DYB""60 MO\I$[>942_R-4*"]%8DGQPMO?:EZ\LY:1^,6'\EU1G=@="=Q>WABM'&4R>K3 MU["H)#M9,R>31LCU"D!EK&5(3$ 1U@6%200W)-UAT& _4?NLG7 P@/)^?Z., M%&7KLMLU_VHLCD?F@?O:PT0E!0%U@4 A@$L.0[)#CMWGQOF)>F6UQM9>IAC! MB7[%/V<,H^B1!^"A!U4&FV!]" M\U68-B12-U M:TZD!P7YB1I8-0+:GD8:P<'Y>(]JR[SUS"4HPIC*;:? 6U6+L6Q![91PI7D> M^$$-Q5](:ZI#(-?&6F. W0W9WY>[;;;.BN2L6,Y I74'0ILA&$=^J/!9BNB- M,:WO4IZ6Z&?J:W40 -O9;90=%B@H6BTNTNJB/IO\43/OJTKW;Z7P]/<.[YFP M@[P'-D>X$39>CTCPV[1M?$4H^[X^"Z_([',M/;!T](D4:JI6K)<8IAZ'P6#F M(A1S! K'8<*U:Z[PR)#UYG'SUBR8C-))0^+6,F:! GSPAAP$;Y),B1796@\[ MB-?W#?4X:'J\-4);:W6N3;AB OV4'#PL?0U:&SF>4N=]P;-1NZ_SI;?,$W*!/.6;HH%$X2K M[<<3G> Z<'#,.N I:ITY2TD-VJ>> \YC O0K86A@U'EK#8\$)A1G8 K+;4F@ MB4QCU!(R,[FF7S/P]5K82QU\2%D;,^A]:2!&;H_>$2!M3/H 2 [0[PC"N%O[ M;-U=UWOM$A??\6:\84*02D&,B8*"' VMHZ @&SK)N4AU>1W3#WQ$KK&0+Q_G MK#J:A<:&NML:J\]7:?-[?J:]4E)'!A;71?E&@7<\ ZDQAV1E5L-)]>7-Q?C%=1]H?%O@Y_'FY5K^&U=\GTRE- M_6*Z>CM[$Y9?WU^LIN''\HP5SY4J&=#H0BNX%BP5$Z"H(!VIEYLTA 9H?PGZ M;G9'@]L)S?(RP/>Z=CPE?^+KF22WH3 >P&6)H PS%"\7^F/PR2=G!7DI[2!W M-6[?_,8Q &T_$XS[6'U[^;RU_OU9))\7-5/ 1*Y]YVV$@(Y#X498H;&XYA3T M T7KF_78\U#=VT"C>.Y^8F(W)_=Y_@O]-3_S&DV6M*Z2LKY25P<(7G"0TA<6 M@I6>M6_EOHN$?9,=>^+P4'.-_U'HS=>P^(++ZQOJ^*,R@LU+G7JCAZ)!8S1^ M/-I]7J=_4"K.<:8]\, %J" D!)L2:,:4UEY:KEHSA8WR02EP66A3UQ =^:Z* M^P1.9P/OT6-^*9Q>*-XFV;_0< ME*XSM6E>XPS+Y*IQ5\Y<>ED*,%()*$'ZBJ[20UO$5'04?MBSY@YX>DZF M,1#8'FSZNPV'6MJA-T%72CC%1=V]?T$2($W6$]K2HJ(0JG;CBC[9VFB5UYYP M#E*J+@//(OI!A%U/#=+WOK8M0MIJ= Q;3J6AOZ6=+<.-$@Z9%Z#CFK4J9G U M]SLR)^G_S$39^KWI,5GZWL,>:8MIH?<1X.>1/LZ722?%BIHT (DCN^SY5N]C M(*&6+$CAG6_]6/Z$."_GC?P0U[J5/<8+KZNHV-P5>E*@OGY0,[,/@],>-A@!H"X9%-:,+]L4)9^+LH6!$+4K)4L.H@@" M&&8O.(F L?4%P#TA1@F 5R&\1M'-("\RY7 MXMZ"PABGF6O]DKB3@'V/O^/!['A6&@$$G^0UV))%2^6+2@EL2#2E7#QM[Q1Z M&$3'T5BMXA%2$I\3JZ_/?CRXM;;(.$!V[^ELRU"=&"T1:P%C#J2I@K78G-S1 M+&R.DJ' (]"=/")-WXR(HT*JA?Y'AZ1'7NLQDO/I-.MZV&8IU"=HA-WMY64_"XT-=4^D$DDZ_%$R!ZPH1=-"6JW12HA,"JOI MUR)/].2^5ZY7WP3JG3"Q9Z[7+@8:7Z[7S:E<'1.UKKR>&^\7;^;G).A7.BY!R4Q'":UOX-)A9B*EQ%O3 MWAUC'B\@2[L9IGN8?OS993?3KSXLYE\6X;Q13MD37VZ<239T#B?/'_.%_#\9 M'&BL+8)T84#'OX!<-$?AA51XHL3ESOEC15#LKC1DBMXIH%?D#'G&P?#,-;*< M?6F=/_L3YH_M@J:#\L=VL-;8/,L'DE:4L 6+B\ B169*VP3>T'0L1^F9EB;D MHR9OO^C\L5V@L&/^V"YV&0','G]A9CS7?H"97!);N7-]A"@\N<76A>AY9HJU MYF)\H?EC.YE\S5LJ%$>9$@NX8FJK&-KL?586C.%!*>M8RJWQ M]%+SQW8R_:[Y8[O88=3Y8]EQGI.B%5?C=N5I#HX"=1!8)*<5:;*1SWCV+S9_ M;!^$M-7H&+:X"1!8L<)L)_1E+%*UOVUY:_MA!6TP+ MO8\ /X,N:DJ)R(-E@!EINRSH@%9) A92\IJAX.ZH5V(OGG7E2,[V?A8:&^HV MD_DXGTY_FR_^'1;Y3%J2NGA.2\<$4,HI<$$+2%H'CJAL"D*0XJU'L[+2W(D@)+2JC COJ6?N"3 MYFF>?XZ)LD:V&<&6]2'\6+-PDXINS; 6M-0&$QI8]N:27<$SQP&M9"RLZ;=% M8XP])LN("'D:@ZJ)]G='D;]$T0R_5 @??%?PD(9H32PP+/$7O/SGAE!H\PCQ MXRQRESVC:;%B%*CD*1SBVH!P6DB]?O0K0>(>^B& M=3WTY75,4CFA$1Y$OD'@J9!S=PL[Q Z= M.7DR^RZ?)MB_*2B0Z#8C%QL%0-$+S0(&TK.QF?1/&?C84GZ M7NFU. @::GJ4>-F^*UO,(1D$'D5MNZ[PLL[:2D/+@8*R'%M3(SPF2U_GH86= MGX7.'DH? 7BV$\#\:KF9T[4O?M7 )2HC; 2/18)RTH%W44,.3J!)6DC;^A5T M@%AC@]0^]K\7E[0UQ@CP]<=\EJ]FM9F"D%%ESAFP4(E(G*1UYTAC.>C($2F* M:_Z2\( 8?8^QH^#G4&6/ "\/70E\G"S_N=ZP8PHR9*MK)RIRY&(HX*47X)RC MN=!Q'ZQLOA$]+D_?9ZB6CE SK8\*06_FL_5=4<(=P1)CPM?O&.KKR&7NR+WY;=:C-LIFK3QD+Q*HE"0X;6J; MS\A2E#8YT_JQ;2 QN!UID!. B[R+A;'7)CU%]U-?K M3CZ7UWCD30@1%3 ,-;.7TU18"I""<9E;07_1^CKA"7'Z)OZT/#);Z7R,\+GA MI;+"G1(Z0N%6@M(J@PLB _>*YABD":9U@=H3XO3=FYJ9_#DH[:G_,4#I8KF: MG^/BWI0V&RLW)'3EK6)&&%#(:#HI*-JPLU">'(3V?-3/B#0R2.UK^KN0:FB' M,<#J_LI[C;/T]3PL+N]C E?)">F@B%(=@:+IP X6BG_]D>)INULMFXEN7TV1 =X8OURNL<#KU,SD"ZYH3E:4AZ86M M:5\"2])>X: 6H,^FN=T=>1!4[)C/L08:[8R'/\(YOB^WYK!9*=YC])%7EGY- M^DBB,CKQ -:G(+U)E=*I 2P>%:!?)N2A%IVW5F]G"J+?T__"Y7(^>S-??)LO M;I+EZ!*EE3D KT0#ZZZ1T7$.(IJH?(C"#RH>?'2 ?AAH9+AY:RWV9J,B/4R6 M\XM%PM>X^((/S"9JJY.."70)#.K#(&VAH?+KQ.RLX(AW:^(?IJ1Z=J0^B43' M 4=CO79&R9NPR)-9F/X7ANGJZ]M9NLJA(V&UK6T99*H,)1F<41RDMM'H%)+W M:@ T'OE\G[2@X^"AA09'$+"\F\^^T-?.?\&XNKK0+-$47?NV%LV03E N()*% MR2.7FLY4S;-M?:/RD!R#X.+&['TVT_((D;)9/]%ZKP6I1;)ZFZA$@*A(-\P( M6E&B/L6UKBI_6)*^8>WA%GX&,GNHN[]O2++^15BZR<-%9B:=XV\C%9>F>4'F;C)R&SI\+['S&*/; _ED0; M:[("I*_,8H*"]J#0@IV(,VS?8R_ W#E/RJ'#RZCLNPA?\ MB'7Y5)[P4"F\5C_X6=2&E4HFJ%,M*=6NYH+2E(PV-K(4,@NM:UD&B-7[_#G0 M](]"J8T=.A]%?US43;.VMKLNT[F>XG(])\QGS#+I=0I02>I'8, MB_5\B(!U4;P!Q)NYWQ6:8L13L'HZ0EOHX"R\B_D MR;V;+VM"WC0LEY,R26O3_4:*?I72Q?G%FAK^_9NWG^>;OK_+U>2\_MT?N+I< M>)_GK_'S(LR6E],Z,XYQ6V2!N#[< ^WEOI":9(I%>)MUY*W+4DXUM['DC;?V M[$>$B!&LE%__=4%1S2=,-;J9X/+OD]77^<7J(X8\F?[X!5>77?$H1K^J4]P< M02.]H&RZ>QVKT M#XL)N4KY'Q?+U?I]8C:[V/K>9T'9FLC-H'"E@6:O(-BS/XR3I!LCD/O6P=EQ M9C*6%_)NB&]M[9>)^0?7_9M+7ZU>W&X"9!^5])J.-L8EA<7*4H#,')BHL_7, M.QD'E:ETV.7OSF4T3S7CVNH/,OG+A/XC&\ ]3?Q?]MZMN:DDV1?_*B?.>_;4 M_1)Q7H"FYW0$ P0PLV/O%T==LD![&XF19+J93__/DBU?9;,DU=(JS_\\ +9E MULK+KZHRL_*B,.A@+&G&!/)!F/$0E$Y0'1!6R!OQNO55T7C<#(/_L[EBZD3M M'2Z W_[Q]O ZH>+&@HJQ_D>%&CC1YTT$[KDS*3K5NM_8T1<. MV/W5U0CB[Q%,W]_.:$V=S_Z%>1OF.;/11N?)W[7!5O=7(@3C/1T8218LV=GF M[2"'T#4,6-W?>(VFBF,G)7YJU[$AK+Y4]KZ'\QH_?+%^%9;+'[/YY\T^?899 M9L:+ 1(/K9E$NW#4-@-]%VW1.4O=.K7G:8J&(>O97(;JPNT&K2U!CDF3*YUP[UAE U# MU3.Z66JNC@Y ]J URLUE,#_STC"=O ;RJ&O)3Z##FR-"\HJ> M88!Z-M<[S43? 8P>-L'Y2&?WF9(F))X07 PU2BEJ9U[O("9B@[FB=6A]![.; MDF'0>3;7* W$W0%H-K.+9XDL]VKPO;IR2&VD[=*@!"%KRI.I3>6=TA"LJN-T MF"K-D\QV$C(,,L_F'N)X87> F-L##LYKSL8RG'^8??ZR_K38Y';,OMZXHV?1 M:V-1>3!U]U1>:HC&)"">)9/2(_6^!U :@4/\76*];S7E,.>H'@()/::A[B'?KK"VHX1;<&D8G(P9*6$ M",I9!B$)"9DGP;5TL>CV;4>>YSS$?;2^SSS$?530 9Q^6RQQ]GG^^L_T) '6LWN]/=FJFA(GK M@E]?+!=Y4=.2:N5+[>GXO MM>*-<-%,E!UL,)?E4)LZP;H!OUE<5DY=#F$060OD'*(L",J6>D<1:3N./*"6 M/B(KC;>7)\CI!42GM(Q:::=?H%TM0Y.4L2Q8\(43"]I:"+$(L,($EJWGB;<^ MR9XD:-J3K)G:A\'I !UT *AWZR^X?+N8+[YAO6*=?[ZJ[/SS&\Y7VQD=KF2O M(HF'%T^+C]5Z9Q4":!_HU%;!*][Z@G((75W"ZQ 8+$;620, MSB1(&3F_[-\>?8E@8BZ"Y\05:]\&X0B">VG:,G7\81P-=P#GS1)]M?A*[_]" MBW+#=%VC-9OW81A^F^?[$@LY0??KZTE&G\*?Y*P+G:PS8%U4M6.H!^]CA*0X M\\6A#K)U:_?V7/3BNXX.P5U;]G1X.#8G?,(U<9_[2YE4 607)0OU]!11UA[M M!B(J \8H'WQD"GWKS-_&+#P_9VO*U= &"0V7PM@WT]@^6OF*"2V3-\W6[N'N^-/%,0"&=C+4&GKB/ MR8'360!7Q3&!CHZ7\6Y/GOD]\3[(>=P\WE\/'1B\+\,YK7C\^ 7Q;B1%;@J) M5 )44E4_-$#@"B'JP#WCK,Z9;8RGQVCI!5@'*'@Q@K0[1#K:< M7>FS05JI4T$HP5I0Q3KP&>ND)ZMBX$EIC*/9//L%!4_@#1Y_/!TKXPY@LG%1 M\IM9B+/SV?K'M?.R^?D9)^^755]38QU9K&E1.32T!$1FQ2K%2VEM)#])4"^6 MS8'J7HPE^]Z!=-.4YO=Y6F)8X:]X^>\9HSU4,!EH1R6'0BE- C2LKL3"Z;@O MGG@^)<0>)[67?>L$X&NDKV=3&W$K9G-K5L-'_+R\#(:]Q/4?B/-/7Q:KV\,< M/GT):U+>K[B:?=ZD[H35E?M\Z]EAGC?_[^J7WR[63__^:,&O;C@;/>[6#:?] MA?P,'1PH 4/M]"L0(82D@6=5(GE2GKG6.5@3AORN$;&ZI>]=WL/+'[NS^E[^ MN*)RJ^U:*+:Q&D,HR3GR2,GV)T&2>P$>523VH_#9&F>:=V,9CYM>K*IQ\?P@ M#[N#&YQ01)8;Q!M/U5M'2"V;V*7G9 M1X%=@7%'?C765JXBD#MDZKAR^AN"9!:2D%I&9)P<^?]7\K*WUO=E'!1W MZ?;\FGNE%L(+9^@$ 8&1Y.0V464C(:42''>.H6B=:/0X-;U Z5B-/\@1;B+^ M#H#T=-D.6FZRISW;<\>:.F@49(%)(8M.:M7:'CRZ=FJ:&IECX-1."1T@ MZJ$EL-FY4TRJ!"7 1$_RT=&!CW5VNK!!.J>S5JVAM)N2:3'4J:G50&E=0N]J M)E?/#U8%RUT/-/H7. T#L STWHZ\7# MT-?55EPGC0&$\[R)CV1!P%/\<*NP.\ M/)HVI-#EP*0 &W25BW:US-& 9I&1I.@3?XK4JL&VU&B%4)W:4DT4URD KY9F MM%B4QP Z"0:J*(10!S0SYQ7C/%AK6C?X>W;9?7MI>WAVWSZB[P!$E[4BE[EG M+U8K7&_SSI!DP]PF^R.0H:E2@I#0@Q#.YQRCS[SUG=UCM/0'H$-TO;-(YTC! M3YP>^NO5*R_+BSZ%/['>H&TXNV3I9H3/==ETDLH@WPQYI7T[IX& \?<=E7#3NM9$>X\AJ%*5(\E!%LJ J6=W/M\KRYSI;,FADZN0W( M2!RI.@DW"DG?\J!1)ZE='B^380=!TT*J4Y^PG0J[PN.E*4!;M>4L9P]::P'* M\EQG2GF06'BTB6>-XY7<7M+0RT7ST>I]%#@'R+J+8_$>!]<=E=Z5ZW37]XO5 MK*KJ=4TE77WS%RZ% 9TE)KU(I)+G:.U+K6OVD%&2/Q7MA=':M$QJ. MI;F7>^J1T3BN+KO:Z6X9$6>&&>\CV2;*Q9J>&15X;2581UQ@8B'X\;:[6X3T MTH9J/)0=*O7.-KZWBZJ4<'XU'<]:GPOW D3>3*A*&0(/!A(G.[=('[D?;T.[ M2\NTQMHI('2$[+O<@'[LO^ER%KD+Q&Z*0I,O5=V=S S9#;RDZ+2PMG7V0PNZ M!V'S!/-8Q]_>1M;ILZE7^WU>%LNOF^F]7KQM[ BVM[B MNK;/?+%Y)>9Y'G$^4U\.^[C8^:D[OX\FNK)'-O23)\EGZ\/J?= MHL9P,5]LOCC+,FE?D(%!.IQ4<1D\)CJPHF'1\>"9'F_ U2 2>W'5)\5A4SUV MT:WT=G#W)V,1;;3H;?4I,9%WR;0%%XH''2RS*F<91\1HDVF5/;6:;@S/IMH[ M%IF?QMI'KSV,RU7XXG.8D;QO>"=SZEVA17IED'UZU""[NW[/F(K6AIS RQ N MYR#$Y!+P$(3306?O6^>7GH:S7N(6D^[:/:#F<)MDL0[G(P9I0TTX"5I#Y"S4 M!E@'A(T1:VMB])I_?U"VU6>WAN_=$?0;LRED0>N/7,X@ MDJKEJK6X@B3*&6J9A8@VC!< >8JR0="T_[[0;*:USM#XL"5;8ZNE,)NDX.GR M7%%*.;)?LH 0?$9DSOHP7N?SL;D;M"KL>]3MKEN89[?+W$= M_JRS.%:+91W'<7D?NBJ+Y:V;KK;7(P>_?IS;CC;2Z.#RPH3(M- 2N-:TI&H. M8M R03(VQ*2,Y]Z-MM-->'EQZ]77(Y:VV9H?\'RCW-67V;>7/QX9WG<[Y_-N MSI/=1M MGQ);C6!]@*([@/7U(?CZGQ>S]8_*UV*^,1_K]I!=%J$D Y)91=N#08@8(J 4 MZ#SSB>?6K2B>)*C#?)+^3(UV*NT G_=XN%K?F@<9G4=PNI8O%Y'!*\D@!UIJ M7"5O9&M?+M(:Y__M?/''9F )+I/+QC_!MNV/'K+VQ I@EVA5Y7\1 "F#1>]JZ(V-J MS"$V-Y3T J%C-?W$ )L#Q=Y%CXVG)Z=$8;45(8!!29:K*1J"YQH2DU[XQ,C5 M;AT8>:[C:XX!4SLE=+ A/6E2O+EN ,&<4D9&!U)*0?+"!#YI!AA4TBHKD=1) M1HX^H*S#>I/G89 =J>0.H/L!O^/\ E=GQ4F36*[]+O!PBY W \[2B?6>>4J45^TII<3WX+WB0#UA3F;.U[ M6<;J3;N;HE[.RM& U% A791Z/)9T4"6VR+V?Q8EWW\4^+ M]QN-U$JKI+G6D"6M(K(3##AN$+())3&E=0JC!,X.)[GC"X6&$#V12CO8(E]M MS-??YW^?+S&4W2":]3TBG;UL@]D-2.HW5M$'L*%?;31>(I;N]P>&=\VHJ?<:>CY?5P\60Q M*U<\N)P21)NCM0QCC.*$B'V*UH[]F?$AVTR)_6#VJ3/E3K;$M=>(9;'$^RF/ M+^:9#I\SKZW'R!)8F1P)GEMP,FO0WG$1(]=!CC-%J!$#'1;BG\Z$&%?='1@4 M>S/_@.U"Q%3&77 1?9TNG>IPGV:ND29[<:)E^NM7>[%N#NULF"16.9(-$R.DD4DP:B,Q98B$Y%Z:5FXS5% M:\# (/SZ?RO\GDK=SZA3]IT[D]>E8%JO;C=Q7KU=K&^F:(>'4[2;]\)N1]%8 MW:Y'DED'+2%$X,G+4B!D52=DV 3!ZPP\1\U=R(&^.,5UY*E;0EQ>!3+G/>TN M$DP,&91U"-%P"TB]*P3M2*GA5BLON .N M>23#@]PZ;P79W#JC+D5%UWS"]7--AMQ'Z_LD0^ZC@@[@]'0BE7&:*5L"H,VL MCBY2X*0S@(RS0#)3QK4.VA^?S39-:N1>>M\KFVT?)72 J-MYGO-%=9TS\CIM@^F\S(8[#42/P= (E6Q1]AF;=,;"\FS M3\Q 3O7>5-2$87+O01?Z@141K6_M=^RFI)=;;T/'U0B?8!\ZWLQN)?-^X7.UO)P04D@,8%., M-0^S )W*#HPNP27&L/C6SO\S+>3=2^U[%?+NHX,. #6H:!1S"D+S#%+6"JW, M:H,F*4#;C%DIVM)=ZZ/MN1?R[@6#0PIY]]%)!SC[&,YQ>V3;)*)SB8YLW.3S MB@PN2@O("PJ9I477O$_5S>NG/=?&0\VA$NX '!](!T3 EQ?S_"M^Q_/%M\VM MQ!V\&RF2X):L.U.G%4?K+SNU^<@=&9(HHFJ]!PT@:UI;>SPPM=9(!R"[W4%_ M>S6;'.=*.PXQ: M*DRW@LS+@1!&*?(G"XWAQR3=[U:F=P&%K&= ^3,9=P>36 M!=*=R] 7.RY#M[?S-:.$7%L=.7H(P190*M3,)45<6R6R8(I'V?IX.YKH7@*8 M!\)F2$WC:#ILG5!\XM'B<1WF^;(#W$=,%\O+V]$QAX,_^<:3C/<>SG,'"0V. MDWP9.B"+/X#BG%!99WM&4\?06M1T"O\[)33$]8U.7GPGE=1CZ;?%LAJXET=4 M%O5>W@K@2I)$Z/MCW2"UD<0DI@$JM!@G7<76"0;4'. MM4I!M2ZL;$G_M(!M JA%)]KM -FO%E^KS46LO _?<+D-.F4KF0PUL;AV(?$8 MH(;9P5GN)48?O&A>^[N+D&FQ-ATN[A=3'JVD#I#V]X]_77S'Y7RS9#\CB:G: MZ;>/GRU?,MF1U%E!Q!] MM5A^6RS)D=_)C!)6>FL0R(;VH$+A$&L7D\RQT.I3D=O6W?N>)&C:6&,W8&RG MM X0>)6F=[.\=C*56>8N^ 12^-J[.I-_QU,";G@,F6G#0NLDMT&$3=N(HQM$ MME=B!\C\F+Y@OCC'=^6^EWC#V4W(-_#LK$L*,)K:'E$S"-Z2@9)]0>0Z)FSM M7^]%X-094>-ZW>/IJ@,@WF?IGC"_ULY-_\+\:K%:OPRK3:=_239'C)"2L*!$ M(=7^[-DQM1=LP'FHV'SUB2=Y6*UNML; MY[)%2.V7D+A*1!T#XGDCX41GC^1@K2#>'=9LM],"=ACATVZJW:!X!"WWO^T^ MRO1-]YL-TQE3*3F"Q9K($B2K2]F#MY%YP54PS4?,-B%\6E^K?V@?KN5^>G@] M+MN[4CCC)GAT7D).<=/$E(-C*H*6!GF0FDG1VOT:2MNT'MAT.&VBJRYZ_]]/ M9?CM^]O962HNN"PD.,YH07%OR%<,!8SV*1N1;5+CC-V\2\>T70M/AZZC=3#A M>?UU^3_W_,L=^3&__>/M[V M [*3Y[9=J^=2BR]V:O'=C>KH%]XNR%R^K,O?URQ647^VQ+_>8'S]&.3 MB*,-BI*5@U#-;"5D@%!O3QAGZ.L(D2#E6'!^G*R)DY:F ND4:JOK M%;NMHPO2QF 1?(@)E%4,B,L G.QZ84PPO/UHO@%T=0*V5F 8 +:C--,3VE[^ MN)F6,,-E+>3\\::6<6[6:&1>6B'H89=-> M!75WWK;284_(O+W:'O)WM:Z92M(92:=&,'2(('=U]&H$EK@RS&).>C3G9@B! MG>R,#1$R9'-LHJZ>L/C[_-O%>K61&-\._552L50\I.3H1"DJ0T!GR=53RAJ+ MTO+1ML:'Y'2"L_8@> QN1VJD4W");>Z>B,H[;4%JRTA.)X?M). Z1".=@DM>L2(,>5BU8#TG5T#);,D61@ZT0+Q.09;,6N>K M/4'.M)D/TX+K$(WT *Y':N0BMSD''D'P.A]%D0D1N= @4D!=K$*77&M@'5'T M.CZHIG4/&FBI ["US;J7N4C&)3AA/"@NR-)%'L!+%4N,+DO3^ES]]R^-W0M0 MHY;&[J'=#I"]N^J23(OLF!4@4R9#PU@%'LFH#5D'K63Q,;5.Q?FW+XW=!Q># M2F/W45('2!M6,%225,ES V;34=N2A**V!LAS8I&KF",;H2MUHZJO9U(4>P02 MVRNQ V0.KO25M6UI=AR*)):4)/L[2A\ 690L^&BX;GWMV[1H^YG4R1Z!SU%4 MV0%$GZ[_)<>-H78,K*_,I!Q)8LI M=I+E#()V;Z3Q;%%V\^D1/:H8[N5TCI MX/T\SRT7U>R.IH W7H$*P@%]Q\"(A-9P)UT8.VE[#\R-EK;=#>8:J*D#L#TY M/=1MOL^@CS---75]C;,1#& M9R53L@XT:@9*!PZ^1 :)H8_*,%G]5@N+VTOL]@N'U4T &"DW3:TD**5J1S>R"8HBZR!E$5+S+O'/=3#<7GK?:S#,/<;+S357@]P'-I)0LIL M/#<< J]>&Z]9N+FV-V'HA/61>!N[C=A173]& V=C2!S:Z6,?_72 NYT])I@E M>ZF@@:)3C0Q@!A\T'2HN6N>MEHZUKE4[N,_':,[)N'@Z6NX=8.?3,F3:UF^! M7R-WWAL%OMK%JB@)49IZA:=#G1#(,V]=?/^ B&D=D7%1BDC ML@RJ74 R/:,3/Y S;L!)(4$E)'.VWH*@43XE#"4UGS*\DY!I+PK&A<[QDN]@ MQ[EQ\R\Y.1.>MDNN+&CK"/ZF%FP&DHB+.9AB>$#?V@V]3\.TGN2XH#E*WD>T MU%N/Z^*=B2"R-*B!A>)!>4M.B$!!FZB1SCKGDFH]I?-18J;M236RU=Q$ QV< M6[?\W*=DE5-,9*5)0!OJ@%PF("#+=NS@ M6'QYL2+IK%:O%E_C;+Y1:XU5D^A(.?35:I8W<]]KT[!+_G^<6E=*92;:O""K BRR4O M(9< 17/#G#.6A].>NM.&($Z J88*>3;-16\-?'X1%Q?K5YO4 MJ];PF#?N.1 MW7NT\=='T#+Z8.Q6TNS&1>KC$YM.I_<.+-1;71TV;1=J[M!E\\&4 D M/KPR#F(H0I#[&:)L?9_Q&"V]S&8Z(3 6(VBI4[1=9:K);*P4S &*D$$Q3IZ= M$@F#WUEM6#0$"M'@)5 M="&.@@538E9)N9*:=YS].57]@>H0_?\$5D;4^ MKJS]^>M_@Y_#^6O:\]<_WI57]7_ADK2Q_G&]8M'9E".YEDS4 MQH':67 I,"#^HW2>.>%:-_QI27\O\^2F.WDG0T,'*^$60Y6%NTQ=[1W;"&:U:QS('D#5Q.MYDF+D?JVJLP(F'*GT,\T69O0^K M-5YL^\QH9XS,.8)(=5208B0>6>]617').1EYN7>7LW.$THY'3WS_TEIUBW9R M[&!KVG$@/'IWM+T\)6&I@B0NYZOU+&@E^>0SD!6B.#*FDVQ]%A] 9B]S+J<[ M#H98'/[__?Y(JYPN3DQ-B8V?;R@D^1\=GEE&LY3'0A*7WY8 MG)__MEC^$9;YS*,OFEM>[R'HL' 8P&M$()TPU#9A<:U;7XS.U+0[\NBP?*Q$ MJ0N,=+!H#LD7(&9?L]\&9T.75U,>][5W_P_9NLO#U2T MNJNC#_=2-*\D\!'7Z_-+X9WQ(*W@C 'CM=V"(:_=^VH,Q)*SYB%EWSHV,AXW MG30,[W)Q=8*A(Y+5/HYZG ??_2^(PDNCA)'6QY1:)^8?3NVTMOTS /(A6FV&WY;9_;_/O],S%DLZ*&]]>7B&_M// M.S[+?@]Z&V7*;U_S8T=^L=1&1-JB0,O:J+J$"$'18(.?X M]HI7C_YM-I^MOF#^ZV*15V>,#(T4:5593)8P'@,$)C@X%IRNS5AD\Y*BW91, M&Q5OA8.'716/EGH')^,U%_^Q6/[/[_/WRT6J._@\?PA__(V MTFY,K&0Z\XL@IC*=_A8%VFQ90M.^2^< PJ8UW$9'5C.== "TC=M_S=G'BV_? MSFL-IQ>!-*^NV4W)M*;36%!J(/4.L'/-P%^7 MBU6M^R5B,QF).M;;V^:B_FBLZ@)N]D9VBD])T]52@3TM"HP,:[MO:%7 M.^\K?OZF:5LHM<;("-*=<(^IW-0H\^?Y[%^87ZQN^@\@=UKH!#('#HH;"3XE MVC)E9LGPDC"* >C8]>Q!>+#/"0]'2[ G2X0P?59,)OQZ#_FR\2 C"[Q.OV(I M)UYD9%&V;F-\^_W3N-5M-/G84;*O6+N"Q*V6E+I(PX*'$KT&I96JS4,R^-I' MA/G(T+?.5CST2&GN'8\,D,.$W#!#Z611W+-[+MCQ<=PS/G8D]S[-U['9K6$\2W0U#EE1YWFM[[ M2ZV#$_7]13R?I;^OKQ)!KIG9E%$&EZ3+L4"2-73EZ\T=)[D@,XZ;)+-QK3,, MGJ)G.B/L&!TO1A)XQ^"YW2;!:>^Y*T KJ\Y$YH8,3.[J.#ZOO(H\J]8E53^G M:MI-J!T"!D+K0'5,7+A\RPQ=O_[S&Z8UYO4BXL?%>:XID;/YNSG^)X9M,6Y M+0P3#'A$!RH35U%P"PQ1!6]]+-KLVV?4#I4XSLC2NW%WPFR2&+OEXM\ MD3#/YN^72#+?:*XLEI<_7[\)%_/TY7KF-A/1"O*7(3-5.TF3%^2=,<"E!+;K&KU][:458$J2Q7@$&2.2#QP2N&P59%\* MILQY3JUO=!XA9=IS;SRT/-['^7!-=' L?B3=; IGMM4*5TMZM0FM2(E19HF@ M5:PM-;. 8#,Y"R%JF8*-[K[W=CRLGB*HEP[-1ZC\/HR:R;\',%T=!Y>N+1,^ M8"BUI)QEQ\R!TMYXB#2^R]A^34D MO%C/4CA?7;*Q#4MP)I7GI0Y9#;6?1X#@.(<0I=4.<["!_\1N^LDK)H;#X4I; MM)?@I!U1*B,OYK.OX?S_8CA??[G+1O+6J4+>1K+&D&B,AQ""IS62LA18AQH. MR6A\] 43MQIN H,VTNO@P-B>HS>^IV26G; R)ZZ4;=SLHX3LX= >5VSX0H?>3&&;]YRADXG&9(#DS*=D49)\%QKX%XY*8R- M= :/%2W:0<^TY\Y8N#E:\AWM*E<1T;3$L,)?\?+?L\2=XII.9J^)#V62@"C0 M@4[&V( V1]OZPNE)@J:M%1T+1\?+OHL^D-?;J7"&L6@2,._JS;_EX%F= 1]D MUM)[&)$5,%ETK7=-$+U",O^=\;4-L1"M(_R#B>OCX&IK [?5R'.[UFQ0SK#/ MTT>]MCQ)N<-^%T^2\2*#Y* MHYTJJ B!G'B03'JC?)*B^=#+DUQ3;J:^7,QN^;K-VA2V&7%A3?0U!!H:0$&6L MC0&$P>2TL,VO-O)1'V-!93@DC]9;![#\%;_C^>);;1&=OLP7YXO//S[, M/G]9W^1R"X?1".!)$#LV)G V9V!.H'79ZV!:!QY^0E*WL#L>#HOQ=-,!U#XM M0\8JFBW]R"-YS")#\,+7\O5""]0S$#QXKEW*V;?.C;U/P\1S5DX(IJ.DWP%Z MWLP2SE?;0U2>^6'W'YG9C86 *U&,DF:T'K:IP6MQD_(LD0A =/8.&UT^A @1PIXXI3"#QC/%__Z<;XUNFP17-'F)V6) M1+E/X#7S$(,)+@CE,0Y)'KO[U,GU?:R*%DWD-;&F_PN7,?P9MGENI#!EM(!" MJ M4U ]WWWJ-/;A.(H^0EX3:_JO89G#:G:^_==? ML9 =<[+.(BK,T)XDZNP6D@'(E%4R4EC4;H#*'WG\-%??X^B^A00G!L'+Y2R3 M[+=>KTHE%5M 1:= 62L@JE33S(HLTA:&.0U0_9V'3M/<>!R%'RZMB=5\.V'] MBGK/K1-><6 ND]F:4LWX\ )<1BYRS(D^'J#KAT^>IE/Q. H_4FX3:_W-CSD) M[5_A>ENJR5B8P69G0*E0(%H48&-63/D@DAK2"N;N4Z?I0SR.MH^0U]2:QOEW M0NJVKY&SQ'VP8+!6*N3,(!H?0%N;)>U50?@\1-&W'SI(S^Z9Z/E@:4U?MY7Q MZ[>PC5+GP@O6J=O:"#J!>/4=[][#;S]TD*+]\U#TX=*: M>#V_>O>/WW_E6WL2C0N\(K2@(/=1U^1,5K&:DLS9DE#*D*ZF=QXZ+*C"GH>> M#Q?7U-[VHE8I+Q-^VQ801L6CTEB;@OE8N^<;\+P$VI)$S(Y<2#'(+'OPX&'Z M?B91M./$-K'.W^+7=8C+B_5L/HO;."!:QS(O@,Z04:D3":*V_4&9E?+6<(=# MQI[O>/0PO3^3J-JQHILZXH(E?)O]&:ZKA;WT.F]&96AC07DZEERT%GPF]Y$0 M:^CC(:&6>\\=IO-G$F [2F@3*_Q77(9_A?EMN#I1?$[%0@J1G(JB,H2<-"CG M3!#9H!!#0BP/GSQ,Z<\DLG:DX#K(R'@9SL,\X<K(C:=1Y+@A%,- MB9DJ$I? DW8A.2&U45:GU'JBX6.T3!.''SM-MHGD.T70U;(J4C BF=<.]E&K=!U%+"!*GH4LCG$<:;;J+G+Z@]$A&M\]7_5H\7> I+]AJ$4SM?KN M]_FWBW7MH;U9:,9QI7((=# C+31'\O'%J=H&R6=-7[GF!]ICM$QSN3CV@=9$ M\ITBZ&J-N1A]X%:1O\XD*&D".&<3,..-=AF-3*T'$CU.S;0[41MM#X#0 :+O M$$2UG*^VP_X0UMLT7*&1<\$-\!(=*.4$.!,M!&+3%8%.VS(RF!Y2U1^H#M'_ M3V!UI#(Z@-<_POG%1BN;JI+9/R\NUQXW3-D@/=D SM4<3U=[)7:V,T;(@)1.9+ U44#1BH(:LP!&7"3O3%:N=2G/ M8[1,NPVUT/-/H7. T/L$S]5FBOE56'WY[7SQQ[;,)+*8!<^ +M=(F'$0./WE M>8S"1QF9:#V?;#AUO0'L$#3\'&(M5-,!Z'X+LV7E#E_^N'64_[9$XG&>+J>[ M":X8\Y+1DJP'.+I"]@&QA#F3X:G1H&I=3#: K&F2S$:O\&^LCYX@MHNA;1O> M+$@ZM"[1U$DVP6J()7%:G,EFIT)*JG4WE@%D35Q*W1H*CT&MD5XZA=KJ ]8I M.+/YYZL=6O%LK4(+,G)-_D@JX%U-ZD.M% D396QMR0^AJQ.PM0+# + =I9D. MT/;[/&/9H\T&K4@5L@@@? WWZI@@2OI6.AM-$8J%.*BX=@_@[4GB-*F\8Y^I M8^JI?QCNK'A7CF?GZ[PX6U-F1+JZ&B-!)HE&6*=;-V\Z@,RI!_B-")O]('JT M#KN Z?OE(N&*=OT5$B5?7LSS50>76],38E3"6V>!EG6IF9L9(B/[AA6E,?A, M:[WUX3R(L*ZA>#P\'L"QM:XF'YY\5V*O_TSG%YDLCX>=2YG32A8A 46,E]'P M4&0&'XHHLC8U*3FWCM -)&VZ'-93[6LCJ*AOY-U:8M=# M'.LOI<57?+=\M?A*-'_!^8I^X?*'KVL+\57]_Z_G%U]QN5'_F?1:D>M5@"-N MHJ,9G.<[1/ HH=ULIWG_A]+XO[7Q1_$ 0LV MU+Z"$FN@U.5-NW(&(24C&9$97.OL[X=43)>(9,7 &&6A3D*KTUM);"K6(4@LR-!Z^.DTG$YWU3/]F$MU9$#B$:06V:/@RH762?I[$3A=*'5Z4!^IKKX"]/?3 MRL\TDR&&XB$;04+C@N054P+&N.!":X9V2)W\3UXS3>>;$^"GM8B[,!%>7JQ( M**L5[35E_KE[_,77VO^YKOR MR']Y,PMQ=CY;_^!GQ7H6C)>0R5@"58J\;#> 5@>4]9Y-M@XCG(BUB5H G7## M[!$C'1S[Q-AR/?O7AHN')\F9#]Z3)UO;E^IJQ,0Z&DA+2-'Q*)*F#UL/1GV: MHHEZ%YT0J TUT@&^GK@CN$9;_'/]:<_\/P[_HT6VI?562XQ,LT3 M%%/[=UFKP->+E!R1DWQM+4P[W:76 (HGZK'4QZU7:XT^._S^)X;EIS\69PX9 MR5-X8+;:V]Y$B*48*++F8ELA);8.'AQ$Z$3=H;I%ZR'Z>YX@)=3AF;2QSC05 M('0M(\_"@J\9W1:C3\A92J9U'O*!I$[4T:IOH.ZMPV<)U=\6%\LS[EQ*3H8Z MVMN 0N4@!!U!!J=%\5)%V;JQR&&4#@/J<[X,.X$&GR=.Z7?/. JRP&OJJTNU M,H;X=9EIR,J6R)F+,K:NQSV,TF$X?%_-A]M/JG_ MZP.6_U7__?N'W^\\_RLNT__\DA9?+Y^]E6*8Y_O)O/>__Q7787:^NLO.:O;U MV_G/IKX?\)*_W'!SG\^K=SU 6&/.L-[39,S_^[BM8;^!\HA&9Y899,$XG<]U M&IST#C A,FNXX=CZ\GPO H_=*&]2QY]8<)=9Y"4Q+UA&R+E>/=M"KE_F'IQP M(LEBTX-!84>+8CAUT]9UC(>I^]OB2/KJ^\A^4**ET MMR?P(JAXLG#;X0 8T M&%9L2%9KYD_HH!]4?3D:%L="R/#S^2AU]8W$G15:Z- PYPS(6"_<3#80LA'T MERB!B:QB:!UEWY/$;F?)'P>5X9 \6F\=P/*J< _SIGG-XGSQ^<>'V>;#J#V:1DR5M%L MZ=?6QQ2S!REJOJQ,%ESP&1*SGOF,H8369O!]&J:I1YH"3$=)OP/T/-4J.1>+ M,?G:<80L7B5E9249<,44)81/YOY L\D[53>_/YD"4ZUTT@&\WLQ2#?E<$<\5 M.E8D!U2L)FS05\ZB!::3B-DZE+YU"<4= J:IXYD"0H?+O0/0[-L$A-FLN1$, M8N8)%*LI]D(BA$"<)FM9$"=NK'*0ESG:>7@B+W-,M?6/RIU+6#IO@R]UCXX, M5$X<(H\*N,PJA"KJTKHG]K]]RY^]8-.@Y<\^.NP"ID/:R&AK-9?65>/!@L(B M(+I8F\"1SRZ1+%7>OBW:OV7+G[W@<5#+GWUTU0$ GSAC;FX;$;/(S'*PP4FR M;8($I[V%Y$..6C$Z;9JWMQU U[0^QO31X,,4U 'H[C/RU^5BM:,XQW$4OG!1 MK[;).??90E#T5?%1)*NL:=_#>QAEW4;?#D3$3[H$-5!/!Z![*NTAI8NO%^=A MC?EV!L09$X$V[-JH1@E:MQ(#> P,=,)HL\5LV_=;.8?_Z$RZ^_8B36\QL,*R0#>EG+N;[CX7E1^[_C^+2H M(_EJE!55W[@C5<7;Z'F0G "C(JAH$YF## DUUHI@DV>E=:+%;DJ.OSR-Z]_G M]*R+Z@5=&KR*-MW(N -36$U/)*N7G"L/"5T6WJL816N'80<9TYII#?3^\"[T M.%%W<-B1"_T-E^L?[\_#?$T.].M_7LPV[O/+']=#_ IGQD4R)[TU==H:><\Q MT0;.HRB"-O-,>VIC] P@:WHT':7ZQ;AZZ!E:MP;Y&>."2U* K,W'E>$:8L@D M-VIW:6@4P =JN ''0H.EG8'6/D'?IFE<[R9:$UN@N062C(, M% H'07D-PD3IT":>,%8V/E"&EW@)6/7Q;+]=9-N=Y\G=4IUX99 M1'K=?*V$$$T&J6)P++@B8NL&UCL)F18YK2V@XV7=(V"V2XCKXGE"H*U25]QS M(,!'X"*A8H4[I5J;T(^0,G'*_O%*_AEL#I!X!\!YM?A:HR6S:A75B*%$+)L/O1H)R&=@>80%2]:RWOB]G-O%VMTMG".E')W.+F5QV-3224D!YSG3'CG'GRT&@(O7J;" M4@ZM3>+':.DI+KB_CI^$S($"G_BDVB3D_R,L9W4!?0AKK$QM8P=)ZB1"G6AD MZX$K&#A7QW=Y8VP4*H=0!IQ+3[RB)S@V%.C(D71A+A))(+4LBO%T@: M-=L",HTQNY@!M4-:+ADA&FD!N<=BG9'\_GBHG9!X_ T]N*<^&%+< #8O6^%#BA,^181$X*,=T/HSX"@EU/GV8[%7ZJ M]W[)_)&R[@ NMTD/QJ!)]8"T=7@!J]T#:$^$R!E''VPAMWJ$G64?>)PH0M$& M'H?*M@-8W+E(^@^LO8XPO_B.RU#GK=![<+6N@;BS6+)1J=1+GFI>,\8A"N6) M+]J*-7K#L74NXU#:>HITM '4*%KI &VW]]'WN$Q53Y_Q)8;E;/YY&_>]PV#Q M+FGF"I!1+T!E7< [HR$39RHE:W5)(YYH@XCLR3QJ?]ZUUU,'0+PKM-N<;&9- MYANFSXPG6]*Q! Z=(3D:.N(D[MM\5Q]=?!%KD7L]N)/ON&RL?*T,-SQ)(%X9?8;)VN/1 M,GQ$Z;.X-AA#N)UCI=I>F(H40I)S&F0$Y8*&H+D&65S-0%$F^A98&6SN/HLX M_QC"[<'=(J&\*Z_HQ;/U;R'-SF?K'W\+?\Z^7GQ]N5@N%W_,YI]?A6_TR?K' M&9+%'KU@D*RC(]8K R%*!C;3(F F<8NMJP_WH6^BH;2C.E=CJ:<#Z+W[AK6O MX/SSILW@O6R!#U@S++7X5-SP1G+/J4P=>&)RKQVA*C*#!. MIJ12+-ZT[F6]FY)A>:_/*F;=0.0= &Y]:>5/'(W8<[)N_WB[6/W"]:?@T3YO1!!?S]9EV-A>7)>B"CBS&VHG0 M>03I@V(D;L;=D"JR_=XZ#%W/)U8^GL@[V/3N2HM\8KSB(QL?N-?U9JC&_TNA M19%DAHRJ),U*B+EU"M=CM P#U+.(IS<5>S/XG'2NP^T?CCC:8==K3C#=X:?< MC3O@(23/E9 %F#*:,.D0'"\%G&2LV)Q"%JWMD-,->/#(]M'[D $/^XBZNU-LTY L"JZ+T188'<>@?'35:Y5@ MBH\^!NFPM&Z/?F!KOY..;]A+L3]O[;>/E+O#R:W6 ]JXHK*+M&J07-4H9*U; M$I"+KK%^)U48M\B^X]9^>^EX:&N_?00^>8>.7VXW&1'ZJK^$34+G8A+9?[7N M2+L SD@-1DC#70C6W6_,\$B+CIV/[PD&A^IMT5:(D^-@9\,A9=%)7<@#L)R# M,LI!C#6;H103%;=(C V"P<$]FT[?QN]P%!PMPLE!L+/AD"@B"&'K/) H:NN: M!$Z15XC!Q[$*KM9I;1BY@4$H3K M9A9, !]\@F),PJ2YT,/:M^U^?$_UY2U@T$"(T^- W6Y$Z+?CV$LJT0D%GIPO M4,K1?L;IJXRQCI/)'N\WBGX,![L>WU.Q=QL<'"W$J7&PNRFI\&38B.# ,97) M*8\*HN$%DD[&!I%JF](A,#B\K^OI&_D=C(+C13@U"'9WH*G2;H.!H$4X- JYN>[ML&_)P/(L2#*18#1OT M)!I'#"5EO>*<_-W[%=^/F 6[GMY516P3N^!H&4Z- G&; [WE@$XM+:/UP%G* M=8X%63;"(0AKA%,N,G4_@?$1NV#7T[NJ:VUB&!PMPZE1P']Q5K^^6"YN6;G; M$196JV(M)[-&UTJ#$.A,2R& X9H\G2(9+\-VA,??T54!:Y-]H9$\I\8%NQ,6 MWW*@W/GTKNI36V#A>!E.C8+= RUX M9L$95&3<2"0<:PW.IP0B^H3*AYC2H$D A\\$.57A:9,=X6@93HT"^C38)$"0R1["-M9 F##H6=3^^JVK.)R7BT#"='P1T@"[4- MC,>H/"L2K*YYIYGLG"AY 65#8"FZC''8A?/.QW=5!H*4X,A(^S/]\O M9O-U+8C_+UPN;GK?;OEZ-__TQ^+3E\7%*LSSBWG^]&6V7/_8=.;83LDS+E@2 M%6@;*KNZ#DBS@@2I9)3&DBR&N)L-2.FJW+(!P$ZMG:EW)?:+9DA^5\;YXNML M7ILQSRNC^<[R*C*AL3J3+UX[TFO,X 36^US)@PA2"3-HDQKTMJ[J,)LX-,UE M/#5J^"_2ZD=9DEN?3=BL+$\94HKDN4>IP7ORX0-'VI"95U(/"I />UU7I9AM M@B+-I3PU<,0O]Z(\<@M_3V*JD]P@R5)O C)MFH(L.R,PJR*L+GG8S>IC;^BJ M3+*-*=1"EA,C8G-N;DY<.GF'';B_+>IY^\=BRVP163.9(8:Z6V9R!%PMUO,I ML^R#X\FI < YFI"N"B4;X.NTFNG(**]_AII]'_$[SK>Q*19]";7G>M*EUHHR MB)Q[R"%+YK60J(<820U(Z:K$LK%1?@KM3 SN;A5?IWXOAV9_;+!LE15)> M 2LU$SNP*X$B.NA#S;[+$+)V((4TF)G5;% 89??3AR'A M&87TCY?AQ"AXM_Z"RSO3::[2K$S(EN4,2LD:3!8%'+V[]I;@(3"+F(:80H\\ M?ECMZ_,)T;>08G>---Y<]\0J,6CI-(*4D8B7OO8*#1&TR[YXK[*]ORX'A\'G+^VBFNWG+;Q?S=+&L4C[SN@15-#F%5B;R$44 AZ;VJ,V.VX)D MD[7N"+R;DIZVJC9H:B#QY]G<\&4X#_.$'[\@DE#+8OEU\\(1^QS^Y(TG:'FX M#\_C=C_D0EMRLC7(E&,=;N<@:H]@M#,J%>NE;#U+=9SNA_[\[\IOLSDMY%DX?[]8S:KZ7M?5NIK5A3];K<^"8I'<5 34=1))+<&/)G.P M4$J$CJ;0#_^&1#NZOKNP+A8@J<@.A%%5;QIAZ2"T,"!$R?6"B MQGA2X#7>&D?-M3@I1$=2:K]@ON5^68Z"YR1 HJ_9=4F"9RI"J$TX+9I@<-R9 M23N(FKZ9V6G@=Z :G@.N]EA2B3-A1!;5:O8UII#!2W20,"I5//WP_F#W\1'8 M>*L<-='BU%@=2;7]HOH,:U6@2!FRKIF?2@H(3#(H11JG&7U_*A-R^MYNIT'; M7B(_'#F+=3@? 3D#!GA*6Z\'E0$;0@9E3 1GZXPIS95FF',NK<=6C#)G==2T MBU&QUEA)'09U[G%8I5G'"=7[FZN;FS/-2TR:F&/1)!)G#A!]8F#1%B9IZ65] MTG&_.VBYPW)W\+Z8DG;_L?T!?/%.8YX-?+8JTYP)S*(RY%' M01F7M&$!7!35*A,%@E0()2O.4U#"JC$NT-M?ANPU'K;#1G^]P+WR"F4? M! V90-U<:1WX$4/Y_$\,RT]_+,Y*;6^?L8#B6$==A$0RM767#\DCESSPUO[% MGB1V>5=R"B@>HJ+GAL!:H7M&,@NZ%'^5:UAX 4]V#9D;& HC+HW@4V*P$MGE MS3ER M*A3NK:3G!L+9=SRK7ERH.6C%>_+[LW+D]V?ZB[RZ1#Z8R,T'M^]+8Y=7)"<# MX;Y*>D8@?%'HG==,)BM,YHQ#R %!6>/!:^E 2B]Y,4Q%,Y6WCG@1S]F'0:-YEZOPO? M4]]^'(.K%B)O>-?6PS7'V3V/?=2+CC,^X57'?4ZO+SO^S[_/EHMY/2'IT+J"%GUT^'72OF\X7K1'\=3H\NC5XNO7V7IC:+R8YSL4 M[=@-!//,%:%I^:.L=Z&^FK\.D/%1\A2AE "\\YYA+M_3Y]#2H%=U$R[371>%AY6#]XM!XF-#E6R_79 M^^4B7Z3UN^5'7'Z?)7SQYVQU)GD,L60/+)-<5"@!8@P,6#(H192.QT'IC_2" M6QBB[V[P\]B[IT5."WTN&@JW#W#4573%P>JJK83/DCL1"SC'."CM%$3E-! ' M@8M0/-E([1#RD(!I8-)&IP\!PS&$U.]_^NQUD0RM&%XR25HU. MH PR\*(8,(P\+EYX$C']Q-9YXO&3(^!8I2W:2G!B$+Q MYS4COM&"%76(HMF,6<0\Q#>K,]_99> MP'"H!A>CB+.#D/?[L*Z^^G;^H?8E1EOS-^HENC8UZNHX(.>ET*E:LFQ=HWR' M@.GLC*8P.5ZX'2#CP2'[\L?;&L;%=^7FQS\VNVMTY(0I98'L+E8[*=?=E4OP M*9FH2X[J_@S:]K&O1ZF;-DNPH:DRLF*Z@]P55U?K,.4D(ZH F=@ )3P9_L@0 M@O6HBE$6S;@8NT-.9Z&R1@AX$FB'JV-B^Z>&I'%9RY+#/%_V5KU_:'.5HK1) M0])*0TW+ 5\W^0J)R+R-P?_L:FC8FWK"S1$*78PFW8FQ&. MR]J"N417Q_QDLO$X6EV\,CAD"-/NI_?D2[?!1 ,I=G :_2.<7URJX?Q\\4=M M7UBC4!](/T'N .5,?+Z]P<_A_%=Z[WR%KQ:K:]_4%%VLD!Z\J=5#C-9F+,:!S"8HI9S0 M]_&U\X![Y/$]P^00'2[:"G3B /)U Y^_XN+S,GS[,DOA?+-R<@HE2,WK.$,2 MB@H9HG 93,#L??1.LT'AH)]$D!\E8-JJEL:W#&W$/#56\/-]%JX64,ZT1% E M(&[J=5SP0*XG?8O,*,F"M3&WP,IC!$P786ZDV$5K*4\(E4TN^/+'V=\_DM%/ MQRQ/1*+7$I3AH4[JI2U16&ZEEJ'(IZXH5YA^^;SX_I>K)UY"X^J;_X^]+VMR M*DG2_45^;^S+(T7!#&;5% ;4C,U36BP>H-N)5"TIZ6)^_?50*A=RU9'BZ(2R MNZTL&Q)(^?*YAWN$+S?(N/F\"6'01FF+@R3803S[?C'_X^H4#,:[H)4![96K M2^03)7M,@<@JH4*,T>WD% :$K;<^?KK7A+98.%2R'3B"U[^?R60<"AM &$_@ M53;5:0D4AJ-3$>OXK(:.X/7OTUS[C^<(!DJP T=P9(M)1_::OK M8'R6R86I2+C5"8S1M=_#\QW#A"'7^ _0,6V#ZAB/0H<*NT/ ;*U&QDR9F B0 M"B>KX5R#8[7>4VCZ'[/D!ILW/3](R<27]P=K^!G(["'N#D#S >>YMH_=O6PN MFO$@*>P.4=9-:MF ZB*"9$Q+-GHSSV^#MA2.UM)^C *&_03? M'81^; WC]7F8?5N]O[A\]!*$_" Y:#0U4!<)@F IZJGIZA M]]?_T^4*ARJC/WB]QW]>7KNK[)X1DJ*5APBAAR MM3C-%*@KCL''Q#T%H"4V7Z3P+%&=54V,@JT#53'U&_;/S'Q>UH4CN)PMJLZO(41S.H@T3= 59> MI;2\".=O%\N?Q_7<%==9IMP@AY1 Z4BRX3&!4R( QBCK5-V49&N'M"MMTTZP M&PE9HRAFXG#H"4Y^[+:;[ -\]OS\.7,F."]SA)T,+5V MOPXSC8Y$SB5W21K,?)>(:E0BIQV*-T)0UH]*)\9V'21'QOHA_"#N?R_EL>EG M9\BB]X%$:^N07:6Y@Y!F-"EO9TAMUX6+L X9\A&> :7G(6\\>^4&'SZ/M*U*2*;8"@7:&V2/U%PJ"NJG9+U%7Z1 M_O[I*UG7ZM7%^NMB.?M?S&?.)B7J:'@6T8*R44"4P0-9B9/:)VM<:W_S!#G3 M/@\>H/>[?J25R#LXR#Y[#W"0G?(C$@RA2U6U @>(YY2C&<]%DPS+'UIL[ MGZ9HVA? AAAJ*/B.SYP-7U\7YZ26U>5W#CU\'O^)K4ZA'6D>YSCB$3'Y9" F MS4$%1UF4KJU>WF6*>$36IG5]6=OCZ&H6]^]E ^Q?ZB7M:EO=(P3%]=QD0&]D M75S"P'D*]W5.7 87I/$[C0X;P-P3Y'1U' W1^UU7TDKD'1Q'U]<0E^*A@_;/ MQ7PS];F6I?)BBD2L90^9SE:T"8*)$83PF&),,N?6L=J3!$V+H&9JOPNG9CKH M %!W>-B6J7)?$E/, N:,KJ,&H+2 9B+.F0=C8EA=;'\L6'ADILM(Y8GG07*:C+UJJJF@B8H2(KYZ"5));>NH7R4F![R MII:P:2/U#N"S.;2W1_C-+6=A.7DO G@>;.UYX."4R^"R%=K(H!)O/9;N04*F MAMOB^^;@WLVO^4^PSS_9!4?%^?U2?J?89G/7'U"<5I#JHV> MRD0%/IH$SB&&8KGFZK>7$DF??@B.Y>:KY;K2XPGP6. M,C*C( 0K0!7FZ#CV%A)'KQ1%B&*W8?"'W"%?DC(-FL;7_7.WRWLH8F\\_;DI MTJ3,8+EN'QUM;SD310-$SUFN\5P)Q(9/=0(%R<>+.LK19$[3B7)T+(ZMP.$8]9<8G>.7L,;\>?3# M-27A@V-(W% (HF3V9''"@T3*=+5&9T5K.!YRN#9O4.GFF-M#KGURHO#*&[X[O>@YEZ1SN9?-H:^ M^N7'S=_9TO&J6O9E9I_)H&62 CBW=;P=(\OF*8#VN5B4H1C5^I:U&?'3)KQ' MQ.P3;Y!'5/_$8RL_5I8N1S*BSXSH Z;K,."Z+3(X90"YMQ1"%\ZPQ4C3ZP_L MYN7QF,I>'"KY'N"RO:4FXRJH70*L>^U5B0&<,+$6C*%P24N1=ZKSV 4P4^_* MVE-9=]6]A^0F5OC?9O/9MXMO-ZL_A9'%@ UUSI[."D)AEE"?BG5UC9QKL57Q MIP^=6.G[J&S10GY3*S[\=8MPK@QFPR*8S2IA0TF+T]X"CURQR%!FW"F@>4[Q MMS]TNB&E312_M_QZN)9Z[DQ\[$B\>:/0+#C+; 1A;9WHB06<50$(YMQ9KF11 M.VUK'Q("'TQU-V^%$\0D$^G^E-%^-8EF>P?]G3+Y*OZWB^5_T+]=GXD0O>15 M!"4BJ.@-92,)-Y.U).=T!L36[TYC\3)QM'YD3+8RB98 Z<50XO-RB'?EL/GR M7[BJW7 ?9U^^KE'1@(I-"HQ?[V$<'FR\?\1\7L]5LC9]P^7V6\/(EB9\)2R$FJZ.+4Q%U MUUQ=$NA)2T$8;303H?F^DK>$ ('1@!'776JIO&0\+XC." M3)LR4U8@RNC!(J4FC&(OYIKW.NY?2S3:(, N?>4@Y70 L3??_CQ?_,"K .9A MICZ'OW[!.9;9^BUIX2'#RDR;H&I1B]5E6SJ5*M>1&&:2L<*;]Q8WH7S:<803 M0W@"Y7< ^?TO<7__L_[-U>:.:/5N?AGH_#?6[!CSJ^^XI-SXS5]UM_P*/RQ) MHF=!25T21M!U\T15!KA RHJVL.QLL,B:UX0>C[UI)RYVZ?^GAU$'%K:37WF_ MF'^GA $O6M[&HV9:8= GL+1,SI$7K*M7+J5MXOE]EOU[_$S)HM#6??) M9%>W?',#7FD&2B3-D3-33.OYOCI)XH!7^U6EU\NSRI M_Z _7R]^1:+D&ZGISE']-LR6FY44BW+[9,<\2CU\.[)&+:0?27I]5.!'1K:H MK0 4QA#LE890I(:HZ=P)SA-T6T:XYO>=YZ M09.J*YU]GV7RFQ]),F=&).43*DB)U;U)&<$Q3>&%"2%RX5DLW10 [LK4M"4> MIVA-H\#EI=G/Q]GJ[V^7B.\H'B%,K3<"*2@%Q[I]0*A<%VV0NKAU@)EB\QA\ M4:)Y#]G83$U; O)2[.=@N+PT^[ER*/^U($76=0P_-B*)4GF9(J>#&"G!-=R" M1\>5SI//88?-9F^.S-6WAR$NQH0:0Z<6*]JFZ?$HD=>$)/Y-HM+7&0K8A M@ KHP)5(GB5XSUTT+LI1PK=1N)FV9F5JFYD>(*=V)_?IXMNWL/RQ*._F9;'\ M=J.MV7=<+S:C-R[3Q/JW7R7Z]D%CX<>B9-2;MW8RZN.R+64ABXP%N$B4@)A" M%F95A*CJ-] HFUO'VZ=]V?;[Q7JU#O-<"_=OC;;Q&'5P3@(W%(,J+'286O)> MD4N2:9"\-%^+/@XG)WUU-@3-K:_.&@"CE]BJC12V>WT#5T9EQ^KQK4!%&]U^%DI@4B<) E5]FQ89 MG',>"D\4]FKF=!RE)[ 9!R?:#-BOG1P D!X.DR?'1-[$RJNK>KQ\5I?I2"XM M,%&S*FD4^) ,V&PYFLQT4LWCJ,%4GFA/WX@P'U?1AXX#[<+7DYP+SM87=73E ME3UC2C9[I2 5ET 55T>XV0!)A\B#(%-7Q^DU.8B-$VWJZ]?K'PJ5%V$O]T-$ M@TRACH)4XBA$1%D7&Z4(/*/V1ECF0S=O@P=E$OWU$?9K*X?!I.E$X.ELY;\N M"T[G^?JR>E&_=5\VQ7 F)2+($.OB4Q/ A50@BN $\RYPT;I ^5B\G725RI07 M5Z. IX?LXT"Y;&/5.KIH*X"8C!.!SF#I(IW!L10Z@\G'2)162!E"T-T\K3_& MQ$D7HTQI)H?!X078PRV'\%0[70T,RO7 ?XI6,1?(O@10R6WO*U :K6KS$-.Z M,X,9SN5)EZ9T\F(R!J#^=4SN+#/#K1(.LC".0EY>(" 34!=C1.9)C;M-*.[/ MSE[,R\LH")_&( ?![73>:AIVE%OK+0^:$BVUA1JJ\"5X$F9O!0F&,_^ MZ/E;4PY?S,/425CF>. [A=#U.>D\\(CQI'QJF;G$F"%S54")6HX>@@&=$95- M3&/HSC@'\OAB'LI.PCS'!. I&&BC8!\Q^TQ:JSV)'!2I#8*F7P67K5-2>A$Z MKM\[V!Q/X2VN"W.< &[_,J]W3TI,6*VES!S$II+&%@71"TK)A1/(E6VX%&=2!FD# M*BA94LR2>0'O=(!8=XE[%BRWHY1('I?-:0<$H&I(.4HM0#'97/:\KED>9F7B4\]0F-#D^7H"A M/'^PO_KR9;GI*;HC*"%%3+:.F%*!$E]$#YX9"Z8(GVW,QIJC%\B,Q>QNAO;O MD1I3X:L70VQSJ/\L"'XFN(V!U9&\3&I015L(QM(I[G1A2I;HXBB#:4;A9C=3 M>K%-/M,CY-1&FKW*>;-,(9S?FM?U 9?KRTCWWL2NU3A;!?:E8MPE DUDT\<8 M,R.L\*DXX#(70JX*X&**8(O.*)4SSOU[9\"3M6N;/25W3M&<3;***]!I\SQ1 M*.63J, @':XHO(^\MRAM%[Y.>L39$*2/]*S5#C0O(/2ZC%&O!'(]0+0N: Y6 M%T&':11TK(IL(/K(P"7A4A%,(O)QT:_7!!C,U.#HPD@_+14+,J[JC M].%Q/CQSG6TPQ LZ4#XK8LT:,"EZI+BV6-MZI\RS1)UTJ_,AL&VKKH:=(L<> M9'R]B^WCIS_"/'_X],=QQA8__[G'&5(\D/\^8GEAO;&14UY< B'?&P4Q<02M MA2B8!+9_P)HXED]?,5^T!U>WI7.MF$HQ M"L^:QQRMB#_IJ'P(9N\%&9.HOX.HXI)R^LNO_IJMSJQQ,@N)8"S/H))(=968 M!RM$8,;JH$3K/H.?")BXTWP:$"Q:::0#..TON!NVZ8RD _1]^(:_+NIK^)DQ M1IO(-5@=R;"U*I3-BOJ:X!)W"5W41]_GM@;=FPVF3=GS+:W_SC8K;^\6Y.)\[%1BN_K[_B\O/7,-_>!]Y< M#]T:YLMUSH$Y"\477;LC'#B.#%+DSA;FLLRL%\O8B\/.(Y+&^&UE/N.#Z5_# MU+:S0Y,*7L1B0;),+M#6DNJD$(2/TCFEI0W=3/X?RMR)&M@1$'Y\8]P#;JT)=H4BXB1@JYNQF?.9"WSA.@?P5;/ !L M+_I(_+DXXHS%XG06FG+04O-:%)2#9@GDJU3Q(FAG3R?N_)FW$QW+]Y*,\ "P MG?8VG63]U(5H64W-Y6C9(K]3>![2;9X M"-PFGK_W;?GW8PCFY^;#K9B8#[JD8H '*T$)YLAAQ0).A&"LXQ12W-EL,$DL$3)ML(B(2:* M]6,VKC#%8M+=]!(VY/O%OX6,9S@=.H%!*/Z7>T=Y7GR>1VLM1M"L)%!6D_]/ M3H,,EGE>I'3>G(P3&,C\B<;<_U*>8$P\O^A X.?K]><%QP/7:! A)V](_5Z# MBZ+>A23*C:))1IW.I=9 YD\TE/^7<@1CXOE%.X);2W>>EUJ)%KDQ)*O"*9J2 MH8!#2A&#D3*:8DVPIY/6#^'\Q;]!O0 7,!J27[3]#\BE=.9!!V'!!\%!Q?KZ M%XT!6X0LQHC2T7+P8]\(G/*;UPNP_9%0_*_X7K9#$E6GXQJ=@*?:.Z]"@.#) ME2:=A+(QII+O5%_V\93V4D_Y$WQE:PNR+H=#']Y'TC.Z]EWW'_$S?Z?=?A8FT9\-AIE\Q-^Y_GC-24W\T*N9X H M%S2S01+$:F.FDZS6,#DP5K H/&>&M5Z.,H"\=D-J?B45S#'?UL7-QZTN._R" M$>0> @=?F *56890D@?D'%4HGH[WYHMBAA X[;/,6*AZ?+),:YUUD,/<2*VR M\^E/.AT6R]_J/ZM2K8,FLG1$OS1@A#!TABE./C]1>J9EHH2-?B]"\U$(SQ#5 MRY29YH"X-^>@I79ZA]NV-=^B35G% -HJBI="3A "A4]&H,%<,*-I/7YK![*F MA5QC( R!V1Y:Z0!H1#5%M+-4&=J.9ZB%EQ*-A>SHBXJ9@=.&$4/T?5:D8+IU M:\Q]*CJ&T3Z*7C25^H2X28N+^7KYX^R/3V>B&*URG1P3&,4*Q1F(: LXRN-" MX8F7)VML5IC^SY?%]_^[_8F7,-G^Y@8A-Y\W\<2^ S6V.$A\'3B*MXLEI;WS M6_RG$)R64A(#G@Q . T^JT#G=Z#N YQX1TY8YC.TF#I-Y!Z#Y64#7 M,]E0:Y[1!ZCC@^JT80G.FP@N!Y^9]3Z$UOL3'J:DEQ$WQXV/]])#EVC:VA@1 MSK3%#$E0KJI($. D]^"#*\H[A\RW;B%\C):>XI;]]/PL=/80>@?@V=[T;5?+ MW#:W*]>:,01K'>FZD'\UQ$J,O)98,1=$LBQCZW3J.9IZ ],^FK\W$ZZA&CJ MU3/7Q@^RR+@LR(,!;H.JD9^N,QD"&.W1:6&-Q-;'WQYD]A1:-0+?V,KJ (_7 M;U"__+C^Y7_.<$E$??WQ&W['\\V)X'6.);JZ>TW7=V1=R, L@G#.)(U6>MO: MV>U&V<3EBD>+R$;04T_H^QN&*JC-J^I]_K:FG+BKS&5 J7A];"CDZD4$9JRP M2HHD;>NP;1"!TQZ_8R#D,1 V5U=/6'PW__-BO=I(3&Z=>J!8@M4--,I&7G/I M!-Y6I@P7,1FN56J]/^@)>5:CK@.L(+B95W<$:P42/05!PP6WKRL,!Y$U<-G2T W0-Y'58?;VJ,GZ M9R+]#7G MX:(N2&61?D6Q!Z\#":7PAK$[>[\>;$H8^+'3AOYM$32VU"<$U&JY/OM8>QDN M]YGEH**H%SPYUU8)2QY54H2J?)!(_Y4<=YH>3C_UE@>BW]UXGY\^<.(&LM'S MP_VEVP,DMDA&G20C\B!+G^N6)C(6K0L4:TH2-B46FH%BRK#Z &7=5?<>DIM8 MX7^;S6??+KY=+=&*/J3("C I#07VD9)4:01H;D7)/.F4=WI$?$;E/WWHQ$K? M1V6+%O*;6O'AKUN$\RRU=5H"QYK6,9)!]#%""3)*S[C><;392\>8^_E/">5C.%ANW9YS1F0D#J;@ RA8!D6E%P3##G(7C2;0 MP(,?OA,0S&E' X=+?6K8;.G^8[[Z$].LS#!O(VM4FH5"I,LDZ^!S2J&\P;JG M!VV(3JJ0=WIQ?0XZCQ$PW0'20*F+UA+N!":URCB%U77!2\P:O>40N$AU<#A" MU$*!$#9&HQ3/K(E[>?#3)P1(&Y4^ )(#Y-O!E=A]3WOC:'^[[MV/25K*G0T8 M%BF:RO6:VC>UW M?X_GLR\;A9X)+!Z9E?7%CH%2GIQYM 4,&3!:*1&3&QV#3U'8VPOHP1!Y%H3- M]-4E&J_K67XOUY>9JS/M$D:=%)14!PV)XB#:G*N3E]I3EB+$^#!\D+1IGZ.F MP-_A&IKX(:'.;@CS']NJ^5M7V/_]=9:^OEKBU>7Y_V)^=5E1]9E A9>&'#[XPM*)GVL>K\: XF+C>5^Q')._WSURV+]];+FX48>K^;YU]EW(I(2Q\OO;,6X>O5M M,?]R^S>'$Y MK __6K\EA8;S_\&P/ NU4:S>ZS,Z*HGEK"!D6: X'VP6D=3;NL2_ =G3WJ]/ M<<:,J]DNP4P6>_'M>S;^\)[^P&;XZ2]N__WJQ6E^)Z#>R M]L^X_';I27Z_2F<0LV%%(OC-W$P? S@=%3"32N%>%!/'KX)LR].TUW:3W)1, MAXF];83.I+AH:R6W[7Y3P$6L?L2T^#*OV=(9LI)Y-A)0U"LC= X"A9@07> Q M)A4$;]TQN!-A.^'5G3Q>&VKGM*?>UA1_,:\Y_:(\;)]'&(>[.Q%'G).[IV0F M&* ;>6")1P_2U\%,.@H(-M"O>-*VD/MDS8<0=3M 5X28O;<&DL#Z)BED?9UT MD%A)V6EN(SCH(@Y^?S!FM4CP&!,RI4,PB WAT$KC0 M+"(SHH36%X$O:H#N($ ,'J [1#N]P^VJE]T)+;SU$,IF)V P:.$B,ZLI#JXSUY0M%J*O$ZTD,I^22I:U MCBQ.<8#N($4_/T!WB-3[&* ;E$+NBP&;<@0EN888G($<#$L.A7#NJ2%,)S] M=Y#&[@_0'2*^#AS%_6&N+EG),%G(!34QP"0X5'1JU]==K; 4WWP*S>D-T#W$ M31PF\PY \\A 3Q>+]L%1;">8H3/8&(A<)D#OZ'16-FLU;JA\B@-TV\7'>^FA M2S1M;2Q'H;CG$;(A9A3*0EDKDFD8S)DI):2UH^.IO_!W/SWO.D!WB- [ ,^S MDUL95YQ8"9!3;:?F.D-,AH$K.L]=Z($QV@.TCS0P?H#E%#![#:9R8K M9[EX7S($8RGRJ\_ +DD--BB,D6,.S ;VQE=8#'W1[3C&-"*U6 MN5(O002#D(2 )'EVE'<(Z9JG^,WZ73H9GWM(/-9>2UU"[Q,NO\\2UF>SLQ@C M(D^"K(?7GHE XF+:@G4*/7U+F33^E+5;!)U"-\L@ #P+L7VUT26TWLWII^-J M\R1[QJV0F><$3.GZ62 UI';-R5"*"A %^$T2TRGV'IMU!#Z3J$SI2WR&NEJ. [] M)0[G^*4V"(Y5;/EML5S/_G>CP=_+A^5LL;SEQU\3D;/U62DJ.)TEY.CJ5&M. MZ9(P ;3(/G)&C+/QVY=WH?04>E#:HK.Y_KKTES]S^1^4IZU^6]2*_K-@4PDD M.; QU,'HID =2P&%:XI!-'TUXV<:CY)W"AT=8^)Q7TUUZBRK254C6WR?Y=G\ MRZBO%TOZ5Y,S"KT3$46?GQ^Z ;,G0*K1EMH3X5&KKTT#=\O<=U-?MJ];]>X.?%ZXME MK6C=M/B>83"B4)@.):LZB= ZB"EKD%9*HT)4[5_F]J7U%)HLV@)Z!!UVZL@? MY_03KM?GETM>^)D)&9E("9RM[UJ%FSI266QDG(HHVO/Q[Y1VH_446BR.A=:] M==@I6A]N%#B31;!2!W.D6M:CE*@=*PQ!&FZC",6C:KVD;E?:=D*C?TEH;*"C M_<_UQ3J<3]WS$>XHWF&5..-7<;W3;VQ")M<** )%,D\\0Z2C\BN(AUE:[+3K5^ M*7^AC3U#4'588\\0G760*CW?,:!E05NX N$5 Q7KQ8@("8)@4<;*KFC=7?:B M&GL& 6)P8\\0[?0.MVV)"R],,6X,V(AU4+B/$"DZAFQ82AI#:^N@EH,LQ:"^45$^M8SGYQIY!&KO?V#-$?!TX MBOM-)D4[%B,Q(*H0E#8>@N<0-W&8S#L S2.-!HI; MGK-18*2J!1<4ZCFC!7CAK"XJ9.=:%\>#%"31.:=E\:.?+:>PY!'QC*ZL#/.[X:&9"E.@2Y1Z^7H)(!Q0[&M"1!9D3 M*U'WN\BFD\:>0^*Q]EKJ$GJOO]:]AN\>7E#Q<7%^3@G./\,RGPG,#'U4H%AM MDDJ*Q)B,H[2&3@(3C75F_,Z,7:D]B9:@(=!YOD1N##UVB=B'5ZFPB,449\%J M;6L;%(*WR4-!P2E]9\'A^,T<^R^[.2(6QT'*GAMPAJAM;S3^N2D7^;0.R_5H MZ\!J#>H#?2N%0N685(9BDZNS;A7X9 J8H%!X85#R\;WF8]3UUMLV$3*;**]+ M5_G3\/I??ES-M#\KQ1OCI:KWVB1$5R)$K2E^=DYR+I-#TWI QL[$]=;V-A$H M6ZBN2TS>"&][=?[Z@NB:IQ^?EQ3"GV\T?55C>F:$-(Z7 -(I"N"+]Q"D21 8 M3SEIQ[@;/PD:0G%O;7$3H7J,Q:(MW:C8?7'^XZ^?UUDXV*LY&4T27<>'#5U[*&9-, M*5!TM* B_8DDD)9OWH -V%TM[N+X_WRM-,?UWZ MS7OV3U^K+3#AW/ O(P577\ MHG-[Q"+SP?M"ATJ66.IB\0+>6@\^AYB2")J7\2]RA@Z\G.#=YHBXVU<]7?J[ MGR8N>I9C+KX AEPW9"<'K@0.Q6$R@25#WQH=;(,G8$[P('-$M.VMH"[AMGGO M7,["^?4-?&0V!)48Y,1CM2 2E"9I<:3 VN6"0C_5)M3PE?HV6;V^I1P1>(>I MJM.[P'OR^^GR/7J>72!O'EC=BU,\ITA"29)BY"X;BJ##^-G'DR3V^G@R9=BW MMPH[Q>B=9\LW?Z6-D#_21VXOJNY'O@EC$)9$+'B0=3=+@NCHB+"96ZMXJ?V# MXU_L#">\U[>7(^)Y;'5W&0=L#IAO.,^7P^8B6A^=BN"T=Z!8DN"9"J!"+H%% MD3B./R;S9YIZ?8,Y(C(/4%*7H/MIOJ$I7"+C 9RK#^U<&O"IC@CC)BBCE;!L M_%QG\"3*"1YCC@BXO174Z4G>'3IG&^5G]R/=T)(MLY.AHRFOF38!"X["GH*.E( .CJ" MCED\M.=U/'O1<&ZFP4Z]^>URE/L,2BE#4712!$ ,38$+TAG-FM6T] M9& @B;MA]&6_&;73X?2518]S>;NHY2R&E*.+#!*F3+DB,W0HQ (YQNRY\.CC M^)=:MRG:#87;?MR2OI,*$ A)7KHX4(4MR"D$Z+YRPPJ3F(U>; M/9J_[/>DPW35;771[1G,E[539R$I)[Q(H#8AAXYU;U?,D(N-E%M:GL(1[D3O MT=7;F^;XE4,'ZJ;9Q/3&NZHN*-"]R<;(B -]/^&GKXCKZXG)SG,>T6JP%NN+ MK1-UOIL"42C$2(+XU>/?;.Y(;&^/GN,C:_J?P)*VE2Q"@-.EP"!!Z\+4S;*(_2*/TUD;R5OHX#G><@VU&0'4-T._'KU MX,:%!^;L7#Z3K7^;A3@[GZUG%#ZK:(TH9K-N@^*CR.J@5:& LX##C5O=71'0/,1]9U%]=(0WF^Q>PMHZ:(R'AK WA19PEGE\'+)$ J9G)0VD7= M^G*I">&]Q;H]HOQPC3<$>I=+A<[N+)H[[EJA,][38J&[LKA>+?1_Q]71JY0N MOEV<5[C07_ZP7/R_S;KL>[<)L_F;OQ*N5HM;_4M'V W5@KPC:KFY-"?8,.7J M?/L<&11=!QS63"S$4"#JXK(2FI*QUDL^C[AAZ@%'_;!'O_TW[@V!Y#PS)3(' MIZ(!Q2T#QU*DY-6RXM&(6,:?(;,'X:>SD6H("I]/KL;6<0<)UPXK<%Q.E$ 6 M2$Q+4$J)^@JFP%F')3,;^=TF])>^J6H"H S?8#5 :[W#<#O+V1@ZT40=\UTM M6OD0P&FD0%@)@:G8&'-K[_D2-E@- <(>&ZR&:*4#H#VPF4<+F;T4!G21I4I( M0XR& U,\L81.&]F\Y>@$-U@-4O3S&ZR&2+V/#58Y6.L4<_6MH5:@<@6>6PY: M9,]ULLJ%IR8$G?P&JT$:N[_!:HCX.G 4][#);B _BZ?4LASQ D:D"+LC@TRKO6 M3Q(];K#J+6[>2S]=HFQK>T+P8JT14)RQH(H@:Q%!@F566.;K)+1Q(^3.-UL- MTO.NFZV&"+T#\#R[4LD8&Y(FJ>A2QSH'2AUB"IL'9#K@8Y0\_7NSU7#-#]UL M-40-'B?\:_U+_2C_O[;=56/)Q[;^>NNQY]X#S^K=]H7G]KR_5U^^+#I.60*E:AZD9I1WD:M(./[8E&-P>H(WOTV0_7QW=F\P MZ]T8JY >9_4A"=W\ZBPZKGE A,)2 B7H8 [&*K BU@H-[:0>OT"R$3,GF!0> MW:2.!I;>K>9 W_+4OSQ#+%P6;B EPRD]"YJB#Q. >7(LD1N7QJEX/<$0 M\=2.L690>^$F^?",Z43RB0PSF*I:A755J:7J\G8H+@ M1;TF-C)'DZ0TNK'O.V(IX]"]U9PG%P6(Z!@H)SDX[S)QH+*,GF&RK6.R002> M3FGB$%3==='CZ:R#X.;Y&B;)+#.V2$ O%"BN!40=& 07/"+7UN76_2Z=ER". M"(C!I89#M-,[W+8O.SZAE;(@,.,#V:KV$)F54))3#"4:SEJ7>KR 4L-!0-BC MU'"(5CH V@,E5,B"BXSDDK.BM).["$[4=8ZJ. Q&.ZN;ST$YP5+#08I^OM1P MB-3[*#4L(C,5?+V>8 84R0.\W*"I8:'N(G#9-X!:!XI<0I, M8I8H(0HC0;$2ME6V.7*NF!6J^7JJ'DL-IXJ/]])#EVC:VEAD2EG4E*8*0S%= MQ@ NA@"H N/>&T'&\J]<4CA(S[N6% X1>@?@>;:6C9/]R!3KOM18;Z?)1T=O M"A0G2N&9CO?F#WLG6E(X2/-#2PJ'J*$#6%W?%?_RX_J7_SG#)1'U]<=O^!W/ M-Q:(,MM47"*[L/AN_N?%>K61&-\Z]^T#$;@$< E>KB1F!9< M^VBD4W#)JW#4RBP$5X"R;O2Q"B%JF4%&Z8M!YC WO^1ZG)QIH[5IP;6/1GH" MUU9H^=7Z/:XWM22;;W_ Y:>O)/XM=R%&)0MCX'-=6)9UIJ3=UGUYUG@3O6+- MUWD.HW#:>K0)(-A>;QV@\H$9^S^N:YQ>AS5^62QGN-I$O"IG0RY<@4[&7%:& MDXV1*+,K140K11I_2\RCY$V+Q^,EL&-IK ,P/L#&UH"=#5Z$ZN8%ULL@3U%J ML@Z$3;I.Z& 16Y:[_]^8?%[/O MX;P>'E?YD,K)"N+.15<+WQ0=&CQ&\#8EA4Z9TCQ#'4;AM/!K!(OGUPNVTM&$ M"/RV_#MQ1A'KXD_,?PO+O^-Z59FITY+?S>LNKQJUU#FYJ^L[[\)\IM- 8^*@ MI!00''$G'(^**',EWVF,O5=L/?A#I\U3V^)I7(E/#*4WWW#Y93;_LA-?TF^37N>JFF#_&,=?@?I8F(O]1^+[[B< M5_.@X_O5%YRG'S^U7SUD/*BY-2(),+R61F43:C]8!F6UCDRB23KLX*SV^.B= M\*1/ T_'D/[$X'J]6/ZY6)*PGF6*2\&UU@SJWE/*L!6=Z\DG0%62U1@<&HJU@,[KI"0XP\C_EF+!"?+$ M+L@4Z@IO:7;Q5@,_=K>K3'8ZV!I3[!,CZF^+Y?I+^(+5:*K,?@GI[YAO.'J2 M37"%>E30.?(H>DA.!:YZ-9G('=!U PFY(.Y%;\V.J8V_4D9.-B]%N MJW[%Y>P[Z>_[U0U)--QXZ1%,<$B6Y,@WESH+U+!LC+6!WPW71[BMNDO5;J@[ MD;OUD90QL5M[-U]=+.L.S=>+^6;RQ6HS$^8F2[DR&N9E5B5DT+E>\-8+DI#( M54=A?*I#__G=F:4/^K!=/V\WZ)S0;?HH@N[@)OT1+D@6Y&(#([FP>+G).D:! MD J&+)BTR%L/A3X$2"=V9=Y Z!U YP%/>ETH]-OUL#1MA/*E=C^IS,B%!9VAVOHM*<3?KKX]BTL?RS*ZZ]A_@57 MLQN)T/<6W_X,\Q_;"O$IAA>V(.^(LPV;2W."T8?%!I-9\,"2SJ!4-N Y(OB< M/1=1,=U\TEJWHP]16>%"3!3[H*@E[B0+2U^,82:@1(&I=9CP0DH?;U5"E*(JFT[JNG*J+?VK?#6H++&;%K \4#K6^]GL!HP\' 6&?T8<#M-(! MT![:'BM3#CEY$,YZ8D,A1=5*0:DCV2+3)9I_CSXY6-0U^.\D'TI7T 8)[7/ M=)YGUQA$)SKZ<)#F!V]3'J"&#F"UX\ T36>]3I)3AT MI'BQ=:STXD8?'G("CJ"GGM"WTR28$*33T4K@PNJ:<2B(TBI((NI$@:.7_M^C M#YLBY*#1AT/4U1,6'QA7Q;+6V=@ C'$2FDH!8AT1Q#/R++(UUHTVT&G/ 6*= MC#XDJ*':7=JDYF%L)!XG4,5I$1;>N'F!4&1,]N53\6 QH-,RDN":CT\__5%-@]2_ M\ZBF(;HXF4+LC$DZ48#%&$!Y38E\$97%7+@*0H=XYQP]0B'V\M$ND/A_N)2BM5!:_#$%$FKCH+4E+-'FU2H#2_*[-*!],S']#I* M:5^LM)1J%XU$CT#=J2BD30A"AKI?77J@3"92E$G)C!,N8FB]E.$ 9S-!T\<^ M &HH\RZPLUO)KQ(BL.PL<,9-?:&2$%!+*%'GG+RAG.((?6BG7:W?-N0^5$L= M!-L/C$?<%.V^>[@F_./B_/SM8OG/L,QGW%KDB=6UIK)NJ5"R/I8*L#;G$@I# M^CHZ'G>EMK=P_6#H/#_F<@P]=HG8A[L7HDN%XLD,&#*= JX@!!T,9+0A)[/*#JW7,0"TJH$2B8&WNL(F6=!49.AE&S\T_Y9,GMSK6V1LS=0 M]U/C:2%U<9Y_O5C.YE\^;)S[&2LHM<@.HK825.$,7'$OYOD3KM?GEZ^49Q3]^UR7;L=4IX#5 M%=X!:WNO%$6CS5JR\9_6GJ)PVDND;N*!9DKL$J*?EV&^(EI6O^#ZGXCS6P_I MFS=N8E%'E2)9H<=Z9^=Y740D*6_E7#+%LR+#'!VGSY(Y[5-P-V!MJ\XN$?MP M)LD9XTY+!;D^-:E4EWH8.JR0*>8P8E)R_(AU_PN T6Y,NT'FX6H[\ +@S3Q/ M/7GB6@:K17GZKQYMVL2^)!UQPD03J4TP58+).L_<9= R4D2@-/E4*4+G"3Q+!9BF>"=H)V,8M[-_4']<)_,C!JE^Q_ZX M 7KH$DW;$@9CF98R+^WJ50'E9$DB1L,T!HA<,M#)61(Z&8>N6N3W([ UR^^#CH;JB M$975 1YW;,=A-@3K60#*(\CK>R7J?6L!F444Q1JA5>M+](:-=9VTEA]R=(Z@ MIY[0MU.3CC+HDXD9O#0"%-;K?Q.!@\D)K+(P#RXG 3PHKBS,CK1O#3\"7*F/5"G!=<^&ND47%<-J,7+ M0,%%O02J[_.6 @^70H9$##KN@U&IMY;@T=Z-IP77/AKI"5Q;H>57Z_>XWERG M;[[] 9>?OI+XK](?+45$&2$*C'4,OB3N/ /OBJ@-UB6IUN6,PRB<]C5X @BV MUUL'J!S2]UJ7 5G&!0AOB+5@,X0ZVTTP+ FM9L6-__Y[6*-Z)Y-A#DE@Q])8 M!V!\O*D-,461C0*M8QW_8"B0T K!(PJOHL*46K\PO(!&]4'JW[E1?8@N.@#5 MZ[#Z^FJ>Z__5U;3?P_FMSL:22RDZ!0@N2U!98G74&:S6/C**)I1M?2/\%#V] M-K /4OEB)/GWN$N:1/1PNW5*9'<1R?0$4W5C5@'/6:#TQTMN@[)9[+()>-"' M]MK2O@]ZQI7XQ%!Z\PV77V;S+SOQI=$PKIR DL@Z2'H.O+ 1-.0S>VUMWQ=(H\F[ZT7E#[-G,:-*&"@F\)0Z1VT@JF0@!V\HAW9:W%W[ ML<>*\OU1-<%RPWU1-;;T.XB=[@>;-V-&MAPAF85EE.KJ$!RH.F:5G+ "+K5W MGD?OF\\R?IZJ:>N!QXFC&NNBQVCJQ[WUUU)&'TLMHJ\M=DH'#S[6!;,8 SI. MYG*WYVSW,.K>I^V$&G,:J!E)QET?>$_M45>R+JA #NB]JGUNF4YU)T$+DP/* M0.GP+D#:FX"=L&5/!UO'T<3$<'N]6/ZY6)+(=F3-A)"X"P9LMC5T1 6.60_% M>VV\ES;:O /(!G[L3M!RIP.M,:4^,:#^MEBNOX0O6&VFRNR7D/Z.^8:CI]AT M40=$$T$4X>LJE3K%7G$H-A;*6;A6=I=9B@>0L!/0_.D [5C:Z'4D&BYGWTE] MWZ_"1Q^T94ID$!HI?.1D0S$J^A5EO5IZ4S(WHX?R=ZG:[4J4G0;J1E)&EYGB M@TNVBTG%BCH=HY3+=D=7^Q&9UEX)9SEY\O$1MN?$O4Z&7+=].SQ42UU"[^$^ M6.5$C(@>PH8MX6M_=EWR.#JKH58)H1/*61>2F=6W:B]IF/P@0@[?9#]%. M[W#;IG_DRA4H154&*8P*NA]JTQD#88YO]$*UT +0' MMG0;EDKTC+)]2<)16M5H&/.FZU9*%@4+K7%UBMOL!RGZ^6WV0Z3>QS;[B(GT M*!$H,/!U1HDF8EF&Q(5(E"FQ^.3XV)/?9C](8_>WV0\17P>.XOYF=96Y339: M8!O^XB<-DW@%H'ID>(JUQ*4A?:Y!"O4]. MX.J2!",4KXTRT?G6R#G];?;MXN.]]- EFK8VYBQZ)Y,@&ZOK\- %"$436T9Z MY76UC-;3!$YJ6L\@/>\ZK6>(T#L S[-KU NS1ECA@(M<1Z8Z!S$8 =P+73(3 MEF/KN2@GNLU^D.:';K,?HH8.8+7/7*$DN#0.(P@*!VJ?@((HZ L+);)8* AL MOMMYK"%01PJM&H%O;&5U@,<=UU)1U$G&9, P(REUT1:EM+T@-3!.CQ-K+Y=7"S/>$(1 M]9TCB2M<] 4B;L.H%I)[6TC30=(':S!$P7J[#N>E22#R5;2 M84'R58XBG.B9@V*TIY-$%M3T -2A&CP]H%86WY*DPWEE>/7Y M*RXQ%"+G+))YIDS<2A7C9=3CF+50?&*L#I#-4T>MC](^;9=L=U!NH^-FV)ZD MEKG6."[F51K;[4'U&TO\6O_]=[SLH#I"/?,0,HY8T[RW=":H:^;:&1<<@QAB MO3.($KP-B;XHZT4Q:'CKM[QNZYH+2XX9#* =A4ZJ" M!>OHMP^RD%DZ$U@\% M+[2N>0BJ#JMK'J*S#N*)'0HFBT468V4H<#K)/ /'DP,ZQ0K]IU'Q<8LU3KRN M>1 @AM0PAM^Z8.L6ZYD&*?KZN M>8C4^ZAK]MEI[HGBX"EK4X($$"7%"LX*BA*H<\^;KF01J[7]<\1'P= M.(K[-;:>:9F,D" 4<:$$(CB1$72P/M4-$EJU;N0ZP;KF0]S$83+O #2/U%D: M8:6BPQ:D$ZF^R53+,1(,MRI'S461:M3(Y13KFMO%QWOIH4LT72T\E-$$AQZ, M-8:R5L; UUF=1:4H78XLRO'KY/L+?_?3\\Y;2 <(O0/P/%M0FX2T"0,#E039 M5]*4&#BG06?GF,@E6]':*9UH7?,@S0^M:QZBA@Y@M4^IK,^"Y6P$L*QT':4? MZ1!G&C(KII00!7>M"_A>3EWS(> ;6UD=X'&W5S?+,(AL'"0T'E0L)$0TG"3) MZ7\IQUA:'Y@OKJ[YD'BLO98Z@-YC+V:_+5:KK=M_]>P3W'M<_S$/WQ;+]>Q_ M,?\'67S]YZ^6L]5L_N77BR5]_8#+V8)D5R@[^AS^.DO&UCF.%E*H*^:2)PO5 M='9(T@YW-FHL; QW>GQ63Z&.>A!H'_+/G2.H8T.[KR"2Q0=B=?D)E]]G"5^3 MT%X3O;/UD^)P')T*VD.2N=0QO1QG^HV'*DR:I*0 K)O$E*@#/WRVX-!DG7/DPHR2 M4T_&\2D4U(]E?)WAZ31.O%>7(7$;@3T<0]R(+RJ=+04%D"5CY,,"*=U@!&OK M*!^)&4/K>O]>>#^%!H*Q#+-;C$V\3>0IF=W7V"=?=WXV0A!=)*[10DA6@LJ[/SZ$^/TMFBPM>^CMS_!_<13(9 Z?0P["/-9T. M*CJ^\&@<"]S(QRINC&46#(;:/HHD'Q\+B%1$"5QGY,=,X<;@<=HU9R\F?MP/ M,_O;U)U\;=J%"/^-LR]?*8!]]1V7=3O3:G7Q[<_-%K _5G16SW]%\@'?9O/- MC=+UNR]]P!^?=OVP=W.2[[?+@JHC[EF8AK,IUC=TH,,)NJ<,-RQ('NKB\7AY MH1D]97M.9.>4=$SRW-C!]]L]E94URB%H2P)1RB.0*.H-KV92&LMM\X'\+[1[ M:@BJ#NR>&J"S#@*XY]LRA.)TVDL.6N8Z^ A5;3Q3$'/6.FBOHSYJ,\O)=4\- M <3@[JDAVND=;MLZHJ2#<[HX$,IH$IC,X+U%2(:[E!+]66Y]0_4"NJ<& 6&/ M[JDA6ND : ]TA6B91#%6 2^!4FO''?B"#HS/=#IPATHTGQ=Q@MU3@Q3]?/?4 M$*GWT3UE(V-)QE3[0NHN9)7)5V."6 J96*',,3U5M73RW5.#-':_>VJ(^#IP M%/<[>;*..45"/**RH% D,H!ZF5TD?2,HCK;UZ*X3[)XZQ$T<)O,.0/-8-T?) M!@M3H**J^ST9R20D#U:ENG@S91%;K^9] =U3S>+CO?30)9JNUF-K;B+CDG)5 MYT"QS"$X%'57BB@)@\0X?C=>?^'O?GK>M7MJB- [ ,^S;3NJ(#>%>T@YTGF, MUD PGD$V3B@MC2_YWULAAFM^:/?4$#5T *O=GH&P6&60TSF=F:LM/P&?,)*N.Q_UY^!Z=::"U_5N#)2I"T]9 M$>"<=,"162=<9"JW?IL>FZ?>^J]>BATU1-*+L*SJ3WXOMY_LW\W3$L,*SZ*V MQ;N@0#A>]Z&5 D'*"$C)&(N&2^7[LZK'^>FM]^JE6%0C!+T(:[JCTW=S(@ZO MZO#I7VU.;Q]Y#DC'M72I.AIEP7/Z8D.Q/BJ)PK?NOC\.9[TU6+T4"VN.JBYM M;8"VMO_J]W@^^W*)KRM%E>2\3=[6U8DDA9@SQ)08&$RQF"2#UN/OGFC!26_Q M7U=7"&WTWZ45/.X;[C']4THHLXETG-;EM:&6&9'ENV 0K-;<%F:D;-[-VXSX M$[XS:(3$ XZ,=K X=7MX(A 5.10LC(Y$AQ:4\VKKJ634F52C%-,]6<>!64R? M]P(=VDHCR)RZY>P48$HTA'$I(;E(KJ06[3N;!/@ M:/*>H.U.)*ZM3@4"Q6L4P(4(7C,/UG(ET'!58NM6LV[;[B(O5M11W,5$L2UM M52J"9&B]R,9PVSJ*>Z%M=T-0=5C;W1"==1!&/5+0F(P-H6@#6"<:*9,+1%DH MC0K&>T2GHV]]K71 7$G#7:#5+]; ?$0/72)IJLB?@?@V6?TNI%<,.=C;=*HS]=JTTX=@#M- M@F2>!].Z16:L.?G'+S,>A(\&<_*'**L#/.[V)B!RM)3&<=":,E!51!T,G1)D M%RW:Z)5UK>< M:L\[J3SYI"#L[V6NH3>4RD>YO>4J-WL+3_36469'(?D30 E MF:.X-S@H3G+O"K*/\_7L&['W"-?\C#MK MF$2L72AT-&CB-617P!5GT0NF2K:C(_8Y*GM[BA@?I4WUUN7EYB:.N1S[5BLE MYRM\C^NKTVM1'OSC_:\F#_FTPR\6F_':Z%KPU@>^FN?M9ZZN[VRD-M%Y-=ZV758DY*>TC.B_)^,5_\BBQDI1&1GU,VC;YW.G/8D;(N+V%-51A3_A@;M: MKL\^D78VZ=>GA/.PG"TV]PDY!F-,BF"+K"MEHX(0. /FG%0J!9/%3NUE] FW M[(9^=V,SCW[X-! :7\^+ED*?&C5;NO^8K_[$-"LSS-M+@1)5C-8K*(PR,&6) MB1B+ NNRE-(ESM*=6\M#<_1ASSO-"SF/=J(=124=>*IW M\^]XN5;BDKNK$M*S)&-DC.P0F97$C)=U#H\CTRDVB22B$[&QLWJ,EI/(Y_=$ MP&($=1RZZZT1L"XIWPKKC%LM"L8[2_\#IS2=BKJZPOZ['GZ\7D9YJN0JJ;N+T%4QJ=<- /G;%UIDRSY=9$A M9H^L[OZ-S0MP!I!W$J=D&\R-I;0NO-F;?US,UC\^8;I8SM8S7+W]_GYVQ=:9 M(=><1$F$%/JB=%T!Y9P$@QJYI% #0^MAMT_1,\U0@$DPUTPM_:Q'O360X.?G M\-56CA_Q.WU8./^];+_QYJ]T?I%)IK?W4%YIXLP68THR"B2F7"=7.8@I!$C, M,ZUYL5RUGF_6F(5IEI5.@N>Z4D@ZA= 84\@]?1 M0U8A:YYBMN7.6?_XHM"G/VJ:E9Y'Q=P80N_BK'Z:J3,O'6-8/!BO MD$F4/( M(8.5Z%VP%I5NG8@\3=$T6RXG\6\-57/PB7UG2V7;V/"/^1+#^>Q_,5^'(S)3 M7"M(4)+'4FLH26Z*V.3U/2V5K"@>.4*4>)^RG?#G7@3^1E#5WL1Q<=RR MPO=A6:7Y'1L7$-[[N2.5"CY-_W&* BV) K$(2%K4U%4CI:XF 3-)ZXC>R#C* M\=&\*/#N7=&',,MG,DH9712$?%FO&=O2L%4+97^:BW4 MWNSBK?5-%P3&'_4[^[N@EI]^N*,:31:-W-DE8?31#S2E2ZF9TB6 ,?51P2@. MCL4,B"YKIST=<^W?>!XEYW!'MOW16\N]GNZDS'5VU$"+$.F_;0 C&0O(8G,O%,MNZ@JDI M YV@^\@H?,P8C@Z)B6\)K\_2GSCX60J_SN@O567.POFKY6Q%6GE+BGSUK!9[W27V(R@:7O[)L;U=*KMU[]OWU-_ MDL9M_L]XU"E&0^+E=9J!(C:#D?0E8?1<<*=4Z_& >Y(Z70'/1*#:S5TWU? ) M..;_.%_$<$ZI<)A_F<5S_&WQSYH]Y<*9#$L9;!71?$,?!.' J1,A)IJQ(',Z, MEK@_FNKI:JJZ!O-8>N\7Z6\6]5VK.NODO'\M;"0)TQ_=+DGP))+E>_*('"^* MUG]\7Z>^W M).+Z^YG21:W7!_,BZZ!3KL&KQ$ DC=J(PL+#9>M/9BL.^,KIBKJFSS2,I9D+ M2+']=$NRQ-7JY>)CO)IOLXRWRUGRK"B?*)@T-9/(D=>U,D BHV-(QM\EBYP%@U*E\?!) M% Q[HF#_C<\3%->O1[JN_'N1__-VTWN]FDG-*6ZL[K75Q%;V@@Z<]>"\1T7' MKWC3>JCV0-*& ?5?[S'M)!7VA,S[+_ SPV,Q3FF(UC%B0RKP=;).\G6=9/2> M-:\WWD/*M*O;>JN\.4%-QZ.M7<_*DT?Y*6$^[4;O1,D+UMD\'IC@=6V(J+N( M2ZWHHZ.'(9LB6X_(;41Z)_4VC:LDI]!K!\9SR,WTO2JXJ#5ZD15803>1"DH" MN=9T.SG#T#BNDVG=*-V [&G+(2>!VR#(CZ?["PBR]CAA;W&9\(X75A(RS.2 M6?*'R')+O );HH?JH[RW#=$$V5?"+"?*,YSQOE@H@/KM*'C MRQ+0=4C_9I5G09O$8_,1=$=1>I'UEN<&\XD*[J?ZTUY&2_PB1)45*";) MP<(D@1E3LK>2"S.%A?[1ZS?/#?JQ('$A)V)PH5])(EL="QABDMRRVM58@PZ; M+,ODI)EHS_-P]"]4YWGNLS *&"X@>_.PR' 78R?F=53<@T0,H)RO,;918'Q( M.MBLLWBP%?OH1,P>$BZR*O2<.946JKL A.XI-MQQ:UDH,3$.*68)*A8'+J50 M6[V4#(5Y]W#Q;>MJT4/PVEO1Z#GQVE"1EPG;W_^QV#'+9,A2> 998][T#CAO M)(B(VG.Z5$H9L@SI9$(NLY1T8M0>J<<+<8L?%2FX_]R3M=HO@IPH?9B8HXUVRP%0P%+(: =[%VHU@ M349?97N>(JFGJ)NV0+7?6JB3-=FL8'6T(;0-)EL__WF-!\6>99+UC*T]$P]Z*^)-DW\$U^)61%[YJ23N!SFIKW@>=XF7>)G.U&8\51^ECW MW''#*/XVM3LN$3.RT/WK$D]BM&&[#VCI!#TGZ/F[T#E"Z!V 9[+NP/(D!AP M=7.5[C,1BBV:D52*TP54197!,L=8]JT\2TDEG54O0G"[P#E#S M6#)OPD=>WN-UA^OJW=SL+2Q07I(M8(ATT996$*.GPN>!S*H87F]I'[\^2 MU".DCM']4_NI&BFB URMJ\%K+O[7W?[ %S4MNM[Y]P[?UY^LSZ'$F-#1E<_CPX?ITU'V'9JF-6.C .$AV%IJI1^4/?66L[716=G( M51(0G<^@D"F(.1)#@7&O+<9B6D^*^2Y1$^.L*0:>!E@CA?2#L/H\L.$)\R.6 MG/5"HU1@@D10VBMP,00H1FEF(GD#?B13]AQ9TT:,YT!9,Z5T@+.?PG4M?W_W M ?&FMNNM]53-/5,B2L,1;'5;52T(=B588-8)9X*P++>.'O?1,DV;VKCN5Q.Y M=XJ?[4DKR4I+,H+@E $E98+ TKK;*"01 J)K/<=_/S73WGUMM#T 0D>(OI?) MS;AZ&[[4<[4UI-PINJ\=@D-!/&0MP#.ZOYGREHLDN.1#ZI[W?7Y_@#A&=T\- M6CY%D!U8E'4!WYO%/-TNJR1_N0KQZGI]@^_X015Y\1I2*+SRH\GL%@^9)V-( M^][HUGF"[]$TK<_3&$RC**(#8#UUD?]R-(((JJ+U)8)24% M&.UU;^;>OW:_"560J*HV#@ M VG$.T:^&MTA)(%N ;YEHK^7\-YP?HRV?RBX?W.69DP;9E(TF[(6Y75- VD# M49CL>7(*FSNI8_#1W\M7;Z _4N<=X/[15(RO2=-?%JO5R[!Y#//\YM=?[OU1WA:DSE(0*C'.0#JM02F-X*Q!0(V^J.QK MG=F E&4#4J89#S4>^J;04 <&\5Y.]RK/Z,B47%.Y0M94;N(>@@H)N(R!:\O( MS)?&-N\!"=/,6AK?K)TBZ0Z \NKCI^O%%]S5"K[[0.+\*:PPOUQ\K*.>=C, MMQMR:F/^JS]PF:Y6^&MY=[-(__7KITTKLK=)3KHG'.E$,F MM6_=8=>,^&DF*HT/SFFTVP&L_S9?8EJ\GU_]<^WV;ODC8>H8G22[K:4E,XXV M OW60O),:)FUD*IULGX/*=,,11H?D19#:.294--J_>.X[2B<8;38:_EHKK )X_(_FP M9,A?S_?P^WKU&_U\,0_Q^LM;>*SC@7 MH11RG+/B"*H@!U=XAF1=RIY'I$OD//9S"+G#<'J!3SOG4N&%HO5%2LM;S#.C M4W3%!#J)08$RL8"7C%@U*C#ND/[7 UJWY Y#ZP6^R9Q+A?VB=7>OU$T3M]%X/1 MRK@,F+'"(D;PP11@*!)FS8)ROO'I'WUX7'U;JF?BJ7ZNCU0V=;]4">0VTG=W(F(>CJ//K[^.KC$CV!U]RZ/ MS)5BI /-:S&V= *<]!&"\8&L! RUG12^30_48[1WF3A]]0<)F#1[ M-0_++VL_J)8YT7])I-'7O-^YWS-G4^84"9)WQ LH)5E-!QN((9(HR"?7S;L$ M1V2GDVJWZ9$^BO[['UQ\[S>-_-$G/[.Q+_I]NL_@AZJ /MAD@-1>:JN1 VF92CNZ&4K1 M8 R="J_(HVF^3>MX:OOU0@_!TT.3=R;M=7"Y;SG]$]T+RW#]B-69)>/,<^'D M1*,#Y6VH:5P&DGX@8N2B-*^2_ Y)TR+N7,AX&I!-U-01ZC8.\6-V>,!@?;9 M,5P A;7,3F<)4JO@(B^UGFHDU.TA:=H@9F+4M5!3/ZB[MUW\,5/,H79*&6 R MUBQ"2."=D%"\,4D6Z4IH'5L/(FS:X&):!#9463\XW"/+F2"+[46@8[1>..24 MWLQ11TRI%!53]JW7\CQ/T;0-,=,BKX62F@6NI_=J'2/%$)!)RPIP4?<.9A3@ M0XD@T"F3K HZMMY[< *Y_68;3PE(SJ6_#JSCCM6MK[OO &)V0>I4P-I:J2.\YBVBSYA)LJ'T:1AMP M-C"0$H-'+T1HWH5S"'W3QC)3X[*Y!CM"YUYV>.0Q( >&SM7IS[4,BOQQI9-+ M:$AXS3MNOD/2M%'-U!ALH:<.XII];# >76+D7<1H#=GV@A");H8!UWE;\#GR.^MM^WV4.0\-0(AS'DWH$3M7?,L[$A$2,>M$H! ME(T,HI86G&>:0F<76&SM/9TT3+TYJ$97_M#QZH=HHE-$;4?[2HO2).W!FE"G M[(4ZVTD%.H@J>$W1A5*MT[H7-U[](&T/'Z]^B.@[ -%ZD//FJ&TG-WM7#-EK M!DS)ZCJF#,$4#DE%QX*AT]5\"=(C(OJ#S#':?6IF]M&B[F44_R]?NY\:YKJ($T.[ ;CP8._GFQR/^X MNK[>-&"&^?O:U[[YT"'T#>=VW,J M#KXW!;*54GH$W.OYV^4BX:IV2B*1]H&8_!D_X_7B4VV4G'&#DNQQ )-R7?K, M.'AG#<24A#)>DQ4:?1[I=VBH4,'XQ,N;[Z\)2?SAH[%J[_? M7FT.A3-DB7UB8%EMXLXUAX(*03BK@RO"YC0ZE/92-\V3RCF@U48A/4*MA?X04+[[XYGW-D7&"@2L%$_GLJ^7WOF^:Z\5D>&0Z6= ?%I8^X>&)#D2:ZN;*6 M#"67Q%*I VQJA0#::+.RDJO1TR1'+H]J/Y'X'$@Z40>'P\IO8#7']W6-WSC M>H,W,R6\R)GN7<=*!HJ1%42F.!B+5J!U)H[_ $IT3#0>^!S0.53*?9F@.[4% MSSS9/O6$:Y&C!I9J8&J\>3?1$ WW'Q> 9]->7CW6' MX8>)E?#IBDY(#8F_OMF]7*R(6Z]XM%Q84-9568L$CAL.Q;@23918>#@+6H=2 M/ RJ%_88,;;FNL7I_F>^4&K6VB!P-(78*XY"'<\!A0XI&9E#:3V1Z$ 2AR'Q MPEX;FNNFGU3:'=:>?O:;:2LE3\6#277[KHPUO!9U899(SK)8I'[05OZ];-EW MOW,8B'K.[X\JY2[1\Y8,\[H_=)O<>TOV>(DW5\OU,H!MPKF>&G(F3-&,"P]Y MW7>CR%*[DA-$5;PL/C@NS=&(&D[',)1=4*I_?&UT>V5N,H'6AU*2YD#RJG-\ MG0+G1(:@M5!1<&:=/LOU>$#BM>>\?FN9=P2?.Q+ZRM"LH)2.Y !)" &*TV4> M/-(5;A(K=$P$&C42?IZB9UC1[25E[D^6>K?)D)F4,842R.DSEKAPO$ T)8,/ M,6-A0C(WUFB)8U!S8?G[8R7=$5Z>PG[-!4I;BX*-@"3K:B;M''BO+5@33=+9 MQ#1:LF$/2<,0=$EY^Q:ROY1E5#71O-VW]:7I-JJG/GB4=53?Y> ,4R)\M!PS M@8+^)=?I-A9"E %8L2@%QL)2:U=R]'U4O]];#K?M"R2;Z;VW8'P=E5*<@6@# M!\=M76/$&-.C[=UZ2$R_DR(.0(34GR;X#U_GQX5QWITMFH_ 4 / H @4 M+)&48@+.O$9KL$39>NS@TY1T I_3U+P//,?+O$OD;)O4T:+&[ 645,L/D2YX M[^EP&>FM574\LF\=<.VCI1/TG*#G[T+G"*%W )[=8KV7B]OYS?++=B"!<3'I M9#)(BS5HU 8H)@A@$^,R>AYU:OX2\A0AO<'F&!T_=)I/%G@'J-E.7;W/@R6# MJX(KP)2@:UR20.@T9=#6VT""0:M;#PQYBHY.AH.WQ,S)XNX ,D_=X-_"4/+Q MK%8E@:Y\*%77>DHD>UR<\R0<*TSK6;;/$M0)B,;Q=D[60$]PPM7;<)5G126Z MK4Y))!,MBUJV3A ^(*&3N^ITY>Z#S1&2[C^KLW?]>I/4 MSG<^O7%^YQ!>SI#DP2()(=:#*$'4X<)T0;' @/ML)>E#3TG>7XCT<[3 MU?756D6_ECW"?O5'NK[-= !??*RW]>HM+DGZ<_J#WQ>O_@@?Z4C6O_X;WMPN MYZO?%M?7?]ITYLS01VFCH8/D'=^8=D"(V M'QK$KI#0P56\M_N1!V) .(BE('F\P8(K=3TQSR8KE"HVCP=.Z3H=#8=]X671 M7GE'8_ 3+J\6=57"\F9,))(A6&)881U"=7M=O:/UDNO-\J^W:QKH;[]=K*[6 M,_AG7F57C$R0HF D3R[ !41 '9S/VM=RP_, ]T#*IXU:+A'G8T*C7]/\--=O MB=OE$SP;)PJ+P4!6Y.LKXQ "I[M2A4#!:/:AG,N.'T3WM$L9?IS#T (6_1Z% MG_$0GH41(H64P=1Q]B1YH5\Z3AQRX#B5X'7GK MY&U3!J:9-??C'8^F0.GYG/R&^3:MC_X]_G\)GU;X:WGQZ=/U5:KI^KH$[O:& M_NB7JX]7&T35 DN'6(,JBK!("(HBJZA5 !N+3"IFC*QU[=,(;$PS]NZ2S\S9 M0#/IR:EEIM\Q&O=MQJ>K^:*4WY=AO@IK\:;4@^ODR0:FTZB89@9>U_@^LVI/A?'OHRNZ[1VE)Y)R8X7\WS2$^9K\*RRJ^*\MT'TM7+<)UNKS=WQJ(\ M_.GQCYK'?<_ISYL-^&OTT/GPN[ZMN1,AA+K7SJ$E;'J5P?& D!Q7*2L376B] M7F(?+6UJ*NI P742](GUM+,4/2;K' AA$%00 >@@T6^=+-EY48P=9^?J\BQ8[)64F,NUC?;DM=_) \U2/W7LI;@ZM?;F]5-F-?@;W/,A' F(X5;%/13"":2AJ Y0BS91VX8 M3\T;3 XB<-HG@5$0.)Z".KB+GV1N>Y(>"Q YHH"]IR,Q=83& \FLB_W[R2('., 'JVO[@#Y_//C0U:CIOL! M$T+Q=#G0N5;@5?3UV<=CHF.MW3@=ZD>1VY=[-QY(Q]-A!W#=(\:9#CE%X\E/ M$:7NS;:>+AO!00C&@Z.+)O/6/:=[2.G+I6L)LQ:R;^;6C5D&^"8LZZGYW+#B M[]%'MB_N>Y[JL>OX6(G<6RW!4MP *M:P,',*"RE:C,%);TOKRK:QZOA>D/', M%=LDRW>8;C?=-YOR6\P;/^#CI]N;;;GN(S+6Y;DS9#%*)B5$Q0,%.\E K"_1 M/OM4&!=%I]9)NR:$]^7+'86OAX;K_ KMB5&Y72)'^H&EL_XS7$XWM(- M^=33C=W!M+>R=^N%2%]16$2@&Y0YT%Y7'RF)>G,ZB,BM]\K7@I/65NX>!2?; MMI1N/]82<,S/B70S+<\[)94L=)V+4J?\$/:=,PDL-[;XR$IFK=>M'D+?Q);J M>&0\LD]C*:4#A[VVXZU[6C?RJJPMYK7%=3U"N#"?))E/X+&VDFBI:Q>) FUR MEME:'[#U)?DL0=-":CP<+,922@<(>\##=EZL0I* \0JX\.NA^ Y",+7(!:.S MQ*+*K6W7DX1,BZB&BGX8#)XL]0Z@<^? _9G(KX?K#=Z\#*L/?[I>_./?,+_' MMVLY;V<&*^NC-0HI>LZN;GLA]KR3(-$:.F\Y86Y]_1](8@]WXDF@V'\U-M=0 M7P DMFJOY;?%P9MJO1W76_ZR#C9[@<"U*J 2L>8H"@'/N-;:JJA%ZW:Y0VF< M.,\Z)@3;ZZ@O#/Z,I781W]W ^:UN=,M=3><%2R?,N$*B9,R YSZ!L[YPFP4K MJ?5[U&$43IR '1-_K?4S\:[>[1[8R@>=K#LG2-?QLIDQ,MO.@.(H(7!K08?U MWM>@+']05O[D"(M]G]^-E]]@)D#OG+:B^Y,,!I+!?V8GO54NG>X_'R5\"4QNF5&"&U3R1:( M]CK@HIILRQW(K'EDVANRXH?9H*>_:-KKZOS&J(&XN[9*>_A#'Y./M?(IT &A MZ]Z!1XS D"6-*7.1XLGFZ02$C=8.VH6=:J"4OCSU]52HS2271R+D%KFPSH-: M[V43/$$0.8#-%'AD0R%(\Z?8891-W)<\IF?>2A]]H6Q?%GK+F&2>J1!)8J4N M*/920$B&@]1">1>$-PF,ACW&6E4U?4 S5]?OKX_3:][54MZ= ML3-&B;D?P649>U1PW2FQ+(TMLB6S<_'4!>-QF/$7#R$)0C*:T#/-X= M<[*Y84AXFYF0;^LD*-+F/<;?+.:U$IBHH$]\_WI.E.#J9F8C2J%K[L?;6)L4 M(S@=!"1#EP5QG3F7C:':AO*)43P6L!X]SI]=R]UL('K.//R$9;'$WS!=A]7J MJERE36'[YH])_K,2&=>.#$:HF\D4Z@+1Z PVR>"2SLZRUH,?3J%W8B?A3&@^ MFT8[L,]'\+KF4I-;GAE%!(I"0^6D B>+@SJ=URGEF,+6]O@X2B=.5?:+V$.U MV,]L[B.8WM.012)0@T^F\'Y/]I P6Z>KAUL69LZZ($#D8'V3M1 X0;6&0@I!<)Z^C:-V> M.Y2V::?Q38K64S75@9_;XA1^O76$Q91]B8#%:(I3DP(O"D(2@15CI2E6=&AX M#W(K1IOE=TEV]RB-GVQVF[D;SWE67YOKG\K/;#0R0Z5$3)A ZE#?FA$A1J$@ M&!XH=M!1-7^5/9'D:<<(]N QM]9K!U[SX^SBF\4-/K%K2GN/%I6#8C7%LS&5 M^DY9VT2$YR5REDSK!XVAM$T[YFBZ/' #377@/33*;V.TR3&;P%L506% ".@Y M*".UE]'(J%K;TW.^8K ?#[ZCJ[GIGK'1*QH>5,-M*B1?S/,3E6SK4KFO_I-T MN12>(E@?65T#R\#)FK;119MHE>!\HK;L8UFZB'J)1L_3'8&CRRD5[_!]Y>KK M?NFW82D:E90ZURDEOOJD@O2?!4B#(4LTPIG6 M/5K[:#EY0\]VDOQVDMG\_?:+5C.'Q24;)$06!2BA6%VV@:"%9HZY'&QJ_6RV MEYB)N[Q;X.#1QITF@K\($_,N7.-J4:HI#O,OJ[?+15TU?<),G ._H+WY.82C ML8U1=BX[=!&"CS6Y633YS\MB M^7&MMI^^;'^X*;!D@7ETR@,/EM5V.UZK&1R@0IM=3 UD#:2N,O"ME_!>$TA32R0 MO*?3QXT YYB&$I@1):K(Y:#^CN\!:1\!TP"IH6(7K:4\(512'8*X_#+[V[N9 M*@63L1*8J+/.C$E YX8"36XX=RR)Z)X;0K+"]#_?+S[_K^TG;J"Q_>+F8KQ;75WFS+J8FOM8&,)J2HZ' +Z/BH.H. M-Q?K?/LBK-(D)CULY>-W+H6GOWW:1.$Y78L&TN\./]OS%(S2(OD(3M5J%V,S M>.$L9"^ML,%G[P=5?!R,H*F]BA8Z?18B1PBX@P?!1QFFW2PWF8*U+@'J>G2< MUQ!KIR)/260RPU;GUL-!]Y#2$V2.T?'#DH<& N\ -R\72S*_Y*B_6KW6%8VV3#M$^<%R@ZDX,N!(.8?>T\TEYF;F)D[:M?GB%HVM:;CKIX>@;9 M_J_H(N]_C-(6[24X,1!>S*\^ANM_PW!]\^$^$Z(()>MV]" 8@HK>0*2 @2Y: MH7/24<>2!L!@[Q=,'%4W 4$;Z75P7;RXOEX7^3SPS0T+/!2LPQ0I/E22N" _ MS4!R*>4H TFF^:RE)RF9V!,Y&2P-Y3QQ@F7[JO_K;K#=^@X5,6>C.%V:4CCR M[7E=QN8">>%:*):#)7$U2*X\]=W3=MB>,SEWLN3[0,[JQ3QO.=B%ABI;'87G MH'/4M;;'0G32@#96.LMDRF904=4P^#PF8+I,R^DZ?0R0$P4\L4/R?_#+S?(V MAUUV2/A,[GBMQ2CDG9=:]2IL'2/-L_!.&/VPWNY)+^3^ITZN[U-5M&@BKZE= MS^OKJS!/N,3/.+_%7[[,27[_W#$25-&1B0!2" L*D>3A*4HS3B+CCJ-.;HC[ M^=R73)=6[N?&HG0A14$R>ZX"35&<&:@XN9R9E\44Y M-0 &]SYT&F=R'+4?+ZV)U?P;QNO%/[]\?:+&D*U2"0P:K(/#-'@,#C)2O%QX M1JZ&Z/G^IT[C&XZCZ!/D=;2F/^,R+AKH^L]AFR"IA$6%(1<>>CY]F.,DXVF\AP:E3CLO%_[T-^:]__>WUZW\/ MRZO/X8^=U5+&4 #$@'EA0*GJZDJ'9,2$55Q;DQY.P7DZX;CO"Z:9^S$.$-I( M<6K;OZ@9^;_O,&RYE'4[O&3U"<_H2.%.(!:23X(YIX,W0TS_W0^=9D#&2);_ M:&E-?>+G>/MQ00@5&AF)$# F"JW6L6&)JA M$2.=\).D-K'*_SW\_6;GC-J4BA,L042M0 6FP!4R2)P7PR@2)<+# &7?^Y\Z3-,7DH<[06 3J_KG.F#K*F\)+SSF$I0#K33Q7ROQ L$30K &6?1)F2&! M^+T/':;H"TFT'2^NR8_TU@"^J+@BR-4VD!2"1SUA-##[< M';'G2-_]U&&:OI#@P15](;NUX<4W>)O4YS/^Y\RYB<)GO7=R*$QH MQ8)A ]1\]S.':?E"0K[.#,>=+18B\LR18."@4F! M^$2(SM!8!.K^O_A,H8_=F&A\=%J[S.0OV@)H\R#ST:! M5"X32"W#ARU+3VKZWH<.4_2%9,:.%U;5#:#%2I<1K.R:/==B? >=" M(C75VVH$Y#3/_]3QU6[G(AF;43!#:UTU[% M3L)???V7?_MYES6**I-34DN ZX0&9R4$Z3@D+HS,RH5LANSKWO\-PR!P(2FW M1H*<.J..UZO%Q^772BT>0J8@!)A5=#?%G.E:JMM"E!=%82$?=@@$[G_J,+5? M2 +N!(%-K.IW5W4U\]6N=34+FTJH0X:1@%J''7MT&F1.DO&L2LY#&FSN?>@P M15](_NUX<4U=WX ?KU+(N]W8*!B%H,K3951KRI M;;O[J<,T?2$)N!,$-K&J_Q+FMY^O=K9(%3!1SIL#(ZZ1K)_(4@(@OD@4R M1W%(;N;>APY3](7DX(X75P=Z_HA?IPZ8P#!S#[$.95MW]WEA,G#K%:DR!5V& MO'O?^]!A>KZ0%-SQXII8SYM1Y_=Z>W=&29?.PPO5](]NT4D4W]S+(>6[U>>%";NG3>&@BP@T[X9_IX?_FZBR.*XICQ!1!E77//! 2M M(Z#4FI$ODX-N/EY[ %W3KF,]^[R>UIKJ 'W;5XO53#BF?/8:N!-T:@Q=F($5 M 1055>=8(>*I4\;SM,2PPI]Q\\_7\W_# M_'[WQC4KF>_I8MY+>UAT5B\'=@0 MNMD38E[5=:EU)<>OY34I:O[^B@SNB]4*;U8SYEPIV5G@9H7L=>A6-M# 4%!5VFEBC'',#70 RY<"B1'"TQ:'9V5ZMP=A*NI^G5'^N1 MY]",U>"$L;C>\)$&39_^ MD=;F'*3806MS#I%R'VMSLH@Q\B" F^) 9>,A>LE!&@I;A/).^N=<_1]A;3N3WF0G/ ,=*2ZWK M$^T/629Q'DWO*YTX1.P7\5#Y&Z;%/%U=7ZT_=K&K8'J[7)2K&Y+JZSG]I_@3 MEL42?P]_X*K=J^717]W^";.-%,9^SV3&DN^="F@;$)02!#[N$ 2Y8-$'9P8N MB._J/7-XR1QW'I.A$ZOHN(+*G-7%K:+..A!!YD Q:?/:P\/)[/3E\A#L['^Y M'$=9W6U.7K^A)!MY-$Z"YKB>,DN.B30(6;(ZFM*GPMD0N(VW>?L,#Y4C*?S[ MF[4K15JP5L(#\!,4-2S#'4W#LU#H*F?IALH=,AF[*:4=X#TI<1&4> TN'G[$(%/ MND/B^VN@LRHF:V\@EV#I3$E)0;/C$(W2P2HZ42(TQLXE[=X^!3UMA-X%?OY* M7"ROPO77.(=N\BJE'3\!/6>R;E*I;:I..O J<6 I&3H8R9LTZ*(Z $3/4S3= M,^HH2&HH_B[@]/Q>:.TDY>YGR$I M.JXOW5XW'7A,]_?/JE@*2T2\L8Z(#ZD>0:^ 69U4,()S-N@1[T=[/W,*G*,23.-'NJ.B=I@2<$&8QJR8E+RI!(K0U9L7<@R]X.4-G"9 M^R$2G'I8Y-YUY%%)98QGP*WS=&V;##%Q#K)DY[1+ 1_F3)\>''D)R]R/!4$; MZ75P7>Q9,BZ85"J1UR8+5V0;M2=/O3@(3(FB1%0J#JH0_Z&6N1\#EH9R[@ M M@QH?Z5XUOKY"6X;$D^09G"]UK;"(#D,T@3=W9EL-/!@/2>?V:5MKJ@/TO9[7 M@3&5KP$.&0>A9"XQ.86AM?792TP7[M)X*&JCA%/Q]'LS,_0S$@%I4T)#)E1R MBR4!<]G4T2&.(@?A@*,0)7E4Y>'TL)-Q=/?[I^G).!MTCA9U%];G-](&D?#A MQ3S_C)_Q>O&I2FMG3+.WA7F"O YU.I$O!J*HN0>/,MF4R**VGMKP+$$3SQ8; M&TKME-$+MFZ6M^GF=EDGDWP(R_>XFI$#%\F!8Y"\MR0?K]=#TL$[I6U2% 8S MW1Y2C^B8IA?DG$@Z3?23 F@]=_V!B/XV#]?K_P+S.M^Q/16K-W@S,TGPE&K6 M)!I&,8(S=80S!^U#"<)G'^T#,_7T$/OA7SE-0\GH\!E3\%V8I$UP^WQ.2V.F4Q7VT*BS=_;UU>_.J/FV4@C5[-P_++6K1O%O33^0T1=[T6 M_C92-59(952 7' M_?WVZN9+%5;5U(M2UM7YN K53_GF_9*LKF\SDH#NU^RW:U-H1$C[IH4Q)#1V M"X-&&TNP!:S)@F*5B!"-SB!YW82@LTRR=6JJJQ8&+#R@BH!V70$; X5JN4 L M7JK$;4R\^42Z'Z:%X1#L-&EA.$!9W96@KXM" KE)TI&P(LNU9S]P",HC>&NX MY89\I1*'P.U?I87A$(5_OX7A$.EWAY_M*W&2SD;CUHN#ZDPB1J$@'0]L83A$X!W@YOGB12<2228XR'4%@BJ&3I6U' HSCMSR;(QJ MWMCZ@U4,'W%UM==-#T"[5^3$;8AT3FR=5Q>)>$Z&6\0"*4N6"BLAV];CWB^F M8O@@Q3Y;,7R(E#NN&'9U7;(4'IQVG,PT&=>HL@/@T^-\UP^V]VM::Z@!]]Q^0-OG_ MO^+-AT7^5LJZFK$2R=X:A!03UE:P""$Z"T$JJ;APRC;OYAU$6!?>3T,\//NZ MUT(Y7?3ZWGU*HG^_QK7"YOE>P6(P(890ZH#@Q,AVVP ^60&A8*8CK$T.KC'D MAM#5A:,U'N*:J^8B'H;?+A>?<'GSY>UUJ&O$Z"D@@ M!!\BL*3)W/G"K1PT-?%?/EF%@/'Y.O:&!;J&%9?LV Z@@@I!U.4QO!N76,=IN(KL. MPH.C=_7$[)ESR*"@0B S)BJ+# 1:(1/)T-G6:>1_R95;Q^2WSJK<#D!\[\WE MQ?TWEQG98:2C:*!0>%8G@6MP22MPQC.6$X^2MQXM^!P]%[J:ZR!$+$923\/7 M]KW/G]L?U%]B6.'__A__'U!+ 0(4 Q0 ( ,F"6%8543VB*P, ,0( > M " 0 !E>#(S+6-O;G-E;G1O9FEN9&5P96YD96YT M " :<1 !E>#,Q,2UR=6QE,3-A>#$T83$U9'@Q-&%C92YH M=&U02P$"% ,4 " #)@EA69#>E$, ' !?'P '@ @ &C M&0 97@S,3(M " 20F !E>#,R,BUS96-T:6]N,3,U,&-E " 5#I !E>&AI8FET,3 R-"TR,#$Y86YN=6%L M " 1)$ 0!E>&AI8FET,3 R-RTR,#(P86YN M=6%L " 6.^ 0!E>&AI8FET,3 S,"TR,#(Q M86YN=6%L8V5O;BYH=&U02P$"% ,4 " #)@EA68*HQ";LM "2.@$ '@ M @ &+VP$ 97AH:6)I=#$P,S$M,C R,6%N;G5A;'!S=70N:'1M M4$L! A0#% @ R8)85J9T%]>F+@ RST! !X ( !@@D" M &5X:&EB:70Q,#,R+3(P,C%A;FYU86QC96]P+FAT;5!+ 0(4 Q0 ( ,F" M6%;../ ZUQP *^< > " 60X @!E>&AI8FET,3 S,RTR M,#(Q0-I#ON0 HN,$ !X ( ! MD[8" &5X:&EB:70Q,#,U+3(P,C)A;FYU86QR " ;YP P!E>&AI8FET,3 S M-BTR,#(R86YN=6%L<'-U="YH=&U02P$"% ,4 " #)@EA6 BCU;4 " ?&AI8FET M,3 X+3(P,3EA;FYU86QN<7-O="YH=&U02P$"% ,4 " #)@EA6C!=KHF,E M !#,04 &@ @ $-2@0 97AH:6)I=#(Q+6-L96%N,G@R,G@R M,RYH=&U02P$"% ,4 " #)@EA6J:= YBHP" !L)F0 $ M@ &H;P0 ;7)K+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0 ( ,F"6%;$VR/#Y"8 M !/4 0 0 " 0"@# !M'-D4$L! A0# M% @ R8)85L6J,Q5^0@ OLT" !0 ( !$L<, &UR:RTR M,#(R,3(S,5]C86PN>&UL4$L! A0#% @ R8)85DOY]EI/& $ _UL, !0 M ( !P@D- &UR:RTR,#(R,3(S,5]D968N>&UL4$L! A0#% M @ R8)85@8MMVH/_@ )QH" !, ( !0R(. &UR:RTR,#(R M,3(S,5]G,2YJ<&=02P$"% ,4 " #)@EA6>N+XJD7C !Z2@$ $P M @ &#( \ ;7)K+3(P,C(Q,C,Q7V@ $P @ '()Q$ ;7)K M+3(P,C(Q,C,Q7VER$0!M&UL4$L! A0#% @ R8)85@0?D D]= $ ?B$1 !0 M ( !??03 &UR:RTR,#(R,3(S,5]P&UL4$L%!@ I "D *?@L .QH%0 $! end

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